PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	HOGASEN, K; MOLLNES, TE; HARBOE, M				HOGASEN, K; MOLLNES, TE; HARBOE, M			HEPARIN-BINDING PROPERTIES OF VITRONECTIN ARE LINKED TO COMPLEX-FORMATION AS ILLUSTRATED BY INVITRO POLYMERIZATION AND BINDING TO THE TERMINAL COMPLEMENT COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ATTACK COMPLEX; HUMAN S-PROTEIN; HUMAN-PLASMA; MONOCLONAL-ANTIBODIES; PLATELET-AGGREGATION; ANTITHROMBIN-III; CELL-SURFACE; NEOANTIGEN; INHIBITOR	Vitronectin (VN, complement S-protein) is a multifunctional protein which participates in cell adhesion, coagulation, fibrinolysis, and protection against complement lysis. VN is incorporated into several complexes, such as the terminal complement complex and thrombin-antithrombin III, and is bound to plasminogen activator inhibitor 1. The present study showed that purified VN spontaneously forms polymers of approximately 1000 kDa with a Stokes radius of 10 nm. The polymers are to a varying extent stabilized by disulfide bonds, but are quite stable even after reduction and alkylation, indicating the importance of noncovalent bonds. Plasma VN circulates mainly as a 65/75-kDa monomer containing a cryptic heparin-binding site which is exposed upon a conformational change induced by different stimuli, such as coagulation, heating, adsorption to surfaces, or exposure to acids, urea, or other denaturating agents. In the present study, VN was demonstrated to expose its heparin-binding site and its conformationally dependent 8E6 epitope when incorporated into the terminal complement complex. We suggest that exposure of the heparin-binding site and a putative hydrophobic binding site of VN are linked events dependent upon the same conformational change. In vivo, complex formation probably induces the heparin-binding site. Such a link might also explain why purified heparin-binding VN spontaneously forms polymers. The heparin-binding site may be involved in the elimination of multimolecular complexes containing VN.			HOGASEN, K (corresponding author), UNIV OSLO,NATL HOSP,INST IMMUNOL & RHEUMATOL,FR QVAMSGT 1,N-0172 OSLO 1,NORWAY.		Mollnes, Tom/ABI-5183-2020					AKAMA T, 1986, J BIOCHEM-TOKYO, V100, P1343, DOI 10.1093/oxfordjournals.jbchem.a121840; ASCH E, 1990, J CLIN INVEST, V85, P1372, DOI 10.1172/JCI114581; CHOI NH, 1990, INT IMMUNOL, V2, P413, DOI 10.1093/intimm/2.5.413; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DEBOER HC, 1992, J BIOL CHEM, V267, P2264; HAYASHI M, 1985, J BIOCHEM-TOKYO, V98, P1135, DOI 10.1093/oxfordjournals.jbchem.a135363; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; IZUMI M, 1989, BIOCHIM BIOPHYS ACTA, V990, P101, DOI 10.1016/S0304-4165(89)80019-4; JENNE D, 1985, THROMB RES, V38, P401, DOI 10.1016/0049-3848(85)90138-0; KUBOTA K, 1990, BIOCHEM BIOPH RES CO, V167, P1355, DOI 10.1016/0006-291X(90)90672-A; MOHRI H, 1991, AM J CLIN PATHOL, V96, P605, DOI 10.1093/ajcp/96.5.605; MOLLNES TE, 1985, SCAND J IMMUNOL, V22, P197, DOI 10.1111/j.1365-3083.1985.tb01871.x; MOLLNES TE, 1985, SCAND J IMMUNOL, V22, P183, DOI 10.1111/j.1365-3083.1985.tb01870.x; Murphy B F, 1989, Int Immunol, V1, P551, DOI 10.1093/intimm/1.5.551; PODACK ER, 1977, J IMMUNOL, V119, P2024; PODACK ER, 1979, J BIOL CHEM, V254, P9908; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; SHIFMAN MA, 1982, J BIOL CHEM, V257, P3243; TOMASINI BR, 1988, BLOOD, V72, P903; WIMAN B, 1988, COMPLEMENT, V5, P180; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	21	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23076	23082						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1385412				2022-12-25	WOS:A1992JY16300058
J	MICHAN, C; ZHOU, LM; GALLEGOS, MT; TIMMIS, KN; RAMOS, JL				MICHAN, C; ZHOU, LM; GALLEGOS, MT; TIMMIS, KN; RAMOS, JL			IDENTIFICATION OF CRITICAL AMINO-TERMINAL REGIONS OF XYLS - THE POSITIVE REGULATOR ENCODED BY THE TOL PLASMID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							META-CLEAVAGE OPERON; ESCHERICHIA-COLI; PSEUDOMONAS-PUTIDA; NUCLEOTIDE-SEQUENCE; CONSTITUTIVE EXPRESSION; PATHWAY OPERON; PROTEIN; GENE; PROMOTER; DNA	The XylS protein is the positive regulator of the promoter controlling the meta-cleavage pathway (Pm) for catabolism of certain alkylbenzoates on the TOL plasmid of Pseudomonas. Transcription from Pm is mediated by XylS either in the presence of benzoate effectors or through XylS hyperproduction. Two regions of the NH2 terminus of XylS (residues 37-45) had been predicted to be involved in effector control of XylS transcriptional activation. Different methods were used to induce mutations in this region, including genetic selections (where Pm controlled a tetracycline resistance gene), bisulfite mutagenesis at a unique restriction site, and extensive oligonucleotide mutagenesis at residues 41 and 45. The mutants fell into four classes based on their phenotypes with respect to effector-mediated activation of a Pm-lacZ fusion: (a) effector profiles similar to wild type, (b) no Pm stimulation with benzoates, (c) altered effector specificity, and (d) higher basal Pm activities, in some cases including changes in effector specificity. In some mutants, higher basal Pm activity was apparently due to mutations that increased XylS stability. Substitutions at Arg-41 resulted in all four mutant phenotypes, indicating that this is a critical residue in XylS for effector stimulation of transcription activity.	CSIC, ESTAC EXPTL ZAIDIN, DEPT BIOQUIM VEGETAL, APTO 419, E-18080 GRANADA, SPAIN; GESELL BIOTECHNOL FORSCH GMBH, NATL RES CTR BIOTECHNOL, DIV MICROBIOL, W-3300 BRAUNSCHWEIG, GERMANY	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental del Zaidin (EEZ); Gesellschaft fur Biotechnologische Forschung mbH			Michan, Carmen/H-6325-2015; Gallegos, María-Trinidad M.T./K-6501-2014	Michan, Carmen/0000-0003-2921-0987; Gallegos, María-Trinidad M.T./0000-0001-7633-8807; Ramos, Juan L./0000-0002-8731-7435				ABRIL MA, 1989, J BACTERIOL, V171, P6782, DOI 10.1128/jb.171.12.6782-6790.1989; BRUNELLE A, 1989, J MOL BIOL, V209, P607, DOI 10.1016/0022-2836(89)90598-6; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; FRANKLIN FCH, 1981, P NATL ACAD SCI-BIOL, V78, P7458, DOI 10.1073/pnas.78.12.7458; GARMENDIA C, 1990, GENE, V88, P73, DOI 10.1016/0378-1119(90)90061-U; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HARAYAMA S, 1990, MOL GEN GENET, V221, P113, DOI 10.1007/BF00280375; HENIKOFF SJC, 1990, METHOD ENZYMOL, V183, P111; INOUYE S, 1986, GENE, V44, P235; INOUYE S, 1984, GENE, V29, P323; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MERMOD N, 1987, MOL GEN GENET, V207, P349, DOI 10.1007/BF00331600; MERMOD N, 1984, EMBO J, V3, P2461, DOI 10.1002/j.1460-2075.1984.tb02156.x; Miller J.H., 1972, EXPT MOL GENETICS; PABO CO, 1984, ANNU REV BIOCHEM, V53, P291; RAMOS JL, 1986, P NATL ACAD SCI USA, V83, P8467, DOI 10.1073/pnas.83.22.8467; RAMOS JL, 1990, NUCLEIC ACIDS RES, V18, P2149, DOI 10.1093/nar/18.8.2149; RAMOSGONZALEZ MI, 1992, J BACTERIOL, V174, P2978; RUSSEL M, 1984, J BACTERIOL, V159, P1034, DOI 10.1128/JB.159.3.1034-1039.1984; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORTLE D, 1978, P NATL ACAD SCI USA, V75, P2170, DOI 10.1073/pnas.75.5.2170; SPOONER RA, 1987, J BACTERIOL, V169, P3581, DOI 10.1128/jb.169.8.3581-3586.1987; SPOONER RA, 1986, J GEN MICROBIOL, V132, P1347; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOBIN JF, 1987, J MOL BIOL, V196, P789, DOI 10.1016/0022-2836(87)90405-0; TOBIN JF, 1990, J MOL BIOL, V211, P75, DOI 10.1016/0022-2836(90)90012-B; WEBSTER C, 1989, GENE, V83, P207, DOI 10.1016/0378-1119(89)90106-6; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHOU LM, 1990, J BACTERIOL, V172, P3707, DOI 10.1128/jb.172.7.3707-3710.1990	32	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22897	22901						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429638				2022-12-25	WOS:A1992JY16300031
J	SHIRAISHI, F; SAVAGEAU, MA				SHIRAISHI, F; SAVAGEAU, MA			THE TRICARBOXYLIC-ACID CYCLE IN DICTYOSTELIUM-DISCOIDEUM .2. EVALUATION OF MODEL CONSISTENCY AND ROBUSTNESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOCHEMICAL SYSTEMS-THEORY	When kinetic models of complex biochemical systems are reconstructed from knowledge of the component reactions that have been characterized in vitro, or when values must be assumed for some of the parameters, errors are invariably encountered, and, as a consequence, the resulting model is frequently internally inconsistent. The simplest and most basic manifestations of such logical inconsistency are the failure of the model to exhibit a steady state or to yield a steady state that is in agreement with the actual steady state of the integrated system, or to yield a steady state that is dynamically stable. Models that are consistent may nonetheless be lacking in robustness, which is manifested as a pathological sensitivity to small changes in the values of their parameters. In this paper, we examine the current model of the tricarboxylic acid cycle in Dictyostelium discoideum (see Shiraishi, F., and Savageau, M. A. (1992) J. Biol. Chem. 267, 22912-22918) with regard to these basic indicators of model quality. This may be viewed as a preliminary analysis; the object is to determine whether or not the model is reasonable and worthy of a more refined analysis and, if not, to diagnose the areas in need of modification before further analysis is undertaken. The results demonstrate that the current model of the tricarboxylic acid cycle is self-consistent and possesses a steady state that is in agreement with experimental evidence. However, the results also suggest that this model is not very robust. The high sensitivities of parameters influencing pyruvate metabolism indicate that the experimental characterization of these reactions might be fruit-fully re-examined. These high sensitivities lead us to predict that this model of the tricarboxylic acid cycle should be accurate only over a very narrow range in variation of the independent variables. This is verified by the results presented in the following paper (Shiraishi, F., and Savageau, M. A. (1992) J. Biol. Chem. 267,22926-22933).	UNIV MICHIGAN,SCH MED,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030054] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-30054] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bode H. W., 1945, NETWORK ANAL FEEDBAC; CRUZ JB, 1973, SYSTEM SENSITIVITY A; IRVINE DH, 1991, CANONICAL NONLINEAR, P90; KELLY PJ, 1979, BIOCHEM J, V184, P589, DOI 10.1042/bj1840589; KELLY PJ, 1979, BIOCHEM J, V184, P581, DOI 10.1042/bj1840581; OKAMOTO M, 1984, BIOCHEMISTRY-US, V23, P1701, DOI 10.1021/bi00303a019; Savageau M, 1976, BIOCH SYSTEMS ANAL S; SAVAGEAU M. A., 1972, CURR TOP CELL REGUL, V6, P63, DOI DOI 10.1016/B978-0-12-152806-5.50010-2; SAVAGEAU MA, 1985, BIOMED BIOCHIM ACTA, V44, P875; SAVAGEAU MA, 1989, J THEOR BIOL, V141, P93, DOI 10.1016/S0022-5193(89)80011-6; SAVAGEAU MA, 1969, J THEOR BIOL, V25, P370, DOI 10.1016/S0022-5193(69)80027-5; SAVAGEAU MA, 1971, ARCH BIOCHEM BIOPHYS, V145, P612, DOI 10.1016/S0003-9861(71)80021-8; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22912; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22926; SORRIBAS A, 1989, MATH BIOSCI, V94, P239, DOI 10.1016/0025-5564(89)90066-7; SORRIBAS A, 1989, MATH BIOSCI, V94, P161, DOI 10.1016/0025-5564(89)90064-3; VOIT EO, 1990, USERS GUIDE ESSYNS; WRIGHT BE, 1992, J BIOL CHEM, V267, P3101	18	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22919	22925						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429642				2022-12-25	WOS:A1992JY16300035
J	MOSS, ML; PALMER, RE; KUZMIC, P; DUNLAP, BE; HENZEL, W; KOFRON, JL; MELLON, WS; ROYER, CA; RICH, DH				MOSS, ML; PALMER, RE; KUZMIC, P; DUNLAP, BE; HENZEL, W; KOFRON, JL; MELLON, WS; ROYER, CA; RICH, DH			IDENTIFICATION OF ACTIN AND HSP-70 AS CYCLOSPORINE-A BINDING-PROTEINS BY PHOTOAFFINITY-LABELING AND FLUORESCENCE DISPLACEMENT ASSAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOPHILIN; FK-506; CALCINEURIN; ACTIVATION; PROFILIN	A novel family of cyclosporin A (CsA) binding proteins was identified by using the biologically active, radioiodinated photoaffinity probe [D-Lys-N(epsilon)-(4-azido-3-[I-125]iodophenyl)propionyl)]8-CsA. In addition to cyclophilin, proteins with molecular masses of 43 kDa and approximately 50-55 kDa were labeled in Jurkat extracts and bovine calf thymus. Sequence analysis of the 43-kDa protein purified from calf thymus and subsequent Western analysis of CsA affinity-purified material from Jurkat extracts identified the 43-kDa component as actin. [D-Lys-N(epsilon)-(5-dimethylamino-1-naphthalenesulfonyl)]8-CsA, a fluorescent analogue of CsA, was prepared and used to measure the binding constants of cyclosporin derivatives to actin by means of a new fluorescence displacement assay. [D-Lys-N(epsilon)-(5-dimethylamino-1-naphthalenesulfonyl)]8-CsA and [N(delta)-t-butoxycarbonyl diaminobutyryl)]8-CsA bind to bovine actin at physiologically relevant concentrations, with dissociation constants of 60 +/- 33 and 570 +/- 380 nM, respectively. Because the ATPase fragment of heat shock cognate 70 (HSC 70) is structurally related to actin, the yeast homologue SSA1 was tested and found to be radiolabeled by the cyclosporin A photoaffinity reagent. The binding constant for [D-Lys-N(epsilon)-(5-dimethylamino-1-naphthalenesulfonyl)]8-CsA to SSA1 was determined and is 53 +/- 48 nM. These results indicate that actin and the 70-kDa heat shock protein family contain a structurally related domain for binding of cyclosporin A-related peptides.	UNIV WISCONSIN,SCH PHARM,425 N CHARTER ST,MADISON,WI 53706; UNIV WISCONSIN,DEPT CHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			Royer, Catherine A/E-5266-2016	Royer, Catherine A/0000-0002-2670-3391; Henzel, William/0000-0003-2940-3797; Kuzmic, Petr/0000-0001-5250-8381	NIAID NIH HHS [AI24650] Funding Source: Medline; NIAMS NIH HHS [AR32007] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024650] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032007] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AEBI JD, 1990, J MED CHEM, V33, P999, DOI 10.1021/jm00165a018; BOREL JF, 1983, TRANSPL P, V15, P2219; BOREL JF, 1989, PHARMACOL REV, V41, P423; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; COLUCCI WJ, 1990, J ORG CHEM, V55, P2895, DOI 10.1021/jo00296a061; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FISCHER G, 1984, BIOCHIM BIOPHYS ACTA, V791, P87, DOI 10.1016/0167-4838(84)90285-1; FLANAGAN WM, 1991, NATURE, V352, P802; FOXWELL BMJ, 1989, MOL PHARMACOL, V36, P543; GOLDSCHMIDTCLERMONT PJ, 1991, CELL, V66, P419, DOI 10.1016/0092-8674(81)90002-7; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HENZEL W, 1987, J CHROMATOGR, V404, P4152; HESS AD, 1983, TRANSPLANT P 17, V1, P1419; INGLESE J, 1989, J MED CHEM, V32, P937, DOI 10.1021/jm00125a002; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KOCK M, 1992, J AM CHEM SOC, V114, P2676; KOFRON JL, 1992, J AM CHEM SOC, V114, P2670, DOI 10.1021/ja00033a047; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; KUZMIC P, 1992, ANAL BIOCHEM, V205, P65, DOI 10.1016/0003-2697(92)90579-V; LAL AA, 1985, J BIOL CHEM, V260, P132; LIN CS, 1991, CELL IMMUNOL, V133, P269, DOI 10.1016/0008-8749(91)90103-I; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOWNDES J, 1988, ANAL BIOCHEM, V80, P2849; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; PALASZYNSKI EW, 1991, CLIN BIOCHEM, V24, P63, DOI 10.1016/0009-9120(91)90252-A; RICH DH, 1990, PEPTIDES CHEM STRUCT, P49; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; RUOHO AE, 1984, MEMBRANES DETERGENTS, P119; SCOLARI F, 1987, TRANSPLANT P, V19, P1745; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SUNDELL CL, 1991, SCIENCE, V253, P1181; TUNG R, 1989, UCLA S MOL CELL BIOL, V86, P321; YEM AW, 1992, J BIOL CHEM, V267, P2868	35	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22054	22059						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429556				2022-12-25	WOS:A1992JW71900014
J	ROGEL, A; HANSKI, E				ROGEL, A; HANSKI, E			DISTINCT STEPS IN THE PENETRATION OF ADENYLATE-CYCLASE TOXIN OF BORDETELLA-PERTUSSIS INTO SHEEP ERYTHROCYTES - TRANSLOCATION OF THE TOXIN ACROSS THE MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI HEMOLYSIN; CALMODULIN-BINDING; IDENTIFICATION; PROTEINS; CALCIUM; PURIFICATION; DOMAINS; HLYA; EXPRESSION; ACTIVATION	Adenylate cyclase (AC) toxin from Bordetella pertussis penetrates eukaryotic cells and upon activation by calmodulin generates unregulated levels of intracellular cAMP. The process of toxin penetration into sheep erythrocytes was resolved into three consecutive steps including insertion, translocation, and intracellular cleavage. Insertion of the toxin into the cell membrane occurred over a wide temperature range (4-36-degrees-C). In contrast, translocation of the toxin, i.e. transfer of the NH2-terminal catalytically active fragment across the membrane, occurred only above 20-degrees-C and was highly temperature-dependent. While a single exposure of the toxin to Ca2+ was sufficient for its insertion into the plasma membrane, toxin translocation required exogenous Ca2+ at mM concentrations. Translocation was not affected by pretreatment of cells with trypsin, N-ethylmaleimide, and sodium carbonate at alkaline PH. The NH2-terminal fragment of the toxin was cleaved in the cell releasing the 45-kDa active AC into the cytosol. The cleavage was blocked by treatment of cells with N-ethylmaleimide. It is hypothesized that the COOH-terminal portion of the toxin creates in the membrane a channel through which the NH2-terminal fragment is translocated.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT CLIN MICROBIOL,IL-91010 JERUSALEM,ISRAEL	Hebrew University of Jerusalem			hanski, emanuel/M-2696-2018	hanski, emanuel/0000-0001-5054-0628				ALLEN DW, 1979, BIOCHIM BIOPHYS ACTA, V551, P1, DOI 10.1016/0005-2736(79)90348-1; BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; BELLALOU J, 1990, INFECT IMMUN, V58, P1195, DOI 10.1128/IAI.58.5.1195-1200.1990; BELLALOU J, 1990, INFECT IMMUN, V58, P3242, DOI 10.1128/IAI.58.10.3242-3247.1990; BENZ R, 1989, INFECT IMMUN, V57, P887, DOI 10.1128/IAI.57.3.887-895.1989; BISSON R, 1987, TRENDS BIOCHEM SCI, V12, P181, DOI 10.1016/0968-0004(87)90087-9; BOEHM DF, 1990, INFECT IMMUN, V58, P1959, DOI 10.1128/IAI.58.6.1959-1964.1990; BOEHM DF, 1990, INFECT IMMUN, V58, P1951, DOI 10.1128/IAI.58.6.1951-1958.1990; BROWNLIE RM, 1988, MICROB PATHOGENESIS, V4, P335, DOI 10.1016/0882-4010(88)90061-7; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; CONFER DL, 1984, ADV CYCLIC NUCL PROT, V17, P183; CROALL DE, 1986, BIOCHIM BIOPHYS ACTA, V882, P287, DOI 10.1016/0304-4165(86)90250-3; EHRMANN IE, 1991, FEBS LETT, V1, P79; FARFEL Z, 1987, BIOCHEM J, V243, P153, DOI 10.1042/bj2430153; FRIEDMAN E, 1987, BIOCHEM J, V243, P145, DOI 10.1042/bj2430145; GENTILE F, 1990, J BIOL CHEM, V265, P10686; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GLASER P, 1989, EMBO J, V8, P967, DOI 10.1002/j.1460-2075.1989.tb03459.x; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; HANSKI E, 1989, TRENDS BIOCHEM SCI, V14, P459, DOI 10.1016/0968-0004(89)90106-0; HANSKI E, 1985, J BIOL CHEM, V260, P5526; HEWLETT EL, 1983, CLIN RES, V31, pA365; HEWLETT EL, 1991, J BIOL CHEM, V266, P17503; HEWLETT EL, 1989, J BIOL CHEM, V264, P19379; HEWLETT EL, 1990, DHHS901164 US PHS DE, P13; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; LADANT D, 1988, J BIOL CHEM, V263, P2612; LADANT D, 1989, J BIOL CHEM, V264, P4015; LADANT D, 1986, J BIOL CHEM, V261, P6264; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDWIG A, 1988, MOL GEN GENET, V214, P553, DOI 10.1007/BF00330494; LUDWIG A, 1991, MOL GEN GENET, V193, P312; MASURE HR, 1988, J BIOL CHEM, V263, P6933; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; ROGEL A, 1988, J BIOL CHEM, V263, P13310; ROGEL A, 1989, EMBO J, V8, P2755, DOI 10.1002/j.1460-2075.1989.tb08417.x; ROGEL A, 1991, J BIOL CHEM, V266, P3154; SHATTUCK RL, 1985, BIOCHEMISTRY-US, V2, P6356; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISS AA, 1986, ANNU REV MICROBIOL, V40, P661, DOI 10.1146/annurev.micro.40.1.661; WELCH RA, 1991, MOL MICROBIOL, V5, P521, DOI 10.1111/j.1365-2958.1991.tb00723.x; WOLFF J, 1980, P NATL ACAD SCI-BIOL, V77, P3841, DOI 10.1073/pnas.77.7.3841	43	103	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22599	22605						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429610				2022-12-25	WOS:A1992JW71900095
J	BENNETT, JL; SUNJOO, JY; CLAYTON, DA				BENNETT, JL; SUNJOO, JY; CLAYTON, DA			CHARACTERIZATION OF A XENOPUS-LAEVIS RIBONUCLEOPROTEIN ENDORIBONUCLEASE - ISOLATION OF THE RNA COMPONENT AND ITS EXPRESSION DURING DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE MITOCHONDRIAL-DNA; NUCLEOLAR 7-2 RNA; SECONDARY STRUCTURE; AMPHIBIAN OOCYTES; OCTAMER MOTIF; RIBOSOMAL-RNA; NUCLEAR GENE; U3 SNRNA; MRP; SITE	In order to facilitate studies of the assembly and transport of the site-specific RNase mitochondrial RNA processing (MRP) ribonucleoprotein, we have characterized it from Xenopus laevis cells. X. laevis RNase MRP displayed a similar spectrum of cleavage activity to that produced by previously isolated mammalian nuclear enzymes. A 277-nucleotide RNA component of the ribonucleoprotein was identified; the gene for the RNA was isolated, sequenced, and found to be 66 and 63% similar to mouse and human RNase MRP RNAs, respectively. Despite the evolutionary distance from its mammalian counterparts, X. laevis RNase MRP RNA contains five regions of homology to the mammalian RNase MRP RNA. Four of these regions correspond to those previously identified as conserved between RNase MRP and RNase P RNAs; the fifth encompasses nucleotides recently discovered to be sufficient for autoantigen binding. The expression and assembly of Xenopus RNase MRP RNA were examined in frog oocytes and developing embryos. RNase MRP RNA was expressed throughout oogenesis; it started to accumulate at stage I and reached a maximum in stage IV. During embryogenesis RNase MRP RNA expression began to elevate at approximately stage 22 and continued to rise through the swimming tadpole stage. When injected into the nucleus of mature oocytes, the X. laevis RNase MRP RNA gene was expressed accurately, and transcripts were packaged into immunoprecipitable particles.			BENNETT, JL (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365, R01GM033088, R37GM033088] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33088-21, GM07365-15] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATCHISON ML, 1990, EMBO J, V9, P3109, DOI 10.1002/j.1460-2075.1990.tb07508.x; BENNETT JL, 1990, MOL CELL BIOL, V10, P2191, DOI 10.1128/MCB.10.5.2191; BIRD AP, 1971, CHROMOSOMA, V35, P300, DOI 10.1007/BF00326280; BROWN DD, 1968, SCIENCE, V160, P272, DOI 10.1126/science.160.3825.272; BROWN DD, 1964, J MOL BIOL, V8, P669, DOI 10.1016/S0022-2836(64)80116-9; BROWN JW, 1990, CELL, V62, P407, DOI 10.1016/0092-8674(90)90003-W; CAIZERGUESFERRER M, 1991, DEVELOPMENT, V112, P317; CALLEN JC, 1983, EXP CELL RES, V143, P115, DOI 10.1016/0014-4827(83)90114-3; CHANG DD, 1989, CELL, V56, P131, DOI 10.1016/0092-8674(89)90991-4; CHANG DD, 1985, EMBO J, V4, P1559, DOI 10.1002/j.1460-2075.1985.tb03817.x; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; CHANG DD, 1987, SCIENCE, V235, P1178, DOI 10.1126/science.2434997; CHASE JW, 1972, DEV BIOL, V27, P504, DOI 10.1016/0012-1606(72)90189-3; CONDIE BG, 1987, DEVELOPMENT, V101, P93; CURRIE RA, 1989, MOL CELL BIOL, V9, P4239, DOI 10.1128/MCB.9.10.4239; Davidson E. H., 1986, GENE ACTIVITY EARLY; DORIA M, 1991, NUCLEIC ACIDS RES, V19, P2315, DOI 10.1093/nar/19.9.2315; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; ELMEZIANE A, 1989, EMBO J, V8, P1649, DOI 10.1002/j.1460-2075.1989.tb03555.x; FORBES DJ, 1983, J CELL BIOL, V97, P62, DOI 10.1083/jcb.97.1.62; GALL JG, 1968, P NATL ACAD SCI USA, V60, P553, DOI 10.1073/pnas.60.2.553; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; GOLD HA, 1989, SCIENCE, V245, P1377, DOI 10.1126/science.2476849; HAMM J, 1990, RNA PROCESSING B; HASHIMOTO C, 1983, J BIOL CHEM, V258, P1379; HEASMAN J, 1984, DEV BIOL, V105, P458, DOI 10.1016/0012-1606(84)90303-8; HINKLEY CS, 1992, MOL CELL BIOL, V12, P638, DOI 10.1128/MCB.12.2.638; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; JAMES BD, 1988, CELL, V52, P19, DOI 10.1016/0092-8674(88)90527-2; KARWAN R, 1991, GENE DEV, V5, P1264, DOI 10.1101/gad.5.7.1264; KRESSMANN A, 1977, COLD SPRING HARB SYM, V42, P1077; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; MATTAJ IW, 1988, STRUCTURE FUNCTION M, P100; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; PARRY HD, 1989, NUCLEIC ACIDS RES, V17, P3633, DOI 10.1093/nar/17.10.3633; REDDY R, 1983, J BIOL CHEM, V258, P1383; REIMER G, 1988, EXP CELL RES, V176, P117, DOI 10.1016/0014-4827(88)90126-7; ROE BA, 1985, J BIOL CHEM, V260, P9759; SAVINO R, 1990, EMBO J, V9, P2299, DOI 10.1002/j.1460-2075.1990.tb07401.x; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STEPHENS DL, 1981, ANAL BIOCHEM, V114, P299, DOI 10.1016/0003-2697(81)90485-1; TAYLOR MA, 1985, DEV BIOL, V110, P230, DOI 10.1016/0012-1606(85)90079-X; TOLLERVEY D, 1987, EMBO J, V6, P469, DOI 10.1002/j.1460-2075.1987.tb04777.x; TOPPER JN, 1990, NUCLEIC ACIDS RES, V18, P793, DOI 10.1093/nar/18.4.793; TOPPER JN, 1990, J BIOL CHEM, V265, P13254; WALLACE RA, 1973, J EXP ZOOL, V184, P321, DOI 10.1002/jez.1401840305; WEBB AC, 1977, DEV BIOL, V56, P219, DOI 10.1016/0012-1606(77)90166-X; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; YUAN Y, 1989, J BIOL CHEM, V264, P14835; YUAN Y, 1991, BIOCHIM BIOPHYS ACTA, V1089, P33, DOI 10.1016/0167-4781(91)90081-V; YUAN Y, 1991, MOL CELL BIOL, V11, P5266, DOI 10.1128/MCB.11.10.5266	52	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21765	21772						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1383227				2022-12-25	WOS:A1992JV01100079
J	MARRERO, PF; POULTER, CD; EDWARDS, PA				MARRERO, PF; POULTER, CD; EDWARDS, PA			EFFECTS OF SITE-DIRECTED MUTAGENESIS OF THE HIGHLY CONSERVED ASPARTATE RESIDUES IN DOMAIN-II OF FARNESYL DIPHOSPHATE SYNTHASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYROPHOSPHATE SYNTHETASE; SACCHAROMYCES-CEREVISIAE; CAROTENOID BIOSYNTHESIS; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; ESCHERICHIA-COLI; GENE; PRENYLTRANSFERASE; IDENTIFICATION; PURIFICATION	Comparison of the farnesyl diphosphate (FPP) synthase amino acid sequences from four species with amino acid sequences from the related enzymes hexaprenyl diphosphate synthase and geranylgeranyl diphosphate synthase show the presence of two aspartate rich highly conserved domains. The aspartate motif ((I, L, or V)XDDXXD) of the second of those domains has homology with at least 9 prenyl transfer enzymes that utilize an allylic prenyl diphosphate as one substrate. In order to investigate the role of this second aspartate-rich domain in rat FPP synthase, we mutated the first or third aspartate to glutamate, expressed the wild-type and mutant enzymes in Escherichia coli, and purified them to apparent homogeneity using a single chromatographic step. Approximately 12 mg of homogeneous protein was isolated from 120 mg of crude bacterial extract. The kinetic parameters of the purified wild-type recombinant FPP synthase containing the DDYLD motif were as follows: V(max) = 0.84 mumol/min/mg; GPP K(m) = 1.0 muM; isopentenyl diphosphate (IPP) K(m) = 2.7 muM. Substitution of glutamate for the first aspartate (EDYLD) decreased the V(max) by over 90-fold. The K(m) for IPP increased, whereas the K(m) for GPP remained the same in this D243E mutant. Substitution of glutamate for the third aspartate (DDYLE) did not result in altered enzyme kinetics in the D247E mutant. These results suggest that the first aspartate in the second domain is involved in the catalysis by FPP synthase.	UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; UNIV UTAH,DEPT CHEM,SALT LAKE CITY,UT 84112	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Utah System of Higher Education; University of Utah			Marrero, Pedro F/I-1919-2015		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30568] Funding Source: Medline; NIGMS NIH HHS [GM 21326] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; ARMSTRONG GA, 1990, P NATL ACAD SCI USA, V87, P9975, DOI 10.1073/pnas.87.24.9975; ASHBY MN, 1992, J BIOL CHEM, V267, P4128; ASHBY MN, 1989, J BIOL CHEM, V264, P635; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; ASHBY MN, 1960, J BIOL CHEM, V1, P286; ASHBY MN, 1990, MOL BIOL ATHEROSCLER, P27; BARNARD GF, 1981, BIOCHIM BIOPHYS ACTA, V661, P87, DOI 10.1016/0005-2744(81)90086-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARATTOLI A, 1991, J BIOL CHEM, V266, P5854; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; EBERHARDT NL, 1975, J BIOL CHEM, V250, P863; FUJISAKI S, 1986, J BIOCHEM-TOKYO, V99, P1327, DOI 10.1093/oxfordjournals.jbchem.a135600; FUJISAKI S, 1990, J BIOCHEM-TOKYO, V108, P995, DOI 10.1093/oxfordjournals.jbchem.a123327; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOODMAN DS, 1960, J LIPID RES, V1, P286; HOLLOWAY PW, 1967, BIOCHEM J, V104, P57, DOI 10.1042/bj1040057; ITAKURA K, 1984, ANNU REV BIOCHEM, V53, P323; JENNINGS SM, 1991, P NATL ACAD SCI USA, V88, P6038, DOI 10.1073/pnas.88.14.6038; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOVICS FM, 1981, BIOCHEMISTRY-US, V20, P1893, DOI 10.1021/bi00510a027; LASKOVICS FM, 1979, J BIOL CHEM, V254, P9458; Maniatis T., 1982, MOL CLONING; PIDZKIEWICZ D, 1977, KINETICS CHEM ENZYME, P127; Poulter C. D., 1981, BIOSYNTHESIS ISOPREN, V1, P161; POULTER CD, 1990, ACCOUNTS CHEM RES, V23, P70, DOI 10.1021/ar00171a003; POULTER CD, 1990, BIOCH CELL WALLS MEM, P169; REED BC, 1975, BIOCHEMISTRY-US, V14, P50, DOI 10.1021/bi00672a009; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STREET IP, 1990, BIOCHEMISTRY-US, V29, P7531, DOI 10.1021/bi00484a023; TERUYA JH, 1990, MOL CELL BIOL, V10, P2315, DOI 10.1128/MCB.10.5.2315; WILKIN DJ, 1990, J BIOL CHEM, V265, P4607; YEH LS, 1977, ARCH BIOCHEM BIOPHYS, V183, P718, DOI 10.1016/0003-9861(77)90405-2	33	128	138	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21873	21878						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400496				2022-12-25	WOS:A1992JV01100094
J	SUGAI, M; CHEN, CH; WU, HC				SUGAI, M; CHEN, CH; WU, HC			STAPHYLOCOCCAL ADP-RIBOSYLTRANSFERASE-SENSITIVE SMALL G-PROTEIN IS INVOLVED IN BREFELDIN-A ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING PROTEIN; PERIPHERAL MEMBRANE-PROTEIN; RHO-GENE-PRODUCT; GOLGI-APPARATUS; INTRACELLULAR-TRANSPORT; RAT HEPATOCYTES; COATED VESICLES; BETA-COP; CELLS; PURIFICATION	An early event in the action of brefeldin A (BFA) is the dissociation of beta-coat protein (beta-COP) from the Golgi membrane. We have recently shown that staphylococcal ADP-ribosyltransferase (epidermal cell differentiation inhibitor (EDIN)), which specifically modifies a small G protein, rho, mimics the action of BFA and disassembles the Golgi apparatus in Vero cells (Sugai, M., Chen, C-h., and Wu, H. C. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 8903-8907). Three independent BFA-resistant cell lines (BER-40 from Vero cells, PtK1, and MDCK) showed cross-resistance to EDIN regarding the release of the beta-COP from the Golgi membrane by EDIN or BFA. BFA as well as EDIN induced disassembly of the actin microfilaments in Vero cells, and they both failed to induce the disassembly of actin microfilaments in BER-40, PtK1, and MDCK cells. BFA inhibited protein secretion in Vero cells but not in BFA-resistant cell lines, whereas EDIN did not inhibit protein secretion in either Vero or other cell lines. AlF4- inhibited the effect of EDIN as well as that of BFA on the distribution of the beta-COP. These results suggest that an EDIN-sensitive rho protein together with trimeric and other small G protein(s) is involved in the regulation of the assembly of coated vesicles and vesicular transport in the Golgi apparatus.			WU, HC (corresponding author), UNIFORMED SERV UNIV HLTH SCI, DEPT MICROBIOL, BETHESDA, MD 20814 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028810] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28810] Funding Source: Medline; PHS HHS [R07317] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHEN C, 1992, IN PRESS EXP CELL RE; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HOSHIJIMA M, 1990, MOL BRAIN RES, V7, P9, DOI 10.1016/0169-328X(90)90067-N; HSU VW, 1992, CELL, V69, P625, DOI 10.1016/0092-8674(92)90226-3; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; OGOROCHI T, 1989, BIOCHEM BIOPH RES CO, V163, P1175, DOI 10.1016/0006-291X(89)92344-9; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1991, CELL, V64, P1183; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SUGAI M, 1990, BIOCHEM BIOPH RES CO, V173, P92, DOI 10.1016/S0006-291X(05)81026-5; SUGAI M, 1992, P NATL ACAD SCI USA, V89, P8903, DOI 10.1073/pnas.89.19.8903; SUGAI M, 1992, J BIOL CHEM, V267, P2600; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAKATSUKI A, 1985, AGR BIOL CHEM TOKYO, V49, P899, DOI 10.1080/00021369.1985.10866826; YOSHIDA T, 1990, EXP CELL RES, V190, P11, DOI 10.1016/0014-4827(90)90137-Y	34	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21297	21299						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400440				2022-12-25	WOS:A1992JV01100007
J	METZ, DC; PATTO, RJ; MROZINSKI, JE; JENSEN, RT; TURNER, RJ; GARDNER, JD				METZ, DC; PATTO, RJ; MROZINSKI, JE; JENSEN, RT; TURNER, RJ; GARDNER, JD			THAPSIGARGIN DEFINES THE ROLES OF CELLULAR CALCIUM IN SECRETAGOGUE-STIMULATED ENZYME-SECRETION FROM PANCREATIC ACINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE CYTOSOLIC CALCIUM; GUINEA-PIG PANCREAS; AMYLASE RELEASE; INOSITOL TRISPHOSPHATE; TUMOR PROMOTER; PLASMA-MEMBRANE; SIGNAL TRANSDUCTION; EXOCRINE PANCREAS; DISPERSED ACINI; CYCLIC-AMP	In the present study we used thapsigargin (TG), an inhibitor of microsomal calcium ATPase, to evaluate the roles of free cytoplasmic calcium and intracellular stored calcium in secretagogue-stimulated enzyme secretion from rat pancreatic acini. Using microspectro-fluorimetry of fura-2-loaded pancreatic acini, we found that TG caused a sustained increase in free cytoplasmic calcium by mobilizing calcium from inositol 1, 4, 5-trisphosphate-sensitive intracellular stores and by increasing influx of extracellular calcium. TG also caused a small increase in basal amylase secretion, inhibited the stimulation of amylase secretion caused by secretagogues that increase inositol 1, 4, 5-trisphosphate, and potentiated the stimulation of amylase secretion caused by 12-O-tetradecanoylphorbol-13-acetate or secretagogues that increase cyclic adenosine 3',5'-monophosphate. Bombesin, which like TG increased free cytoplasmic calcium, also potentiated the stimulation of amylase secretion caused by secretagogues that increase cyclic adenosine 3',5'-monophosphate, but did not inhibit the stimulation of amylase secretion caused by secretagogues that increase inositol 1, 4, 5-trisphosphate. Finally, TG inhibited the sustained phase of cholecystokinin-stimulated amylase secretion and potentiated the time course of vasoactive intestinal peptide-stimulated amylase secretion. The present findings indicate that stimulation of amylase secretion by secretagogues that increase inositol 1, 4, 5-trisphosphate does not depend on increased free cytoplasmic calcium per se. In contrast, TG-induced potentiation of the stimulation of secretagogues that increase cellular cyclic adenosine 3',5'-monophosphate appears to result from increased free cytoplasmic calcium per se.	NIDR,CLIN INVEST & PATIENT CARE BRANCH,BETHESDA,MD 20892; NIDDKD,DIGEST DIS BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ABDELLATIF AA, 1986, PHARMACOL REV, V38, P227; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BISSONNETTE BM, 1984, AM J PHYSIOL, V246, pG710, DOI 10.1152/ajpgi.1984.246.6.G710; CESKA M, 1969, CLIN CHIM ACTA, V26, P445, DOI 10.1016/0009-8981(69)90072-2; CESKA M, 1969, CLIN CHIM ACTA, V26, P437, DOI 10.1016/0009-8981(69)90071-0; CHEW CS, 1991, CELL REGUL, V2, P27, DOI 10.1091/mbc.2.1.27; DORMER RL, 1984, BIOCHEM BIOPH RES CO, V119, P876, DOI 10.1016/0006-291X(84)90855-6; ELY JA, 1991, J BIOL CHEM, V266, P18635; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; GARDNER JD, 1977, J PHYSIOL-LONDON, V270, P439, DOI 10.1113/jphysiol.1977.sp011961; GARDNER JD, 1987, PHYSL GASTROINTESTIN, P1109; GARDNER JD, 1977, AM J PHYSIOL, V236, pE754; GARDNER JD, 1980, AM J PHYSIOL, pG458; GARDNER JD, 1981, PHYSL GASTROINTESTIN, P831; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOOTMAN SR, 1987, PHYSL GASTROINTESTIN, P1129; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; JENSEN RT, 1982, J BIOL CHEM, V257, P5554; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; KASS GEN, 1990, J BIOL CHEM, V265, P17486; KRAUSE KH, 1989, CELL CALCIUM, V10, P351, DOI 10.1016/0143-4160(89)90061-4; KRIMS PE, 1988, PANCREAS, V3, P383, DOI 10.1097/00006676-198808000-00003; KURAN CY, 1990, AM J PHYSIOL, V258, pC1006; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MATOZAKI T, 1989, J BIOL CHEM, V264, P14729; MERRITT JE, 1987, J BIOL CHEM, V262, P17362; MUALLEM S, 1988, AM J PHYSIOL, V255, pG229, DOI 10.1152/ajpgi.1988.255.2.G229; MUALLEM S, 1990, J BIOL CHEM, V265, P2011; MUALLEM S, 1989, ANNU REV PHYSIOL, V51, P83; MUALLEM S, 1988, AM J PHYSIOL, V255, pG221, DOI 10.1152/ajpgi.1988.255.2.G221; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OCHS DL, 1985, AM J PHYSIOL, V249, pG389, DOI 10.1152/ajpgi.1985.249.3.G389; OGAMI Y, 1989, JPN J PHYSIOL, V39, P571, DOI 10.2170/jjphysiol.39.571; OHUCHI K, 1988, BRIT J PHARMACOL, V94, P917, DOI 10.1111/j.1476-5381.1988.tb11604.x; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PANDOL SJ, 1985, J BIOL CHEM, V260, P81; PANDOL SJ, 1989, CELL CALCIUM, V10, P255, DOI 10.1016/0143-4160(89)90008-0; PEIKIN SR, 1978, AM J PHYSIOL-ENDOC M, V235, P743; PETERSEN OH, 1991, CELL CALCIUM, V12, P135, DOI 10.1016/0143-4160(91)90015-7; POWERS RE, 1985, AM J PHYSIOL, V248, pC535, DOI 10.1152/ajpcell.1985.248.5.C535; PRALONG WF, 1988, FEBS LETT, V242, P7984; PUTNEY JW, 1983, BIOCHEM J, V212, P483, DOI 10.1042/bj2120483; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; SATO S, 1989, AM J PHYSIOL, V257, pG202, DOI 10.1152/ajpgi.1989.257.2.G202; SCHEELE G, 1979, J BIOL CHEM, V254, P346; STREB H, 1983, NATURE, V306, P6769; STUENKEL EL, 1989, BIOCHEM BIOPH RES CO, V158, P863, DOI 10.1016/0006-291X(89)92802-7; TAKEMURA H, 1990, CELL CALCIUM, V11, P11, DOI 10.1016/0143-4160(90)90044-U; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; TRIMBLE ER, 1986, BIOCHEM J, V239, P257, DOI 10.1042/bj2390257; TRIMBLE ER, 1987, P NATL ACAD SCI USA, V84, P3146, DOI 10.1073/pnas.84.10.3146; TSUNODA Y, 1990, AM J PHYSIOL, V259, pG792, DOI 10.1152/ajpgi.1990.259.5.G792; TSUNODA Y, 1990, AM J PHYSIOL, V258, pC147, DOI 10.1152/ajpcell.1990.258.1.C147; VALDEZ IH, 1991, AM J PHYSIOL, V261, pG359, DOI 10.1152/ajpgi.1991.261.2.G359; VOLPE P, 1988, P NATL ACAD SCI USA, V85, P1091, DOI 10.1073/pnas.85.4.1091; YULE DI, 1988, FEBS LETT, V239, P358, DOI 10.1016/0014-5793(88)80951-7	63	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20620	20629						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383205				2022-12-25	WOS:A1992JT97800021
J	WANG, F; MILLET, I; BOTTOMLY, K; VIGNERY, A				WANG, F; MILLET, I; BOTTOMLY, K; VIGNERY, A			CALCITONIN GENE-RELATED PEPTIDE INHIBITS INTERLEUKIN-2 PRODUCTION BY MURINE LYMPHOCYTES-T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL GROWTH-FACTOR; SKELETAL-MUSCLE; MESSENGER-RNA; EXPRESSION; CDNA; CGRP; ACTIVATION; CLONING; PROLIFERATION; NEUROPEPTIDE	Evidence from the literature suggests that the nervous and the immune systems closely interact via neuromediators, which affect the immune system, and cytokines, which control nerve cell growth and activity. Calcitonin gene-related peptide (CGRP) is a neuropeptide that has been identified in numerous tissues including immune organs and inhibits the proliferation of spleen cells. We investigated whether CGRP altered the function of T lymphocytes. We present evidence that CGRP induces a dose-dependent cAMP accumulation in interleukin 2-producing T(H1) cells and inhibits their production of interleukin 2. These effects are prevented by CGRP8-37, a CGRP antagonist that is missing the first 7 amino acids. This CGRP-mediated inhibition of interleukin 2 production is accompanied by a decrease in interleukin 2 mRNA accumulation. CGRP also inhibits the accumulation of mRNA coding for tumor necrosis factor-alpha and -beta and interferon-gamma. Thus, we have identified one mechanism by which CGRP inhibits the proliferation of spleen cells.	YALE UNIV, SCH MED, DEPT ORTHOPAED & REHABIL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT IMMUNOBIOL, NEW HAVEN, CT 06510 USA	Yale University; Yale University; Yale University; Yale University					NIADDK NIH HHS [AM 35004] Funding Source: Medline; NIAMS NIH HHS [AR01694] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM035004] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K04AR001694] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALVAREZ FJ, 1988, BRAIN RES, V442, P391, DOI 10.1016/0006-8993(88)91532-6; BELLINGER DL, 1990, ANN NY ACAD SCI, V594, P17; BENDTSEN F, 1991, J HEPATOL, V12, P118, DOI 10.1016/0168-8278(91)90920-7; BOTTOMLY K, 1991, CURRENT PROTOCOLS IM; CHIBA T, 1989, AM J PHYSIOL, V256, pE331, DOI 10.1152/ajpendo.1989.256.2.E331; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; GILLIS S, 1981, P NATL ACAD SCI-BIOL, V78, P1133, DOI 10.1073/pnas.78.2.1133; GILLIS S, 1978, J IMMUNOL, V120, P2027; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; Goetzl E J, 1990, Adv Immunol, V48, P161, DOI 10.1016/S0065-2776(08)60754-3; GRAY PW, 1983, P NATL ACAD SCI-BIOL, V80, P5842, DOI 10.1073/pnas.80.19.5842; HEIJNEN CJ, 1991, IMMUNOL REV, V119, P41, DOI 10.1111/j.1600-065X.1991.tb00577.x; HOPPENER JWM, 1987, J CLIN ENDOCR METAB, V64, P809; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KROEMER G, 1989, IMMUNOL TODAY, V10, P246, DOI 10.1016/0167-5699(89)90262-4; LAUFER R, 1987, EMBO J, V6, P901, DOI 10.1002/j.1460-2075.1987.tb04836.x; LEIGHTON B, 1988, NATURE, V335, P632, DOI 10.1038/335632a0; LI CB, 1987, J IMMUNOL, V138, P4496; LOTZ M, 1988, SCIENCE, V241, P1218, DOI 10.1126/science.2457950; LURIA S, 1991, P NATL ACAD SCI USA, V88, P5326, DOI 10.1073/pnas.88.12.5326; MCGILLIS JP, 1991, J IMMUNOL, V147, P3482; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; MUNOZ E, 1990, J EXP MED, V172, P95, DOI 10.1084/jem.172.1.95; NONG YH, 1989, J IMMUNOL, V143, P45; NOVAK TJ, 1990, P NATL ACAD SCI USA, V87, P9353, DOI 10.1073/pnas.87.23.9353; PAYAN DG, 1986, ADV IMMUNOL, V39, P299; PENNICA D, 1985, P NATL ACAD SCI USA, V82, P6060, DOI 10.1073/pnas.82.18.6060; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; RAPPAPORT RS, 1982, J EXP MED, V155, P943, DOI 10.1084/jem.155.3.943; ROBERTSON CN, 1990, J UROLOGY, V144, P614, DOI 10.1016/S0022-5347(17)39537-X; SAWADA S, 1987, J IMMUNOL, V139, P1797; SCHIFTER S, 1991, PEPTIDES, V12, P365, DOI 10.1016/0196-9781(91)90027-M; STEENBERGH PH, 1985, FEBS LETT, V183, P408, DOI 10.1016/0014-5793(85)80820-6; UMEDA Y, 1988, BIOCHEM BIOPH RES CO, V154, P227, DOI 10.1016/0006-291X(88)90674-2; VIGNERY A, 1991, AM J PHYSIOL, V261, pF1026, DOI 10.1152/ajprenal.1991.261.6.F1026; VIGNERY A, 1991, J CELL PHYSIOL, V149, P301, DOI 10.1002/jcp.1041490217; VIGNERY A, 1991, AM J PHYSIOL, V260, pF704, DOI 10.1152/ajprenal.1991.260.5.F704; VILLEMAIN F, 1987, ANN NY ACAD SCI, V496, P669, DOI 10.1111/j.1749-6632.1987.tb35828.x; YOKOTA T, 1985, P NATL ACAD SCI USA, V82, P68, DOI 10.1073/pnas.82.1.68; ZAIDI M, 1989, BIOCHEM BIOPH RES CO, V158, P214, DOI 10.1016/S0006-291X(89)80200-1; ZIER KS, 1984, DIABETES, V33, P552, DOI 10.2337/diabetes.33.6.552	42	101	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21052	21057						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383217				2022-12-25	WOS:A1992JT97800085
J	ASAI, K; NAKANISHI, K; ISOBE, I; EKSIOGLU, YZ; HIRANO, A; HAMA, K; MIYAMOTO, T; KATO, T				ASAI, K; NAKANISHI, K; ISOBE, I; EKSIOGLU, YZ; HIRANO, A; HAMA, K; MIYAMOTO, T; KATO, T			NEUROTROPHIC ACTION OF GLIOSTATIN ON CORTICAL-NEURONS - IDENTITY OF GLIOSTATIN AND PLATELET-DERIVED ENDOTHELIAL-CELL GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CILIARY NEURONOTROPHIC FACTOR; PURIFICATION; CULTURE; BRAIN; IDENTIFICATION; SPECIFICITY; EXPRESSION; CLONING; PROTEIN; GLIA	Gliostatin is a polypeptide growth inhibitor of apparent M(r) = 100,000 with a homodimeric structure comprising two 50-kDa subunits, acting on astrocyte as well as astrocytoma cells (Asai, K., Hirano, T., Kaneko, S., Moriyama, A., Nakanishi, K., Isobe, I., Eksioglu, Y. Z., and Kato, T. (1992) J. Neurochem., 59, 307-317). The amino acid sequences of 13 tryptic peptides including the amino terminus were completely identical to those of platelet-derived endothelial cell growth factor (PD-ECGF) (Ishikawa, F., Miyazono, K., Hellman, U., Drexler, H., Wernstedt, C., Hagiwara, K., Usuki, K., Takaku, F., Risau, W., and Heldin, C.-H. (1989) Nature 338, 557-562). Gliostatin and PD-ECGF, purified from human placenta, shared growth inhibition on glial cells and growth promotion on endothelial cells, and exhibited similar values for half-maximal dose of glial growth inhibition (ID50 = 1.3 nM) and the half-maximal concentration of endothelial growth promotion (EC50 = 1.0 nM), suggesting that both factors evoke the biological actions through an identical receptor on each cell surface. We have further demonstrated evidence of a novel neurotrophic action of gliostatin/PD-ECGF toward embryonic rat cortical neurons in culture. The half-maximal concentration of gliostatin/PD-ECGF for neurotrophic action was 0.3 nm. All actions on glial, endothelial, and neuronal cells, were abolished by a monoclonal antibody against gliostatin. These data indicate that gliostatin/PD-ECGF may play important roles on development and regeneration of the central nervous system and may also involve the induction of angiogenesis for the formation of blood brain barrier.	NAGOYA CITY UNIV,SCH MED,DEPT BIOREGULAT RES,MIZUHO KU,NAGOYA,AICHI 467,JAPAN; ONO PHARMACEUT CO LTD,MINASE RES INST,MISHIMA,OSAKA 618,JAPAN	Nagoya City University; Ono Pharmaceutical Co Ltd			Asai, Kiyofumi/H-2356-2014	Asai, Kiyofumi/0000-0001-7015-2251				ASAI K, 1992, J NEUROCHEM, V59, P307, DOI 10.1111/j.1471-4159.1992.tb08905.x; ASAI K, 1991, BRAIN RES, V556, P344, DOI 10.1016/0006-8993(91)90328-S; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BARBIN G, 1984, J NEUROCHEM, V43, P1468, DOI 10.1111/j.1471-4159.1984.tb05410.x; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; BOOYSE FM, 1975, THROMB DIATH HAEMOST, V34, P825, DOI 10.1055/s-0038-1654001; DOHERTY P, 1984, J NEUROCHEM, V42, P116; EASTER SS, 1985, SCIENCE, V230, P507, DOI 10.1126/science.4048944; ENGELE J, 1991, J NEUROSCI, V11, P3070; FURUKAWA S, 1986, BIOCHEM BIOPH RES CO, V136, P57, DOI 10.1016/0006-291X(86)90876-4; FURUKAWA T, 1992, NATURE, V356, P668, DOI 10.1038/356668a0; HASHIDA S, 1984, Journal of Applied Biochemistry, V6, P56; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HORIUCHI I, 1985, NEUROCHEM INT, V7, P497, DOI 10.1016/0197-0186(85)90174-3; ISHIKAWA F, 1989, NATURE, V338, P557, DOI 10.1038/338557a0; ITO J, 1987, NEUROCHEM INT, V11, P331, DOI 10.1016/0197-0186(87)90054-4; KATO K, 1981, J NEUROCHEM, V36, P793, DOI 10.1111/j.1471-4159.1981.tb01663.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LILIEN LE, 1988, NEURON, V1, P485; LIM R, 1987, DEV BRAIN RES, V33, P49, DOI 10.1016/0165-3806(87)90175-1; LIN LFH, 1990, J BIOL CHEM, V265, P8942; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MANTHORPE M, 1986, BRAIN RES, V367, P282, DOI 10.1016/0006-8993(86)91603-3; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; MIYAZONO K, 1985, BIOCHEM BIOPH RES CO, V126, P83, DOI 10.1016/0006-291X(85)90574-1; RUDGE JS, 1987, DEV BRAIN RES, V32, P103, DOI 10.1016/0165-3806(87)90143-X; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; THOENEN H, 1987, REV PHYSL BIOCH PHAR, V109, P146; USUKI K, 1991, J BIOL CHEM, V266, P20525; USUKI K, 1989, P NATL ACAD SCI USA, V86, P7427, DOI 10.1073/pnas.86.19.7427; USUKI K, 1990, CELL REGUL, V1, P557; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	36	67	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20311	20316						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400349				2022-12-25	WOS:A1992JR85800089
J	MOTOKURA, T; KEYOMARSI, K; KRONENBERG, HM; ARNOLD, A				MOTOKURA, T; KEYOMARSI, K; KRONENBERG, HM; ARNOLD, A			CLONING AND CHARACTERIZATION OF HUMAN CYCLIN D3, A CDNA CLOSELY RELATED IN SEQUENCE TO THE PRAD1 CYCLIN-D1 PROTOONCOGENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE MESSENGER-RNAS; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; CHROMOSOMAL-ABNORMALITIES; CANDIDATE ONCOGENE; GENE; G1; YEAST; TUMOR; RETINOBLASTOMAS	Cyclins regulate cell cycle progression by complexing with and activating cdc2 or related kinases. PRAD1/cyclin D1 is a recently discovered putative oncogene in several types of human tumors and may regulate G1-S phase progression. We have cloned a related human cDNA, called cyclin D3, from a placental cDNA library by cross-hybridization with PRAD1. In synchronized HeLa cells, the mRNA levels of PRAD1 and cyclin D3 were regulated reciprocally through the cell cycle: cyclin D3 mRNA levels peaked in S phase, where PRAD1 mRNA was lowest in S. In normal human mammary epithelial (70N) cells synchronized by growth factor deprivation and subsequent growth factor stimulation, PRAD1 expression peaked in G1 and declined before S phase, while cyclin D3 expression rose later in G1 and remained elevated in S. Therefore, the close relationship (53.1% identity) between PRAD1 and cyclin D3 does not necessarily imply redundant functions of these candidate G1 cyclins; they may have distinct roles in progression from G1 through S phase.	MASSACHUSETTS GEN HOSP, ENDOCRINE UNIT, FRUIT ST, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CELL GROWTH & REGULAT, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Keyomarsi, Khandan/H-2716-2016; Motokura, Toru/X-3682-2019	Keyomarsi, Khandan/0000-0002-5440-0849; 	NCI NIH HHS [CA08949, CA55909] Funding Source: Medline; NIDDK NIH HHS [DK11794] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055909, F32CA008949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; BAND V, 1990, CANCER RES, V50, P7351; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; Battey, 1986, BASIC METHODS MOL BI; BENEDICT WF, 1983, CANCER GENET CYTOGEN, V10, P311, DOI 10.1016/0165-4608(83)90090-0; BUENO A, 1991, CELL, V66, P149, DOI 10.1016/0092-8674(91)90147-Q; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUSNETSOVA LE, 1982, HUM GENET, V61, P201, DOI 10.1007/BF00296442; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1992, CYTOGENET CELL GENET, V61, P5, DOI 10.1159/000133359; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH KA, 1990, CELL, V63, P1117, DOI 10.1016/0092-8674(90)90404-3; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PLUMB M, 1983, NUCLEIC ACIDS RES, V11, P2391, DOI 10.1093/nar/11.8.2391; PRIGOGINA EL, 1988, CANCER GENET CYTOGEN, V32, P183, DOI 10.1016/0165-4608(88)90281-6; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SCHOUTEN HC, 1990, CANCER GENET CYTOGEN, V47, P73, DOI 10.1016/0165-4608(90)90265-C; SQUIRE J, 1984, HUM GENET, V66, P46, DOI 10.1007/BF00275185; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	39	158	162	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20412	20415						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1383201				2022-12-25	WOS:A1992JR85800103
J	SHEFF, DR; RUBENSTEIN, PA				SHEFF, DR; RUBENSTEIN, PA			ISOLATION AND CHARACTERIZATION OF THE RAT-LIVER ACTIN N-ACETYLAMINOPEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE AMINOPEPTIDASE; SACCHAROMYCES-CEREVISIAE; AMINO TERMINUS; PROTEINS; PURIFICATION; YEAST; CELL; FORMYLMETHIONINE; HEMOGLOBIN; HYDROLASE	Actins from most eukaryotes undergo a unique posttranslational modification of the amino terminus called "processing." Processing consists of the removal of an amino-terminal Ac-Met or Ac-Cys to leave an acidic amino-terminal residue. We have previously demonstrated that this reaction is not catalyzed by the ribosomally associated methionine aminopeptidase or by other previously described acetylaminopeptidases. Here we present the isolation and characterization of the actin N-acetylaminopeptidase (ANAP) from rat liver. A five-step purification protocol achieves a 4100-fold purification of the enzyme with an overall 8% recovery of activity. ANAP is a 77-kDa monomer with a pI of 4.6. Using unprocessed yeast actin as a substrate, the K(m) of ANAP is 3.5 muM. Purified ANAP was used to generate a polyclonal antibody. The antibody has been used along with activity assays to demonstrate the presence of ANAP in a variety of rat tissues. Finally, evidence is presented that in mammals, ANAP may function with a second, as yet unpurified, component to process actin amino termini.	UNIV IOWA,COLL MED,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa				Rubenstein, Peter/0000-0003-1225-4414	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337, R01GM033689] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33689, T32GM07337] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOYAGI T, 1969, J ANTIBIOT, V22, P283, DOI 10.7164/antibiotics.22.283; BOISSEL JP, 1988, J BIOL CHEM, V263, P8443; BROWN JL, 1979, J BIOL CHEM, V254, P1447; BROWN JL, 1976, J BIOL CHEM, V251, P1009; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHANG YH, 1990, J BIOL CHEM, V265, P19892; COOK RK, 1991, J BIOL CHEM, V266, P16825; GADE W, 1978, J BIOL CHEM, V253, P5012; HANADA K, 1983, PROTEINASE INHIBITOR, P25; HENNESSEY ES, 1991, EUR J BIOCHEM, V197, P345, DOI 10.1111/j.1432-1033.1991.tb15917.x; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; KOBAYASHI K, 1987, J BIOL CHEM, V262, P11435; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P4742, DOI 10.1073/pnas.71.12.4742; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; RADHAKRISHNA G, 1988, MOL BIOL INTRACELLUL, P109; REDMAN KL, 1985, J BIOL CHEM, V260, P4857; RICH DH, 1985, BIOCHEMISTRY-US, V24, P3165, DOI 10.1021/bi00334a014; RUBENSTEIN PA, 1987, METHOD CELL BIOL, V28, P231; RUBENSTEINPA, 1986, MICROBIOLOGY, P283; SHEFF DR, 1989, J BIOL CHEM, V264, P11491; SHEFF DR, 1992, J BIOL CHEM, V267, P2671; Sherman F., 1986, METHODS YEAST GENETI; SOLOMON LR, 1985, J BIOL CHEM, V260, P7659; TRAUTSCHOLD I, 1967, BIOCHEM PHARMACOL, V16, P59, DOI 10.1016/0006-2952(67)90186-4; UMEZAWA H, 1982, ANNU REV MICROBIOL, V36, P75, DOI 10.1146/annurev.mi.36.100182.000451; Umezawa H, 1976, Methods Enzymol, V45, P678; WINSTON S, 1987, CURRENT PROTOCOLS MO, P1081; WITHEILER J, 1972, J BIOL CHEM, V247, P2217; YOSHIDA A, 1972, J BIOL CHEM, V247, P952; YOSHIDA A, 1970, P NATL ACAD SCI USA, V67, P1600, DOI 10.1073/pnas.67.3.1600	33	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20217	20224						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400339				2022-12-25	WOS:A1992JR85800075
J	BAUMANN, H; MORELLA, KK; CAMPOS, SP; CAO, Z; JAHREIS, GP				BAUMANN, H; MORELLA, KK; CAMPOS, SP; CAO, Z; JAHREIS, GP			ROLE OF CAAT-ENHANCER BINDING-PROTEIN ISOFORMS IN THE CYTOKINE REGULATION OF ACUTE-PHASE PLASMA-PROTEIN GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ALPHA-1-ACID GLYCOPROTEIN; TRANSCRIPTIONAL ACTIVATOR PROTEIN; GLUCOCORTICOID-RESPONSE ELEMENTS; HEPATOCYTE-STIMULATING FACTORS; C-REACTIVE PROTEIN; HAPTOGLOBIN GENE; ANGIOTENSINOGEN GENE; FIBRINOGEN GENES; NUCLEAR-PROTEIN; C/EBP FAMILY	Rat hepatic cells respond to interleukin (IL) -1, IL-6, and dexamethasone treatment by increasing the transcription rate of acute-phase plasma protein genes. The same conditions lead to changes in the expression of CAAT-enhancer binding protein (C/EBP) isoforms which are specific to the hepatic cell line. To identify the relationship between C/EBP isoforms and acute-phase protein gene activation, the hormone-specific expression of C/EBPalpha, beta, and delta was determined in H-35 and HTC cells and was compared to acute-phase liver. C/EBPbeta was found to be the principal isoform in hepatoma cells and to be strongly stimulated by cytokines and dexamethasone in H-35 cells. Transactivating functions were observed for all three C/EBP isoforms by cotransfection of CAT gene reporter constructs containing cytokine and glucocorticoid response elements of acute-phase protein genes and expression plasmids for mouse C/EBPalpha, beta, and delta into rat and human hepatoma cells. The degree of C/EBP-mediated transactivation was, however, extremely variable among the different regulatory elements. Transcription run-on reactions with nuclei from transiently transfected H-35 cells indicated that cotransfected C/EBPbeta increases basal expression of reporter gene constructs as well as the dexamethasone-mediated stimulation of constructs containing the glucocorticoid response elements of the rat alpha1-acid glycoprotein gene, but did not accelerate or enhance hormone-dependent transcription activation of reporter gene plasmids containing the IL-6 regulatory element of the beta-fibrinogen gene. Activation of the reporter gene constructs appeared to be temporally and quantitatively correlated with the amount of nuclear C/EBP as determined by two-dimensional Western and Southwestern blot analyses.	SUNY BUFFALO,BUFFALO,NY 14260; CHILDRENS HOSP,DEPT PEDIAT,DIV ENDOCRINOL,BUFFALO,NY 14222; CARNEGIE INST WASHINGTON,BALTIMORE,MD 21210	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Carnegie Institution for Science	BAUMANN, H (corresponding author), ROSWELL PK CANC INST,DEPT MOLEC & CELLULAR BIOL,BUFFALO,NY 14263, USA.				NCI NIH HHS [CA26122] Funding Source: Medline; NIDDK NIH HHS [DK33886] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033886] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; ARCONE R, 1988, NUCLEIC ACIDS RES, V16, P3195, DOI 10.1093/nar/16.8.3195; BAUMANN H, 1989, IN VITRO CELL DEV B, V25, P115; BAUMANN H, 1990, J BIOL CHEM, V265, P19420; BAUMANN H, 1990, MOL BIOL MED, V7, P147; BAUMANN H, 1990, MOL CELL BIOL, V10, P5967, DOI 10.1128/MCB.10.11.5967; BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BAUMANN H, 1986, J CELL BIOL, V102, P370, DOI 10.1083/jcb.102.2.370; BAUMANN H, 1983, J BIOL CHEM, V258, P563; BAUMANN H, 1990, J BIOL CHEM, V265, P22275; BAUMANN H, 1991, J BIOL CHEM, V266, P20390; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAUMANN H, 1986, MOL CELL BIOL, V6, P2551, DOI 10.1128/MCB.6.7.2551; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHEN HM, 1991, J BIOL CHEM, V266, P2946; CHENG J, 1990, NUCLEIC ACIDS RES, V18, P4261, DOI 10.1093/nar/18.14.4261; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; Fey G H, 1990, Prog Liver Dis, V9, P89; FOWLKES DM, 1984, P NATL ACAD SCI-BIOL, V81, P2313, DOI 10.1073/pnas.81.8.2313; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HUANG JH, 1990, MOL CELL BIOL, V10, P3619, DOI 10.1128/MCB.10.7.3619; KLEIN ES, 1988, MOL ENDOCRINOL, V2, P1343, DOI 10.1210/mend-2-12-1343; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LI SP, 1990, J BIOL CHEM, V265, P4136; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MARINKOVIC S, 1990, MOL CELL BIOL, V10, P1573, DOI 10.1128/MCB.10.4.1573; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; PROWSE KR, 1990, J BIOL CHEM, V261, P10201; PRUITT SC, 1988, GENE, V66, P121, DOI 10.1016/0378-1119(88)90230-2; RON D, 1990, MOL CELL BIOL, V10, P1023, DOI 10.1128/MCB.10.3.1023; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; WILLIAMS PM, 1991, MOL CELL BIOL, V11, P4959, DOI 10.1128/MCB.11.10.4959; WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181; WON KA, 1990, MOL CELL BIOL, V10, P3965, DOI 10.1128/MCB.10.8.3965; WON KA, 1991, MOL CELL BIOL, V11, P3001, DOI 10.1128/MCB.11.6.3001	45	131	132	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19744	19751						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1382074				2022-12-25	WOS:A1992JP59300108
J	MASON, SW; LI, J; GREENBLATT, J				MASON, SW; LI, J; GREENBLATT, J			HOST FACTOR REQUIREMENTS FOR PROCESSIVE ANTITERMINATION OF TRANSCRIPTION AND SUPPRESSION OF PAUSING BY THE N-PROTEIN OF BACTERIOPHAGE-LAMBDA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-TERMINATION PROTEIN; NUSA GENE PROTEIN; PHAGE-LAMBDA; ESCHERICHIA-COLI; RNA-POLYMERASE; RECOGNITION SITE; COLIPHAGE-LAMBDA; NUT SITE; RHO; SEQUENCE	The N protein of phage lambda prevents termination of transcription by Escherichia coli RNA polymerase at Rho-dependent and -independent terminators in the lambda early operons. The modification of RNA polymerase by N requires an N-utilization (nut) site, present in each lambda early operon, and involves the E. coli factors NusA, NusB, NusG, and ribosomal protein S10. We show that, in the presence of NusA, N inhibits pausing by RNA polymerase and Rho-dependent termination in vitro at three sites in the lamda terminator tR1 which are located less than 100 base pairs downstream from nutR. NusA is also sufficient for partial antitermination at sites located farther downstream from nutL and nutR if there is a high concentration of N in the reaction. At low concentrations of N, the additional factors NusB, S10, and NusG are essential for antitermination at distal sites. In these conditions, the presence of NusA, NusB, S10, and NusG in the reaction enables N-modified RNA polymerase to elongate efficiently and processively through Rho-dependent and -independent terminators over distances as great as 7 kilobases downstream from the lambda nut sites. This substantial processivity of antitermination in vitro also occurs in vivo and probably reflects the stable association of N, NusA, NusB, S10, and NusG with RNA polymerase and nut site RNA in elongation complexes transcribing the lambda chromosome.	UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto; University of Toronto				Mason, Stephen/0000-0002-6662-9624				ADHYA S, 1974, P NATL ACAD SCI USA, V71, P2534, DOI 10.1073/pnas.71.6.2534; BARIK S, 1987, CELL, V50, P885, DOI 10.1016/0092-8674(87)90515-0; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHEN CYA, 1986, CELL, V46, P1023, DOI 10.1016/0092-8674(86)90701-4; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; CHENG SWC, 1991, SCIENCE, V254, P1205, DOI 10.1126/science.1835546; COURT D, 1969, VIROLOGY, V39, P348, DOI 10.1016/0042-6822(69)90060-9; DAMBLY C, 1971, MOL GEN GENET, V113, P244, DOI 10.1007/BF00339545; Daniels D., 1983, LAMBDA 2, VII; DAS A, 1983, P NATL ACAD SCI-BIOL, V80, P5530, DOI 10.1073/pnas.80.18.5530; DAS A, 1985, P NATL ACAD SCI USA, V82, P4070, DOI 10.1073/pnas.82.12.4070; DAS A, 1984, CELL, V38, P165, DOI 10.1016/0092-8674(84)90537-3; DOWNING WL, 1990, J BACTERIOL, V172, P1621, DOI 10.1128/jb.172.3.1621-1627.1990; FRANKLIN NC, 1974, J MOL BIOL, V185, P701; FRIEDMAN DI, 1990, GENE DEV, V4, P2210, DOI 10.1101/gad.4.12a.2210; FRIEDMAN DI, 1974, VIROLOGY, V58, P141, DOI 10.1016/0042-6822(74)90149-4; FRIEDMAN DI, 1973, J MOL BIOL, V81, P505, DOI 10.1016/0022-2836(73)90519-6; FRIEDMAN DI, 1976, VIROLOGY, V73, P119, DOI 10.1016/0042-6822(76)90066-0; FRIEDMAN DI, 1981, P NATL ACAD SCI-BIOL, V78, P1115, DOI 10.1073/pnas.78.2.1115; FRIEDMAN DI, 1988, BACTERIOPHAGES, V2; GODA Y, 1985, NUCLEIC ACIDS RES, V13, P2569, DOI 10.1093/nar/13.7.2569; GOTTESMAN ME, 1980, J MOL BIOL, V140, P57, DOI 10.1016/0022-2836(80)90356-3; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; GREENBLA.J, 1972, P NATL ACAD SCI USA, V69, P3606, DOI 10.1073/pnas.69.12.3606; GREENBLATT J, 1981, J MOL BIOL, V147, P11, DOI 10.1016/0022-2836(81)90076-0; GREENBLATT J, 1981, CELL, V24, P421, DOI 10.1016/0092-8674(81)90332-9; GREENBLATT J, 1980, J BIOL CHEM, V255, P1465; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; KEPPEL F, 1974, Biochimie (Paris), V56, P1503; LAU LF, 1983, J BIOL CHEM, V258, P9391; LAU LF, 1985, J BIOL CHEM, V260, P574; LAU LF, 1982, P NATL ACAD SCI-BIOL, V79, P6171, DOI 10.1073/pnas.79.20.6171; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LEASON KR, 1988, J BACTERIOL, V170, P5051, DOI 10.1128/jb.170.11.5051-5058.1988; LI J, 1992, J BIOL CHEM, V267, P6012; Maniatis T., 1982, MOL CLONING; MASON SW, 1991, GENE DEV, V5, P1504, DOI 10.1101/gad.5.8.1504; MASON SW, 1992, J MOL BIOL, V223, P55, DOI 10.1016/0022-2836(92)90715-V; MORGAN WD, 1983, J BIOL CHEM, V258, P9553; NODWELL JR, 1991, GENE DEV, V5, P2141, DOI 10.1101/gad.5.11.2141; OLSON ER, 1982, CELL, V31, P61, DOI 10.1016/0092-8674(82)90405-6; OPPENHEIM AB, 1982, J MOL BIOL, V158, P327, DOI 10.1016/0022-2836(82)90201-7; PELTZ SW, 1985, SCIENCE, V228, P91, DOI 10.1126/science.3156406; RICHARDSON JP, 1991, CELL, V64, P1047, DOI 10.1016/0092-8674(91)90257-Y; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; ROBERTS JW, 1988, CELL, V52, P5, DOI 10.1016/0092-8674(88)90523-5; ROSENBERG M, 1978, NATURE, V272, P414, DOI 10.1038/272414a0; SALSTROM JS, 1978, J MOL BIOL, V124, P195, DOI 10.1016/0022-2836(78)90156-0; SCHMIDT MC, 1987, J MOL BIOL, V195, P809, DOI 10.1016/0022-2836(87)90486-4; STEINBERG RA, 1971, NATURE-NEW BIOL, V230, P76, DOI 10.1038/newbio230076a0; SULLIVAN SL, 1992, J BACTERIOL, V174, P1339, DOI 10.1128/jb.174.4.1339-1344.1992; SULLIVAN SL, 1992, CELL, V68, P989, DOI 10.1016/0092-8674(92)90041-A; SWINDLE J, 1988, J BIOL CHEM, V263, P10229; WARD DF, 1983, J MOL BIOL, V168, P73, DOI 10.1016/S0022-2836(83)80323-4; WHALEN W A, 1990, New Biologist, V2, P975; WHAOLEN W, 1988, P NATL ACAD SCI USA, V85, P2492; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; YANG XJ, 1989, P NATL ACAD SCI USA, V86, P5301, DOI 10.1073/pnas.86.14.5301; ZOU LL, 1991, J BIOL CHEM, V266, P10201; ZUBER M, 1987, P NATL ACAD SCI USA, V84, P4514, DOI 10.1073/pnas.84.13.4514	60	95	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19418	19426						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1388170				2022-12-25	WOS:A1992JP59300062
J	ANDREE, HAM; STUART, MCA; HERMENS, WT; REUTELINGSPERGER, CPM; HEMKER, HC; FREDERIK, PM; WILLEMS, GM				ANDREE, HAM; STUART, MCA; HERMENS, WT; REUTELINGSPERGER, CPM; HEMKER, HC; FREDERIK, PM; WILLEMS, GM			CLUSTERING OF LIPID-BOUND ANNEXIN-V MAY EXPLAIN ITS ANTICOAGULANT EFFECT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-BINDING-PROTEIN; VASCULAR ANTICOAGULANT; PROTHROMBINASE COMPLEX; UNILAMELLAR VESICLES; TISSUE FACTOR; INHIBITS COAGULATION; LIPOCORTIN FAMILY; FACTOR-VIIA; VAC-ALPHA; A-II	In 1985 we isolated a new vascular anticoagulant protein VAC-alpha, now called annexin V, with a high binding affinity (K(d) < 10(-10) M) for phospholipids. Its anticoagulant effect was attributed to displacement of coagulation factors from the phospholipid membrane. The present study demonstrates that the inhibition of prothrombinase activity by annexin V strongly depends on the curvature of the membrane surface and on the calcium concentration. Half-maximal inhibition of prothrombinase on and binding of annexin V to small vesicles, composed of 20% phosphatidylserine and 80% phosphatidylcholine, requires 2-3 mm calcium. With large vesicles and planar bilayers considerably less calcium is required for inhibition of prothrombinase and for lipid binding. Half-maximal binding of annexin V to large vesicles and to planar bilayers occurs at 0.7 and 0.2 mm calcium, respectively. This seemingly confirms the displacement model. The displacement of coagulation factors, however, proved to be incomplete, with residual surface concentrations of factors Xa, Va, and prothrombin sufficient for effective production of thrombin. Cryoelectron microscopy revealed that annexin V binding to large vesicles caused planar facets, indicating the formation of large sheets of clustered annexin V. Apparently, the formation of these two-dimensional arrays is promoted by calcium and hampered by high surface curvature. It is speculated that the complete inhibition (>99%) of prothrombinase activity by annexin V is caused by the reduced lateral mobility of prothrombin and factor Xa in rigid sheets of annexin V covering the membrane.	UNIV LIMBURG,CARDIOVASC RES INST,POB 616,6200 MD MAASTRICHT,NETHERLANDS; UNIV LIMBURG,DEPT PATHOL,ELECTRON MICROSCOPY UNIT,6200 MD MAASTRICHT,NETHERLANDS; UNIV LIMBURG,DEPT BIOCHEM,6200 MD MAASTRICHT,NETHERLANDS	Hasselt University; Maastricht University; Hasselt University; Maastricht University; Hasselt University; Maastricht University			Stuart, Marc/B-6274-2008	Stuart, Marc/0000-0003-0667-6338; Hemker, Coen/0000-0003-1669-2358				ANDREE HAM, 1990, J BIOL CHEM, V265, P4923; BEVERS EM, 1982, EUR J BIOCHEM, V122, P81, DOI 10.1111/j.1432-1033.1982.tb05850.x; CARSON SD, 1988, THROMB RES, V50, P669, DOI 10.1016/0049-3848(88)90325-8; CHAP H, 1988, BIOCHEM BIOPH RES CO, V150, P972, DOI 10.1016/0006-291X(88)90724-3; CORSEL JW, 1986, J COLLOID INTERF SCI, V111, P544, DOI 10.1016/0021-9797(86)90058-5; CUYPERS PA, 1983, J BIOL CHEM, V258, P2426; DEKRUIJFF B, 1975, BIOCHIM BIOPHYS ACTA, V406, P6, DOI 10.1016/0005-2736(75)90038-3; FLAHERTY MJ, 1990, J LAB CLIN MED, V115, P174; FREDERIK PM, 1991, BIOCHIM BIOPHYS ACTA, V1062, P133, DOI 10.1016/0005-2736(91)90384-K; FUJIKAWA K, 1972, BIOCHEMISTRY-US, V11, P4892, DOI 10.1021/bi00776a003; FUNAKOSHI T, 1987, BIOCHEMISTRY-US, V26, P5572, DOI 10.1021/bi00391a053; GENDREAU MA, 1989, J BIOL CHEM, V264, P6972; GIESEN PLA, 1991, J BIOL CHEM, V266, P1379; GIESEN PLA, 1991, J BIOL CHEM, V266, P18720; GOVERSRIEMSLAG JWP, 1985, THROMB RES, V38, P375, DOI 10.1016/0049-3848(85)90136-7; GRAMZINSKI RA, 1989, BLOOD, V73, P983; HAUPTMANN R, 1989, EUR J BIOCHEM, V185, P63, DOI 10.1111/j.1432-1033.1989.tb15082.x; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; IWASAKI A, 1987, J BIOCHEM, V102, P1261, DOI 10.1093/oxfordjournals.jbchem.a122165; KONDO S, 1987, THROMB RES, V48, P449, DOI 10.1016/0049-3848(87)90402-6; KOP JMM, 1984, J BIOL CHEM, V259, P3993; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KUMAR A, 1984, BIOCHIM BIOPHYS ACTA, V769, P419, DOI 10.1016/0005-2736(84)90326-2; LENTZ BR, 1980, BIOCHEMISTRY-US, V19, P2555, DOI 10.1021/bi00553a003; LINDHOUT T, 1982, BIOCHEMISTRY-US, V21, P5494, DOI 10.1021/bi00265a018; MANN KG, 1990, BLOOD, V76, P1; MASSARI S, 1977, BIOCHEMISTRY-US, V16, P1189, DOI 10.1021/bi00625a025; MAURERFOGY I, 1988, EUR J BIOCHEM, V174, P585, DOI 10.1111/j.1432-1033.1988.tb14139.x; MICHAELSON DM, 1973, BIOCHEMISTRY-US, V12, P2637, DOI 10.1021/bi00738a014; MOSSER G, 1991, J MOL BIOL, V217, P241, DOI 10.1016/0022-2836(91)90538-H; NORDLUND JR, 1981, BIOCHEMISTRY-US, P6415; REUTELINGSPERGER CPM, 1985, EUR J BIOCHEM, V151, P625, DOI 10.1111/j.1432-1033.1985.tb09150.x; REUTELINGSPERGER CPM, 1988, EUR J BIOCHEM, V173, P171, DOI 10.1111/j.1432-1033.1988.tb13981.x; ROMISCH J, 1990, BIOCHEM J, V272, P223; TAIT JF, 1989, J BIOL CHEM, V264, P7944; TAIT JF, 1988, BIOCHEMISTRY-US, V27, P6268, DOI 10.1021/bi00417a011; THIAGARAJAN P, 1990, J BIOL CHEM, V265, P17420; WILLEMS G M, 1991, Journal of Biomaterials Science Polymer Edition, V2, P217	38	202	210	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17907	17912						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1387643				2022-12-25	WOS:A1992JM22300065
J	WANG, H; DECHANT, E; KAVANAUGH, M; NORTH, RA; KABAT, D				WANG, H; DECHANT, E; KAVANAUGH, M; NORTH, RA; KABAT, D			EFFECTS OF ECOTROPIC MURINE RETROVIRUSES ON THE DUAL-FUNCTION CELL-SURFACE RECEPTOR BASIC-AMINO-ACID TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED ANIMAL-CELLS; PLASMA-MEMBRANE; ENVELOPE GLYCOPROTEIN; LEUKEMIA VIRUSES; GENE; PROTEIN; INTERFERENCE; MUTANT	The widely expressed Na+-independent transporter for basic amino acids (system y+) is the cell surface receptor (ecoR) for ecotropic host-range mouse retro-viruses (murine leukemia viruses (MuLVs)), a class of retroviruses that naturally infects only mice or rats. Accordingly, expression of mouse ecoR cDNA in mink CCL64 fibroblasts yields cells (CEN cells) that have y+ transporter activity above the endogenous background and that bind and are infected by ecotropic MuLVs. The effect of ecotropic MuLV infection on expression of y+ transporter was analyzed in mouse and in mink CEN fibroblasts. Chronic infection with ecotropic MuLVs caused 50-70% loss (down-modulation) of mouse y+ transporter in plasma membranes, detected as a reduced V(max) for uptake and outflow of L-[H-3]-arginine with no effect on K(m) values. Down-modulation was specific for mouse y+ and did not affect other transporters or the endogenous mink y+, suggesting that it results from specific interaction between mouse y+ and the viral envelope glycoprotein gp70 in the infected cells. Because this partial loss of mouse y+ from cell surfaces is insufficient to explain the complete interference to superinfection that occurs in cells chronically infected with ecotropic MuLVs, alternative explanations for interference are proposed. In contrast to the y+ down-modulation caused by chronic infection, binding of extracellular envelope glycoprotein gp70 at 37-degrees-C resulted in noncompetitive inhibition of amino acid import by mouse y+ but had no effect on export through this same transporter or on any transporter properties of mink y+. The effects of gp70 on transport kinetics suggest that it slows the rate-limiting step of the amino acid import cycle, a conformational transition of the empty transporter in which the binding site moves from the inside back to the outside of the cell, and that gp70 has no effect on the rate-limiting step of the amino acid export cycle. Infected cells retain substantial y+ activity. Moreover, the virus binding site on ecoR is in a mobile region that changes conformation during the amino acid transport cycle.	OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, PORTLAND, OR 97201 USA	Oregon Health & Science University	WANG, H (corresponding author), OREGON HLTH SCI UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA.		North, Richard/GQA-6156-2022		NATIONAL CANCER INSTITUTE [R01CA025810] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003160, R37DA003160] Funding Source: NIH RePORTER; NCI NIH HHS [CA25810] Funding Source: Medline; NIDA NIH HHS [DA03160] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BOUR S, 1991, J VIROL, V65, P6387, DOI 10.1128/JVI.65.12.6387-6396.1991; CHRISTENSEN HN, 1989, METHOD ENZYMOL, V173, P576; CLOYD MW, 1980, J EXP MED, V151, P542, DOI 10.1084/jem.151.3.542; CRISE B, 1992, J VIROL, V66, P2296, DOI 10.1128/JVI.66.4.2296-2301.1992; DELWART EL, 1989, J VIROL, V63, P273, DOI 10.1128/JVI.63.1.273-280.1989; DEVES R, 1992, J PHYSIOL-LONDON, V446, pP409; DIXON WJ, 1951, INTRO STATISTICAL AN, P105; EVANS LH, 1977, J VIROL, V24, P865, DOI 10.1128/JVI.24.3.865-874.1977; GAZZOLA GC, 1981, ANAL BIOCHEM, V115, P368, DOI 10.1016/0003-2697(81)90019-1; HANDELIN BL, 1985, VIROLOGY, V140, P183, DOI 10.1016/0042-6822(85)90458-1; KABAT D, 1989, VIROLOGY, V171, P64; KAWAMURA I, 1989, J VIROL, V63, P3748, DOI 10.1128/JVI.63.9.3748-3754.1989; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KLASSE PJ, 1992, AIDS, V6, P325, DOI 10.1097/00002030-199203000-00011; KLEINERMAN ES, 1987, J IMMUNOL, V139, P2329; KOZAK SL, 1990, J VIROL, V64, P3500, DOI 10.1128/JVI.64.7.3500-3508.1990; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MILLER AD, 1985, MOL CELL BIOL, V5, P431, DOI 10.1128/MCB.5.3.431; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; RUTA M, 1980, J VIROL, V35, P844, DOI 10.1128/JVI.35.3.844-853.1980; SAHA K, 1992, J VIROL, V66, P2639, DOI 10.1128/JVI.66.5.2639-2646.1992; SITBON M, 1986, CELL, V47, P851, DOI 10.1016/0092-8674(86)90800-7; Stein WD, 1986, TRANSPORT DIFFUSION, P231; STEVENSON M, 1988, CELL, V53, P483, DOI 10.1016/0092-8674(88)90168-7; SZUREK PF, 1988, J VIROL, V62, P357, DOI 10.1128/JVI.62.1.357-360.1988; TINOCO I, 1978, PHYSICAL CHEM PRINCI, P294; Vile R G, 1991, Nature, V352, P666, DOI 10.1038/352666a0; WANG H, 1991, J VIROL, V65, P6468, DOI 10.1128/JVI.65.12.6468-6477.1991; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WEISS R, 1984, RNA TUMOR VIRUSES, P209; WHITE MF, 1982, J BIOL CHEM, V257, P4450; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WHITE MF, 1982, J BIOL CHEM, V257, P4443; WILLEY RL, 1992, J VIROL, V66, P226, DOI 10.1128/JVI.66.1.226-234.1992	35	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23617	23624						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429703				2022-12-25	WOS:A1992JZ23900032
J	BEARD, CA; SABORIO, JL; TEWARI, D; KRIEGLSTEIN, KG; HENSCHEN, AH; MANNING, JE				BEARD, CA; SABORIO, JL; TEWARI, D; KRIEGLSTEIN, KG; HENSCHEN, AH; MANNING, JE			EVIDENCE FOR 2 DISTINCT MAJOR PROTEIN-COMPONENTS, PAR-1 AND PAR-2, IN THE PARAFLAGELLAR ROD OF TRYPANOSOMA-CRUZI - COMPLETE NUCLEOTIDE-SEQUENCE OF PAR-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; MESSENGER-RNAS; GENES; BRUCEI; DNA; TRANSCRIPTION; DEHYDROGENASE; LEISHMANIA; DROSOPHILA; CALMODULIN	The previously identified major protein components of the paraflagellar rod in Trypanosoma cruzi, PAR 1 and PAR 2, were analyzed to determine if they are distinct proteins or different conformations of a single polypeptide as has been suggested for other trypanosomatids. Amino acid sequence analysis showed PAR 1 and PAR 2 to be two distinct polypeptides. Antibodies specific against either PAR 1 or PAR 2 were shown to each react with a distinct band in Western blots of paraflagellar isolates of T. cruzi and other trypanosomatids if rigorous protease inhibition was used. The PAR 2 message was isolated and characterized by Northern blot and nucleic acid sequence analysis. Preliminary analysis of the PAR 2 gene indicates that PAR 2 is a member of a multigene family with all members residing on a single chromosome.	UNIV CALIF IRVINE, DEPT MOLEC BIOL & BIOCHEM, IRVINE, CA 92717 USA	University of California System; University of California Irvine					NIAID NIH HHS [AI 18873] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018873] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel FM, 1991, CURRENT PROTOCOLS MO; BEARD CA, 1985, MOL BIOCHEM PARASIT, V16, P199, DOI 10.1016/0166-6851(85)90087-8; BEARD CA, 1988, MOL BIOCHEM PARASIT, V28, P227, DOI 10.1016/0166-6851(88)90007-2; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BRENER Z, 1973, ANNU REV MICROBIOL, V27, P347, DOI 10.1146/annurev.mi.27.100173.002023; BRUN R, 1979, ACTA TROP, V36, P289; CHUNG SH, 1990, NUCLEIC ACIDS RES, V18, P4561, DOI 10.1093/nar/18.15.4561; DESOUZA W, 1984, INT REV CYTOL, V86, P197, DOI 10.1016/S0074-7696(08)60180-1; DESOUZA W, 1980, J PARASITOL, V66, P229, DOI 10.2307/3280809; DRAGON EA, 1987, MOL CELL BIOL, V7, P1271, DOI 10.1128/MCB.7.3.1271; ENGMAN DM, 1987, MOL BIOCHEM PARASIT, V22, P115, DOI 10.1016/0166-6851(87)90041-7; FICKETT JW, 1982, NUCLEIC ACIDS RES, V10, P5303, DOI 10.1093/nar/10.17.5303; FOUTS DL, 1981, NUCLEIC ACIDS RES, V9, P7053, DOI 10.1093/nar/9.24.7053; GALLO JM, 1985, EUR J CELL BIOL, V36, P163; HELMS C, 1985, DNA-J MOLEC CELL BIO, V4, P39, DOI 10.1089/dna.1985.4.39; HENSCHEN A, 1986, ADV METHODS PROTEIN, P244; HYAMS JS, 1982, J CELL SCI, V55, P199; ISMACH R, 1989, J PROTOZOOL, V36, P617, DOI 10.1111/j.1550-7408.1989.tb01105.x; KENDALL G, 1990, EMBO J, V9, P2751, DOI 10.1002/j.1460-2075.1990.tb07462.x; KIMMEL BE, 1985, GENE, V35, P237, DOI 10.1016/0378-1119(85)90002-2; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANAR DE, 1984, MOL BIOCHEM PARASIT, V11, P119, DOI 10.1016/0166-6851(84)90059-8; LOTTSPEICH F, 1985, HIGH PERFORMANCE LIQ, P139; MAINGON R, 1988, EUR J BIOCHEM, V171, P285, DOI 10.1111/j.1432-1033.1988.tb13788.x; MICHELS PAM, 1986, EMBO J, V5, P1049, DOI 10.1002/j.1460-2075.1986.tb04321.x; NELSON DJ, 1979, J BIOL CHEM, V254, P3959; ROZEK CE, 1983, CELL, V32, P23, DOI 10.1016/0092-8674(83)90493-2; SABORIO JL, 1989, J BIOL CHEM, V264, P4071; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLAEPPI K, 1989, J CELL BIOL, V109, P1695, DOI 10.1083/jcb.109.4.1695; SWINDLE J, 1988, EMBO J, V7, P1121, DOI 10.1002/j.1460-2075.1988.tb02921.x; TSCHUDI C, 1985, P NATL ACAD SCI USA, V82, P3998, DOI 10.1073/pnas.82.12.3998; WONG S, 1989, MOL BIOCHEM PARASIT, V37, P147, DOI 10.1016/0166-6851(89)90111-4; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	35	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21656	21662						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400477				2022-12-25	WOS:A1992JV01100063
J	ELHAG, GA; BOURQUE, DP				ELHAG, GA; BOURQUE, DP			NUCLEAR-ENCODED TOBACCO CHLOROPLAST RIBOSOMAL PROTEIN-L24 - PROTEIN IDENTIFICATION, SEQUENCE-ANALYSIS OF CDNAS ENCODING ITS CYTOPLASMIC PRECURSOR, AND MESSENGER-RNA AND GENOMIC DNA ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; SPC-OPERON; SACCHAROMYCES-CEREVISIAE; POLYADENYLATION SIGNALS; STRUCTURAL-ANALYSIS; GENE ORGANIZATION; TRANSIT PEPTIDE; PLANT GENES; EXPRESSION	Using a Nicotiana tabacum leaf cDNA library in the expression vector lambdagt11, two cDNAs encoding the full-length precursor polypeptide (M(r) 20,696) of tobacco chloroplast ribosomal protein L24 were identified and sequenced. These cDNAs encode a mature protein of 146 amino acids (M(r) 16,418) with a transit peptide of 41 amino acids (M(r) 4,278). The mature tobacco L24 protein has 78, 65, 45, and 35% sequence identity with ribosomal proteins L24 of pea, spinach, Bacillus subtilis, and Escherichia coli, respectively. The transit peptide of tobacco L24 is 54 and 57% identical with that of L24 chloroplast ribosomal proteins of pea and spinach, respectively. An expressed beta-galactosidase: L24 fusion protein, bound to nitrocellulose filters, was used as affinity matrix to purify monospecific antibody to L24 protein. Using this monospecific antibody, protein L24 was identified among high performance liquid chromatography (HPLC)-purified tobacco chloroplast ribosome 50 S subunit proteins. The predicted amino terminus of the mature L24 protein was confirmed by partial sequencing of the HPLC-purified L24 protein. Northern blot analysis revealed a single mRNA band (0.85-0.90 kilobase) corresponding in size to full-length L24 cDNA. The presence of multiple genes for L24 is suggested by Southern blot hybridization and characterization of two cDNAs for L24 which only differ in their 3'-noncoding sequences.	UNIV ARIZONA,DEPT BIOCHEM,TUCSON,AZ 85721; UNIV ARIZONA,DEPT CELLULAR & MOLEC BIOL,TUCSON,AZ 85721	University of Arizona; University of Arizona					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026937] Funding Source: NIH RePORTER; NCRR NIH HHS [507RR07002] Funding Source: Medline; NIGMS NIH HHS [GM26937] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOVICH N, 1984, MOL CELL BIOL, V4, P1871, DOI 10.1128/MCB.4.9.1871; AOTA S, 1988, NUCLEIC ACIDS RES, V16, pR315, DOI 10.1093/nar/16.suppl.r315; BARTSCH M, 1982, P NATL ACAD SCI-BIOL, V79, P6871, DOI 10.1073/pnas.79.22.6871; BEDBROOK J, 1981, PLANT MOL BIOL NEWSL, V2, P24; BISANZSEYER C, 1992, PLANT MOL BIOL, V18, P337, DOI 10.1007/BF00034960; BONHAMSMITH PC, 1990, CHROMOSOMES EUKARYOT, P179; Bourque D. P., 1982, METHODS CHLOROPLAST, P617; BOZZONI I, 1981, NUCLEIC ACIDS RES, V9, P1069, DOI 10.1093/nar/9.5.1069; BRANLANT C, 1973, FEBS LETT, V35, P265, DOI 10.1016/0014-5793(73)80301-1; BRANLANT C, 1977, EUR J BIOCHEM, V74, P155, DOI 10.1111/j.1432-1033.1977.tb11377.x; CAPEL MS, 1982, J BIOL CHEM, V257, P7746; CAROL P, 1991, GENE, V103, P139, DOI 10.1016/0378-1119(91)90266-E; CERRETTI DP, 1988, J MOL BIOL, V204, P309, DOI 10.1016/0022-2836(88)90578-5; CERRETTI DP, 1983, NUCLEIC ACIDS RES, V11, P2599, DOI 10.1093/nar/11.9.2599; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Dabbs ER, 1986, STRUCTURE FUNCTION G, P733; DEAN C, 1986, NUCLEIC ACIDS RES, V14, P2229, DOI 10.1093/nar/14.5.2229; DEAN D, 1981, NATURE, V289, P89, DOI 10.1038/289089a0; DHAESE P, 1983, EMBO J, V2, P419, DOI 10.1002/j.1460-2075.1983.tb01439.x; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; ELHAG GA, 1992, NUCLEIC ACIDS RES, V20, P689, DOI 10.1093/nar/20.4.689; ELHAG GA, 1992, BIOCHEMISTRY-US, V131, P6856; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIED HM, 1981, J BIOL CHEM, V256, P176; GANTT JS, 1990, J BIOL CHEM, V265, P2763; GANTT JS, 1986, MOL GEN GENET, V202, P186, DOI 10.1007/BF00331635; GANTT JS, 1988, CURR GENET, V14, P519, DOI 10.1007/BF00521278; GANTT JS, 1991, EMBO J, V10, P3073, DOI 10.1002/j.1460-2075.1991.tb07859.x; GIESE K, 1989, BIOCHEMISTRY-US, V28, P3525, DOI 10.1021/bi00434a056; GIESE K, 1991, FEBS LETT, V288, P72, DOI 10.1016/0014-5793(91)81005-S; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HEIDECKER G, 1986, ANNU REV PLANT PHYS, V37, P439, DOI 10.1146/annurev.arplant.37.1.439; HENKIN TM, 1989, NUCLEIC ACIDS RES, V17, P7469, DOI 10.1093/nar/17.18.7469; HEWLETT NG, 1986, METHOD ENZYMOL, V118, P201; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; HUMPHREY T, 1988, TRENDS GENET, V4, P243, DOI 10.1016/0168-9525(88)90028-5; HUNT AG, 1987, PLANT MOL BIOL, V8, P23, DOI 10.1007/BF00016431; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JOHNSON LM, 1985, CELL, V43, P369, DOI 10.1016/0092-8674(85)90042-X; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P9627, DOI 10.1093/nar/15.23.9627; KEMP DJ, 1981, P NATL ACAD SCI-BIOL, V78, P4520, DOI 10.1073/pnas.78.7.4520; KROL A, 1978, NUCLEIC ACIDS RES, V5, P4933, DOI 10.1093/nar/5.12.4933; LEE KY, 1988, EMBO J, V7, P1241, DOI 10.1002/j.1460-2075.1988.tb02937.x; LEER RJ, 1985, NUCLEIC ACIDS RES, V13, P5027, DOI 10.1093/nar/13.14.5027; MARTIN W, 1990, CURR GENET, V18, P553, DOI 10.1007/BF00327027; MATTHEAKIS LC, 1988, J BACTERIOL, V170, P4484, DOI 10.1128/jb.170.10.4484-4492.1988; MATTHEAKIS LC, 1989, P NATL ACAD SCI USA, V886, P448; MONK RJ, 1981, CELL, V24, P301, DOI 10.1016/0092-8674(81)90319-6; MOUNT DW, 1986, NUCLEIC ACIDS RES, V14, P443, DOI 10.1093/nar/14.1.443; NIERHAUS KH, 1980, RIBOSOMES STRUCTURE, P267; NISHI K, 1987, J BACTERIOL, V169, P4854, DOI 10.1128/jb.169.10.4854-4856.1987; NISHI K, 1986, EMBO J, V5, P1373, DOI 10.1002/j.1460-2075.1986.tb04369.x; NOWOTNY V, 1982, P NATL ACAD SCI-BIOL, V79, P7238, DOI 10.1073/pnas.79.23.7238; OGDEN RC, 1987, METHOD ENZYMOL, V152, P61; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; PHUA SH, 1989, J BIOL CHEM, V264, P1968; ROTENBERG MO, 1986, MOL CELL BIOL, V6, P674, DOI 10.1128/MCB.6.2.674; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT GW, 1986, ANNU REV BIOCHEM, V55, P879; SCHMIDT RJ, 1984, J CELL BIOL, V98, P2011, DOI 10.1083/jcb.98.6.2011; SCHMIDT RJ, 1983, J CELL BIOL, V96, P1451, DOI 10.1083/jcb.96.5.1451; SHEETS MD, 1989, GENE DEV, V3, P1401, DOI 10.1101/gad.3.9.1401; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; SIGEL MB, 1983, METHOD ENZYMOL, V93, P3; Silhavy T.J., 1984, EXPT GENE FUSIONS; SLOOF P, 1978, NUCLEIC ACIDS RES, V5, P3503, DOI 10.1093/nar/5.10.3503; SMITH HH, 1979, USDA TECH B, V1586, P1; SMITH HH, 1975, HDB GENETICS, V2, P281; SMOOKER PM, 1990, J BIOL CHEM, V265, P16699; SMOOKER PM, 1991, BIOCHIMIE, V73, P845, DOI 10.1016/0300-9084(91)90064-8; STERN DB, 1991, PLANT CELL, V3, P285; TAKAIWA F, 1982, EUR J BIOCHEM, V124, P13, DOI 10.1111/j.1432-1033.1982.tb05901.x; THEOLOGIS A, 1985, J MOL BIOL, V183, P53, DOI 10.1016/0022-2836(85)90280-3; THOMPSON MD, 1992, PLANT MOL BIOL, V18, P931, DOI 10.1007/BF00019207; TOHDOH N, 1982, GENE, V17, P213, DOI 10.1016/0378-1119(82)90074-9; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; Wittmann-Liebold Brigitte, 1986, STRUCTURE FUNCTION G, P326; WITTMANNLIEBOLD B, 1979, FEBS LETT, V108, P75, DOI 10.1016/0014-5793(79)81182-5; YATES JL, 1980, P NATL ACAD SCI-BIOL, V77, P1837, DOI 10.1073/pnas.77.4.1837; YOKOI F, 1990, FEBS LETT, V276, P88, DOI 10.1016/0014-5793(90)80514-J; ZHOU DX, 1989, MOL GEN GENET, V219, P204, DOI 10.1007/BF00261178	81	4	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21705	21711						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400480				2022-12-25	WOS:A1992JV01100070
J	KAMBOURIS, NG; BURKE, DJ; CREUTZ, CE				KAMBOURIS, NG; BURKE, DJ; CREUTZ, CE			CLONING AND CHARACTERIZATION OF A CYSTEINE PROTEINASE FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLEOMYCIN HYDROLASE; CATHEPSIN-B; THIOL PROTEASE; GENE-PRODUCT; YEAST; SEQUENCE; AMINOPEPTIDASE; PURIFICATION; DIFFERENTIATION; INVOLVEMENT	We have isolated a gene from Saccharomyces cerevisiae that encodes a protein homologous to the mammalian cysteine proteinase bleomycin hydrolase. Sequence comparison between the yeast and rabbit proteins indicates an amino acid identity of 41.5% over 277 residues and a similarity of 78.3% when conservative substitutions are included. The apparent mass of the yeast protein by sodium dodecyl sulfate-polyacrylamide gel electrophoresis is 47 kDa, although sequence analysis indicates two potential initiator methionines that suggest calculated masses of either 51 or 55 kDa. The protein is nonessential in yeast as haploid mutants disrupted at several positions along the open reading frame remain viable. Furthermore, these mutants do not exhibit any readily observable growth defects under varying conditions of temperature, nutrients, osmotic strength, or exogenous bleomycin. However, the purified protein does exhibit marked hydrolytic activity toward the substrate arginine 4-methyl-7-coumarylamide (K(m) = 12.8 muM, V(max) = 2.56 mumol mg-1 h-1), and yeast cells engineered to express this protein at higher levels maintain increased resistance to bleomycin compared to wild-type cells. Because this protein represents the first example of a cysteine proteinase identified in yeast, we have named it Ycp1 (yeast cysteine proteinase).	UNIV VIRGINIA, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, DEPT BIOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040334] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33151] Funding Source: Medline; NIGMS NIH HHS [R29GM-40334] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHSTETTER T, 1982, BIOCHEM BIOPH RES CO, V109, P341, DOI 10.1016/0006-291X(82)91726-0; BARRETT AJ, 1980, BIOCHEM J, V187, P909, DOI 10.1042/bj1870909; BENNETT JM, 1979, ANN INTERN MED, V90, P945, DOI 10.7326/0003-4819-90-6-945; Broach J. R., 1983, EXPT MANIPULATION GE, P83; Brocklehurst K., 1987, HYDROLYTIC ENZYMES, P39; CIGAN AM, 1987, GENE, V59, P1; COOPER A, 1989, MOL CELL BIOL, V9, P2706, DOI 10.1128/MCB.9.6.2706; CREUTZ CE, 1991, YEAST, V7, P229, DOI 10.1002/yea.320070305; DAVIS TN, 1987, METHOD ENZYMOL, V139, P248; DELAISSE JM, 1984, BIOCHEM BIOPH RES CO, V125, P441, DOI 10.1016/0006-291X(84)90560-6; DOBSON MJ, 1982, NUCLEIC ACIDS RES, V10, P2625, DOI 10.1093/nar/10.8.2625; DOCHERTY K, 1982, P NATL ACAD SCI-BIOL, V79, P4613, DOI 10.1073/pnas.79.15.4613; DUNN AD, 1991, J BIOL CHEM, V266, P20198; FILDERMAN AE, 1988, BIOCHEM PHARMACOL, V37, P1111, DOI 10.1016/0006-2952(88)90518-7; FUCHS R, 1988, BIOL CHEM H-S, V369, P469, DOI 10.1515/bchm3.1988.369.1.469; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; HAYASHI R, 1975, J BIOCHEM-TOKYO, V77, P1313; HENIKOFF S, 1983, CELL, V33, P607, DOI 10.1016/0092-8674(83)90441-5; HOLLAND JP, 1983, J BIOL CHEM, V258, P5291; HUSAIN SS, 1969, BIOCHEM J, V114, P279, DOI 10.1042/bj1140279; JONES EW, 1991, J BIOL CHEM, V266, P7963; JONES EW, 1991, METHOD ENZYMOL, V194, P428; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; KIRSCHKE H, 1989, BIOCHEM J, V264, P467, DOI 10.1042/bj2640467; KREIGER TJ, 1991, J BIOL CHEM, V266, P8376; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KRETSINGER RH, 1986, NATURE, V320, P573, DOI 10.1038/320573a0; LANGFORD CJ, 1984, CELL, V36, P645, DOI 10.1016/0092-8674(84)90344-1; LAZO JS, 1988, MALIGNANT CELL RESIS; LOH YP, 1982, P NATL ACAD SCI-BIOL, V79, P108, DOI 10.1073/pnas.79.1.108; METZ G, 1976, BIOCHIM BIOPHYS ACTA, V429, P933, DOI 10.1016/0005-2744(76)90338-7; MOEHLE CM, 1987, MOL CELL BIOL, V7, P4390, DOI 10.1128/MCB.7.12.4390; MOEHLE CM, 1989, J CELL BIOL, V108, P309, DOI 10.1083/jcb.108.2.309; MOORE CW, 1980, J ANTIBIOT, V33, P1369, DOI 10.7164/antibiotics.33.1369; NISHIMURA C, 1989, BIOCHEM BIOPH RES CO, V163, P788, DOI 10.1016/0006-291X(89)92291-2; NISHIMURA C, 1987, BIOCHEMISTRY-US, V26, P1574, DOI 10.1021/bi00380a013; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RITONJA A, 1985, FEBS LETT, V181, P169, DOI 10.1016/0014-5793(85)81136-4; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEBTI SM, 1989, BIOCHEM PHARMACOL, V38, P141, DOI 10.1016/0006-2952(89)90160-3; SEBTI SM, 1989, BIOCHEMISTRY-US, V28, P6544, DOI 10.1021/bi00442a003; SEBTI SM, 1987, BIOCHEMISTRY-US, V26, P4213, DOI 10.1021/bi00388a006; SEBTI SM, 1988, PHARMACOL THERAPEUT, V38, P321, DOI 10.1016/0163-7258(88)90009-5; SEIFERT HS, 1986, P NATL ACAD SCI USA, V83, P735, DOI 10.1073/pnas.83.3.735; SHERMAN F, 1987, METHODS YEAST GENETI; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; WIEDERANDERS B, 1991, FEBS LETT, V286, P189, DOI 10.1016/0014-5793(91)80971-5; WILLIAMS S, 1986, BIOTECHNIQUES, V4, P139; WOLF DH, 1978, FEBS LETT, V91, P59, DOI 10.1016/0014-5793(78)80017-9; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	53	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21570	21576						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400467				2022-12-25	WOS:A1992JV01100049
J	LEE, MJ; SANDIG, M; WANG, E				LEE, MJ; SANDIG, M; WANG, E			STATIN, A PROTEIN SPECIFICALLY PRESENT IN NONPROLIFERATING CELLS, IS A PHOSPHOPROTEIN AND FORMS A COMPLEX WITH A 45-KILODALTON SERINE THREONINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PROTEIN; PROLIFERATION; MARKER; FIBROBLASTS; EXPRESSION	The protein statin is found in nuclei of nonproliferating cells. Here we report that statin is a phosphoprotein, phosphorylated at serine residues in cultured cells. During immunoprecipitation with anti-statin (S44) antibody, a 45-kDa protein co-precipitates with the 57-kDa statin. In vitro kinase assays demonstrate that the S44 immunoprecipitates can phosphorylate, besides statin, immunoglobulins, enolase, and casein, at either serine or serine/threonine residues. Kinase assays with immunoprecipitated proteins performed on casein- or enolase-impregnated gels show that these substrates are phosphorylated by the 45-kDa (p45) protein. When the S44 immunoprecipitates from human cultured fibroblasts with different in vitro life-spans were compared, the p45 kinase activity was present only in young nongrowing and senescent cells, but not in young growing ones. In other cell cultures, the kinase is detected only in protein complexes precipitated from quiescent 3T3 cells, but not from cycling 3T3 cells or from transformed human glioma (U251-4) cells. Cell fractionation studies, indicating that the phosphorylating activity of S44 immunoprecipitates correlates both qualitatively and quantitatively with the amount of statin present, provide strong evidence that in vivo statin is specifically associated with the p45 kinase. These results suggest that the nonproliferation-specific nature of statin is indeed related to the phosphorylated property of this protein and maybe contributed by the associated kinase.	SIR MORTIMER B DAVIS JEWISH HOSP,LADY DAVIS INST MED RES,BLOOMFIELD CTR RES AGING,MONTREAL H3T 1E2,QUEBEC,CANADA; MCGILL UNIV,DEPT MED,MONTREAL H3T 1E2,QUEBEC,CANADA; MCGILL UNIV,DEPT ANAT,MONTREAL H3T 1E2,QUEBEC,CANADA	Lady Davis Institute; McGill University; McGill University; McGill University					NIA NIH HHS [R01AG 07444] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG007444] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BEEMON K, 1978, J VIROL, V28, P552; BISSONNETTE R, 1990, J CELL SCI, V95, P247; CHING G, 1990, J CELL BIOL, V110, P255, DOI 10.1083/jcb.110.2.255; COOPER JA, 1984, J BIOL CHEM, V259, P7835; GEAHLEN RL, 1986, ANAL BIOCHEM, V153, P151, DOI 10.1016/0003-2697(86)90074-6; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; MATHEWS MB, 1984, NATURE, V309, P374, DOI 10.1038/309374a0; OLASHAW NE, 1983, REV BIOL RES AGING, V1, P225; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; RITTLING SR, 1986, P NATL ACAD SCI USA, V83, P3316, DOI 10.1073/pnas.83.10.3316; SCHIPPER HM, 1990, BRAIN RES, V528, P250, DOI 10.1016/0006-8993(90)91665-4; SESTER U, 1989, EXP CELL RES, V182, P550, DOI 10.1016/0014-4827(89)90258-9; SWIM HE, 1957, AM J HYG, V66, P235, DOI 10.1093/oxfordjournals.aje.a119897; WANG E, 1985, J CELL BIOL, V100, P1466, DOI 10.1083/jcb.100.5.1466; WANG E, 1986, EXP CELL RES, V167, P135, DOI 10.1016/0014-4827(86)90211-9; WANG E, 1985, J HISTOCHEM CYTOCHEM, V33, P587, DOI 10.1177/33.6.3889143; WANG E, 1985, J CELL BIOL, V100, P545, DOI 10.1083/jcb.100.2.545; YOUNG F, 1990, NATURE, V347, P494	18	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21773	21781						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400486				2022-12-25	WOS:A1992JV01100080
J	GILON, P; HENQUIN, JC				GILON, P; HENQUIN, JC			INFLUENCE OF MEMBRANE-POTENTIAL CHANGES ON CYTOPLASMIC CA2+ CONCENTRATION IN AN ELECTRICALLY EXCITABLE CELL, THE INSULIN-SECRETING PANCREATIC B-CELL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-INDUCED OSCILLATIONS; BETA-CELLS; CALCIUM OSCILLATIONS; PYRIDINE-NUCLEOTIDES; RB-86+ FLUXES; ION CHANNELS; ISLETS; CA-2+; FLUORESCENCE; TOLBUTAMIDE	Glucose stimulation of insulin release involves metabolism of the sugar and elevation of cytoplasmic calcium (Ca2+i) in pancreatic B-cells. We compared the dynamic changes of metabolism (fluorescence of endogenous reduced pyridine nucleotides, NAD(P)H), membrane potential (intracellular microelectrodes), and Ca2+i (fura-2 technique), in intact mouse islets. Glucose (15 mM) sequentially triggered an increase in NAD(P)H fluorescence, a depolarization with electrical activity, and a rise in Ca2+i. The change in NAD(P)H was monophasic and regular, whereas the changes in membrane potential and Ca2+i were multiphasic, with steady-state regular oscillations of similar average frequencies (about 2.2/min). Digital image analysis revealed that Ca2+i oscillations were synchronous in all regions of the islets. Omission of extracellular Ca2+ abolished the rise in Ca2+i but not the increase in NAD(P)H. Both electrical and Ca2+i oscillations disappeared in low external Ca2+ (1 mM), and became larger but slower in high Ca2+ (10 mM). Sustained depolarization (by tolbutamide, arginine, or high K+) and hyperpolarization (by diazoxide) of B-cells caused sustained increases and decreases of Ca2+i, respectively. In conclusion, the changes in membrane potential induced by various secretagogues trigger synchronous changes in Ca2+i in all B-cells of the islets. The oscillatory pattern of the electrical and Ca2+i responses induced by glucose is not accompanied by and thus probably not due to similar oscillations of metabolism.	CATHOLIC UNIV LOUVAIN, FAC MED,UNITE DIABETOL & NUTR,UCL 5474, AVE HIPPOCRATE 54, B-1200 BRUSSELS, BELGIUM; UNIV SAARLAND, INST PHYSIOL, W-6650 HOMBURG, GERMANY	Universite Catholique Louvain; Saarland University								AMMALA C, 1991, NATURE, V353, P849, DOI 10.1038/353849a0; Atwater I, 1980, Horm Metab Res Suppl, VSuppl 10, P100; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; COOK DL, 1991, TRENDS NEUROSCI, V14, P411, DOI 10.1016/0166-2236(91)90033-Q; CURRY DL, 1968, ENDOCRINOLOGY, V83, P572, DOI 10.1210/endo-83-3-572; DEAN PM, 1968, NATURE, V219, P389, DOI 10.1038/219389a0; DOUGLAS WW, 1968, BRIT J PHARMACOL, V34, P451, DOI 10.1111/j.1476-5381.1968.tb08474.x; DUNNE MJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P67, DOI 10.1016/0304-4157(91)90012-L; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; GRAPENGIESSER E, 1988, BIOCHEM BIOPH RES CO, V151, P1299, DOI 10.1016/S0006-291X(88)80503-5; GRAPENGIESSER E, 1990, MOL PHARMACOL, V37, P461; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GYLFE E, 1991, CELL CALCIUM, V12, P229, DOI 10.1016/0143-4160(91)90023-8; GYLFE E, 1988, J BIOL CHEM, V263, P13750; HENQUIN JC, 1990, DIABETES, V39, P1457, DOI 10.2337/diabetes.39.11.1457; HENQUIN JC, 1978, ENDOCRINOLOGY, V102, P723, DOI 10.1210/endo-102-3-723; HENQUIN JC, 1982, BIOCHEM PHARMACOL, V31, P1407, DOI 10.1016/0006-2952(82)90036-3; HENQUIN JC, 1981, AM J PHYSIOL, V240, pE245, DOI 10.1152/ajpendo.1981.240.3.E245; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; HIRIART M, 1991, ENDOCRINOLOGY, V128, P3193, DOI 10.1210/endo-128-6-3193; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; LONGO EA, 1991, J BIOL CHEM, V266, P9314; MEISSNER HP, 1990, METHOD ENZYMOL, V192, P235; MEISSNER HP, 1976, J PHYSIOL-PARIS, V72, P757; PANTEN U, 1986, DIABETOLOGIA, V29, P648, DOI 10.1007/BF00869265; PANTEN U, 1973, DIABETOLOGIA, V9, P477, DOI 10.1007/BF00461692; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RIBALET B, 1980, AM J PHYSIOL, V239, pC124, DOI 10.1152/ajpcell.1980.239.3.C124; SALOMON D, 1986, EXP CELL RES, V162, P507, DOI 10.1016/0014-4827(86)90354-X; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SHERMAN A, 1988, BIOPHYS J, V54, P411, DOI 10.1016/S0006-3495(88)82975-8; SMITH PA, 1990, FEBS LETT, V261, P187, DOI 10.1016/0014-5793(90)80667-8; SORIA B, 1991, DIABETES, V40, P1069, DOI 10.2337/diabetes.40.8.1069; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; VALDEOLMILLOS M, 1989, FEBS LETT, V259, P19, DOI 10.1016/0014-5793(89)81484-X; WANG JL, 1990, BIOCHEM BIOPH RES CO, V166, P813, DOI 10.1016/0006-291X(90)90882-N; WOLLHEIM CB, 1986, ANN NY ACAD SCI, V488, P317; YADA T, 1992, CELL CALCIUM, V13, P69, DOI 10.1016/0143-4160(92)90031-M	39	243	245	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20713	20720						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400388				2022-12-25	WOS:A1992JT97800033
J	NIKAIDO, K; AMES, GF				NIKAIDO, K; AMES, GF			PURIFICATION AND CHARACTERIZATION OF THE PERIPLASMIC LYSINE-BINDING, ARGININE-BINDING, ORNITHINE-BINDING PROTEIN (LAO) FROM SALMONELLA-TYPHIMURIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE TRANSPORT COMPONENT; AMINO-ACID TRANSPORT; PRELIMINARY-X-RAY; ESCHERICHIA-COLI; ACTIVE-TRANSPORT; SYSTEMS; CRYSTALLIZATION; MODEL; HISJ	The lysine-, arginine-, ornithine-binding protein (LAO) from Salmonella typhimurium has been purified to homogeneity and characterized. The dissociation constants (K(D)) were determined by equilibrium dialysis assay to be 14, 15, and 29 nM for L-arginine, L-lysine, and L-ornithine respectively. L-Histidine was found to be a relatively good ligand (K(D), 500 nM). Methods have been developed for the separation of liganded from unliganded LAO, for the estimation of bound ligand, and for unliganding LAO. Liganded and unliganded LAO are shown to have distinct UV spectra. The UV spectrum also varies with the nature of the substrate. Inhibition studies with substrate analogs yielded information useful for understanding the nature of the ligand-binding pocket.			NIKAIDO, K (corresponding author), UNIV CALIF BERKELEY, DIV BIOCHEM & MOLEC BIOL, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK012121, R37DK012121, R01DK043747] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43747, DK12121] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS MD, 1989, J BIOL CHEM, V264, P15739; AMES GF, 1992, FASEB J, V6, P2660, DOI 10.1096/fasebj.6.9.1377140; AMES GFL, 1972, J BIOL CHEM, V247, P4309; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; EASLEY CW, 1969, BIOCHIM BIOPHYS ACTA, V175, P211, DOI 10.1016/0005-2795(69)90161-5; FERROLUZZIAMES G, 1976, P NATL ACAD SCI USA, V73, P1877, DOI 10.1073/pnas.73.6.1877; HIGGINS CF, 1981, P NATL ACAD SCI-BIOL, V78, P6038, DOI 10.1073/pnas.78.10.6038; KANG CH, 1989, J MOL BIOL, V207, P643, DOI 10.1016/0022-2836(89)90475-0; KERPPOLA RE, 1992, J BIOL CHEM, V267, P2329; KERPPOLA RE, 1990, THESIS U CALIFORNIA; KUSTU SG, 1979, J BACTERIOL, V138, P218, DOI 10.1128/JB.138.1.218-234.1979; KUSTU SG, 1973, J BACTERIOL, V116, P107, DOI 10.1128/JB.116.1.107-113.1973; KUSTU SG, 1974, J BIOL CHEM, V249, P6976; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVER JE, 1972, J BIOL CHEM, V247, P4317; LEVER JE, 1972, ANAL BIOCHEM, V50, P73, DOI 10.1016/0003-2697(72)90487-3; MAO B, 1982, J BIOL CHEM, V257, P1131; MILLER DM, 1983, J BIOL CHEM, V258, P3665; Miller JH., 1972, EXPT MOL GENETICS; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; NOHNO T, 1986, MOL GEN GENET, V205, P260, DOI 10.1007/BF00430437; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PETRONILLI V, 1991, J BIOL CHEM, V266, P16293; PETRONILLI V, 1991, BIOPHYS  J, V59, P322; PFLUGRATH JW, 1988, J MOL BIOL, V200, P163, DOI 10.1016/0022-2836(88)90341-5; PFLUGRATH JW, 1985, NATURE, V314, P257, DOI 10.1038/314257a0; QUAY S, 1974, J BIOL CHEM, V249, P7011; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; ROSEN BP, 1973, J BIOL CHEM, V248, P1211; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; SHIFRIN S, 1966, J BIOL CHEM, V241, P3424; SLETZINGER M, 1968, J MED CHEM, V11, P261, DOI 10.1021/jm00308a015; TRAKHANOV SD, 1989, J MOL BIOL, V207, P847, DOI 10.1016/0022-2836(89)90253-2; ZUKIN RS, 1986, BIOPHYS J, V49, P1229, DOI 10.1016/S0006-3495(86)83752-3	37	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20706	20712						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400387				2022-12-25	WOS:A1992JT97800032
J	BARTLETT, JD; LUETHY, JD; CARLSON, SG; SOLLOTT, SJ; HOLBROOK, NJ				BARTLETT, JD; LUETHY, JD; CARLSON, SG; SOLLOTT, SJ; HOLBROOK, NJ			CALCIUM IONOPHORE-A23187 INDUCES EXPRESSION OF THE GROWTH ARREST AND DNA DAMAGE INDUCIBLE CCAAT ENHANCER-BINDING PROTEIN (C/EBP)-RELATED GENE, GADD153 - CA2+ INCREASES TRANSCRIPTIONAL ACTIVITY AND MESSENGER-RNA STABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS; KINASE-C; INTRACELLULAR CALCIUM; HYDROGEN-PEROXIDE; MAMMALIAN-CELLS; LIVER NUCLEI; HEAT-SHOCK; ACTIVATION; TOXICITY; INHIBITOR	gadd153 is a CCAAT/enhancer-binding protein (C/EBP)-related gene whose expression is induced in response to growth arrest and DNA damage. This investigation explored the possibility that Ca2+ might play a role in regulating expression of gadd153. We have demonstrated that treatment of HeLa cells with the calcium ionophores A23187 and ionomycin leads to the induction of gadd153 mRNA. The induction was rapid; increases in mRNA were detected by 90 min of treatment, and near maximum levels were achieved within 5-h exposure to A23187. Elevated mRNA levels resulted from both an increase in the rate of gadd153 transcription and an increase in the stability of the gadd153 mRNA. The response was not dependent on protein kinase C nor was it coupled to c-fos expression. Buffering intracellular and extracellular Ca2+ by combined treatment with BAPTA-AM (acetoxymethyl ester form of bis(aminophenoxy)ethane N,N'-tetraacetic acid) and EGTA prevented the induction of gadd153 mRNA by A23187. In addition, these treatments prevented the induction of gadd153 mRNA in response to the DNA damaging agent methyl methanesulfonate. We conclude that intracellular Ca2+ plays a role in regulating gadd153 expression. More specifically, Ca2+ likely plays a role in the induction of gadd153 mRNA following DNA damage.	NIA, MOLEC GENET LAB, BALTIMORE, MD 21224 USA; NIA, CARDIOVASC SCI LAB, BALTIMORE, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)			Bartlett, John/L-9832-2017	Bartlett, John/0000-0003-2052-6299				BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERTRAND R, 1991, BIOCHEM PHARMACOL, V42, P77, DOI 10.1016/0006-2952(91)90683-V; BOOBIS AR, 1990, BIOCHEM PHARMACOL, V39, P1277, DOI 10.1016/0006-2952(90)90003-4; BORNER C, 1988, P NATL ACAD SCI USA, V85, P2110, DOI 10.1073/pnas.85.7.2110; BURGOYNE RD, 1989, NATURE, V342, P72, DOI 10.1038/342072a0; Campbell A.K, 1983, INTRACELLULAR CALCIU; CANTONI O, 1989, EUR J BIOCHEM, V182, P209, DOI 10.1111/j.1432-1033.1989.tb14819.x; CHEN Q, 1992, J BIOL CHEM, V267, P8207; CHOI AMK, 1992, EXP CELL RES, V199, P85, DOI 10.1016/0014-4827(92)90464-J; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; DYPBUKT JM, 1990, FREE RADICAL RES COM, V8, P347, DOI 10.3109/10715769009053368; FARGNOLI J, 1990, P NATL ACAD SCI USA, V87, P846, DOI 10.1073/pnas.87.2.846; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; HOLBROOK NJ, 1992, MOL CELL BIOL, V12, P1528, DOI 10.1128/MCB.12.4.1528; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; JONES DP, 1989, J BIOL CHEM, V264, P6398; KAINA B, 1989, NATO ADV SCI I A-LIF, V182, P149; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; MCMAHON G, 1984, P NATL ACAD SCI-BIOL, V81, P7461, DOI 10.1073/pnas.81.23.7461; MOORE JP, 1986, J BIOL CHEM, V261, P8158; MORGAN JI, 1988, CELL CALCIUM, V9, P303, DOI 10.1016/0143-4160(88)90011-5; MUEL AS, 1986, J CELL PHYSIOL, V127, P167, DOI 10.1002/jcp.1041270120; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6858, DOI 10.1073/pnas.87.17.6858; POLLA BS, 1988, J CELL BIOL, V107, P373, DOI 10.1083/jcb.107.1.373; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SPURGEON HA, 1990, AM J PHYSIOL, V258, pH574, DOI 10.1152/ajpheart.1990.258.2.H574; WAYBILL MM, 1991, AM J PHYSIOL, V261, pE49, DOI 10.1152/ajpendo.1991.261.1.E49; WEINSTEIN IB, 1991, ENVIRON HEALTH PERSP, V93, P175, DOI 10.2307/3431186	39	128	128	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20465	20470						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400365				2022-12-25	WOS:A1992JR85800111
J	BERRETTINI, M; SCHLEEF, RR; HEEB, MJ; HOPMEIER, P; GRIFFIN, JH				BERRETTINI, M; SCHLEEF, RR; HEEB, MJ; HOPMEIER, P; GRIFFIN, JH			ASSEMBLY AND EXPRESSION OF AN INTRINSIC FACTOR-IX ACTIVATOR COMPLEX ON THE SURFACE OF CULTURED HUMAN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; COAGULATION FACTOR-XI; WASHED HUMAN-PLATELETS; CONTACT ACTIVATION; HAGEMAN-FACTOR; TISSUE-FACTOR; HUMAN-PLASMA; LIGHT CHAIN; FUNCTIONAL-CHARACTERIZATION; PLASMINOGEN-ACTIVATOR	Endothelial cells expose specific receptors for blood clotting factors and, upon perturbation, can initiate and propagate the reactions of the extrinsic pathway of blood coagulation leading to fibrin formation on the cell surface. The existence of an intrinsic mechanism of Factor IX activation on cultured human umbilical vein cells (HUVECs) was investigated by studies of the interaction between HUVECs and two proteins of the contact activation system, the cofactor high molecular weight kininogen (H-kininogen) and the zymogen Factor XI. In the presence of zinc ions (10-300 muM), I-125-labeled H-kininogen bound to HUVECs in a time-dependent, reversible, and saturable manner, with calcium ions exerting an inhibitory effect on the zinc-dependent binding. Analysis of the binding data by the LIGAND computer program indicated that HUVECs, in the presence of 2 mM CaCl2 and 100 muM ZnCl2 at 37-degrees-C, bound 1.14 x 10(7) H-kininogen molecules per cell with an apparent dissociation constant of 55 nM. HUVEC-bound H-kininogen functions as the cell surface receptor for both I-125-labeled Factor XI and I-125-labeled Factor XIa, since HUVECs cultured in contact factor-depleted serum do not detectably bind either the zymogen or the enzyme in the absence of H-kininogen and zinc ions. In the presence of saturating concentrations of H-kininogen, 2 mM CaCl2 and 100 muM ZnCl2, the binding of I-125-labeled Factor XI and Factor XIa to HUVECs was time-dependent, reversible, and saturable, with apparent dissociation constants of 4.5 and 1.5 nM, respectively. HUVEC-bound complexes of H-kininogen and Factor XI generated Factor XIa activity only after the addition of purified Factor XIIa, and cell-bound Factor XIa in turn activated Factor IX, as documented by a H-3-labeled activation peptide release assay for H-3-Factor IX activation. The results indicate that cultured HUVECs provide a surface for the assembly and expression of an intrinsic Factor IX activator complex that may participate in the initiation of blood coagulation at sites of vascular injury.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute				Griffin, John/0000-0002-4302-2547	NHLBI NIH HHS [HL-21544] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021544] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERRETTINI M, 1989, J BIOL CHEM, V264, P11738; BERRETTINI M, 1986, BLOOD, V68, P455; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; BOUMA BN, 1983, BLOOD, V62, P1123; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; COLMAN RW, 1984, J CLIN INVEST, V73, P1249, DOI 10.1172/JCI111326; COLUCCI M, 1983, J CLIN INVEST, V71, P1893, DOI 10.1172/JCI110945; ESMON NL, 1982, J BIOL CHEM, V257, P859; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUJIKAWA K, 1973, BIOCHEMISTRY-US, V12, P4938, DOI 10.1021/bi00748a019; GREENGARD JS, 1984, BIOCHEMISTRY-US, V23, P6863, DOI 10.1021/bi00321a090; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; Griffin J H, 1976, Methods Enzymol, V45, P56; GUSTAFSON EJ, 1986, J CLIN INVEST, V78, P310, DOI 10.1172/JCI112567; GUSTAFSON EJ, 1989, J CLIN INVEST, V84, P28, DOI 10.1172/JCI114151; KERBIRIOU DM, 1979, J BIOL CHEM, V254, P2020; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMLE B, 1987, SEMIN THROMB HEMOST, V13, P106, DOI 10.1055/s-2007-1003480; LOSKUTOFF DJ, 1977, P NATL ACAD SCI USA, V74, P3093; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDLE RJ, 1976, P NATL ACAD SCI USA, V73, P4179, DOI 10.1073/pnas.73.11.4179; MARCUM JA, 1984, J CLIN INVEST, V74, P341, DOI 10.1172/JCI111429; MAYNARD JR, 1977, BLOOD, V50, P387; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; RODGERS GM, 1983, P NATL ACAD SCI-BIOL, V80, P7001, DOI 10.1073/pnas.80.22.7001; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; SILVERBERG M, 1980, THROMB RES, V20, P173, DOI 10.1016/0049-3848(80)90383-7; SINHA D, 1984, J CLIN INVEST, V73, P1550, DOI 10.1172/JCI111361; STENFLO J, 1976, J BIOL CHEM, V251, P355; STERN D, 1985, P NATL ACAD SCI USA, V82, P2523, DOI 10.1073/pnas.82.8.2523; STERN DM, 1983, P NATL ACAD SCI-BIOL, V80, P4119, DOI 10.1073/pnas.80.13.4119; STERN DM, 1984, P NATL ACAD SCI-BIOL, V81, P913, DOI 10.1073/pnas.81.3.913; STERN DM, 1985, J BIOL CHEM, V260, P6717; TANS G, 1983, J BIOL CHEM, V258, P8215; THOMPSON RE, 1979, P NATL ACAD SCI USA, V76, P4862, DOI 10.1073/pnas.76.10.4862; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; VANDERGRAAF F, 1982, J BIOL CHEM, V257, P4300; VANDERGRAAF F, 1983, J BIOL CHEM, V258, P9669; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; VANIWAARDEN F, 1988, BLOOD, V71, P1268; WALSH PN, 1986, BLOOD, V68, P225; WALSH PN, 1981, BLOOD, V57, P106; WEKSLER BB, 1977, P NATL ACAD SCI USA, V74, P3922, DOI 10.1073/pnas.74.9.3922; WIGGINS RC, 1977, P NATL ACAD SCI USA, V74, P4636, DOI 10.1073/pnas.74.10.4636; WIGGINS RC, 1980, J CLIN INVEST, V65, P197, DOI 10.1172/JCI109651; ZUR M, 1980, J BIOL CHEM, V255, P5703	47	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19833	19839						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400299				2022-12-25	WOS:A1992JR85800016
J	ENAN, E; LIU, PCC; MATSUMURA, F				ENAN, E; LIU, PCC; MATSUMURA, F			2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN CAUSES REDUCTION OF GLUCOSE TRANSPORTING ACTIVITIES IN THE PLASMA-MEMBRANES OF ADIPOSE-TISSUE AND PANCREAS FROM THE GUINEA-PIG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC CYTOSOL; TOXICITY; RATS; MECHANISM; INSULIN; TCDD; RECEPTOR; ENZYMES	Toxicity from 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) exposure results in severe metabolic imbalances leading to a loss of fat stores in many animal species, a phenomenon known as the wasting syndrome. In this paper, we report that TCDD treatment at very low doses (0.03-1 mug/kg, single intraperitoneal injection) causes a profound reduction of glucose uptake by guinea pig adipose tissue, pancreas and brain. This effect of TCDD is dose-dependent, with a dose as small as 0.03 mug/kg resulting in a significant decrease. In adipose tissue, the decrease begins within 6 h of treatment and persists at least 28 days. The V(max) of glucose transport was decreased by TCDD treatment, whereas the K(m) was unchanged. Liver behaves oppositely to adipose tissue. At early stages of treatment (6-12 h) glucose uptake was depressed, while at later stages (24-96 h) it was increased. In situ (explant tissue culture) treatment with TCDD yields similar trends as in vivo studies for glucose uptake in all three tissues. In adipose tissue culture TCDD starts reducing glucose uptake after 30 minutes. The inhibitory potencies of three dioxin congeners on adipose glucose transporting activities follows the same order of their toxicities in vivo. TCDD's effect on glucose transport is sensitive to cytochalasin B, a specific inhibitor of glucose transporter proteins. Based on these observations and the importance of glucose transporters to cellular energy maintenance, we conclude that at least in guinea pigs the reduction of glucose transporters in various tissues is one of the major causes for TCDD-induced wasting syndrome, which is so prominent in this species.			ENAN, E (corresponding author), UNIV CALIF DAVIS,DEPT ENVIRONM TOXICOL,DAVIS,CA 95616, USA.				NIEHS NIH HHS [ESO5233, ESO3575] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003575] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BREWSTER DW, 1988, BIOCHEM PHARMACOL, V37, P2247, DOI 10.1016/0006-2952(88)90588-6; BREWSTER DW, 1987, TOXICOL APPL PHARM, V89, P408, DOI 10.1016/0041-008X(87)90160-8; BREWSTER DW, 1984, BIOCHEM BIOPH RES CO, V122, P810, DOI 10.1016/S0006-291X(84)80106-0; BREWSTER DW, 1988, J TOXICOL ENV HEALTH, V25, P495, DOI 10.1080/15287398809531227; BREWSTER DW, 1985, THESIS MICHIGAN STAT; CHU DT, 1990, BIOCHEM SOC T, V18, P1247, DOI 10.1042/bst0181247; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; EBNER K, 1988, J ENVIRON SCI HEAL B, V23, P427, DOI 10.1080/03601238809372617; GASIEWICZ TA, 1980, TOXICOL APPL PHARM, V54, P469, DOI 10.1016/0041-008X(80)90174-X; GASIEWICZ TA, 1979, TOXICOL APPL PHARM, V51, P329, DOI 10.1016/0041-008X(79)90475-7; GREENLEE WF, 1979, J BIOL CHEM, V254, P9814; HENDLEY ED, 1987, AM J PHYSIOL, V253, pR434, DOI 10.1152/ajpregu.1987.253.3.R434; HORUK R, 1983, J BIOL CHEM, V258, P7425; ISMAIL SMM, 1991, PESTIC BIOCHEM PHYS, V39, P219, DOI 10.1016/0048-3575(91)90117-5; LAKSHMAN MR, 1989, J PHARMACOL EXP THER, V248, P62; OLSON JR, 1980, TOXICOL APPL PHARM, V55, P67, DOI 10.1016/0041-008X(80)90221-5; PETERSON RE, 1984, BRANBURY REPORT, V18, P291; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1976, J BIOL CHEM, V251, P4936; POLAND A, 1984, BANBURY REPORT, V18, P1; PORTER EV, 1982, METHOD ENZYMOL, V90, P25; POTTER CL, 1983, TOXICOL APPL PHARM, V69, P89, DOI 10.1016/0041-008X(83)90123-0; ROZMAN KK, 1991, DIOXIN 91, P28; SCHWETZ B A, 1973, Environmental Health Perspectives, V5, P87, DOI 10.2307/3428117; SEEFELD MD, 1984, TOXICOL APPL PHARM, V73, P311, DOI 10.1016/0041-008X(84)90337-5; SWIFT LL, 1981, TOXICOL APPL PHARM, V59, P489, DOI 10.1016/0041-008X(81)90302-1; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; WEBER LWD, 1991, TOXICOLOGY, V66, P133, DOI 10.1016/0300-483X(91)90214-L	29	80	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19785	19791						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400292				2022-12-25	WOS:A1992JR85800008
J	TROELSEN, JT; OLSEN, J; NOREN, O; SJOSTROM, H				TROELSEN, JT; OLSEN, J; NOREN, O; SJOSTROM, H			A NOVEL INTESTINAL TRANSFACTOR (NF-LPH1) INTERACTS WITH THE LACTASE-PHLORHIZIN HYDROLASE PROMOTER AND CO-VARIES WITH THE ENZYMATIC-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT-TYPE HYPOLACTASIA; MESSENGER-RNA; INTRACELLULAR-TRANSPORT; LACTOSE-INTOLERANCE; EPITHELIAL-CELLS; BIOSYNTHESIS; TRANSCRIPTION; PROTEINS; EXPRESSION; RAT	The promoter of the pig lactase-phlorizin hydrolase was cloned and showed to be functional in the human intestinal cell line Caco2. The proximal promoter was analyzed for binding of nuclear proteins from small intestine and liver. DNase I footprinting and electrophoretic mobility shift assays show, that an intestinal nuclear factor (NF-LPH1) binds to a sequence (-40 to -54) located close to the TATA-box. Enterocytes from newborn pigs with high lactase activity contain high amounts of NF-LPH1, whereas enterocytes from adult pigs with low lactase activity contain low amounts of NF-LPH1. The liver does not contain lactase activity, and NF-LPH1 is not present in liver nuclear extracts in detectable amounts. This indicates that NF-LPH1 is involved in the decline of lactase at weaning and may be of importance for the molecular explanation of hypolactasia in humans. It was demonstrated by transfection of two different promoter-reporter gene constructs into Caco2 cells, that there are additional cis-element(s) in the region -142 to approximately -980, which are important for the transcription of the lactase-phlorizin hydrolase gene.			TROELSEN, JT (corresponding author), UNIV COPENHAGEN,PANUM INST,DEPT BIOCHEM C,BLEGDAMSVEJ 3,DK-2200 COPENHAGEN,DENMARK.		Troelsen, Jesper Thorvald T/B-6264-2013	Troelsen, Jesper Thorvald T/0000-0002-4177-3267; Olsen, Jorgen/0000-0003-1974-6446				AURICCHIO S, 1963, LANCET, V2, P324; BOLL W, 1991, AM J HUM GENET, V48, P889; BULLER HA, 1987, J BIOL CHEM, V262, P17206; BULLER HA, 1990, J BIOL CHEM, V265, P6978; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAHLQVIST A, 1968, ANAL BIOCHEM, V22, P99, DOI 10.1016/0003-2697(68)90263-7; DAHLQVIST A, 1963, GASTROENTEROLOGY, V45, P488, DOI 10.1016/S0016-5085(19)34844-9; DANIELSEN EM, 1984, BIOCHEM BIOPH RES CO, V122, P82; ESCHER JC, 1992, J CLIN INVEST, V89, P480, DOI 10.1172/JCI115609; FREUND JN, 1989, FEBS LETT, V248, P39, DOI 10.1016/0014-5793(89)80427-2; FREUND JN, 1990, CELL MOL BIOL, V36, P729; GHOSH D, 1991, TRENDS BIOCHEM SCI, V16, P445, DOI 10.1016/0968-0004(91)90173-S; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; LACEY S W, 1991, Gastroenterology, V100, pA223; LLOYD M, 1992, J CLIN INVEST, V89, P524, DOI 10.1172/JCI115616; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; MONTGOMERY RK, 1991, FASEB J, V5, P2824, DOI 10.1096/fasebj.5.13.1916106; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; OLSEN J, 1991, J BIOL CHEM, V266, P18089; PINTO M, 1983, BIOL CELL, V47, P323; POTTER J, 1985, BIOCH GENET, V23, P432; SAHI T, 1973, LANCET, V2, P823; Sambrook J, 1989, MOL CLONING LABORATO; SANGILD PT, 1991, 5TH P INT S DIG PHYS, P73; SCHATT MD, 1990, EMBO J, V9, P481, DOI 10.1002/j.1460-2075.1990.tb08134.x; SEBASTIO G, 1989, AM J HUM GENET, V45, P489; Semenza G, 1989, METABOLIC BASIS INHE, V6th, P2975; SKOVBJERG H, 1980, GUT, V21, P360, DOI 10.1136/gut.21.5.360; STERCHI EE, 1990, J CLIN INVEST, V86, P1329, DOI 10.1172/JCI114842; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879; WITTE J, 1990, J CLIN INVEST, V86, P1338, DOI 10.1172/JCI114843; 1991, LANCET, V338, P663	38	72	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20407	20411						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400359				2022-12-25	WOS:A1992JR85800102
J	WATT, SL; LUNSTRUM, GP; MCDONOUGH, AM; KEENE, DR; BURGESON, RE; MORRIS, NP				WATT, SL; LUNSTRUM, GP; MCDONOUGH, AM; KEENE, DR; BURGESON, RE; MORRIS, NP			CHARACTERIZATION OF COLLAGEN TYPE-XII AND TYPE-XIV FROM FETAL BOVINE CARTILAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAINS; IX COLLAGEN; EXTRACELLULAR-MATRIX; VITREOUS-HUMOR; II COLLAGEN; PROTEOGLYCAN; PROTEIN; MOLECULES; SEQUENCE; FIBRILS	The structurally related type XII-like collagen molecules TL-A and TL-B were recently identified in fetal bovine epiphyseal cartilage and subsequently shown to be collagen types XII and XIV, respectively. By indirect immunofluorescent staining of cartilage using monoclonal antibodies to the NC3 domains of each molecule, it was shown that type XII collagen was present predominantly around cartilage canals, the articular surface, subperichondrial margins, and the perichondrium, was less so in the remaining cartilage matrix, and was absent from the growth plate region. In the permanent cartilage of trachea, type XII stained somewhat more intensely in the margins beneath the loose connective tissue. Type XIV collagen localized more uniformly throughout the articular cartilage and was also absent from the growth plate region, whereas in tracheal cartilage, its distribution was similar to type XII. We have characterized the structure of these cartilage molecules and compared them with those from fetal bovine skin. Extraction of cartilage with 1 M NaCl and differential NaCl precipitation yields a fraction enriched for these two collagens. Analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting with monoclonal antibodies to the large amino-terminal non-triple-helical domain, NC3, revealed the presence in cartilage of two forms of type XII collagen: type XIIB, the molecule previously identified in chick and bovine tissues, and type XIIA, a much larger form equivalent to the molecule recently identified in WISH-transformed epithelial cell culture medium (Lunstrum, G. P., McDonough, A. M., Marinkovich, M. P., Keene, D. R., Morris, N. P., and Burgeson, R. E. (1992) J. Biol. Chem. 267, 20087-20092). Digestion with bacterial collagenase shows that the increased mass is present in the NC3A domain. Additional purification by velocity sedimentation and observation of rotary-shadowed images demonstrates molecules with extended non-triple-helical arms approximately 80 nm in length analogous to the WISH cell molecules. Electrophoretic mobilities of bands corresponding to type XIIA, but not type XIIB, are sensitive to chondroitinase ABC, indicating that type XIIA is a chondroitin sulfate proteoglycan and that modification occurs predominantly within the NC3A domain distal to NC3B. Neither type XIIB from skin nor type XIIA from WISH cells are chondroitinase-sensitive. By similar analysis, a portion of the type XIV collagen chains in cartilage was also sensitive to chondroitinase digestion. Chondroitin sulfate is apparently not located on its NC3 domain. As in skin, collagen types XII and XIV have subtly different distributions within cartilage and type XII may have a tissue-specific structure.	OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT DERMATOL,PORTLAND,OR 97201; SHRINERS HOSP CRIPPLED CHILDREN,PORTLAND,OR	Oregon Health & Science University; Oregon Health & Science University					NIGMS NIH HHS [R29 GM38862] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUBERTFOUCHER E, 1992, J BIOL CHEM, V267, P15759; BREWTON RG, 1991, J BIOL CHEM, V266, P4752; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; DUBLET B, 1989, J BIOL CHEM, V264, P13150; DUBLET B, 1991, J BIOL CHEM, V266, P6853; ENGVALL E, 1986, J CELL BIOL, V103, P2457, DOI 10.1083/jcb.103.6.2457; EYRE DR, 1991, SEMIN ARTHRITIS RHEU, V21, P2, DOI 10.1016/0049-0172(91)90035-X; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; FISHER LW, 1989, J BIOL CHEM, V264, P4571; GORDON MK, 1989, CONNECT TISSUE RES, V20, P179, DOI 10.3109/03008208909023886; GORDON MK, 1987, P NATL ACAD SCI USA, V84, P6040, DOI 10.1073/pnas.84.17.6040; HUBER S, 1988, J BIOL CHEM, V263, P752; KEENE DR, 1991, J CELL BIOL, V113, P971, DOI 10.1083/jcb.113.4.971; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LUNSTRUM GP, 1991, J CELL BIOL, V113, P963, DOI 10.1083/jcb.113.4.963; LUNSTRUM GP, 1992, J BIOL CHEM, V267, P20087; MCCORMICK D, 1987, P NATL ACAD SCI USA, V84, P4044, DOI 10.1073/pnas.84.12.4044; MORRIS NP, 1986, J BIOL CHEM, V261, P5638; MULLERGLAUSER W, 1986, J CELL BIOL, V102, P1931, DOI 10.1083/jcb.102.5.1931; MURAGAKI Y, 1990, P NATL ACAD SCI USA, V87, P2400, DOI 10.1073/pnas.87.7.2400; NAKAHARA H, 1990, DEV BIOL, V142, P481, DOI 10.1016/0012-1606(90)90370-X; NISHIMURA I, 1989, J BIOL CHEM, V264, P20033; OLSEN BR, 1989, CONNECT TISSUE RES, V23, P115, DOI 10.3109/03008208909002411; RHODES C, 1988, J BIOL CHEM, V263, P6063; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SANDELL LJ, 1991, J CELL BIOL, V114, P1307, DOI 10.1083/jcb.114.6.1307; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; SUGRUE SP, 1989, J CELL BIOL, V109, P938; SVOBODA KK, 1988, P NATL ACAD SCI USA, V85, P7496, DOI 10.1073/pnas.85.20.7496; Van der Rest M, 1987, STRUCTURE FUNCTION C, P195; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VANDERREST M, 1991, BIOCHEM SOC T, V19, P820, DOI 10.1042/bst0190820; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; WRIGHT DW, 1988, J ULTRA MOL STRUCT R, V100, P224, DOI 10.1016/0889-1605(88)90039-0; WU JJ, 1989, CONNECT TISSUE RES, V20, P241, DOI 10.3109/03008208909023893; WU JJ, 1984, BIOCHEM BIOPH RES CO, V123, P1033, DOI 10.1016/S0006-291X(84)80237-5; YADA T, 1990, J BIOL CHEM, V265, P6992; YAMAGATA M, 1991, J CELL BIOL, V115, P209, DOI 10.1083/jcb.115.1.209	40	98	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20093	20099						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400327				2022-12-25	WOS:A1992JR85800056
J	DEFILIPPI, P; SILENGO, L; TARONE, G				DEFILIPPI, P; SILENGO, L; TARONE, G			ALPHA-6.BETA-1 INTEGRIN (LAMININ RECEPTOR) IS DOWN-REGULATED BY TUMOR-NECROSIS-FACTOR-ALPHA AND INTERLEUKIN-1 BETA IN HUMAN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; FIBRONECTIN RECEPTOR; ADHESION MOLECULES; IMMUNE INTERFERON; EXPRESSION; PROTEINS; ATTACHMENT; IDENTIFICATION; ACTIVATION; COLLAGEN	Endothelial cells from human umbilical vein (HEC) express several distinct integrin complexes that mediate the interaction with the basal membrane components. In this paper we show that treatment with tumor necrosis factor-alpha (TNF-alpha) down-regulates the expression of the laminin receptor alpha-6.beta-1 integrin in cultured HEC. After 48 h of treatment with TNF-alpha, the level of expression of the alpha-6.beta-1 complex reached 20% of the control value. The down-regulation of the alpha-6.beta-1 integrin is caused by a decreased expression of the alpha-6 subunit, whereas the synthesis of the beta-1 subunit remains constant. Northern blot analysis shows that the decreased level of alpha-6 subunit synthesis is caused by down-regulation of alpha-6 mRNA in TNF-alpha-treated HEC. TNF-alpha treatment does not alter the expression of alpha-2, alpha-3, and alpha-5 integrins, also present on endothelial cell surface, thus showing that this cytokine has a selective action on distinct integrin complexes. Down-regulation of alpha-6.beta-1 correlates with pronounced reduction in adhesion of TNF-alpha-treated HEC to laminin, but not to fibronectin-coated culture dishes. In addition to TNF-alpha, interleukin-1-beta also decreases the expression of the alpha-6.beta-1 integrin and reduces adhesion to laminin, thus suggesting that this regulation plays an important role in inflammation.			DEFILIPPI, P (corresponding author), UNIV TURIN,DIPARTIMENTO GENET BIOL & CHIM MED,VIA SANTENA 5BIS,I-10126 TURIN,ITALY.		DEFILIPPI, Paola/L-2232-2014	Tarone, Guido/0000-0003-4805-086X; Defilippi, Paola/0000-0001-6427-4906				ALBELDA SM, 1989, J CLIN INVEST, V83, P1992, DOI 10.1172/JCI114109; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BUSSOLINO F, 1988, J BIOL CHEM, V263, P11856; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHARO IF, 1987, J BIOL CHEM, V262, P9935; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONFORTI G, 1989, BLOOD, V73, P1576; CONNOLLY DT, 1986, ANAL BIOCHEM, V152, P136, DOI 10.1016/0003-2697(86)90131-4; DANIELSON PE, 1988, DNA CELL BIOL, V7, P2261; DEFILIPPI P, 1991, J BIOL CHEM, V266, P7638; DEFILIPPI P, 1991, J CELL BIOL, V114, P855, DOI 10.1083/jcb.114.4.855; DEJANA E, 1988, BLOOD, V71, P566; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; GIMBRONE MA, 1976, PROGR HEMOSTASIS THR, P1; GOODMAN SL, 1991, J CELL BIOL, V113, P931, DOI 10.1083/jcb.113.4.931; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; JIRIK FR, 1989, J IMMUNOL, V142, P144; KRAMER RH, 1990, J CELL BIOL, V111, P1233, DOI 10.1083/jcb.111.3.1233; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPUGNANI MG, 1991, J CELL BIOL, V112, P479, DOI 10.1083/jcb.112.3.479; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LAPIERRE LA, 1988, J EXP MED, V167, P794, DOI 10.1084/jem.167.3.794; MAUVIEL A, 1991, J INVEST DERMATOL, V96, P243, DOI 10.1111/1523-1747.ep12462185; MOCCHETTI I, 1987, NEUROPHARMACOLOGY, V26, P855, DOI 10.1016/0028-3908(87)90062-1; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; POBER JS, 1988, AM J PATHOL, V133, P426; POBER JS, 1991, LAB INVEST, V64, P301; POBER JS, 1986, J IMMUNOL, V137, P1893; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; ROSSINO P, 1990, EXP CELL RES, V189, P100, DOI 10.1016/0014-4827(90)90262-9; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SEELENTAG WK, 1987, EMBO J, V6, P2261, DOI 10.1002/j.1460-2075.1987.tb02499.x; SHALABY MR, 1989, CELL IMMUNOL, V121, P372, DOI 10.1016/0008-8749(89)90036-1; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SOLISHERRUZO JA, 1988, J BIOL CHEM, V263, P5841; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; STOLPEN AH, 1986, AM J PATHOL, V123, P16; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TARONE G, 1990, J LIPID MEDIATOR, V2, pS45; TARONE G, 1982, J CELL BIOL, V94, P179, DOI 10.1083/jcb.94.1.179; VANHINSBERGH VWM, 1990, BLOOD, V75, P1991; VOGEL BE, 1990, J BIOL CHEM, V265, P5934	46	95	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18303	18307						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1388151				2022-12-25	WOS:A1992JN50200012
J	GUO, NH; KRUTZSCH, HC; VOGEL, T; ROBERTS, DD				GUO, NH; KRUTZSCH, HC; VOGEL, T; ROBERTS, DD			INTERACTIONS OF A LAMININ-BINDING PEPTIDE FROM A 33-KDA PROTEIN RELATED TO THE 67-KDA LAMININ RECEPTOR WITH LAMININ AND MELANOMA-CELLS ARE HEPARIN-DEPENDENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; INTEGRIN ALPHA-7-BETA-1; MALIGNANT MELANOCYTES; SULFATED GLYCOLIPIDS; SYNTHETIC PEPTIDE; THROMBOSPONDIN; GLYCOPROTEIN; ADHESION; EXPRESSION; MIGRATION	A laminin-binding peptide (peptide G), predicted from the cDNA sequence for a 33-kDa protein related to the 67-kDa laminin receptor, specifically inhibits binding of laminin to heparin and sulfatide. Since the peptide binds directly to heparin and inhibits interaction of another heparin-binding protein with the same sulfated ligands, this inhibition is due to direct competition for binding to sulfated glycoconjugates rather than an indirect effect of interaction with the binding site on laminin for the 67-kDa receptor. Direct binding of laminin to the peptide is also inhibited by heparin. This interaction may result from contamination of the laminin with heparan sulfate, as binding is enhanced by the addition of substoichiometric amounts of heparin but inhibited by excess heparin and two heparin-binding proteins. Furthermore, laminin binds more avidly to a heparin-binding peptide derived from thrombospondin than to the putative receptor peptide. Adhesion of A2058 melanoma cells on immobilized peptide G is also heparin-dependent, whereas adhesion of the cells on laminin is not. Antibodies to the beta-1-integrin chain or laminin block adhesion of the melanoma cells to laminin but not to peptide G. Thus, the reported inhibition of melanoma cell adhesion to endothelial cells by peptide G may result from inhibition of binding of laminin or other proteins to sulfated glycoconjugate receptors rather than from specific inhibition of laminin binding to the 67-kDa receptor.	NCI,PATHOL LAB,BLDG 10,RM 2A33,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Roberts, David D./A-9699-2008	Roberts, David D./0000-0002-2481-2981				AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; AUTH D, 1992, P NATL ACAD SCI USA, V89, P4368, DOI 10.1073/pnas.89.10.4368; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BUSCH SJ, 1992, J CELL BIOL, V116, P31, DOI 10.1083/jcb.116.1.31; CASTRONOVO V, 1991, CANCER RES, V51, P5672; CASTRONOVO V, 1991, J BIOL CHEM, V266, P20440; CASTRONOVO V, 1991, BIOCHEM BIOPH RES CO, V177, P177, DOI 10.1016/0006-291X(91)91965-F; CHARONIS AS, 1988, J CELL BIOL, V107, P1253, DOI 10.1083/jcb.107.3.1253; DAVIS SC, 1992, J BIOL CHEM, V267, P5508; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; FUNAHASHI M, 1982, ANAL BIOCHEM, V126, P414, DOI 10.1016/0003-2697(82)90537-1; GEOGHEGAN T, 1979, P NATL ACAD SCI USA, V76, P5587, DOI 10.1073/pnas.76.11.5587; GROSSO LE, 1991, BIOCHEMISTRY-US, V30, P3346, DOI 10.1021/bi00227a026; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; KELLER KM, 1989, BIOCHEMISTRY-US, V28, P8100, DOI 10.1021/bi00446a021; KEPPEL E, 1991, J CELL SCI, V100, P789; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; RAMOS DM, 1990, CANCER RES, V50, P728; ROBERTS DD, 1988, CANCER RES, V48, P6785; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; TARABOLETTI G, 1990, J BIOL CHEM, V265, P12253; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; YOW HK, 1988, P NATL ACAD SCI USA, V85, P6394, DOI 10.1073/pnas.85.17.6394; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767; ZABRENETZKY VS, 1990, CANCER RES, V50, P5937	29	36	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17743	17747						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1387642				2022-12-25	WOS:A1992JM22300043
J	DAIFOTIS, AG; WEIR, EC; DREYER, BE; BROADUS, AE				DAIFOTIS, AG; WEIR, EC; DREYER, BE; BROADUS, AE			STRETCH-INDUCED PARATHYROID HORMONE-RELATED PEPTIDE GENE-EXPRESSION IN THE RAT UTERUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RIBONUCLEIC-ACID; SMOOTH-MUSCLE; MYOMETRIUM	We previously observed a peak in parathyroid hormone-related peptide (PTHrP) mRNA expression in preterm rat myometrium and found that this peak was dependent on intrauterine occupancy. We explored the possibility that mechanotransduction might control PTHrP gene expression in the uterus. This was done by developing an intrauterine balloon system that allowed us to reproduce experimentally the mechanical effects of the fetal pup in utero. An increase in PTHrP mRNA in the unoccupied horn of a unilaterally pregnant rat could be elicited as rapidly as 1 h after balloon inflation and was maintained for up to 72 h. The same response was seen in uterine horns from virgin animals and could be reproduced by three different methods of imposing a physical stretch. Balloon-induced stretch also increased mRNA expression in a muscle bath system in vitro. Mechanotransduction appears to be largely, if not entirely, responsible for the preterm peak in PTHrP mRNA expression.	YALE UNIV,DEPT INTERNAL MED,DIV ENDOCRINE,NEW HAVEN,CT 06510; YALE UNIV,COMPARAT MED SECT,NEW HAVEN,CT 06510; YALE UNIV,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR030102, R01AR030102] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 30102] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CASEY L, 1992, J CLIN ENDOCR METAB, V74, P950; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FERGUSON JE, 1992, P NATL ACAD SCI USA, V89, P8384, DOI 10.1073/pnas.89.17.8384; Fuchs A. R., 1969, Biology of Reproduction, V1, P344, DOI 10.1095/biolreprod1.4.344; FUCHS AR, 1983, CAN J BIOCHEM CELL B, V61, P615, DOI 10.1139/o83-077; GUTKOWSKA J, 1989, ENDOCR REV, V10, P519, DOI 10.1210/edrv-10-4-519; KAWANO M, 1988, PROSTAGLANDINS, V35, P305, DOI 10.1016/0090-6980(88)90125-6; KOMURO I, 1991, J BIOL CHEM, V266, P1265; MOK LLS, 1989, J BONE MINER RES, V4, P433; PHILLIPPE M, 1992, LIFE SCI, V50, P1189, DOI 10.1016/0024-3205(92)90462-X; SHEW RL, 1991, J BONE MINER RES, V6, P955; STEWART AF, 1990, J CLIN ENDOCR METAB, V71, P1410, DOI 10.1210/jcem-71-6-1410; THIEDE MA, 1991, ENDOCRINOLOGY, V128, P2317, DOI 10.1210/endo-128-5-2317; THIEDE MA, 1990, P NATL ACAD SCI USA, V87, P6969, DOI 10.1073/pnas.87.18.6969; THIEDE MA, 1991, ENDOCRINOLOGY, V129, P1958, DOI 10.1210/endo-129-4-1958; WATHES DC, 1982, J REPROD FERTIL, V65, P497, DOI 10.1530/jrf.0.0650497; WATSONP, 1991, FASEB J, V5, P2013; YAMAMOTO M, 1992, P NATL ACAD SCI USA, V89, P5326, DOI 10.1073/pnas.89.12.5326	18	85	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23455	23458						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385422				2022-12-25	WOS:A1992JZ23900006
J	HOMMA, T; AKAI, Y; BURNS, KD; HARRIS, RC				HOMMA, T; AKAI, Y; BURNS, KD; HARRIS, RC			ACTIVATION OF S6 KINASE BY REPEATED CYCLES OF STRETCHING AND RELAXATION IN RAT GLOMERULAR MESANGIAL CELLS - EVIDENCE FOR INVOLVEMENT OF PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PHORBOL ESTER STIMULATION; REDUCED RENAL MASS; ANGIOTENSIN-II; GROWTH-FACTOR; VENTRICULAR HYPERTROPHY; COLLAGEN PRODUCTION; HYPERTENSIVE RAT; CARDIAC-MUSCLE; PHOSPHORYLATION	Quiescent rat glomerular mesangial cells were exposed to repeated cycles of stretching and relaxation, and the effects on the rate of collagen production, proliferation, and S6 kinase activity were investigated. Stretch/relaxation induced increases in production of both collagen and non-collagenous proteins. Proliferation of mesangial cells was stimulated by stretch/relaxation and epidermal growth factor, but not by angiotensin II; however, administration of angiotensin II augmented stretch/relaxation-induced cell proliferation. Cytosolic S6 kinase activity was stimulated by stretch/relaxation, angiotensin II, epidermal growth factor, or phorbol 12-myristate 13-acetate. The increased S6 kinase activity was detectable within 30 min after initiation of stretch/relaxation and was blocked by either inhibitors of protein kinase C or prior down-regulation of protein kinase C following prolonged incubation with phorbol 12-myristate 13-acetate. Both translocation of protein kinase C from the cytosolic to the membrane fraction and phosphorylation of an endogenous 80-kDa protein were observed within 5 min of initiation of stretch/relaxation. These results demonstrate that in mesangial cells, mechanical factors alone can induce increases in production of collagen and non-collagenous proteins and in cell proliferation. The observation that stretch/relaxation induced stimulation of S6 kinase activity through protein kinase C-dependent mechanisms suggests that activation of protein kinase C may be a key event in initiating adaptive responses of mesangial cells to increased workload.	VANDERBILT UNIV, MED CTR,SCH MED,DEPT MED,DIV NEPHROL, MED CTR N S 3223, NASHVILLE, TN 37232 USA; DEPT VET AFFAIRS MED CTR, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT PEDIAT, NASHVILLE, TN 37232 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038226, P50DK039261] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38226, DK39261] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLO SN, 1991, J BIOL CHEM, V266, P22003; ANDERSON S, 1985, J CLIN INVEST, V76, P612, DOI 10.1172/JCI112013; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BRATTSAND G, 1989, SCAND J IMMUNOL, V30, P233, DOI 10.1111/j.1365-3083.1989.tb01206.x; BRENNER BM, 1985, AM J PHYSIOL, V249, pF324, DOI 10.1152/ajprenal.1985.249.3.F324; COOPER G, 1985, J CLIN INVEST, V75, P1403, DOI 10.1172/JCI111842; DZAU VJ, 1987, AM J CARDIOL, V60, pI99; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GRIENDLING KK, 1987, HYPERTENSION, V9, P181; HARALSON MA, 1987, LAB INVEST, V57, P513; HARPER PA, 1984, KIDNEY INT, V26, P875, DOI 10.1038/ki.1984.231; HARRIS RC, 1992, AM J PHYSIOL, V263, pF127, DOI 10.1152/ajprenal.1992.263.1.F127; HARRIS RC, 1992, LAB INVEST, V66, P548; HARRIS RC, 1988, J CLIN INVEST, V82, P1028, DOI 10.1172/JCI113659; HARRIS RC, 1990, J AM SOC NEPHROL, V1, P719; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1081, DOI 10.1016/0022-2828(88)90588-3; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HOMMA T, 1990, J BIOL CHEM, V265, P17613; HOMMA T, 1990, AM J PHYSIOL, V258, pC862, DOI 10.1152/ajpcell.1990.258.5.C862; HOSGETTER TH, 1981, AM J PHYSIOL, V241, pF85; HOSTETTER TH, 1981, KIDNEY INT, V19, P410, DOI 10.1038/ki.1981.33; HOSTETTER TH, 1986, KIDNEY INT, V30, P509, DOI 10.1038/ki.1986.215; HOVAKHOFER I, 1985, J BIOL CHEM, V260, P10314; KIRA Y, 1984, AM J PHYSIOL, V246, pC247, DOI 10.1152/ajpcell.1984.246.3.C247; KOLLROS PR, 1987, LAB INVEST, V56, P410; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KORECKY B, 1978, AM J PHYSIOL, V234, pH123, DOI 10.1152/ajpheart.1978.234.2.H123; KOZMA SC, 1989, CELL SIGNAL, V1, P219, DOI 10.1016/0898-6568(89)90039-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILES WC, 1986, J BIOL CHEM, V261, P5307; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEIDELL RS, 1986, AM J PHYSIOL, V251, P1076; MEIER KE, 1990, J BIOL CHEM, V265, P4635; MENE P, 1989, PHYSIOL REV, V69, P1347, DOI 10.1152/physrev.1989.69.4.1347; MINAFRA IP, 1986, J SUBMICR CYTOL PATH, V18, P795; NIELSEN PJ, 1982, J BIOL CHEM, V257, P2316; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; OWENS GK, 1983, CIRC RES, V53, P491, DOI 10.1161/01.RES.53.4.491; OWENS GK, 1982, CIRC RES, V51, P280, DOI 10.1161/01.RES.51.3.280; PENNINGTON SR, 1990, J BIOL CHEM, V265, P2456; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; PHAN SH, 1985, J CLIN INVEST, V76, P241, DOI 10.1172/JCI111953; ROJKIND M, 1979, GASTROENTEROLOGY, V76, P710; SAKAI T, 1987, ANAT EMBRYOL, V176, P373; SCHLONDORFF D, 1987, FASEB J, V1, P272, DOI 10.1096/fasebj.1.4.3308611; SCHUNKERT H, 1990, J CLIN INVEST, V86, P1913, DOI 10.1172/JCI114924; SCHWARTZ SM, 1984, PROG CARDIOVASC DIS, V26, P355, DOI 10.1016/0033-0620(84)90010-0; SCOTTBURDEN T, 1988, BIOCHEM BIOPH RES CO, V151, P583, DOI 10.1016/0006-291X(88)90634-1; SETOYAMA C, 1986, BIOCHEM BIOPH RES CO, V136, P1042, DOI 10.1016/0006-291X(86)90438-9; SIMONSON MS, 1989, EXP CELL RES, V184, P484, DOI 10.1016/0014-4827(89)90346-7; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; SUGDEN PH, 1991, BIOCHEM J, V273, P21, DOI 10.1042/bj2730021; SUMPIO BE, 1988, ARCH SURG-CHICAGO, V123, P1233; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; WILSON CB, 1986, KIDNEY, V2, P800; WOLF G, 1992, AM J PATHOL, V140, P95; ZAK R, 1974, CIRC RES, V35, P17; ZASLOFF M, 1971, P NATL ACAD SCI USA, V68, P3059, DOI 10.1073/pnas.68.12.3059; ZIERHUT W, 1989, CIRC RES, V65, P1417, DOI 10.1161/01.RES.65.5.1417	63	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23129	23135						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429660				2022-12-25	WOS:A1992JY16300066
J	REING, J; DURKIN, ME; CHUNG, AE				REING, J; DURKIN, ME; CHUNG, AE			LAMININ-B1 EXPRESSION IS REQUIRED FOR LAMININ DEPOSITION INTO THE EXTRACELLULAR-MATRIX OF PC12-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE PROTEINS; NERVE GROWTH-FACTOR; CELL-LINE PC12; NEURITE OUTGROWTH; MESSENGER-RNA; A-CHAIN; MONOCLONAL-ANTIBODIES; MULTIDOMAIN PROTEIN; IV COLLAGEN; F9 CELLS	The extracellular matrix of rat pheochromocytoma PC12 cells was shown by indirect immunofluorescence to consist of a network of fibronectin. The matrix did not contain laminin. The cells synthesized messenger RNA for fibronectin, laminin B2, and s-laminin but not for entactin or the B1 and A chains of laminin. Laminin B2 but not laminin B1 was detectable in the culture medium and in cell lysates. A full-length cDNA clone for the B1 chain of laminin was constructed in the plasmid p-444, which contains the neomycin-resistance marker and human beta-actin promoter. PC12 cells were transfected with this recombinant plasmid, and stable neomycin-resistant clones were isolated and characterized. Clones that synthesized laminin B1 messenger RNA were found to deposit a laminin-containing matrix. In many of these clones the deposition of the fibronectin matrix was greatly diminished. The laminin matrix was predominantly localized in the intercellular spaces forming a honeycomb pattern. The morphology of the laminin-synthesizing transfected cells was markedly different from the parental cells. The cells grew in tight clusters that were resistant to dissociating agents. It is concluded that the B1 chain of laminin contains information that is required for the formation of a stable laminin-containing extracellular matrix network either by interaction with cell surface receptors or other extracellular matrix components. Furthermore, expression of the laminin B1 gene may be a central regulatory point in determining extracellular matrix composition during embryogenesis.	UNIV PITTSBURGH, DEPT BIOL SCI, PITTSBURGH, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NCI NIH HHS [CA-21246] Funding Source: Medline; NIGMS NIH HHS [GM-25690] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA021246] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025690] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BEGOVAC PC, 1990, J CELL BIOL, V110, P461, DOI 10.1083/jcb.110.2.461; CARLIN BE, 1983, J BIOL CHEM, V258, P7729; CHUNG AE, 1979, CELL, V16, P277, DOI 10.1016/0092-8674(79)90005-9; CHUNG AE, 1977, CANCER RES, V37, P2072; DARRIBERE T, 1990, J CELL BIOL, V110, P1813, DOI 10.1083/jcb.110.5.1813; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; DONG LJ, 1991, DIFFERENTIATION, V48, P157, DOI 10.1111/j.1432-0436.1991.tb00254.x; DURKIN ME, 1986, DIFFERENTIATION, V32, P260, DOI 10.1111/j.1432-0436.1986.tb00582.x; DURKIN ME, 1988, BIOCHEMISTRY-US, V27, P5198, DOI 10.1021/bi00414a038; DURKIN ME, 1988, J CELL BIOL, V107, P2749, DOI 10.1083/jcb.107.6.2749; EKBLOM M, 1990, CELL, V60, P337, DOI 10.1016/0092-8674(90)90748-4; FUR JL, 1986, J HISTOCHEM CYTOCHEM, V34, P483, DOI 10.1177/34.4.3512698; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; GREEN TL, 1992, J BIOL CHEM, V267, P2014; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JAFFE R, 1984, LAB INVEST, V51, P88; KESHMIRIAN J, 1989, J NEUROCYTOL, V18, P491, DOI 10.1007/BF01474545; KLEIN G, 1988, CELL, V55, P331, DOI 10.1016/0092-8674(88)90056-6; KLEINMAN HK, 1987, DEV BIOL, V122, P373, DOI 10.1016/0012-1606(87)90302-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMOUREUX P, 1990, J CELL BIOL, V110, P71, DOI 10.1083/jcb.110.1.71; LAURIE GW, 1989, J CELL BIOL, V109, P1351, DOI 10.1083/jcb.109.3.1351; Maniatis T., 1982, MOL CLONING; MARTIN GR, 1988, ADV PROTEIN CHEM, V39, P1; MCDONALD JA, 1988, ANNU REV BIOCHEM, V57, P375; MCKEOWNLONGO PJ, 1988, FIBRONECTIN, P163; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SEIF I, 1991, Methods in Molecular and Cellular Biology, V2, P216; TIMPL R, 1986, INT REV EXP PATHOL, V29, P1; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TOMASELLI KJ, 1988, J CELL BIOL, V107, P1241, DOI 10.1083/jcb.107.3.1241; TOMASELLI KJ, 1990, NEURON, V5, P651, DOI 10.1016/0896-6273(90)90219-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAN YJ, 1984, J CELL BIOL, V98, P971, DOI 10.1083/jcb.98.3.971; WU CY, 1988, BIOCHEMISTRY-US, V27, P8780, DOI 10.1021/bi00424a014	42	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23143	23150						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1385414				2022-12-25	WOS:A1992JY16300068
J	AKIYAMA, Y; KAMITANI, S; KUSUKAWA, N; ITO, K				AKIYAMA, Y; KAMITANI, S; KUSUKAWA, N; ITO, K			INVITRO CATALYSIS OF OXIDATIVE FOLDING OF DISULFIDE-BONDED PROTEINS BY THE ESCHERICHIA-COLI DSBA (PPFA) GENE-PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS-ISOMERASE; MOLECULAR CHAPERONES; CELL; MEMBRANE; TRANSLOCATION; THIOREDOXIN; BIOGENESIS; SYSTEMS; YEAST	It was shown previously that the Escherichia coli gene ppfA (dsbA) encodes a periplasmic protein, and its inactivation leads to a deficiency in disulfide bond formation of envelope proteins (Kamitani, S., Akiyama, Y., and Ito, K. (1992) EMBO J. 11, 57-62; Bardwell, J. C. A., McGovern, K., and Beckwith, J. (1991) Cell 67, 581-589). The DsbA/PpfA protein was overproduced, purified, and examined for its activities in vitro. Its abundance in a wild-type cell was estimated to be about 850 molecules which probably exist as homodimers as suggested by size exclusion chromatography. Purified DsbA markedly stimulated disulfide bond formation of E. coli alkaline phosphatase, either in vitro synthesized or purified and denatured, as well as of reduced bovine ribonuclease A. The DsbA-catalyzed rapid disulfide bond formation occurred after a lag period which appeared to be determined by the redox state of the reaction mixture and concentration of DsbA. Inclusion of higher concentrations of oxidized glutathione or DsbA shortened the lag period. We propose that DsbA, which proved to directly catalyze disulfide bond formation, may also have a role in maintaining the bacterial periplasm oxidative.	TAKARA SHUZO BIOTECHNOL RES LABS, OTSU, SHIGA 52021, JAPAN		AKIYAMA, Y (corresponding author), KYOTO UNIV, INST VIRUS RES, KYOTO 60601, JAPAN.			Kamitani, Shigeki/0000-0002-1268-4652				AKIYAMA Y, 1985, EMBO J, V4, P3351, DOI 10.1002/j.1460-2075.1985.tb04088.x; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BABA T, 1990, J BACTERIOL, V172, P7005, DOI 10.1128/jb.172.12.7005-7010.1990; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BLACKBURN P, 1979, J BIOL CHEM, V254, P2484; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; DESHAIES RJ, 1988, TRENDS BIOCHEM SCI, V13, P384, DOI 10.1016/0968-0004(88)90180-6; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOODSELL DS, 1991, TRENDS BIOCHEM SCI, V16, P203, DOI 10.1016/0968-0004(91)90083-8; HAYANO T, 1991, BIOCHEMISTRY-US, V30, P3041, DOI 10.1021/bi00226a009; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; INOUYE H, 1977, J MOL BIOL, V110, P75, DOI 10.1016/S0022-2836(77)80099-5; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KUMAMOTO CA, 1991, MOL MICROBIOL, V5, P19, DOI 10.1111/j.1365-2958.1991.tb01821.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; LANDRY SJ, 1991, TRENDS BIOCHEM SCI, V16, P159, DOI 10.1016/0968-0004(91)90060-9; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P619, DOI 10.1021/bi00217a005; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; NEU HC, 1965, J BIOL CHEM, V240, P3685; NOIVA R, 1992, J BIOL CHEM, V267, P3553; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; PIGIET VP, 1986, P NATL ACAD SCI USA, V83, P7643, DOI 10.1073/pnas.83.20.7643; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; STOCK JB, 1977, J BIOL CHEM, V252, P7850; TACHIKAWA H, 1991, J BIOCHEM, V110, P306, DOI 10.1093/oxfordjournals.jbchem.a123576; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WIENHUES U, 1992, BIOESSAYS, V14, P17, DOI 10.1002/bies.950140105; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411	33	116	123	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22440	22445						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429594				2022-12-25	WOS:A1992JW71900071
J	RUF, W; MILES, DJ; REHEMTULLA, A; EDGINGTON, TS				RUF, W; MILES, DJ; REHEMTULLA, A; EDGINGTON, TS			TISSUE FACTOR RESIDUES 157-167 ARE REQUIRED FOR EFFICIENT PROTEOLYTIC ACTIVATION OF FACTOR-X AND FACTOR-VII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-VII; BLOOD-COAGULATION; EXTRINSIC PATHWAY; FACTOR-IX; RECOGNITION; RECEPTOR; BINDING; SITES; SUPERFAMILY; INITIATION	The cell surface receptor tissue factor (TF) initiates coagulation by supporting the proteolytic activation of factors X and IX as well as VII to active serine proteases. Architectural similarity of TF to the cytokine receptor family suggests a strand-loop-strand structure for TF residues 151-174. Site-directed Ala exchanges in the predicted surface loop demonstrated that residues Tyr157, Lys159, Ser163, Gly164, Lys165, and Lys166 are important for function. Addition of side chain atoms at the Ser162 position decreased function, whereas the Ala exchange was tolerated. The dysfunctional mutants bound VII with high affinity and fully supported the catalysis of small peptidyl substrates by the mutant TF . VIIa complex. Lys159 --> Ala substitution was compatible with efficient activation of factor X, whereas the Tyr157 --> Ala exchange and mutations in the carboxyl aspect of the predicted loop resulted in diminished activation of factor X. The specific plasma procoagulant activity of all functionally deficient mutants increased 7- to 200-fold upon the supplementation of VIIa suggesting that TF residues 157-167 also provide important interactions that accelerate the activation of VII to VIIa. These data are consistent with assignment of the TF 157-167 region as contributing to protein substrate recognition and cleavage by the TF . VIIa complex.			RUF, W (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL-16411] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS BS, 1991, GENE, V98, P265, DOI 10.1016/0378-1119(91)90184-D; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; Creighton T. E., 1984, PROTEINS; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; JANIN J, 1990, J BIOL CHEM, V265, P16027; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; LAWSON JH, 1991, J BIOL CHEM, V266, P11317; LESK AM, 1982, J MOL BIOL, V160, P325, DOI 10.1016/0022-2836(82)90179-6; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NEMERSON Y, 1985, THROMB RES, V40, P351, DOI 10.1016/0049-3848(85)90270-1; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; PAKULA AA, 1986, P NATL ACAD SCI USA, V83, P8829, DOI 10.1073/pnas.83.23.8829; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; REHEMTULLA A, 1992, BIOCHEM J, V282, P737, DOI 10.1042/bj2820737; REHEMTULLA A, 1991, J BIOL CHEM, V266, P10294; RUF W, 1991, P NATL ACAD SCI USA, V88, P8430, DOI 10.1073/pnas.88.19.8430; RUF W, 1992, J BIOL CHEM, V267, P6375; RUF W, 1991, THROMB HAEMOSTASIS, V66, P529; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; SILVERBERG SA, 1977, J BIOL CHEM, V252, P8481; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	26	72	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22206	22210						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429572				2022-12-25	WOS:A1992JW71900035
J	VANHUIJSDUIJNEN, RH; WHELAN, J; PESCINI, R; BECKERANDRE, M; SCHENK, AM; DELAMARTER, JF				VANHUIJSDUIJNEN, RH; WHELAN, J; PESCINI, R; BECKERANDRE, M; SCHENK, AM; DELAMARTER, JF			A T-CELL ENHANCER COOPERATES WITH NF-KAPPA-B TO YIELD CYTOKINE INDUCTION OF E-SELECTIN GENE-TRANSCRIPTION IN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION MOLECULE-1; BINDING PROTEINS; EXPRESSION; ELAM-1; ACTIVATION; CLONING; SITES	ELAM1 (endothelial leukocyte adhesion molecule 1, also known as E-selectin) is a highly tissue-specific adhesion molecule that is transiently and exclusively expressed on cytokine-induced endothelial cells. We have identified two proximal ELAM1 promoter elements and their DNA-binding factors that are, in addition to NF-kappaB, essential for ELAM1 transcription. Mutation of either element in promoter constructs carrying the first 383 nucleotides of the ELAM1 promoter markedly diminished the expression of a fused chloramphenicol acetyltransferase reporter gene. Although multimers of either element failed to display enhancer activity on its own, fusion of the most upstream of these to the NF-kappaB element had a strong stimulatory effect. This site, ACATCAT, is recognized by a factor we have called NF-ELAM1. The site corresponds to NF-ELAM1's preferential binding sequence (A/T)CA(G/T)CA(G/T) as determined in a target definition assay. This element is identical to the T-cell deltaA enhancer found in the T-cell receptor-alpha, -beta, and CD3delta genes. Our results suggest that the deltaA/NF-ELAM1 element can function as a modulator of NF-kappaB in endothelial cells both as well as a T-cell enhancer.			VANHUIJSDUIJNEN, RH (corresponding author), GLAXO INST MOLEC BIOL,CHEMIN AULX,CH-1228 PLAN LES OUATES,SWITZERLAND.		Whelan, James/F-6402-2011; van Huijsduijnen, Rob A.M. Hooft/B-3653-2009	Whelan, James/0000-0001-5754-025X; van Huijsduijnen, Rob A.M. Hooft/0000-0002-2261-9424				AUASUBEL FM, 1989, CURRENT PROTOCOLS MO; BAEUERLE PA, 1991, MOL ASPECTS CELL REG, V6, P409; BECKERANDRE M, 1992, EUR J BIOCHEM, V206, P401, DOI 10.1111/j.1432-1033.1992.tb16940.x; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; CARLOS T, 1991, J BLOOD, V77, P2266; COLLINS T, 1991, J BIOL CHEM, V266, P2466; CULLEN BR, 1987, METHOD ENZYMOL, V152, P692; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBRINA A, 1989, IMMUNOLOGY, V67, P502; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; FICKLING SA, 1992, IN PRESS EXP CELL RE; GEORGOPOULOS K, 1990, EMBO J, V9, P109, DOI 10.1002/j.1460-2075.1990.tb08086.x; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HESSION C, 1990, P NATL ACAD SCI USA, V87, P1673, DOI 10.1073/pnas.87.5.1673; LARIGAN D, 1992, DNA CELL BIOL, V11, P149; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LUSCINSKAS FW, 1991, J IMMUNOL, V146, P1617; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; VANHUIJSDUIJNEN RH, 1992, BIOTECHNIQUES, V12, P6; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; WHELAN J, 1989, MOL CELL BIOL, V9, P3253, DOI 10.1128/MCB.9.8.3253	32	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22385	22391						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1385398				2022-12-25	WOS:A1992JW71900063
J	HILL, JR; MORRIS, DR				HILL, JR; MORRIS, DR			CELL-SPECIFIC TRANSLATION OF S-ADENOSYLMETHIONINE DECARBOXYLASE MESSENGER-RNA - REGULATION BY THE 5' TRANSCRIPT LEADER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOGEN-ACTIVATED LYMPHOCYTES; ORNITHINE DECARBOXYLASE; EUKARYOTIC RIBOSOMES; ENZYMATIC AMPLIFICATION; INCREASED EFFICIENCY; PROTEIN-SYNTHESIS; RIBONUCLEIC-ACID; SARCOMA VIRUS; INITIATION; SEQUENCE	The mRNA encoding S-adenosylmethionine decarboxylase (AdoMetDC) has an unusual distribution in polysomes from cells of T lymphocyte origin. It associates predominantly with monosomes and small polysomes with none located in the preribosomal or ribonucleoprotein pool. In sharp contrast, it associates broadly with larger polysomes in several nonlymphoid cell lines, including fibroblasts and the adrenal carcinoma line, Y1. The AdoMetDC 5'-transcript leader (5'-TL) is highly conserved between human and bovine mRNAs. It has a length of about 330 nucleotides and contains a 21-nucleotide upstream open reading frame (uORF) approximately 14 nucleotides downstream of the cap site. The AdoMetDC 5'-TL, when used to replace the 5'-TL of the human growth hormone gene in a chimeric expression construct, causes a suppressed polysomal distribution of the chimeric mRNA identical to that of the endogenous AdoMetDC mRNA in the T cell line, Jurkat. In contrast, mRNA encoded by the same chimeric construct, when expressed in Y1 cells, mimics the broad polysomal distribution of the endogenous AdoMetDC mRNA. Mutations that remove the uORF, or prevent its initiation, abolish the translational suppression in T cells, establishing that the uORF is a negative element that modulates the cell-specific polysomal distribution of AdoMetDC mRNA.	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Morris, David/G-4503-2011		NATIONAL CANCER INSTITUTE [R01CA039053] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007266, P01GM042508] Funding Source: NIH RePORTER; NCI NIH HHS [CA39053] Funding Source: Medline; NIGMS NIH HHS [GM42508, GM07266-16] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABASTADO JP, 1991, NEW BIOL, V3, P511; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DASSO MC, 1990, EUR J BIOCHEM, V187, P361, DOI 10.1111/j.1432-1033.1990.tb15313.x; Davis R H, 1988, Adv Exp Med Biol, V250, P627; DEGEN JL, 1983, J BIOL CHEM, V258, P2153; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; FILLINGA.RH, 1973, BIOCHEMISTRY-US, V12, P4479, DOI 10.1021/bi00746a028; FRIEDMAN KD, 1988, NUCLEIC ACIDS RES, V16, P8718, DOI 10.1093/nar/16.17.8718; GODEFROYCOLBURN T, 1981, J BIOL CHEM, V256, P1762; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GREENE JM, 1988, CURRENT PROTOCOLS; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; KAMEJI T, 1987, J BIOL CHEM, V262, P2427; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; KASPAR RL, 1992, J BIOL CHEM, V267, P508; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, GENE EXPRESSION, V1, P111; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LODISH HF, 1971, J BIOL CHEM, V246, P7131; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MACH M, 1986, J BIOL CHEM, V261, P1697; Maniatis T., 1982, MOL CLONING; Marton LJ, 1987, INHIB POLYAM METABOL, P79; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCCONLOGUE L, 1984, P NATL ACAD SCI-BIOL, V81, P540, DOI 10.1073/pnas.81.2.540; MEEROVITCH K, 1989, GENE DEV, V3, P1026, DOI 10.1101/gad.3.7.1026; MORRIS DR, 1991, J CELL BIOCHEM, V46, P102, DOI 10.1002/jcb.240460203; MORRIS DR, 1981, MED BIOL, V59, P314; PAJUNEN A, 1988, J BIOL CHEM, V263, P17040; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; PELLETIER J, 1969, NATURE, V244, P682; POSO H, 1982, BIOCHEMISTRY-US, V21, P3116, DOI 10.1021/bi00256a013; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARNOW P, 1989, P NATL ACAD SCI USA, V86, P5795, DOI 10.1073/pnas.86.15.5795; SEDMAN SA, 1990, J VIROL, V64, P453, DOI 10.1128/JVI.64.1.453-457.1990; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SEYFRIED CE, 1982, BIOCHIM BIOPHYS ACTA, V716, P169, DOI 10.1016/0304-4165(82)90265-3; SHIRAHATA A, 1986, J BIOL CHEM, V261, P3833; STANLEY BA, 1989, J BIOL CHEM, V264, P21073; STIMAC E, 1987, J CELL PHYSIOL, V133, P590, DOI 10.1002/jcp.1041330323; TABOR CW, 1984, ADV ENZYMOL RAMB, V56, P251; TAHARA SM, 1991, J BIOL CHEM, V266, P3594; THEIL EC, 1990, J BIOL CHEM, V265, P4771; VANDOREN K, 1984, J VIROL, V50, P606, DOI 10.1128/JVI.50.2.606-614.1984; WATSON CJ, 1985, DNA CLONING PRACTICA, V1, P79; WEAVER RF, 1979, NUCLEIC ACIDS RES, V7, P1175, DOI 10.1093/nar/7.5.1175; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0; WHITE MW, 1990, BIOCHEM J, V268, P657, DOI 10.1042/bj2680657; WHITE MW, 1987, EUR J BIOCHEM, V170, P87, DOI 10.1111/j.1432-1033.1987.tb13670.x; WHITE MW, 1988, PHYSL POLYAMINES, P331; YAMAMOTO T, 1980, P NATL ACAD SCI-BIOL, V77, P176, DOI 10.1073/pnas.77.1.176; YAMAMOTO T, 1980, CELL, V22, P787, DOI 10.1016/0092-8674(80)90555-3; [No title captured]	61	81	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21886	21893						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400498				2022-12-25	WOS:A1992JV01100096
J	MILSTONE, DS; SHAW, SK; PARKER, KL; SZYF, M; SEIDMAN, JG				MILSTONE, DS; SHAW, SK; PARKER, KL; SZYF, M; SEIDMAN, JG			AN ELEMENT REGULATING ADRENAL-SPECIFIC STEROID 21-HYDROXYLASE EXPRESSION IS LOCATED WITHIN THE SLP GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEX-LIMITED PROTEIN; BETA-GLOBIN GENE; TRANSGENIC MICE; COMPLEMENT COMPONENT; MURINE 21-HYDROXYLASE; SEQUENCE-ANALYSIS; 4TH COMPONENT; TUMOR-CELLS; HIGH-LEVEL; ENHANCER	In this report we demonstrate that a transcriptional regulatory element for one gene lies within a second, seemingly unrelated gene. Specifically, the 3' portion of the murine sex-limited protein (slp) gene, located within the class III region of the major histocompatibility complex, contains an element that regulates expression of the linked steroid 21-hydroxylase gene. A 4.2-kilobase (kb) major histocompatibility complex region, located between -2.2 and -6.4 kb upstream of 21OH-A, is required for expression of a chloramphenicol acetyltransferase reporter gene in transgenic mice. Two short regions of DNA, located between -5.3 and -6.0 kb, stimulate chloramphenicol acetyltransferase expression in Y1 adrenocortical tumor cells, and both of these active regions lie within the slp gene. A 21-base pair sequence, which is required for activity of the most 3' region, does not contain any of over 100 previously identified transcriptional regulatory elements. This juxtaposition of structural and regulatory elements of otherwise unrelated genes suggests a mechanism by which the evolutionarily conserved genetic linkage of 21OH-A and slp (or the homologous complement component C4) might provide a selective advantage. Analogous genetic arrangements may explain other examples of conserved linkage of disparate genes.	HARVARD UNIV,SCH MED,DEPT GENET,HOWARD HUGHES MED INST,BOSTON,MA 02115; DUKE UNIV,MED CTR,DEPT MED,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Duke University	MILSTONE, DS (corresponding author), BRIGHAM & WOMENS HOSP,LONGWOOD MED RES CTR,DEPT PATHOL,DIV VASC RES,221 LONGWOOD AVE,BOSTON,MA 02115, USA.			Shaw, Sunil/0000-0001-9701-6065	NHLBI NIH HHS [R01-HL19874] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHAPLIN DD, 1985, IMMUNOL REV, V87, P61, DOI 10.1111/j.1600-065X.1985.tb01145.x; CHAPLIN DD, 1983, P NATL ACAD SCI-BIOL, V80, P6947, DOI 10.1073/pnas.80.22.6947; CHAPLIN DD, 1986, P NATL ACAD SCI USA, V83, P9601, DOI 10.1073/pnas.83.24.9601; CHUNG BC, 1986, P NATL ACAD SCI USA, V83, P4243, DOI 10.1073/pnas.83.12.4243; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FENTON RG, 1988, SCIENCE, V241, P1089, DOI 10.1126/science.2970670; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HANDLER JD, 1989, ENDOCR RES, V15, P31, DOI 10.1080/07435808909039087; HANDLER JD, 1988, J BIOL CHEM, V263, P13068; HEMENWAY C, 1986, NUCLEIC ACIDS RES, V14, P2539, DOI 10.1093/nar/14.6.2539; HIROCHIKA H, 1988, GENE DEV, V2, P54, DOI 10.1101/gad.2.1.54; KAWAGUCHI H, 1990, EUR J IMMUNOL, V20, P739, DOI 10.1002/eji.1830200405; LOCKER J, 1990, J DNA SEQUENCING MAP, V1, P3; LORENI F, 1988, MOL CELL BIOL, V8, P2350, DOI 10.1128/MCB.8.6.2350; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOREL Y, 1989, P NATL ACAD SCI USA, V86, P6582, DOI 10.1073/pnas.86.17.6582; OGATA RT, 1991, J IMMUNOL, V147, P2756; OGATA RT, 1989, J BIOL CHEM, V264, P16565; OGATA RT, 1985, J IMMUNOL, V135, P4239; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PARKER KL, 1986, J BIOL CHEM, V261, P5353; PARKER KL, 1985, P NATL ACAD SCI USA, V82, P7860, DOI 10.1073/pnas.82.23.7860; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; RICE DA, 1990, J BIOL CHEM, V265, P8052; Sambrook J, 1989, MOL CLONING LABORATO; SCHIMMER BP, 1985, METHOD ENZYMOL, V109, P350; SCHREFFLER DC, 1982, HISTOCOMPATIBILITY A, P110; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; STAVENHAGEN JB, 1988, CELL, V55, P247, DOI 10.1016/0092-8674(88)90047-5; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; WHITE PC, 1985, P NATL ACAD SCI USA, V82, P1089, DOI 10.1073/pnas.82.4.1089; ZIMMERMAN K, 1990, MOL CELL BIOL, V10, P2096, DOI 10.1128/MCB.10.5.2096	39	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21924	21927						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400503				2022-12-25	WOS:A1992JV01100102
J	CHUNG, AB; STEPIEN, G; HARAGUCHI, Y; LI, K; WALLACE, DC				CHUNG, AB; STEPIEN, G; HARAGUCHI, Y; LI, K; WALLACE, DC			TRANSCRIPTIONAL CONTROL OF NUCLEAR GENES FOR THE MITOCHONDRIAL MUSCLE ADP/ATP TRANSLOCATOR AND THE ATP SYNTHASE BETA-SUBUNIT - MULTIPLE FACTORS INTERACT WITH THE OXBOX REBOX PROMOTER SEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C OXIDASE; THYROID-HORMONE; DNA-BINDING; SKELETAL-MUSCLE; DIMERIZATION DOMAINS; CONTRACTILE ACTIVITY; REGULATORY PROTEINS; MOUSE MUSCLE; EXPRESSION; RECEPTOR	The OXBOX promoter regions of the genes for the muscle-specific adenine nucleotide translocator (ANT1) and the beta subunit of the ATPsynthase (ATPsynbeta) have been implicated in the increased transcription of these nuclear-encoded oxidative phosphorylation (OXPHOS) genes in heart and skeletal muscle. DNA binding, electrophoretic mobility shift (gel-shift) assays now reveal that the OXBOX region has two unique but overlapping elements, the 13-base pair (bp) OXBOX and an 8-bp REBOX. The OXBOX binding factors are found only in myogenic cell lines, whereas the REBOX factors are ubiquitous. Methylation interference experiments have defined the boundaries of the OXBOX and REBOX elements, confirmed that the OXBOX factors are muscle-specific, and shown that the OXBOX and REBOX factors do not bind concurrently. The binding of the REBOX factors was found to be sensitive to NADH and thyroxine, suggesting that it may modulate OXPHOS gene expression in response to environmental and hormonal changes. Hence, the OXBOX/REBOX complex provides one mechanism by which mammalian energy metabolism can be adapted to developmental and environmental demands.	EMORY UNIV,SCH MED,DEPT GENET & MOLEC MED,ATLANTA,GA 30322	Emory University					NHLBI NIH HHS [HL45572] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045572] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; CHODOSH LA, 1988, CURRENT PROTOCOLS MO; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUBOC D, 1990, TRANSPLANTATION, V50, P751; DUBOC D, 1988, J APPL PHYSIOL, V64, P2692, DOI 10.1152/jappl.1988.64.6.2692; ESUMI K, 1991, AM J PHYSIOL, V260, pH1743, DOI 10.1152/ajpheart.1991.260.6.H1743; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GAY NJ, 1985, EMBO J, V4, P3519, DOI 10.1002/j.1460-2075.1985.tb04111.x; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HAAS RC, 1990, J BIOL CHEM, V265, P6921; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HALVORSEN YDC, 1991, MOL CELL BIOL, V11, P1777, DOI 10.1128/MCB.11.4.1777; HOCHACHKA PW, 1991, P NATL ACAD SCI USA, V88, P5764, DOI 10.1073/pnas.88.13.5764; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; JAMESON JL, 1989, J BIOL CHEM, V264, P16190; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; JOSTE V, 1989, EUR J BIOCHEM, V184, P255, DOI 10.1111/j.1432-1033.1989.tb15015.x; KADENBACH B, 1990, BIOCHIM BIOPHYS ACTA, V1015, P368, DOI 10.1016/0005-2728(90)90042-3; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KOUDELKA GB, 1988, P NATL ACAD SCI USA, V85, P4633, DOI 10.1073/pnas.85.13.4633; KOUZARIDES T, 1991, ONCOGENE, V6, P195; LI K, 1989, J BIOL CHEM, V264, P13998; LI K, 1990, J BIOL CHEM, V265, P20585; LLOUBES R, 1988, J MOL BIOL, V204, P1049, DOI 10.1016/0022-2836(88)90062-9; LUNARDI J, 1991, J BIOL CHEM, V266, P16534; MORGAN JG, 1988, MOL CELL BIOL, V8, P2628, DOI 10.1128/MCB.8.6.2628; MOSKALUK CA, 1989, VIROLOGY, V169, P236, DOI 10.1016/0042-6822(89)90062-7; MULLE C, 1988, P NATL ACAD SCI USA, V85, P5728, DOI 10.1073/pnas.85.15.5728; MUTVEI A, 1989, EUR J BIOCHEM, V180, P235, DOI 10.1111/j.1432-1033.1989.tb14638.x; NECKELMANN N, 1989, GENOMICS, V5, P829, DOI 10.1016/0888-7543(89)90125-0; SAATCIOGLU F, 1990, MOL CELL BIOL, V10, P6408, DOI 10.1128/MCB.10.12.6408; SCHLERF A, 1988, EMBO J, V7, P2387, DOI 10.1002/j.1460-2075.1988.tb03083.x; SCHROTH GP, 1991, NUCLEIC ACIDS RES, V19, P511, DOI 10.1093/nar/19.3.511; SCHROTH GP, 1989, NATURE, V340, P487, DOI 10.1038/340487a0; SCHULTHEISS HP, 1984, EUR J BIOCHEM, V143, P599, DOI 10.1111/j.1432-1033.1984.tb08412.x; STEPIEN G, 1992, J BIOL CHEM, V267, P14592; SUZUKI H, 1989, J BIOL CHEM, V264, P1368; SUZUKI H, 1991, J BIOL CHEM, V266, P2333; TORRONI A, 1990, J BIOL CHEM, V265, P20589; TOVAR K, 1989, NUCLEIC ACIDS RES, V17, P6515, DOI 10.1093/nar/17.16.6515; WEBSTER KA, 1990, J CELL PHYSIOL, V142, P566, DOI 10.1002/jcp.1041420316; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WILLIAMS RS, 1986, J BIOL CHEM, V261, P376; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YANAMURA W, 1988, BIOCHEMISTRY-US, V27, P4909, DOI 10.1021/bi00413a048; YUN Y, 1990, MOL ENDOCRINOL, V4, P931, DOI 10.1210/mend-4-6-931; ZHANG XK, 1991, J BIOL CHEM, V266, P8248; ZHANG XK, 1991, NEW BIOL, V3, P169; ZWIEB C, 1989, GENE DEV, V3, P606, DOI 10.1101/gad.3.5.606	57	95	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21154	21161						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400425				2022-12-25	WOS:A1992JT97800099
J	ZIERLER, M; CHRISTY, RJ; HUANG, RCC				ZIERLER, M; CHRISTY, RJ; HUANG, RCC			NUCLEAR-PROTEIN BINDING TO THE 5' ENHANCER REGION OF THE INTRACISTERNAL-A PARTICLE LONG TERMINAL REPEAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; RNA POLYMERASE-II; TRANSCRIPTION FACTOR; BLOTTING PROCEDURE; GENE; DNA; PROMOTER; IDENTIFICATION; EXPRESSION; SEQUENCES	The interactions of nuclear proteins from embryonal carcinoma cells (PCC3) with the long terminal repeats (LTRs) of murine intracisternal A particle (IAP) genes were studied. Two protein-DNA complexes were detected between PCC3 nuclear extract and IAP LTRs in a gel mobility shift assay. An additional complex was observed when enriched fractions from a heparin-agarose column were used as the source of proteins. Two regions within the LTR of IAP 81 were identified as the sites of protein interaction by DNase I protection. One region encompasses 43 nucleotides within the U3 region at the 5' end of LTR 81. The other covers a 78 base pair region lying within 100 nucleotides upstream from the transcription initiation site. Studies using constructs containing intact or deleted versions of the LTR fused to the bacterial chloramphenicol acetyltransferase gene indicated that the absence of the 5' 47 base pairs reduced the level of chloramphenicol acetyltransferase transcription to 20% of that driven by the entire LTR. Southwestern analysis of PCC3 nuclear extracts and column fractions revealed that a 28,000- and a 46,000-dalton protein were the major species that interact with the 5' end of IAP LTR 81.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	Johns Hopkins University					NATIONAL CANCER INSTITUTE [R01CA048263] Funding Source: NIH RePORTER; NCI NIH HHS [5 RO1 CA48263] Funding Source: Medline; NIGMS NIH HHS [5 T33 GM07231] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPEL MC, 1978, DIABETOLOGIA, V15, P327, DOI 10.1007/BF02573827; BAKKER O, 1991, NUCLEIC ACIDS RES, V19, P1213, DOI 10.1093/nar/19.6.1213; BENOIST C, 1980, NUCLEIC ACIDS RES, V8, P127, DOI 10.1093/nar/8.1.127; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURT DW, 1984, NUCLEIC ACIDS RES, V12, P8579, DOI 10.1093/nar/12.22.8579; CALARCO PG, 1969, J EXP ZOOL, V171, P253, DOI 10.1002/jez.1401710303; CANIVET M, 1980, EUR J CANCER, V16, P609, DOI 10.1016/0014-2964(80)90200-5; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHANGYEH A, 1991, NUCLEIC ACIDS RES, V19, P3667, DOI 10.1093/nar/19.13.3667; CHRISTY RJ, 1985, NUCLEIC ACIDS RES, V13, P289, DOI 10.1093/nar/13.1.289; CHRISTY RJ, 1988, MOL CELL BIOL, V8, P1093, DOI 10.1128/MCB.8.3.1093; DEOCA FH, 1983, J VIROL, V46, P307, DOI 10.1128/JVI.46.1.307-310.1983; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; ENDERS AC, 1965, PREIMPLANTATION STAG, P29; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FALZON M, 1988, J VIROL, V62, P4070, DOI 10.1128/JVI.62.11.4070-4077.1988; FALZON M, 1991, MOL CELL BIOL, V11, P117, DOI 10.1128/MCB.11.1.117; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM DI, 1976, NEUROPATH APPL NEURO, V2, P451, DOI 10.1111/j.1365-2990.1976.tb00519.x; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HOWE CC, 1986, MOL CELL BIOL, V6, P150, DOI 10.1128/MCB.6.1.150; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEITER EH, 1984, AM J PATHOL, V114, P46; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LUEDERS KK, 1977, CELL, V12, P963, DOI 10.1016/0092-8674(77)90161-1; LUEDERS KK, 1984, MOL CELL BIOL, V4, P2128, DOI 10.1128/MCB.4.10.2128; Maxam A M, 1980, Methods Enzymol, V65, P499; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; MORGAN RA, 1987, DEV GENET, V8, P125, DOI 10.1002/dvg.1020080302; MORGAN RA, 1988, DEVELOPMENT, V102, P23; MOSHIER JA, 1985, INTERRELATIONSHIP AG, P101; ONO M, 1980, CELL, V21, P465, DOI 10.1016/0092-8674(80)90483-3; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; SCHEIDEREIT C, 1984, P NATL ACAD SCI-BIOL, V81, P3029, DOI 10.1073/pnas.81.10.3029; SHENONG GLC, 1982, J VIROL, V42, P411, DOI 10.1128/JVI.42.2.411-421.1982; SILVA CM, 1987, P NATL ACAD SCI USA, V84, P1744, DOI 10.1073/pnas.84.7.1744; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEIHER H, 1983, SCIENCE, V219, P626, DOI 10.1126/science.6297005; WIVEL NA, 1971, INT J CANCER, V7, P167, DOI 10.1002/ijc.2910070119; WUJCIK KM, 1984, J VIROL, V52, P29, DOI 10.1128/JVI.52.1.29-36.1984	45	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21200	21206						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400431				2022-12-25	WOS:A1992JT97800106
J	KAMATH, AV; YANOFSKY, C				KAMATH, AV; YANOFSKY, C			CHARACTERIZATION OF THE TRYPTOPHANASE OPERON OF PROTEUS-VULGARIS - CLONING, NUCLEOTIDE-SEQUENCE, AMINO-ACID HOMOLOGY, AND INVITRO SYNTHESIS OF THE LEADER PEPTIDE AND REGULATORY ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; STRUCTURAL GENE; INDOLE-LYASE; EXPRESSION; RESIDUES; MECHANISM; TRANSPORT; INDUCTION; SITE	The tryptophanase (tna) operon of Proteus vulgaris was cloned and characterized and found to be organized similarly to the tna operon of Escherichia coli. Both operons contain two major structural genes, tnaA and tnaB, that encode tryptophanase and a tryptophan permease, respectively. tnaA of P. vulgaris is preceded by a transcribed leader region, encoding a 34-residue leader peptide, TnaC, that contains a single tryptophan residue. The tnaC coding region also has a boxA-like sequence. Regulatory studies performed in P. vulgaris, and with a plasmid carrying the P. vulgaris tna operon in E. coli, established that expression of the Proteus operon was induced by tryptophan and was subject to catabolite repression. Site-directed mutagenesis studies established that translation of the tnaC coding region was essential for induction. Synthesis of the P. vulgaris leader peptide was demonstrated in an in vitro coupled transcription-translation system. Interestingly, the 5 amino acid residues of the TnaC peptide surrounding the sole tryptophan residue are identical in P. vulgaris and E. coli. We conclude that the tna operon of P. vulgaris is also regulated by tryptophan-induced transcription antitermination. Homology of tryptophanase and tryptophan permease of P. vulgaris to related proteins from other species is described.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM009738, R37GM009738] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 09738] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BILEZIKIAN JP, 1967, J MOL BIOL, V27, P495, DOI 10.1016/0022-2836(67)90054-X; BOTSFORD JL, 1971, J BACTERIOL, V105, P303, DOI 10.1128/JB.105.1.303-312.1971; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; DEELEY MC, 1981, J BACTERIOL, V147, P787, DOI 10.1128/JB.147.3.787-796.1981; DEMOSS RD, 1969, J BACTERIOL, V98, P167, DOI 10.1128/JB.98.1.167-171.1969; FRIEDMAN DI, 1988, BACTERIOPHAGES, V2, P263; GOLLNICK P, 1990, J BACTERIOL, V172, P3100, DOI 10.1128/jb.172.6.3100-3107.1990; HEATWOLE VM, 1991, J BACTERIOL, V173, P108, DOI 10.1128/jb.173.1.108-115.1991; HENIKOFF S, 1987, METHOD ENZYMOL, V125, P157; HOCH JA, 1966, BIOCHEMISTRY-US, V5, P2229, DOI 10.1021/bi00871a011; HOFFMAN PS, 1981, J BACTERIOL, V148, P736, DOI 10.1128/JB.148.2.736-738.1981; IWAMORI S, 1991, J FERMENT BIOENG, V72, P147, DOI 10.1016/0922-338X(91)90207-W; KAGAMIYAMA H, 1972, J BIOL CHEM, V247, P1576; KAZARINOFF MN, 1977, J BIOL CHEM, V252, P7598; LOWRY OH, 1951, J BIOL CHEM, V193, P265; METZLER CM, 1991, J BIOL CHEM, V266, P9374; MILES EW, 1986, VITAMIN B6 PYRIDOXAL, P253; Miller J.H., 1972, EXPT MOL GENETICS; NAKAMURA K, 1979, J BACTERIOL, V137, P595, DOI 10.1128/JB.137.1.595-604.1979; NEWTON WA, 1964, P NATL ACAD SCI USA, V51, P382, DOI 10.1073/pnas.51.3.382; NIHIRA T, 1979, EUR J BIOCHEM, V101, P341, DOI 10.1111/j.1432-1033.1979.tb19726.x; PHILLIPS RS, 1990, BIOCHEMISTRY-US, V29, P8608, DOI 10.1021/bi00489a016; PHILLIPS RS, 1989, J BIOL CHEM, V264, P10627; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARSERO JP, 1991, J BACTERIOL, V173, P3231, DOI 10.1128/JB.173.10.3231-3234.1991; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIMARD C, 1975, CAN J MICROBIOL, V21, P841, DOI 10.1139/m75-125; SIMARD C, 1975, CAN J MICROBIOL, V21, P828, DOI 10.1139/m75-123; SIMPSON RB, 1980, NUCLEIC ACIDS RES, V8, P759; SMITH OH, 1962, METHOD ENZYMOL, V5, P794, DOI 10.1016/S0076-6879(62)05315-X; SNELL EE, 1975, ADV ENZYMOL RAMB, V42, P287; STEWART V, 1986, J BACTERIOL, V166, P217, DOI 10.1128/jb.166.1.217-223.1986; STEWART V, 1986, J BACTERIOL, V167, P383, DOI 10.1128/jb.167.1.383-386.1986; STEWART V, 1985, J BACTERIOL, V164, P731, DOI 10.1128/JB.164.2.731-740.1985; SUBBIAH S, 1989, J MOL BIOL, V209, P539, DOI 10.1016/0022-2836(89)90592-5; SUELTER CH, 1976, FEBS LETT, V66, P230, DOI 10.1016/0014-5793(76)80510-8; TAWATA Y, 1991, FEBS LETT, V284, P270; VAALER GL, 1989, BIOCHEMISTRY-US, V28, P7306, DOI 10.1021/bi00444a024; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WOOKEY PJ, 1991, J BACTERIOL, V170, P4946; YANOFSKY C, 1991, J BACTERIOL, V173, P6009, DOI 10.1128/jb.173.19.6009-6017.1991; YOSHIDA H, 1974, FEBS LETT, V48, P56, DOI 10.1016/0014-5793(74)81061-6; ZUBAY G, 1970, LACTOSE OPERON	45	45	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19978	19985						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400314				2022-12-25	WOS:A1992JR85800039
J	ZUTTER, MM; FONG, AM; KRIGMAN, HR; SANTORO, SA				ZUTTER, MM; FONG, AM; KRIGMAN, HR; SANTORO, SA			DIFFERENTIAL REGULATION OF THE ALPHA-2-BETA-1 AND ALPHA-IIB BETA-3 INTEGRIN GENES DURING MEGAKARYOCYTIC DIFFERENTIATION OF PLURIPOTENTIAL K562 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET GLYCOPROTEIN-IIIA; FIBRONECTIN RECEPTOR; TRANSCRIPTIONAL REGULATION; TERMINAL DIFFERENTIATION; DECREASED EXPRESSION; ADHESION RECEPTORS; MEMBRANE-RECEPTORS; LINE; SUBUNIT; ALPHA-5-BETA-1-INTEGRIN	Expression of the alpha2beta1 and alpha(IIb)beta3 integrin genes is differentially regulated during megakaryocytic differentiation of pluripotent K562 cells induced with phorbol 12,13-dibutyrate. Upon megakaryocytic differentiation, steady-state alpha2 mRNA increased markedly from the undetectable level present in the uninduced cells. The level of beta1 mRNA did not change. Expression of alpha(IIb)beta3 is regulated differently. Beta3 mRNA was undetectable in uninduced cells but increased significantly following induction. Alpha(IIb) mRNA was detectable at a low level prior to induction, but at an increased level following differentiation. Altered mRNA stability did not contribute to changes in mRNA levels. Nuclear run-off experiments revealed a 20-fold increase in alpha2 gene transcription upon megakaryocytic differentiation, but no change in transcription of the beta1 gene. Transcription of both the alpha(IIb) and beta3 genes increased 10- and 5-fold, respectively. Thus, the increase in alpha2beta1 protein which accompanies the megakaryocytic differentiation of K562 cells is a consequence of the increased steady-state level of alpha2 mRNA due to transcriptional activation of the alpha2 gene. The long-lived beta1 mRNA is not altered during differentiation. In contrast, increased alpha(IIb)beta3 protein appears due to increased steady-state levels of both alpha(IIb) and beta3 mRNAs that result from transcriptional activation of both integrin genes.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,BOX 8118,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NHLBI NIH HHS [T32 HL07038, HL 40506] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040506, T32HL007038] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; AGURA ED, 1992, BLOOD, V79, P602; AKIYAMA SK, 1987, J BIOL CHEM, V262, P17536; ALBELDA SM, 1990, CANCER RES, V50, P6757; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; BROWER DL, 1989, NATURE, V342, P285, DOI 10.1038/342285a0; BURGER SR, 1992, IN PRESS EXP CELL RE; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHEN WT, 1986, J CELL BIOL, V103, P1073, DOI 10.1083/jcb.103.3.1073; CLARK RAF, 1990, J INVEST DERMATOL, V94, pS128, DOI 10.1111/1523-1747.ep12876104; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; Davis L, 1986, BASIC METHODS MOL BI, P51; DEDHAR S, 1989, J CELL PHYSIOL, V138, P291, DOI 10.1002/jcp.1041380210; DEDHAR S, 1990, J CELL BIOL, V110, P481, DOI 10.1083/jcb.110.2.481; DEFILIPPI P, 1991, J BIOL CHEM, V266, P7638; DUBAND JL, 1986, J CELL BIOL, V102, P160, DOI 10.1083/jcb.102.1.160; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GILTAY JC, 1988, BLOOD, V71, P1171; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HEINO J, 1989, J BIOL CHEM, V264, P380; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HICKSTEIN DD, 1988, J BIOL CHEM, V263, P13863; HICKSTEIN DD, 1989, J BIOL CHEM, V264, P21812; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KORETZ K, 1991, AM J PATHOL, V138, P741; LEARY JF, 1987, LEUKEMIA RES, V11, P807, DOI 10.1016/0145-2126(87)90065-8; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOZZIO BB, 1979, LEUKEMIA RES, V3, P363, DOI 10.1016/0145-2126(79)90033-X; LOZZIO BB, 1981, P SOC EXP BIOL MED, V166, P546; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; NICHOLSON LJ, 1991, J CELL SCI, V98, P225; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; PONCZ M, 1987, J BIOL CHEM, V262, P8476; PRANDINI MH, 1988, BIOCHEM BIOPH RES CO, V156, P595, DOI 10.1016/S0006-291X(88)80884-2; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; UZAN G, 1991, J BIOL CHEM, V266, P8932; VOLK T, 1990, CELL, V63, P525, DOI 10.1016/0092-8674(90)90449-O; ZIMRIN AB, 1988, J CLIN INVEST, V81, P1470, DOI 10.1172/JCI113478; ZUTTER MM, 1990, AM J PATHOL, V137, P863	48	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20233	20238						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400341				2022-12-25	WOS:A1992JR85800077
J	JOOSS, K; MULLER, R				JOOSS, K; MULLER, R			ANALYSIS OF TEMPERATURE-SENSITIVE FUNCTIONS OF FOS - LACK OF A CORRELATION BETWEEN TRANSFORMATION AND TRE-DEPENDENT TRANSACTIVATION	ONCOGENE			English	Article							INDUCE CELLULAR-TRANSFORMATION; ROUS-SARCOMA VIRUS; PROTO-ONCOGENE FOS; C-FOS; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; AUTO-REGULATION; BINDING DOMAIN; JUN; CELLS	We have identified and characterized a mutant v-Fos protein (DN16G) that is temperature sensitive for transformation. This protein contains an asparagine to glycine substitution at position 156 in the basic region encompassing the DNA contact site. This point mutation also strongly decreases trans-activation in a transient expression assay, using the collagenase 12-O-tetradecanoyl phorbol 13-acetate (TPA)-responsive element (TRE) as the target element. However, the apparent correlation between trans-activation and transformation does not hold in view of the observation that under certain temperature conditions (DN16G at 39.5-degrees-C and E300 at 37-degrees-C) both proteins showed similarly poor transactivation properties, but dramatically differed in their transforming potential. These findings clearly suggest that the activation of transcription via TREs as analysed in this study is not a crucial mechanism in Fos-induced transformation.	UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,EMIL MANNKOPFF STR 2,W-3550 MARBURG,GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ADAMS SL, 1982, CELL, V30, P373, DOI 10.1016/0092-8674(82)90235-5; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4784; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAMATA N, 1992, MOL CELL BIOL, V12, P876, DOI 10.1128/MCB.12.2.876; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LUCIBELLO F C, 1991, Critical Reviews in Oncogenesis, V2, P259; LUCIBELLO FC, 1988, ONCOGENE, V3, P43; LUCIBELLO FC, 1991, NEW BIOL, V3, P671; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; LUCIBELLO FC, 1990, EMBO J, V9, P2828; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MILLER AD, 1984, CELL, V36, P51; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; NEUBERG M, 1991, ONCOGENE, V6, P1325; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUERMANN M, 1991, ONCOGENE, V6, P567; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; VERMA IM, 1986, TRENDS GENET, V2, P93, DOI 10.1016/0168-9525(86)90191-5; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x	48	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1933	1939						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408134				2022-12-25	WOS:A1992JP42400005
J	MORREAU, H; GALJART, NJ; WILLEMSEN, R; GILLEMANS, N; ZHOU, XY; DAZZO, A				MORREAU, H; GALJART, NJ; WILLEMSEN, R; GILLEMANS, N; ZHOU, XY; DAZZO, A			HUMAN LYSOSOMAL PROTECTIVE PROTEIN - GLYCOSYLATION, INTRACELLULAR-TRANSPORT, AND ASSOCIATION WITH BETA-GALACTOSIDASE IN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER KIDNEY-CELLS; GLYCOPROTEIN DEGRADATION; HUMAN-FIBROBLASTS; MOLECULAR-WEIGHT; CATHEPSIN-D; RAT-LIVER; NEURAMINIDASE; CDNA; EXPRESSION; CLONING	In lysosomes beta-galactosidase and neuraminidase acquire a stable and active conformation through their association with the protective protein. The latter is homologous to serine carboxypeptidases and has cathepsin A-like activity which is distinct from its protective function towards the two glycosidases. To define signals in the human protective protein important for its intracellular transport, and to determine the site of its association with beta-galactosidase, we have generated a set of mutated protective protein cDNAs carrying targeted base substitutions. These mutants were either singly transfected into COS-1 cells or cotransfected together with wild type human beta-galactosidase. We show that all point mutations cause either a complete or partial retention of the protective protein precursor in the endoplasmic reticulum. This abnormal accumulation leads to degradation of the mutant proteins probably in this compartment. Only the oligosaccharide chain on the 32-kDa subunit acquires the mannose 6-phosphate recognition marker, the one on the 20-kDa subunit seems to be merely essential for the stability of the mature protein. In cotransfection experiments, wild type beta-galactosidase and protective protein appear to assemble already as precursors, soon after synthesis, in the endoplasmic reticulum. Mutated protective protein precursors that are retained in the endoplasmic reticulum or pre-Golgi complex interact with and withhold normal beta-galactosidase molecules in the same compartments, thereby preventing their normal routing.	ERASMUS UNIV,CTR MED GENET,DEPT CELL BIOL & GENET,POB 1738,3000 DR ROTTERDAM,NETHERLANDS; ERASMUS UNIV,DEPT CLIN GENET,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam			Galjart, Niels/D-1146-2010; zhou, xingyu/GXF-7454-2022	Galjart, Niels/0000-0003-1964-3607; 				BREDDAM K, 1986, CARLSBERG RES COMMUN, V51, P83, DOI 10.1007/BF02907561; DAZZO A, 1982, P NATL ACAD SCI-BIOL, V79, P4535, DOI 10.1073/pnas.79.15.4535; DONG JM, 1989, J BIOL CHEM, V264, P7377; FRISCH A, 1981, J BIOL CHEM, V256, P8242; GALJAARD H, 1980, GENETIC METABOLIC DI; GALJART NJ, 1988, CELL, V54, P755, DOI 10.1016/S0092-8674(88)90999-3; GALJART NJ, 1991, J BIOL CHEM, V266, P14754; GALJART NJ, 1990, J BIOL CHEM, V265, P4678; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOOGEVEEN AT, 1983, J BIOL CHEM, V258, P2143; HORST M, 1991, BIOCHEM J, V273, P355, DOI 10.1042/bj2730355; ISIDORO C, 1991, BIOCHEM J, V273, P363, DOI 10.1042/bj2730363; JACKMAN HL, 1992, J BIOL CHEM, V267, P2872; JACKMAN HL, 1990, J BIOL CHEM, V265, P11265; LAU MMH, 1989, J BIOL CHEM, V264, P21376; LAZZARINO DA, 1988, J BIOL CHEM, V263, P10118; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MORREAU H, 1989, J BIOL CHEM, V264, P20655; MURPHY G, 1988, NUCLEIC ACIDS RES, V16, P5198, DOI 10.1093/nar/16.11.5198; NANBA E, 1990, BIOCHEM BIOPH RES CO, V173, P141, DOI 10.1016/S0006-291X(05)81033-2; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; OSHIMA A, 1988, BIOCHEM BIOPH RES CO, V157, P238, DOI 10.1016/S0006-291X(88)80038-X; PALMERI S, 1986, AM J HUM GENET, V38, P137; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; POTIER M, 1990, BIOCHEM J, V267, P197, DOI 10.1042/bj2670197; PROIA RL, 1984, J BIOL CHEM, V259, P3350; ROTH M, 1971, ANAL CHEM, V43, P880, DOI 10.1021/ac60302a020; Sambrook J, 1989, MOL CLONING LABORATO; SCHEIBE R, 1990, BIOMED BIOCHIM ACTA, V49, P547; SEGAL HL, 1984, CURR TOP CELL REGUL, V24, P229; TAYLOR S, 1973, ANAL BIOCHEM, V56, P140, DOI 10.1016/0003-2697(73)90178-4; VANDERHORST GTJ, 1989, J BIOL CHEM, V264, P1317; VERHEIJEN F, 1982, BIOCHEM BIOPH RES CO, V108, P868, DOI 10.1016/0006-291X(82)90911-1; VERHEIJEN FW, 1985, EUR J BIOCHEM, V149, P315, DOI 10.1111/j.1432-1033.1985.tb08928.x; WILLEMSEN R, 1986, EUR J CELL BIOL, V40, P9; WINKLER JR, 1984, J BIOL CHEM, V259, P5369; YAMAMOTO Y, 1987, INT J BIOCHEM, V19, P435, DOI 10.1016/0020-711X(87)90064-4; YAMAMOTO Y, 1990, DNA CELL BIOL, V9, P119, DOI 10.1089/dna.1990.9.119; YAMAMOTO Y, 1982, J BIOCHEM, V92, P13, DOI 10.1093/oxfordjournals.jbchem.a133910; ZHOU XY, 1991, EMBO J, V10, P4041, DOI 10.1002/j.1460-2075.1991.tb04980.x	42	48	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17949	17956						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1387645				2022-12-25	WOS:A1992JM22300072
J	YU, YG; WEISS, RL				YU, YG; WEISS, RL			ARGININE TRANSPORT IN MITOCHONDRIA OF NEUROSPORA-CRASSA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; VACUOLAR MEMBRANE; WILD-TYPE; ORNITHINE; LOCALIZATION; POKY	Transport of arginine into mitochondria of Neurospora crassa has been studied. Arginine transport was found to be saturable (K(m) = 6.5 mM) and to have a pH optimum of pH 7.5. Mitochondrial arginine transport appeared to be facilitated transport rather than active transport because: (i) the arginine concentration within the mitochondrial matrix after transport was similar to that of the reaction medium, and (ii) uncouplers and substrates of oxidative phosphorylation did not affect the transport rate. The basic amino acids ornithine, lysine, and D-arginine inhibited arginine transport. The arginine transport system could be irreversibly blocked by treating mitochondria with the reactive arginine derivative, N-nitrobenzyloxycarbonyl-arginyl diazomethane.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036552] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36552] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONSON DL, 1981, BIOCHEMISTRY-US, V20, P7064, DOI 10.1021/bi00528a002; BASABE JR, 1976, ANAL BIOCHEM, V92, P356; BORKOVICH KA, 1987, J BIOL CHEM, V262, P7081; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYLA J, 1977, FEBS LETT, V72, P331; COTY WA, 1974, J BIOL CHEM, V249, P2593; CRAMER CL, 1983, ANAL BIOCHEM, V128, P384, DOI 10.1016/0003-2697(83)90390-1; CYBIS J, 1975, J BACTERIOL, V123, P196, DOI 10.1128/JB.123.1.196-202.1975; DAVIS RH, 1988, TRENDS BIOCHEM SCI, V13, P101, DOI 10.1016/0968-0004(88)90050-3; DAVIS RH, 1962, ARCH BIOCHEM BIOPHYS, V97, P185, DOI 10.1016/0003-9861(62)90063-2; DAVIS RH, 1983, J BACTERIOL, V154, P1046, DOI 10.1128/JB.154.3.1046-1053.1983; GAMBLE JG, 1973, J BIOL CHEM, V248, P610; HINDE RW, 1986, J BIOL CHEM, V261, P5848; HOMMES FA, 1983, BIOCHEM MED METAB B, V30, P313, DOI 10.1016/0006-2944(83)90022-4; KADOWAKI H, 1976, BIOCHIM BIOPHYS ACTA, V437, P158, DOI 10.1016/0304-4165(76)90357-3; KATKOCIN DM, 1976, J BACTERIOL, V127, P1270, DOI 10.1128/JB.127.3.1270-1277.1976; KELLER DM, 1968, BIOCHIM BIOPHYS ACTA, V153, P113, DOI 10.1016/0005-2728(68)90151-5; KWONG E, 1982, J NUTR, V112, P2081; LAMBOWITZ AM, 1972, J BIOL CHEM, V247, P4850; LAMBOWITZ AM, 1972, J BIOL CHEM, V247, P4859; MCGIVAN JD, 1977, BIOCHEM J, V162, P147, DOI 10.1042/bj1620147; PAEK YL, 1989, J BIOL CHEM, V264, P7285; SHIH VE, 1981, J INHERIT METAB DIS, V4, P95, DOI 10.1007/BF02263608; SUBRAMANIAN KN, 1973, J BACTERIOL, V115, P284, DOI 10.1128/JB.115.1.284-290.1973; VOGEL HJ, 1964, AM NAT, V98, P435, DOI 10.1086/282338; WEISS RL, 1976, J BACTERIOL, V126, P1173, DOI 10.1128/JB.126.3.1173-1179.1976; WEISS RL, 1973, J BIOL CHEM, V248, P5409; WOLF EC, 1980, J BIOL CHEM, V255, P9189; ZEREZ CR, 1986, J BIOL CHEM, V261, P8877	29	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15491	15495						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1386360				2022-12-25	WOS:A1992JG11300038
J	WARIISHI, H; VALLI, K; GOLD, MH				WARIISHI, H; VALLI, K; GOLD, MH			MANGANESE(II) OXIDATION BY MANGANESE PEROXIDASE FROM THE BASIDIOMYCETE PHANEROCHAETE-CHRYSOSPORIUM - KINETIC MECHANISM AND ROLE OF CHELATORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGNIN-DEGRADING BASIDIOMYCETE; EXTRACELLULAR HEME ENZYME; SPECTRAL CHARACTERIZATION; HORSERADISH-PEROXIDASE; OXIDIZED STATES; MODEL COMPOUNDS; DEGRADATION; BIODEGRADATION; INVITRO	Manganese oxidation by manganese peroxidase (MnP) was investigated. Stoichiometric, kinetic, and Mn(II) binding studies demonstrated that MnP has a single manganese binding site near the heme, and two Mn(III) equivalents are formed at the expense of one H2O2 equivalent. Since each catalytic cycle step is irreversible, the data fit a peroxidase ping-pong mechanism rather than an ordered bi-bi ping-pong mechanism. Mn(III)-organic acid complexes oxidize terminal phenolic substrates in a second-order reaction. Mn(III)-lactate and -tartrate also react slowly with H2O2, with third-order kinetics. The latter slow reaction does not interfere with the rapid MnP oxidation of phenols. Oxalate and malonate are the only organic acid chelators secreted by the fungus in significant amounts. No relationship between stimulation of enzyme activity and chelator size was found, suggesting that the substrate is free Mn(II) rather than a Mn(II)-chelator complex. The enzyme competes with chelators for free Mn(II). Optimal chelators, such as malonate, facilitate Mn(III) dissociation from the enzyme, stabilize Mn(III) in aqueous solution, and have a relatively low Mn(II) binding constant.	OREGON GRAD INST SCI & TECHNOL,DEPT CHEM & BIOL SCI,19600 NW VON NEUMANN DR,BEAVERTON,OR 97006									AITKEN MD, 1990, ARCH BIOCHEM BIOPHYS, V276, P405, DOI 10.1016/0003-9861(90)90739-L; ALIC M, 1987, APPL ENVIRON MICROB, V53, P1464, DOI 10.1128/AEM.53.7.1464-1469.1987; ARCHIBALD FS, 1982, ARCH BIOCHEM BIOPHYS, V214, P452, DOI 10.1016/0003-9861(82)90049-2; BUSWELL JA, 1987, CRC CR REV BIOTECHN, V6, P1, DOI 10.3109/07388558709086984; CASELLA L, 1991, BIOCHEM J, V279, P245, DOI 10.1042/bj2790245; COTTON ML, 1973, CAN J CHEM, V51, P582, DOI 10.1139/v73-088; CUI F, 1990, HOLZFORSCHUNG, V44, P279, DOI 10.1515/hfsg.1990.44.4.279; Davies G, 1968, INORG CHEM, V7, P146, DOI 10.1021/ic50059a031; DEMMER H, 1980, COORDINATION COMPOUN, V56, P1; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; Eigen M., 1963, PURE APPL CHEM, V6, P97, DOI [10.1351/pac196306010097, DOI 10.1351/PAC196306010097]; EVANS WP, 1954, J CHEM SOC, P550, DOI 10.1039/jr9540000550; GIERER J, 1973, ACTA CHEM SCAND, V27, P2909, DOI 10.3891/acta.chem.scand.27-2909; GLENN JK, 1986, ARCH BIOCHEM BIOPHYS, V251, P688, DOI 10.1016/0003-9861(86)90378-4; GLENN JK, 1985, ARCH BIOCHEM BIOPHYS, V242, P329, DOI 10.1016/0003-9861(85)90217-6; GOLD MH, 1989, ACS SYM SER, V389, P127; HAMMEL KE, 1991, ENZYME MICROB TECH, V13, P15, DOI 10.1016/0141-0229(91)90182-A; HARRIS RZ, 1991, J BIOL CHEM, V266, P8751; IRVING H, 1962, J CHEM SOC, P5222, DOI 10.1039/jr9620005222; JOLK V, 1964, J CHROMATOGR, V14, P71; KIRK TK, 1987, ANNU REV MICROBIOL, V41, P465, DOI 10.1146/annurev.mi.41.100187.002341; Klebanoff S.J., 1991, PEROXIDASES CHEM BIO, P1; KUWAHARA M, 1984, FEBS LETT, V169, P247, DOI 10.1016/0014-5793(84)80327-0; LACKNER R, 1991, BIOCHEM BIOPH RES CO, V178, P1092, DOI 10.1016/0006-291X(91)91004-V; LEISOLA MSA, 1987, J BIOL CHEM, V262, P419; MCAULEY A, 1967, J CHEM SOC, P4458; MINO Y, 1988, J BIOL CHEM, V263, P7029; PASZCZYNSKI A, 1986, ARCH BIOCHEM BIOPHYS, V244, P750, DOI 10.1016/0003-9861(86)90644-2; PEASE EA, 1989, J BIOL CHEM, V264, P13531; PRIBNOW D, 1989, J BIOL CHEM, V264, P5036; RENGANATHAN V, 1986, BIOCHEMISTRY-US, V25, P1626, DOI 10.1021/bi00355a027; SARKANEN KV, 1971, LIGNINS; TAKAO S, 1965, APPL MICROBIOL, V13, P732, DOI 10.1128/AEM.13.5.732-737.1965; THOMPSON DHP, 1987, J AM CHEM SOC, V109, P2003, DOI 10.1021/ja00241a017; TIEN M, 1987, CRIT REV MICROBIOL, V15, P141, DOI 10.3109/10408418709104456; TRIPATHY KK, 1967, INDIAN J CHEM, V5, P511; TUOR U, 1992, BIOCHEMISTRY-US, V31, P4986, DOI 10.1021/bi00136a011; VALLI K, 1992, APPL ENVIRON MICROB, V58, P221, DOI 10.1128/AEM.58.1.221-228.1992; VALLI K, 1991, J BACTERIOL, V173, P345, DOI 10.1128/jb.173.1.345-352.1991; VALLI K, 1992, J BACTERIOL, V174, P2131, DOI 10.1128/JB.174.7.2131-2137.1992; WARIISHI H, 1990, J BIOL CHEM, V265, P2070; WARIISHI H, 1989, J BIOL CHEM, V264, P14185; WARIISHI H, 1989, BIOCHEMISTRY-US, V28, P6017, DOI 10.1021/bi00440a044; WARIISHI H, 1988, BIOCHEMISTRY-US, V27, P5365, DOI 10.1021/bi00414a061; WARIISHI H, 1989, J BIOL CHEM, V264, P3335; WARIISHI H, 1991, BIOCHEM BIOPH RES CO, V176, P269, DOI 10.1016/0006-291X(91)90919-X	46	876	907	8	117	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23688	23695						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429709				2022-12-25	WOS:A1992JZ23900042
J	MATHERLY, LH; ANGELES, SM; CZAJKOWSKI, CA				MATHERLY, LH; ANGELES, SM; CZAJKOWSKI, CA			CHARACTERIZATION OF TRANSPORT-MEDIATED METHOTREXATE RESISTANCE IN HUMAN TUMOR-CELLS WITH ANTIBODIES TO THE MEMBRANE CARRIER FOR METHOTREXATE AND TETRAHYDROFOLATE COFACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-HYDROXYSUCCINIMIDE ESTER; DIHYDROFOLATE-REDUCTASE; FOLATE TRANSPORT; LEUKEMIA-CELLS; L1210 CELLS; PROTEIN; BINDING; INVITRO; DEGLYCOSYLATION; IDENTIFICATION	An earlier report (Matherly, L. H., Czajkowski, C. A., and Angeles, S. M. (1991) Cancer Res. 51, 3420-3426) described a K562 human erythroleukemia line (K562.4CF), characterized by an elevated uptake capacity for methotrexate (MTX) and 5-formyltetrahydrofolate, and the identification of a highly glycosylated membrane transporter (GP-MTX) by radioaffinity labeling with N-hydroxysuccinimide [H-3] methotrexate. In the present study, radioaffinity-labeled GP-MTX from K562.4CF cells was isolated by Ricinus communis agglutinin I-agarose affinity chromatography, coupled with gel filtration and preparative electrophoresis. Antiserum to the purified, radiolabeled protein was raised in a rabbit and screened by immunoblot analysis of K562.4CF plasma membrane proteins or purified GP-MTX. The antiserum detected a broad GP-MTX band centered at 92 kDa on 7.5% gels. On 4-10% gels, the apparent molecular mass for GP-MTX shifted to 99 kDa. Antiserum specificity was established by quantitatively converting the immunoreactive glycoprotein in plasma membrane homogenates to its N- and O-deglycosylated forms with N- and O-glycanases, respectively. Whereas the methotrexate uptake capacity of K562.4CF cells was elevated 6.1-fold over parental cells, the GP-MTX content on immunoblots was increased approximately 3-fold. For two methotrexate-resistant K562 lines (33- and 70-fold), decreased drug uptake (28 and 18% of parental levels) closely correlated with their reduced GP-MTX contents. A GP-MTX isoform was also detected on immunoblots of membrane proteins from CCRF-CEM human lymphoblastic leukemia cells. With a transport-impaired CCRF-CEM line (13% of wild type uptake), an aberrant electrophoretic migration for GP-MTX was observed, establishing the presence of structural modifications in the transport protein. These structural differences were independent of carrier glycosylation since they were detected following the glycosidase treatments. These findings implicate important roles for distinct carrier-specific alterations in the expression of diminished drug transport in methotrexate-resistant human tumor cells.			MATHERLY, LH (corresponding author), MICHIGAN CANC FDN,DEV THERAPEUT PROGRAM,110 E WARREN AVE,DETROIT,MI 48201, USA.							AVRUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P334, DOI 10.1016/0005-2736(71)90331-2; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; FABRE I, 1984, CANCER RES, V44, P3190; FAN JG, 1991, J BIOL CHEM, V266, P14862; FAN JG, 1991, BIOCHEMISTRY-US, V30, P4573, DOI 10.1021/bi00232a030; FLINTOFF WF, 1983, ARCH BIOCHEM BIOPHYS, V223, P433, DOI 10.1016/0003-9861(83)90607-0; FRY DW, 1982, J BIOL CHEM, V257, P1890; GALIVAN J, 1979, CANCER RES, V39, P735; GOLDMAN ID, 1985, PHARMACOL THERAPEUT, V28, P77, DOI 10.1016/0163-7258(85)90083-X; GREEN DE, 1955, J BIOL CHEM, V217, P551; HANKS JH, 1949, P SOC EXP BIOL MED, V71, P196; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HENDERSON GB, 1984, J BIOL CHEM, V259, P4558; HENDERSON GB, 1980, ARCH BIOCHEM BIOPHYS, V202, P144, DOI 10.1016/0003-9861(80)90416-6; JANSEN G, 1990, J BIOL CHEM, V265, P18272; KESSEL D, 1965, SCIENCE, V150, P752, DOI 10.1126/science.150.3697.752; KESSEL D, 1968, CANCER RES, V28, P564; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHERLY LH, 1991, CANCER RES, V51, P3420; MATHERLY LH, 1984, CANCER RES, V44, P2325; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NEILANDS JB, 1955, METHOD ENZYMOL, V1, P449, DOI 10.1016/0076-6879(55)01074-4; NORRIS MD, 1991, CANCER, V68, P981, DOI 10.1002/1097-0142(19910901)68:5<981::AID-CNCR2820680512>3.0.CO;2-W; OHNUMA T, 1985, CANCER RES, V45, P1815; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PRICE EM, 1987, BIOCHEMISTRY-US, V26, P4757, DOI 10.1021/bi00389a024; RODENHUIS S, 1986, CANCER RES, V46, P6513; ROSOWSKY A, 1980, BIOCHEM PHARMACOL, V29, P648, DOI 10.1016/0006-2952(80)90391-3; ROSOWSKY A, 1985, CANCER RES, V45, P6205; ROSOWSKY A, 1985, J MED CHEM, V28, P660, DOI 10.1021/jm50001a021; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; Segrest JP, 1972, METHOD ENZYMOL, V28, P54, DOI DOI 10.1016/0076-6879(72)28007-7; SIROTNAK FM, 1981, CANCER RES, V41, P4447; SIROTNAK FM, 1985, CANCER RES, V45, P3992; TAKASAKI S, 1976, J BIOL CHEM, V251, P3603; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; WOODWARD HD, 1987, BIOCHEMISTRY-US, V26, P5315, DOI 10.1021/bi00391a015; YANG CH, 1992, J BIOL CHEM, V267, P6628; YANG CH, 1988, J BIOL CHEM, V263, P9703	40	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23253	23260						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429671				2022-12-25	WOS:A1992JY16300084
J	TSIRKA, S; COFFINO, P				TSIRKA, S; COFFINO, P			DOMINANT NEGATIVE MUTANTS OF ORNITHINE DECARBOXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFLUOROMETHYLORNITHINE; INHIBITION; TURNOVER; CLONING; ENZYME; ALPHA; SITES	Conserved lysines of mouse ornithine decarboxylase were individually mutated to arginines. The mutations at amino acid residues 69, 115, and 169 greatly reduced or abolished enzymatic activity. Lysine 69 is the site of Schiff base formation with the cofactor pyridoxal phosphate; the functional role of the other two lysines essential for activity is not known. Coexpression of wild type ornithine decarboxylase along with the lysine 115 to arginine mutant reduced the activity of the former without diminishing the amount of wild type protein. This form of negative complementation was seen when wild type and mutant protein were coexpressed either by in vitro translation or in bacteria. The data are consistent with the conclusion that a wild type and mutant subunit form a heterodimer that is enzymatically inactive.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,BOX 0414,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Tsirka, Stella/AAD-4018-2019		NCI NIH HHS [R01 CA29048] Funding Source: Medline; NIGMS NIH HHS [R01 GM45335] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045335] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bey P., 1987, INHIBITION POLYAMINE, P1; COFFINO P, 1989, ORNITHINE DECARBOXYL, P135; FOZARD JR, 1980, EUR J PHARMACOL, V65, P379, DOI 10.1016/0014-2999(80)90342-8; FOZARD JR, 1980, SCIENCE, V208, P505; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1992, MOL CELL BIOL, V12, P2178, DOI 10.1128/MCB.12.5.2178; GUPTA M, 1985, J BIOL CHEM, V260, P2941; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; JACKSON FR, 1990, J MOL EVOL, V31, P325, DOI 10.1007/BF02101126; JOBLING MG, 1990, NUCLEIC ACIDS RES, V18, P5315, DOI 10.1093/nar/18.17.5315; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURAMITSU S, 1987, BIOCHEM BIOPH RES CO, V146, P416, DOI 10.1016/0006-291X(87)90545-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU L, 1991, BIOCHEM J, V277, P671, DOI 10.1042/bj2770671; MACRAE M, 1987, MOL CELL BIOL, V7, P564, DOI 10.1128/MCB.7.1.564; PHILLIPS MA, 1987, J BIOL CHEM, V262, P8721; PILZ RB, 1990, J BIOL CHEM, V265, P8880; POULIN R, 1992, J BIOL CHEM, V267, P150; PRICHARD ML, 1981, BIOCHEM BIOPH RES CO, V100, P1597; Queen C, 1983, J Mol Appl Genet, V2, P1; ROBEY EA, 1985, P NATL ACAD SCI USA, V82, P361, DOI 10.1073/pnas.82.2.361; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; WETTERS TV, 1989, MOL CELL BIOL, V9, P5484, DOI 10.1128/MCB.9.12.5484; WHITE MW, 1987, EUR J BIOCHEM, V170, P87, DOI 10.1111/j.1432-1033.1987.tb13670.x	25	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23057	23062						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429654				2022-12-25	WOS:A1992JY16300055
J	BENAMIRA, M; SINGH, U; MARNETT, LJ				BENAMIRA, M; SINGH, U; MARNETT, LJ			SITE-SPECIFIC FRAMESHIFT MUTAGENESIS BY A PROPANODEOXYGUANOSINE ADDUCT POSITIONED IN THE (CPG)4 HOT-SPOT OF SALMONELLA-TYPHIMURIUM HISD3052 CARRIED ON AN M13 VECTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMULTANEOUS PARTIAL INTERCALATION; SINGLE ACETYLAMINOFLUORENE ADDUCT; RESTRICTION ENDONUCLEASES HINDII; LOCATED OPPOSITE DEOXYADENOSINE; DNA-SEQUENCE ANALYSIS; ESCHERICHIA-COLI; NUCLEIC-ACID; CARCINOGEN N-ACETOXY-N-2-ACETYLAMINOFLUORENE; OXADIAZABICYCLONONENE RESIDUES; TRANSIENT MISALIGNMENT	Malondialdehyde induces frameshift mutations in Salmonella typhimurium strain hisD3052. The ability of propanodeoxyguanosine (PdG), a structural analog of the major malondialdehyde-deoxyguanosine adduct, to induce site-specific frameshift mutations was tested in the (CpG)4 hot-spot of hisD3052 carried on an M13 vector (M13MB102). PdG was introduced at position 6248 of duplex M13MB102 by ligation of the oligonucleotide 5'-CGC(PdG)CGGCATG-3' into a heteroduplex containing an 11-nucleotide gap in the (-)strand between the SphI and BssHII restriction sites and deoxyuridine in place of thymidine in the (+)strand. Ligation proceeded with 70% efficiency, and closed circular duplex DNA molecules were isolated in 40% yield. The adducted genome was sensitive to cleavage by SphI but resistant to cleavage by BssHII. Transformation of Escherichia coli strain JM105 with adducted M13MB102 led to 25% reduced survival relative to unadducted M13MB102 and produced frameshift mutations in 2.5% of the progeny phage. All of the mutations were deletions, and 70% occurred by deletion of CpG. Unadducted genomes exhibited a 40-fold lower mutation frequency, and all the mutations were single-base deletions at the sites of ligation of the 11-mer. These results illustrate that PdG, a structural analog of the major malondialdehyde-deoxyguanosine adduct, induces frameshift mutations in M13MB102 and that single-stranded nicks are efficient premutagenic lesions in this recombinant bacteriophage.	VANDERBILT UNIV,MED CTR,SCH MED,CTR MOLEC TOXICOL,DEPT BIOCHEM,AB HANCOCK JR MEM LAB CANC RES,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,CTR MOLEC TOXICOL,DEPT CHEM,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University					NATIONAL CANCER INSTITUTE [R35CA047479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47479] Funding Source: Medline; NIEHS NIH HHS [ES 00267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; BASU AK, 1988, CHEM RES TOXICOL, V1, P53, DOI 10.1021/tx00001a010; BASU AK, 1983, CARCINOGENESIS, V4, P331, DOI 10.1093/carcin/4.3.331; BASU AK, 1987, BIOCHEMISTRY-US, V26, P5626, DOI 10.1021/bi00392a007; BASU AK, 1989, P NATL ACAD SCI USA, V86, P7677, DOI 10.1073/pnas.86.20.7677; BASU AK, 1984, CANCER RES, V44, P2848; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; BELGUISEVALLADIER P, 1991, BIOCHEMISTRY-US, V30, P10091, DOI 10.1021/bi00106a005; BELL DA, 1991, MUTAT RES, V252, P35, DOI 10.1016/0165-1161(91)90249-8; BENASUTTI M, 1988, CHEM RES TOXICOL, V1, P160, DOI 10.1021/tx00003a006; BERNHEIM F, 1948, J BIOL CHEM, V174, P257; BICHARA M, 1985, J MOL BIOL, V183, P341, DOI 10.1016/0022-2836(85)90005-1; BODNAR JW, 1983, J BIOL CHEM, V258, P5206; BOOSALIS MS, 1989, J BIOL CHEM, V264, P11360; BURNOUF D, 1989, P NATL ACAD SCI USA, V86, P4147, DOI 10.1073/pnas.86.11.4147; CEBULA TA, 1990, PROG CLIN BIOL RES, V340, P367; CHENG KC, 1991, P NATL ACAD SCI USA, V88, P9974, DOI 10.1073/pnas.88.22.9974; CMARIK JL, 1992, J BIOL CHEM, V267, P6672; CUPPLES CG, 1990, GENETICS, V125, P275; ECHOLS H, 1990, MUTAT RES, V236, P301, DOI 10.1016/0921-8777(90)90013-U; FOWLER KW, 1982, J AM CHEM SOC, V104, P1050, DOI 10.1021/ja00368a023; FREUND AM, 1989, P NATL ACAD SCI USA, V86, P7465, DOI 10.1073/pnas.86.19.7465; FUCHS RPP, 1984, J MOL BIOL, V177, P173, DOI 10.1016/0022-2836(84)90063-9; FUCHS RPP, 1981, NATURE, V294, P657, DOI 10.1038/294657a0; FUSCOE JC, 1988, MUTAT RES, V201, P241, DOI 10.1016/0027-5107(88)90131-5; George W. O., 1968, J CHEM SOC B, P132, DOI DOI 10.1039/J29680000132; GREEN CL, 1984, P NATL ACAD SCI-BIOL, V81, P13, DOI 10.1073/pnas.81.1.13; GROLLMAN A P, 1989, Proceedings of the American Association for Cancer Research Annual Meeting, V30, P682; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; IDE H, 1991, J BIOL CHEM, V266, P1469; ISONO K, 1974, P NATL ACAD SCI USA, V71, P1612, DOI 10.1073/pnas.71.5.1612; JANERO DR, 1990, FREE RADICAL BIO MED, V9, P515, DOI 10.1016/0891-5849(90)90131-2; JAWORSKI A, 1989, J MOL BIOL, V207, P513, DOI 10.1016/0022-2836(89)90461-0; JIRICNY J, 1986, NUCLEIC ACIDS RES, V14, P1943, DOI 10.1093/nar/14.5.1943; JIRICNY J, 1986, NUCLEIC ACIDS RES, V14, P6579, DOI 10.1093/nar/14.16.6579; JOHNSON DL, 1986, BIOCHEMISTRY-US, V25, P449, DOI 10.1021/bi00350a026; JOYCE CM, 1984, J BACTERIOL, V158, P636, DOI 10.1128/JB.158.2.636-643.1984; KOEHL P, 1989, NUCLEIC ACIDS RES, V17, P9531, DOI 10.1093/nar/17.23.9531; KOFFELSCHWARTZ N, 1984, J MOL BIOL, V177, P33, DOI 10.1016/0022-2836(84)90056-1; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P3262, DOI 10.1021/bi00227a014; KOUCHAKDJIAN M, 1990, BIOCHEMISTRY-US, V29, P4456, DOI 10.1021/bi00470a028; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUPCHELLA E, 1991, ENVIRON MOL MUTAGEN, V18, P224, DOI 10.1002/em.2850180404; LAMBERT IB, 1992, P NATL ACAD SCI USA, V89, P1310, DOI 10.1073/pnas.89.4.1310; LASKO DD, 1987, BIOCHEMISTRY-US, V26, P3072, DOI 10.1021/bi00385a019; LAWRENCE CW, 1990, NUCLEIC ACIDS RES, V18, P2153, DOI 10.1093/nar/18.8.2153; LUNDQUIST RC, 1982, CELL, V31, P53, DOI 10.1016/0092-8674(82)90404-4; Maniatis T, 1989, DECONTAMINATION DILU; MARINELLI ER, 1990, CHEM RES TOXICOL, V3, P49, DOI 10.1021/tx00013a009; MARNETT LJ, 1986, J AM CHEM SOC, V108, P1348, DOI 10.1021/ja00266a065; MARNETT LJ, 1985, MUTAT RES, V148, P25; MASUREKAR M, 1991, GENETICS, V127, P453; MESSING J, 1983, METHOD ENZYMOL, V101, P20; Miller J. H., 1972, EXPT MOL GENETICS, P433; MUKAI FH, 1976, SCIENCE, V191, P868, DOI 10.1126/science.766187; NAIR V, 1984, J AM CHEM SOC, V106, P3370, DOI 10.1021/ja00323a061; NASER LJ, 1988, BIOCHEMISTRY-US, V27, P4357, DOI 10.1021/bi00412a024; OHARA SM, 1991, MUTAT RES, V247, P45, DOI 10.1016/0027-5107(91)90032-J; OSMAN MM, 1972, HELV CHIM ACTA, V55, P239, DOI 10.1002/hlca.19720550127; PALEJWALA VA, 1991, BIOCHEMISTRY-US, V30, P8736, DOI 10.1021/bi00100a004; REID TM, 1990, BIOCHEMISTRY-US, V29, P6153, DOI 10.1021/bi00478a007; RICHARDSON FC, 1991, MOL CARCINOGEN, V4, P162, DOI 10.1002/mc.2940040212; RIPLEY LS, 1986, P NATL ACAD SCI USA, V83, P6954, DOI 10.1073/pnas.83.18.6954; RIPLEY LS, 1988, J MOL BIOL, V200, P665, DOI 10.1016/0022-2836(88)90479-2; SCHAAPER RM, 1990, CARCINOGENESIS, V11, P1087, DOI 10.1093/carcin/11.7.1087; SETO H, 1991, CHEM PHARM BULL, V39, P515; SETO H, 1983, B CHEM SOC JPN, V56, P1799, DOI 10.1246/bcsj.56.1799; SETO H, 1986, CHEM PHARM BULL, V34, P5079; Spalding J. W., 1988, NATL TOXICOL PROGRAM, V331, P5; STONE K, 1990, CHEM RES TOXICOL, V3, P467, DOI 10.1021/tx00017a013; STREISINGER G, 1985, GENETICS, V109, P633; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; USHAY HM, 1981, BIOCHEMISTRY-US, V20, P3744, DOI 10.1021/bi00516a012; VOIGT JM, 1990, BIOCHEMISTRY-US, V29, P1632, DOI 10.1021/bi00458a039; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YAU TM, 1979, MECH AGEING DEV, V11, P137, DOI 10.1016/0047-6374(79)90031-9	82	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22392	22400						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429591				2022-12-25	WOS:A1992JW71900064
J	VOLONTE, C; GREENE, LA				VOLONTE, C; GREENE, LA			NERVE GROWTH FACTOR-ACTIVATED PROTEIN KINASE-N - CHARACTERIZATION AND RAPID NEAR HOMOGENEITY PURIFICATION BY NUCLEOTIDE AFFINITY-EXCHANGE CHROMATOGRAPHY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; PC12 CELLS; PHEOCHROMOCYTOMA CELLS; PURINE ANALOGS; TYROSINE PHOSPHORYLATION; RIBOSOMAL PROTEIN-S6; CYCLIC AMP; MITOGEN; PC12-CELLS; EXPRESSION	Protein kinase N (PKN) is a protein kinase rapidly activated by nerve growth factor (NGF) and other agents in PC12 pheochromocytoma and additional cell types. PKN is selectively inhibited by purine analogs, and this property has served both as a diagnostic for PKN activity and to establish its apparent involvement in certain pathways of the NGF mechanism of action. The present work has focused on further characterization, identification, and purification of NGF-activated PKN. We show here that PKN can be substantially enriched by elution from ion exchange resins with ATP. We exploited this novel technique (nucleotide affinity exchange chromatography) to devise two alternative isolation schemes for PKN. One utilizes sequential chromatographic steps and provides a preparation that is apparently 60% homogeneous for PKN and represents a total enrichment of approximately 10,000-fold. The other is a single column procedure and includes prewashes with NAD. This method yields material that is about 5-10% homogeneous for PKN, requires about 1 h, and can be applied to multiple samples in parallel. The ATP elution technique furthermore distinguishes NGF-regulated from basal PKN activity and thereby suggests the presence of distinct PKN isoforms. The applications of sucrose gradient centrifugation, gel filtration chromatography, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)/silver staining, affinity labeling with 8-azido-ATP/SDS-PAGE, and autophosphorylation (after SDS-PAGE, blotting and renaturation) all indicate that PKN has an apparent molecular mass of 45-47 kDa and is mainly monomeric in solution. These and additional properties appear to distinguish PKN from many previously described protein kinases.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	Columbia University; Columbia University			Volonté, Cinzia/N-6474-2013	Volonté, Cinzia/0000-0001-7362-8307	NINDS NIH HHS [NS-16036] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016036] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ALETTA JM, 1988, J CELL BIOL, V106, P1573, DOI 10.1083/jcb.106.5.1573; BATISTATOU A, 1992, MOL BIOL CELL, V3, P363, DOI 10.1091/mbc.3.3.363; BLENIS J, 1986, EMBO J, V5, P3441, DOI 10.1002/j.1460-2075.1986.tb04667.x; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CREMINS J, 1986, J CELL BIOL, V103, P887, DOI 10.1083/jcb.103.3.887; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENE LA, 1990, J NEUROSCI, V10, P1479; HALEGOUA S, 1980, CELL, V22, P571, DOI 10.1016/0092-8674(80)90367-0; HAMA T, 1986, P NATL ACAD SCI USA, V83, P2353, DOI 10.1073/pnas.83.8.2353; HASHIMOTO S, 1990, J NEUROCHEM, V55, P970, DOI 10.1111/j.1471-4159.1990.tb04586.x; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; LANDRETH GE, 1990, J NEUROCHEM, V55, P514, DOI 10.1111/j.1471-4159.1990.tb04165.x; LEVI A, 1991, ANNU REV PHARMACOL, V31, P205; LEVI A, 1988, MOL NEUROBIOL, V2, P201, DOI 10.1007/BF02935346; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; MIYASAKA T, 1991, P NATL ACAD SCI USA, V88, P2653, DOI 10.1073/pnas.88.7.2653; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; MUTOH T, 1988, J BIOL CHEM, V263, P15853; PINES J, 1990, New Biologist, V2, P389; POTTER RL, 1982, METHOD ENZYMOL, V91, P613; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; ROMANO C, 1987, J NEUROSCI, V7, P1294; ROWLAND EA, 1987, J BIOL CHEM, V262, P7504; ROWLANDGAGNE E, 1990, J NEUROCHEM, V54, P424, DOI 10.1111/j.1471-4159.1990.tb01890.x; SANO M, 1990, J NEUROCHEM, V55, P427, DOI 10.1111/j.1471-4159.1990.tb04154.x; TSAO H, 1990, J BIOL CHEM, V265, P15471; VOLONTE C, 1992, BIOTECHNIQUES, V12, P854; VOLONTE C, 1989, J CELL BIOL, V109, P2395, DOI 10.1083/jcb.109.5.2395; VOLONTE C, 1992, J NEUROCHEM, V58, P700, DOI 10.1111/j.1471-4159.1992.tb09774.x; VOLONTE C, 1990, J BIOL CHEM, V265, P11050; Volonte C, 1990, GROWTH FACTORS, V2, P321; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	39	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21663	21670						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400478				2022-12-25	WOS:A1992JV01100064
J	MALCOLM, KC; FITZPATRICK, FA				MALCOLM, KC; FITZPATRICK, FA			EPOXYEICOSATRIENOIC ACIDS INHIBIT CA2+ ENTRY INTO PLATELETS STIMULATED BY THAPSIGARGIN AND THROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROLEUKEMIA-CELLS; ARACHIDONIC-ACID; INTRACELLULAR CALCIUM; MESANGIAL CELLS; PLASMA-MEMBRANE; HEL CELLS; EPOXYGENASE; METABOLITES; MOBILIZATION; AGGREGATION	The epoxyeicosatrienoic acids derived from the cytochrome P-450 pathway of arachidonic acid metabolism have a unique platelet antiaggregatory profile. This prompted us to examine their influence on cellular Ca2+ mobilization. 14,15-cis-Epoxyeicosatrienoic acid and related compounds inhibited the rise in cytosolic Ca2+ following agonist stimulation of platelets by thapsigargin, a receptor-independent agonist, and thrombin, a receptor-dependent agonist. The epoxyeicosatrienoic acids selectively inhibited the entry of Ca2+ from the exterior of the platelets but did not alter Ca2+ discharge from intracellular pools. The magnitude of inhibition by 14,15-cis-epoxyeicosatrienoic acid was proportional to the rate of Ca2+ entry. 14,15-cis-Epoxyeicosatrienoic acid also inhibited the rate of influx of Mn2+, a cation which enters platelets via pathways similar to Ca2+. The magnitude of inhibition was proportional to the rate of Mn2+ entry, suggesting that epoxyeicosatrienoic acids act on divalent cation channels in a fashion which depends on the state of opening of the channel. Selective inhibition of Ca2+ entry into platelets may account for the antiaggregatory effects of the epoxyeicosatrienoic acids. We are unaware of other endogenous compounds exhibiting this property, suggesting that epoxyeicosatrienoic acids may be useful to probe agonist-stimulated Ca2+ mobilization in nonexcitable cells.	UNIV COLORADO, HLTH SCI CTR, DEPT PHARMACOL C-236, 4200 E 9TH AVE, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041026] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM41026] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNSTROM K, 1992, J BIOL CHEM, V267, P3686; BERNSTROM K, 1991, MOL PHARMACOL, V39, P114; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BRASS LF, 1991, J BIOL CHEM, V266, P958; CAPDEVILA JH, 1987, BIOCHEM BIOPH RES CO, V146, P638, DOI 10.1016/0006-291X(87)90576-6; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; CHARO IF, 1976, BIOCHEM BIOPH RES CO, V72, P1462, DOI 10.1016/S0006-291X(76)80178-7; CONRAD GW, 1986, J CELL BIOL, V103, P439, DOI 10.1083/jcb.103.2.439; FITZPATRICK FA, 1988, PHARMACOL REV, V40, P229; FITZPATRICK FA, 1986, J BIOL CHEM, V261, P5334; FORCE T, 1990, CLIN RES, V38, pA371; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALENDA SP, 1990, BIOCHEM J, V267, P479, DOI 10.1042/bj2670479; HALLAM TJ, 1985, J PHYSIOL-LONDON, V368, P131, DOI 10.1113/jphysiol.1985.sp015850; HALLAM TJ, 1985, FEBS LETT, V186, P175, DOI 10.1016/0014-5793(85)80703-1; HARRIS RC, 1990, J CELL PHYSIOL, V144, P429, DOI 10.1002/jcp.1041440310; JONES DA, 1991, BIOCHEM BIOPH RES CO, V180, P8, DOI 10.1016/S0006-291X(05)81247-1; KARARA A, 1989, J BIOL CHEM, V264, P19822; KARARA A, 1992, BIOCHEM BIOPH RES CO, V182, P1320, DOI 10.1016/0006-291X(92)91877-S; KARARA A, 1990, FEBS LETT, V268, P227, DOI 10.1016/0014-5793(90)81014-F; KUTSKY P, 1983, PROSTAGLANDINS, V26, P13, DOI 10.1016/0090-6980(83)90070-9; LANIADOSCHWARTZMAN M, 1988, J BIOL CHEM, V263, P2536; MALCOLM KC, 1992, J PHARMACOL EXP THER, V260, P1244; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MCGIFF JC, 1988, CLIN PHYSIOL BIOCH, V6, P179; MERRITT JE, 1988, J BIOL CHEM, V263, P6161; MUSTARD JF, 1989, METHOD ENZYMOL, V169, P3; OLIW EH, 1982, J BIOL CHEM, V257, P3771; OZAKI Y, 1992, CELL CALCIUM, V13, P19, DOI 10.1016/0143-4160(92)90026-O; PFISTER SL, 1991, AM J PHYSIOL, V261, pH843, DOI 10.1152/ajpheart.1991.261.3.H843; PRITCHARD KA, 1990, AM J PATHOL, V136, P1383; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RITTENHOUSESIMMONS S, 1977, J CLIN INVEST, V60, P495, DOI 10.1172/JCI108801; SCHWARTZMAN M, 1985, NATURE, V314, P620, DOI 10.1038/314620a0; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SNYDER G, 1986, BIOCHEM BIOPH RES CO, V139, P1188, DOI 10.1016/S0006-291X(86)80303-5; SULDAN Z, 1991, BLOOD, V78, P2887; THASTRUP O, 1987, BIOCHIM BIOPHYS ACTA, V927, P65, DOI 10.1016/0167-4889(87)90066-8; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; THASTRUP O, 1987, BIOCHEM BIOPH RES CO, V142, P654, DOI 10.1016/0006-291X(87)91464-1; TOTO R, 1987, BIOCHIM BIOPHYS ACTA, V919, P132, DOI 10.1016/0005-2760(87)90199-8; YOSHIDA S, 1990, ARCH BIOCHEM BIOPHYS, V280, P346, DOI 10.1016/0003-9861(90)90340-5; ZSCHAUER A, 1988, NATURE, V334, P703, DOI 10.1038/334703a0	43	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19854	19858						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400301				2022-12-25	WOS:A1992JR85800019
J	METSIS, M; CINTRA, A; SOLFRINI, V; ERNFORS, P; BORTOLOTTI, F; MORRASUTTI, DG; OSTENSON, CG; EFENDIC, S; AGERBERTH, B; MUTT, V; PERSSON, H; FUXE, K				METSIS, M; CINTRA, A; SOLFRINI, V; ERNFORS, P; BORTOLOTTI, F; MORRASUTTI, DG; OSTENSON, CG; EFENDIC, S; AGERBERTH, B; MUTT, V; PERSSON, H; FUXE, K			MOLECULAR-CLONING OF PEC-60 AND EXPRESSION OF ITS MESSENGER-RNA AND PEPTIDE IN THE GASTROINTESTINAL-TRACT AND IMMUNE-SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPSIN-INHIBITOR; SEQUENCE; RAT; ACID	The peptide PEC-60, structurally related to the pancreatic secretory trypsin inhibitor, inhibits glucose-induced insulin secretion. Here we report on the structure of a cDNA clone from pig duodenum encoding PEC-60. The cDNA encodes a 86-amino acid long precursor protein containing a 26-amino acid signal sequence, implying that the mature PEC-60 peptide is secreted from cells. Analysis of porcine duodenum demonstrated a high expression of a 0.6-kilobase long PEC-60 mRNA in this tissue, as well as the presence of strong PEC-60-like immunoreactivity in the cytoplasm of the majority of the goblet cells of the epithelium. High levels of PEC-60 mRNA were also found in the bone marrow and the peripheral blood and moderate levels in the spleen. A strong PEC-60-like immunoreactivity was localized in the monocytes of peripheral blood. Radioimmunoassay revealed high levels of pig PEC-60-like immunoreactivity in pig plasma suggesting that the PEC-60 peptide is efficiently released from cells. These findings imply that the gastrointestinal peptide PEC-60 is formed, stored, and secreted from monocytes present within the bone marrow and in the peripheral blood, indicating a role of the PEC-60 peptide in the immune system in addition to its function as a gastrointestinal peptide.	KAROLINSKA INST,DEPT HISTOL & NEUROBIOL,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA INST,DEPT ENDOCRINOL,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA INST,DEPT BIOCHEM,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet	METSIS, M (corresponding author), KAROLINSKA INST,DEPT MED CHEM,MOLEC NEUROBIOL LAB,BOX 60400,S-10401 STOCKHOLM 60,SWEDEN.		Metsis, Madis/F-7080-2016	Metsis, Madis/0000-0003-1667-677X; Fuxe, Kjell/0000-0001-8491-4288				AGERBERTH B, 1989, P NATL ACAD SCI USA, V86, P8590, DOI 10.1073/pnas.86.21.8590; AHREN B, 1991, PANCREAS, V6, P324, DOI 10.1097/00006676-199105000-00010; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DESCHENES RJ, 1984, P NATL ACAD SCI-BIOL, V81, P726, DOI 10.1073/pnas.81.3.726; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ERICSSON A, 1987, P NATL ACAD SCI USA, V84, P5585, DOI 10.1073/pnas.84.16.5585; FUKUOKA SI, 1989, NUCLEIC ACIDS RES, V17, P10111, DOI 10.1093/nar/17.23.10111; FUXE K, 1991, ACTA PHYSIOL SCAND, V143, P357, DOI 10.1111/j.1748-1716.1991.tb09244.x; FUXE K, 1990, 20TH ANN M SOC NEUR, V16, P800; GREENE LJ, 1969, J BIOL CHEM, V244, P2646; HOKFELT T, 1980, NATURE, V284, P515, DOI 10.1038/284515a0; ITOH N, 1983, NATURE, V304, P547, DOI 10.1038/304547a0; KAZAL LA, 1948, J AM CHEM SOC, V70, P3034, DOI 10.1021/ja01189a060; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Mutt V., 1988, ADV METAB DISORD, V11, P1; PERSSON H, 1988, NEUROPEPTIDE, P43; PROUDFOOT NJ, 1974, NATURE, V252, P359, DOI 10.1038/252359a0; SAID SI, 1988, ADV METAB DISORD, V11, P369; SAMBROOK J, 1990, MOL CLONING LABORATO; TSCHESCHE H, 1970, EUR J BIOCHEM, V16, P187, DOI 10.1111/j.1432-1033.1970.tb01071.x; UHL GR, 1986, IN SITU HYBRIDIZATIO; VANDERHAEGHEN JJ, 1975, NATURE, V257, P604, DOI 10.1038/257604a0; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; ZAMBONI L, 1967, J CELL BIOL, V35, P148	25	17	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19829	19832						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400298				2022-12-25	WOS:A1992JR85800015
J	SHIRABE, K; YUBISUI, T; BORGESE, N; TANG, CY; HULTQUIST, DE; TAKESHITA, M				SHIRABE, K; YUBISUI, T; BORGESE, N; TANG, CY; HULTQUIST, DE; TAKESHITA, M			ENZYMATIC INSTABILITY OF NADH-CYTOCHROME-B5 REDUCTASE AS A CAUSE OF HEREDITARY METHEMOGLOBINEMIA TYPE-I (RED-CELL TYPE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME B5 REDUCTASE; AMINO-ACID SEQUENCE; ENCODING NITRATE REDUCTASE; SITE-DIRECTED MUTAGENESIS; RAT-LIVER MICROSOMES; NADH-BINDING SITE; NADPH-CYTOCHROME-P-450 REDUCTASE; CONGENITAL METHEMOGLOBINEMIA; HUMAN-ERYTHROCYTES; ESCHERICHIA-COLI	Nucleotide substitutions in the gene for NADH-cytochrome b5 reductase were identified in three independent probands of hereditary methemoglobinemia type I. Patients in Kagoshima and Okinawa in Japan were shown to possess the same base change, from guanine to adenine at codon 57, which results in amino acid substitution from Arg to Gln. This nucleotide change was the same as formerly found in a patient in Toyoake, Japan (Katsube, T., Sakamoto, N., Kobayashi, Y., Seki, R., Hirano, M., Tanishima, K., Tomoda, A., Takazakura, E., Yubisui, T., Takeshita, M., Sakaki, Y., and Fukumaki, Y. (1991) Am. J. Hum. Genet. 48, 799-808). A type I patient in Italy was shown to have a base change from guanine to adenine at codon 105 which causes substitution from Val to Met. To characterize the enzymes of type I patients, Arg-57 --> Gln and Val-105 --> Met mutant enzymes were overexpressed in Escherichia coli and purified to homogeneity. k(cat)/K(m) values (NADH) of these two enzymes were 25% in Arg-57 --> Gln and 14.5% in Val-105 --> Met compared with that of the wild type enzyme, while the value of type II (generalized, severe form of the disease) mutant enzyme was 3% of the normal value (Yubisui, T., Shirabe, K., Takeshita, M., Kobayashi, Y., Fukumaki, Y., Sakaki, Y., and Takano, T. (1991) J. Biol. Chem. 266, 66-70). The type I mutant enzymes were less heat-stable and more susceptible to proteinase treatment than the wild type. From these results we conclude that restriction of enzyme deficiency to red cells in hereditary methemoglobinemia type I may be generally derived from instability and increased proteolytic susceptibility of variant NADH-cytochrome b5 reductases due to a point mutation.	UNIV MILAN, CNR, CTR CYTOPHARMACOL, I-20129 MILAN, ITALY; UNIV MILAN, DIPARTIMENTO FARMACOL, I-20129 MILAN, ITALY; UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48104 USA	Consiglio Nazionale delle Ricerche (CNR); University of Milan; University of Milan; University of Michigan System; University of Michigan	SHIRABE, K (corresponding author), OITA MED UNIV, DEPT BIOCHEM, HASAMA, OITA 87955, JAPAN.		Borgese, Nica/GWZ-8895-2022	Borgese, Nica/0000-0002-7537-3974				BEUTLER E, 1968, BLOOD, V31, P131, DOI 10.1182/blood.V31.2.131.131; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BORGESE N, 1987, J CLIN INVEST, V80, P1296, DOI 10.1172/JCI113205; CHENG CL, 1988, EMBO J, V7, P3309, DOI 10.1002/j.1460-2075.1988.tb03201.x; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; CRAWFORD NM, 1988, P NATL ACAD SCI USA, V85, P5006, DOI 10.1073/pnas.85.14.5006; ETLINGER JD, 1977, P NATL ACAD SCI USA, V74, P54, DOI 10.1073/pnas.74.1.54; FRIEMANN A, 1991, MOL GEN GENET, V227, P97, DOI 10.1007/BF00260713; GRAY GR, 1973, LANCET, V2, P530; HARRIS H, 1980, PRINCIPLES HUMAN BIO; HOPKINSO.DA, 1970, ANN HUM GENET, V34, P1, DOI 10.1111/j.1469-1809.1970.tb00214.x; HULTQUIST DE, 1971, NATURE-NEW BIOL, V229, P252, DOI 10.1038/newbio229252a0; HYDE GE, 1991, J BIOL CHEM, V266, P23542; IYANAGI T, 1977, BIOCHEMISTRY-US, V16, P2725, DOI 10.1021/bi00631a021; JAFFE ER, 1989, METABOLIC BASIS INHE, P2267; JOHNSTONE IL, 1990, GENE, V90, P181, DOI 10.1016/0378-1119(90)90178-T; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KARPLUS PA, 1984, BIOCHEMISTRY-US, V23, P6576, DOI 10.1021/bi00321a046; KATSUBE T, 1991, AM J HUM GENET, V48, P799; KEYES SR, 1980, J BIOL CHEM, V255, P1357; KOBAYASHI Y, 1990, BLOOD, V75, P1408; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEROUX A, 1975, NATURE, V258, P619, DOI 10.1038/258619a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MURAKAMI H, 1986, DNA-J MOLEC CELL BIO, V5, P1, DOI 10.1089/dna.1986.5.1; MURAKAMI K, 1989, J BIOCHEM, V105, P312, DOI 10.1093/oxfordjournals.jbchem.a122659; OSHINO N, 1971, J BIOCHEM, V69, P155, DOI 10.1093/oxfordjournals.jbchem.a129444; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; OZOLS J, 1985, J BIOL CHEM, V260, P1953; PIETRINI G, 1992, J CELL BIOL, V117, P975, DOI 10.1083/jcb.117.5.975; PRCHAL JT, 1990, AM J MED, V89, P516, DOI 10.1016/0002-9343(90)90384-P; PRINS HK, 1966, BLOOD-J HEMATOL, V27, P145, DOI 10.1182/blood.V27.2.145.145; REDDY VVR, 1977, J BIOL CHEM, V252, P2797; RICE RH, 1971, J BIOL CHEM, V246, P831; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFER DA, 1981, BIOCHEM BIOPH RES CO, V100, P1555, DOI 10.1016/0006-291X(81)90696-3; SCOTT EM, 1959, BIOCHIM BIOPHYS ACTA, V34, P584, DOI 10.1016/0006-3002(59)90324-5; SHIRABE K, 1989, BIOCHIM BIOPHYS ACTA, V1008, P189, DOI 10.1016/0167-4781(80)90007-X; SHIRABE K, 1991, J BIOL CHEM, V266, P7531; STRITTMATTER P, 1965, J BIOL CHEM, V240, P4481; SUTTER TR, 1990, J BIOL CHEM, V265, P16428; TANAKA K, 1988, FEBS LETT, V236, P159, DOI 10.1016/0014-5793(88)80306-5; TANISHIMA K, 1985, BLOOD, V66, P1288; TISCHLER ME, 1977, FEBS LETT, V76, P99, DOI 10.1016/0014-5793(77)80129-4; TOMATSU S, 1989, GENE, V80, P353; VEECH RL, 1969, BIOCHEM J, V115, P609, DOI 10.1042/bj1150609a; WILLIAMS GT, 1985, EXP CELL RES, V160, P419, DOI 10.1016/0014-4827(85)90189-2; YUBISUI T, 1980, J BIOL CHEM, V255, P2454; YUBISUI T, 1987, P NATL ACAD SCI USA, V84, P3609, DOI 10.1073/pnas.84.11.3609; YUBISUI T, 1986, J BIOCHEM-TOKYO, V99, P407, DOI 10.1093/oxfordjournals.jbchem.a135495; YUBISUI T, 1991, J BIOL CHEM, V266, P66	53	57	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20416	20421						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400360				2022-12-25	WOS:A1992JR85800104
J	TAMEMOTO, H; KADOWAKI, T; TOBE, K; UEKI, K; IZUMI, T; CHATANI, Y; KOHNO, M; KASUGA, M; YAZAKI, Y; AKANUMA, Y				TAMEMOTO, H; KADOWAKI, T; TOBE, K; UEKI, K; IZUMI, T; CHATANI, Y; KOHNO, M; KASUGA, M; YAZAKI, Y; AKANUMA, Y			BIPHASIC ACTIVATION OF 2 MITOGEN-ACTIVATED PROTEIN-KINASES DURING THE CELL-CYCLE IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE KINASE; EPIDERMAL GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; MAP KINASE; FIBROBLASTIC CELLS; SENSITIVE METHOD; XENOPUS OOCYTES; INSULIN; INVITRO; MATURATION	We studied mitogen-activated protein kinase (MAPK) activities during the cell cycle of Chinese hamster ovary (CHO) cells using site-specific antibodies against extracellular signal-regulated kinase-1, a 44-kDa MAPK (Boulton, T. G., Yancopoulos, G. D., Gregory, J. S., Slauer, C., Moomaw, C., Hsu, J., and Cobb, M. H. (1990) Science 249, 64-67). These antibodies detected two distinct MAPKs (44- and 42-kDa MAPKs) in CHO cells. CHO cells were arrested at metaphase in the M phase by treatment with nocodazole, and activities of MAPKs were analyzed at specific time points after release from arrest. Immune complex kinase assay and renaturation and phosphorylation assay in substrate-containing gel revealed that both 44- and 42-kDa MAPKs had activities in the G1 through S and G2/M phases and were activated biphasically, in the G1 phase and around the M phase. MAPKs were inactivated in metaphase-arrested cells. The amount of MAPKs did not change significantly in the cell cycle. In the G1, S, and G2/M phases, MAPKs were phosphorylated on both tyrosine and threonine residues and dephosphorylated in metaphase-arrested cells. Our data suggest that MAPKs may play some role in the cell cycle other than G0/G1 transition.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN; ASAHI LIFE FDN,INST DIABET CARE & RES,CHIYODA KU,TOKYO 100,JAPAN; GIFU PHARMACEUT UNIV,DEPT BIOL,GIFU 502,JAPAN; KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,KOBE 650,JAPAN	University of Tokyo; Asahi Life Foundation; Gifu Pharmaceutical University; Kobe University								AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11495; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDO A, 1992, J BIOL CHEM, V267, P12788; AYN NG, 1990, J BIOL CHEM, V265, P11487; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHATANI Y, 1992, J BIOL CHEM, V267, P9911; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOPER JA, 1989, MOL CELL BIOL, V9, P3143, DOI 10.1128/MCB.9.7.3143; COOPER JA, 1984, MOL CELL BIOL, V4, P30, DOI 10.1128/MCB.4.1.30; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GOTOH Y, 1990, EUR J BIOCHEM, V193, P671, DOI 10.1111/j.1432-1033.1990.tb19385.x; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HOSHI M, 1988, J BIOL CHEM, V263, P5396; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TOBE K, 1991, J BIOL CHEM, V266, P24793; TOBEY RA, 1967, J CELL PHYSIOL, V70, P63, DOI 10.1002/jcp.1040700109	31	143	145	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20293	20297						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400347				2022-12-25	WOS:A1992JR85800086
J	YU, H; TOYOSHIMA, I; STEUER, ER; SHEETZ, MP				YU, H; TOYOSHIMA, I; STEUER, ER; SHEETZ, MP			KINESIN AND CYTOPLASMIC DYNEIN BINDING TO BRAIN MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY GRANULES; AXONAL-TRANSPORT; SOLUBLE FACTORS; MICROTUBULES; LOCALIZATION; MOTOR; IDENTIFICATION; ORGANELLES; MOVEMENT; MOTILITY	Movement of cellular organelles in a directional manner along polar microtubules is driven by the motor proteins, kinesin and cytoplasmic dynein. The binding of these proteins to a microsomal fraction from embryonic chicken brain is investigated here. Both motors exhibit saturation binding to the vesicles, and proteolysis of vesicle membrane proteins abolishes binding. The maximal binding for kinesin is 12 +/- 1.7 and 43 +/- 2 pmol per mg of vesicle protein with or without 1 mM ATP, respectively. The maximal binding for cytoplasmic dynein is 55 +/- 3.8 and 73 +/- 3.7 pmol per mg of vesicle protein with or without ATP, respectively. These values correspond to 1-6 sites per vesicle of 100-nm diameter. The nonhydrolyzable ATP analog, adenyl-5'-yl imidodiphosphate (AMP-PNP), inhibited kinesin binding to vesicles but increased kinesin binding to microtubules. An antibody to the kinesin light chain also inhibited vesicle binding to kinesin. In the absence but not presence of ATP, competition between the two motors for binding was observed. We suggest that there are two distinguishable binding sites for kinesin and cytoplasmic dynein on these organelles in the presence of ATP and a shared site in the absence of ATP.	DUKE UNIV,MED CTR,DEPT CELL BIOL,BOX 3709,DURHAM,NC 27710	Duke University			Yu, Hanry/L-6050-2019; Yu, Hanry/C-7375-2011; Yu, Hanry/C-1031-2013	Yu, Hanry/0000-0002-0339-3685; Yu, Hanry/0000-0002-0339-3685	NIGMS NIH HHS [GM36277] Funding Source: Medline; NINDS NIH HHS [NS23345] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036277] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023345] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; Chambers J. M., 1983, GRAPHICAL METHODS DA, P94; COHN S, 1987, NATURE, V326, P16, DOI 10.1038/326016a0; DABORA SL, 1988, CELL, V54, P27, DOI 10.1016/0092-8674(88)90176-6; GROLIG F, 1988, EUR J CELL BIOL, V47, P22; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HISANAGA S, 1989, CELL MOTIL CYTOSKEL, V12, P264, DOI 10.1002/cm.970120407; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Kelly RB, 1990, CURR OPIN CELL BIOL, V2, P105, DOI 10.1016/S0955-0674(05)80039-0; LACEY ML, 1992, J BIOL CHEM, V267, P4793; LASEK RJ, 1985, NATURE, V316, P645, DOI 10.1038/316645a0; MCINTOSH JR, 1989, J BIOL CHEM, V264, P6001; MILLER RH, 1987, SCIENCE, V235, P220, DOI 10.1126/science.2432661; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; ROTHWELL SW, 1989, J CELL BIOL, V108, P2313, DOI 10.1083/jcb.108.6.2313; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SCHROER TA, 1988, J CELL BIOL, V107, P1785, DOI 10.1083/jcb.107.5.1785; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SCHROER TA, 1991, ANNU REV PHYSIOL, V53, P629, DOI 10.1146/annurev.ph.53.030191.003213; SHEETZ MP, 1987, BIOESSAYS, V7, P165, DOI 10.1002/bies.950070406; SHEETZ MP, 1989, TRENDS NEUROSCI, V12, P474, DOI 10.1016/0166-2236(89)90099-4; SHERLINE P, 1977, J CELL BIOL, V72, P380, DOI 10.1083/jcb.72.2.380; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; SUPRENANT KA, 1982, J CELL BIOL, V93, P164, DOI 10.1083/jcb.93.1.164; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vale RD, 1990, CURR OPIN CELL BIOL, V2, P15, DOI 10.1016/S0955-0674(05)80025-0; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V40, P559, DOI 10.1016/0092-8674(85)90204-1; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	34	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20457	20464						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400364				2022-12-25	WOS:A1992JR85800110
J	SUNDARESAN, V; GANLY, P; HASLETON, P; RUDD, R; SINHA, G; BLEEHEN, NM; RABBITTS, P				SUNDARESAN, V; GANLY, P; HASLETON, P; RUDD, R; SINHA, G; BLEEHEN, NM; RABBITTS, P			P53 AND CHROMOSOME-3 ABNORMALITIES, CHARACTERISTIC OF MALIGNANT LUNG-TUMORS, ARE DETECTABLE IN PREINVASIVE LESIONS OF THE BRONCHUS	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; REACTION PCR; THRB GENE; BAMHI POLYMORPHISM; RSAI POLYMORPHISM; SUPPRESSOR GENE; D3S32 LOCUS; REGION 3P21; CELL-LINES; CANCER	Bronchial epithelial dysplasia is believed to precede invasive squamous cell carcinoma of the lung. Six paired dysplasia and tumour samples were distinguished histologically in sections of formalin-fixed paraffin-embedded lung tissue from patients with lung cancer. Additionally, samples of dysplastic bronchial epithelium were obtained from patients without lung tumours. Microdissection of the unstained sections provided dysplastic and tumour samples from which DNA was prepared for comparison with the patients' constitutional genotype, using polymerase chain reaction-based restriction fragment length polymorphism analysis. All six samples of tumour and the paired adjacent samples of bronchial dysplasia showed loss of heterozygosity (LOH) at loci on the short arm of chromosome 3. Five of the six cases showed involvement of the p53 gene as assessed by LOH at the AccII site within the gene, and by immunoreactivity to CM-1, an antibody which recognizes the mutated form of the p53 protein in paraffin-embedded material. Of the dysplastic samples, obtained from patients without invasive tumours, all three showed LOH at 3p; one sample showed LOH at the AccII polymorphic locus within the p53 gene, and another sample, uninformative at this locus, stained positively with this antibody. These results indicate that somatic genetic changes are present in preinvasive lesions in the bronchus.	MRC,CLIN ONCOL & RADIOTHERAPEUT UNIT,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND; ADDENBROOKES HOSP,DEPT HISTOPATHOL,CAMBRIDGE CB2 2QQ,ENGLAND; LONDON CHEST HOSP,DEPT RESP MED,LONDON E2 9JX,ENGLAND; WYTHENSHAWE HOSP,REG CARDIOTHORAC CTR,DEPT PATHOL,MANCHESTER M23 9LT,LANCS,ENGLAND; LONDON CHEST HOSP,DEPT PATHOL,LONDON E2 9JX,ENGLAND	University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of London; Queen Mary University London; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of London; Queen Mary University London				Ganly, Peter/0000-0003-0335-2063				AUERBACH O, 1962, NEW ENGL J MED, V267, P111, DOI 10.1056/NEJM196207192670301; AUERBACH O, 1957, NEW ENGL J MED, V256, P97, DOI 10.1056/NEJM195701172560301; AUERBACH O, 1979, NEW ENGL J MED, V300, P381, DOI 10.1056/NEJM197902223000801; BARTEK J, 1991, ONCOGENE, V6, P1699; BUYS C, 1991, EUR J CANCER S2, V27, P82; CHIBA I, 1990, ONCOGENE, V5, P1603; DELACALLEMARTIN O, 1990, NUCLEIC ACIDS RES, V18, P4963, DOI 10.1093/nar/18.16.4963; DONTI E, 1990, HUM GENET, V84, P391; ERLANDSSON R, 1990, ONCOGENE, V5, P1207; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GANLY PS, 1992, GENOMICS, V12, P221, DOI 10.1016/0888-7543(92)90369-4; GANLY PS, 1991, NUCLEIC ACIDS RES, V19, P3761, DOI 10.1093/nar/19.13.3761; GANLY PS, 1991, NUCLEIC ACIDS RES, V19, P3760; GANLY PS, 1991, NUCLEIC ACIDS RES, V19, P3757, DOI 10.1093/nar/19.13.3757-a; GANLY PS, 1991, NUCLEIC ACIDS RES, V19, P3758, DOI 10.1093/nar/19.13.3758; GEBERT JF, 1991, ONCOGENE, V6, P1859; GORADIA TM, 1991, GENOMICS, V10, P748, DOI 10.1016/0888-7543(91)90459-R; GREENWALD BD, 1992, CANCER RES, V52, P741; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HOULE B, 1991, GENE CHROMOSOME CANC, V3, P358, DOI 10.1002/gcc.2870030506; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HUNG J, 1991, LASER SURG MED, V11, P99, DOI 10.1002/lsm.1900110203; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KIM JH, 1991, J NATL CANCER I, V83, P938, DOI 10.1093/jnci/83.13.938; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MELTZER SJ, 1991, P NATL ACAD SCI USA, V88, P4976, DOI 10.1073/pnas.88.11.4976; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MITSUDOMI T, 1992, ONCOGENE, V7, P171; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OKA K, 1991, MOL CARCINOGEN, V4, P10, DOI 10.1002/mc.2940040104; PAABO S, 1989, J BIOL CHEM, V264, P9709; PAL N, 1990, ONCOGENE, V5, P1665; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; RABBITTS P, 1989, GENE CHROMOSOME CANC, V1, P95, DOI 10.1002/gcc.2870010115; RABBITTS PH, 1991, DIAGN ONCOL, V1, P298; SHIBATA D, 1988, CANCER RES, V48, P4564; SOZZI G, 1991, CANCER RES, V51, P400; STRETCH JR, 1991, CANCER RES, V51, P5976; TOKUDA Y, 1990, J CLIN PATHOL, V43, P748, DOI 10.1136/jcp.43.9.748; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; WILKINS RJ, 1988, LANCET, V1, P329; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; YAMADA Y, 1991, CANCER RES, V51, P5800	47	288	291	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1989	1997						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408139				2022-12-25	WOS:A1992JP42400012
J	HANCOCK, K; LEBLANC, AJ; DONZE, D; HAJDUK, SL				HANCOCK, K; LEBLANC, AJ; DONZE, D; HAJDUK, SL			IDENTIFICATION OF NUCLEAR ENCODED PRECURSOR TRANSFER-RNAS WITHIN THE MITOCHONDRION OF TRYPANOSOMA-BRUCEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICED TRANSFER-RNA; YEAST MITOCHONDRIA; LIGASE ACTIVITIES; RIBONUCLEASE-P; PROTEIN IMPORT; DNA; TRANSCRIPTION; ORGANIZATION; TRANSPORT; GENES	RNAs that function in mitochondria are typically encoded by the mitochondrial DNA. However, the mitochondrial tRNAs of Trypanosoma brucei are encoded by the nuclear DNA and therefore must be imported into the mitochondrion. It is becoming evident that RNA import into mitochondria is phylogenetically widespread and is essential for cellular processes, but virtually nothing is known about the mechanism of RNA import. We have identified and characterized mitochondrial precursor tRNAs in T. brucei. The identification of mitochondrially located precursor tRNAs clearly indicates that mitochondrial tRNAs are imported as precursors. The mitochondrial precursor tRNAs hybridize to cloned nuclear tRNA genes, label with [alpha-P-32]CTP using yeast tRNA nucleotidyltransferase and in isolated mitochondria via an endogenous nucleotidyltransferase-like activity, and are processed to mature tRNAs by Escherichia coli and yeast mitochondrial RNase P. We show that T. brucei mitochondrial extract contains an RNase P activity capable of processing a prokaryotic tRNA precursor as well as the T. brucei tRNA precursors. Precursors for tRNA(Asn) and tRNA(Leu) were detected on Northern blots of mitochondrial RNA, and the 5' ends of these RNAs were characterized by primer extension analysis. The structure of the precursor tRNAs and the significance of nuclear encoded precursor tRNAs within the mitochondrion are discussed.	UNIV ALABAMA, SCH MED, DEPT BIOCHEM, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH DENT, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NIAID NIH HHS [AI21401] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021401, R21AI021401] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTMAN S, 1989, ADV ENZYMOL RAMB, V62, P1; ALTMAN S, 1990, J BIOL CHEM, V265, P20053; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; CAMPBELL DA, 1989, MOL BIOCHEM PARASIT, V37, P257, DOI 10.1016/0166-6851(89)90157-6; CAMPBELL DA, 1989, NUCLEIC ACIDS RES, V17, P9479, DOI 10.1093/nar/17.22.9479; CHEN JY, 1990, J BIOL CHEM, V265, P16221; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; DELP G, 1991, NUCLEIC ACIDS RES, V19, P713, DOI 10.1093/nar/19.4.713; DEROBERTIS EM, 1981, CELL, V23, P89, DOI 10.1016/0092-8674(81)90273-7; DEUTSCHER MP, 1984, CRC CR REV BIOCH MOL, V17, P45, DOI 10.3109/10409238409110269; DEUTSCHER MP, 1982, ENZYMES, V15, P183, DOI DOI 10.1016/S1874-6047(08)60279-6; FAIRLAMB AH, 1978, J CELL BIOL, V76, P293, DOI 10.1083/jcb.76.2.293; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GOPINATHAN KP, 1990, TRANSFER RNAS OTHER, P103; GRAY MW, 1988, PHILOS T R SOC B, V319, P135, DOI 10.1098/rstb.1988.0038; HANCOCK K, 1990, J BIOL CHEM, V265, P19208; HANCOCK K, 1992, IN PRESS NUCLEIC ACI, V20; HANICJOYCE PJ, 1990, J BIOL CHEM, V265, P13782; HARADA F, 1975, NUCLEIC ACIDS RES, V2, P865, DOI 10.1093/nar/2.6.865; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; JOYCE PBM, 1989, NUCLEIC ACIDS RES, V17, P5461, DOI 10.1093/nar/17.14.5461; MARCHFELDER A, 1990, NUCLEIC ACIDS RES, V18, P1401, DOI 10.1093/nar/18.6.1401; MARECHALDROUARD L, 1988, NUCLEIC ACIDS RES, V16, P4777, DOI 10.1093/nar/16.11.4777; MARECHALDROUARD L, 1990, NUCLEIC ACIDS RES, V18, P3689, DOI 10.1093/nar/18.13.3689; MARTIN NC, 1985, J BIOL CHEM, V260, P1479; MELTON DA, 1980, NATURE, V284, P143, DOI 10.1038/284143a0; MOTTRAM JC, 1991, NUCLEIC ACIDS RES, V19, P3995, DOI 10.1093/nar/19.14.3995; MOTTRAM JC, 1991, J BIOL CHEM, V266, P18313; NISHIKURA K, 1981, J MOL BIOL, V145, P405, DOI 10.1016/0022-2836(81)90212-6; OCONNOR JP, 1991, MOL CELL BIOL, V11, P425, DOI 10.1128/MCB.11.1.425; PACE NR, 1990, J BIOL CHEM, V265, P3587; PADAYATTY JD, 1990, TRANSFER RNAS OTHER, P129; PRITCHARD AE, 1990, NUCLEIC ACIDS RES, V18, P173, DOI 10.1093/nar/18.1.173; Sambrook J, 1989, MOL CLONING LABORATO; SIMPSON AM, 1989, NUCLEIC ACIDS RES, V17, P5427, DOI 10.1093/nar/17.14.5427; SLOOF P, 1985, NUCLEIC ACIDS RES, V13, P4171, DOI 10.1093/nar/13.11.4171; SUYAMA Y, 1967, BIOCHEMISTRY-US, V6, P2829, DOI 10.1021/bi00861a025; SUYAMA Y, 1978, ARCH BIOCHEM BIOPHYS, V191, P437, DOI 10.1016/0003-9861(78)90382-X; SUYAMA Y, 1986, CURR GENET, V10, P411, DOI 10.1007/BF00418415; TOBIAN JA, 1985, CELL, V43, P415, DOI 10.1016/0092-8674(85)90171-0; VANDERVEEN R, 1986, CELL, V44, P225, DOI 10.1016/0092-8674(86)90756-7; VESTWEBER D, 1989, NATURE, V338, P170, DOI 10.1038/338170a0; WHITE TC, 1987, NUCLEIC ACIDS RES, V15, P3275, DOI 10.1093/nar/15.8.3275; ZASLOFF M, 1982, NATURE, V300, P81, DOI 10.1038/300081a0; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436	48	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23963	23971						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385429				2022-12-25	WOS:A1992JZ23900080
J	LINNEKIN, D; EVANS, G; MICHIEL, D; FARRAR, WL				LINNEKIN, D; EVANS, G; MICHIEL, D; FARRAR, WL			CHARACTERIZATION OF A 97-KDA PHOSPHOTYROSYLPROTEIN REGULATED BY MULTIPLE CYTOKINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; RECEPTOR-BETA-CHAIN; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CELL-LINE; ERYTHROPOIETIN RECEPTOR; INTERLEUKIN-2 RECEPTOR; GM-CSF; RAPID PHOSPHORYLATION; EXPRESSION CLONING	We have examined the signal transduction pathways of a number of cytokines that interact with receptors that are members of the hematopoietin receptor superfamily. A 97-kDa protein was phosphorylated on tyrosine in response to stimulation of appropriate target cells with interleukin (IL)-2, IL-3, granulocyte-macrophage colony-stimulating factor (CSF), granulocyte-CSF, or erythropoietin. These data suggest that a 97-kDa phosphotyrosylprotein represents a point of convergence for signal transduction by a number of growth factor receptors that do not have homology with any known protein tyrosine kinase. To address the possibility that p97 may represent a tyrosine kinase involved in multiple signal transduction pathways, we tested the capacity of this protein to bind a tyrosine kinase substrate or ATP. Indeed, a 97-kDa phosphotyrosylprotein purified from IL-2-stimulated lymphoid cells as well as granulocyte-macrophage-CSF-stimulated myeloid cells bound to a polymer of glutamic acid and tyrosine which is a tyrosine kinase substrate. Further, a 97-kDa phosphotyrosylprotein present in both lineages also bound 8-azido-ATP. These data indicate that a 97-kDa phosphotyrosylprotein with properties consistent with those of a protein tyrosine kinase is involved in the signal transduction pathways of certain members of the newly identified hematopoietin receptor superfamily and may represent an early point of convergence in the stimulus-response coupling of multiple cytokine receptors.	NCI, FREDERICK CANC RES & DEV CTR, BIOL RESPONSE MODIFIERS PROGRAM, MOLEC IMMUNOREGULAT LAB, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR,DYN CORP, PROGRAM RESOURCES INC, BIOL RESPONSE MODIFIERS PROGRAM, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR, DYN CORP, PROGRAM RESOURCES INC, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [N01-CO-74102] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELGHANY M, 1990, P NATL ACAD SCI USA, V87, P7061, DOI 10.1073/pnas.87.18.7061; BRAUN S, 1984, J BIOL CHEM, V259, P2051; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; D'Andrea AD, 1990, CURR OPIN CELL BIOL, V2, P648, DOI 10.1016/0955-0674(90)90106-O; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DOI T, 1989, EUR J IMMUNOL, V19, P2375, DOI 10.1002/eji.1830191229; EVANS SW, 1987, BIOCHEM J, V244, P683, DOI 10.1042/bj2440683; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; FARRAR WL, 1990, ANN NY ACAD SCI, V594, P240; GARCIA GG, 1992, BIOCHEM J, V285, P851, DOI 10.1042/bj2850851; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GLAZER RI, 1987, ANAL BIOCHEM, V164, P2124; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KANAKURA Y, 1991, BLOOD, V77, P243; KANAKURA Y, 1990, BLOOD, V76, P706; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; LINNEKIN D, 1990, BIOCHEM J, V271, P317, DOI 10.1042/bj2710317; LINNEKIN D, 1992, P NATL ACAD SCI USA, V89, P6237, DOI 10.1073/pnas.89.14.6237; MICHIEL DF, 1991, CYTOKINE, V3, P428, DOI 10.1016/1043-4666(91)90047-H; QUELLE FW, 1991, J BIOL CHEM, V266, P609; SANTOLI D, 1987, J IMMUNOL, V139, P3348; SORENSEN PHB, 1989, BLOOD, V73, P406; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; ULRICH A, 1990, CELL, V61, P203; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; ZU Y, 1990, BIOCHEMISTRY-US, V29, P105	36	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23993	23998						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385430				2022-12-25	WOS:A1992JZ23900084
J	MICHAELI, J; BUSQUETS, X; ORLOW, I; YOUNES, A; COLOMER, D; MARKS, PA; RIFKIND, RA; KOLESNICK, RN				MICHAELI, J; BUSQUETS, X; ORLOW, I; YOUNES, A; COLOMER, D; MARKS, PA; RIFKIND, RA; KOLESNICK, RN			A RISE AND FALL IN 1,2-DIACYLGLYCEROL CONTENT SIGNAL HEXAMETHYLENE BISACETAMIDE-INDUCED ERYTHROPOIESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN KINASE-C; MURINE ERYTHROLEUKEMIA-CELLS; INDUCED DIFFERENTIATION; ERYTHROID DIFFERENTIATION; PITUITARY-CELLS; PHORBOL ESTERS; EXPRESSION; PHOSPHATIDYLINOSITOL; TRANSLOCATION; SENSITIVITY	Previous studies have suggested a role for protein kinase C (PKC) during induction of murine erythroleukemia cell (MELC) differentiation by hexamethylene bisacetamide (HMBA) (Melloni, E., Pontremoli, S., Viotti, P. L., Patrone, M., Marks, P. A., and Rifkind, R. A. (1989) J. Biol. Chem. 264, 18414-18418). The present studies assess the effect of HMBA on the content of 1,2-diacylglycerol (DG), the physiologic activator of PKC, in MELC variants. Exposure of parental Sc9 cells to HMBA induced a rapid rise and fall in DG content. The DG level increased within seconds from 225 pmol.10(6) cells-1 to a maximum of 305 pmol-10(6) cells-1 at 5 min. Thereafter, DG content fell reaching control levels at 30 min and 46% of control at 4 h. Similar DG elevations were detected in HMBA-resistant, phorbol ester-resistant, and vincristine-resistant MELC lines. Early DG elevation was followed by the characteristic rapid fall in both the phorbol ester-resistant and vincristine-resistant lines, both of which differentiate rapidly in response to HMBA. In contrast, in an HMBA-resistant MELC the DG level failed to fall for at least 10 h. Selection of HMBA-resistant cells for vincristine resistance restores both HMBA sensitivity and the rapid fall in DG content. Addition of a synthetic DG, 1-oleyl-2-acetyl glycerol (OAG), along with HMBA and every 2 h for the next 48 h blocked differentiation, as measured by accumulation of benzidine-reactive cells or by the commitment assay in methyl-cellulose. However, if addition of OAG was delayed for just a few minutes, until endogenous DG levels began to fall, differentiation was no longer inhibited. Rapid elevation of DG content is the earliest reported event during HMBA action and a subsequent fall in the DG content appears to be a critical step in the process of commitment to terminal differentiation.	MEM SLOAN KETTERING CANC CTR,SIGNAL TRANSDUCT LAB,1275 YORK AVE,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEWITT WALLACE RES LAB,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University			Busquets, Xavier/M-5574-2018; COLOMER, DOLORS/ABG-6894-2020	Busquets, Xavier/0000-0003-1157-5590; COLOMER, DOLORS/0000-0001-7486-8484	NATIONAL CANCER INSTITUTE [P30CA008748, R01CA042385] Funding Source: NIH RePORTER; NCI NIH HHS [CA-08748, CA-42385] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASS DA, 1987, J BIOL CHEM, V262, P6643; CHEN ZX, 1982, P NATL ACAD SCI-BIOL, V79, P471, DOI 10.1073/pnas.79.2.471; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; EXTON JH, 1990, J BIOL CHEM, V265, P1; FALETTO DL, 1985, CELL, V43, P315, DOI 10.1016/0092-8674(85)90037-6; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GIROLDI L, 1986, CARCINOGENESIS, V7, P1183, DOI 10.1093/carcin/7.7.1183; GUSELLA J, 1976, CELL, V9, P221, DOI 10.1016/0092-8674(76)90113-6; HOCKBERGER P, 1989, NATURE, V338, P340, DOI 10.1038/338340a0; KASZKIN M, 1991, CANCER RES, V51, P4328; KOLESNICK RN, 1990, J BIOL CHEM, V265, P10900; KOLESNICK RN, 1987, J BIOL CHEM, V262, P9204; MARKS PA, 1987, CANCER RES, V47, P659; MELLONI E, 1987, P NATL ACAD SCI USA, V84, P5282, DOI 10.1073/pnas.84.15.5282; MELLONI E, 1988, P NATL ACAD SCI USA, V85, P3835, DOI 10.1073/pnas.85.11.3835; MELLONI E, 1989, J BIOL CHEM, V264, P18414; MICHAELI J, 1990, MOL CELL BIOL, V10, P3535, DOI 10.1128/MCB.10.7.3535; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PINCUS SM, 1984, BIOCHEM BIOPH RES CO, V125, P491, DOI 10.1016/0006-291X(84)90567-9; POWELL T, 1992, P NATL ACAD SCI USA, V89, P147; PREISS J, 1986, J BIOL CHEM, V261, P8597; REBECCHI MJ, 1983, J BIOL CHEM, V258, P227; REUBEN RC, 1976, P NATL ACAD SCI USA, V73, P862, DOI 10.1073/pnas.73.3.862; RIFKIND RA, 1990, MECHANISMS DIFFERENT, V2, P93; ROVERA G, 1977, P NATL ACAD SCI USA, V74, P2894, DOI 10.1073/pnas.74.7.2894; STALFORS P, 1988, NATURE, V335, P554; YAMASAKI H, 1977, P NATL ACAD SCI USA, V74, P3451, DOI 10.1073/pnas.74.8.3451; YOUNES A, 1992, J BIOL CHEM, V267, P842	28	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23463	23466						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429688				2022-12-25	WOS:A1992JZ23900008
J	NAKAMURA, M; TSUNODA, A; SAKOE, K; GU, J; NISHIKAWA, A; TANIGUCHI, N; SAITO, M				NAKAMURA, M; TSUNODA, A; SAKOE, K; GU, J; NISHIKAWA, A; TANIGUCHI, N; SAITO, M			TOTAL METABOLIC FLOW OF GLYCOSPHINGOLIPID BIOSYNTHESIS IS REGULATED BY UDP-GLCNAC - LACTOSYLCERAMIDE BETA-1-]3N-ACETYLGLUCOSAMINYLTRANSFERASE AND CMP-NEUAC LACTOSYLCERAMIDE ALPHA-2-]3 SIALYLTRANSFERASE IN HUMAN HEMATOPOIETIC-CELL LINE HL-60 DURING DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTOR; NEOLACTO-SERIES GANGLIOSIDES; PROTEIN KINASE-C; MONOCYTIC DIFFERENTIATION; MONOCLONAL-ANTIBODY; GRANULOCYTIC DIFFERENTIATION; PHORBOL ESTERS; ANTIGENS; GM3; EXPRESSION	We have previously reported that ganglioside GM3 was remarkably increased during monoeytoid differentiation of human myelogenous leukemia cell line HL-60 cells and that neolacto series gangliosides (NeuAcn-Lc) were enriched during granulocytoid differentiation. In addition, HL-60 was differentiated into monocytic lineage by exogenous GM3 and into granulocytoid by NeuAc-nLc. In the present report, the enzymatic bases of glycosphingolipid biosynthesis in HL-60 during differentiation induced by 12-O-tetradecanoylphorbol-13-acetate and all-trans-retinoic acid were investigated. The following results were of particular interest. (i) Lactosylceramide alpha2-->3sialyltransferase (GM3 synthase) was remarkably up-regulated during monocyte differentiation, while the GM3 synthase level did not change in granulocytic differentiation. (ii) By contrast, lactosylceramide beta1-->3N-acetylglucosaminyltransferase (Lc3Cer synthase) was down-regulated during monocytic differentiation, while the activity of Lc3Cer synthase was found to increase in granulocytic differentiation. (iii) The activities of four downstream glycosyltransferases (for synthesis of NeuAc-nLc) were found to increase or to remain unchanged during monocytic and granulocytic differentiation. These results strongly suggested the following. The dramatic GM3 increase and the decrease of NeuAc-nLc during monocytic differentiation are the consequences of the up-regulation of GM3 synthase and the down-regulation of Lc3Cer synthase, although the downstream enzymes are ready to catalyze their enzyme reactions. The notable increase of NeuAc-nLc and the relative decrease of GM3 during granulocytic differentiation are the results of the unchanged level of GM3 synthase and the up-regulation of LC3Cer synthase together with the activation of the downstream glycosyltransferases. These results suggest that these two key upstream glycosyltransferases, GM3 synthase and Lc3Cer synthase, play critical roles in regulating the glycosphingolipid biosynthesis in HL-60 cells during differentiation. This switching mechanism of these two glycosyltransferases, together with our previous findings, might be one of the most important parts of the determining system of differentiation direction in human myeloid cells into monocytic or granulocytic lineages.	JICHI MED SCH,INST HEMATOL,DIV HEMOPOIESIS,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; OSAKA UNIV,FAC MED,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN	Jichi Medical University; Osaka University			Taniguchi, Naoyuki/I-4182-2014; Nishikawa, Atsushi/E-6766-2013; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; Nishikawa, Atsushi/0000-0003-4325-1160; 				BASU M, 1984, J BIOL CHEM, V259, P2557; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BURCZAK JD, 1984, J LIPID RES, V25, P1541; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHEN C, 1989, BIOCHEMISTRY-US, V28, P2229, DOI 10.1021/bi00431a039; CHIEN JL, 1978, J BIOL CHEM, V253, P4031; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; FEIZI T, 1981, TRENDS BIOCHEM SCI, V6, P333, DOI 10.1016/0968-0004(81)90119-5; FUJIMOTO J, 1987, LAB INVEST, V57, P350; GAHMBERG CG, 1975, J BIOL CHEM, V250, P2438; GU J, 1992, J BIOL CHEM, V267, P2994; HAKOMORI S, 1983, J BIOL CHEM, V258, P1819; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; HASHIMOTO Y, 1984, J BIOCHEM-TOKYO, V95, P1543, DOI 10.1093/oxfordjournals.jbchem.a134766; HIRABAYASHI Y, 1985, J BIOL CHEM, V260, P3328; HOLMES EH, 1987, J BIOL CHEM, V262, P15649; ITO M, 1989, J BIOL CHEM, V264, P9510; IVATT RJ, 1981, P NATL ACAD SCI-BIOL, V78, P4021, DOI 10.1073/pnas.78.7.4021; KANNAGI R, 1983, P NATL ACAD SCI-BIOL, V80, P2844, DOI 10.1073/pnas.80.10.2844; KASAI N, 1984, J BIOCHEM-TOKYO, V96, P261, DOI 10.1093/oxfordjournals.jbchem.a134821; KITAGAWA S, 1989, J BIOL CHEM, V264, P16149; KOEFFLER HP, 1981, CANCER RES, V41, P919; KREUTTER D, 1987, J BIOL CHEM, V262, P1633; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LI CY, 1973, J HISTOCHEM CYTOCHEM, V21, P1; MAGNANI JL, 1980, ANAL BIOCHEM, V109, P399, DOI 10.1016/0003-2697(80)90667-3; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MOMOI T, 1986, J BIOL CHEM, V261, P6270; NAKAMURA M, 1989, BIOCHEM BIOPH RES CO, V161, P782, DOI 10.1016/0006-291X(89)92668-5; NAKAMURA M, 1991, CANCER RES, V51, P1940; NISHIKAWA A, 1990, BIOCHIM BIOPHYS ACTA, V1035, P313, DOI 10.1016/0304-4165(90)90094-D; NOJIRI H, 1986, P NATL ACAD SCI USA, V83, P782, DOI 10.1073/pnas.83.3.782; NOJIRI H, 1988, J BIOL CHEM, V263, P7443; NOJIRI H, 1984, BLOOD, V64, P534; NOZAWA S, 1989, CANCER RES, V49, P6401; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; SAITO M, 1985, BIOCHEM BIOPH RES CO, V132, P223, DOI 10.1016/0006-291X(85)91011-3; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHIGETA K, 1987, J BIOL CHEM, V262, P1358; STEVENS VL, 1989, CANCER RES, V49, P3229; SUZUKI Y, 1991, J BIOCHEM-TOKYO, V109, P354; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; 1977, LIPIDS, V12, P455	49	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23507	23514						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429695				2022-12-25	WOS:A1992JZ23900017
J	WARD, SG; REIF, K; LEY, S; FRY, MJ; WATERFIELD, MD; CANTRELL, DA				WARD, SG; REIF, K; LEY, S; FRY, MJ; WATERFIELD, MD; CANTRELL, DA			REGULATION OF PHOSPHOINOSITIDE KINASES IN T-CELLS - EVIDENCE THAT PHOSPHATIDYLINOSITOL 3-KINASE IS NOT A SUBSTRATE FOR T-CELL ANTIGEN RECEPTOR-REGULATED TYROSINE KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; SIGNAL TRANSDUCTION; LYMPHOCYTES-T; BOVINE BRAIN; INTACT-CELLS; RAT-LIVER; ACTIVATION; PROTEIN; PHOSPHORYLATION; PATHWAY	A phosphoinositide kinase that can phosphorylate phosphatidylinositol (PtdIns) is present in 4G10 monoclonal antibody (mAb) phosphotyrosine immunoprecipitates isolated from T cells activated via the T cell antigen receptor (TCR).CD3 complex. This PtdIns kinase is not the PtdIns 3-kinase that associates with activated protein tyrosine kinases in fibroblasts, since Western blotting and immunoprecipitation experiments with antibodies specific for the p85alpha subunit of the PtdIns 3-kinase indicate that this polypeptide is not immunoprecipitated by the 4G10 mAb from TCR. CD3-activated Jurkat cells. Moreover, immunoprecipitated PtdIns 3-kinase isolated from T cells with p85 antibodies is inhibited when PtdIns is presented in Nonidet P-40, whereas the PtdIns kinase activity present in 4G10 mAb phosphotyrosine immunoprecipitates is enhanced in the presence of Nonidet P-40. In vitro kinase assays of PtdIns 3-kinase immunoprecipitated with p85 antibodies from T cells indicate that it associates with a serine kinase that can phosphorylate a p85 polypeptide. However, no protein tyrosine kinase activity capable of tyrosine phosphorylating p85 in vitro associates with p85alpha immunoprecipitates in quiescent or TCR.CD3-activated T cells. These data suggest that the TCR.CD3 complex does not regulate PtdIns 3-kinase activity by a mechanism that involves protein tyrosine kinases.	IMPERIAL CANC RES FUND,LYMPHOCYTE ACTIVAT LAB,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,CELL SURFACE BIOCHEM LAB,LONDON WC2A 3PX,ENGLAND; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND	Cancer Research UK; Cancer Research UK; Ludwig Institute for Cancer Research			Ward, Stephen/AAE-4341-2020; Reif, Karin/AAD-4692-2020	Reif, Karin/0000-0001-5490-8389; Fry, Michael/0000-0001-8518-1370; Ward, Stephen G./0000-0002-6795-6002				ALEXANDER DR, 1990, BIOCHEM J, V268, P303, DOI 10.1042/bj2680303; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; BAGNASCO M, 1989, EUR J IMMUNOL, V19, P823, DOI 10.1002/eji.1830190507; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CANTLEY LJ, 1992, CELL BIOCH B S, V16, P175; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COCHET C, 1991, J BIOL CHEM, V266, P637; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DASGUPTA JD, 1992, J EXP MED, V175, P285, DOI 10.1084/jem.175.1.285; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FREIDRICH B, 1989, EUR J IMMUNOL, V19, P17; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HAYASHI H, 1991, BIOCHEM J, V280, P769, DOI 10.1042/bj2800769; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; IMBODEN JB, 1985, IMMUNOL TODAY, V6, P328, DOI 10.1016/0167-5699(85)90129-X; INOKUCHI S, 1990, J BIOL CHEM, V265, P5983; ISAKOV N, 1987, IMMUNOL REV, V95, P89, DOI 10.1111/j.1600-065X.1987.tb00501.x; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7772; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LEY SC, 1991, EUR J IMMUNOL, V21, P2203, DOI 10.1002/eji.1830210931; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MARAIS RM, 1989, EUR J BIOCHEM, V181, P401; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MERIDA I, 1991, J IMMUNOL, V147, P2202; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OFLYNN K, 1984, BIOCHEM J, V219, P661, DOI 10.1042/bj2190661; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANTALEO G, 1987, EUR J IMMUNOL, V17, P55, DOI 10.1002/eji.1830170110; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5433; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; REDIJK M, 1992, EMBO J, V11, P1365; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; THOMPSON PA, 1992, ONCOGENE, V7, P719; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WARD SG, 1992, EUR J IMMUNOL, V22, P45, DOI 10.1002/eji.1830220108; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WEISS MJ, 1984, P NATL ACAD SCI-BIOL, V81, P6836, DOI 10.1073/pnas.81.21.6836; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; ZACHARY I, 1991, J BIOL CHEM, V266, P24126	56	53	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23862	23869						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385426				2022-12-25	WOS:A1992JZ23900065
J	DERKX, FHM; DEINUM, J; LIPOVSKI, M; VERHAAR, M; FISCHLI, W; SCHALEKAMP, MADH				DERKX, FHM; DEINUM, J; LIPOVSKI, M; VERHAAR, M; FISCHLI, W; SCHALEKAMP, MADH			NONPROTEOLYTIC ACTIVATION OF PRORENIN BY ACTIVE SITE-DIRECTED RENIN INHIBITORS AS DEMONSTRATED BY RENIN-SPECIFIC MONOCLONAL-ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA INACTIVE RENIN; IDENTIFICATION; PREKALLIKREIN; CONVERSION; KALLIKREIN; SYSTEM; RATS	Incubation of human plasma prorenin (PR), the enzymatically inactive precursor of renin (EC 3.4.23.15), with a number of nonpeptide high-affinity active site-directed renin inhibitors induces a conformational change in PR, which was detected by a monoclonal antibody that reacts with active renin but not with native inactive PR. This conformational change also occurred when inactive PR was activated during exposure to low pH. Nonproteolytically acid-activated PR, and inhibitor-"activated" PR, as well as native PR, were retained on a blue Sepharose column, in contrast to proteolytically activated PR. Kinetic analysis of the activation of plasma prorenin by renin inhibitor (INH) indicated that native plasma contains an open intermediary form of prorenin, PR(oi), in which the active site is exposed and which is in rapid equilibrium with the inactive closed form, PR(c). PR(oi) reacts with inhibitor to form a reversible complex, PR(oi).INH, which undergoes a conformational change resulting in a tight complex of a modified open form of prorenin, PR(o), and the inhibitor, PR(oi).INH --> PR(o).INH. The PR(oi)-to-PR(o) conversion leads to the expression of an epitope on the renin part of the molecule that is recognized by a renin-specific monoclonal antibody. Presumably, PR(o) corresponds to the enzymatically active form of PR that is formed during exposure to low pH. Thus, it seems that the propeptide of PR interacts with the renin part of the molecule not only at or near the enzyme's active site but also at some distance from the active site. Interference with the first interaction by renin inhibitor leads to destabilization of the propeptide, by which the second interaction is disrupted and the enzyme assumes its active conformation. The results of this study may provide a model for substrate-mediated prorenin activation and increase the likelihood that enzymatically active prorenin is formed in vivo.	ERASMUS UNIV,UNIV HOSP DYKZIGT,DEPT INTERNAL MED 1,RM H 362,3015 GD ROTTERDAM,NETHERLANDS; F HOFFMANN LA ROCHE & CO LTD,PRECLIN RES,DIV PHARMA,CH-4002 BASEL,SWITZERLAND	Erasmus University Rotterdam; Roche Holding			Verhaar, Marianne/A-6577-2008	Verhaar, Marianne/0000-0002-3276-6428; Lipovsky, Myriam/0000-0002-5387-9288				CUMIN F, 1985, J BIOL CHEM, V290, P9154; DEGASPARO M, 1989, BRIT J CLIN PHARMACO, V27, P587; DERKX FHM, 1987, J BIOL CHEM, V262, P2472; DERKX FHM, 1979, NATURE, V280, P315, DOI 10.1038/280315a0; DERKX FHM, 1986, J CLIN ENDOCR METAB, V63, P1008, DOI 10.1210/jcem-63-4-1008; DERKX FHM, 1983, HYPERTENSION, V5, P244, DOI 10.1161/01.HYP.5.2.244; DERKX FHM, 1991, AM J HYPERTENS, V4, P602, DOI 10.1093/ajh/4.7.602; FISCHLI W, 1991, HYPERTENSION, V18, P22, DOI 10.1161/01.HYP.18.1.22; GALEN FX, 1984, J CLIN INVEST, V74, P723, DOI 10.1172/JCI111488; Guesdon J L, 1981, Methods Enzymol, V73, P471; HEINRIKSON RL, 1989, AM J HYPERTENS, V2, P367, DOI 10.1093/ajh/2.5.367; HEINRIKSON RL, 1990, HYPERTENSION PATHOPH, P1179; HIROSE S, 1985, J BIOL CHEM, V260, P6400; HSUEH WA, 1991, HYPERTENSION, V17, P469, DOI 10.1161/01.HYP.17.4.469; HSUEH WA, 1981, HYPERTENSION, V3, P22; INAGAMI T, 1982, J CLIN ENDOCR METAB, V55, P619, DOI 10.1210/jcem-55-4-619; KITZ R, 1962, J BIOL CHEM, V237, P3245; KLEINERT HD, 1988, HYPERTENSION, V11, P613, DOI 10.1161/01.HYP.11.6.613; LECKIE BJ, 1980, NATURE, V288, P702, DOI 10.1038/288702a0; MENARD J, 1985, J HYPERTENS, V3, pS275; MULLINS JJ, 1990, NATURE, V344, P541, DOI 10.1038/344541a0; OSMOND DH, 1975, CAN J PHYSL PHARM, V51, P705; SEALEY JE, 1976, AM J MED, V61, P731, DOI 10.1016/0002-9343(76)90154-6; SEALEY JE, 1979, P NATL ACAD SCI USA, V76, P5914, DOI 10.1073/pnas.76.11.5914; SEALEY JE, 1989, AM J HYPERTENS, V2, P358, DOI 10.1093/ajh/2.5.358; SHINAGAWA T, 1990, P NATL ACAD SCI USA, V87, P1927, DOI 10.1073/pnas.87.5.1927; SIELECKI AR, 1989, SCIENCE, V243, P1346, DOI 10.1126/science.2493678; SIMON D, 1987, CLIN EXP HYPERTENS A, V9, P133; YAMAUCHI T, 1990, J BIOCHEM-TOKYO, V107, P27, DOI 10.1093/oxfordjournals.jbchem.a123005	29	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22837	22842						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429632				2022-12-25	WOS:A1992JY16300023
J	DUBIEL, W; FERRELL, K; PRATT, G; RECHSTEINER, M				DUBIEL, W; FERRELL, K; PRATT, G; RECHSTEINER, M			SUBUNIT-4 OF THE 26-S PROTEASE IS A MEMBER OF A NOVEL EUKARYOTIC ATPASE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MULTICATALYTIC PROTEINASE COMPLEX; SUBSTRATE-SPECIFICITY; DEPENDENT PROTEASE; 26S COMPLEX; UBIQUITIN; YEAST; PEPTIDES; PATHWAY; KINASE; CELLS	Ubiquitinated proteins are degraded by a 26 S ATP-dependent protease. SDS-polyacrylamide gel electrophoresis analysis of the purified 26 S enzyme reveals more than 20 polypeptides ranging in apparent molecular masses from 20 to 110 kDa. Although many of the subunits smaller than 30 kDa are members of the multicatalytic protease family, the identity and function of the larger polypeptides have remained unknown. We report here the cDNA sequence for subunit 4, a 51-kDa chain of the 26 S protease. Subunit 4 belongs to a recently identified eukaryotic ATPase family, which includes proteins involved in peroxisome formation, secretion, and human immunodeficiency virus gene expression. Subunit 4 also shows weak similarity to ClpA, the ATP-binding subunit of the Escherichia coli protease, Clp.			DUBIEL, W (corresponding author), UNIV UTAH,SCH MED,DEPT BIOCHEM,SALT LAKE CITY,UT 84132, USA.			Dubiel, Wolfgang/0000-0002-3393-0701	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037009] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37009] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMON T, 1990, J BIOL CHEM, V265, P20723; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Dayhoff M.O., 1978, ATLAS PROTEIN SEQ ST; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; GOTTESMAN S, 1989, ANNU REV GENET, V23, P163, DOI 10.1146/annurev.ge.23.120189.001115; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; HAMMARBACK JA, 1990, J BIOL CHEM, V265, P12763; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOUGH R, 1986, J BIOL CHEM, V261, P2400; HOUGH R, 1987, J BIOL CHEM, V262, P8303; Hough R. F., 1988, UBIQUITIN, P101, DOI 10.1007/978-1-4899-2049-2_5; KANAYAMA HO, 1992, EUR J BIOCHEM, V206, P567, DOI 10.1111/j.1432-1033.1992.tb16961.x; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KURTH J, 1990, BIOL CHEM H-S, V371, P675, DOI 10.1515/bchm3.1990.371.2.675; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; ORINO E, 1991, FEBS LETT, V284, P206, DOI 10.1016/0014-5793(91)80686-W; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERS JM, 1991, EUR J CELL BIOL, V56, P422; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; TANAKA K, 1992, NEW BIOL, V4, P173; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	44	188	191	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22699	22702						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429620				2022-12-25	WOS:A1992JY16300002
J	HWANG, DS; KORNBERG, A				HWANG, DS; KORNBERG, A			OPPOSED ACTIONS OF REGULATORY PROTEINS, DNAA AND ICIA, IN OPENING THE REPLICATION ORIGIN OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL ORIGIN; INITIATION; INVITRO; SEQUENCE; HYBRID; LAMBDA; BINDS	The opening of the three tandem 13-mers (iterons) in the replication origin (oriC) of Escherichia coli by DnaA protein, assisted by protein HU or IHF (Hwang, D. S., and Kornberg, A. (1992) J. Biol. Chem. 267, 23083-23086), represents an essential early stage in the initiation of chromosomal replication (Bramhill, D., and Kornberg, A. (1988) Cell 54, 915-918). We now show by mutational alterations of the 13-mer region that oriC function, both in vitro and in vivo, requires AT-richness in the left 13-mer and sequence specificity in the middle and right 13-mers. Interactions of DnaA protein with the middle and right 13-mers are crucial for the opening of the region. Binding of the protein to the top strand of the 13-mers appeared to maintain single-strandedness in the bottom strand. IciA protein, the inhibitor of initiation, binds the three 13-mers and blocks the opening of the region. The degrees of inhibition by IciA protein of 13-mer opening and of oriC plasmid replication observed with mutant forms of the 13-mers could be correlated with the binding affinity of IciA protein. Whereas the binding of IciA protein to the 13-mers did not affect the binding of DnaA protein to its four 9-mer boxes, interaction of DnaA protein with the 13-mers was blocked. The selective interactions of DnaA and IciA proteins with the 13-mer region appear to be components of the on/off switch that controls initiation of E. coli chromosomal replication.	STANFORD UNIV,MED CTR,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University								ASAI T, 1990, EMBO J, V9, P4065, DOI 10.1002/j.1460-2075.1990.tb07628.x; BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; DODSON M, 1989, J BIOL CHEM, V264, P10719; Furth M., 1983, LAMBDA 2, P145; GILLE H, 1991, EMBO J, V10, P1579, DOI 10.1002/j.1460-2075.1991.tb07678.x; HILL CW, 1981, P NATL ACAD SCI-BIOL, V78, P7069, DOI 10.1073/pnas.78.11.7069; HWANG DS, 1990, CELL, V63, P325, DOI 10.1016/0092-8674(90)90165-B; HWANG DS, 1992, J BIOL CHEM, V267, P2209; HWANG DS, 1992, J BIOL CHEM, V267, P23083; Kornberg A., 1992, DNA REPLICATION; KOWALSKI D, 1989, EMBO J, V8, P4335, DOI 10.1002/j.1460-2075.1989.tb08620.x; OGAWA T, 1985, P NATL ACAD SCI USA, V82, P3562, DOI 10.1073/pnas.82.11.3562; OKA A, 1980, MOL GEN GENET, V178, P9, DOI 10.1007/BF00267207; POLACZEK P, 1990, New Biologist, V2, P265; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7124; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; SMITH DW, 1985, EMBO J, V4, P1319, DOI 10.1002/j.1460-2075.1985.tb03779.x; THONY B, 1991, P NATL ACAD SCI USA, V88, P4066, DOI 10.1073/pnas.88.10.4066; YUNG BYM, 1989, J BIOL CHEM, V264, P6146; ZYLICZ M, 1908, MOL GEN GENET, V196, P401; ZYSKIND JW, 1983, P NATL ACAD SCI-BIOL, V80, P1164, DOI 10.1073/pnas.80.5.1164	25	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23087	23091						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429656				2022-12-25	WOS:A1992JY16300060
J	OLSON, MW; KAGUNI, LS				OLSON, MW; KAGUNI, LS			3'-]5' EXONUCLEASE IN DROSOPHILA MITOCHONDRIAL-DNA POLYMERASE - SUBSTRATE-SPECIFICITY AND FUNCTIONAL COORDINATION OF NUCLEOTIDE POLYMERIZATION AND MISPAIR HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE-INHIBITION; FIDELITY; MELANOGASTER; MECHANISM; GAMMA; SUBUNIT; EMBRYOS; ALPHA; MUTAGENESIS; PRIMASE	A mispair-specific 3'-->5' exonuclease copurifies quantitatively with the near-homogeneous Drosophila gamma polymerase (Kaguni, L. S., and Olson, M. W. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 6469-6473). The exonuclease and polymerase exhibit similar reaction requirements and optima, suggesting functional coordination of their activities. Under nonpolymerization conditions, the 3'-->5' exonuclease hydrolyzes 3'-terminal mispairs approximately 15-fold more efficiently than 3'-terminal base pairs on primed single-stranded DNA substrates, whereas it does not discriminate between any of three specific mispairs (dAMP:dAMP; dGMP:dGMP; dGMP:dAMP). Under polymerization conditions, gamma polymerase does not extend a 3'-terminal mispair from the "stationary" state, even in the presence of a large excess of the next correct nucleotide. Instead, 3'-terminal mispairs are hydrolyzed quantitatively by the 3'-->5' exonuclease over the reaction time course. During DNA synthesis by gamma polymerase in the "polymerization" mode, limited misincorporation and subsequent mispair extension do occur. Here, it appears that mis-incorporation and not mispair extension is rate-limiting. Template-primer challenge experiments suggest that the mechanism of template-primer transfer from the 3'-->5' exonuclease active site to the DNA polymerase active site is intermolecular; transfer from the exonuclease to polymerase mode appears to require dissociation and reassociation of mitochondrial DNA polymerase.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045295] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45295] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; BYRNES JJ, 1977, BIOCHEMISTRY-US, V16, P3740, DOI 10.1021/bi00636a002; CLAYTON DA, 1974, P NATL ACAD SCI USA, V71, P2777, DOI 10.1073/pnas.71.7.2777; COTTERILL SM, 1987, P NATL ACAD SCI USA, V84, P5635, DOI 10.1073/pnas.84.16.5635; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; DRAKE JW, 1969, NATURE, V221, P1132, DOI 10.1038/2211132a0; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; Fansler B S, 1974, Methods Enzymol, V29, P53; INSDORF NF, 1989, J BIOL CHEM, V264, P21498; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; KAGUNI LS, 1989, P NATL ACAD SCI USA, V86, P6469, DOI 10.1073/pnas.86.17.6469; Kornberg A., 1991, DNA REPLICATION; KUNKEL TA, 1987, P NATL ACAD SCI USA, V84, P4865, DOI 10.1073/pnas.84.14.4865; KUNKEL TA, 1988, BIOCHIM BIOPHYS ACTA, V951, P1, DOI 10.1016/0167-4781(88)90020-6; KUNKEL TA, 1985, J BIOL CHEM, V260, P2866; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1989, BIOCHEMISTRY-US, V28, P988, DOI 10.1021/bi00429a011; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; LOEB LA, 1982, ANNU REV BIOCHEM, V52, P429; LONGLEY MJ, 1991, J BIOL CHEM, V266, P24702; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MIZRAHI V, 1986, P NATL ACAD SCI USA, V83, P5769, DOI 10.1073/pnas.83.16.5769; MOSBAUGH DW, 1980, J BIOL CHEM, V255, P239; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P3085, DOI 10.1073/pnas.86.9.3085; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; QUE BG, 1978, BIOCHEMISTRY-US, V17, P1603, DOI 10.1021/bi00602a004; REEMS JA, 1991, J BIOL CHEM, V266, P4878; REYLAND ME, 1988, J BIOL CHEM, V263, P6518; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WERNETTE CM, 1988, BIOCHEMISTRY-US, V27, P6046, DOI 10.1021/bi00416a033; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764; WEYMOUTH LA, 1978, P NATL ACAD SCI USA, V75, P1924, DOI 10.1073/pnas.75.4.1924	35	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23136	23142						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429661				2022-12-25	WOS:A1992JY16300067
J	VAZIRI, C; DOWNES, CP				VAZIRI, C; DOWNES, CP			ASSOCIATION OF A RECEPTOR AND G-PROTEIN-REGULATED PHOSPHOLIPASE-C WITH THE CYTOSKELETON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ERYTHROCYTE-MEMBRANES; SIGNAL TRANSDUCTION; TURKEY ERYTHROCYTES; PLASMA-MEMBRANES; STREPTOLYSIN-O; BOVINE BRAIN; PURIFICATION; KINASE; CELLS	Approximately 98% of turkey erythrocyte phospholipase C (PLC) is cytosolic and is released by hypotonic lysis of the cells and extensive washing of the resultant erythrocyte ghosts. Well washed turkey erythrocyte ghosts retain a fraction of tightly associated PLC, which is activated by the P2y-purinergic receptor and G-protein present in ghost membranes. The particulate PLC is sufficient to couple to all the available purinergic receptor-regulated G-protein. In contrast to ghosts, turkey erythrocyte plasma membrane preparations contain no detectable PLC. To investigate the subcellular location of the ghost-associated PLC, cytoskeletons were prepared by Triton X-100 extraction of turkey erythrocyte ghosts. The ghost-associated PLC was quantitatively recovered in cytoskeleton preparations. Cytoskeleton-associated PLC was solubilized by sodium cholate extraction, partially purified, and shown to reconstitute with PLC-free plasma membrane preparations in an agonist and guanine nucleotide-dependent fashion, indicating that the cytoskeleton-associated PLC is G-protein-regulated. Dissociation of erythrocyte ghost cytoskeletons with the actin-binding protein DNase 1 resulted in a dose-dependent inhibition of agonist and guanine nucleotide-stimulated PLC responses in ghosts and caused release of PLC from ghost or cytoskeleton preparations. These data demonstrate the specific association of a receptor and G-protein-regulated PLC with a component of the detergent-insoluble cytoskeleton and indicate that the integrity of the actin cytoskeleton is important for localization and effective coupling of PLC to the relevant G-protein.			VAZIRI, C (corresponding author), UNIV DUNDEE, INST MED SCI, DEPT BIOCHEM, DUNDEE DD1 4HN, SCOTLAND.							BALDASSARE JJ, 1989, BIOCHEMISTRY-US, V28, P6010, DOI 10.1021/bi00440a043; BANNO Y, 1992, J BIOL CHEM, V267, P6488; BEAM KG, 1979, J CELL BIOL, V83, P1, DOI 10.1083/jcb.83.1.1; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BOYER JL, 1990, J BIOL CHEM, V265, P13515; CARTER HR, 1990, BIOCHIM BIOPHYS ACTA, V1054, P119, DOI 10.1016/0167-4889(90)90213-W; COHEN WD, 1986, METHOD ENZYMOL, V134, P232; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DUNCAN JL, 1975, J CELL BIOL, V67, P160, DOI 10.1083/jcb.67.1.160; HARDEN TK, 1988, BIOCHEM J, V252, P583, DOI 10.1042/bj2520583; HITCHCOCK SE, 1976, CELL, V7, P531, DOI 10.1016/0092-8674(76)90203-8; IRVINE RF, 1978, J NEUROCHEM, V31, P1427, DOI 10.1111/j.1471-4159.1978.tb06568.x; KATAN M, 1987, EUR J BIOCHEM, V168, P413, DOI 10.1111/j.1432-1033.1987.tb13435.x; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARIDES E, 1987, CELL, V51, P345, DOI 10.1016/0092-8674(87)90631-3; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; MARTIN TFJ, 1989, J BIOL CHEM, V264, P20917; MCBRIDE K, 1991, P NATL ACAD SCI USA, V88, P7111, DOI 10.1073/pnas.88.16.7111; MCGOUGH AM, 1990, P NATL ACAD SCI USA, V87, P5208, DOI 10.1073/pnas.87.13.5208; MCPHEE F, 1991, BIOCHEM J, V275, P187, DOI 10.1042/bj2750187; MORRIS AJ, 1990, J BIOL CHEM, V265, P13508; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAYRASTRE B, 1991, BIOCHIM BIOPHYS ACTA, V1056, P19, DOI 10.1016/S0005-2728(05)80068-4; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; ROY G, 1991, J BIOL CHEM, V266, P11495; SHEETZ MP, 1979, J CELL BIOL, V81, P266, DOI 10.1083/jcb.81.1.266; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STUTCHFIELD J, 1991, EUR J BIOCHEM, V197, P119, DOI 10.1111/j.1432-1033.1991.tb15889.x; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THOMAS GMH, 1991, EMBO J, V10, P2507, DOI 10.1002/j.1460-2075.1991.tb07790.x; VAZIRI C, 1992, BIOCHEM J, V284, P917, DOI 10.1042/bj2840917; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WALLACE MA, 1985, J BIOL CHEM, V260, P9527	37	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22973	22981						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429646				2022-12-25	WOS:A1992JY16300043
J	ANDRESS, DL; BIRNBAUM, RS				ANDRESS, DL; BIRNBAUM, RS			HUMAN OSTEOBLAST-DERIVED INSULIN-LIKE GROWTH-FACTOR (IGF) BINDING PROTEIN-5 STIMULATES OSTEOBLAST MITOGENESIS AND POTENTIATES IGF ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR (IGF)-BINDING PROTEIN-1; MESSENGER RIBONUCLEIC-ACID; VASCULAR ENDOTHELIAL-CELLS; FETAL-RAT BONE; FACTOR-I; ENRICHED CULTURES; DNA-SYNTHESIS; COLLAGEN-SYNTHESIS; MOLECULAR-CLONING; INHIBITS BINDING	Insulin-like growth factor (IGF)-binding proteins (IGFBPs) either inhibit or enhance IGF-stimulated cellular effects. While inhibition occurs by sequestration of IGF from cell-surface receptors, the exact mechanism of IGF-enhancement remains undefined. Human osteoblast-like bone cells in culture secrete several IGF-binding proteins, one of which we have previously identified as IGFBP-5. In this study we purified a 23-kDa IGFBP-5 from cultures of human osteoblast-like cells using ligand affinity chromatography and reversed-phase high performance liquid chromatography and tested its bioactivity in serum-free cultures of normal mouse osteoblast-like cells. Binding studies with radioiodinated IGF showed similar and relatively low affinities for IGF-I and IGF-II consistent with a carboxyl truncated IGF-binding protein. Mitogenic assays demonstrated that the binding protein, when coincubated with IGF-I or -II, enhanced mitogenesis. This enhancement was unique from other binding proteins in not requiring a preincubation period or serum cofactors. Furthermore, the osteoblast-derived IGFBP-5 stimulated mitogenesis in the absence of exogenous or endogenous IGF. Using radioiodinated IGFBP-5 we found that the binding protein could associate with the osteoblast surface, an effect which did not require IGF nor an interaction with the IGF receptors. We suggest that osteoblast-derived IGFBP-5 may stimulate osteoblast mitogenesis in at least two ways, by association with IGF and by a second pathway that is independent of IGF receptor activation.	VET ADM MED CTR,CTR GERIAT RES EDUC & CLIN,TACOMA,WA 98493; VET ADM MED CTR,RES SERV,SEATTLE,WA 98108; VET ADM MED CTR,RES SERV,TACOMA,WA 98493; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98108	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle	ANDRESS, DL (corresponding author), VET ADM MED CTR,MED SERV,111A,1660 S COLUMBIAN WAY,SEATTLE,WA 98108, USA.							ANDRESS DL, 1991, BIOCHEM BIOPH RES CO, V176, P213, DOI 10.1016/0006-291X(91)90911-P; BAUTISTA CM, 1991, BIOCHEM BIOPH RES CO, V176, P756, DOI 10.1016/S0006-291X(05)80249-9; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BAXTER RC, 1986, J CLIN INVEST, V78, P1504, DOI 10.1172/JCI112742; BENNETT A, 1984, ENDOCRINOLOGY, V115, P1577, DOI 10.1210/endo-115-4-1577; BICSAK TA, 1990, ENDOCRINOLOGY, V126, P2184, DOI 10.1210/endo-126-4-2184; BLAT C, 1989, J BIOL CHEM, V264, P12449; BLUM WF, 1989, ENDOCRINOLOGY, V125, P766, DOI 10.1210/endo-125-2-766; BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; BOOTH BA, 1990, ENDOCRINOLOGY, V127, P2630, DOI 10.1210/endo-127-6-2630; BOWSHER RR, 1991, ENDOCRINOLOGY, V128, P815; BRINKMAN A, 1991, MOL ENDOCRINOL, V5, P987, DOI 10.1210/mend-5-7-987; BURCH WM, 1990, J CLIN ENDOCR METAB, V70, P173, DOI 10.1210/jcem-70-1-173; BUSBY WH, 1988, J BIOL CHEM, V263, P14203; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CANALIS E, 1988, ENDOCRINOLOGY, V122, P22, DOI 10.1210/endo-122-1-22; CANALIS E, 1988, J CLIN INVEST, V81, P277, DOI 10.1172/JCI113318; CANALIS E, 1991, ENDOCRINOLOGY, V129, P2457, DOI 10.1210/endo-129-5-2457; CANALIS E, 1988, CALCIFIED TISSUE INT, V43, P346, DOI 10.1007/BF02553277; CENTRELLA M, 1990, ENDOCRINOLOGY, V126, P39, DOI 10.1210/endo-126-1-39; CHEN TL, 1991, ENDOCRINOLOGY, V128, P2489, DOI 10.1210/endo-128-5-2489; CHEN TL, 1991, CALCIFIED TISSUE INT, V48, P278, DOI 10.1007/BF02556380; CLEMMONS DR, 1990, J CELL PHYSIOL, V145, P129, DOI 10.1002/jcp.1041450118; CLEMMONS DR, 1986, J CLIN INVEST, V77, P1548, DOI 10.1172/JCI112470; CLEMMONS DR, 1991, MODERN CONCEPTS INSU, P475; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; DEUL TF, 1987, ANN REV CELL BIOL, V3, P4533; ERNST M, 1989, ENDOCRINOLOGY, V125, P825, DOI 10.1210/endo-125-2-825; ERNST M, 1990, ENDOCRINOLOGY, V127, P807, DOI 10.1210/endo-127-2-807; FEYEN JHM, 1991, J BIOL CHEM, V266, P19469; FROLIK CA, 1988, BIOCHEM BIOPH RES CO, V151, P1011, DOI 10.1016/S0006-291X(88)80466-2; GOPINATH R, 1989, J ENDOCRINOL, V120, P231, DOI 10.1677/joe.0.1200231; HOCK JM, 1988, ENDOCRINOLOGY, V122, P254, DOI 10.1210/endo-122-1-254; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES JI, 1991, P NATL ACAD SCI USA, V88, P7481, DOI 10.1073/pnas.88.17.7481; JONES JI, 1992, 74TH ANN M END SOC S, P372; JUNG LJ, 1991, SCIENCE, V251, P1330, DOI 10.1126/science.2003219; KNAUER DJ, 1980, P NATL ACAD SCI-BIOL, V77, P7252, DOI 10.1073/pnas.77.12.7252; KOISTINEN R, 1990, BIOCHEM BIOPH RES CO, V173, P408, DOI 10.1016/S0006-291X(05)81073-3; LATOUR D, 1990, MOL ENDOCRINOL, V4, P1806, DOI 10.1210/mend-4-12-1806; LIPFORD GB, 1990, ANAL BIOCHEM, V187, P133, DOI 10.1016/0003-2697(90)90430-H; MARTIN JL, 1990, J BIOL CHEM, V265, P4124; MCCARTHY TL, 1990, J BIOL CHEM, V265, P15353; MCCARTHY TL, 1990, ENDOCRINOLOGY, V126, P1569, DOI 10.1210/endo-126-3-1569; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P301, DOI 10.1210/endo-124-1-301; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo-124-3-1247; MOHAN S, 1988, BIOCHIM BIOPHYS ACTA, V966, P44, DOI 10.1016/0304-4165(88)90127-4; MOHAN S, 1989, J CELL PHYSIOL, V140, P169, DOI 10.1002/jcp.1041400120; MOHAN S, 1989, P NATL ACAD SCI USA, V86, P8338, DOI 10.1073/pnas.86.21.8338; RITVOS O, 1988, ENDOCRINOLOGY, V122, P2150, DOI 10.1210/endo-122-5-2150; ROSS M, 1989, BIOCHEM J, V258, P267, DOI 10.1042/bj2580267; SCHMID C, 1991, BIOCHEM BIOPH RES CO, V179, P579, DOI 10.1016/0006-291X(91)91410-E; SCHMID C, 1989, BIOCHEM BIOPH RES CO, V160, P788, DOI 10.1016/0006-291X(89)92502-3; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; TRESSEL TJ, 1991, BIOCHEM BIOPH RES CO, V178, P625, DOI 10.1016/0006-291X(91)90154-Y; YAMADA KM, 1991, J BIOL CHEM, V266, P12809	59	323	332	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22467	22472						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1385400				2022-12-25	WOS:A1992JW71900075
J	BENNETT, SE; MOSBAUGH, DW				BENNETT, SE; MOSBAUGH, DW			CHARACTERIZATION OF THE ESCHERICHIA-COLI URACIL-DNA GLYCOSYLASE.INHIBITOR PROTEIN COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE GENE; BACILLUS-SUBTILIS; SACCHAROMYCES-CEREVISIAE; BACTERIOPHAGE PBS2; REPAIR ENZYME; N-GLYCOSIDASE; RAT-LIVER; PURIFICATION; NUCLEAR; INHIBITOR	The Bacillus subtilis bacteriophage PBS2 uracil-DNA glycosylase inhibitor (Ugi) protein was characterized and shown to form a stable complex with Escherichia coli uracil-DNA glycosylase (Ung). As determined by mass spectrometry, the Ugi protein had a molecular weight of 9,474. We confirmed this value by sedimentation equilibrium centrifugation and determined that Ugi exists as a monomeric protein in solution. Amino acid analysis performed on both Ugi and Ung proteins was in excellent agreement with the amino acid composition predicted from the respective nucleotide sequence of each gene. The Ung.Ugi complex was resolved from its constitutive components by nondenaturing polyacrylamide gel electrophoresis and shown to possess a 1:1 stoichiometry. Analytical ultracentrifugation studies revealed that the Ung.Ugi complex had a molecular weight of 35,400, consistent with the complex containing one molecule each of Ung and Ugi. The acidic isoelectric points of the protein species were 6.6 (Ung) and 4.2 (Ugi), whereas the Ung.Ugi complex had an isoelectric point of 4.9. Dissociation of the Ung.Ugi complex by SDS-polyacrylamide gel electrophoresis revealed no apparent alteration in the molecular weight of either polypeptide subsequent to binding. Furthermore, when the Ung.Ugi complex was treated with urea and resolved by urea-polyacrylamide gel electrophoresis, both uracil-DNA glycosylase and inhibitor activities were recovered from the dissociated complex. Thus, the complex seems to be reversible. In addition, we demonstrated that the Ugi interaction with Ung prevents enzyme binding to DNA and dissociates uracil-DNA glycosylase from a preformed DNA complex.	OREGON STATE UNIV,DEPT AGR CHEM,CORVALLIS,OR 97331; OREGON STATE UNIV,DEPT BIOCHEM,CORVALLIS,OR 97331; OREGON STATE UNIV,DEPT BIOPHYS,CORVALLIS,OR 97331; OREGON STATE UNIV,ENVIRONM HLTH SCI CTR,CORVALLIS,OR 97331	Oregon State University; Oregon State University; Oregon State University; Oregon State University					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032823] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES00210] Funding Source: Medline; NIGMS NIH HHS [GM32823] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASLAND R, 1990, GENOMICS, V7, P139, DOI 10.1016/0888-7543(90)90532-Y; ANDERSON CTM, 1980, NUCLEIC ACIDS RES, V8, P875; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERS PMJ, 1986, J BACTERIOL, V166, P905, DOI 10.1128/jb.166.3.905-913.1986; CARADONNA SJ, 1980, J BIOL CHEM, V255, P2293; CONE R, 1977, BIOCHEMISTRY-US, V16, P3194, DOI 10.1021/bi00633a024; CONE R, 1980, J BIOL CHEM, V255, P354; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DOMENA JD, 1985, BIOCHEMISTRY-US, V24, P7320, DOI 10.1021/bi00346a045; DOMENA JD, 1988, BIOCHEMISTRY-US, V27, P6742, DOI 10.1021/bi00418a015; DUNCAN BK, 1984, GENE, V28, P211, DOI 10.1016/0378-1119(84)90258-0; FRANKLIN WA, 1988, EMBO J, V7, P3617, DOI 10.1002/j.1460-2075.1988.tb03240.x; FRIEDBERG EC, 1975, J VIROL, V16, P315, DOI 10.1128/JVI.16.2.315-321.1975; GUPTA PK, 1981, CANCER RES, V41, P3133; HITZEMAN RA, 1978, J BIOL CHEM, V253, P8518; HOLLAND JP, 1979, J BIOL CHEM, V254, P9839; KARRAN P, 1981, BIOCHEMISTRY-US, V20, P6092, DOI 10.1021/bi00524a027; KULBE KD, 1975, BIOCHEM BIOPH RES CO, V67, P35, DOI 10.1016/0006-291X(75)90279-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAL J, 1981, CHROMOSOME DAMAGE RE, P117; LEBLANC JP, 1982, J BIOL CHEM, V257, P3477; LEE TD, 1989, 37TH P AM SOC MASS S; LINDAHL T, 1977, J BIOL CHEM, V252, P3286; LINN S, 1981, CHROMOSOME DAMAGE RE, P97; MARTY L, 1984, BIOCHEM BIOPH RES CO, V118, P767; MCKEEKIN TL, 1952, SCIENCE, V116, P142; MEJEAN V, 1991, NARES, V18, P6693; MEYER-SIEGLER K, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P4; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; MOSBAUGH DW, 1988, REV BIOCHEM TOXICOL, V9, P69; MULLER SJ, 1991, BIOCHIM BIOPHYS ACTA, V1088, P197, DOI 10.1016/0167-4781(91)90055-Q; NOWAK K, 1981, FEBS LETT, V134, P143, DOI 10.1016/0014-5793(81)80587-X; OLSEN LC, 1989, EMBO J, V8, P3121, DOI 10.1002/j.1460-2075.1989.tb08464.x; PRICE AR, 1972, J VIROL, V9, P602, DOI 10.1128/JVI.9.4.602-610.1972; PRICE AR, 1973, J BIOL CHEM, V248, P1372; REISNER AH, 1984, METHOD ENZYMOL, V104, P439; SAKUMI K, 1990, MUTAT RES, V236, P161, DOI 10.1016/0921-8777(90)90003-N; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SEAL G, 1987, BIOCHIM BIOPHYS ACTA, V925, P226, DOI 10.1016/0304-4165(87)90113-9; SLUPPHAUG G, 1991, NUCLEIC ACIDS RES, V19, P5131, DOI 10.1093/nar/19.19.5131; TAKAHASHI I, 1963, NATURE, V197, P794, DOI 10.1038/197794a0; VARSHNEY U, 1988, J BIOL CHEM, V263, P7776; VIAENE A, 1989, NUCLEIC ACIDS RES, V17, P1251, DOI 10.1093/nar/17.3.1251; WANG Z, 1989, J BIOL CHEM, V264, P1163; WANG ZG, 1988, J BACTERIOL, V170, P1082, DOI 10.1128/jb.170.3.1082-1091.1988; WANG ZG, 1991, GENE, V99, P31; WILLIAMS MV, 1990, J BACTERIOL, V172, P2979, DOI 10.1128/jb.172.6.2979-2985.1990; WORRAD DM, 1988, J VIROL, V62, P4774, DOI 10.1128/JVI.62.12.4774-4777.1988	49	75	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22512	22521						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429601				2022-12-25	WOS:A1992JW71900082
J	DUBIEL, W; PRATT, G; FERRELL, K; RECHSTEINER, M				DUBIEL, W; PRATT, G; FERRELL, K; RECHSTEINER, M			PURIFICATION OF AN 11-S REGULATOR OF THE MULTICATALYTIC PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEASE; MOLECULAR-WEIGHT PROTEINASE; RED-BLOOD-CELLS; MACROPAIN PROTEASOME; ENDOGENOUS INHIBITOR; CDNA CLONING; GENE FAMILY; 26S COMPLEX; RAT-LIVER; UBIQUITIN	We have identified and purified a protein complex from human red blood cells that activates the multicatalytic protease (MCP). The complex, which we call the regulator, sediments at 11 S and is composed of 30-kDa subunits. The regulator does not hydrolyze fluorogenic peptides, but when multicatalytic protease and regulator are combined, MCP cleaves succinyl-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin and Leu-Leu-Glu-p-nitroanilide as much as 60-fold faster. Hydrolysis of several other fluorogenic peptides is stimulated to a lesser extent, and activated MCP does not degrade ubiquitin-lysozyme conjugates, bovine serum albumin, or lysozyme. Latent and activated forms of MCP display similar sensitivity to protease inhibitors, suggesting that activation does not generate new kinds of catalytic sites. In addition, ATP suppresses peptide hydrolysis by activated and latent MCPs to the same extent. Activation involves binding of regulator to MCP, and activated MCP migrates slower on native acrylamide gels. Dissociation of the MCP regulator complex during prolonged sedimentation on glycerol gradients releases active regulator and MCP molecules capable of being reactivated. Moreover, two-dimensional electrophoresis does not reveal changes in MCP or regulator subunits following activation. Thus, activation appears to result from reversible association of regulator subunits with MCP.	UNIV UTAH,SCH MED,DEPT BIOCHEM,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah				Dubiel, Wolfgang/0000-0002-3393-0701	NIGMS NIH HHS [GM 39007] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R43GM039007] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMON T, 1990, J BIOL CHEM, V265, P20723; ARRIBAS J, 1990, J BIOL CHEM, V265, P13969; BAUMEISTER W, 1988, FEBS LETT, V241, P239, DOI 10.1016/0014-5793(88)81069-X; CARLSON N, 1987, J CELL BIOL, V104, P547, DOI 10.1083/jcb.104.3.547; DEMARTINO GN, 1991, BIOCHIM BIOPHYS ACTA, V1079, P29, DOI 10.1016/0167-4838(91)90020-Z; DEMARTINO GN, 1982, BIOCHEMISTRY-US, V21, P4297, DOI 10.1021/bi00261a019; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; EMORI Y, 1991, MOL CELL BIOL, V11, P344, DOI 10.1128/MCB.11.1.344; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FAGAN JM, 1991, BIOCHEM J, V277, P779, DOI 10.1042/bj2770779; FUJIWARA T, 1990, J BIOL CHEM, V265, P16604; FUJIWARA T, 1989, BIOCHEMISTRY-US, V28, P7332, DOI 10.1021/bi00444a028; HAASS C, 1989, EMBO J, V8, P2373, DOI 10.1002/j.1460-2075.1989.tb08366.x; HAASS C, 1990, GENE, V90, P235, DOI 10.1016/0378-1119(90)90185-T; HAASS C, 1990, NUCLEIC ACIDS RES, V18, P4018, DOI 10.1093/nar/18.13.4018; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOUGH R, 1987, J BIOL CHEM, V262, P8303; HOUGH R, 1986, J BIOL CHEM, V261, P2391; Hough R. F., 1988, UBIQUITIN, P101, DOI 10.1007/978-1-4899-2049-2_5; IMAJOH S, 1986, J BIOCHEM-TOKYO, V100, P633, DOI 10.1093/oxfordjournals.jbchem.a121755; KOPP F, 1986, BIOCHIM BIOPHYS ACTA, V872, P253, DOI 10.1016/0167-4838(86)90278-5; LEE DH, 1992, BIOCHEM BIOPH RES CO, V182, P452, DOI 10.1016/0006-291X(92)91753-D; LEE LW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P178, DOI 10.1016/0167-4838(90)90165-C; LEE WJ, 1990, BIOCHEM INT, V22, P163; LI XC, 1991, BIOCHEMISTRY-US, V30, P9709, DOI 10.1021/bi00104a020; MASON RW, 1990, BIOCHEM J, V265, P479, DOI 10.1042/bj2650479; MCGUIRE MJ, 1986, BIOCHIM BIOPHYS ACTA, V873, P2279; MELLGREN RL, 1990, INTRACELLULAR CALCIU; MURACHI T, 1989, BIOCHEM INT, V18, P263; MURAKAMI K, 1986, P NATL ACAD SCI USA, V83, P7588, DOI 10.1073/pnas.83.20.7588; NISHIMURA T, 1991, J BIOL CHEM, V266, P11842; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ORINO E, 1991, FEBS LETT, V284, P206, DOI 10.1016/0014-5793(91)80686-W; ORLOWSKI M, 1991, BIOCHEMISTRY-US, V30, P5999, DOI 10.1021/bi00238a025; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1981, BIOCHEM BIOPH RES CO, V101, P814; PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2; PONTREMOLI S, 1988, P NATL ACAD SCI USA, V85, P1740, DOI 10.1073/pnas.85.6.1740; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; RIVETT AJ, 1989, J BIOL CHEM, V264, P12215; SHIBA E, 1992, BIOCHEM BIOPH RES CO, V182, P461, DOI 10.1016/0006-291X(92)91754-E; SORIMACHI H, 1990, EUR J BIOCHEM, V193, P775, DOI 10.1111/j.1432-1033.1990.tb19399.x; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; SUZUKI K, 1990, CELL STRUCT FUNCT, V15, P1, DOI 10.1247/csf.15.1; TAKEYAMA Y, 1986, FEBS LETT, V194, P110, DOI 10.1016/0014-5793(86)80060-6; TAMURA T, 1990, FEBS LETT, V264, P91, DOI 10.1016/0014-5793(90)80773-C; TANAKA K, 1988, J BIOL CHEM, V263, P16209; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; YU B, 1991, J BIOL CHEM, V266, P17396; YUKAWA M, 1991, BIOCHEM BIOPH RES CO, V178, P256, DOI 10.1016/0006-291X(91)91807-O; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	52	337	345	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22369	22377						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429590				2022-12-25	WOS:A1992JW71900061
J	FOUCAUD, C; POOLMAN, B				FOUCAUD, C; POOLMAN, B			LACTOSE TRANSPORT-SYSTEM OF STREPTOCOCCUS-THERMOPHILUS - FUNCTIONAL RECONSTITUTION OF THE PROTEIN AND CHARACTERIZATION OF THE KINETIC MECHANISM OF TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MEMBRANE-VESICLES; MELIBIOSE CARRIER; SOLUTE TRANSPORT; TRANSLOCATION; PH; PHOSPHOLIPIDS; PERMEASE; BACTERIA; EFFLUX	The kinetic mechanism of the lactose transport system of Streptococcus thermophilus was studied in membrane vesicles fused with cytochrome c oxidase containing liposomes and in proteoliposomes in which cytochrome c oxidase was coreconstituted with the lactose transport protein. Selective manipulation of the components of the proton (and sodium) motive force indicated that both a membrane potential and a PH gradient could drive transport. The galactoside/proton stoichiometry was close to unity. Experiments which discriminate between the effects of internal pH and DELTApH as driving force on galactoside/proton symport showed that the carrier is highly activated at alkaline internal pH values, which biases the transport system kinetically toward the pH component of the proton motive force. Galactoside efflux increased with increasing pH with a pK(a) of about 8, whereas galactoside exchange (and counterflow) exhibited a pH optimum around 7 with pK(a) values of 6 and 8, respectively. Imposition of DELTApH (interior alkaline) retarded the rate of efflux at any pH value tested, whereas the rate of exchange was stimulated by an imposed DELTApH at pH 5.8, not affected at pH 7.0, and inhibited at pH 8.0 and 9.0. The results have been evaluated in terms of random and ordered association/dissociation of galactoside and proton on the inner surface of the membrane. Imposition of DELTAPSI (interior negative) decreased the rate of efflux but had no effect on the rate of exchange, indicating that the unloaded transport protein carries a net negative charge and that during exchange and counterflow the carrier recycles in the protonated form.	UNIV GRONINGEN,DEPT MICROBIOL,KERKLAAN 30,9751 NN HAREN,NETHERLANDS	University of Groningen			Poolman, Bert/D-1882-2012					BASSILANA M, 1987, J BIOL CHEM, V262, P16865; CITTI JE, 1965, J BACTERIOL, V89, P937, DOI 10.1128/JB.89.4.937-942.1965; CLEMENT NR, 1981, BIOCHEMISTRY-US, V20, P1534, DOI 10.1021/bi00509a019; DRIESSEN AJM, 1987, J BIOL CHEM, V262, P12438; DRIESSEN AJM, 1992, IN PRESS METHODS ENZ; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; ELLIKER PR, 1956, J DAIRY SCI, V39, P1611, DOI 10.3168/jds.S0022-0302(56)94896-2; GARCIA ML, 1983, BIOCHEMISTRY-US, V22, P2525; HUTKINS RW, 1991, APPL ENVIRON MICROB, V57, P941, DOI 10.1128/AEM.57.4.941-944.1991; KABACK HR, 1990, BACTERIA, V12, P151; KACZOROWSKI GJ, 1979, BIOCHEMISTRY-US, V18, P3691, DOI 10.1021/bi00584a009; KACZOROWSKI GJ, 1979, BIOCHEMISTRY-US, V18, P3697, DOI 10.1021/bi00584a010; KAGAWA Y, 1973, J BIOL CHEM, V248, P676; KONINGS WN, 1989, CRC CR REV MICROBIOL, V16, P419, DOI 10.3109/10408418909104474; LEBLANC G, 1990, ION COUPLED SUGAR TR; LOLKEMA JS, 1982, BIOCHIM BIOPHYS ACTA, V681, P85, DOI 10.1016/0005-2728(82)90281-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALONEY PC, 1973, BIOCHIM BIOPHYS ACTA, V330, P196, DOI 10.1016/0005-2736(73)90225-3; NEWMAN MJ, 1981, J BIOL CHEM, V256, P1804; OKO N, 1982, BIOCHIM BIOPHYS ACTA, V691, P332; OTTO R, 1982, J BACTERIOL, V149, P733, DOI 10.1128/JB.149.2.733-738.1982; PAGE MGP, 1987, BIOCHIM BIOPHYS ACTA, V897, P112, DOI 10.1016/0005-2736(87)90319-1; POOLMAN B, 1992, J BIOL CHEM, V267, P9150; POOLMAN B, 1989, J BACTERIOL, V171, P244, DOI 10.1128/jb.171.1.244-253.1989; POOLMAN B, 1990, J BACTERIOL, V172, P4037, DOI 10.1128/jb.172.7.4037-4047.1990; POOLMAN B, 1990, MOL MICROBIOL, V4, P1629, DOI 10.1111/j.1365-2958.1990.tb00539.x; POOLMAN B, 1987, MICROBIOL REV, V51, P498, DOI 10.1128/MMBR.51.4.498-508.1987; SHINBO T, 1978, ARCH BIOCHEM BIOPHYS, V187, P414, DOI 10.1016/0003-9861(78)90052-8; THOMAS TD, 1984, APPL ENVIRON MICROB, V48, P186, DOI 10.1128/AEM.48.1.186-191.1984; VELD GI, 1992, BIOCHIM BIOPHYS ACTA, V1104, P250; VIITANEN P, 1983, BIOCHEMISTRY-US, V22, P2531, DOI 10.1021/bi00279a034; WILSON DM, 1985, MEMBRANE BIOCHEM, V5, P269, DOI 10.3109/09687688509150282; WRIGHT JK, 1986, BIOCHIM BIOPHYS ACTA, V855, P391; YU CA, 1975, J BIOL CHEM, V250, P1383	34	64	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22087	22094						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429561				2022-12-25	WOS:A1992JW71900019
J	GUEST, PC; ARDEN, SD; BENNETT, DL; CLARK, A; RUTHERFORD, NG; HUTTON, JC				GUEST, PC; ARDEN, SD; BENNETT, DL; CLARK, A; RUTHERFORD, NG; HUTTON, JC			THE POSTTRANSLATIONAL PROCESSING AND INTRACELLULAR SORTING OF PC2 IN THE ISLETS OF LANGERHANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETORY-GRANULE; NEWLY SYNTHESIZED PROINSULIN; ISOLATED RAT ISLETS; CARBOXYPEPTIDASE-H; ENDOPLASMIC-RETICULUM; CELLS; IDENTIFICATION; BIOSYNTHESIS; PROTEINS; CONSTITUENTS	Proinsulin conversion in the insulin secretory granule is mediated by two sequence-specific endoproteases related to the Kex2 homologues, PC2 and PC3 (Bennett, D. L., Bailyes, E. M., Nielsen, E., Guest, P. C., Rutherford, N. G., Arden, S. D., and Hutton, J. C. (1992) J. Biol. Chem. 267, 15229-15236; Bailyes, E. M., Bennett, D. L., and Hutton, J. C. (1992) Enzyme, in press). Radiolabeling studies using isolated rat islets showed that PC2 was synthesized initially as a 76-kDa glycoprotein which was converted by limited proteolysis to the mature 64-66-kDa form. Conversion was initiated approximately 1 h after synthesis and proceeded via intermediates of 71, 68, and 66 kDa with a t1/2 of 140 min. Release of only the 66- and 64-66-kDa radiolabeled forms of PC2 was induced by glucose and then only at times more than 2 h following synthesis. Proinsulin conversion, by contrast, was more rapid (delay = 30 min, t1/2 = 60 min), and release commenced as soon as 1 h after synthesis with the secreted material being comprised of the precursor, intermediate, and mature forms of insulin. Ultrastructural analysis of islet beta cells showed that PC2 was concentrated in secretory granules. Subcellular fractionation combined with immunoblot analysis showed that insulinoma secretory granules contained only the mature 64-66-kDa form of PC2, whereas fractions enriched in Golgi and endoplasmic reticulum contained a mixture of the 76- and 66-kDa forms of the enzyme. These results indicate that post-translational proteolysis of PC2 is initiated before sorting into the regulated pathway of secretion and that the relative proportions of proinsulin and PC2 packaged into secretory granules will change with physiological conditions.	UNIV OXFORD,RADCLIFFE INFIRM,NUFFIELD DEPT CLIN MED,DIABET RES LABS,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary; University of Oxford	GUEST, PC (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,HILLS RD,CAMBRIDGE CB2 2QR,ENGLAND.			guest, paul/0000-0002-5030-7137	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARVAN P, 1991, J BIOL CHEM, V266, P14171; AXEN R, 1967, NATURE, V214, P1302, DOI 10.1038/2141302a0; BAILYES EM, 1992, IN PRESS ENZYME; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BARRETT AJ, 1977, LYSOZOMES LABORATORY, P9; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BOWERS GN, 1975, CLIN CHEM, V21, P1988; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREENAN SO, 1991, J BIOL CHEM, V266, P21504; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BRETZ R, 1977, EUR J BIOCHEM, V77, P181, DOI 10.1111/j.1432-1033.1977.tb11656.x; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; DAVIDSON HW, 1987, BIOCHEM J, V245, P575, DOI 10.1042/bj2450575; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DAVIDSON HW, 1982, ANN REV PHYSL, V44, P625; GOLD G, 1984, DIABETES, V33, P556, DOI 10.2337/diabetes.33.6.556; GRAY IP, 1987, DIABETES, V36, P684, DOI 10.2337/diabetes.36.6.684; GUEST PC, 1989, BIOCHEM J, V257, P431, DOI 10.1042/bj2570431; GUEST PC, 1989, BIOCHEM J, V264, P503, DOI 10.1042/bj2640503; GUEST PC, 1991, ENDOCRINOLOGY, V129, P734, DOI 10.1210/endo-129-2-734; HEATON DA, 1991, BRIT MED J, V129, P3053; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; HUTTON JC, 1987, BIOCHEM J, V244, P449, DOI 10.1042/bj2440449; HUTTON JC, 1982, BIOCHEM J, V204, P171, DOI 10.1042/bj2040171; HUTTON JC, 1983, BIOCHEM J, V210, P297, DOI 10.1042/bj2100297; HUTTON JC, 1982, DIABETOLOGIA, V23, P365; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KIRCHMAIR R, 1992, FEBS LETT, V297, P302, DOI 10.1016/0014-5793(92)80560-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG I, 1991, PEPTIDE BIOSYTHESIS, P00141; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; MOLLOY SS, 1992, IN PRESS P NATL ACAD; NAGAMATSU S, 1987, ENDOCRINOLOGY, V120, P1225, DOI 10.1210/endo-120-4-1225; ORCI L, 1985, CELL, V42, P671, DOI 10.1016/0092-8674(85)90124-2; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; SANDO H, 1972, J CLIN INVEST, V51, P1476, DOI 10.1172/JCI106944; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMITH LF, 1966, AM J MED, V40, P662, DOI 10.1016/0002-9343(66)90145-8; SOPWITH AM, 1981, DIABETOLOGIA, V21, P224; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; THOMAS G, 1988, ANNU REV PHYSIOL, V50, P323; WARD WK, 1987, DIABETOLOGIA, V30, P698, DOI 10.1007/BF00296991	49	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22401	22406						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429592				2022-12-25	WOS:A1992JW71900065
J	LOKESHWAR, VB; BOURGUIGNON, LYW				LOKESHWAR, VB; BOURGUIGNON, LYW			THE LYMPHOMA TRANSMEMBRANE GLYCOPROTEIN GP85 (CD44) IS A NOVEL GUANINE NUCLEOTIDE-BINDING PROTEIN WHICH REGULATES GP85 (CD44)-ANKYRIN INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; CELL-SURFACE GLYCOPROTEINS; GTP-BINDING; MONOCLONAL-ANTIBODIES; PERTUSSIS TOXIN; HOMING RECEPTOR; PLASMA-MEMBRANE; ALPHA-SUBUNITS; EXPRESSION; ANKYRIN	In this study, we have used photoaffinity labeling by [P-32]azido-GTP as well as [P-32]ADP-ribosylation by pertussis toxin (PT) and cholera toxin (CT) to identify GTP-binding proteins associated with mouse T-lymphoma plasma membranes. Our results indicate that GP85 (CD44) can be photoaffinity labeled by [P-32] azido-GTP and [P-32]ADP-ribosylated by both PT and CT. Using purified GP85 (CD44) obtained by Triton X-100 extraction, wheat germ agglutinin-Sepharose, and anti-GP85 (CD44) antibody affinity chromatographies, we have further characterized GP85 (CD44) as a GTP-binding protein. GP85 (CD44) is found to bind guanosine 5'-3-O-(thio)triphosphate (GTPgammaS) in a time- and dose-dependent manner with a dissociation constant of 0.83 nM. Importantly, GP85 (CD44) appears to display a GTPase activity which hydrolyzes [gamma-P-32]GTP at a rate of 0.011 mol of P(i) released/mol of GP85 (CD44)/min. This GTPase activity can be readily inhibited by PT- or CT-mediated ribosylation of GP85 (CD44). Most interestingly, GTP binding significantly enhances the interaction of purified GP85 (CD44) with ankyrin, whereas ADP-ribosylation of GP85 (CD44) by PT or CT inhibits the GTP-induced increase in ankyrin binding to GP85 (CD44). In addition to GP85 (CD44) being the first reported transmembrane GTP-binding protein, these results suggest that GTP plays an important role in promoting the interaction between GP85 (CD44) and its underlying membrane cytoskeleton through ankyrin.	UNIV MIAMI, SCH MED, DEPT CELL BIOL & ANAT, MIAMI, FL 33101 USA	University of Miami					NIGMS NIH HHS [GM 36353] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036353] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT V, 1980, J BIOL CHEM, V255, P2540; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BERG EL, 1989, IMMUNOL REV, V108, P5, DOI 10.1111/j.1600-065X.1989.tb00010.x; BIRNBAUMER L, 1991, BIOL REPROD, V44, P207, DOI 10.1095/biolreprod44.2.207; BOURGUIGNON LYW, 1990, J IMMUNOL, V144, P2242; BOURGUIGNON LYW, 1986, J CELL BIOL, V102, P2115, DOI 10.1083/jcb.102.6.2115; BOURGUIGNON LYW, 1991, J BIOL CHEM, V266, P11761; BOURGUIGNON LYW, 1992, MOL CELL BIOL, V12, P4464, DOI 10.1128/MCB.12.10.4464; BOURGUIGNON LYW, 1985, J CELL BIOL, V101, P477, DOI 10.1083/jcb.101.2.477; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDD RC, 1987, J IMMUNOL, V138, P3120; CANTIELLO HF, 1989, J BIOL CHEM, V264, P20867; CARTER WG, 1988, J BIOL CHEM, V263, P4193; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; ERDOS JJ, 1981, ADV CYCL NUCL RES<D>, V14, P69; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HARDEN TK, 1989, INOSITOL LIPIDS CELL, P113; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HUET S, 1989, J IMMUNOL, V143, P798; HUGHES EN, 1983, J BIOL CHEM, V258, P1014; KABCENELL AK, 1990, J BIOL CHEM, V265, P9366; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; KALOMIRIS EL, 1988, J CELL BIOL, V106, P319, DOI 10.1083/jcb.106.2.319; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LESLEY J, 1985, IMMUNOGENETICS, V22, P149, DOI 10.1007/BF00563512; LESLEY J, 1990, EXP CELL RES, V187, P224, DOI 10.1016/0014-4827(90)90085-O; LOCHRIE MA, 1988, BIOCHEMISTRY-US, V27, P4957, DOI 10.1021/bi00414a001; LOKESHWAR VB, 1991, J BIOL CHEM, V266, P17983; LOWRY DR, 1989, NATURE, V341, P384; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; ONEILL LAJ, 1990, J BIOL CHEM, V265, P3146; PANG IH, 1990, J BIOL CHEM, V265, P18707; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; RODBELL M, 1971, J BIOL CHEM, V246, P1877; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMITT HD, 1989, J CELL BIOL, V109, P2677; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STJOHN T, 1990, CELL, V60, P45, DOI 10.1016/0092-8674(90)90714-P; STYRE L, 1986, REV CELL BIOL, V2, P391; SUNYER T, 1989, MOL ENDOCRINOL, V3, P1115, DOI 10.1210/mend-3-7-1115; TAYLOR CW, 1990, BIOCHEM J, V272, P1; THOMPSON RC, 1988, TRENDS BIOCHEM SCI, V13, P91, DOI 10.1016/0968-0004(88)90047-3; TROWBRIDGE IS, 1985, NATURE, V315, P666, DOI 10.1038/315666a0; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; WOLFFE EJ, 1990, J BIOL CHEM, V265, P341; YATANI A, 1987, SCIENCE, V235, P207, DOI 10.1126/science.2432660; ZHOU DFH, 1989, J IMMUNOL, V143, P3390	61	92	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22073	22078						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429559				2022-12-25	WOS:A1992JW71900017
J	MORII, N; TERUUCHI, T; TOMINAGA, T; KUMAGAI, N; KOZAKI, S; USHIKUBI, F; NARUMIYA, S				MORII, N; TERUUCHI, T; TOMINAGA, T; KUMAGAI, N; KOZAKI, S; USHIKUBI, F; NARUMIYA, S			A RHO GENE-PRODUCT IN HUMAN BLOOD-PLATELETS .2. EFFECTS OF THE ADP-RIBOSYLATION BY BOTULINUM C3 ADP-RIBOSYLTRANSFERASE ON PLATELET-AGGREGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSTRIDIUM-BOTULINUM; GPIIB-IIIA; G-PROTEIN; IDENTIFICATION; CELLS; RAS; PURIFICATION; SUBSTRATE; BINDING; TOXIN	In the accompanying paper (Nemoto, Y., Namba, T., Teru-uchi, T., Ushikubi, F., Morii, N., and Narumiya, S. (1992) J. Biol. Chem. 267,20916-20920), we have identified rhoA protein as the sole substrate protein for botulinum C3 ADP-ribosyltransferase (C3 exoenzyme) in human blood platelets. Here we examined the role of rhoA protein in platelet functions. C3 exoenzyme added to washed platelets dose- and time-dependently ADP-ribosylated rhoA protein in situ in the cells. Concomitant with this modification, inhibition of thrombin-induced platelet aggregation was observed. This inhibition was not reversed by washing the treated platelets, but was not found when C3 exoenzyme was pretreated with mouse monoclonal anti-C3 exoenzyme antibody. C3 exoenzyme treatment did not affect thrombin-induced inositol 1,4,5-trisphosphate production. Secretion of preloaded [C-14]serotonin was delayed by the enzyme treatment, but the extent of the secretion was not influenced. In addition, the enzyme treatment did not change the expression of the glycoprotein IIb-IIIa complex on the platelet surface. The enzyme treatment also suppressed platelet aggregation induced by phorbol myristate acetate. These results suggest that rhoA protein plays a role mainly in the aggregation process downstream from receptor-phospholipase C coupling. This, together with the previous finding that rhoA protein modulates stress fiber formation in cultured fibroblasts (Paterson, H. F., Self, A. J., Garrett, M. D., Just, I., Aktories, K., and Hall, A. (1990) J. Cell Biol. 1111, 1001-1007), suggests that rhoA protein regulates the assembly of actin filaments and the avidity of the platelet integrin (glycoprotein IIb-IIIa) in the aggregation process.	UNIV OSAKA PREFECTURE, COLL AGR, DEPT VET SCI, SAKAI, OSAKA 591, JAPAN	Osaka Metropolitan University	MORII, N (corresponding author), KYOTO UNIV, FAC MED, DEPT PHARMACOL, SAKYO KU, KYOTO 606, JAPAN.							AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CARROLL RC, 1982, CELL, V30, P385, DOI 10.1016/0092-8674(82)90236-7; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MORII N, 1991, J BIOL CHEM, V266, P7646; MORII N, 1990, J BIOCHEM-TOKYO, V107, P769, DOI 10.1093/oxfordjournals.jbchem.a123123; MORII N, 1988, J BIOL CHEM, V263, P12420; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; NEMOTO Y, 1992, J BIOL CHEM, V267, P20916; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; PACKHAM MA, 1984, THROMB HAEMOSTASIS, V51, P140; PAINTER RG, 1984, EXP CELL RES, V155, P198, DOI 10.1016/0014-4827(84)90781-X; PAINTER RG, 1985, J CELL BIOL, V100, P652, DOI 10.1083/jcb.100.2.652; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PHILLIPS DR, 1977, J CLIN INVEST, V60, P535, DOI 10.1172/JCI108805; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SEKINE A, 1989, J BIOL CHEM, V264, P8602; WEISS HJ, 1974, J CLIN INVEST, V54, P421, DOI 10.1172/JCI107778; WHITE JG, 1990, PLATELET 1990 PLATEL, P1	30	157	161	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20921	20926						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400407				2022-12-25	WOS:A1992JT97800065
J	SINDELAR, P; CHOJNACKI, T; VALTERSSON, C				SINDELAR, P; CHOJNACKI, T; VALTERSSON, C			PHOSPHATIDYLETHANOLAMINE DOLICHOL ACYLTRANSFERASE - CHARACTERIZATION AND PARTIAL-PURIFICATION OF A NOVEL RAT-LIVER ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-TISSUES; RETINOL ESTERIFICATION; PLASMA-MEMBRANES; PHOSPHATE; LOCALIZATION; LIPOPROTEIN; MICROSOMES; ESTERS; POLYPRENOLS; HYDROLYSIS	Incubation of rat or human post-heparin plasma with [H-3]dolichol incorporated in liposomes consisting of dioleoyl phosphatidylcholine:dioleoyl phosphatidylethanolamine (3:1) resulted in the formation of radioactive dolichyl oleate. Non-heparinized plasma did not esterify dolichol, and, hence, the enzyme involved is probably associated with the cell surface and released into the blood by heparin. The major location of this activity was the liver, and, therefore, a partial purification of the enzyme from heparinized rat liver perfusates was performed using DEAE-Sephacel and heparin-Sepharose chromatography. The dolichol acyltransferase activity copurified with hepatic lipase activity in a lipid-protein complex of 350 kDa. Optimal acylation is achieved at pH 7.5 in the presence of 5% plasma and 20 mM Ca2+. Esterification can only be obtained when dolichol is present in a phospholipid bilayer, and the reaction is strongly stimulated by unsaturated phosphatidylethanolamine or phosphatidylserine. Radiolabeling experiments demonstrated that the primary acyl donor is phosphatidylethanolamine from which the fatty acid is transferred exclusively from position 1. Neither cholesterol nor retinol are esterified by the enzyme, and the reaction is not stimulated by acyl-CoA. Both the extracellular localization and the mechanism of transacylation clearly distinguish this new enzyme from the acyl-CoA:dolichol acyltransferase described earlier in microsomes.	KAROLINSKA INST,HUDDINGE HOSP,CTR CLIN RES,S-14186 HUDDINGE,SWEDEN; UNIV STOCKHOLM,INST BIOCHEM,S-10691 STOCKHOLM,SWEDEN; POLISH ACAD SCI,INST BIOCHEM & BIOPHYS,PL-02532 WARSAW,POLAND	Karolinska Institutet; Stockholm University; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences								BENGTSSON G, 1980, BIOCHEM J, V189, P625, DOI 10.1042/bj1890625; Brown M S, 1979, Harvey Lect, V73, P163; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; CHOJNACKI T, 1975, ANAL BIOCHEM, V69, P114, DOI 10.1016/0003-2697(75)90572-2; Dallner G, 1974, Methods Enzymol, V31, P191; DEROPP JS, 1985, J BIOL CHEM, V260, P5669; EGGENS I, 1983, BIOCHIM BIOPHYS ACTA, V751, P355, DOI 10.1016/0005-2760(83)90294-1; Ehnholm C, 1986, Methods Enzymol, V129, P716; ELMBERGER PG, 1987, EUR J BIOCHEM, V168, P1, DOI 10.1111/j.1432-1033.1987.tb13379.x; ELMBERGER PG, 1988, J LIPID RES, V29, P1651; Fiske CH, 1925, J BIOL CHEM, V66, P375; GOLDSTEIN JL, 1976, CELL, V7, P85, DOI 10.1016/0092-8674(76)90258-0; HEMMING FW, 1983, BIOSYNTHESIS ISOPREN, V2, P305; IBATA K, 1983, BIOCHEM J, V213, P305, DOI 10.1042/bj2130305; ISHINAGA M, 1990, AGR BIOL CHEM TOKYO, V54, P943, DOI 10.1080/00021369.1990.10870053; KALEN A, 1990, LIPIDS, V25, P93, DOI 10.1007/BF02562211; KEENAN RW, 1982, BIOCHIM BIOPHYS ACTA, V711, P490, DOI 10.1016/0005-2760(82)90063-7; KEENAN RW, 1976, BIOCHEMISTRY-US, V15, P1586, DOI 10.1021/bi00652a032; KUUSI T, 1979, BIOCHEM J, V181, P245, DOI 10.1042/bj1810245; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI CS, 1984, FEBS LETT, V169, P279, DOI 10.1016/0014-5793(84)80333-6; LANDS WEM, 1963, J BIOL CHEM, V238, P898; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALVAR TM, 1985, ARCH BIOCHEM BIOPHYS, V238, P401, DOI 10.1016/0003-9861(85)90180-8; MANKOWSKI T, 1976, BIOCHEMISTRY-US, V15, P2125, DOI 10.1021/bi00655a015; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; ONG DE, 1988, J BIOL CHEM, V263, P5787; RAPPORT MM, 1957, J NEUROCHEM, V1, P303, DOI 10.1111/j.1471-4159.1957.tb12086.x; RIP JW, 1988, BIOCHIM BIOPHYS ACTA, V959, P58, DOI 10.1016/0005-2760(88)90149-X; RIP JW, 1981, J BIOL CHEM, V256, P1929; ROSS AC, 1982, J BIOL CHEM, V257, P2453; ROSS AC, 1982, J LIPID RES, V23, P133; RUPAR CA, 1982, J BIOL CHEM, V257, P3090; RUPAR CA, 1978, LIPIDS, V13, P291, DOI 10.1007/BF02533673; SCHER MG, 1981, BIOCHEM BIOPH RES CO, V99, P675, DOI 10.1016/0006-291X(81)91797-6; SIGGIA S, 1948, ANAL CHEM, V20, P762, DOI 10.1021/ac60020a026; STRUCK DK, 1980, BIOCH GLYCOPROTEINS, P35; TOLLBOM O, 1988, J BIOL CHEM, V263, P1347; TOLLBOM O, 1989, J BIOL CHEM, V264, P9836; TOLLBOM O, 1986, BRIT J EXP PATHOL, V67, P757; VALTERSSON C, 1985, J BIOL CHEM, V260, P2742; VANDUIJN G, 1986, BIOCHIM BIOPHYS ACTA, V861, P211; WAITE M, 1973, J BIOL CHEM, V248, P7985; WEINSTEIN JN, 1986, METHOD ENZYMOL, V128, P657; WONG TK, 1982, J BIOL CHEM, V257, P6619	45	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20594	20599						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400381				2022-12-25	WOS:A1992JT97800017
J	TERADA, N; OR, R; WEINBERG, K; DOMENICO, J; LUCAS, JJ; GELFAND, EW				TERADA, N; OR, R; WEINBERG, K; DOMENICO, J; LUCAS, JJ; GELFAND, EW			TRANSCRIPTION OF IL-2 AND IL-4 GENES IS NOT INHIBITED BY CYCLOSPORINE-A IN COMPETENT T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-2; CALCIUM IONOPHORES; PHORBOL ESTERS; LYMPHOCYTES-T; EXPRESSION; PROGRESSION; ACTIVATION; RECEPTOR; BINDING; SIGNALS	Cyclosporin A (CsA) inhibits T-cell proliferation primarily by blocking the transcription of several early activation genes, especially those of the important T-cell growth factors IL-2 and IL-4. This effect seems to be mediated through inhibition of the activity of the transcription factor NF-AT which is essential for IL-2 and probably for IL-4 gene transcription. However, once T cells are rendered "competent" to proliferate following a brief exposure to the phorbol ester, phorbol 12,13-dibutyrate (PDBu), and the calcium ionophore, ionomycin, CsA no longer inhibits cell cycle progression supported by the presence of PDBu alone. Here it is shown that transcription of the IL-2 and IL-4 genes occurs normally throughout this "progression" phase, even in the presence of CsA. However, further production of functional NF-AT, which began during the competence phase of the cell cycle, is inhibited. These data indicate that, although the primary initiation of transcription of IL2 and IL-4 mRNA during induction of competence may be NF-AT-dependent and CsA-sensitive, the augmentation in the progression phase is both NF-AT-independent and CsA-resistant.	CHILDRENS HOSP,DIV RES IMMUNOL,LOS ANGELES,CA 90027	Children's Hospital Los Angeles	TERADA, N (corresponding author), RAYMOND & BEVERLY SACKLER FDN,NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DIV BASIC SCI,DENVER,CO 80224, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026490, R29AI025071, R01AI029704] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-29704, AI-25071, AI-26490] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARAI N, 1989, J IMMUNOL, V142, P274; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN M, 1988, J IMMUNOL, V131, P504; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FUJITA T, 1983, P NATL ACAD SCI-BIOL, V80, P7437, DOI 10.1073/pnas.80.24.7437; GELFAND EW, 1984, J CELL PHYSIOL, V121, P533, DOI 10.1002/jcp.1041210312; KUMAGAI N, 1988, J IMMUNOL, V141, P3747; KUMAGAI N, 1988, J CELL PHYSIOL, V137, P329, DOI 10.1002/jcp.1041370217; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; OATES JA, 1989, NEW ENGL J MED, V321, P1725; OR R, 1992, CLIN IMMUNOL IMMUNOP, V64; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; RENZ H, 1991, J IMMUNOL, V146, P3049; TANIGUCHI T, 1983, NATURE, V302, P305, DOI 10.1038/302305a0; TERADA N, 1990, BLOOD, V75, P453; TERADA N, 1991, J IMMUNOL, V147, P698; TORDAI A, 1992, BIOCHEM BIOPH RES CO, V185, P363, DOI 10.1016/S0006-291X(05)80994-5; WEINBERG K, 1990, NEW ENGL J MED, V322, P1718, DOI 10.1056/NEJM199006143222406	20	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21207	21210						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400432				2022-12-25	WOS:A1992JT97800107
J	BALBONA, K; TRAN, H; GODYNA, S; INGHAM, KC; STRICKLAND, DK; ARGRAVES, WS				BALBONA, K; TRAN, H; GODYNA, S; INGHAM, KC; STRICKLAND, DK; ARGRAVES, WS			FIBULIN BINDS TO ITSELF AND TO THE CARBOXYL-TERMINAL HEPARIN-BINDING REGION OF FIBRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA FIBRONECTIN; EXTRACELLULAR-MATRIX; PROTEIN; DOMAINS; GLYCOPROTEIN; COMPONENT; SITE; C1Q	Fibulin is a recently described extracellular matrix (ECM) and plasma glycoprotein (Argraves, W. S., Tran, H., Burgess, W. H., and Dickerson, K. (1990) J. Cell Biol. 111, 3155-3164). In this report, ligand affinity chromatography and solid-phase binding analyses were performed to determine which ECM protein(s) interact with fibulin. Fibulin-Sepharose bound two polypeptides of 240 and 100 kDa from the culture medium of metabolically radiolabeled fibroblasts. These two proteins were identified as fibronectin (FN) and fibulin, respectively, based on their electrophoretic behavior and reactivity with monoclonal antibodies. Consistent with the findings of affinity chromatography, fibulin bound to surfaces coated with FN (either plasma or cellular form) or fibulin but not with other ECM proteins, such as laminin, merosin, and types I and IV collagen. The binding of fibulin to solid-phase FN was estimated to have a K(d) of 139 nM, whereas the K(d) for self-interaction was 322 nM. Evaluation of proteolytic fragments from all regions of FN allowed a fibulin-binding site to be localized within a 23-kDa heparin-binding fragment containing type III repeats 13-14. Heparin did not compete for the interaction between fibulin and FN, suggesting that the binding sites for fibulin and heparin are distinct.	AMER RED CROSS,BIOCHEM LAB,ROCKVILLE,MD 20855	American Red Cross					NIGMS NIH HHS [GM-42912] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042912] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; ARGRAVES WS, 1989, CELL, V58, P623, DOI 10.1016/0092-8674(89)90097-4; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; BORSI L, 1986, ANAL BIOCHEM, V155, P335, DOI 10.1016/0003-2697(86)90443-4; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; DEBEER FC, 1981, J EXP MED, V154, P1134, DOI 10.1084/jem.154.4.1134; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; HYNES RO, 1989, SPRINGER SERIES MOL, P39; INGHAM KC, 1983, MOL IMMUNOL, V20, P287, DOI 10.1016/0161-5890(83)90068-8; INGHAM KC, 1990, BIOCHEM J, V272, P605, DOI 10.1042/bj2720605; INGHAM KC, 1985, EUR J BIOCHEM, V148, P219, DOI 10.1111/j.1432-1033.1985.tb08828.x; ISEMURA M, 1987, J BIOL CHEM, V262, P8926; KIMIZUKA F, 1991, J BIOCHEM-TOKYO, V110, P284, DOI 10.1093/oxfordjournals.jbchem.a123572; KLUGE M, 1990, EUR J BIOCHEM, V193, P651, DOI 10.1111/j.1432-1033.1990.tb19383.x; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANN DM, 1990, J BIOL CHEM, V265, P5317; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; MOSESSON MW, 1975, BIOCHIM BIOPHYS ACTA, V386, P509, DOI 10.1016/0005-2795(75)90294-9; Mosher D F, 1980, Prog Hemost Thromb, V5, P111; SALONEN EM, 1985, J BIOL CHEM, V260, P2302; SALONEN EM, 1984, J BIOL CHEM, V259, P1496; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; SPENCE SG, 1992, DEV BIOL, V151, P473, DOI 10.1016/0012-1606(92)90186-K	24	97	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20120	20125						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400330				2022-12-25	WOS:A1992JR85800060
J	CHANDRASEKARAN, EV; JAIN, RK; MATTA, KL				CHANDRASEKARAN, EV; JAIN, RK; MATTA, KL			MUCIN BIOSYNTHESIS REVISITED - THE ENZYMATIC TRANSFER OF GAL IN BETA-1,3 LINKAGE TO THE GALNAC MOIETY OF THE CORE STRUCTURE R(1)-GLCNAC-BETA-1,6GALNAC-ALPHA-O-R(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOSACCHARIDES; GLYCOPROTEINS; TRACHEA	Synthetic glycosides containing the core, -GlcNAcbeta1,6GalNAcalpha-, acted as acceptors for beta-galactosyltransferase of human ovarian tumor. A significant amount of Gal was transferred from UDP-Gal (100 nmol) to the alpha-benzylglycoside of LacNAcbeta1,6GalNAc (LGBn) (25.1 nmol of Gal) and the alpha-ortho-nitrophenylglycosides of LacNAcbeta1,6GalNAc (22.0 nmol of Gal), GlcNAcbeta1,6GalNAc (15.5 nmol of Gal), and Fucalpha1,3GlcNAcbeta1,6GalNAc (25.9 nmol of Gal); LacNAcbeta1,6(Galbeta1,3)GalNAcalpha-O-Bn (where Bn is benzyl) was almost inactive (only 1.2 nmol of Gal), indicating the Gal transfer to the alpha-GalNAc moiety. The product from LGBn was isolated in microgram quantities and identified by fast atom bombardment mass spectrometry as LacNAcbeta1,6(Galbeta1,3)GalNAcalpha-O-Bn. The alphaGalNAc:beta1,3Gal transferase was present in high concentration in ovarian tumor tissue (ovarian cancer serum --> 1.4; ascitic fluid --> 0.9; tumor --> 17.4). Asialo Cowper's gland mucin (ACGM) at 5 mg/ml reaction mixture inhibited the transfer of Gal to LGBn (25.2 and 53.4% respectively for 2 and 18 h incubation at 37-degrees-C); inhibition by LGBn was 13.4 and 24.5%, respectively. In contrast to the inhibition by ACGM (25.2-31.6%), there was substantial increase (13.4-35. 7%) in the inhibition by LGBn, when the incubation for 2 h at 37-degrees-C was continued for 40 h at 4-degrees-C, indicating the high affinity of LGBn for the enzyme at lower temp. K(m) for LGBn in presence of ACGM was 7.6 mM and in absence, 2.7 mm; K(m) for ACGM (M(r) 200,000) in presence of LGBn was 16.1 muM and K(i) for ACGM (as the inhibitor) was 41.7 muM. In comparison with two normal ovarian tissues, the enzyme was found to be low (55-67%) in three ovarian tumors and high (146-260%) in two ovarian and one uterus tumors, as measured with ACGM; the synthetic acceptors showed similar activities. The enzyme had nearly the same extent of activity in the pH range 6-8. Fucalpha1,3GlcNAcbeta1,6GalNAcalpha-O-ONP had the highest affinity for the enzyme. The present study demonstrates the feasibility of beta1,3Gal attachment on alphaGalNAc, which has already been substituted by beta1,6GlcNAc, then elongated by beta1,4Gal and also terminated by alpha1,3Fuc.			CHANDRASEKARAN, EV (corresponding author), ROSWELL PK CANC INST,DEPT GYNECOL ONCOL,BUFFALO,NY 14263, USA.				NATIONAL CANCER INSTITUTE [R01CA035329] Funding Source: NIH RePORTER; NCI NIH HHS [CA35329] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIGAD G, 1962, J BIOL CHEM, V237, P2736; BROCKHAUSEN I, 1985, BIOCHEMISTRY-US, V24, P1866, DOI 10.1021/bi00329a010; BROCKHAUSEN I, 1992, BIOCHEM CELL BIOL, V70, P99, DOI 10.1139/o92-015; HANISCH FG, 1986, EUR J BIOCHEM, V155, P239, DOI 10.1111/j.1432-1033.1986.tb09482.x; HOUNSELL EF, 1985, EUR J BIOCHEM, V148, P367, DOI 10.1111/j.1432-1033.1985.tb08848.x; JAIN RK, 1992, CARBOHYD RES, V288, P243; JOURDIAN GW, 1971, J BIOL CHEM, V246, P430; LUDOWIEG.JJ, 1968, CARBOHYD RES, V8, P185, DOI 10.1016/S0008-6215(00)80154-8; MENDICINO J, 1982, J BIOL CHEM, V257, P3987; SHEARES BT, 1983, J BIOL CHEM, V258, P9893; VANHALBEEK H, 1985, FEBS LETT, V187, P81, DOI 10.1016/0014-5793(85)81219-9; WILLIAMS D, 1980, J BIOL CHEM, V255, P1253; YAZAWA S, 1990, ANAL BIOCHEM, V187, P374, DOI 10.1016/0003-2697(90)90472-L; YAZAWA S, 1986, CARBOHYD RES, V149, P241, DOI 10.1016/S0008-6215(00)90381-1	14	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19929	19937						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400309				2022-12-25	WOS:A1992JR85800032
J	LEE, TC; UEMURA, Y; SNYDER, F				LEE, TC; UEMURA, Y; SNYDER, F			A NOVEL COA-INDEPENDENT TRANSACETYLASE PRODUCES THE ETHANOLAMINE PLASMALOGEN AND ACYL ANALOGS OF PLATELET-ACTIVATING-FACTOR (PAF) WITH PAF AS THE ACETATE DONOR IN HL-60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; VASCULAR ENDOTHELIAL-CELLS; HUMAN NEUTROPHILS; LIPID EXTRACT; BOVINE BRAIN; RAT SPLEEN; ACETYLTRANSFERASE; BIOSYNTHESIS; MICROSOMES; 1-ALKYL-2-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE	In this study, we demonstrate the presence of unique membrane-associated transacetylase that transfers the acetate group from platelet-activating factor (PAF) to lysoplasmalogen (in the presence of EDTA and sodium acetate) with the formation of 1-alk-1-enyl-2-acetyl-sn-glycero-3-phosphoethanolamine (alk-1-enylacetyl-GPE). The identity of alk-1-enylacetyl-GPE was confirmed by acid hydrolysis, phospholipases A2 or C treatment and derivatization by fluorodinitrobenzene. The transacetylase has no requirement for Ca2+, Mg2+, or CoA and a broad pH optimum (7.0-8.0) with K(m) values of 12.0 muM for PAF and 106.4 muM for lysoplasmalogens. The enzyme activity from the isolated membrane fraction is not change when whole cells are supplemented with 20:4, induce to differentiate into granulocytes, or treated with ionophore A23187. Radyllyso-sn-glycero-3-phosphocholine (GPC), radyllyso-GPE, acyllyso-sn-glycero-3-phosphoserine (GPS), acyllyso-sn-glycero-3-phosphoinositol (GPI), alkyllyso-sn-glycero-3-phosphate (GP), acyllyso-GP, or cis-9-octadecen-1-ol can also serve as acetate acceptors, whereas alkylglycerol, acylglycerol, or cholesterol are inactive. Differences in substrate acceptor specificity, sensitivity toward phenylmethylsulfonyl fluoride, and response to temperature suggest that the CoA-independent transacetylase and the CoA-independent transacylase that transfers long-chain acyl moieties are two separate enzymes. With intact differentiated HL-60 cells, [H-3]acetate from [H-3]PAF can be incorporated into alk-1-enylacetyl-GPE in the presence of ionophore A23187, but not in its absence. Moreover, phospholipase A2 inhibitors (p-bromophenacyl bromide and mepacrine) block the transacetylation process in whole cell system. These results indicate the production of alk-1-enyllyso-GPE is a rate-limiting factor for the subsequent transacetylation step during cell activation. We conclude that the transacetylase may participate in the biosynthesis of ethanolamine plasmalogen and acyl analogs of PAF, in vivo, fine-tuning of PAF biological responses, and cross-talk between de novo and remodeling pathways of PAF biosynthesis.			LEE, TC (corresponding author), OAK RIDGE ASSOCIATED UNIV,DIV MED SCI,OAK RIDGE,TN 37831, USA.				NHLBI NIH HHS [HL35495-05A1, HL27109-11A1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL027109, R01HL035495] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BILLAH MM, 1986, J BIOL CHEM, V261, P5824; BLANK ML, 1981, J BIOL CHEM, V256, P175; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRAQUET P, 1987, PHARMACOL REV, V39, P97; CHILTON FH, 1984, J BIOL CHEM, V259, P2014; CHILTON FH, 1988, J BIOL CHEM, V263, P5260; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; GARCIA MC, 1991, BIOCHIM BIOPHYS ACTA, V1083, P37, DOI 10.1016/0005-2760(91)90122-X; GOMEZCAMBRONERO J, 1985, BIOCHIM BIOPHYS ACTA, V845, P511, DOI 10.1016/0167-4889(85)90218-6; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; LEE TC, 1985, J BIOL CHEM, V260, P952; LEE TC, 1988, J BIOL CHEM, V263, P1755; LEE TC, 1986, J BIOL CHEM, V261, P5373; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD JIS, 1991, BIOCHIM BIOPHYS ACTA, V1084, P105, DOI 10.1016/0005-2760(91)90209-Z; MAVIS RD, 1972, J BIOL CHEM, V247, P2835; MENCIAHUERTA JM, 1983, J IMMUNOL, V131, P2958; MUELLER HW, 1991, BIOCHEM BIOPH RES CO, V176, P1557, DOI 10.1016/0006-291X(91)90465-J; NEILANDS JB, 1955, OUTLINES ENZYME CHEM; NIETO ML, 1991, J BIOL CHEM, V266, P18699; NINIO E, 1982, BIOCHIM BIOPHYS ACTA, V710, P23, DOI 10.1016/0005-2760(82)90185-0; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; QIAN CG, 1989, J LIPID MEDIATOR, V1, P113; RENKONEN O, 1968, J LIPID RES, V9, P34; RENOOIJ W, 1981, BIOCHIM BIOPHYS ACTA, V663, P545, DOI 10.1016/0005-2760(81)90182-X; SATOUCHI K, 1987, LIPIDS, V22, P285, DOI 10.1007/BF02533994; SNYDER F, 1990, AM J PHYSIOL, V259, pC697, DOI 10.1152/ajpcell.1990.259.5.C697; SNYDER F, 1992, PROG LIPID RES, V31, P65, DOI 10.1016/0163-7827(92)90016-C; SUGIURA T, 1987, J BIOL CHEM, V262, P1199; SUGIURA T, 1990, BIOCHIM BIOPHYS ACTA, V1047, P223, DOI 10.1016/0005-2760(90)90520-8; TESSNER TG, 1987, J BIOL CHEM, V262, P12660; TESSNER TG, 1990, J BIOL CHEM, V265, P21032; TOKUMURA A, 1987, BIOCHEM BIOPH RES CO, V145, P415, DOI 10.1016/0006-291X(87)91338-6; TOKUMURA A, 1989, J LIPID RES, V30, P219; TRIGGIANI M, 1991, J IMMUNOL, V147, P660; UEMURA Y, 1991, J BIOL CHEM, V266, P8268; VENABLE ME, 1991, J BIOL CHEM, V266, P18691; WHATLEY RE, 1992, PROSTAGLANDINS, V43, P21, DOI 10.1016/0090-6980(92)90061-W; WINKLER JD, 1991, BIOCHIM BIOPHYS ACTA, V1081, P3239; WOODARD DS, 1987, J BIOL CHEM, V262, P2520; WYKLE RL, 1980, J BIOL CHEM, V255, P256; YASUDA K, 1988, BIOMED ENVIRON MASS, V16, P137, DOI 10.1002/bms.1200160124	42	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19992	20001						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400315				2022-12-25	WOS:A1992JR85800041
J	MAO, XH; GREEN, JM; SAFER, B; LINDSTEN, T; FREDERICKSON, RM; MIYAMOTO, S; SONENBERG, N; THOMPSON, CB				MAO, XH; GREEN, JM; SAFER, B; LINDSTEN, T; FREDERICKSON, RM; MIYAMOTO, S; SONENBERG, N; THOMPSON, CB			REGULATION OF TRANSLATION INITIATION-FACTOR GENE-EXPRESSION DURING HUMAN T-CELL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INITIATION; CAP-BINDING-PROTEIN; MESSENGER-RNA; HELA-CELLS; STIMULATES PHOSPHORYLATION; FACTORS EIF-4F; LYMPHOCYTES-T; GROWTH-FACTOR; CLONING; INHIBITION	Activation of quiescent T cells leads to a dramatic increase in the rate of protein synthesis. It is believed that this pronounced increase of protein synthesis is regulated primarily at the level of translational initiation. Although considerable evidence demonstrates that translational initiation can be regulated at the post-translational level by the phosphorylation/dephosphorylation of translation initiation factors (eIFs) such as eIF-4E and eIF-2alpha, additional mechanisms of eIF gene expression may also play a role in the regulation of translation in quiescent cells and/or during their subsequent induction to enter the cell cycle. To address this issue, gene expression of eIF-2alpha, -4E, and -4A was studied in quiescent human peripheral blood T cells following stimulation through the T cell receptor-CD3 complex. Quiescent T cells expressed low levels of eIF-2alpha, -4E, and -4A mRNAs and proteins as compared to proliferating T cells. Activation of resting T cells resulted in a rapid increase (20-50-fold) in the levels of these three mRNAs. This increase did not require new protein synthesis. Furthermore, transcription rates of these three eIF genes showed only minor increase over the induction period as measured by nuclear run-on assays. Despite the rapid increase in initiation factor mRNA levels, increases in eIF protein levels lagged significantly behind. Western blot analysis also showed that the protein levels of the three eIFs were differentially increased. eIF-4A protein levels increased in proportion to the observed increase in cellular protein synthetic activity while the increases in eIF-4E and eIF-2alpha proteins were proportionately less. The low levels of eIF proteins in quiescent T cells appear to correlate with low protein synthesis rate in such cells. The induction of eIF proteins by post-transcriptional/translational mechanisms appears to contribute to the pronounced stimulation of protein synthesis that occurs during T cell activation.	UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT PATHOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA; NHLBI, MOLEC HEMATOL LAB, PROT BIOSYNTH SECT, BETHESDA, MD 20892 USA; MCGILL UNIV, DEPT BIOCHEM, MONTREAL H3G 1Y6, QUEBEC, CANADA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); McGill University	MAO, XH (corresponding author), UNIV MICHIGAN, MED CTR, DEPT MICROBIOL IMMUNOL, ANN ARBOR, MI 48109 USA.			Green, Jonathan/0000-0002-7449-4387	NATIONAL CANCER INSTITUTE [R29CA054521] Funding Source: NIH RePORTER; NCI NIH HHS [CA54521] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHERN T, 1973, BIOCHIM BIOPHYS ACTA, V331, P91, DOI 10.1016/0005-2787(73)90422-X; AHERN T, 1974, NATURE, V248, P519, DOI 10.1038/248519a0; ALONI R, 1992, MOL CELL BIOL, V12, P2203, DOI 10.1128/MCB.12.5.2203; AMALDI F, 1989, TRENDS BIOCHEM SCI, V14, P175, DOI 10.1016/0968-0004(89)90269-7; ASHMAN RF, 1984, FUNDAMENTAL IMMUNOLO, P267; BRANDHORST BP, 1974, J MOL BIOL, V85, P451, DOI 10.1016/0022-2836(74)90444-6; BU X, 1991, FEBS LETT, V283, P219, DOI 10.1016/0014-5793(91)80592-Q; COHEN RB, 1990, EMBO J, V9, P3831, DOI 10.1002/j.1460-2075.1990.tb07601.x; COOPER HL, 1977, J CELL PHYSIOL, V93, P213, DOI 10.1002/jcp.1040930207; COOPER HL, 1969, J BIOL CHEM, V244, P5590; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DONALDSON RW, 1991, J BIOL CHEM, V266, P3162; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; EDERY I, 1983, J BIOL CHEM, V258, P1398; ERICKSON JM, 1981, GENE, V16, P1, DOI 10.1016/0378-1119(81)90055-X; ERNST H, 1987, J BIOL CHEM, V262, P1206; FREDERICKSON RM, 1992, MOL CELL BIOL, V12, P1239, DOI 10.1128/MCB.12.3.1239; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GREEN RC, 1977, EXP CELL RES, V110, P215, DOI 10.1016/0014-4827(77)90287-7; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HERMAN RC, 1977, BIOCHEMISTRY-US, V16, P3460, DOI 10.1021/bi00634a026; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; KAY JE, 1975, BIOCHIM BIOPHYS ACTA, V378, P241, DOI 10.1016/0005-2787(75)90112-4; KAY JE, 1966, BIOCHEM J, V100, P815, DOI 10.1042/bj1000815; KAY JE, 1971, BIOCHIM BIOPHYS ACTA, V247, P322, DOI 10.1016/0005-2787(71)90680-0; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LAWSON TG, 1989, BIOCHEMISTRY-US, V28, P4729, DOI 10.1021/bi00437a033; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LEDBETTER JA, 1986, J IMMUNOL, V137, P3299; LENGYEL J, 1975, CELL, V5, P281, DOI 10.1016/0092-8674(75)90103-8; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; NIELSEN PJ, 1988, EMBO J, V7, P2097, DOI 10.1002/j.1460-2075.1988.tb03049.x; NIELSEN PJ, 1985, NUCLEIC ACIDS RES, V13, P6867, DOI 10.1093/nar/13.19.6867; OCHOA S, 1983, ARCH BIOCHEM BIOPHYS, V223, P325, DOI 10.1016/0003-9861(83)90598-2; RAY BK, 1985, J BIOL CHEM, V260, P7651; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SAFER B, 1983, CELL, V33, P7, DOI 10.1016/0092-8674(83)90326-4; SILVERMAN TA, 1992, J BIOL CHEM, V267, P9738; SONENBERG N, 1978, P NATL ACAD SCI USA, V75, P4843, DOI 10.1073/pnas.75.10.4843; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; SOOD AK, 1981, P NATL ACAD SCI-BIOL, V78, P616, DOI 10.1073/pnas.78.1.616; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; WELLINGTON C L, 1992, Current Biology, V2, P216, DOI 10.1016/0960-9822(92)90544-K; WETTENHALL REH, 1979, BIOCHIM BIOPHYS ACTA, V563, P400, DOI 10.1016/0005-2787(79)90059-5	56	62	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20444	20450						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400363				2022-12-25	WOS:A1992JR85800108
J	MERTENS, G; CASSIMAN, JJ; VANDENBERGHE, H; VERMYLEN, J; DAVID, G				MERTENS, G; CASSIMAN, JJ; VANDENBERGHE, H; VERMYLEN, J; DAVID, G			CELL-SURFACE HEPARAN-SULFATE PROTEOGLYCANS FROM HUMAN VASCULAR ENDOTHELIAL-CELLS - CORE PROTEIN CHARACTERIZATION AND ANTITHROMBIN-III BINDING-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LUNG FIBROBLASTS; LIPOPROTEIN-LIPASE; GROWTH-FACTOR; BASEMENT-MEMBRANES; MOLECULAR-CLONING; DISTINCT MEMBRANE; HIGH-AFFINITY; MATRIX; CULTURES; FORMS	Human aortic endothelial cells (HAEC) and human umbilical vein endothelial cells (HUVEC) were labeled with (SO42-)-S-35 for 48 h. The membrane-associated proteoglycans were solubilized from these monolayers with detergent and purified by ion-exchange chromatography on Mono Q, incorporation in liposomes, and gel filtration. The liposome-intercalated proteoglycans were I-125-iodinated and treated with heparitinase before SDS-polyacrylamide gel electrophoresis. Radiolabeled proteins with apparent molecular masses of 130, 60, 46, 35, and 30 kDa (HAEC) and 180, 130, 62, 43, and 35 kDa (HUVEC) were detected by autoradiography. Further characterization by affinity chromatography on immobilized monoclonal antibodies and by Northern blot analysis provided evidence for the expression of syndecan, glypican, and fibroglycan in human endothelial cells. Most of the heparan sulfate which accumulated in the subendothelial matrix was implanted on a 400-kDa core protein. This protein was immunologically related to perlecan and bound to fibronectin. Binding studies on immobilized antithrombin III suggested that all membrane-associated heparan sulfate proteoglycan forms had the capacity to bind to antithrombin III but that high affinity binding was more typical for glypican. Most of the proteoglycans isolated from the extracellular matrix also bound only with low affinity to antithrombin III. These results imply that glypican may specifically contribute to the antithrombotic properties of the vascular wall.	CATHOLIC UNIV LEUVEN,CTR HUMAN GENET,CAMPUS GASTHUISBERG,O&N6,HERESTR 49,B-3000 LOUVAIN,BELGIUM; CATHOLIC UNIV LEUVEN,CTR THROMBOSIS & VASC RES,B-3000 LOUVAIN,BELGIUM	KU Leuven; KU Leuven								ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; BENGTSSON G, 1980, BIOCHEM J, V189, P625, DOI 10.1042/bj1890625; CHAJEKSHAUL T, 1989, BIOCHIM BIOPHYS ACTA, V1014, P178, DOI 10.1016/0167-4889(89)90031-1; COLBURN P, 1982, BIOCHEM BIOPH RES CO, V104, P220, DOI 10.1016/0006-291X(82)91962-3; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; GRIESMACHER A, 1987, EUR J BIOCHEM, V168, P95, DOI 10.1111/j.1432-1033.1987.tb13392.x; HEREMANS A, 1988, J BIOL CHEM, V263, P4731; HEREMANS A, 1990, J BIOL CHEM, V265, P8716; HEREMANS A, 1989, J CELL BIOL, V109, P3199, DOI 10.1083/jcb.109.6.3199; HOYER LW, 1973, J CLIN INVEST, V52, P2737, DOI 10.1172/JCI107469; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KINSELLA MG, 1988, BIOCHEMISTRY-US, V27, P2136, DOI 10.1021/bi00406a048; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; LINDBLOM A, 1989, BIOCHEM J, V261, P145, DOI 10.1042/bj2610145; LORIES V, 1992, J BIOL CHEM, V267, P1116; LORIES V, 1987, J BIOL CHEM, V262, P854; LORIES V, 1989, J BIOL CHEM, V264, P7009; LORIES V, 1986, EUR J BIOCHEM, V158, P351, DOI 10.1111/j.1432-1033.1986.tb09758.x; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MARCUM JA, 1984, BIOCHEMISTRY-US, V23, P1730, DOI 10.1021/bi00303a023; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; MILLERANDERSSON M, 1974, THROMB RES, V5, P439, DOI 10.1016/0049-3848(74)90001-2; OOHIRA A, 1983, J BIOL CHEM, V258, P2014; PEJLER G, 1987, BIOCHEM J, V248, P69, DOI 10.1042/bj2480069; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SAKU T, 1989, J BIOL CHEM, V264, P3514; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SAXENA U, 1991, P NATL ACAD SCI USA, V88, P2254, DOI 10.1073/pnas.88.6.2254; SHIMADA K, 1981, J CLIN INVEST, V68, P995, DOI 10.1172/JCI110354; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	38	218	221	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20435	20443						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400362				2022-12-25	WOS:A1992JR85800107
J	DAVIS, LH; DAVIS, JQ; BENNETT, V				DAVIS, LH; DAVIS, JQ; BENNETT, V			ANKYRIN REGULATION - AN ALTERNATIVELY SPLICED SEGMENT OF THE REGULATORY DOMAIN FUNCTIONS AS AN INTRAMOLECULAR MODULATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROCYTE ANKYRIN; CYTOPLASMIC DOMAIN; ANION-EXCHANGER; BRAIN ANKYRIN; BINDING-SITES; MEMBRANE; SPECTRIN; ASSOCIATION; ISOFORM; PHOSPHORYLATION	This study of two forms of ankyrin (protein 2.1 and 2.2) from human erythrocytes has revealed a role for alternate exon usage at the level of regulation of protein interactions. The smaller form of ankyrin (protein 2.2), which lacks a portion of the regulatory domain due to alternative splicing of pre-mRNA, exhibits increased affinity for the cytoplasmic domain of the anion exchanger, spectrin, and tubulin. Direct evidence that at least one of these associations is modulated by the alternatively spliced segment of the regulatory domain is provided by experiments utilizing a polypeptide that is comprised of residues 1513-1674 corresponding to the portion of the regulatory domain missing from protein 2.2. Addition of this regulatory domain polypeptide to binding assays reversed the increase in affinity of protein 2.2 for the anion exchanger. The inhibitory activity of the regulatory domain polypeptide in these assays is accompanied by a direct interaction with a site that is available on the smaller form of ankyrin and is distinct from the binding site for the anion exchanger. These results support the idea that the alternatively spliced segment within the regulatory domain of erythrocyte ankyrin performs a repressor function and acts through an allosteric mechanism involving interaction(s) at a site separate from the binding site for the anion exchanger.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University	DAVIS, LH (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710, USA.				NIADDK NIH HHS [AM29808] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM029808] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNETT V, 1981, P NATL ACAD SCI-BIOL, V78, P7550, DOI 10.1073/pnas.78.12.7550; BENNETT V, 1978, J BIOL CHEM, V253, P2292; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONBOY JG, 1988, P NATL ACAD SCI USA, V85, P9062, DOI 10.1073/pnas.85.23.9062; DAVIS JQ, 1986, J BIOL CHEM, V261, P6198; DAVIS JQ, 1984, J BIOL CHEM, V259, P3550; DAVIS LH, 1991, J BIOL CHEM, V266, P11163; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; GEORGATOS SD, 1985, J CELL BIOL, V100, P1955, DOI 10.1083/jcb.100.6.1955; HALL TG, 1987, J BIOL CHEM, V262, P10537; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KORDELI E, 1990, J CELL BIOL, V110, P1341, DOI 10.1083/jcb.110.4.1341; KORDELI E, 1991, J CELL BIOL, V114, P1243, DOI 10.1083/jcb.114.6.1243; KUNIMOTO M, 1991, J CELL BIOL, V115, P1319, DOI 10.1083/jcb.115.5.1319; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LAMBERT S, 1991, J CELL BIOL, V115, P43; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU PW, 1985, J BIOL CHEM, V260, P4958; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; OTTO E, 1991, J CELL BIOL, V114, P241, DOI 10.1083/jcb.114.2.241; PETERS L, 1991, J CELL BIOL, V114, P1243; Sambrook J, 1989, MOL CLONING LABORATO; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SOONG CJ, 1987, ARCH BIOCHEM BIOPHYS, V254, P509, DOI 10.1016/0003-9861(87)90131-7; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANG TK, 1988, P NATL ACAD SCI USA, V85, P3713, DOI 10.1073/pnas.85.11.3713; VOTER WA, 1984, J BIOL CHEM, V259, P430	30	78	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18966	18972						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1388161				2022-12-25	WOS:A1992JN50200107
J	RAHMAN, MA; NELSON, H; WEISSBACH, H; BROT, N				RAHMAN, MA; NELSON, H; WEISSBACH, H; BROT, N			CLONING, SEQUENCING, AND EXPRESSION OF THE ESCHERICHIA-COLI PEPTIDE METHIONINE SULFOXIDE REDUCTASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDIZED ALPHA-1-PROTEINASE INHIBITOR; ENZYMATIC REDUCTION; PROTEINS; RESIDUES; BIOCHEMISTRY; DNA; THIOREDOXIN; PROBES; FLUID	The gene encoding peptide methionine sulfoxide reductase was cloned from an Escherichia coli genomic library using an oligonucleotide probe based on the amino-terminal sequence of the protein. The nucleotide sequence revealed that the gene codes for a polypeptide of 212 amino acid residues with a calculated molecular weight of 23,314. The protein has been overexpressed in E. coli and is present as a soluble active species.	ROCHE INST MOLEC BIOL,ROCHE RES CTR,NUTLEY,NJ 07110	Roche Holding								ABRAMS WR, 1981, P NATL ACAD SCI-BIOL, V78, P7483, DOI 10.1073/pnas.78.12.7483; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BLACK S, 1960, J BIOL CHEM, V235, P2910; BROT N, 1981, P NATL ACAD SCI-BIOL, V78, P2155, DOI 10.1073/pnas.78.4.2155; BROT N, 1991, BIOFACTORS, V3, P91; BROT N, 1982, ANAL BIOCHEM, V122, P291, DOI 10.1016/0003-2697(82)90283-4; BROT N, 1984, METHOD ENZYMOL, V107, P352; BROT N, 1982, TRENDS BIOCHEM SCI, V7, P137, DOI 10.1016/0968-0004(82)90204-3; BROT N, 1983, ARCH BIOCHEM BIOPHYS, V223, P271, DOI 10.1016/0003-9861(83)90592-1; Brot N., 1988, CHEM FUNCT GROUPS, P851; CARP H, 1982, P NATL ACAD SCI-BIOL, V79, P2041, DOI 10.1073/pnas.79.6.2041; COCHRANE CG, 1983, J CLIN INVEST, V71, P754, DOI 10.1172/JCI110823; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EJIRI SI, 1979, J BACTERIOL, V139, P161, DOI 10.1128/JB.139.1.161-164.1979; FLISS H, 1982, BIOCHEM BIOPH RES CO, V109, P194, DOI 10.1016/0006-291X(82)91584-4; GARNER MH, 1980, P NATL ACAD SCI-BIOL, V77, P1274, DOI 10.1073/pnas.77.3.1274; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HUNKAPILLER MW, 1986, METHODS PROTEIN MICR, P315; JOHNSON D, 1979, J BIOL CHEM, V254, P4022; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANCHEZ J, 1983, PLANT PHYSIOL, V73, P619, DOI 10.1104/pp.73.3.619; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPECTOR A, 1988, J BIOL CHEM, V263, P4984; SPECTOR A, 1982, BIOCHEM BIOPH RES CO, V108, P429, DOI 10.1016/0006-291X(82)91884-8; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TRUSCOTT RJW, 1977, BIOCHIM BIOPHYS ACTA, V492, P43, DOI 10.1016/0005-2795(77)90212-4; WALLACE RB, 1981, NUCLEIC ACIDS RES, V9, P879, DOI 10.1093/nar/9.4.879; WONG PS, 1980, BIOCHEM BIOPH RES CO, V96, P1449, DOI 10.1016/0006-291X(80)90113-8; 1992, TAQ DYEDEOXY TERMINA; 1990, STEP BY STEP PROTOCO	35	66	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15549	15551						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1386361				2022-12-25	WOS:A1992JG11300047
J	LANDESMAN, Y; PAGANO, M; DRAETTA, G; ROTTER, V; FUSENIG, NE; KIMCHI, A				LANDESMAN, Y; PAGANO, M; DRAETTA, G; ROTTER, V; FUSENIG, NE; KIMCHI, A			MODIFICATIONS OF CELL-CYCLE CONTROLLING NUCLEAR PROTEINS BY TRANSFORMING GROWTH-FACTOR-BETA IN THE HACAT KERATINOCYTE CELL-LINE	ONCOGENE			English	Note							RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR; INHIBITION; PROLIFERATION; EXPRESSION; SUPPRESSION; KINASE		WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL; GERMAN CANC RES CTR,EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAM,W-6900 HEIDELBERG,GERMANY; GERMAN CANC RES CTR,INST BIOCHEM,DIV DIFFERENTIAT & CARCINOGENESIS INVITRO,W-6900 HEIDELBERG,GERMANY; WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; European Molecular Biology Laboratory (EMBL); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Weizmann Institute of Science				pagano, michele/0000-0003-3210-2442				BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LIKE B, 1986, J BIOL CHEM, V261, P3426; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NIELSENHAMILTON M, 1990, CURR TOP DEV BIOL, V24, P95; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; RESNITZKY D, 1991, CELL GROWTH DIFFER, V2, P33; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; TIEFENBRUN N, 1991, ONCOGENE, V6, P1001; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; YARDEN A, 1986, SCIENCE, V234, P1419, DOI 10.1126/science.3097823; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952	33	31	31	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1661	1665						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1385861				2022-12-25	WOS:A1992JE81300026
J	YUAN, HB; DOUGLAS, MG				YUAN, HB; DOUGLAS, MG			THE MITOCHONDRIAL F1ATPASE ALPHA-SUBUNIT IS NECESSARY FOR EFFICIENT IMPORT OF MITOCHONDRIAL PRECURSORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; YEAST NUCLEAR GENE; COMPLEX; TRANSLOCATION; F1-ATPASE; VIABILITY; MATRIX; ATPASE	The mitochondrial import and assembly of the F1ATPase subunits requires, respectively, the participation of the molecular chaperones hsp70SSA1 and hsp70SSC1 and other components operating on opposite sides of the mitochondrial membrane. In previous studies, both the homology and the assembly properties of the F1ATPase alpha-subunit (ATP1p) compared to the groEL homologue, hsp60, have led to the proposal that this subunit could exhibit chaperone-like activity. In this report the extent to which this subunit participates in protein transport has been determined by comparing import into mitochondria that lack the F1ATPase alpha-subunit (DELTA-ATP1) versus mitochondria that lack the other major catalytic subunit, the F1ATPase beta-subunit (DELTA-ATP2). Yeast mutants lacking the alpha-subunit but not the beta-subunit grow much more slowly than expected on fermentable carbon sources and exhibit delayed kinetics of protein import for several mitochondrial precursors such as the F1-beta subunit, hsp60MIF4 and subunits 4 and 5 of the cytochrome oxidase. In vitro and in vivo the F1-beta-subunit precursor accumulates as a translocation intermediate in absence of the F1-alpha-subunit. In the absence of both the ATPase subunits yeast grows at the same rate as a strain lacking only the beta-subunit, and import of mitochondrial precursors is restored to that of wild type. These data indicate that the F1-alpha-subunit likely functions as an "assembly partner" to influence protein import rather than functioning directly as a chaperone. These data are discussed in light of the relationship between the import and assembly of proteins in mitochondria.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CB 7260 FAC LAB OFF BLDG,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036537] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36537] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; AVNI A, 1991, J BIOL CHEM, V266, P7317; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BOUSQUET I, 1991, EMBO J, V10, P2023, DOI 10.1002/j.1460-2075.1991.tb07732.x; BOWMAN S, 1991, J BIOL CHEM, V266, P7517; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHEN WJ, 1987, J BIOL CHEM, V262, P15605; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; DOUGLAS MG, 1991, INTRACELLULAR TRAFFI, P658; GASSER SM, 1982, J BIOL CHEM, V257, P3034; Glick B, 1991, Trends Cell Biol, V1, P99, DOI 10.1016/0962-8924(91)90037-A; HALLBERG E, 1989, NATURE, V337, P620; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HOWRWICH A, 1990, CURR OPIN CELL BIOL, V2, P625; HWANG ST, 1991, J BIOL CHEM, V266, P21083; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; LUIS A, 1990, J BIOL CHEM, V265, P7413; Maniatis T., 1982, MOL CLONING; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; OSTERMANN J, 1990, FEBS LETT, V277, P281, DOI 10.1016/0014-5793(90)80865-G; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; PFANNER N, 1990, J BIOL CHEM, V265, P16324; REID GA, 1982, J BIOL CHEM, V257, P3062; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SHERMAN F, 1979, METHODS YEAST GENETI, P1; TAKEDA M, 1986, J BIOL CHEM, V261, P5126; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819	36	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14697	14702						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1386080				2022-12-25	WOS:A1992JF08800033
J	TRIPATHI, RK; HEARING, VJ; URABE, K; AROCA, P; SPRITZ, RA				TRIPATHI, RK; HEARING, VJ; URABE, K; AROCA, P; SPRITZ, RA			MUTATIONAL MAPPING OF THE CATALYTIC ACTIVITIES OF HUMAN TYROSINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IA OCULOCUTANEOUS ALBINISM; SINGLE BASE INSERTION; MAMMALIAN TYROSINASE; GENE MUTATION; DNA; PIGMENTATION; MELANIN; MOUSE; BIOSYNTHESIS; PATIENT	Tyrosinase (EC 1.14.18.1) is a copper-containing metalloglycoprotein that catalyzes several steps in the melanin pigment biosynthetic pathway; the hydroxylation of tyrosine to L-3,4-dihydroxyphenylalanine (dopa) and the subsequent oxidation of dopa to dopaquinone. It has been proposed that tyrosinase is also able to oxidize 5,6-dihydroxyindole (DHI), a later product in the melanogenic pathway, to indole-5,6-quinone. Tyrosinase enzymatic activity is deficient in patients with classic type I oculocutaneous albinism (OCA), and more than 50 distinct mutations have now been identified in the tyrosinase genes of such patients. To determine the effects of the various tyrosinase gene mutations on the catalytic activities of the enzyme, we carried out site-directed mutagenesis of human tyrosinase cDNA, transiently expressed the mutant cDNAs in transfected HeLa cells, and assayed the resultant encoded proteins for tyrosine hydroxylase, dopa, and DHI oxidase activities, and resulting melanin production. The tyrosine hydroxylase activity of normal tyrosinase is thermostable, whereas its dopa oxidase and DHI oxidase activities are temperature-sensitive. Although all amino acid substitutions tested generally affected the dopa oxidase and DHI oxidase activities in parallel, several exerted distinctly different effects on the tyrosine hydroxylase activities. Together, these results confirm the DHI oxidase activity of mammalian tyrosinase and suggest that the dopa oxidase and DHI oxidase activities of tyrosinase share a common catalytic site, whereas the tyrosine hydroxylase catalytic site is at least partially distinct in the tyrosinase polypeptide.	UNIV WISCONSIN, DEPT MED GENET, GENET LAB 317, 445 HENRY MALL, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT PEDIAT, MADISON, WI 53706 USA; NCI, CELL BIOL LAB, BETHESDA, MD 20892 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Aroca, Pilar/P-2141-2017	Aroca, Pilar/0000-0002-7557-6931	NIAMS NIH HHS [AR-39892] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039892] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BENIGNI JD, 1965, J HETEROCYCLIC CHEM, V2, P387, DOI 10.1002/jhet.5570020413; BOUCHARD B, 1989, J EXP MED, V169, P2029, DOI 10.1084/jem.169.6.2029; BRAMHALL S, 1969, ANAL BIOCHEM, V31, P146, DOI 10.1016/0003-2697(69)90251-6; CHINTAMANENI CD, 1991, P NATL ACAD SCI USA, V88, P5272, DOI 10.1073/pnas.88.12.5272; DUCKWORTH HW, 1970, J BIOL CHEM, V245, P1613; GIEBEL LB, 1991, J CLIN INVEST, V87, P1119, DOI 10.1172/JCI115075; GIEBEL LB, 1991, AM J HUM GENET, V48, P1159; GIEBEL LB, 1991, GENOMICS, V9, P435, DOI 10.1016/0888-7543(91)90409-8; GIEBEL LB, 1990, NUCLEIC ACIDS RES, V18, P4947, DOI 10.1093/nar/18.16.4947; GIEBEL LB, 1990, P NATL ACAD SCI USA, V87, P3255, DOI 10.1073/pnas.87.9.3255; GIEBEL LB, 1991, J MED GENET, V28, P464, DOI 10.1136/jmg.28.7.464; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; HEARING VJ, 1987, METHOD ENZYMOL, V142, P154; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; HEARING VJ, 1976, BIOCHEM J, V157, P549, DOI 10.1042/bj1570549; HUSAIN I, 1982, J INVEST DERMATOL, V78, P243, DOI 10.1111/1523-1747.ep12506603; JIMENEZ M, 1988, P NATL ACAD SCI USA, V85, P3830, DOI 10.1073/pnas.85.11.3830; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; KIKUCHI H, 1990, HUM GENET, V85, P123; KING RA, 1991, MOL BIOL MED, V8, P19; KORNER A, 1982, SCIENCE, V217, P1163, DOI 10.1126/science.6810464; Lerch K, 1988, Prog Clin Biol Res, V256, P85; LERNER AB, 1949, J BIOL CHEM, V178, P185; LERNER AB, 1950, PHYSIOL REV, V30, P91, DOI 10.1152/physrev.1950.30.1.91; LERNER AB, 1951, J BIOL CHEM, V191, P799; MARTINEZ JH, 1985, BIOCHEM INT, V11, P729; OETTING WS, 1991, AM J HUM GENET, V49, P199; OETTING WS, 1991, J INVEST DERMATOL, V97, P15, DOI 10.1111/1523-1747.ep12477808; PALUMBO A, 1987, BIOCHIM BIOPHYS ACTA, V925, P203, DOI 10.1016/0304-4165(87)90110-3; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POMERANT SH, 1967, J BIOL CHEM, V242, P5308; POMERANT.SH, 1966, J BIOL CHEM, V241, P161; SHIMAO K, 1962, BIOCHIM BIOPHYS ACTA, V62, P205; SPRITZ RA, 1991, AM J HUM GENET, V48, P318; SPRITZ RA, 1990, NEW ENGL J MED, V322, P1724, DOI 10.1056/NEJM199006143222407; TAKEDA A, 1990, J BIOL CHEM, V265, P17792; TOMITA Y, 1989, BIOCHEM BIOPH RES CO, V164, P990, DOI 10.1016/0006-291X(89)91767-1; TRIPATHI RK, 1991, GENE EXPRESSION, V1, P103; TRIPATHI RK, 1988, BIOCHEM J, V252, P481, DOI 10.1042/bj2520481; TRIPATHI RK, 1992, AM J MED GENET, V43, P865, DOI 10.1002/ajmg.1320430523; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; TSUKAMOTO K, 1992, BIOCHEM J, V286, P491, DOI 10.1042/bj2860491; WITKOP CJ, 1989, METABOLIC BASIS INHE; WITTBJER A, 1989, ACTA DERM-VENEREOL, V69, P125; ZHANG H, 1988, NUCLEIC ACIDS RES, V16, P1220, DOI 10.1093/nar/16.3.1220	46	127	130	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23707	23712						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429711				2022-12-25	WOS:A1992JZ23900044
J	BAZZI, MD; NELSESTUEN, GL				BAZZI, MD; NELSESTUEN, GL			AUTOPHOSPHORYLATION OF PROTEIN-KINASE-C MAY REQUIRE A HIGH-ORDER OF PROTEIN-PHOSPHOLIPID AGGREGATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER BINDING; X-100 MIXED MICELLES; RAT-BRAIN; CELLULAR-REGULATION; ACTIVATION; PHOSPHATIDYLSERINE; SUBSTRATE; SPECIFICITY; CALCIUM; PHOSPHORYLATION	The activation of protein kinase C (PKC) usually displays cofactor requirements that include phosphatidylserine (PS), diacylglycerol, and calcium. A complicating factor is that good exogenous substrates of PKC are polycationic proteins or peptides that form aggregates with PS in the assay. This study examined the autophosphorylation of PKC using assays with phospholipid provided in the form of vesicles or phospholipid-Triton mixed micelles. The results showed a close correlation between PKC autophosphorylation and the formation of aggregated assay components. Aggregation occurred primarily by the action of Mg2+ on phospholipids and appeared to underlie a number of major features of PKC autophosphorylation. For example, autophosphorylation required higher concentrations of PS than phosphorylation of exogenous substrates. This appeared to be the result of the different PS requirements of aggregation by divalent metal ions and cationic substrates. An unanticipated result was that aggregation of mixed micelles showed specificity for PS, high cooperativity with respect to several agents, and a requirement for calcium. These parameters were remarkably similar to those describing PKC autophosphorylation. Several major implications are evident in this study. Since the autophosphorylation assay is not a well defined system of monodisperse materials, autophosphorylation of PKC may proceed by intra- or interpeptide mechanism. The uniform correlation between aggregation and production of PKC activity suggested that kinetic parameters may represent interactions of assay components other than the enzyme. Aggregation, which appeared necessary for in vitro activation of PKC, may represent the expression of important but undefined in vivo requirements for this enzyme's function.			BAZZI, MD (corresponding author), UNIV MINNESOTA, DEPT BIOCHEM, 1479 GORTNER AVE, ST PAUL, MN 55108 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038819] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38819] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P5002, DOI 10.1021/bi00390a018; BAZZI MD, 1992, BIOCHEMISTRY-US, V31, P1125, DOI 10.1021/bi00119a022; BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P6776, DOI 10.1021/bi00418a020; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; BELL RM, 1991, J BIOL CHEM, V266, P4661; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLUMBERG PM, 1988, CANCER RES, V48, P1; BOLEN EJ, 1992, BIOCHEMISTRY-US, V31, P5945, DOI 10.1021/bi00140a034; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; HANNUN YA, 1986, J BIOL CHEM, V261, P9341; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HANNUN YA, 1990, J BIOL CHEM, V265, P2962; HUANG KP, 1986, J BIOL CHEM, V261, P2134; KAIBUCHI K, 1981, J BIOL CHEM, V256, P7146; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MH, 1989, J BIOL CHEM, V264, P14797; LEE MH, 1992, BIOCHEMISTRY-US, V31, P5176, DOI 10.1021/bi00137a013; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MCLAUGHLIN S, 1981, J GEN PHYSIOL, V77, P445, DOI 10.1085/jgp.77.4.445; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; NELSESTUEN GL, 1991, J BIOENERG BIOMEMBR, V23, P43; NEWTON AC, 1990, BIOCHEMISTRY-US, V29, P6656, DOI 10.1021/bi00480a015; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; NEWTON AC, 1987, J BIOL CHEM, V262, P10185; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOOIJ EHD, 1962, BIOCHIM BIOPHYS ACTA, V62, P608, DOI 10.1016/0006-3002(62)90254-8; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; SNOEK GT, 1988, BIOCHEM J, V255, P629; SOUVIGNET C, 1991, J BIOL CHEM, V266, P40; WALKER JM, 1988, J BIOL CHEM, V263, P4537	40	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22891	22896						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429637				2022-12-25	WOS:A1992JY16300030
J	HAYASHI, H; KAMOHARA, S; NISHIOKA, Y; KANAI, F; MIYAKE, N; FUKUI, Y; SHIBASAKI, F; TAKENAWA, T; EBINA, Y				HAYASHI, H; KAMOHARA, S; NISHIOKA, Y; KANAI, F; MIYAKE, N; FUKUI, Y; SHIBASAKI, F; TAKENAWA, T; EBINA, Y			INSULIN-TREATMENT STIMULATES THE TYROSINE PHOSPHORYLATION OF THE ALPHA-TYPE 85-KDA SUBUNIT OF PHOSPHATIDYLINOSITOL 3-KINASE INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; RECEPTOR KINASE-ACTIVITY; EPIDERMAL GROWTH-FACTOR; PDGF BETA-RECEPTOR; BOVINE BRAIN; INTACT-CELLS; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; SERINE KINASE	After adding insulin to cells overexpressing the insulin receptor, the activity of phosphatidylinositol (PI) 3-kinase in the anti-phosphotyrosine immunoprecipitates was rapidly and greatly increased. This enzyme may therefore be a substrate for the insulin receptor tyrosine kinase and may be one of the mediators of insulin signal transduction. However, it is unclear whether or not activated tyrosine kinase of the insulin receptor directly phosphorylates PI 3-kinase at tyrosine residue(s) and whether insulin stimulates the specific activity of PI 3-kinase. We reported previously that the 85-kDa subunit of purified PI 3-kinase was phosphorylated at tyrosine residue(s) by the insulin receptor in vitro. To examine the tyrosine phosphorylation of PI 3-kinase and change of its activity by insulin treatment in vivo, we used a specific antibody to the 85-kDa subunit of PI 3-kinase. The activity of PI 3-kinase in immunoprecipitates with the antibody against the p85 subunit of PI 3-kinase was increased about 3-fold by insulin treatment of cells overexpressing insulin receptors. Insulin treatment also stimulated the tyrosine, serine, and threonine phosphorylation of the alpha-type 85-kDa subunit of PI 3-kinase in vivo. Phosphatase treatment of the immunoprecipitates abolished the increase in PI 3-kinase activity. The phosphorylation(s) of the kinase itself, tyrosine phosphorylation(s) of associated protein(s), or the complex formation of the phosphorylated PI 3-kinase with associated proteins may increase the activity of PI 3-kinase.	UNIV TOKUSHIMA,INST ENZYME RES,DEPT ENZYME GENET,3-18-15 KURAMOTO CHO,TOKUSHIMA 770,JAPAN; UNIV TOKYO,DEPT AGR CHEM,BIOCHEM LAB,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOSIGNAL RES,ITABASHI KU,TOKYO 173,JAPAN	Tokushima University; University of Tokyo			Fukui, Yasuhisa/E-8806-2010	Hayashi, Hideki/0000-0003-4585-6542; Kamohara, Seika/0000-0002-2482-6611				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BALLOTTI R, 1986, BIOCHEM BIOPH RES CO, V139, P179, DOI 10.1016/S0006-291X(86)80096-1; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; HAYASHI H, 1991, BIOCHEM J, V280, P769, DOI 10.1042/bj2800769; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KAPLAN D R, 1988, Biochimica et Biophysica Acta, V948, P345; KASUGA M, 1982, J BIOL CHEM, V257, P9891; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS RE, 1990, J BIOL CHEM, V265, P947; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MARGOLIS RN, 1988, P NATL ACAD SCI USA, V85, P7526; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MORGAN DO, 1987, P NATL ACAD SCI USA, V84, P41, DOI 10.1073/pnas.84.1.41; MORGAN DO, 1986, P NATL ACAD SCI USA, V83, P328, DOI 10.1073/pnas.83.2.328; MORGAN DO, 1986, BIOCHEMISTRY-US, V25, P1364, DOI 10.1021/bi00354a026; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NOLAN RD, 1990, J BIOL CHEM, V265, P2441; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANG DT, 1985, J BIOL CHEM, V260, P7131; PERROTTI N, 1987, P NATL ACAD SCI USA, V84, P3137, DOI 10.1073/pnas.84.10.3137; PIGNATARO OP, 1990, J BIOL CHEM, V265, P1718; REESJONES RW, 1985, J BIOL CHEM, V260, P4461; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTHENBERG P, 1990, HDB EXPT PHARM INSUL, V92, P209; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STADTMAUER LA, 1983, J BIOL CHEM, V258, P6682; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TOBE K, 1990, DIABETES, V39, P528, DOI 10.2337/diabetes.39.5.528; ULLICH A, 1985, NATURE, V313, P756; WHITE MF, 1985, J BIOL CHEM, V260, P9470; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	52	75	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22575	22580						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1385401				2022-12-25	WOS:A1992JW71900091
J	EMILIE, D; MAILLOT, MC; NICOLAS, JF; FIOR, R; GALANAUD, P				EMILIE, D; MAILLOT, MC; NICOLAS, JF; FIOR, R; GALANAUD, P			ANTAGONISTIC EFFECT OF INTERFERON-GAMMA ON TAT-INDUCED TRANSACTIVATION OF HIV LONG TERMINAL REPEAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR NECROSIS FACTOR; CD8+ T-CELLS; REPLICATION INVITRO; LYMPHOCYTE-T; FACTOR-ALPHA; IFN-GAMMA; HTLV-III; KAPPA-B; INFECTION	Interferon-gamma (IFN-gamma) has been shown to inhibit human immunodeficiency virus (HIV) replication in macrophages. However, the site of its effect on the HIV infectious cycle is unknown. We show here that IFN-gamma inhibits the transactivation of HIV long terminal repeat (LTR) during viral infection and that it antagonizes tat effect in HT4LacZ-1 cells. HT4LacZ-1 is an indicator CD4+ HeLa cell line for HIV infectivity, because it harbors a HIV LTR-LacZ gene susceptible to transactivation by tat. It was used in combination with a computer-assisted image analyzer to quantify: (i) the number of transactivated foci following HIV infection, (ii) their individual level of transactivation, and (iii) the fusion potency of infected cells. IFN-gamma induced a 75% decrease of the number of transactivated foci following infection of HT4LacZ-1 cells by HIV. The remaining 25% foci still susceptible to transactivation were transactivated at a lower level than in control cultures, and the fusion potency of infected cells was strongly decreased. IFN-gamma acted after HIV entry into the cell and independently of reverse transcription. IFN-gamma antagonized tat-induced LTR transactivation: it inhibited transactivation of HT4LacZ-1 cells when tat was provided either from a SV40-based expression vector of tat or by polyethylene glycol-induced cell fusion with HeLa-tat-III cells. These results suggest that IFN-gamma affects the expression or the activity of cellular factors interacting with tat and that the high level of IFN-gamma production associated with HIV infection plays a role in the establishment of HIV latency.	INST PASTEUR,CNRS,UA 1148,UNITE BIOL MOLEC DEV,F-75724 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	EMILIE, D (corresponding author), INSERM,U131,32 RUE CARNETS,F-92140 CLAMART,FRANCE.			NICOLAS, JEAN FRANCOIS/0000-0003-4204-803X				BALTIMORE D, 1989, NEW ENGL J MED, V321, P1673, DOI 10.1056/NEJM198912143212409; BARRY PA, 1991, J VIROL, V65, P1392, DOI 10.1128/JVI.65.3.1392-1399.1991; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BRINCHMANN JE, 1990, J IMMUNOL, V144, P2961; CHESEBRO B, 1988, J VIROL, V62, P3779, DOI 10.1128/JVI.62.10.3779-3788.1988; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DASGUPTA P, 1990, P NATL ACAD SCI USA, V87, P8090, DOI 10.1073/pnas.87.20.8090; DEVERGNE O, 1991, AIDS, V5, P1071, DOI 10.1097/00002030-199109000-00002; DRYSDALE CM, 1991, J VIROL, V65, P3044, DOI 10.1128/JVI.65.6.3044-3051.1991; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; EMILIE D, 1990, AIDS, V4, P791, DOI 10.1097/00002030-199008000-00011; EMILIE D, 1990, J CLIN INVEST, V86, P148, DOI 10.1172/JCI114678; FUCHS D, 1989, J ACQ IMMUN DEF SYND, V2, P158; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GREENE WC, 1991, NEW ENGL J MED, V324, P308, DOI 10.1056/NEJM199101313240506; HADIDA F, 1992, J CLIN INVEST, V89, P53, DOI 10.1172/JCI115585; HAMMER SM, 1986, P NATL ACAD SCI USA, V83, P8734, DOI 10.1073/pnas.83.22.8734; HARTSHORN KL, 1987, AIDS RES HUM RETROV, V3, P125, DOI 10.1089/aid.1987.3.125; HEAGY W, 1990, J ACQ IMMUN DEF SYND, V3, P584; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; ISRAEL N, 1989, J IMMUNOL, V143, P3956; KANNAGI M, 1990, J VIROL, V64, P3399, DOI 10.1128/JVI.64.7.3399-3406.1990; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KOENIG S, 1988, P NATL ACAD SCI USA, V85, P8638, DOI 10.1073/pnas.85.22.8638; KORNBLUTH RS, 1990, CLIN IMMUNOL IMMUNOP, V54, P200, DOI 10.1016/0090-1229(90)90082-2; KORNBLUTH RS, 1989, J EXP MED, V169, P1137, DOI 10.1084/jem.169.3.1137; KOYANAGI Y, 1988, SCIENCE, V241, P1673, DOI 10.1126/science.3047875; LANE HC, 1989, J CLIN IMMUNOL, V9, P351, DOI 10.1007/BF00918667; MELTZER MS, 1990, IMMUNOL TODAY, V11, P217, DOI 10.1016/0167-5699(90)90086-O; MURRAY HW, 1988, ANN INTERN MED, V108, P595, DOI 10.7326/0003-4819-108-4-595; NAKASHIMA H, 1986, INT J CANCER, V38, P433, DOI 10.1002/ijc.2910380320; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; OHARA CJ, 1989, PATHOLOGY PATHOPHYSI, P36; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; POPIK W, 1991, P NATL ACAD SCI USA, V88, P9573, DOI 10.1073/pnas.88.21.9573; RINALDO C, 1988, J IMMUNOL, V140, P3389; ROCANCOURT D, 1990, J VIROL, V64, P2660, DOI 10.1128/JVI.64.6.2660-2668.1990; ROSEN CA, 1986, J VIROL, V57, P379, DOI 10.1128/JVI.57.1.379-384.1986; SANCEAU J, 1987, P NATL ACAD SCI USA, V84, P2906, DOI 10.1073/pnas.84.9.2906; STAHMER I, 1991, EUR J IMMUNOL, V21, P1873, DOI 10.1002/eji.1830210814; TSUBOTA H, 1989, J EXP MED, V169, P1421, DOI 10.1084/jem.169.4.1421; WAINHOBSON S, 1991, SCIENCE, V252, P961, DOI 10.1126/science.2035026; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; Wheelock E F, 1973, Adv Immunol, V16, P123, DOI 10.1016/S0065-2776(08)60297-7; WONG GHW, 1988, J IMMUNOL, V140, P120; YAMAMOTO JK, 1986, J INTERFERON RES, V6, P143, DOI 10.1089/jir.1986.6.143	48	52	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20565	20570						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400376				2022-12-25	WOS:A1992JT97800012
J	KULMBURG, P; JUDEWICZ, N; MATHIEU, M; LENOUVEL, F; SEQUEVAL, D; FELENBOK, B				KULMBURG, P; JUDEWICZ, N; MATHIEU, M; LENOUVEL, F; SEQUEVAL, D; FELENBOK, B			SPECIFIC BINDING-SITES FOR THE ACTIVATOR PROTEIN, ALCR, IN THE ALCA PROMOTER OF THE ETHANOL REGULON OF ASPERGILLUS-NIDULANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON CATABOLITE REPRESSION; POSITIVE REGULATORY GENE; GLUCOCORTICOID RECEPTOR; DNA RECOGNITION; CREA GENE; DOMAIN; CLONING; EXPRESSION; COMPLEX; DIMER	ALCR is the specific activator of the Aspergillus nidulans ethanol-utilization pathway, mediating the induction of its own transcription and that of the structural genes alcA and aldA, encoding respectively, alcohol dehydrogenase I and aldehyde dehydrogenase. ALCR is a DNA binding protein in which 6 cysteines are coordinated in a zinc binuclear cluster. This domain was fused to glutathione-S-transferase (GST) and isolated as a GST-ALCR(7-58*) fusion protein from Escherichia coli. Mobility shift assays showed that the ALCR fusion protein binds at sites upstream of the alcA promoter. DNaseI protection footprinting experiments revealed three specific binding sites, two that are direct repeats and one that is an inverted repeat with the same half-site 5'-CCGCA-3'. The half-sites are separated by a variable number of nucleotides in both types of target. The interaction of the ALCR fusion protein with direct and inverted repeats were examined by using interference and protection footprinting assays. In both binding sites, modification of the guanines in the half-sites interfered with the formation of the DNA complex, but the adjacent ones did not. Our results suggest that the ALCR protein makes contact in the major groove of the DNA helix of the half-sites. The functionality of two out of three binding sites of the GST-ALCR protein was demonstrated after their deletion. Therefore, the region encompassing these binding sites is a cis-acting element involved in the full induction of the alcA gene.	UNIV PARIS 11,CTR ORSAY,INST GENET & MICROBIOL,BATIMENT 409,F-91405 ORSAY,FRANCE	UDICE-French Research Universities; Universite Paris Saclay								BAILEY C, 1975, EUR J BIOCHEM, V51, P573, DOI 10.1111/j.1432-1033.1975.tb03958.x; BALEJA JD, 1992, NATURE, V356, P450, DOI 10.1038/356450a0; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; DALE RMK, 1985, PLASMID, V13, P141; DOWZER CEA, 1989, CURR GENET, V15, P457, DOI 10.1007/BF00376804; DOWZER CEA, 1991, MOL CELL BIOL, V11, P5701, DOI 10.1128/MCB.11.11.5701; DYNAN WS, 1989, CELL, V58, P1, DOI 10.1016/0092-8674(89)90393-0; FELENBOK B, 1988, GENE, V73, P385, DOI 10.1016/0378-1119(88)90503-3; FELENBOK B, 1991, J BIOTECHNOL, V17, P11, DOI 10.1016/0168-1656(91)90023-O; FREEMONT PS, 1991, BIOCHEM J, V278, P1; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GWYNNE DI, 1987, GENE, V51, P205, DOI 10.1016/0378-1119(87)90309-X; HALVORSEN YDC, 1990, J BIOL CHEM, V265, P13283; HALVORSEN YDC, 1991, MOL CELL BIOL, V11, P1771; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KRAULIS PJ, 1992, NATURE, V356, P448, DOI 10.1038/356448a0; KULMBURG P, 1991, FEBS LETT, V280, P11, DOI 10.1016/0014-5793(91)80193-7; KULMBURG P, 1992, MOL CELL BIOL, V12, P1932, DOI 10.1128/MCB.12.5.1932; LOCKINGTON R, 1987, MOL MICROBIOL, V1, P275, DOI 10.1111/j.1365-2958.1987.tb01933.x; LOCKINGTON RA, 1985, GENE, V33, P137, DOI 10.1016/0378-1119(85)90088-5; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; Maxam A M, 1980, Methods Enzymol, V65, P499; PAN T, 1990, BIOCHEMISTRY-US, V29, P3023, DOI 10.1021/bi00464a019; PATEMAN JA, 1983, PROC R SOC SER B-BIO, V217, P243, DOI 10.1098/rspb.1983.0009; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PICKETT M, 1987, GENE, V51, P217, DOI 10.1016/0378-1119(87)90310-6; RAIBAUD O, 1989, MOL MICROBIOL, V3, P455; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARAI A, 1989, P NATL ACAD SCI USA, V86, P6513, DOI 10.1073/pnas.86.17.6513; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TILBURN J, 1983, GENE, V26, P205, DOI 10.1016/0378-1119(83)90191-9; UPSHALL A, 1986, MOL GEN GENET, V204, P349, DOI 10.1007/BF00425521; WILSON C, 1990, ANNU REV CELL BIOL, V6, P679, DOI 10.1146/annurev.cellbio.6.1.679	39	51	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21146	21153						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400424				2022-12-25	WOS:A1992JT97800098
J	ROUET, P; RAGUENEZ, G; TRONCHE, F; YANIV, M; NGUYEN, C; SALIER, JP				ROUET, P; RAGUENEZ, G; TRONCHE, F; YANIV, M; NGUYEN, C; SALIER, JP			A POTENT ENHANCER MADE OF CLUSTERED LIVER-SPECIFIC ELEMENTS IN THE TRANSCRIPTION CONTROL SEQUENCES OF HUMAN ALPHA-1-MICROGLOBULIN BIKUNIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TRYPSIN INHIBITOR; REACTIVE PROTEIN PROMOTER; SITE-DIRECTED MUTAGENESIS; RAT ALBUMIN PROMOTER; NUCLEAR FACTORS; BINDING PROTEIN; HEPATOMA-CELLS; DNA-BINDING; TRANSTHYRETIN; REGION	Alpha1-microglobulin (A1M) and bikunin are plasma proteins which are present both as free molecules and as complexes with either IgA heavy chains for A1M or the H1, H2, and H3 heavy chains of the inter-alpha-inhibitor family for bikunin. Mature A1M and bikunin originate from the cleavage of an A1M/bikunin precursor (ABP) synthesized from a single gene with liver-specific expression. Five kilobases of the 5'-flanking region of the human ABP gene were sequenced. Deletion mutants of this region subcloned upstream of a CAT reporter gene were transfected into HepG2 hepatoma cells. A segment covering the -2.7- to -2.8-kb area is required for full activity of the ABP gene. This segment contains a cluster of six elements (boxes 1-6, 5' to 3') which are potential binding sites for the liver-enriched trans-acting factors HNF-1, HNF-4, HNF-3, HNF-1, HNF-3, and HNF-4, respectively. This cluster enhances the activity of heterologous minimal promoters in a position- and distance-independent fashion in HepG2 cells. This enhancer activity is restricted to liver cells as the cluster is unable to activate promoters in Chinese hamster ovary (CHO) or HeLa cells. By band-shift experiments we have shown that the liver-enriched transcription factors HNF-1, or HNF-3, do bind to boxes 1 and 4, or 3, respectively. The combination of a weak promoter and a strong distant and liver-specific enhancer distinguishes the ABP gene from most other plasma protein genes expressed in hepatocytes.	INSERM,U78,BP 73,F-76233 BOIS GUILLAUME,FRANCE; EUROPEAN INST PEPTIDE RES,F-76233 BOIS GUILLAUME,FRANCE; INST PASTEUR,CNRS,UNITE VIRUS ONCOGENES 1149,F-75724 PARIS,FRANCE; INSERM,U136,F-13288 MARSEILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm)			TRONCHE, François/F-3895-2011; Nguyen, Catherine/M-4119-2016	Nguyen, Catherine/0000-0001-9376-6360; Rouet, Philippe/0000-0001-6204-2079				AKERSTROM B, 1990, TRENDS BIOCHEM SCI, V15, P240, DOI 10.1016/0968-0004(90)90037-C; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; COSTA RH, 1991, NUCLEIC ACIDS RES, V19, P4139, DOI 10.1093/nar/19.15.4139; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; De Simone V, 1991, CURR OPIN CELL BIOL, V3, P960, DOI 10.1016/0955-0674(91)90114-E; DIARRAMEHRPOUR M, 1990, EUR J BIOCHEM, V191, P131, DOI 10.1111/j.1432-1033.1990.tb19102.x; ESCRIBANO J, 1988, BIOCHEM BIOPH RES CO, V155, P1424, DOI 10.1016/S0006-291X(88)81300-7; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; Gebhard W., 1986, PROTEINASE INHIBITOR, P389; GODOVAC-ZIMMERMANN J, 1988, TRENDS BIOCHEM SCI, V13, P64, DOI 10.1016/0968-0004(88)90031-X; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; HAM J, 1991, EMBO J, V10, P2931, DOI 10.1002/j.1460-2075.1991.tb07843.x; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; KAUMEYER JF, 1986, NUCLEIC ACIDS RES, V14, P7839, DOI 10.1093/nar/14.20.7839; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; Locker J, 1990, DNA Seq, V1, P3, DOI 10.3109/10425179009041342; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; MCKEEHAN WL, 1986, J BIOL CHEM, V261, P5378; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; NAGATA A, 1991, P NATL ACAD SCI USA, V88, P4020, DOI 10.1073/pnas.88.9.4020; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PETROPOULOS I, 1991, J BIOL CHEM, V266, P24220; RAMJI DP, 1991, NUCLEIC ACIDS RES, V19, P1139, DOI 10.1093/nar/19.5.1139; RAYMONDJEAN M, 1991, NUCLEIC ACIDS RES, V19, P6145, DOI 10.1093/nar/19.22.6145; ROUET P, 1992, IN PRESS BIOTECHNIQU; SALIER JP, 1990, J BIOL CHEM, V265, P7062; SALIER JP, 1990, TRENDS BIOCHEM SCI, V15, P435, DOI 10.1016/0968-0004(90)90282-G; SALIER JP, 1987, P NATL ACAD SCI USA, V84, P8272, DOI 10.1073/pnas.84.23.8272; Sambrook J, 1989, MOL CLONING LABORATO; TONIATTI C, 1990, EMBO J, V9, P4467, DOI 10.1002/j.1460-2075.1990.tb07897.x; TRONCHE F, 1991, J MOL BIOL, V222, P31, DOI 10.1016/0022-2836(91)90735-O; TRONCHE F, 1989, MOL CELL BIOL, V9, P4759, DOI 10.1128/MCB.9.11.4759; VETR H, 1991, BIOL CHEM HOPPESEYLE, V371, P1185; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469	40	53	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20765	20773						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383209				2022-12-25	WOS:A1992JT97800041
J	HATA, A; RIDINGER, DN; SUTHERLAND, SD; EMI, M; KWONG, LK; SHUHUA, J; LUBBERS, A; GUYGRAND, B; BASDEVANT, A; IVERIUS, PH; WILSON, DE; LALOUEL, JM				HATA, A; RIDINGER, DN; SUTHERLAND, SD; EMI, M; KWONG, LK; SHUHUA, J; LUBBERS, A; GUYGRAND, B; BASDEVANT, A; IVERIUS, PH; WILSON, DE; LALOUEL, JM			MISSENSE MUTATIONS IN EXON-5 OF THE HUMAN LIPOPROTEIN-LIPASE GENE - INACTIVATION CORRELATES WITH LOSS OF DIMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC TRIGLYCERIDE LIPASE; RADIATION INACTIVATION; NONSENSE MUTATION; ADIPOSE-TISSUE; I HYPERLIPOPROTEINEMIA; MOLECULAR-PROPERTIES; POSTHEPARIN PLASMA; PANCREATIC LIPASE; DNA-SEQUENCE; BOVINE-MILK	Most missense mutations of the lipoprotein lipase (LPL) gene identified among LPL-deficient subjects cluster in a segment of the sequence that encodes the catalytic triad as well as functional elements involved in the activation of the lipase at lipid-water interfaces. Consequently, loss of activity may result either from direct alterations of such functional elements or from less specific effects on protein folding and stability. This issue was addressed by examining biochemical properties of four such variants (A176T, G188E, G195E, and S244T) in a heterologous expression system (COS-1 cells). Variant G195E (GGA --> GAA) was previously unreported. In all instances, inactive enzyme was recovered in medium, albeit at reduced levels. Cellular synthesis and extracellular degradation were similar to those for wild type, suggesting that reduced secretion resulted from increased intracellular degradation. When cell extracts were subjected to heparin-Superose affinity chromatography followed by elution on a linear salt gradient, all variants exhibited a single, inactive, low affinity immunoreactive peak. By contrast, wild-type enzyme presented an additional, high affinity, active species, which we interpret as homodimeric enzyme. Substitution of the active-site serine (S132A) led to loss of activity but maintenance of the high affinity species. When large amounts of the G188E variant were applied to the column, small but significant amounts of high affinity, active enzyme were recovered. Systematic substitutions at residue 188 showed that only glycine could accommodate structural constraints at this position. We conclude that the mutations examined did not impart lipase deficiency by affecting specific functional elements of the enzyme. Rather, they appear to affect protein folding and stability, and thereby formation and maintenance of subunit assembly.	HOWARD HUGHES MED INST, SALT LAKE CITY, UT 84132 USA; VET AFFAIRS MED CTR, SALT LAKE CITY, UT 84148 USA; UNIV UTAH, HLTH SCI CTR, DEPT INTERNAL MED, DIV ENDOCRINOL & METAB, SALT LAKE CITY, UT 84132 USA; HOP HOTEL DIEU, SERV NUTR, PARIS, FRANCE; DEPT HUMAN GENET, SALT LAKE CITY, UT 84132 USA	Howard Hughes Medical Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039593, R01HL045753, R01HL145753] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00064] Funding Source: Medline; NHLBI NIH HHS [HL39593, HL45753] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMEIS D, 1991, J CLIN INVEST, V87, P1165, DOI 10.1172/JCI115114; ASHBY P, 1978, BIOCHEM J, V171, P305, DOI 10.1042/bj1710305; AUGUSTIN J, 1978, J BIOL CHEM, V253, P2912; BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326, DOI 10.1161/01.ATV.9.3.326; BEG OU, 1990, P NATL ACAD SCI USA, V87, P3474, DOI 10.1073/pnas.87.9.3474; BENGTSSON G, 1981, EUR J BIOCHEM, V113, P547, DOI 10.1111/j.1432-1033.1981.tb05097.x; BENGTSSON G, 1979, BIOCHIM BIOPHYS ACTA, V575, P471, DOI 10.1016/0005-2760(79)90118-8; BENGTSSONOLIVECRONA G, 1985, BIOCHEM J, V226, P409, DOI 10.1042/bj2260409; BENSADOU.A, 1974, J BIOL CHEM, V249, P2220; BLOW D, 1991, NATURE, V351, P444, DOI 10.1038/351444a0; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; Brunzell J D, 1986, Adv Exp Med Biol, V201, P227; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; BURDETTE RA, 1986, J BIOL CHEM, V261, P2016; CHAJEKSHAUL T, 1988, BIOCHIM BIOPHYS ACTA, V963, P183, DOI 10.1016/0005-2760(88)90279-2; CHEN GH, 1989, P NATL ACAD SCI USA, V86, P3447, DOI 10.1073/pnas.86.10.3447; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DATTA S, 1988, J BIOL CHEM, V263, P1107; DEEB SS, 1989, BIOCHEMISTRY-US, V28, P4132, DOI 10.1021/bi00436a001; DEREWENDA U, 1992, BIOCHEMISTRY-US, V31, P1532, DOI 10.1021/bi00120a034; DEREWENDA ZS, 1991, J BIOL CHEM, V266, P23112; DEVLIN RH, 1990, AM J HUM GENET, V46, P112; DICHEK HL, 1991, J BIOL CHEM, V266, P473; EMI M, 1990, J BIOL CHEM, V265, P5910; EMI M, 1990, AM J HUM GENET, V47, P107; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P14418; GARFINKEL AS, 1972, J LIPID RES, V13, P63; GARFINKEL AS, 1983, J LIPID RES, V24, P775; GARFINKEL AS, 1987, PLASMA LIPOPROTEINS, P335; GOTODA T, 1991, J CLIN INVEST, V88, P1856, DOI 10.1172/JCI115507; HATA A, 1990, NUCLEIC ACIDS RES, V18, P5407, DOI 10.1093/nar/18.18.5407; HATA A, 1990, AM J HUM GENET, V47, P721; Hayden M.R., 1991, CURRENT OPINION LIPI, V2, P104; HENDERSON HE, 1990, MOL BIOL MED, V7, P511; HENDERSON HE, 1991, J CLIN INVEST, V87, P2005, DOI 10.1172/JCI115229; IKEDA Y, 1989, BIOCHIM BIOPHYS ACTA, V1003, P254, DOI 10.1016/0005-2760(89)90231-2; Iverius P H, 1986, Methods Enzymol, V129, P691; IVERIUS PH, 1976, J BIOL CHEM, V251, P7791; IVERIUS PH, 1985, AM J PHYSIOL, V249, pE107, DOI 10.1152/ajpendo.1985.249.1.E107; KEMPNER ES, 1991, METHOD ENZYMOL, V197, P280; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALOUEL JM, 1992, CURR OPIN LIPIDOL, V3, P86; MA YH, 1991, NEW ENGL J MED, V324, P1761, DOI 10.1056/NEJM199106203242502; MA YH, 1992, J BIOL CHEM, V267, P1918; MONSALVE MV, 1990, J CLIN INVEST, V86, P728, DOI 10.1172/JCI114769; OLIVECRONA T, 1971, BIOCHEM BIOPH RES CO, V43, P524, DOI 10.1016/0006-291X(71)90645-0; OLIVECRONA T, 1982, EUR J BIOCHEM, V124, P629, DOI 10.1111/j.1432-1033.1982.tb06640.x; OLIVECRONA T, 1985, J BIOL CHEM, V260, P6888; Olivecrona T., 1987, LIPOPROTEIN LIPASE, P15; ORITA M, 1990, GENOMICS, V8, P271, DOI 10.1016/0888-7543(90)90282-Y; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; PAULWEBER B, 1991, ATHEROSCLEROSIS, V86, P239, DOI 10.1016/0021-9150(91)90220-W; PERSSON B, 1989, EUR J BIOCHEM, V179, P39, DOI 10.1111/j.1432-1033.1989.tb14518.x; QUINN D, 1983, PROG LIPID RES, V22, P35, DOI 10.1016/0163-7827(83)90003-6; SARDA L, 1958, BIOCHIM BIOPHYS ACTA, V30, P513, DOI 10.1016/0006-3002(58)90097-0; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; Smith L.C., 1984, P263; SOCORRO L, 1985, J BIOL CHEM, V260, P6324; TAKAGI A, 1992, J CLIN INVEST, V89, P581, DOI 10.1172/JCI115624; VANNIER C, 1989, J BIOL CHEM, V264, P13206; WALLACE DM, 1987, METHOD ENZYMOL, V152, P33; WALLACE RB, 1987, METHOD ENZYMOL, V152, P432; WALLINDER L, 1982, BIOCHIM BIOPHYS ACTA, V711, P107, DOI 10.1016/0005-2760(82)90015-7; WANG CS, 1992, BIOCHIM BIOPHYS ACTA, V1123, P1, DOI 10.1016/0005-2760(92)90165-R; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907	71	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20132	20139						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400331				2022-12-25	WOS:A1992JR85800062
J	SUDO, T; MIYAZAWA, H; HANAOKA, F; ISHII, S				SUDO, T; MIYAZAWA, H; HANAOKA, F; ISHII, S			THE C-MYB PROTOONCOGENE PRODUCT BINDS TO BUT DOES NOT ACTIVATE THE PROMOTER OF THE DNA POLYMERASE-ALPHA GENE	ONCOGENE			English	Article							TEMPERATURE-SENSITIVE MUTANT; V-MYB; CELL-PROLIFERATION; NUCLEOTIDE-SEQUENCE; EXPRESSION; REPLICATION; PROGENITOR; REGION	The myb proto oncogene product (c-Myb) is a transcriptional reglator and its expression and function are tightly linked to the cellular entry into S phase and DNA synthesis. It has been shown [Venturelli, D., Travali, S. & Calabretta, B. (1990). Proc. Natl. Acad. Sci. USA, 87, 5963-59671 that inhibition of T-cell proliferation by a myb antisense oligomer is accompanied by down-regulation of DNA polymerase-alpha-expression. To examine whether the transcription of the DNA polymerase-alpha-gene is directly regulated by c-Myb, we have identified and characterized the 5' regulatory region of the human DNA polymerase-alpha-gene. Two major and several minor transcription start sites were identified by nuclease S1 mapping. DNA sequence analysis showed that the promoter region contains no TATA box, one CCAAT box and putative Ap-1, AP-2 and E2F binding sites. In DNAase I footprinting, the bacterially expressed c-Myb protected six sites in the 5' flanking region of the human DNA polymerase-alpha-gene. However, c-Myb did not activate the DNA polymerase-alpha-gene promoter in a cotransfection assay. Our results suggest that an unknown factor(s) is required for the c-Myb-induced activation of the DNA polymerase-alpha-gene promoter, or c-Myb does not directly activate this promoter.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC GENET LAB,TSUKUBA,IBARAKI 305,JAPAN; INST PHYS & CHEM RES,CELLULAR PHYSIOL LAB,SAITAMA 35101,JAPAN; UNIV TOKYO,INST MED SCI,MINATO KU,TOKYO 108,JAPAN	RIKEN; RIKEN; University of Tokyo			Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				ARAKI E, 1988, NUCLEIC ACIDS RES, V16, P1627, DOI 10.1093/nar/16.4.1627; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; CAMPBELL JL, 1986, ANNU REV BIOCHEM, V55, P733, DOI 10.1146/annurev.bi.55.070186.003505; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HU YL, 1991, ONCOGENE, V6, P1549; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; Maniatis T., 1982, MOL CLONING; MIYAZAWA H, 1986, BIOCHEM BIOPH RES CO, V139, P135; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; MURAKAMI Y, 1985, P NATL ACAD SCI USA, V82, P1761, DOI 10.1073/pnas.82.6.1761; NAGASE T, 1990, J BIOL CHEM, V265, P17300; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NAKAGOSHI H, 1992, IN PRESS ONCOGENE; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; RUSHLOW KE, 1982, SCIENCE, V216, P1421, DOI 10.1126/science.6283631; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; TAKADATAKAYAMA R, 1991, J BIOL CHEM, V266, P15716; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016; WATSON RJ, 1987, EMBO J, V6, P1643, DOI 10.1002/j.1460-2075.1987.tb02413.x; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; [No title captured]	36	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1999	2006						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408140				2022-12-25	WOS:A1992JP42400013
J	RUI, H; DJEU, JY; EVANS, GA; KELLY, PA; FARRAR, WL				RUI, H; DJEU, JY; EVANS, GA; KELLY, PA; FARRAR, WL			PROLACTIN RECEPTOR TRIGGERING - EVIDENCE FOR RAPID TYROSINE KINASE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; GROWTH-HORMONE RECEPTOR; ERYTHROPOIETIN RECEPTOR; SIGNAL TRANSDUCTION; EXPRESSION CLONING; MOLECULAR-CLONING; PROTEIN-KINASE; LIGAND-BINDING; CYTOPLASMIC REGION; LYMPHOMA-CELLS	The mechanism of action of prolactin (PRL) has remained obscure despite the unveiling of the primary structure of PRL receptors. The present study demonstrates rapid PRL receptor-mediated tyrosine phosphorylation of at least three cellular proteins, designated p120, p97, and p40, in a rat T-lymphoma (Nb2-11C) as revealed by antiphosphotyrosine immunoblotting. One of the phosphotyrosyl proteins, p120, co-purified with activated PRL receptor complexes obtained using either anti-ligand or anti-receptor antibodies. Furthermore, in vitro incubation of affinity-purified PRL receptor complexes from PRL-stimulated cells with ATP in the presence of a tyrosine phosphatase inhibitor, resulted in a 10-15-fold increase in the phosphotyrosine content of p120, as revealed by antiphosphotyrosine immunoblotting. Parallel experiments utilizing [gamma-P-32]ATP confirmed a rapid and time-dependent incorporation of phosphate into p120 in the same affinity-purified PRL receptor complexes. These data provide strong evidence for the involvement of a tyrosine kinase in PRL signal transduction and suggest the presence of a tyrosine kinase within the activated PRL receptor complex.	NCI, FREDERICK CANC RES & DEV CTR, BIOL RESPONSE MODIFIERS PROGRAM, MOLEC IMMUNOREGULAT LAB, FREDERICK, MD 21702 USA; UNIV S FLORIDA, H LEE MOFFITT CANC INST & RES CTR, TAMPA, FL 33612 USA; NCI, FREDERICK CANC RES & DEV CTR,DYNCORP, PROGRAM RESOURCES INC, BIOL CARCINOGENESIS DEV PROGRAM, FREDERICK, MD 21702 USA; FAC MED NECKER ENFANTS MALAD, INSERM, U344, UNITE ENDOCRINOL MOLEC, F-75730 PARIS 15, FRANCE	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; State University System of Florida; University of South Florida; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Kelly, Paul/A-7951-2008		FIC NIH HHS [5FO5 TWO4300-02] Funding Source: Medline; NCI NIH HHS [N01-CO-74102] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004300] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI S, 1991, J BIOL CHEM, V266, P20110; AUGUSTINE JA, 1990, BIOCHIM BIOPHYS ACTA, V1052, P313, DOI 10.1016/0167-4889(90)90227-5; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BOUTIN JM, 1989, MOL ENDOCRINOL, V3, P1455, DOI 10.1210/mend-3-9-1455; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DAVIS JA, 1989, MOL ENDOCRINOL, V3, P674, DOI 10.1210/mend-3-4-674; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; EDERY M, 1989, P NATL ACAD SCI USA, V86, P2112, DOI 10.1073/pnas.86.6.2112; FARRAR WL, 1991, LYMPHOKINE CYTOK RES, V10, P291; FERRIS DK, 1989, LYMPHOKINE RES, V8, P215; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GOUT PW, 1980, CANCER RES, V40, P2433; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1989, P NATL ACAD SCI USA, V87, P9655; HUGHES JP, 1985, ANNU REV PHYSIOL, V47, P469, DOI 10.1146/annurev.ph.47.030185.002345; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KORNBERG LJ, 1989, BIOCHIM BIOPHYS ACTA, V1011, P205, DOI 10.1016/0167-4889(89)90211-5; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; LESUEUR L, 1991, P NATL ACAD SCI USA, V88, P824, DOI 10.1073/pnas.88.3.824; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; NICOLL CS, 1980, FED PROC, V39, P2563; OKAMURA H, 1989, ENDOCRINOLOGY, V124, P2499, DOI 10.1210/endo-124-5-2499; RAYHEL EJ, 1988, BIOCHEM J, V249, P333, DOI 10.1042/bj2490333; ROZAKISADCOCK M, 1991, J BIOL CHEM, V266, P16472; RUSSELL DH, 1989, TRENDS PHARMACOL SCI, V10, P40, DOI 10.1016/0165-6147(89)90106-5; SALTZMAN EM, 1989, J BIOL CHEM, V264, P19979; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; STRED SE, 1990, ENDOCRINOLOGY, V127, P2506, DOI 10.1210/endo-127-5-2506; STUBBART JR, 1991, ENDOCRINOLOGY, V129, P1659, DOI 10.1210/endo-129-3-1659; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEBB CF, 1988, BIOCHEM J, V250, P215, DOI 10.1042/bj2500215; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YULEE LY, 1990, MOL CELL ENDOCRINOL, V68, P21; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087	49	123	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24076	24081						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385436				2022-12-25	WOS:A1992JZ23900097
J	KAHLE, P; BURTON, LE; SCHMELZER, CH; HERTEL, C				KAHLE, P; BURTON, LE; SCHMELZER, CH; HERTEL, C			THE AMINO TERMINUS OF NERVE GROWTH-FACTOR IS INVOLVED IN THE INTERACTION WITH THE RECEPTOR TYROSINE KINASE P140TRKA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRK PROTOONCOGENE; NGF RECEPTOR; CELLS; BINDING; LINE	The amino terminus of nerve growth factor (NGF) is susceptible to proteolytic cleavage. A comparison of the bioactivity of highly purified full-length recombinant human (1-118)rhNGF and NH2-terminal truncated (10-118)rhNGF revealed lower potency of (10-118)rhNGF with regard to early NGF responses in neuron-like PC12 cells. Approximately 50 times higher concentrations of (10-118)rhNGF than (1-118)rhNGF were required to elicit the same extent of tyrosine phosphorylation of key enzymes in different second messenger pathways, i.e. the NGF receptor tyrosine kinase p140trkA, phospholipase C(gamma-1), and the extracellular signal-regulated kinase ERK1. A similar reduced potency for induction of the transcription factor c-Fos was observed with (10-118)rhNGF compared to (1-118)rhNGF. The lower potency of (10-118)rhNGF in triggering early responses correlated with its 40-fold lower affinity for PC12 cells. Whereas (10-118)rhNGF had a more than 300-fold lower affinity for the high affinity receptor p140trkA than (1-118)rhNGF, amino-terminal truncation of NGF changed its affinity for the low affinity receptor p75NGFR only slightly (5-10-fold). These observations suggest that amino acids 1-9 of NGF are important for binding to the signal transducing receptor p140trkA. Proteolytic cleavage of the NGF amino terminus, therefore, reduces its potency in starting several second messenger pathways leading to neuronal differentiation of PC12 cells.	F HOFFMANN LA ROCHE & CO LTD,DIV PHARMA,PRECLIN RES 70334,CH-4002 BASEL,SWITZERLAND; GENENTECH INC,S SAN FRANCISCO,CA 94080	Roche Holding; Roche Holding; Genentech								BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BURTON LE, 1992, IN PRESS J NEUROCHEM; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; FIELDS KL, 1975, P NATL ACAD SCI USA, V72, P1296, DOI 10.1073/pnas.72.4.1296; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IBANEZ CF, 1990, EMBO J, V9, P1477, DOI 10.1002/j.1460-2075.1990.tb08265.x; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAHLE P, 1992, J BIOL CHEM, V267, P13917; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KNUSEL B, 1990, EXP NEUROL, V110, P274, DOI 10.1016/0014-4886(90)90039-U; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MEAKIN SO, 1992, P NATL ACAD SCI USA, V89, P2374, DOI 10.1073/pnas.89.6.2374; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; OEMAR BS, 1991, J BIOL CHEM, V266, P24241; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RADZIEJEWSKI C, 1992, BIOCHEMISTRY-US, V31, P4431, DOI 10.1021/bi00133a007; Rodbard D, 1975, Methods Enzymol, V37, P3; SCHMELZER CH, 1992, IN PRESS J NEUROCHEM; TAYLOR R A V, 1991, Society for Neuroscience Abstracts, V17, P712; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; VALE RD, 1985, METHOD ENZYMOL, V109, P21; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650	30	62	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22707	22710						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429622				2022-12-25	WOS:A1992JY16300004
J	GATI, WP; PATERSON, ARP; TYRRELL, DLJ; CASS, CE; MORAVEK, J; ROBINS, MJ				GATI, WP; PATERSON, ARP; TYRRELL, DLJ; CASS, CE; MORAVEK, J; ROBINS, MJ			NUCLEOBASE TRANSPORTER-MEDIATED PERMEATION OF 2',3'-DIDEOXYGUANOSINE IN HUMAN ERYTHROCYTES AND HUMAN T-LYMPHOBLASTOID CCRF-CEM CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONFACILITATED DIFFUSION; NUCLEOSIDE TRANSPORT; LEUKEMIA-CELLS; MAMMALIAN-CELLS; CULTURED-CELLS; PURINE; 2',3'-DIDEOXYNUCLEOSIDES; MEMBRANE; INHIBITION; ADENOSINE	Several 2',3'-dideoxynucleosides (ddNs), agents that inhibit the replication of human immunodeficiency virus and hepatitis B virus, enter mammalian cells by simple diffusion. In this report, we show that the membrane permeation of 2',3'-dideoxyguanosine (ddG) in human erythrocytes and CCRF-CEM cells, in contrast with that of other ddNs, is transporter-mediated. Inward fluxes of ddG in both cell types were inhibited by adenine, hypoxanthine, and acyclovir, but not by inhibitors of nucleoside transport (nitrobenzylthioinosine, dipyridamole, dilazep). Fluxes of ddG in human erythrocytes were attributable to a single, rate-saturable process (K(m), 380 +/- 90 muM and V(max), 7.9 +/- 0.8 pmol/s/mul cell water) that was competitively inhibited by adenine (K(i), 16 muM). These results showed that ddG entered human erythrocytes and CCRF-CEM cells by a transporter-mediated process that was also the basis for entry of purine nucleobases. In contrast, inward fluxes of 2,6-diaminopurine-2',3'-dideoxyriboside (ddDAPR), a prodrug of ddG, were not affected by purine nucleobases or nucleoside transport inhibitors in either cell type. Thus, the permeation properties of ddDAPR resembled those of 2',3'-dideoxyadenosine, a diffusional permeant (cell uptake is transporter-independent), and contrasted with those of ddG, the deamination product of ddDAPR. This study demonstrated that the nucleobase moiety of ddNs is an important determinant of membrane permeation.	UNIV ALBERTA,DEPT MED MICROBIOL & INFECT DIS,EDMONTON T6G 2H7,ALBERTA,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2H7,ALBERTA,CANADA; MORAVEK BIOCHEM INC,BREA,CA 92621; BRIGHAM YOUNG UNIV,DEPT CHEM,PROVO,UT 84602	University of Alberta; University of Alberta; Brigham Young University	GATI, WP (corresponding author), UNIV ALBERTA,DEPT PHARMACOL,EDMONTON T6G 2H7,ALBERTA,CANADA.							AHLUWALIA G, 1987, BIOCHEM PHARMACOL, V36, P3797, DOI 10.1016/0006-2952(87)90440-0; ARONOW B, 1986, J BIOL CHEM, V261, P2014; ARONOW B, 1986, MOL CELL BIOL, V6, P2957, DOI 10.1128/MCB.6.8.2957; AUGUST EM, 1991, MOL PHARMACOL, V39, P246; CRAWFORD CR, 1990, J BIOL CHEM, V265, P9732; CRAWFORD CR, 1990, BIOCHIM BIOPHYS ACTA, V1024, P289, DOI 10.1016/0005-2736(90)90357-T; DIBISCEGLIE AM, 1988, ANN INTERN MED, V108, P390, DOI 10.7326/0003-4819-108-3-390; DOMIN BA, 1988, BIOCHEM BIOPH RES CO, V154, P825, DOI 10.1016/0006-291X(88)90214-8; DOMIN BA, 1988, J BIOL CHEM, V263, P9276; DOMIN BA, 1991, BIOCHEM PHARMACOL, V42, P147, DOI 10.1016/0006-2952(91)90693-Y; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; GATI WP, 1984, BIOCHEM PHARMACOL, V33, P3325, DOI 10.1016/0006-2952(84)90101-1; GATI WP, 1989, BIOCHEM J, V263, P957, DOI 10.1042/bj2630957; GATI WP, 1989, RED BLOOD CELL MEMBR, P635; HAO Z, 1988, MOL PHARMACOL, V34, P431; HARLEY ER, 1982, CANCER RES, V42, P1289; LEE B, 1989, ANTIMICROB AGENTS CH, V33, P336, DOI 10.1128/AAC.33.3.336; MAHONY WB, 1988, J BIOL CHEM, V263, P9285; MAHONY WB, 1991, BIOCHEM PHARMACOL, V41, P263, DOI 10.1016/0006-2952(91)90485-N; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; MITSUYA H, 1991, FASEB J, V5, P2369, DOI 10.1096/fasebj.5.10.1712326; OLIVER JM, 1971, CAN J BIOCHEM CELL B, V49, P262, DOI 10.1139/o71-038; PATERSON ARP, 1984, BIOCHEM J, V224, P1001, DOI 10.1042/bj2241001; PATERSONARP, 1991, ROLE ADENOSINE ADENI, P133; PAUL B, 1975, J MED CHEM, V18, P968, DOI 10.1021/jm00244a003; PLAGEMANN PGW, 1987, BIOCHIM BIOPHYS ACTA, V905, P17, DOI 10.1016/0005-2736(87)90004-6; PLAGEMANN PGW, 1984, J MEMBRANE BIOL, V81, P255, DOI 10.1007/BF01868718; PLAGEMANN PGW, 1989, BIOCHEM PHARMACOL, V38, P3469, DOI 10.1016/0006-2952(89)90116-0; PLAGEMANN PGW, 1989, MOL PHARMACOL, V36, P185; PRUS KL, 1990, CANCER RES, V50, P1817; STEIN WD, 1986, TRANSPORT DIFFUSION, P72; SUZUKI S, 1988, BIOCHEM BIOPH RES CO, V156, P1144, DOI 10.1016/S0006-291X(88)80752-6; ZIMMERMAN TP, 1987, J BIOL CHEM, V262, P5748	33	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22272	22276						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429579				2022-12-25	WOS:A1992JW71900045
J	KAVANAUGH, MP; ARRIZA, JL; NORTH, RA; AMARA, SG				KAVANAUGH, MP; ARRIZA, JL; NORTH, RA; AMARA, SG			ELECTROGENIC UPTAKE OF GAMMA-AMINOBUTYRIC-ACID BY A CLONED TRANSPORTER EXPRESSED IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BRAIN GABA TRANSPORTER; RAT-BRAIN; GLIAL-CELLS; MEMBRANE; CLONING; NEUROTRANSMITTERS; SYNAPTOSOMES; MECHANISM; SODIUM	GAT-1, a gamma-aminobutyric acid (GABA) transporter cloned from rat brain, was expressed in Xenopus oocytes. Voltage-clamp measurements showed concentration-dependent, inward currents in response to GABA (K0.5 4.7 muM). The transport current required extracellular sodium and chloride ions; the Hill coefficient for chloride was 0.7, and that for sodium was 1.7. Correlation of current and [H-3]GABA uptake measurements indicate that flux of one positive charge occurs per molecule of GABA transported. Membrane hyperpolarization from -40 to -100 mV increased the transport current approximately 3-fold. The results indicate that the transport of one molecule of GABA involves the co-transport of two sodium ions and one chloride ion.			KAVANAUGH, MP (corresponding author), OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA.		North, Richard/GQA-6156-2022	Amara, Susan/0000-0001-8914-1106	NATIONAL INSTITUTE ON DRUG ABUSE [R37DA003160, R01DA003160, R37DA007595, R01DA007595] Funding Source: NIH RePORTER; NIDA NIH HHS [DA03160, DA07595] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BLAUSTEIN MP, 1976, J MEMBRANE BIOL, V30, P153, DOI 10.1007/BF01869665; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; CLARK JA, 1992, NEURON, V9, P337, DOI 10.1016/0896-6273(92)90172-A; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HAYCOCK JW, 1978, J NEUROCHEM, V30, P1113, DOI 10.1111/j.1471-4159.1978.tb12406.x; IVERSEN LL, 1975, BIOCHEM PHARMACOL, V24, P933, DOI 10.1016/0006-2952(75)90422-0; IVERSEN LL, 1968, J NEUROCHEM, V15, P1141, DOI 10.1111/j.1471-4159.1968.tb06831.x; KAILA K, 1992, J PHYSIOL-LONDON, V453, P627, DOI 10.1113/jphysiol.1992.sp019248; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P1207, DOI 10.1021/bi00600a011; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KROGSGAARDLARSEN P, 1975, J NEUROCHEM, V25, P797, DOI 10.1111/j.1471-4159.1975.tb04410.x; LAEUGER P, 1991, ELECTROGENIC ION PUM, P61; MALCHOW RP, 1990, P NATL ACAD SCI USA, V87, P8945, DOI 10.1073/pnas.87.22.8945; MARTIN DL, 1972, J NEUROCHEM, V19, P841, DOI 10.1111/j.1471-4159.1972.tb01398.x; NELSON H, 1990, FEBS LETT, V269, P181, DOI 10.1016/0014-5793(90)81149-I; RADIAN R, 1983, BIOCHEMISTRY-US, V22, P142; UMBACH JA, 1990, BIOPHYS J, V57, P1217, DOI 10.1016/S0006-3495(90)82640-0	22	124	128	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22007	22009						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429551				2022-12-25	WOS:A1992JW71900006
J	BOUABOULA, M; LEGOUX, P; PESSEGUE, B; DELPECH, B; DUMONT, X; PIECHACZYK, M; CASELLAS, P; SHIRE, D				BOUABOULA, M; LEGOUX, P; PESSEGUE, B; DELPECH, B; DUMONT, X; PIECHACZYK, M; CASELLAS, P; SHIRE, D			STANDARDIZATION OF MESSENGER-RNA TITRATION USING A POLYMERASE CHAIN-REACTION METHOD INVOLVING COAMPLIFICATION WITH A MULTISPECIFIC INTERNAL CONTROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE GENE-EXPRESSION; REACTION ASSAY; QUANTITATION; CELLS; TRANSCRIPTION; INTERLEUKIN-2; RECEPTOR; TISSUES; INVIVO; PCR	We describe a simplified and reliable polymerase chain reaction-based method for assaying RNAs of low abundancy. The technique involves the co-amplification of cellular RNA-derived cDNA with a multispecific cDNA of synthetic origin added as an internal standard, using primer pairs common to both templates. We show that the co-amplified templates accumulate in a parallel manner throughout both the exponential and nonexponential phases of amplification, even when the starting amounts of the templates differ by up to 2 orders of magnitude. This finding means that preliminary experiments designed to determine either the late exponential region or the amplification efficiency for each pair of primers are unnecessary. This has enabled us to develop a greatly simplified quantitation protocol. We illustrate our approach by quantifying the effect of the immunosuppressor cyclosporin A on the accumulation of interleukin-4, interferon-gamma, and interleukin-2 receptor mRNAs in phytohemagglutinin-stimulated human peripheral blood mononuclear cells.	SANOFI RECH,DEPT IMMUNOPHARMACOL,371 RUE PROFESSEUR J BLAYAC,F-34184 MONTPELLIER,FRANCE; SANOFI ELF BIO RECH,LABEGE,FRANCE; UNIV MONTPELLIER 2,BIOL MOLEC LAB,CNRS,UNITE RECH GENET MOLEC 1191,F-34060 MONTPELLIER,FRANCE	Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier			PIECHACZYK, Marc/E-7896-2013	PIECHACZYK, Marc/0000-0003-1367-2597				BECKERANDRE M, 1989, NUCLEIC ACIDS RES, V17, P9437, DOI 10.1093/nar/17.22.9437; CHELLY J, 1990, EUR J BIOCHEM, V187, P691, DOI 10.1111/j.1432-1033.1990.tb15355.x; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CHIRMULE N, 1991, J IMMUNOL METHODS, V137, P141, DOI 10.1016/0022-1759(91)90403-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELIDOW BC, 1989, GENE ANAL TECH, V6, P120, DOI 10.1016/0735-0651(89)90002-2; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FRYE RA, 1989, ONCOGENE, V4, P1153; FUNK CD, 1991, J BIOL CHEM, V266, P12508; GAUCHAT JF, 1989, EUR J IMMUNOL, V19, P1079, DOI 10.1002/eji.1830190618; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GRABSTEIN K, 1986, J IMMUNOL, V136, P4503; GRANELLIPIPERNO A, 1986, J EXP MED, V163, P922, DOI 10.1084/jem.163.4.922; HEMAR A, 1990, EUR J IMMUNOL, V20, P2629, DOI 10.1002/eji.1830201216; HOOF T, 1991, ANAL BIOCHEM, V196, P161, DOI 10.1016/0003-2697(91)90133-E; KAASHOEK JGJ, 1991, LYMPHOKINE CYTOK RES, V10, P231; LEVENSON C, 1990, PCR PROTOCOLS GUIDE, P99; MOHLER KM, 1991, MOL IMMUNOL, V28, P437, DOI 10.1016/0161-5890(91)90157-F; MONTGOMERY RA, 1991, J IMMUNOL, V147, P554; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; MURRAY LJ, 1990, EUR J IMMUNOL, V20, P163, DOI 10.1002/eji.1830200124; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P71; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SHIRE D, 1990, GENE, V93, P183, DOI 10.1016/0378-1119(90)90223-E; STIEGER M, 1991, J VIROL METHODS, V34, P149, DOI 10.1016/0166-0934(91)90095-H; URDEA MS, 1988, NUCLEIC ACIDS RES, V16, P4937, DOI 10.1093/nar/16.11.4937; WACHTER L, 1986, NUCLEIC ACIDS RES, V14, P7985, DOI 10.1093/nar/14.20.7985; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717	29	370	371	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21830	21838						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400493				2022-12-25	WOS:A1992JV01100088
J	ZHANG, JZ; REDMAN, CM				ZHANG, JZ; REDMAN, CM			IDENTIFICATION OF B-BETA CHAIN DOMAINS INVOLVED IN HUMAN FIBRINOGEN ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTARY DEOXYRIBONUCLEIC-ACID; RECOMBINANT HUMAN FIBRINOGEN; HEP G2 CELLS; DNA; BIOSYNTHESIS; MUTAGENESIS; SEQUENCES; SECRETION; EFFICIENT; MODEL	Fibrinogen chains are assembled in a stepwise manner in the rough endoplasmic reticulum prior to secretion of the final six-chain dimeric molecule. Previous studies indicated that the synthesis of Bbeta may be a rate-limiting factor in the assembly of human fibrinogen. To determine the domains of Bbeta which interact with the other two component chains of fibrinogen, deletion mutants of Bbeta were transiently co-expressed, together with Aalpha and gamma chains, in COS cells, and fibrinogen assembly and secretion were measured. Deletion of the COOH-terminal half of the Bbeta chain (amino acids 208-461) did not affect assembly and secretion. Assembly of Aalpha, gamma, and Bbeta also occurred when the first NH2-terminal 72 amino acids of Bbeta were deleted, but not when 93 amino acids were deleted. This indicates that the Bbeta domain between amino acids 73 and 93 is necessary for the assembly of the three fibrinogen chains. This domain marks the start of the alpha-helical "coiled-coil" region of fibrinogen.	NEW YORK BLOOD CTR,LINDSLEY F KIMBALL RES INST,NEW YORK,NY 10021	New York Blood Center					NHLBI NIH HHS [HL37457] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037457] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMONDHIRY HAB, 1975, BLOOD, V45, P607; BLOMBACK B, 1972, ANN NY ACAD SCI, V202, P77, DOI 10.1111/j.1749-6632.1972.tb16323.x; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3244, DOI 10.1021/bi00282a032; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3250, DOI 10.1021/bi00282a033; Crabtree G. R., 1987, MOL BASIS BLOOD DISE, P631; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DANISHEFSKY K, 1990, BIOCHIM BIOPHYS ACTA, V1048, P202, DOI 10.1016/0167-4781(90)90057-9; DOOLITTLE RF, 1978, J MOL BIOL, V120, P311, DOI 10.1016/0022-2836(78)90070-0; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; FARRELL DH, 1991, BIOCHEMISTRY-US, V30, P9414, DOI 10.1021/bi00103a004; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARTWIG R, 1991, J BIOL CHEM, V266, P6578; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; KANT JA, 1983, P NATL ACAD SCI-BIOL, V80, P3953, DOI 10.1073/pnas.80.13.3953; KUDRYK B, 1982, EUR J BIOCHEM, V125, P673, DOI 10.1111/j.1432-1033.1982.tb06735.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIU CY, 1985, J BIOL CHEM, V260, P4390; RAO SPS, 1991, J MOL BIOL, V222, P6578; RIXON MW, 1983, BIOCHEMISTRY-US, V22, P3237, DOI 10.1021/bi00282a031; ROY SN, 1991, J BIOL CHEM, V266, P4758; ROY SN, 1990, J BIOL CHEM, V265, P6389; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058; YU S, 1980, BIOCHEM BIOPH RES CO, V96, P1032, DOI 10.1016/0006-291X(80)90056-X; YU S, 1984, J BIOL CHEM, V259, P574; YU S, 1987, THROMB RES, V46, P281, DOI 10.1016/0049-3848(87)90290-8; YU S, 1983, J BIOL CHEM, V258, P3407; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	28	44	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21727	21732						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400483				2022-12-25	WOS:A1992JV01100073
J	FILHOL, O; BAUDIER, J; DELPHIN, C; LOUEMACKENBACH, P; CHAMBAZ, EM; COCHET, C				FILHOL, O; BAUDIER, J; DELPHIN, C; LOUEMACKENBACH, P; CHAMBAZ, EM; COCHET, C			CASEIN KINASE-II AND THE TUMOR SUPPRESSOR PROTEIN P53 ASSOCIATE IN A MOLECULAR-COMPLEX THAT IS NEGATIVELY REGULATED UPON P53 PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE T-ANTIGEN; EPIDERMAL GROWTH-FACTOR; SV40-TRANSFORMED CELLS; CATALYTIC SUBUNIT; CARCINOMA-CELLS; BETA-SUBUNIT; CALF THYMUS; WILD-TYPE; ONCOGENE; TRANSFORMATION	Selective immunoisolation of P53 from Sf9 cells co-expressing wild-type P53 and casein kinase II yielded a preparation containing casein kinase II, thus suggesting that the two proteins may associate in a molecular complex in the intact cell. Such a complex could indeed be demonstrated in vitro between purified recombinant P53 and oligomeric casein kinase II and was shown to dissociate when P53 became phosphorylated by the kinase. This suggested that the P53 C-terminal domain, which contains the casein kinase II phosphorylation site was involved in the protein-protein interaction; this was confirmed by the fact that an anti-P53 monoclonal antibody directed to that domain inhibited the P53-casein kinase II association. Studies with isolated recombinant casein kinase II subunits disclosed that although the alpha (catalytic) subunit could phosphorylate P53, the formation of a stable P53-casein kinase II association required the presence of the beta subunit of the kinase. This was confirmed by immunoisolation of a P53-beta subunit complex from cells expressing both polypeptides. Although the biological significance of a reversible P53-casein kinase II molecular complex in the control of cell proliferation processes remains to be defined, these observations suggest the possibility of a novel mechanism regulating P53 and casein kinase II activities in the intact cell.	CEN,INSERM,U244,F-38041 GRENOBLE,FRANCE; CEN,DEPT BIOL MOLEC & STRUCT,INSERM,U309,85X,F-38041 GRENOBLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)			Filhol-Cochet, Odile/I-3962-2016; Baudier, Jacques/O-2183-2016	Cochet, Claude/0000-0002-1772-4270; jacques, baudier/0000-0001-8427-4444; Filhol, Odile/0000-0003-1964-7958				ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CARROLL D, 1988, COLD SPRING HARB SYM, V53, P91, DOI 10.1101/SQB.1988.053.01.014; COCHET C, 1983, MOL CELL ENDOCRINOL, V30, P247, DOI 10.1016/0303-7207(83)90062-X; COCHET C, 1983, J BIOL CHEM, V258, P1403; DAHMUS GK, 1984, J BIOL CHEM, V259, P9001; DAHMUS ME, 1981, J BIOL CHEM, V256, P3319; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEIGE JJ, 1983, BIOCHEMISTRY-US, V22, P1452, DOI 10.1021/bi00275a020; FEIGE JJ, 1980, FEBS LETT, V121, P139, DOI 10.1016/0014-5793(80)81283-X; FEIGE JJ, 1985, RECENT PROGR POLYAMI, V13, P181; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; FILHOL O, 1991, BIOCHEM BIOPH RES CO, V180, P945, DOI 10.1016/S0006-291X(05)81157-X; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FIRZLAFF J M, 1989, New Biologist, V1, P44; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; HATHAWAY GM, 1979, J BIOL CHEM, V254, P762; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HATHAWAY GM, 1981, J BIOL CHEM, V256, P1442; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, ONCOGENE HDB, P403; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; LANE DP, 1987, ONCOGENE, V1, P241; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1984, EUR J BIOCHEM, V145, P593, DOI 10.1111/j.1432-1033.1984.tb08598.x; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; PADMANABHA R, 1987, J BIOL CHEM, V262, P1829; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROVINSKI B, 1988, ONCOGENE, V2, P445; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P124; VANROY F, 1984, MOL CELL BIOL, V4, P232, DOI 10.1128/MCB.4.2.232	47	120	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20577	20583						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400378				2022-12-25	WOS:A1992JT97800014
J	LEE, JI; HWANG, PP; HANSEN, C; WILSON, TH				LEE, JI; HWANG, PP; HANSEN, C; WILSON, TH			POSSIBLE SALT BRIDGES BETWEEN TRANSMEMBRANE ALPHA-HELICES OF THE LACTOSE CARRIER OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC PERMEASE; MEMBRANE-PROTEINS; PROTON TRANSLOCATION; DIRECTED MUTAGENESIS; MELIBIOSE CARRIER; CYTOPLASMIC SIDE; GENETIC-ANALYSIS; COOH TERMINUS; TRANSPORT; TOPOLOGY	Although it is energetically extremely unfavorable to have charged amino acid residues of a polypeptide in the hydrophobic environment of the membrane phospholipid bilayer, a few such charged residues are found in membrane-spanning regions of membrane proteins. Ion pairs (salt bridges) would be much more stable in low dielectric media than single ionized residues. This paper provides indirect evidence for a salt bridge between Asp-240 and Lys-319 in the lactose carrier of Escherichia coli. When Asp-240 was changed to alanine by site-directed mutagenesis, there was a loss of the ability to accumulate methyl-beta-D-thiogalactopyranoside (TMG), melibiose, or lactose. Fast-growing revertants were isolated on melibiose minimal agar plates. Two second-site revertants were isolated: Asp-240 --> Ala plus Gly-268 --> Val and Asp-240 --> Ala plus Lys-319 --> Gln. These revertants showed extremely poor accumulation of TMG, melibiose, and lactose, but showed significant "downhill" lactose entry into beta-galactosidase-containing cells with sugar concentrations of 2 and 5 mM. It is concluded that there is some important interaction between Asp-240 and Lys-319, possibly a salt bridge.	HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School			Hwang, Pung-Pung/AAH-1538-2022; Hwang, Pung-Pung/AEQ-4633-2022		NIDDK NIH HHS [DK05736] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK005736, R01DK005736] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BROOKER RJ, 1990, RES MICROBIOL, V141, P309, DOI 10.1016/0923-2508(90)90004-A; BROOKER RJ, 1991, J BIOL CHEM, V266, P4131; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CARRASCO N, 1986, BIOCHEMISTRY-US, V25, P4486, DOI 10.1021/bi00364a004; CARRASCO N, 1985, ANN NY ACAD SCI, V456, P305, DOI 10.1111/j.1749-6632.1985.tb14880.x; CARRASCO N, 1984, P NATL ACAD SCI-BIOL, V81, P4672, DOI 10.1073/pnas.81.15.4672; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FELLE H, 1980, BIOCHEMISTRY-US, V19, P3585, DOI 10.1021/bi00556a026; FOSTER DL, 1983, J BIOL CHEM, V258, P31; GARTY H, 1988, J BIOL CHEM, V263, P5550; HELLER KB, 1979, J BACTERIOL, V140, P395, DOI 10.1128/JB.140.2.395-399.1979; HOBSON AC, 1977, J BACTERIOL, V131, P830, DOI 10.1128/JB.131.3.830-838.1977; HONIG BH, 1984, P NATL ACAD SCI-BIOL, V81, P5412, DOI 10.1073/pnas.81.17.5412; KABACK HR, 1988, ANNU REV PHYSIOL, V50, P243; KABACK HR, 1988, PHIL T R SOC LOND B, V326, P425; KARLISH SJD, 1985, SODIUM PUMP, P487; KHORANA HG, 1988, J BIOL CHEM, V263, P7439; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOLKEMA JS, 1988, BIOCHEMISTRY-US, V27, P8307, DOI 10.1021/bi00422a003; LOPILATO J, 1986, MOL GEN GENET, V205, P285, DOI 10.1007/BF00430440; MACARA IG, 1981, BIOCHEMISTRY-US, V20, P5695, DOI 10.1021/bi00523a009; MANOIL C, 1988, TRENDS GENET, V4, P223, DOI 10.1016/0168-9525(88)90154-0; MCCARTHY MP, 1992, STRUCTURE BIOL MEMBR, P395; MENICK DR, 1987, BIOCHEMISTRY-US, V26, P6638, DOI 10.1021/bi00395a012; MILLER MJ, 1990, P NATL ACAD SCI USA, V87, P4900, DOI 10.1073/pnas.87.13.4900; MITCHELL P, 1976, BIOCHEM SOC T, V4, P399, DOI 10.1042/bst0040399; PUTTNER IB, 1986, BIOCHEMISTRY-US, V25, P4483; REITHMEIER RAF, 1992, STRUCTURE BIOL MEMBR, P337; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SECKLER R, 1986, BIOCHEMISTRY-US, V25, P2403, DOI 10.1021/bi00357a016; SECKLER R, 1983, J BIOL CHEM, V258, P817; SENIOR AE, 1983, BIOCHIM BIOPHYS ACTA, V726, P81, DOI 10.1016/0304-4173(83)90001-0; STERN LJ, 1989, J BIOL CHEM, V264, P14202; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; WEST IC, 1970, BIOCHEM BIOPH RES CO, V41, P655, DOI 10.1016/0006-291X(70)90063-X; WILSON DM, 1981, BIOCHIM BIOPHYS ACTA, V649, P377, DOI 10.1016/0005-2736(81)90427-2; WILSON DM, 1987, BIOCHIM BIOPHYS ACTA, V904, P191, DOI 10.1016/0005-2736(87)90368-3; WILSON DM, 1986, METHOD ENZYMOL, V125, P377; WILSON TH, 1990, BIOCHIM BIOPHYS ACTA, V1029, P113, DOI 10.1016/0005-2736(90)90443-R	43	102	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20758	20764						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400392				2022-12-25	WOS:A1992JT97800040
J	STUEHR, DJ; IKEDASAITO, M				STUEHR, DJ; IKEDASAITO, M			SPECTRAL CHARACTERIZATION OF BRAIN AND MACROPHAGE NITRIC-OXIDE SYNTHASES - CYTOCHROME-P-450-LIKE HEMEPROTEINS THAT CONTAIN A FLAVIN SEMIQUINONE RADICAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYTOCHROME P-450 REDUCTASE; L-ARGININE; PHENYLALANINE-HYDROXYLASE; SPECTROSCOPIC PROPERTIES; MURINE MACROPHAGES; LIGAND COMPLEXES; FLAVOPROTEIN; STATE; IDENTIFICATION; PURIFICATION	Nitric oxide (NO) is synthesized in mammals where it acts as a signal molecule for neurotransmission, vasorelaxation, and cytotoxicity. The NO synthases isolated from brain and cytokine-activated macrophages are FAD- and FMN-containing flavoproteins that display considerable sequence homology to NADPH-cytochrome P-450 reductase. However, the nature of their catalytic centers is unknown. We have found that both isoenzymes contain 2 mol of iron-protoporphyrin IX/mol of enzyme homodimer. The optical and EPR spectroscopic properties of the heme groups were found to be remarkably similar to those of high-spin cytochrome P-450. The heme iron in the resting NO synthase is ferric and five-coordinate with a cysteine thiolate as the proximal axial ligand. In addition, the EPR spectra of the resting NO synthases contained a free radical signal attributable to a bound flavin semiquinone that appeared to interact magnetically with the ferric heme iron. NO production was inhibited by carbon monoxide, implying a role for the heme groups in catalysis.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA	Case Western Reserve University	STUEHR, DJ (corresponding author), CLEVELAND CLIN, IMMUNOL SECT, CLEVELAND, OH 44195 USA.		Ikeda-Saito, Masao/K-2703-2015; Ikeda-Saito, Masao/A-5992-2008		NATIONAL CANCER INSTITUTE [R01CA053914, R29CA053914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039492, R01GM039359] Funding Source: NIH RePORTER; NCI NIH HHS [CA53914] Funding Source: Medline; NIGMS NIH HHS [GM39492, GM39359] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Brunori, 1972, HEMOGLOBIN MYOGLOBIN; CHEVION M, 1977, J BIOL CHEM, V252, P3637; DAVIS MD, 1989, J BIOL CHEM, V264, P8585; DAWSON JH, 1983, J BIOL CHEM, V258, P3637; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; DIX TA, 1987, BIOCHEMISTRY-US, V26, P3354, DOI 10.1021/bi00386a016; DUNFORD HB, 1982, ADV INORG BIOCHEM, V4, P41; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; IYANAGI T, 1974, BIOCHEMISTRY-US, V13, P1701, DOI 10.1021/bi00705a023; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; Joseph M.H., 1986, HPLC SMALL MOL PRACT; KWON NS, 1989, J BIOL CHEM, V264, P20496; KWON NS, 1990, J BIOL CHEM, V265, P13442; LEONE AM, 1991, J BIOL CHEM, V266, P23790; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; NAHRI LO, 1986, J BIOL CHEM, V261, P7160; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; OHNISHI T, 1981, J BIOL CHEM, V256, P5577; Ohnishi T, 1982, IRON SULFUR PROTEINS, V4, P285; Ortiz de Montellano PR, 1986, CYTOCHROME P450 STRU, P217; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; OTVOS JD, 1986, BIOCHEMISTRY-US, V25, P7220, DOI 10.1021/bi00370a068; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; POULOS TL, 1985, J BIOL CHEM, V260, P6122; PRINCE RC, 1988, BIOCHIM BIOPHYS ACTA, V952, P220, DOI 10.1016/0167-4838(88)90119-7; SALERNO JC, 1980, BIOCHEM J, V192, P759; SATO M, 1977, BIOCHIM BIOPHYS ACTA, V498, P403, DOI 10.1016/0304-4165(77)90279-3; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SLAPPENDEL S, 1982, BIOCHIM BIOPHYS ACTA, V708, P259, DOI 10.1016/0167-4838(82)90435-6; STUEHR DJ, 1987, J IMMUNOL, V139, P518; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; TSAI R, 1970, P NATL ACAD SCI USA, V66, P1157, DOI 10.1073/pnas.66.4.1157; VERMILION JL, 1978, J BIOL CHEM, V253, P8812; WALLICK DE, 1984, BIOCHEMISTRY-US, V23, P1295, DOI 10.1021/bi00301a043; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WHITE RE, 1982, J BIOL CHEM, V257, P3073; WHITTAKER JW, 1984, J BIOL CHEM, V259, P4476; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YU CA, 1974, J BIOL CHEM, V249, P94	52	363	363	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20547	20550						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383204				2022-12-25	WOS:A1992JT97800007
J	DEENEY, JT; TORNHEIM, K; KORCHAK, HM; PRENTKI, M; CORKEY, BE				DEENEY, JT; TORNHEIM, K; KORCHAK, HM; PRENTKI, M; CORKEY, BE			ACYL-COA ESTERS MODULATE INTRACELLULAR CA2+ HANDLING BY PERMEABILIZED CLONAL PANCREATIC BETA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RINM5F INSULINOMA CELLS; ACID-BINDING-PROTEIN; ATP ADP RATIO; FATTY-ACIDS; COENZYME-A; FREE CA-2+; MALONYL-COA; CARNITINE ACYLTRANSFERASE; STARVED RATS; KINASE-C	Cytosolic free Ca2+ rises in pancreatic beta-cells in response to glucose stimulation and is part of the coupling to insulin secretion. This study evaluates a possible role for cytosolic long chain acyl-CoA esters in modulating Ca2+ handling by clonal beta-cells (HIT). Intact cells incubated with 20 muM free palmitic acid exhibited a 40% decrease in basal cytosolic free Ca2+. In contrast, acyl-CoA esters, up to a chain length of 16, but not the corresponding fatty acids, significantly lowered the Ca2+ set point maintained by cells permeabilized with saponin. The maximum response to the various acyl-CoA esters increased with increasing chain length, with no differences in the half-maximally effective concentration of 0.5 muM. Long chain acyl-CoA esters caused a 40-50% increase in Ca-45(2+) influx into a non-mitochondrial pool in the permeabilized HIT cells, consistent with a stimulatory effect on the endoplasmic reticulum Ca2+-ATPase activity, but did not affect inositol 1,4,5-trisphosphate-induced Ca2+-efflux. Thapsigargin, an inhibitor of endoplasmic reticulum Ca2+-ATPase activity, blocked the decrease in the Ca2+ set point caused by acyl-CoA esters. The ability of acyl-CoA esters to lower the Ca2+ set point depended on the ATP/ADP ratio (or free ADP); the Ca2+ set point was lowered by 36 +/- 3.6% at an ATP/ADP ratio of 90 and by 14 +/- 1.9% at an ATP/ADP ratio of 7. Depletion of cellular protein kinase C did not prevent the acyl-CoA-induced lowering of the Ca2+ set point. These findings suggest that the increases in long chain acyl-CoA esters may play a role in restoring cytosolic free Ca2+ through activation of Ca2+-ATPases.	BOSTON UNIV, SCH MED, DIV DIABET & METAB, BOSTON, MA 02118 USA; UNIV PENN, SCH MED, DEPT PEDIAT, PHILADELPHIA, PA 19104 USA; UNIV GENEVA, CTR MED UNIV, DIV BIOCHIM CLIN, CH-1211 GENEVA 4, SWITZERLAND	Boston University; University of Pennsylvania; University of Geneva			; Corkey, Barbara/E-7712-2015	Tornheim, Keith/0000-0002-6235-5128; Deeney, Jude/0000-0003-0988-9419; Corkey, Barbara/0000-0002-5467-1630	NIDDK NIH HHS [DK35914, DK31559] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035914, R37DK035914, R01DK031559] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGIUS L, 1987, CLIN SCI, V73, P3, DOI 10.1042/cs0730003; ANDERSON MP, 1990, P NATL ACAD SCI USA, V87, P7334, DOI 10.1073/pnas.87.18.7334; BERNE C, 1975, BIOCHEM J, V152, P667, DOI 10.1042/bj1520667; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BOYLAN JG, 1992, BIOCHEMISTRY-US, V31, P557, DOI 10.1021/bi00117a037; BRONFMAN M, 1988, BIOCHEM BIOPH RES CO, V152, P987, DOI 10.1016/S0006-291X(88)80381-4; BURRIER RE, 1987, BIOCHIM BIOPHYS ACTA, V919, P221, DOI 10.1016/0005-2760(87)90261-X; CAMPILLO JE, 1979, DIABETOLOGIA, V16, P267, DOI 10.1007/BF01221954; CHANCE B, 1975, ANAL BIOCHEM, V66, P498, DOI 10.1016/0003-2697(75)90617-X; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; CORKEY BE, 1988, METHOD ENZYMOL, V166, P55; CORKEY BE, 1988, J BIOL CHEM, V263, P4247; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; CORKEY BE, 1990, PROG CLIN BIOL RES, V321, P217; CORKEY BE, 1988, J BIOL CHEM, V263, P4254; CRESPIN SR, 1973, J CLIN INVEST, V52, P1979, DOI 10.1172/JCI107382; DEAN PM, 1973, DIABETOLOGIA, V9, P115, DOI 10.1007/BF01230690; FARESE RV, 1986, ENDOCRINOLOGY, V118, P1498, DOI 10.1210/endo-118-4-1498; GOBERNA R, 1974, HORM METAB RES, V6, P256, DOI 10.1055/s-0028-1093862; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; HUANG WH, 1989, J BIOL CHEM, V264, P2605; HUANG WH, 1986, BIOCHEM INT, V12, P521; LI QL, 1990, J BIOCHEM-TOKYO, V107, P699, DOI 10.1093/oxfordjournals.jbchem.a123111; LONGO EA, 1991, J BIOL CHEM, V266, P9314; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MATSCHINSKY FM, 1989, INT CONGR SER, V800, P17; MCGARRY JD, 1981, BIOCHEM J, V200, P217, DOI 10.1042/bj2000217; MCGARRY JD, 1979, J BIOL CHEM, V254, P8163; ORDWAY RW, 1989, SCIENCE, V244, P1176, DOI 10.1126/science.2471269; PETERRIESCH B, 1988, J CLIN INVEST, V81, P1154, DOI 10.1172/JCI113430; POWELL GL, 1985, FED PROC, V44, P81; PRENTKI M, 1988, J BIOL CHEM, V263, P11044; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; PRENTKI M, 1983, J BIOL CHEM, V258, P7597; RASMUSSEN JT, 1990, BIOCHEM J, V265, P849, DOI 10.1042/bj2650849; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TIPPETT PS, 1982, J BIOL CHEM, V257, P2839; TIPPETT PS, 1982, J BIOL CHEM, V257, P2846; TORNHEIM K, 1991, J BIOL CHEM, V266, P15675; VARA E, 1986, METABOLISM, V35, P266, DOI 10.1016/0026-0495(86)90212-X; WEIBEL ER, 1969, J CELL BIOL, V42, P68, DOI 10.1083/jcb.42.1.68; Williamson J R, 1979, Methods Enzymol, V55, P200; Williamson J.R., 1969, METHOD ENZYMOL, V13, P434, DOI 10.1016/0076-687913072-4; WOLDEGIORGIS G, 1985, ANAL BIOCHEM, V150, P8, DOI 10.1016/0003-2697(85)90434-8; WOLDEGIORGIS G, 1982, J BIOL CHEM, V257, P4783; WOLF BA, 1989, BIOCHEMISTRY-US, V28, P4291, DOI 10.1021/bi00436a026	50	89	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19840	19845						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400300				2022-12-25	WOS:A1992JR85800017
J	REDDY, CD; DASGUPTA, P; SAIKUMAR, P; DUDEK, H; RAUSCHER, FJ; REDDY, EP				REDDY, CD; DASGUPTA, P; SAIKUMAR, P; DUDEK, H; RAUSCHER, FJ; REDDY, EP			MUTATIONAL ANALYSIS OF MAX - ROLE OF BASIC, HELIX LOOP HELIX LEUCINE ZIPPER DOMAINS IN DNA-BINDING, DIMERIZATION AND REGULATION OF MYC-MEDIATED TRANSCRIPTIONAL ACTIVATION	ONCOGENE			English	Article							ESCHERICHIA-COLI; PROTO-ONCOGENE; GROWTH-FACTOR; PROTEINS; EXPRESSION; CELLS; OLIGOMERIZATION; PURIFICATION; SPECIFICITY; ENHANCER	The Max protein forms a heterodimeric complex with the Myc family of proteins and binds to DNA in a sequence-specific manner. We investigated the role of the helix-loop-helix (HLH), leucine zipper (LZ) and basic domains of Max in protein complex formation, DNA-binding activity and transcriptional regulation. We mutagenized the basic, HLH and LZ domains of Max and studied the ability of the normal and mutant proteins to bind to DNA as both homo- and heterodimers and their ability to heterodimerize with Myc. Helix-1 and helix-2 regions of Max were found to be critical for homodimer formation and subsequent DNA binding, while the LZ was essential for heterodimer formation. In transient transfection assays the Myc protein functioned as a transcriptional activator while Max protein repressed the trans-activation observed with Myc.	FELS INST CANC RES & MOLEC BIOL,3420 N BROAD ST,PHILADELPHIA,PA 19140; WISTAR INST,PHILADELPHIA,PA 19104	The Wistar Institute			Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [P01CA052009, P01CA021124] Funding Source: NIH RePORTER; NCI NIH HHS [CA10817, CA52009, CA21124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENNEROT CD, 1987, P NATL ACAD SCI USA, V84, P6796; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BEREBERICH S, 1992, ONCOGENE, V7, P775; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COLLUM RG, 1990, CANCER CELL-MON REV, V2, P69; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI L, 1992, ADV CANCER RES, V58, P95, DOI 10.1016/S0065-230X(08)60292-4; MIKSICEK R, 1986, CELL, V46, P283, DOI 10.1016/0092-8674(86)90745-2; MIYAMOTO C, 1985, P NATL ACAD SCI USA, V82, P7232, DOI 10.1073/pnas.82.21.7232; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SETH A, 1986, GENE, V42, P49, DOI 10.1016/0378-1119(86)90149-6; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; WIEGLER M, 1978, CELL, V14, P725; ZIMMERMAN K, 1990, Critical Reviews in Oncogenesis, V2, P75	37	62	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2085	2092						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408152				2022-12-25	WOS:A1992JP42400027
J	DAI, ZH; STILES, AD; MOATSSTAATS, B; VANWYK, JJ; DERCOLE, AJ				DAI, ZH; STILES, AD; MOATSSTAATS, B; VANWYK, JJ; DERCOLE, AJ			INTERACTION OF SECRETED INSULIN-LIKE GROWTH FACTOR-I (IGF-I) WITH CELL-SURFACE RECEPTORS IS THE DOMINANT MECHANISM OF IGF-IS AUTOCRINE ACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUMINAL ER PROTEINS; SOMATOMEDIN-C; TISSUE CONCENTRATIONS; EPITHELIAL-CELLS; RAT; DNA; TRANSFORMATION; STIMULATION; CULTURE; BINDING	In a prior report we presented evidence that insulin-like growth factor-I (IGF-I) can act in an autocrine fashion by demonstrating that FRTL-5 cells transfected with hIGF-IA fusion genes express and secrete biologically active IGF-I that renders the stimulation of DNA synthesis in FRTL-5 cells independent of their requirement for exogenous IGFs or insulin. To determine if IGF-I's autocrine actions require secretion or can be mediated by interactions with intracellular receptors, we have created a new line of FRTL-5 cells that express a mutant IGF-IA precursor containing the endoplasmic reticulum retention amino acid sequence, Lys-Asp-Glu-Leu (KDEL), at its carboxyl terminus. The mutant IGF-IA/KDEL precursor expressed by stably transfected FRTL-5 cells was shown to be retained intracellularly and to have biological activity comparable with mature IGF-I, as judged by the activity of partially purified IGF-IA/KDEL in wild type FRTL-5 cells. Expression of IGF-IA/KDEL in FRTL-5 cells, however, neither augmented TSH-stimulated DNA synthesis nor stimulated IGF-binding protein-5 expression, as does IGF-IA expression in transfected FRTL-5 cells and the addition of exogenous IGF-I to wild type FRTL-5 cells. IGF-IA/KDEL expression, however, desensitized FRTL-5 cells to the actions of exogenous IGF-I despite having only minimal effects on cell surface type I receptor number, suggesting that intracellular IGF-I is capable of significant biological actions. The failure of IGF-IA/KDEL to replicate the actions of secreted IGF-I, taken together with the findings that a monoclonal antibody against IGF-I blocked IGF-I's actions in IGF-I-secreting transfected FRTL-5 cells, provides evidence that IGF-I secretion and interaction with cell surface type I IGF receptors is the dominant mechanism of IGF-I's autocrine actions.	UNIV N CAROLINA,DEPT PEDIAT,CB 7220,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NHLBI NIH HHS [HL-38902] Funding Source: Medline; NICHD NIH HHS [HD-08299] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD008299] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038902] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CASCIERI MA, 1988, ENDOCRINOLOGY, V122, P1314, DOI 10.1210/endo-122-4-1314; CHATELAIN P, 1991, ACTA PAEDIATR SC   S, V80, P92; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMMONS DR, 1991, ADV EXP MED BIOL, V293, P113; CONOVER CA, 1988, ACTA ENDOCRINOL-COP, V118, P513, DOI 10.1530/acta.0.1180513; DAI ZH, 1992, ENDOCRINOLOGY, V130, P3175, DOI 10.1210/en.130.6.3175; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DERCOLE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P935, DOI 10.1073/pnas.81.3.935; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; FURLANETTO RW, 1977, J CLIN INVEST, V60, P648, DOI 10.1172/JCI108816; GLANVILLE N, 1981, NATURE, V292, P267, DOI 10.1038/292267a0; HANNINK M, 1988, J CELL BIOL, V107, P287, DOI 10.1083/jcb.107.1.287; HEATON JH, 1986, ENDOCRINOLOGY, V118, P2555, DOI 10.1210/endo-118-6-2555; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; LEROITH D, 1991, MOL CELL ENDOCRINOL, V77, pC57, DOI 10.1016/0303-7207(91)90054-V; MACIEL RMB, 1988, J CLIN INVEST, V82, P1546, DOI 10.1172/JCI113764; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; MATHEWS LS, 1987, GROWTH HORMONE BASIC, P373; MCCUSKER RH, 1988, J CELL PHYSIOL, V137, P505, DOI 10.1002/jcp.1041370316; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; RETSCHBOGART GZ, 1990, AM J RESP CELL MOL, V3, P227, DOI 10.1165/ajrcmb/3.3.227; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; STILES AD, 1989, AM J RESP CELL MOL, V1, P21, DOI 10.1165/ajrcmb/1.1.21; TAKAHASHI S, 1990, ENDOCRINOLOGY, V126, P736, DOI 10.1210/endo-126-2-736; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TRAMONTANO D, 1986, ENDOCRINOLOGY, V119, P940, DOI 10.1210/endo-119-2-940; VANWYK JJ, 1987, GROWTH HORMONE BASIC, P337; VANWYK JJ, 1986, HUMAN GROWTH HORMONE, P585; ZHANG H, 1988, NUCLEIC ACIDS RES, V16, P1220, DOI 10.1093/nar/16.3.1220	37	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19565	19571						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1382073				2022-12-25	WOS:A1992JP59300082
J	FUJIMORI, T; JENCKS, WP				FUJIMORI, T; JENCKS, WP			THE KINETICS FOR THE PHOSPHORYL TRANSFER STEPS OF THE SARCOPLASMIC-RETICULUM CALCIUM ATPASE ARE THE SAME WITH STRONTIUM AND WITH CALCIUM BOUND TO THE TRANSPORT SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIMITING CONFORMATIONAL CHANGE; TRANSIENT-STATE KINETICS; ADENOSINE-TRIPHOSPHATASE; ENERGY INTERCONVERSION; CA2+-DEPENDENT ATPASE; REACTION-MECHANISM; ACETYL PHOSPHATE; MULTIPLE METALS; INDUCED RELEASE; BINDING-SITES	Rate constants for most of the steps of the reaction cycle of the sarcoplasmic reticulum calcium-ATPase are similar or identical with Ca2+ or Sr2+ as the transported ions in spite of the large differences in the size and affinity of Ca2+ and Sr2+ (5 mM MgCl2, 100 mM KCl, pH 7.0,25-degrees-C). Phosphorylation of (c)E.Sr2 and (c)E. Ca2 by ATP occurs with k(p) = 220-235 s-1, whereas phosphorylation of E.ATP + Ca2+ or Sr2+ is consistent with k(b) = 50-70 s-1. Hydrolysis of E approximately P.Sr2 and E approximately P. Ca2 occurs with k(t) = 20 s-1, and the addition of 7 mm ADP to E approximately P.Sr2 or to E approximately P-Ca2 gives a burst of approximately 43% dephosphorylation, followed by dephosphorylation with k = 46 s-1. However, one Sr2+ ion dissociates from (c)E.Sr2 and from (c)E.ATP.Sr2 with k congruent-to 120 s-1, whereas one Ca2+ ion dissociates from (c)E.Ca2 with k = 38 s-1 and from (c)E.ATP.Ca2 with k = 80 s-1.	BRANDEIS UNIV, DEPT BIOCHEM, WALTHAM, MA 02254 USA	Brandeis University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020888, R01GM020888] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20888] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN DG, 1977, SCIENCE, V195, P996, DOI 10.1126/science.841325; BERMAN MC, 1990, BIOCHIM BIOPHYS ACTA, V1029, P235, DOI 10.1016/0005-2736(90)90159-L; BODLEY AL, 1987, J BIOL CHEM, V262, P13997; CHIESI M, 1980, BIOCHEMISTRY-US, V19, P2912, DOI 10.1021/bi00554a015; COTTON FA, 1988, ADV INORG CHEM RAD, P144; de Meis L, 1977, Biochemistry, V16, P4455, DOI 10.1021/bi00639a020; de Meis L, 1974, Biochemistry, V13, P5032, DOI 10.1021/bi00721a026; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DUPONT Y, 1982, BIOCHIM BIOPHYS ACTA, V688, P75, DOI 10.1016/0005-2736(82)90580-6; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; Edsall J T, 1978, Adv Biophys, V10, P137; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FABIATO A, 1981, J GEN PHYSIOL, V78, P457, DOI 10.1085/jgp.78.5.457; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FERNANDEZBELDA F, 1984, J BIOL CHEM, V259, P9687; FERNANDEZBELDA F, 1986, BIOCHEMISTRY-US, V25, P8083, DOI 10.1021/bi00372a043; FROEHLICH JP, 1985, BIOCHEMISTRY-US, V24, P126, DOI 10.1021/bi00322a018; FROEHLICH JP, 1980, FED PROC, V39, P2151; FUJIMORI T, 1990, J BIOL CHEM, V265, P16262; FUJIMORI T, 1992, J BIOL CHEM, V267, P18475; GUILLAIN F, 1980, J BIOL CHEM, V255, P2072; GUIMARAESMOTTA H, 1984, J BIOL CHEM, V259, P8699; HANEL AM, 1990, BIOCHEMISTRY-US, V29, P5210, DOI 10.1021/bi00473a030; HANEL AM, 1991, BIOCHEMISTRY-US, V30, P11320, DOI 10.1021/bi00111a019; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; HIROMI K, 1979, KINETICS FAST ENZYME, P220; HOLGUIN JA, 1986, ARCH BIOCHEM BIOPHYS, V251, P9, DOI 10.1016/0003-9861(86)90045-7; IKEMOTO N, 1975, J BIOL CHEM, V250, P7219; INESI G, 1980, J BIOL CHEM, V255, P3025; JENCKS WP, 1983, CURR TOP MEMBR TRANS, V19, P1; KHANANSHVILI D, 1990, FEBS LETT, V260, P83, DOI 10.1016/0014-5793(90)80071-P; KNOWLES AF, 1975, J BIOL CHEM, V250, P1949; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MAKINOSE M, 1973, FEBS LETT, V37, P140, DOI 10.1016/0014-5793(73)80443-0; MERMIER P, 1976, EUR J BIOCHEM, V69, P79, DOI 10.1111/j.1432-1033.1976.tb10860.x; NAKAMURA J, 1986, BIOCHIM BIOPHYS ACTA, V870, P495, DOI 10.1016/0167-4838(86)90258-X; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P11331, DOI 10.1021/bi00111a020; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P8626, DOI 10.1021/bi00423a018; PETITHORY JR, 1986, BIOCHEMISTRY-US, V25, P4493, DOI 10.1021/bi00364a006; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; PICKART CM, 1984, J BIOL CHEM, V259, P1629; PICKART CM, 1982, J BIOL CHEM, V257, P5319; SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P8698; STAHL N, 1984, BIOCHEMISTRY-US, V23, P5389, DOI 10.1021/bi00318a002; STAHL N, 1987, BIOCHEMISTRY-US, V26, P7654, DOI 10.1021/bi00398a019; STEINFELD JI, 1989, CHEM KINETICS DYNAMI, P27; SUMIDA M, 1980, J BIOL CHEM, V255, P1497; TAKAKUWA Y, 1979, BIOCHEM BIOPH RES CO, V88, P1209, DOI 10.1016/0006-291X(79)91108-2; VERJOVSKIALMEIDA S, 1978, BIOCHEMISTRY-US, V17, P5006, DOI 10.1021/bi00616a023; WAKABAYASHI S, 1987, J BIOL CHEM, V262, P11524; WANG T, 1986, J BIOL CHEM, V261, P6307; WEBER A, 1966, BIOCHEM Z, V345, P329; YAMADA S, 1972, J BIOCHEM, V72, P417, DOI 10.1093/oxfordjournals.jbchem.a129917	56	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18466	18474						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1388154				2022-12-25	WOS:A1992JN50200038
J	TOZAWA, K; ODAKA, M; DATE, T; YOSHIDA, M				TOZAWA, K; ODAKA, M; DATE, T; YOSHIDA, M			MOLECULAR DISSECTION OF THE BETA-SUBUNIT OF F1-ATPASE INTO PEPTIDE-FRAGMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATE SYNTHASE; MITOCHONDRIAL ATP SYNTHASE; THERMOPHILIC BACTERIUM PS3; ESCHERICHIA-COLI; ADENINE-NUCLEOTIDES; GLUTAMIC-ACID; BINDING; RECONSTITUTION; MUTAGENESIS; COMPLEX	Partial digestion of the native beta-subunit of F1-ATPase from the thermophilic Bacillus strain PS3 by three different proteases produced a limited number of peptide fragments. In most cases, the peptides remained associated, and the gross structure of the beta-subunit was not destroyed. Furthermore, most peptides were able to reassociate into the form of the beta-subunit after denaturating urea treatment. Therefore, the cleaved sites are most likely located in water-exposed loop regions in the tertiary structure of the protein. Almost all peptides were analyzed, and 17 cleaved sites were determined. From the analysis of the distribution of cleaved sites and deletions or insertions in the multiple amino acid sequence alignment of proteins homologous to the beta-subunit, locations of five loops and four candidate loops in the beta-subunit are suggested. There are two large loops in the central region of the beta-subunit sequence, and dicyclohexylcarbodiimide-reactive Glu190 is located in one of them. Tyr341, involved in putative catalytic ATP binding, is also found in one of the loops. Then, taking cleaved sites as a reference, two kinds of expression plasmids, each of which carried genes of two complementary peptide fragments, 1-193 and 198-473 or 1-284 and 285-473, were constructed and expressed in Escherichia coli. For each plasmid, two peptides were coexpressed, associated into a stable beta-subunit form in E. coli cells, and purified without dissociation. When these beta-subunits were denatured by urea and applied to polyacrylamide gel without denaturant, a protein band with the same mobility as that of the beta-subunit appeared, indicating that reassociation of peptide fragments into the form of the beta-subunit occurred upon removal of urea. These beta-subunits retained the ability to reconstitute the alpha-3-beta-3-gamma complexes even though the efficiency of reconstitution and the recovered ATPase activities were decreased. These complexes were stable at high or low temperature, and ATPase activities were sensitive to inhibition by N3-.	TOKYO INST TECHNOL, RESOURCES UTILIZAT RES LAB, R-1, YOKOHAMA, KANAGAWA 227, JAPAN; KANAZAWA MED UNIV, DEPT BIOCHEM, KAHOKU, ISHIKAWA 92002, JAPAN	Tokyo Institute of Technology; Kanazawa Medical University			Odaka, Masafumi/C-2378-2013					BENNER SA, 1991, ADV ENZYME REGUL, V31, P121, DOI 10.1016/0065-2571(91)90012-B; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DUNN SD, 1980, J BIOL CHEM, V255, P113; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GARBOCZI DN, 1990, J BIOL CHEM, V265, P14632; GARBOCZI DN, 1988, J BIOL CHEM, V263, P15694; HISABORI T, 1986, J BIOCHEM-TOKYO, V100, P663, DOI 10.1093/oxfordjournals.jbchem.a121758; ISSARTEL JP, 1984, BIOCHEMISTRY-US, V23, P6591, DOI 10.1021/bi00321a048; KAGAWA Y, 1986, J BIOCHEM-TOKYO, V100, P923, DOI 10.1093/oxfordjournals.jbchem.a121805; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIWA K, 1989, P NATL ACAD SCI USA, V86, P6484, DOI 10.1073/pnas.86.17.6484; ODAKA M, 1990, BIOCHEM BIOPH RES CO, V168, P372, DOI 10.1016/0006-291X(90)91718-8; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; OHTA S, 1980, J BIOCHEM-TOKYO, V87, P1609, DOI 10.1093/oxfordjournals.jbchem.a132904; OHTSUBO M, 1987, BIOCHEM BIOPH RES CO, V146, P705, DOI 10.1016/0006-291X(87)90586-9; SATOH H, 1989, SEKAGAKU, V91; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; THORNTON JM, 1991, NATURE, V354, P105, DOI 10.1038/354105a0; TSUTSUMI S, 1991, BIOCHIM BIOPHYS ACTA, V1098, P13, DOI 10.1016/0005-2728(91)90003-7; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5; YOKOYAMA K, 1989, J BIOL CHEM, V264, P21837; YOSHIDA M, 1979, J BIOL CHEM, V254, P9525; YOSHIDA M, 1981, J BIOL CHEM, V256, P148; YOSHIDA M, 1982, J BIOL CHEM, V257, P33; YOSHIDA M, 1975, J BIOL CHEM, V250, P7910; YOSHIDA M, 1977, J BIOL CHEM, V252, P3480	29	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16484	16490						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1386603				2022-12-25	WOS:A1992JJ45800077
J	ZHANG, K; WANG, ZQ; GLUCK, S				ZHANG, K; WANG, ZQ; GLUCK, S			A CYTOSOLIC INHIBITOR OF VACUOLAR H+-ATPASES FROM MAMMALIAN KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; AMINO-ACID-SEQUENCE; BOVINE KIDNEY; URINARY ACIDIFICATION; HEART-MITOCHONDRIA; PROTEIN INHIBITOR; PROTON PUMP; PURIFICATION; ELECTROPHORESIS; NA+,K+-ATPASE	Regulation of the vacuolar H+-ATPase in organellar and transepithelial acidification has been attributed to the effects of the proton electrochemical gradient across the membrane or to changes in the number of proton pumps. We now report the identification and purification of a protein from bovine kidney cytosol that inhibits both ATPase activity and proton translocating activity of vacuolar H+-ATPases. Its relative molecular weight (M(r)) is 6300, similar to that for protein inhibitors of the mitochondrial F0F1-ATPase. The newly identified cytosolic inhibitor protein may participate in the physiologic regulation of the vacuolar H+-ATPase by suppressing activity directly.	WASHINGTON UNIV, JEWISH HOSP ST LOUIS,SCH MED,DIV RENAL, 216 S KINGSHIGHWAY BLVD, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR032087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038848, P01DK009976] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR32087] Funding Source: Medline; NIDDK NIH HHS [DK38848, DK09976] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASTANI B, 1991, J CLIN INVEST, V88, P126, DOI 10.1172/JCI115268; BROWN D, 1988, NATURE, V331, P622, DOI 10.1038/331622a0; CHU A, 1988, METHOD ENZYMOL, V157, P36; CINTRON NM, 1979, J BIOL CHEM, V254, P3439; DIANOUX AC, 1987, EUR J BIOCHEM, V163, P155, DOI 10.1111/j.1432-1033.1987.tb10749.x; EBNER E, 1977, J BIOL CHEM, V252, P671; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FRANGIONE B, 1981, P NATL ACAD SCI-BIOL, V78, P7403, DOI 10.1073/pnas.78.12.7403; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; GLUCK S, 1988, AM J PHYSIOL, V254, pF71, DOI 10.1152/ajprenal.1988.254.1.F71; GLUCK S, 1982, P NATL ACAD SCI-BIOL, V79, P4327, DOI 10.1073/pnas.79.14.4327; GLUCK S, 1984, J CLIN INVEST, V73, P1704, DOI 10.1172/JCI111378; GLUCK S, 1987, J BIOL CHEM, V262, P15780; HARIKUMAR P, 1983, J BIOL CHEM, V258, P403; HARRIS DA, 1986, EUR J BIOCHEM, V157, P181, DOI 10.1111/j.1432-1033.1986.tb09654.x; HASHIMOTO T, 1990, J BIOCHEM-TOKYO, V107, P17; HUSAIN I, 1985, BIOCHIM BIOPHYS ACTA, V806, P64, DOI 10.1016/0005-2728(85)90082-9; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; KLEIN G, 1980, BIOCHEMISTRY-US, V19, P2919, DOI 10.1021/bi00554a016; MULBERG AE, 1991, J BIOL CHEM, V266, P20590; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Penefsky H S, 1979, Methods Enzymol, V55, P304; POWER J, 1983, BIOCHIM BIOPHYS ACTA, V724, P128, DOI 10.1016/0005-2728(83)90034-8; PULLMAN ME, 1963, J BIOL CHEM, V238, P3762; ROUSLIN W, 1987, J BIOL CHEM, V262, P3472; SATRE M, 1975, BIOCHIM BIOPHYS ACTA, V387, P241, DOI 10.1016/0005-2728(75)90107-3; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEINMETZ PR, 1986, AM J PHYSIOL, V251, pF173, DOI 10.1152/ajprenal.1986.251.2.F173; WANG ZQ, 1990, J BIOL CHEM, V265, P21957; YAMADA EW, 1988, J BIOL CHEM, V263, P11498; ZHANG K, 1992, J BIOL CHEM, V267, P9701	32	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14539	14542						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1386077				2022-12-25	WOS:A1992JF08800007
J	LIN, LL; LIN, AY; DEWITT, DL				LIN, LL; LIN, AY; DEWITT, DL			INTERLEUKIN-1-ALPHA INDUCES THE ACCUMULATION OF CYTOSOLIC PHOSPHOLIPASE-A(2) AND THE RELEASE OF PROSTAGLANDIN-E(2) IN HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TUMOR-NECROSIS-FACTOR; GROUP-II PHOSPHOLIPASE-A2; EXPRESSION; PROTEIN; PURIFICATION; CELLS	Treatment of the human lung fibroblast cell line, WI-38, with interleukin-1alpha (IL-1alpha) results in a large increase in the production of cytosolic phosholipase A2 (cPLA2) and prostaglandin E2 (PGE2). The IL-1-induced accumulation of cPLA2 is closely correlated with increased PGE2 release. In contrast to cPLA2, the level of cyclooxygenase remains unchanged following IL-1alpha treatment. The glucocorticoid, dexamethasone, blocks the IL-1alpha-mediated increases in both cPLA2 and PGE2 without affecting the cyclooxygenase level. Taken together, these data suggest that in these cells, the regulation of prostaglandin production by IL-1 and glucocorticoid can be attributed to the level of cPLA2. These results provide a new mechanism for the effect of IL-1 and glucocorticoids on eicosanoid synthesis and provide additional support for an important role of cPLA2 in the inflammatory response.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA	Michigan State University	LIN, LL (corresponding author), GENET INST, 87 CAMBRIDGE PK DR, CAMBRIDGE, MA 02140 USA.							BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; ELIAS JA, 1987, J IMMUNOL, V138, P3812; FU JY, 1990, J BIOL CHEM, V265, P16737; GILMAN SC, 1988, ARTHRITIS RHEUM, V31, P127, DOI 10.1002/art.1780310118; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; GUY GR, 1991, J BIOL CHEM, V266, P14343; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HARA S, 1991, J BIOCHEM, V110, P163, DOI 10.1093/oxfordjournals.jbchem.a123550; HARA S, 1989, J BIOCHEM-TOKYO, V105, P395, DOI 10.1093/oxfordjournals.jbchem.a122675; HULKOWER KI, 1992, BIOCHEM BIOPH RES CO, V184, P712, DOI 10.1016/0006-291X(92)90648-5; IKEDA U, 1990, ATHEROSCLEROSIS, V84, P183, DOI 10.1016/0021-9150(90)90089-2; KERR JS, 1989, BIOCHEM BIOPH RES CO, V165, P1079, DOI 10.1016/0006-291X(89)92712-5; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; NAKANO T, 1990, J BIOL CHEM, V265, P12745; OBANION MK, 1991, J BIOL CHEM, V266, P23261; OKA S, 1991, J BIOL CHEM, V266, P9956; PERNAS P, 1991, BIOCHEM BIOPH RES CO, V178, P1298, DOI 10.1016/0006-291X(91)91035-B; PFEILSCHIFTER J, 1991, BIOCHEM J, V273, P199, DOI 10.1042/bj2730199; PFEILSCHIFTER J, 1989, EUR J BIOCHEM, V181, P237, DOI 10.1111/j.1432-1033.1989.tb14717.x; RAZ A, 1989, P NATL ACAD SCI USA, V86, P1657, DOI 10.1073/pnas.86.5.1657; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; TAKAYAMA K, 1991, FEBS LETT, V282, P326, DOI 10.1016/0014-5793(91)80506-X	31	254	257	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23451	23454						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429687				2022-12-25	WOS:A1992JZ23900005
J	RIBBA, AS; VOORBERG, J; MEYER, D; PANNEKOEK, H; PIETU, G				RIBBA, AS; VOORBERG, J; MEYER, D; PANNEKOEK, H; PIETU, G			CHARACTERIZATION OF RECOMBINANT VONWILLEBRAND-FACTOR CORRESPONDING TO MUTATIONS IN TYPE-IIA AND TYPE-IIB VONWILLEBRAND DISEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE GLYCOPROTEIN-IB; VON WILLEBRAND FACTOR; MURINE MONOCLONAL-ANTIBODY; RISTOCETIN-INDUCED BINDING; FACTOR-VIII; FACTOR VWF; ARTERY SUBENDOTHELIUM; MULTIMERIC STRUCTURE; PLATELET-ADHESION; IIB/IIIA COMPLEX	Type IIA and IIB von Willebrand disease (vWD) result from defects in von Willebrand factor (vWF). Although both type IIA and IIB vWD are characterized by the absence of high molecular weight multimers in plasma, vWF from patients with type IIA vWD demonstrates a decreased affinity for the platelet receptor glycoprotein Ib (GPIb), whereas vWF from patients with type IIB vWD show an increased affinity for GPIb. To investigate how structural alterations in vWF affect its interaction with GPIb, we reproduced the reported potential mutations in type IIA and IIB vWD in vWF cDNA and expressed the recombinant proteins in COS-1 cells. The type IIA vWF potential mutation was represented by a G --> A transversion which results in the substitution of Lys for Glu at position 875 in the mature vWF subunit (rvWFLyS875). The type IIB vWF mutation corresponds to a duplicated ATG codon, resulting in three contiguous methionines starting at position 540-541 in the normal vWF sequence (rvWFduplMet540-541). The subunit composition and multimeric structure of both mutant proteins were similar to the wild-type rvWF. The rvWFLys875 bound to fixed platelets in the presence of ristocetin similar to wild-type rvWF. The rvWFduplMet540-541 bound to fixed platelets in the absence of agonist. The rvWFLys875 appears to interact normally with GPIb, and the decreased affinity for the platelet receptor observed in plasma is probably a consequence of prior reduction in multimeric size resulting from the defect. In contrast, the duplication of Met540-541 increases the reactivity of vWF for its platelet receptor.	HOP BICETRE, INSERM, U143, PARIS, FRANCE; NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV, DEPT MOLEC BIOL, CENT LAB, AMSTERDAM, NETHERLANDS	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay			ribba, anne-sophie/N-3109-2013	Ribba, Anne-Sophie/0000-0001-5342-8455; Voorberg, Jan/0000-0003-4585-2621				ARDAILLOU N, 1978, THROMB RES, V12, P817, DOI 10.1016/0049-3848(78)90276-1; BAHNAK BR, 1992, BIOCHEM BIOPH RES CO, V182, P561, DOI 10.1016/0006-291X(92)91769-M; BARUCH D, 1989, PLATELET DISORDERS; BERKOWITZ SD, 1987, J CLIN INVEST, V79, P524, DOI 10.1172/JCI112843; BERNDT MC, 1991, THROMB HAEMOSTASIS, V65, P748; CHANG HY, 1989, BLOOD S, V74, pA131; CHRISTOPHE O, 1991, BLOOD, V78, P2310; COLLER BS, 1983, BLOOD, V61, P99; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; COONEY KA, 1991, J CLIN INVEST, V87, P1227, DOI 10.1172/JCI115123; COONEY KA, 1992, P NATL ACAD SCI USA, V89, P2869, DOI 10.1073/pnas.89.7.2869; DEMARCO L, 1985, P NATL ACAD SCI USA, V82, P7424; DEMARCO L, 1990, J CLIN INVEST, V86, P785, DOI 10.1172/JCI114775; DENT JA, 1990, P NATL ACAD SCI USA, V87, P6306, DOI 10.1073/pnas.87.16.6306; DONNER M, 1991, EUR J HAEMATOL, V47, P342; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GINSBURG D, 1985, SCIENCE, V228, P1401, DOI 10.1126/science.3874428; GINSBURG D, 1989, P NATL ACAD SCI USA, V86, P3723, DOI 10.1073/pnas.86.10.3723; GIRMA JP, 1986, BLOOD, V67, P1356; GRALNICK HR, 1985, P NATL ACAD SCI USA, V82, P5968, DOI 10.1073/pnas.82.17.5968; HOLMBERG L, 1991, BLOOD S, V78, pA150; IANNUZZI MC, 1991, AM J HUM GENET, V48, P757; KAO KJ, 1979, J CLIN INVEST, V63, P656, DOI 10.1172/JCI109348; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; KRONER PA, 1991, J BIOL CHEM, V266, P19146; KRONER PA, 1992, BLOOD, V79, P2048; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVERGNE JM, 1992, IN PRESS BR J HAEMAT; LILLICRAP D, 1991, BRIT J HAEMATOL, V79, P612, DOI 10.1111/j.1365-2141.1991.tb08089.x; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LOPEZFERNANDEZ MF, 1987, VOX SANG, V52, P15, DOI 10.1111/j.1423-0410.1987.tb02981.x; LYNCH DC, 1985, CELL, V41, P49, DOI 10.1016/0092-8674(85)90060-1; LYONS SE, 1992, J BIOL CHEM, V267, P4424; MANCUSO DJ, 1991, BIOCHEMISTRY-US, V30, P253, DOI 10.1021/bi00215a036; MANCUSO DJ, 1989, J BIOL CHEM, V264, P19514; MANCUSO DJ, 1991, BLOOD S, V78, pA67; MEULIEN P, 1992, THROMB HAEMOSTASIS, V67, P154; MEYER D, 1987, ANN NY ACAD SCI, V509, P118, DOI 10.1111/j.1749-6632.1987.tb30989.x; MEYER D, 1984, BRIT J HAEMATOL, V57, P609, DOI 10.1111/j.1365-2141.1984.tb08550.x; MOHRI H, 1989, J BIOL CHEM, V264, P17361; MOHRI H, 1988, J BIOL CHEM, V263, P17901; NISHINO M, 1989, BLOOD, V74, P1591; PIETU G, 1992, BIOCHEM J, V284, P711, DOI 10.1042/bj2840711; RABINOWITZ I, 1991, BLOOD S, V78, pA179; RANDI AM, 1991, J CLIN INVEST, V87, P1220, DOI 10.1172/JCI115122; RANDI AM, 1991, BLOOD, V78, pA179; READ MS, 1978, P NATL ACAD SCI USA, V75, P4514, DOI 10.1073/pnas.75.9.4514; RIBBA AS, 1991, BLOOD, V78, P1738; ROTH GJ, 1986, BIOCHEMISTRY-US, V25, P8357, DOI 10.1021/bi00374a004; RUGGERI ZM, 1980, NEW ENGL J MED, V302, P1047, DOI 10.1056/NEJM198005083021902; RUGGERI ZM, 1982, BLOOD, V60, P1453; RUGGERI ZM, 1987, BLOOD, V70, P895; SADLER JE, 1985, P NATL ACAD SCI USA, V82, P6394, DOI 10.1073/pnas.82.19.6394; SAKARIASSEN KS, 1979, NATURE, V279, P636, DOI 10.1038/279636a0; SAKARIASSEN KS, 1986, BRIT J HAEMATOL, V63, P681, DOI 10.1111/j.1365-2141.1986.tb07552.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULLEK J, 1984, J CLIN INVEST, V73, P421, DOI 10.1172/JCI111228; SUGIMOTO M, 1991, J BIOL CHEM, V266, P18172; TULEY EA, 1991, P NATL ACAD SCI USA, V88, P6377, DOI 10.1073/pnas.88.14.6377; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; VERWEIJ CL, 1985, NUCLEIC ACIDS RES, V13, P4699, DOI 10.1093/nar/13.13.4699; VOORBERG J, 1990, EMBO J, V9, P797, DOI 10.1002/j.1460-2075.1990.tb08176.x; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195; WARE J, 1991, P NATL ACAD SCI USA, V88, P2946, DOI 10.1073/pnas.88.7.2946	64	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23209	23215						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429668				2022-12-25	WOS:A1992JY16300078
J	OVERMEYER, JH; MALTESE, WA				OVERMEYER, JH; MALTESE, WA			ISOPRENOID REQUIREMENT FOR INTRACELLULAR-TRANSPORT AND PROCESSING OF MURINE LEUKEMIA-VIRUS ENVELOPE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; NEURO-BLASTOMA CELLS; C-TERMINAL REGION; VESICULAR TRANSPORT; MEVALONATE SYNTHESIS; MOLECULAR-BIOLOGY; YPT1 PROTEIN; MEMBRANE; GLYCOPROTEINS; ERYTHROLEUKEMIA	Lovastatin blocks the biosynthesis of the isoprenoid precursor, mevalonate. When Friend murine erythroleukemia (MEL) cells are cultured in medium containing lovastatin, the precursor of murine leukemia virus envelope glycoprotein (gPr90env) fails to undergo proteolytic processing, which normally occurs in the Golgi complex. Consequently, newly synthesized envelope proteins are not incorporated into viral particles that are shed into the culture medium. gPr90env appears to be localized in a pre-Golgi membrane compartment, based on its enrichment in subcellular fractions containing NADPH-cytochrome c reductase activity and the sensitivity of its carbohydrate chains to digestion with endoglycosidase H. Arrest of gPr90env processing occurs at concentrations of lovastatin that are not cytostatic, and the effect of the inhibitor is prevented by addition of mevalonate to the medium. The low molecular mass GTP-binding proteins, rab1p and rab6p, which are believed to function in early steps of the exocytic pathway, are normally modified posttranslationally by geranylgeranyl isoprenoids. However, in MEL cells treated with 1 muM lovastatin, nonisoprenylated forms of these proteins accumulate in the cytosol prior to arrest of gPr90env processing. These observations suggest that lovastatin may prevent viral envelope precursors from reaching the Golgi compartment by blocking the isoprenylation of rab proteins required for ER to Golgi transport.	GEISINGER MED CLIN, WEIS CTR RES, 100 N ACAD AVE, DANVILLE, PA 17822 USA	Geisinger Medical Center					NCI NIH HHS [CA34569] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034569] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BEDGOOD RM, 1992, J BIOL CHEM, V267, P7060; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DUNCAN HM, 1966, J BIOL CHEM, V241, P1694; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FITTING T, 1982, J BIOL CHEM, V257, P4011; FREED EO, 1987, J VIROL, V61, P2852, DOI 10.1128/JVI.61.9.2852-2856.1987; FREED EO, 1989, J VIROL, V63, P4670, DOI 10.1128/JVI.63.11.4670-4675.1989; GLINIAK BC, 1991, J BIOL CHEM, V266, P22991; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOLDSTEIN JL, 1979, J BIOL CHEM, V254, P5403; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HASELTINE WA, 1991, FASEB J, V5, P2349, DOI 10.1096/fasebj.5.10.1829694; HAUBRUCK H, 1989, EMBO J, V8, P1427, DOI 10.1002/j.1460-2075.1989.tb03524.x; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; HORI Y, 1991, ONCOGENE, V6, P515; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYLES DS, 1981, J VIROL, V39, P263, DOI 10.1128/JVI.39.1.263-272.1981; MALTESE WA, 1979, J CELL PHYSIOL, V101, P459, DOI 10.1002/jcp.1041010312; MALTESE WA, 1990, J BIOL CHEM, V265, P17883; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MALTESE WA, 1985, J CELL PHYSIOL, V125, P540, DOI 10.1002/jcp.1041250326; MALTESE WA, 1985, J BIOL CHEM, V260, P1524; MALTESE WA, 1992, ACS SYM SER, V10, P48; MURRAY MJ, 1979, J BIOL CHEM, V254, P1340; MUSHA T, 1992, J BIOL CHEM, V267, P9821; NEWMAN CMH, 1992, J BIOL CHEM, V267, P11329; PIQUE C, 1992, J VIROL, V66, P906, DOI 10.1128/JVI.66.2.906-913.1992; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; POLONOFF E, 1982, J BIOL CHEM, V257, P4023; REPKO EM, 1989, J BIOL CHEM, V264, P9945; ROSNER MR, 1980, P NATL ACAD SCI-BIOL, V77, P6420, DOI 10.1073/pnas.77.11.6420; RUTA M, 1982, J BIOL CHEM, V257, P126; SCHIMMEL SD, 1973, P NATL ACAD SCI USA, V70, P3195, DOI 10.1073/pnas.70.11.3195; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SINENSKY M, 1990, J BIOL CHEM, V265, P19937; ULMER JB, 1991, J BIOL CHEM, V266, P9173; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	50	23	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22686	22692						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429616				2022-12-25	WOS:A1992JW71900106
J	VANSCHRAVENDIJK, CFH; KIEKENS, R; PIPELEERS, DG				VANSCHRAVENDIJK, CFH; KIEKENS, R; PIPELEERS, DG			PANCREATIC BETA-CELL HETEROGENEITY IN GLUCOSE-INDUCED INSULIN-SECRETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEWLY SYNTHESIZED PROINSULIN; B-CELLS; PITUITARY-CELLS; STORED INSULIN; RELEASE; RAT; ISLETS; GROWTH	Rat pancreatic beta cells differ in their individual sensitivity to glucose-inducible metabolic changes. The present study examines whether beta cells with a higher metabolic threshold require higher glucose levels for stimulation of their secretory activity. Purified beta cells were distributed according to their metabolic redox state at 7.5 mM glucose; the metabolically responsive (high responsive) and unresponsive (low responsive) subpopulations of comparable size and viability were reaggregated in the presence of [H-3]tyrosine and then perfused at 2.8 mM glucose with 10-min pulses of increasing glucose concentration. Glucose elicited first-phase insulin release in both high and low responsive subpopulations from, respectively, 4.2 and 8.3 mM on. The amplitude of both secretory responses increased dose dependently, the rates in the high responsive sub-population being 2-fold higher than in the low responsive one. At all stimulating glucose levels, fractional release of H-3-labeled insulin was 3- to 4-fold higher than that of immunoreactive insulin. Preferential release of newly formed insulin was already maximally stimulated at 4.2 mM glucose in the high responsive subpopulation, whereas it increased dose-dependently in the low responsive one. These results indicate the existence of intercellular differences in the secretory activity of glucose-exposed beta cells, both in terms of glucose sensitivity and of amplitude. This heterogeneity in beta cell secretory responsiveness parallels that which has been previously described for the cellular metabolic and biosynthetic functions. It is concluded that glucose dose-dependently recruits beta cells into both biosynthetic and secretory activities. Co-existence of inactive and activated cells can explain preferential release of newly synthesized over preformed hormone during glucose stimulation.			VANSCHRAVENDIJK, CFH (corresponding author), VRIJE UNIV BRUSSELS,DEPT METAB & ENDOCRINOL,LAARBEEKLAAN 103,B-1090 BRUSSELS,BELGIUM.			Pipeleers, Daniel/0000-0002-6440-2485				ARVAN P, 1991, J BIOL CHEM, V266, P14171; BOSCO D, 1991, ENDOCRINOLOGY, V129, P3157, DOI 10.1210/endo-129-6-3157; ELLERKMANN E, 1991, ENDOCRINOLOGY, V129, P838, DOI 10.1210/endo-129-2-838; GOLD G, 1982, SCIENCE, V218, P56, DOI 10.1126/science.6181562; GRILL V, 1979, J CLIN INVEST, V64, P700, DOI 10.1172/JCI109512; HALBAN PA, 1982, ENDOCRINOLOGY, V110, P1183, DOI 10.1210/endo-110-4-1183; HIRIART M, 1991, ENDOCRINOLOGY, V128, P3193, DOI 10.1210/endo-128-6-3193; JETTON TL, 1992, P NATL ACAD SCI USA, V89, P2619, DOI 10.1073/pnas.89.7.2619; KIEKENS R, 1992, J CLIN INVEST, V89, P117, DOI 10.1172/JCI115551; KINEMAN RD, 1990, ENDOCRINOLOGY, V127, P2229, DOI 10.1210/endo-127-5-2229; MATCHINSKY FM, 1990, DIABETES, V39, P647; MILLER JA, 1990, PROG ENERG COMBUST, V16, P347, DOI 10.1016/0360-1285(90)90043-3; PARSONS JA, 1992, ENDOCRINOLOGY, V130, P1459, DOI 10.1210/en.130.3.1459; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P824, DOI 10.1210/endo-117-3-824; PIPELEERS DG, 1992, DIABETES, V41, P777, DOI 10.2337/diabetes.41.7.777; REAVEN EP, 1979, J CLIN INVEST, V64, P591, DOI 10.1172/JCI109498; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; SALOMON D, 1986, EXP CELL RES, V162, P507, DOI 10.1016/0014-4827(86)90354-X; SANDO H, 1973, DIABETES, V22, P354, DOI 10.2337/diab.22.5.354; SANDO H, 1972, J CLIN INVEST, V51, P1476, DOI 10.1172/JCI106944; SCHUIT FC, 1988, P NATL ACAD SCI USA, V85, P3865, DOI 10.1073/pnas.85.11.3865; SMITH PF, 1984, ENDOCRINOLOGY, V115, P2484, DOI 10.1210/endo-115-6-2484; STUDER H, 1989, ENDOCR REV, V10, P125, DOI 10.1210/edrv-10-2-125; SWENNE I, 1992, DIABETOLOGIA, V35, P193, DOI 10.1007/BF00400917; VANDEWINKEL M, 1983, BIOCHEM BIOPH RES CO, V114, P835, DOI 10.1016/0006-291X(83)90857-4; VANSCHRAVENDIJK CFH, 1990, DIABETOLOGIA, V33, P649, DOI 10.1007/BF00400565	27	134	134	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21344	21348						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400446				2022-12-25	WOS:A1992JV01100016
J	GANGULY, C; BAINES, IC; KORN, ED; SELLERS, J				GANGULY, C; BAINES, IC; KORN, ED; SELLERS, J			REGULATION OF THE ACTIN-ACTIVATED ATPASE AND INVITRO MOTILITY ACTIVITIES OF MONOMERIC AND FILAMENTOUS ACANTHAMOEBA MYOSIN-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; 3 PHOSPHORYLATION SITES; AMINO-ACID-SEQUENCE; HEAVY-CHAIN; CYTOPLASMIC MYOSINS; LIGHT CHAIN; PURIFICATION; TAIL; QUANTITATION; CASTELLANII	The actin-activated Mg2+-ATPase activity of filamentous Acanthamoeba myosin II is inhibited by phosphorylation of 3 serine residues at the tip of the tail of each heavy chain. From previous studies, it had been concluded that the activity of each molecule in the filament was regulated by the global state of phosphorylation of the filament and was independent of its own phosphorylation state. The actin-activated Mg2+-ATPase activity of monomeric phosphorylated myosin II was not known because it polymerizes under the ionic conditions necessary for the expression of this activity. We have now found conditions to maintain myosin II monomeric and active during the enzyme assay. The actin-activated Mg2+-ATPase activities of monomeric dephosphorylated and phosphorylated myosin II were found to be the same as the activity of filamentous dephosphorylated myosin II. These results support the conclusion that phosphorylation regulates filamentous myosin II by affecting filament conformation. Consistent with their equivalent enzymatic activities, monomeric and filamentous dephosphorylated myosin II were equally active in an in vitro motility assay in which myosin adsorbed to a surface drives the movement of F-actin. In contrast to their very different enzymatic activities, however, filamentous and monomeric phosphorylated myosin II had similar activities in the in vitro motility assay; both were much less active than monomeric and filamentous dephosphorylated myosin II. One interpretation of these results is that the rate-limiting steps in the two assays are different and that, while the rate-limiting step for actin-activated Mg2+-ATPase activity is regulated only at the level of the filament, the rate-limiting step for motility can also be regulated at the level of the monomer.	NHLBI,CELL BIOL LAB,BLDG 3,RM B122,BETHESDA,MD 20892; NHLBI,MOLEC CARDIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Korn, Edward D/F-9929-2012	Korn, Edward/0000-0003-3867-6295				ATKINSON MAL, 1989, J BIOL CHEM, V264, P4127; ATKINSON MAL, 1986, J BIOL CHEM, V261, P1844; ATKINSON MAL, 1986, J BIOL CHEM, V261, P3382; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CIESIOLKA T, 1988, ANAL BIOCHEM, V168, P280, DOI 10.1016/0003-2697(88)90319-3; COLLINS JH, 1982, J BIOL CHEM, V257, P4529; COLLINS JH, 1980, J BIOL CHEM, V255, P8011; COLLINS JH, 1982, BIOCHEMISTRY-US, V21, P6910, DOI 10.1021/bi00269a045; COLLINS JH, 1981, J BIOL CHEM, V256, P2586; COTE GP, 1984, J BIOL CHEM, V259, P2781; COTE GP, 1981, J BIOL CHEM, V256, P2811; GANGULY C, 1992, J BIOL CHEM, V267, P20905; GANGULY C, 1990, J BIOL CHEM, V265, P9993; HAMMER JA, 1987, J CELL BIOL, V105, P913, DOI 10.1083/jcb.105.2.913; HAYASHI H, 1989, J BIOCHEM-TOKYO, V105, P875, DOI 10.1093/oxfordjournals.jbchem.a122771; HOMSHER E, 1992, AM J PHYSIOL, V262, pC714, DOI 10.1152/ajpcell.1992.262.3.C714; IKEBE M, 1985, J BIOL CHEM, V260, P27; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KUZNICKI J, 1985, J BIOL CHEM, V260, P1967; KUZNICKI J, 1983, J BIOL CHEM, V259, P6011; MARUTA H, 1977, J BIOL CHEM, V252, P6501; OKAGAKI T, 1991, J BIOCHEM, V109, P858, DOI 10.1093/oxfordjournals.jbchem.a123471; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POLLARD TD, 1978, J BIOL CHEM, V253, P4798; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; SINARD JH, 1989, J CELL BIOL, V109, P1537, DOI 10.1083/jcb.109.4.1537; SINARD JH, 1989, J CELL BIOL, V109, P1529, DOI 10.1083/jcb.109.4.1529; STOSCHECK CM, 1987, ANAL BIOCHEM, V160, P301, DOI 10.1016/0003-2697(87)90051-0; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; UMEMOTO S, 1989, J BIOL CHEM, V264, P1431; WIJMENGA SS, 1987, J BIOL CHEM, V262, P15803	33	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20900	20904						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400404				2022-12-25	WOS:A1992JT97800061
J	RAN, S; FULLER, CM; ARRATE, MP; LATORRE, R; BENOS, DJ				RAN, S; FULLER, CM; ARRATE, MP; LATORRE, R; BENOS, DJ			FUNCTIONAL RECONSTITUTION OF A CHLORIDE CHANNEL PROTEIN FROM BOVINE TRACHEA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTIC-FIBROSIS; ION CHANNELS; POTASSIUM CHANNELS; EPITHELIUM; MEMBRANES; VESICLES; PART	We characterized the electrophysiological properties of a chloride channel protein isolated from bovine trachea after incorporation into planar lipid bilayers, and studied the effects of thiol-modulating agents on channel regulation both in bilayers and vesicular iodide uptake studies. Our experiments showed that this protein formed perfectly anion-selective channels in the bilayer, with an anion permeability sequence of I- (2.1) > NO3- (1.7) > Br- (1.2) > Cl- (1.0). The conductance of this channel was 25-30 picosiemens in 150 mM Cl-, and saturated with increasing chloride concentration. This channel could be completely inhibited by 4,4'-bis(isothiocyano)-2,2'-stilbenedisulfonate. Immunoblot analysis, using polyclonal antibodies (anti-p38), revealed one major band at 140 kDa. Upon reduction with dithiothreitol, 64- and 38-kDa polypeptides were observed. Functional experiments showed that reduction was accompanied by loss of I-125- uptake and single-channel activity. In the presence of dithiothreitol, only the low molecular mass protein forms (64 and 38 kDa) were detected by anti-p38 antibodies on Western blots. Cross-linking of S-S bonds with Cu2+-o-phenanthroline led to activation of chloride channels in vesicles and bilayers. Over-aggregation of chloride channels by this S-S cross-linking reagent caused inhibition of I-125- uptake by 80-100% and the abolishment of single-channel activity. We propose that the native chloride channel from bovine trachea can exist in vivo in different structural and functional forms depending upon its thiol-disulfide oxidation reduction status. The oxidized form has a molecular mass of 140 kDa and represents a fully active chloride channel. Inactivation of this channel might occur by over-aggregation of protein subunits, or by dissociation of the 140-kDa subunit by disulfide bond reduction.	UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294; UNIV CHILE,DEPT BIOL,CTR ESTUDIOS CIENT SANTIAGO,SANTIAGO,CHILE	University of Alabama System; University of Alabama Birmingham; Universidad de Chile			Fuller, Cathy/B-4046-2011		NIDDK NIH HHS [DK 42017] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK042017] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ O, 1985, J ELECTROPHYSIOL TEC, V12, P159; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ASANO S, 1987, J BIOL CHEM, V262, P13263; Bormann J, 1988, Adv Biochem Psychopharmacol, V45, P47; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; FRIZZELL RA, 1987, TRENDS NEUROSCI, V10, P190, DOI 10.1016/0166-2236(87)90144-5; FRIZZELL RA, 1990, CURRENT TOPICS MEMBR, V37, P247; HALM DR, 1988, AM J PHYSIOL, V254, pC505, DOI 10.1152/ajpcell.1988.254.4.C505; KOBASHI K, 1968, BIOCHIM BIOPHYS ACTA, V158, P239, DOI 10.1016/0304-4165(68)90136-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; LUKACS GL, 1990, J GEN PHYSIOL, V96, P707, DOI 10.1085/jgp.96.4.707; MORRIS AP, 1992, IN PRESS AM J PHYSL; PRESTON CL, 1992, IN PRESS AM J PHYSL; RAN S, 1991, J BIOL CHEM, V266, P4782; RAN S, 1992, J BIOL CHEM, V267, P3618; REDHEAD CR, 1992, P NATL ACAD SCI USA, V89, P3716, DOI 10.1073/pnas.89.9.3716; THINNES FP, 1990, BIOL CHEM H-S, V371, P1047, DOI 10.1515/bchm3.1990.371.2.1047; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P5340; TSAI LM, 1991, J GEN PHYSIOL, V98, P723, DOI 10.1085/jgp.98.4.723; WELSH MJ, 1986, SCIENCE, V232, P1648, DOI 10.1126/science.2424085; WELSH MJ, 1985, P NATL ACAD SCI USA, V82, P8823, DOI 10.1073/pnas.82.24.8823; WELSH MJ, 1986, NATURE, V322, P467, DOI 10.1038/322467a0; WELSH MJ, 1986, PFLUG ARCH EUR J PHY, V407, pS116, DOI 10.1007/BF00584940; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WHITE MM, 1981, BIOPHYS J, V35, P455, DOI 10.1016/S0006-3495(81)84801-1	27	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20630	20637						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383206				2022-12-25	WOS:A1992JT97800022
J	LALA, AK; KAUL, P				LALA, AK; KAUL, P			INCREASED EXPOSURE OF HYDROPHOBIC SURFACE IN MOLTEN GLOBULE STATE OF ALPHA-LACTALBUMIN - FLUORESCENCE AND HYDROPHOBIC PHOTOLABELING STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPACT STATE; PROTEIN; ION; PH; TRYPTOPHYL; VESICLES; BINDING; FUSION; NMR	The involvement of molten globule state as a distinct intermediate in the denaturation process in proteins is well documented. However, the structural characterization of such an intermediate is far from complete. We have, using fluorescence and fluorescence quenching, studied the molten globule state of bovine alpha-lactalbumin. Unlike the native state, where all the 4 tryptophans are buried in the protein, 2 tryptophans are exposed in the molten globule state. Using the hydrophobic photoactivable reagent [H-3]diazofluorene, we observe an increased hydrophobic exposure in the molten globule state. These structural characteristics conform to the current views on the molten globule state, i.e. it has similar secondary structure but a poorly defined tertiary structure. Our fluorescence studies indicate the involvement of a premolten globule state in the native to molten globule state transition. This premolten globule state exists at pH 5.0 and has a very compact structure involving increased hydrophobic interactions in the protein interior. These results are also supported by circular dichroism studies.			LALA, AK (corresponding author), INDIAN INST TECHNOL,DEPT CHEM,BIOMEMBRANE LAB,BOMBAY 400076,INDIA.							ANJANEYULU PSR, 1984, INDIAN J CHEM B, V23, P802; BARSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263; BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BREW K, 1970, J BIOL CHEM, V245, P4559; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; DOLGIKH DA, 1985, EUR BIOPHYS J BIOPHY, V13, P109, DOI 10.1007/BF00256531; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; HANSSENS I, 1980, BIOCHIM BIOPHYS ACTA, V602, P539, DOI 10.1016/0005-2736(80)90333-8; HANSSENS I, 1984, BIOCHEM BIOPH RES CO, V119, P509, DOI 10.1016/S0006-291X(84)80277-6; JIANG JX, 1990, J BIOL CHEM, V265, P8636; KIM J, 1986, BIOCHEMISTRY-US, V25, P7867, DOI 10.1021/bi00372a012; KOGA K, 1985, BIOCHEMISTRY-US, V24, P7257, DOI 10.1021/bi00346a035; KRONMAN MJ, 1965, BIOCHEMISTRY-US, V4, P526, DOI 10.1021/bi00879a023; KRONMAN MJ, 1989, CRIT REV BIOCHEM MOL, V24, P565, DOI 10.3109/10409238909080054; KRONMAN MJ, 1972, BIOCHIM BIOPHYS ACTA, V285, P124, DOI 10.1016/0005-2795(72)90186-9; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; KUWAJIMA K, 1978, BIOPHYS CHEM, V8, P247, DOI 10.1016/0301-4622(78)87006-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LINDAHL L, 1984, ANAL BIOCHEM, V140, P390; MITANI M, 1986, J BIOL CHEM, V261, P8824; MUSCI G, 1984, BIOCHEMISTRY-US, V95, P1098; Parker C. A., 1968, PHOTOLUMINESCENCE SO, P220; PRADHAN D, 1987, J BIOL CHEM, V262, P8242; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; ROBBINS FM, 1970, BIOCHIM BIOPHYS ACTA, V221, P234, DOI 10.1016/0005-2795(70)90263-1; ROBBINS FM, 1972, J BIOL CHEM, V247, P3062; Stern O, 1919, PHYS Z, V20, P183; WHARTON SA, 1988, J GEN VIROL, V69, P1847, DOI 10.1099/0022-1317-69-8-1847	30	86	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19914	19918						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400308				2022-12-25	WOS:A1992JR85800029
J	MOFFAT, GJ; VIK, DP; NOACK, D; TACK, BF				MOFFAT, GJ; VIK, DP; NOACK, D; TACK, BF			COMPLETE STRUCTURE OF THE MURINE C4B-BINDING PROTEIN GENE AND REGULATION OF ITS EXPRESSION BY DEXAMETHASONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; GLUCOCORTICOID RECEPTOR-BINDING; ALTERNATIVE PATHWAY PROTEINS; DECAY-ACCELERATING FACTOR; ACUTE-PHASE PROTEIN; CALF THYMUS DNA; MESSENGER-RNA; C4-BINDING PROTEIN; FACTOR-H; TRANSCRIPTION FACTORS	C4b-binding protein (C4BP) is involved in the fluid-phase regulation of the classical pathway of complement. A murine genomic library was screened, and five clones were selected that covered the remaining four exons in the 5'-region of the C4BP gene. Together with previous work (Barnum, S. R., Kristensen, T., Chaplin, D. D., Seldin, M. F., and Tack, B. F. (1989) Biochemistry 28, 8312-8317), the entire C4BP gene has now been shown to be 23 kilobases (kb) long and comprised of 10 exons ranging in size from 86 to 442 base pairs (bp). Primer extension analysis revealed the major transcription start site to be 46 bp upstream of the published cDNA start site. Northern blot analysis of RNA isolated from several mouse tissues demonstrated that the C4BP gene is expressed in a liver-specific manner. Several regions homologous to known response elements were identified upstream of the C4BP gene including a strong hepatocyte nuclear factor 1 binding site and four putative glucocorticoid response elements. Furthermore, dexamethasone increased C4BP mRNA and protein levels in the mouse liver cell line, NMuLi. The stimulation of C4BP gene expression was rapid and independent of protein synthesis. These results suggest dexamethasone induction of the C4BP gene is a primary response and therefore a transcriptional effect. Inhibition of the dexamethasone effect on C4BP by actinomycin D supports this theory. These studies also provide evidence that, for optimal induction of the C4BP gene, the glucocorticoid receptor complex may cooperatively interact with accessory transcription factors. It is likely that stimulation of C4BP gene expression by dexamethasone may allude to a mechanism by which glucocorticoids exert their anti-inflammatory effects.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NCRR NIH HHS [MO1 RR00833] Funding Source: Medline; NIAID NIH HHS [AI17354] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI017354] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTUS MS, 1991, J BIOL CHEM, V266, P21190; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASO T, 1991, BIOCHEM BIOPH RES CO, V174, P222, DOI 10.1016/0006-291X(91)90509-6; BANKIER AT, 1983, TECHNIQUES NUCLEIC A, V85, P1; BARNUM SR, 1989, BIOCHEMISTRY-US, V28, P8312, DOI 10.1021/bi00447a008; BARNUM SR, 1990, COMPLEMENT INFLAMMAT, V7, P71, DOI 10.1159/000463131; BAUMANN H, 1990, MOL CELL BIOL, V10, P5967, DOI 10.1128/MCB.10.11.5967; BAUMANN H, 1983, J BIOL CHEM, V258, P563; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BORA NS, 1989, J EXP MED, V169, P597, DOI 10.1084/jem.169.2.597; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; BURGE J, 1981, J IMMUNOL, V126, P232; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARROLL MC, 1988, J EXP MED, V167, P1271, DOI 10.1084/jem.167.4.1271; CAVANAUGH AH, 1990, BIOCHEMISTRY-US, V29, P989, DOI 10.1021/bi00456a022; CAVANAUGH AH, 1990, BIOCHEMISTRY-US, V29, P996, DOI 10.1021/bi00456a023; Chen C L, 1980, Ann N Y Acad Sci, V349, P28, DOI 10.1111/j.1749-6632.1980.tb29512.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORDINGLEY MG, 1988, NUCLEIC ACIDS RES, V16, P609, DOI 10.1093/nar/16.2.609; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DAUCHEL H, 1990, EUR J IMMUNOL, V20, P1669, DOI 10.1002/eji.1830200808; DECORDOBA SR, 1991, J EXP MED, V173, P1073, DOI 10.1084/jem.173.5.1073; DECORDOBA SR, 1985, J EXP MED, V161, P1189, DOI 10.1084/jem.161.5.1189; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERREIRA A, 1977, J EXP MED, V146, P1001, DOI 10.1084/jem.146.4.1001; FUJISAKU A, 1989, J BIOL CHEM, V264, P2118; FUJITA T, 1979, J EXP MED, V150, P267, DOI 10.1084/jem.150.2.267; FUJITA T, 1978, J EXP MED, V148, P1044, DOI 10.1084/jem.148.4.1044; GIGLI I, 1979, P NATL ACAD SCI USA, V76, P6596, DOI 10.1073/pnas.76.12.6596; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HILLARP A, 1988, J BIOL CHEM, V263, P12759; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAIDOH T, 1981, J IMMUNOL, V126, P463; KARIN M, 1980, NATURE, V286, P295, DOI 10.1038/286295a0; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KATZ Y, 1988, J IMMUNOL, V141, P559; KESAVAN P, 1990, ONCOGENE, V5, P483; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRISTENSEN T, 1987, BIOCHEMISTRY-US, V26, P4668, DOI 10.1021/bi00389a012; LAPPIN DF, 1990, BIOCHEM J, V271, P767, DOI 10.1042/bj2710767; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MOFFAT GJ, 1989, CLIN EXP IMMUNOL, V78, P54; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; MUNOZCANOVES P, 1989, BIOCHEMISTRY-US, V28, P9891, DOI 10.1021/bi00452a002; NAGASAWA S, 1980, J IMMUNOL, V125, P578; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PETERSEN DD, 1989, P NATL ACAD SCI USA, V86, P7800, DOI 10.1073/pnas.86.20.7800; POST TW, 1990, J IMMUNOL, V144, P740; POST TW, 1989, FASEB J, V3, P368; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; REYCAMPOS J, 1988, J EXP MED, V167, P664, DOI 10.1084/jem.167.2.664; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; RINGOLD GM, 1977, P NATL ACAD SCI USA, V74, P2879, DOI 10.1073/pnas.74.7.2879; RINGOLD GM, 1984, P NATL ACAD SCI-BIOL, V81, P3964, DOI 10.1073/pnas.81.13.3964; RINGOLD GM, 1975, CELL, V6, P299, DOI 10.1016/0092-8674(75)90181-6; RIPOCHE J, 1988, J EXP MED, V168, P1917, DOI 10.1084/jem.168.5.1917; SAEKI T, 1989, BIOCHEM BIOPH RES CO, V164, P1446, DOI 10.1016/0006-291X(89)91832-9; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; VIK DP, 1989, CURR TOP MICROBIOL I, V153, P147; WHALEY K, 1980, J EXP MED, V151, P501, DOI 10.1084/jem.151.3.501; WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181; WONG WT, 1991, BIOCHEM J, V275, P313, DOI 10.1042/bj2750313; WONG WW, 1989, J EXP MED, V169, P847, DOI 10.1084/jem.169.3.847; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZHANG HY, 1991, J BIOL CHEM, V266, P24332	78	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20400	20406						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400358				2022-12-25	WOS:A1992JR85800101
J	WALKER, FJ				WALKER, FJ			CHARACTERIZATION OF THE INTERACTION BETWEEN THE HEAVY AND LIGHT-CHAINS OF BOVINE FACTOR-VA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; HUMAN FACTOR-VIII; CALCIUM-BINDING SITE; COAGULATION FACTOR-V; ISOLATED SUBUNITS; PHOSPHOLIPID-VESICLES; BLOOD-COAGULATION; FACTOR-XA; EXPRESSION; THROMBIN	Bovine factor Va has been previously been shown to consist of heavy (M(r) = 94,000) and light chains (M(r) = 81,000), that interact in a manner dependent upon the presence of either calcium or manganese ions. In an attempt to understand the mechanism of subunit interaction we have studied the effects of temperature and ions on factor Va stability. The rates of formation of factor Va from isolated chains and dissociation were temperature-dependent with an energy of activation of 6.2 and 1.3 kcal mol-1, respectively. The yield of factor Va from isolated chains was inversely related to the amount of time the chains were incubated at 4-degrees-C. Incubation of individual chains revealed that the heavy chain is cold-labile, an effect that is reversible. Manganese ion was observed to prevent the conversion to the inactive form. High salt tends to stabilize the two-chain structure of factor Va, but is inhibitory to its formation from isolated chains. High concentrations of either manganese or calcium ions also inhibited reconstitution of activity. The light chain, in particular, was sensitive to the presence of manganese or calcium ion. Heavy chain that had been cleaved by activated protein C had a weakened interaction with the light chain, and the resulting complex had no procoagulant activity. Cooling of the heavy chain to 4-degrees-C enhanced its intrinsic fluorescence. Manganese ion prevented some of this enhancement. The heavy chain fluorescence returned to the room temperature value with a half-life of approximately 10 min. In the presence of manganese ion relaxation was accelerated. The intrinsic fluorescence of activated protein C-cleaved heavy chain was not increased when the temperature was decreased. These data suggest that the heavy chain can exist in two forms. Elevated temperature converts it to a form that can bind ions and have a productive interaction with the light chain. However, conditions that prevent the heavy chain from combining with the light chain also stabilize the two subunit structure, suggesting that the high affinity of the complex is due to conformational changes that occur after chain interaction.	UNIV CONNECTICUT,CTR HLTH,DEPT MED,FARMINGTON,CT 06032; UNIV CONNECTICUT,CTR HLTH,DEPT LAB MED,FARMINGTON,CT 06032	University of Connecticut; University of Connecticut	WALKER, FJ (corresponding author), AMER RED CROSS,BLOOD SERV,209 FARMINGTON AVE,FARMINGTON,CT 06032, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040328] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 40328] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; ESMON CT, 1979, J BIOL CHEM, V254, P964; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; GUINTO ER, 1982, J BIOL CHEM, V257, P38; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; HIBBARD LS, 1980, J BIOL CHEM, V255, P638; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; KRISHNASWAMY S, 1989, J BIOL CHEM, V264, P3160; LAROCCA D, 1991, CANCER RES, V51, P4994; LAUE TM, 1984, BIOCHEMISTRY-US, V23, P1339, DOI 10.1021/bi00302a001; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; ODEGAARD B, 1987, J BIOL CHEM, V262, P11233; ORTEL TL, 1984, P NATL ACAD SCI-BIOL, V81, P4761, DOI 10.1073/pnas.81.15.4761; POOLE S, 1981, J MOL BIOL, V153, P273, DOI 10.1016/0022-2836(81)90278-3; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TRACY PB, 1983, P NATL ACAD SCI-BIOL, V80, P2380, DOI 10.1073/pnas.80.8.2380; TRACY PB, 1979, J BIOL CHEM, V254, P354; VANDEWAART P, 1983, BIOCHEMISTRY-US, V22, P2427, DOI 10.1021/bi00279a019; VANDEWAART P, 1984, BIOCHIM BIOPHYS ACTA, V799, P38, DOI 10.1016/0304-4165(84)90324-6; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WALKER FJ, 1990, J BIOL CHEM, V265, P1484; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	27	5	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19896	19900						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400306				2022-12-25	WOS:A1992JR85800026
J	WONG, WY; HAVARSTEIN, LS; MORGAN, IM; VOGT, PK				WONG, WY; HAVARSTEIN, LS; MORGAN, IM; VOGT, PK			C-JUN CAUSES FOCUS FORMATION AND ANCHORAGE-INDEPENDENT GROWTH IN CULTURE BUT IS NONTUMORIGENIC	ONCOGENE			English	Note							CHICKEN-EMBRYO FIBROBLASTS; DNA-BINDING ACTIVITY; ONCOGENE JUN; AP-1; FOS; TRANSFORMATION; ENCODES; PROTEIN; MEMBER; FAMILY	The RCAS retroviral vector was used to express chicken and mouse cellular Jun proteins in chicken embryo fibroblasts. Both mouse and chicken proteins induced foci of transformed cells with low to moderate efficiency compared with viral Jun, but were as effective as the viral protein in promoting anchorage-independent growth. Viral Jun and a recombinant between viral and cellular Jun induced tumors in 1-day-old chicks; the cellular Jun proteins were uniformly non-tumorigenic.	NORRIS CANC CTR,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033; UNIV SO CALIF,LOS ANGELES CTY MED CTR,DEPT PEDIAT,1129 N STATE ST,LOS ANGELES,CA 90033	University of Southern California; University of Southern California			Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500; Havarstein, Leiv Sigve/0000-0001-8250-4322	NCI NIH HHS [CA 42564] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BALL AR, 1988, COLD SPRING HARB SYM, V53, P687, DOI 10.1101/SQB.1988.053.01.078; BERGER I, 1991, ONCOGENE, V6, P561; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CASTELLAZZI M, 1990, ONCOGENE, V5, P1285; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; CHENG YC, 1987, J BIOL CHEM, V262, P2187; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; NISHIMURA T, 1988, ONCOGENE, V3, P659; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2	22	31	31	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2077	2080						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408150				2022-12-25	WOS:A1992JP42400025
J	DALLMANN, HG; FLYNN, TG; DUNN, SD				DALLMANN, HG; FLYNN, TG; DUNN, SD			DETERMINATION OF THE 1-ETHYL-3-[(3-DIMETHYLAMINO)PROPYL]-CARBODIIMIDE-INDUCED CROSS-LINK BETWEEN THE BETA AND EPSILON SUBUNITS OF ESCHERICHIA-COLI F1-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; MITOCHONDRIAL ATP-SYNTHASE; BINDING CHANGE MECHANISM; OXIDATIVE-PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; NUCLEOTIDE-SEQUENCE; UNC OPERON; SECONDARY-STRUCTURE; PROTEINS; F1	The zero-length cross-link between the inhibitory epsilon-subunit and one of three catalytic beta-subunits of Escherichia coli F1-ATPase (alpha-3-beta-3-gamma-delta-epsilon), induced by a water-soluble carbodiimide, 1-ethyl-3-[(3-dimethylamino) propyl]-carbodiimide (EDC), has been determined at the amino acid level. Lability of cross-linked beta-epsilon to base suggested an ester cross-link rather than the expected amide. A 10-kDa cross-linked CNBr fragment derived from beta-epsilon was identified by electrophoresis on high percentage polyacrylamide gels. Sequence analysis of this peptide revealed the constituent peptides to be Asp-380 to Met-431 of beta and Glu-96 to Met-138 of epsilon. Glu-381 of beta was absent from cycle 2 indicating that it was one of the cross-linked residues, but no potential cross-linked residue in epsilon was identified in this analysis. A form of epsilon containing a methionine residue in place of Val-112 (epsilon-V112M) was produced by site-directed mutagenesis. Epsilon-V112M was incorporated into F1-ATPase which was then cross-linked with EDC. An 8-kDa cross-linked CNBr fragment of beta-epsilon-V112M was shown to contain the peptide of epsilon between residues Glu-96 and Met-112 and the peptide of beta between residues Asp-380 and Met-431. Again residue Glu-381 of beta was notably reduced and no missing residue from the epsilon-peptide could be identified, but the peptide sequence limited the possible choices to Ser-106, Ser-107, or Ser-108. Furthermore, an epsilon-mutant in which Ser-108 was replaced by cysteine could no longer be cross-linked to a beta-subunit in F1-ATPase by EDC. Both mutant forms of epsilon-supported growth of an uncC-deficient E. coli strain and inhibited F1-ATPase. These results indicate that the EDC-induced cross-link between the beta and epsilon-subunits of F1-ATPase is an ester linkage between beta-Glu-381 and, likely, epsilon-Ser-108. As these residues must be located immediately adjacent to one another in F1-ATPase, our results define a site of subunit-subunit contact between beta and epsilon.	UNIV WESTERN ONTARIO, DEPT BIOCHEM, LONDON N6A 5C1, ONTARIO, CANADA; QUEENS UNIV, DEPT BIOCHEM, KINGSTON K7L 3N6, ONTARIO, CANADA	Western University (University of Western Ontario); Queens University - Canada			Dunn, Stanley/D-3418-2013					AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; BOUTRY M, 1985, EMBO J, V4, P2159, DOI 10.1002/j.1460-2075.1985.tb03910.x; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAGG PD, 1986, BIOCHIM BIOPHYS ACTA, V851, P385, DOI 10.1016/0005-2728(86)90075-7; BRUSILOW WSA, 1983, J BACTERIOL, V155, P1265, DOI 10.1128/JB.155.3.1265-1270.1983; BULLOUGH DA, 1989, J BIOL CHEM, V264, P9155; CARTER P, 1987, METHOD ENZYMOL, V154, P382; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COZENS AL, 1987, J MOL BIOL, V194, P359, DOI 10.1016/0022-2836(87)90667-X; CROSS RL, 1984, CURR TOP CELL REGUL, V24, P335; CURTIS SE, 1987, J BACTERIOL, V169, P80, DOI 10.1128/jb.169.1.80-86.1987; DOWNIE JA, 1980, J BACTERIOL, V143, P8, DOI 10.1128/JB.143.1.8-17.1980; DUNN SD, 1987, BIOCHEMISTRY-US, V26, P4488, DOI 10.1021/bi00388a047; DUNN SD, 1980, J BIOL CHEM, V255, P113; DUNN SD, 1985, J BIOL CHEM, V260, P418; DUNN SD, 1982, J BIOL CHEM, V257, P7354; DUNN SD, 1986, ANAL BIOCHEM, V159, P35, DOI 10.1016/0003-2697(86)90304-0; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; FALK G, 1985, BIOCHEM J, V228, P391, DOI 10.1042/bj2280391; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIBSON F, 1978, J BACTERIOL, V134, P728, DOI 10.1128/JB.134.3.728-736.1978; GIBSON F, 1977, BIOCHEM J, V162, P665, DOI 10.1042/bj1620665; HAWTHORNE CA, 1988, BIOCHEM BIOPH RES CO, V151, P926; JACKSON PJ, 1988, FEBS LETT, V229, P224, DOI 10.1016/0014-5793(88)80832-9; KRUMHOLZ LR, 1989, NUCLEIC ACIDS RES, V17, P7993, DOI 10.1093/nar/17.19.7993; KUKI M, 1988, J BIOL CHEM, V263, P17437; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGET PP, 1979, ARCH BIOCHEM BIOPHYS, V197, P83, DOI 10.1016/0003-9861(79)90222-4; LARSON RJ, 1977, BIOCHEMISTRY-US, V16, P4266, DOI 10.1021/bi00638a021; LEE RSF, 1989, FEBS LETT, V253, P269, DOI 10.1016/0014-5793(89)80973-1; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4134, DOI 10.1021/bi00313a019; Maniatis T., 1982, MOL CLONING; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P10987, DOI 10.1021/bi00109a025; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; OHTA S, 1988, J BIOL CHEM, V263, P11257; PASSADOR L, 1989, J BACTERIOL, V171, P6234, DOI 10.1128/jb.171.11.6234-6242.1989; PATEL AM, 1990, MOL MICROBIOL, V4, P1941, DOI 10.1111/j.1365-2958.1990.tb02043.x; PATEL AM, 1992, J BACTERIOL, V174, P3541, DOI 10.1128/JB.174.11.3541-3548.1992; SAISHU T, 1986, BIOCHIM BIOPHYS ACTA, V867, P97, DOI 10.1016/0167-4781(86)90069-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SMITH JB, 1977, BIOCHEMISTRY-US, V16, P306, DOI 10.1021/bi00621a023; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; SZEWCZYK B, 1988, ANAL BIOCHEM, V168, P48, DOI 10.1016/0003-2697(88)90008-5; TOZER RG, 1987, J BIOL CHEM, V262, P10706; TYBULEWICZ VLJ, 1984, J MOL BIOL, V179, P185, DOI 10.1016/0022-2836(84)90465-0; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; WALDMEYER B, 1985, J BIOL CHEM, V260, P5184; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WILLING A, 1990, J BIOL CHEM, V265, P6596; WOOD JM, 1987, J BIOL CHEM, V262, P2180; [No title captured]	58	83	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18953	18960						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1388160				2022-12-25	WOS:A1992JN50200105
J	LEVINGER, L; VASISHT, V; GREENE, V; ARJUN, I				LEVINGER, L; VASISHT, V; GREENE, V; ARJUN, I			THE EFFECTS OF STEM-I AND LOOP-A ON THE PROCESSING OF 5-S RIBOSOMAL-RNA FROM DROSOPHILA-MELANOGASTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5S RIBOSOMAL-RNA; BINDING-SITE; TRANSCRIPTION; GENE; PRECURSOR; SEQUENCES; NUCLEASE; REQUIRES; COMPLEX; COMMON	The 135-nucleotide Drosophila melanogaster 5 S RNA precursor is processed by removal of 15 nucleotides from its 3' end before incorporation into the large ribosomal subunit. Mature 5 S RNA consists of five helical stem-loops; stem IV and part of V are dispensible, whereas stem III and the 1/118 G-C base pair closest to the processing site at nucleotide 120 are required for processing (Preiser, P., and Levinger, L. (1991) J. Biol. Chem. 266, 7509-7516; Preiser, P., and Levinger, L. (1991) J. Biol. Chem. 266, 23602-23605). We have investigated the effects of stem I and loop A transversions, transitions, selected additions and deletions on 5 S RNA processing. Stem I single substitutions generally prevent processing, whereas compensatory double substitutions restore a range of processing rates. Proximal to the processing site, stem I double substitutions inhibit processing. In the distal portion of stem I and loop A, the processing effect of paired sequence changes varies widely in an irregular pattern. The 7/112 GU pair and nucleotide 13A least tolerate sequence changes; several mutations clustered close to the stem I-loop A boundary stimulate processing. We interpret these results in terms of the RNA helix path and possible RNA-protein contacts.			LEVINGER, L (corresponding author), CUNY YORK COLL,DEPT NAT SCI,BIOL DISCIPLINE,JAMAICA,NY 11451, USA.				NIGMS NIH HHS [GM4603, GM08153] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABOCK MG, 1992, IN PRESS COMPUTATION; BROW DA, 1987, J BIOL CHEM, V262, P13959; DINGERMANN T, 1981, NUCLEIC ACIDS RES, V9, P3908; ESCHALIER G, 1970, IN VITRO, V6, P162; GARRETT RA, 1981, TRENDS BIOCHEM SCI, V6, P137, DOI 10.1016/0968-0004(81)90051-7; HAMADA H, 1979, CELL, V17, P163, DOI 10.1016/0092-8674(79)90304-0; HUBER PW, 1986, J BIOL CHEM, V261, P3002; HUBER PW, 1986, P NATL ACAD SCI USA, V83, P1593, DOI 10.1073/pnas.83.6.1593; IMBODEN MA, 1992, J BIOL CHEM, V267, P24601; IYER RK, 1988, GENE ANAL TECH, V5, P125, DOI 10.1016/0735-0651(88)90012-X; JACQ B, 1977, J MOL BIOL, V117, P785, DOI 10.1016/0022-2836(77)90069-9; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; PACE B, 1984, J BIOL CHEM, V259, P1454; PIPER PW, 1983, EMBO J, V2, P353, DOI 10.1002/j.1460-2075.1983.tb01430.x; PREISER P, 1990, THESIS U DELAWARE NE; PREISER PR, 1991, J BIOL CHEM, V266, P7509; PREISER PR, 1991, J BIOL CHEM, V266, P23602; PRICE DH, 1987, J BIOL CHEM, V262, P3244; RINKE J, 1982, CELL, V29, P149, DOI 10.1016/0092-8674(82)90099-X; ROMANIUK PJ, 1988, NUCLEIC ACIDS RES, V16, P2295, DOI 10.1093/nar/16.5.2295; ROMANIUK PJ, 1989, MOL BIOL RNA P UCLA, P123; RUBIN GM, 1975, CELL, V6, P207, DOI 10.1016/0092-8674(75)90011-2; RYNER L, 1988, MOL CELL BIOL, V7, P495; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULMAN LH, 1988, SCIENCE, V240, P1591, DOI 10.1126/science.2454505; SHARP S, 1984, NUCLEIC ACIDS RES, V12, P7617, DOI 10.1093/nar/12.20.7617; SHARP SJ, 1988, MOL CELL BIOL, V8, P1266, DOI 10.1128/MCB.8.3.1266; STAHL DA, 1984, J BIOL CHEM, V259, P1448; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; TEKAMP PA, 1980, J BIOL CHEM, V255, P9501; TOWER J, 1986, MOL CELL BIOL, V6, P3451, DOI 10.1128/MCB.6.10.3451; VANKNIPPENBERG PH, 1990, BIOCHIM BIOPHYS ACTA, V1051, P14; XING YY, 1989, GENE DEV, V3, P1008, DOI 10.1101/gad.3.7.1008; ZHANG P, 1989, NUCLEIC ACIDS RES, V17, P7295, DOI 10.1093/nar/17.18.7295	34	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23683	23687						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429708				2022-12-25	WOS:A1992JZ23900041
J	CHEN, SRW; ZHANG, L; MACLENNAN, DH				CHEN, SRW; ZHANG, L; MACLENNAN, DH			CHARACTERIZATION OF A CA2+ BINDING AND REGULATORY SITE IN THE CA2+ RELEASE CHANNEL (RYANODINE RECEPTOR) OF RABBIT SKELETAL-MUSCLE SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE; CA-2+ RELEASE; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; PLANAR BILAYERS; PROTEINS; COMPLEX; CDNA; PURIFICATION; RECONSTITUTION	A region in the skeletal muscle ryanodine receptor between amino acids 4014 and 4765 was expressed as a trpE fusion protein. Overlay studies revealed that this region bound Ca2+ and ruthenium red, an indicator of Ca2+-binding sites. Ca2+ binding was mapped to subregion 13b between amino acids 4246 and 4377, encompassing a predicted high affinity Ca2+-binding site, and to subregion 13c between amino acids 4364 and 4529, encompassing two predicted high affinity Ca2+-binding sites. Ca2+ binding was then mapped to three shorter sequences, 22(13b1), 36(13c1), and 35(13c2), amino acids long, each encompassing one of the three predicted Ca2+-binding sites. Site-directed polyclonal antibodies were raised against these three short sequences and purified on antigen affinity columns. The antibody against sequence 13c2, lying between residues 4478 and 4512, specifically recognized both denatured and native forms of the ryanodine receptor, suggesting that at least part of the 35 amino acid sequence containing the Ca2+-binding site is surface-exposed. The affinity purified antibody increased the Ca2+ sensitivity of ryanodine receptor channels incorporated into planar lipid bilayers, resulting in increased open probability and opening time without altering channel conductance. The antibody-activated channel was still modulated by Ca2+, Mg2+, ATP, ryanodine, and ruthenium red. These observations suggest that sequence 13c2 may be involved in Ca2+-induced Ca2+ release.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto								ANDERSON K, 1989, J BIOL CHEM, V264, P1329; CAMPBELL KP, 1981, J BIOL CHEM, V256, P4626; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; CHARUK JHM, 1990, ANAL BIOCHEM, V188, P123, DOI 10.1016/0003-2697(90)90539-L; CHEN SRW, 1992, FASEB J, V6, P22; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; ENDO M, 1985, CURR TOP MEMBR TRANS, V25, P181; FILL M, 1991, BIOCHEM J, V273, P449, DOI 10.1042/bj2730449; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P441, DOI 10.1073/pnas.85.2.441; HYMEL L, 1988, BIOCHEM BIOPH RES CO, V152, P308, DOI 10.1016/S0006-291X(88)80715-0; INUI M, 1987, J BIOL CHEM, V262, P1740; KIRINO Y, 1983, J BIOCHEM-TOKYO, V94, P1111, DOI 10.1093/oxfordjournals.jbchem.a134454; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1988, BIOCHEM BIOPH RES CO, V151, P441, DOI 10.1016/0006-291X(88)90613-4; LAI FA, 1987, BIOCHEM BIOPH RES CO, V143, P704, DOI 10.1016/0006-291X(87)91411-2; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; MARKS AR, 1990, J BIOL CHEM, V265, P13143; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; NAGASAKI K, 1983, J BIOCHEM-TOKYO, V94, P1101, DOI 10.1093/oxfordjournals.jbchem.a134453; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OTSU K, 1990, J BIOL CHEM, V265, P13472; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; ROUSSEAU E, 1989, AM J PHYSIOL, V256, pH328, DOI 10.1152/ajpheart.1989.256.2.H328; ROUSSEAU E, 1988, ARCH BIOCHEM BIOPHYS, V267, P75, DOI 10.1016/0003-9861(88)90010-0; Sambrook J, 1989, MOL CLONING LABORATO; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	36	86	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23318	23326						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1385418				2022-12-25	WOS:A1992JY16300093
J	INIGUEZLLUHI, JA; SIMON, MI; ROBISHAW, JD; GILMAN, AG				INIGUEZLLUHI, JA; SIMON, MI; ROBISHAW, JD; GILMAN, AG			G-PROTEIN BETA-GAMMA SUBUNITS SYNTHESIZED IN SF9 CELLS - FUNCTIONAL-CHARACTERIZATION AND THE SIGNIFICANCE OF PRENYLATION OF GAMMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; GTP-BINDING; CATALYTIC SUPPORT; ADENYLATE-CYCLASE; ADP-RIBOSYLATION; BOVINE BRAIN; K+-CHANNEL; TRANSDUCIN; RECEPTOR; ALPHA	Heterotrimeric guanine nucleotide-binding regulatory proteins (G proteins) consist of a nucleotide-binding alpha subunit and a high-affinity complex of beta and gamma subunits. There is molecular heterogeneity of beta and gamma, but the significance of this diversity is poorly understood. Different G protein beta and gamma subunits have been expressed both singly and in combinations in Sf9 cells. Although expression of individual subunits is achieved in all cases, betagamma subunit activity (support of pertussis toxin-catalyzed ADP-ribosylation of rG(ialpha1)) is detected only when beta and gamma are expressed concurrently. Of the six combinations of betagamma tested (beta1 or beta2 with gamma1, gamma2, or gamma3), only one, beta2gamma1, failed to generate a functional complex. Each of the other five complexes has been purified by subunit exchange chromatography using G(oalpha)-agarose as the chromatographic matrix. We have detected differences in the abilities of the purified proteins to support ADP-ribosylation of G(ialpha1); these differences are attributable to the gamma component of the complex. When assayed for their ability to inhibit calmodulin-stimulated type-I adenylylcyclase activity or to potentiate G(salpha)-stimulated type-II adenylylcyclase, recombinant beta1gamma1 and transducin betagamma are approximately 10 and 20 times less potent, respectively, than the other complexes examined. Prenylation and/or further carboxyl-terminal processing of gamma are not required for assembly of the betagamma subunit complex but are indispensable for high affinity interactions of betagamma with either G protein alpha subunits or adenylylcyclases.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; GEISINGER MED CLIN, WEIS CTR RES, DANVILLE, PA 17822 USA; CALTECH, DEPT BIOL, PASADENA, CA 91125 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Geisinger Medical Center; California Institute of Technology				Iniguez-Lluhi, Jorge/0000-0001-7010-089X	NIGMS NIH HHS [GM34236, GM34497, GM39867] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034236, R01GM034497, R37GM034497, R29GM039867, R37GM034236, R01GM039867] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOYER JL, 1989, J BIOL CHEM, V264, P13917; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; BUBIS J, 1990, J BIOL CHEM, V265, P12995; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CASEY PJ, 1991, METHOD ENZYMOL, V195, P315; CERIONE RA, 1987, BIOCHEMISTRY-US, V26, P1485, DOI 10.1021/bi00379a041; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GAO B, 1987, J BIOL CHEM, V262, P17254; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HAGA K, 1992, J BIOL CHEM, V267, P2222; HEKMAN M, 1987, EUR J BIOCHEM, V169, P431, DOI 10.1111/j.1432-1033.1987.tb13630.x; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; KURACHI Y, 1989, NATURE, V337, P555, DOI 10.1038/337555a0; LAW SF, 1991, J BIOL CHEM, V266, P17885; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; NAKAYAMA N, 1988, MOL CELL BIOL, V8, P3777, DOI 10.1128/MCB.8.9.3777; OHGURO H, 1991, EMBO J, V10, P3669, DOI 10.1002/j.1460-2075.1991.tb04934.x; OKABE K, 1990, J BIOL CHEM, V265, P12854; PAGE M J, 1990, Methods (Orlando), V1, P221, DOI 10.1016/S1046-2023(05)80321-4; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; SUGIMOTO K, 1985, FEBS LETT, V191, P235, DOI 10.1016/0014-5793(85)80015-6; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	50	282	283	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23409	23417						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429682				2022-12-25	WOS:A1992JY16300106
J	WOEHLKE, G; LAUSSERMAIR, E; SCHWARZ, E; OESTERHELT, D; REINKE, H; BEYREUTHER, K; DIMROTH, P				WOEHLKE, G; LAUSSERMAIR, E; SCHWARZ, E; OESTERHELT, D; REINKE, H; BEYREUTHER, K; DIMROTH, P			SEQUENCE OF THE BETA-SUBUNIT OF OXALOACETATE DECARBOXYLASE FROM KLEBSIELLA-PNEUMONIAE - A CORRECTION OF THE C-TERMINAL PART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY; ZENTRUM MOLEK BIOL,W-6900 HEIDELBERG,GERMANY	Max Planck Society; Ruprecht Karls University Heidelberg	WOEHLKE, G (corresponding author), SWISS FED INST TECHNOL,INST MIKROBIOL,CH-8092 ZURICH,SWITZERLAND.			Woehlke, Gunther/0000-0001-8462-9962				DIMROTH P, 1986, METHOD ENZYMOL, V125, P530; LAUSSERMAIR E, 1989, J BIOL CHEM, V264, P14710; Mamur J, 1961, J MOL BIOL, V3, P208; Rodriguez R.L., 1983, RECOMBINANT DNA TECH; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARZ E, 1988, J BIOL CHEM, V263, P9640; SCHWARZ E, 1985, EMBO J, V4, P1599, DOI 10.1002/j.1460-2075.1985.tb03823.x; Simmons JS, 1926, J INFECT DIS, V39, P209, DOI 10.1093/infdis/39.3.209; VANDERREST ME, 1992, J BIOL CHEM, V267, P8971	9	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22804	22805						2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429628				2022-12-25	WOS:A1992JY16300018
J	EKSTROM, RC; CARNEY, EM; LAMM, MLG; HUNZICKERDUNN, M				EKSTROM, RC; CARNEY, EM; LAMM, MLG; HUNZICKERDUNN, M			REVERSAL OF THE DESENSITIZED STATE OF PIG OVARIAN FOLLICULAR HUMAN CHORIOGONADOTROPIN-SENSITIVE ADENYLYLCYCLASE BY GUANOSINE 5'-O-(2-THIODIPHOSPHATE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; HUMAN CHORIONIC-GONADOTROPIN; GTP-BINDING PROTEINS; HORMONE LH RECEPTORS; ADENYLATE-CYCLASE; LUTEINIZING-HORMONE; GRANULOSA-CELLS; REGULATORY SITE; LIGAND-BINDING; BOVINE BRAIN	We investigated the stability of the desensitized state of the human choriogonadotropin (hCG)-sensitive adenylylcyclase of the pig ovarian follicle. A 20,000 x g membrane preparation of pig follicular membranes was incubated under conditions which resulted in the hormone-induced desensitization of the hCG-responsive adenylylcyclase. The desensitized state was maintained upon subsequent incubation of the membranes with GTP, GDP, GMP, ATP, ADP, AMP, CTP, UTP, adenyl-5'-yl imidodiphosphate (AMP-P(NH)P), and adenyl (beta,gamma-methylene)-diphosphonate (AMP-P(CH2)P); however, the desensitized state was reverted to a fully active state upon incubation with guanosine 5'-O-(2-thiodiphosphate) (GDPbetaS) and guanosine 5'-O-(3-thiotriphosphate) (GTPgammaS). The reversal effect of GDPbetaS on hCG-responsive adenylylcyclase activity was time- and temperature-dependent, and showed a selectivity for GDPbetaS over adenosine 5'-O-(2-thiodiphosphate) (ADPbetaS) (half-maximal effective dose of 12 muM versus 260 muM, respectively). GDPbetaS had no effect on the binding affinity or apparent number of luteinizing hormone (LH)/CG receptors or on the dissociation rate of I-125-hCG from the receptor. GDPbetaS promoted an hCG- and time-dependent release of guanine nucleotides from the membranes. A model is proposed which accounts for the unique characteristics of LH/CG-sensitive adenylylcyclase desensitization and subsequent reactivation by GDPbetaS.	NORTHWESTERN UNIV, SCH MED, DEPT CELL MOLEC & STRUCT BIOL, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA	Northwestern University								ABRAMOWITZ J, 1982, ENDOCRINOLOGY, V111, P970, DOI 10.1210/endo-111-3-970; AMIRZALTSMAN Y, 1980, ENDOCRINOLOGY, V106, P1166, DOI 10.1210/endo-106-4-1166; AMSTERDAM A, 1980, P NATL ACAD SCI-BIOL, V77, P3440, DOI 10.1073/pnas.77.6.3440; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BOCKAERT J, 1976, J BIOL CHEM, V251, P2653; BRANDT DR, 1985, J BIOL CHEM, V260, P266; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P4155, DOI 10.1073/pnas.75.9.4155; CASSEL D, 1976, BIOCHIM BIOPHYS ACTA, V452, P538, DOI 10.1016/0005-2744(76)90206-0; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EKSTROM RC, 1989, ENDOCRINOLOGY, V125, P2470, DOI 10.1210/endo-125-5-2470; EKSTROM RC, 1990, ENDOCRINOLOGY, V127, P2578, DOI 10.1210/endo-127-5-2578; EKSTROM RC, 1989, ENDOCRINOLOGY, V124, P956, DOI 10.1210/endo-124-2-956; EZRA E, 1980, J BIOL CHEM, V255, P653; EZRA E, 1981, J BIOL CHEM, V256, P5377; GOSPODAROWICZ D, 1973, J BIOL CHEM, V248, P5042; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HUHTANIEMI IT, 1981, ENDOCRINOLOGY, V108, P1931, DOI 10.1210/endo-108-5-1931; HUNZICKERDUNN M, 1981, BIOL REPROD, V24, P279, DOI 10.1095/biolreprod24.2.279; HUNZICKERDUNN M, 1981, ENDOCRINOLOGY, V109, P345, DOI 10.1210/endo-109-2-345; HUNZICKERDUNN M, 1976, ENDOCRINOLOGY, V99, P185, DOI 10.1210/endo-99-1-185; HUNZICKERDUNN M, 1976, ENDOCRINOLOGY, V99, P198, DOI 10.1210/endo-99-1-198; JAKOBS KH, 1983, NATURE, V303, P177, DOI 10.1038/303177a0; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; LAMPRECHT SA, 1977, J CYCLIC NUCL PROT, V3, P69; LAMPRECHT SA, 1973, J ENDOCRINOL, V57, P217, DOI 10.1677/joe.0.0570217; LAPOLT PS, 1990, ENDOCRINOLOGY, V126, P3277, DOI 10.1210/endo-126-6-3277; LEE CY, 1973, BIOCHEMISTRY-US, V12, P4609, DOI 10.1021/bi00747a011; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MARSH JM, 1973, BIOCHIM BIOPHYS ACTA, V304, P197, DOI 10.1016/0304-4165(73)90128-1; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAMBI P, 1985, J BIOL CHEM, V260, P2165; NAMBI P, 1984, J BIOL CHEM, V259, P4629; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; PALCZEWSKI K, 1988, J BIOL CHEM, V263, P14067; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; RAO MC, 1977, ENDOCRINOLOGY, V101, P512, DOI 10.1210/endo-101-2-512; RASENICK MM, 1989, BRAIN RES, V488, P105, DOI 10.1016/0006-8993(89)90698-7; Rodbell M, 1975, Adv Cyclic Nucleotide Res, V5, P3; ROSS EM, 1980, ANNU REV BIOCHEM, V49, P553, DOI 10.1146/annurev.bi.49.070180.002533; SCHWALL RH, 1984, ENDOCRINOLOGY, V114, P1114, DOI 10.1210/endo-114-4-1114; SEGALOFF DL, 1981, ENDOCRINOLOGY, V108, P632, DOI 10.1210/endo-108-2-632; SIBLEY DR, 1988, ENDOCR REV, V9, P38, DOI 10.1210/edrv-9-1-38; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394; ZOR U, 1976, BIOCHIM BIOPHYS ACTA, V428, P761, DOI 10.1016/0304-4165(76)90206-3	53	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22183	22189						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429569				2022-12-25	WOS:A1992JW71900032
J	MUKAI, K; ITOH, S; MORIMOTO, H				MUKAI, K; ITOH, S; MORIMOTO, H			STOPPED-FLOW KINETIC-STUDY OF VITAMIN-E REGENERATION REACTION WITH BIOLOGICAL HYDROQUINONES (REDUCED FORMS OF UBIQUINONE, VITAMIN-K, AND TOCOPHEROLQUINONE) IN SOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; LIPID-PEROXIDATION; ANTIOXIDANT ACTIVITY; ALPHA-TOCOPHEROL; MITOCHONDRIA; CHAIN; RESONANCE; RADICALS; HOMOLOGS; TISSUES	A kinetic study of the regeneration reaction of vitamin E (tocopherol) with eight biological hydroquinones (HQs) (ubiquinol-10 (Q10H-2 1); ubiquinol-0 (Q0H-2 2); vitamin K1 HQ (VK1H2 3); vitamin K3 HQ (VK3H2 4); alpha-, beta-, gamma-tocopherol-HQs (alpha-, beta-, and gamma-TQH-2 5-7); and 2,3,5-trimethyl-1,4-HQ (TMQH-2 8)) in solution was performed. The second-order rate constants (k4) for the reaction of HQs 1-8 with alpha-tocopheroxyl and 5,7-diisopropyltocopheroxyl radicals in ethanol, benzene, and isopropyl alcohol/water (5:1, v/v) solutions were measured with a stopped-flow spectrophotometer. The order of magnitude of k4 values obtained for HQs is VK1H2 > VK3H2 > alpha-TQH-2 > beta-TQH-2 is similar to gamma-TQH-2 is similar to TMQH-2 > Q10H-2 > Q0H-2, being independent of the kinds of tocopheroxyl radicals and the polarity of the solvents. The log of the k4 values obtained for HQs was found to correlate with their peak oxidation potentials. Comparing the k2 value (2.68 x 10(6) m-1 s-1 obtained for the reaction of alpha-tocopheroxyl with vitamin C (sodium ascorbate) with those (k4 = 2.54 x 10(5) and 8.15 x 10(5) m-1 s-1) obtained for the reaction of alpha-tocopheroxyl with Q10H-2 and alpha-TQH-2 in isopropyl alcohol/water mixtures, the former is approximately 11 and 3 times as reactive as the latter, respectively. On the other hand, the k2 value obtained for sodium ascorbate is smaller than the k4 values obtained for VK1H2 and VK3H2. These results suggest that mixtures of vitamin E and these HQs (as well as those of vitamins E and C) may function synergistically as antioxidants in various tissues and mitochondria.			MUKAI, K (corresponding author), EHIME UNIV, FAC SCI, DEPT CHEM, BUNKYO CHO 2-5, MATSUYAMA, EHIME 790, JAPAN.							BEYER RE, 1986, BIOMEDICAL CLIN ASPE, V5, P17; BOOTH RFG, 1982, BIOCHEM INT, V5, P151; BURLAKOVA YB, 1979, BIOPHYSICS-USSR, V24, P989; BURTON GW, 1986, ACCOUNTS CHEM RES, V19, P194, DOI 10.1021/ar00127a001; BURTON GW, 1981, J AM CHEM SOC, V103, P6472, DOI 10.1021/ja00411a035; FREI B, 1990, P NATL ACAD SCI USA, V87, P4879, DOI 10.1073/pnas.87.12.4879; IKENOYA S, 1981, CHEM PHARM BULL, V29, P158; KAGAN V, 1990, BIOCHEM BIOPH RES CO, V169, P851, DOI 10.1016/0006-291X(90)91971-T; KAGAN VE, 1990, FREE RADICAL BIO MED, V9, P117, DOI 10.1016/0891-5849(90)90114-X; KATAYAMA K, 1980, BIOCHEM BIOPH RES CO, V95, P971, DOI 10.1016/0006-291X(80)91568-5; MARUBAYASHI S, 1984, BIOCHIM BIOPHYS ACTA, V797, P1; MELLORS A, 1966, J BIOL CHEM, V241, P4353; MUKAI K, 1990, BIOCHIM BIOPHYS ACTA, V1035, P77, DOI 10.1016/0304-4165(90)90176-W; MUKAI K, 1989, J ORG CHEM, V54, P552, DOI 10.1021/jo00264a010; MUKAI K, 1982, CHEM PHYS LIPIDS, V30, P337, DOI 10.1016/0009-3084(82)90027-5; MUKAI K, 1986, B CHEM SOC JPN, V59, P3113, DOI 10.1246/bcsj.59.3113; MUKAI K, 1991, J BIOL CHEM, V266, P274; NAUMOV VV, 1983, BIOFIZIKA+, V28, P730; NIKI E, 1984, J BIOL CHEM, V259, P4177; NIKI E, 1987, CHEM PHYS LIPIDS, V44, P227, DOI 10.1016/0009-3084(87)90052-1; OKAMOTO T, 1988, J CHROMATOGR-BIOMED, V430, P11, DOI 10.1016/S0378-4347(00)83129-1; PACKER JE, 1979, NATURE, V278, P737, DOI 10.1038/278737a0; RIEKER A, 1965, LIEBIGS ANN CHEM, V689, P78; ROBESON CD, 1962, J AM CHEM SOC, V84, P3196, DOI 10.1021/ja00875a040; SCARPA M, 1984, BIOCHIM BIOPHYS ACTA, V801, P215, DOI 10.1016/0304-4165(84)90070-9; STOCKER R, 1991, P NATL ACAD SCI USA, V88, P1646, DOI 10.1073/pnas.88.5.1646; SUGINO K, 1987, SURGERY, V101, P746; SUGINO K, 1989, SURGERY, V105, P200; TAKAYANAGI R, 1980, BIOCHEM J, V192, P853, DOI 10.1042/bj1920853; TAKESHIGE K, 1980, BIOMEDICAL CLIN ASPE, V2, P15; YAMADA I, 1990, SOIL SCI PLANT NUTR, V36, P505, DOI 10.1080/00380768.1990.10416920	31	111	119	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22277	22281						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429580				2022-12-25	WOS:A1992JW71900046
J	YAMAGUCHI, M; MICHISHITA, M; HIRAYOSHI, K; YASUKAWA, K; OKUMA, M; NAGATA, K				YAMAGUCHI, M; MICHISHITA, M; HIRAYOSHI, K; YASUKAWA, K; OKUMA, M; NAGATA, K			DOWN-REGULATION OF INTERLEUKIN-6 RECEPTORS OF MOUSE MYELOMONOCYTIC LEUKEMIC-CELLS BY LEUKEMIA INHIBITORY FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; NECROSIS-FACTOR RECEPTORS; GROWTH-FACTOR RECEPTORS; IL-6 SIGNAL TRANSDUCER; HIGH-AFFINITY; T-CELLS; GM-CSF; NEURONAL DIFFERENTIATION; MOLECULAR-CLONING; MURINE IL-6	We examined the effect of leukemia inhibitory factor (LIF) on the expression of interleukin 6 receptors (IL-6R) on mouse myelomonocytic leukemic M1 cells. Binding studies using I-125-labeled human and murine IL-6 revealed that LIF caused a decrease in IL-6 binding to M1 cells. The decrease became evident within 1 h, and the maximum decrease was observed at 3-6 h. Scatchard plot analysis revealed that M1 cells had a single class of high affinity receptors for IL-6 and that LIF-induced decrease in IL-6 binding was due to a decrease in the number of IL-6R on the cell surface and not to changes in their affinity. The affinity of IL-6R on M1 cells to human IL-6 (K(d) = 2.25 nM) was about 10-fold lower than that to murine IL-6 (K(d) = 200 pM). The amount of IL-6 secreted into culture media by M1 cells that were treated with LIF for up to 12 h was not enough to cause receptor down-regulation. Northern blot analysis demonstrated that IL-6R mRNA was down-regulated by LIF treatment, and similar regulation was also observed when the cells were treated with IL-6. The time course of the IL-6R mRNA level was similar to that of IL-6R expression on the cell surface, suggesting that the main mechanism responsible for the loss of high affinity IL-6R was the regulation of IL-6R mRNA. Although the half-life of IL-6R on the cell surface was about 30 min, the addition of LIF reduced it to 16 min, suggesting the existence of an additional mechanism responsible for the loss of high affinity IL-6R on the cell surface.	KYOTO UNIV,DEPT CELL BIOL,CHEST DIS RES INST,KYOTO 606,JAPAN; KYOTO UNIV,DIV INTERNAL MED 1,KYOTO 606,JAPAN; TOSOH CORP,BIOTECHNOL RES LAB,KANAGAWA 252,JAPAN	Kyoto University; Kyoto University; Tosoh Corporation								ABE E, 1981, P NATL ACAD SCI-BIOL, V78, P4990, DOI 10.1073/pnas.78.8.4990; BAUER J, 1989, J EXP MED, V170, P1537, DOI 10.1084/jem.170.5.1537; BAUMANN H, 1989, J BIOL CHEM, V264, P8046; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; CARMICHAEL J, 1987, CANCER RES, V47, P936; COULIE PG, 1989, EUR J IMMUNOL, V19, P2107, DOI 10.1002/eji.1830191121; DANLEY DE, 1991, FEBS LETT, V283, P135, DOI 10.1016/0014-5793(91)80571-J; FERNANDEZBOTRAN R, 1989, J EXP MED, V169, P379, DOI 10.1084/jem.169.2.379; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; GOUGH NM, 1989, CANCER CELL-MON REV, V1, P77; HENSCHLER R, 1991, FEBS LETT, V283, P47, DOI 10.1016/0014-5793(91)80550-M; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1988, J BIOL CHEM, V263, P9238; HILTON DJ, 1988, P NATL ACAD SCI USA, V85, P5971, DOI 10.1073/pnas.85.16.5971; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; HIRANO T, 1985, P NATL ACAD SCI USA, V82, P5490, DOI 10.1073/pnas.82.16.5490; HIRAYOSHI K, 1991, FEBS LETT, V282, P401, DOI 10.1016/0014-5793(91)80523-6; HORII Y, 1988, J IMMUNOL, V141, P1529; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; IKEBUCHI K, 1987, P NATL ACAD SCI USA, V84, P9035, DOI 10.1073/pnas.84.24.9035; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LEARY AG, 1990, BLOOD, V75, P1960; LOTEM J, 1988, BLOOD, V72, P1595; LOTEM J, 1989, LEUKEMIA, V3, P804; LOTEM J, 1975, INT J CANCER, V15, P731, DOI 10.1002/ijc.2910150504; METCALF D, 1988, LEUKEMIA, V2, P216; METCALF D, 1985, LEUKEMIA RES, V9, P35, DOI 10.1016/0145-2126(85)90020-7; METCALF D, 1989, LEUKEMIA, V3, P349; MICHISHITA M, 1990, J BIOL CHEM, V265, P8751; MIYAURA C, 1989, BIOCHEM BIOPH RES CO, V158, P660, DOI 10.1016/0006-291X(89)92772-1; NABHOLZ M, 1987, EUR J IMMUNOL, V17, P783, DOI 10.1002/eji.1830170608; NAGATA K, 1979, J CELL PHYSIOL, V98, P167, DOI 10.1002/jcp.1040980118; NESBITT JE, 1992, MOL BIOL CELL, V3, P103, DOI 10.1091/mbc.3.1.103; NICOLA NA, 1987, IMMUNOL TODAY, V8, P134, DOI 10.1016/0167-5699(87)90140-X; NOVICK D, 1989, J EXP MED, V170, P1409, DOI 10.1084/jem.170.4.1409; PARK LS, 1989, J BIOL CHEM, V264, P5420; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; ROBB RJ, 1987, J IMMUNOL, V139, P855; SAITO T, 1991, J IMMUNOL, V147, P168; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SHABO Y, 1988, BLOOD, V72, P2070; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SNYERS L, 1990, P NATL ACAD SCI USA, V87, P2838, DOI 10.1073/pnas.87.7.2838; SUGITA T, 1990, J EXP MED, V171, P2001, DOI 10.1084/jem.171.6.2001; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1987, J EXP MED, V166, P967, DOI 10.1084/jem.166.4.967; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TOMIDA M, 1986, FEBS LETT, V207, P271, DOI 10.1016/0014-5793(86)81503-4; TOMIDA M, 1984, J BIOL CHEM, V259, P978; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; VINK A, 1988, EUR J IMMUNOL, V18, P607, DOI 10.1002/eji.1830180418; WALKER F, 1985, CELL, V43, P269, DOI 10.1016/0092-8674(85)90032-7; WATANABE N, 1988, J BIOL CHEM, V263, P10262; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546	60	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22035	22042						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429553				2022-12-25	WOS:A1992JW71900011
J	COLL, RJ; MURPHY, AJ				COLL, RJ; MURPHY, AJ			FLUORIDE-INHIBITED CALCIUM ATPASE OF SARCOPLASMIC-RETICULUM - MAGNESIUM AND FLUORIDE STOICHIOMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; ADENOSINE-TRIPHOSPHATASE; REACTION-MECHANISM; FLUORESCENCE MEASUREMENTS; BINDING-SITES; CAATPASE; CA-2+-ATPASE; AFFINITY; PHOSPHORYLATION; PUMP	The sarcoplasmic reticulum (SR) CaATPase is inactivated by fluoride in the presence of magnesium (Murphy, A. J., and Coll, R. J. (1992) J. Biol. Chem. 267, 5229-5235). The inactive complex is very stable and can be isolated free of other components by 48 h of dialysis at 4-degrees-C (Murphy, A. J., and Coll, R. J. (1992) J. Biol. Chem. 267, 16990-16994). In this study, we used a fluoride-specific electrode to determine that the amount of tightly bound fluoride in the complex was 9.4 +/- 2 nmol mg-1 SR protein. The rate constant of inactivation was very similar to the rate constant of fluoride incorporation and varied directly as the square of the fluoride concentration. Luminal Ca2+ accelerated reactivation of the inhibited enzyme, and the rate constants of activity regain and fluoride release were very similar. Although required for inhibition, added magnesium did not accelerate reactivation. Analysis for magnesium using antipyrylazo III of the inhibited enzyme showed 4.1 +/- 0.4 nmol mg-1 SR protein. As there is much evidence in the literature supportive of an estimate of calcium pumps equal to approximately 4-5 nmol mg-1 SR protein, our results indicate that each inhibited enzyme contains two tightly bound fluorides and one tightly bound magnesium.			COLL, RJ (corresponding author), UNIV PACIFIC, SCH DENT, DEPT BIOCHEM, SAN FRANCISCO, CA 94115 USA.				NIGMS NIH HHS [GM31083] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031083] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN JP, 1982, J BIOL CHEM, V257, P8300; ANDERSON KW, 1983, J BIOL CHEM, V258, P4276; CHIESI M, 1980, BIOCHEMISTRY-US, V19, P2912, DOI 10.1021/bi00554a015; COLL RJ, 1984, J BIOL CHEM, V259, P4249; COLL RJ, 1986, BIOCHEM BIOPH RES CO, V138, P652, DOI 10.1016/S0006-291X(86)80546-0; DEMEIS L, 1982, J BIOL CHEM, V257, P1289; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; DUPONT Y, 1982, BIOCHEM BIOPH RES CO, V106, P1272, DOI 10.1016/0006-291X(82)91250-5; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FROEHLICH JP, 1975, J BIOL CHEM, V250, P2013; GARRAHAN PJ, 1976, BIOCHIM BIOPHYS ACTA, V448, P121, DOI 10.1016/0005-2736(76)90081-X; GUILLAIN F, 1982, J BIOL CHEM, V257, P7366; HIGHSMITH S, 1984, BIOCHEM BIOPH RES CO, V124, P183, DOI 10.1016/0006-291X(84)90934-3; HIGHSMITH S, 1984, J BIOL CHEM, V259, P4651; INESI G, 1984, J BIOL CHEM, V259, P996; INESI G, 1992, ADV ENZYMOL RELAT AR, V65, P185; Jencks W P, 1980, Adv Enzymol Relat Areas Mol Biol, V51, P75; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; LEVY D, 1990, J BIOL CHEM, V265, P19524; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MURPHY AJ, 1992, J BIOL CHEM, V267, P16995; MURPHY AJ, 1988, BIOCHIM BIOPHYS ACTA, V946, P57, DOI 10.1016/0005-2736(88)90457-9; MURPHY AJ, 1990, BIOCHEMISTRY-US, V29, P11236, DOI 10.1021/bi00503a012; MURPHY AJ, 1992, J BIOL CHEM, V267, P5229; MURPHY AJ, 1992, J BIOL CHEM, V267, P16990; MYUNG J, 1991, FEBS LETT, V278, P35, DOI 10.1016/0014-5793(91)80077-G; PANG DC, 1977, J BIOL CHEM, V252, P3262; PICKART CM, 1984, J BIOL CHEM, V259, P1629; PUNZENGRUBER C, 1978, EUR J BIOCHEM, V92, P349, DOI 10.1111/j.1432-1033.1978.tb12754.x; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P8698; TAKAKUWA Y, 1982, J BIOL CHEM, V257, P426; TAKISAWA H, 1978, J BIOCHEM-TOKYO, V83, P1275, DOI 10.1093/oxfordjournals.jbchem.a132034; YAMADA S, 1980, J BIOL CHEM, V255, P3108	35	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21584	21587						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400469				2022-12-25	WOS:A1992JV01100051
J	PAULAIS, M; TURNER, RJ				PAULAIS, M; TURNER, RJ			ACTIVATION OF THE NA+-K+-2CL- COTRANSPORTER IN RAT PAROTID ACINAR-CELLS BY ALUMINUM FLUORIDE AND PHOSPHATASE INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OKADAIC ACID; PROTEIN PHOSPHATASES; CELLULAR-REGULATION; NA+/H+ EXCHANGE; SECRETION; CALCIUM; BINDING; TISSUES; VOLUME; CL	The bumetanide-sensitive component of pH(i) recovery from an NH4Cl-induced acute alkaline load was used as a measure of Na+-K+-2Cl- cotransport activity in rat parotid acini. Acinar treatment with NaF/AlCl3 (15 mM NaF plus 10 muM AlCl3) induced a 5-fold stimulation in the initial rate of bumetanide-sensitive pH(i) recovery. This effect was dependent on NaF concentration (K1/2 almost-equal-to 7 mM) and was blunted in the presence of the Al3+ chelator desferal mesylate suggesting that it might be due to the aluminofluoride ion, AlF4-. NaF/AlCl3 treatment did not increase acinar intracellular cAMP levels but did result in an increase in intracellular calcium concentration (from 87 +/- 5 to 181 +/- 2 nM) and in acinar cell shrinkage (12 +/- 1 %). But the stimulation of the Na+-K+-2Cl- cotransporter by NaF/AlCl3 persisted in acini which had been depleted of their intracellular Ca2+ stores. In these acini no effect of NaF/AlCl3 on intracellular calcium or cell volume was observed, indicating that stimulation of the cotransporter was not secondary to either of these phenomena. The effect of NaF/AlCl3 on the cotransporter was blocked by the protein kinase inhibitor K252a indicating the involvement of a protein phosphorylation event. This result is consistent with either NaF/AlCl3-dependent protein kinase activation or phosphatase inhibition. The stimulation of the cotransporter by NaF/AlCl3 was mimicked by the protein phosphatase inhibitor calyculin A; however, this effect was not blocked by K252a suggesting that a different protein kinase from that associated with NaF/AlCl3 may be involved. The data indicate that the Na+-K+-2Cl- cotransporter in this tissue is under tight regulatory control, in all likelihood via multiple protein kinase/phosphatase systems. The physiological roles of these regulatory events in modulating acinar fluid secretion driven by the Na+-K+-2Cl-cotransporter remain to be elucidated.	NIDR,CLIN INVEST & PATIENT CARE BRANCH,BLDG 10,RM 1A06,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Paulais, Marc/Q-6692-2017; Paulais, Marc/E-5623-2017	Paulais, Marc/0000-0002-4895-2110; 				BAUM BJ, 1990, METHOD ENZYMOL, V192, P26; BLACKMORE PF, 1985, J BIOL CHEM, V260, P4477; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, J BIOL CHEM, V264, P21435; COOK DI, 1989, HDB PHYSL 6, V3, P1; FOSKETT JK, 1990, AM J PHYSIOL, V259, pC998; FOSKETT JK, 1989, SCIENCE, V244, P1582, DOI 10.1126/science.2500708; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; HESCHELER J, 1988, PFLUG ARCH EUR J PHY, V412, P248, DOI 10.1007/BF00582504; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; ISHIHARA H, 1985, BIOCHEM BIOPH RES CO, V159, P933; IWATSUKI N, 1985, JPN J PHYSIOL, V35, P933, DOI 10.2170/jjphysiol.35.933; MACKENZIE CW, 1980, BIOCHIM BIOPHYS ACTA, V614, P413, DOI 10.1016/0005-2744(80)90231-4; MANGANEL M, 1991, J BIOL CHEM, V266, P10182; MELVIN JE, 1988, J BIOL CHEM, V263, P19564; MELVIN JE, 1992, AM J PHYSIOL, V262, pG393, DOI 10.1152/ajpgi.1992.262.3.G393; MELVIN JE, 1987, BIOCHEM BIOPH RES CO, V145, P754, DOI 10.1016/0006-291X(87)91029-1; MERTZ LM, 1990, AM J PHYSIOL, V258, pC654, DOI 10.1152/ajpcell.1990.258.4.C654; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177, DOI 10.1152/ajpcell.1987.253.2.C177; PAULAIS M, 1992, J CLIN INVEST, V89, P1142, DOI 10.1172/JCI115695; PETERSEN OH, 1984, NATURE, V307, P693, DOI 10.1038/307693a0; PEWITT EB, 1990, J BIOL CHEM, V265, P20747; PIRANI D, 1987, PFLUG ARCH EUR J PHY, V408, P178, DOI 10.1007/BF00581349; RALL TW, 1958, J BIOL CHEM, V232, P1065; SHACTERNOIMAN E, 1983, J BIOL CHEM, V258, P4214; SHAHED AR, 1988, J DENT RES, V67, P462, DOI 10.1177/00220345880670020501; SOLTOFF SP, 1989, J GEN PHYSIOL, V93, P285, DOI 10.1085/jgp.93.2.285; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; TOJYO Y, 1991, AM J PHYSIOL, V260, pC194, DOI 10.1152/ajpcell.1991.260.2.C194; TURNER RJ, 1986, J MEMBRANE BIOL, V94, P143, DOI 10.1007/BF01871194; TURNER RJ, 1992, BIOL SALIVARY GLANDS; Wiseman A., 1970, HDB EXPT PHARM, P48	36	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21558	21563						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1383225				2022-12-25	WOS:A1992JV01100047
J	SCHULTZ, JR; GONG, EL; MCCALL, MR; NICHOLS, AV; CLIFT, SM; RUBIN, EM				SCHULTZ, JR; GONG, EL; MCCALL, MR; NICHOLS, AV; CLIFT, SM; RUBIN, EM			EXPRESSION OF HUMAN APOLIPOPROTEIN-A-II AND ITS EFFECT ON HIGH-DENSITY-LIPOPROTEINS IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY-ARTERY DISEASE; HEPATIC TRIGLYCERIDE LIPASE; PARTICLE-SIZE DISTRIBUTION; ISCHEMIC HEART-DISEASE; CHOLESTEROL-ACYLTRANSFERASE; STRUCTURAL ORGANIZATION; NUCLEOTIDE-SEQUENCE; GEL-ELECTROPHORESIS; ACID SEQUENCE; MESSENGER-RNA	Apolipoproteins A-I and A-II comprise approximately 70 and 20%, respectively, of the total protein content of HDL. Evidence suggests that apoA-I plays a central role in determining the structure and plasma concentration of HDL, while the role of apoA-II is uncertain. To help define the function of apoA-II and determine what effect increasing its plasma concentration has on HDL, transgenic mice expressing human apoA-II and both human apoA-I and human apoA-II were produced. Human apoA-II mRNA is expressed exclusively in the livers of transgenic animals, and the protein exists as a dimer as it does in humans. High level expression of human apoA-II did not increase HDL concentrations or decrease plasma concentrations of murine apoA-I and apoA-II in contrast to what was observed in mice overexpressing human apoA-I. The primary effect of overexpressing human apoA-II was the appearance of small HDL particles composed exclusively of human apoA-II. HDL from mice transgenic for both human apoA-I and human apoA-II displayed a unique size distribution when compared with either apoA-I or apoA-II transgenic mice and contain particles with both these human apolipoproteins. These results in mice, indicating that human apoA-II participates in determining HDL size, parallel results from human studies.	LAWRENCE BERKELEY LAB, DIV LIFE SCI, 1 CYCLOTRON RD, BERKELEY, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018574, R01HL046281] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL46281, HL18574] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], CURR OPIN LIPIDOL; ASSMANN G, 1977, J CLIN INVEST, V60, P242, DOI 10.1172/JCI108761; BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63, DOI 10.1016/0006-291X(87)90451-7; BREWER HB, 1972, P NATL ACAD SCI USA, V69, P1304, DOI 10.1073/pnas.69.5.1304; CHAJEKSHAUL T, 1991, P NATL ACAD SCI USA, V88, P6731, DOI 10.1073/pnas.88.15.6731; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; CHEUNG MC, 1991, J LIPID RES, V32, P383; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEEB SS, 1991, J BIOL CHEM, V266, P13654; DEEB SS, 1990, AM J HUM GENET, V46, P822; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P16380; EDELSTEIN C, 1976, BIOCHEMISTRY-US, V15, P1262, DOI 10.1021/bi00651a014; EGGERMAN TL, 1991, J LIPID RES, V32, P821; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELDING C J, 1981, Proceedings of the National Academy of Sciences of the United States of America, V78, P3911, DOI 10.1073/pnas.78.6.3911; FIELDING CJ, 1982, MED CLIN N AM, V66, P363, DOI 10.1016/S0025-7125(16)31425-0; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; FUNKE H, 1991, J CLIN INVEST, V87, P371, DOI 10.1172/JCI114997; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; HADDAD IA, 1986, J BIOL CHEM, V261, P3268; HOGAN B, 1986, MANIPULATING MOUSE E; HWANG JL, 1985, J BIOL CHEM, V260, P5660; KARATHANASIS SK, 1983, P NATL ACAD SCI-BIOL, V80, P6147, DOI 10.1073/pnas.80.20.6147; KARATHANASIS SK, 1985, P NATL ACAD SCI USA, V82, P6374, DOI 10.1073/pnas.82.19.6374; KNOTT TJ, 1985, NUCLEIC ACIDS RES, V13, P6387, DOI 10.1093/nar/13.17.6387; KUBO M, 1982, J BIOCHEM, V92, P865, DOI 10.1093/oxfordjournals.jbchem.a134000; LACKNER KJ, 1984, BIOCHEM BIOPH RES CO, V122, P877, DOI 10.1016/0006-291X(84)91172-0; LACKNER KJ, 1985, NUCLEIC ACIDS RES, V13, P4597, DOI 10.1093/nar/13.12.4597; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUSIS AJ, 1983, J BIOL CHEM, V258, P5071; Maniatis T., 1982, MOL CLONING; MILLER GJ, 1975, LANCET, V1, P16; MILLER NE, 1981, BRIT MED J, V282, P1741, DOI 10.1136/bmj.282.6278.1741; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; MOORE MN, 1984, BIOCHEM BIOPH RES CO, V123, P1, DOI 10.1016/0006-291X(84)90371-1; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; NICHOLS AV, 1987, J LIPID RES, V28, P719; NICOLOSI RJ, 1984, J LIPID RES, V25, P879; NOMA A, 1983, ATHEROSCLEROSIS, V37, P157; PAIGEN B, 1987, P NATL ACAD SCI USA, V84, P3763, DOI 10.1073/pnas.84.11.3763; PUCHOIS P, 1987, ATHEROSCLEROSIS, V68, P35, DOI 10.1016/0021-9150(87)90091-8; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; SCANU AM, 1982, CRC CR REV BIOCH MOL, V13, P109, DOI 10.3109/10409238209108711; SCHAEFER EJ, 1982, ARTERIOSCLEROSIS, V2, P16, DOI 10.1161/01.ATV.2.1.16; SHENG J, 1990, METABOLISM, V39, P155, DOI 10.1016/0026-0495(90)90069-O; SOUTAR AK, 1975, BIOCHEMISTRY-US, V14, P3057, DOI 10.1021/bi00685a003; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAELS B, 1990, ENDOCRINOLOGY, V127, P1144, DOI 10.1210/endo-127-3-1144; STAELS B, 1989, J LIPID RES, V30, P1137; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STOFFEL W, 1983, H-S Z PHYSIOL CHEM, V364, P227, DOI 10.1515/bchm2.1983.364.1.227; TSAO YK, 1985, J BIOL CHEM, V260, P5222; WALSH A, 1989, J BIOL CHEM, V264, P6488	55	98	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21630	21636						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400473				2022-12-25	WOS:A1992JV01100059
J	LIUKKONEN, J; HAATAJA, S; TIKKANEN, K; KELM, S; FINNE, J				LIUKKONEN, J; HAATAJA, S; TIKKANEN, K; KELM, S; FINNE, J			IDENTIFICATION OF N-ACETYLNEURAMINYL ALPHA-2-]3 POLY-N-ACETYLLACTOSAMINE GLYCANS AS THE RECEPTORS OF SIALIC ACID-BINDING STREPTOCOCCUS-SUIS STRAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANE; BLOOD-GROUP ACTIVITIES; ESCHERICHIA-COLI; MYCOPLASMA-PNEUMONIAE; POLYACRYLAMIDE GELS; ADHESION RECEPTORS; SUGAR CHAINS; OLIGOSACCHARIDES; GLYCOSPHINGOLIPIDS; GLYCOPROTEINS	Streptococcus suis is a common cause of sepsis, meningitis, and other serious infections in young piglets and also causes meningitis in humans. The cell-binding specificity of sialic acid-recognizing strains of Streptococcus suis was investigated. Treatment of human erythrocytes with sialidase or mild periodate abolished hemagglutination. Hemagglutination inhibition experiments with sialyl oligosaccharides indicated that the adhesin preferred the sequence NeuN Acalpha2-3Galbeta1-4Glc(NAc). Resialylation of desialylated erythrocytes with Galbeta1-3(4)GlcNAc alpha2-3-sialyltransferase induced a strong hemagglutination, whereas no or only weak hemagglutination was obtained with cells resialylated with two other sialyltransferases. Binding of radiolabeled bacteria to blots of erythrocyte membrane proteins revealed binding to the poly-N-acetyllactosamine-containing components Band 3, Band 4.5, and polyglycosyl ceramides and to glycophorin A. The involvement of glycophorin A as a major ligand was excluded by the strong hemagglutination of trypsin-treated erythrocytes and En(a-) erythrocytes defective in glycophorin A. Sensitivity of the hemagglutination toward endo-beta-galactosidase treatment of erythrocytes and inhibition by purified poly-N-acetyllactosaminyl glycopeptides indicated that the adhesin bound to glycans containing the following structure: NeuNAcalpha2-3Galbeta1-4GlcNAcbeta1-3Galbeta1-	UNIV TURKU, DEPT MED BIOCHEM, KIINAMYLLNKATU 10, SF-20520 TURKU 52, FINLAND; UNIV KUOPIO, DEPT BIOCHEM & BIOTECHNOL, SF-70211 KUOPIO, FINLAND; UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; UNIV KIEL, INST BIOCHEM, W-2300 KIEL 1, GERMANY	University of Turku; University of Eastern Finland; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Kiel			Haataja, Sauli/AAR-5103-2020; Kelm, Soerge/C-5403-2013; Finne, Jukka/B-6881-2008	Kelm, Soerge/0000-0001-5277-9421; Finne, Jukka/0000-0002-8076-3344				BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BRENNAN MJ, 1991, J BIOL CHEM, V266, P18827; DEAL CD, 1990, J BIOL CHEM, V265, P12774; DZANDU JK, 1985, BIOCHEM BIOPH RES CO, V126, P50, DOI 10.1016/0006-291X(85)90569-8; EVANS DG, 1988, INFECT IMMUN, V56, P2896, DOI 10.1128/IAI.56.11.2896-2906.1988; FINNE J, 1980, REV FR TRANSFUS IMMU, V23, P545, DOI 10.1016/S0338-4535(80)80158-9; FINNE J, 1980, EUR J BIOCHEM, V104, P181, DOI 10.1111/j.1432-1033.1980.tb04414.x; FINNE J, 1982, METHOD ENZYMOL, V83, P269; FIRON N, 1982, BIOCHEM BIOPH RES CO, V105, P1426, DOI 10.1016/0006-291X(82)90947-0; FUKUDA MN, 1979, J BIOL CHEM, V254, P5458; GAHMBERG CG, 1976, J BIOL CHEM, V251, P6108; GAHMBERG CG, 1977, J BIOL CHEM, V252, P5888; ISHIKAWA H, 1987, INFECT IMMUN, V55, P1607, DOI 10.1128/IAI.55.7.1607-1609.1987; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KORHONEN TK, 1985, ENTEROBACTERIAL SURF, P301; Koscielak J, 1978, Methods Enzymol, V50, P211; KOSCIELAK J, 1976, EUR J BIOCHEM, V71, P9, DOI 10.1111/j.1432-1033.1976.tb11083.x; KRIVAN HC, 1988, P NATL ACAD SCI USA, V85, P6157, DOI 10.1073/pnas.85.16.6157; KRUSIUS T, 1978, EUR J BIOCHEM, V92, P289, DOI 10.1111/j.1432-1033.1978.tb12747.x; KURL DN, 1989, INFECT IMMUN, V57, P384, DOI 10.1128/IAI.57.2.384-389.1989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE N, 1990, J BIOL CHEM, V265, P20476; LINDSTEDT R, 1991, INFECT IMMUN, V59, P1086, DOI 10.1128/IAI.59.3.1086-1092.1991; LOOMES LM, 1984, NATURE, V307, P560, DOI 10.1038/307560a0; MORELL AG, 1972, METHODS ENZYMOLOGY B, V28, P205; MOTOYOSHI F, 1990, CLIN IMMUNOL IMMUNOP, V54, P495, DOI 10.1016/0090-1229(90)90061-T; MOURICOUT M, 1990, INFECT IMMUN, V58, P98, DOI 10.1128/IAI.58.1.98-106.1990; MURAMATSU T, 1988, BIOCHIMIE, V70, P1587, DOI 10.1016/0300-9084(88)90294-5; MURRAY PA, 1982, BIOCHEM BIOPH RES CO, V106, P390, DOI 10.1016/0006-291X(82)91122-6; NIKKILA EA, 1960, SCAND J CLIN LAB INV, V12, P209, DOI 10.3109/00365516009062424; Ofek I., 1990, CURR TOP MICROBIOL, V151, P91; PARKKINEN J, 1986, INFECT IMMUN, V54, P37, DOI 10.1128/IAI.54.1.37-42.1986; PARKKINEN J, 1991, THROMB HAEMOSTASIS, V65, P483; PARKKINEN J, 1988, J CLIN INVEST, V81, P860, DOI 10.1172/JCI113395; PARKKINEN J, 1987, METHOD ENZYMOL, V138, P289, DOI 10.1016/0076-6879(87)38024-3; PAULSON JC, 1987, METHOD ENZYMOL, V138, P162; ROBERTS DD, 1989, J BIOL CHEM, V264, P9289; SADLER JE, 1982, METHOD ENZYMOL, V83, P458; SKINNER MK, 1983, BIOCHEM J, V209, P281, DOI 10.1042/bj2090281; SMIT H, 1984, INFECT IMMUN, V46, P578, DOI 10.1128/IAI.46.2.578-584.1984; STROMBERG N, 1990, J BIOL CHEM, V265, P11251; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAISANENRHEN V, 1983, FEBS LETT, V159, P233, DOI 10.1016/0014-5793(83)80453-0; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WINDSOR RS, 1977, VET REC, V101, P378, DOI 10.1136/vr.101.19.378; YAMASHITA Y, 1989, MOL IMMUNOL, V26, P905; ZANEN HC, 1979, PATHOGENIC STREPTOCO, P232; ZHU BCR, 1985, J BIOL CHEM, V260, P4041	50	48	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21105	21111						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400420				2022-12-25	WOS:A1992JT97800092
J	NUGENT, MA; EDELMAN, ER				NUGENT, MA; EDELMAN, ER			TRANSFORMING GROWTH-FACTOR BETA-1 STIMULATES THE PRODUCTION OF BASIC FIBROBLAST GROWTH-FACTOR BINDING PROTEOGLYCANS IN BALB/C3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBENDOTHELIAL EXTRACELLULAR-MATRIX; PLASMINOGEN-ACTIVATOR PRODUCTION; HEPARAN-SULFATE PROTEOGLYCAN; CAPILLARY ENDOTHELIAL-CELLS; HIGH-AFFINITY RECEPTORS; SMOOTH-MUSCLE CELLS; TGF-BETA; PROTEOLYTIC DEGRADATION; SURFACE PROTEOGLYCAN; ANGIOGENIC PROTEIN	Basic fibroblast growth factor (bFGF) binds to cell surface receptors and to heparan sulfate proteoglycans. Heparan sulfate binding may limit bFGF degradation and be an obligatory step for bFGF cell interaction. Transforming growth factor-beta1 (TGF-beta1) is a potent regulator of proteoglycan production and composition. The possibility that TGF-beta1 synergistically regulates bFGF activity by altering bFGF-proteoglycan interactions was investigated. TGF-beta1 increased I-125-bFGF binding to the extracellular matrix (ECM) of Balb/c3T3 cells 2-4-fold by increasing the number of bFGF binding sites. Increased bFGF binding correlated with a 2-5-fold increase in the production of sulfated proteoglycans, including heparan sulfate proteoglycans. TGF-beta1 selectively stimulated production of high molecular mass proteoglycans (190-300 kDa) in conditioned medium and stimulated all proteoglycans in ECM. I-125-bFGF bound to TGF-beta1 induced proteoglycans immobilized onto cationic nylon filters. Furthermore, ECM isolated from TGF-beta1-treated cells incorporated more mitogenically active bFGF than native ECM. The mitogenic potential of the ECM was significantly reduced by treatment with heparinase. These results suggest that the ability of TGF-beta1 to stimulate binding of bFGF to ECM, increase ECM heparan sulfate proteoglycan, and potentiate the mitogenic activity of bFGF are linked. Thus one aspect of TGF-beta1/bFGF synergy may involve modulation of the ECM.	HARVARD UNIV,MIT,DIV HLTH SCI & TECHNOL,CAMBRIDGE,MA 02139; BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School				Nugent, Matthew/0000-0002-8630-4712	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K12AG000294] Funding Source: NIH RePORTER; NIA NIH HHS [K12 AG00294] Funding Source: Medline; NIGMS NIH HHS [F32 GM14003] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; ASSOIAN RK, 1984, CELL, V36, P35, DOI 10.1016/0092-8674(84)90071-0; ASSOIAN RK, 1985, J BIOL CHEM, V260, P9613; BAIRD A, 1987, BIOCHEM BIOPH RES CO, V142, P428, DOI 10.1016/0006-291X(87)90292-0; BAIRD A, 1986, BIOCHEM BIOPH RES CO, V138, P476, DOI 10.1016/0006-291X(86)90305-0; BAIRD A, 1990, PEPTIDE GROWTH FACTO, V1, P369; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BASSOLS A, 1988, J BIOL CHEM, V263, P3039; BIKFALVI A, 1989, EXP CELL RES, V181, P75, DOI 10.1016/0014-4827(89)90183-3; BRADSHAW RA, 1990, PEPTIDE GROWTH FACTO, V1, P17; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHEN JK, 1987, P NATL ACAD SCI USA, V84, P5287, DOI 10.1073/pnas.84.15.5287; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DODGE GR, 1990, J BIOL CHEM, V265, P18023; EDELMAN ER, 1991, BIOMATERIALS, V12, P619, DOI 10.1016/0142-9612(91)90107-L; FENG P, 1986, J BIOL CHEM, V261, P14167; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FOLKMAN J, 1988, AM J PATHOL, V130, P393; FRATERSCHRODER M, 1986, BIOCHEM BIOPH RES CO, V137, P295, DOI 10.1016/0006-291X(86)91209-X; GLOBUS RK, 1988, ENDOCRINOLOGY, V123, P98, DOI 10.1210/endo-123-1-98; GLOBUS RK, 1989, ENDOCRINOLOGY, V124, P1439; GONZALEZ AM, 1990, J CELL BIOL, V110, P753, DOI 10.1083/jcb.110.3.753; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; HIRAKI Y, 1988, BIOCHIM BIOPHYS ACTA, V969, P91, DOI 10.1016/0167-4889(88)90092-4; HORTON WE, 1989, J CELL PHYSIOL, V141, P8, DOI 10.1002/jcp.1041410103; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; INOUE H, 1989, J CELL PHYSIOL, V138, P329, DOI 10.1002/jcp.1041380216; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KLAGSBRUN M, 1985, P NATL ACAD SCI USA, V82, P805, DOI 10.1073/pnas.82.3.805; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; Linker A., 1972, METHODS ENZYMOL, P902; LOBB RR, 1984, BIOCHEMISTRY-US, V23, P6295, DOI 10.1021/bi00321a001; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; MASSAGUE J, 1985, J CELL BIOL, V100, P1508, DOI 10.1083/jcb.100.5.1508; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MOENNER M, 1986, P NATL ACAD SCI USA, V83, P5024, DOI 10.1073/pnas.83.14.5024; MORALES TI, 1988, J BIOL CHEM, V263, P12828; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; NUGENT MA, 1989, CANCER RES, V49, P3884; NUGENT MA, 1989, J BIOL CHEM, V264, P18060; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; PLOUET J, 1989, J CELL PHYSIOL, V141, P392, DOI 10.1002/jcp.1041410221; RAPRAEGER A, 1989, ANAL BIOCHEM, V179, P361, DOI 10.1016/0003-2697(89)90145-0; RAPRAEGER A, 1989, J CELL BIOL, V109, P2509, DOI 10.1083/jcb.109.5.2509; RASMUSSEN S, 1988, J CELL BIOL, V107, P1959, DOI 10.1083/jcb.107.5.1959; REDINI F, 1988, FEBS LETT, V234, P172, DOI 10.1016/0014-5793(88)81327-9; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; RIZZINO A, 1988, DEV BIOL, V130, P411, DOI 10.1016/0012-1606(88)90337-5; Roberts AB, 1990, PEPTIDE GROWTH FACTO, P419; ROGELJ S, 1989, J CELL BIOL, V109, P823, DOI 10.1083/jcb.109.2.823; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; SPORN MB, 1990, PEPTIDE GROWTH FACTO, V1, P3; TAKAHARA K, 1987, CELL, V49, P415; VIGNY M, 1988, J CELL PHYSIOL, V137, P321, DOI 10.1002/jcp.1041370216; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YANG VC, 1985, J BIOL CHEM, V260, P1849; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; [No title captured]	68	41	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21256	21264						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400436				2022-12-25	WOS:A1992JT97800115
J	BLOCK, C; FREYERMUTH, S; BEYERSMANN, D; MALVIYA, AN				BLOCK, C; FREYERMUTH, S; BEYERSMANN, D; MALVIYA, AN			ROLE OF CADMIUM IN ACTIVATING NUCLEAR-PROTEIN KINASE-C AND THE ENZYME BINDING TO NUCLEAR-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER NUCLEI; PHORBOL ESTER; PLASMA-MEMBRANE; TRANSCRIPTION FACTOR; CELLULAR-REGULATION; NIH-3T3 CELLS; ZINC; RECEPTOR; ASSOCIATION; METALLOTHIONEIN	Specific effects of cadmium on nuclear protein kinase C activity were found with 3T3/10T1/2 mouse fibroblast and rat liver nuclei. Treatment of the mouse fibroblasts in culture with 12-O-tetradecanoylphorbol-13-acetate resulted in the stimulation of nuclear protein kinase C activity in a "fixed" pool which is defined by its resistance to chelator extraction, whereas the chelator extractable enzyme activity, defined as the "labile" pool was unaffected. Cadmium was found to potentiate the effect of the phorbol ester, directed specifically to nuclei, since the particulate protein kinase C activity was not changed under similar treatment. In a reconstituted system consisting of rat liver nuclei and rat brain protein kinase C, cadmium stimulated the binding of the enzyme to a 105-kDa nuclear protein. The binding of a 105-kDa protein to protein kinase C is attributed strictly due to the cadmium effect, whereas a 50-kDa protein binding to protein kinase C was only enhanced by cadmium. We propose a mechanistic model, where cadmium substitutes zinc in the regulatory domain of protein kinase C rendering the putative protein-protein binding site exposed.	CNRS, CTR NEUROCHIM STRASBOURG, NEUROBIOL MOLEC INTERACT CELLULAIRES LAB, F-67084 STRASBOURG, FRANCE; UNIV BREMEN, INST ZELLBIOL & BIOCHEM, W-2800 BREMEN 33, GERMANY	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Bremen								ANDERSEN RD, 1990, NUCLEIC ACIDS RES, V18, P6049, DOI 10.1093/nar/18.20.6049; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BELL RM, 1991, J BIOL CHEM, V266, P631; BUCKLEY AR, 1988, P NATL ACAD SCI USA, V85, P8649, DOI 10.1073/pnas.85.22.8649; COUSINS RJ, 1985, PHYSIOL REV, V65, P238, DOI 10.1152/physrev.1985.65.2.238; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FARRAR WL, 1985, NATURE, V315, P233, DOI 10.1038/315233a0; GARDNER KH, 1991, BIOCHEMISTRY-US, V30, P11292, DOI 10.1021/bi00111a015; HALSEY DL, 1987, J BIOL CHEM, V262, P2234; HARRISON SA, 1991, J BIOL CHEM, V266, P19438; HEINRICH U, 1989, EXP PATHOL-JENA, V37, P253, DOI 10.1016/S0232-1513(89)80063-5; HOVECAR BA, 1991, J BIOL CHEM, V266, P28; HUBBARD SR, 1991, SCIENCE, V254, P1776; KISS Z, 1988, FEBS LETT, V231, P41, DOI 10.1016/0014-5793(88)80698-7; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; MALVIYA AN, 1992, TRENDS BIOCHEM SCI, V17, P176, DOI 10.1016/0968-0004(92)90259-C; MASMOUDI A, 1989, J BIOL CHEM, V264, P1172; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PAN T, 1990, BIOCHEMISTRY-US, V29, P9218, DOI 10.1021/bi00491a016; PAPADOPOULOS V, 1989, J CELL BIOL, V108, P553, DOI 10.1083/jcb.108.2.553; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PEI J, 1990, J BIOL CHEM, V265, P14061; ROGUE P, 1990, J BIOL CHEM, V265, P4161; SIMONS TJB, 1991, J MEMBRANE BIOL, V123, P63, DOI 10.1007/BF01993964; SMITH JB, 1989, J BIOL CHEM, V264, P7115; SPEIZER LA, 1989, J BIOL CHEM, V264, P5581; TANAKA S, 1991, FEBS LETT, V294, P267, DOI 10.1016/0014-5793(91)81445-E; THOMAS TP, 1988, CANCER RES, V48, P1910; WEBSTER LC, 1991, MOL CELL BIOL, V11, P4287, DOI 10.1128/MCB.11.9.4287; WITTERS LA, 1985, NATURE, V315, P777, DOI 10.1038/315777a0; WOLF M, 1985, J BIOL CHEM, V260, P5718; ZALEWSKI PD, 1990, FEBS LETT, V273, P131, DOI 10.1016/0014-5793(90)81067-X	37	78	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19824	19828						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400297				2022-12-25	WOS:A1992JR85800014
J	KUMAR, R; GARDNER, MF; RICHMAN, DD; HOSTETLER, KY				KUMAR, R; GARDNER, MF; RICHMAN, DD; HOSTETLER, KY			EQUAL INHIBITION OF HIV REPLICATION BY STEREOISOMERS OF PHOSPHATIDYL-AZIDOTHYMIDINE - LACK OF STEREOSPECIFICITY OF LYSOSOMAL PHOSPHOLIPASE-A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; PURIFICATION; AGENTS; ASSAY; A2	Glycerol-1-P and glycerol-3-P stereoisomers of dipalmitoylphosphatidylazidothymidine were synthesized and found to have equal antiretroviral activity in HIV-infected HT4-6C cells. It was anticipated that the glycerol-1-P isomer would be less active because of slow metabolic conversion by cellular phospholipases A and C, but the antiretroviral results suggested that the human cell line (HT4-6C) may have phospholipases capable of hydrolyzing 2,3-dipalmitoyl-sn-glycerol-1-phospho-5'-azidothymidine (AZT). To evaluate this possibility, we purified lysosomal phospholipase A1, an enzyme known to play a major role in cellular phospholipid catabolism. This enzyme rapidly hydrolyzed both the sn-1 and sn-3 isomers of dipalmitoylphosphatidyl-AZT. We synthesized sn-2,3-dipalmitoyl-glycero-1-phosphocholine and found that it is also hydrolyzed readily by lysosomal phospholipase A1 although the V(max), 59 mumol mg-1 h-1, is slightly lower than that of the sn-1,2-dipalmitoyl-glycero-3-phosphocholine, 89 mumol mg-1 h-1. In conclusion, our studies show that sn-2,3-dipalmitoyl-glycerol-1-phospho-AZT is equal in antiviral activity to sn-1,2-dipalmitoyl-glycero-3-phospho-AZT in HIV-infected HT4-6C cells. This surprising result is due in part to the lack of stereospecificity of lysosomal phospholipase A1.	UNIV CALIF SAN DIEGO, DEPT MED 0676, DIV ENDOCRINOL & METAB, 306 CLIN SCI BLDG, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PATHOL, LA JOLLA, CA 92093 USA; VICAL INC, SAN DIEGO, CA 92121 USA; VET ADM MED CTR, SAN DIEGO, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Hostetler, Karl/0000-0002-1155-2885	DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB067019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027670, U01AI030457] Funding Source: NIH RePORTER; NHLBI NIH HHS [HB-67019] Funding Source: Medline; NIAID NIH HHS [AI-27670, AI-30457] Funding Source: Medline	DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG YY, 1967, J BIOL CHEM, V242, P516; HOSTETLER KY, 1991, J BIOL CHEM, V266, P11714; HOSTETLER KY, 1991, METHOD ENZYMOL, V197, P125; HOSTETLER KY, 1982, J BIOL CHEM, V257, P13367; HOSTETLER KY, 1990, J BIOL CHEM, V265, P6112; KUBO M, 1987, J PHARMACOL EXP THER, V240, P88; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1990, ANTIMICROB AGENTS CH, V34, P436, DOI 10.1128/AAC.34.3.436; STEIM JM, 1990, BIOCHEM BIOPH RES CO, V171, P451, DOI 10.1016/0006-291X(90)91414-N; VANDEENEN LLM, 1963, BIOCHIM BIOPHYS ACTA, V70, P538; VANDENBOSCH H, 1968, BIOCHIM BIOPHYS ACTA, V164, P215, DOI 10.1016/0005-2760(68)90148-3; WAITE M, 1967, BIOCHIM BIOPHYS ACTA, V137, P498, DOI 10.1016/0005-2760(67)90131-2; WAITE M, 1971, BIOCHEMISTRY-US, V10, P2377, DOI 10.1021/bi00788a031; WELLS MA, 1971, BIOCHIM BIOPHYS ACTA, V248, P80, DOI 10.1016/0005-2760(71)90077-4; WELLS MA, 1969, METHOD ENZYMOL, V14, P178	17	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20288	20292						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400346				2022-12-25	WOS:A1992JR85800085
J	WEISSKER, SN; MULLER, BF; HOMFELD, A; DEPPERT, W				WEISSKER, SN; MULLER, BF; HOMFELD, A; DEPPERT, W			SPECIFIC AND COMPLEX INTERACTIONS OF MURINE P53 WITH DNA	ONCOGENE			English	Article							LARGE-T-ANTIGEN; TRANSFORMATION-RELATED PROTEIN; CELL-CYCLE CONTROL; A MOUSE CELLS; WILD-TYPE P53; MONOCLONAL-ANTIBODY; MUTANT P53; TRANSCRIPTIONAL ACTIVATION; NUCLEAR-LOCALIZATION; BINDING-PROTEIN	Biologically active mutant p53 from Balb/c mouse tumor cells (Meth A) was analysed for its specific interaction with DNA. Restricted phage lambda-DNA, representing DNA of high complexity with regard to sequence and secondary structure, was used to probe for such an activity in a target-bound DNA-binding assay, using doubly immunopurified p53. A single lambda-DNA fragment was specifically retained with very high affinity (K(D) = 10(-10) M). Specific DNA binding was shown to be an intrinsic property of p53, as it could be blocked with p53-specific monoclonal antibodies PAb122 and PAb421. The characteristics of the DNA binding of p53 to this lambda-DNA fragment, as well as the structural properties of this fragment, suggested the possibility that p53 might be able to interact with nuclear matrix attachment region (MAR) DNA. Indeed, established genomic MAR elements were specifically bound by Meth A p53, whereas no binding was observed to an AT-rich control DNA. The interaction of p53 with MAR elements in vitro is compatible with the idea that p53 in vivo is involved in the regulation of replication and/or expression of cellular DNA. Complex DNA interactions were not restricted to mutant p53 from Meth A cells. Mutant p53 of a different conformational phenotype (PAb246+ 'wild-type' as opposed to PAb246- 'mutant' for p53 from Meth A cells) from minimally transformed T3T3 cells, as well as genotypic wild-type p53 expressed by a recombinant baculovirus in insect cells, exhibited similar DNA-binding properties.	UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY	Heinrich Pette Institute; University of Hamburg								AMATI B, 1990, MOL CELL BIOL, V10, P5442, DOI 10.1128/MCB.10.10.5442; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BADING H, 1987, ONCOGENE, V1, P395; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BARTEK J, 1990, ONCOGENE, V5, P893; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BRUN C, 1990, MOL CELL BIOL, V10, P5453; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P159; CASEY G, 1991, ONCOGENE, V6, P1791; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; DEFROMENTEL CC, 1986, EXP CELL RES, V164, P35, DOI 10.1016/0014-4827(86)90452-0; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1990, ONCOGENE, V5, P1701; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GETZENBERG RH, 1991, J CELL BIOCHEM, V47, P289, DOI 10.1002/jcb.240470402; GILLESPIE PG, 1991, P NATL ACAD SCI USA, V88, P2563, DOI 10.1073/pnas.88.6.2563; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HERBOMEL P, 1990, New Biologist, V2, P937; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINZPETER M, 1986, VIROLOGY, V148, P159, DOI 10.1016/0042-6822(86)90411-3; HINZPETER M, 1987, ONCOGENE, V1, P119; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1983, CELL BIOL INT REP, V7, P513, DOI 10.1016/0309-1651(83)90154-6; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1990, ONCOGENE, V5, P973; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OROURKE RW, 1990, ONCOGENE, V5, P1829; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; PHIVAN L, 1990, PROG MOL SUBCELL BIO, V11, P1; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHIRMBECK R, 1988, VIROLOGY, V165, P527, DOI 10.1016/0042-6822(88)90597-1; SCHIRMBECK R, 1989, J VIROL, V63, P2308, DOI 10.1128/JVI.63.5.2308-2316.1989; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHOHATFOORD O, 1991, NUCLEIC ACIDS RES, V19, P5191; STEINMEYER K, 1990, ONCOGENE, V5, P1691; STEINMEYER K, 1988, ONCOGENE, V3, P501; Summers MD, 1987, TEXAS AGR EXPT STATI; VONKRIES JP, 1991, CELL, V64, P123, DOI 10.1016/0092-8674(91)90214-J; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YOUISHROUACH E, 1991, NATURE, V352, P345; ZERRAHN J, 1992, IN PRESS ONCOGENE	62	24	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1921	1932						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408133				2022-12-25	WOS:A1992JP42400004
J	SHI, GY; HAU, JS; WANG, SJ; WU, IS; CHANG, BI; LIN, MT; CHOW, YH; CHANG, WC; WING, LYC; JEN, CJ; WU, HL				SHI, GY; HAU, JS; WANG, SJ; WU, IS; CHANG, BI; LIN, MT; CHOW, YH; CHANG, WC; WING, LYC; JEN, CJ; WU, HL			PLASMIN AND THE REGULATION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR BIOSYNTHESIS IN HUMAN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FAST-ACTING INHIBITOR; MESSENGER-RNA LEVELS; MYOCARDIAL-INFARCTION; THROMBOLYTIC THERAPY; STREPTOKINASE COMPLEX; FIBRINOLYTIC-ACTIVITY; BINDING-SITES; THROMBIN; RELEASE	Plasmin inhibited the biosynthesis of tissue-type plasminogen activator (tPA) antigen by human umbilical vein endothelial cells (HUVEC) in a dose-dependent manner. The amount of tPA antigen found in the 24-h conditioned medium of cells treated with 100 nM plasmin for 1 h was 20-30% of that in the control group. However, in contrast to tPA, such treatment led to a 3-fold increase in plasminogen activator inhibitor (PAI) activity, whereas the amount of PAI type 1 antigen was unchanged. The effects of plasmin on HUVEC were binding- and catalytic activity-dependent and were specifically blocked by epsilon-aminocaproic acid. Microplasmin, which has no kringle domains, was less effective in reducing tPA antigen biosynthesis or enhancing PAI activity in HUVEC. Kringle domains of plasmin affected neither tPA antigen nor PAI activity of the cells. Other proteases including chymotrypsin, trypsin, and collagenase at comparable concentrations did not have a significant effect on the biosynthesis of tPA antigen or PAI activity of HUVEC. Thrombin stimulated the biosynthesis of tPA and PAI-1 antigens by HUVEC. Thrombin also stimulated an increase in the protein kinase activity in HUVEC, whereas plasmin inhibited the protein kinase activity of the cells. It is possible that plasmin regulates the biosynthesis of tPA in HUVEC through the signal transduction pathway involving protein kinase.	NATL CHENG KUNG UNIV, COLL MED, DEPT BIOCHEM, TAINAN 701, TAIWAN; NATL CHENG KUNG UNIV, COLL MED, DEPT PHARMACOL, TAINAN, TAIWAN; NATL CHENG KUNG UNIV, COLL MED, DEPT PHYSIOL, TAINAN, TAIWAN	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University			Chow, Yen-Hung/E-3863-2010					ANDREOTTI F, 1988, AM J CARDIOL, V62, P635, DOI 10.1016/0002-9149(88)90669-8; BACHMANN F, 1984, SEMIN THROMB HEMOST, V10, P6, DOI 10.1055/s-2007-1004403; BARNATHAN ES, 1988, J BIOL CHEM, V263, P7792; BAUER PI, 1984, BIOCHEM J, V218, P119, DOI 10.1042/bj2180119; CALIFF RM, 1992, AM J CARDIOL, V69, pA12, DOI 10.1016/0002-9149(92)91168-4; DICHEK D, 1989, BLOOD, V74, P222; ERICKSON LA, 1984, J CLIN INVEST, V74, P1465, DOI 10.1172/JCI111559; ESMON CT, 1983, BLOOD, V62, P1155; GRAM J, 1987, ACTA MED SCAND, V221, P149; HAJJAR KA, 1987, J CLIN INVEST, V80, P1712, DOI 10.1172/JCI113262; HAJJAR KA, 1990, J BIOL CHEM, V265, P2908; HAJJAR KA, 1991, J BIOL CHEM, V266, P21962; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HANSS M, 1987, J LAB CLIN MED, V109, P97; HUANG RS, 1991, J BIOL CHEM, V266, P18435; JOHNSON AJ, 1969, THROMB DIATH HAEMOST, V21, P259; KOOISTRA T, 1991, ARTERIOSCLER THROMB, V11, P1042, DOI 10.1161/01.ATV.11.4.1042; KRUITHOF EKO, 1984, BLOOD, V64, P907; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN EG, 1989, J BIOL CHEM, V264, P16030; LEVIN EG, 1983, P NATL ACAD SCI-BIOL, V80, P6804, DOI 10.1073/pnas.80.22.6804; LEVIN EG, 1979, THROMB RES, V15, P869, DOI 10.1016/0049-3848(79)90195-6; LEVIN EG, 1982, J CELL BIOL, V94, P631, DOI 10.1083/jcb.94.3.631; LEVIN EG, 1988, J BIOL CHEM, V263, P9360; LEVIN EG, 1986, THROMB HAEMOSTASIS, V56, P115; LEVIN EG, 1991, J BIOL CHEM, V266, P174; LEVIN EG, 1984, J CLIN INVEST, V74, P1988, DOI 10.1172/JCI111620; LOLLAR P, 1980, J BIOL CHEM, V255, P279; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; LOSKUTOFF DJ, 1983, P NATL ACAD SCI-BIOL, V80, P2956, DOI 10.1073/pnas.80.10.2956; LOSKUTOFF DJ, 1979, J CLIN INVEST, V64, P329, DOI 10.1172/JCI109457; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARDER VJ, 1988, NEW ENGL J MED, V318, P1585, DOI 10.1056/NEJM198806163182406; MARDER VJ, 1988, NEW ENGL J MED, V318, P1512, DOI 10.1056/NEJM198806093182306; NILSSON IM, 1985, BRIT MED J, V290, P1453, DOI 10.1136/bmj.290.6480.1453; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; RAMAKRISHNAN V, 1990, J BIOL CHEM, V265, P2755; RUNGE MS, 1989, CIRCULATION, V79, P217, DOI 10.1161/01.CIR.79.2.217; RUSSELL ME, 1990, J BIOL CHEM, V265, P2569; SANTELL L, 1988, J BIOL CHEM, V263, P16802; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SHI GY, 1988, J BIOL CHEM, V263, P17071; SHI GY, 1990, THROMB RES, V58, P317, DOI 10.1016/0049-3848(90)90101-H; SPRENGERS ED, 1987, BLOOD, V69, P381; SUMMARIA L, 1976, J BIOL CHEM, V251, P5810; VANHINSBERGH VWM, 1987, THROMB HAEMOSTASIS, V57, P148; VANMOURIK JA, 1984, J BIOL CHEM, V259, P14914; VERHEIJEN JH, 1984, THROMB HAEMOSTASIS, V51, P392; VERSTRAETE M, 1986, BLOOD, V67, P1529; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WIMAN B, 1990, AM J CARDIOL, V66, pG54, DOI 10.1016/0002-9149(90)90397-J; WIMAN B, 1985, J LAB CLIN MED, V105, P265; WU HL, 1990, J BIOL CHEM, V265, P19658; WU HL, 1987, P NATL ACAD SCI USA, V84, P8292, DOI 10.1073/pnas.84.23.8292; WU HL, 1987, P NATL ACAD SCI USA, V84, P8793, DOI 10.1073/pnas.84.24.8793	55	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19363	19368						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1388168				2022-12-25	WOS:A1992JP59300053
J	GAMBEL, AM; DESROSIERS, MG; MENICK, DR				GAMBEL, AM; DESROSIERS, MG; MENICK, DR			CHARACTERIZATION OF A P-TYPE CA2+-ATPASE FROM FLAVOBACTERIUM-ODORATUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CALCIUM-TRANSPORT; SARCOPLASMIC-RETICULUM; STREPTOCOCCUS-FAECALIS; MEMBRANE-VESICLES; SALMONELLA-TYPHIMURIUM; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; K+-ATPASE; CA-2+-ATPASE; SYSTEMS	In most bacterial cell types studied, low intracellular free calcium is maintained by a variety of secondary exchangers which utilize transmembrane ion gradients. Prokaryotic calcium ATPases appear to be extremely uncommon, and none have been reported in Gram-negative organisms. We demonstrate ATP-dependent calcium uptake in everted membrane vesicles of Flavobacterium odoratum, a common Gram-negative soil and water bacterium. Calcium is transported with an apparent initial rate of 10 nmol/min mg of protein. It is inhibited by 20-mu-M orthovanadate, a specific P-type ATPase inhibitor, but significantly, it is unaffected by the addition of N-ethylmaleimide, N,N-dicyclohexylcarbodiimide, valinomycin, or nigericin. Because the Ca2+-ATPase makes up a high proportion of the total ATPase activity it is easily detected by a soluble ATP hydrolysis assay, with an initial rate for calcium-dependent ATPase activity in vesicles of 25-40 nmol/min.mg at pH 7.8 and 25-degrees-C. The calcium-dependent activity is preferentially solubilized by the detergent C12E8 and can be precipitated at 55-80% ammonium sulfate in a fraction free of other contaminating ATPase activities. This partially purified fraction is enriched 15-fold and demonstrates an apparent K(m) for calcium of 2-mu-M, and for ATP of 130-mu-M. The IC50 for vanadate is 1.6-mu-M. These values are similar to those obtained for the eukaryotic sarcoplasmic reticulum calcium ATPase. The enzyme is rapidly phosphorylated by [gamma-P-32]ATP in a calcium-dependent, vanadate-inhibitable manner. The phosphorylated species migrates with an apparent molecular mass of 60 kDa by NaDodSO4-polyacrylamide gel electrophoresis, and the phosphoryl group is sensitive to alkaline conditions, a characteristic of the acylphosphate linkage found in ATPases. These data demonstrate that the majority of calcium transport in F. odoratum is facilitated by a P-type ATPase.	MED UNIV S CAROLINA,DEPT MED,DIV CARDIOL,171 ASHLEY AVE,CHARLESTON,SC 29425; MED UNIV S CAROLINA,DEPT BIOCHEM,CHARLESTON,SC 29425; MED UNIV S CAROLINA,GAZES CARDIAC RES INST,CHARLESTON,SC 29425	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina					PHS HHS [R01 44202] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMBUDKAR SV, 1986, J BIOL CHEM, V261, P5596; AMBUDKAR SV, 1984, J BIOL CHEM, V259, P6142; ANDO A, 1981, BIOCHIM BIOPHYS ACTA, V640, P179, DOI 10.1016/0005-2736(81)90543-5; BELLIVEAU JW, 1978, ARCH BIOCHEM BIOPHYS, V186, P98, DOI 10.1016/0003-9861(78)90468-X; BHATTACHARYYA P, 1976, J BIOL CHEM, V251, P5614; BISHOP JE, 1987, J BIOL CHEM, V262, P4658; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKMAN RW, 1968, BIOCHEMISTRY-US, V7, P2554, DOI 10.1021/bi00847a016; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; DAVIDSON VL, 1981, BIOCHIM BIOPHYS ACTA, V637, P53, DOI 10.1016/0005-2728(81)90209-7; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DEMEIS L, 1969, BIOCHIM BIOPHYS ACTA, V172, P343; DEVRIJ W, 1985, J BACTERIOL, V164, P1294, DOI 10.1128/JB.164.3.1294-1300.1985; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FUJIMORI T, 1990, J BIOL CHEM, V265, P16262; FURST P, 1985, J BIOL CHEM, V260, P50; Futai M., 1987, ION TRANSPORT PROKAR, P4; GOLUB EE, 1974, J BACTERIOL, V119, P840, DOI 10.1128/JB.119.3.840-843.1974; HASSELBACH W, 1974, MEMBRANE ADENOSINE T, V4, P159; HIGHSMITH SR, 1983, J BIOL CHEM, V258, P6858; HOUNG HS, 1986, J BACTERIOL, V168, P1040, DOI 10.1128/jb.168.2.1040-1044.1986; HUGENTOBLER G, 1983, J BIOL CHEM, V258, P7611; INESI G, 1971, SCIENCE, V171, P901, DOI 10.1126/science.171.3974.901; JASPER P, 1978, J BACTERIOL, V133, P1323, DOI 10.1128/JB.133.3.1323-1328.1978; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KOBAYASHI H, 1978, J BIOL CHEM, V253, P2085; KOSKKOSICKA D, 1983, BIOCHEMISTRY-US, V22, P2559, DOI 10.1021/bi00279a037; KUMAR G, 1979, EUR J BIOCHEM, V100, P365, DOI 10.1111/j.1432-1033.1979.tb04179.x; LOCKAU W, 1982, Z NATURFORSCH C, V37, P658; LOCKAU W, 1983, BIOCH BOPHYS ACTA, V773, P124; Lynn A.R., 1987, ION TRANSPORT PROKAR, P181; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MARTIN RB, 1979, Q REV BIOPHYS, V12, P181, DOI 10.1017/S0033583500002754; MATSUSHITA T, 1986, EUR J BIOCHEM, V156, P95, DOI 10.1111/j.1432-1033.1986.tb09553.x; NELSON N, 1980, METHOD ENZYMOL, V69, P301; NUCIFORA G, 1989, P NATL ACAD SCI USA, V86, P3544, DOI 10.1073/pnas.86.10.3544; ROSEN BP, 1987, BIOCHIM BIOPHYS ACTA, V906, P101, DOI 10.1016/0304-4157(87)90007-4; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; Silhavy T.J., 1984, EXPT GENE FUSIONS; SILVER S, 1975, J BACTERIOL, V122, P880, DOI 10.1128/JB.122.3.880-885.1975; SNAVELY MD, 1991, J BIOL CHEM, V266, P815; SNAVELY MD, 1991, J BIOL CHEM, V266, P824; SOLIOZ M, 1987, J BIOL CHEM, V262, P7358; SOLIOZ M, 1980, CALCIUM BINDING PROT, P101; TSUCHIYA T, 1975, J BIOL CHEM, V250, P7687; Walderhaug M.O., 1987, ION TRANSPORT PROKAR, P85	47	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15923	15931						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1386366				2022-12-25	WOS:A1992JG11300099
J	ULBRANDT, ND; LONDON, E; OLIVER, DB				ULBRANDT, ND; LONDON, E; OLIVER, DB			DEEP PENETRATION OF A PORTION OF ESCHERICHIA-COLI SECA PROTEIN INTO MODEL MEMBRANES IS PROMOTED BY ANIONIC PHOSPHOLIPIDS AND BY PARTIAL UNFOLDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN; TRANSLOCATION ATPASE; PRECURSOR PROTEINS; PLASMA-MEMBRANE; INNER MEMBRANES; TRIGGER FACTOR; PH; VESICLES; FLUORESCENCE; CONFORMATION	SecA protein, a principal component of the protein export machinery of Escherichia coli, is found both in the cytoplasm and inner membrane of cells. Previous in vitro and in vivo studies demonstrated that the interaction of SecA with the inner membrane requires the presence of physiological levels of anionic (acidic) phospholipids. In this report the degree of SecA insertion into model membranes and the conformational changes associated with this event have been examined. The extent of association of SecA with model membranes was determined by photolabeling with a hydrophobic reagent, and the depth of insertion of the protein into the phospholipid bilayer was determined by the amount of quenching of SecA fluorescence by both brominated and spin-labeled phospholipids. These methods demonstrated that SecA penetrates deep within the acyl chain region of the phospholipid bilayer. It was also found that SecA penetration into vesicles was associated with a major conformational change in the protein. This change can be induced by higher temperatures and involves a partial unfolding event as judged by differential scanning calorimetry, SecA fluorescence and increased sensitivity to proteolysis. These properties suggest the induction of a molten-globule-like conformation in a portion of the SecA polypeptide. This change was also induced at lower temperatures by the presence of membranes containing a physiological amount of the anionic phospholipid, phosphatidylglycerol. The partial unfolding and concomitant deep insertion of SecA into membranes may aid in the insertion of precursor proteins into the inner membrane and may influence possible interactions between SecA and the integral membrane export machinery components.	SUNY STONY BROOK, DEPT MICROBIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	ULBRANDT, ND (corresponding author), SUNY STONY BROOK, DEPT BIOCHEM & CELL BIOL, STONY BROOK, NY 11794 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031986, R01GM042033] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 42033, GM 31986] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKITA M, 1990, J BIOL CHEM, V265, P8164; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BENSON SA, 1985, ANNU REV BIOCHEM, V54, P101; BLEWITT MG, 1985, BIOCHEMISTRY-US, V24, P5458, DOI 10.1021/bi00341a027; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOLEN EJ, 1990, BIOCHEMISTRY-US, V29, P9638, DOI 10.1021/bi00493a019; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; BRUNNER J, 1981, BIOCHEMISTRY-US, V20, P7174, DOI 10.1021/bi00528a019; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; Cabelli RJ, 1991, THESIS STATE U NEW Y; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; CHEN LL, 1985, P NATL ACAD SCI USA, V82, P4384, DOI 10.1073/pnas.82.13.4384; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; DOLGIKH DA, 1985, EUR BIOPHYS J BIOPHY, V13, P109, DOI 10.1007/BF00256531; DUMONT ME, 1988, J BIOL CHEM, V263, P2087; EVERETT J, 1986, J BIOL CHEM, V261, P6725; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HU VW, 1984, J BIOL CHEM, V259, P2226; HUGHSON FM, 1991, BIOCHEMISTRY-US, V30, P4113, DOI 10.1021/bi00231a001; JIANG JX, 1991, BIOCHEMISTRY-US, V30, P3857, DOI 10.1021/bi00230a008; JIANG JX, 1990, J BIOL CHEM, V265, P8636; KIMURA E, 1991, J BIOL CHEM, V266, P6600; KREMER JMH, 1977, BIOCHEMISTRY-US, V16, P3932, DOI 10.1021/bi00636a033; KUMAMOTO C, 1983, J BACTERIOL, V163, P267; KUSTERS R, 1989, J BIOL CHEM, V264, P20827; KUSTERS R, 1991, J BIOL CHEM, V266, P8659; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MARKELLO T, 1985, BIOCHEMISTRY-US, V24, P2895, DOI 10.1021/bi00333a012; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; MCINTOSH TJ, 1987, BIOCHEMISTRY-US, V26, P1783, DOI 10.1021/bi00380a042; MITCHELL WM, 1969, BIOCHIM BIOPHYS ACTA, V178, P194, DOI 10.1016/0005-2744(69)90150-8; MORRISON WR, 1964, ANAL BIOCHEM, V7, P218, DOI 10.1016/0003-2697(64)90231-3; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; RAMSAY G, 1989, BIOCHEMISTRY-US, V28, P529, DOI 10.1021/bi00428a018; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHMIDT MG, 1989, J BACTERIOL, V171, P643, DOI 10.1128/jb.171.2.643-649.1989; SHINKAI A, 1990, BIOCHEM BIOPH RES CO, V172, P1217, DOI 10.1016/0006-291X(90)91578-G; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; ZHAO JM, 1986, P NATL ACAD SCI USA, V83, P2002, DOI 10.1073/pnas.83.7.2002	54	167	167	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15184	15192						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1386084				2022-12-25	WOS:A1992JF08800099
J	CHAO, R; KHAN, W; HANNUN, YA				CHAO, R; KHAN, W; HANNUN, YA			RETINOBLASTOMA PROTEIN DEPHOSPHORYLATION INDUCED BY D-ERYTHRO-SPHINGOSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GENE-PRODUCT; CELL-CYCLE; KINASE-C; SUSCEPTIBILITY GENE; PHOSPHORYLATION; SPHINGOLIPIDS; INHIBITION; DIFFERENTIATION; MODULATION; COMPLEX	The retinoblastoma gene product (Rb), a nuclear phosphoprotein, functions as a tumor suppressor that is inactivated in retinoblastoma and other malignancies. The hypophosphorylated forms of Rb are observed in the G0/G1 phase of the cell cycle, whereas the hyperphosphorylated forms predominate in S and G2/M phases, suggesting that phosphorylation/dephosphorylation of Rb may regulate progression through the growth cycle. However, little is known about the intracellular signals that regulate phosphorylation/dephosphorylation of Rb. We show that D-erythro-sphingosine potently induces early dephosphorylation of Rb. Initial dephosphorylation was observed as early as 1 h after treatment of hematopoietic cells with sphingosine, whereas complete shift to the dephosphorylated form was seen 4 h after treatment. These effects occurred at concentrations of sphingosine as low as 100-500 nM, with maximal effects observed at 1-2.5 muM. These effects were specific to sphingosine, inasmuch as other lipids, amphiphiles, and long chain amino bases, as well as structural analogs of sphingosine, failed to induce dephosphorylation of Rb. Also, activation of second messenger systems including protein kinase C, cAMP-dependent kinases, and calcium ionophores, as well as inhibition of serine/threonine protein phosphatases, failed to induce dephosphorylation of Rb. Induction of Rb dephosphorylation by sphingosine preceded inhibition of growth and a specific arrest in the G0/G1 phase of the cell cycle. These studies, for the first time, identify an intracellular activator of Rb.	DUKE UNIV,MED CTR,DEPT MED,BOX 3355,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; THORNTHWAITE JT, 1980, CYTOMETRY, V1, P229, DOI 10.1002/cyto.990010309; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILSON E, 1988, J BIOL CHEM, V263, P9304	28	78	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23459	23462						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385423				2022-12-25	WOS:A1992JZ23900007
J	TSUJITA, T; OKUDA, H				TSUJITA, T; OKUDA, H			FATTY-ACID ETHYL-ESTER SYNTHASE IN RAT ADIPOSE-TISSUE AND ITS RELATIONSHIP TO CARBOXYLESTERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONOXIDATIVE ETHANOL-METABOLISM; PURIFICATION; LIVER; HYDROLASE; LIPASE; LOCALIZATION; ENZYME	Fatty acid ethyl ester (FAEE) synthase was obtained from rat adipose tissue in an electrophoretically homogeneous form. The enzyme associated with carboxylesterase activity was purified by acetone precipitation followed by successive chromatographies on DEAE-cellulose, phenyl-Sepharose, and Sephadex G-100 gel. The two activities in rat adipose tissue were associated as judged by their co-elution profiles, co-purifications at different steps, co-precipitations by antibody raised against purified FAEE synthase, and identical profiles of inhibition by diisopropyl fluorophosphate. The enzyme catalyzed the hydrolyses of both tri- and monoacylglycerols, and the susceptibilities of substrates increase with decreasing acyl chain length of the fatty acid moiety. Ethyl oleate-hydrolyzing activity was about one-eighth of the synthesizing activity. The N-terminal amino acid sequence of the first 27 residues of the purified enzyme was identical to that of the carboxylesterase from rat liver. With a polyclonal rabbit antibody against the rat adipose tissue FAEE synthase, the enzyme was demonstrated in the liver, lung, and testis, but not in the kidney. The antibody removed the FAEE-synthesizing activities in adipose tissue (86%), liver (23%), lung (62%), and testis (82%). These results suggest that carboxylesterase contributes to the nonoxidative ethanol metabolism (FAEE synthesis) in various organs.			TSUJITA, T (corresponding author), EHIME UNIV,SCH MED,DEPT MED BIOCHEM,SHIGENOBU,EHIME 79102,JAPAN.							BJORNTORP P, 1990, J INTERN MED, V228, P557; CHEN RF, 1967, J BIOL CHEM, V242, P173; GAUSTAD R, 1991, BIOCHEM J, V274, P693, DOI 10.1042/bj2740693; HARANO T, 1988, J BIOCHEM-TOKYO, V103, P149, DOI 10.1093/oxfordjournals.jbchem.a122221; HARRISON EH, 1988, BIOCHIM BIOPHYS ACTA, V963, P28, DOI 10.1016/0005-2760(88)90334-7; JAMES LK, 1966, ADV ENZYMOL RAMB, V28, P1; Krisch K., 1971, ENZYMES            A, V5, P43; LANGE LG, 1983, J CLIN INVEST, V72, P724, DOI 10.1172/JCI111022; LANGE LG, 1982, P NATL ACAD SCI-BIOL, V79, P3954, DOI 10.1073/pnas.79.13.3954; LAPOSATA EA, 1986, SCIENCE, V231, P497, DOI 10.1126/science.3941913; LAPOSATA EA, 1990, J BIOL CHEM, V265, P9688; LAPOSATA EA, 1989, ARCH PATHOL LAB MED, V113, P762; MCLAREN DA, 1970, ADV ENZYMOL REL S BI, V33, P245; MENTLEIN R, 1984, BIOCHEM PHARMACOL, V33, P1243, DOI 10.1016/0006-2952(84)90176-X; MENTLEIN R, 1987, BIOCHIM BIOPHYS ACTA, V913, P27, DOI 10.1016/0167-4838(87)90228-7; MENTLEIN R, 1988, BIOCHIM BIOPHYS ACTA, V964, P319, DOI 10.1016/0304-4165(88)90032-3; MENTLEIN R, 1986, J BIOL CHEM, V261, P7816; MICKEL FS, 1989, J BIOL CHEM, V264, P12895; MOGELSON S, 1984, BIOCHEMISTRY-US, V23, P4075, DOI 10.1021/bi00313a010; OAKESHOTT JG, 1987, P NATL ACAD SCI USA, V84, P3359, DOI 10.1073/pnas.84.10.3359; RILEY DJS, 1990, BIOCHEMISTRY-US, V29, P3848, DOI 10.1021/bi00468a007; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; TORNQVIST H, 1976, J BIOL CHEM, V251, P813; TSUJITA T, 1982, BIOCHIM BIOPHYS ACTA, V715, P181, DOI 10.1016/0304-4165(82)90357-9; TSUJITA T, 1990, J LIPID RES, V31, P831; TSUJITA T, 1988, J BIOCHEM, V103, P327, DOI 10.1093/oxfordjournals.jbchem.a122269; TSUJITA T, 1970, NATURE, V227, P680	27	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23489	23494						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429692				2022-12-25	WOS:A1992JZ23900014
J	GRASSL, SM				GRASSL, SM			HUMAN PLACENTAL BRUSH-BORDER MEMBRANE NA+-PANTOTHENATE COTRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLES; TRANSPORT	Membrane transport pathways for transplacental transfer of the water-soluble vitamin pantothenate were investigated by assessing the possible presence of a Na+-pantothenate cotransport mechanism in the maternal facing membrane of human placental epithelial cells. The presence of Na+-pantothenate cotransport was determined from radiolabeled tracer flux measurements of pantothenate uptake using preparations of purified brush-border membrane vesicles. Compared with other cations the imposition of an inward Na+ gradient stimulated vesicle uptake of pantothenate to levels approximately 40-fold greater than those observed at equilibrium. The observed stimulation of pantothenate uptake was not the result of indirect electrostatic coupling to an inside positive Na+ diffusion potential. In the absence of Na+ and pantothenate concentration gradients an inside negative voltage difference induced a Na+-dependent net influx of pantothenate, suggesting the presence of an electrogenic Na+-pantothenate cotransport mechanism. The effect of biotin on the kinetics of Na+-dependent pantothenate uptake and the effect of pantothenate on the kinetics of Na+-dependent biotin uptake suggested that placental absorption of biotin and pantothenate from the maternal circulation occurs by a common Na+ cotransport mechanism in apical brush-border membrane.			GRASSL, SM (corresponding author), SUNY HLTH SCI CTR,DEPT PHARMACOL,766 IRVING AVE,SYRACUSE,NY 13210, USA.				NIDDK NIH HHS [DK37907] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK037907] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER H, 1975, AM J CLIN NUTR, V28, P56, DOI 10.1093/ajcn/28.1.59; BARBARAT B, 1986, J BIOL CHEM, V261, P4455; BARBARAT B, 1991, J PHYSIOL-LONDON, V443, P79, DOI 10.1113/jphysiol.1991.sp018823; BOWERS GN, 1966, CLIN CHEM, V12, P70; EARL DCN, 1965, BIOCHEM J, V94, P721, DOI 10.1042/bj0940721; GRASSL SM, 1989, J BIOL CHEM, V264, P11103; GRASSL SM, 1992, J BIOL CHEM, V267, P17760; GRASSL SM, 1987, J BIOL CHEM, V262, P2682; ILLSLEY NP, 1990, BIOCHIM BIOPHYS ACTA, V1029, P218, DOI 10.1016/0005-2736(90)90157-J; JORGENSEN PL, 1968, BIOCHIM BIOPHYS ACTA, V151, P212, DOI 10.1016/0005-2744(68)90176-9; KELLY LK, 1987, AM J PHYSIOL, V252, pC38; Machlin, 1991, HDB VITAMINS; MOISEENOK A G, 1988, Fiziologicheskii Zhurnal SSSR Imeni I M Sechenova, V74, P113; NEAME KD, 1972, ELEMENTARY KINETICS, P56; NELSON MM, 1957, J NUTR, V62, P395; OGIN C, 1989, BIOCHIM BIOPHYS ACTA, V980, P248, DOI 10.1016/0005-2736(89)90406-9; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; TRUMAN P, 1984, BIOCHIM BIOPHYS ACTA, V779, P129; WALLACH DFH, 1966, METHOD ENZYMOL, V8, P165	19	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22902	22906						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429639				2022-12-25	WOS:A1992JY16300032
J	KLUMP, H; DIRUGGIERO, J; KESSEL, M; PARK, JB; ADAMS, MWW; ROBB, FT				KLUMP, H; DIRUGGIERO, J; KESSEL, M; PARK, JB; ADAMS, MWW; ROBB, FT			GLUTAMATE-DEHYDROGENASE FROM THE HYPERTHERMOPHILE PYROCOCCUS-FURIOSUS - THERMAL-DENATURATION AND ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARCHAEBACTERIUM SULFOLOBUS-SOLFATARICUS; IRON-SULFUR PROTEIN; PURIFICATION; FERREDOXIN; DOMAINS	Pyrococcus furiosus is a marine hyperthermophile that grows optimally at 100-degrees-C. Glutamate dehydrogenase (GDH) from P. furiosus is a hexamer of identical subunits and has an M(r) = 270,000 +/- 5500 at 25-degrees-C. Electron micrographs showed that the subunit arrangement is similar to that of GDH from bovine liver (i.e. 3/2 symmetry in the form of a triangular antiprism). However, GDH from P.furiosus is inactive at temperatures below 40-degrees-C and undergoes heat activation above 40-degrees-C. Both NAD+ and NADP+ are utilized as cofactors. Apparently the inactive enzyme also binds cofactors, since the enzyme maintains the ability to bind to an affinity column (Cibacron blue F3GA) and is specifically eluted with NADP+. Conformational changes that accompany activation and thermal denaturation were detected by precision differential scanning microcalorimetry. Thermal denaturation starts at 110-degrees-C and is completed at 118-degrees-C. DELTA(cal) = 414 Kcal [mol GDH]-1. T(m) = 113-degrees-C. This increase in heat capacity indicates an extensive irreversible unfolding of the secondary structure as evidenced also by a sharp increase in absorbance at 280 nm and inactivation of the enzyme. The process of heat activation of GDH from 40 to 80-degrees-C is accompanied by a much smaller increase in absorbance at 280 nm and a reversible increase in heat capacity with DELTA(cal) = 187 Kcal [mol GDH]-1 and T(m) = 57-degrees-C. This absorbance change as well as the moderate increase in heat capacity suggest that thermal activation leads to some exposure of hydrophobic groups to solvent water as the GDH structure is opened slightly. The increase in absorbance at 280 nm during activation is only 12% of that for denaturation. Overall, GDH appears to be well adapted to correspond with the growth response of P. furiosus to temperature.	UNIV CAPE TOWN,DEPT BIOCHEM,RONDEBOSCH 7700,SOUTH AFRICA; UNIV MARYLAND,DEPT MICROBIOL,COLL PK,MD 20742; UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602; UNIV GEORGIA,CTR METALLOENZYME STUDIES,ATHENS,GA 30602	University of Cape Town; University System of Maryland; University of Maryland College Park; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	KLUMP, H (corresponding author), UNIV MARYLAND,CTR MARINE BIOTECHNOL,600 E LOMBARD ST,BALTIMORE,MD 21202, USA.			Robb, Frank/0000-0001-5833-6496; Adams, Michael/0000-0002-9796-5014				ADAMS MWW, 1990, FEMS MICROBIOL REV, V75, P125; AONO S, 1989, J BACTERIOL, V171, P3433, DOI 10.1128/jb.171.6.3433-3439.1989; BLUMENTALS II, 1990, APPL ENVIRON MICROB, V56, P1992, DOI 10.1128/AEM.56.7.1992-1998.1990; BRYANT FO, 1989, J BIOL CHEM, V264, P5070; CONSALVI V, 1991, EUR J BIOCHEM, V196, P459, DOI 10.1111/j.1432-1033.1991.tb15837.x; COSTANTINO HR, 1990, J BACTERIOL, V172, P3654, DOI 10.1128/jb.172.7.3654-3660.1990; EGGEN R, 1990, FEMS MICROBIOL LETT, V71, P17; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; JOSEPHS R, 1971, J MOL BIOL, V55, P147, DOI 10.1016/0022-2836(71)90188-4; McCord Adams Marilyn, 1991, PROTOCOLS ARCHAEBACT, P1; MUKUND S, 1991, J BIOL CHEM, V266, P14208; MUKUND S, 1990, J BIOL CHEM, V265, P11508; PRIVALOV PL, 1974, J MOL BIOL, V86, P665, DOI 10.1016/0022-2836(74)90188-0; ROBB FT, 1992, BIOCHIM BIOPHYS ACTA, V1192, P267; SCHINKINGER MF, 1991, BIOCHIM BIOPHYS ACTA, V1073, P142, DOI 10.1016/0304-4165(91)90194-L; SHRAKE A, 1989, BIOCHEMISTRY-US, V28, P6281, DOI 10.1021/bi00441a021; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; 1990, BIORAD TECHNICAL B B, V1107	19	78	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22681	22685						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429615				2022-12-25	WOS:A1992JW71900105
J	ADACHI, Y; COPELAND, TD; TAKAHASHI, C; NOSAKA, T; AHMED, A; OROSZLAN, S; HATANAKA, M				ADACHI, Y; COPELAND, TD; TAKAHASHI, C; NOSAKA, T; AHMED, A; OROSZLAN, S; HATANAKA, M			PHOSPHORYLATION OF THE REX PROTEIN OF HUMAN T-CELL LEUKEMIA-VIRUS TYPE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; HTLV-I; MESSENGER-RNA; STRUCTURAL PROTEINS; ACTIVATOR PROTEIN; GENE-PRODUCT; EXPRESSION; SEQUENCE; P40X; DNA	Rex protein, the posttranscriptional regulator of human T-cell leukemia virus type I (HTLV-I), is required for the control of viral structural protein expression and virus replication. Rex is a phosphoprotein found predominantly in the cell nucleolus, whose function is thought to be regulated by its nucleolar localization and phosphorylation. Therefore, we investigated the in vivo phosphorylation of Rex protein in more detail. Phosphorylation of Rex occurred in all HTLV-I-infected cell lines examined in vivo, primarily at serine residues and to a very small extent at threonine residues. Treatment of cells with 12-O-tetradecanoylphorbol-13-acetate (TPA) led to significant but transient enhancement of the incorporation of [P-32]orthophosphate into Rex protein. N-terminal truncation of Rex protein abolished TPA-dependent phosphorylation. Chymotryptic digestion of phosphorylated Rex yielded two phosphopeptides. In vivo phosphorylation sites were identified as serine residues 70 and 177 and threonine residue 174. Serine 70 was a TPA-dependent phosphorylation site within a regulatory domain. We have already shown that the protein kinase C inhibitor H-7 (1-(5-isoquinolinylsulfonyl)-2-methylpiperazine specifically blocked accumulation of viral unspliced gag-pol mRNA. Therefore, the phosphorylation at serine 70 may be involved in the regulation of Rex function in response to extracellular stimuli.	KYOTO UNIV, INST VIRUS RES, KYOTO 606, JAPAN; NCI, FREDERICK CANC RES & DEV CTR, BASIC RES PROGRAM, MOLEC VIROL & CARCINOGENESIS LAB, FREDERICK, MD 21702 USA	Kyoto University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI Y, 1988, BIOL CHEM H-S, V369, P223; ADACHI Y, 1990, ADV SEC MESS PHOSPH, V24, P478; ADACHI Y, 1990, BIOCHEM BIOPH RES CO, V169, P469, DOI 10.1016/0006-291X(90)90355-Q; ADACHI Y, 1991, J BIOL CHEM, V266, P3968; ASE K, 1988, FEBS LETT, V236, P396, DOI 10.1016/0014-5793(88)80064-4; CHAN PK, 1986, J BIOL CHEM, V261, P1868; CHEN ISY, 1985, SCIENCE, V229, P54, DOI 10.1126/science.2990037; CHIDA K, 1986, J BIOL CHEM, V261, P3013; COCHRANE A, 1989, VIROLOGY, V171, P264, DOI 10.1016/0042-6822(89)90535-7; COHEN P, 1982, NATURE, V296, P613, DOI 10.1038/296613a0; CURRAN T, 1984, CELL, V36, P259; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; GRASSMANN R, 1991, J VIROL, V65, P3721, DOI 10.1128/JVI.65.7.3721-3727.1991; HARADA S, 1986, VIROLOGY, V154, P249, DOI 10.1016/0042-6822(86)90451-4; HAUBER J, 1988, J VIROL, V62, P4801, DOI 10.1128/JVI.62.12.4801-4804.1988; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HOFER L, 1991, J VIROL, V65, P3379, DOI 10.1128/JVI.65.6.3379-3383.1991; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; INOUE J, 1987, P NATL ACAD SCI USA, V84, P3653, DOI 10.1073/pnas.84.11.3653; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TH, 1984, SCIENCE, V226, P57, DOI 10.1126/science.6089350; MISHINA M, 1984, NATURE, V307, P604, DOI 10.1038/307604a0; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; MORI K, 1987, J GEN VIROL, V68, P499, DOI 10.1099/0022-1317-68-2-499; NAGASHIMA K, 1986, J VIROL, V60, P394, DOI 10.1128/JVI.60.2.394-399.1986; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOSAKA T, 1989, P NATL ACAD SCI USA, V86, P9798, DOI 10.1073/pnas.86.24.9798; PASTI G, 1986, NATURE, V324, P375, DOI 10.1038/324375a0; PATSKAN GJ, 1985, J BIOL CHEM, V260, P2899; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; SABE H, 1988, INT J CANCER, V41, P880, DOI 10.1002/ijc.2910410619; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SLAMON DJ, 1984, SCIENCE, V226, P61, DOI 10.1126/science.6089351; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; TATENO M, 1984, J EXP MED, V159, P1105, DOI 10.1084/jem.159.4.1105; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	45	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21977	21981						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400509				2022-12-25	WOS:A1992JV01100110
J	CAPDEVILA, JH; WEI, S; YAN, J; KARARA, A; JACOBSON, HR; FALCK, JR; GUENGERICH, FP; DUBOIS, RN				CAPDEVILA, JH; WEI, S; YAN, J; KARARA, A; JACOBSON, HR; FALCK, JR; GUENGERICH, FP; DUBOIS, RN			CYTOCHROME-P-450 ARACHIDONIC-ACID EPOXYGENASE - REGULATORY CONTROL OF THE RENAL EPOXYGENASE BY DIETARY SALT LOADING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS EPOXYEICOSATRIENOIC ACIDS; MICROSOMAL CYTOCHROME-P-450; OMEGA-HYDROXYLASE; MEPHENYTOIN 4-HYDROXYLASE; MESSENGER-RNA; CDNA CLONING; 2 FORMS; METABOLISM; EXPRESSION; SEQUENCE	The rat kidney microsomal epoxygenase catalyzed the asymmetric epoxidation of arachidonic acid to generate as major products: 8(R),9(S)-, 11 (R), 12(S)- and 14(S),15(R)-epoxyeicosatrienoic acids with optical purities of 97, 88, and 70%, respectively. Inhibition studies utilizing a panel of polyclonal antibodies to several rat liver cytochrome P-450 isoforms, indicated that the renal epoxygenase(s) belongs to the cytochrome P-450 2C gene family. Dietary salt, administered either as a 2-2.5% (w/v) solution in the drinking water or as a modified solid diet containing 8% NaCl (w/w), resulted in marked and selective increases in the renal microsomal epoxygenase activity (416 and 260% of controls, for the liquid and solid forms of NaCl, respectively) with no significant changes in the microsomal omega/omega-1 oxygenase or in the hepatic arachidonic acid monooxygenase reaction. Immunoblotting studies demonstrated that dietary salt induced marked increases in the concentration of a cytochrome P-450 isoform(s) recognized by polyclonal antibodies raised against human liver cytochrome P-450 2C10 or rat liver cytochrome P-450 2C11. Comparisons of the stereochemical selectivity of the induced and non-induced microsomal epoxygenase(s) with that of purified rat liver cytochrome P-450 2C11 suggest that the salt-induced protein(s) is catalytically and structurally different from liver cytochrome P-450 2C11. The in vivo significance of dietary salt in regulating the activities of the kidney endogenous arachidonic acid epoxygenase was established by the demonstration of a salt-induced 10-20-fold increase in the urinary output of epoxygenase metabolites. These results, in conjunction with published evidence demonstrating the potent biological activities of its metabolites, suggest a role for the epoxygenase in the renal response to dietary salt.	VANDERBILT UNIV, MED CTR, SCH MED, DIV NEPHROL, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DIV GASTROENTEROL, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA; SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Texas System; University of Texas Southwestern Medical Center Dallas			DuBois, Raymond N./AAX-8869-2020	Falck, John/0000-0002-9219-7845	NCI NIH HHS [CA44353] Funding Source: Medline; NICHD NIH HHS [NIHDK 38226] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		CAPDEVILA JH, 1991, METHOD ENZYMOL, V206, P441; CAPDEVILA JH, 1990, METHOD ENZYMOL, V187, P385; CAPDEVILA JH, 1990, J BIOL CHEM, V265, P10865; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; CARROLL MA, 1990, AM J PHYSIOL, V258, pF1084; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; CHACOS N, 1983, ARCH BIOCHEM BIOPHYS, V223, P639, DOI 10.1016/0003-9861(83)90628-8; COREY EJ, 1980, J AM CHEM SOC, V102, P1433, DOI 10.1021/ja00524a043; FALCK JR, 1982, TETRAHEDRON LETT, V23, P1755, DOI 10.1016/S0040-4039(00)86732-5; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; GUENGERICH FP, 1982, BIOCHEMISTRY-US, V21, P6019, DOI 10.1021/bi00266a045; GUENGERICH FP, 1992, FASEB J, V6, P745, DOI 10.1096/fasebj.6.2.1537465; HARDWICK JP, 1987, J BIOL CHEM, V262, P801; HIRT DL, 1989, J CLIN INVEST, V84, P1805, DOI 10.1172/JCI114365; IWAI N, 1991, HYPERTENSION, V17, P161, DOI 10.1161/01.HYP.17.2.161; JACOBSON HR, 1984, PROSTAGLANDINS MEMBR; JOHNSON EF, 1992, FASEB J, V6, P700, DOI 10.1096/fasebj.6.2.1537459; JOHNSON EF, 1990, BIOCHEMISTRY-US, V29, P873, DOI 10.1021/bi00456a004; KARARA A, 1989, J BIOL CHEM, V264, P19822; KARARA A, 1992, BIOCHEM BIOPH RES CO, V182, P1320, DOI 10.1016/0006-291X(92)91877-S; KARARA A, 1990, FEBS LETT, V268, P227, DOI 10.1016/0014-5793(90)81014-F; KARARA A, 1991, J BIOL CHEM, V266, P7561; KATOH T, 1991, AM J PHYSIOL, V261, pF578, DOI 10.1152/ajprenal.1991.261.4.F578; KIMURA S, 1989, DNA-J MOLEC CELL BIO, V8, P503, DOI 10.1089/dna.1.1989.8.503; KIMURA S, 1989, DNA-J MOLEC CELL BIO, V8, P517, DOI 10.1089/dna.1.1989.8.517; LAETHEM RM, 1992, J BIOL CHEM, V267, P5552; LAPUERTA L, 1988, AM J MED SCI, V295, P275, DOI 10.1097/00000441-198804000-00010; MALEE MP, 1991, P NATL ACAD SCI USA, V88, P4731, DOI 10.1073/pnas.88.11.4731; MATSUBARA S, 1987, J BIOL CHEM, V262, P13366; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; MOSSET P, 1986, TETRAHEDRON LETT, V27, P6035, DOI 10.1016/S0040-4039(00)85391-5; MOUSTAKIS CA, 1985, J AM CHEM SOC, V107, P5283, DOI 10.1021/ja00304a048; MULLER J, 1991, ENDOCR RES, V17, P165; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; PORTER TD, 1991, J BIOL CHEM, V266, P13469; ROMERO MF, 1991, ADV PROSTAG THROMB L, V21, P205; Sambrook J, 1989, MOL CLONING LABORATO; SHIBATA H, 1991, ENDOCRINOLOGY, V128, P2534, DOI 10.1210/endo-128-5-2534; SHIMADA T, 1986, J BIOL CHEM, V261, P909; TREMBLAY A, 1991, J BIOL CHEM, V266, P2245; UMBENHAUER DR, 1987, BIOCHEMISTRY-US, V26, P1094, DOI 10.1021/bi00378a016; WAXMAN DJ, 1985, BIOCHEMISTRY-US, V24, P4409, DOI 10.1021/bi00337a023; YOKOTANI N, 1989, J BIOL CHEM, V264, P21665	44	152	154	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21720	21726						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400482				2022-12-25	WOS:A1992JV01100072
J	HOSHINO, T; KOSETERAI, K; SATO, K				HOSHINO, T; KOSETERAI, K; SATO, K			SOLUBILIZATION AND RECONSTITUTION OF THE PSEUDOMONAS-AERUGINOSA HIGH-AFFINITY BRANCHED-CHAIN AMINO-ACID-TRANSPORT SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; BINDING-PROTEIN; BRA GENES; PAO; CLONING; PURIFICATION; PERMEASE; CARRIER	The high affinity branched-chain amino acid transport system (LIV-I) in Pseudomonas aeruginosa is composed of five components: BraC, a periplasmic binding protein for branched-chain amino acids; BraD and BraE, integral membrane proteins; BraF and BraG, putative nucleotide-binding proteins. By using a T7 RNA polymerase/promoter system we overproduced the BraD, BraE, BraF, and BraG proteins in Escherichia coli. The proteins were found to form a complex in the E. coli membrane and solubilized from the membrane with octyl glucoside. The LIV-I transport system was reconstituted into proteoliposomes from solubilized proteins by a detergent dilution procedure. In this reconstituted system, leucine transport was completely dependent on the presence of all five Bra components and on ATP loaded internally to the proteoliposomes. Alanine and threonine in addition to branched-chain amino acids were transported by the proteoliposomes, reflecting the substrate specificity of the BraC protein. GTP replaced ATP well as an energy source, and CTP and UTP also replaced ATP partially. Consumption of loaded ATP and concomitant production of orthophosphate were observed only when BraC and leucine, a substrate for LIV-I, were added together to the proteoliposomes, indicating that the LIV-I transport system has an ATPase activity coupled to translocation of branched-chain amino acids across the membrane.			HOSHINO, T (corresponding author), MITSUBISHI KASEI INST LIFE SCI,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN.							AMANUMA H, 1974, J BIOCHEM, V76, P1165, DOI 10.1093/oxfordjournals.jbchem.a130669; AMANUMA H, 1976, J BIOCHEM, V79, P1167, DOI 10.1093/oxfordjournals.jbchem.a131172; AMBUDKAR SV, 1986, J BIOL CHEM, V261, P79; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BERGER EA, 1974, J BIOL CHEM, V249, P7747; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOOS W, 1983, BIOCHIM BIOPHYS ACTA, V737, P443; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; GERLACH E, 1963, BIOCHEM Z, V337, P477; HILES ID, 1987, J MOL BIOL, V195, P125, DOI 10.1016/0022-2836(87)90332-9; HOSHINO T, 1989, J BACTERIOL, V171, P6300, DOI 10.1128/jb.171.11.6300-6306.1989; HOSHINO T, 1979, J BACTERIOL, V139, P705, DOI 10.1128/JB.139.3.705-712.1979; HOSHINO T, 1990, J BACTERIOL, V172, P5531, DOI 10.1128/jb.172.10.5531-5539.1990; HOSHINO T, 1980, J BACTERIOL, V141, P1055, DOI 10.1128/JB.141.3.1055-1063.1980; HOSHINO T, 1990, J BACTERIOL, V172, P5540, DOI 10.1128/jb.172.10.5540-5543.1990; HOSHINO T, 1991, J BACTERIOL, V173, P1855, DOI 10.1128/jb.173.6.1855-1861.1991; HOSHINO T, 1990, MOL GEN GENET, V220, P461, DOI 10.1007/BF00391754; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PLATE CA, 1979, J BACTERIOL, V137, P221, DOI 10.1128/JB.137.1.221-225.1979; RICHARME G, 1992, BIOCHIM BIOPHYS ACTA, V1104, P201, DOI 10.1016/0005-2736(92)90151-B; Sambrook J., 1989, MOL CLONING LAB MANU; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YAMATO Y, 1980, J BACTERIOL, V144, P36; [No title captured]	32	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21313	21318						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400443				2022-12-25	WOS:A1992JV01100011
J	LIMON, I; COUPRY, I; LANIER, SM; PARINI, A				LIMON, I; COUPRY, I; LANIER, SM; PARINI, A			PURIFICATION AND CHARACTERIZATION OF MITOCHONDRIAL IMIDAZOLINE-GUANIDINIUM RECEPTIVE SITE FROM RABBIT KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL PROXIMAL TUBULE; BINDING-SITES; H-3 IDAZOXAN; OUTER-MEMBRANE; PROTEINS; CELLS; LIVER; RESOLUTION; DRUGS	The imidazoline-guanidinium receptive site (IGRS) is a membrane-bound protein that may mediate some of the pharmacological effects of imidazoline and guanidinium compounds. The structure and functionality of this protein are unknown but, in addition to its location at the plasma membrane, it is found in high density in the outer membrane of mitochondria (Tesson, F., Prip-Buus, C., Lemoine, A., Pegorier, J.-P., and Parini, A. (1991) J. Biol. Chem. 266, 155-160). Using a two-step procedure, we report the purification of mitochondrial IGRS from rabbit kidney to the apparent homogeneity. After solubilization of mitochondrial membranes with digitonin, an apparently homogeneous IGRS preparation was obtained by two sequential purification steps, chromatofocusing and hydroxylapatite-agarose chromatography. One- and two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of the purified preparation after silver staining or radioiodination indicated that IGRS binding subunit was purified at the apparent homogeneity since a single band (M(r) approximately 60,000) was observed. IGRS behaves as an acidic protein (pI 5.5) whose binding activity is regulated by H+ concentration near a physiological pH of 7.4. The ability to achieve rapid purification of IGRS should facilitate efforts to define molecular properties and functionality of this protein.	MED UNIV S CAROLINA,DEPT PHARMACOL,CHARLESTON,SC 29208	Medical University of South Carolina	LIMON, I (corresponding author), FAC MED NECKER ENFANTS MALAD,CNRS,URA 1482,F-75015 PARIS,FRANCE.		Limon, Isabelle/AAJ-6169-2020; COUPRY, Isabelle/L-4900-2014; Limon, Isabelle/P-2750-2017	Limon, Isabelle/0000-0002-8773-6971; Limon, Isabelle/0000-0002-8773-6971; Parini, Angelo/0000-0002-9848-8838; Lanier, Stephen/0000-0002-2740-7607	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS024821, R01NS024821] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-24821] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANTKIEWICZMICHALUK L, 1988, MOL PHARMACOL, V34, P272; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BIDET M, 1990, BIOCHIM BIOPHYS ACTA, V1024, P173, DOI 10.1016/0005-2736(90)90221-9; BOUSQUET P, 1984, J PHARMACOL EXP THER, V230, P232; BROWN CM, 1990, BRIT J PHARMACOL, V99, P803, DOI 10.1111/j.1476-5381.1990.tb13010.x; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; COUPRY I, 1990, J PHARMACOL EXP THER, V252, P293; GASNIER F, 1987, BIOCHIM BIOPHYS ACTA, V925, P297, DOI 10.1016/0304-4165(87)90195-4; GORBUNOFF MJ, 1984, ANAL BIOCHEM, V136, P425, DOI 10.1016/0003-2697(84)90239-2; KOLODZIEJ MP, 1992, BIOCHEM J, V282, P415, DOI 10.1042/bj2820415; LACHAUDPETTITI V, 1991, EUR J PHARM-MOLEC PH, V206, P23, DOI 10.1016/0922-4106(91)90142-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGIN D, 1990, MOL PHARMACOL, V37, P876; LANGIN D, 1989, EUR J PHARMACOL, V159, P199, DOI 10.1016/0014-2999(89)90707-3; MICHEL MC, 1989, MOL PHARMACOL, V35, P324; MICHEL MC, 1989, TRENDS PHARMACOL SCI, V10, P342, DOI 10.1016/0165-6147(89)90002-3; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARINI A, 1989, J BIOL CHEM, V264, P11874; PAVLICA RJ, 1990, BIOCHIM BIOPHYS ACTA, V1022, P115, DOI 10.1016/0005-2736(90)90407-F; PFANNER N, 1991, TRENDS BIOCHEM SCI, V16, P63, DOI 10.1016/0968-0004(91)90026-R; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TESSON F, 1991, J BIOL CHEM, V266, P155; WIKBERG JES, 1990, J NEUROCHEM, V55, P192, DOI 10.1111/j.1471-4159.1990.tb08838.x; ZONNENSCHEIN R, 1990, EUR J PHARMACOL, V190, P203, DOI 10.1016/0014-2999(90)94127-J	24	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21645	21649						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400475				2022-12-25	WOS:A1992JV01100061
J	RAPAPORT, D; FUCHS, O; NUDEL, U; YAFFE, D				RAPAPORT, D; FUCHS, O; NUDEL, U; YAFFE, D			EXPRESSION OF THE DUCHENNE MUSCULAR-DYSTROPHY GENE-PRODUCTS IN EMBRYONIC STEM-CELLS AND THEIR DIFFERENTIATED DERIVATIVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SKELETAL-MUSCLE; BRAIN; MEMBRANE; RNA; ISOFORMS; TERMINUS; PROMOTER; LINE	Three protein products of the Duchenne muscular dystrophy (DMD) gene were identified so far. These include the two very similar muscle and brain type dystrophins, which are encoded by 14-kilobase (kb) mRNAs, and Dp71, which is much smaller. Dp71 is encoded by a 6.5-kb mRNA, which is transcribed from approximately 6% of the giant dystrophin gene. The present investigation shows that Dp71 is the first product of the DMD gene detectable during development. It is already expressed in the pluripotent embryonic stem cells. The two 14-kb mRNAs encoding the dystrophins are detectable only after differentiation of specialized cell types. The possible implication of these findings with regard to the ontogenetic activation and the evolution of the DMD gene are discussed.	WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ARAHATA K, 1988, NATURE, V333, P861, DOI 10.1038/333861a0; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAR S, 1990, BIOCHEM J, V272, P557, DOI 10.1042/bj2720557; BARNEA E, 1990, NEURON, V5, P881, DOI 10.1016/0896-6273(90)90348-J; BOYCE FM, 1991, P NATL ACAD SCI USA, V88, P1276, DOI 10.1073/pnas.88.4.1276; DENDUNNEN JT, 1992, NEUROMUSCULAR DISORD, V1, P327; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; EVANS MJ, 1983, CANCER SURV, V2, P185; FEENER CA, 1989, NATURE, V338, P509, DOI 10.1038/338509a0; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HELLIWELL TR, 1992, AM J HUM GENET, V50, P508; HOFFMAN EP, 1991, ANN NEUROL, V30, P605, DOI 10.1002/ana.410300414; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LEDERFEIN D, 1992, P NATL ACAD SCI USA, V89, P5346, DOI 10.1073/pnas.89.12.5346; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; Makover A, 1991, Neuromuscul Disord, V1, P39, DOI 10.1016/0960-8966(91)90041-P; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NUDEL U, 1989, NATURE, V337, P76, DOI 10.1038/337076a0; NUDEL U, 1988, NATURE, V331, P635, DOI 10.1038/331635a0; NUDEL U, 1992, NEUROMUSCULAR DEV DI, P341; RAPAPORT D, 1992, DIFFERENTIATION, V49, P187, DOI 10.1111/j.1432-0436.1992.tb00666.x; RECAN D, 1992, J CLIN INVEST, V89, P712, DOI 10.1172/JCI115640; SHINAR D, 1989, DIFFERENTIATION, V41, P116, DOI 10.1111/j.1432-0436.1989.tb00739.x; SMITH AG, 1987, DEV BIOL, V121, P1, DOI 10.1016/0012-1606(87)90132-1; TURNER PR, 1991, J CELL BIOL, V115, P1701, DOI 10.1083/jcb.115.6.1701; WATKINS SC, 1988, NATURE, V333, P863, DOI 10.1038/333863a0; WILLIAMS DA, 1990, J PHYSIOL-LONDON, V428, P243, DOI 10.1113/jphysiol.1990.sp018210; YAFFE D, 1977, DIFFERENTIATION, V7, P159, DOI 10.1111/j.1432-0436.1977.tb01507.x; ZUBRZYCKAGAARN EF, 1988, NATURE, V333, P466, DOI 10.1038/333466a0	30	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21289	21292						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400438				2022-12-25	WOS:A1992JV01100005
J	BALLOU, LR; CHAO, CP; HOLNESS, MA; BARKER, SC; RAGHOW, R				BALLOU, LR; CHAO, CP; HOLNESS, MA; BARKER, SC; RAGHOW, R			INTERLEUKIN-1-MEDIATED PGE2 PRODUCTION AND SPHINGOMYELIN METABOLISM - EVIDENCE FOR THE REGULATION OF CYCLOOXYGENASE GENE-EXPRESSION BY SPHINGOSINE AND CERAMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; LEUKEMIA HL-60 CELLS; GH3 PITUITARY-CELLS; PROSTAGLANDIN-E2 PRODUCTION; FACTOR RECEPTOR; PHORBOL ESTERS; SYNTHASE; DIFFERENTIATION; STIMULATION	We recently demonstrated that sphingosine enhances interleukin-1beta (IL-1)-mediated prostaglandin E2 (PGE2) production in human dermal fibroblasts (Ballou, L. R., Barker, S. C., Postlethwaite, A. E., and Kang, A. H. (1990) J. Immunol. 145, 4245-4251). Because sphingosine and ceramide are interconvertable, we extended previous studies by treating cells with C2-ceramide (C2-cer), a membrane-soluble analogue of ceramide, and found that C2-cer stimulates IL-1-mediated PGE2 production to the same degree as sphingosine. In an effort to elucidate the mechanistic basis by which sphingosine and C2-cer affect PGE2 production, we examined the effect of these molecules on the expression of genes encoding cyclooxygenase (EC 1.14.99.1, Cox) and phospholipase A2 (EC 3.1.1.4, PLA2), the rate-limiting enzymes in PGE2 biosynthesis. We found that sphingosine and C2-cer treatment resulted in an 8-fold induction of Cox mRNA within 1-2 h which declined thereafter; concomitant changes in Cox protein were also observed. In contrast, expression of phospholipase A2 remained unaltered. We also found that IL-1-mediated PGE2 production was dramatically enhanced in cells treated simultaneously with sphingomyelinase which led us to directly test the effect of IL-1 on sphingomyelin turnover. IL-1 treatment induced the hydrolysis of a significant fraction of prelabeled sphingomyelin which was accompanied by increased levels of intracellular ceramide. Taken together, our results suggest that enhanced Cox expression may account for the observed enhancement of IL-1-mediated PGE2 production by sphingosine and C2-cer. These data also suggest that endogenous sphingomyelin metabolites, generated in response to IL-1, may play an important role in IL-1 signal transduction.	UNIV TENNESSEE CTR HLTH SCI,DEPT BIOCHEM,MEMPHIS,TN 38163; UNIV TENNESSEE CTR HLTH SCI,DEPT PHARMACOL,MEMPHIS,TN 38163; VET AFFAIRS MED CTR,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center	BALLOU, LR (corresponding author), UNIV TENNESSEE CTR HLTH SCI,DEPT MED,DIV CONNECT TISSUE DIS,956 COURT AVE,RM G326,MEMPHIS,TN 38163, USA.				NIAMS NIH HHS [AR39166, AR26034] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR026034, P50AR039166] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAILEY JM, 1985, J LIPID RES, V26, P54; BALLOU LR, 1990, J IMMUNOL, V145, P4245; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHANG J, 1986, J IMMUNOL, V136, P1283; DAVIS RJ, 1988, J BIOL CHEM, V263, P5373; DIAZ A, 1989, J BIOL CHEM, V264, P11554; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; ELIAS JA, 1987, J IMMUNOL, V138, P3812; ERCOLANI L, 1988, J BIOL CHEM, V263, P15355; FU JY, 1990, J BIOL CHEM, V265, P16737; GAVER RC, 1966, J AM CHEM SOC, V88, P3643, DOI 10.1021/ja00967a032; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HUBSCHER G., 1960, JOUR LIPID RES, V1, P433; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK RN, 1990, J BIOL CHEM, V265, P18803; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KOLESNICK RN, 1988, J BIOL CHEM, V263, P6534; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; MAJERUS PW, 1984, CELL, V37, P701, DOI 10.1016/0092-8674(84)90405-7; MCKNIGHT SG, 1991, CURR OPIN BIOL, V3, P213; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PREISS J, 1986, J BIOL CHEM, V261, P8579; RAZ A, 1989, P NATL ACAD SCI USA, V86, P1657, DOI 10.1073/pnas.86.5.1657; RAZ A, 1988, J BIOL CHEM, V263, P3022; ROSSI V, 1985, SCIENCE, V229, P174, DOI 10.1126/science.2409598; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WU KK, 1988, J BIOL CHEM, V263, P19043; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X	36	277	280	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20044	20050						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400321				2022-12-25	WOS:A1992JR85800049
J	HOLLOWAY, MP; LAGAMMA, EF				HOLLOWAY, MP; LAGAMMA, EF			TISSUE-SPECIFIC DNASEI HYPERSENSITIVITY REGIONS ARE LOCATED IN THE 5'-REGION OF THE RAT PREPROENKEPHALIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROENKEPHALIN GENE; CAMP-INDUCIBLE ENHANCER; MESSENGER-RNA; ADRENAL-MEDULLA; TRANSCRIPTIONAL REGULATION; DEPENDENT REGULATION; MUSCARINIC RECEPTOR; TRANSGENIC MICE; CYCLIC-AMP; EXPRESSION	Extracellular stimuli affecting mechanisms of transcriptional control of the preproenkephalin gene link stimulus-secretion-synthesis coupling to transmitter phenotypic expression. In order to define distal and proximal genomic regions that might participate in transcriptionally active protein-DNA interactions, DNaseI hypersensitivity assays were conducted. Four DNaseI-hypersensitive regions were identified at -3000, -2500, -1800, and -200 base pairs (bp) relative to the somatic start site. The appearance of a site over the proximal promoter/enhancer region (-200 bp) is of interest since we and others have published a detailed footprint and functional analysis of this region using rat tissues. While liver (which does not express proenkephalin mRNA) displays essentially no hypersensitivity here, adrenal gland preparations show a strong signal and striatal tissue a significantly weaker signal. Cholinergic induction of proenkephalin mRNA was not associated with a change in hypersensitivity pattern. These data suggest that chromatin structure may have an influence on preproenkephalin transcriptional control and that cholinergic-inducible cis-acting DNA elements may reside within subdomains of at least these four hypersensitivity sites. Understanding the basis of this open chromatin structure should aid in identifying genomic mechanisms involved in tissue-specific expression and suggest avenues of future study.	SUNY STONY BROOK,DEPT PEDIAT,HSC 11-060,STONY BROOK,NY 11794; SUNY STONY BROOK,DEPT NEUROBIOL & BEHAV,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				LaGamma, Edmund/0000-0001-9720-1949				ASHKENAZI A, 1989, NATURE, V340, P146, DOI 10.1038/340146a0; BLACK IB, 1987, SCIENCE, V236, P1263, DOI 10.1126/science.2884727; BORSOOK D, 1991, Society for Neuroscience Abstracts, V17, P546; BURCH JBE, 1983, CELL, V33, P65, DOI 10.1016/0092-8674(83)90335-5; CHU HM, 1991, NUCLEIC ACIDS RES, V19, P2721, DOI 10.1093/nar/19.10.2721; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; DURKIN RC, 1992, BIOCHIM BIOPHYS ACTA, V1131, P349, DOI 10.1016/0167-4781(92)90040-7; FERNANDO JCR, 1991, EUR J PHARM-MOLEC PH, V207, P297, DOI 10.1016/0922-4106(91)90003-Z; GARRETT JE, 1989, MOL CELL BIOL, V9, P4381, DOI 10.1128/MCB.9.10.4381; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; JOSHI J, 1991, MOL ENDOCRINOL, V5, P1069, DOI 10.1210/mend-5-8-1069; KESHET E, 1989, EMBO J, V8, P2917, DOI 10.1002/j.1460-2075.1989.tb08441.x; KEW D, 1990, MOL ENDOCRINOL, V4, P337, DOI 10.1210/mend-4-2-337; KILPATRICK DL, 1985, P NATL ACAD SCI USA, V82, P7467, DOI 10.1073/pnas.82.21.7467; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P10222, DOI 10.1073/pnas.88.22.10222; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; KORNER M, 1989, NEURON, V3, P563, DOI 10.1016/0896-6273(89)90266-3; KUENZLE CC, 1983, COLD SPRING HARB SYM, V48, P493, DOI 10.1101/SQB.1983.048.01.054; La Gamma E F, 1991, Mol Cell Neurosci, V2, P427; La Gamma E F, 1991, Mol Cell Neurosci, V2, P517; LAGAMMA EF, 1989, INT J DEV NEUROSCI, V7, P499, DOI 10.1016/0736-5748(89)90009-9; LAGAMMA EF, 1989, MOL BRAIN RES, V5, P131, DOI 10.1016/0169-328X(89)90004-1; LAGAMMA EF, 1988, MOL BIOL STRESS, P153; LAUFER R, 1989, MOL NEUROBIOL, V3, P1, DOI 10.1007/BF02935587; LOHR D, 1985, NUCLEIC ACIDS RES, V13, P8409, DOI 10.1093/nar/13.23.8409; MIRKOVITCH J, 1991, GENE DEV, V5, P83, DOI 10.1101/gad.5.1.83; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORI N, 1990, COLD SH Q B, V55, P255; RATTNER A, 1991, MOL CELL BIOL, V11, P1017, DOI 10.1128/MCB.11.2.1017; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; ROSEN H, 1984, J BIOL CHEM, V259, P4309; ROSEN H, 1991, P NATL ACAD SCI USA, V88, P3705, DOI 10.1073/pnas.88.9.3705; SCHULTZBERG M, 1978, NEUROSCIENCE, V3, P1169, DOI 10.1016/0306-4522(78)90137-9; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; UHL GR, 1988, J NEUROSCI, V8, P4755; VANDENBERGH DJ, 1989, NEURON, V3, P507, DOI 10.1016/0896-6273(89)90209-2; VANNGUYEN T, 1990, J NEUROSCI, V10, P2825; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; WEISINGER B, 1992, J BIOL CHEM, V267, P4508; WOTTON D, 1989, P NATL ACAD SCI USA, V86, P4195, DOI 10.1073/pnas.86.11.4195; WU C, 1984, NATURE, V309, P329; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; YOSHIKAWA K, 1989, FEBS LETT, V246, P193, DOI 10.1016/0014-5793(89)80281-9; ZINN SA, 1991, J BIOL CHEM, V266, P23850	49	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19819	19823						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400296				2022-12-25	WOS:A1992JR85800013
J	PENNYPACKER, KR; HONG, JS; DOUGLASS, J; MCMILLIAN, MK				PENNYPACKER, KR; HONG, JS; DOUGLASS, J; MCMILLIAN, MK			CONSTITUTIVE EXPRESSION OF AP-1 TRANSCRIPTION FACTORS IN THE RAT ADRENAL - EFFECTS OF NICOTINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; NERVE GROWTH-FACTOR; C-FOS EXPRESSION; MESSENGER-RNA; PHOSPHORYLATION; JUN; ACTIVATION; PROTEINS; PROENKEPHALIN; MEDULLA	The AP-1 proteins (c-fos and fos-related antigens and jun proteins) are transcription factors that are induced in most cells by various stimuli, but the expression of these proteins is low or undetectable in the basal state. Our data indicate that the rat adrenal gland contains a basally expressed elevated level of AP-1 proteins and mRNAs (40- and 35-kDa fos-related antigens, a 39-kDa c-jun protein, c-jun, junB, and junD mRNA), as well as high basal AP-1 DNA binding activity. Both the medulla and cortex contained equivalent levels of fos-related antigens and c-jun protein; however, the majority of AP-1 DNA binding was detected in the medulla. Handling of rats for several days prior to sacrifice failed to affect protein expression or binding; on the other hand, repeated injections of nicotine increased AP-1 DNA binding. A single nicotine injection 60 min prior to removing the adrenals caused a significant reduction in AP-1 DNA binding without any detectable changes in AP-1 protein expression. Pretreatment of adrenal nuclear extracts with alkaline phosphatase prior to incubation with the AP-1 oligomer decreased binding activity. Thus, unlike most tissues where AP-1 DNA binding activity is controlled by increased expression of AP-1 proteins, DNA binding in the rat adrenal gland appears to be controlled at the post-translational level, possibly through dephosphorylation.	OREGON HLTH SCI UNIV,INST VOLLUM,PORTLAND,OR 97201	Oregon Health & Science University	PENNYPACKER, KR (corresponding author), NIEHS,NEUROPHARMACOL SECT,MOLEC & INTEGRAT NEUROSCI LAB,MD 14-06,POB 12233,RES TRIANGLE PK,NC 27709, USA.		Pennypacker, Keith/I-5092-2012; Hong, Jau-Shyong/F-1920-2019	Hong, Jau-Shyong/0000-0002-3056-8401				BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE AJ, 1992, J NEUROCHEM, V58, P1420, DOI 10.1111/j.1471-4159.1992.tb11358.x; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; DECRISTOFARO JD, 1990, NEUROSCIENCE, V35, P203, DOI 10.1016/0306-4522(90)90135-Q; DRAGUNOW M, 1987, NATURE, V210, P249; FOSSOM L, 1991, J NEUROCHEM, V7, P2070; FOSSOM LH, 1991, MOL PHARMACOL, V40, P193; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRAYBIEL AM, 1990, P NATL ACAD SCI USA, V87, P6912, DOI 10.1073/pnas.87.17.6912; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GUBITS RM, 1988, MOL BRAIN RES, V3, P197, DOI 10.1016/0169-328X(88)90067-8; KANAMATSU T, 1986, P NATL ACAD SCI USA, V83, P9245, DOI 10.1073/pnas.83.23.9245; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P10222, DOI 10.1073/pnas.88.22.10222; LAGAMMA EF, 1989, MOL BRAIN RES, V5, P17, DOI 10.1016/0169-328X(89)90013-2; LAGAMMA EF, 1988, DEV BRAIN RES, V39, P177, DOI 10.1016/0165-3806(88)90021-1; LAGAMMA EF, 1985, P NATL ACAD SCI USA, V82, P8252, DOI 10.1073/pnas.82.23.8252; LAGAMMA EF, 1984, SCIENCE, V224, P1102, DOI 10.1126/science.6144183; MANEK JR, 1990, GENE DEV, V4, P955; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; PELTOHUIKKO M, 1991, NEUROSCI LETT, V126, P163, DOI 10.1016/0304-3940(91)90544-4; PENNYPACKER KR, IN PRESS MOL BRAIN R; PENNYPACKER KR, 1992, IN PRESS J NEUROCHEM; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; ROBERTSON GS, 1989, EUR J PHARMACOL, V159, P99, DOI 10.1016/0014-2999(89)90049-6; RYSECK RP, 1991, ONCOGENE, V6, P533; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; SAKAURAIYAMASHI.T, 1991, EUR J NEUROSCI, V3, P764; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; SONNENBERG JL, 1989, J NEUROSCI RES, V24, P72, DOI 10.1002/jnr.490240111; YOUNG ST, 1991, P NATL ACAD SCI USA, V88, P1291, DOI 10.1073/pnas.88.4.1291	39	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20148	20152						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400333				2022-12-25	WOS:A1992JR85800064
J	STYLIANOU, E; ONEILL, LAJ; RAWLINSON, L; EDBROOKE, MR; WOO, P; SAKLATVALA, J				STYLIANOU, E; ONEILL, LAJ; RAWLINSON, L; EDBROOKE, MR; WOO, P; SAKLATVALA, J			INTERLEUKIN-1 INDUCES NF-KAPPA-B THROUGH ITS TYPE-I BUT NOT ITS TYPE-II RECEPTOR IN LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DNA-BINDING SUBUNIT; HUMAN-IMMUNODEFICIENCY-VIRUS; IL-1 RECEPTOR; FACTOR-ALPHA; TRANSCRIPTION FACTOR; HUMAN-FIBROBLASTS; GENE-EXPRESSION; PHORBOL ESTER; MESSENGER-RNA	It is not known whether one or both of the interleukin 1 (IL1) receptors mediates the induction of the DNA-binding protein NF-kappa-B. Nuclear extracts of the murine lines EL4.NOB.1 and 70Z/3, which bear the type I (80 kDa) and type II (67 kDa) IL1 receptor, respectively, were analyzed by an electrophoretic mobility shift assay. A 265-base pair sequence of the human serum amyloid A gene or a synthetic oligonucleotide each containing the NF-kappa-B site were used as the DNA probes. IL1 induction of NF-kappa-B was rapid (optimal at 15-30 min) and transient in both cell types. The IL1 receptor antagonist (IL1ra), which binds strongly to the type I receptor, inhibited the NF-kappa-B response in both cell lines. IL1ra did not bind to the type II receptor on 70Z/3 cells as judged by competition for binding with I-125-IL1-alpha. When I-125-IL1ra binding to 70Z/3 cells was measured, a small number (10/cell) of high affinity sites (K(d) = 5 x 10(-12) M) were detected. These were likely to have been type I receptor because an antibody to this inhibited the NF-kappa-B induction in 70Z/3 cells (as well as EL4). Potential signal transduction mechanisms involving protein kinase C or oxygen radicals were studied. Phorbol 12-myristate 13-acetate induced NF-kappa-B with a similar time course to IL1 in 70Z/3 but only after 4 h in EL4.IL1 was unaffected by a protein kinase C inhibitor (staurosporine). H2O2 did not mimic IL1, and IL1 was not inhibited by an antioxidant. The type I receptor mediates the induction of NF-kappa-B in response to IL1 via a signaling mechanism that still remains to be identified.	UNIV DUBLIN TRINITY COLL,DEPT BIOCHEM,DUBLIN 2,IRELAND; CLIN RES CTR,MOLEC RHEUMATOL SECT,HARROW HA1 3UJ,MIDDX,ENGLAND	Trinity College Dublin	STYLIANOU, E (corresponding author), STRANGEWAYS RES LAB,CYTOKINE BIOCHEM GRP,CAMBRIDGE CB1 4RN,ENGLAND.							BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BAUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63; BAUERLE PA, 1989, GENE DEV, V3, P1689; BIRD TA, 1988, J BIOL CHEM, V263, P12063; BIRD TA, 1990, J BIOL CHEM, V265, P235; BIRD TA, 1990, J BIOL CHEM, V265, P13578; BIRD TA, 1986, NATURE, V324, P263, DOI 10.1038/324263a0; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BOMSZTYK K, 1991, CELL REGUL, V2, P329, DOI 10.1091/mbc.2.4.329; BOMSZTYK K, 1989, P NATL ACAD SCI USA, V86, P8034, DOI 10.1073/pnas.86.20.8034; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIZZONITE R, 1989, P NATL ACAD SCI USA, V86, P8029, DOI 10.1073/pnas.86.20.8029; CURTIS BM, 1989, P NATL ACAD SCI USA, V86, P3045, DOI 10.1073/pnas.86.9.3045; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINARELLO CA, 1991, BLOOD, V77, P1627; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; DRIPPS DJ, 1991, J BIOL CHEM, V266, P20311; EDBROOKE MR, 1989, MOL CELL BIOL, V9, P1908, DOI 10.1128/MCB.9.5.1908; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GUESDON F, 1991, J IMMUNOL, V147, P3402; GUY GR, 1991, J BIOL CHEM, V266, P14343; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARUCHA PT, 1991, J IMMUNOL, V147, P2603; MATSUSHIMA K, 1986, J IMMUNOL, V136, P4496; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P392, DOI 10.1016/0167-5699(90)90155-3; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; Schmitz M L, 1991, Trends Cell Biol, V1, P130, DOI 10.1016/0962-8924(91)90118-S; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SPRIGGS MK, 1990, J BIOL CHEM, V265, P22499; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; WOO P, 1987, J BIOL CHEM, V262, P15790	47	214	218	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15836	15841						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1386364				2022-12-25	WOS:A1992JG11300088
J	KRISHNASWAMY, S				KRISHNASWAMY, S			THE INTERACTION OF HUMAN FACTOR-VIIA WITH TISSUE FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-X; EXTRINSIC PATHWAY; PHOSPHOLIPID-VESICLES; BLOOD-COAGULATION; COFACTOR FUNCTION; ENZYME COMPLEXES; CELL-LINE; ACTIVATION; BINDING; EXPRESSION	The interaction of factor VIIa with tissue factor (TF) results in an increase in the catalytic efficiency for the hydrolysis of several synthetic peptidyl p-nitroanilide substrates by factor VIIa. The binding of human recombinant factor VIIa to recombinant human TF incorporated into vesicles containing phosphatidylcholine (TF/PC) or phosphatidylcholine/phosphatidylserine (TF/PCPS) was studied using the increased rate of H-D-phenylalanyl L-pipecoyl L-arginine p-nitroanilide (S2238) hydrolysis as a signal for the interaction. The saturable dependence of rate on increasing concentrations of factor VIIa or TF/PCPS yielded no obvious evidence for cooperativity and could be analyzed according to the interaction of factor VIIa with independent noninteracting sites (K(d) = 259 +/- 60 pM, n = 1.05 +/- 0.12 mol of factor VIIa/mol of TF at saturation). Identical titration curves and equilibrium parameters were derived from titrations using TF/PC or TF in the absence of phospholipids, indicating that possible protein-membrane interactions do not further stabilize the extrinsic Xase complex. The dissociation constant for the interaction of factor VIIa with TF/PCPS inferred from measurements of factor X activation (K(d) = 197 +/- 38 pM) was comparable with the values obtained from measurements of S2238 hydrolysis. In contrast to the membrane-independent nature of the enzyme-cofactor interaction, the rate of factor X activation was reduced by approximately 50-fold when the enzyme complex was assembled using solution-phase TF. Collectively, the results indicate that the membrane dependence of extrinsic Xase function primarily results from an influence of the membrane surface on factor X utilization.			KRISHNASWAMY, S (corresponding author), EMORY UNIV,SCH MED,DEPT MED,DIV HEMATOL & ONCOL,ATLANTA,GA 30322, USA.				NHLBI NIH HHS [HL-38337, HL-47465] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047465, R29HL038337] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BACH R, 1988, BIOCHEMISTRY-US, V27, P4227, DOI 10.1021/bi00412a004; BACH R, 1990, P NATL ACAD SCI USA, V87, P6995, DOI 10.1073/pnas.87.18.6995; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; Berman M., 1978, SAAM MANUAL; Berman M, 1983, CONSAM USERS GUIDE; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; BROZE GJ, 1982, J CLIN INVEST, V70, P526, DOI 10.1172/JCI110644; Cleland W W, 1979, Methods Enzymol, V63, P103; CRAMER BJW, 1988, BIOCHEM J, V239, P757; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; DRAKE TA, 1989, J CELL BIOL, V109, P389, DOI 10.1083/jcb.109.1.389; DRAKE TA, 1989, AM J PATHOL, V134, P1087; ESMON NL, 1982, J BIOL CHEM, V257, P859; EVANS SA, 1982, J BIOL CHEM, V257, P3014; FAIR DS, 1987, J BIOL CHEM, V262, P11692; FORMAN SD, 1986, P NATL ACAD SCI USA, V83, P4675, DOI 10.1073/pnas.83.13.4675; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GUHA A, 1986, P NATL ACAD SCI USA, V83, P299, DOI 10.1073/pnas.83.2.299; Hem ker HC, 1983, HDB SYNTHETIC SUBSTR; KRISHNASWAMY S, 1992, FASEB J, V6, pA328; KUMAR A, 1991, J BIOL CHEM, V266, P915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; LAWSON JH, 1992, IN PRESS METHODS ENZ; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; NEMERSON Y, 1982, PROG HEMOST THROMB, V6, P237; PABORSKY LR, 1989, BIOCHEMISTRY-US, V28, P8072, DOI 10.1021/bi00446a016; PABORSKY LR, 1991, J BIOL CHEM, V266, P21911; PEDERSEN AH, 1990, J BIOL CHEM, V265, P16786; ROY S, 1991, J BIOL CHEM, V266, P22063; RUF W, 1991, P NATL ACAD SCI USA, V88, P8430, DOI 10.1073/pnas.88.19.8430; RUF W, 1992, J BIOL CHEM, V267, P6375; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; SAKAI T, 1989, J BIOL CHEM, V264, P9980; SILVERBERG SA, 1977, J BIOL CHEM, V252, P8481; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015; ZUR M, 1978, J BIOL CHEM, V253, P2203; ZUR M, 1980, J BIOL CHEM, V255, P5703	48	91	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23696	23706						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429710				2022-12-25	WOS:A1992JZ23900043
J	SHARIFI, BG; LAFLEUR, DW; PIROLA, CJ; FORRESTER, JS; FAGIN, JA				SHARIFI, BG; LAFLEUR, DW; PIROLA, CJ; FORRESTER, JS; FAGIN, JA			ANGIOTENSIN-II REGULATES TENASCIN GENE-EXPRESSION IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEIN; CHICK MYOTENDINOUS ANTIGEN; MESSENGER-RNA; MOLECULAR-FORMS; FIBRONECTIN; TISSUES; CYTOTACTIN; GROWTH; SITES; ATHEROSCLEROSIS	Angiotensin II, a vasoactive peptide, has been implicated in the pathophysiology of a number of vascular wall abnormalities. Since aberrant extracellular matrix deposition contributes to the pathogenesis of vessel wall disease, we examined the potential involvement of angiotensin II in the regulation of extracellular matrix synthesis by vascular smooth muscle cells. Immunoprecipitation of newly synthesized matrix proteins showed that, under serum-free conditions, cultured vascular smooth muscle cells constitutively produced high levels of fibronectin, small amounts of laminin, and a barely detectable amount of tenascin. Angiotensin II treatment increased synthesis of a 230-kDa tenascin glycoprotein by 9-fold and fibronectin synthesis by only 30-40% during a 24-h treatment period, without stimulating laminin production or a general increase in the synthesis of secreted proteins. Concomitant treatment with saralasin, a competitive inhibitor of angiotensin II, prevented the stimulation observed with angiotensin II. The stimulation of immunoprecipitable tenascin was preceded by an increase in tenascin mRNA. Levels of tenascin transcripts (8.4 and 7.0 kilobase) were significantly increased within 2 h after angiotensin II treatment, reached a maximum (10- to 12-fold) by 4 h, and remained elevated after 18 h. The induction was completely blocked by actinomycin D. Serum also induced tenascin mRNA, but with a different time course. Serum induction of tenascin mRNA was also evident at 2 h, maximal at 4 h, but declined to control levels at 8 h. These results indicate that angiotensin II exerts a rapid and selective stimulation of tenascin biosynthesis, at least in part at a transcriptional level. This suggests that angiotensin II may alter the composition of the extracellular matrix of the vessel wall by stimulating synthesis of the antiadhesive protein tenascin.			SHARIFI, BG (corresponding author), UNIV CALIF LOS ANGELES, SCH MED,CEDARS SINAI MED CTR,DIV CARDIOL, DAVIS BLDG 1016, 8700 BEVERLY BLVD, LOS ANGELES, CA 90048 USA.			Pirola, Carlos/0000-0001-8234-4058				AUFDERHEIDE E, 1988, J CELL BIOL, V107, P2341, DOI 10.1083/jcb.107.6.2341; BARNES MJ, 1985, COLLAGEN REL RES, V5, P65; BELL L, 1990, AM J PATHOL, V137, P7; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BOBIK A, 1990, BIOCHEM BIOPH RES CO, V166, P580, DOI 10.1016/0006-291X(90)90848-H; BOURDON MA, 1985, J CELL BIOCHEM, V28, P183, DOI 10.1002/jcb.240280302; CARNEMOLLA B, 1989, J CELL BIOL, V108, P1139, DOI 10.1083/jcb.108.3.1139; CHAMLEYCAMPBELL JH, 1981, ATHEROSCLEROSIS, V40, P347, DOI 10.1016/0021-9150(81)90145-3; CHIQUET M, 1984, J CELL BIOL, V98, P1937, DOI 10.1083/jcb.98.6.1937; CHIQUET M, 1984, J CELL BIOL, V98, P1926, DOI 10.1083/jcb.98.6.1926; CHIQUETEHRISMANN R, 1990, FASEB J, V4, P2598, DOI 10.1096/fasebj.4.9.1693347; CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092-8674(86)90374-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANILOFF JK, 1989, J CELL BIOL, V108, P625, DOI 10.1083/jcb.108.2.625; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; ERICKSON HP, 1987, J CELL BIOL, V105, P1387, DOI 10.1083/jcb.105.3.1387; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FORNEYPRESCOTT M, 1991, AM J PATHOL, V139, P1291; FORRESTER JS, 1991, J AM COLL CARDIOL, V17, P758, DOI 10.1016/S0735-1097(10)80196-2; GATCHALIAN CL, 1989, J CELL BIOL, V108, P1873, DOI 10.1083/jcb.108.5.1873; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GIBBONS GH, 1990, CLIN RES, V38, pA287; GRIENDLING KK, 1988, CLIN EXP PHARMACOL P, V15, P105, DOI 10.1111/j.1440-1681.1988.tb01051.x; GRUMET M, 1985, P NATL ACAD SCI USA, V82, P8075, DOI 10.1073/pnas.82.23.8075; GULCHER JR, 1989, P NATL ACAD SCI USA, V86, P1588, DOI 10.1073/pnas.86.5.1588; HEICKENDORFF L, 1988, INT J BIOCHEM, V20, P381, DOI 10.1016/0020-711X(88)90205-4; HOFFMAN S, 1988, J CELL BIOL, V106, P519, DOI 10.1083/jcb.106.2.519; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IP JH, 1990, J AM COLL CARDIOL, V15, P1667, DOI 10.1016/0735-1097(90)92845-S; KOUKOULIS GK, 1991, HUM PATHOL, V22, P636, DOI 10.1016/0046-8177(91)90285-W; LEE YH, 1988, CANCER RES, V48, P2904; LIAU G, 1989, J BIOL CHEM, V264, P10315; LYONSGIORDANO B, 1987, BIOCHEM BIOPH RES CO, V148, P1264, DOI 10.1016/S0006-291X(87)80269-3; MACKIE EJ, 1988, J CELL BIOL, V107, P2757, DOI 10.1083/jcb.107.6.2757; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; NAFTILAN AJ, 1989, HYPERTENSION, V13, P706, DOI 10.1161/01.HYP.13.6.706; OYAMA F, 1991, CANCER RES, V51, P4876; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; SIRI A, 1991, NUCLEIC ACIDS RES, V19, P525, DOI 10.1093/nar/19.3.525; SMITH JB, 1984, P NATL ACAD SCI-BIOL, V81, P7812, DOI 10.1073/pnas.81.24.7812; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; WELLER A, 1991, J CELL BIOL, V112, P355, DOI 10.1083/jcb.112.2.355	44	85	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23910	23915						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385427				2022-12-25	WOS:A1992JZ23900072
J	KIM, CM; GOLDSTEIN, JL; BROWN, MS				KIM, CM; GOLDSTEIN, JL; BROWN, MS			CDNA CLONING OF MEV, A MUTANT PROTEIN THAT FACILITATES CELLULAR UPTAKE OF MEVALONATE, AND IDENTIFICATION OF THE POINT MUTATION RESPONSIBLE FOR ITS GAIN OF FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; RECEPTOR-MEDIATED ENDOCYTOSIS; HUMAN-FIBROBLASTS; RAT-LIVER; EXPRESSION; ACID; MECHANISM; SEQUENCE; INHIBITION; REDUCTASE	We report the expression cloning of pMev, a cDNA that facilitates cellular uptake of mevalonate. pMev was isolated from the met-18b-2 clone of Chinese hamster ovary (CHO) cells, which were selected for growth in low concentrations of mevalonate when synthesis is blocked by compactin (Faust, J. R., and Krieger, M. (1987) J. Biol. Chem. 262,1996-2004). pMev encodes a 494-residue protein, Mev, that is predicted to have 12 membrane-spanning regions, consistent with a membrane transporter. Surprisingly, levels of Mev mRNA and protein are similar in CHO and met-18b-2 cells. The Mev gene differs from the wild-type gene by a single base change that substitutes a cysteine for phenylalanine in the 10th membrane-spanning region. met-18b-2 cells are heterozygous for this dominant gain-of-function mutation. Transfection of a cDNA encoding pMev, but not the wild-type cDNA, elicited a marked increase in [H-3]mevalonate uptake and incorporation into cellular lipids in stably and transiently transfected cells. The availability of pMev will facilitate studies of [H-3]mevalonate incorporation into trace products, including p21ras and other prenylated proteins.			KIM, CM (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline; NIGMS NIH HHS [GM 07062, GM 08014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BEISIEGEL U, 1981, J BIOL CHEM, V256, P4071; BROWN MS, 1978, J BIOL CHEM, V253, P1121; BROWN MS, 1980, J LIPID RES, V21, P505; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVINE SE, 1992, P NATL ACAD SCI USA, V889, P4564; FAUST J, 1987, J BIOL CHEM, V262, P1996; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Glomset J. A., 1991, CURR OPIN LIPIDOL, V2, P118; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HARLOW E, 1988, ANTIBODIES LABORATOR; HELLSTROM KH, 1973, J CLIN INVEST, V52, P1303, DOI 10.1172/JCI107301; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; KRIEGER M, 1981, J MOL BIOL, V150, P167, DOI 10.1016/0022-2836(81)90447-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JS, 1991, DNA CELL BIOL, V10, P67, DOI 10.1089/dna.1991.10.67; LEHRMAN MA, 1987, J BIOL CHEM, V262, P3354; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; NAVE JF, 1985, BIOCHEM J, V227, P247, DOI 10.1042/bj2270247; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; PARKER TS, 1984, J CLIN INVEST, V74, P795, DOI 10.1172/JCI111495; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SNYDER SH, 1991, NATURE, V354, P187, DOI 10.1038/354187a0; TANAKA RD, 1990, P NATL ACAD SCI USA, V87, P2872, DOI 10.1073/pnas.87.8.2872; van der Eb A J, 1980, Methods Enzymol, V65, P826; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	41	116	122	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23113	23121						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429658				2022-12-25	WOS:A1992JY16300064
J	MOLLER, C; HANSSON, A; ENBERG, B; LOBIE, PE; NORSTEDT, G				MOLLER, C; HANSSON, A; ENBERG, B; LOBIE, PE; NORSTEDT, G			GROWTH-HORMONE (GH) INDUCTION OF TYROSINE PHOSPHORYLATION AND ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASES IN CELLS TRANSFECTED WITH RAT GH RECEPTOR CDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN BASIC-PROTEIN; SERINE THREONINE KINASES; BINDING-PROTEIN; GENE-EXPRESSION; MESSENGER-RNA; HUMAN-SERUM; FACTOR-I; INSULIN; ASSAY; IDENTIFICATION	The mechanism of growth hormone (GH) action was studied in Chinese hamster ovary (CHO) cells transfected with GH receptor cDNA. Cytosolic extracts from GH- or phorbol ester (12-O-tetradecanoyl 4beta-phorbol 13-acetate)-treated cells, transfected with full-length GH receptor cDNA, had an enhanced ability to phosphorylate myelin basic protein. Myelin basic protein, a substrate for mitogen-activated protein (MAP) kinase, was maximally phosphorylated using extracts from cells treated with 50 nm bovine GH for 10 min. In addition, GH treatment resulted in an increased cell proliferation by 30-60%. GH and 12-O-tetradecanoyl 4beta-phorbol 13-acetate cause tyrosine phosphorylation of two proteins with M(r) of 40,000 and 42,000 that are also recognized by MAP kinase antibodies. These proteins were identified as MAP kinases by analyzing phosphotyrosine immunoprecipitates on Western blots using MAP kinase antibodies. In addition, GH induces mitogenicity, as well as MAP kinase activation, in CHO cells expressing a receptor in which 184 amino acids had been deleted in the carboxyl-terminal part of the intracellular domain. No GH effects were seen in untransfected cells, in CHO cells expressing a truncated GH receptor containing only 5 of 349 amino acids in the intracellular domain, or in cells expressing the soluble GH-binding protein. In conclusion, our data show that GH treatment of CHO cells, reconstituted with GH receptors, initiates a phosphorylation cascade which includes MAP kinase.	UNIV QUEENSLAND,DEPT PHYSIOL & PHARMACOL,ST LUCIA,QLD 4072,AUSTRALIA; KAROLINSKA INST,NOVUM,DEPT MED NUTR,S-14157 HUDDINGE,SWEDEN; KAROLINSKA INST,DEPT PHYSIOL CHEM,S-10401 STOCKHOLM 60,SWEDEN	University of Queensland; Karolinska Institutet; Karolinska Institutet	MOLLER, C (corresponding author), KAROLINSKA INST,NOVUM,CTR BIOTECHNOL,S-14157 HUDDINGE,SWEDEN.							AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; AMIT T, 1990, J CLIN ENDOCR METAB, V71, P474, DOI 10.1210/jcem-71-2-474; BARNARD R, 1991, ENDOCRINOLOGY, V128, P1459, DOI 10.1210/endo-128-3-1459; BAUMBACH WR, 1989, GENE DEV, V3, P1199, DOI 10.1101/gad.3.8.1199; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BILLESTRUP N, 1985, ENDOCRINOLOGY, V116, P1175, DOI 10.1210/endo-116-3-1175; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CAHILL AL, 1991, J NEUROCHEM, V57, P1832, DOI 10.1111/j.1471-4159.1991.tb06392.x; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; COCHET C, 1991, J BIOL CHEM, V266, P637; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; EMTNER M, 1990, MOL ENDOCRINOL, V4, P2014, DOI 10.1210/mend-4-12-2014; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSSON A, 1991, CELL SIGNAL, V3, P293, DOI 10.1016/0898-6568(91)90057-2; HERINGTON AC, 1987, MOL CELL ENDOCRINOL, V53, P203, DOI 10.1016/0303-7207(87)90175-4; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOBIE PE, 1991, J BIOL CHEM, V266, P22645; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALLER J, 1991, Current Biology, V1, P334, DOI 10.1016/0960-9822(91)90104-5; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MEJER KE, 1991, J BIOL CHEM, V266, P1914; MELLOUL D, 1984, EMBO J, V3, P983, DOI 10.1002/j.1460-2075.1984.tb01917.x; MOLLER C, 1991, J MOL ENDOCRINOL, V7, P213, DOI 10.1677/jme.0.0070213; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PALEN E, 1987, J BIOL CHEM, V262, P3518; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SLOOTWEG MC, 1991, J MOL ENDOCRINOL, V6, P179, DOI 10.1677/jme.0.0060179; STUBBART JR, 1991, ENDOCRINOLOGY, V129, P1659, DOI 10.1210/endo-129-3-1659; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	41	151	154	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23403	23408						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1385420				2022-12-25	WOS:A1992JY16300105
J	AGELLON, LB; ZHANG, PQ; JIANG, XC; MENDELSOHN, L; TALL, AR				AGELLON, LB; ZHANG, PQ; JIANG, XC; MENDELSOHN, L; TALL, AR			THE CCAAT ENHANCER-BINDING PROTEIN TRANSACTIVATES THE HUMAN CHOLESTERYL ESTER TRANSFER PROTEIN GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED TRANSCRIPTIONAL ACTIVATOR; HIGH-DENSITY LIPOPROTEINS; HEPATOMA-CELLS; LIVER; C/EBP; EXPRESSION; ALBUMIN; INVITRO; FAMILY; DNA	The plasma cholesteryl ester transfer protein (CETP), primarily synthesized in the liver of several species, is expressed at very low levels in a number of transformed human liver cell lines. The human CETP gene promotor contains a sequence that closely resembles the binding site for the transcription factor CCAAT/enhancer-binding protein (C/EBP). This site is capable of binding C/EBP, as shown by electrophoretic mobility shift and DNase I footprint analyses. Transient expression of the bacterial chloramphenicol acetyltransferase gene under the control of the human CETP gene promotor gave low activities in the human hepatoma cell line, HepG2. However, in the presence of C/EBP, CAT activity was markedly elevated indicating that CETP gene promoter activity was enhanced. In primary cultures of isolated hepatocytes, CETP mRNA was lost rapidly and in parallel with the C/EBP mRNA. C/EBP may play an important role in the proper maintenance of CETP gene promoter activity, and its low levels in proliferating or cultured cells may account for the low level of the CETP gene expression in immortalized human liver cell lines or cultured hepatocytes.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,DIV MOLEC MED,NEW YORK,NY 10032	Columbia University	AGELLON, LB (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,INST HUMAN NUTR,NEW YORK,NY 10032, USA.		Tall, Alan/AAT-8528-2021		NHLBI NIH HHS [HL21006, HL43165] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006, R01HL043165] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGELLON LB, 1990, BIOCHEMISTRY-US, V29, P1372, DOI 10.1021/bi00458a004; AGELLON LB, 1991, J BIOL CHEM, V266, P10796; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CAO Z, 1991, GENE DEV, V5, P1530; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DRAYNA D, 1987, NATURE, V327, P632, DOI 10.1038/327632a0; FAUST RA, 1987, ARTERIOSCLEROSIS, V7, P267, DOI 10.1161/01.ATV.7.3.267; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENDRIKS HFJ, 1990, METHOD ENZYMOL, V190, P49; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; JIANG XC, 1992, IN PRESS J CLIN INVE; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; PAPE ME, 1991, J BIOL CHEM, V266, P12829; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; QUINET E, 1991, J CLIN INVEST, V87, P1559, DOI 10.1172/JCI115169; QUINET EM, 1990, J CLIN INVEST, V85, P357, DOI 10.1172/JCI114446; RO HS, 1991, MOL CELL BIOL, V11, P2303, DOI 10.1128/MCB.11.4.2303; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; STEWART MJ, 1991, J BIOL CHEM, V266, P11594; STEWART MJ, 1990, MOL CELL BIOL, V10, P5007, DOI 10.1128/MCB.10.9.5007; SWENSON TL, 1987, J BIOL CHEM, V262, P16271; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; YAMASHITA S, 1990, J CLIN INVEST, V86, P688, DOI 10.1172/JCI114764	34	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22336	22339						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429586				2022-12-25	WOS:A1992JW71900055
J	BRIGLE, KE; WESTIN, EH; HOUGHTON, MT; GOLDMAN, ID				BRIGLE, KE; WESTIN, EH; HOUGHTON, MT; GOLDMAN, ID			INSERTION OF AN INTRACISTERNAL-A PARTICLE WITHIN THE 5'-REGULATORY REGION OF A GENE ENCODING FOLATE-BINDING PROTEIN IN L1210 LEUKEMIA-CELLS IN RESPONSE TO LOW FOLATE SELECTION - ASSOCIATION WITH INCREASED PROTEIN EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TRANSPORT; INTEGRATION SITES; MURINE L1210; DNA; ACTIVATION; ACID; SEQUENCE; ONCOGENE; PROMOTER; GROWTH	We have previously described a subline of L1210 murine leukemia cells (LL1) selected in a low level of 5-formyltetrahydrofolate which overexpresses a membrane-bound folate-binding protein (FBP1) and exhibits a rearrangement at the locus encoding this protein. Genomic clones containing the entire FBP1-encoding DNA from both L1210 and LL1 were isolated and characterized. Sequence analysis indicates that, with exception of the 5'-region, the FBP1-encoding locus in both cell lines is identical. The rearrangement in LL1 results from the insertion of an intracisternal A particle (IAP) in the head-to-head (antisense) orientation 72 base pairs (bp) upstream of the FBP1 ATG start codon. The IAP likely provides an alternative promoter for FBP1 expression which may produce a novel transcript with enhanced stability. Presence of the IAP appears to inactivate or relocate normal cis-acting regulatory sequences as expression of the FBP1 transcript in LL1 is not regulated by the folate status of the cell.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,BOX 230,MCV STN,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL,RICHMOND,VA 23298	Virginia Commonwealth University; Virginia Commonwealth University					NCI NIH HHS [CA-09340, CA-39807] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039807] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOTA S, 1987, GENE, V56, P1, DOI 10.1016/0378-1119(87)90153-3; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BRIGLE KE, 1991, J BIOL CHEM, V266, P17243; BUTTERWORTH CE, 1992, JAMA-J AM MED ASSOC, V267, P528, DOI 10.1001/jama.267.4.528; CAMPBELL IG, 1991, CANCER RES, V51, P5329; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY RJ, 1988, MOL CELL BIOL, V8, P1093, DOI 10.1128/MCB.8.3.1093; CONEY LR, 1991, CANCER RES, V51, P6125; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DICKSON C, 1990, J VIROL, V64, P784, DOI 10.1128/JVI.64.2.784-793.1990; ELWOOD PC, 1989, J BIOL CHEM, V264, P5806; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1988, J MEMBRANE BIOL, V101, P247, DOI 10.1007/BF01872839; HENDERSON GB, 1990, BIOCHEM PHARMACOL, V39, P2019, DOI 10.1016/0006-2952(90)90624-T; HOROWITZ M, 1984, EMBO J, V3, P2937, DOI 10.1002/j.1460-2075.1984.tb02235.x; JANSEN G, 1990, CANCER RES, V50, P7544; JANSEN G, 1991, CANCER CHEMOTH PHARM, V28, P115, DOI 10.1007/BF00689699; JANSEN G, 1989, CANCER RES, V49, P2455; Kamen B A, 1980, Methods Enzymol, V66, P678, DOI 10.1016/0076-6879(80)66527-6; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; KUFF EL, 1985, MOL CELL BIOL, V5, P474, DOI 10.1128/MCB.5.3.474; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LAZO PA, 1990, P NATL ACAD SCI USA, V87, P170, DOI 10.1073/pnas.87.1.170; MIETZ JA, 1992, MOL CELL BIOL, V12, P220, DOI 10.1128/MCB.12.1.220; MILLER PN, 1989, TERATOLOGY, V39, P375, DOI 10.1002/tera.1420390409; MOOSLEHNER K, 1990, J VIROL, V64, P3056, DOI 10.1128/JVI.64.6.3056-3058.1990; NUSSE R, 1990, MOL CELL BIOL, V10, P4170, DOI 10.1128/MCB.10.8.4170; RECHAVI G, 1982, NATURE, V300, P607, DOI 10.1038/300607a0; ROHDEWOHLD H, 1987, J VIROL, V61, P336, DOI 10.1128/JVI.61.2.336-343.1987; SADASIVAN E, 1989, J BIOL CHEM, V264, P5806; SADASIVAN E, 1987, BIOCHIM BIOPHYS ACTA, V925, P36, DOI 10.1016/0304-4165(87)90145-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIROTNAK FM, 1984, J BIOL CHEM, V259, P3139; TARUSCIO D, 1991, CHROMOSOMA, V101, P141, DOI 10.1007/BF00355364; WESTERHOF GR, 1991, CANCER RES, V51, P5507; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	36	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22351	22355						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429588				2022-12-25	WOS:A1992JW71900058
J	EISENSTEIN, E; HAN, MS; WOO, TS; RITCHEY, JM; GIBBONS, I; YANG, YR; SCHACHMAN, HK				EISENSTEIN, E; HAN, MS; WOO, TS; RITCHEY, JM; GIBBONS, I; YANG, YR; SCHACHMAN, HK			NEGATIVE COMPLEMENTATION IN ASPARTATE-TRANSCARBAMYLASE - ANALYSIS OF HYBRID ENZYME MOLECULES CONTAINING DIFFERENT ARRANGEMENTS OF POLYPEPTIDE-CHAINS FROM WILD-TYPE AND INACTIVE MUTANT CATALYTIC SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BISUBSTRATE ANALOG N-(PHOSPHONACETYL)-L-ASPARTATE; CONCERTED ALLOSTERIC TRANSITION; AMINO-ACID SUBSTITUTIONS; ESCHERICHIA-COLI; INTERCHAIN INTERACTIONS; SULFHYDRYL-GROUPS; ACTIVE-SITES; CARBAMOYLTRANSFERASE; BINDING; MODEL	A comprehensive set of hybrid molecules of aspartate transcarbamylase (ATCase) from Escherichia coli has been constructed of wild-type and mutationally altered catalytic chains. The mutant enzymes that were virtually devoid of activity contained a replacement of Gly-128 in the catalytic polypeptide chains by either Asp or Arg. The kinetic properties of these hybrid enzyme-like molecules were analyzed to evaluate the basis for the unusual quaternary constraint demonstrated by an intersubunit hybrid containing one wild-type catalytic subunit, one inactive mutant subunit (containing the Gly to Asp replacement), and three wild-type regulatory subunits. A similar intersubunit hybrid was constructed from the wild-type catalytic subunit and the mutant in which Gly-128 was replaced by Arg, and it too demonstrated a pronounced decrease in activity relative to that expected for a hybrid containing three active sites. Moreover, neither of these hybrid holoenzymes exhibited the cooperativity with respect to aspartate that is characteristic of wild-type ATCase. In contrast, hybrid holoenzymes containing at least one wild-type chain in each catalytic subunit showed cooperativity. Also, hybrid enzymes containing different arrangements of five, four, three, or two wild-type catalytic chains with an appropriate complement of mutant chains had specific activities proportional to the number of wild-type chains in the holoenzymes. Exceptions were observed only in hybrids in which one of the two subunits in the holoenzyme was composed completely of mutant catalytic chains. For these hybrids the negative complementation was manifested as a much lower enzyme activity than expected from the number of wild-type chains in the enzyme and the loss of cooperativity. Thus, the activity and allosteric properties of these hybrids is dependent on the arrangement of catalytic chains in the holoenzyme, in contrast to results obtained for hybrids containing native and chemically modified catalytic chains. Intrasubunit hybrid catalytic trimers containing one or two wild-type chains exhibited one-third and two-thirds the activity of the intact wild-type catalytic subunit, respectively, indicating the dominant negative effect that was seen in intersubunit hybrid holoenzymes is absent within trimers.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,229 WENDELL M STANLEY HALL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,VIRUS LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley					NIGMS NIH HHS [GM 12159, GM 11067] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM012159, R01GM012159, F32GM011067] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEWELL NM, 1989, ANNU REV BIOPHYS BIO, V18, P71, DOI 10.1146/annurev.bb.18.060189.000443; BECKWITH JR, 1962, J MOL BIOL, V5, P618, DOI 10.1016/S0022-2836(62)80090-4; BETHELL MR, 1968, P NATL ACAD SCI USA, V60, P1442, DOI 10.1073/pnas.60.4.1442; BLACKBURN MN, 1977, BIOCHEMISTRY-US, V16, P5084, DOI 10.1021/bi00642a022; COLLINS KD, 1971, J BIOL CHEM, V246, P6599; COLLINS KD, 1969, J BIOL CHEM, V244, P1869; DAVIES GE, 1970, J BIOL CHEM, V245, P1175; EISENSTEIN E, 1990, BIOCHEMISTRY-US, V29, P3724, DOI 10.1021/bi00467a019; EISENSTEIN E, 1989, P NATL ACAD SCI USA, V86, P3094, DOI 10.1073/pnas.86.9.3094; EISENSTEIN E, 1989, PROTEIN FUNCTION PRA, P135; GERHART JC, 1968, BIOCHEMISTRY-US, V7, P538, DOI 10.1021/bi00842a600; GERHART JC, 1962, J BIOL CHEM, V237, P891; GIBBONS I, 1974, P NATL ACAD SCI USA, V71, P4452, DOI 10.1073/pnas.71.11.4452; GIBBONS I, 1975, P NATL ACAD SCI USA, V72, P4298, DOI 10.1073/pnas.72.11.4298; GIBBONS I, 1976, BIOCHEMISTRY-US, V15, P1324, DOI 10.1021/bi00651a024; GIBBONS I, 1976, BIOCHEMISTRY-US, V15, P52, DOI 10.1021/bi00646a009; HONZATKO RB, 1982, J MOL BIOL, V160, P219, DOI 10.1016/0022-2836(82)90175-9; HOWLETT GJ, 1977, BIOCHEMISTRY-US, V16, P5091, DOI 10.1021/bi00642a023; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; JUSTESEN J, 1975, J BACTERIOL, V123, P851, DOI 10.1128/JB.123.3.851-854.1975; KANTROWITZ ER, 1988, SCIENCE, V241, P669, DOI 10.1126/science.3041592; KANTROWITZ ER, 1990, TRENDS BIOCHEM SCI, V15, P53, DOI 10.1016/0968-0004(90)90176-C; KE HM, 1984, P NATL ACAD SCI-BIOL, V81, P4037, DOI 10.1073/pnas.81.13.4037; KRAUSE KL, 1987, J MOL BIOL, V193, P527, DOI 10.1016/0022-2836(87)90265-8; KRAUSE KL, 1985, P NATL ACAD SCI USA, V82, P1643, DOI 10.1073/pnas.82.6.1643; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NEWELL JO, 1989, J BIOL CHEM, V264, P2476; PETERSON CB, 1991, P NATL ACAD SCI USA, V88, P458, DOI 10.1073/pnas.88.2.458; ROBEY EA, 1986, P NATL ACAD SCI USA, V83, P5934, DOI 10.1073/pnas.83.16.5934; ROBEY EA, 1985, P NATL ACAD SCI USA, V82, P361, DOI 10.1073/pnas.82.2.361; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHACHMAN HK, 1988, J BIOL CHEM, V263, P18583; SUBRAMANI S, 1981, J BIOL CHEM, V256, P1255; SUBRAMANI S, 1982, J BIOL CHEM, V257, P2219; SUBRAMANI S, 1980, J BIOL CHEM, V255, P8136; SYVANEN JM, 1973, J MOL BIOL, V76, P363, DOI 10.1016/0022-2836(73)90510-X; WALL KA, 1979, J BIOL CHEM, V254, P1910; WALLKA, 1979, J BIOL CHEM, V254, P11917; WENTE SR, 1987, P NATL ACAD SCI USA, V84, P31, DOI 10.1073/pnas.84.1.31; Yang Y R, 1978, Methods Enzymol, V51, P35; YANG YR, 1987, ANAL BIOCHEM, V163, P188, DOI 10.1016/0003-2697(87)90111-4; YANG YR, 1988, ENZYME DYNAMICS REGU, P394; YOUNG TS, 1985, THESIS DUKE U	44	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22148	22155						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429567				2022-12-25	WOS:A1992JW71900027
J	FERRANTI, P; MALORNI, A; MARINO, G; PUCCI, P; GOODWIN, GH; MANFIOLETTI, G; GIANCOTTI, V				FERRANTI, P; MALORNI, A; MARINO, G; PUCCI, P; GOODWIN, GH; MANFIOLETTI, G; GIANCOTTI, V			MASS-SPECTROMETRIC ANALYSIS OF THE HMGY PROTEIN FROM LEWIS LUNG-CARCINOMA - IDENTIFICATION OF PHOSPHORYLATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOBILITY-GROUP PROTEINS; AMINO-ACID SEQUENCES; NUCLEAR PROTEINS; CDC2 KINASE; HISTONE H-1; CELLS; DNA; BINDING; FRACTIONATION; CASEIN	The primary structure of the Lewis lung carcinoma protein HMGY belonging to the nuclear group of proteins HMGI (high mobility group I) was determined using electrospray and fast atom bombardment mass spectrometry. It was demonstrated that the sequence of the tumor protein corresponds to the amino acid sequence derived from the cDNA from cultured cells and that the N-terminal serine residue is N-acetylated. Moreover, the two high performance liquid chromatography-purified forms Y1 and Y2 of the protein HMGY were shown to differ at the level of serine phosphorylation, since they contain three phosphate and two phosphate groups, respectively, in the C-terminal region. No other modification was detected in the remaining part of the molecule.	UNIV TRIESTE,DIPARTIMENTO BIOCHIM BIOFIS & CHIM MACROMOLEC,VIA A VALERIO 38,I-34127 TRIESTE,ITALY; CTR INGN GENET,NAPLES,ITALY; INST CANC RES,CHESTER BEATTY RES INST,SUTTON SM2 5PX,SURREY,ENGLAND; CNR,SERV SPETTROMETRIA MASSA,I-80131 NAPLES,ITALY	University of Trieste; University of London; Institute of Cancer Research - UK; Consiglio Nazionale delle Ricerche (CNR)			Ferranti, Pasquale/ABF-8111-2021	FERRANTI, Pasquale/0000-0002-6250-6512; PUCCI, Pietro/0000-0002-5885-1495; MANFIOLETTI, GUIDALBERTO/0000-0001-7913-2601				ELTON TS, 1987, BIOCHEM BIOPH RES CO, V143, P260, DOI 10.1016/0006-291X(87)90659-0; FASHENA JS, 1992, MOL CELL BIOL, V12, P894; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; GIANCOTTI V, 1991, EUR J BIOCHEM, V198, P211, DOI 10.1111/j.1432-1033.1991.tb16003.x; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GOODWIN GH, 1985, EUR J BIOCHEM, V149, P47, DOI 10.1111/j.1432-1033.1985.tb08891.x; ISENBERG I, 1979, ANNU REV BIOCHEM, V48, P159, DOI 10.1146/annurev.bi.48.070179.001111; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; LUND T, 1987, BIOCHEM BIOPH RES CO, V146, P725, DOI 10.1016/0006-291X(87)90589-4; LUND T, 1990, BIOCHEM BIOPH RES CO, V171, P342, DOI 10.1016/0006-291X(90)91399-D; LUND T, 1987, EUR J BIOCHEM, V166, P21, DOI 10.1111/j.1432-1033.1987.tb13477.x; LUND T, 1983, FEBS LETT, V152, P163, DOI 10.1016/0014-5793(83)80370-6; LUND T, 1985, FEBS LETT, V180, P163; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; MEIJER L, 1991, EUR J BIOCHEM, V196, P557, DOI 10.1111/j.1432-1033.1991.tb15850.x; MORRIS HR, 1983, BIOCHEM BIOPH RES CO, V117, P299, DOI 10.1016/0006-291X(83)91575-9; NAYLOR S, 1986, J AM CHEM SOC, V108, P6359, DOI 10.1021/ja00280a037; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; OHE Y, 1986, J BIOCHEM-TOKYO, V100, P359, DOI 10.1093/oxfordjournals.jbchem.a121722; OHE Y, 1989, J BIOCHEM-TOKYO, V106, P844, DOI 10.1093/oxfordjournals.jbchem.a122941; PALVIMO J, 1989, FEBS LETT, V257, P101, DOI 10.1016/0014-5793(89)81796-X; PALVIMO J, 1986, BIOCHEM BIOPH RES CO, V134, P617, DOI 10.1016/S0006-291X(86)80464-8; PETRILLI P, 1986, BIOCHEM BIOPH RES CO, V140, P28, DOI 10.1016/0006-291X(86)91053-3; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUCCI P, 1992, BIOL MASS SPECTROM, V21, P22, DOI 10.1002/bms.1200210106; REEVES R, 1987, P NATL ACAD SCI USA, V84, P6531, DOI 10.1073/pnas.84.18.6531; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; REEVES R, 1990, J BIOL CHEM, V265, P8753; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; VANFLETEREN JR, 1988, BIOCHEM J, V255, P647; VONHOLT C, 1979, FEBS LETT, V100, P201, DOI 10.1016/0014-5793(79)80337-3	35	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22486	22489						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429598				2022-12-25	WOS:A1992JW71900078
J	SUGITA, M; FUJII, H; INAGAKI, F; SUZUKI, M; HAYATA, C; HORI, T				SUGITA, M; FUJII, H; INAGAKI, F; SUZUKI, M; HAYATA, C; HORI, T			POLAR GLYCOSPHINGOLIPIDS IN ANNELIDA - A NOVEL SERIES OF GLYCOSPHINGOLIPIDS CONTAINING CHOLINE PHOSPHATE FROM THE EARTHWORM, PHERETIMA-HILGENDORFI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN-BOTTLE FLY; FRESH-WATER BIVALVE; LUCILIA-CAESAR; HYRIOPSIS-SCHLEGELII; SUGAR SEQUENCES; LARVAE; SPERMATOZOA	A novel series of glycosphingolipids containing choline phosphate has been demonstrated in whole tissues of the earthworm, Pheretima hilgendorfi. The thin layer chromatographic pattern of the total polar glycolipids revealed the presence of more than three components with positive reactions toward orcinol-sulfuric acid (sugar), molybdate (phosphate), and Dragendorff's (choline) spray reagents. Two of these polar glycolipids (PGL1 and PGL2) were purified by the use of successive column chromatography on QAE-Sephadex A-25 and silicic acid (Iatrobeads) and detected during elution by the presence of galactose-bound choline phosphate. The structural elucidation of the oligosaccharide moieties was performed by compositional sugar analysis, hydrogen fluoride degradation, proton magnetic resonance spectroscopy, fast atom bombardment mass spectrometry, and methylation analysis. Thus, the structures of PGL1 and PGL2 were deduced to be as follows: cholinephosphoryl --> 6Galbeta1-1Cer and cholinephosphoryl-->6Galbeta1-6Galbeta1-1Cer. Although the oligosaccharide structures of both PGL1 and PGL2 have previously been found in other organisms, the presence of a choline phosphate group as an oligosaccharide substituent is the first finding in nature. The main molecular species of the ceramide moieties were composed of beheninyl- and lignocerinyloctadecasphingenines and their nonadecasphingenine homologues.	TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC PHYSIOL,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT MEMBRANE BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; SHIGA JR COLL CULTURAL STUDIES,YOKAICHI,SHIGA 527,JAPAN	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science	SUGITA, M (corresponding author), SHIGA UNIV,FAC LIBERAL ARTS & EDUC,DEPT CHEM,OTSU,SHIGA 520,JAPAN.							BJORNDAL H, 1970, ANGEW CHEM, V82, P643; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; FOLCH J, 1957, J BIOL CHEM, V226, P497; HORI T, 1977, J BIOCHEM-TOKYO, V81, P107, DOI 10.1093/oxfordjournals.jbchem.a131424; HORI T, 1977, J BIOCHEM-TOKYO, V82, P1281, DOI 10.1093/oxfordjournals.jbchem.a131815; HORI T, 1983, J BIOL CHEM, V258, P2239; HORI T, 1981, J BIOL CHEM, V256, P979; ITONORI S, 1991, BIOCHIM BIOPHYS ACTA, V1081, P321, DOI 10.1016/0005-2760(91)90289-T; ITONORI S, 1991, J BIOCHEM-TOKYO, V110, P479, DOI 10.1093/oxfordjournals.jbchem.a123607; Jansson P-E., 1976, CHEM COMMUN U STOCKH, V8, P1; King EJ, 1932, BIOCHEM J, V26, P292, DOI 10.1042/bj0260292; OKAMURA N, 1985, P NATL ACAD SCI USA, V82, P6779, DOI 10.1073/pnas.82.20.6779; ROE JH, 1955, J BIOL CHEM, V212, P335; SUGITA M, 1989, J BIOL CHEM, V264, P15028; SUGITA M, 1982, J BIOCHEM-TOKYO, V92, P327, DOI 10.1093/oxfordjournals.jbchem.a133938; SUGITA M, 1982, J BIOCHEM-TOKYO, V92, P881, DOI 10.1093/oxfordjournals.jbchem.a134002; SUGITA M, 1981, J BIOCHEM-TOKYO, V90, P1529, DOI 10.1093/oxfordjournals.jbchem.a133620; SUGITA M, 1990, J BIOCHEM-TOKYO, V107, P899, DOI 10.1093/oxfordjournals.jbchem.a123145; SUGITA M, 1992, YUKAGAKU, V41, P568	19	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22595	22598						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429609				2022-12-25	WOS:A1992JW71900094
J	AFFORD, SC; PONGRACZ, J; STOCKLEY, RA; CROCKER, J; BURNETT, D				AFFORD, SC; PONGRACZ, J; STOCKLEY, RA; CROCKER, J; BURNETT, D			THE INDUCTION BY HUMAN INTERLEUKIN-6 OF APOPTOSIS IN THE PROMONOCYTIC CELL-LINE U937 AND HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; GROWTH-FACTOR; PROTEIN-SYNTHESIS; T-CELLS; DEATH; RNA; DIFFERENTIATION; BETA	Apoptosis of neutrophils at sites of inflammation in vivo is thought to lead to their recognition and safe elimination by macrophages. Little is known, however, about the regulation of apoptosis in myeloid cells. We report here that the human promonocytic leukemic cell line, U937, and mature human neutrophils can be induced to become apoptotic when cultured with interleukin-6. Apoptosis of U937 cells, assessed morphologically and by the presence of DNA fragmentation, was increased significantly in a dose-dependent fashion by concentrations of 0.5-100 ng/ml interleukin-6. Apoptosis of U937 cells was evident after 48 h of incubation with 20 ng/ml interleukin-6, and the effect was eliminated by adsorption of interleukin-6 with a specific monoclonal antibody. Apoptosis was not evident in the presence of the differentiating agent phorbol 12-myristate 13 acetate; the induction of apoptosis in U937 cells was not therefore a consequence of differentiation. Apoptosis of mature neutrophils was enhanced after 24 h in culture with interleukin-6. Interleukin-6 might be an important factor in the normal resolution of inflammation through the induction of apoptosis of neutrophils.	GEN HOSP,LUNG IMMUNOBIOCHEM RES LAB,CLIN TEACHING BLOCK,STEELHOUSE LANE,BIRMINGHAM B4 6NH,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT MED,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT IMMUNOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; E BIRMINGHAM DIST GEN HOSP,DEPT HISTOPATHOL,BIRMINGHAM B9 5ST,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham			Pongracz, Judit E/N-7927-2018; Pongracz, Judit E/J-7517-2019	Pongracz, Judit E/0000-0002-0278-5556; Pongracz, Judit E/0000-0002-0278-5556	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; ANDUS T, 1987, FEBS LETT, V221, P18, DOI 10.1016/0014-5793(87)80344-7; CASTELL JV, 1990, HEPATOLOGY, V12, P1179, DOI 10.1002/hep.1840120517; CHEN L, 1988, FEBS LETT, V239, P299, DOI 10.1016/0014-5793(88)80939-6; CONTENT J, 1982, P NATL ACAD SCI-BIOL, V79, P2768, DOI 10.1073/pnas.79.9.2768; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GRIGG JM, 1991, LANCET, V338, P720, DOI 10.1016/0140-6736(91)91443-X; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HIRANO T, 1985, P NATL ACAD SCI USA, V82, P5490, DOI 10.1073/pnas.82.16.5490; JEPSEN LV, 1982, SCAND J CLIN LAB INV, V42, P235; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SEHGAL PB, 1980, NATURE, V288, P95, DOI 10.1038/288095a0; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; TELFORD WG, 1991, CELL PROLIFERAT, V24, P447, DOI 10.1111/j.1365-2184.1991.tb01173.x; VANDAMME J, 1987, J EXP MED, V165, P914, DOI 10.1084/jem.165.3.914; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WHYTE M K B, 1992, American Review of Respiratory Disease, V145, pA278; WHYTE M K B, 1991, American Review of Respiratory Disease, V143, pA331; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	25	127	128	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21612	21616						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400472				2022-12-25	WOS:A1992JV01100056
J	DAVIS, RC; WONG, H; NIKAZY, J; WANG, K; HAN, Q; SCHOTZ, MC				DAVIS, RC; WONG, H; NIKAZY, J; WANG, K; HAN, Q; SCHOTZ, MC			CHIMERAS OF HEPATIC LIPASE AND LIPOPROTEIN-LIPASE - DOMAIN LOCALIZATION OF ENZYME-SPECIFIC PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PANCREATIC LIPASE; N-LINKED GLYCOSYLATION; MESSENGER-RNA LEVELS; TRIGLYCERIDE LIPASE; GENE FAMILY; MOLECULAR-CLONING; CDNA SEQUENCE; TRIAD FORMS; GUINEA-PIG; EXPRESSION	Chimeric molecules between human lipoprotein lipase (LPL) and rat hepatic lipase (HL) were used to identify structural elements responsible for functional differences. Based on the close sequence homology with pancreatic lipase, both LPL and HL are believed to have a two-domain structure composed of an amino-terminal (NH2-terminal) domain containing the catalytic Ser-His-Asp triad and a smaller carboxyl-terminal (COOH-terminal) domain. Experiments with chimeric lipases containing the HL NH2-terminal domain and the LPL COOH-terminal domain (HL/LPL) or the reverse chimera (LPL/HL) showed that the NH2-terminal domain is responsible for the catalytic efficiency (V(max)/K(m)) of these enzymes. Furthermore, it was demonstrated that the stimulation of LPL activity by apolipoprotein C-II and the inhibition of activity by 1 M NaCl originate in structural features within the NH2-terminal domain. HL and LPL bind to vascular endothelium, presumably by interaction with cell surface heparan sulfate proteoglycans. However, the two enzymes differ significantly in their heparin affinity. Experiments with the chimeric lipases indicated that heparin binding avidity was primarily associated with the COOH-terminal domain. Specifically, both HL and the LPL/HL chimera were eluted from immobilized heparin by 0.75 M NaCl, whereas 1.1 M NaCl was required to elute LPL and the HL/LPL chimera. Finally, HL is more active than LPL in the hydrolysis of phospholipid substrates. However, the ratio of phospholipase to neutral lipase activity in both chimeric lipases was enhanced by the presence of the heterologous COOH-terminal domain, demonstrating that this domain strongly influences substrate specificity. The NH2-terminal domain thus controls the kinetic parameters of these lipases, whereas the COOH-terminal domain modulates substrate specificity and heparin binding.	UNIV CALIF LOS ANGELES, DEPT MED, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	DAVIS, RC (corresponding author), VET ADM WADSWORTH MED CTR, DEPT LIPID RES, LOS ANGELES, CA 90073 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028481] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28481] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMEIS D, 1990, J BIOL CHEM, V265, P6552; BEG OU, 1990, P NATL ACAD SCI USA, V87, P3474, DOI 10.1073/pnas.87.9.3474; BENGTSSONOLIVECRONA G, 1986, EUR J BIOCHEM, V161, P281, DOI 10.1111/j.1432-1033.1986.tb10444.x; Borgstrom B., 1984, P151; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHAILLAN C, 1992, BIOCHEM BIOPH RES CO, V184, P206, DOI 10.1016/0006-291X(92)91179-T; CHANG SF, 1991, FEBS LETT, V289, P69, DOI 10.1016/0014-5793(91)80910-U; CHENG CF, 1985, J BIOL CHEM, V260, P720; COOPER DA, 1989, BIOCHIM BIOPHYS ACTA, V1008, P92, DOI 10.1016/0167-4781(89)90174-7; DAVIS RC, 1990, J BIOL CHEM, V265, P6291; DECARO J, 1981, BIOCHIM BIOPHYS ACTA, V671, P129, DOI 10.1016/0005-2795(81)90126-4; DEEB SS, 1989, BIOCHEMISTRY-US, V28, P4132, DOI 10.1021/bi00436a001; DEREWENDA ZS, 1991, J BIOL CHEM, V266, P23112; DOOLITTLE MH, 1987, J LIPID RES, V28, P1326; EMI M, 1990, J BIOL CHEM, V265, P5910; EMMERICH J, 1992, J BIOL CHEM, V267, P4161; ENERBACK S, 1987, GENE, V58, P1, DOI 10.1016/0378-1119(87)90023-0; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P14418; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P9481; GARFINKEL AS, 1983, J LIPID RES, V24, P775; GOERS JWF, 1987, ANAL BIOCHEM, V166, P27, DOI 10.1016/0003-2697(87)90541-0; Hayden M.R., 1991, CURRENT OPINION LIPI, V2, P104; HEERY DM, 1990, TRENDS GENET, V6, P173; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Kerfelec B, 1986, Pancreas, V1, P430, DOI 10.1097/00006676-198609000-00007; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; KOMAROMY MC, 1987, P NATL ACAD SCI USA, V84, P1526, DOI 10.1073/pnas.84.6.1526; KUCERA GL, 1988, J BIOL CHEM, V263, P1920; LALOUEL JM, 1992, CURR OPIN LIPIDOL, V3, P86; LOWE ME, 1989, J BIOL CHEM, V264, P20042; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; OKA K, 1989, ANN NY ACAD SCI, V556, P173; Olivecrona T, 1990, CURR OPIN LIPIDOL, V1, P222; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; PERSSON B, 1989, EUR J BIOCHEM, V179, P39, DOI 10.1111/j.1432-1033.1989.tb14518.x; PETERSON J, 1986, BIOCHIM BIOPHYS ACTA, V878, P65, DOI 10.1016/0005-2760(86)90344-9; ROJAS C, 1991, EUR J BIOCHEM, V197, P315, DOI 10.1111/j.1432-1033.1991.tb15913.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SEMENKOVICH CF, 1990, J BIOL CHEM, V265, P5429; SENDA M, 1987, P NATL ACAD SCI USA, V84, P4369, DOI 10.1073/pnas.84.13.4369; STAHNKE G, 1991, J LIPID RES, V32, P477; STAHNKE G, 1987, DIFFERENTIATION, V35, P45, DOI 10.1111/j.1432-0436.1987.tb00150.x; TWU JS, 1984, BIOCHIM BIOPHYS ACTA, V792, P330, DOI 10.1016/0005-2760(84)90201-7; Verger R., 1984, P83; WARREN RJ, 1991, J LIPID RES, V32, P1333; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; WONG H, 1991, P NATL ACAD SCI USA, V88, P11290, DOI 10.1073/pnas.88.24.11290	52	100	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21499	21504						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400461				2022-12-25	WOS:A1992JV01100038
J	HOLMBERG, L; MELANDER, Y; NYGARD, O				HOLMBERG, L; MELANDER, Y; NYGARD, O			RIBOSOME-BOUND EUKARYOTIC ELONGATION FACTOR-II PROTECTS 5-S RIBOSOMAL-RNA FROM MODIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICIN-A-CHAIN; ESCHERICHIA-COLI; FACTOR-II; CROSS-LINKING; BIOLOGICAL PROPERTIES; 70S RIBOSOMES; BINDING SITE; TRANSFER-RNA; FACTOR EF-2; 23S RNA	The interaction between eukaryotic elongation factor eEF-2 and reconstituted 80 S ribosomes was investigated by analyzing the accessibility of 5 S ribosomal RNA for chemical and enzymatic modification. Ribosomes reconstituted from derived subunits were modified, and the positions of the modified sites were identified by primer extension using a 5 S rRNA-specific probe. All reactive sites were located between nucleotides 38 and 99, and most of them were found in putative single-stranded regions of the 5 S rRNA. Conversion of the ribosomes to the post-translocation type of particles by treatment with the translational inhibitor ricin resulted in the exposure of 3 additional bases for chemical modification, suggesting that the 5 S rRNA was more exposed in this type of ribosome. After binding of eEF-2 in complex with the non-hydrolyzable GTP analogue guanosine 5'-(beta, gamma-methylene)-triphosphate, most of the exposed bases in the 5 S rRNA were protected against both chemical and enzymatic modification.	UNIV STOCKHOLM, ARRHENIUS LAB, DEPT ZOOL CELL BIOL, S-10691 STOCKHOLM, SWEDEN	Stockholm University								BRAWERMAN G, 1972, BIOCHEMISTRY-US, V11, P637, DOI 10.1021/bi00754a027; BRUNEL C, 1991, J MOL BIOL, V221, P293; BURMA DP, 1984, BIOCHEM BIOPH RES CO, V124, P970, DOI 10.1016/0006-291X(84)91053-2; CHRISTIANSEN J, 1990, RIBOSOMES PROTEIN SY; CONWAY TW, 1964, P NATL ACAD SCI USA, V52, P1462, DOI 10.1073/pnas.52.6.1462; CUATRECA.P, 1967, J BIOL CHEM, V242, P1541; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; ENDO Y, 1987, J BIOL CHEM, V262, P5908; ENDO Y, 1991, J MOL BIOL, V221, P193, DOI 10.1016/0022-2836(91)90814-M; FARBER NM, 1981, J MOL BIOL, V146, P241, DOI 10.1016/0022-2836(81)90434-4; GRUMMT F, 1974, EUR J BIOCHEM, V43, P343, DOI 10.1111/j.1432-1033.1974.tb03418.x; HAPKE B, 1976, J MOL BIOL, V105, P97, DOI 10.1016/0022-2836(76)90196-0; HERR W, 1979, J MOL BIOL, V130, P421, DOI 10.1016/0022-2836(79)90432-7; JOHNSON AE, 1982, J MOL BIOL, V156, P113, DOI 10.1016/0022-2836(82)90462-4; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; NILSSON L, 1984, BIOCHIM BIOPHYS ACTA, V782, P49, DOI 10.1016/0167-4781(84)90105-2; NILSSON L, 1986, EUR J BIOCHEM, V161, P111, DOI 10.1111/j.1432-1033.1986.tb10130.x; NYGARD O, 1987, BIOCHIM BIOPHYS ACTA, V908, P46, DOI 10.1016/0167-4781(87)90020-0; NYGARD O, 1987, BIOCHIM BIOPHYS ACTA, V910, P245; NYGARD O, 1990, EUR J BIOCHEM, V191, P1, DOI 10.1111/j.1432-1033.1990.tb19087.x; NYGARD O, 1989, EUR J BIOCHEM, V179, P603, DOI 10.1111/j.1432-1033.1989.tb14589.x; NYGARD O, 1990, J BIOL CHEM, V265, P6030; NYGARD O, 1982, EMBO J, V1, P357, DOI 10.1002/j.1460-2075.1982.tb01174.x; OLSNES S, 1973, BIOCHEMISTRY-US, V12, P3121, DOI 10.1021/bi00740a028; OVCHINNIKOV LP, 1978, FEBS LETT, V88, P21, DOI 10.1016/0014-5793(78)80598-5; PALEOLOGUE A, 1986, FEBS LETT, V208, P373, DOI 10.1016/0014-5793(86)81052-3; Sambrook J, 1989, MOL CLONING LABORATO; SARGE KD, 1991, BIOCHIM BIOPHYS ACTA, V1088, P57, DOI 10.1016/0167-4781(91)90153-D; SILBERKLANG M, 1983, NUCLEIC ACIDS RES, V11, P605, DOI 10.1093/nar/11.3.605; SKOLD SE, 1983, NUCLEIC ACIDS RES, V11, P4923, DOI 10.1093/nar/11.14.4923; SPIRIN AS, 1969, COLD SPRING HARB SYM, V34, P197, DOI 10.1101/SQB.1969.034.01.026; TAKAHASHI Y, 1985, EUR J BIOCHEM, V152, P279, DOI 10.1111/j.1432-1033.1985.tb09195.x; TERAO K, 1975, BIOCHIM BIOPHYS ACTA, V402, P230, DOI 10.1016/0005-2787(75)90042-8; UCHIUMI T, 1986, EUR J BIOCHEM, V156, P37, DOI 10.1111/j.1432-1033.1986.tb09545.x; VANDIGGELEN OP, 1973, EUR J BIOCHEM, V39, P511; WESTHOF E, 1989, J MOL BIOL, V207, P417, DOI 10.1016/0022-2836(89)90264-7; WOOL IG, 1984, TRENDS BIOCHEM SCI, V9, P14, DOI 10.1016/0968-0004(84)90040-9	37	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21906	21910						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400500				2022-12-25	WOS:A1992JV01100099
J	KAWAI, T; NISHIKIMI, M; OZAWA, T; YAGI, K				KAWAI, T; NISHIKIMI, M; OZAWA, T; YAGI, K			A MISSENSE MUTATION OF L-GULONO-GAMMA-LACTONE OXIDASE CAUSES THE INABILITY OF SCURVY-PRONE OSTEOGENIC DISORDER RATS TO SYNTHESIZE L-ASCORBIC-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-ANALYSIS; MESSENGER-RNAS; GENE; LIVER; PROTEINS; ENZYME	The osteogenic disorder Shionogi (ODS) rat is a mutant Wistar rat that is subject to scurvy, because it lackS L-gulono-gamma-lactone oxidase, a key enzyme in L-ascorbic acid biosynthesis. Sequencing of polymerase chain reaction-amplified cDNAs for mutant and normal rat L-gulono-gamma-lactone oxidases demonstrated that the mutant cDNA has a single base mutation from G to A at nucleotide 182, which mutation alters the 61st amino acid residue from Cys to Tyr. To test the effect of this mutation on the expression of L-gulono-gamma-lactone oxidase, we inserted a region of the cDNAs coding for normal and mutant L-gulono-gamma-lactone oxidases into an expression vector, pSVL, and transfected COS-1 cells with such vectors. The result indicated that the defined amino acid substitution does decrease both the amount of immunologically detectable protein and the level of enzyme activity to about one-tenth of their normal values, while it does not affect the amount of the mRNA produced in the transfected cells. This situation is similar to our previous observation that L-gulono-gamma-lactone oxidase is expressed in the liver of the ODS rat at a very low level irrespective of the presence of a normal amount of L-gulono-gamma-lactone oxidase-specific mRNA of a normal size (Nishikimi, M., Koshizaka, T., Kondo, K., and Yagi, K. (1989) Experientia (Basel) 45, 126-129). Thus it became clear that the Cys --> Tyr substitution is responsible for the L-gulono-gamma-lactone oxidase deficiency in the ODS rat.	INST APPL BIOCHEM,YAGI MEM PK,MITAKE,GIFU 50501,JAPAN; NAGOYA UNIV,FAC MED,DEPT BIOL CHEM,NAGOYA,AICHI 466,JAPAN	Nagoya University								BURNS JJ, 1976, METABOLIC PATHWAYS, V1, P394; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; KITO M, 1991, BIOCHEM INT, V24, P131; KOSHIZAKA T, 1989, J CLIN BIOCHEM NUTR, V7, P185; KOSHIZAKA T, 1988, J BIOL CHEM, V263, P1619; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835; Markwell M A, 1981, Methods Enzymol, V72, P296; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; MIZUSHIMA Y, 1984, EXPERIENTIA, V40, P359, DOI 10.1007/BF01952551; NISHIKIMI M, 1989, EXPERIENTIA, V45, P126, DOI 10.1007/BF01954844; NISHIKIMI M, 1988, BIOCHEM INT, V16, P615; NISHIKIMI M, 1976, ARCH BIOCHEM BIOPHYS, V175, P427, DOI 10.1016/0003-9861(76)90530-0; NISHIKIMI M, 1992, J BIOL CHEM, V267, P21967; NISHIKIMI M, 1989, BIOCHEM BIOPH RES CO, V159, P19, DOI 10.1016/0006-291X(89)92398-X; NISHIKIMI M, 1988, ARCH BIOCHEM BIOPHYS, V267, P842, DOI 10.1016/0003-9861(88)90093-8; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	23	62	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21973	21976						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400508				2022-12-25	WOS:A1992JV01100109
J	NISHIKIMI, M; KAWAI, T; YAGI, K				NISHIKIMI, M; KAWAI, T; YAGI, K			GUINEA-PIGS POSSESS A HIGHLY MUTATED GENE FOR L-GULONO-GAMMA-LACTONE OXIDASE, THE KEY ENZYME FOR L-ASCORBIC-ACID BIOSYNTHESIS MISSING IN THIS SPECIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL CONTROL; MESSENGER-RNAS; SEQUENCE; SUBSTITUTIONS; ELEMENTS; SIGNALS; REGIONS; RAT	Guinea pigs cannot synthesize L-ascorbic acid because of their deficiency in L-gulono-gamma-lactone oxidase, a key enzyme for the biosynthesis of this vitamin in higher animals. In this study we isolated the L-gulono-gamma-lactone oxidase gene of the rat and the homologue of this gene of the guinea pig by screening rat and guinea pig genomic DNA libraries in lambda phage vectors, respectively, using a rat L-gulono-gamma-lactone oxidase cDNA as a probe. Sequencing analysis showed that the amino acid sequence of the rat enzyme is encoded by 12 exons and that all the intron/exon boundaries follow the GT/AG rule. On the other hand, regions corresponding to exons I and V were not identified in the guinea pig L-gulono-gamma-lactone oxidase gene homologue. Other defects found in this gene homologue are a deletion of the nucleotide sequence corresponding to a 3' 84-base pair part of rat exon VI, a 2-base pair deletion in the remaining exon VI-related region, and nonconformance to the GT/AG rule at one of the putative intron/exon boundaries. Furthermore, a large number of mutations were found in the amino acid-coding regions of the guinea pig sequence; more than half of them lead to nonconservative amino acid changes, and there are three stop codons as well. Thus it is clear that the guinea pig homologue of the L-gulono-gamma-lactone oxidase gene exists as a pseudogene that randomly accumulated a large number of mutations without functional constraint since the gene ceased to be active during evolution. On the basis of the neutral theory of evolution, the date of the loss of L-gulono-gamma-lactone oxidase in the ancestors of the guinea pig was roughly calculated to be less than 20 million years ago.			NISHIKIMI, M (corresponding author), INST APPL BIOCHEM, YAGI MEM PK, GIFU 50501, JAPAN.							BENOIST C, 1980, NUCLEIC ACIDS RES, V8, P127, DOI 10.1093/nar/8.1.127; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BURNS JJ, 1957, NATURE, V180, P552, DOI 10.1038/180553a0; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GRAUR D, 1991, NATURE, V351, P649, DOI 10.1038/351649a0; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HAYASHIDA H, 1983, P NATL ACAD SCI-BIOL, V80, P2671, DOI 10.1073/pnas.80.9.2671; HENDRIKS W, 1987, P NATL ACAD SCI USA, V84, P5320, DOI 10.1073/pnas.84.15.5320; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JUKES T H, 1969, P21; Kimura MA, 1985, NEUTRAL THEORY MOL E; KOSHIZAKA T, 1988, J BIOL CHEM, V263, P1619; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; Maniatis T., 1982, MOL CLONING; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MIYATA T, 1980, J MOL EVOL, V16, P23, DOI 10.1007/BF01732067; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NEI M, 1986, MOL BIOL EVOL, V3, P418; NISHIKIMI M, 1976, P NATL ACAD SCI USA, V73, P2066, DOI 10.1073/pnas.73.6.2066; NISHIKIMI M, 1988, ARCH BIOCHEM BIOPHYS, V267, P842, DOI 10.1016/0003-9861(88)90093-8; RAMJI DP, 1991, NUCLEIC ACIDS RES, V19, P1139, DOI 10.1093/nar/19.5.1139; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SWIMMER C, 1985, NUCLEIC ACIDS RES, V13, P8053, DOI 10.1093/nar/13.22.8053	26	116	122	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21967	21972						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400507				2022-12-25	WOS:A1992JV01100108
J	OKADA, Y; GONOJI, Y; NAKA, K; TOMITA, K; NAKANISHI, I; IWATA, K; YAMASHITA, K; HAYAKAWA, T				OKADA, Y; GONOJI, Y; NAKA, K; TOMITA, K; NAKANISHI, I; IWATA, K; YAMASHITA, K; HAYAKAWA, T			MATRIX METALLOPROTEINASE-9 (92-KDA GELATINASE TYPE-IV COLLAGENASE) FROM HT-1080 HUMAN FIBROSARCOMA CELLS - PURIFICATION AND ACTIVATION OF THE PRECURSOR AND ENZYMATIC-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHEUMATOID SYNOVIAL FIBROBLASTS; HUMAN 72-KDA PROGELATINASE; TISSUE INHIBITOR; BASEMENT-MEMBRANE; TUMOR INVASION; CARCINOMA; STROMELYSIN; MECHANISMS; PROCOLLAGENASE; AUTOACTIVATION	Matrix metalloproteinase 9 (MMP-9) has been purified as an inactive zymogen of M(r) 92,000 (proMMP-9) from the culture medium of HT 1080 human fibrosarcoma cells. The NH2-terminal sequence of proMMP-9 is Ala-Pro-Arg-Gln-Arg-Gln-Ser-Thr-Leu-Val-Leu-Phe-Pro, which is identical to that of the 92-kDa type IV collagenase/gelatinase. The zymogen can be activated by 4-aminophenylmercuric acetate, yielding an intermediate form of M(r) 83,000 and an active species of M(r) 67,000, the second of which has a new NH2 terminus of Met-Arg-Thr-Pro-Arg-(Cys)-Gly-Val-Pro-Asp-Leu-Gly-Arg-Phe-Gln-Thr-Phe-Glu. Immunoblot analyses demonstrate that this activation process is achieved by sequential processing of both NH2- and COOH-terminal peptides. TIMP-1 complexed with proMMP-9 inhibits the conversion of the intermediate form to the active species of M(r) 67,000. The proenzyme is fully activated by cathepsin G, trypsin, alpha-chymotrypsin, and MMP-3 (stromelysin 1) but not by plasmin, leukocyte elastase, plasma kallikrein, thrombin, or MMP-1 (tissue collagenase). During the activation by MMP-3, proMMP-9 is converted to an active species of M(r) 64,000 that lacks both NH2- and COOH-terminal peptides. In addition, HOCl partially activates the zymogen by reacting with an intermediate species of M(r) 83,000. The enzyme degrades type I gelatin rapidly and also cleaves native collagens including alpha2 chain of type I collagen, collagen types III, IV, and V at undenaturing temperatures. These results indicate that MMP-9 has different activation mechanisms and substrate specificity from those of MMP-2 (72-kDa gelatinase/type IV collagenase).	KANAZAWA UNIV, SCH MED, DEPT ORTHOPED SURG, KANAZAWA, ISHIKAWA 920, JAPAN; FUJI CHEM IND CO LTD, TAKAOKA 933, JAPAN; AICHI GAKUIN UNIV, SCH DENT, DEPT BIOCHEM, NAGOYA 464, JAPAN	Kanazawa University; Aichi Gakuin University	OKADA, Y (corresponding author), KANAZAWA UNIV, SCH MED, DEPT PATHOL, 13-1 TAKARA MACHI, KANAZAWA, ISHIKAWA 920, JAPAN.		Okada, Yasunori/B-5550-2014	Okada, Yasunori/0000-0001-9208-4755				BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; BERNHARD EJ, 1990, CANCER RES, V50, P3872; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; CHEN JM, 1991, J BIOL CHEM, V266, P5113; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; DAVIS GE, 1990, CANCER RES, V50, P1113; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; DOCHERTY AJP, 1990, ANN RHEUM DIS, P469; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HARRIS ED, 1972, BIOCHIM BIOPHYS ACTA, V258, P566, DOI 10.1016/0005-2744(72)90249-5; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KODAMA S, 1990, J IMMUNOL METHODS, V127, P103, DOI 10.1016/0022-1759(90)90345-V; KODAMA S, 1987, COLLAGEN REL RES, V7, P341; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; LYONS JG, 1991, BIOCHEMISTRY-US, V30, P1449, DOI 10.1021/bi00220a001; MACKAY AR, 1990, J BIOL CHEM, V265, P21929; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MINAMOTO T, 1988, HUM PATHOL, V19, P815, DOI 10.1016/S0046-8177(88)80265-X; MIYAZAKI K, 1990, CANCER RES, V50, P7758; MOLL UM, 1990, CANCER RES, V50, P6162; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; Nagase H, 1992, Matrix Suppl, V1, P421; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; NAGASE H, 1980, ANAL BIOCHEM, V107, P385, DOI 10.1016/0003-2697(80)90400-5; ODERMATT E, 1983, BIOCHEM J, V211, P295, DOI 10.1042/bj2110295; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OKADA Y, 1988, BIOCHEM J, V254, P731, DOI 10.1042/bj2540731; OKADA Y, 1990, BIOCHEM BIOPH RES CO, V171, P610, DOI 10.1016/0006-291X(90)91190-4; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OKADA Y, 1986, J BIOL CHEM, V261, P14245; OKADA Y, 1989, FEBS LETT, V244, P473, DOI 10.1016/0014-5793(89)80586-1; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; PEPPIN GJ, 1986, P NATL ACAD SCI USA, V83, P4322, DOI 10.1073/pnas.83.12.4322; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; REICH R, 1988, CANCER RES, V48, P3307; Ruoslahti E, 1978, Ann N Y Acad Sci, V312, P178, DOI 10.1111/j.1749-6632.1978.tb16802.x; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SHAH SV, 1987, J CLIN INVEST, V79, P25, DOI 10.1172/JCI112790; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; STETLERSTEVENSON WG, 1990, CANCER METAST REV, V9, P289, DOI 10.1007/BF00049520; STRICKLIN GP, 1992, MATRIX METALLOPROTEI, P325; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YAMAGATA S, 1988, BIOCHEM BIOPH RES CO, V151, P158, DOI 10.1016/0006-291X(88)90573-6; YAMAGATA S, 1989, BIOCHEM BIOPH RES CO, V158, P228, DOI 10.1016/S0006-291X(89)80202-5; YURCHENCO PD, 1984, BIOCHEMISTRY-US, V23, P1839, DOI 10.1021/bi00303a040	54	501	512	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21712	21719						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400481				2022-12-25	WOS:A1992JV01100071
J	CYR, DM; LU, XY; DOUGLAS, MG				CYR, DM; LU, XY; DOUGLAS, MG			REGULATION OF HSP70 FUNCTION BY A EUKARYOTIC DNAJ HOMOLOG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; STRESS PROTEINS; BINDING; YEAST; NUCLEOTIDES; TRANSLOCATION	We report that a purified cytoplasmic Hsp70 homolog from saccharomyces cerevisiae, HSp70SSA1, exhibits a weak ATPase activity, which is stimulated by a purified eukaryotic dnaJp homolog (YDJ1p). Stable complex formation between Hsp70SSA1 and the permanently unfolded protein carboxymethylated alpha-lactalbumin (CMLA) was assayed by native gel electrophoresis. The affinity of Hsp70SSA1 for CMLA appeared to be regulated by YDJ1p. Significant reduction in both CMLA-Hsp70SSA1 Complex formation and the release of CMLA pre-bound to Hsp70SSA1 was observed only in the presence of both YDJ1p and ATP. Thus, Hsp70SSA1 and YDJ1p interact functionally in the execution of Hsp70SSA1 chaperone activities in the eukaryotic cell.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine				Cyr, Douglas/0000-0002-4928-3414	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036537] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36537] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANG D, 1991, J BIOL CHEM, V266, P24233; ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; BLUMBERG H, 1991, NATURE, V349, P327; BORK P, 1992, TRENDS BIOCHEM SCI, V17, P29; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; CYR DM, 1991, J BIOL CHEM, V266, P21700; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; GAO BC, 1991, J BIOL CHEM, V266, P19565; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P1912; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIEBEREK K, 1991, J BIOL CHEM, V266, P14491; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SHOLOMAI J, 1980, J BIOL CHEM, V255, P6789; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0	28	236	240	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20927	20931						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400408				2022-12-25	WOS:A1992JT97800066
J	DELAIRE, M; LABIA, R; SAMAMA, JP; MASSON, JM				DELAIRE, M; LABIA, R; SAMAMA, JP; MASSON, JM			SITE-DIRECTED MUTAGENESIS AT THE ACTIVE-SITE OF ESCHERICHIA-COLI TEM-1 BETA-LACTAMASE - SUICIDE INHIBITOR-RESISTANT MUTANTS REVEAL THE ROLE OF ARGININE-244 AND METHIONINE-69 IN CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-ALBUS-G; BACILLUS-LICHENIFORMIS 749/C; PENICILLANIC ACID SULFONE; CLAVULANIC ACID; CRYSTAL-STRUCTURE; INACTIVATION; RESOLUTION; MECHANISM; SUBSTRATE; ENZYMES	Arginine 244 is a highly conserved residue in Class A beta-lactamases, while methionine 69 is not. Informational suppression experiments show that replacement of M69 by a leucine, or that of R244 by most other amino acids lead to clavulanic acid-resistant phenotypes. The arginyl 244 side chain is tightly held in a network of interactions within the active site. Its replacement by a glutamine or a threonine perturbs the enzyme kinetics but to a smaller extent than would have been predicted if it were directly involved in substrate binding. Clavulanic acid and sulbactam still interact specifically with the mutant enzymes but are much less efficiently metabolized. Substitutions at position 244 also unveil interactions between the C6 substituent of substrates and the Asn132/Glu104 region of the active site. Methionine 69 is located in a region of strong structural constraints and presents an unusual conformation. Molecular dynamics simulation showed that its replacement by a leucine does not release the strain in this area and induces only minor structural changes. Accordingly, the kinetic behavior of the mutant is only marginally perturbed, except for suicide inhibitors. Both clavulanic acid and sulbactam are well degraded by the mutant enzyme, while irreversible inactivation is dramatically decreased. The contribution of both residues to catalysis is discussed in the light of the kinetic and structural data.	CNRS,INST NATL SCI APPLIQUEES,205 ROUTE NARBONNE,F-31077 TOULOUSE,FRANCE; CNRS,DEPT BIOL STRUCT & INGN PROT,PHARMACOL & TOXICOL FONDAMENTALES LAB,F-31077 TOULOUSE,FRANCE; MUSEUM NATL HIST NAT,CNRS,URA 401,F-75231 PARIS 05,FRANCE; CNRS,INST BIOL MOLEC & CELLULAIRE,CRISTALLOG BIOL LAB,F-67084 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite de Toulouse; Institut National des Sciences Appliquees de Toulouse; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; BELAAOUAJ A, 1991, 31ST INT C ANT AG CH, P256; BLANCHINROLAND S, 1989, PROTEIN ENG, V2, P473, DOI 10.1093/protein/2.6.473; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER DG, 1981, BIOCHEMISTRY-US, V20, P3680, DOI 10.1021/bi00516a003; BRENNER DG, 1984, BIOCHEMISTRY-US, V23, P5833, DOI 10.1021/bi00319a024; CARTWRIGHT SJ, 1983, MED RES REV, V3, P341, DOI 10.1002/med.2610030402; CHARNAS RL, 1981, BIOCHEMISTRY-US, V20, P3214, DOI 10.1021/bi00514a035; CHARNAS RL, 1978, BIOCHEMISTRY-US, V17, P2185, DOI 10.1021/bi00604a025; COLLATZ E, 1990, MOL MICROBIOL, V4, P1615, DOI 10.1111/j.1365-2958.1990.tb00537.x; DELAIRE M, 1991, PROTEIN ENG, V4, P805, DOI 10.1093/protein/4.7.805; DIDEBERG O, 1987, BIOCHEM J, V245, P911, DOI 10.1042/bj2450911; FISHER J, 1978, BIOCHEMISTRY-US, V17, P2180, DOI 10.1021/bi00604a024; FRERE JM, 1982, BIOCHEM J, V207, P429, DOI 10.1042/bj2070429; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HERZBERG O, 1991, J MOL BIOL, V217, P701, DOI 10.1016/0022-2836(91)90527-D; JACOBDUBUISSON F, 1991, PROTEIN ENG, V4, P811, DOI 10.1093/protein/4.7.811; JELSCH C, 1992, FEBS LETT, V299, P135, DOI 10.1016/0014-5793(92)80232-6; JORIS B, 1988, BIOCHEM J, V250, P313, DOI 10.1042/bj2500313; KNOWLES JR, 1985, ACCOUNTS CHEM RES, V18, P97, DOI 10.1021/ar00112a001; KNOX JR, 1991, J MOL BIOL, V220, P435, DOI 10.1016/0022-2836(91)90023-Y; LABIA R, 1973, FEBS LETT, V33, P42, DOI 10.1016/0014-5793(73)80154-1; LABIA R, 1979, ANN INST PASTEUR MIC, VB130, P295; LAMOTTEBRASSEUR J, 1991, BIOCHEM J, V279, P213, DOI 10.1042/bj2790213; LENFANT F, 1991, J BIOL CHEM, V266, P17187; LENFANT F, 1990, BIOCHIMIE, V72, P495, DOI 10.1016/0300-9084(90)90073-P; MANAVATHU EK, 1991, 31ST INT C ANT AG CH, P101; Maniatis T., 1982, MOL CLONING; MOEWS PC, 1990, PROTEINS, V7, P156, DOI 10.1002/prot.340070205; NORMANLY J, 1986, P NATL ACAD SCI USA, V83, P6548, DOI 10.1073/pnas.83.17.6548; OCALLAGHAN CH, 1972, ANTIMICROB AGENTS CH, V1, P283, DOI 10.1128/AAC.1.4.283; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764	34	85	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20600	20606						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400382				2022-12-25	WOS:A1992JT97800018
J	DELL, KR; WILLIAMS, LT				DELL, KR; WILLIAMS, LT			A NOVEL FORM OF FIBROBLAST GROWTH-FACTOR RECEPTOR-2 - ALTERNATIVE SPLICING OF THE 3RD IMMUNOGLOBULIN-LIKE DOMAIN CONFERS LIGAND-BINDING SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; EXPRESSION; FAMILY; MEMBER; GENE; IDENTIFICATION; PURIFICATION; MESODERM; CLONING; DIFFERENTIATION	The fibroblast growth factor receptor 2 (FGFR2) gene is expressed as alternatively spliced mRNAs that encode bacterially expressed kinase, the keratinocyte growth factor receptor, or K-sam. We have now isolated a novel FGFR2 cDNA that is identical with the previously cloned human bacterially expressed kinase, except in the third immunoglobulin-like domain. The ligand binding properties of FGFR2 were studied by expressing the protein in rat L6 muscle myoblasts. Unlike human bacterially expressed kinase which binds acidic and basic FGF with similar affinities, FGFR2 bound acidic FGF with approximately 1000-fold higher affinity than basic FGF. These results indicate that alternative splicing of the FGFR2 gene in the region encoding the carboxyl-terminal half of the third immunoglobulin domain determines the ligand specificity of this group of receptors.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043821] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL43821] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVIVI A, 1991, ONCOGENE, V6, P1089; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOSPODAROWICZ D, 1986, CELL DIFFER DEV, V19, P1, DOI 10.1016/0045-6039(86)90021-7; GOSPODAROWICZ D, 1974, NATURE, V249, P123, DOI 10.1038/249123a0; GOSPODAROWICZ D, 1975, J BIOL CHEM, V250, P2515; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MARICS I, 1989, ONCOGENE, V4, P335; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUTA M, 1988, ONCOGENE, V3, P9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; THOMAS KA, 1987, FASEB J, V1, P434, DOI 10.1096/fasebj.1.6.3315806; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	31	97	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21225	21229						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400433				2022-12-25	WOS:A1992JT97800110
J	ZHANG, GH; MELVIN, JE				ZHANG, GH; MELVIN, JE			SECRETAGOGUE-INDUCED MOBILIZATION OF AN INTRACELLULAR MG2+ POOL IN RAT SUBLINGUAL MUCOUS ACINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; CYTOSOLIC FREE MAGNESIUM; PAROTID ACINI; INOSITOL TRISPHOSPHATE; FLUORESCENT INDICATOR; CALCIUM RELEASE; CA-2+ RELEASE; TRANSPORT; MG-2+; CL	The regulation of the intracellular free Mg2+ concentration ([Mg2+]i) was monitored in rat sublingual mucous acini using dual wavelength microfluorometry of the Mg2+-sensitive dye mag-fura-2. Acini attached to coverslips and superfused continuously with a Mg2+-containing medium (0.8 mM) have a steady-state [Mg2+]i of 0.35 +/- 0.01 mM. Adjusting the extra-cellular Mg2+ concentration to 0 and 10 mM or removing extracellular Na+ did not alter the resting [Mg2+]i. Stimulation with the Ca 2+-mobilizing, muscarinic agonist, carbachol, induced a sustained increase in [Mg2+]i (approximately 50%; t1/2 < 20 s; K(d) approximately 1.5 muM), the magnitude and the duration of which were unchanged in Mg2+-depleted medium indicating that the rise in [Mg2+]i was generated by Mg2+ release from an intracellular Mg2+ pool. Forskolin, which increases the intracellular cAMP content, produced a small, transient increase in the [Mg2+]i (<10%). Muscarinic stimulation in a Ca2+-free medium blunted the initial increase in [Mg2+]i by approximately 50%, whereas the sustained increase in [Mg2+]i was lost. When the muscarinic-induced increase in [Ca2+]i, was blocked by 8-(diethylamino)octyl 3,4,5-trimethoxybenzoate, an inhibitor of the agonist-sensitive intracellular Ca2+ release pathway, both the initial and the sustained phases of the increase in [Mg2+]i were virtually eliminated. Thapsigargin and 2,5-di-(terbutyl)-1,4-benzohydroquinone, which increase [Ca2+]i by inhibiting microsomal Ca2+-ATPase, caused a dramatic increase in [Mg2+]i. Stimulation in a Na+-free medium or in the presence of bumetanide, an inhibitor of Na+/K+/2Cl-cotransport blunted the agonist-induced rise in [Mg2+]i (approximately 50%), whereas ouabain, a Na+,K+-ATPase inhibitor, had no significant effect. FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone), a mitochondrial uncoupler, mobilized an intracellular Mg2+ pool as well. The carbachol-induced increase in [Mg2+]i was markedly inhibited by FCCP (approximately 80%), suggesting that the same pool(s) of Mg2+ were primarily involved. The above results provide strong evidence that Ca2+-mobilizing agonists increase cytoplasmic free [Mg2+] by releasing an intracellular pool of Mg2+ that is associated with a rise in the [Na+]i.	UNIV ROCHESTER,DEPT DENT RES,601 ELMWOOD AVE,BOX 611,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT NEUROBIOL & ANAT,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NIDCR NIH HHS [P50 DE07003, R01 DE08921] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE008921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE007003] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AMBUDKAR IS, 1988, PFLUG ARCH EUR J PHY, V412, P75, DOI 10.1007/BF00583733; BAUM BJ, 1987, J DENT RES, V66, P628, DOI 10.1177/00220345870660S204; BURI A, 1990, EXP PHYSIOL, V75, P751, DOI 10.1113/expphysiol.1990.sp003457; Cittadini A, 1991, Magnes Res, V4, P23; COOK DI, 1988, PFLUG ARCH EUR J PHY, V413, P67, DOI 10.1007/BF00581230; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; DAI LJ, 1991, J CLIN INVEST, V88, P1255, DOI 10.1172/JCI115429; DELPIRE E, 1991, J PHYSIOL-LONDON, V441, P219, DOI 10.1113/jphysiol.1991.sp018747; DISSING S, 1990, AM J PHYSIOL, V259, pG1044, DOI 10.1152/ajpgi.1990.259.6.G1044; FERAY JC, 1986, BIOCHIM BIOPHYS ACTA, V856, P76, DOI 10.1016/0005-2736(86)90012-X; FLATMAN PW, 1988, J PHYSIOL-LONDON, V397, P471, DOI 10.1113/jphysiol.1988.sp017013; FLATMAN PW, 1991, ANNU REV PHYSIOL, V53, P259, DOI 10.1146/annurev.ph.53.030191.001355; FRENKEL EJ, 1989, J PHYSIOL-LONDON, V414, P385, DOI 10.1113/jphysiol.1989.sp017694; FUJISE H, 1988, J PHYSIOL-LONDON, V405, P605, DOI 10.1113/jphysiol.1988.sp017351; GRUBBS RD, 1991, AM J PHYSIOL, V260, pC1158, DOI 10.1152/ajpcell.1991.260.6.C1158; GRUBBS RD, 1984, J BIOL CHEM, V259, P2184; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUILLEMETTE G, 1991, CELL CALCIUM, V12, P51, DOI 10.1016/0143-4160(91)90084-R; GYLFE E, 1990, BIOCHIM BIOPHYS ACTA, V1055, P82, DOI 10.1016/0167-4889(90)90094-T; HORN VJ, 1988, J BIOL CHEM, V263, P12454; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; ISHIJIMA S, 1991, AM J PHYSIOL, V261, pC1074, DOI 10.1152/ajpcell.1991.261.6.C1074; IWATSUKI N, 1985, JPN J PHYSIOL, V35, P933, DOI 10.2170/jjphysiol.35.933; LANDIS CA, 1979, J PHYSIOL-LONDON, V297, P369, DOI 10.1113/jphysiol.1979.sp013045; LENNARD R, 1991, J PHYSIOL-LONDON, V435, P483, DOI 10.1113/jphysiol.1991.sp018520; MANGANEL M, 1989, J MEMBRANE BIOL, V111, P191, DOI 10.1007/BF01871782; MARUYAMA Y, 1983, NATURE, V302, P827, DOI 10.1038/302827a0; MATSUKAWA R, 1990, ARCH BIOCHEM BIOPHYS, V280, P362, DOI 10.1016/0003-9861(90)90343-W; MCMILLIAN MK, 1987, BIOCHEM BIOPH RES CO, V148, P1017, DOI 10.1016/S0006-291X(87)80233-4; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MELVIN JE, 1991, AM J PHYSIOL, V261, pG1043, DOI 10.1152/ajpgi.1991.261.6.G1043; MELVIN JE, 1991, MECH AGEING DEV, V61, P33, DOI 10.1016/0047-6374(91)90005-K; MERTZ LM, 1992, J MEMBRANE BIOL, V126, P183; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; MURPHY E, 1989, P NATL ACAD SCI USA, V86, P2981, DOI 10.1073/pnas.86.8.2981; NAKAYAMA S, 1991, J PHYSIOL-LONDON, V435, P559, DOI 10.1113/jphysiol.1991.sp018525; NAUNTOFTE B, 1988, AM J PHYSIOL, V255, pC508, DOI 10.1152/ajpcell.1988.255.4.C508; NAUNTOFTE B, 1986, AM J PHYSIOL, V251, pC175, DOI 10.1152/ajpcell.1986.251.2.C175; PETERSEN OH, 1988, ANNU REV PHYSIOL, V50, P65; PUTNEY JW, 1976, J PHARMACOL EXP THER, V198, P375; RAJU B, 1989, AM J PHYSIOL, V256, pC540, DOI 10.1152/ajpcell.1989.256.3.C540; ROMANI A, 1991, J BIOL CHEM, V266, P24376; RUTTER GA, 1990, BIOCHEM J, V271, P627, DOI 10.1042/bj2710627; SCHACHTER M, 1990, BIOCHIM BIOPHYS ACTA, V1035, P378, DOI 10.1016/0304-4165(90)90103-4; SOLTOFF SP, 1989, J GEN PHYSIOL, V93, P285, DOI 10.1085/jgp.93.2.285; SQUIRE LG, 1987, BIOCHIM BIOPHYS ACTA, V899, P171, DOI 10.1016/0005-2736(87)90397-X; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; TURNER RJ, 1986, J MEMBRANE BIOL, V94, P143, DOI 10.1007/BF01871194; TURNER RJ, 1992, BIOL SALIVARY GLANDS, P105; VOLPE P, 1990, AM J PHYSIOL, V258, pC1077, DOI 10.1152/ajpcell.1990.258.6.C1077; ZHANG GH, 1992, IN PRESS AM J PHYSL; [No title captured]	52	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20721	20727						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383208				2022-12-25	WOS:A1992JT97800034
J	KAO, J; RYAN, J; BRETT, G; CHEN, JX; SHEN, H; FAN, YG; GODMAN, G; FAMILLETTI, PC; WANG, F; PAN, YCE; STERN, D; CLAUSS, M				KAO, J; RYAN, J; BRETT, G; CHEN, JX; SHEN, H; FAN, YG; GODMAN, G; FAMILLETTI, PC; WANG, F; PAN, YCE; STERN, D; CLAUSS, M			ENDOTHELIAL MONOCYTE-ACTIVATING POLYPEPTIDE-II - A NOVEL TUMOR-DERIVED POLYPEPTIDE THAT ACTIVATES HOST-RESPONSE MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR-PERMEABILITY FACTOR; NECROSIS FACTOR-ALPHA; PROCOAGULANT ACTIVITY; TISSUE FACTOR; VONWILLEBRAND-FACTOR; MURINE TUMORS; CELLS SECRETE; GROWTH-FACTOR; INTERLEUKIN-1; EXPRESSION	An important means by which tumor cells influence the vasculature is through the production of soluble mediators altering vascular properties. A almost-equal-to 22-kDa polypeptide was purified to homogeneity from conditioned medium of murine methylcholanthrene A (meth A) fibrosarcoma cells by ion-exchange chromatography and preparative sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), based on its ability to induce tissue factor procoagulant activity in endothelial cells (ECs). The final product migrated as a broad band on reduced and nonreduced SDS-PAGE and had an unique amino-terminal sequence. This meth A-derived polypeptide modulated EC coagulant properties through the induction of tissue factor, induced monocyte migration and tissue factor expression, and was also chemotactic for granulocytes. Injection of the polypeptide into mouse footpads resulted in an inflammatory response with tissue swelling and polymorphonuclear leukocyte infiltration. The ability of this mediator to activate ECs and monocytes has led us to name it EMAP II (endothelial monocyte-activating polypeptide). EMAP II is distinct from a previously described almost-equal-to 40-kDa meth A-derived polypeptide termed EMAP I. Through its potential to activate host effector mechanisms, EMAP II could contribute to the biology of immunogenic tumors, such as the meth A fibrosarcoma.	HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT PROT BIOCHEM,NUTLEY,NJ 07110; HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT BIOPROC DEV,NUTLEY,NJ 07110	Roche Holding; Roche Holding	KAO, J (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL,PES 11-518,630 W 168TH ST,NEW YORK,NY 10032, USA.			Clauss, Matthias/0000-0001-5180-3899	NHLBI NIH HHS [HL42833, HL42507, HL21006] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042507, P50HL021006, R01HL042833] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON PJ, 1985, ANAL BIOCHEM, V148, P105, DOI 10.1016/0003-2697(85)90634-7; ASHER A, 1987, J IMMUNOL, V138, P963; BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAUS SM, 1991, BLOOD, V78, P376; CLAUSS M, 1990, J BIOL CHEM, V265, P7078; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; CONWAY EM, 1989, THROMB RES, V53, P231, DOI 10.1016/0049-3848(89)90098-4; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DVORAK HF, 1979, JNCI-J NATL CANCER I, V62, P1459; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; FAMILLETTI PC, 1988, BIO-TECHNOL, V6, P41, DOI 10.1038/nbt0188-41; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; GRANSTEIN RD, 1986, J CLIN INVEST, V77, P1020, DOI 10.1172/JCI112354; HARANAKA K, 1984, INT J CANCER, V34, P263, DOI 10.1002/ijc.2910340219; HUMPHREYS M, 1989, J IMMUNOL METHODS, V120, P271; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KARPATI RM, 1991, J IMMUNOL, V146, P2043; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCARROLL DR, 1985, J CLIN INVEST, V75, P1089, DOI 10.1172/JCI111802; MURRAY JC, 1989, BRIT J CANCER, V60, P729, DOI 10.1038/bjc.1989.348; NAWROTH P, 1988, J EXP MED, V168, P6637; NAWROTH P, 1986, J EXP MED, V164, P740; NAWROTH PP, 1986, P NATL ACAD SCI USA, V83, P3460, DOI 10.1073/pnas.83.10.3460; OLD L, 1961, CANCER RES, V1, P1281; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; PALLADINO MA, 1987, J IMMUNOL, V138, P4023; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; QUINTANA A, 1983, EUR J CANCER CLIN ON, V19, P1031, DOI 10.1016/0277-5379(83)90073-1; RUFF MR, 1980, J IMMUNOL, V125, P1671; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; WEBB DSA, 1991, J IMMUNOL, V146, P3682	46	161	181	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20239	20247						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400342				2022-12-25	WOS:A1992JR85800078
J	MARSTON, SB; REDWOOD, CS				MARSTON, SB; REDWOOD, CS			INHIBITION OF ACTIN-TROPOMYOSIN ACTIVATION OF MYOSIN MGATPASE ACTIVITY BY THE SMOOTH-MUSCLE REGULATORY PROTEIN CALDESMON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATIVE THIN-FILAMENTS; HEAVY-MEROMYOSIN; ATPASE ACTIVITY; SKELETAL-MUSCLE; CA-2+ REGULATION; F-ACTIN; BINDING; CALMODULIN; ACTOMYOSIN; MECHANISM	Caldesmon inhibition of actin-tropomyosin activation of myosin MgATPase activity was investigated. >90% inhibition of ATPase activation correlated with 0.035-0.1 caldesmon bound per actin monomer over a wide range of conditions. Caldesmon inhibited sheep aorta actin-tropomyosin activation of skeletal muscle heavy meromyosin (HMM) by 85%, but had no effect on the binding affinity of HMM . ADP . P(i) to actin. At ratios of 2 and 0.12 subfragment 1 (S1):1 actin, addition of caldesmon inhibited the ATPase activation by up to 95%, but did not alter the fraction of S1 . ADP . P(i) associated with actin-tropomyosin. We concluded that caldesmon inhibited actomyosin ATPase by slowing the rate-limiting step of the activation pathway. At concentrations comparable to the ATPase measurements, S1 displaced caldesmon from native thin filaments both in the absence (rigor) and the presence of MgATP. We therefore concluded that caldesmon could displace S1 . ADP . P(i) from actin-tropomyosin only under exceptional circumstances. An expressed mutant of caldesmon comprising just the C-terminal 99 amino acids bound actin 10 times weaker than whole caldesmon but otherwise inhibited actin-tropomyosin activation with the same potency and same mechanism as intact caldesmon. Thus, the entire inhibitory function of caldesmon resides in its extreme C terminus.			MARSTON, SB (corresponding author), NATL HEART & LUNG INST, DEPT CARDIAC MED, LONDON SW3 6LY, ENGLAND.			Marston, Steven/0000-0001-6054-6070	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARTEGI A, 1990, J BIOL CHEM, V265, P2231; BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BREMEL RD, 1973, COLD SPRING HARB SYM, V37, P267, DOI 10.1101/SQB.1973.037.01.037; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CHALOVICH JM, 1987, J BIOL CHEM, V262, P5711; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; CHALOVICH JM, 1988, CELL BIOPHYS, V12, P73, DOI 10.1007/BF02918351; CHALOVICH JM, 1991, J MUSCLE RES CELL M, V12, P503, DOI 10.1007/BF01738438; CHALOVICH JM, 1990, ANN NY ACAD SCI, V599, P85; DABROWSKA R, 1985, BIOCHIM BIOPHYS ACTA, V842, P70, DOI 10.1016/0304-4165(85)90295-8; GEEVES MA, 1984, J MUSCLE RES CELL M, V5, P351, DOI 10.1007/BF00818255; HAEBERLE J R, 1991, Biophysical Journal, V59, p58A; HAI CM, 1989, ANNU REV PHYSIOL, V51, P285, DOI 10.1146/annurev.physiol.51.1.285; HORIUCHI KY, 1991, BIOCHEMISTRY-US, V30, P712, DOI 10.1021/bi00217a019; IKEBE M, 1988, J BIOL CHEM, V263, P3055; LASH JA, 1986, J BIOL CHEM, V261, P6155; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MARSTON S, 1990, BIOCHEM J, V272, P305, DOI 10.1042/bj2720305; MARSTON S, 1992, J MUSCLE RES CELL M, V13, P206, DOI 10.1007/BF01874158; MARSTON S, 1988, FEBS LETT, V238, P147, DOI 10.1016/0014-5793(88)80245-X; MARSTON S, 1975, BIOCHEMISTRY-US, V14, P3868, DOI 10.1021/bi00688a021; MARSTON SB, 1982, BIOCHEM J, V203, P453, DOI 10.1042/bj2030453; MARSTON SB, 1984, J MUSCLE RES CELL M, V5, P559, DOI 10.1007/BF00713261; MARSTON SB, 1983, PROG BIOPHYS MOL BIO, V41, P1, DOI 10.1016/0079-6107(83)90024-X; MARSTON SB, 1985, J MUSCLE RES CELL M, V6, P669, DOI 10.1007/BF00712237; MARSTON SB, 1988, BIOCHEM BIOPH RES CO, V155, P197, DOI 10.1016/S0006-291X(88)81068-4; MARSTON SB, 1991, BIOCHEM J, V279, P1; MARSTON SB, 1989, BIOCHEM J, V259, P303, DOI 10.1042/bj2590303; MARSTON SB, 1980, BIOCHEM J, V185, P355, DOI 10.1042/bj1850355; MARSTON SB, 1991, MUSCLE MOTILITY, V2, P351; MURPHY RA, 1979, ANNU REV PHYSIOL, V41, P737, DOI 10.1146/annurev.ph.41.030179.003513; PRITCHARD K, 1989, BIOCHEM J, V257, P839, DOI 10.1042/bj2570839; REDWOOD CS, 1990, FEBS LETT, V270, P53, DOI 10.1016/0014-5793(90)81233-E; REDWOOD CS, 1992, J MUSCLE RES CELL M, V13, P251; REDWOOD CS, 1992, THESIS LONDON U; SELLERS JR, 1982, J BIOL CHEM, V257, P3880; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SOBUE K, 1982, BIOMED RES-TOKYO, V3, P188, DOI 10.2220/biomedres.3.188; Straub FB, 1942, STUD I MED CHEM U SZ, V2, P3; TAGGART MJ, 1988, FEBS LETT, V242, P171, DOI 10.1016/0014-5793(88)81009-3; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; VELAZ L, 1990, J BIOL CHEM, V265, P2929	42	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16796	16800						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1387396				2022-12-25	WOS:A1992JL05300012
J	PAK, Y; HUANG, LC; LILLEY, KJ; LARNER, J				PAK, Y; HUANG, LC; LILLEY, KJ; LARNER, J			INVIVO CONVERSION OF [H-3] MYOINOSITOL TO [H-3] CHIROINOSITOL IN RAT-TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-DEHYDROGENASE COMPLEX; COVALENTLY BOUND INOSITOL; INSULIN MEDIATORS; TORPEDO ACETYLCHOLINESTERASE; IDENTIFICATION; PURIFICATION; MYOINOSITOL; MECHANISM; KIDNEY; LIVER	We report here the in vivo conversion of [H-3]myoinositol to [H-3]chiroinositol. After labeling intraperitoneally with [H-3]myoinositol for 3 days to reach radioisotope equilibrium in urine, [H-3]chiroinositol was isolated from tissues and purified after 6 N HCl hydrolysis by two sequential paper chromatographies and high performance liquid chromatography (HPLC). Percent conversion of [H-3]myoinositol to [H-3]chiroinositol was highest in urine (36%), liver (8.8%), muscle (8.8%), and blood (7.6%) with intestine, brain, kidney, spleen, and heart decreasing in percentage from 2.8 to 0.7%. Labeling of other inositol isomers including scyllo-, neo-, and epi-, and mucoinositol was minimal, approximately 0.06% of [H-3]myoinositol. Glucose was unlabeled, but glucuronate, the product of myoinositol oxidation, was labeled up to 1.5% of the [H-3] myoinositol. Acid hydrolysates of combined inositol-containing phospholipids contain significant labeled chiroinositol. [H-3]Phosphatidylinositols and [H-3]glycosylphosphatidylinositols were extracted from liver, muscle, and blood, isolated by thin layer chromatography, and inositols purified by HPLC after acid hydrolysis. Percent conversion of [H-3]myoinositol to [H-3] chiroinositol was highest in blood (60.4%) followed by muscle (7.7%) and liver (2.2%).	UNIV VIRGINIA, SCH MED, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia				Pak, Yunbae/0000-0002-8594-5673	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK014334, P30DK038942] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37 DK14334, P30 DK38942] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BOGARDUS C, 1984, J CLIN INVEST, V73, P1185, DOI 10.1172/JCI111304; CLEMENTS RS, 1979, J LAB CLIN MED, V93, P210; DAUGHADAY WH, 1955, J BIOL CHEM, V212, P869; DEANJOHNSON M, 1989, J BIOL CHEM, V264, P1274; DENTON RM, 1989, ANN NY ACAD SCI, V573, P285, DOI 10.1111/j.1749-6632.1989.tb15005.x; DREW EA, 1983, PHYSL BIOCH STORAGE; EISENBER.F, 1967, J BIOL CHEM, V242, P1375; FUTERMAN AH, 1985, BIOCHEM BIOPH RES CO, V129, P312, DOI 10.1016/0006-291X(85)91439-1; HIPPS PP, 1982, METHOD ENZYMOL, V89, P593; HIPPS PP, 1973, BIOCHEMISTRY-US, V12, P4705, DOI 10.1021/bi00747a025; HOFFMANNOSTENHO.O, 1978, CYCLITOLS PHOSPHOINO, P233; HOLUB BJ, 1985, INOSITOL PHOSPHOINOS, P31; KELLY KL, 1987, P NATL ACAD SCI USA, V84, P6404, DOI 10.1073/pnas.84.18.6404; KENNINGTON AS, 1990, NEW ENGL J MED, V323, P373, DOI 10.1056/NEJM199008093230603; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LARNER J, 1989, ANN NY ACAD SCI, V573, P297, DOI 10.1111/j.1749-6632.1989.tb15006.x; LARNER J, 1988, COLD SPRING HARB SYM, V53, P965, DOI 10.1101/SQB.1988.053.01.111; LARNER J, 1988, BIOCHEM BIOPH RES CO, V151, P1416, DOI 10.1016/S0006-291X(88)80520-5; LOW MG, 1987, BIOCHEM J, V241, P615, DOI 10.1042/bj2410615; MALCHOFF CD, 1987, ENDOCRINOLOGY, V120, P1327, DOI 10.1210/endo-120-4-1327; MATO JM, 1987, BIOCHEM BIOPH RES CO, V146, P764, DOI 10.1016/0006-291X(87)90595-X; MATO JM, 1987, J BIOL CHEM, V262, P2131; MICHELL R H, 1986, P1; NIWA T, 1983, J CHROMATOGR, V277, P25, DOI 10.1016/S0378-4347(00)84820-3; REDDY CC, 1981, J BIOL CHEM, V256, P8510; ROMERO G, 1988, SCIENCE, V240, P509, DOI 10.1126/science.3282305; ROMERO G, 1992, IN PRESS ADV PHARM; SALTIEL AR, 1986, P NATL ACAD SCI USA, V83, P5793, DOI 10.1073/pnas.83.16.5793; SHEN L, 1967, ARCH BIOCHEM BIOPHYS, V122, P474, DOI 10.1016/0003-9861(67)90221-4; UMEZAWA H, 1965, J ANTIBIOT TOKYO A, V18, P1; WALTER EI, 1990, J IMMUNOL, V144, P1030; WANG WT, 1990, ANAL BIOCHEM, V188, P432, DOI 10.1016/0003-2697(90)90632-J; WOBER G, 1969, MONATSH CHEM, V100, P369, DOI 10.1007/BF00938275; WRIGHT RS, 1971, J CHROMATOGR, V59, P220, DOI 10.1016/S0021-9673(01)80033-9	35	85	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16904	16910						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1387397				2022-12-25	WOS:A1992JL05300030
J	TAKEDA, A; WU, JJ; MAIZEL, AL				TAKEDA, A; WU, JJ; MAIZEL, AL			EVIDENCE FOR MONOMERIC AND DIMERIC FORMS OF CD45 ASSOCIATED WITH A 30-KDA PHOSPHORYLATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; CELL ANTIGEN RECEPTOR; TYROSINE PHOSPHATASE CD45; LEUKOCYTE-COMMON ANTIGEN; HUMAN LYMPHOCYTES-T; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODIES; TRANSFERRIN RECEPTOR; ADHESION MOLECULE; MESSENGER-RNA	Glycoprotein CD45, a transmembrane protein tyrosine phosphatase of leukocytes, is topographically similar to the epidermal growth factor receptor, a transmembrane tyrosine kinase. Since the latter is thought to be allosterically regulated through conversion between monomeric and dimeric forms, we sought to determine whether CD45 undergoes similar oligomerization. Our analysis, employing a thiol-cleavable and homobifunctional chemical cross-linker, dithiobis succinimidyl propionate, revealed that CD45 indeed formed homodimers. In addition, a protein of molecular mass 30,000 daltons (30 kDa) was found to be associated with both the CD45 monomer and dimer. The 30-kDa protein was phosphorylated and was not labeled by cell surface radioiodination. Distinct differences in protein tyrosine phosphatase activity were detected among the various populations of CD45 separated by sucrose gradient ultracentrifugation. However, the differences observed could not be explained simply by dimerization and instead suggest the presence of other factor(s) involved in the regulation of CD45 enzyme activity.	MIRIAM HOSP, DEPT PATHOL, PROVIDENCE, RI 02906 USA	Lifespan Health Rhode Island; Miriam Hospital	TAKEDA, A (corresponding author), BROWN UNIV, ROGER WILLIAMS MED CTR, DEPT PATHOL, PROVIDENCE, RI 02908 USA.				NCI NIH HHS [CA 45148, P30 CA13943] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA045148, P30CA013943] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOURGUIGNON LYW, 1985, J CELL BIOL, V101, P477, DOI 10.1083/jcb.101.2.477; CIKES M, 1973, J NATL CANCER I, V50, P347, DOI 10.1093/jnci/50.2.347; CLARK EA, 1989, IMMUNOL TODAY, V10, P225, DOI 10.1016/0167-5699(89)90257-0; CONE RE, 1976, IMMUNOCHEMISTRY, V13, P571, DOI 10.1016/0019-2791(76)90168-3; ENNS CA, 1991, J BIOL CHEM, V266, P13272; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KIENER PA, 1989, J IMMUNOL, V143, P23; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P8628, DOI 10.1073/pnas.85.22.8628; LEDBETTER JA, 1991, J IMMUNOL, V146, P1577; LESLEY J, 1984, CELL IMMUNOL, V83, P14, DOI 10.1016/0008-8749(84)90220-X; LOMANT AJ, 1976, J MOL BIOL, V104, P243, DOI 10.1016/0022-2836(76)90011-5; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; OMARY MB, 1980, J BIOL CHEM, V255, P1662; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OSTERGAARD HL, 1991, SCIENCE, V253, P1423, DOI 10.1126/science.1654595; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RUTISHAUSER U, 1982, P NATL ACAD SCI-BIOL, V79, P685, DOI 10.1073/pnas.79.2.685; SAGA Y, 1986, P NATL ACAD SCI USA, V83, P6940, DOI 10.1073/pnas.83.18.6940; SAMELSON LE, 1990, J IMMUNOL, V145, P2448; SARMIENTO M, 1982, IMMUNOL REV, V68, P135, DOI 10.1111/j.1600-065X.1982.tb01063.x; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SCHRAVEN B, 1990, NATURE, V345, P71, DOI 10.1038/345071a0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TELFER JC, 1991, SCIENCE, V254, P439, DOI 10.1126/science.1925604; THOMAS ML, 1987, P NATL ACAD SCI USA, V84, P5360, DOI 10.1073/pnas.84.15.5360; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TORIMOTO Y, 1991, J IMMUNOL, V147, P2514; TROWBRIDGE IS, 1978, J EXP MED, V148, P313, DOI 10.1084/jem.148.1.313; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VOLAREVIC S, 1990, P NATL ACAD SCI USA, V87, P7085, DOI 10.1073/pnas.87.18.7085; WANG K, 1975, J BIOL CHEM, V250, P6622; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	50	84	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16651	16659						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1386605				2022-12-25	WOS:A1992JJ45800101
J	WEXLER, NS				WEXLER, NS			THE TIRESIAS COMPLEX - HUNTINGTONS-DISEASE AS A PARADIGM OF TESTING FOR LATE-ONSET DISORDERS	FASEB JOURNAL			English	Review						HEREDITARY; GENETIC COUNSELING; GENETIC DECISION MAKING; PSYCHOSOCIAL REACTION TO GENETIC INFORMATION; NEURODEGENERATIVE DISEASE	DNA MARKERS; GENE; PREGNANCY	Huntington's disease represents the first disorder for which positional cloning techniques successfully localized an autosomal gene-in 1983. Events since that time have proved the gene recalcitrant to identification and characterization. Since 1986, presymptomatic and prenatal testing for Huntington's disease has been available internationally, although on a limited basis. Testing for Huntington's disease provides an excellent model for designing service programs for genetic testing for late-onset, fatal disorders, particularly when the gene is not yet in hand and no therapeutic intervention is possible. Special training and precautions must be in place before presymptomatic genetic testing should be offered.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PSYCHIAT,NEW YORK,NY 10032	Columbia University	WEXLER, NS (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT NEUROL,NEW YORK,NY 10032, USA.							BALL DM, 1992, FASEB J, V6; CONNEALLY PM, 1988, NUCLEIC ACID PROBES, P137; CONNEALLY PM, 1985, PROG CLIN BIOL RES, V77, P53; GILLIAM TC, 1987, CELL, V50, P565, DOI 10.1016/0092-8674(87)90029-8; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HARPER PS, 1991, AM J HUM GENET S62, V49; HAYDEN MR, 1988, AM J HUM GENET, V43, P689; HAYDEN MR, 1987, LANCET, V1, P1284; HOLTZMAN NA, 1989, PROCEED CAUTION, V157; HUGGINS M, 1990, AM J HUM GENET, V47, P4; KAHNEMAN D, 1982, SCI AM, V246, P161; MACDONALD ME, 1989, J CLIN INVEST, V84, P1013, DOI 10.1172/JCI114222; MACDONALD ME, 1989, NEURON, V3, P183, DOI 10.1016/0896-6273(89)90031-7; MEISSEN GJ, 1991, AM J MED GENET, V39, P404, DOI 10.1002/ajmg.1320390408; QUAID KA, 1989, CLIN GENET, V36, P431; QUARRELL OWJ, 1987, LANCET, V1, P1281; SOPHOCLES, 1957, 8 GREAT TRAGEDIES, P65; TVERSKY A, 1981, SCIENCE, V211, P453, DOI 10.1126/science.7455683; TYLER A, 1990, J MED GENET, V27, P488, DOI 10.1136/jmg.27.8.488; Wexler N., 1992, CODE CODES SCI SOCIA, P211; WEXLER NS, 1985, ARCH NEUROL-CHICAGO, V42, P20, DOI 10.1001/archneur.1985.04060010026009; WEXLER NS, 1991, GENETICS ETHICS HUMA; World Federation of Neurology, 1989, J NEUROL SCI, V94, P327; 1990, J MED GENET, V27, P34	24	50	52	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1992	6	10					2820	2825		10.1096/fasebj.6.10.1386047	http://dx.doi.org/10.1096/fasebj.6.10.1386047			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1386047				2022-12-25	WOS:A1992JD95400010
J	LEE, S; FRANCOEUR, AM; LIU, S; WANG, E				LEE, S; FRANCOEUR, AM; LIU, S; WANG, E			TISSUE-SPECIFIC EXPRESSION IN MAMMALIAN BRAIN, HEART, AND MUSCLE OF S1, A MEMBER OF THE ELONGATION FACTOR-1-ALPHA GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR 1-ALPHA EF-1-ALPHA; 2 GENES; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; CHROMOSOMAL GENE; BINDING PROTEIN; FACTOR-I; XENOPUS; YEAST; TRANSCRIPT	Elongation factor-1 alpha (EF-1alpha) is an ubiquitous protein that functions in peptide elongation during mRNA translation. We previously reported the isolation of a rat S1 protein that is antigenically related to statin, a nonproliferation-specific protein; this S1 gene shares a high degree of homology to EF-1alpha. We constructed specific riboprobes to the two genes, based on the difference in the 3' noncoding regions of both S1 and EF-1alpha mRNAs. Northern analysis and RNase protection assays have revealed that S1 mRNA is present only in brain, heart, and muscle, while EF-1alpha mRNA has been detected in all tissues surveyed so far. The same tissue specificity has been observed in mouse, suggesting that S1 expression is conserved between these two mammalian species. S1 transcript was detected in late brain embryogenesis (day 20), but in lower amounts than in 3-month-old adult brain. We show that the relative levels of both S1 and EF-1alpha transcripts and their respective tissue abundances remain unchanged during the aging process. The function of S1 is not yet known; but these results suggest that it may be involved in specific control mechanisms for protein synthesis in tissues where cells (i.e. neurons and myocytes) are permanently locked in a state of nonproliferation.	MCGILL UNIV,JEWISH GEN HOSP,LADY DAVIS INST MED RES,BLOOMFIELD CTR RES AGING,MONTREAL H3T 1E2,QUEBEC,CANADA; MCGILL UNIV,DEPT MED,MONTREAL H3A 2T5,QUEBEC,CANADA; MCGILL UNIV,DEPT ANAT,MONTREAL H3A 2T5,QUEBEC,CANADA	Lady Davis Institute; McGill University; McGill University; McGill University					NIA NIH HHS [AG 07444] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG007444, R01AG007444] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANN DK, 1992, J BIOL CHEM, V267, P699; ANN DK, 1991, J BIOL CHEM, V266, P10429; BRANDS JHGM, 1986, EUR J BIOCHEM, V155, P167, DOI 10.1111/j.1432-1033.1986.tb09472.x; CAVALLIUS J, 1986, EXP GERONTOL, V21, P149, DOI 10.1016/0531-5565(86)90068-9; CAVALLIUS J, 1989, T AGING RES, V13, P125; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPPARD NJ, 1991, J CELL BIOL, V112, P237, DOI 10.1083/jcb.112.2.237; DEVER TE, 1989, J BIOL CHEM, V264, P20518; DJE MK, 1990, NUCLEIC ACIDS RES, V18, P3489, DOI 10.1093/nar/18.12.3489; GIORDANO T, 1989, EXP GERONTOL, V24, P501, DOI 10.1016/0531-5565(89)90056-9; GREENBERG JR, 1987, FEBS LETT, V224, P54, DOI 10.1016/0014-5793(87)80421-0; HAYASHI Y, 1989, J BIOCHEM-TOKYO, V106, P560, DOI 10.1093/oxfordjournals.jbchem.a122895; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOVEMANN B, 1988, NUCLEIC ACIDS RES, V16, P3175, DOI 10.1093/nar/16.8.3175; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; LU X, 1989, Nucleic Acids Research, V17, P442, DOI 10.1093/nar/17.1.442; NAGATA S, 1984, EMBO J, V3, P1825, DOI 10.1002/j.1460-2075.1984.tb02053.x; OHTA K, 1990, J BIOL CHEM, V265, P3240; RATTAN SIS, 1991, MUTAT RES, V256, P115, DOI 10.1016/0921-8734(91)90005-V; RATTAN SIS, 1986, C INSERM, V147, P135; Sambrook J, 1989, MOL CLONING LABORATO; SHEPHERD JCW, 1989, P NATL ACAD SCI USA, V86, P7520, DOI 10.1073/pnas.86.19.7520; SONG JM, 1989, MOL CELL BIOL, V9, P4571, DOI 10.1128/MCB.9.10.4571; SUNDSTROM P, 1990, J BACTERIOL, V172, P2036, DOI 10.1128/jb.172.4.2036-2045.1990; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; VANHEMERT FJ, 1984, EMBO J, V3, P1109, DOI 10.1002/j.1460-2075.1984.tb01937.x; WALLDORF U, 1985, P NATL ACAD SCI USA, V82, P5795, DOI 10.1073/pnas.82.17.5795; WEBSTER GC, 1985, MOL BIOL AGING GENE, P263; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0	29	103	107	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24064	24068						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385435				2022-12-25	WOS:A1992JZ23900095
J	SHIRAISHI, F; SAVAGEAU, MA				SHIRAISHI, F; SAVAGEAU, MA			THE TRICARBOXYLIC-ACID CYCLE IN DICTYOSTELIUM-DISCOIDEUM .3. ANALYSIS OF STEADY-STATE AND DYNAMIC BEHAVIOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOCHEMICAL SYSTEMS-THEORY	The examination of model robustness in the previous paper (Shiraishi, F., and Savageau, M. A. (1992) J. Biol. Chem. 267, 22919-22925 led to the suggestion that the current model for the tricarboxylic acid cycle in Dictyostelium discoideum is ill-determined with respect to one or more of the features reflecting pyruvate metabolism. This conclusion is further supported here by results of steady state and dynamic analyses. The tricarboxylic acid cycle, according to the current model, is poised on a knife's edge with its behavior rigidly determined; any alteration of the system's components leads to nonviable behavior, as exemplified by explosive accumulation of pyruvate and loss of steady state in response to a minute change in the level of malate dehydrogenase. With the additional results in this paper, we are able to refine the diagnosis of the problem and suggest three different areas of the current model that might profitably be re-examined by experiment. These include the kinetics of the reactions at the malate branch point, the turnover times for the alanine, glutamate, and aspartate pools in vivo, and the dynamic mass balances for the cofactor NAD. We also suggest a minimal modification in the current model that could alleviate or circumvent some of these problems.	UNIV MICHIGAN,SCH MED,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIGMS NIH HHS [GM-30054] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030054] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBE KR, 1992, J BIOL CHEM, V267, P3106; Bode H. W., 1945, NETWORK ANAL FEEDBAC; Chua L.O., 1969, INTRO NONLINEAR NETW; CORNISHBOWDEN A, 1989, J THEOR BIOL, V136, P365, DOI 10.1016/S0022-5193(89)80154-7; IRVINE DH, 1990, SIAM J NUMER ANAL, V27, P704, DOI 10.1137/0727042; KACSER H, 1981, GENETICS, V97, P639; KELLY PJ, 1979, BIOCHEM J, V184, P589, DOI 10.1042/bj1840589; Savageau M, 1976, BIOCH SYSTEMS ANAL S; SAVAGEAU MA, 1992, J THEOR BIOL, V154, P131, DOI 10.1016/S0022-5193(05)80194-8; SAVAGEAU MA, 1989, J THEOR BIOL, V141, P93, DOI 10.1016/S0022-5193(89)80011-6; SAVAGEAU MA, 1971, ARCH BIOCHEM BIOPHYS, V145, P612, DOI 10.1016/S0003-9861(71)80021-8; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22912; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22934; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22919; SORRIBAS A, 1989, MATH BIOSCI, V94, P239, DOI 10.1016/0025-5564(89)90066-7; SORRIBAS A, 1989, MATH BIOSCI, V94, P161, DOI 10.1016/0025-5564(89)90064-3; VANVALKENBURG ME, 1958, NETWORK ANAL; Voit E., 1991, CANONICAL NONLINEAR; VOIT EO, 1990, USERS GUIDE ESSYNS	19	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22926	22933						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429643				2022-12-25	WOS:A1992JY16300036
J	GROVES, JD; TANNER, MJA				GROVES, JD; TANNER, MJA			GLYCOPHORIN-A FACILITATES THE EXPRESSION OF HUMAN BAND-3-MEDIATED ANION TRANSPORT IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANE; AMINO-ACID SEQUENCE; RED-CELL MEMBRANE; EXCHANGE PROTEIN; SIALOGLYCOPROTEIN-ALPHA; MONOCLONAL-ANTIBODIES; MESSENGER-RNAS; BAND-3 PROTEIN; CDNA SEQUENCE; WRB-ANTIGEN	The effects of human red cell glycophorin A (GPA) on the expression of the human erythrocyte anion transporter (band 3, AE1) has been examined in Xenopus oocytes. The coexpression of GPA with band 3 increased stilbene disulfonate-sensitive chloride transport into the oocytes. The effect of GPA was particularly noticeable at low band 3 concentrations and less marked at high band 3 cRNA concentrations. The enhancement of chloride transport was specific to GPA and was not observed when either glycophorin B or glycophorin C was coexpressed with band 3. Immunoprecipitations of whole oocyte homogenates showed the amount of band 3 synthesized was not affected by GPA at subsaturating cRNA concentrations. More band 3 was detected at the oocyte surface by immunoprecipitation when GPA was also expressed. Chymotrypsin treatment of intact oocytes was also used to assess surface band 3 and greater cleavage of band 3 by chymotrypsin was observed when GPA was present. Band 3 synthesis and assembly into canine pancreatic microsomes in the reticulocyte cell-free translation system was not altered by cotranslation of GPA. We suggest that GPA facilitates the translocation of band 3 to the plasma membrane at some point during band 3 biosynthesis in Xenopus oocytes. However, GPA is not essential for the expression of band 3 in red cells, since GPA-deficient individuals have apparently normal levels of band 3. Other GPA-independent mechanisms must also allow translocation of band 3 to the surface membrane in erythroid cells and oocytes. GPA may affect the rate of accumulation of band 3 at the cell surface, rather than the final level in the plasma membrane.	UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND	University of Bristol								ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; ANSTEE DJ, 1986, BRIT J HAEMATOL, V64, P211, DOI 10.1111/j.1365-2141.1986.tb04113.x; ANSTEE DJ, 1982, MEMBRANES TRANSPORT, V2, P427; Ausubel FM, 1991, CURRENT PROTOCOLS MO, V1; BARTEL D, 1989, EMBO J, V4, P1927; BERGER SL, 1987, METHOD ENZYMOL, V152, P227; BLANCHARD D, 1987, J BIOL CHEM, V262, P5808; BULLER AL, 1990, J MEMBRANE BIOL, V115, P179, DOI 10.1007/BF01869456; CASEY JR, 1991, J BIOL CHEM, V266, P15726; COLIN Y, 1986, J BIOL CHEM, V261, P229; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; COX JV, 1987, J CELL BIOL, V105, P1405, DOI 10.1083/jcb.105.3.1405; DAHR W, 1986, BIOL CHEM H-S, V367, P1033, DOI 10.1515/bchm3.1986.367.2.1033; DAHR W, 1975, J IMMUNOGENET, V2, P249; DAHR W, 1986, RECENT ADV BLOOD GRO, P23; GAHMBERG CG, 1976, J BIOL CHEM, V251, P6108; GARCIA AM, 1989, J BIOL CHEM, V264, P19607; HIGH S, 1987, BIOCHEM J, V243, P277, DOI 10.1042/bj2430277; JAY D, 1986, ANNU REV BIOCHEM, V55, P511, DOI 10.1146/annurev.bi.55.070186.002455; JENNINGS ML, 1989, ANNU REV BIOPHYS BIO, V18, P397, DOI 10.1146/annurev.bb.18.060189.002145; KIM HRC, 1988, MOL CELL BIOL, V8, P4416, DOI 10.1128/MCB.8.10.4416; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOURY MJ, 1987, J CELL PHYSIOL, V133, P438, DOI 10.1002/jcp.1041330304; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARIDES E, 1989, ANNU REV CELL BIOL, V5, P427; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; MARCHESI VT, 1976, ANNU REV BIOCHEM, V45, P667, DOI 10.1146/annurev.bi.45.070176.003315; MARTON LSG, 1973, BIOCHEM BIOPH RES CO, V52, P1457, DOI 10.1016/0006-291X(73)90664-5; MAWBY WJ, 1982, BIOCHEM J, V205, P465, DOI 10.1042/bj2050465; MERRY AH, 1986, BIOCHEM J, V233, P93, DOI 10.1042/bj2330093; MORGAN M, 1985, EMBO J, V4, P1927, DOI 10.1002/j.1460-2075.1985.tb03872.x; NIGG EA, 1980, BIOCHEMISTRY-US, V19, P1887, DOI 10.1021/bi00550a024; OKUBO K, 1991, J BIOL CHEM, V266, P16420; RIDGWELL K, 1983, BIOCHEM J, V209, P273, DOI 10.1042/bj2090273; SCHEELE G, 1980, J CELL BIOL, V87, P611, DOI 10.1083/jcb.87.3.611; SIEBERT PD, 1987, P NATL ACAD SCI USA, V84, P6735, DOI 10.1073/pnas.84.19.6735; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; TANNER MJA, 1976, BIOCHEM J, V155, P701, DOI 10.1042/bj1550701; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; TANNER MJA, 1976, BIOCHEM J, V153, P271, DOI 10.1042/bj1530271; TATE CG, 1988, BIOCHEM J, V254, P743, DOI 10.1042/bj2540743; TELEN MJ, 1990, BLOOD, V76, P842; TOKUNAGA E, 1979, J IMMUNOGENET, V6, P383; TOMITA M, 1975, P NATL ACAD SCI USA, V72, P2964, DOI 10.1073/pnas.72.8.2964; WAINWRIGHT SD, 1989, BIOCHEM J, V258, P211, DOI 10.1042/bj2580211; YANNOUKAKOS D, 1991, BLOOD, V78, P1117	49	151	153	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22163	22170						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1385395				2022-12-25	WOS:A1992JW71900029
J	MOORE, WR; SCHATZMAN, GL				MOORE, WR; SCHATZMAN, GL			PURIFICATION OF 2,3-OXIDOSQUALENE CYCLASE FROM RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LANOSTEROL; CYCLIZATION; MOLECULES; PROTEIN	A rapid and simple purification of milligram amounts of 2,3-oxidosqualene cyclase, an integral membrane enzyme that catalyzes the cyclization of squalene epoxide to lanosterol, is reported. Several nonionic detergents (Triton X-100, Tween 80, Emulphogene, and lauryl maltoside) were evaluated for solubilization of oxidosqualene cyclase from rat liver microsomes. At a detergent concentration of 5 mg/ml, lauryl maltoside was approximately 10 times more effective than Emulphogene in the solubilization of oxidosqualene cyclase; Triton X-100 and Tween 80 were less effective than Emulphogene as judged by the relative specific activities of the solubilized enzyme. Treatment of microsomes with lauryl maltoside resulted in a selective solubilization of the cyclase with concomitant activation of the enzyme. The solubilized enzyme was purified to homogeneity by fast protein liquid chromatography. The purified enzyme consists of a single subunit that has an apparent molecular weight of 65,000 as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The enzyme obeys saturation kinetics and the apparent K(m) of (2,3)-oxidosqualene is 15 muM; the apparent k(cat)/k(m) is 200 M-1.min-1. An improved assay of the enzyme that utilizes high performance liquid chromatography methods is also described.			MOORE, WR (corresponding author), MARION MERRELL DOW RES INST,2110 E GALBRAITH RD,CINCINNATI,OH 45215, USA.							BARTON DHR, 1975, J CHEM SOC PERK T 1, P1134, DOI 10.1039/p19750001134; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATTEL L, 1986, LIPIDS, V21, P31, DOI 10.1007/BF02534300; CHENG TY, 1979, J BIOL CHEM, V254, P11258; COREY EJ, 1967, J AM CHEM SOC, V89, P2797, DOI 10.1021/ja00987a089; COREY EJ, 1991, J AM CHEM SOC, V113, P4025, DOI 10.1021/ja00010a073; CORNFORT.JW, 1968, ANGEW CHEM INT EDIT, V7, P903, DOI 10.1002/anie.196809031; CORNFORT.JW, 1965, J AM CHEM SOC, V87, P3224, DOI 10.1021/ja01092a038; DEAN P D G, 1971, Steroidologia, V2, P143; DEAN PDG, 1967, J BIOL CHEM, V242, P3014; DEWAR MJS, 1984, J AM CHEM SOC, V106, P1744, DOI 10.1021/ja00318a033; DURIATTI A, 1988, BIOCHEM BIOPH RES CO, V151, P1378, DOI 10.1016/S0006-291X(88)80515-1; DURIATTI A, 1985, BIOCHEM PHARMACOL, V34, P2765, DOI 10.1016/0006-2952(85)90578-7; DURRIATI A, 1985, BIOCHEM PHARMACOL, V34, P2765; JAYME M, 1970, J AM CHEM SOC, V92, P2059, DOI 10.1021/ja00710a044; JOLIDON S, 1990, BIOCHEM SOC T, V18, P47, DOI 10.1042/bst0180047; KUSANO M, 1991, CHEM PHARM BULL, V39, P239; MAUDGAL RK, 1958, J AM CHEM SOC, V80, P2589, DOI 10.1021/ja01543a063; NADEAU RG, 1969, METHOD ENZYMOL, V15, P346; Neugebauer J.M., 1988, GUIDE PROPERTIES USE; RAHIER A, 1981, LIPIDS, V21, P52; REES HH, 1968, BIOCHEM J, V107, P417, DOI 10.1042/bj1070417; SAAT YA, 1976, J BIOL CHEM, V251, P5155; SCHROEPFER GJ, 1982, ANNU REV BIOCHEM, V51, P555, DOI 10.1146/annurev.bi.51.070182.003011; VANTAMELEN EE, 1982, J AM CHEM SOC, V104, P6480, DOI 10.1021/ja00387a070; VANTAMELEN EE, 1975, ACCOUNTS CHEM RES, V8, P152, DOI 10.1021/ar50089a002; YAMAMOTO S, 1969, P NATL ACAD SCI USA, V63, P110, DOI 10.1073/pnas.63.1.110	27	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22003	22006						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429550				2022-12-25	WOS:A1992JW71900005
J	AKAZAWA, C; SASAI, Y; NAKANISHI, S; KAGEYAMA, R				AKAZAWA, C; SASAI, Y; NAKANISHI, S; KAGEYAMA, R			MOLECULAR CHARACTERIZATION OF A RAT NEGATIVE REGULATOR WITH A BASIC HELIX-LOOP-HELIX STRUCTURE PREDOMINANTLY EXPRESSED IN THE DEVELOPING NERVOUS-SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; DROSOPHILA-MELANOGASTER; AUTORADIOGRAPHIC ANALYSIS; CELL-DIFFERENTIATION; TRANSGENE EXPRESSION; GENE-COMPLEX; MOUSE RETINA; N-MYC; PROTEIN; SEQUENCE	We report here the cDNA cloning and characterization of a rat basic helix-loop-helix (HLH) factor, designated HES-5. This factor has a distant sequence homology to Drosophila hairy and Enhancer-of-split proteins, both of which are required for normal neurogenesis. DNase I footprinting analyses show that HES-5 binds to the sequence CACNAG (called N box), a recognition sequence of Enhancer-of-split proteins. Although HES-5 does not bind to the sequence CANNTG (called E box) recognized by other HLH factors, it attenuates the binding of E47, an HLH activator, to E box by forming a hetero-oligomer. In cotransfection analyses using NIH 3T3 cells, HES-5 significantly represses transcription originating from the promoter containing the N box sequences. Furthermore, HES-5 also partially inhibits the E47-induced expression from the promoter containing E boxes. Northern blot, RNase protection, and in situ hybridization analyses demonstrate that the HES-5 mRNA is specifically expressed in the nervous system. Prominent expression is observed in the ventricular zones of the embryonal brain vesicles and the outer nuclear layer of the neural retina. These results suggest that the negative regulator HES-5 may play an important role in neural development.			AKAZAWA, C (corresponding author), KYOTO UNIV,FAC MED,INST IMMUNOL,SAKYO KU,KYOTO 606,JAPAN.							BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLANKS JC, 1977, J COMP NEUROL, V174, P317, DOI 10.1002/cne.901740208; BOTAS J, 1982, EMBO J, V1, P307, DOI 10.1002/j.1460-2075.1982.tb01165.x; CAMPOSORTEGA JA, 1990, EUR J BIOCHEM, V190, P1, DOI 10.1111/j.1432-1033.1990.tb15538.x; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P263, DOI 10.1002/cne.901880205; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; FUJITA S, 1963, J COMP NEUROL, V120, P37, DOI 10.1002/cne.901200104; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; Gilbert SF, 1991, DEV BIOL; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; JAN YN, 1990, TRENDS NEUROSCI, V13, P493, DOI 10.1016/0166-2236(90)90083-M; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; OBERDICK J, 1990, SCIENCE, V248, P223, DOI 10.1126/science.2109351; OBERDICK J, 1988, NEURON, V1, P367, DOI 10.1016/0896-6273(88)90186-9; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; TSUCHIDA K, 1990, EUR J BIOCHEM, V193, P751, DOI 10.1111/j.1432-1033.1990.tb19396.x; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; VANDAELE S, 1991, GENE DEV, V5, P1136, DOI 10.1101/gad.5.7.1136; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215	35	276	286	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21879	21885						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400497				2022-12-25	WOS:A1992JV01100095
J	CHO, WL; RAIKHEL, AS				CHO, WL; RAIKHEL, AS			CLONING OF CDNA FOR MOSQUITO LYSOSOMAL ASPARTIC PROTEASE - SEQUENCE-ANALYSIS OF AN INSECT LYSOSOMAL-ENZYME SIMILAR TO CATHEPSIN-D AND CATHEPSIN-E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITELLOGENIN MESSENGER-RNA; MYELIN BASIC-PROTEIN; FAT-BODY; TRANSLATIONAL REGULATION; MOLECULAR-CLONING; DEGRADATION; PRECURSOR; GLUCOCORTICOIDS; IDENTIFICATION; PEPSINOGEN	A cDNA coding for the lysosomal aspartic protease from the mosquito (mLAP) was cloned and sequenced. The mLAP cDNA is 1420 base pairs long with an open reading frame of 387 amino acids. The deduced amino acid sequence contains a signal pre-propeptide sequence of 18 amino acids followed by 369 amino acids with a 35-amino acid putative pro-enzyme domain in the NH2-terminal. The amino acid sequence of mLAP is 92 and 81% similar to human cathepsin D and cathepsin E, respectively. Typical cleavage sites for cathepsin D processing into light and heavy chains are lacking in mLAP. A single glycosylation site occurs in the mLAP sequence at a position corresponding to the first glycosylation site of cathepsins D. The mLAP sequence shares putative phosphorylation determinants, which in cathepsins D are linked to the formation of mannose 6-phosphate. In the mosquito fat body, lysosomal enzymes specifically degrade organelles involved in the biosynthesis and secretion of vitellogenin. The mLAP mRNA accumulates to its highest level 24 h after initiation of vitellogenin synthesis and 12 h before the peak of mLAP protein accumulation and its enzymatic activity. Translational regulation of mLAP mRNA may occur. The 5'-untranslated region of mLAP mRNA is similar to elements conferring negative translational control by steroids.	MICHIGAN STATE UNIV, PROGRAM GENET, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, DEPT ENTOMOL, E LANSING, MI 48824 USA	Michigan State University; Michigan State University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024716, R01AI024716] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-24716] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; ATHAUDA SBP, 1990, BIOCHEM BIOPH RES CO, V168, P878, DOI 10.1016/0006-291X(90)92403-M; Ausubel F, 1990, CURRENT PROTOCOLS MO, V1; AZUMA T, 1989, J BIOL CHEM, V264, P16748; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BERNIER L, 1987, J NEUROSCI, V7, P2703; BOSE SG, 1988, BIOCHEM BIOPH RES CO, V155, P436, DOI 10.1016/S0006-291X(88)81105-7; BROCK ML, 1983, CELL, V34, P207, DOI 10.1016/0092-8674(83)90151-4; Cardelli J.A., 1988, P363; CHO WL, 1991, INSECT BIOCHEM, V21, P165, DOI 10.1016/0020-1790(91)90047-I; CHRISPEELS MJ, 1992, CELL, V68, P613, DOI 10.1016/0092-8674(92)90134-X; CONNER GE, 1989, BIOCHEM J, V263, P601, DOI 10.1042/bj2630601; Dean R.L., 1985, P155; FAUST PL, 1989, J BIOL CHEM, V264, P479; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; GLAUMANN H, 1981, INT REV CYTOL, V73, P149, DOI 10.1016/S0074-7696(08)61288-7; GORDON DA, 1988, J BIOL CHEM, V263, P2625; GRUSBY MJ, 1990, NUCLEIC ACIDS RES, V18, P4008, DOI 10.1093/nar/18.13.4008; Hagedorn H.H., 1989, P279; Hagedorn H.H., 1985, P205; HARRIS TJR, 1982, NUCLEIC ACIDS RES, V10, P2177, DOI 10.1093/nar/10.7.2177; HAYS AR, 1990, ROUX ARCH DEV BIOL, V199, P114, DOI 10.1007/BF02029559; HORIUCHI H, 1988, J BACTERIOL, V170, P272, DOI 10.1128/jb.170.1.272-278.1988; ICHIMARU E, 1990, J BIOCHEM-TOKYO, V108, P1009, DOI 10.1093/oxfordjournals.jbchem.a123299; IMAI T, 1983, P NATL ACAD SCI-BIOL, V80, P7405, DOI 10.1073/pnas.80.24.7405; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUMAR S, 1989, P NATL ACAD SCI USA, V86, P6807, DOI 10.1073/pnas.86.17.6807; Kunkel J.G., 1985, P83; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEA ARDEN O., 1964, J MED ENTOMOL, V1, P40, DOI 10.1093/jmedent/1.1.40; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; Locke M., 1980, P227; MEYUHAS O, 1987, MOL CELL BIOL, V7, P2691, DOI 10.1128/MCB.7.8.2691; NAGAO E, 1987, INSECT BIOCHEM, V17, P531, DOI 10.1016/0020-1790(87)90051-5; NEWMAN S, 1987, P NATL ACAD SCI USA, V84, P886, DOI 10.1073/pnas.84.3.886; NIELSEN DA, 1990, MOL CELL BIOL, V10, P371, DOI 10.1128/MCB.10.1.371; NORDIN JH, 1984, COMP BIOCHEM PHYS B, V79, P379, DOI 10.1016/0305-0491(84)90392-4; ORCI L, 1984, J CELL BIOL, V98, P222, DOI 10.1083/jcb.98.1.222; OSIR EO, 1986, INSECT BIOCHEM, V16, P471, DOI 10.1016/0020-1790(86)90023-5; RACIOPPI JV, 1986, INSECT BIOCHEM, V16, P255, DOI 10.1016/0020-1790(86)90104-6; Raikhel A.S., 1992, Advances in Disease Vector Research, V9, P1; RAIKHEL AS, 1986, J INSECT PHYSIOL, V32, P879, DOI 10.1016/0022-1910(86)90103-4; RAIKHEL AS, 1986, TISSUE CELL, V18, P125, DOI 10.1016/0040-8166(86)90012-1; RAIKHEL AS, 1986, J INSECT PHYSIOL, V32, P597, DOI 10.1016/0022-1910(86)90088-0; RAIKHEL AS, 1992, ANNU REV ENTOMOL, V37, P217, DOI 10.1146/annurev.en.37.010192.001245; RUNEBERGROOS P, 1991, EUR J BIOCHEM, V202, P1021, DOI 10.1111/j.1432-1033.1991.tb16465.x; SAMBROK J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEWALE JG, 1984, P NATL ACAD SCI-BIOL, V81, P3703, DOI 10.1073/pnas.81.12.3703; SMITH RE, 1966, J CELL BIOL, V31, P319, DOI 10.1083/jcb.31.2.319; SOGAWA K, 1983, J BIOL CHEM, V258, P5306; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; UENO E, 1989, J BIOCHEM-TOKYO, V105, P878, DOI 10.1093/oxfordjournals.jbchem.a122772; VERDI JM, 1989, J NEUROCHEM, V52, P321, DOI 10.1111/j.1471-4159.1989.tb10935.x; VERDI JM, 1990, J BIOL CHEM, V265, P20314; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wyatt G.R., 1980, P201; YONEZAWA S, 1988, J BIOL CHEM, V263, P16504	60	83	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21823	21829						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400492				2022-12-25	WOS:A1992JV01100087
J	LEACH, KL; RUFF, VA; JARPE, MB; ADAMS, LD; FABBRO, D; RABEN, DM				LEACH, KL; RUFF, VA; JARPE, MB; ADAMS, LD; FABBRO, D; RABEN, DM			ALPHA-THROMBIN STIMULATES NUCLEAR DIGLYCERIDE LEVELS AND DIFFERENTIAL NUCLEAR-LOCALIZATION OF PROTEIN-KINASE-C ISOZYMES IN IIC9-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; PHOSPHATIDYLCHOLINE BREAKDOWN; SIGNAL TRANSDUCTION; CULTURED FIBROBLASTS; MITOGENIC RESPONSE; LIVER NUCLEI; RAT-BRAIN; CELLS; PHOSPHORYLATION; HEPATOCYTES	The mechanism by which an agonist, binding to a cell surface receptor, exerts an effect on events in the nucleus is not known. We have previously shown (Leach, K. L., Ruff, V. A., Wright, T. M., Pessin, M. S., and Raben, D. M. (1991) J. Biol. Chem. 266, 3215-3221) that alpha-thrombin treatment of IIC9 cells results in increased levels of cellular 1,2-diacylglycerol (DAG) and activation of protein kinase C (PKC). Here, we have examined whether changes in nuclear PKC and nuclear DAG also are induced following alpha-thrombin treatment. IIC9 cells were treated with 500 ng/ml alpha-thrombin, and nuclei were then isolated. Western blot analysis using isozyme-specific antibodies demonstrated the presence of PKC alpha, but not PKC epsilon or zeta in the nuclei of cells treated with either phorbol 12-myristate 13-acetate or alpha-thrombin. The increase in nuclear PKC alpha levels was accompanied by a 10-fold increase in nuclear PKC specific activity and stimulated phosphorylation of at least six nuclear proteins. The rise in nuclear PKC levels occurred rapidly and reached a maximum at 30-60 s, which was followed by a decline back to the control level over the next 15 min. In addition, alpha-thrombin treatment resulted in an immediate rise in DAG mass levels in the nuclear fractions. Kinetic analysis indicated that a maximum increase in DAG levels occurred 2.5-5 min after the addition of alpha-thrombin and remained elevated for at least 30 min. In cells labeled with [H-3]myristic acid, alpha-thrombin treatment induced an increase in radiolabeled nuclear diglycerides, suggesting that the stimulated nuclear DAGs are derived, at least in part, from phosphatidylcholine. Our results suggest that increases in both nuclear DAG levels and PKC activity following alpha-thrombin treatment may play a role in mediating thrombin-induced nuclear responses such as changes in gene expression and cellular proliferation.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205; UPJOHN CO,DEPT BIOCHEM,KALAMAZOO,MI 49001; CIBA GEIGY AG,DIV PHARMACEUT,CH-4002 BASEL,SWITZERLAND	Johns Hopkins University; Pfizer; Novartis	LEACH, KL (corresponding author), UPJOHN CO,DEPT CELL BIOL,7239-267-3,KALAMAZOO,MI 49001, USA.							ADAMS LD, 1987, CURRENT PROTOCOLS MO; AMES BN, 1960, J BIOL CHEM, V235, P769; AUGERT G, 1989, J BIOL CHEM, V264, P21689; BOCCKINO SB, 1985, J BIOL CHEM, V260, P4201; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER AP, 1986, J BIOL CHEM, V261, P9421; DEGEN JL, 1985, J BIOL CHEM, V260, P2426; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; EXTON JH, 1990, J BIOL CHEM, V265, P1; FIELDS AP, 1989, J BIOL CHEM, V264, P21896; FIELDS AP, 1990, J CELL SCI, V96, P107; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; HAGIWARA M, 1990, BIOCHEM BIOPH RES CO, V168, P161, DOI 10.1016/0006-291X(90)91688-O; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HORNBECK P, 1988, P NATL ACAD SCI USA, V85, P2279, DOI 10.1073/pnas.85.7.2279; HUANG KP, 1988, J BIOL CHEM, V263, P14839; IRVING HR, 1987, J BIOL CHEM, V262, P3440; JOHNSON HM, 1985, J IMMUNOL, V134, P967; KARIN M, 1991, HORMONAL CONTROL REG, P235; KILEY SC, 1991, J BIOL CHEM, V266, P23761; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LEACH KL, 1988, J BIOL CHEM, V263, P13223; LEACH KL, 1989, J CELL BIOL, V109, P605; LOW DA, 1982, NATURE, V298, P476, DOI 10.1038/298476a0; MACFARLANE DE, 1986, J BIOL CHEM, V261, P6947; MARAIS RM, 1990, FEBS LETT, V277, P151, DOI 10.1016/0014-5793(90)80831-3; MASMOUDI A, 1989, J BIOL CHEM, V264, P1172; MCBRIDE K, 1991, P NATL ACAD SCI USA, V88, P7111, DOI 10.1073/pnas.88.16.7111; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; MESSING RO, 1991, J BIOL CHEM, V266, P23428; NAOR Z, 1988, MOL ENDOCRINOL, V2, P1043, DOI 10.1210/mend-2-11-1043; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6858, DOI 10.1073/pnas.87.17.6858; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1990, J BIOL CHEM, V265, P22434; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; PESSIN MS, 1989, J BIOL CHEM, V264, P8729; PREISS J, 1986, J BIOL CHEM, V261, P8597; ROSCOFF PM, 1988, CELL, V54, P73; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SAMUELS DS, 1989, FEBS LETT, V259, P57, DOI 10.1016/0014-5793(89)81493-0; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; THOMAS TP, 1988, CANCER RES, V48, P1910; USUDA N, 1991, J CELL BIOL, V112, P1241, DOI 10.1083/jcb.112.6.1241; WRIGHT TM, 1990, BIOCHEM J, V267, P501, DOI 10.1042/bj2670501; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374	51	117	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21816	21822						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400491				2022-12-25	WOS:A1992JV01100086
J	LOKESHWAR, VB; BOURGUIGNON, LYW				LOKESHWAR, VB; BOURGUIGNON, LYW			TYROSINE PHOSPHATASE-ACTIVITY OF LYMPHOMA CD45 (GP180) IS REGULATED BY A DIRECT INTERACTION WITH THE CYTOSKELETON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE-COMMON ANTIGEN; EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE-C; F-ACTIN-BINDING; HUMAN-PLACENTA; T-CELLS; SIGNAL TRANSDUCTION; T200 GLYCOPROTEIN; MESSENGER-RNA; LY-5 ISOFORMS	GP180 is one of the major transmembrane glycoproteins in mouse T-lymphoma cells. This molecule is an isoform of CD45 and is known to contain an intrinsic protein tyrosine phosphatase (PTPase) activity. Using several complementary biochemical techniques, we have found that fodrin (a spectrin-like protein) is preferentially co-isolated with CD45 (GP180), suggesting that a complex between CD45 (GP180) and the cytoskeleton exists in mouse T-lymphoma cells. Furthermore, we have determined that this CD45 (GP180)-fodrin complex is dissociated by high salt treatment. Using in vitro binding assays, we have shown that CD45 (GP180) binds directly and specifically to fodrin (K(d) almost-equal-to 1.1 nM) or spectrin (K(d) almost-equal-to 3.2 nM) in a saturable manner. Additional analyses indicate that a 48-kDa phosphopeptide of CD45 (GP180) contains the fodrin/spectrin-binding domain. Most importantly, the direct binding of fodrin/spectrin to CD45 (GP180) is found to significantly stimulate the PTPase activity of CD45. Enzyme kinetic analysis indicates that fodrin and spectrin increase the V(max) of CD45 (GP180)-mediated dephosphorylation by 7.5 and 3.2-fold, respectively, without significantly changing the K(m) value. These results strongly suggest that the cytoskeletal proteins, fodrin and spectrin, play an important role in the regulation of the CD45 (GP180) PTPase activity during lymphocyte activation.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,MIAMI,FL 33101	University of Miami					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036353] Funding Source: NIH RePORTER; NCI NIH HHS [1F32CA06057] Funding Source: Medline; NIGMS NIH HHS [GM 36353] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUTERO M, 1987, EUR J IMMUNOL, V17, P1503, DOI 10.1002/eji.1830171018; BENNETT V, 1983, METHOD ENZYMOL, V96, P314; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOURGUIGNON LYW, 1985, J CELL BIOL, V101, P477, DOI 10.1083/jcb.101.2.477; BOURGUIGNON LYW, 1984, ENERGETICS SECRETION, V1, P83; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GLENNEY JR, 1982, J BIOL CHEM, V257, P9781; GLENNEY JR, 1982, CELL, V28, P843, DOI 10.1016/0092-8674(82)90063-0; GLENNEY JR, 1982, P NATL ACAD SCI-BIOL, V79, P4002, DOI 10.1073/pnas.79.13.4002; HALL LR, 1988, J IMMUNOL, V141, P2781; JOHNSON NA, 1989, J BIOL CHEM, V264, P6220; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KALOMIRIS EL, 1988, J CELL BIOL, V106, P319, DOI 10.1083/jcb.106.2.319; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; MINAMI Y, 1991, J BIOL CHEM, V266, P9222; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OSTERGAARD HL, 1991, SCIENCE, V253, P1423, DOI 10.1126/science.1654595; PIKE LJ, 1984, J BIOL CHEM, V259, P9913; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; SAGA Y, 1987, P NATL ACAD SCI USA, V84, P5364, DOI 10.1073/pnas.84.15.5364; SAGA Y, 1990, IMMUNOGENETICS, V31, P296, DOI 10.1007/BF02115003; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SHACKELFORD DA, 1986, J BIOL CHEM, V261, P8334; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; SUCHARD SJ, 1987, BIOCHIM BIOPHYS ACTA, V896, P35, DOI 10.1016/0005-2736(87)90353-1; THOMAS ML, 1987, P NATL ACAD SCI USA, V84, P5360, DOI 10.1073/pnas.84.15.5360; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; THOMAS ML, 1987, CELL, V41, P8393; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; YAMADA A, 1990, EUR J IMMUNOL, V20, P1655, DOI 10.1002/eji.1830200806; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1988, BIOCHEMISTRY-US, V27, P3113, DOI 10.1021/bi00409a001	46	71	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21551	21557						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400466				2022-12-25	WOS:A1992JV01100046
J	BLOMQUIST, JF; BAENZIGER, JU				BLOMQUIST, JF; BAENZIGER, JU			DIFFERENTIAL SORTING OF LUTROPIN AND THE FREE ALPHA-SUBUNIT IN CULTURED BOVINE PITUITARY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; GONADOTROPIN-RELEASING HORMONE; HAMSTER OVARY CELLS; FOLLICLE-STIMULATING-HORMONE; GLYCOPROTEIN HORMONES; LUTEINIZING-HORMONE; SIALYLATED OLIGOSACCHARIDES; STRUCTURAL ELUCIDATION; SECRETION; THYROTROPIN	The glycoprotein hormones lutropin (LH) and follitropin (FSH) are both synthesized by gonadotrophs in the anterior pituitary but are stored in separate secretory granules prior to secretion. Despite having highly homologous beta-subunits and alpha-subunits with the identical amino acid sequence, the Asn-linked oligosaccharides on LH terminate with SO4-GalNAc while those on FSH terminate with sialic acid-Gal. In addition to LH and FSH, gonadotrophs secrete uncombined (free) alpha-subunit which bears the same sulfated oligosaccharides as LH. We have examined the synthesis and secretion of LH and free alpha-subunit in primary cultures of bovine pituitary cells in order to determine if the sulfated oligosaccharides have any impact on sorting. Our results show that newly synthesized free alpha-subunit is secreted exclusively via the constitutive pathway with a t1/2 of 1.8 h and is never found in dense-core secretory granules. In contrast, LH dimer is secreted by both the constitutive and the regulated pathways. Constitutive secretion and arrival in a dense secretory granule both occur with t1/2 values of 1-1.5 h for newly synthesized LH. Sulfation occurs immediately prior to arrival of LH in the secretory granule and is followed by a period of 1-1.5 h before the LH-containing granules become sensitive to release by gonadotropin releasing hormone. As a result the t1/2 for LH secretion in the presence of gonadotropin releasing hormone is 3.5 h. Sulfation of the free alpha-subunit oligosaccharides is not, therefore, sufficient to direct the alpha-subunit to secretory granules, and the information required for directing LH to granules must reside either in the beta-subunit or the alphabeta-complex.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Baenziger, Jacques U/E-9430-2012		NIDDK NIH HHS [R01-DK41738] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041738] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAENZIGER JU, 1988, BIOCHIM BIOPHYS ACTA, V947, P287, DOI 10.1016/0304-4157(88)90012-3; BAENZIGER JU, 1991, BIOL CARBOHYDRATES, V3, P1; CLAYTON RN, 1989, J ENDOCRINOL, V120, P11, DOI 10.1677/joe.0.1200011; CORLESS CL, 1987, J CELL BIOL, V104, P1173, DOI 10.1083/jcb.104.5.1173; CORLESS CL, 1985, ENDOCRINOLOGY, V117, P1699, DOI 10.1210/endo-117-4-1699; DACHEUX F, 1976, CELL TISSUE RES, V174, P245, DOI 10.1007/BF00222162; GREEN ED, 1985, J BIOL CHEM, V260, P5623; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; GREEN ED, 1984, P NATL ACAD SCI-BIOL, V81, P5320, DOI 10.1073/pnas.81.17.5320; INOUE K, 1984, CELL TISSUE RES, V235, P77; KAETZEL DM, 1988, J BIOL CHEM, V263, P6344; KEENE JL, 1989, J BIOL CHEM, V264, P4769; MATSUUCHI L, 1991, J CELL BIOL, V112, P843, DOI 10.1083/jcb.112.5.843; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6354, DOI 10.1073/pnas.84.18.6354; MATZUK MM, 1988, MOL ENDOCRINOL, V2, P95, DOI 10.1210/mend-2-2-95; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; Rennels E G, 1980, Int Rev Physiol, V22, P1; SCHALLY AV, 1971, SCIENCE, V173, P1036, DOI 10.1126/science.173.4001.1036; STANNARD BS, 1988, J BIOL CHEM, V263, P8309; TOOZE SA, 1991, J CELL BIOL, V115, P1491, DOI 10.1083/jcb.115.6.1491; VONZASTROW M, 1987, J CELL BIOL, V105, P2675, DOI 10.1083/jcb.105.6.2675; WEISS J, 1990, ENDOCRINOLOGY, V127, P2364, DOI 10.1210/endo-127-5-2364; WHITCOMB RW, 1990, J CLIN ENDOCR METAB, V70, P1654, DOI 10.1210/jcem-70-6-1654; WINTERS SJ, 1985, J CLIN ENDOCR METAB, V60, P344, DOI 10.1210/jcem-60-2-344; YING SY, 1988, ENDOCR REV, V9, P267, DOI 10.1210/edrv-9-2-267	26	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20798	20803						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383211				2022-12-25	WOS:A1992JT97800046
J	BRADFORD, PG; WANG, XH; JIN, YY; HUI, P				BRADFORD, PG; WANG, XH; JIN, YY; HUI, P			TRANSCRIPTIONAL REGULATION AND INCREASED FUNCTIONAL EXPRESSION OF THE INOSITOL TRISPHOSPHATE RECEPTOR IN RETINOIC ACID-TREATED HL-60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMYELOCYTIC LEUKEMIA-CELLS; HUMAN-NEUTROPHILS; NUCLEOTIDE-SEQUENCE; FREE CALCIUM; BETA-ACTIN; DIFFERENTIATION; 1,4,5-TRISPHOSPHATE; PROTEIN; CDNA; INDUCTION	The inositol trisphosphate (InsP3) receptor is an essential regulator of intracellular calcium in many cells including chemoattractant- and cytokine-stimulated neutrophils and differentiated promyelocytic leukemic (HL-60) cells. We examined the expression and function of the InsP3 receptor and the transcriptional regulation of the InsP3 receptor gene in HL-60 cells and in HL-60 cells treated for 1-5 days with 1 muM retinoic acid. Radioligand binding studies using membranes from control and retinoic acid-treated HL-60 cells showed that the B(max) of InsP3 receptor increased progressively from 0.24 to 0.69 pmol/mg protein during 5 days retinoic acid treatment with no change in K(D) (19 nM). During this period, maximal InsP3-stimulated Ca2+ mobilization increased 2-3-fold. InsP3 receptor mRNA was present at low levels in HL-60 cells but was increased significantly after treatment with retinoic acid, reaching maximal levels of approximately 4-fold greater than untreated cells after 4 days treatment with retinoic acid. Nuclear run-on assays indicated that the elevated steady state level of InsP3 receptor mRNA in retinoic acid-treated HL-60 cells was primarily the result of enhanced transcription of the InsP3 receptor gene. Furthermore, the transcriptional enhancing effect of retinoic acid was seen in the presence of cycloheximide, suggesting that the InsP3 receptor gene is directly regulated by retinoic acid. The studies also demonstrate that the InsP3 receptor mRNA is rapidly degraded in HL-60 cells by a mechanism that also requires protein synthesis.			BRADFORD, PG (corresponding author), SUNY BUFFALO,DEPT PHARMACOL & THERAPEUT,BUFFALO,NY 14214, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039588] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39588] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD PG, 1985, MOL PHARMACOL, V27, P74; BRADFORD PG, 1986, J BIOL CHEM, V261, P5644; BRADFORD PG, 1991, BIOCHEM J, V280, P205, DOI 10.1042/bj2800205; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CASTAIGNE S, 1990, BLOOD, V76, P1704; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; COLLINS SJ, 1979, J EXP MED, V149, P969, DOI 10.1084/jem.149.4.969; COLLINS SJ, 1987, BLOOD, V70, P1233; DOUGHERTY RW, 1984, BIOCHEM J, V222, P307, DOI 10.1042/bj2220307; FURUICHI T, 1989, NUCLEIC ACIDS RES, V17, P5385, DOI 10.1093/nar/17.13.5385; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HICKSTEIN DD, 1988, J BIOL CHEM, V263, P13863; HICKSTEIN DD, 1989, J BIOL CHEM, V264, P21812; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; NIEDEL J, 1980, P NATL ACAD SCI-BIOL, V77, P1000, DOI 10.1073/pnas.77.2.1000; NORDQUIST DT, 1988, J NEUROSCI, V8, P4780; PRENTKI M, 1984, J BIOL CHEM, V259, P3777; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARTZ EL, 1988, CANCER RES, V48, P2683; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; SMOLEN JE, 1985, J IMMUNOL, V134, P1859; SMOLEN JE, 1990, HEMATOLOGY, P780; SPAT A, 1986, NATURE, V319, P514, DOI 10.1038/319514a0; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; WHITE JR, 1983, BIOCHEM BIOPH RES CO, V113, P44, DOI 10.1016/0006-291X(83)90429-1; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077	34	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20959	20964						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383213				2022-12-25	WOS:A1992JT97800071
J	LOW, BC; ROSS, IK; GRIGOR, MR				LOW, BC; ROSS, IK; GRIGOR, MR			ANGIOTENSIN-II STIMULATES GLUCOSE-TRANSPORT ACTIVITY IN CULTURED VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SPONTANEOUSLY HYPERTENSIVE RATS; NECROSIS-FACTOR-ALPHA; EARLY GENE-EXPRESSION; FACTOR-A-CHAIN; MESSENGER-RNA; 3T3-L1 PREADIPOCYTES; PHORBOL ESTER; PROTEIN; SERUM	The glucose transport system in cultured rat vascular smooth muscle cells has been examined by measuring the uptake of 2-deoxyglucose. Angiotensin II (Ang II) stimulated 2-deoxyglucose uptake in cells made quiescent by removing serum from the culture medium in a dose- and time-dependent manner that was shown to be receptor-mediated. Epidermal growth factor (EGF), fetal calf serum, thrombin, and arginine vasopressin also stimulated glucose transport. Cycloheximide did not affect the immediate-early (30 min) activation by either Ang II or EGF, but abolished any further increase. This suggested that, whereas the initial activation of glucose transport was independent of protein synthesis, the sustained increase required the synthesis of new glucose transporters. This was supported by 4-fold and 2-fold accumulations of GLUT-1 mRNA 4 h after exposure to Ang II and EGF, respectively. The induction of GLUT-1 mRNA was preceded by rapid and transient expression of c-fos and c-jun protoonco-genes. In nuclear run-on assays, nuclei from Ang II-treated cells showed increased synthesis of GLUT-1 mRNA at 30 min and 1 h after hormone treatment. In contrast, in cells exposed to actinomycin D, pretreatment with Ang II had no effect on the turnover rates of GLUT-1 mRNA. These results are consistent with Ang II acting to stimulate the rate of transcription of the GLUT-1 gene leading to increased production of GLUT-1 protein and glucose transport.	UNIV OTAGO,DEPT BIOCHEM,POB 56,DUNEDIN 9001,NEW ZEALAND	University of Otago			Low, Boon Chuan/H-8049-2012	Low, Boon Chuan/0000-0003-0756-096X				BERK BC, 1987, J BIOL CHEM, V262, P5065; BERK BC, 1985, J CLIN INVEST, V75, P1083, DOI 10.1172/JCI111772; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORNELIUS P, 1991, J CELL PHYSIOL, V146, P298, DOI 10.1002/jcp.1041460215; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DELEEUW WJF, 1989, NUCLEIC ACIDS RES, V17, P10137, DOI 10.1093/nar/17.23.10137; GIBBONS GH, 1990, CLIN RES, V38, P287; GOULD GW, 1989, BIOCHEMISTRY-US, V28, P9447, DOI 10.1021/bi00450a030; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HADRAVA V, 1989, HYPERTENSION, V13, P589, DOI 10.1161/01.HYP.13.6.589; HARRIS EL, 1990, BIOCHEM BIOPH RES CO, V170, P1249, DOI 10.1016/0006-291X(90)90528-U; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; ITOH H, 1991, BIOCHEM BIOPH RES CO, V176, P1601, DOI 10.1016/0006-291X(91)90471-I; JONES TLZ, 1989, J BIOL CHEM, V264, P7874; KAHN BB, 1990, DIABETES CARE, V13, P548, DOI 10.2337/diacare.13.6.548; KITAGAWA T, 1989, BIOCHIM BIOPHYS ACTA, V980, P100, DOI 10.1016/0005-2736(89)90205-8; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; NABIKA T, 1985, J BIOL CHEM, V260, P4661; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PAQUET JL, 1990, J HYPERTENS, V8, P565, DOI 10.1097/00004872-199006000-00010; PEKALA P, 1990, J BIOL CHEM, V265, P18051; ROLLINS BJ, 1988, J BIOL CHEM, V263, P16523; Sambrook J, 1989, MOL CLONING LABORATO; SCHELLING P, 1979, J CELL PHYSIOL, V98, P503, DOI 10.1002/jcp.1040980309; SCHELLING P, 1991, J HYPERTENS, V9, P3; SCOTTBURDEN T, 1988, BIOCHEM BIOPH RES CO, V151, P583, DOI 10.1016/0006-291X(88)90634-1; SCOTTBURDEN T, 1989, HYPERTENSION, V13, P295, DOI 10.1161/01.HYP.13.4.295; SILVERMAN M, 1991, ANNU REV BIOCHEM, V60, P757, DOI 10.1146/annurev.bi.60.070191.003545; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TAKEUCHI K, 1990, BIOCHEM BIOPH RES CO, V172, P1189, DOI 10.1016/0006-291X(90)91574-C; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; WILLIAMS SA, 1988, J BIOL CHEM, V263, P19513; ZAR JH, 1974, MULTIPLE COMP BIOSTA, P151	42	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20740	20745						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400389				2022-12-25	WOS:A1992JT97800037
J	MONIA, BP; JOHNSTON, JF; ECKER, DJ; ZOUNES, MA; LIMA, WF; FREIER, SM				MONIA, BP; JOHNSTON, JF; ECKER, DJ; ZOUNES, MA; LIMA, WF; FREIER, SM			SELECTIVE-INHIBITION OF MUTANT HA-RAS MESSENGER-RNA EXPRESSION BY ANTISENSE OLIGONUCLEOTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLADDER-CARCINOMA ONCOGENE; PRECURSOR PROTEIN GENE; DOUBLE-HELIX FORMATION; ALZHEIMERS-DISEASE; POINT MUTATION; STRUCTURAL FEATURES; GTPASE ACTIVITY; P21 EXPRESSION; HUMAN CANCER; ANTI-SENSE	A biological reporter gene assay was employed to determine the crucial parameters for maximizing selective targeting of a Ha-ras codon 12 point mutation (G --> T) using phosphorothioate antisense oligonucleotides. We have tested a series of oligonucleotides ranging in length between 5 and 25 bases, each centered around the codon 12 point mutation. Our results indicate that selective targeting of this point mutation can be achieved with phosphorothioate antisense oligonucleotides, but this selectivity is critically dependent upon oligonucleotide length and concentration. The maximum selectivity observed in antisense experiments, 5-fold for a 17-base oligonucleotide, was closely predicted by a simple thermodynamic model that relates the fraction of mutant to wild type target bound as a function of oligonucleotide concentration and affinity. These results suggest thermodynamic analysis of oligonucleotide/target interactions is useful in predicting the specificity that can be achieved by an antisense oligonucleotide targeted to a single base point mutation.	ISIS PHARMACEUT, DEPT MED CHEM, CARLSBAD, CA 92008 USA	Isis Pharmaceuticals Inc	MONIA, BP (corresponding author), ISIS PHARMACEUT, DEPT MOLEC & CELLULAR BIOL, 2280 FARADAY AVE, CARLSBAD, CA 92008 USA.			Ecker, David/0000-0003-4350-9037				ABOULELA F, 1985, NUCLEIC ACIDS RES, V13, P4811, DOI 10.1093/nar/13.13.4811; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BAVISOTTO L, 1991, J EXP MED, V174, P1097, DOI 10.1084/jem.174.5.1097; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BORER PN, 1974, J MOL BIOL, V86, P843, DOI 10.1016/0022-2836(74)90357-X; BOS JL, 1989, CANCER RES, V49, P4682; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BROWN D, 1989, ONCOGENE RES, V4, P243; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CARTWRIGHT T, 1992, CHIMICAOGGI, V32, P26; CHANG EH, 1989, ANTI-CANCER DRUG DES, V4, P221; CHANG EH, 1991, BIOCHEMISTRY-US, V30, P8283, DOI 10.1021/bi00098a001; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329; DAAKA Y, 1990, ONCOGENE RES, V5, P267; DEWET JR, 1985, P NATL ACAD SCI USA, V82, P7870; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DOLNICK BJ, 1990, BIOCHEM PHARMACOL, V40, P671, DOI 10.1016/0006-2952(90)90300-A; FREIER SM, 1985, BIOCHEMISTRY-US, V24, P4533, DOI 10.1021/bi00338a008; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GILES RV, 1992, ANTI-CANCER DRUG DES, V7, P37; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HAUSEN P, 1970, EUR J BIOCHEM, V14, P278, DOI 10.1111/j.1432-1033.1970.tb00287.x; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HELENE C, 1989, OLIGODEOXYNUCLEOTIDE, P137; HOKE GD, 1991, NUCLEIC ACIDS RES, V19, P5743, DOI 10.1093/nar/19.20.5743; INOUE H, 1987, FEBS LETT, V215, P327, DOI 10.1016/0014-5793(87)80171-0; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LEVY Y, 1991, J CLIN INVEST, V88, P696, DOI 10.1172/JCI115355; MAHER LJ, 1988, NUCLEIC ACIDS RES, V16, P3341, DOI 10.1093/nar/16.8.3341; MANNE V, 1985, P NATL ACAD SCI USA, V82, P376, DOI 10.1073/pnas.82.2.376; MANSON J, 1990, LYMPHOKINE RES, V9, P35; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; MORRISON RS, 1991, J BIOL CHEM, V266, P728; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NECKERS L, 1992, Critical Reviews in Oncogenesis, V3, P175; OWEN RD, 1990, P NATL ACAD SCI USA, V87, P3866, DOI 10.1073/pnas.87.10.3866; PETERSHEIM M, 1983, BIOCHEMISTRY-US, V22, P256, DOI 10.1021/bi00271a004; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; REDDY EP, 1983, SCIENCE, V220, P1061, DOI 10.1126/science.6844927; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SAISONBEHMOARAS T, 1991, EMBO J, V10, P1111, DOI 10.1002/j.1460-2075.1991.tb08051.x; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; STEIN CA, 1988, CANCER RES, V48, P2659; STEIN H, 1969, SCIENCE, V166, P393, DOI 10.1126/science.166.3903.393; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TANAKA T, 1992, J EXP MED, V175, P597, DOI 10.1084/jem.175.2.597; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TIDD DM, 1988, ANTI-CANCER DRUG DES, V3, P117; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; VICKERS T, 1991, NUCLEIC ACIDS RES, V19, P3359, DOI 10.1093/nar/19.12.3359; WASYLYK B, 1988, P NATL ACAD SCI USA, V85, P7952, DOI 10.1073/pnas.85.21.7952; WEINBERG RA, 1988, CANCER-AM CANCER SOC, V61, P1963, DOI 10.1002/1097-0142(19880515)61:10<1963::AID-CNCR2820611005>3.0.CO;2-8; WU T, 1990, J ORG CHEM, V55, P4717, DOI 10.1021/jo00302a044; WU TF, 1989, NUCLEIC ACIDS RES, V17, P3501, DOI 10.1093/nar/17.9.3501; YU Z, 1989, Journal of Experimental Pathology (New York), V4, P97; ZON G, 1988, PHARM RES-DORDR, V5, P539, DOI 10.1023/A:1015985728434	69	240	286	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19954	19962						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400312				2022-12-25	WOS:A1992JR85800036
J	SWARTZ, DR; MOSS, RL				SWARTZ, DR; MOSS, RL			INFLUENCE OF A STRONG-BINDING MYOSIN ANALOG ON CALCIUM-SENSITIVE MECHANICAL-PROPERTIES OF SKINNED SKELETAL-MUSCLE FIBERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT PSOAS FIBERS; ACTOMYOSIN ATPASE ACTIVITY; X-RAY-DIFFRACTION; TROPONIN-TROPOMYOSIN; THIN-FILAMENT; CA-2+ SENSITIVITY; ADENOSINE-TRIPHOSPHATASE; LABELED TROPOMYOSIN; FORCE GENERATION; REGULATORY SITES	The ability of strong-binding myosin heads to activate the thin filament was investigated by incubating skinned single muscle fibers with N-ethylmaleimide-(NEM) modified myosin subfragment-1 (S1). Isometric force was influenced in a complex manner: during maximal calcium activation, NEM-S1 inhibited force with half-maximal inhibition at 20 muM while at submaximal calcium, NEM-S1 potentiated force with greatest effect at 6 muM. When fibers were treated with NEM-SI (4-8 muM), the tension-pCa (-log [Ca2+]) relationship became less steep (i.e. the Hill coefficient decreased from 5.4 to 3.0 upon treatment with NEM-S1), but the midpoint was unchanged. These results support the idea that strong binding of intrinsic heads contributes to the cooperativity observed in Ca2+ activation of force. The NEM-S1-induced increase in force at low Ca2+ was associated with an acceleration of a kinetic transition, and this transition was activated to near maximum while force was not. The rate of force redevelopment following restretch (k(tr)) at submaximal calcium was increased by NEM-S1 in a concentration-dependent manner, yielding a maximum rate at low [Ca2+] which was similar to that observed during full activation. The effects of NEM-S1 on force and k(tr) indicate that strong-binding myosin cross-bridges are involved in activation of the thin filament.			SWARTZ, DR (corresponding author), UNIV WISCONSIN, DEPT PHYSIOL, MADISON, WI 53706 USA.				NCRR NIH HHS [RR 00570] Funding Source: Medline; NHLBI NIH HHS [HL25861, HL08400-01] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000570] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008400, R01HL025861] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRABAREK Z, 1983, J BIOL CHEM, V258, P14098; BRANDT PW, 1987, J MOL BIOL, V195, P885, DOI 10.1016/0022-2836(87)90492-X; BRANDT PW, 1990, J MOL BIOL, V212, P473, DOI 10.1016/0022-2836(90)90326-H; BRANDT PW, 1982, J GEN PHYSIOL, V79, P997, DOI 10.1085/jgp.79.6.997; BREMEL RD, 1972, NATURE-NEW BIOL, V238, P97, DOI 10.1038/newbio238097a0; BRENNER B, 1988, Pfluegers Archiv European Journal of Physiology, V412, pR79; BRENNER B, 1988, P NATL ACAD SCI USA, V85, P3265, DOI 10.1073/pnas.85.9.3265; BRENNER B, 1986, P NATL ACAD SCI USA, V83, P3542, DOI 10.1073/pnas.83.10.3542; BRENNER B, 1986, BIOPHYS J, V50, P1101, DOI 10.1016/S0006-3495(86)83554-8; BRENNER B, 1986, BIOPHYS J, V50, P685, DOI 10.1016/S0006-3495(86)83509-3; BRENNER B, 1990, MOL MECHANISMS MUSCU; BURTON K, 1989, J PHYSIOL-LONDON, V418, pP66; CARTER SG, 1982, J BIOCHEM BIOPH METH, V7, P7, DOI 10.1016/0165-022X(82)90031-8; CHALOVICH JM, 1986, J BIOL CHEM, V261, P5088; CHALOVICH JM, 1981, J BIOL CHEM, V256, P575; DANTZIG JA, 1988, P NATL ACAD SCI USA, V85, P6716, DOI 10.1073/pnas.85.18.6716; EDMAN KAP, 1980, ACTA PHYSIOL SCAND, V109, P15, DOI 10.1111/j.1748-1716.1980.tb06559.x; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ELSALEH SC, 1986, J MUSCLE RES CELL M, V7, P387, DOI 10.1007/BF01753582; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FARROW AJ, 1988, J MUSCLE RES CELL M, V9, P261, DOI 10.1007/BF01773896; GILLIS JM, 1975, J MOL BIOL, V99, P445, DOI 10.1016/S0022-2836(75)80137-9; GODT RE, 1982, J GEN PHYSIOL, V80, P279, DOI 10.1085/jgp.80.2.279; GREENE L, 1982, J BIOL CHEM, V257, P3993; GREENE LE, 1986, J BIOL CHEM, V282, P1279; GREENE LE, 1980, P NATL ACAD SCI USA, V77, P2626; GUTH K, 1987, J BIOL CHEM, V262, P13627; Haselgrove J. C., 1972, COLD SPRING HARB SYM, V37, P341; HILL TL, 1983, BIOPHYS J, V44, P383, DOI 10.1016/S0006-3495(83)84312-4; HOAR PE, 1987, PFLUG ARCH EUR J PHY, V410, P30, DOI 10.1007/BF00581892; Huxley H. E., 1972, COLD SPRING HARB SYM, V37, P361; ISHII Y, 1987, BIOCHEMISTRY-US, V26, P4922, DOI 10.1021/bi00390a005; ISHII Y, 1990, BIOCHEMISTRY-US, V29, P1160, DOI 10.1021/bi00457a010; KRESS M, 1986, J MOL BIOL, V188, P325, DOI 10.1016/0022-2836(86)90158-0; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; LEHRER SS, 1988, BIOCHEMISTRY-US, V27, P5899, DOI 10.1021/bi00416a012; LU Z, 1991, Biophysical Journal, V59, p417A; LU Z, 1992, BIOPHYS J, V61, P294; MEEUSEN RL, 1979, J CELL BIOL, V82, P57, DOI 10.1083/jcb.82.1.57; METZGER JM, 1989, J GEN PHYSIOL, V93, P855, DOI 10.1085/jgp.93.5.855; MILLAR NC, 1990, J BIOL CHEM, V265, P20234; MOSS RL, 1979, J PHYSIOL-LONDON, V292, P177, DOI 10.1113/jphysiol.1979.sp012845; MOSS RL, 1983, BIOPHYS J, V43, P115, DOI 10.1016/S0006-3495(83)84329-X; MOSS RL, 1986, J PHYSIOL-LONDON, V377, P487, DOI 10.1113/jphysiol.1986.sp016199; MOSS RL, 1985, J GEN PHYSIOL, V86, P585, DOI 10.1085/jgp.86.4.585; NAGASHIMA H, 1982, J MOL BIOL, V155, P409, DOI 10.1016/0022-2836(82)90479-X; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PARRY DAD, 1973, J MOL BIOL, V75, P33, DOI 10.1016/0022-2836(73)90527-5; PATE E, 1989, J MUSCLE RES CELL M, V10, P181, DOI 10.1007/BF01739809; PEMRICK S, 1976, BIOCHEMISTRY-US, V15, P5193, DOI 10.1021/bi00668a038; REISLER E, 1974, BIOCHEMISTRY-US, V13, P2014, DOI 10.1021/bi00707a003; ROSENFELD SS, 1985, J BIOL CHEM, V260, P252; SEKINE T, 1964, BIOCHIM BIOPHYS ACTA, V81, P336, DOI 10.1016/0926-6569(64)90049-5; Squire J, 1981, STRUCTURAL BASIS MUS; SWARTZ DR, 1991, J CELL BIOL, V59, pA587; TOBACMAN LS, 1987, BIOCHEMISTRY-US, V26, P492, DOI 10.1021/bi00376a022; TOBACMAN LS, 1990, J BIOL CHEM, V265, P931; TRAYER HR, 1988, BIOCHEMISTRY-US, V27, P5718, DOI 10.1021/bi00415a049; TRYBUS KM, 1980, P NATL ACAD SCI-BIOL, V77, P7209, DOI 10.1073/pnas.77.12.7209; WAKABAYASHI T, 1975, J MOL BIOL, V93, P477, DOI 10.1016/0022-2836(75)90241-7; WALKER JW, 1990, BIOPHYS J, V57, pA538; WALKER JW, 1992, J BIOL CHEM, V267, P2459; WALKER JW, 1991, BIOPHYS J, V59, P418; WALSH TP, 1984, J MOL BIOL, V182, P265; WATERSON JG, 1975, EUR J BIOCHEM, V56, P79; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WEEDS AG, 1977, J MOL BIOL, V111, P129, DOI 10.1016/S0022-2836(77)80119-8; WELLS JA, 1980, BIOCHEMISTRY-US, V19, P1711, DOI 10.1021/bi00549a030; WILLIAMS DL, 1988, BIOCHEMISTRY-US, V27, P6987, DOI 10.1021/bi00418a048; ZOT AS, 1989, BIOCHEMISTRY-US, V28, P6751, DOI 10.1021/bi00442a031; [No title captured]	71	148	148	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20497	20506						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400367				2022-12-25	WOS:A1992JR85800116
J	BLACKMORE, PF; OAKES, SG; SOMERS, KD				BLACKMORE, PF; OAKES, SG; SOMERS, KD			ALTERED H1 HISTAMINE-RECEPTOR SIGNALING IN BALB/3T3 CELLS TRANSFORMED BY V-K-RAS AND V-H-RAS ONCOGENES	ONCOGENE			English	Article							SMOOTH-MUSCLE CELLS; GROWTH-FACTOR; TUMOR; PROTEIN; ACTIVATE; H-1	Transformation of Balb/3T3 cells with the v-K-ras oncogene resulted in the expression of functional Ca2+-mobilizing receptors for histamine, whereas v-H-ras-transformed Balb/3T3 cells failed to show a similar response to histamine. Stimulation of histamine receptors in v-K-ras-transformed cells produced a dose-dependent increase in intracellular free calcium ([Ca2+]i), which was inhibited by the H-1 histamine antagonist pyrilamine but unaffected by the H-1 histamine receptor antagonist cimetidine. Histamine-mediated elevation of [Ca2+]i was partially inhibited by the removal of extracellular Ca2+, which indicates that the H-1 histamine receptors mobilize intracellular Ca2+ and also promote Ca2+ influx. H-1 histamine receptors were identified in both v-K-ras- and v-H-ras-transformed Balb/3T3 cells, but not in untransformed cells, using the specific H-1 antagonist [H-3]-pyrilamine. Transformation of Balb/3T3 cells with the viral ras oncogene results in a complex regulation of H-1 histamine receptors. K-ras and H-ras transformation results in the expression of H-1 histamine receptors; however, H-1 receptor expression and Ca2+ mobilization are uncoupled in v-H-ras-transformed cells.	EASTERN VIRGINIA MED SCH,DEPT MICROBIOL & IMMUNOL,NORFOLK,VA 23501	Eastern Virginia Medical School	BLACKMORE, PF (corresponding author), EASTERN VIRGINIA MED SCH,DEPT PHARMACOL,POB 1980,NORFOLK,VA 23501, USA.							BATHOLEYNS J, 1984, CANCER RES, V44, P639; BATHOLEYNS J, 1985, TRENDS PHARMACOL SCI, V6, P123; BURTIN C, 1982, BRIT J CANCER, V45, P54, DOI 10.1038/bjc.1982.7; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DOWNWARD J, 1988, P NATL ACAD SCI USA, V85, P5774, DOI 10.1073/pnas.85.16.5774; FISCHER SM, 1990, CARCINOGENESIS, V11, P991, DOI 10.1093/carcin/11.6.991; GALLOPIN L, 1984, AGENTS ACTIONS, V14, P494; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HILL SJ, 1990, PHARMACOL REV, V42, P45; MARSHALL CJ, 1988, J CELL SCI S, V10, P157; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MITSUHASHI M, 1989, MOL PHARMACOL, V35, P751; MITSUHASHI M, 1989, J CELL BIOCHEM, V40, P183, DOI 10.1002/jcb.240400207; MITSUHASHI M, 1988, J CELL PHYSIOL, V134, P367, DOI 10.1002/jcp.1041340307; MITSUHASHI M, 1989, MOL PHARMACOL, V35, P311; SOMERS KD, 1980, CELL BIOL INT REP, V4, P487, DOI 10.1016/0309-1651(80)90036-3; SOMERS KD, 1980, CANCER RES, V40, P4410; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TILLY BC, 1990, J CELL BIOL, V110, P1211, DOI 10.1083/jcb.110.4.1211; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x	26	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2053	2057						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408146				2022-12-25	WOS:A1992JP42400020
J	LARSEN, J; BEUG, H; HAYMAN, MJ				LARSEN, J; BEUG, H; HAYMAN, MJ			THE V-SKI ONCOGENE COOPERATES WITH THE V-SEA ONCOGENE IN ERYTHROID TRANSFORMATION BY BLOCKING ERYTHROID-DIFFERENTIATION	ONCOGENE			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; MYELOID CELLS; HISTONE H-5; EXPRESSION; TRANSCRIPTION; GROWTH; LEUKEMIA; PROTEIN; MUSCLE; GENES	The avian retrovirus oncogene v-ski was analysed for its ability to alter the differentiation program of erythroid cells and to cooperate with tyrosine kinase oncogenes in leukemogenesis. For this, a retrovirus combining v-ski with a temperature-sensitive version of the v-sea oncogene was constructed. In transformed erythroblasts, v-ski disturbed the concerted expression of several erythrocyte genes, leading to an abnormal erythroblast phenotype. Expression levels of hemoglobin and erythrocyte anion transporter (band 3) were elevated, while expression of the erythroid-specific histone H5 was strongly suppressed. v-ski could also be shown to repress or severely retard the temperature-induced erythroid differentiation of v-ski/ts-v-sea-transformed cells. The undifferentiated celts had an abnormal erythroblast or early reticulocyte phenotype characterized by unusually low levels of histone H5. In chicks, the v-ski/ts-v-sea virus displayed enhanced leukemogenicity compared with viruses containing just the single oncogenes. Thus, v-ski cooperates with tyrosine kinase oncogenes in a similar fashion to the v-erbA oncogene, however the pattern of genes affected by these two oncogenes is different.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)					NCI NIH HHS [CA28146, CA42573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042573, P01CA028146] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; BERGMAN MG, 1988, J CELL SCI, V91, P201; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1989, EUR J CLIN INVEST, V19, P491, DOI 10.1111/j.1365-2362.1989.tb00265.x; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; BEUG H, 1991, NUCLEAR HORMONE RECE, P355; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FUERSTENBERG S, 1990, J VIROL, V64, P5891, DOI 10.1128/JVI.64.12.5891-5902.1990; GRAF T, 1978, NATURE, V275, P496, DOI 10.1038/275496a0; HAYMAN MJ, 1991, CANCER CELL-MON REV, V3, P302; HAYMAN MJ, 1992, IN PRESS CANCER SURV; JANSSON M, 1987, ONCOGENE, V1, P167; KAHN P, 1986, 12 S COMP RES LEUK R, P41; KAMPS MP, 1988, ONCOGENE, V2, P305; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; KOWENZ E, 1987, MODERN TRENDS HUMAN, V7, P199; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; METZ T, 1992, ONCOGENE, V7, P597; NAGASE T, 1990, NUCLEIC ACIDS RES, V18, P337, DOI 10.1093/nar/18.2.337; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1991, MOL CELL BIOCHEM, V104, P7; PAIN B, 1990, New Biologist, V2, P284; SCHMIDT JA, 1986, CELL, V46, P41, DOI 10.1016/0092-8674(86)90858-5; SCHROEDER C, 1990, ONCOGENE, V5, P1445; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; Stavnezer E., 1988, ONCOGENE HDB, P393; STRIFE A, 1988, CANCER RES, V48, P1035; SUN JM, 1989, SCIENCE, V245, P68, DOI 10.1126/science.2740916; SUTRAVE P, 1991, ONCOGENE, V6, P353; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	42	29	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1903	1911						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408132				2022-12-25	WOS:A1992JP42400002
J	MAZUMDER, S; MUKHERJEE, T; GHOSH, J; RAY, M; BHADURI, A				MAZUMDER, S; MUKHERJEE, T; GHOSH, J; RAY, M; BHADURI, A			ALLOSTERIC MODULATION OF LEISHMANIA-DONOVANI PLASMA-MEMBRANE CA2+-ATPASE BY ENDOGENOUS CALMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-MEMBRANE; CA-2+-DEPENDENT ATPASE; INTRACELLULAR CALCIUM; TRYPANOSOMA-BRUCEI; PROTEIN; PROMASTIGOTES; CA-2+-ATPASE; PURIFICATION; TRANSPORT; CRUZI	The plasma membrane of the human pathogen Leishmania donovani possesses a high-affinity transmembrane Ca2+-ATPase that has its catalytic site oriented toward the cytoplasmic milieu (Ghosh, J., Ray, M., Sarkar, S., and Bhaduri, A. (1990) J. Biol. Chem. 265, 11345-11351). When the enzyme is studied in its more authentic, physiologically relevant, membrane-associated form, it exhibits pronounced sigmoidal kinetics with Ca2+ (K0.5 almost-equal-to 700 nM) in a trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid buffering system that effectively complexes all available Mg2+. Addition of exogenous Mg2+ (60-mu-m) completely abolishes sigmoidicity and establishes strictly hyperbolic kinetics, and the K(m) for Ca2+ reduces to 100 nM. Mg2+ can be replaced by heterologous calmodulin. The exclusive dependence of the enzyme on only Ca2+ for its activity and its positive allosteric modulation by Mg2+ distinguish this enzyme from other well-characterized plasma membrane Ca2+-ATPases. Employing this Ca2+-ATPase as the assay system, a soluble endogenous activating protein factor was purified that, by several criteria, corresponds to authentic calmodulin. The parasite calmodulin shifts the kinetics to hyperbolic kinetics, increases the V(max) 2-fold, and most important lowers the K(m) (almost-equal-to 100 nm) to a physiological level. The interaction with endogenous calmodulin thus converts the enzyme from a totally inactive to a fully active state.	JADAVPUR UNIV,DEPT PHARM,DIV VIRAL DIS,CALCUTTA 700032,W BENGAL,INDIA	Jadavpur University	MAZUMDER, S (corresponding author), INDIAN INST EXPTL MED,DIV ENZYME,LEISHMANIA GRP,4 RAJA SC MULLICK RD,CALCUTTA 700032,W BENGAL,INDIA.							ALEXANDER J, 1975, J PROTOZOOL, V22, P502, DOI 10.1111/j.1550-7408.1975.tb05219.x; BAIS R, 1975, ANAL BIOCHEM, V63, P271, DOI 10.1016/0003-2697(75)90215-8; BENAIM G, 1990, BIOCHIM BIOPHYS ACTA, V1027, P79, DOI 10.1016/0005-2736(90)90051-O; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARAFOLI E, 1991, ANNU REV PHYSIOL, V53, P531, DOI 10.1146/annurev.physiol.53.1.531; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CHAKRABORTY P, 1988, MOL BIOCHEM PARASIT, V28, P55, DOI 10.1016/0166-6851(88)90180-6; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DWYER DM, 1984, MOL BIOCHEM PARASIT, V10, P139, DOI 10.1016/0166-6851(84)90002-1; GHOSH J, 1990, J BIOL CHEM, V265, P11345; GIETZEN K, 1981, BIOCHEM BIOPH RES CO, V101, P418, DOI 10.1016/0006-291X(81)91276-6; GOMEZ ML, 1989, MOL BIOCHEM PARASIT, V36, P101, DOI 10.1016/0166-6851(89)90182-5; IWASA Y, 1982, FEBS LETT, V142, P67, DOI 10.1016/0014-5793(82)80221-4; KLEE CB, 1980, ANNU REV BIOCHEM, V49, P489, DOI 10.1146/annurev.bi.49.070180.002421; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOWRY OH, 1957, METHOD ENZYMOL, V3, P845; Martell A. E., 1971, SPECIAL PUBLICATION, V17; MCLAUGHLIN J, 1985, MOL BIOCHEM PARASIT, V15, P189, DOI 10.1016/0166-6851(85)90119-7; MERRIL CR, 1984, METHOD ENZYMOL, V104, P441; ONEAL SG, 1979, BIOCHEM BIOPH RES CO, V89, P845, DOI 10.1016/0006-291X(79)91855-2; PERSHADSINGH HA, 1980, J BIOL CHEM, V255, P4087; PHILOSOPH H, 1989, J BIOL CHEM, V264, P10420; RASMUSSEN H, 1977, PHYSIOL REV, V57, P421, DOI 10.1152/physrev.1977.57.3.421; SCARBOROUGH GA, 1975, J BIOL CHEM, V250, P1106; SEEBECK T, 1983, MOL BIOCHEM PARASIT, V9, P197, DOI 10.1016/0166-6851(83)90097-X; SILLEN LG, 1971, SPECIAL PUBLICATION, V25; TELLEZINON MT, 1985, MOL BIOCHEM PARASIT, V17, P143, DOI 10.1016/0166-6851(85)90013-1; TRAVIS SM, 1986, BIOCHIM BIOPHYS ACTA, V862, P39, DOI 10.1016/0005-2736(86)90466-9; TSCHUDI C, 1985, P NATL ACAD SCI USA, V82, P3998, DOI 10.1073/pnas.82.12.3998; TUANA BS, 1982, J BIOL CHEM, V257, P4440; VANMAN TC, 1983, METHOD ENZYMOL, V102, P296; VOORHEIS HP, 1982, J BIOL CHEM, V257, P2300; WANG JH, 1977, J BIOL CHEM, V252, P4175; ZILBERSTEIN D, 1988, BIOCHEM J, V256, P13, DOI 10.1042/bj2560013; ZILBERSTEIN D, 1985, P NATL ACAD SCI USA, V82, P1716, DOI 10.1073/pnas.82.6.1716; [No title captured]	38	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18440	18446						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1388152				2022-12-25	WOS:A1992JN50200034
J	SHIMAMURA, M; OKU, M; YAMAGATA, T				SHIMAMURA, M; OKU, M; YAMAGATA, T			A NOVEL GANGLIOSIDE EXPRESSED BY MOUSE HEMATOPOIETIC-CELL LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; BONE-MARROW CELLS; GRANULOCYTIC DIFFERENTIATION; LYMPHOCYTES-T; GLYCOSPHINGOLIPIDS; THYMOCYTES; SEQUENCE; CERAMIDE; GAMMA; DISIALOGANGLIOSIDE	Mouse progenitor T cell-derived cell lines were established by fusion of cells of hematopoietic organs such as bone marrow and fetal liver with T lymphoma (BW5147) to determine their characteristic cell-surface components. The hybridomas with the phenotype of Thy-1+,CD3-,CD4-,CD8- and expression of T cell receptor gene mRNA (BM216 and FL339) were selected for progenitor T cell-derived cell lines, and their ganglioside compositions were studied. A ganglioside component with a mobility slightly faster than that of bovine brain G(D1a). on high-performance thin-layer chromatography was found in the cell extracts of these cell lines as one of the most abundant components and was absent in the extract of the parental cell line (BW5147). The structure of the ganglioside was determined to be: NeuAc-alpha-Gal-beta-Gal-beta,-Gal-alpha-Gal-beta-Glc-beta-ceramide. Gangliosides with such a sequence have never been found before, suggesting the possibility that the ganglioside is expressed as a surface marker of the cells in hematopoietic organs committed to a specific cell lineage, presumably to T cell lineage.	MITSUBISHI KASEI INST LIFE SCI, GLYCOCONJUGATE RES LAB, MACHIDA, TOKYO 194, JAPAN		SHIMAMURA, M (corresponding author), MITSUBISHI KASEI INST LIFE SCI, MOLEC IMMUNOL LAB, 11 MINAMIOOYA, MACHIDA, TOKYO 194, JAPAN.							AIHARA Y, 1986, EUR J IMMUNOL, V16, P1391, DOI 10.1002/eji.1830161113; AIZAWA S, 1988, P NATL ACAD SCI USA, V85, P3180, DOI 10.1073/pnas.85.9.3180; ARAKAWA M, 1974, J BIOCHEM, V75, P707, DOI 10.1093/oxfordjournals.jbchem.a130443; BARTOSZEWICZ Z, 1986, CARBOHYD RES, V151, P77, DOI 10.1016/S0008-6215(00)90331-8; BECKER DM, 1985, NATURE, V317, P430, DOI 10.1038/317430a0; CALAME K, 1988, ADV IMMUNOL, V43, P235; DABROWSKI J, 1980, BIOCHEMISTRY-US, V19, P5652, DOI 10.1021/bi00565a030; DABROWSKI J, 1981, ARCH BIOCHEM BIOPHYS, V210, P405, DOI 10.1016/0003-9861(81)90203-4; DABROWSKI U, 1984, J BIOL CHEM, V259, P7648; EZINE S, 1984, NATURE, V309, P629, DOI 10.1038/309629a0; GASA S, 1983, J LIPID RES, V24, P174; HAKOMORI S, 1986, SCI AM, V254, P44, DOI 10.1038/scientificamerican0586-44; HAKOMORI S, 1984, J BIOL CHEM, V259, P4672; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; HEDRICK SM, 1984, NATURE, V308, P153, DOI 10.1038/308153a0; HYMAN R, 1974, J NATL CANCER I, V52, P429, DOI 10.1093/jnci/52.2.429; ITO K, 1989, P NATL ACAD SCI USA, V86, P631, DOI 10.1073/pnas.86.2.631; ITO M, 1986, J BIOL CHEM, V261, P14278; IWAMORI M, 1990, P JPN C BIOCH LIPIDS, V32, P117; IWAMOTO A, 1986, J EXP MED, V163, P1203, DOI 10.1084/jem.163.5.1203; KNIEP B, 1983, BIOCHEMISTRY-US, V22, P251, DOI 10.1021/bi00271a003; KOEFFLER HP, 1983, BLOOD, V62, P709; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; Maniatis T., 1982, MOL CLONING; MUTHING J, 1987, EUR J BIOCHEM, V163, P407, DOI 10.1111/j.1432-1033.1987.tb10813.x; MUTHING J, 1989, BIOCHEMISTRY-US, V28, P2923; NAKAMURA K, 1991, J BIOCHEM-TOKYO, V110, P832, DOI 10.1093/oxfordjournals.jbchem.a123667; NOJIRI H, 1988, J BIOL CHEM, V263, P7443; NOJIRI H, 1985, CANCER RES, V45, P6100; PAULSON JC, 1978, J BIOL CHEM, V253, P5617; Reinhold V N, 1972, Methods Enzymol, V25, P244, DOI 10.1016/S0076-6879(72)25021-2; SHIMAMURA M, 1988, J BIOL CHEM, V263, P12124; SHIMAMURA M, 1991, FEBS LETT, V290, P213, DOI 10.1016/0014-5793(91)81262-7; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; TAKAGAKI Y, 1989, J IMMUNOL, V142, P2112; TAKI T, 1985, J BIOL CHEM, V260, P6219; TAKI T, 1982, J BIOCHEM-TOKYO, V91, P665, DOI 10.1093/oxfordjournals.jbchem.a133739; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; TRENTIN JJ, 1971, AM J PATHOL, V65, P621; WOLF NS, 1979, CLIN HAEMATOL, V8, P469	41	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18810	18813						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1388159				2022-12-25	WOS:A1992JN50200085
J	KATO, Y; UCHIDA, K; KAWAKISHI, S				KATO, Y; UCHIDA, K; KAWAKISHI, S			OXIDATIVE FRAGMENTATION OF COLLAGEN AND PROLYL PEPTIDE BY CU(II)/H2O2 - CONVERSION OF PROLINE RESIDUE TO 2-PYRROLIDONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACIDS; PROTEINS; DEGRADATION; MECHANISM; CLEAVAGE; TRYPTOPHAN; RADIOLYSIS; RADICALS; ION	Oxidative degradation of collagen and the model peptides by Cu(II)/H2O2 has been studied. The depolymerization of collagen was predominantly observed by use of gel filtration chromatography. Polyproline was used as a model for collagen, and the oxidative modification was examined by amino acid analysis. Glutamic acid and gamma-aminobutyric acid were identified in the hydrolysates of oxidized polyproline. The formation of glutamic acid was reduced by treatment with NaBH4. The model peptide, (Pro-Pro-Gly)10, was also degraded by Cu(II)/H2O2, and a new N-terminal glycine was generated in proportion to the reaction time. Hydroxyl radical scavengers show only partial inhibition of the degradation of (Pro-Pro-Gly)10. In order to estimate the fragmentation mechanism, we used N-tert-butoxycarbonyl (Boc)-L-prolylglycine as a model for collagen and (Pro-Pro-Gly)10. The degradation products were isolated and characterized. Then N-tert-Boc-2-pyrrolidone, which provides gamma-aminobutyric acid by acid hydrolysis, was identified. The formation of a 2-pyrrolidone compound from oxidized BOC-L-prolylglycine is direct evidence for the scission of the peptide bond. The time-dependent formation of N-tert-Boc-2-pyrrolidone and liberation of glycine from N-tert-Boc-L-prolylglycine exposed to Cu(II)/H2O2 was observed. These results suggest that the cleavage of the peptide bond (Pro-Gly) was caused by oxidation of the proline residue, which led to the formation of the 2-pyrrolidone compound. We confirmed that proline oxidation leads to the fragmentation of proteins, accompanied by the formation of a 2-pyrrolidone structure.	NAGOYA UNIV,DEPT FOOD SCI & TECHNOL,CHEM PLANT PROD LAB,FURO CHO,CHIKUSA KU,NAGOYA 46401,JAPAN	Nagoya University			Kato, Yoji/W-4779-2019	Kato, Yoji/0000-0002-8295-7337; Uchida, Koji/0000-0003-3894-5299				AMICI A, 1989, J BIOL CHEM, V264, P3341; BATEMAN RC, 1985, J BIOL CHEM, V260, P9088; BOWES JH, 1962, RADIAT RES, V16, P211, DOI 10.2307/3571153; COOPER B, 1985, BIOCHEM J, V228, P615, DOI 10.1042/bj2280615; CREMO CR, 1992, BIOCHEMISTRY-US, V31, P491, DOI 10.1021/bi00117a027; CURRAN SF, 1984, FEBS LETT, V176, P155, DOI 10.1016/0014-5793(84)80931-X; FONG LG, 1987, J LIPID RES, V28, P1466; GREHN L, 1986, ACTA CHEM SCAND B, V40, P745, DOI 10.3891/acta.chem.scand.40b-0745; HUNT JV, 1988, BIOCHEM J, V250, P87, DOI 10.1042/bj2500087; KANO Y, 1987, J BIOCHEM-TOKYO, V102, P839, DOI 10.1093/oxfordjournals.jbchem.a122123; KATO Y, 1992, J AGR FOOD CHEM, V40, P9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARX G, 1985, BIOCHEM J, V236, P397; MONBOISSE JC, 1983, BIOCHEM PHARMACOL, V32, P53, DOI 10.1016/0006-2952(83)90651-2; MONBOISSE JC, 1988, BIOCHIM BIOPHYS ACTA, V965, P29, DOI 10.1016/0304-4165(88)90147-X; NAGASAWA T, 1973, B CHEM SOC JPN, V46, P1269, DOI 10.1246/bcsj.46.1269; POSTON JM, 1987, FASEB J, V46, P1979; SCHUESSLER H, 1984, INT J RADIAT BIOL, V45, P267, DOI 10.1080/09553008414550381; STADTMAN ER, 1991, J BIOL CHEM, V266, P17201; TAPUHI Y, 1981, ANAL BIOCHEM, V115, P123, DOI 10.1016/0003-2697(81)90534-0; UCHIDA K, 1990, BIOCHEM BIOPH RES CO, V169, P265, DOI 10.1016/0006-291X(90)91463-3; UCHIDA K, 1992, J AGR FOOD CHEM, V40, P9, DOI 10.1021/jf00013a002; UCHIDA K, 1989, AGR BIOL CHEM TOKYO, V53, P3285, DOI 10.1080/00021369.1989.10869852; UCHIDA K, 1988, AGR BIOL CHEM TOKYO, V52, P1529; WOLFF SP, 1986, TRENDS BIOCHEM SCI, V11, P27, DOI 10.1016/0968-0004(86)90228-8; WOLFF SP, 1986, BIOCHEM J, V234, P399, DOI 10.1042/bj2340399	26	75	75	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23646	23651						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429705				2022-12-25	WOS:A1992JZ23900036
J	FAGAN, JM; WAXMAN, L				FAGAN, JM; WAXMAN, L			THE ATP-INDEPENDENT PATHWAY IN RED-BLOOD-CELLS THAT DEGRADES OXIDANT-DAMAGED HEMOGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEOLYTIC SYSTEM; HUMAN-ERYTHROCYTES; OXYGEN RADICALS; MAMMALIAN-CELLS; CYSTEINE PROTEINASES; RAT-LIVER; DEGRADATION; PURIFICATION; INHIBITORS; PROTEASE	Studies were carried out to characterize further the cytoplasmic ATP- and ubiquitin-independent proteolytic system in red blood cells that degrades hemoglobin damaged by exposure to oxidants (Fagan, J. M., Waxman, L., and Goldberg, A. L. (1986) J. Biol. Chem. 261, 5705-5713). Several proteases were ruled out as having a major role in the degradation of oxidant-treated hemoglobin (Ox-Hb). Acid hydrolases are not active in this process since the degradation of Ox-Hb has a pH optimum between 6 and 8. The calpains are also not involved since inhibitors of cysteine proteases (leupeptin and trans-epoxysuccinyl-L-leucylamido-(3-methyl)butane) did not diminish the increased proteolysis in intact erythrocytes treated with oxidants or in lysates to which Ox-Hb was added. The degradation of Ox-Hb was unaffected by inhibitors of serine and aspartic proteases. Removal of the high M(r) multicatalytic proteinase by immunoprecipitation also did not significantly affect the degradation of Ox-Hb in erythrocyte lysates. The degradation of Ox-Hb was sensitive to metal chelators and sulfhydryl-modifying reagents but not to specific inhibitors of known metalloproteases. Insulin, which is rapidly degraded in lysates, completely blocked the degradation of Ox-Hb. Insulin- and Ox-Hb-hydrolyzing activity was also inhibited following immunoprecipitation of the 100-kDa metalloinsulinase. The metalloinsulinase, which is inhibited by sulfhydryl-modifying reagents and which requires divalent metals, may therefore participate in the degradation of hemoglobin damaged by oxidants in erythrocytes.			FAGAN, JM (corresponding author), RUTGERS STATE UNIV,DEPT ANIM SCI,POB 231,NEW BRUNSWICK,NJ 08903, USA.							BALOW RM, 1986, J BIOL CHEM, V261, P2409; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; Beutler E, 1983, METABOLIC BASIS INHE, P1629; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COUCH CB, 1983, CELL, V32, P257, DOI 10.1016/0092-8674(83)90516-0; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1987, J BIOL CHEM, V262, P9914; DAVIES KJA, 1987, J BIOL CHEM, V262, P8227; DEFLORA A, 1985, BLOOD, V66, P294; ETLINGER JD, 1977, P NATL ACAD SCI USA, V74, P54, DOI 10.1073/pnas.74.1.54; FAGAN JM, 1991, BIOCHEM J, V277, P779, DOI 10.1042/bj2770779; FAGAN JM, 1986, J BIOL CHEM, V261, P5705; FAGAN JM, 1985, 13TH P INT C BIOCH, P96; GAETANI GF, 1979, BRIT J HAEMATOL, V43, P39, DOI 10.1111/j.1365-2141.1979.tb03717.x; GARCIA JV, 1988, BIOCHEMISTRY-US, V27, P4237, DOI 10.1021/bi00412a006; GARCIA JV, 1987, J CELL BIOL, V100, P449; GOLDBERG AL, 1982, SCIENCE, V215, P1107, DOI 10.1126/science.7038874; GORDON PB, 1989, PROTEOLYTIC ENZYMES, P201; GREENLEE WJ, 1984, BIOCHEM BIOPH RES CO, V122, P791, DOI 10.1016/S0006-291X(84)80103-5; HASHIDA S, 1980, J BIOCHEM-TOKYO, V88, P1805, DOI 10.1093/oxfordjournals.jbchem.a133155; JOCHEN A, 1987, BIOCHEM BIOPH RES CO, V142, P205, DOI 10.1016/0006-291X(87)90472-4; KIRSCHNER RJ, 1983, J BIOL CHEM, V258, P967; KIRSCHNER RJ, 1982, FED PROC, V41, P865; KIRSCHNER RJ, 1981, METHOD ENZYMOL, V80, P702; KOMINAMI E, 1987, BIOCHEM BIOPH RES CO, V144, P749, DOI 10.1016/S0006-291X(87)80028-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBBY P, 1979, AM J PHYSIOL, V237, pE35, DOI 10.1152/ajpendo.1979.237.1.E35; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; MELLONI E, 1982, ARCH BIOCHEM BIOPHYS, V216, P495, DOI 10.1016/0003-9861(82)90238-7; MOMAND J, 1987, BIOCHEMISTRY-US, V26, P7798, DOI 10.1021/bi00398a040; MORELLI A, 1987, BLOOD, V69, P1753; MORIHARA K, 1974, ADV ENZYMOL RAMB, V41, P179; MUMFORD RA, 1982, BIOCHEM BIOPH RES CO, V109, P1303, DOI 10.1016/0006-291X(82)91919-2; MURACHI T, 1981, ADV ENZYME REGUL, V19, P407; NISHINO N, 1979, BIOCHEMISTRY-US, V18, P4340, DOI 10.1021/bi00587a012; NISHINO N, 1980, J BIOL CHEM, V255, P3482; ORLOWSKI M, 1988, BIOCHEMISTRY-US, V27, P597, DOI 10.1021/bi00402a015; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; POWERS JC, 1986, PROTEINASE INHIBITOR, P237; RASNICK D, 1978, BIOCHEMISTRY-US, V17, P4363, DOI 10.1021/bi00614a002; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; ROQUES BP, 1980, NATURE, V288, P286, DOI 10.1038/288286a0; SACCHETTA P, 1990, BIOCHIM BIOPHYS ACTA, V1037, P337, DOI 10.1016/0167-4838(90)90035-E; SHII K, 1986, P NATL ACAD SCI USA, V83, P4147, DOI 10.1073/pnas.83.12.4147; SHII K, 1986, DIABETES, V35, P675, DOI 10.2337/diabetes.35.6.675; SUDA H, 1976, ARCH BIOCHEM BIOPHYS, V177, P196, DOI 10.1016/0003-9861(76)90429-X; TACK BF, 1980, J BIOL CHEM, V255, P8842; TANAKA K, 1986, J BIOL CHEM, V261, P5197; Umezawa H, 1976, Methods Enzymol, V45, P678; UMEZAWA H, 1977, PROTEINASES MAMMALIA, P637; WANG KKW, 1990, TRENDS PHARMACOL SCI, V11, P139, DOI 10.1016/0165-6147(90)90060-L; WAXMAN L, 1985, J BIOL CHEM, V260, P1994; WILLIAMSON DH, 1974, METHOD ENZYMAT AN, P1679; YAMAMOTO K, 1984, BIOCHIM BIOPHYS ACTA, V790, P208, DOI 10.1016/0167-4838(84)90024-4; YAMAMOTO K, 1987, BIOCHEM BIOPH RES CO, V148, P267, DOI 10.1016/0006-291X(87)91105-3; YOSHIMOTO T, 1979, BIOCHIM BIOPHYS ACTA, V569, P184, DOI 10.1016/0005-2744(79)90053-6	56	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23015	23022						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429649				2022-12-25	WOS:A1992JY16300049
J	HOLLAND, MR; VENABLE, ME; WHATLEY, RE; ZIMMERMAN, GA; MCINTYRE, TM; PRESCOTT, SM				HOLLAND, MR; VENABLE, ME; WHATLEY, RE; ZIMMERMAN, GA; MCINTYRE, TM; PRESCOTT, SM			ACTIVATION OF THE ACETYL-COENZYME A-LYSOPLATELET-ACTIVATING FACTOR ACETYLTRANSFERASE REGULATES PLATELET-ACTIVATING-FACTOR SYNTHESIS IN HUMAN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LYSO-PAF-ACETYLTRANSFERASE; RAT SPLENIC MICROSOMES; COA ACETYLTRANSFERASE; HUMAN-NEUTROPHILS; 1-ALKYL-2-LYSO-SN-GLYCERO-3-PHOSPHOCHOLINE-ACETYL-COA ACETYLTRANSFERASE; INDEPENDENT TRANSACYLASE; SPLEEN MICROSOMES; ARACHIDONIC-ACID; MODULATION	Platelet-activating factor (1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine; PAF) is a phospholipid with many physiological actions. It is synthesized by endothelial cells and a variety of others in response to stimulation with receptor-mediated agonists. In endothelial cells it remains associated with the surface of the cell and serves as a signal for adhesive interactions with leukocytes. Thus, its synthesis must be precisely regulated. In previous work we have shown that PAF synthesis is regulated at the initiating step, a phospholipase A2. Here we demonstrate that the subsequent step of PAF synthesis, the acetyl-CoA:lyso-PAF acetyltransferase, is rapidly activated when cells are exposed to thrombin or other agonists. We found that the activity increased from basal values (5 nmol/mg/min) to approximately 3-fold higher within 1 min following the addition of agonists. The enzyme activity returned to basal levels within 10 min. The pattern of activation and inactivation suggested covalent modification of the enzyme. This was supported in experiments in which we showed that homogenates had stable enhanced activity and that there was no evidence for an activator or inhibitor. Pretreatment of the cells with vanadate, an inhibitor of protein phosphatases, markedly prolonged the activation state. In subsequent studies we pretreated intact cells with vanadate to block inactivation of the enzyme and then measured the accumulation of PAF in response to thrombin. We found that it was markedly augmented and prolonged. From this we conclude that the synthesis of PAF in intact cells is regulated by the activity of the acetyltransferase. We characterized requirements for activation of acetyltransferase and found that it was not dependent on the influx of intracellular calcium but that calcium entry did influence the length of time for which the enzyme was activated. The acetyltransferase in endothelial cells was shown to be a specific enzyme that did not catalyze the transfer of long chain acyl groups from acyl-CoA to lysophospholipids and demonstrated modest specificity for the acceptor lysophospholipids. These results suggest that activation of the acetyltransferase is a crucial determinant of the amount of PAF synthesized in activated endothelial cells.	UNIV UTAH,NORA ECCLES HARRISON CARDIOVASC RES & TRAINING INST,BLDG 500,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT INTERNAL MED,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT BIOCHEM,SALT LAKE CITY,UT 84112; VET ADM MED CTR,SALT LAKE CITY,UT 84148	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Holland, Matthew/0000-0001-6595-0240	NHLBI NIH HHS [HL 43689, HL 07576, HL 34127] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007576, R01HL034127, R29HL043689] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERT DH, 1984, BIOCHIM BIOPHYS ACTA, V796, P92, DOI 10.1016/0005-2760(84)90242-X; ALONSO F, 1982, J BIOL CHEM, V257, P3376; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLUMENTHAL DK, 1988, BIOCHEM BIOPH RES CO, V156, P860, DOI 10.1016/S0006-291X(88)80923-9; BUSSOLINO F, 1988, J BIOL CHEM, V263, P11856; CLUZEL M, 1989, J IMMUNOL, V143, P3659; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DOMENECH C, 1987, J BIOL CHEM, V262, P5671; FENNELL DF, 1991, ARTERIOSCLER THROMB, V11, P97, DOI 10.1161/01.ATV.11.1.97; GHIGO D, 1988, J BIOL CHEM, V263, P19437; GOMEZCAMBRONERO J, 1985, BIOCHIM BIOPHYS ACTA, V845, P511, DOI 10.1016/0167-4889(85)90218-6; GOMEZCAMBRONERO J, 1985, BIOCHIM BIOPHYS ACTA, V845, P516, DOI 10.1016/0167-4889(85)90219-8; GOMEZCAMBRONERO J, 1987, BIOCHEM J, V246, P893; HERRICKDAVIS K, 1991, J BIOL CHEM, V266, P18620; HOLLAND MR, 1991, TRENDS CARDIOVAS MED, V1, P117, DOI 10.1016/1050-1738(91)90005-Y; JOLY F, 1990, BIOCHEM J, V271, P501, DOI 10.1042/bj2710501; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LEE TC, 1985, J BIOL CHEM, V260, P952; LEE TC, 1986, J BIOL CHEM, V261, P5373; LENIHAN DJ, 1984, BIOCHEM BIOPH RES CO, V120, P834, DOI 10.1016/S0006-291X(84)80182-5; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; MCINTYRE TM, 1986, P NATL ACAD SCI USA, V83, P2204, DOI 10.1073/pnas.83.7.2204; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; MUELLER HW, 1984, J LIPID RES, V25, P383; MUELLER HW, 1991, BIOCHEM BIOPH RES CO, V176, P1557, DOI 10.1016/0006-291X(91)90465-J; MUELLER HW, 1983, J BIOL CHEM, V258, P6213; NIES AS, 1991, J PHARMACOL EXP THER, V259, P590; NIETO ML, 1988, J BIOL CHEM, V263, P4607; NIETO ML, 1991, J BIOL CHEM, V266, P18699; PRESCOTT SM, 1984, P NATL ACAD SCI-BIOL, V81, P3534, DOI 10.1073/pnas.81.11.3534; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; REINHOLD SL, 1989, J BIOL CHEM, V264, P21652; RUDEL LL, 1973, J LIPID RES, V14, P64; SEARGEANT LE, 1979, BIOCHEM J, V181, P247, DOI 10.1042/bj1810247; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; SWENDSEN CL, 1983, BIOCHEM BIOPH RES CO, V113, P72, DOI 10.1016/0006-291X(83)90433-3; UEMURA Y, 1991, J BIOL CHEM, V266, P8268; VENABLE ME, 1991, J BIOL CHEM, V266, P18691; WHATLEY RE, 1989, J BIOL CHEM, V264, P6325; WHATLEY RE, 1992, PROSTAGLANDINS, V43, P21, DOI 10.1016/0090-6980(92)90061-W; WHATLEY RE, 1988, ARTERIOSCLEROSIS, V8, P321, DOI 10.1161/01.ATV.8.3.321; WHATLEY RE, 1990, J BIOL CHEM, V265, P15550; WYKLE RL, 1980, J BIOL CHEM, V255, P256; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529	44	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22883	22890						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429636				2022-12-25	WOS:A1992JY16300029
J	TROULLIER, A; GIRARDET, JL; DUPONT, Y				TROULLIER, A; GIRARDET, JL; DUPONT, Y			FLUOROALUMINATE COMPLEXES ARE BIFUNCTIONAL ANALOGS OF PHOSPHATE IN SARCOPLASMIC-RETICULUM CA2+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-PHOSPHATE; BINDING-SITE; CALCIUM-PUMP; INORGANIC-PHOSPHATE; FLUORIDE COMPLEXES; STRUCTURAL ANALOGS; CATALYTIC SITE; F-ACTIN; ATPASE; MECHANISM	The mechanism of inhibition of the sarcoplamc reticulum (SR) Ca2+-ATPase by the fluoroaluminate complexes was investigated. First, AlF4- was shown to bind to the Ca2+-free conformation of the enzyme by a slow quasi-irreversible process. The rate constants of the reaction are k+ = 16 x 10(3) M-1 s-1 and k- < 1.5 10(-3) s-1. We directly measured a stoichiometry of about 4.8 nmol of AlF4- bound/mg of protein. Mg2+ was a necessary cofactor for the reaction with a dissociation constant of 3 mm. It was demonstrated (Dupont, Y., and Pougeois, R. (1983) FEBS Lett. 156, 93-98) that phosphorylation by P(i) induced a dehydration of the catalytic site. The same process has been shown here to occur upon AlF4- binding either by the use of Me2SO or by demonstration of an increase of bound 2',3'-O-(2,4,6-trinitrocyclohexadienyldene)adenosine triphosphate fluorescence. Phosphorylation by P(i) is inhibited by the binding of AlF4-. Second, a fluoroaluminate complex, presumably AlF4-, was also shown to bind to the Ca2+-bound conformation of the Ca2+-ATPase in the presence of ADP and stabilize a E1.Ca2.ADP.AlF(x) complex. The dissociation constant of the nucleotidic site for ADP was shifted to the micromolar range. The Ca2+ ions bound on the external high affinity sites became occluded upon binding of (ADP + AlF(x)). We propose that AlF4- mimics P(i) binding to the Ca2+-free conformation of the ATPase and stabilizes an intermediate similar to the acyl-phosphate derivative; it also acts as an analogue of the gamma-phosphate of ATP and stabilizes an E1.[Ca2].ADP-AlF4 complex where the Ca2+ ions are occluded.			TROULLIER, A (corresponding author), CEN, DEPT BIOL MOLEC & STRUCT, BIOPHYS MOLEC & CELLULAIRE LAB, CNRS, F-38041 GRENOBLE, FRANCE.							ANTONNY B, 1992, J BIOL CHEM, V267, P6710; ANTONNY B, 1990, FEBS LETT, V268, P277, DOI 10.1016/0014-5793(90)81027-L; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; CARLIER MF, 1988, BIOCHEMISTRY-US, V27, P3555, DOI 10.1021/bi00410a005; COMBEAU C, 1988, J BIOL CHEM, V263, P17429; COMBEAU C, 1989, J BIOL CHEM, V264, P19017; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DUPONT Y, 1982, FEBS LETT, V139, P237, DOI 10.1016/0014-5793(82)80860-0; DUPONT Y, 1984, ANAL BIOCHEM, V142, P504, DOI 10.1016/0003-2697(84)90496-2; DUPONT Y, 1976, BIOCHEM BIOPH RES CO, V71, P544, DOI 10.1016/0006-291X(76)90821-4; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; DUPONT Y, 1977, EUR J BIOCHEM, V72, P185, DOI 10.1111/j.1432-1033.1977.tb11238.x; DUPONT Y, 1982, BIOCHEM BIOPH RES CO, V106, P1272, DOI 10.1016/0006-291X(82)91250-5; DUPONT Y, 1983, FEBS LETT, V156, P93, DOI 10.1016/0014-5793(83)80255-5; DUPONT Y, 1988, METHOD ENZYMOL, V157, P206; FERNANDEZBELDA F, 1984, J BIOL CHEM, V259, P9687; GUILLAIN F, 1980, J BIOL CHEM, V255, P2072; HASSELBACH W, 1963, BIOCHEM Z, V339, P94; HASSELBACH W, 1972, FEBS LETT, V20, P311, DOI 10.1016/0014-5793(72)80094-2; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; INESI G, 1988, METHOD ENZYMOL, V157, P154; ISSARTEL JP, 1991, BIOCHEMISTRY-US, V30, P4726, DOI 10.1021/bi00233a013; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; LACAPERE JJ, 1981, J BIOL CHEM, V256, P2302; LUNARDI J, 1988, P NATL ACAD SCI USA, V85, P8958, DOI 10.1073/pnas.85.23.8958; Martell A.E., 1989, CRITICAL STABILITY C; MARTIN RB, 1988, BIOCHEM BIOPH RES CO, V155, P1194; MISSIAEN L, 1988, BIOCHEM J, V253, P827, DOI 10.1042/bj2530827; MISSIAEN L, 1989, BIOCHEM J, V261, P655, DOI 10.1042/bj2610655; MURPHY AJ, 1992, J BIOL CHEM, V267, P5229; NAKAMOTO RK, 1984, J BIOL CHEM, V259, P2961; NARAYANAN N, 1991, BIOCHIM BIOPHYS ACTA, V1070, P83, DOI 10.1016/0005-2736(91)90149-3; ROBINSON JD, 1986, J BIOENERG BIOMEMBR, V18, P521, DOI 10.1007/BF00743148; ROSSET R, 1985, J CHIM PHYS PCB, V82, P647, DOI 10.1051/jcp/1985820647; SERPERSU EH, 1982, EUR J BIOCHEM, V122, P347, DOI 10.1111/j.1432-1033.1982.tb05887.x; THORLEYL.DA, 1973, EUR J BIOCHEM, V40, P403, DOI 10.1111/j.1432-1033.1973.tb03209.x; VILSEN B, 1992, J BIOL CHEM, V267, P3539; 1982, IUPAC CHEM DATA 21	40	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22821	22829						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429630				2022-12-25	WOS:A1992JY16300021
J	YANG, ZH; WENSEL, TG				YANG, ZH; WENSEL, TG			N-MYRISTOYLATION OF THE ROD OUTER SEGMENT-G PROTEIN, TRANSDUCIN, IN CULTURED RETINAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; NH2-TERMINAL BLOCKING GROUP; MEMBRANE ASSOCIATION; ALPHA-SUBUNITS; GAMMA-SUBUNIT; GTP-BINDING; BETA-GAMMA; BOVINE; IDENTIFICATION; TRANSFORMATION	Bovine retinas incubated with [H-3]myristic acid incorporated detectable radiolabel into only a few proteins. The most heavily labeled was the alpha subunit of the rod outer segment G protein transducin (G(talpha)). The radiolabeled protein was specifically eluted from illuminated membranes in the presence of GTP, displaying the unique solubility properties of G(talpha). It comigrated with G(talpha) in electrophoresis and chromatography and was immunoprecipitated by G(talpha)-specific antibodies. The radiolabel was confirmed by hydrolysis, chemical derivatization, and chromatography to be amide-linked myristic acid. The solubility of the myristoylated G(talpha) indicates that myristoylation is not sufficient to cause tight membrane association of this normally membrane-bound subunit. Incorporation of [H-3]myristate was blocked by the protein synthesis inhibitor cycloheximide, suggesting that that fatty acid group is introduced during or soon after translation in the rod inner segment.	BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030	Baylor College of Medicine				Wensel, Theodore/0000-0003-3518-9352	NEI NIH HHS [EY07981] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007981] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AITKEN A, 1982, FEBS LETT, V150, P314, DOI 10.1016/0014-5793(82)80759-X; Ames A 3rd, 1980, Neurochem Int, V1C, P393, DOI 10.1016/0197-0186(80)90075-3; ANANT JS, 1992, J BIOL CHEM, V267, P687; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CARR SA, 1982, P NATL ACAD SCI-BIOL, V79, P6128, DOI 10.1073/pnas.79.20.6128; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; CODINA J, 1991, J RECEPTOR RES, V11, P589; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DIZHOOR AM, 1992, INVEST OPHTH VIS SCI, V33, P1006; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1983, J BIOL CHEM, V258, P503; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HARLOW E, 1988, ANTIBODIES LABORATOR; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LIPKIN VM, 1987, RETINAL PROTEINS, P39; MAGEE AI, 1985, EMBO J, V4, P1137, DOI 10.1002/j.1460-2075.1985.tb03751.x; MCILHINNEY RAJ, 1990, TRENDS BIOCHEM SCI, V15, P387; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NEUBERT TA, 1992, INVEST OPHTH VIS SCI, V33, P872; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; QIN N, 1992, J BIOL CHEM, V267, P8458; RAMDAS L, 1991, BIOCHEMISTRY-US, V30, P11637, DOI 10.1021/bi00114a005; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RIBEIRONETO FAP, 1989, P NATL ACAD SCI USA, V86, P2577, DOI 10.1073/pnas.86.8.2577; SPIEGEL AM, 1991, TRENDS BIOCHEM SCI, V16, P338, DOI 10.1016/0968-0004(91)90139-M; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STRYER L, 1991, J BIOL CHEM, V266, P10711; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; WENSEL T G, 1992, Biophysical Journal, V61, pA98; WENSEL TG, 1988, ENZYME DYNAMICS REGU, P102; WOOD R, 1983, J CHROMATOGR, V254, P237, DOI 10.1016/S0021-9673(01)88338-2	41	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23197	23201						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429667				2022-12-25	WOS:A1992JY16300076
J	BOLES, JO; TOLLESON, WH; SCHMIDT, JC; DUNLAP, RB; ODOM, JD				BOLES, JO; TOLLESON, WH; SCHMIDT, JC; DUNLAP, RB; ODOM, JD			SELENOMETHIONYL DIHYDROFOLATE-REDUCTASE FROM ESCHERICHIA-COLI - COMPARATIVE BIOCHEMISTRY AND SE-77 NUCLEAR-MAGNETIC-RESONANCE SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIWAVELENGTH ANOMALOUS DIFFRACTION; CRYSTAL-STRUCTURES; ALPHA-CHYMOTRYPSIN; PURIFICATION; BINDING; ENZYME; PROTEINS; COMPLEX; LIVER; METHOTREXATE	The biosynthetic replacement of Met residues by selenomethionine (SeMet) facilitates the determination of three-dimensional structure by multiwavelength anomalous diffraction (Yang, W., Hendrickson, W. A., Crouch, R. J., and Satow, Y. (1990) Science 249, 1398-1405). In an effort to examine any biochemical effects due to the replacement of Met residues by SeMet, we chose to compare the kinetic and binding properties of selenomethionyl dihydrofolate reductase with those of the wt enzyme. There are 5 Met residues in Escherichia coli dihydrofolate reductase with 2 located in the Met-20 loop, which is a sequence of residues forming a lid over the active site. Utilizing plasmid pWT8, which affords 10-15% soluble protein as E. coli dihydrofolate reductase, we readily isolated both the. SeMet and wt enzymes from E.coli DL41 utilizing a novel purification protocol. Both enzymes exhibited essentially the same kinetic and binding properties, including specific activities (45 mumol/min/mg), K(m) (7,8-dihydrofolate = 0.39 muM; NADPH = 2.0 muM), k(cat) (13.5/s), and 1:1 noncovalent inhibitory binding ratios with methotrexate. The inhibitory effects of divalent and monovalent cations on activity were also assessed, with the SeMet-containing enzyme exhibiting a uniformly greater sensitivity than the wt enzyme. We conclude that the biochemical properties of dihydrofolate reductase are virtually unperturbed by SeMet inclusion. Analysis of SeMet dihydrofolate reductase by Se-77 nuclear magnetic resonance spectroscopy revealed five distinct resonances, thus indicating the potential value of this technique in employing selenium as a nonperturbing NMR probe of protein structure and function.	UNIV S CAROLINA,DEPT CHEM & BIOCHEM,COLUMBIA,SC 29208; UNIV S CAROLINA,DEPT PEDIAT,CHILDRENS CANC RES LAB,COLUMBIA,SC 29208	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia			Tolleson, William/T-9345-2019	Tolleson, William/0000-0002-7682-3113	NATIONAL CANCER INSTITUTE [R01CA015645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042907] Funding Source: NIH RePORTER; NCI NIH HHS [CA 15645] Funding Source: Medline; NCRR NIH HHS [1-510-RR0245-1] Funding Source: Medline; NIGMS NIH HHS [GM 42907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACCANARI DP, 1981, J BIOL CHEM, V256, P1738; BOLES JO, 1991, BIOCHEMISTRY-US, V30, P11073, DOI 10.1021/bi00110a009; BOLIN JT, 1982, J BIOL CHEM, V257, P13650; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYSTROFF C, 1990, BIOCHEMISTRY-US, V29, P3263, DOI 10.1021/bi00465a018; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; DUNLAP RB, 1988, PHOSPHORUS SULFUR, V38, P217, DOI 10.1080/03086648808079718; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; ERICKSON JS, 1973, BIOCHEMISTRY-US, V12, P372, DOI 10.1021/bi00727a002; FARNUM MF, 1991, BIOCHEMISTRY-US, V30, P11567, DOI 10.1021/bi00113a012; FUTTERMAN S, 1957, J BIOL CHEM, V228, P1031; GETTINS P, 1991, J BIOL CHEM, V266, P3422; GETTINS P, 1991, J BIOL CHEM, V266, P4804; GRAVES BJ, 1990, BIOCHEMISTRY-US, V29, P2679, DOI 10.1021/bi00463a009; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P41; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; HOUSE KL, 1992, IN PRESS J AM CHEM S; HUENNEKENS FM, 1970, CHEM BIOL PTERIDINES, P329; JARABAK J, 1971, ARCH BIOCHEM BIOPHYS, V142, P417, DOI 10.1016/0003-9861(71)90505-4; KAMEN BA, 1976, ANAL BIOCHEM, V70, P54, DOI 10.1016/S0003-2697(76)80047-4; LUTHRA NP, 1981, ANAL BIOCHEM, V117, P94, DOI 10.1016/0003-2697(81)90697-7; LUTHRA NP, 1983, J MAGN RESON, V52, P318, DOI 10.1016/0022-2364(83)90203-2; LUTHRA NP, 1982, J BIOL CHEM, V257, P1142; MANIATIS T, 1982, MOL CLONING LABORATO, P75; MATTHEWS DA, 1977, SCIENCE, V197, P452, DOI 10.1126/science.17920; MATTHEWS DA, 1985, J BIOL CHEM, V260, P381; MCCULLOUGH JL, 1971, BIOCHEM PHARMACOL, V20, P561, DOI 10.1016/0006-2952(71)90143-2; MULLEN GP, 1986, BIOCHEMISTRY-US, V25, P5625, DOI 10.1021/bi00367a042; MULLEN GP, 1985, J AM CHEM SOC, V107, P7187, DOI 10.1021/ja00310a078; NIXON PF, 1968, J BIOL CHEM, V243, P4722; ODOM JD, 1979, J AM CHEM SOC, V101, P5815, DOI 10.1021/ja00513a058; POE M, 1972, BIOCHEMISTRY-US, V11, P1023, DOI 10.1021/bi00756a012; ROWE PB, 1973, J BIOL CHEM, V248, P984; SHEPHERD L, 1969, CAN J BIOCHEM CELL B, V47, P877, DOI 10.1139/o69-137; STONE SR, 1982, BIOCHEMISTRY-US, V21, P3757, DOI 10.1021/bi00259a006; WILLIAMS MN, 1977, J BIOL CHEM, V252, P6871; WILLIAMS TJ, 1977, ARCH BIOCHEM BIOPHYS, V181, P569, DOI 10.1016/0003-9861(77)90263-6; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	39	34	36	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22217	22223						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429574				2022-12-25	WOS:A1992JW71900037
J	KADOWAKI, M; POSO, AR; MORTIMORE, GE				KADOWAKI, M; POSO, AR; MORTIMORE, GE			PARALLEL CONTROL OF HEPATIC PROTEOLYSIS BY PHENYLALANINE AND PHENYLPYRUVATE THROUGH INDEPENDENT INHIBITORY SITES AT THE PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID CONTROL; PERFUSED-RAT-LIVER; PROTEIN-DEGRADATION; SKELETAL-MUSCLE; PRIMARY CULTURE; TRANSFER-RNA; HEPATOCYTES; LEUCINE; DEPRIVATION; ALANINE	Intracellular protein degradation in the rat hepatocyte is regulated by 7 amino acids of which Leu, Gln, and Tyr play major roles. Although Phe is known to inhibit proteolysis as effectively as Tyr at high concentrations, it has not been regarded as an active regulator because of its rapid hydroxylation to Tyr. We now show that proteolytic responses to Phe during liver perfusion differ strikingly from effects of the multiphasic regulators Leu, Gln, and Tyr in eliciting mirror image responses at half-normal and normal plasma concentrations. Since response curves to phenylpyruvate and Phe were identical, we considered the possibility that phenylpyruvate mediated its anomalous inhibition intracellularly. However, when phenylpyruvate was produced from phenyllactate intracellularly at a rate providing the same rate of transamination (and intracellular concentration) as that derived from the uptake of phenylpyruvate, no response was obtained. Hence, the effect of phenylpyruvate was not initiated within the cell but more likely from the plasma membrane. Comparable evidence for Phe is less direct. Recent findings indicate that recognition sites for Leu and Gln are located at the plasma membrane. Since Phe augments the concerted inhibition by Leu and Gln at 4-fold normal levels, Phe is probably recognized in close proximity to them. However, the failure of phenylpyruvate to substitute for Phe in this interaction suggests that proteolytic inhibition by phenylpyruvate and Phe is mediated through similar, although independent, plasma membrane sites.	PENN STATE UNIV, MILTON S HERSHEY MED CTR, COLL MED, DEPT CELLULAR & MOLEC PHYSIOL, HERSHEY, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NIDDK NIH HHS [DK 21624] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021624] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLOUIN A, 1977, J CELL BIOL, V72, P441, DOI 10.1083/jcb.72.2.441; CARR FPA, 1981, BIOCHEM J, V198, P655, DOI 10.1042/bj1980655; HUTSON SM, 1978, J BIOL CHEM, V253, P8126; KADOWSKI M, 1908, INTRACELLULAR PROTEO, P488; KHAIRALLAH EA, 1976, J BIOL CHEM, V251, P1375; KILBERG MS, 1983, J BIOL CHEM, V258, P1524; KLEINHANS B, 1985, FED PROC, V44, P1091; LIVESEY G, 1985, J CHROMATOGR, V337, P98, DOI 10.1016/0378-4347(85)80012-8; MIOTTO G, 1989, BIOCHEM BIOPH RES CO, V158, P797, DOI 10.1016/0006-291X(89)92792-7; MIOTTO G, 1992, J BIOL CHEM, V267, P22066; MITCH WE, 1984, BIOCHEM J, V222, P579, DOI 10.1042/bj2220579; MORI K, 1976, TETRAHEDRON, V32, P1101, DOI 10.1016/0040-4020(76)85032-6; MORTIMORE GE, 1988, J BIOL CHEM, V263, P19545; MORTIMORE GE, 1991, J BIOL CHEM, V266, P1021; MORTIMORE GE, 1989, DIABETES METAB REV, V5, P49, DOI 10.1002/dmr.5610050105; MORTIMORE GE, 1987, J BIOL CHEM, V262, P16322; MORTIMORE GE, 1988, METHOD ENZYMOL, V166, P461; NALECZ KA, 1984, BIOCHIM BIOPHYS ACTA, V805, P1; POSO AR, 1984, P NATL ACAD SCI-BIOL, V81, P4270, DOI 10.1073/pnas.81.14.4270; POSO AR, 1982, J BIOL CHEM, V257, P2114; RABKIN R, 1991, J LAB CLIN MED, V117, P505; RUDIGER HW, 1972, BIOCHEM J, V126, P445, DOI 10.1042/bj1260445; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SHIMAN R, 1982, J BIOL CHEM, V257, P1213; TAPUHI Y, 1981, ANAL BIOCHEM, V115, P123, DOI 10.1016/0003-2697(81)90534-0; TISCHLER ME, 1982, J BIOL CHEM, V257, P1613; VENERANDO R, 1991, FASEB J, V5, pA1178; WANG SR, 1985, IN VITRO CELL DEV B, V21, P526; WEBER WW, 1966, J BIOL CHEM, V241, P1345	29	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22060	22065						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429557				2022-12-25	WOS:A1992JW71900015
J	MASQUILIER, D; SASSONECORSI, P				MASQUILIER, D; SASSONECORSI, P			TRANSCRIPTIONAL CROSS-TALK - NUCLEAR FACTORS CREM AND CREB BIND TO AP-1 SITES AND INHIBIT ACTIVATION BY JUN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION PATHWAYS; CYCLIC-AMP; LEUCINE ZIPPER; ADENYLATE-CYCLASE; FOS GENE; POSITIVE REGULATION; ENHANCER ELEMENTS; 2ND MESSENGERS; V-JUN	The proteins Fos and Jun dimerize to constitute the transcription factor AP-1 which is known to respond to treatment with phorbol esters. AP-1 binds to 12-O-tetradecanoylphorbol-13-acetate-responsive elements (TREs) palindromic sequences. cAMP-responsive elements (CREs) are very similar to TREs and CRE-binding proteins are similar in structure to Fos and Jun. Thus, the two main signal transduction pathways have closely related nuclear effectors which could possibly overlap and/or cross-talk. The gene CRE modulator (CREM) encodes both antagonists and an activator of the cAMP transcriptional response by alternative splicing. In this report we show that CREM antagonists are able to block the transcriptional activation elicited by c-Jun. The mechanism by which this repression is obtained does not require heterodimerization between CREM and the Fos and/or Jun proteins. In contrast, we show that both CREM and CRE-binding proteins (CREB) are able to bind TREs and therefore compete with c-Jun for this site. Removal of the phosphorylation domain in CREM does not affect the down-regulatory function. We also show that c-Fos does not affect the inhibitory function of CREM on c-Jun and that the transcriptional activation elicited by the other members of the jun family (JunB, JunD, and v-Jun) is also down-regulated by CREM.	FAC MED STRASBOURG, CNRS,GENET MOLEC EUCARYOTES LABS,INST CHIM BIOL, INSERM,U184, F-67085 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BELL JD, 1985, J BIOL CHEM, V260, P2625; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BORRELLI E, 1992, IN PRESS CRIT REV ON; BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; BUSCH SJ, 1990, ONCOGENE, V5, P1549; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DEGROOT RP, 1992, IN PRESS ONCOGENE; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DELI E, 1988, FEBS LETT, V231, P407, DOI 10.1016/0014-5793(88)80860-3; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1991, P NATL ACAD SCI USA, V88, P5448, DOI 10.1073/pnas.88.12.5448; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KELLEHER DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4316, DOI 10.1073/pnas.81.14.4316; Kessler S W, 1981, Methods Enzymol, V73, P442; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MELLSTROM B, 1991, ONCOGENE, V6, P1959; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NARANJO JR, 1991, ONCOGENE, V6, P223; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SASSONECORSI P, 1988, P NATL ACAD SCI USA, V85, P7192, DOI 10.1073/pnas.85.19.7192; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SASSONECORSI P, 1990, ONCOGENE, V5, P427; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; Woodgett J R, 1990, Semin Cancer Biol, V1, P389; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	73	198	199	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22460	22466						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429597				2022-12-25	WOS:A1992JW71900074
J	NAG, B; PASSMORE, D; KENDRICK, T; BHAYANI, H; SHARMA, SD				NAG, B; PASSMORE, D; KENDRICK, T; BHAYANI, H; SHARMA, SD			N-LINKED OLIGOSACCHARIDES OF MURINE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II MOLECULE - ROLE IN ANTIGENIC PEPTIDE BINDING, T-CELL RECOGNITION, AND CLONAL NONRESPONSIVENESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IA MOLECULES; DIFFERENTIAL GLYCOSYLATION; SURFACE EXPRESSION; LIPID-MEMBRANES; ALPHA-CHAINS; PURIFIED IA; B-CELLS; SEQUENCE; MUTAGENESIS; DOMAIN	To evaluate the functional role of the N-linked oligosaccharides of major histocompatibility complex (MHC) class II molecules, affinity-purified murine IA(s) class II molecules were deglycosylated in the presence of asparagine amidase enzyme. The deglycosylated IA(s) molecules were characterized by 12% SDS-polyacrylamide gel analysis under reduced and native conditions and the complete enzymatic removal of all three N-linked sugar components from the alpha/beta heterodimer was confirmed by lectin-link Western blot analysis. Like the native IA(s) molecules, the deglycosylated IA(s) molecules were fully capable of binding an antigenic peptide from myelin basic protein MBP(89-101). The kinetics of dissociation of preformed complexes of IA(s).MBP(89-101) and deglycosylated IA(s).MBP(89-101) were compared at 4 and at 37-degrees-C. Both complexes were equally stable at 4-degrees-C; however, at 37-degrees-C the deglycosylated IA(s).MBP(89-101) complexes showed an increased rate of dissociation as compared with the native IA(s).MBP(89-101) complexes. When tested for their ability to recognize the T cell receptor on T cells, both complexes bound to cloned HS-1 T cells that recognize and respond to IA(s).MBP (89-101). Finally, the complexes of deglycosylated IA(s).MBP(89-101) were tested for the induction of in vitro nonresponsiveness and compared with native IA(s).MBP(89-101) complexes. Both complexes were capable of inducing 95-100% nonresponsiveness in a proliferation assay. These results suggest that the N-linked oligosaccharide of MHC class II molecules may not be essential for either antigenic peptide binding or T cell recognition. In addition results obtained here provide evidence that the carbohydrate moities of MHC class II molecules may not be involved in induction of T cell clonal anergy.			NAG, B (corresponding author), ANERGEN INC,REDWOOD CITY,CA 94063, USA.							BARBOSA JA, 1987, J EXP MED, V166, P1329, DOI 10.1084/jem.166.5.1329; BENOIST CO, 1983, P NATL ACAD SCI-BIOL, V80, P534, DOI 10.1073/pnas.80.2.534; BUUS S, 1986, P NATL ACAD SCI USA, V83, P3968, DOI 10.1073/pnas.83.11.3968; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CHOI E, 1983, SCIENCE, V221, P283, DOI 10.1126/science.6407114; COWING C, 1983, P NATL ACAD SCI-BIOL, V80, P6000, DOI 10.1073/pnas.80.19.6000; CULLEN SE, 1981, J IMMUNOL, V127, P1478; ESTESS P, 1986, P NATL ACAD SCI USA, V83, P3594, DOI 10.1073/pnas.83.11.3594; FROHMAN M, 1985, J IMMUNOL, V134, P2269; GOLDSTEIN SAN, 1985, J EXP MED, V162, P1381, DOI 10.1084/jem.162.4.1381; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KRIEGER J, 1988, J IMMUNOL, V140, P388; MALISSEN M, 1983, SCIENCE, V221, P750, DOI 10.1126/science.6410508; MIYAZAKI J, 1986, J EXP MED, V163, P856, DOI 10.1084/jem.163.4.856; NAG B, 1992, J IMMUNOL, V148, P2040; NAG B, 1991, J IMMUNOL METHODS, V142, P105, DOI 10.1016/0022-1759(91)90297-S; NAG B, 1992, J IMMUNOL, V148, P369; NEEL D, 1987, BIOCHEM J, V244, P433, DOI 10.1042/bj2440433; PASSMORE D, 1992, IN PRESS J IMMUNOL M; QUILL H, 1987, J IMMUNOL, V138, P3704; ROOF RW, 1990, P NATL ACAD SCI USA, V87, P1735, DOI 10.1073/pnas.87.5.1735; ROTHENHAUSLER B, 1990, P NATL ACAD SCI USA, V87, P352, DOI 10.1073/pnas.87.1.352; SADEGHNASSERI S, 1989, NATURE, V337, P274, DOI 10.1038/337274a0; SANTOSAGUADO J, 1987, MOL CELL BIOL, V7, P982, DOI 10.1128/MCB.7.3.982; SHARMA SD, 1991, P NATL ACAD SCI USA, V88, P11465, DOI 10.1073/pnas.88.24.11465; SHIROISHI T, 1985, J IMMUNOL, V134, P623; SWIEDLER SJ, 1985, J BIOL CHEM, V260, P4046; TROTTER J, 1985, J IMMUNOL, V134, P2322; WATTS TH, 1986, P NATL ACAD SCI USA, V83, P9660, DOI 10.1073/pnas.83.24.9660; WEI BY, 1991, J IMMUNOL, V146, P2358	30	27	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22624	22629						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1385402				2022-12-25	WOS:A1992JW71900098
J	SRIVASTAVA, G; KAUR, KJ; HINDSGAUL, O; PALCIC, MM				SRIVASTAVA, G; KAUR, KJ; HINDSGAUL, O; PALCIC, MM			ENZYMATIC TRANSFER OF A PREASSEMBLED TRISACCHARIDE ANTIGEN TO CELL-SURFACES USING A FUCOSYL-TRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUCOSYL-TRANSFERASE; SIALIC ACIDS; LEWIS-A; RECOGNITION; DETERMINANT; OLIGOSACCHARIDES; BINDING; ELAM-1; FETUIN; LEX	The Lewis alpha(1-->3/4)-fucosyltransferase (Le-FucT) is known to fucosylate both Type I (betaGal(1-->3)betaGlcNAc) and Type II (betaGal(1-->4)betaGlcNAc) sequences even when these are sialylated at OH-3 or fucosylated at OH-2 of the terminal Gal residues. These acceptor sequences are ubiquitous on mammalian cell-surface glycoproteins and glycolipids. The Le-FucT enzyme is therefore a potential candidate as a universal reagent for the modification of cell surfaces. We have found that a readily accessible, partially purified Le-FucT from human milk, which normally uses GDP-fucose (a 6-deoxy sugar) as the donor for the transfer of a single fucose residue, will also transfer a fucose residue substituted on C-6 by a very large sterically demanding structure, in this instance, a synthetic blood group antigen. As a demonstration of the ability of the Le-FucT to modify glycoconjugates in a mild and specific manner, we chemically synthesized the complex sugar-nucleotide alphaGal(1-->3)[alphaFuc(1-->2)]-betaGal-O-(CH2)8COHN(6)-beta-L-fucose-GDP (13) which is a GDP-fucose analog where the human blood group B trisaccharide antigen is covalently linked to C-6 of fucose through an amino group. It is shown that, in enzyme-linked immunosorbent assays, the Le-FucT uses both immobilized betaGal(1-->3)betaGlcNAc-bovine serum albumin conjugates and fetuin as acceptor substrates and renders them blood group B-active as detected by a monoclonal anti-B blood-grouping antibody. The fucose residue to which the B-trisaccharide is linked therefore becomes covalently attached to the acceptor oligosaccharide chains of those glycoproteins. Incubation of type "O" erythrocytes with the Le-FucT and complex donor 13 results in the covalent transfer of alphaGal(1-->3)[alphaFuc(1-->2)]betaGal-O-(CH2)8COHN(6)-beta-L-Fuc to cell-surface acceptors since the cells become phenotypically "B" and are agglutinated by the same antibody. It is proposed that the Le-FucT represents a powerful new tool with the ability to label animal cell surfaces with preassembled oligosaccharide and possibly also other complex recognition markers.	UNIV ALBERTA, DEPT CHEM, EDMONTON T6G 2G2, ALBERTA, CANADA	University of Alberta			Gagneja, Kanwalinderjit K/K-3204-2017	Gagneja, Kanwalinderjit K/0000-0001-7844-8583				BENDIAK B, 1989, BIOCHEMISTRY-US, V28, P6491, DOI 10.1021/bi00441a050; BERGH MLE, 1988, BANBURY REPORT, V29, P59; BEYER TA, 1981, ADV ENZYMOL, V52, P24; Brandley B K, 1991, Semin Cell Biol, V2, P281; Dennis JW, 1992, CELL SURFACE CARBOHY, P161; GAHMBERG CG, 1988, ANAL BIOCHEM, V170, P520, DOI 10.1016/0003-2697(88)90667-7; GOKHALE UB, 1990, CAN J CHEM, V68, P1063, DOI 10.1139/v90-165; GROSS HJ, 1987, EUR J BIOCHEM, V168, P595, DOI 10.1111/j.1432-1033.1987.tb13458.x; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; KELM S, 1986, CARBOHYD RES, V149, P59, DOI 10.1016/S0008-6215(00)90369-0; KESHVARA LM, 1992, GLYCOCONJUGATE J, V9, P16, DOI 10.1007/BF00731173; KLUKOWSKA JF, 1990, GENE DEV, V4, P11288; KOBATA A, 1988, BIOCHIMIE, V70, P1575, DOI 10.1016/0300-9084(88)90293-3; LEMIEUX RU, 1975, J AM CHEM SOC, V97, P4076, DOI 10.1021/ja00847a035; LEMIEUX RU, 1985, CAN J CHEM, V63, P2664, DOI 10.1139/v85-442; MONTREUIL J, 1982, COMPR BIOCHEM, V19B, P1; PALCIC MM, 1990, CARBOHYD RES, V196, P133, DOI 10.1016/0008-6215(90)84112-8; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PALCIC MM, 1989, CARBOHYD RES, V190, P1, DOI 10.1016/0008-6215(89)84141-2; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PINTO BM, 1983, CARBOHYD RES, V124, P313, DOI 10.1016/0008-6215(83)88466-3; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; TOWNSEND RR, 1986, BIOCHEMISTRY-US, V25, P5716, DOI 10.1021/bi00367a055; VARKI A, 1991, TRENDS GLYCOSCI GLYC, V3, P122; WALSH WL, 1972, TRANSFUSION, V12, P352; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275	27	59	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22356	22361						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429589				2022-12-25	WOS:A1992JW71900059
J	VULLIET, R; HALLORAN, SM; BRAUN, RK; SMITH, AJ; LEE, G				VULLIET, R; HALLORAN, SM; BRAUN, RK; SMITH, AJ; LEE, G			PROLINE-DIRECTED PHOSPHORYLATION OF HUMAN TAU-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; PAIRED HELICAL FILAMENTS; CENTRAL NERVOUS-SYSTEM; ALZHEIMER-DISEASE; ABNORMAL PHOSPHORYLATION; NEUROFIBRILLARY TANGLES; KINASE; IDENTIFICATION; BINDING; BRAIN	The primary sequence of the microtubule-associated protein tau contains multiple repeats of the sequence -X-Ser/Thr-Pro-X-, the consensus sequence for the proline-directed protein kinase (p34cdc2/p58cyclin A). When phosphorylated by proline-directed protein kinase in vitro, tau was found to incorporate up to 4.4 mol of phosphate/mol of protein. Isoelectric focusing of the tryptic phosphopeptides demonstrated the presence of five distinct peptides with pl values of approximately 6.9, 6.5, 5.6-5.9, 4.7, and 3.6. Mapping of the tryptic phosphopeptides by high performance liquid chromatography techniques demonstrated three distinct peaks. Data from gas phase sequencing, amino acid analysis, and phosphoamino acid analysis suggest that proline-directed protein kinase phosphorylates tau at four sites. Each site demonstrates the presence of a proline residue on the carboxyl-terminal side of the phosphorylated residue. Two phosphorylation sites are located adjacent to the three-repeat microtubule-binding domain that has been found to be required for the in vivo co-localization of tau protein to microtubules. Two other putative phosphorylation sites are located within the identified epitope of the monoclonal antibody Tau-1. Phosphorylation of these sites altered the immunoreactivity of tau to Tau-1 antibody. Since the neuronal microtubule-associated protein tau is multiply phosphorylated in Alzheimer's disease, and Tau-1 immunoreactivity is similarly reduced in neurofibrillary tangles and enhanced after dephosphorylation, phosphorylation at one or more of these sites may correlate with abnormally phosphorylated sites in tau protein in Alzheimer's disease.	SCHWEIZER INST ALLERGIE & ASTHMA FORSCH, CH-7270 DAVOS, SWITZERLAND; STANFORD UNIV, BECKMAN CTR, STANFORD, CA 94305 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, CTR NEUROL DIS, BOSTON, MA 02115 USA	Stanford University; Harvard University; Brigham & Women's Hospital	VULLIET, R (corresponding author), UNIV CALIF DAVIS, SCH VET MED, DEPT VET PHARMACOL & TOXICOL, DAVIS, CA 95616 USA.		Lee, Gloria/F-5965-2011	Lee, Gloria/0000-0002-8633-1534; Braun, Rudolf/0000-0002-1778-9613	NIGMS NIH HHS [GM39300] Funding Source: Medline; NINDS NIH HHS [1RO1-NS28765-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028765] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIZAWA H, 1990, J BIOL CHEM, V265, P13849; BAUDIER J, 1987, J BIOL CHEM, V262, P17584; BAUDIER J, 1988, J BIOL CHEM, V263, P5876; BENOREPARSONS M, 1989, ARCH BIOCHEM BIOPHYS, V272, P274, DOI 10.1016/0003-9861(89)90220-8; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRION JP, 1988, NEUROSCIENCE, V25, P139, DOI 10.1016/0306-4522(88)90013-9; BRION JP, 1991, BIOCHEM J, V273, P127, DOI 10.1042/bj2730127; BRUGG B, 1991, J CELL BIOL, V114, P735, DOI 10.1083/jcb.114.4.735; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CACERES A, 1991, J NEUROSCI, V11, P1515; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; CHAPIN SJ, 1991, J CELL SCI, V98, P27; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GUAN RJ, 1992, J NEUROCHEM, V58, P1365, DOI 10.1111/j.1471-4159.1992.tb11351.x; Hall F L, 1990, Proc West Pharmacol Soc, V33, P213; HALL FL, 1990, J BIOL CHEM, V265, P6944; HALL FL, 1991, J BIOL CHEM, V266, P17430; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; HALLORAN SM, 1992, FASEB J, V6, pA1558; HARLOW E, 1988, ANTIBODIES LAB MANUA, P486; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; HAYES TE, 1991, NEW BIOL, V3, P259; HIMMLER A, 1989, MOL CELL BIOL, V9, P1389, DOI 10.1128/MCB.9.4.1389; ISHIGURO K, 1991, NEUROSCI LETT, V128, P195, DOI 10.1016/0304-3940(91)90259-V; ISHIGURO K, 1988, J BIOCHEM-TOKYO, V104, P319, DOI 10.1093/oxfordjournals.jbchem.a122465; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; Kosik KS, 1990, CURR OPIN CELL BIOL, V2, P101, DOI 10.1016/S0955-0674(05)80038-9; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KOWALL NW, 1987, ANN NEUROL, V22, P639, DOI 10.1002/ana.410220514; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LINDWALL G, 1984, J BIOL CHEM, V259, P2241; MEININGER V, 1989, INT REV CYTOL, V114, P21; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; OLMSTED JB, 1986, ANNU REV CELL BIOL, V2, P421, DOI 10.1146/annurev.cb.02.110186.002225; PAPASOZOMENOS SC, 1987, CELL MOTIL CYTOSKEL, V8, P210, DOI 10.1002/cm.970080303; PAPASOZOMENOS SC, 1991, P NATL ACAD SCI USA, V88, P4543, DOI 10.1073/pnas.88.10.4543; SELKOE DJ, 1989, ANNU REV NEUROSCI, V12, P463, DOI 10.1146/annurev.ne.12.030189.002335; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WOOD JG, 1986, P NATL ACAD SCI USA, V83, P4040, DOI 10.1073/pnas.83.11.4040	53	180	189	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22570	22574						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429606				2022-12-25	WOS:A1992JW71900090
J	GETTINS, P; CHOAY, J; CREWS, BC; ZETTLMEISSL, G				GETTINS, P; CHOAY, J; CREWS, BC; ZETTLMEISSL, G			ROLE OF TRYPTOPHAN-49 IN THE HEPARIN-COFACTOR ACTIVITY OF HUMAN ANTITHROMBIN-III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-THROMBIN-III; HIGH-AFFINITY HEPARIN; H-1-NMR SPECTROSCOPY; ESCHERICHIA-COLI; DERMATAN SULFATE; BINDING-SITE; FACTOR-XA; PROTEINS; SEQUENCE; RESIDUES	To probe the functional role of tryptophan 49 in human antithrombin III, a mutant antithrombin, W49K, has been expressed in baby hamster kidney cells. The mutation reduces the affinity for heparin pentasaccharide by 1.8 kcal mol-1 but does not alter the heparin enhancement of the rate of factor X(a) inhibition. H-1 NMR spectra of W49K antithrombin show that the structure of the protein and the mode of heparin binding appear to be unaltered by the mutation, although tryptophan 49 is perturbed by heparin binding. F-19 NMR spectra of 6-fluorotryptophan-substituted antithrombin show that tryptophan 49 is in a solvent-exposed environment. The heparin-induced fluorescence enhancement of W49K antithrombin is significantly different from that of wild-type antithrombin. Pentasaccharide induces only a 24% enhancement of antithrombin fluorescence, while high affinity heparin induces an enhancement of 40%. The results indicate that tryptophan 49 is probably a heparin contact residue but can be mutated without altering the remaining heparin-antithrombin interactions or the heparin-induced conformational change and resultant activation toward Factor X(a). Hydrophobic as well as charge interactions are thus probably involved in the specificity of the antithrombin-heparin pentasaccharide interaction. The lower fluorescence enhancements suggest that the heparin-induced 40% fluorescence enhancement used as the hallmark of activating heparin species is not the best indicator of the structural change in antithrombin that results in enhancement of the rate of proteinase inhibition.	VANDERBILT UNIV, MED CTR, SCH MED, CTR MOLEC TOXICOL, NASHVILLE, TN 37232 USA; BEHRINGWERKE AG, RES LABS, W-3550 MARBURG, GERMANY; SANOFI RECH, CTR CHOAY, F-94256 GENTILLY, FRANCE	Vanderbilt University; Sanofi-Aventis; Sanofi France	GETTINS, P (corresponding author), VANDERBILT UNIV, MED CTR, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA.				NCRR NIH HHS [S10 RR05805] Funding Source: Medline; NHLBI NIH HHS [HL32595] Funding Source: Medline; NIEHS NIH HHS [ES 00267] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR005805] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; BJORK L, 1992, IN PRESS BIOCH J; BLACKBURN MN, 1984, J BIOL CHEM, V259, P939; BLINDER MA, 1989, J BIOL CHEM, V264, P5128; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BORG JY, 1988, J CLIN INVEST, V81, P1292, DOI 10.1172/JCI113447; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; CHANDRA T, 1983, P NATL ACAD SCI-BIOL, V80, P1845, DOI 10.1073/pnas.80.7.1845; Choay J, 1981, Ann N Y Acad Sci, V370, P644, DOI 10.1111/j.1749-6632.1981.tb29770.x; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; EINARSSON R, 1977, BIOCHIM BIOPHYS ACTA, V490, P104, DOI 10.1016/0005-2795(77)90110-6; GETTINS P, 1987, BIOCHEMISTRY-US, V26, P1391, DOI 10.1021/bi00379a027; GETTINS P, 1987, BIOCHEMISTRY-US, V26, P4403, DOI 10.1021/bi00388a032; GROOTENHUIS PDJ, 1991, J AM CHEM SOC, V113, P2743, DOI 10.1021/ja00007a058; GROSS KH, 1988, J MAGN RESON, V76, P87, DOI 10.1016/0022-2364(88)90203-X; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HUDZIAK RM, 1982, CELL, V31, P137, DOI 10.1016/0092-8674(82)90413-5; JORDAN R, 1979, J BIOL CHEM, V254, P2902; KALK A, 1976, J MAGN RESON, V24, P343, DOI 10.1016/0022-2364(76)90115-3; KOIDE T, 1984, P NATL ACAD SCI-BIOL, V81, P289, DOI 10.1073/pnas.81.2.289; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANCHANTIN GF, 1973, J BIOL CHEM, V248, P5956; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LEMIEUX RU, 1989, CHEM SOC REV, V18, P347, DOI 10.1039/cs9891800347; LOBERMANN H, 1984, J MOL BIOL, P731; MILETICH JP, 1980, ANAL BIOCHEM, V105, P304, DOI 10.1016/0003-2697(80)90462-5; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; NORDENMAN B, 1978, EUR J BIOCHEM, V90, P1, DOI 10.1111/j.1432-1033.1978.tb12567.x; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1981, J BIOL CHEM, V256, P1065; OWEN MC, 1987, BLOOD, V69, P1275; OWEN W G, 1973, Thrombosis Research, V3, P705, DOI 10.1016/0049-3848(73)90017-0; Petersen TE, 1979, PHYSL INHIBITORS BLO, P43; PETERSON CB, 1987, J BIOL CHEM, V262, P7559; PETITOU M, 1987, CARBOHYD RES, V167, P67, DOI 10.1016/0008-6215(87)80268-9; QUIOCHO FA, 1989, PURE APPL CHEM, V61, P1293, DOI 10.1351/pac198961071293; SHAH N, 1990, THROMB RES, V57, P343, DOI 10.1016/0049-3848(90)90250-G; SINAY P, 1984, CARBOHYD RES, V132, pC5, DOI 10.1016/0008-6215(84)85236-2; SIXL F, 1990, BIOCHEM J, V266, P545, DOI 10.1042/bj2660545; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; SYKES BD, 1974, P NATL ACAD SCI USA, V71, P469, DOI 10.1073/pnas.71.2.469; THALER E, 1975, BRIT J HAEMATOL, V31, P233, DOI 10.1111/j.1365-2141.1975.tb00853.x; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VILLANUEVA GB, 1983, J BIOL CHEM, V258, P1010; Zettlmeissl G, 1988, Behring Inst Mitt, P26; ZETTLMEISSL G, 1990, Patent No. 384122	51	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21946	21953						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400504				2022-12-25	WOS:A1992JV01100105
J	OHMICHI, M; DECKER, SJ; SALTIEL, AR				OHMICHI, M; DECKER, SJ; SALTIEL, AR			NERVE GROWTH-FACTOR STIMULATES THE TYROSINE PHOSPHORYLATION OF A 38-KDA PROTEIN THAT SPECIFICALLY ASSOCIATES WITH THE SRC HOMOLOGY DOMAIN OF PHOSPHOLIPASE-C-GAMMA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRK PROTOONCOGENE PRODUCT; PC12 PHEOCHROMOCYTOMA CELLS; COOH-TERMINAL TRUNCATION; HUMAN INSULIN-RECEPTOR; KINASE-ACTIVITY; RAT PHEOCHROMOCYTOMA; SIGNAL TRANSDUCTION; PHORBOL ESTERS; PC-12 CELLS; C-GAMMA	The cellular actions of nerve growth factor (NGF) involve changes in protein phosphorylation, initiated by the binding and subsequent activation of its tyrosine kinase receptor, the trk protooncogene (pp140c-trk). Upon exposure to NGF, a 38-kDa tyrosine-phosphorylated protein (pp38) is identified in both PC-12 pheochromocytoma cells and NIH3T3 cells transfected with the full-length human pp140c-trk cDNA (3T3-c-trk) that is specifically coimmunoprecipitated with pp140c-trk or phosphatidylinositol-phospholipase C (PLC)-gamma1. In both PC-12 and 3T3-c-trk cells, NGF rapidly stimulates the association of pp140c-trk and pp38 with a fusion protein containing the src homology (SH) domains of PLCgamma1. This phosphorylation and subsequent association are specific for NGF, since epidermal growth factor, platelet-derived growth factor, and insulin do not stimulate the tyrosine phosphorylation of these proteins or their association with the PLCgamma1 SH domains, although the receptors for these growth factors do undergo tyrosine phosphorylation and association with the PLC-gamma1 fusion protein under these conditions. Furthermore, the NGF-dependent pp38-SH binding is specific for the SH2 domains of PLC-gamma1, since the phosphoprotein does not bind to fusion proteins containing SH domains of ras GTPase-activating protein or the p85 subunit of phosphatidylinositol 3 kinase. Both amino- and carboxyl-terminal SH2 domains of PLC-gamma1 are necessary for the association of pp38 with PLC-gamma1, although each SH2 domain is sufficient for the association of pp140c-trk with PLC-gamma1. In both PC-12 and 3T3-c-trk cells, the phosphorylation and association of pp38 with PLCgamma1 is rapid, occurring maximally at 1 min and declining thereafter. Moreover, this effect of NGF is dose-dependent over a physiological concentration of the growth factor. The specificity and rapidity of pp38 phosphorylation and its association with PLC-gamma1 suggest that it may be an important component in signal transduction for NGF.	WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105; UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT MICROBIOL,ANN ARBOR,MI 48109	Pfizer; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828	NCI NIH HHS [CA37754] Funding Source: Medline; NIDDK NIH HHS [DK33804] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033804, R23DK033804] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALETTA TM, 1988, J CELL BIOL, V105, P1573; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAN BL, 1989, P NATL ACAD SCI USA, V86, P1756, DOI 10.1073/pnas.86.6.1756; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; HALEGOUA S, 1980, CELL, V22, P571, DOI 10.1016/0092-8674(80)90367-0; HAMA T, 1986, P NATL ACAD SCI USA, V83, P2353, DOI 10.1073/pnas.83.8.2353; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HU P, 1992, IN PRESS MOL CELL BI; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOIZUMI S, 1988, J NEUROSCI, V8, P715; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P2832; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRETH G, 1980, NATURE, V283, P202, DOI 10.1038/283202a0; LANDRETH GE, 1985, J CELL BIOL, V100, P677, DOI 10.1083/jcb.100.3.677; LEE KY, 1985, CELL, V57, P1101; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARGOLIS B, 1990, EMBO J, V9, P4357; MATHUDA Y, 1987, J BIOL CHEM, V262, P2832; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MEISENHELDER J, 1989, CELL, V57, P1108; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MIYASAKA T, 1991, P NATL ACAD SCI USA, V88, P2653, DOI 10.1073/pnas.88.7.2653; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NAKANISHI N, 1985, J BIOL CHEM, V260, P7791; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; OHMICHI M, 1992, BIOCHEMISTRY-US, V31, P4034, DOI 10.1021/bi00131a019; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; OHMICHI M, 1992, J BIOL CHEM, V267, P14604; OHMICHI M, 1991, BIOCHEM BIOPH RES CO, V179, P217, DOI 10.1016/0006-291X(91)91357-I; OHMICHI M, 1992, IN PRESS NEURON; RAWLAND EA, 1987, J BIOL CHEM, V262, P7504; SALTIEL AR, 1991, MOL CELL ENDOCRINOL, V81, pC197, DOI 10.1016/0303-7207(91)90198-2; SUN XJ, 1988, SCIENCE, V242, P1697; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; ZHU G, IN PRESS P NATL ACAD	53	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21601	21606						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400471				2022-12-25	WOS:A1992JV01100054
J	SASAKI, T; NAKA, M; NAKAMURA, F; TANAKA, T				SASAKI, T; NAKA, M; NAKAMURA, F; TANAKA, T			RUTHENIUM RED INHIBITS THE BINDING OF CALCIUM TO CALMODULIN REQUIRED FOR ENZYME ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; LIGHT CHAIN KINASE; SMOOTH-MUSCLE MYOSIN; RABBIT SKELETAL-MUSCLE; TRYPTIC FRAGMENTS; PYRUVATE-DEHYDROGENASE; MARINE-INVERTEBRATES; MODULATOR PROTEIN; BOVINE HEART; SEA-ANEMONE	The Ca2+-calmodulin (CaM)-dependent activation of myosin light chain kinase is inhibited by ruthenium red competitively with respect to Ca2+, with a K(i) value of 8.6 muM. The binding of Ca2+ to CaM is inhibited by micromolar concentrations of ruthenium red. In the absence of Ca2+, CaM has two binding sites for ruthenium red with the dissociation constants of 0.36 and 8.7 muM, respectively. Ca2+ antagonizes the binding of ruthenium red to the low-affinity site on CaM. Binding of ruthenium red to the high-affinity site is not affected by Ca2+. The low- and high-affinity sites for ruthenium red are shown to be located in the NH2-terminal half and the COOH-terminal half of CaM, respectively. Lower concentrations of ruthenium red are needed for enzyme inactivation than for the dissociation of enzyme-CaM-Sepharose complex, suggesting these events have different Ca2+ requirements. Moreover, ruthenium red inhibits Ca2+-induced contraction of depolarized vascular smooth muscle in a competitive manner with respect to Ca2+. These results suggest that ruthenium red may be a new type of CaM antagonist that inhibits the binding of Ca2+ to CaM and thereby inhibits Ca2+-CaM-dependent enzymes and smooth muscle contraction competitively with respect to Ca2+.	MIE UNIV,SCH MED,DEPT MOLEC & CELLULAR PHARMACOL,2-174 EDOBASHI,TSU,MIE 514,JAPAN	Mie University								Adair GS, 1925, J BIOL CHEM, V63, P529; ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; ADELSTEIN RS, 1978, J BIOL CHEM, V253, P8347; ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; ANDERSSON A, 1983, EUR J BIOCHEM, V134, P459, DOI 10.1111/j.1432-1033.1983.tb07589.x; Beavo J A, 1974, Methods Enzymol, V38, P299; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN NC, 1969, J MOL BIOL, V46, P39, DOI 10.1016/0022-2836(69)90056-4; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; COX JA, 1981, J BIOL CHEM, V256, P3218; COX JA, 1988, CALCIUM CALCIUM BIND, P141; CROUCH TH, 1980, BIOCHEMISTRY-US, V19, P3962; DABROWSKA R, 1978, BIOCHEMISTRY-US, V17, P253, DOI 10.1021/bi00595a010; Dahlquist F W, 1978, Methods Enzymol, V48, P270; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; DONATO R, 1989, CELL CALCIUM, V10, P81, DOI 10.1016/0143-4160(89)90048-1; ENDO T, 1985, ENDOCRINOLOGY, V117, P527, DOI 10.1210/endo-117-2-527; FORBES MS, 1979, CELL TISSUE RES, V200, P367; FORSEN S, 1986, CALCIUM CELL FUNCTIO, V6, P113; GUERINI D, 1985, ANAL BIOCHEM, V150, P178, DOI 10.1016/0003-2697(85)90458-0; GUERINI D, 1984, J BIOL CHEM, V259, P5172; GUPTA MP, 1989, CAN J CARDIOL, V5, P55; HAIECH J, 1981, BIOCHEMISTRY-US, V20, P3890, DOI 10.1021/bi00516a035; HANSFORD RG, 1987, BIOCHEM J, V241, P145, DOI 10.1042/bj2410145; HATHAWAY DR, 1983, ANAL BIOCHEM, V135, P37, DOI 10.1016/0003-2697(83)90726-1; HIDAKA H, 1976, J BIOL CHEM, V251, P7508; HIDAKA H, 1981, P NATL ACAD SCI-BIOL, V78, P4354, DOI 10.1073/pnas.78.7.4354; HIDAKA H, 1980, MOL PHARMACOL, V17, P66; HUANG CY, 1981, P NATL ACAD SCI-BIOL, V78, P871, DOI 10.1073/pnas.78.2.871; IKURA M, 1984, BIOCHEMISTRY-US, V23, P3124, DOI 10.1021/bi00309a003; INAGAKI M, 1983, PHARMACOLOGY, V27, P125, DOI 10.1159/000137861; KINCAID RL, 1986, P NATL ACAD SCI USA, V83, P1193, DOI 10.1073/pnas.83.5.1193; KINCAID RL, 1984, ADV CYCLIC NUCL PROT, V16, P77; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEE CB, 1978, BIOCHEMISTRY-US, V17, P120, DOI 10.1021/bi00594a017; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPORTE DC, 1979, BIOCHEMISTRY-US, V18, P2820, DOI 10.1021/bi00580a021; LEVIN RM, 1977, MOL PHARMACOL, V13, P690; LINSE S, 1991, J BIOL CHEM, V266, P8050; LUFT JH, 1971, ANAT REC, V171, P347, DOI 10.1002/ar.1091710302; MASUOKA H, 1990, BIOCHEM BIOPH RES CO, V169, P315, DOI 10.1016/0006-291X(90)91470-D; MCCORMACK JG, 1983, BIOCHEM J, V214, P581, DOI 10.1042/bj2140581; MILLS JS, 1985, J BIOL CHEM, V260, P5100; MILOS M, 1986, BIOCHEMISTRY-US, V25, P6279, DOI 10.1021/bi00368a067; MINOWA O, 1984, J BIOCHEM-TOKYO, V96, P1175, DOI 10.1093/oxfordjournals.jbchem.a134935; NACCACHE PH, 1980, BIOCHEM BIOPH RES CO, V97, P62, DOI 10.1016/S0006-291X(80)80134-3; NEWTON DL, 1984, J BIOL CHEM, V259, P4419; NISHIKAWA M, 1980, NATURE, V287, P863, DOI 10.1038/287863a0; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; Smith RM, 1974, CRITICAL STABILITY C, V1-6; TANAKA T, 1980, BIOCHEM BIOPH RES CO, V92, P313, DOI 10.1016/0006-291X(80)91554-5; TANAKA T, 1983, PHARMACOLOGY, V26, P249, DOI 10.1159/000137808; TANAKA T, 1986, MOL PHARMACOL, V29, P264; TEO TS, 1973, J BIOL CHEM, V248, P5950; VOGEL HJ, 1984, BIOCHEM BIOPH RES CO, V122, P1350, DOI 10.1016/0006-291X(84)91240-3; WALSH M, 1977, J BIOL CHEM, V252, P7440; YAZAWA M, 1980, J BIOCHEM, V87, P1313, DOI 10.1093/oxfordjournals.jbchem.a132869	59	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21518	21523						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1383224				2022-12-25	WOS:A1992JV01100041
J	BISHOPRIC, NH; SATO, B; WEBSTER, KA				BISHOPRIC, NH; SATO, B; WEBSTER, KA			BETA-ADRENERGIC REGULATION OF A MYOCARDIAL ACTIN GENE VIA A CYCLIC AMP-INDEPENDENT PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATRIAL-NATRIURETIC-FACTOR; CA-2+ RELEASE CHANNEL; RAT CARDIAC MYOCYTES; PROTEIN-KINASE-C; SARCOPLASMIC-RETICULUM; CALCIUM IONOPHORE; CELL HYPERTROPHY; SKELETAL-MUSCLE; GROWTH-FACTOR; HUMAN-HEART	The skeletal alpha-actin gene encodes a major component of the embryonic cardiac sarcomere that is strongly and selectively re-induced during beta-adrenoceptor-mediated hypertrophy in neonatal rat cardiac myocytes. We present evidence that beta-adrenergic induction of this gene is mediated, not by cAMP, but by a calcium-dependent pathway involving ryanodine-sensitive calcium stores. Nifedipine-induced blockade of the plasma membrane L-type calcium entry channel prevented induction of skeletal alpha-actin mRNA by isoproterenol. Activation of calcium entry by the dihydropyridine agonist Bay K8644 independently induced skeletal alpha-actin mRNA, as did cholera toxin-mediated activation of G(s). Induction of skeletal alpha-actin mRNA by compounds that directly elevate cAMP was weak relative to their effects on other cAMP-dependent phenomena and required calcium entry. In addition, selective inhibition of protein kinase A with KT5720 did not block beta-adrenergic induction of skeletal alpha-actin. Calcium ionophore A23187 did not induce skeletal actin, but prevented its induction by isoproterenol. Ryanodine had bimodal effects: 10(-10) M ryanodine induced skeletal alpha-actin mRNA, whereas 10(-6) M ryanodine prevented skeletal actin induction by beta-adrenergic stimuli. We postulate that beta-adrenergic stimulation of skeletal alpha-actin mRNA requires G-protein-coupled calcium channel activation and compartmentalized calcium release in a manner independent of the cAMP/protein kinase A signal pathway.	DEPT VET AFFAIRS MED CTR,CARDIOVASC RES INST,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	BISHOPRIC, NH (corresponding author), SRI INT,DIV LIFE SCI M111,333 RAVENSWOOD AVE,MENLO PK,CA 94025, USA.			Webster, Keith A/0000-0002-6431-3642	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL044578, R01HL044578] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44578] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BISHOPRIC NH, 1987, J CLIN INVEST, V80, P1194, DOI 10.1172/JCI113179; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; BOHELER KR, 1991, J CLIN INVEST, V88, P323, DOI 10.1172/JCI115295; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; BRISTOW MR, 1984, J CLIN INVEST, V74, P212, DOI 10.1172/JCI111404; BUCKINGHAM ME, 1985, ESSAYS BIOCHEM, V20, P77; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CITRI Y, 1980, NATURE, V287, P297, DOI 10.1038/287297a0; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROVE JR, 1987, SCIENCE, V238, P530; HARTZELL HC, 1991, NATURE, V351, P573, DOI 10.1038/351573a0; HUNTER DR, 1983, CIRC RES, V53, P703, DOI 10.1161/01.RES.53.5.703; INUI M, 1987, J BIOL CHEM, V262, P15637; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LANGER GA, 1990, AM J PHYSIOL, V259, pH592, DOI 10.1152/ajpheart.1990.259.2.H592; LAPOINTE MC, 1990, HYPERTENSION, V15, P20, DOI 10.1161/01.HYP.15.1.20; LIPP P, 1990, FEBS LETT, V275, P181, DOI 10.1016/0014-5793(90)81467-3; LYNCH C, 1991, AM J PHYSIOL, V260, pH785, DOI 10.1152/ajpheart.1991.260.3.H785; MANN DL, 1989, CIRC RES, V64, P1079, DOI 10.1161/01.RES.64.6.1079; MCDERMOTT PJ, 1989, CIRC RES, V64, P542, DOI 10.1161/01.RES.64.3.542; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; PESSAH IN, 1991, MOL PHARMACOL, V39, P679; QURESHI SA, 1991, MOL CELL BIOL, V11, P102, DOI 10.1128/MCB.11.1.102; RESENDEZ E, 1985, MOL CELL BIOL, V5, P1212, DOI 10.1128/MCB.5.6.1212; REUTER H, 1982, NATURE, V297, P501, DOI 10.1038/297501a0; RIABOWOL KT, 1988, NATURE, V336, P83, DOI 10.1038/336083a0; ROCHASINGH KJ, 1989, CIRCULATION S2, V80, P93; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SEI CA, 1991, J BIOL CHEM, V266, P15910; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHUNTOH H, 1988, J NEUROCHEM, V51, P1565, DOI 10.1111/j.1471-4159.1988.tb01126.x; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; SPRINGHORN JP, 1989, BIOCHEM J, V258, P73, DOI 10.1042/bj2580073; SUTKO JL, 1985, FED PROC, V44, P2984; SWYNGHEDAUW B, 1986, PHYSIOL REV, V66, P710, DOI 10.1152/physrev.1986.66.3.710; TARAZI RC, 1983, AM J MED, V75, P80, DOI 10.1016/0002-9343(83)90123-7; WEBSTER KA, 1992, IN PRESS J MOL CELL; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999	46	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20932	20936						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383212				2022-12-25	WOS:A1992JT97800067
J	EISEMAN, E; BOLEN, JB				EISEMAN, E; BOLEN, JB			SIGNAL TRANSDUCTION BY THE CYTOPLASMIC DOMAINS OF FC-EPSILON-RI-GAMMA AND TCR-ZETA IN RAT BASOPHILIC LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; PROTEIN-TYROSINE KINASE; HIGH-AFFINITY RECEPTOR; T-CELL; ANTIGEN RECEPTOR; IMMUNOGLOBULIN-E; TRANSFECTED CELLS; MOLECULAR-CLONING; SURFACE EXPRESSION; IGE RECEPTOR	The gamma subunit of the high affinity IgE receptor, FcepsilonRI, is a member of a family of proteins which form disulfide-linked dimers. This family also includes the zeta- and eta-chains of the T cell receptor. Engagement of FcepsilonRI activates src-related protein tyrosine kinases in basophils and mast cells. However, the role of individual subunits of FcepsilonRI in this activation is still not known. In an effort to determine the function of FcepsilonRI-gamma, we used chimeric proteins containing the extracellular and transmembrane domains of the alpha chain of the human interleukin 2 receptor (Tac) and the cytoplasmic domains of either T cell receptor-zeta or FcepsilonRI-gamma. We show that while cross-linking of the Tac chimeras in the rat basophilic leukemia cell line RBL-2H3 resulted in the tyrosine phosphorylation of a subset of proteins and a portion of the degranulation normally observed after FcepsilonRI-mediated stimulation, no detectable activation of p56lyn or pp60c-src was observed. In contrast, an apparent transient deactivation of these two kinases was observed after Tac chimera cross-linking. These observations suggest that FcepsilonRI-gamma is responsible for some, but not all, of the signaling that occurs after engagement of its receptor, and that other receptor subunits may also play important roles in this signaling process.			EISEMAN, E (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, POB 4000, PRINCETON, NJ 08543 USA.							ALBER G, 1991, J BIOL CHEM, V266, P22613; ANDERSON P, 1989, NATURE, V341, P159, DOI 10.1038/341159a0; ANDERSON P, 1990, P NATL ACAD SCI USA, V87, P2274, DOI 10.1073/pnas.87.6.2274; BANIYASH M, 1989, J BIOL CHEM, V264, P13252; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BOLEN JB, 1991, ADV CANCER RES, V57, P103; EISEMAN E, 1992, NATURE, V355, P78; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; HUPPI KD, 1991, J IMMUNOL, V143, P3787; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; KUROSAKI T, 1992, J EXP MED, V175, P447, DOI 10.1084/jem.175.2.447; KUSTER H, 1990, J BIOL CHEM, V265, P6448; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LECONIAT M, 1990, IMMUNOGENETICS, V32, P183, DOI 10.1007/BF02114971; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LETOURNEUR F, 1989, IMMUNOGENETICS, V29, P265, DOI 10.1007/BF00717911; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MILLER L, 1989, SCIENCE, V244, P334, DOI 10.1126/science.2523561; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; OHNO H, 1990, INT IMMUNOL, V2, P1117, DOI 10.1093/intimm/2.11.1117; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK DJ, 1991, J BIOL CHEM, V266, P24237; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RA C, 1989, J BIOL CHEM, V264, P15323; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RODEWALD HR, 1991, J BIOL CHEM, V266, P15974; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; STEPHAN V, 1992, J BIOL CHEM, V267, P5434; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; VARINBLANK N, 1990, J BIOL CHEM, V265, P15685; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x	46	50	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21027	21032						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383215				2022-12-25	WOS:A1992JT97800081
J	RANDI, AM; JORIEUX, S; TULEY, EA; MAZURIER, C; SADLER, JE				RANDI, AM; JORIEUX, S; TULEY, EA; MAZURIER, C; SADLER, JE			RECOMBINANT VONWILLEBRAND-FACTOR ARG578-]GLN - A TYPE-IIB VONWILLEBRAND DISEASE MUTATION AFFECTS BINDING TO GLYCOPROTEIN-IB BUT NOT TO COLLAGEN OR HEPARIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND FACTOR; PLATELET MEMBRANE; HEMOPHILIA-A; BOTROCETIN; DOMAIN; COMPLEX; IDENTIFICATION; RISTOCETIN; SITES; IX	von Willebrand factor (vWF) is a multimeric plasma glycoprotein that mediates platelet adhesion to the subendothelium via binding to platelet glycoprotein Ib (GPIb) and to components of the vessel wall. Recently, missense mutations that cause type IIB von Willebrand disease (vWD) were described, clustered within a disulfide loop in the A1 domain of vWF that has binding sites for GPIb, collagen, and heparin. In type IIB vWD, plasma vWF exhibits increased affinity for platelet GPIb, but decreased binding to collagen and heparin. The effect was studied of a type IIB vWD mutation, Arg578 --> Gln, on the interaction of vWF with GPIb, collagen, and heparin. Recombinant wild type rvWF and mutant rvWF(R578Q) were expressed in COS-7 cells. Ristocetin-induced binding of rvWF(R578Q) to GPIb was markedly increased compared with rvWF, confirming that the Arg578 --> Gln mutation causes the characteristic gain-of-function abnormality of type IIB vWD; botrocetin-induced binding was only slightly increased. Binding to collagen type III and heparin-agarose was compared for rvWF(R578Q) and plasma vWF from patients with four different type IIB mutations: Arg543 --> Trp, Arg545 --> Cys, Val553 --> Met, Arg578 --> Gln. For all of the plasma samples, binding to collagen and to heparin was reduced compared with normal plasma. In contrast, binding of rvWF(R578Q) to collagen and heparin was normal compared with wild type rvWF. Therefore, the Arg578 --> Gln mutation increases the affinity of vWF for GPIb but does not directly impair vWF interaction with collagen or heparin. Arg578 may therefore be necessary to prevent normal vWF from interacting with GPIb. In type IIB vWD, the defective binding of plasma vWF to collagen and heparin may be secondary to post-synthetic modifications that occur in vivo, such as the loss of high molecular weight vWF multimers.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,HOWARD HUGHES MED INST,660 S EUCLID,BOX 8022,ST LOUIS,MO 63110; CTR REG TRANSFUS SANGUINE,RECH HEMOSTASE LAB,LILLE,FRANCE; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,DEPT MED & BIOCHEM,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT MOLEC BIOPHYS,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Howard Hughes Medical Institute; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)			Sadler, Evan/D-8556-2011	Sadler, J. Evan/0000-0001-5705-469X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088, P50HL014147] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HLBI 07088, HLBI 14147] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIHARA M, 1988, THROMB HAEMOSTASIS, V59, P485; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8326, DOI 10.1021/bi00447a010; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8317, DOI 10.1021/bi00447a009; BRINKHOUS KM, 1980, BLOOD, V55, P517; BROWN JE, 1986, THROMB RES, V43, P303, DOI 10.1016/0049-3848(86)90150-7; COONEY KA, 1991, J CLIN INVEST, V87, P1227, DOI 10.1172/JCI115123; COONEY KA, 1992, P NATL ACAD SCI USA, V89, P2869, DOI 10.1073/pnas.89.7.2869; DEGROOT PG, 1989, P NATL ACAD SCI USA, V86, P3793; DEGROOT PG, 1987, SEMIN THROMB HEMOST, V13, P416, DOI 10.1055/s-2007-1003518; DEMARCO L, 1985, P NATL ACAD SCI USA, V82, P7424; DEMARCO L, 1990, J CLIN INVEST, V86, P785, DOI 10.1172/JCI114775; DEROMEUF C, 1991, THROMB HAEMOSTASIS, V65, pA970; FUJIMURA Y, 1987, J BIOL CHEM, V262, P1734; GILCHRIST M, 1990, THROMB RES, V57, P659, DOI 10.1016/0049-3848(90)90084-P; GIRMA JP, 1990, THROMB HAEMOSTASIS, V64, P326; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HOWARD MA, 1984, BRIT J HAEMATOL, V57, P25, DOI 10.1111/j.1365-2141.1984.tb02862.x; KRONER PA, 1992, BLOOD, V79, P2048; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAZURIER C, 1990, BRIT J HAEMATOL, V76, P372, DOI 10.1111/j.1365-2141.1990.tb06371.x; MOHRI H, 1989, J BIOL CHEM, V264, P17361; MOHRI H, 1988, J BIOL CHEM, V263, P17901; NISHIKUBO T, 1991, THROMB HAEMOSTASIS, V65, P1128; NISHIO K, 1990, AM J HEMATOL, V33, P261, DOI 10.1002/ajh.2830330409; RAINES G, 1990, THROMB RES, V60, P201, DOI 10.1016/0049-3848(90)90181-B; RANDI AM, 1991, J CLIN INVEST, V87, P1220, DOI 10.1172/JCI115122; RANDI AM, 1991, THROMB HAEMOSTASIS, V65, pA764; RIBBA AS, 1991, BLOOD, V78, P1738; RUGGERI ZM, 1980, NEW ENGL J MED, V302, P1047, DOI 10.1056/NEJM198005083021902; RUGGERI ZM, 1980, J CLIN INVEST, V65, P1453; SADLER JE, 1991, J BIOL CHEM, V266, P22777; SOUTAR AK, 1990, PROTEIN FUNCTION, P69; SUGIMOTO M, 1991, J BIOL CHEM, V266, P18172; TULEY EA, 1991, P NATL ACAD SCI USA, V88, P6377, DOI 10.1073/pnas.88.14.6377; WAGNER DD, 1991, CELL, V64, P403, DOI 10.1016/0092-8674(91)90648-I; WARE J, 1991, P NATL ACAD SCI USA, V88, P2946, DOI 10.1073/pnas.88.7.2946	36	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21187	21192						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400429				2022-12-25	WOS:A1992JT97800104
J	ADAMSON, P; MARSHALL, CJ; HALL, A; TILBROOK, PA				ADAMSON, P; MARSHALL, CJ; HALL, A; TILBROOK, PA			POSTTRANSLATIONAL MODIFICATIONS OF P21(RHO)PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; BOVINE BRAIN MEMBRANES; C-TERMINAL CYSTEINE; RHOA GENE-PRODUCT; GAMMA-SUBUNIT; ISOPRENOID MODIFICATION; PRENYLATED PROTEINS; METHYL-ESTER; RAS PROTEINS; IDENTIFICATION	Post-translational modifications of the ras proteins, which are required for plasma membrane localization and biological function of the proteins, have been shown to include prenylation and carboxymethylation at the carboxyl terminal cysteine residue of the cysteine-aliphatic amino acid-aliphatic amino acid-any amino acid (CAAX) box. In addition, p21Ha-ras and p21N-ras, but not p21K-ras (B), are palmitoylated. The three mammalian rho proteins (A, B, and C) are also members of the ras superfamily but have distinct biological activities and different intracellular distributions from p21(ras). Analysis showed all three rho proteins are modified by a COOH-terminal carboxymethylation similar to p21ras, whereas p21rhoC labeled with [H-3]mevalonic acid in vivo revealed the presence of a C20 prenoid, similar to that already described for p21rhoA. However, in vivo and in vitro studies of p21rhoB showed this protein to be modified by both C15 and C20 prenoids. Mutation of C193 in the CAAX box abolished prenylation, whereas mutation of the adjacent C192 resulted in a significant reduction in the amount of the C20, but not C15 prenoid, recovered from p21rhoB. In vivo labeling studies with [H-3]palmitic acid and mutational analysis showed that both cysteine residues at 189 and 192 upstream of the CAAX box in p21rhoB are sites for palmitoylation. We conclude that there are different populations of post-translationally modified p21rhoB in the cell and that the sequence specificity for geranylgeranyl- and farnesyltransferases may be more complicated than previously proposed.	INST CANC RES, CHESTER BEATTY LABS, CELL & MOLEC BIOL SECT, 237 FULHAM RD, LONDON SW3 6JB, ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK								ADMSON P, 1992, IN PRESS J CELL BIOL; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BINSTOCK J, 1984, METHOD ENZYMOL, V106, P310; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; EPSTEIN WW, 1990, P NATL ACAD SCI USA, V87, P7352, DOI 10.1073/pnas.87.19.7352; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; HALL A, 1986, J BIOL CHEM, V261, P963; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HANCOCK JF, 1992, IN PRESS RAS SUPER F; HORI Y, 1991, ONCOGENE, V6, P515; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; HOSHIJIMA M, 1990, MOL BRAIN RES, V7, P9, DOI 10.1016/0169-328X(90)90067-N; KATAYAMA M, 1991, J BIOL CHEM, V266, P12639; KAWAHARA Y, 1990, BIOCHEM BIOPH RES CO, V170, P673, DOI 10.1016/0006-291X(90)92144-O; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MALTESE WA, 1990, J BIOL CHEM, V265, P17883; MOORES SL, 1991, J BIOL CHEM, V266, P14603; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; YAMAMOTO K, 1988, J BIOL CHEM, V263, P9926; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869	41	331	339	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20033	20038						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400319				2022-12-25	WOS:A1992JR85800047
J	LUNSTRUM, GP; MCDONOUGH, AM; MARINKOVICH, MP; KEENE, DR; MORRIS, NP; BURGESON, RE				LUNSTRUM, GP; MCDONOUGH, AM; MARINKOVICH, MP; KEENE, DR; MORRIS, NP; BURGESON, RE			IDENTIFICATION AND PARTIAL-PURIFICATION OF A LARGE, VARIANT FORM OF TYPE-XII COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IX COLLAGEN; EXTRACELLULAR-MATRIX; ANCHORING FIBRILS; LAMININ VARIANTS; VII PROCOLLAGEN; VITREOUS-HUMOR; II COLLAGEN; CARTILAGE; PROTEOGLYCAN; MOLECULE	A large, alternate form of type XII collagen has been identified in cultures of the human epidermoid cell line WISH. This form, designated XIIA, is comprised of alpha chains that are approximately 90 kDa larger than the 220-kDa alpha chain previously characterized in extracts of fetal chicken and bovine tissues. Results from both collagenase digestion and rotary shadow analysis of partially purified material show that the increase is due to a larger NC3 domain. While both the large (XIIA) and the small (XIIB) forms of type XII collagen are identified in pulse-chase radiolabeling of fetal bovine skin explant culture, they are not related in a precursor-product fashion. Inhibition studies with alpha,alpha'-dipyridyl indicate that proper folding of the collagen helix is required for complete assembly and secretion of type XIIA in WISH cell culture. The 310-kDa alpha1A chain is likely to represent the bovine equivalent of a second translation product, estimated to be 340 kDa, predicted from analysis of one complete chick cDNA sequence. Additionally, the amino-terminal amino acid sequence of the 220-kDa bovine alpha1B chain was determined. This sequence is very near a potential alternate splice site predicted from analysis of chicken type XII cDNA.	SHRINERS HOSP CRIPPLED CHILDREN, 3101 SW SAM JACKSON PK RD, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT CELL BIOL & ANAT, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT DERMATOL, PORTLAND, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University								AUBERTFOUCHER E, 1992, J BIOL CHEM, V267, P15759; BACHINGER HP, 1990, J BIOL CHEM, V265, P10095; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BREWTON RG, 1991, J BIOL CHEM, V266, P4752; BURGESON RE, 1988, ANNU REV CELL BIOL, V4, P551, DOI 10.1146/annurev.cb.04.110188.003003; DUBLET B, 1990, ANN NY ACAD SCI, V580, P436, DOI 10.1111/j.1749-6632.1990.tb17953.x; DUBLET B, 1989, J BIOL CHEM, V264, P13150; DUBLET B, 1991, J BIOL CHEM, V266, P6853; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; EYRE DR, 1991, ARTICULAR CARTILAGE, P119; GORDON MK, 1989, CONNECT TISSUE RES, V20, P179, DOI 10.3109/03008208909023886; GORDON MK, 1989, J BIOL CHEM, V264, P19772; GORDON MK, 1991, EUR J BIOCHEM, V201, P333, DOI 10.1111/j.1432-1033.1991.tb16290.x; GORDON MK, 1987, P NATL ACAD SCI USA, V84, P6040, DOI 10.1073/pnas.84.17.6040; KEENE DR, 1991, J CELL BIOL, V113, P971, DOI 10.1083/jcb.113.4.971; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LUNSTRUM GP, 1986, J BIOL CHEM, V261, P9042; LUNSTRUM GP, 1991, J CELL BIOL, V113, P963, DOI 10.1083/jcb.113.4.963; LUNSTRUM GP, 1987, J BIOL CHEM, V262, P13706; MORRIS NP, 1986, J BIOL CHEM, V261, P5638; MULLERGLAUSER W, 1986, J CELL BIOL, V102, P1931, DOI 10.1083/jcb.102.5.1931; PAULSSON M, 1991, J BIOL CHEM, V266, P17545; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; SHIMOKOMAKI M, 1990, ANN NY ACAD SCI, V580, P1, DOI 10.1111/j.1749-6632.1990.tb17912.x; Van der Rest M, 1987, STRUCTURE FUNCTION C, P195; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VANDERREST M, 1985, J BIOL CHEM, V260, P220; VAUGHAN L, 1985, J BIOL CHEM, V260, P4758; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; WATT SL, 1992, J BIOL CHEM, V267, P20093; WU JJ, 1989, CONNECT TISSUE RES, V20, P241, DOI 10.3109/03008208909023893; WU JJ, 1984, BIOCHEM BIOPH RES CO, V123, P1033, DOI 10.1016/S0006-291X(84)80237-5; YADA T, 1990, J BIOL CHEM, V265, P6992; YAMAGATA M, 1991, J CELL BIOL, V115, P209, DOI 10.1083/jcb.115.1.209; YAMAUCHI M, 1986, BIOCHEMISTRY-US, V25, P1997, DOI 10.1021/bi00356a024	37	41	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20087	20092						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400326				2022-12-25	WOS:A1992JR85800055
J	PILON, M; RIETVELD, AG; WEISBEEK, PJ; DEKRUIJFF, B				PILON, M; RIETVELD, AG; WEISBEEK, PJ; DEKRUIJFF, B			SECONDARY STRUCTURE AND FOLDING OF A FUNCTIONAL CHLOROPLAST PRECURSOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIT PEPTIDE; SPINACH FERREDOXIN; ESCHERICHIA-COLI; APOCYTOCHROME-C; IMPORT RECEPTOR; TRANSLOCATION; BINDING; MITOCHONDRIAL; TRANSPORT; ENVELOPE	Ferredoxin is a chloroplast stroma protein which is cytosolically synthesized as a precursor with an amino-terminal extension called the transit sequence that is needed for the post-translational uptake by the chloroplast. To characterize the secondary and tertiary structure elements, the full precursor, the holo- and apo- (without iron-sulfur cluster) forms of the mature protein, and the chemically synthesized transit peptide were obtained and analyzed separately. Circular dichroism, tryptophan fluorescence quenching, and protease accessibility experiments indicate that the precursor has a low content of defined secondary structure and resembles unfolded proteins; these properties are due to both the mature part and the transit sequence. This result provides an explanation for the lack of cytosolic factor requirement of this protein for import. In an import competition assay, the isolated transit peptide had an affinity for the chloroplasts comparable to the full precursor. Interestingly and of possible importance to the import process, the transit peptide has conformational flexibility as it adopts alternative secondary structures in different environments.	UNIV UTRECHT,DEPT MOLEC CELL BIOL,3584 CH UTRECHT,NETHERLANDS; UNIV UTRECHT,CTR BIOMEMBRANES & LIPID ENZYMOL,3584 CH UTRECHT,NETHERLANDS	Utrecht University; Utrecht University	PILON, M (corresponding author), UNIV UTRECHT,INST MOLEC BIOL & MED BIOTECHNOL,PADUALAAN 8,3584 CH UTRECHT,NETHERLANDS.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buchanan BB, 1971, METHOD ENZYMOL, V23, P413, DOI [10.1016/S0076-6879(71)23115-3, DOI 10.1016/S0076-6879(71)23115-3]; BUVINGER WE, 1989, J BIOL CHEM, V264, P1195; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHUA NH, 1979, J CELL BIOL, V81, P461, DOI 10.1083/jcb.81.3.461; DAHLINC, 1991, PLANT CELL, V3, P1131; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DEJONGH HHJ, 1990, BIOCHIM BIOPHYS ACTA, V1029, P105, DOI 10.1016/0005-2736(90)90442-Q; DELLACIOPPA G, 1986, P NATL ACAD SCI USA, V83, P6873, DOI 10.1073/pnas.83.18.6873; DELLACIOPPA G, 1988, EMBO J, V7, P1299, DOI 10.1002/j.1460-2075.1988.tb02944.x; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; FLUGGE UI, 1991, NATURE, V353, P364, DOI 10.1038/353364a0; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; JONES JD, 1990, J BIOENERG BIOMEMBR, V22, P213, DOI 10.1007/BF00763166; JORDI W, 1989, J BIOL CHEM, V264, P2292; KEEGSTRA K, 1989, CELL, V56, P247, DOI 10.1016/0092-8674(89)90898-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI HM, 1990, P NATL ACAD SCI USA, V87, P6748, DOI 10.1073/pnas.87.17.6748; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PAGANI S, 1984, EUR J BIOCHEM, V142, P361, DOI 10.1111/j.1432-1033.1984.tb08295.x; PAGANI S, 1986, BIOCHIM BIOPHYS ACTA, V870, P538, DOI 10.1016/0167-4838(86)90263-3; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; Parker C. A., 1968, PHOTOLUMINESCENCE SO, P220; PERRY SE, 1991, J BIOL CHEM, V266, P11882; PILON M, 1990, J BIOL CHEM, V265, P3358; PILON M, 1992, J BIOL CHEM, V267, P2548; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; REID GA, 1982, J BIOL CHEM, V257, P3062; REISS B, 1987, MOL GEN GENET, V209, P116, DOI 10.1007/BF00329845; ROBINSON C, 1984, EUR J BIOCHEM, V142, P337, DOI 10.1111/j.1432-1033.1984.tb08291.x; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNELL DJ, 1990, J CELL BIOL, V111, P1825, DOI 10.1083/jcb.111.5.1825; SCHNELL DJ, 1991, J BIOL CHEM, V266, P3335; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMEEKENS S, 1989, MOL GEN GENET, V216, P178, DOI 10.1007/BF00332249; SMEEKENS S, 1987, PLANT MOL BIOL, V9, P377, DOI 10.1007/BF00014912; SMEEKENS S, 1985, NUCLEIC ACIDS RES, V13, P3179, DOI 10.1093/nar/13.9.3179; THEG SM, 1989, J BIOL CHEM, V264, P6730; TSUKIHARA T, 1981, J BIOCHEM-TOKYO, V90, P1763, DOI 10.1093/oxfordjournals.jbchem.a133654; VANDENBROECK G, 1985, NATURE, V313, P358, DOI 10.1038/313358a0; VANTHOF R, 1991, FEBS LETT, V291, P350, DOI 10.1016/0014-5793(91)81318-3; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; WALKER DA, 1987, METHOD ENZYMOL, V148, P145; WRIGHT PE, 1988, BIOCHEMISTRY-US, V27, P7167, DOI 10.1021/bi00419a001; YOCUM CF, 1982, METHODS CHLOROPLAST, P973	54	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19907	19913						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400307				2022-12-25	WOS:A1992JR85800028
J	NEGRINI, M; CASTAGNOLI, A; SABBIONI, S; RECANATINI, E; GIOVANNINI, G; POSSATI, L; STANBRIDGE, EJ; NENCI, I; BARBANTIBRODANO, G				NEGRINI, M; CASTAGNOLI, A; SABBIONI, S; RECANATINI, E; GIOVANNINI, G; POSSATI, L; STANBRIDGE, EJ; NENCI, I; BARBANTIBRODANO, G			SUPPRESSION OF TUMORIGENESIS BY THE BREAST-CANCER CELL-LINE MCF-7 FOLLOWING TRANSFER OF A NORMAL HUMAN CHROMOSOME-11	ONCOGENE			English	Article							MESSENGER RIBONUCLEIC-ACID; WILMS TUMOR; RETINOBLASTOMA GENE; RECEPTOR ASSAYS; CARCINOMA-CELLS; PROTO-ONCOGENE; TRANSFER XMMCT; ARM DELETIONS; HUMAN HOMOLOG; ALLELE LOSS	Breast cancer development is associated with several genetic abnormalities. Loss of heterozygosity in the short arm of chromosome 11 has been observed in 30% of tumors. We found homozygosity at five chromosome 11 polymorphic loci in genomic DNA of the MCF-7 breast carcinoma cell line, suggesting a possible loss of one chromosome 11. We have studied the transformed and tumorigenic phenotypes of MCF-7 cells following introduction of a normal human chromosome 11 via microcell fusion. MCF-7/H11 cell hybrids, containing chromosome 11, showed in vitro characteristics similar to the parental cell line. However, tumorigenicity in athymic mice was completely suppressed. Since tumor formation by MCF-7 cells is estrogen dependent, we have analysed the expression of the estrogen receptor and of the estrogen-activated gene pS2. No difference was detected between the parental MCF-7 cells and the derived chromosome 11 cell hybrids, indicating that the mechanism of MCF-7 tumor suppression by chromosome 11-associated functions does not directly involve the estrogen/estrogen receptor molecular pathway.	UNIV ANCONA,INST BIOMED SCI,I-60131 MONTE DAGO,ITALY; UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717; UNIV FERRARA,INST MICROBIOL,I-44100 FERRARA,ITALY; UNIV FERRARA,INST RADIOL,I-44100 FERRARA,ITALY; UNIV FERRARA,INST PATHOL ANAT & HISTOL,I-44100 FERRARA,ITALY	Marche Polytechnic University; University of California System; University of California Irvine; University of Ferrara; University of Ferrara; University of Ferrara	NEGRINI, M (corresponding author), UNIV FERRARA,INTERDEPT CTR CANC RES,VIA LUIGI BORSARI 46,I-44100 FERRARA,ITALY.		Negrini, Massimo/J-2377-2016	Negrini, Massimo/0000-0002-0007-1920	PHS HHS [19104] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BARKER D, 1984, AM J HUM GENET, V36, P1159; BARTEK J, 1990, ONCOGENE, V5, P893; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BERGER SL, 1979, BIOCHEMISTRY-US, V18, P5143, DOI 10.1021/bi00590a018; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DEVILEE P, 1991, ONCOGENE, V6, P1705; DEVILEE P, 1991, ONCOGENE, V6, P311; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; DICKSON RB, 1986, SCIENCE, V232, P1540, DOI 10.1126/science.3715461; DOWDY SF, 1990, GENE CHROMOSOME CANC, V2, P318, DOI 10.1002/gcc.2870020410; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FOURNIER REK, 1977, P NATL ACAD SCI USA, V74, P319, DOI 10.1073/pnas.74.1.319; GENDLER SJ, 1990, INT J CANCER, V45, P431, DOI 10.1002/ijc.2910450309; GENUARDI M, 1989, AM J HUM GENET, V45, P73; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KOENDERS A, 1983, EUR J CANCER CLIN ON, V19, P1221, DOI 10.1016/0277-5379(83)90199-2; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KUGOH HM, 1990, ONCOGENE, V5, P1637; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE JH, 1989, CANCER RES, V49, P1220; LOH WE, 1992, P NATL ACAD SCI USA, V89, P1755, DOI 10.1073/pnas.89.5.1755; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; MACKAY J, 1988, LANCET, V2, P1384; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MCGUIRE WL, 1977, CANCER RES, V37, P637; MISRA BC, 1989, AM J HUM GENET, V45, P565; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OSHIMURA M, 1990, J CELL BIOCHEM, V42, P135, DOI 10.1002/jcb.240420304; PROSSER J, 1990, ONCOGENE, V5, P1573; QUAN F, 1986, NUCLEIC ACIDS RES, V14, P5321, DOI 10.1093/nar/14.13.5321; READ LD, 1989, MOL ENDOCRINOL, V3, P295, DOI 10.1210/mend-3-2-295; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SACEDA M, 1989, MOL ENDOCRINOL, V3, P1782, DOI 10.1210/mend-3-11-1782; Sambrook J, 1989, MOL CLONING LABORATO; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; Saxon P J, 1987, Methods Enzymol, V151, P313, DOI 10.1016/S0076-6879(87)51026-6; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMIDTKE J, 1984, HUM GENET, V67, P428, DOI 10.1007/BF00291404; SCRABLE HJ, 1987, NATURE, V329, P645, DOI 10.1038/329645a0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOULE HD, 1980, CANCER LETT, V10, P177, DOI 10.1016/0304-3835(80)90042-7; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; THEILLET C, 1990, ONCOGENE, V5, P147; THEILLET C, 1989, ONCOGENE, V4, P915; THEILLET C, 1986, CANCER RES, V46, P4776; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; VARLEY JM, 1988, ONCOGENE, V3, P87; VARLEY JM, 1989, ONCOGENE, V4, P725; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WILLIAMS BP, 1988, ONCOGENE, V3, P345; YEE D, 1988, CANCER RES, V48, P6691; ZHOU DJ, 1988, ONCOGENE, V2, P279	70	20	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2013	2018						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408142				2022-12-25	WOS:A1992JP42400015
J	REYNOLDS, PJ; HURLEY, TR; SEFTON, BM				REYNOLDS, PJ; HURLEY, TR; SEFTON, BM			FUNCTIONAL-ANALYSIS OF THE SH2 AND SH3 DOMAINS OF THE LCK TYROSINE PROTEIN-KINASE	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; PHOSPHORYLATED CELLULAR PROTEINS; AMINO-TERMINAL DOMAIN; PHOSPHOLIPASE-C; SRC GENE; TRANSFORMING ACTIVITY; DIRECTED MUTAGENESIS; COMPLEMENTARY-DNA; POINT MUTATIONS; V-SRC	p56lck is a lymphoid cell-specific member of the src family of cytoplasmic tyrosine kinases. In helper and cytotoxic T cells it is physically associated with the CD4 and CD8 surface antigens and appears to play a role in signal transduction during T-cell activation. p56lck contains both an SH3 and an SH2 Src homology domain. Such domains have been suggested to play a role in the regulation of the activity or function of both receptor and non-receptor tyrosine protein kinases. Deletion of either or both domains in p56lck was found here to activate the protein and to lead to increased phosphorylation of the autophosphorylation site, Tyr-394, in vivo. These findings are consistent with the hypothesis that these domains participate in repression of the kinase activity of p56lck. None of the deleted forms was capable of transformation of fibroblasts. Deletion of the SH3 domain of a constitutively activated form of p56lck, p56lckF505, did not diminish the transforming activity of this protein. This suggests that this domain is dispensable for the transformation of fibroblasts by p56lck. In contrast, deletion of the SH2 domain abolished the transforming potential of activated p56lckF505. However, interpretation of this effect is made somewhat difficult because the mutation also lowered the steady-state abundance of the protein.	SALK INST,MOLEC BIOL & VIROL LAB,POB 85800,SAN DIEGO,CA 92186; UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093	Salk Institute; University of California System; University of California San Diego					NCI NIH HHS [CA 14129, CA 42350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BRYANT D, 1982, J VIROL, V44, P683, DOI 10.1128/JVI.44.2.683-691.1982; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIRAI J, 1990, MOL CELL BIOL, V10, P1307; HURLEY TR, 1989, ONCOGENE, V4, P265; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KAMPS MP, 1988, ONCOGENE, V2, P305; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KITAMURA N, 1983, J VIROL, V46, P985, DOI 10.1128/JVI.46.3.985-992.1983; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOGA Y, 1988, CANCER RES, V48, P856; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUO K, 1990, ONCOGENE, V5, P921; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Potts W M, 1988, Oncogene Res, V3, P343; RAYMOND VW, 1987, VIROLOGY, V160, P400, DOI 10.1016/0042-6822(87)90011-0; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VORONOVA AF, 1985, MOL CELL BIOL, V4, P2705; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WENDLER PA, 1989, ONCOGENE, V4, P231; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	54	43	47	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1949	1955						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408136				2022-12-25	WOS:A1992JP42400007
J	WALKER, CW; BOOM, JDG; MARSH, AG				WALKER, CW; BOOM, JDG; MARSH, AG			1ST NONVERTEBRATE MEMBER OF THE MYC GENE FAMILY IS SEASONALLY EXPRESSED IN AN INVERTEBRATE TESTIS	ONCOGENE			English	Article							HUMAN C-MYC; STAR PISASTER-OCHRACEUS; DNA-BINDING; SEA STAR; DROSOPHILA-MELANOGASTER; NUCLEOTIDE-SEQUENCE; ASTERIAS-VULGARIS; GERMINAL CELLS; PROTEIN; ONCOGENES	We have cloned and characterized the first non-vertebrate member of the myc gene family, pAv-myc, from testes of the Northern sea star, Asterias vulgaris (Echinodermata). We have used an oligonucleotide that is complementary to the virtually 100% conserved vertebrate c-myc box A in the second exon and a cDNA library constructed from spermatogenically active testes. Relatives of this echinoderm existed approximately 100 million years prior to the origin of the earliest known organism for which c-myc sequence is currently available (the trout). Nonetheless, our cDNA encodes a protein with approximately 30% amino acid identity and 46% overall conservation to human c-myc. Regions of substantially higher conservation (63-95%) correspond in order to the transcriptional activation (boxes A, B and C), casein kinase II phosphorylation, nuclear-targeting, basic DNA-binding and oligomerization domains in the second and third exons of human c-myc. Sea star c-myc cDNA detects a 2.7-kb transcript on Northern blots of monthly samples of testicular tissue from field-collected individuals (n = 6-8), indicating peak expression during active spermatogenesis. This is also the first example of seasonal variation in expression of c-myc during spermatogenesis in laboratory or natural populations of any animal. It is intriguing to speculate about the potential oncogenic character of c-myc in this invertebrate, in which tumors have not yet been observed, and about the possibility that c-myc is more widely present in eucaryotes than has been anticipated.	UNIV MARYLAND,COMB,BALTIMORE,MD 21203; SIMON FRASER UNIV,INST MOLEC BIOL & BIOCHEM,BURNABY V5A 1S6,BC,CANADA	University System of Maryland; University of Maryland Baltimore; Simon Fraser University	WALKER, CW (corresponding author), UNIV NEW HAMPSHIRE,DEPT ZOOL,DURHAM,NH 03824, USA.							ARGUAT C, 1991, GENE, V97, P231; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHENG GH, 1989, MOL CELL BIOL, V9, P2332, DOI 10.1128/MCB.9.6.2332; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DANG CV, 1989, MOL CELL BIOL, V9, P2477, DOI 10.1128/MCB.9.6.2477; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DEPINHO RA, 1987, GENE DEV, V1, P1131; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GEORGE DG, 1990, METHOD ENZYMOL, V183, P333; HOWELL AM, 1987, J MOL EVOL, V25, P29, DOI 10.1007/BF02100038; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; INGVARSSON S, 1988, MOL CELL BIOL, V8, P3168, DOI 10.1128/MCB.8.8.3168; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KHANDJIAN EW, 1986, MOL BIOL REP, V11, P107, DOI 10.1007/BF00364822; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KOVESDI I, 1985, MOL CELL BIOL, V5, P3001, DOI 10.1128/MCB.5.11.3001; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LUDWIG SR, 1989, P NATL ACAD SCI USA, V86, P7092, DOI 10.1073/pnas.86.18.7092; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAKELA TP, 1991, THESIS HELSINKI FINL; MIFFLIN D, 1988, BIOSCIENCE REP, V8, P415, DOI 10.1007/BF01121638; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PETERS EC, 1988, AM FISH SOC SPECIAL, V18, P74; PRENDERGAST GC, 1990, NATURE, V342, P392; Sambrook J, 1989, MOL CLONING LABORATO; SARID J, 1987, P NATL ACAD SCI USA, V84, P170, DOI 10.1073/pnas.84.1.170; SARID J, 1988, NUCLEIC ACIDS RES, V16, P4725, DOI 10.1093/nar/16.10.4725; SHILO BZ, 1981, P NATL ACAD SCI-BIOL, V78, P6789, DOI 10.1073/pnas.78.11.6789; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SPARKS AK, 1972, INVERTEBRATE PATHOLO, P271; STEWART MA, 1986, VIROLOGY, V154, P121, DOI 10.1016/0042-6822(86)90435-6; STEWART TA, 1984, SCIENCE, V226, P707, DOI 10.1126/science.6494906; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SUGIYAMA A, 1989, P NATL ACAD SCI USA, V86, P9144, DOI 10.1073/pnas.86.23.9144; VANBENEDEN RJ, 1986, P NATL ACAD SCI USA, V83, P3698; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; WALKER CW, 1980, J MORPHOL, V166, P81, DOI 10.1002/jmor.1051660107; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P2146, DOI 10.1073/pnas.80.8.2146; WATTS SA, 1990, TISSUE CELL, V22, P435, DOI 10.1016/0040-8166(90)90073-I; WATTS SA, 1990, BIOL BULL, V179, P159, DOI 10.2307/1541750; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907	50	29	33	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2007	2012						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408141				2022-12-25	WOS:A1992JP42400014
J	DSCHIDA, WJ; BOWMAN, BJ				DSCHIDA, WJ; BOWMAN, BJ			STRUCTURE OF THE VACUOLAR ATPASE FROM NEUROSPORA-CRASSA AS DETERMINED BY ELECTRON-MICROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASES; TRANSLOCATING ATPASES; QUATERNARY STRUCTURE; F1-LIKE STRUCTURE; PLASMA-MEMBRANES; PURIFICATION; F1; TRIPHOSPHATASE; MITOCHONDRIA; HOMOLOGY	We have examined the structure of the vacuolar ATPase of Neurospora crassa using negatively stained preparations of vacuolar membranes and of detergent-solubilized and gradient-purified ATPase complexes. We also examined the peripheral sector (V1) of the enzyme after it had been removed and purified. Using different stains, vacuolar membranes displayed ball-and-stalk structures similar to those of the intact mitochondrial ATPase. However, the vacuolar ATPase was clearly different from the mitochondrial ATPase in both size and structural features. The vacuolar enzyme had a much larger head domain with a distinct cleft down the middle of the complex. This domain was held above the membrane by a prominent stalk. Most intriguing was the presence of basal components. These structures appeared to project from the vacuolar membrane near the base of the stalks. Detergent-solubilized, gradient-purified ATPases displayed the same head, stalk, and basal features as those found with the intact enzyme on vacuolar membranes. The mitochondrial ATPase was significantly smaller, and no clefted head domains or basal components were observed. When V1 and F1 particles were directly compared, a significant difference in size and shape between these two soluble ATPase sectors was apparent. V1 retained all of the features seen in the globular head of the intact complex: V-shaped, triangular, and square forms around a stain-filled core.	UNIV CALIF SANTA CRUZ, DEPT BIOL, SINSHEIMER LABS, SANTA CRUZ, CA 95064 USA	University of California System; University of California Santa Cruz					NIGMS NIH HHS [GM 28703, GM 08132] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008132, R01GM028703] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P967; ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; BOWMAN BJ, 1981, J BIOL CHEM, V256, P2343; BOWMAN BJ, 1986, J MEMBRANE BIOL, V94, P83, DOI 10.1007/BF01871190; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BOWMAN EJ, 1986, P NATL ACAD SCI USA, V83, P48, DOI 10.1073/pnas.83.1.48; BOWMAN EJ, 1988, METHOD ENZYMOL, V157, P562; BOWMAN R, 1992, GENE, V114, P157; BROWN D, 1987, J CELL BIOL, V105, P1637, DOI 10.1083/jcb.105.4.1637; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; KANASEKI T, 1969, J CELL BIOL, V42, P202, DOI 10.1083/jcb.42.1.202; KLINK R, 1991, BOT ACTA, V104, P122, DOI 10.1111/j.1438-8677.1991.tb00207.x; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MORIYAMA Y, 1991, FEBS LETT, V291, P92, DOI 10.1016/0014-5793(91)81111-K; MORRE DJ, 1991, PLANTA, V184, P343, DOI 10.1007/BF00195335; NOLTA KV, 1991, J BIOL CHEM, V266, P18318; SCHMIDT W, 1982, EUR J CELL BIOL, V27, P96; Sebald W, 1979, Methods Enzymol, V55, P344; SEBALD W, 1984, HPLUS ATPASE ATP SYN, P67; SZE H, 1985, ANNU REV PLANT PHYS, V36, P175, DOI 10.1146/annurev.pp.36.060185.001135; TAIZ SL, 1991, BOT ACTA, V104, P117, DOI 10.1111/j.1438-8677.1991.tb00206.x; TIEDGE H, 1983, EUR J BIOCHEM, V132, P37, DOI 10.1111/j.1432-1033.1983.tb07322.x; TSUPRUN VL, 1984, FEBS LETT, V167, P285, DOI 10.1016/0014-5793(84)80144-1; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	31	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18783	18789						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1388158				2022-12-25	WOS:A1992JN50200081
J	MOONEY, RA; FREUND, GG; WAY, BA; BORDWELL, KL				MOONEY, RA; FREUND, GG; WAY, BA; BORDWELL, KL			EXPRESSION OF A TRANSMEMBRANE PHOSPHOTYROSINE PHOSPHATASE INHIBITS CELLULAR-RESPONSE TO PLATELET-DERIVED GROWTH-FACTOR AND INSULIN-LIKE GROWTH FACTOR-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-TYROSINE-PHOSPHATASE; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; T-CELLS; RECEPTOR; CD45; FAMILY; ACTIVATION; ASSOCIATION; CLONING	Tyrosine phosphorylation is a mechanism of signal transduction shared by many growth factor receptors and oncogene products. Phosphotyrosine phosphatases (PTPases) potentially modulate or counter-regulate these signaling pathways. To test this hypothesis, the transmembrane PTPase CD45 (leukocyte common antigen) was expressed in the murine cell line C127. Hormone-dependent autophosphorylation of the platelet-derived growth factor (PDGF) and insulin-like growth factor-1 (IGF-1) receptors was markedly reduced in cells expressing the transmembrane PTPase. Tyrosine phosphorylation of other PDGF-dependent phosphoproteins (160, 140, and 55 kDa) and IGF-1-dependent phosphoproteins (145 kDa) was similarly decreased. Interestingly, the pattern of growth factor-independent tyrosine phosphorylations was comparable in cells expressing the PTPase and control cells. This suggests a selectivity or accessibility of the PTPase limited to a subset of cellular phosphotyrosyl proteins. The maximum mitogenic response to PDGF and IGF-1 in cells expressing the PTPase was decreased by 67 and 71%, respectively. These results demonstrate that a transmembrane PTPase can both affect the tyrosine phosphorylation state of growth factor receptors and modulate proximal and distal cellular responses to the growth factors.			MOONEY, RA (corresponding author), UNIV ROCHESTER,SCH MED & DENT,DEPT PATHOL & LAB MED,601 ELMWOOD AVE,ROCHESTER,NY 14642, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038138] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-38138] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; COOPER JA, 1989, PEPTIDES PROTEIN PHO, P85; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P8628, DOI 10.1073/pnas.85.22.8628; MEISENHELDER J, 1989, CELL, V57, P1008; MOONEY RA, 1992, ENDOCRINOLOGY, V130, P1533, DOI 10.1210/en.130.3.1533; MOONEY RA, 1992, J BIOL CHEM, V267, P14054; OMARY MB, 1980, J EXP MED, V152, P842, DOI 10.1084/jem.152.4.842; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SAMELSON LE, 1990, J IMMUNOL, V145, P2448; STREULI M, 1988, J IMMUNOL, V141, P3910; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, J BIOL CHEM, V263, P6722; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401	29	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23443	23446						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429686				2022-12-25	WOS:A1992JZ23900003
J	DUELAND, S; TRAWICK, JD; NENSETER, MS; MACPHEE, AA; DAVIS, RA				DUELAND, S; TRAWICK, JD; NENSETER, MS; MACPHEE, AA; DAVIS, RA			EXPRESSION OF 7-ALPHA-HYDROXYLASE IN NONHEPATIC CELLS RESULTS IN LIVER PHENOTYPIC RESISTANCE OF THE LOW-DENSITY-LIPOPROTEIN RECEPTOR TO CHOLESTEROL REPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN HEPATOCYTES; RAT HEPATOCYTES; ACID; REDUCTASE; GENE; 25-HYDROXYCHOLESTEROL; SECRETION; HAMSTER; PATHWAY; ENZYME	The goal of this study was to understand why the expression of low density lipoprotein (LDL) receptors by the liver is poorly down-regulated by cholesterol. We examined the hypothesis that 7alpha-hydroxylase may indirectly induce the expression of the LDL receptor by metabolizing, i.e. inactivating oxysterol repressors. Non-hepatic Chinese hamster ovary cells, transfected with a plasmid encoding 7alpha-hydroxylase, expressed both the mRNA and functional activity of this liver-specific enzyme. In the presence of 5% serum, expression of the LDL receptor by transfected cells was >20 times that of non-transfected cells despite a 50% increased content of cholesterol ester. Both cell types displayed an almost complete repression of the LDL receptor by the oxysterol 25-hydroxycholesterol, suggesting that transcriptional control of the LDL receptor gene remained intact in the transfected cells. However, only cells expressing 7alpha-hydroxylase showed a derepression of the LDL receptor with time. This transient sensitivity to 25-hydroxycholesterol repression was attributed to a 3-fold greater rate of metabolism of [H-3]25-hydroxycholesterol. The paradoxical induction of LDL receptor mRNA in transfected cells having greater amounts of cholesterol esters suggests that 7alpha-hydroxylase may preferentially use oxysterols rather than cholesterol as substrates. The combined data are consistent with the proposal that 7alpha-hydroxylase indirectly induces the LDL receptor gene by metabolizing (inactivating) oxysterol repressors. Liver-specific expression of 7alpha-hydroxylase can account for the relative resistance of hepatic LDL receptors to down-regulation.	SAN DIEGO STATE UNIV,DEPT BIOL,SAN DIEGO,CA 92182; UNIV COLORADO,SCH MED,ATHEROSCLEROSIS RES CTR,DENVER,CO 80262	California State University System; San Diego State University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NHLBI NIH HHS [HL30560] Funding Source: Medline; NIDDK NIH HHS [DK34914] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034914] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AXELSON M, 1992, J BIOL CHEM, V267, P1701; AYAKI Y, 1989, J BIOL CHEM, V264, P3818; BILHEIMER DW, 1984, NEW ENGL J MED, V311, P1658, DOI 10.1056/NEJM198412273112603; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHANG TY, 1981, J BIOL CHEM, V256, P6174; CHIN DJ, 1982, P NATL ACAD SCI-BIOL, V79, P1185, DOI 10.1073/pnas.79.4.1185; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RA, 1983, J BIOL CHEM, V258, P3661; EDGE SB, 1986, J BIOL CHEM, V261, P3800; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARDERSPENGEL K, 1982, P NATL ACAD SCI-BIOL, V79, P6355, DOI 10.1073/pnas.79.20.6355; HAVEKES LM, 1986, HEPATOLOGY, V6, P1356, DOI 10.1002/hep.1840060623; HUI DY, 1981, J BIOL CHEM, V256, P5646; HYLEMON PB, 1989, ANAL BIOCHEM, V182, P212, DOI 10.1016/0003-2697(89)90581-2; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; LEE LY, 1989, NUCLEIC ACIDS RES, V17, P1259, DOI 10.1093/nar/17.3.1259; LEIGHTON JK, 1991, MOL CELL BIOL, V11, P2049, DOI 10.1128/MCB.11.4.2049; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; MYANT NB, 1977, J LIPID RES, V18, P135; PANGBURN SH, 1981, J BIOL CHEM, V256, P3340; SCHNITZERPOLOKOFF R, 1982, J BIOL CHEM, V257, P472; SIPERSTEIN MD, 1952, P SOC EXP BIOL MED, V81, P720, DOI 10.3181/00379727-81-19999; SLATER HR, 1980, J BIOL CHEM, V255, P19219; SMITH JR, 1990, J BIOL CHEM, V265, P2306; SPADY DK, 1986, J CLIN INVEST, V77, P1474, DOI 10.1172/JCI112460; SUDHOF TC, 1987, CELL, V262, P10773; SWELL L, 1981, BIOCHIM BIOPHYS ACTA, V663, P163, DOI 10.1016/0005-2760(81)90202-2; TAKAGI K, 1989, J BIOL CHEM, V264, P12352; TAYLOR FR, 1985, METHOD ENZYMOL, V110, P9; WU GY, 1984, HEPATOLOGY, V4, P1190, DOI 10.1002/hep.1840040615	30	47	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22695	22698						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429619				2022-12-25	WOS:A1992JY16300001
J	BRAUN, BR; KASSAVETIS, GA; GEIDUSCHEK, EP				BRAUN, BR; KASSAVETIS, GA; GEIDUSCHEK, EP			BENDING OF THE SACCHAROMYCES-CEREVISIAE 5S RIBOSOMAL-RNA GENE IN TRANSCRIPTION FACTOR COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL CONTROL REGION; RNA POLYMERASE-III; SITE-SPECIFIC RECOMBINATION; PROMOTER ELEMENTS; SEQUENCE ELEMENTS; ESCHERICHIA-COLI; DNA INTERACTIONS; RIBOSOMAL-RNA; PROTEIN; BINDING	Bending of the yeast 5S rRNA gene by its transcription factors (TF) IIIA, IIIC, and IIIB has been investigated by two electrophoretic methods that exploit the anomalous mobility of bent DNA in tight gel networks. A minor bend is induced by TFIIIA, and a very strong bend, centered at its upstream DNA-binding site, is induced by TFIIIB. Despite binding to different DNA sequences on the 5S rRNA gene and the previously analyzed tRNA(Glu) gene, TFIIIB generates nearly identical bends in each site. Fully assembled transcription factor complexes bend the 5S rRNA gene in the same net direction as does TFIIIB alone.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego								ARCHAMBAULT J, 1992, J BIOL CHEM, V267, P3282; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; BRAUN BR, 1993, IN PRESS J MOL BIOL; BRAUN BR, 1992, THESIS U CALIFORNIA; CHALLICE JM, 1989, J BIOL CHEM, V264, P20060; CROTHERS DM, 1991, METHOD ENZYMOL, V208, P118; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; EVANS CF, 1991, BIOCHEM BIOPH RES CO, V176, P826, DOI 10.1016/S0006-291X(05)80260-8; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GEIDUSCHEK EP, 1992, IN PRESS TRANSCRIPTI; GOTTESFELD JM, 1987, NATURE, V329, P460, DOI 10.1038/329460a0; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KELLER HJ, 1990, MOL CELL BIOL, V10, P5166, DOI 10.1128/MCB.10.10.5166; KLEKAMP MS, 1982, J BIOL CHEM, V257, P8432; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LEVEILLARD T, 1991, J BIOL CHEM, V266, P5162; LEVENE SD, 1989, SCIENCE, V245, P396, DOI 10.1126/science.2756426; NASH HA, 1990, TRENDS BIOCHEM SCI, V15, P222, DOI 10.1016/0968-0004(90)90034-9; PARSONS MC, 1990, J BIOL CHEM, V265, P5095; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PIELER T, 1987, CELL, V48, P91, DOI 10.1016/0092-8674(87)90359-X; PRENTKI P, 1987, NUCLEIC ACIDS RES, V15, P10060, DOI 10.1093/nar/15.23.10060; RAIBAUD O, 1989, J MOL BIOL, V205, P471, DOI 10.1016/0022-2836(89)90218-0; REYNOLDS WF, 1988, MOL CELL BIOL, V8, P5056, DOI 10.1128/MCB.8.11.5056; SAKONJU S, 1980, CELL, V19, P13, DOI 10.1016/0092-8674(80)90384-0; Sambrook J, 1989, MOL CLONING LABORATO; SCHROTH GP, 1991, NUCLEIC ACIDS RES, V19, P511, DOI 10.1093/nar/19.3.511; SCHROTH GP, 1989, NATURE, V340, P487, DOI 10.1038/340487a0; SHARP SJ, 1988, MOL CELL BIOL, V8, P1266, DOI 10.1128/MCB.8.3.1266; SHI YG, 1991, J BIOL CHEM, V266, P8015; SWANSON RN, 1991, P NATL ACAD SCI USA, V88, P4887, DOI 10.1073/pnas.88.11.4887; TAYLOR MJ, 1985, J BIOL CHEM, V260, P4531; TENHEGGELERBORDIER B, 1992, EMBO J, V11, P667, DOI 10.1002/j.1460-2075.1992.tb05098.x; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; ULANOVSKY L, 1990, NATURE, V343, P190, DOI 10.1038/343190a0; VIDALINGIGLIARDI D, 1991, P NATL ACAD SCI USA, V88, P229, DOI 10.1073/pnas.88.1.229; WOLFFE AP, 1990, J BIOL CHEM, V265, P4592; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0; ZINKEL SS, 1990, BIOPOLYMERS, V29, P29, DOI 10.1002/bip.360290106; ZWIEB C, 1990, NUCLEIC ACIDS RES, V18, P583, DOI 10.1093/nar/18.3.583	50	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22562	22569						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429605				2022-12-25	WOS:A1992JW71900089
J	MIOTTO, G; VENERANDO, R; KHURANA, KK; SILIPRANDI, N; MORTIMORE, GE				MIOTTO, G; VENERANDO, R; KHURANA, KK; SILIPRANDI, N; MORTIMORE, GE			CONTROL OF HEPATIC PROTEOLYSIS BY LEUCINE AND ISOVALERYL-L-CARNITINE THROUGH A COMMON LOCUS - EVIDENCE FOR A POSSIBLE MECHANISM OF RECOGNITION AT THE PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID CONTROL; ISOLATED RAT HEPATOCYTES; PROTEIN-DEGRADATION; COLLOIDAL SILICA; LIVER LYSOSOMES; DEPRIVATION; ALANINE; MODULATION	Deprivation-induced proteolysis in the perfused rat liver is controlled through the multiphasic action of 7 regulatory amino acids of which L-leucine plays the dominant role. Recently, isovaleryl-L-carnitine (IVC) was shown to mimic the leucine's effects, suggesting that the two molecules share structural features that are recognized at a common site(s). In this study we find that each evokes identical responses consisting of inhibitory effects at 0.08 and 0.8 mM, separated by a sharp zonal loss of inhibition at 0.15 mM. As monitored by density shifts of beta-hexosaminidase in colloidal silica gradients, macroautophagy is suppressed by both. Responses to Leu and IVC at 0.08 and 0.15 mM are stereospecific and require a reactive group at the alpha-carbon (or equivalent) and a high degree of branched chain specificity. In addition, 0.5 mM Ala coregulates with IVC and Leu by decreasing the zonal loss at 0.15 mM. The fact that the multiphasic responses can be duplicated with equimolar mixtures of Leu + IVC indicates that both react at the same site(s). IVC is readily taken up by a saturable process, but owing to its rapid hydrolysis in the cell, the ratio of internal to external IVC remains low over a 4-fold concentration range. These findings, together with a kinetic analysis of concerted responses to regulatory amino acids, suggest that the recognition sites are at a position in the cell, possibly at the plasma membrane, to react reversibly with plasma amino acids.	PENN STATE UNIV, MILTON S HERSHEY MED CTR, COLL MED, DEPT CELLULAR & MOLEC PHYSIOL, HERSHEY, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health			Miotto, Giovanni/S-1903-2016	Miotto, Giovanni/0000-0002-4278-4873	NIDDK NIH HHS [DK 21624] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021624] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOHMER T, 1968, BIOCHIM BIOPHYS ACTA, V152, P559, DOI 10.1016/0005-2760(68)90096-9; CARO LHP, 1989, EUR J BIOCHEM, V181, P717, DOI 10.1111/j.1432-1033.1989.tb14782.x; CRABB DW, 1978, J BIOL CHEM, V253, P1481; GRINDE B, 1981, BIOCHIM BIOPHYS ACTA, V676, P43, DOI 10.1016/0304-4165(81)90007-6; HIRSIMAKI P, 1983, PATHOBIOLOGY CELL ME, P201; HOKLAND BM, 1988, BIOCHIM BIOPHYS ACTA, V961, P324; LEVERVE XM, 1987, FEBS LETT, V219, P455, DOI 10.1016/0014-5793(87)80271-5; MIOTTO G, 1989, BIOCHEM BIOPH RES CO, V158, P797, DOI 10.1016/0006-291X(89)92792-7; MIOTTO G, 1990, FASEB Journal, V4, pA848; MORTIMORE GE, 1988, J BIOL CHEM, V263, P19545; MORTIMORE GE, 1991, J BIOL CHEM, V266, P1021; MORTIMORE GE, 1989, DIABETES METAB REV, V5, P49, DOI 10.1002/dmr.5610050105; MORTIMORE GE, 1987, J BIOL CHEM, V262, P16322; MORTIMORE GE, 1988, METHOD ENZYMOL, V166, P461; PATEL TB, 1981, J BIOL CHEM, V256, P9009; POSO AR, 1984, P NATL ACAD SCI-BIOL, V81, P4270, DOI 10.1073/pnas.81.14.4270; POSO AR, 1982, J BIOL CHEM, V257, P2114; SEGLEN PO, 1980, BIOCHIM BIOPHYS ACTA, V630, P103, DOI 10.1016/0304-4165(80)90141-5; SEGLEN PO, 1987, LYSOSOMES THEIR ROLE, P371; SURMACZ CA, 1983, AM J PHYSIOL, V245, pC52, DOI 10.1152/ajpcell.1983.245.1.C52; SURMACZ CA, 1983, AM J PHYSIOL, V245, pC61, DOI 10.1152/ajpcell.1983.245.1.C61; SURMACZ CA, 1987, BIOCHEM J, V242, P453, DOI 10.1042/bj2420453; TAM JP, 1989, METHOD ENZYMOL, V168, P7; WARD WF, 1978, J BIOL CHEM, V253, P3581; WERT JJ, 1992, BIOCHEM BIOPH RES CO, V186, P1327, DOI 10.1016/S0006-291X(05)81551-7	25	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22066	22072						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429558				2022-12-25	WOS:A1992JW71900016
J	WONG, DL; LESAGE, A; SIDDALL, B; FUNDER, JW				WONG, DL; LESAGE, A; SIDDALL, B; FUNDER, JW			GLUCOCORTICOID REGULATION OF PHENYLETHANOLAMINE N-METHYLTRANSFERASE INVIVO	FASEB JOURNAL			English	Article						RU28362; DEXAMETHASONE; TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL CONTROL; RAT ADRENAL MEDULLA	S-ADENOSYLMETHIONINE; NUCLEOTIDE-SEQUENCE; CHROMAFFIN CELLS; ADRENAL-MEDULLA; MESSENGER-RNA; GENE; CLONING; CORTICOSTERONE; EXPRESSION; ACID	In vivo, supraphysiological doses of glucocorticoids are required to restore adrenal medullary, phenylethanolamine N-methyltransferase (PNMT, E.C. 2.1.1.28) activity after hypophysectomy. However, in vitro, phenylethanolamine N-methyltransferase gene expression appears normally glucocorticoid-responsive. To explore this paradox, rats were given dexamethasone or the type II-specific glucocorticoid RU28362 (1-1000 mug/day), and adrenal phenylethanolamine N-methyltransferase activity and mRNA levels were determined. At low doses (1-30 mug/day), neither steroid altered mRNA whereas at higher doses (100-1000 mug/day), mRNA rose 10- to 20-fold, with dexamethasone approximately 3 times as potent as RU28362. In contrast, enzyme activity fell with low doses of either steroid, consistent with suppression of ACTH and endogenous steroidogenesis. At higher doses of RU28362, enzyme activity remained low and unchanged despite increased mRNA expression, whereas higher doses of dexamethasone progressively restored the enzyme to normal. These findings suggest 1) that glucocorticoid regulation of phenylethanolamine N-methyltransferase activity occurs largely independent of gene expression; 2) that glucocorticoid effects on enzyme activity are primarily indirect, probably through cosubstrate regulation and/or enzyme stabilization; and 3) that these effects are not mediated via a classical (type II) glucocorticoid receptor mechanism, given the high doses of dexamethasone and corticosterone required and the inability of RU28362 to mimic the effects of these less selective steroids.			WONG, DL (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT PSYCHIAT & BEHAV SCI,NANCY PRITZKER LAB DEV & MOLEC NEUROBIOL,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH039437] Funding Source: NIH RePORTER; NIMH NIH HHS [MH39437] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAETGE EE, 1988, P NATL ACAD SCI USA, V85, P3648, DOI 10.1073/pnas.85.10.3648; BAETGE EE, 1986, P NATL ACAD SCI USA, V83, P5454, DOI 10.1073/pnas.83.15.5454; BANERJI TK, 1985, LIFE SCI, V38, P343; BATTER DK, 1988, J NEUROSCI RES, V19, P367, DOI 10.1002/jnr.490190313; BOHN MC, 1981, DEV BIOL, V82, P1, DOI 10.1016/0012-1606(81)90423-1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIARANELLO RD, 1978, MOL PHARMACOL, V14, P478; DAVIS LG, 1986, METHOD MOL BIOL, P143; GYERMAK L, 1975, ANESTHESIOLOGY, V442, P419; JIANG W, 1989, INT J DEV NEUROSCI, V7, P513, DOI 10.1016/0736-5748(89)90010-5; JINGDONG Z, 1985, BIOTECHNOLOGY, V3, P1014; KANEDA N, 1988, J BIOL CHEM, V263, P7672; KROZOWSKI ZS, 1983, P NATL ACAD SCI-BIOL, V80, P6056, DOI 10.1073/pnas.80.19.6056; LEGASCOGNE C, 1987, SCIENCE, V237, P1212; MARGOLIS FL, 1966, SCIENCE, V154, P275, DOI 10.1126/science.154.3746.275; MEZEY E, 1989, NUCLEIC ACIDS RES, V17, P2125, DOI 10.1093/nar/17.5.2125; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; PARKER LN, 1967, SOC EXP BIOL MED, V126, P734; ROSS ME, 1990, J NEUROSCI, V10, P520; SAMBROOK J, 1990, MOL CLONING LABORATO; WAN DCC, 1989, EUR J PHARM-MOLEC PH, V172, P107, DOI 10.1016/0922-4106(89)90002-3; WONG DL, 1982, J NEUROSCI, V2, P758; WONG DL, 1985, BRAIN RES, V330, P209, DOI 10.1016/0006-8993(85)90679-1; WONG DL, 1987, BRAIN RES, V410, P32, DOI 10.1016/S0006-8993(87)80017-3; WURTMAN RJ, 1966, J BIOL CHEM, V241, P2301	26	62	63	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1992	6	14					3310	3315		10.1096/fasebj.6.14.1426768	http://dx.doi.org/10.1096/fasebj.6.14.1426768			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JZ734	1426768				2022-12-25	WOS:A1992JZ73400013
J	GORR, SU; HAMILTON, JW; COHN, DV				GORR, SU; HAMILTON, JW; COHN, DV			REGULATED, BUT NOT CONSTITUTIVE, SECRETORY PROTEINS BIND PORCINE CHYMOTRYPSINOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; PITUITARY-TUMOR CELLS; TRANS-GOLGI NETWORK; CHROMOGRANIN-A; POLYACRYLAMIDE GELS; ANTERIOR-PITUITARY; SECRETOGRANIN-I; GRANULES; CALCIUM; PATHWAYS	Endocrine and exocrine cells exhibit both a constitutive and a regulated secretory pathway. In the latter pathway, secretory proteins are stored at a high concentration in secretory granules and are released by exocytosis in response to appropriate external stimuli. Sorting between the two secretory pathways is believed to take place in the trans-Golgi tubular network. To account for experimental data, it has been proposed that sorting receptors exist which bind a variety of regulated secretory proteins, including foreign secretory proteins introduced into the cells by transfection. In support of the sorting receptor hypothesis Chung et al. (Chung, K.-N., Walter, P., Aponte, G. W., and Moore, H.-P. H. (1989) Science 243, 192-197) isolated a group of 25-kDa canine pancreatic "hormone-binding proteins" that bound regulated but not constitutive secretory proteins. To determine if similar proteins are present in other species and tissues, we have screened porcine pancreas, parathyroid, adrenal medulla, and pituitary glands. A 31-kDa protein, similar to that identified by Chung et al. (1989), which binds to regulated but not to constitutive secretory proteins was identified in porcine pancreas. This protein was not detected in the parathyroid, adrenal medulla, or pituitary glands, however, which argues against it serving as a general sorting receptor. NH2-terminal sequencing, immunoreactivity, and proteolytic activity data indicate that the porcine 31-kDa protein is similar if not identical to porcine chymotrypsinogen A or B.	UNIV LOUISVILLE,SCH DENT,DEPT BIOL & BIOPHYS SCI,CALCIUM REGULATING HORMONES LAB,LOUISVILLE,KY 40292; DEPT VET AFFAIRS MED CTR,CALCIUM ENDOCRINOL LAB,KANSAS CITY,MO 64128; UNIV KANSAS,MED CTR,SCH MED,DEPT BIOCHEM,KANSAS CITY,KS 66103	University of Louisville; University of Kansas; University of Kansas Medical Center	GORR, SU (corresponding author), UNIV LOUISVILLE,SCH DENT,ENDOCRINE CELL BIOL LAB,LOUISVILLE,KY 40292, USA.				NIDDK NIH HHS [DK38296] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038296] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BURGESS TL, 1985, J CELL BIOL, V101, P639, DOI 10.1083/jcb.101.2.639; BURGESS TL, 1984, J CELL BIOL, V99, P2223, DOI 10.1083/jcb.99.6.2223; CHARLES M, 1967, BIOCHIM BIOPHYS ACTA, V140, P395, DOI 10.1016/0005-2795(67)90514-4; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; COHN DV, 1991, EXTRA INTRACELLULAR, P83; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GORR SU, 1988, BONE MINER, V4, P17; GORR SU, 1989, AM J PHYSIOL, V257, pE247, DOI 10.1152/ajpendo.1989.257.2.E247; GORR SU, 1990, J BIOL CHEM, V265, P3012; GORR SU, 1987, CALCIUM REGULATION B, V9, P49; GUMBINER B, 1982, CELL, V28, P51, DOI 10.1016/0092-8674(82)90374-9; HASHIMOTO S, 1987, J CELL BIOL, V105, P1579, DOI 10.1083/jcb.105.4.1579; HELLERMAN JG, 1984, P NATL ACAD SCI-BIOL, V81, P5340, DOI 10.1073/pnas.81.17.5340; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; JUNG LJ, 1991, SCIENCE, V251, P1330, DOI 10.1126/science.2003219; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOORE HPH, 1986, NATURE, V321, P443, DOI 10.1038/321443a0; MOORE HPH, 1989, SECRETION ITS CONTRO, P190; NEURATH H, 1961, CIBA F S EXOCRINE PA, P67; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; ORCI L, 1987, NATURE, V326, P77, DOI 10.1038/326077a0; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; PEANASKY RJ, 1969, BIOCHIM BIOPHYS ACTA, V181, P82, DOI 10.1016/0005-2795(69)90229-3; PIMPLIKAR SW, 1992, J BIOL CHEM, V267, P4110; RAVAZZOLA M, 1976, ENDOCRINOLOGY, V98, P950, DOI 10.1210/endo-98-4-950; REAVES BJ, 1991, MOL CELL ENDOCRINOL, V79, pC141, DOI 10.1016/0303-7207(91)90085-7; REGGIO H, 1978, J CELL BIOL, V78, P951, DOI 10.1083/jcb.78.3.951; ROBICHON A, 1991, ENDOCRINOLOGY, V128, P1974, DOI 10.1210/endo-128-4-1974; ROOS N, 1988, SCANNING MICROSCOPY, V2, P323; ROSA P, 1989, J CELL BIOL, V109, P17, DOI 10.1083/jcb.109.1.17; SCHWEITZER ES, 1990, J CELL SCI, V96, P375; SEIDAH NG, 1983, FEBS LETT, V159, P68, DOI 10.1016/0014-5793(83)80418-9; SHIELDS PP, 1990, J BIOL CHEM, V265, P10905; SOSSIN WS, 1990, J CELL BIOL, V110, P1, DOI 10.1083/jcb.110.1.1; TOOZE J, 1987, J CELL BIOL, V105, P1215, DOI 10.1083/jcb.105.3.1215; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAHAIR JF, 1989, J CELL BIOL, V109, P3231, DOI 10.1083/jcb.109.6.3231; WAGNER DD, 1991, CELL, V64, P403, DOI 10.1016/0092-8674(91)90648-I; WALTER P, 1983, METHOD ENZYMOL, V96, P84	43	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21595	21600						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400470				2022-12-25	WOS:A1992JV01100053
J	BLOCHBERGER, TC; CORNUET, PK; HASSELL, JR				BLOCHBERGER, TC; CORNUET, PK; HASSELL, JR			ISOLATION AND PARTIAL CHARACTERIZATION OF LUMICAN AND DECORIN FROM ADULT CHICKEN CORNEAS - A KERATAN SULFATE-CONTAINING ISOFORM OF DECORIN IS DEVELOPMENTALLY REGULATED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE PROTEIN; CARTILAGE PROTEOGLYCAN; LINKAGE-REGION; RICH PROTEOGLYCANS; EMBRYONIC CHICKEN; COLLAGEN FIBRILS; MONKEY CORNEA; STROMA; OLIGOSACCHARIDES; TRANSPARENCY	The proteoglycans extracted from adult chicken were initially purified by DEAE-chromatography. Digestion of these proteoglycans with chondroitinase ABC generated a single 40-kDa core protein while digestion with keratanase generated a single 52-kDa core protein. Digestion with both enzymes combined, however, increased the amount of 40-kDa core protein produced. This suggested that the 40-kDa core protein exists with chondroitin/dermatan sulfate (C/DS) side chains alone and with both C/DS and keratan sulfate (KS) side chains. The proteoglycan fraction was initially digested with chondroitinase ABC, and the M(r) = 40,000 core protein derived from proteoglycans containing C/DS side chains alone was isolated. Amino-terminal sequencing showed it to be the chick cognate of decorin. The remaining proteoglycans were then digested with keratanase, and both the 40-kDa core protein and the 52-kDa core proteins derived from KS-containing proteoglycans were purified. The M(r) = 40,000 core protein derived from proteoglycans containing both C/DS and KS side chains had the same amino-terminal sequence as decorin and cross-reacted with antibodies to decorin. Sequence from the 52-kDa core protein derived from KS-containing proteoglycans showed it to be lumican. The results of this study suggest that adult chick corneas contain two isoforms of decorin: one containing C/DS side chains and the other, a hybrid, containing both C/DS and KS side chains. Embryonic corneas did not contain the hybrid isoform of decorin. These results suggest that different post-translational modifications occur to the decorin gene product during corneal development and maturation.	UNIV PITTSBURGH, SCH MED, DEPT OPHTHALMOL, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	BLOCHBERGER, TC (corresponding author), EYE & EAR INST PITTSBURGH, PITTSBURGH, PA 15213 USA.				NATIONAL EYE INSTITUTE [R01EY008104, P30EY008098] Funding Source: NIH RePORTER; NEI NIH HHS [5 R01 EY08104, 5 P30 EY08098] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANTONSSON P, 1989, J BIOL CHEM, V264, P16170; AXELSSON I, 1980, EXP EYE RES, V31, P57, DOI 10.1016/0014-4835(80)90090-1; AXELSSON I, 1975, BIOCHEM J, V145, P491, DOI 10.1042/bj1450491; BENEDEK GB, 1971, APPL OPTICS, V10, P459, DOI 10.1364/AO.10.000459; BETTELHEIM FA, 1975, BIOCHIM BIOPHYS ACTA, V381, P203, DOI 10.1016/0304-4165(75)90202-0; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; CONRAD GW, 1982, J BIOL CHEM, V257, P464; DOEGE K, 1987, J BIOL CHEM, V262, P17757; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; FUNDERBURGH JL, 1986, DEV BIOL, V116, P267, DOI 10.1016/0012-1606(86)90130-2; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P14226; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; GREGORY JD, 1982, J BIOL CHEM, V257, P6965; HASSELL JR, 1979, J BIOL CHEM, V254, P2346; HASSELL JR, 1983, ARCH BIOCHEM BIOPHYS, V222, P362, DOI 10.1016/0003-9861(83)90532-5; Hay E D, 1969, Monogr Dev Biol, V1, P1; JOST CJ, 1991, J BIOL CHEM, V266, P13336; LI W, 1992, ARCH BIOCHEM BIOPHYS, V296, P190, DOI 10.1016/0003-9861(92)90562-B; Maurice DM, 1984, EYE B, V1, P1; MIDURA RJ, 1989, J BIOL CHEM, V264, P1423; MIDURA RJ, 1989, J BIOL CHEM, V264, P1414; NAKAZAWA K, 1983, ARCH BIOCHEM BIOPHYS, V222, P105, DOI 10.1016/0003-9861(83)90507-6; NAKAZAWA K, 1984, J BIOL CHEM, V259, P3751; NAKAZAWA K, 1983, J BIOL CHEM, V258, P6051; NILSSON B, 1983, J BIOL CHEM, V258, P6056; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; RADA JA, 1991, INVEST OPHTH VIS SCI, V32, P1010; SANDERSON RD, 1988, P NATL ACAD SCI USA, V85, P9562, DOI 10.1073/pnas.85.24.9562; SCHRECENGOST PK, 1992, ARCH BIOCHEM BIOPHYS, V292, P54, DOI 10.1016/0003-9861(92)90050-7; SCOTT JE, 1988, BIOCHEM J, V253, P607, DOI 10.1042/bj2530607; SCOTT JE, 1991, BIOCHEM SOC T, V19, P877, DOI 10.1042/bst0190877; STEIN T, 1982, H-S Z PHYSIOL CHEM, V363, P825, DOI 10.1515/bchm2.1982.363.2.825; TANTRAVAHI RV, 1986, P NATL ACAD SCI USA, V83, P9207, DOI 10.1073/pnas.83.23.9207	35	67	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20613	20619						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400383				2022-12-25	WOS:A1992JT97800020
J	KOOY, J; TOH, BH; PETTITT, JM; ERLICH, R; GLEESON, PA				KOOY, J; TOH, BH; PETTITT, JM; ERLICH, R; GLEESON, PA			HUMAN AUTOANTIBODIES AS REAGENTS TO CONSERVED GOLGI COMPONENTS - CHARACTERIZATION OF A PERIPHERAL, 230-KDA COMPARTMENT-SPECIFIC GOLGI PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; BREFELDIN-A; ENDOPLASMIC-RETICULUM; MONOCLONAL-ANTIBODY; CELL BIOLOGY; APPARATUS; IDENTIFICATION; COMPLEX; NETWORK; CISTERNAE	We have used a serum from a patient with Sjogren's syndrome containing high titer (100,000) anti-Golgi autoantibodies and lower titer (20,000) anti-nuclear autoantibodies to characterize the Golgi complex. The Sjogren's syndrome serum immunoprecipitated a number of components of molecular mass 35-230 kDa from detergent extracts of [S-35]methionine-labeled HeLa cells; at high dilution, the serum precipitated one major 230-kDa component. Using the Sjogren's syndrome serum, cDNA clones encoding the Golgi autoantigen were isolated from a lambdagt11 HeLa cell cDNA library. Autoantibodies from the Sjogren's syndrome serum, affinity purified from a recombinant bacterial fusion protein generated from one of the cDNA clones, showed Golgi staining of human, mouse, and chicken cells by immunofluorescence. The purified autoantibodies immunoprecipitated and immunoblotted a 230-kDa component. A rabbit anitserum raised to the recombinant fusion protein specifically stained the Golgi complex by immunofluorescence and reacted with a 230-kDa protein by immunoprecipitation and immunoblotting. The 230-kDa protein was recovered in both the 100,000 x g sedimentable and soluble fractions in cell lysates and in the aqueous phase of Triton X-114 extracts. The 230-kDa autoantigen was dissociated from the Golgi complex by 15-min brefeldin A treatment, dissociation kinetics similar to that of mannosidase II. However, unlike mannosidase II, autoantigen staining was markedly reduced after drug treatment. Removal of brefeldin A resulted in reassociation of the autoantigen with the Golgi complex. The epitopes recognized by the affinity purified human and rabbit antibodies were ultrastructurally localized to the cytosolic face of one side of the Golgi stack, probably the trans-face. Taken together, the 230-kDa protein is a conserved, peripheral membrane component specifically associated with one Golgi compartment. We suggest that this peripheral Golgi protein may have a role in the compartment-specific structural organization of the Golgi or in sorting and transport of proteins.	MONASH UNIV, ALFRED HOSP,SCH MED,DEPT PATHOL & IMMUNOL, COMMERCIAL RD, MELBOURNE, VIC 3181, AUSTRALIA	Florey Institute of Neuroscience & Mental Health; Monash University				Gleeson, Paul/0000-0002-5336-6503				AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BLASCHEK MA, 1988, SCAND J RHEUMATOL, V17, P291, DOI 10.3109/03009748809098799; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BURKE B, 1982, EMBO J, V1, P1621, DOI 10.1002/j.1460-2075.1982.tb01364.x; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CHICHEPORTICHE Y, 1984, J CELL BIOL, V99, P2200, DOI 10.1083/jcb.99.6.2200; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; Duden R, 1991, Trends Cell Biol, V1, P14, DOI 10.1016/0962-8924(91)90064-G; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FRANZUSOFF A, 1992, NATURE, V355, P173, DOI 10.1038/355173a0; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; FRITZLER MJ, 1984, J IMMUNOL, V132, P2904; GONATAS JO, 1989, J BIOL CHEM, V264, P646; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; KOHLER G, 1976, EUR J IMMUNOL, V6, P292, DOI 10.1002/eji.1830060411; KOOY J, 1991, IMMUNOLOGY, V72, P418; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; RALTON JE, 1989, EUR J BIOCHEM, V186, P637, DOI 10.1111/j.1432-1033.1989.tb15254.x; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; REEVES WH, 1986, P NATL ACAD SCI USA, V83, P9507, DOI 10.1073/pnas.83.24.9507; RODRIGUEZ JL, 1982, CLIN EXP IMMUNOL, V49, P579; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SARASTE J, 1987, J CELL BIOL, V105, P2021, DOI 10.1083/jcb.105.5.2021; SCHERER WF, 1953, J EXP MED, V97, P695, DOI 10.1084/jem.97.5.695; SCHICKEDANZ J, 1986, VIROLOGY, V148, P47, DOI 10.1016/0042-6822(86)90402-2; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRAUS W, 1982, J HISTOCHEM CYTOCHEM, V30, P491, DOI 10.1177/30.5.6176617; TAATJES DJ, 1988, J BIOL CHEM, V263, P6302; Tan E.M., 1989, ADV IMMUNOL, V44, P151, DOI [10.1016/S0065-2776(08)60641-0, DOI 10.1016/S0065-2776(08)60641-0]; TAN EM, 1991, CELL, V67, P841, DOI 10.1016/0092-8674(91)90356-4; TAN EM, 1989, J CLIN INVEST, V84, P1, DOI 10.1172/JCI114127; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; WILSON DW, 1991, TRENDS BIOCHEM SCI, V16, P334, DOI 10.1016/0968-0004(91)90138-L; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; YUAN L, 1987, J CELL BIOL, V105, P215, DOI 10.1083/jcb.105.1.215	47	104	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20255	20263						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400343				2022-12-25	WOS:A1992JR85800080
J	KAUR, P; ROSEN, BP				KAUR, P; ROSEN, BP			MUTAGENESIS OF THE C-TERMINAL NUCLEOTIDE-BINDING SITE OF AN ANION-TRANSLOCATING ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED ARSENATE RESISTANCE; ESCHERICHIA-COLI; DIRECTED MUTAGENESIS; MOLECULAR CHARACTERIZATION; CATALYTIC SUBUNIT; ADENYLATE KINASE; CYSTIC-FIBROSIS; EXCISION REPAIR; P-GLYCOPROTEIN; ARSA PROTEIN	An oxyanion-translocating ATPase encoded by a bacterial plasmid confers resistance to antimonials and arsenicals in Escherichia coli by extrusion of the toxic oxyanions from the cytosol. The anion pump is composed of two polypeptides, the ArsA and ArsB proteins. Purified ArsA protein is an oxyanion-stimulated ATPase with two nucleotide-binding consensus sequences, one in the N-terminal half and one in the C-terminal half of the protein. The ArsA protein can be labeled with [alpha-P-32]ATP by a UV-catalyzed reaction. Previously reported mutations in the N-terminal site abolish photoadduct formation. Using site-directed mutagenesis the glycine-rich region of the C-terminal putative nucleotide-binding sequence was altered. Three C-terminal site mutant proteins (GR337, KE340, KN340) were analyzed, as well as one additional N-terminal mutant protein (KE21). Strains bearing the mutated plasmids were arsenite sensitive to varying degrees. The purified ArsA protein from mutant KE340 retained approximately 20% of the wild type oxyanion-stimulated ATPase activity, while the purified proteins from the other mutants were catalytically inactive. The KE21 mutation in the N-terminal nucleotide-binding site eliminated photoadduct formation with [alpha-P-32] ATP, while the purified proteins with mutations in the C-terminal site retained the ability to form a photoadduct. Each mutant protein was capable of forming a membrane-bound complex in arsB expressing strains. These results suggest first that both sites are required for resistance and ATPase activity, and second that the conserved lysyl residue in the glycine-rich loop of the C-terminal nucleotide-binding site is not essential for catalytic activity.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM, 540 E CANFIELD AVE, DETROIT, MI 48201 USA	Wayne State University				Rosen, Barry P./0000-0002-5230-4271	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019793] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19793] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ARISPE N, 1992, P NATL ACAD SCI USA, V89, P1539, DOI 10.1073/pnas.89.5.1539; BELL AW, 1986, J BIOL CHEM, V261, P7652; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHEN CM, 1986, J BIOL CHEM, V261, P5030; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DEBOER PAJ, 1989, CELL, V56, P641, DOI 10.1016/0092-8674(89)90586-2; FRANCISCO MJDS, 1989, MOL MICROBIOL, V3, P15, DOI 10.1111/j.1365-2958.1989.tb00098.x; FRY DC, 1985, BIOCHEMISTRY-US, V24, P4680, DOI 10.1021/bi00338a030; FUTAI M, 1983, MICROBIOL REV, V47, P285, DOI 10.1128/MMBR.47.3.285-312.1983; HSU CM, 1989, J BIOL CHEM, V264, P17349; HSU CM, 1991, J BIOL CHEM, V266, P2327; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KARKARIA CE, 1991, ARCH BIOCHEM BIOPHYS, V288, P107, DOI 10.1016/0003-9861(91)90170-N; KAUR P, 1992, PLASMID, V27, P29, DOI 10.1016/0147-619X(92)90004-T; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MEVARECH M, 1980, P NATL ACAD SCI-BIOL, V77, P6476, DOI 10.1073/pnas.77.11.6476; MOBLEY HLT, 1983, MOL GEN GENET, V191, P421, DOI 10.1007/BF00425757; MOBLEY HLT, 1982, P NATL ACAD SCI-BIOL, V79, P6119, DOI 10.1073/pnas.79.20.6119; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; RAO R, 1988, J BIOL CHEM, V263, P15957; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7451, DOI 10.1021/bi00484a014; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROSEN BP, 1984, BIOCHEM BIOPH RES CO, V124, P760, DOI 10.1016/0006-291X(84)91023-4; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P6577, DOI 10.1073/pnas.86.17.6577; SENIOR AE, 1985, CURR TOP MEMBR TRANS, V23, P135; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SILVER S, 1982, P NATL ACAD SCI-BIOL, V79, P6114, DOI 10.1073/pnas.79.20.6114; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; THIAGALINGAM S, 1991, J BIOL CHEM, V266, P11395; TISA LS, 1990, J BIOENERG BIOMEMBR, V22, P493, DOI 10.1007/BF00762959; TISA LS, 1990, J BIOL CHEM, V265, P190; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5; YUE VT, 1977, BIOCHEMISTRY-US, V16, P4678, DOI 10.1021/bi00640a023; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	46	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19272	19277						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1388167				2022-12-25	WOS:A1992JP59300041
J	KLINE, D; KLINE, JT				KLINE, D; KLINE, JT			THAPSIGARGIN ACTIVATES A CALCIUM INFLUX PATHWAY IN THE UNFERTILIZED MOUSE EGG AND SUPPRESSES REPETITIVE CALCIUM TRANSIENTS IN THE FERTILIZED EGG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ STORES; LACRIMAL ACINAR-CELLS; GOLDEN-HAMSTER EGGS; TUMOR PROMOTER; INOSITOL PHOSPHATES; PLASMA-MEMBRANE; CA-2+; ENTRY; OSCILLATIONS; INHIBITION	At fertilization, the sperm initiates development of the mouse egg by inducing a large transient increase in the intracellular Ca2+ concentration ([Ca2+]i), which is followed by repetitive transient increases in [Ca2+]i. To determine how the repetitive Ca2+ transients are produced, thapsigargin, an inhibitor of the endoplasmic reticulum Ca-ATPase, was used to deplete intracellular Ca2+ stores within the egg. In the unfertilized egg, thapsigargin (1-50-mu-M) caused a slowly rising and falling transient increase in [Ca2+]i with or without extracellular Ca2+. An influx pathway for Ca2+ is activated by thapsigargin, since an immediate increase in [Ca2+]i occurred when Ca2+ was added to eggs after thapsigargin treatment in a Ca2+,Mg2+-free medium. This suggests that Ca2+ entry in the mouse egg may be coupled to the emptying of an intracellular store. The magnitude of the first Ca2+ transient at fertilization was reduced by as much as 84% in eggs pretreated with thapsigargin. Reduction of extracellular Ca2+, by addition of a Ca2+ chelator, suppressed the repetitive Ca2+ transients following fertilization. The Ca2+ transients also require filling of an intracellular store; they were suppressed when thapsigargin was added before or after fertilization. These results support the hypothesis that the first sperm-induced Ca2+ transient at fertilization depletes an intracellular Ca2+ store, triggering an increase in plasma membrane Ca2+ permeability, and that the enhanced Ca2+ influx causes repetitive Ca2+ transients due to the periodic filling and emptying of an intracellular Ca2+ store.			KLINE, D (corresponding author), KENT STATE UNIV, DEPT BIOL SCI, KENT, OH 44242 USA.		Kline, Douglas/AAH-5955-2020	Kline, Douglas/0000-0003-2555-6729	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026032] Funding Source: NIH RePORTER; NICHD NIH HHS [HD26032] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALONSO MT, 1991, BIOCHEM J, V280, P783, DOI 10.1042/bj2800783; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BIAN JH, 1991, J BIOL CHEM, V266, P8801; CUTHBERTSON KSR, 1985, NATURE, V316, P541, DOI 10.1038/316541a0; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; DUPONT G, 1991, CELL CALCIUM, V12, P73, DOI 10.1016/0143-4160(91)90010-C; ELY JA, 1991, J BIOL CHEM, V266, P18635; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; FODER B, 1989, CELL CALCIUM, V10, P477, DOI 10.1016/0143-4160(89)90025-0; GOUY H, 1990, EUR J IMMUNOL, V20, P2269, DOI 10.1002/eji.1830201016; GRODEN DL, 1991, CELL CALCIUM, V12, P279, DOI 10.1016/0143-4160(91)90002-V; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hiramoto Y, 1984, Cell Struct Funct, V9 Suppl, ps139; HOGAN B, 1986, MANIPULATING MOUSE E; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IGUSA Y, 1983, J PHYSIOL-LONDON, V340, P611, DOI 10.1113/jphysiol.1983.sp014783; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; JAFFE LF, 1990, NATO ADV SCI I H-CEL, V45, P389; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; KLINE D, 1992, DEV BIOL, V149, P80, DOI 10.1016/0012-1606(92)90265-I; KLINE D, 1992, Biophysical Journal, V61, pA124; KWAN CY, 1990, J BIOL CHEM, V265, P678; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LAW GJ, 1990, BIOCHEM J, V267, P359, DOI 10.1042/bj2670359; LLOPIS J, 1991, BIOCHEM J, V277, P553, DOI 10.1042/bj2770553; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MIYAZAKI S, 1986, DEV BIOL, V118, P259, DOI 10.1016/0012-1606(86)90093-X; MIYAZAKI S, 1988, J CELL BIOL, V106, P345, DOI 10.1083/jcb.106.2.345; MUALLEM S, 1991, BIOCHEM J, V279, P367, DOI 10.1042/bj2790367; PAPP B, 1991, J BIOL CHEM, V266, P14593; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; POLVERINO AJ, 1991, BIOCHEM J, V278, P849, DOI 10.1042/bj2780849; PRESTON SF, 1991, CELL REGUL, V2, P915, DOI 10.1091/mbc.2.11.915; PUTNEY JW, 1990, PHARMACOL THERAPEUT, V48, P427, DOI 10.1016/0163-7258(90)90059-B; ROBINSON IM, 1991, J NEUROCHEM, V56, P1587, DOI 10.1111/j.1471-4159.1991.tb02055.x; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SOMOGYI R, 1991, J BIOL CHEM, V266, P11068; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466	42	128	128	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17624	17630						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1387638				2022-12-25	WOS:A1992JM22300025
J	WOLF, WA; KUHN, DM				WOLF, WA; KUHN, DM			ROLE OF ESSENTIAL SULFHYDRYL-GROUPS IN DRUG-INTERACTIONS AT THE NEURONAL 5-HT TRANSPORTER - DIFFERENCES BETWEEN AMPHETAMINES AND 5-HT UPTAKE INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5-HYDROXYTRYPTAMINE TRANSPORTER; CORTICAL MEMBRANES; ESCHERICHIA-COLI; BINDING; MECHANISM; SEROTONIN; PROTEIN	The sulfhydryl-selective alkylating agent, N-ethylmaleimide (NEM), has been used as a tool to discern whether different binding domains exist on the neuronal serotonin (5-HT) transporter for 5-HT and 5-HT uptake inhibitors (Reith, M. E. A., Allen, D. L., Sershen, H., and Lajtha, A. (1984) J. Neurochem. 43, 249-255; Graham, D., Esnaud, H., Habert, E., and Langer, S. Z. (1989) Biochem. Pharmacol. 38, 3819-3826). However, relatively high concentrations of NEM and long incubation times have been required for inactivation of the transporter-binding site which raises the possibility that NEM is reacting with other nucleophilic groups (Smyth, D. G., Blumenfeld, O. O., and Konigsberg, W. (1964) Biochem. J. 91, 589-595). In the present work, the reactivity and essential nature of sulfhydryl groups associated with substrate/inhibitor binding to the neuronal 5-HT transporter was assessed. [H-3]Paroxetine, a potent and selective 5-HT uptake inhibitor, was used to label the 5-HT transporter. The effects of a relatively wide range of sulfhydryl reagents on [H-3]paroxetine binding in digitonin-solubilized preparations of rat brain neuronal membranes and the relative abilities of different classes of drugs to protect against NEM-induced inactivation of [H-3]paroxetine binding were studied. It was observed that digitonin-solubilized preparations were more sensitive than membrane preparations to the inactivating effects of NEM. The pK(a) of the reactive group was estimated to be 6.17, in the range expected for a reactive sulfhydryl. Sulfhydryls essential to ligand binding reacted preferentially with hydrophobic compounds (p-hydroxymercuribenzoate = dithiobisnitrobenzoate > methyl methanethiosulfonate > N-phenylmaleimide > N-ethylmaleimide) and were unreactive toward hydrophilic reagents such as iodoacetate and iodoacetamide. 5-HT, 5-HT uptake inhibitors and cocaine protected the digitonin-solubilized transporter from NEM-induced inactivation while the amphetamine-related releasing agents p-chloroamphetamine and fenfluramine were ineffective. The observation that the binding of some, but not all, ligands requires reduced sulfhydryl groups, suggests that differential mechanisms and/or different binding domains do exist for agents which interact at the neuronal 5-HT trans porter.	WAYNE STATE UNIV, SCH MED, DEPT PSYCHIAT, CELLULAR & CLIN NEUROBIOL PROGRAM, DETROIT, MI 48201 USA	Wayne State University	WOLF, WA (corresponding author), LAFAYETTE CLIN, 951 E LAFAYETTE, DETROIT, MI 48207 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007172] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 07172] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Bennett J., 1985, NEUROTRANSMITTER REC, V2nd, P61; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNS RF, 1983, ANAL BIOCHEM, V132, P74, DOI 10.1016/0003-2697(83)90427-X; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DAVENPORT JW, 1988, J BIOL CHEM, V263, P16007; FOMENKO AM, 1990, EUR J PHARM-MOLEC PH, V189, P175, DOI 10.1016/0922-4106(90)90021-O; FULLER RW, 1980, NEUROCHEM RES, V5, P241, DOI 10.1007/BF00964612; FULLER RW, 1990, ANN N Y ACAD SCI, V600, P68; GRAHAM D, 1989, BIOCHEM PHARMACOL, V38, P3819, DOI 10.1016/0006-2952(89)90591-1; GUIDOTTI G, 1964, J BIOL CHEM, V239, P1474; HABERT E, 1986, EUR J PHARMACOL, V122, P197, DOI 10.1016/0014-2999(86)90103-2; HABERT E, 1985, EUR J PHARMACOL, V118, P107, DOI 10.1016/0014-2999(85)90668-5; HOLLAWAY MR, 1964, BIOCHIM BIOPHYS ACTA, V92, P111, DOI 10.1016/0926-6569(64)90275-5; LEMBERGER L, 1985, CLIN NEUROPHARMACOL, V8, P299, DOI 10.1097/00002826-198512000-00001; LINDLEY H, 1960, BIOCHEM J, V74, P577, DOI 10.1042/bj0740577; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; POOLMAN B, 1983, EUR J BIOCHEM, V135, P41, DOI 10.1111/j.1432-1033.1983.tb07615.x; REITH MEA, 1984, J NEUROCHEM, V43, P249, DOI 10.1111/j.1471-4159.1984.tb06703.x; Riordan J.F., 1967, METHOD ENZYMOL, V11, P541; ROBILLARD GT, 1981, BIOCHEMISTRY-US, V20, P5025, DOI 10.1021/bi00520a032; ROBILLARD GT, 1982, EUR J BIOCHEM, V127, P597; ROBILLARD GT, 1987, FEBS LETT, V224, P391, DOI 10.1016/0014-5793(87)80490-8; SMYTH DG, 1964, BIOCHEM J, V91, P589, DOI 10.1042/bj0910589	23	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20820	20825						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400397				2022-12-25	WOS:A1992JT97800049
J	BUSAM, KJ; ROBERTS, AB; SPORN, MB				BUSAM, KJ; ROBERTS, AB; SPORN, MB			INHIBITION OF MITOGEN-INDUCED C-FOS EXPRESSION IN MELANOMA-CELLS BY RETINOIC ACID INVOLVES THE SERUM RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; INDUCIBLE BINDING; GENE-EXPRESSION; ANTISENSE RNA; VITAMIN-A; TRANSCRIPTION; INDUCTION; ACTIVATION; SEQUENCES; ONCOGENE	To investigate the mechanism(s) by which all-trans-retinoic acid (RA) inhibits cell growth, we studied its effect on the expression of c-fos and c-jun in B16 melanoma cells. RA differentially inhibited proto-oncogene induction by mitogens, such as phorbol 12-myristate 13-acetate and serum. Suppression of c-fos was achieved with doses of RA as low as 10(-10) M and required pretreatment of cells with RA for a minimum of 2 h. In contrast, inhibition of c-jun required pretreatment for greater than 16 h with at least 10(-8) M RA and coincided with the observed decrease in cell growth. RA blocked c-fos induction by inhibiting transcription. This inhibition of transcription occurs through the serum response element (SRE), since the SRE alone was sufficient to confer down-regulation by RA to a minimal c-fos promoter construct. Thus, the SRE plays a critical role in the suppression of c-fos transcription by RA.	NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BUESCHER M, 1988, Oncogene, V3, P301; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1984, CELL, V36, P259; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; KOENIG H, 1989, EMBO (European Molecular Biology Organization) Journal, V8, P2559; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; LEVINE N, 1980, LANCET, V2, P224; LOTAN R, 1979, CANCER RES, V39, P4767; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MENGER H, 1988, BLOOD, V72, P567; MILLER AD, 1984, CELL, V36, P51; MILLER WH, 1990, ONCOGENE, V5, P511; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; PRYWES R, 1988, COLD SPRING HARB SYM, V53, P739, DOI 10.1101/SQB.1988.053.01.084; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; REPRESA J, 1990, DEVELOPMENT, V110, P1081; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; RIVERA V M, 1990, New Biologist, V2, P751; ROBERTS AB, 1984, RETINOIDS, V2, P209; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHERMAN MI, 1986, RETINOIDS CELL DIFFE; SIEGFRIED Z, 1989, ONCOGENE, V4, P3; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VELCICH A, 1990, MOL CELL BIOL, V9, P3576; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YANGYEN HF, 1991, NEW BIOL, V3, P1206	55	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19971	19977						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400313				2022-12-25	WOS:A1992JR85800038
J	KIM, HK; STORCH, J				KIM, HK; STORCH, J			MECHANISM OF FREE FATTY-ACID TRANSFER FROM RAT-HEART FATTY ACID-BINDING PROTEIN TO PHOSPHOLIPID-MEMBRANES - EVIDENCE FOR A COLLISIONAL PROCESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBCELLULAR-DISTRIBUTION; UNILAMELLAR VESICLES; ENERGY-PRODUCTION; LIVER; KINETICS; CHOLESTEROL; P2-PROTEIN; PALMITATE; ADIPOCYTE; EXCHANGE	Fatty acid binding proteins (FABP) are a family of low molecular weight proteins found in many tissues that actively utilize free fatty acids (ffa). FABP would be expected to have a particularly important role in the heart, where over 80% of energy requirements are derived from oxidation of long chain fatty acids. The precise physiological function of heart FABP (H-FABP) has not been definitively identified, although it is thought to play a role in intracellular ffa transport. To examine the possible role of H-FABP in cardiac myocyte transfer of ffa, we examined the transfer of fluorescent anthroyloxy ffa (AOffa) from H-FABP to model phospholipid membranes, using a resonance energy transfer assay. In contrast to previous observations of ffa transfer from liver FABP and from membranes, transfer from H-FABP to membranes appears to occur by a different mechanism. AO-palmitate (16:0) transfer was 1.5-fold slower than AO-stearate (18:0) transfer, and mono-unsaturation did not affect the transfer rate. The AOffa transfer rate from H-FABP increased with increasing ionic strength and decreased slightly between pH 7 and 9. These results suggest that the rate of ffa transfer from H-FABP to membranes is independent of the ffa aqueous solubility. Thermodynamic analysis showed that the free energy of activation for the ffa transfer process arises primarily from an enthalpic component, with only a small entropic contribution, again suggesting the lack of an aqueous phase route of ffa delivery. Finally, the ffa transfer rate was found to be directly dependent on the concentration of acceptor membranes. These data therefore suggest that transfer of AOffa from H-FABP to membranes may occur via collisional interactions between the protein and membranes.	HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health				Storch, Judith/0000-0001-5482-1777	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038389, R29DK038389] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38389, R01 DK038389] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BORCHERS T, 1989, BIOCHIM BIOPHYS ACTA, V1002, P54, DOI 10.1016/0005-2760(89)90063-5; CHARLTON SC, 1982, BIOCHEMISTRY-US, V21, P4023, DOI 10.1021/bi00260a018; CISTOLA DP, 1989, BIOCHEMISTRY-US, V28, P3628, DOI 10.1021/bi00434a072; CISTOLA DP, 1988, BIOCHEMISTRY-US, V27, P711, DOI 10.1021/bi00402a033; CRISMAN TS, 1987, J MOL CELL CARDIOL, V19, P423, DOI 10.1016/S0022-2828(87)80394-2; DAWIDOWICZ EA, 1987, CURR TOP MEMBR TRANS, V29, P175; DOODY MC, 1980, BIOCHEMISTRY-US, V19, P108, DOI 10.1021/bi00542a017; FOURNIER NC, 1983, J BIOL CHEM, V258, P2929; FOURNIER NC, 1983, BIOCHEMISTRY-US, V22, P1863, DOI 10.1021/bi00277a019; FOURNIER NC, 1985, BIOCHEMISTRY-US, V24, P2387, DOI 10.1021/bi00330a039; GLATZ JFC, 1984, J BIOL CHEM, V259, P4295; GLATZ JFC, 1985, INT J BIOCHEM, V17, P13, DOI 10.1016/0020-711X(85)90080-1; GLATZ JFC, 1985, CHEM PHYS LIPIDS, V38, P115, DOI 10.1016/0009-3084(85)90061-1; GLATZ JFC, 1985, BIOCHIM BIOPHYS ACTA, V837, P57, DOI 10.1016/0005-2760(85)90085-2; GLATZ JFC, 1983, ANAL BIOCHEM, V132, P89, DOI 10.1016/0003-2697(83)90429-3; Gomori G, 1942, J LAB CLIN MED, V27, P955; GURD FRN, 1960, LIPID CHEM, P283; HUANG C, 1974, METHOD ENZYMOL, V32, P212; JAGSCHIES G, 1985, EUR J BIOCHEM, V452, P537; KIM HK, 1992, J BIOL CHEM, V267, P77; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASSEY JB, 1984, BIOCHIM BIOPHYS ACTA, V794, P274, DOI 10.1016/0005-2760(84)90156-5; MASSEY JB, 1982, BIOCHEMISTRY-US, V21, P3630, DOI 10.1021/bi00258a016; MASSEY JB, 1981, J BIOL CHEM, V257, P5444; MCLEAN LR, 1984, BIOCHIM BIOPHYS ACTA, V776, P21, DOI 10.1016/0005-2736(84)90246-3; NEELY JR, 1974, ANNU REV PHYSIOL, V36, P413, DOI 10.1146/annurev.ph.36.030174.002213; OCKNER RK, 1982, J BIOL CHEM, V257, P7872; OFFNER GD, 1986, J BIOL CHEM, V261, P5584; POWNALL HJ, 1991, BIOCHEMISTRY-US, V30, P5690; ROSEMAN MA, 1980, BIOCHEMISTRY-US, V19, P439, DOI 10.1021/bi00544a006; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1986, J BIOL CHEM, V261, P8218; SADDIK M, 1991, J BIOL CHEM, V266, P8162; SAID B, 1984, J BIOL CHEM, V259, P1155; STORCH J, 1990, J BIOL CHEM, V265, P7827; STORCH J, 1990, MOL CELL BIOCHEM, V98, P141; STORCH J, 1986, BIOCHEMISTRY-US, V25, P1717, DOI 10.1021/bi00355a041; STORCH J, 1989, J BIOL CHEM, V264, P8708; SWEETSER DA, 1987, ANNU REV NUTR, V7, P337, DOI 10.1146/annurev.nu.07.070187.002005; THILO L, 1977, BIOCHIM BIOPHYS ACTA, V469, P326, DOI 10.1016/0005-2736(77)90168-7; TRAPP BD, 1984, J NEUROCHEM, V43, P944, DOI 10.1111/j.1471-4159.1984.tb12828.x; UYEMURA K, 1977, J NEUROCHEM, V29, P61, DOI 10.1111/j.1471-4159.1977.tb03924.x; WOOTAN MG, 1990, BIOCHEMISTRY-US, V29, P9305, DOI 10.1021/bi00492a001; [No title captured]	47	88	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20051	20056						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400322				2022-12-25	WOS:A1992JR85800050
J	MAHONY, WB; DOMIN, BA; DALUGE, SM; MILLER, WH; ZIMMERMAN, TP				MAHONY, WB; DOMIN, BA; DALUGE, SM; MILLER, WH; ZIMMERMAN, TP			ENANTIOMERIC SELECTIVITY OF CARBOVIR TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN-ERYTHROCYTE-MEMBRANE; MOUSE LEUKEMIA-CELLS; ANTI-HIV ACTIVITY; NONFACILITATED DIFFUSION; CELLULAR PHARMACOLOGY; ADENOSINE TRANSPORT; NUCLEOSIDE ANALOG; REVERSE-TRANSCRIPTASE; MAMMALIAN-CELLS	Carbovir (9-[4alpha-(hydroxymethyl)cyclopent-2-ene-1alpha-yl]guanine) (CBV) is a carbocyclic analogue of 2',3'-dideoxyguanosine that exhibits potent and selective in vitro activity against human immunodeficiency virus. Antiviral activity is associated with only the (-)-enantiomer. The transport characteristics of both (-)-CBV and (+)-CBV were investigated in human erythrocytes at 37-degrees-C using a papaverine-stop assay. The influx of both enantiomers appeared saturable and was inhibited >90% by a combination of adenine (a low K(m) permeant of the nucleobase carrier) and dilazep (a potent inhibitor of nucleoside transport). The influx of (-)-CBV and (+)-CBV proceeded primarily via the nucleobase carrier with V(max) (picomoles/second/5 mul of cells)/K(m) (millimolar) values of 17/0.12 and 140/1.9, respectively. To a lesser extent, the influx of (-)-CBV and (+)-CBV also occurred via the nucleoside transporter. Although both compounds exhibited a similar low affinity for this latter carrier (K(m) approximately 2 mM), the V(max) for (-)-CBV influx was approximately 4-fold higher than the V(max) for (+)-CBV influx. We conclude that both CBV enantiomers enter human erythrocytes by two transporters that are enantiomerically selective.	WELLCOME RES LABS, DIV ORGAN CHEM, RES TRIANGLE PK, NC 27709 USA	Wellcome Research Laboratories	MAHONY, WB (corresponding author), WELLCOME RES LABS, DIV EXPTL THERAPY, 3030 CORNWALLIS RD, RES TRIANGLE PK, NC 27709 USA.							AGARWAL RP, 1989, AIDS RES HUM RETROV, V5, P541, DOI 10.1089/aid.1989.5.541; AHLUWALIA G, 1987, BIOCHEM PHARMACOL, V36, P3797, DOI 10.1016/0006-2952(87)90440-0; AUGUST EM, 1991, MOL PHARMACOL, V39, P246; BECKETT AH, 1991, BIOCHEM SOC T, V19, P443, DOI 10.1042/bst0190443; BONDOC LL, 1990, BIOCHEMISTRY-US, V29, P9839, DOI 10.1021/bi00494a013; BROUWER KR, 1990, DRUG METAB DISPOS, V18, P1078; BUSSO ME, 1990, AIDS RES HUM RETROV, V6, P1139, DOI 10.1089/aid.1990.6.1139; CARTER SG, 1990, ANTIMICROB AGENTS CH, V34, P1297, DOI 10.1128/AAC.34.6.1297; CLELAND WW, 1963, NATURE, V198, P463, DOI 10.1038/198463a0; CLELAND WW, 1967, ADV ENZYMOL RAMB, V29, P1; COATES JAV, 1991, ANTIVIR RES, V15, P161, DOI 10.1016/0166-3542(91)90033-N; COOK RD, 1990, STATISTICAL METHODOL, P180; COONEY DA, 1986, BIOCHEM PHARMACOL, V35, P2065, DOI 10.1016/0006-2952(86)90571-X; DAGNINO L, 1991, J BIOL CHEM, V266, P6312; DEMIRANDA P, 1983, J ANTIMICROB CHEMOTH, V12, P29, DOI 10.1093/jac/12.suppl_B.29; DMIN BA, 1990, P AM ASSOC CANC RES, V31, P10; DOMIN BA, 1988, BIOCHEM BIOPH RES CO, V154, P825, DOI 10.1016/0006-291X(88)90214-8; DOMIN BA, 1988, J BIOL CHEM, V263, P9276; EXALL AM, 1991, J CHEM SOC PERK T 1, P2467, DOI 10.1039/p19910002467; GATI WP, 1984, BIOCHEM PHARMACOL, V33, P3325, DOI 10.1016/0006-2952(84)90101-1; GATI WP, 1989, BIOCHEM J, V263, P957, DOI 10.1042/bj2630957; GU JG, 1991, J NEUROCHEM, V56, P548, DOI 10.1111/j.1471-4159.1991.tb08184.x; HUANG SH, 1991, PHARMACEUT RES, V8, P739, DOI 10.1023/A:1015850017201; LEATHERBARROW RJ, 1990, ANAL BIOCHEM, V184, P274, DOI 10.1016/0003-2697(90)90680-8; MAGNANI M, 1989, BIOCHEM INT, V19, P227; MAHER TJ, 1991, DRUG DEVELOP RES, V24, P149, DOI 10.1002/ddr.430240202; MAHONY WB, 1986, ANAL BIOCHEM, V154, P235, DOI 10.1016/0003-2697(86)90521-X; MAHONY WB, 1988, J BIOL CHEM, V263, P9285; MAHONY WB, 1991, BIOCHEM PHARMACOL, V41, P263, DOI 10.1016/0006-2952(91)90485-N; PARKER WB, 1991, J BIOL CHEM, V266, P1754; PATERSON ARP, 1981, PHARMACOL THERAPEUT, V12, P515, DOI 10.1016/0163-7258(81)90096-6; PATERSON ARP, 1983, REGULATORY FUNCTION, P203; PATERSON ARP, 1991, ROLE ADENOSINE ADENI, P133; PATERSON ARP, 1986, MEMBRANE TRANSPORT A, P309; PLAGEMANN PGW, 1989, BIOCHIM BIOPHYS ACTA, V1010, P7, DOI 10.1016/0167-4889(89)90177-8; PLAGEMANN PGW, 1984, BIOCHEM PHARMACOL, V33, P1783, DOI 10.1016/0006-2952(84)90350-2; PLAGEMANN PGW, 1989, BIOCHEM PHARMACOL, V38, P3469, DOI 10.1016/0006-2952(89)90116-0; PLAGEMANN PGW, 1989, MOL PHARMACOL, V36, P185; PRUS KL, 1990, CANCER RES, V50, P1817; SCHAEFFER HJ, 1978, NATURE, V272, P583, DOI 10.1038/272583a0; SCOTT AK, 1991, DRUG NEWS PERSPECT, V4, P476; SEGAL IH, 1975, ENZYME KINETICS, P39; SPECTOR T, 1981, ANAL BIOCHEM, V115, P403, DOI 10.1016/0003-2697(81)90025-7; TAUBE RA, 1972, BIOCHIM BIOPHYS ACTA, V255, P6, DOI 10.1016/0005-2736(72)90003-X; ULLMAN B, 1988, J BIOL CHEM, V263, P12391; VINCE R, 1990, BIOCHEM BIOPH RES CO, V168, P912, DOI 10.1016/0006-291X(90)91115-9; VINCE R, 1988, BIOCHEM BIOPH RES CO, V156, P1046, DOI 10.1016/S0006-291X(88)80950-1; VINCE R, 1990, J MED CHEM, V33, P17, DOI 10.1021/jm00163a004; WHITE EL, 1989, BIOCHEM BIOPH RES CO, V161, P393, DOI 10.1016/0006-291X(89)92611-9; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; ZIMMERMAN TP, 1978, P NATL ACAD SCI USA, V75, P6220, DOI 10.1073/pnas.75.12.6220; ZIMMERMAN TP, 1987, J BIOL CHEM, V262, P5748	52	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19792	19797						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400293				2022-12-25	WOS:A1992JR85800009
J	VANVELDHOVEN, PP; VANHOVE, G; ASSELBERGHS, S; EYSSEN, HJ; MANNAERTS, GP				VANVELDHOVEN, PP; VANHOVE, G; ASSELBERGHS, S; EYSSEN, HJ; MANNAERTS, GP			SUBSTRATE SPECIFICITIES OF RAT-LIVER PEROXISOMAL ACYL-COA OXIDASES - PALMITOYL-COA OXIDASE (INDUCIBLE ACYL-COA OXIDASE), PRISTANOYL-COA OXIDASE (NONINDUCIBLE ACYL-COA OXIDASE), AND TRIHYDROXYCOPROSTANOYL-COA OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL CARRIER PROTEIN-2; FATTY-ACID OXIDATION; BETA-OXIDATION; SUBCELLULAR-LOCALIZATION; ZELLWEGER SYNDROME; SKIN FIBROBLASTS; LIGNOCERIC ACID; GLUTARYL-COA; CHAIN; METABOLISM	Rat liver peroxisomes contain three acyl-CoA oxidases: palmitoyl-CoA oxidase, pristanoyl-CoA oxidase, and trihydroxycoprostanoyl-CoA oxidase. The three oxidases were separated by anion-exchange chromatography of a partially purified oxidase preparation, and the column eluate was analyzed for oxidase activity with different acyl-CoAs. Short chain mono (hexanoyl-) and dicarboxylyl (glutaryl-)-CoAs and prostaglandin E2-CoA were oxidized exclusively by palmitoyl-CoA oxidase. Long chain mono (palmitoyl-) and dicarboxylyl (hexadecanedioyl-) -CoAs were oxidized by palmitoyl-CoA oxidase and pristanoyl-CoA oxidase, the former enzyme catalyzing approximately 70% of the total eluate activity. The very long chain lignoceroyl-CoA was also oxidized by palmitoyl-CoA oxidase and pristanoyl-CoA oxidase, the latter enzyme catalyzing approximately 65% of the total eluate activity. Long chain 2-methyl branched acyl-CoAs (2-methylpalmitoyl-CoA and pristanoyl-CoA) were oxidized for approximately 90% by pristanoyl-CoA oxidase, the remaining activity being catalyzed by trihydroxycoprostanoyl-CoA oxidase. The short chain 2-methylhexanoyl-CoA was oxidized by trihydroxycoprostanoyl-CoA oxidase and pristanoyl-CoA oxidase (approximately 60 and 40%, respectively, of the total eluate activity). Trihydroxycoprostanoyl-CoA was oxidized exclusively by trihydroxycoprostanoyl-CoA oxidase. No oxidase activity was found with isovaleryl-CoA and isobutyryl-CoA. Substrate dependences of palmitoyl-CoA oxidase and pristanoyl-CoA oxidase were very similar when assayed with the same (common) substrate. Since the two oxidases were purified to a similar extent and with a similar yield, the contribution of each enzyme to substrate oxidation in the column eluate probably reflects its contribution in the intact liver.	REGA INST,B-3000 LOUVAIN,BELGIUM	KU Leuven	VANVELDHOVEN, PP (corresponding author), CATHOLIC UNIV LEUVEN,CAMPUS GASTHUISBERG,AFDELING FARMACOL,B-3000 LOUVAIN,BELGIUM.		, Van Veldhoven Paul/U-6359-2019	, Van Veldhoven Paul/0000-0002-4478-2564				BENNETT MJ, 1991, J INHERIT METAB DIS, V14, P165, DOI 10.1007/BF01800589; CASTEELS M, 1988, J BIOL CHEM, V263, P4654; CASTEELS M, 1990, J LIPID RES, V31, P1865; CERDAN S, 1988, J BIOL CHEM, V263, P11664; CHEN RF, 1967, J BIOL CHEM, V242, P173; DICZFALUSY U, 1991, J CLIN INVEST, V88, P978, DOI 10.1172/JCI115401; FIORELLA PD, 1991, J BIOL CHEM, V266, P16572; FOERSTER EC, 1981, BIOCHEM J, V196, P705, DOI 10.1042/bj1960705; FURATA S, 1982, BIOCHEM BIOPH RES CO, V105, P639; GERBLING H, 1989, PLANT PHYSIOL, V91, P1387, DOI 10.1104/pp.91.4.1387; GERBLING H, 1988, PLANT PHYSIOL, V88, P13, DOI 10.1104/pp.88.1.13; INESTROSA NC, 1980, BIOCHEM BIOPH RES CO, V95, P7, DOI 10.1016/0006-291X(80)90696-8; JAKOBS BS, 1991, BIOCHEM BIOPH RES CO, V178, P842, DOI 10.1016/0006-291X(91)90967-C; JEDLITSCHKY G, 1991, J BIOL CHEM, V266, P24763; KASE BF, 1986, BIOCHIM BIOPHYS ACTA, V877, P37, DOI 10.1016/0005-2760(86)90115-3; KASE F, 1983, J LIPID RES, V24, P1560; KAWAGUCHI A, 1981, J BIOCHEM-TOKYO, V89, P337, DOI 10.1093/oxfordjournals.jbchem.a133207; KELLER GA, 1989, J CELL BIOL, V108, P1353, DOI 10.1083/jcb.108.4.1353; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LAZO O, 1990, J LIPID RES, V31, P583; LEIGHTON F, 1989, J BIOL CHEM, V264, P10347; MANNAERTS GP, 1990, BIOCHEM SOC T, V18, P87, DOI 10.1042/bst0180087; MANNAERTS GP, 1979, J BIOL CHEM, V254, P4585; MANNAERTS GP, 1991, NESTLE NUTR WORKS SE, V24, P1; MIURA S, 1984, J BIOL CHEM, V259, P6397; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; MOSER HW, 1989, METABOLIC BASIS INHE, V2, P1511; OSUMI T, 1980, J BIOCHEM, V87, P1735, DOI 10.1093/oxfordjournals.jbchem.a132918; POLLTHE BT, 1988, AM J HUM GENET, V42, P422; POOSCH MS, 1989, BIOCHIM BIOPHYS ACTA, V1006, P291, DOI 10.1016/0005-2760(89)90016-7; PRYDZ K, 1986, J LIPID RES, V27, P622; RICHARDS EW, 1990, BIOCHIM BIOPHYS ACTA, V1044, P361, DOI 10.1016/0005-2760(90)90081-8; SCHEPERS L, 1988, J BIOL CHEM, V263, P2724; SCHEPERS L, 1990, J BIOL CHEM, V265, P5242; SINGH I, 1981, BIOCHEM BIOPH RES CO, V102, P1223, DOI 10.1016/S0006-291X(81)80142-8; SINGH I, 1984, P NATL ACAD SCI-BIOL, V81, P4203, DOI 10.1073/pnas.81.13.4203; SKORIN C, 1992, BIOCHEM J, V281, P561, DOI 10.1042/bj2810561; SUZUKI H, 1989, BIOCHIM BIOPHYS ACTA, V990, P25, DOI 10.1016/S0304-4165(89)80007-8; THOMAS J, 1980, BIOCHEM J, V190, P485, DOI 10.1042/bj1900485; TSUNEOKA M, 1988, J BIOCHEM-TOKYO, V104, P560, DOI 10.1093/oxfordjournals.jbchem.a122510; VAMECQ J, 1984, BIOCHEM J, V221, P203, DOI 10.1042/bj2210203; VANHOVE G, 1991, J BIOL CHEM, V266, P24670; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P24676; WANDERS RJA, 1990, J INHERIT METAB DIS, V13, P4, DOI 10.1007/BF01799330; WANDERS RJA, 1991, CLIN CHIM ACTA, V202, P123, DOI 10.1016/0009-8981(91)90043-C; WANDERS RJA, 1990, BIOCHEM BIOPH RES CO, V172, P490, DOI 10.1016/0006-291X(90)90699-N	46	126	126	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20065	20074						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400324				2022-12-25	WOS:A1992JR85800052
J	WALTER, MR; COOK, WJ; ZHAO, BG; CAMERON, RP; EALICK, SE; WALTER, RL; REICHERT, P; NAGABHUSHAN, TL; TROTTA, PP; BUGG, CE				WALTER, MR; COOK, WJ; ZHAO, BG; CAMERON, RP; EALICK, SE; WALTER, RL; REICHERT, P; NAGABHUSHAN, TL; TROTTA, PP; BUGG, CE			CRYSTAL-STRUCTURE OF RECOMBINANT HUMAN INTERLEUKIN-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATORY FACTOR-I; 3-DIMENSIONAL STRUCTURE; MACROMOLECULAR CRYSTALLOGRAPHY; INTERFERON-GAMMA; ESCHERICHIA-COLI; GROWTH-HORMONE; CDNA CLONE; T-CELLS; LYMPHOCYTES; RECEPTOR	The crystal structure of recombinant human interleukin-4 (rhuIL-4) was initially determined at 3.5-angstrom resolution by multiple isomorphous replacement techniques and subsequently refined to a resolution of 2.35 angstrom by simulated annealing. The final crystallographic R-factor, based on all data in the range 6.0-2.35 angstrom (7470 reflections), is 0.232. Bond lengths and bond angles in the molecule have root mean square deviations from ideal values of 0.016 angstrom and 2.4-degrees, respectively. The overall structure is highly compact and globular with a predominantly hydrophobic core. The main structural feature of rhuIL-4 is a four alpha-helix bundle, which composes approximately 58% of the structure. The helices are arranged in a left-handed antiparallel bundle with two overhand connections. Within these connections is a two-stranded antiparallel beta-sheet. Both the tertiary and secondary structures of rhuIL-4 are similar to those of human granulocyte-macrophage colony-stimulating factor. Critical regions for receptor binding are proposed.	UNIV ALABAMA,CTR MACROMOLEC CRYSTALLOG,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT BIOCHEM,BIRMINGHAM,AL 35294; SCHERING PLOUGH CORP,RES INST,BLOOMFIELD,NJ 07003	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Merck & Company; Schering Plough Corporation	WALTER, MR (corresponding author), UNIV ALABAMA,DEPT PATHOL,BIRMINGHAM,AL 35294, USA.				NCI NIH HHS [CA-13148] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; BANCHEREAU J, 1990, HEMATOPOIETIC GROWTH, P433; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BOEY H, 1989, J ALLERGY CLIN IMMUN, V83, P978, DOI 10.1016/0091-6749(89)90115-2; BOSCO M, 1990, J IMMUNOL, V145, P3136; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CABRILLAT H, 1987, BIOCHEM BIOPH RES CO, V149, P995, DOI 10.1016/0006-291X(87)90507-9; CARR C, 1991, BIOCHEMISTRY-US, V30, P1515, DOI 10.1021/bi00220a011; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; COOK WJ, 1991, J MOL BIOL, V218, P675, DOI 10.1016/0022-2836(91)90253-3; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CURTIS BM, 1991, PROTEINS, V11, P111, DOI 10.1002/prot.340110204; DEFRANCE T, 1987, J IMMUNOL, V139, P1135; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; GRACE MJ, 1989, 7TH P INT C IMM, P213; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KARRAY S, 1988, J EXP MED, V168, P85, DOI 10.1084/jem.168.1.85; KAWAKAMI Y, 1988, J EXP MED, V168, P2183, DOI 10.1084/jem.168.6.2183; LE HV, 1988, J BIOL CHEM, V263, P10817; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; LUNDELL D, 1990, J IND MICROBIOL, V5, P215, DOI 10.1007/BF01569679; MCKNIGHT AJ, 1991, EUR J IMMUNOL, V21, P1187, DOI 10.1002/eji.1830210514; MIYAJIMA A, 1988, FASEB J, V2, P2462, DOI 10.1096/fasebj.2.9.2836253; NOMA Y, 1986, NATURE, V319, P640, DOI 10.1038/319640a0; PARK LS, 1987, J EXP MED, V166, P476, DOI 10.1084/jem.166.2.476; PAUL WE, 1991, BLOOD, V77, P1859; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; POSTLETHWAITE AE, 1991, J CLIN INVEST, V87, P2147, DOI 10.1172/JCI115247; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; RAMANATHAN L, 1989, BIOCHIM BIOPHYS ACTA, V1007, P283, DOI 10.1016/0167-4781(89)90149-8; REDFIELD C, 1991, BIOCHEMISTRY-US, V30, P11029, DOI 10.1021/bi00110a004; SENDA T, 1990, P JPN ACAD B-PHYS, V66, P77, DOI 10.2183/pjab.66.77; SPITS H, 1988, J IMMUNOL, V141, P29; SPITS H, 1987, J IMMUNOL, V139, P1442; TAYLOR CW, 1990, BLOOD, V75, P1114; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; THORNHILL MH, 1990, J IMMUNOL, V144, P3060; TROTTA PP, 1991, AM J REPROD IMMUNOL, V25, P124, DOI 10.1111/j.1600-0897.1991.tb01079.x; TUNGEKAR MF, 1991, CANCER RES, V51, P261; WALTER MR, 1992, J MOL BIOL, V224, P1075, DOI 10.1016/0022-2836(92)90470-5; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WERSALL P, 1991, CANCER IMMUNOL IMMUN, V33, P45, DOI 10.1007/BF01742527; WINDSOR WT, 1990, BIOPHYS J, V57, pA423; WINDSOR WT, 1991, BIOCHEMISTRY-US, V30, P1259, DOI 10.1021/bi00219a014; YOKOTA T, 1986, P NATL ACAD SCI USA, V83, P5894, DOI 10.1073/pnas.83.16.5894	52	125	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20371	20376						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400355				2022-12-25	WOS:A1992JR85800097
J	BERGSAGEL, PL; TIMBLIN, CR; ECKHARDT, L; LASKOV, R; KUEHL, WM				BERGSAGEL, PL; TIMBLIN, CR; ECKHARDT, L; LASKOV, R; KUEHL, WM			SEQUENCE AND EXPRESSION OF A MURINE CDNA-ENCODING PC326, A NOVEL GENE EXPRESSED IN PLASMACYTOMAS BUT NOT NORMAL PLASMA-CELLS	ONCOGENE			English	Article							TRANSLOCATED MYC GENE; C-MOS; SACCHAROMYCES-CEREVISIAE; MOUSE MYELOMA; BETA-SUBUNIT; G-PROTEIN; EXTINCTION; ONCOGENE; ENHANCER; HYBRIDS	Using a subtractive cDNA approach we have identified a gene, PC326, expressed in 13 of 14 murine plasmacytoma cell lines, but not in any B- or pre-B-lymphoma cell lines. It expresses 4.6-kb and 5.2-kb mRNAs that encode a 747 amino acid protein containing two highly acidic domains flanking a novel, moderately acidic 20 amino acid sequence that is repeated 7.5 times. Sequence comparison identifies an additional 43 amino acid domain that is homologous to a repeated sequence found in the members of the beta-transducin gene family. The PC326 mRNA is detectable in testis but in no other murine tissues, including plasma cells induced by lipopolysaccharide stimulation of splenocytes. Somatic cell hybrids derived from plasmacytomas and fibroblast or T-cell lines have a fibroblastic or T-cell phenotype respectively. Unlike B-cell-specific genes (e.g. immunoglobulin), the expression of which is extinguished in these hybrids, PC326 mRNA appears to be irreversibly turned on in these hybrids. Since PC326 is not expressed in normal plasma cells, it appears that its expression is a cause or consequence of the tumorigenic process that generates murine plasmacytomas.	NCI, USN, MED ONCOL BRANCH, BLDG 8, ROOM 5101, BETHESDA, MD 20889 USA; COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA; HEBREW UNIV JERUSALEM, HADASSAH MED SCH, HUBERT H HUMPHREY CTR EXPTL MED & CANC RES, IL-91010 JERUSALEM, ISRAEL	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy; Columbia University; Hebrew University of Jerusalem			Bergsagel, Peter Leif/A-7842-2011	Bergsagel, Peter Leif/0000-0003-1523-7388				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BANROQUES J, 1989, MOL CELL BIOL, V9, P3710, DOI 10.1128/MCB.9.9.3710; Battey, 1986, BASIC METHODS MOL BI; BERGMAN Y, 1990, EMBO J, V9, P849, DOI 10.1002/j.1460-2075.1990.tb08182.x; BERGSAGEL PL, 1992, J IMMUNOL, V148, P590; BRANDT SJ, 1990, J CLIN INVEST, V86, P592, DOI 10.1172/JCI114749; CANAANI E, 1983, P NATL ACAD SCI-BIOL, V80, P7118, DOI 10.1073/pnas.80.23.7118; COHEN JB, 1983, NATURE, V306, P797, DOI 10.1038/306797a0; DELIDAKIS C, 1991, GENETICS, V129, P803; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; GATTONICELLI S, 1983, NATURE, V306, P795, DOI 10.1038/306795a0; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GREENBERG A, 1987, MOL CELL BIOL, V7, P936, DOI 10.1128/MCB.7.2.936; GREENBERG A, 1989, INT J CANCER, V43, P87, DOI 10.1002/ijc.2910430118; HARTLEY DA, 1988, CELL, V55, P785, DOI 10.1016/0092-8674(88)90134-1; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; ICHO T, 1988, J BIOL CHEM, V263, P1467; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KOSHLAND ME, 1985, ANNU REV IMMUNOL, V3, P425; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAYEV AS, 1980, NUCLEIC ACIDS RES, V8, P1201, DOI 10.1093/nar/8.6.1201; LASKOV R, 1991, INT J CANCER, V48, P574, DOI 10.1002/ijc.2910480416; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; TIMBLIN C, 1990, CURR TOP MICROBIOL, V166, P141; TIMBLIN C, 1990, NUCLEIC ACIDS RES, V18, P1587, DOI 10.1093/nar/18.6.1587; WEISSINGER EM, 1991, P NATL ACAD SCI USA, V88, P8735, DOI 10.1073/pnas.88.19.8735; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; YOCHEM J, 1987, J MOL BIOL, V195, P233, DOI 10.1016/0022-2836(87)90646-2; YU H, 1989, CELL, V58, P441, DOI 10.1016/0092-8674(89)90425-X; ZALLER DM, 1988, MOL CELL BIOL, V8, P1932, DOI 10.1128/MCB.8.5.1932	39	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1992	7	10					2059	2064						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408147				2022-12-25	WOS:A1992JP42400021
J	ZALATAN, F; PLATT, T				ZALATAN, F; PLATT, T			EFFECTS OF DECREASED CYTOSINE CONTENT ON RHO-INTERACTION WITH THE RHO-DEPENDENT TERMINATOR TRP T' IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION TERMINATION; TRYPTOPHAN OPERON; ATPASE ACTIVITY; MESSENGER-RNA; MUTAGENESIS; EXPRESSION; SEQUENCE; MUTANTS; SITES	We have introduced multiple cytosine-to-uracil mutations in the rho-dependent transcription terminator trp t' and have characterized a subset of the resulting mutant derivatives in vitro for termination efficiency, affinity for rho, and stimulation of rho-ATPase activity. No specific cytosine residue appears to be required for termination, and at least 13 of the 28 cytosine residues in the 104 nucleotide trp t' region can be mutated with little effect on termination efficiency. One derivative with 11 mutations is significantly less efficient than other derivatives with a similar number of mutations, implying that the pattern of alterations, as well as the number, can affect termination efficiency. Derivatives with 20 and 28 cytosines mutated are non-functional in termination, consistent with the idea that cytosines are required for rho-dependent termination. Our results are inconsistent, however, with the hypothesis that the termination efficiency is directly related to the cytosine/guanine ratio in the nascent transcript. The results support the idea that neither RNA binding affinity nor ATPase activation per se are accurate predictors of rho-dependent termination efficiency.	UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT BIOCHEM,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NIGMS NIH HHS [GM22830] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALIFANO P, 1991, CELL, V64, P553; BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4635; BUTLER JS, 1987, P NATL ACAD SCI USA, V84, P4022, DOI 10.1073/pnas.84.12.4022; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; DAS A, 1976, P NATL ACAD SCI USA, V73, P1959, DOI 10.1073/pnas.73.6.1959; FAUS I, 1989, BIOCHEMISTRY-US, V28, P3510, DOI 10.1021/bi00434a054; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; FOLK WR, 1983, CELL, V33, P585, DOI 10.1016/0092-8674(83)90439-7; GALLOWAY JL, 1988, J BIOL CHEM, V263, P1761; GALLOWAY JL, 1986, REGULATION GENE EXPR, P155; GUARENTE L, 1979, J MOL BIOL, V132, P189; HART CM, 1991, J BIOL CHEM, V266, P24140; HOWARD BH, 1976, J BIOL CHEM, V251, P2520; INOKO H, 1977, P NATL ACAD SCI USA, V74, P1162, DOI 10.1073/pnas.74.3.1162; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDICK R, 1990, J MOL BIOL, V216, P25, DOI 10.1016/S0022-2836(05)80058-0; LOWERY C, 1977, J BIOL CHEM, V252, P1375; LOWERYGO.C, 1974, P NATL ACAD SCI USA, V71, P2003, DOI 10.1073/pnas.71.5.2003; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; Miller J.H., 1972, EXPT MOL GENETICS; MINKLEY EG, 1973, J MOL BIOL, V78, P577, DOI 10.1016/0022-2836(73)90479-8; MORGAN WD, 1985, NUCLEIC ACIDS RES, V13, P3739, DOI 10.1093/nar/13.10.3739; MOTT JE, 1985, EMBO J, V4, P1887, DOI 10.1002/j.1460-2075.1985.tb03865.x; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; PLATT T, 1992, IN PRESS TRANSCRIPTI; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; SHORTLE D, 1983, METHOD ENZYMOL, V100, P457; WU AM, 1981, P NATL ACAD SCI-BIOL, V78, P2913, DOI 10.1073/pnas.78.5.2913; WU AM, 1980, CELL, V19, P829, DOI 10.1016/0092-8674(80)90073-2	34	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19082	19088						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1388163				2022-12-25	WOS:A1992JP59300014
J	DEEG, MA; HUMPHREY, DR; YANG, SH; FERGUSON, TR; REINHOLD, VN; ROSENBERRY, TL				DEEG, MA; HUMPHREY, DR; YANG, SH; FERGUSON, TR; REINHOLD, VN; ROSENBERRY, TL			GLYCAN COMPONENTS IN THE GLYCOINOSITOL PHOSPHOLIPID ANCHOR OF HUMAN ERYTHROCYTE ACETYLCHOLINESTERASE - NOVEL FRAGMENTS PRODUCED BY TRIFLUOROACETIC-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; VARIANT SURFACE GLYCOPROTEIN; MASS-SPECTROMETRY; LEISHMANIA-MAJOR; PROTEINS; IDENTIFICATION; INOSITOL	Inositol glycans were prepared from reductively radiomethylated human erythrocyte acetylcholinesterase by sequential treatment with Proteinase K, methanolic KOH, and phosphatidylinositol-specific phospholipase C. Four glycans denoted alpha-delta were resolved by anion exchange high performance liquid chromatography (HPLC). Each glycan was subjected to hydrolysis in 4 M trifluoroacetic acid, and their hexose and hexose phosphate compositions were determined by anion exchange HPLC. The predominant glycan a showed a relative stoichiometry of 2 mannoses, 1 mannose 6-phosphate, 1 radiomethylated glucosamine, 1 radiomethylated ethanolamine, and 1 inositol. In contrast, the stoichiometry of glycan-beta was 1 mannose, 2 mannose 6-phosphates, 1 radiomethylated glucosamine, 2 radiomethylated ethanolamines, and 1 inositol. Glycans-alpha and beta were analyzed by electrospray ionization-mass spectrometry, and respective parent ions of m/z 1266 and 1417 were observed. The fragmentation pattern produced by collision-induced dissociation mass spectrometry of these parent ions was consistent with a common linear core glycan sequence prior to radiomethylation of ethanolamine-phosphate-mannose-mannose-mannose-glucosamine-inositol. Glycan-alpha contained a single additional radiomethylated phosphoethanolamine branching from the mannose adjacent to glucosamine, whereas glycan-beta contained two additional radiomethylated phosphoethanolamines, one branching from each of the mannoses nearest to glucosamine. Trifluoroacetic acid hydrolysis did not cleave within the N,N-dimethylglucosamine-inositol-phosphate moiety in these glycans, and this component was resolved by anion exchange HPLC and structurally confirmed by mass spectrometry. Dephosphorylation of this component by treatment with 50% HF produced N,N-dimethylglucosamine-inositol, and this conjugate was shown to have a characteristic elution time on cation exchange chromatography in an amino acid analyzer. Both of these fragments involving an intact radiomethylated glucosamine-inositol bond are proposed as new diagnostic indicators in the search for minor glycoinositol phospholipids in cells and tissues.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHARMACOL, CLEVELAND, OH 44106 USA; HARVARD UNIV, SCH PUBL HLTH, DIV BIOL SCI, BOSTON, MA 02115 USA	Case Western Reserve University; Harvard University; Harvard T.H. Chan School of Public Health					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008441, P01DK038181] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016577] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38181, DK08441] Funding Source: Medline; NINDS NIH HHS [NS16577] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALDWIN MA, 1990, ANAL BIOCHEM, V191, P174, DOI 10.1016/0003-2697(90)90405-X; BUTIKOFER P, 1990, J BIOL CHEM, V265, P18983; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEEG MA, 1992, J BIOL CHEM, V267, P18581; Ferguson M. A. J., 1992, LIPID MODIFICATION P, P191; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4547; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GNAGEY AL, 1987, J BIOL CHEM, V262, P13290; HAAS R, 1985, ANAL BIOCHEM, V148, P154, DOI 10.1016/0003-2697(85)90640-2; HAAS R, 1986, BIOCHEMISTRY-US, V25, P3098, DOI 10.1021/bi00359a005; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HENNER DJ, 1988, NUCLEIC ACIDS RES, V16, P10383, DOI 10.1093/nar/16.21.10383; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MCCONVILLE MJ, 1989, J BIOL CHEM, V264, P757; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROBERTS WL, 1988, BIOCHEM BIOPH RES CO, V150, P271, DOI 10.1016/0006-291X(88)90516-5; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; ROSENBERRY TL, 1984, J BIOL CHEM, V259, P5643; ROSENBERRY TL, 1989, METHOD CELL BIOL, V32, P231; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SMITH R, 1987, BIOCHEM J, V248, P285, DOI 10.1042/bj2480285; TURCO SJ, 1989, J BIOL CHEM, V264, P6711; WALTER EI, 1990, J IMMUNOL, V144, P1030	27	98	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18573	18580						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1388156				2022-12-25	WOS:A1992JN50200052
J	HOFMANN, KP; PULVERMULLER, A; BUCZYLKO, J; VANHOOSER, P; PALCZEWSKI, K				HOFMANN, KP; PULVERMULLER, A; BUCZYLKO, J; VANHOOSER, P; PALCZEWSKI, K			THE ROLE OF ARRESTIN AND RETINOIDS IN THE REGENERATION PATHWAY OF RHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; G-PROTEIN; METARHODOPSIN-II; 48-KDA PROTEIN; DISK MEMBRANE; SCHIFF-BASE; ACTIVATION; BINDING; LIGHT; MECHANISM	Phototransduction results from a cascade of reactions that culminate in a neuronal signal. Photoisomerization of rhodopsin's chromophore, 11-cis-retinal to all-trans-retinal, leads to the formation of the activated photoproduct metarhodopsin II (Meta II). Subsequently, Meta II initiates the excitation events by activating many copies of the rod cell-specific G-proteins (G(t) or transducin). To terminate the signal, the long-lived Meta II must be quenched. Deactivation of Meta II involves phosphorylation by rhodopsin kinase followed by the binding of arrestin. In order to recycle rhodopsin for phototransduction, arrestin must dissociate, and the chromophore must be replaced. In this study, we show that the reduction of the photolyzed chromophore all-trans-retinal to all-trans-retinol is essential for recycling photoactivated rhodopsin. Once this reduction has occurred, the arrestin blockade of the receptor is removed, the chromophore site becomes accessible for regeneration, and the phosphates can be hydrolyzed. If the reduction does not occur, we demonstrate that free all-trans-retinal can react with the apoprotein to form pseudo-photoproducts that are spectrally identical to the photoinduced metarhodopsin species (Meta I/II/III). The Meta II-like product, M380, interacts tightly with arrestin and kinase, however, it does not measurably interact with G(t). The persistent blockade by arrestin and the low affinity for G(t) together prevent activation of the visual cascade. Therefore, any insufficiency in the reduction of all-trans-retinal to all-trans-retinol may lead to the accumulation of M380-arrestin in situ, which may effect adaptational processes.	GOOD SAMARITAN HOSP,RS DOW NEUROL SCI INST,1120 NW 20TH AVE,PORTLAND,OR 97209; UNIV FREIBURG,INST BIOPHYS & STRAHLENBIOL,W-7800 FREIBURG,GERMANY	University of Freiburg					PHS HHS [09339] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAUMANN C, 1972, J PHYSIOL-LONDON, V222, P643, DOI 10.1113/jphysiol.1972.sp009819; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCZYLKO J, 1991, P NATL ACAD SCI USA, V88, P2568, DOI 10.1073/pnas.88.6.2568; CHABRE M, 1979, VISION RES, V19, P1005, DOI 10.1016/0042-6989(79)90226-8; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CUSANOVICH MA, 1982, METHOD ENZYMOL, V81, P443; DUGGAN DE, 1957, ARCH BIOCHEM BIOPHYS, V68, P1, DOI 10.1016/0003-9861(57)90320-X; FUTTERMAN S, 1964, J BIOL CHEM, V239, P81; GRAYKELLER MP, 1990, J BIOL CHEM, V265, P15323; HOFMANN KP, 1986, PHOTOBIOCH PHOTOBIOP, V13, P309; HOFMANN KP, 1983, BIOCHIM BIOPHYS ACTA, V725, P60, DOI 10.1016/0005-2728(83)90224-4; HOFMANN KP, 1992, SIGNAL TRANSDUCTION, P71; KAHLERT M, 1990, NATURE, V345, P537, DOI 10.1038/345537a0; KUHN H, 1981, CURR TOP MEMBR TRANS, V15, P171; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONGSTAFF C, 1986, P NATL ACAD SCI USA, V83, P4209, DOI 10.1073/pnas.83.12.4209; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; PALCZEWSKI K, 1991, FEBS LETT, V295, P195, DOI 10.1016/0014-5793(91)81416-6; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; PALCZEWSKI K, 1992, NEURON, V8, P117, DOI 10.1016/0896-6273(92)90113-R; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; PEPPERBERG DR, 1988, P NATL ACAD SCI USA, V85, P5531, DOI 10.1073/pnas.85.15.5531; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SCHLEICHER A, 1987, J MEMBRANE BIOL, V95, P271, DOI 10.1007/BF01869489; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; THOMPSON P, 1984, BIOCHEM J, V220, P773, DOI 10.1042/bj2200773; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032	31	137	139	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15701	15706						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1386362				2022-12-25	WOS:A1992JG11300069
J	BALL, DM; HARPER, PS				BALL, DM; HARPER, PS			PRESYMPTOMATIC TESTING FOR LATE-ONSET GENETIC-DISORDERS - LESSONS FROM HUNTINGTONS-DISEASE	FASEB JOURNAL			English	Review						PREDICTIVE TESTING; HIGH-RISK PARENT; EARLY GENE DETECTION; LINKED MARKERS; INFORMED CONSENT		Huntington's disease is an inherited, neurodegenerative disorder, usually of adult onset. Since the identification of linked markers, more than 1000 presymptomatic tests have been performed worldwide and multiple ethical issues have been encountered in relation to informed consent, testing of children, exclusion testing during pregnancy, and confidentiality. Further ethical problems are anticipated after identification of the causal mutation (or mutations). As Huntington's disease is a model for other disorders of adult onset for which testing is becoming possible, the successful resolution of these ethical issues is of great importance. A failure to do so might discredit genetic testing as a whole.			BALL, DM (corresponding author), UNIV WALES COLL MED, INST MED GENET, HEATH PK, CARDIFF CF4 4XN, S GLAM, WALES.							[Anonymous], 1989, J NEUROL SCI, V94, P327; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HARPER PS, 1991, AM J HUM GENET, V49, P62; HARPER PS, HUNTINGTONS DISEASE, P373; HARPER PS, 1991, HUNTINGTONS DISEASE, P127; HAYDEN MR, 1988, AM J HUM GENET, V43, P689; MORRIS M, 1988, LANCET, V2, P1069, DOI 10.1016/S0140-6736(88)90078-5; QUARRELL OWJ, 1987, LANCET, V1, P1281; TYLER A, 1990, J MED GENET, V27, P488, DOI 10.1136/jmg.27.8.488; WENT L, 1990, J MED GENET, V27, P34, DOI 10.1136/jmg.27.1.34; WEXLER NS, 1992, FASEB J, V6, P2820, DOI 10.1096/fasebj.6.10.1386047	11	6	6	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1992	6	10					2818	2819		10.1096/fasebj.6.10.1386046	http://dx.doi.org/10.1096/fasebj.6.10.1386046			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1386046				2022-12-25	WOS:A1992JD95400009
J	PLATANIAS, LC; COLAMONICI, OR				PLATANIAS, LC; COLAMONICI, OR			INTERFERON-ALPHA INDUCES RAPID TYROSINE PHOSPHORYLATION OF THE ALPHA-SUBUNIT OF ITS RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TRANSCRIPTIONAL INDUCTION; HUMAN-CELLS; BINDING; EXPRESSION; ACTIVATION; HYDROLYSIS; GENES	The mechanisms of generation of second messengers after binding of interferon alpha (IFNalpha) to its receptor remain unknown. We have studied the phosphorylation of the alpha subunit of the IFNalpha receptor, which is recognized by the monoclonal antibody IFNa receptor 3. Immunoblotting experiments showed that IFNalpha induced rapid tyrosine phosphorylation of the alpha subunit in the IFNalpha-sensitive H-929, U-266, and Daudi cell lines. Immunoprecipitation experiments performed with P-32-labeled cells showed that the alpha subunit is phosphorylated before IFNalpha treatment and that the level of phosphorylation increases after IFNalpha stimulation. Phosphoamino acid analysis confirmed the IFNalpha-induced tyrosine phosphorylation and demonstrated that the base-line phosphorylation corresponded to serine phosphorylation that increased 50% upon IFNalpha treatment. Tyrosine phosphorylation of the alpha subunit was time- and dose-dependent, further demonstrating the specificity of the process. Phosphorylation of the alpha subunit of the receptor occurred rapidly after IFNalpha binding, both at 37 and 4-degrees-C. Exposure of the cells to the tyrosine kinase inhibitor genistein blocked the IFNalpha-induced tyrosine phosphorylation of this subunit of the IFNalpha receptor. In contrast H7, a specific protein kinase C inhibitor, and acute and chronic exposure to phorbol esters had no effect on tyrosine phosphorylation, suggesting that protein kinase C does not regulate the tyrosine phosphorylation of the alpha subunit of the IFNalpha receptor. No IFNalpha-induced tyrosine phosphorylation was observed in the IFNalpha-resistant U-937 cell line that expresses a variant IFNalpha receptor. Altogether these data suggest that tyrosine phosphorylation of the a subunit may play a role in the signal transduction pathway of IFNalpha.	UNIV CHICAGO,DEPT MED,HEMATOL ONCOL SECT,CHICAGO,IL 60615	University of Chicago					NATIONAL CANCER INSTITUTE [R35CA042557] Funding Source: NIH RePORTER; NCI NIH HHS [CA42557] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUET M, 1980, NATURE, V284, P459, DOI 10.1038/284459a0; BRANCA AA, 1981, NATURE, V294, P768, DOI 10.1038/294768a0; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; COLAMONICI OR, 1991, PHARMACOL THERAPEUT, V52, P227, DOI 10.1016/0163-7258(91)90010-J; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; GAZDAR AF, 1986, BLOOD, V67, P1542; IMPROTA T, 1992, J INTERFERON RES, V12, P87, DOI 10.1089/jir.1992.12.87; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KESSLER DS, 1991, J BIOL CHEM, V266, P23471; KESSLER DS, 1988, EMBO J, V7, P3779, DOI 10.1002/j.1460-2075.1988.tb03262.x; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LARNER AC, 1986, J BIOL CHEM, V261, P453; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1989, GENE DEV, V3, P1203; NASAO H, 1990, J EXP MED, V171, P637; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PFEFFER LM, 1991, PHARMACOL THERAPEUT, V52, P149, DOI 10.1016/0163-7258(91)90005-7; PFEFFER LM, 1990, P NATL ACAD SCI USA, V87, P6537, DOI 10.1073/pnas.87.17.6537; PFEFFERLM, 1991, P NATL ACAD SCI USA, V88, P7998; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; SHARON M, 1989, J IMMUNOL, V143, P2530; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	28	71	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24053	24057						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385434				2022-12-25	WOS:A1992JZ23900093
J	AHMED, SA; MILES, EW				AHMED, SA; MILES, EW			EVIDENCE FOR 2 CONFORMERS OF THE BETA-SUBUNIT OF TRYPTOPHAN SYNTHASE IN SOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE O-SULFATE; ESCHERICHIA-COLI; PYRIDOXAL 5'-PHOSPHATE; SALMONELLA-TYPHIMURIUM; MONOCLONAL-ANTIBODIES; B-PROTEIN; SYNTHETASE; INACTIVATION; MECHANISM; BINDING	To explain our finding that the dimeric beta subunit of tryptophan synthase is only 50% inactivated by beta-chloro-L-alanine (Ahmed, S. A., Ruvinov, S. B., Kayastha, A. M., and Miles, E. W. (1991) J. Biol. Chem. 266, 21548-21557), we have extended our investigation using spectroscopic, steady-state kinetic, and electrophoretic methods. The spectroscopic properties of the half-active beta2 dimer and the reactivation after alkali treatment show that the inactivation proceeds by an "enamine" mechanism. Although the fully active beta2 dimer associates with the tryptophan synthase alpha subunit to form alpha2beta2 complex, the inactive beta subunits in the half-active enzyme associate weakly or not at all with the alpha subunit. Our results provide evidence for two conformers of the beta subunit in solution: one is rapidly inactivated by beta-chloro-L-alanine and the other is not inactivated. Thermal inactivation studies and non-denaturing polyacrylamide gel electrophoresis of the half-active enzyme show that the beta2 dimer exists in both homologous and heterologous combinations of these two forms. After removal of the reaction products and unreacted beta-chloro-L-alanine from the half-active beta2 dimer by gel filtration, further incubation with beta-chloro-L-alanine results in the loss of 50% of the remaining activity. This result suggests that the subunits undergo rearrangement via an intermediate monomer form to regenerate the two conformers of the active beta subunit. This mechanism of rearrangement is supported by our finding that the extent of inactivation increases at lower concentrations of the beta2 dimer.			AHMED, SA (corresponding author), NIDDKD, BIOCHEM PHARMACOL LAB, BLDG 8, RM 2A-05, BETHESDA, MD 20892 USA.							ADACHI O, 1974, J BIOL CHEM, V249, P5430; AHMED SA, 1986, BIOCHEMISTRY-US, V25, P4233, DOI 10.1021/bi00363a010; AHMED SA, 1986, BIOCHEMISTRY-US, V25, P3118, DOI 10.1021/bi00359a008; AHMED SA, 1991, J BIOL CHEM, V266, P21548; Arnone A, 1985, TRANSAMINASES, P138; BALK H, 1981, EUR J BIOCHEM, V121, P105, DOI 10.1111/j.1432-1033.1981.tb06437.x; BARTHOLMES P, 1976, BIOCHEMISTRY-US, V15, P4712, DOI 10.1021/bi00666a027; CHAFFOTTE AF, 1987, J MOL BIOL, V197, P131, DOI 10.1016/0022-2836(87)90615-2; CHAFFOTTE AF, 1984, EUR J BIOCHEM, V139, P47, DOI 10.1111/j.1432-1033.1984.tb07974.x; CREIGHTON TE, 1966, J BIOL CHEM, V241, P980; DREWE WF, 1985, BIOCHEMISTRY-US, V24, P3977, DOI 10.1021/bi00336a027; FAEDER EJ, 1971, BIOCHEMISTRY-US, V10, P1041; FLURI R, 1971, J BIOL CHEM, V246, P6620; GOLDBERG ME, 1968, BIOCHEMISTRY-US, V7, P3662, DOI 10.1021/bi00850a045; GOLDBERG ME, 1991, TRENDS BIOCHEM SCI, V16, P358, DOI 10.1016/0968-0004(91)90148-O; HATHAWAY GM, 1970, BIOCHEMISTRY-US, V9, P1801, DOI 10.1021/bi00810a020; HATHAWAY GM, 1969, BIOCHEMISTRY-US, V8, P989, DOI 10.1021/bi00831a032; HEILMANN HD, 1981, HOPPESEYLERS Z PHYSL, V342, P1567; HENIS YI, 1989, ALLOSTERIC ENZYMES, P153; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JAGER J, 1991, INT UNION B, V199, P117; JANSONIUS JN, 1985, TRANSAMINASES, P110; JOHNSON R. J., 1970, Methods in Enzymology, V18A, P433, DOI 10.1016/0076-6879(71)18345-0; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; KUMAGAI H, 1971, BIOCHEM BIOPH RES CO, V44, P1271, DOI 10.1016/S0006-291X(71)80223-1; LANE AN, 1983, EUR J BIOCHEM, V129, P561; LANE AN, 1984, EMBO J, V3, P279, DOI 10.1002/j.1460-2075.1984.tb01797.x; LEVITZKI A, 1974, J MOL BIOL, V90, P451, DOI 10.1016/0022-2836(74)90227-7; LIKOS JJ, 1982, BIOCHEMISTRY-US, V21, P4377, DOI 10.1021/bi00261a029; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; Miles E.W., 1986, PYRIDOXAL PHOSPHAT B, V1, P253; MILES EW, 1975, BIOCHEM BIOPH RES CO, V64, P248, DOI 10.1016/0006-291X(75)90245-4; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1970, J BIOL CHEM, V245, P6016; MILES EW, 1977, J BIOL CHEM, V252, P6594; MILES EW, 1968, BIOCHEMISTRY-US, V7, P2742, DOI 10.1021/bi00848a008; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; SEIFERT T, 1985, BIOCHEMISTRY-US, V24, P339, DOI 10.1021/bi00323a016; SILVA JL, 1986, BIOCHEMISTRY-US, V25, P5780, DOI 10.1021/bi00367a065; TANIZAWA K, 1983, BIOCHEMISTRY-US, V22, P3594, DOI 10.1021/bi00284a009; THORNBERRY NA, 1991, J BIOL CHEM, V266, P21657; TSCHOPP J, 1980, BIOCHEMISTRY-US, V19, P4521, DOI 10.1021/bi00560a021; UENO H, 1982, BIOCHEMISTRY-US, V21, P4387, DOI 10.1021/bi00261a030; WADA H, 1962, J BIOL CHEM, V237, P127; WILSON DA, 1965, J BIOL CHEM, V240, P4801; YANG XJ, 1992, PROTEIN EXPRES PURIF, V3, P347, DOI 10.1016/1046-5928(92)90011-K; Yanofsky C., 1972, ENZYMES, P1, DOI [10.1016/s1874-6047(08)60445-x, DOI 10.1016/S1874-6047(08)60445-X]; ZETINA CR, 1980, J BIOL CHEM, V255, P4381	49	4	4	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23309	23317						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429678				2022-12-25	WOS:A1992JY16300092
J	FOLLI, F; SAAD, MJA; BACKER, JM; KAHN, CR				FOLLI, F; SAAD, MJA; BACKER, JM; KAHN, CR			INSULIN STIMULATION OF PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY AND ASSOCIATION WITH INSULIN-RECEPTOR SUBSTRATE-1 IN LIVER AND MUSCLE OF THE INTACT RAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; GROWTH FACTOR-I; DEPENDENT DIABETES-MELLITUS; KINASE-ACTIVITY; TYROSINE PHOSPHORYLATION; SKELETAL-MUSCLE; ENDOGENOUS SUBSTRATE; SIGNAL TRANSDUCTION; PDGF RECEPTOR; PROTEINS	Growth factors stimulate the enzyme phosphatidylinositol (PI) 3-kinase in cells in culture. Insulin rapidly stimulates tyrosine phosphorylation of its endogenous substrate, insulin receptor substrate 1 (IRS-1), and in vitro IRS-1 associates with PI 3-kinase, thus activating the enzyme. We have examined whether insulin is capable of stimulating the PI 3-kinase pathway in two physiological target tissues for the actions of insulin in vivo, liver and skeletal muscle. After intraportal injection of insulin into anesthetized rats, there was a 2-fold stimulation of total hepatic PI 3-kinase activity in liver and muscle extracts and a 10- to 20-fold increase in PI 3-kinase activity immunoprecipitated with anti-IRS-1 antibodies. Stimulation of PI 3-kinase was accompanied by an association between this enzyme and IRS-1 as detected by immunoprecipitation of liver and muscle extracts with anti-IRS-1 antibodies and Western blotting with antibodies to the 85-kDa subunit of PI 3-kinase. Immunoprecipitation with anti-p85 antibodies and phosphotyrosine immunoblotting revealed no tyrosine phosphorylation of PI 3-kinase, but demonstrated co-precipitation of tyrosine-phosphorylated IRS-1, as well as another phosphotyrosine protein of approximately 135-140 kDa. Thus, IRS-1 phosphorylation plays a significant role in the activation of PI 3-kinase in vivo by insulin.	HARVARD UNIV,SCH MED,BOSTON,MA 02215	Harvard University; Harvard Medical School	FOLLI, F (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215, USA.		folli, franco/J-2795-2018; Saad, Mario/ABD-8262-2020; Kahn, Ronald/AAY-2435-2021	folli, franco/0000-0001-9824-5222; Kahn, Ronald/0000-0002-7583-9228	NIDDK NIH HHS [DK 36836, DK 33201] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033201, P30DK036836] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNER P, 1987, DIABETOLOGIA, V30, P437, DOI 10.1007/BF00292549; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; BEGUINOT F, 1989, ENDOCRINOLOGY, V125, P1599, DOI 10.1210/endo-125-3-1599; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARO JF, 1986, J CLIN INVEST, V78, P249, DOI 10.1172/JCI112558; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CONDORELLI G, 1989, J BIOL CHEM, V264, P12633; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FRIEDENBERG GR, 1987, J CLIN INVEST, V79, P240; GIORGINO F, 1992, ENDOCRINOLOGY, V130, P1433, DOI 10.1210/en.130.3.1433; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; HAYASHI H, 1991, BIOCHEM J, V280, P769, DOI 10.1042/bj2800769; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KASUGA M, 1990, DIABETES CARE, V13, P317, DOI 10.2337/diacare.13.3.317; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KELLER SR, 1991, J BIOL CHEM, V266, P12817; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORGAN DO, 1987, P NATL ACAD SCI USA, V84, P41, DOI 10.1073/pnas.84.1.41; OBERMAIERKUSSER B, 1989, J BIOL CHEM, V264, P9497; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROSSETTI L, 1987, J CLIN INVEST, V79, P1510, DOI 10.1172/JCI112981; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SAAD MJA, 1992, IN PRESS J CLIN INVE; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SOEDA E, 1980, NATURE, V283, P445, DOI 10.1038/283445a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKAYAMA S, 1988, J CLIN ENDOCR METAB, V66, P992, DOI 10.1210/jcem-66-5-992; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TAYLOR SI, 1990, DIABETES CARE, V13, P257, DOI 10.2337/diacare.13.3.257; THIES RS, 1990, DIABETES, V39, P250, DOI 10.2337/diabetes.39.2.250; TOBE K, 1990, DIABETES, V39, P528, DOI 10.2337/diabetes.39.5.528; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YONEZAWA K, 1992, J BIOL CHEM, V267, P440	59	244	250	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22171	22177						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1385396				2022-12-25	WOS:A1992JW71900030
J	MARTINPARRAS, L; HERNANDEZ, P; MARTINEZROBLES, ML; SCHVARTZMAN, JB				MARTINPARRAS, L; HERNANDEZ, P; MARTINEZROBLES, ML; SCHVARTZMAN, JB			INITIATION OF DNA-REPLICATION IN COLE1 PLASMIDS CONTAINING MULTIPLE POTENTIAL ORIGINS OF REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAPILLOMAVIRUS TYPE-1 DNA; GEL-ELECTROPHORESIS; BACTERIAL PLASMIDS; YEAST CHROMOSOMES; RIBOSOMAL DNA; RNA-I; INVIVO; AMPLIFICATION; CEREVISIAE; DROSOPHILA	We have investigated the frequency of replication origin usage in bacterial plasmids containing more than one potential origin. Escherichia coli recA- cells were selectively transformed with pBR322 monomers, dimers, or trimers. Plasmid DNA was isolated and digested with a restriction enzyme that cut the monomer only once, and the replicative intermediates (RIs) were analyzed by neutral/neutral two-dimensional agarose gel electrophoresis. Evidence for initiation outside the linearized plasmid was found only for oligomers. Moreover, in dimers, the intensity of the signal indicative for external initiation was equivalent to that reflecting internal initiation, whereas it was approximately twice as strong in trimers. To determine whether initiation could occur simultaneously at two origins in a single plasmid, we studied the replication of a neodimer in which both units could be unambiguously distinguished. The results showed that although both origins were equally competent to initiate replication, only one was active per plasmid. These observations strongly suggest that in ColE1 plasmids, replication initiates at a single site even when there are several identical potential origins per plasmid. In addition to the conventional two-dimensional gel patterns, novel specific patterns were observed with intensities that varied from one DNA sample to another. These unique patterns were the result of breakage of the RIs at a replication fork. This type of breakage changes both the mass and shape of RIs. When the entire population of RIs is affected, a new population of molecules is formed that may generate a novel pattern in two-dimensional gels.	CSIC,CTR INVEST BIOL,VELAZQUEZ 144,E-28006 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consiglio Nazionale delle Ricerche (CNR)			Schvartzman, Jorge B/J-9171-2014	Pablo, Hernandez/0000-0002-8113-1277				BAKER TA, 1991, NATURE, V353, P794, DOI 10.1038/353794a0; BELL L, 1983, ANAL BIOCHEM, V130, P527, DOI 10.1016/0003-2697(83)90628-0; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1991, BIOESSAYS, V13, P317, DOI 10.1002/bies.950130702; BREWER BJ, 1988, CANCER CELL, V6, P229; BRUAND C, 1991, EMBO J, V10, P2171, DOI 10.1002/j.1460-2075.1991.tb07752.x; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; COZZARELLI NR, 1980, SCIENCE, V207, P953, DOI 10.1126/science.6243420; CROSA JH, 1975, MOL GEN GENET, V140, P39, DOI 10.1007/BF00268987; CROSA JH, 1980, J BIOL CHEM, V255, P1075; CROSA JH, 1976, NATURE, V261, P516, DOI 10.1038/261516a0; DAHR V, 1991, MOL CELL BIOL, V11, P6268; DELIDAKIS C, 1989, EMBO J, V8, P891, DOI 10.1002/j.1460-2075.1989.tb03450.x; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; Hamlin JL, 1991, CURR OPIN CELL BIOL, V3, P414, DOI 10.1016/0955-0674(91)90068-A; HECK MMS, 1990, J CELL BIOL, V110, P903, DOI 10.1083/jcb.110.4.903; HERNANDEZ P, 1988, PLANT MOL BIOL, V10, P413, DOI 10.1007/BF00014947; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; HYRIEN O, 1992, NUCLEIC ACIDS RES, V20, P1463, DOI 10.1093/nar/20.7.1463; INUZUKA N, 1980, J BIOL CHEM, V255, P1071; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; Kornberg A., 1992, DNA REPLICATION; KRYSAN PJ, 1991, MOL CELL BIOL, V11, P1464, DOI 10.1128/MCB.11.3.1464; LACATENA RM, 1981, NATURE, V294, P623, DOI 10.1038/294623a0; LEWIN B, 1990, GENES, V4, P857; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LINSKENS MHK, 1990, NUCLEIC ACIDS RES, V18, P647, DOI 10.1093/nar/18.3.647; LIU Y, 1990, J VIROL, V64, P5903, DOI 10.1128/JVI.64.12.5903-5911.1990; MARTINPARRAS L, 1991, J MOL BIOL, V220, P843, DOI 10.1016/0022-2836(91)90357-C; MASAI H, 1990, J BIOL CHEM, V265, P15124; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; NAWOTKA KA, 1988, MOL CELL BIOL, V8, P1408, DOI 10.1128/MCB.8.4.1408; NORDSTROM K, 1984, PLASMID, V12, P71, DOI 10.1016/0147-619X(84)90054-4; Pritchard R. H., 1978, DNA SYNTHESIS PRESEN, P1; SCHVARTZMAN JB, 1990, MOL CELL BIOL, V10, P3078, DOI 10.1128/MCB.10.6.3078; SCOTT JR, 1984, MICROBIOL REV, V48, P1; SKRYABIN KG, 1984, NUCLEIC ACIDS RES, V12, P2955, DOI 10.1093/nar/12.6.2955; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; SUMMERS DK, 1984, CELL, V36, P1097, DOI 10.1016/0092-8674(84)90060-6; TIMMIS K, 1974, P NATL ACAD SCI USA, V71, P4556, DOI 10.1073/pnas.71.11.4556; TIMMIS K, 1976, NATURE, V261, P512, DOI 10.1038/261512a0; TOMIZAWA J, 1981, P NATL ACAD SCI USA, V48, P6096; VAUGHN JP, 1990, CELL, V61, P1075, DOI 10.1016/0092-8674(90)90071-L; WALDECK W, 1984, EMBO J, V3, P2173, DOI 10.1002/j.1460-2075.1984.tb02109.x; WALMSLEY RM, 1984, MOL GEN GENET, V195, P260, DOI 10.1007/BF00332757; WANG JC, 1987, BIOCHIM BIOPHYS ACTA, V909, P1, DOI 10.1016/0167-4781(87)90040-6; WOOD DC, 1984, J BIOL CHEM, V259, P1184; YEE TW, 1990, P NATL ACAD SCI USA, V87, P1278, DOI 10.1073/pnas.87.4.1278	51	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22496	22505						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429600				2022-12-25	WOS:A1992JW71900080
J	HECK, DE; LASKIN, DL; GARDNER, CR; LASKIN, JD				HECK, DE; LASKIN, DL; GARDNER, CR; LASKIN, JD			EPIDERMAL GROWTH-FACTOR SUPPRESSES NITRIC-OXIDE AND HYDROGEN-PEROXIDE PRODUCTION BY KERATINOCYTES - POTENTIAL ROLE FOR NITRIC-OXIDE IN THE REGULATION OF WOUND-HEALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TYROSINE KINASE-ACTIVITY; MACROPHAGE-INDUCED ANGIOGENESIS; HEPATOCYTE PROTEIN-SYNTHESIS; NECROSIS FACTOR-ALPHA; L-ARGININE; ULTRAVIOLET-LIGHT; INHIBITION; CELLS; OXIDATION; INDUCTION	In the skin, wounding initiates a complex array of physiological processes mediated by growth factors and inflammatory mediators which stimulate tissue repair and protect against infection. We report that primary cultures of human keratinocytes and a mouse keratinocyte cell line respond to the inflammatory stimuli gamma-interferon and lipopolysaccharide or tumor necrosis factor-alpha by producing nitric oxide and hydrogen peroxide, two reactive mediators that are important in nonspecific host defense. Nitric oxide is produced by the l-arginine- and NADPH-dependent enzyme, nitric oxide synthase. In murine keratinocytes, optimal enzymatic activity was found to be dependent on Ca2+ and calmodulin as well as on glutathione. Inflammatory mediators were also found to inhibit the growth of keratinocytes, an effect that could be reversed by a nitric oxide synthase inhibitor. Epidermal growth factor (EGF), which promotes wound healing by stimulating cellular proliferation, was found to be a potent antagonist of reactive nitrogen and reactive oxygen intermediate production by keratinocytes. EGF also reversed the growth inhibitory actions of the inflammatory mediators. These data suggest that nitric oxide produced by keratinocytes is important in the control of cellular proliferation during wound healing. Our findings that EGF effectively regulates the production of free radicals by keratinocytes may represent an important pathway by which this growth factor not only stimulates epidermal cell proliferation but also facilitates the resolution of inflammation following wounding.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT ENVIRONM & COMMUNITY MED,PISCATAWAY,NJ 08854; RUTGERS STATE UNIV,DEPT PHARMACOL & TOXICOL,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick				Laskin, Debra/0000-0003-1832-7311				BARKER JNWN, 1991, LANCET, V337, P211, DOI 10.1016/0140-6736(91)92168-2; BASS DA, 1983, J IMMUNOL, V130, P1910; BILLIAR TR, 1989, J EXP MED, V169, P1467, DOI 10.1084/jem.169.4.1467; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CURRAN RD, 1991, FASEB J, V5, P2085, DOI 10.1096/fasebj.5.7.1707021; DING A, 1990, J IMMUNOL, V145, P940; FAALAND CA, 1991, MOL CELL BIOL, V11, P2697, DOI 10.1128/MCB.11.5.2697; GOUSTIN AS, 1986, CANCER RES, V46, P1015; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GRINNELL F, 1990, J TRAUMA, V30, pS144; HECK DE, 1991, CANCER CHEMOTH PHARM, V28, P344, DOI 10.1007/BF00685687; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HIBBS JB, 1987, J IMMUNOL, V138, P550; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; HUNT TK, 1988, TRAUMA SEPSIS SHOCK, P443; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; KWON NS, 1989, J BIOL CHEM, V264, P20496; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; MCCORD JM, 1978, ANN INTERN MED, V89, P122, DOI 10.7326/0003-4819-89-1-122; MERMELSTEIN FH, 1989, MOL PHARMACOL, V36, P848; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAKANE N, 1992, FASEB J, V6, pA36; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PUNJABI C, 1992, IN PRESS J IMMUNOL; RADI R, 1991, J BIOL CHEM, V266, P4244; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SEGAL W, 1989, HUMAN MONOCYTES, P94; STUEHR DJ, 1987, J IMMUNOL, V139, P518; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARIO G, 1991, J IMMUNOL, V146, P3469; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; WOLFF DJ, 1992, BIOCHEM J, V285, P201, DOI 10.1042/bj2850201	38	258	267	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21277	21280						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1383221				2022-12-25	WOS:A1992JV01100002
J	HUTH, JR; MOUNTJOY, K; PERINI, F; BEDOWS, E; RUDDON, RW				HUTH, JR; MOUNTJOY, K; PERINI, F; BEDOWS, E; RUDDON, RW			DOMAIN-DEPENDENT PROTEIN FOLDING IS INDICATED BY THE INTRACELLULAR KINETICS OF DISULFIDE BOND FORMATION OF HUMAN CHORIONIC GONADOTROPIN-BETA SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHORIOCARCINOMA CELLS; RIBONUCLEASE-A; FORM; INTERMEDIATE; SECRETION; NMR; LYSOZYME; PATHWAY; BINDING; REGION	We have measured the intracellular rates of formation of the six disulfide bonds in the human chorionic gonadotropin beta subunit (hCG-beta) to determine whether the folding pathway of this molecule can be described by a simple sequential model. If such a model is correct, the formation of disulfide bonds, which is indicative of tertiary structural changes during protein folding, should occur in a discrete order. The individual rates of disulfide bridging were determined by identifying the extent of disulfide bond formation in hCG-beta intermediates purified from choriocarcinoma cells that had been metabolically labeled for 40 or 120 s and chased for 0 to 25 min. The results of these kinetic studies describe a folding pathway in which the disulfide bonds between cysteines 34-88, 38-57, 9-90 and 23-72 stabilize, in a discrete order, the putative domain(s) involving amino acids 1-90 of hCG-beta. However, the S-S bonds 93-100 and 26-110 begin to form before the complete formation of the disulfide bonds that stabilize the amino acid 1-90 domain(s), and continue to form after complete formation of these disulfide bonds, suggesting that hCG-beta does not fold by a simple sequential pathway. The order of completion of each of the six disulfide bonds of hCG-beta is: 34-88 (t1/2 = 1-2 min), 38-57 (t1/2 = 2-3 min), 9-90 and 23-72, 93-100, and 26-110. Moreover, 60-100% of each of the six disulfide bonds form posttranslationally, and nonnative disulfide bonds do not form in detectable amounts during intracellular folding of hCG-beta.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,600 S 42ND ST,OMAHA,NE 68198; UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109; UNIV NEBRASKA,MED CTR,DEPT PHARMACOL,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center; University of Michigan System; University of Michigan; University of Nebraska System; University of Nebraska Medical Center					NATIONAL CANCER INSTITUTE [R01CA032949] Funding Source: NIH RePORTER; NCI NIH HHS [CA32949] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEDOWS E, 1992, J BIOL CHEM, V267, P8880; BEEBE JS, 1990, J BIOL CHEM, V265, P312; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BYCROFT M, 1990, NATURE, V346, P488, DOI 10.1038/346488a0; CHATRENET B, 1992, J BIOL CHEM, V267, P3038; CHEN F, 1991, J BIOL CHEM, V266, P6904; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; FLANAGAN JM, 1992, P NATL ACAD SCI USA, V89, P748, DOI 10.1073/pnas.89.2.748; GLINIAK BC, 1991, J BIOL CHEM, V266, P22991; GODZIK A, 1992, P NATL ACAD SCI USA, V89, P2629, DOI 10.1073/pnas.89.7.2629; GOLDENBERG DP, 1989, NATURE, V338, P127, DOI 10.1038/338127a0; HEROLD M, 1991, BIOCHEMISTRY-US, V30, P3612, DOI 10.1021/bi00229a004; HUTH JR, 1992, J BIOL CHEM, V267, P8870; JENG MF, 1991, J MOL BIOL, V221, P1045, DOI 10.1016/0022-2836(91)80191-V; KEUTMANN HT, 1987, P NATL ACAD SCI USA, V84, P2038, DOI 10.1073/pnas.84.7.2038; KEUTMANN HT, 1992, IN PRESS MOL ENDOCRI; LESK AM, 1981, P NATL ACAD SCI-BIOL, V78, P4304, DOI 10.1073/pnas.78.7.4304; MIRANKER A, 1991, NATURE, V349, P633, DOI 10.1038/349633a0; MISE T, 1981, J BIOL CHEM, V256, P6587; PETERS BP, 1984, J BIOL CHEM, V259, P5123; POLLAK S, 1990, ENDOCRINOLOGY, V126, P199, DOI 10.1210/endo-126-1-199; PTITSYN OB, 1991, FEBS LETT, V285, P176, DOI 10.1016/0014-5793(91)80799-9; RUDDON RW, 1979, P NATL ACAD SCI USA, V76, P5143, DOI 10.1073/pnas.76.10.5143; RUDDON RW, 1989, ENDOCRINOLOGY, V124, P862, DOI 10.1210/endo-124-2-862; RUDDON RW, 1987, J BIOL CHEM, V262, P12533; RUDDON RW, 1981, J BIOL CHEM, V256, P1389; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; SPACKMAN DH, 1960, J BIOL CHEM, V235, P648; STALEY JP, 1992, P NATL ACAD SCI USA, V89, P1519, DOI 10.1073/pnas.89.5.1519; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; TANIYAMA Y, 1990, J BIOL CHEM, V265, P7570; UDGAONKAR JB, 1990, P NATL ACAD SCI USA, V87, P8197, DOI 10.1073/pnas.87.21.8197; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	34	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21396	21403						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400452				2022-12-25	WOS:A1992JV01100024
J	ISSAKIDIS, E; MIGINIACMASLOW, M; DECOTTIGNIES, P; JACQUOT, JP; CRETIN, C; GADAL, P				ISSAKIDIS, E; MIGINIACMASLOW, M; DECOTTIGNIES, P; JACQUOT, JP; CRETIN, C; GADAL, P			SITE-DIRECTED MUTAGENESIS REVEALS THE INVOLVEMENT OF AN ADDITIONAL THIOREDOXIN-DEPENDENT REGULATORY SITE IN THE ACTIVATION OF RECOMBINANT SORGHUM LEAF NADP-MALATE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME REGULATION; ZEA-MAYS; REDUCTIVE ACTIVATION; PHENOTYPIC SELECTION; KINETIC-PROPERTIES; LIGHT-ACTIVATION; ACTIVE DITHIOL; FERREDOXIN; CHLOROPLASTS; LEAVES	The chloroplastic enzyme NADP-malate dehydrogenase is activated by a reversible thiol/disulfide interchange with reduced thioredoxin. Its target disulfide bridge is considered to be located at the amino terminus. To further substantiate the regulatory role of this disulfide, site-directed mutagenesis has been used to replace each or both of the amino-terminal cysteines of the sorghum leaf NADP-malate dehydrogenase, expressed in Escherichia coli, by serines. A truncation mutant lacking the amino terminus has also been produced. Surprisingly, the mutant proteins still required activation by reduced thioredoxin. However, their activation was almost instantaneous, whereas the native enzyme reached full activity after a 10-20 min preincubation. The s1/2 for reduced thioredoxin was decreased 2-fold in the mutants, but their K(m) values for NADPH and oxaloacetate did not change significantly. The inhibition of activation by NADP and inhibition of activity by thiol-derivatizing agents were also retained. These results are interpreted as an indication that two thioredoxin-dependent reduction steps are involved in NADP-dependent malate dehydrogenase light activation, hence that two disulfides per monomer participate in the process. The overall activation rate would depend on a conformational change following the reduction of the amino-terminal disulfide bridge. The amino terminus also plays a role in the dimerization of the protein.	UNIV PARIS 11, PHYSIOL VEGETALE MOLEC LAB,CNRS, UNITE RECH ASSOCIEE 1128,BT 430, F-91405 ORSAY, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Jacquot, Jean-Pierre/A-1571-2012	Jacquot, Jean-Pierre/0000-0003-4975-8587; Issakidis-Bourguet, Emmanuelle/0000-0002-6144-4364				ABERG A, 1989, J BIOL CHEM, V264, P12249; ASHTON AR, 1983, ARCH BIOCHEM BIOPHYS, V227, P406, DOI 10.1016/0003-9861(83)90470-8; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; CRAWFORD NA, 1989, ARCH BIOCHEM BIOPHYS, V271, P223, DOI 10.1016/0003-9861(89)90273-7; CRETIN C, 1990, EUR J BIOCHEM, V192, P299, DOI 10.1111/j.1432-1033.1990.tb19227.x; DECOTTIGNIES P, 1988, J BIOL CHEM, V263, P11780; DECOTTIGNIES P, 1990, CURRENT RES PHOTOSYN, V4, P247; DROUX M, 1987, ARCH BIOCHEM BIOPHYS, V252, P426, DOI 10.1016/0003-9861(87)90049-X; DROUX M, 1987, ARCH BIOCHEM BIOPHYS, V256, P372, DOI 10.1016/0003-9861(87)90458-9; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FERTE N, 1986, EUR J BIOCHEM, V154, P587, DOI 10.1111/j.1432-1033.1986.tb09439.x; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HATCH MD, 1970, ANN REV PLANT PHYSIO, V21, P141, DOI 10.1146/annurev.pp.21.060170.001041; HATCH MD, 1969, BIOCHEM BIOPH RES CO, V34, P589, DOI 10.1016/0006-291X(69)90778-5; JACQUOT JP, 1984, PHYSIOL VEG, V22, P487; JACQUOT JP, 1991, EUR J BIOCHEM, V199, P47, DOI 10.1111/j.1432-1033.1991.tb16090.x; JACQUOT JP, 1984, ARCH BIOCHEM BIOPHYS, V228, P170, DOI 10.1016/0003-9861(84)90058-4; JENKINS CLD, 1986, PLANT SCI, V45, P1, DOI 10.1016/0168-9452(86)90064-6; KAGAWA T, 1977, ARCH BIOCHEM BIOPHYS, V184, P290, DOI 10.1016/0003-9861(77)90353-8; KAGAWA T, 1988, ARCH BIOCHEM BIOPHYS, V260, P674, DOI 10.1016/0003-9861(88)90497-3; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMARECHAL P, 1989, J CHROMATOGR, V477, P305, DOI 10.1016/S0021-9673(01)89639-4; MAYHEW SG, 1971, ANAL BIOCHEM, V42, P191, DOI 10.1016/0003-2697(71)90025-X; METZLER MC, 1989, PLANT MOL BIOL, V12, P713, DOI 10.1007/BF00044162; MIGINIACMASLOW M, 1990, BIOCHIM BIOPHYS ACTA, V1017, P273, DOI 10.1016/0005-2728(90)90193-8; MILANEZ S, 1991, J BIOL CHEM, V266, P10694; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; OGDEN RC, 1987, METHOD ENZYMOL, V152, P61; PERROTRECHENMANN C, 1983, PLANT SCI LETT, V30, P219, DOI 10.1016/0304-4211(83)90221-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIBE R, 1983, PLANTA, V157, P548, DOI 10.1007/BF00396887; SCHEIBE R, 1991, BIOCHIM BIOPHYS ACTA, V1076, P1, DOI 10.1016/0167-4838(91)90212-I; SCHEIBE R, 1984, BIOCHIM BIOPHYS ACTA, V788, P241, DOI 10.1016/0167-4838(84)90267-X; SCHURMANN P, 1979, BIOCHIM BIOPHYS ACTA, V569, P309, DOI 10.1016/0005-2744(79)90067-6; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WOLOSIUK RA, 1979, J BIOL CHEM, V254, P1627; WOLOSIUK RA, 1977, FEBS LETT, V81, P253, DOI 10.1016/0014-5793(77)80529-2	42	75	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21577	21583						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400468				2022-12-25	WOS:A1992JV01100050
J	MURAKAMIMUROFUSHI, K; SHIODA, M; KAJI, K; YOSHIDA, S; MUROFUSHI, H				MURAKAMIMUROFUSHI, K; SHIODA, M; KAJI, K; YOSHIDA, S; MUROFUSHI, H			INHIBITION OF EUKARYOTIC DNA POLYMERASE-ALPHA WITH A NOVEL LYSOPHOSPHATIDIC ACID (PHYLPA) ISOLATED FROM MYXOAMOEBAE OF PHYSARUM-POLYCEPHALUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CULTURED MESANGIAL CELLS; FACTOR MESSENGER-RNAS; PHOSPHATIDIC-ACID; PHOSPHOLIPASE-C; STIMULATION; METABOLISM; RECEPTOR; COMPLEX; INFLUX	A specific inhibitor of DNA polymerase a was isolated from the lipid fraction prepared from myxoamoebae of a true slime mold, Physarum polycephalum. The purified substance was subjected to structural studies by fast atom bombardment mass spectroscopy, infrared spectroscopy, and two-dimensional nuclear magnetic resonance spectroscopy. The structure of this substance was thereby suggested to be a novel lysophosphatidic acid (LPA) composed of cyclic phosphate and cyclopropane-containing hexadecanoic acid. Then we named this substance PHYLPA (Physarum LPA). PHYLPA inhibited more than 80% of the affinity-purified calf thymus DNA polymerase alpha activity at a concentration of 10 mug/ml (approximately 20 muM). Inhibition was observed for DNA polymerase alpha but not for DNA polymerase beta or gamma from various eukaryotic species, nor did it inhibit DNA polymerase I from E. coli. From kinetic analyses, the inhibition was considered to be caused by the interaction of PHYLPA with the template DNA.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT PHYSIOL CHEM & NUTR,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,ITABASHI KU,TOKYO 173,JAPAN; NAGOYA UNIV,SCH MED,DIS MECHANISM & CONTROL RES INST,SYOWA KU,NAGOYA,AICHI 466,JAPAN	University of Tokyo; University of Tokyo; Nagoya University	MURAKAMIMUROFUSHI, K (corresponding author), OCHANOMIZU UNIV,FAC SCI,DEPT BIOL,BUNKYO KU,TOKYO 112,JAPAN.							AGWU DE, 1989, BIOCHEM BIOPH RES CO, V159, P79, DOI 10.1016/0006-291X(89)92407-8; ALTIN JG, 1987, BIOCHEM J, V247, P613, DOI 10.1042/bj2470613; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BISHOP WR, 1986, J BIOL CHEM, V261, P2513; CERNY RL, 1986, ORG MASS SPECTROM, V21, P655, DOI 10.1002/oms.1210211009; COCO L, 1980, BIOCHEM BIOPH RES CO, V96, P890; DITTMER JC, 1964, J LIPID RES, V5, P126; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; Fansler B S, 1974, Methods Enzymol, V29, P53; HAJRA AK, 1986, ENZYMES LIPID METABO, V2, P199; HOKIN MR, 1953, J BIOL CHEM, V203, P967; KENNEDY EUGENE P., 1962, HARVEY LECTURES, V57, P143; KNAUSS TC, 1990, J BIOL CHEM, V265, P14457; MAY WS, 1986, P NATL ACAD SCI USA, V83, P1281, DOI 10.1073/pnas.83.5.1281; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MURAKAMIMUROFUSHI K, 1984, CELL STRUCT FUNCT, V9, P311, DOI 10.1247/csf.9.311; MURAYAMA T, 1987, J BIOL CHEM, V262, P5522; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OHSAKO S, 1981, J BIOL CHEM, V256, P945; OTONAESS AB, 1976, BIOCHIM BIOPHYS ACTA, V454, P193; PHILIPSON KD, 1984, J BIOL CHEM, V259, P16; PUTNEY JW, 1980, NATURE, V284, P345, DOI 10.1038/284345a0; SALMON DM, 1980, NATURE, V284, P344, DOI 10.1038/284344a0; SCHIEBEL W, 1980, FEBS LETT, V121, P81, DOI 10.1016/0014-5793(80)81271-3; SHIODA M, 1987, BIOCHEM BIOPH RES CO, V146, P61, DOI 10.1016/0006-291X(87)90690-5; SHIODA M, 1991, BIOCHEMISTRY-US, V30, P11403, DOI 10.1021/bi00112a006; SHIODA M, 1982, P NATL ACAD SCI-BIOL, V79, P7209, DOI 10.1073/pnas.79.23.7209; SIEGMANN DW, 1987, BIOCHEM BIOPH RES CO, V145, P228, DOI 10.1016/0006-291X(87)91310-6; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; TAMAI K, 1988, BIOCHIM BIOPHYS ACTA, V950, P263, DOI 10.1016/0167-4781(88)90122-4; TANAKA M, 1987, CANCER RES, V47, P5971; TANIGUCHI M, 1984, CELL STRUCT FUNCT, V3, P181; TYSON CA, 1976, J BIOL CHEM, V251, P1326; UMEKAWA H, 1988, J BIOCHEM-TOKYO, V104, P333, DOI 10.1093/oxfordjournals.jbchem.a122469; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; YOSHIDA S, 1989, BIOCHIM BIOPHYS ACTA, V1007, P61, DOI 10.1016/0167-4781(89)90130-9; YOSHIDA S, 1979, J BIOCHEM-TOKYO, V85, P1387, DOI 10.1093/oxfordjournals.jbchem.a132465; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	40	83	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21512	21517						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400463				2022-12-25	WOS:A1992JV01100040
J	STETTLER, S; MARIOTTE, S; RIVA, M; SENTENAC, A; THURIAUX, P				STETTLER, S; MARIOTTE, S; RIVA, M; SENTENAC, A; THURIAUX, P			AN ESSENTIAL AND SPECIFIC SUBUNIT OF RNA POLYMERASE-III-(C) IS ENCODED BY GENE RPC34 IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMON SUBUNITS; GROWTH-RATE; YEAST; TRANSCRIPTION; MUTANTS; MUTAGENESIS; PROTEIN; FAMILY; DNA; SELECTION	The RPC34 gene of Saccharomyces cerevisiae was cloned by immunological screening, using antibodies raised against the C34 polypeptide of the RNA polymerase III (C). This single copy gene was located near the centromere of chromosome XIV. It included a coding sequence of 317 amino acids that strictly matched two internal oligopeptides of C34. This polypeptide is a specific component of RNA polymerase III, with no significant homology to any other RNA polymerase subunit known so far. It is an essential subunit, since inactivation by deletion or nonsense mutations led to a recessive lethal phenotype. Moreover, a partially blocked mutant, rpc34-F297, had a reduced tRNA synthesis in vivo but no detectable effect on 5 S RNA synthesis. The latter phenotype was observed for all conditionally defective RNA polymerase III mutants isolated so far.	CTR ETUD SACLAY, CEA,DEPT BIOL CELLULAIRE & MOLEC, SERV BIOCHIM & GENET MOLEC,BAT 142, F-91191 GIF SUR YVETTE, FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay								ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; BUHLER JM, 1976, J BIOL CHEM, V251, P1712; CARLES C, 1991, J BIOL CHEM, V266, P24092; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; DALESSIO JM, 1979, J BIOL CHEM, V254, P1282; DEQUARDCHABLAT M, 1991, J BIOL CHEM, V266, P15300; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GUDENUS R, 1988, GENETICS, V119, P517; HOTTINGER H, 1982, MOL GEN GENET, V188, P219, DOI 10.1007/BF00332678; HUET J, 1985, J BIOL CHEM, V260, P5304; HUISMAN O, 1987, GENETICS, V116, P191; JAEHNING JA, 1977, J BIOL CHEM, V252, P8762; JAMES P, 1991, J BIOL CHEM, V266, P5616; JONES EW, 1977, GENETICS, V85, P23; KLAPHOLZ S, 1982, GENETICS, V100, P387; KOLODZIEJ P, 1989, MOL CELL BIOL, V9, P5387, DOI 10.1128/MCB.9.12.5387; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LILJELUND P, 1992, IN PRESS P NATL ACAD; MANN C, 1987, CELL, V48, P627, DOI 10.1016/0092-8674(87)90241-8; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MARTINDALE DW, 1990, NUCLEIC ACIDS RES, V18, P2953, DOI 10.1093/nar/18.10.2953; MCGOLDRICK EM, 1989, J GEN MICROBIOL, V135, P2407; MORTIMER RK, 1991, METHOD ENZYMOL, V194, P827; MORTIN MA, 1982, DEV BIOL, V103, P343; MOSRIN C, 1990, MOL CELL BIOL, V10, P4737, DOI 10.1128/MCB.10.9.4737; NEIGEBORN L, 1990, NUCLEIC ACIDS RES, V18, P4179, DOI 10.1093/nar/18.14.4179; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RIVA M, 1986, P NATL ACAD SCI USA, V83, P1554, DOI 10.1073/pnas.83.6.1554; RIVA M, 1982, J BIOL CHEM, V257, P4570; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUET A, 1980, J BIOL CHEM, V255, P6450; SCAFE C, 1990, MOL CELL BIOL, V10, P1010, DOI 10.1128/MCB.10.3.1010; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SENTENAC A, 1992, IN PRESS TRANSCRIPTI; SHERMAN F, 1991, METHOD ENZYMOL, V194, P1; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; Treich Isabelle, 1992, Gene Expression, V2, P31; VALENZUELA P, 1976, BIOCHEM BIOPH RES CO, V71, P1319, DOI 10.1016/0006-291X(76)90799-3; WALDRON C, 1975, J BACTERIOL, V122, P855, DOI 10.1128/JB.122.3.855-865.1975; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	52	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21390	21395						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400451				2022-12-25	WOS:A1992JV01100023
J	KANG, S; WELLS, RD				KANG, S; WELLS, RD			CENTRAL NON-PUR.PYR SEQUENCES IN OLIGO(DG.DC) TRACTS AND METAL-IONS INFLUENCE THE FORMATION OF INTRAMOLECULAR DNA TRIPLEX ISOMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOPURINE-HOMOPYRIMIDINE SEQUENCES; HANDED Z-DNA; H-DNA; PLASMIDS; CELLS; CONFORMATIONS; REPLICATION; SPECIFICITY; POLYPURINE; ADOPT	The effect of the central non-Pur.Pyr sequences in oligo(dG.dC) inserts on determining the type of intramolecular DNA triplex isomers formed in negatively supercoiled plasmids was investigated. Different triplex types (H-r3, H-r5, and H-y3), revealed by a combination of chemical probing and Maxam-Gilbert sequencing reactions, were adopted by the oligo(dG.dC) tracts depending on the length and composition of the central non-Pur.Pyr sequences (0, 3, or 5 base pairs) and the kind of metal ions. The H-r3 triplex conformer, one isomer of a Pur.Pur.Pyr structure, was formed in the (C)20 and (C)10GCG(C)10 inserts in plasmids in the presence of certain metal ions. Interestingly, H-r5, the other isomer of the Pur.Pur.Pyr triplex which had not been detected previously, was formed in a (C)9GAATT(C)9 insert in the presence of either Mg2+ or Ca2+. Alternatively, H-y3, one isomer of a Pyr.Pur.Pyr triplex, was formed in the (C)9GAATT(C)9 insert in the absence of metal ions. Thus, central non-Pur.Pyr sequences and metal ions play a role as determinants of the types of intramolecular triplexes formed; they also reduce the requirement of longer Pur.Pyr repeat sequences to form intramolecular triplexes. Furthermore, the effects of MgCl2 concentration and pH on the formation of triplex isomers were examined. The Pur.Pur.Pyr conformations (H-r3 and H-r5) may be the favored conformations in the cellular milieu, since they are stable at physiological pH and metal ion concentration.	TEXAS A&M UNIV SYST,TEXAS MED CTR,INST BIOSCI & TECHNOL,COLL STN,TX 77843	Texas A&M University System; Texas A&M University College Station					NIGMS NIH HHS [GM30822] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030822] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNUES J, 1989, EMBO J, V8, P2087, DOI 10.1002/j.1460-2075.1989.tb03617.x; BERNUES J, 1990, NUCLEIC ACIDS RES, V18, P4067, DOI 10.1093/nar/18.14.4067; BIANCHI A, 1990, J BIOL CHEM, V265, P21789; BRINTON BT, 1991, J BIOL CHEM, V266, P5153; COLLIER DA, 1988, J BIOL CHEM, V263, P7397; GLOVER JNM, 1990, BIOCHEMISTRY-US, V29, P11110, DOI 10.1021/bi00502a014; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; JOHNSTON BH, 1988, SCIENCE, V241, P1800, DOI 10.1126/science.2845572; KANG S, 1992, J BIOL CHEM, V267, P19435; KANG S, 1992, J BIOL CHEM, V267, P1259; KARLOVSKY P, 1990, FEBS LETT, V274, P39, DOI 10.1016/0014-5793(90)81324-H; KLEIN RD, 1982, J BIOL CHEM, V257, P2954; KOHWI Y, 1991, GENE DEV, V5, P2547, DOI 10.1101/gad.5.12b.2547; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOHWI Y, 1992, J MOL BIOL, V223, P817, DOI 10.1016/0022-2836(92)90242-C; KOHWI Y, 1991, NUCLEIC ACIDS RES, V19, P4267; MANIATIS T, 1982, MOL CLONING LABORATO, P90; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCLEAN MJ, 1987, NUCLEIC ACIDS RES, V15, P6917, DOI 10.1093/nar/15.17.6917; MCLEAN MJ, 1986, P NATL ACAD SCI USA, V83, P5884, DOI 10.1073/pnas.83.16.5884; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; PALECEK E, 1991, CRIT REV BIOCHEM MOL, V26, P151, DOI 10.3109/10409239109081126; PANYUTIN IG, 1992, J BIOL CHEM, V267, P5495; SHIMIZU M, 1989, J BIOL CHEM, V264, P5944; SHIMIZU M, 1990, BIOCHEMISTRY-US, V29, P4704, DOI 10.1021/bi00471a027; ULRICH MJ, 1992, J BIOL CHEM, V267, P18649; USDIN K, 1989, J BIOL CHEM, V264, P15681; WEINREB A, 1990, J BIOL CHEM, V265, P1352; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307	30	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20887	20891						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400403				2022-12-25	WOS:A1992JT97800059
J	BURKE, PA; GRIFFIN, RG; KLIBANOV, AM				BURKE, PA; GRIFFIN, RG; KLIBANOV, AM			SOLID-STATE NMR ASSESSMENT OF ENZYME ACTIVE-CENTER STRUCTURE UNDER NONAQUEOUS CONDITIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; ORGANIC-SOLVENTS; CHLOROMETHYL KETONE; ALPHA-CHYMOTRYPSIN; INHIBITOR COMPLEX; C-13 NMR; SERINE PROTEASES; LINE-SHAPES; TRYPSIN; CATALYSIS	By using solid-state NMR spectroscopy, the integrity of the active center of alpha-chymotrypsin was investigated under a variety of nonaqueous conditions. Specifically, C-13 cross-polarization/magic angle spinning NMR was used to analyze the ability of alpha-chymotrypsin to stabilize a transition state intermediate analog after freezing, drying, and addition of organic solvents (both anhydrous and hydrated) to the resultant powder. Lyophilization disrupted 42 +/- 5% of the active centers; it was determined that this occurred during drying, as opposed to freezing. Seven anhydrous solvents caused 0-50% additional disruption, which occurred immediately on addition of the solvent to the enzyme powder. The extent of structural integrity loss correlated with the solvent hydrophobicity, indicating that further dehydration, i.e. stripping of water retained by the enzyme during lyophilization, was the cause. Enzyme samples prepared with lyoprotecting additives, sucrose and ammonium sulfate, exhibited varying degrees of stabilization against the drying step of lyophilization. Moreover, when hydrophilic anhydrous solvents, which had the highest propensity to strip bound water, were added to the resultant enzyme powders, no additional damage occurred.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139; MIT,FRANCIS BITTER NATL MAGNET LAB,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)					NIGMS NIH HHS [GM 39794] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM039794, R01GM039794] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS KAH, 1990, J AM CHEM SOC, V112, P9418, DOI 10.1021/ja00181a068; AFFLECK R, 1992, P NATL ACAD SCI USA, V89, P1100, DOI 10.1073/pnas.89.3.1100; Akhadov Y.Y, 2013, DIELECTRIC PROPERTIE; ALLEN PJ, 1991, J MAGN RESON, V92, P614, DOI 10.1016/0022-2364(91)90357-Y; BURKE PA, 1989, J AM CHEM SOC, V111, P8290, DOI 10.1021/ja00203a046; DAVIS JH, 1976, CHEM PHYS LETT, V42, P390, DOI 10.1016/0009-2614(76)80392-2; DORDICK JS, 1989, ENZYME MICROB TECH, V11, P194, DOI 10.1016/0141-0229(89)90094-X; FARNEY DE, 1963, J AM CHEM SOC, V85, P997; FINK AL, 1986, CRYOBIOLOGY, V23, P28, DOI 10.1016/0011-2240(86)90015-5; Finney J. L., 1984, Comments on Molecular and Cellular Biophysics. Comments on Modern Biology: Part A, V2, P129; FINUCANE MD, 1989, BIOCHEM J, V258, P853, DOI 10.1042/bj2580853; FISHBEIN WN, 1979, ADV CHEM SER, V180, P55; FITZPATRICK PA, 1991, J AM CHEM SOC, V113, P3166, DOI 10.1021/ja00008a054; Franks F., 1985, BIOPHYSICS BIOCH LOW; GORMAN LAS, 1992, BIOTECHNOL BIOENG, V39, P392, DOI 10.1002/bit.260390405; GRIFFIN RG, 1981, TIME DOMAIN SURFACE; GUINN RM, 1991, BIOTECHNOL BIOENG, V37, P303, DOI 10.1002/bit.260370403; Gurd F R, 1979, Adv Protein Chem, V33, P73, DOI 10.1016/S0065-3233(08)60459-3; HARNED HS, 1964, PHYSICAL CHEM ELECTR; HUANG TH, 1984, BIOCHEMISTRY-US, V23, P5933, DOI 10.1021/bi00320a007; Janz G., 1972, NONAQUEOUS ELECTROLY, V1; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; KANERVA LT, 1989, J AM CHEM SOC, V111, P6864, DOI 10.1021/ja00199a069; KENIRY MA, 1984, NATURE, V307, P383, DOI 10.1038/307383a0; KLIBANOV AM, 1989, TRENDS BIOCHEM SCI, V14, P141, DOI 10.1016/0968-0004(89)90146-1; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LAITINEN HA, 1975, CHEM ANAL; LIANG TC, 1987, BIOCHEMISTRY-US, V26, P7603, DOI 10.1021/bi00398a011; LIU WR, 1991, BIOTECHNOL BIOENG, V37, P177, DOI 10.1002/bit.260370210; MALTHOUSE JPG, 1983, J AM CHEM SOC, V105, P1685, DOI 10.1021/ja00344a062; MALTHOUSE JPG, 1985, BIOCHEMISTRY-US, V24, P3478, DOI 10.1021/bi00335a014; MATTHEWS HR, 1977, BIOCHIM BIOPHYS ACTA, V497, P1, DOI 10.1016/0304-4165(77)90134-9; Mehring M., 1983, HIGH RESOLUTION NMR; Milton Silverstein R., 1981, SPECTROMETRIC IDENTI; ONG EB, 1965, J BIOL CHEM, V240, P694; Perrin D. D., 2012, BUFFERS PH METAL ION; PRZYBYCIEN TM, 1989, BIOCHIM BIOPHYS ACTA, V995, P231, DOI 10.1016/0167-4838(89)90041-1; Rekker RF., 1977, HYDROPHOBIC FRAGMENT; RICE DM, 1981, J AM CHEM SOC, V103, P7707, DOI 10.1021/ja00416a002; Robinson R.A., 1959, ELECTROLYTE SOLUTION, DOI DOI 10.1073?PNAS.0305836101; Rupley J. A., 1980, ACS S SERIES, V127, P111; RUPLEY JA, 1983, TRENDS BIOCHEM SCI, V8, P18, DOI 10.1016/0968-0004(83)90063-4; RUSSELL AJ, 1988, J BIOL CHEM, V263, P11624; SCHOELLMANN G, 1963, BIOCHEMISTRY-US, V2, P252, DOI 10.1021/bi00902a008; SCHULTZ PG, 1990, CHEM ENG NEWS, V68, P26, DOI 10.1021/cen-v068n022.p026; SCHULZE B, 1991, BIOTECHNOL BIOENG, V38, P1001, DOI 10.1002/bit.260380907; SCOTT AI, 1986, TETRAHEDRON, V42, P3269, DOI 10.1016/S0040-4020(01)87391-9; SEGAL DM, 1971, BIOCHEMISTRY-US, V10, P3728; SINGER SJ, 1962, ADV PROTEIN CHEM, V17, P1; STEITZ TA, 1982, ANNU REV BIOPHYS BIO, V11, P419, DOI 10.1146/annurev.bb.11.060182.002223; WAGNER G, 1976, BIOPHYS STRUCT MECH, V2, P139, DOI 10.1007/BF00863706; WAGNER G, 1983, Q REV BIOPHYS, V16, P1, DOI 10.1017/S0033583500004911; WITTEBORT RJ, 1987, J CHEM PHYS, V86, P5411, DOI 10.1063/1.452565; ZAKS A, 1986, J AM CHEM SOC, V108, P2767, DOI 10.1021/ja00270a053; ZAKS A, 1988, J BIOL CHEM, V263, P3194; ZAKS A, 1988, J BIOL CHEM, V263, P8017	57	69	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20057	20064						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400323				2022-12-25	WOS:A1992JR85800051
J	OHLSEN, KL; GRALLA, JD				OHLSEN, KL; GRALLA, JD			DNA MELTING WITHIN STABLE CLOSED COMPLEXES AT THE ESCHERICHIA-COLI RRNB P1 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL STRINGENT CONTROL; FACTOR-INDEPENDENT ACTIVATION; RIBOSOMAL-RNA TRANSCRIPTION; RATE-DEPENDENT REGULATION; LAC PS PROMOTER; GUANOSINE TETRAPHOSPHATE; UPSTREAM ACTIVATION; MECHANISM INVIVO; POLYMERASE; INVITRO	Several transcription complexes are shown to form on the E. coli ribosomal rrnB P1 promoter in vitro. These include two closed complexes that are sensitive to heparin attack, and one open complex. The closed complexes are unusual in that they are both highly specific and stable, properties associated with the atypical DNA sequence of this promoter. The effector ppGpp does not prevent closed complex formation but does reduce the level of open complexes that form.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,405 HILGARD AVE,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NIGMS NIH HHS [GM 35754, GM 07185] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035754, T32GM007185] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOROWIEC JA, 1987, J MOL BIOL, V195, P89, DOI 10.1016/0022-2836(87)90329-9; BOROWIEC JA, 1985, J MOL BIOL, V184, P587, DOI 10.1016/0022-2836(85)90305-5; BROSIUS J, 1981, J MOL BIOL, V148, P107, DOI 10.1016/0022-2836(81)90508-8; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CASHEL M, 1969, J BIOL CHEM, V244, P3133; CASHEL M, 1987, ESCHERICHIA COLI SAL, V2, P1410; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; COWING DW, 1989, J MOL BIOL, V210, P521, DOI 10.1016/0022-2836(89)90128-9; GAAL T, 1989, J BACTERIOL, V171, P4852, DOI 10.1128/jb.171.9.4852-4861.1989; GLASER G, 1983, NATURE, V302, P74, DOI 10.1038/302074a0; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; GOURSE RL, 1983, CELL, V32, P1347, DOI 10.1016/0092-8674(83)90315-X; GRALLA JD, 1991, CELL, V66, P415, DOI 10.1016/0092-8674(81)90001-5; HAMMING J, 1980, NUCLEIC ACIDS RES, V8, P3947, DOI 10.1093/nar/8.17.3947; HOFER B, 1985, NUCLEIC ACIDS RES, V13, P5995, DOI 10.1093/nar/13.16.5995; Jinks-Robertson S., 1987, ESCHERICHIA COLI SAL, P1358; KAJITANI M, 1984, J BIOL CHEM, V259, P1951; KINGSTON RE, 1981, J MOL BIOL, V146, P433, DOI 10.1016/0022-2836(81)90041-3; KINGSTON RE, 1981, CELL, V27, P523, DOI 10.1016/0092-8674(81)90394-9; KINGSTON RE, 1981, J BIOL CHEM, V256, P2787; KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544; KOVACIC RT, 1987, J BIOL CHEM, V262, P13654; LAMOND AI, 1985, CELL, V41, P6, DOI 10.1016/0092-8674(85)90050-9; LAZZARINI RA, 1971, J BIOL CHEM, V246, P4381; LAZZARINI RA, 1971, J BIOL CHEM, V246, P420; LEIRMO S, 1991, J MOL BIOL, V220, P555, DOI 10.1016/0022-2836(91)90100-K; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MECSAS J, 1991, J MOL BIOL, V220, P585, DOI 10.1016/0022-2836(91)90102-C; MEIKLEJOHN AL, 1989, J MOL BIOL, V207, P661, DOI 10.1016/0022-2836(89)90236-2; MIURA A, 1981, CELL, V25, P773, DOI 10.1016/0092-8674(81)90185-9; NEIDHARDT FC, 1963, BIOCHIM BIOPHYS ACTA, V68, P365; NEWLANDS JT, 1991, J MOL BIOL, V220, P569, DOI 10.1016/0022-2836(91)90101-B; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; OHLSEN KL, 1992, IN PRESS MOL MICROBI; OOSTRA BA, 1977, MOL GEN GENET, V152, P1, DOI 10.1007/BF00264932; SARMIENTOS P, 1983, CELL, V32, P1337, DOI 10.1016/0092-8674(83)90314-8; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SASSEDWIGHT S, 1988, J MOL BIOL, V202, P107, DOI 10.1016/0022-2836(88)90523-2; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; STEFANO JE, 1982, P NATL ACAD SCI-BIOL, V79, P1069, DOI 10.1073/pnas.79.4.1069; STENT GS, 1961, P NATL ACAD SCI USA, V47, P2005, DOI 10.1073/pnas.47.12.2005; VANOOYEN AJJ, 1976, CELL, V8, P123, DOI 10.1016/0092-8674(76)90193-8; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133	44	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19813	19818						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400295				2022-12-25	WOS:A1992JR85800012
J	REDL, B; HOLZFEIND, P; LOTTSPEICH, F				REDL, B; HOLZFEIND, P; LOTTSPEICH, F			CDNA CLONING AND SEQUENCING REVEALS HUMAN TEAR PREALBUMIN TO BE A MEMBER OF THE LIPOPHILIC-LIGAND CARRIER PROTEIN SUPERFAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING PROTEIN; BETA-LACTOGLOBULIN; MOLECULAR-CLONING; ALPHA-1-ACID GLYCOPROTEIN; LACRIMAL GLAND; MESSENGER-RNA; LACTOFERRIN; RESOLUTION; HOMOLOGY; FLUID	The gene encoding human tear prealbumin, a major component of the protein fraction of tear fluid, was cloned from total cDNA of lacrimal gland by polymerase chain reaction using synthetic oligonucleotides derived from N-terminal amino acid sequences of the purified protein. Sequence analysis and a computer-assisted homology search revealed this protein to be a member of the lipocalin superfamily, consisting of hydrophobic-ligand carriers. The deduced amino acid sequence of tear prealbumin shares 58% identity with von Ebner's gland protein from rat, which is supposed to be involved in taste reception. In addition, significant homology has also been found with other members of the lipocalins, e.g. with beta-lactoglobulin. The predicted secondary structure of tear prealbumin resembles that of beta-lactoglobulin in the number and positions of nine beta-sheets and one alpha-helix at the C-terminal part of the protein, thus indicating a three-dimensional structure similar to beta-lactoglobulin. Protein sequencing revealed that the observed electrophoretic heterogeneity of tear prealbumin is due to subtle differences at the N terminus of the protein. The function of tear prealbumin as a lipophilic carrier was further supported by the fact that it binds [H-3]retinol in vitro. Although this protein was originally described to be tear-specific, a tear prealbumin-specific antiserum also reacted with proteins of human saliva, sweat, and nasal mucus.	MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	Max Planck Society	REDL, B (corresponding author), UNIV INNSBRUCK,FAK MED,INST MIKROBIOL,FRITZ PREGLSTR 3,A-6020 INNSBRUCK,AUSTRIA.							AKERSTROM B, 1990, TRENDS BIOCHEM SCI, V15, P240, DOI 10.1016/0968-0004(90)90037-C; ALEXANDER LJ, 1989, NUCLEIC ACIDS RES, V17, P6739, DOI 10.1093/nar/17.16.6739; ALLANSMITH M, 1967, IMMUNOLOGY, V12, P225; ANDERSON BF, 1989, J MOL BIOL, V209, P711, DOI 10.1016/0022-2836(89)90602-5; ANDREWS JS, 1970, EXP EYE RES, V10, P223, DOI 10.1016/S0014-4835(70)80032-X; BAIER G, 1990, J CHROMATOGR-BIOMED, V525, P319, DOI 10.1016/S0378-4347(00)83408-8; BONAVIDA B, 1969, NATURE, V221, P375, DOI 10.1038/221375a0; BOONSTRA A, 1988, CURR EYE RES, V7, P893, DOI 10.3109/02713688808997246; BROEKHUYSE RM, 1974, INVEST OPHTH VISUAL, V13, P550; BROOKS DE, 1986, J BIOL CHEM, V26, P4956; CANCEDDA FD, 1990, J BIOL CHEM, V265, P19060; CHAO CCW, 1986, CURR EYE RES, V5, P895, DOI 10.3109/02713688608995169; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COLLET C, 1989, BIOCHEM BIOPH RES CO, V164, P1380, DOI 10.1016/0006-291X(89)91822-6; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P542; DENTE L, 1985, NUCLEIC ACIDS RES, V13, P3941, DOI 10.1093/nar/13.11.3941; Fleming A, 1922, BRIT J EXP PATHOL, V3, P252; FORD LO, 1974, J MOL BIOL, V88, P349, DOI 10.1016/0022-2836(74)90487-2; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GACHON AM, 1979, EXP EYE RES, V29, P539, DOI 10.1016/0014-4835(79)90154-4; GACHON AM, 1982, CURR EYE RES, V5, P301; GAZQUEZ JMCD, 1989, ENZYME, V41, P116, DOI 10.1159/000469063; GODOVAC-ZIMMERMANN J, 1988, TRENDS BIOCHEM SCI, V13, P64, DOI 10.1016/0968-0004(88)90031-X; HENZEL WJ, 1988, J BIOL CHEM, V263, P16682; HOLDEN HM, 1987, EMBO J, V6, P1565, DOI 10.1002/j.1460-2075.1987.tb02401.x; HUBER R, 1987, J MOL BIOL, V198, P499, DOI 10.1016/0022-2836(87)90296-8; JANSSEN PT, 1983, EXP EYE RES, V36, P773, DOI 10.1016/0014-4835(83)90031-3; JANSSEN PT, 1983, INVEST OPHTH VIS SCI, V24, P623; JOSEPHSON AS, 1968, J IMMUNOL, V100, P1080; JULKUNEN M, 1988, P NATL ACAD SCI USA, V85, P8845, DOI 10.1073/pnas.85.23.8845; KAUMEYER JF, 1986, NUCLEIC ACIDS RES, V14, P7839, DOI 10.1093/nar/14.20.7839; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE KH, 1987, SCIENCE, V235, P1053, DOI 10.1126/science.3493528; NAGATA A, 1991, P NATL ACAD SCI USA, V88, P4020, DOI 10.1073/pnas.88.9.4020; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; PERVAIZ S, 1987, FASEB J, V1, P209, DOI 10.1096/fasebj.1.3.3622999; PEVSNER J, 1990, J BIOL CHEM, V265, P6118; PEVSNER J, 1985, P NATL ACAD SCI USA, V82, P3050, DOI 10.1073/pnas.82.9.3050; PEVSNER J, 1988, SCIENCE, V241, P336, DOI 10.1126/science.3388043; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINDLER M, 1976, J BIOL CHEM, V251, P4330; SCHMALE H, 1990, NATURE, V343, P366, DOI 10.1038/343366a0; SELSTED ME, 1982, EXP EYE RES, V34, P305, DOI 10.1016/0014-4835(82)90079-3; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P561; SPENCE AM, 1989, P NATL ACAD SCI USA, V86, P7843, DOI 10.1073/pnas.86.20.7843; SPENCE AM, 1989, P NATL ACAD SCI USA, V86, P5463; UBELS JL, 1986, INVEST OPHTH VIS SCI, V27, P1261; UBELS JL, 1989, INVEST OPHTH VIS SCI, V30, P952; VANHAERINGEN NJ, 1981, SURV OPHTHALMOL, V26, P84, DOI 10.1016/0039-6257(81)90145-4; VANHAERINGEN NJ, 1974, EXP EYE RES, V20, P271; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WEINBERG ED, 1974, SCIENCE, V184, P952, DOI 10.1126/science.184.4140.952; YOUNG WH, 1973, AM J OPTOM PHYS OPT, V50, P12	57	145	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20282	20287						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400345				2022-12-25	WOS:A1992JR85800084
J	SUN, AQ; YUKSEL, KU; GRACY, RW				SUN, AQ; YUKSEL, KU; GRACY, RW			INTERACTIONS BETWEEN THE CATALYTIC CENTERS AND SUBUNIT INTERFACE OF TRIOSEPHOSPHATE ISOMERASE PROBED BY REFOLDING, ACTIVE-SITE MODIFICATION, AND SUBUNIT EXCHANGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIOSE PHOSPHATE ISOMERASE; PROTEIN-TURNOVER; REACTION PATHWAY; PHOSPHOGLYCOLOHYDROXAMATE COMPLEX; MAGNETIC-RESONANCE; PIG-HEART; ENZYME; INACTIVATION; DEGRADATION; INTERMEDIATE	The effects of unfolding, refolding, and hybridization of triosephosphate isomerase (TPI) subunits from different species and subunits which have been specifically modified at the active site have been examined. These effects have been evaluated in terms of changes in catalytic parameters, CD spectra, and susceptibility to denaturation. Dissociation followed by reassociation yields an active dimer but with increased K(m), reduced k(cat), and increased susceptibility to inactivation and unfolding in denaturants. These data suggest that while the general structure of the refolded dimer is similar to the native enzyme, its complete original structure is not restored. Covalent reaction of the active site Glu165 with the substrate analogue 3-chloroacetol phosphate (CAP) results in dimers with increased susceptibility to unfolding and inactivation by denaturants (i.e. the rates of inactivation and unfolding are (TPI(CAP))2 > (TPI-TPI(CAP)) > (TPI)2). These data point to the interactions between the catalytic center and the subunit interface. Subunits of TPI from different species, in spite of structural differences at the subunit interface, hybridized to active heterodimers. Subunit hybridization was random among monomers from different mammals, preferential between yeast and mammalian or avian monomers. Hybridization did not occur between avian and mammalian monomers under these conditions. These data provide information on the elements in the interface of the dimer and the relationship of the catalytic center with the subunit interface.	UNIV TEXAS, TEXAS COLL OSTEOPATH MED, DEPT BIOCHEM & MOLEC BIOL, MOLEC AGING UNIT, FT WORTH, TX 76107 USA	University of Texas System; University of Texas Arlington					NATIONAL INSTITUTE ON AGING [R37AG001274, R01AG001274] Funding Source: NIH RePORTER; NIA NIH HHS [AG 01274] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHERN TJ, 1987, P NATL ACAD SCI USA, V84, P675, DOI 10.1073/pnas.84.3.675; ALBER T, 1982, Journal of Molecular and Applied Genetics, V1, P419; ALBER T, 1981, PHILOS T ROY SOC B, V293, P159, DOI 10.1098/rstb.1981.0069; Anfinsen C B, 1967, Harvey Lect, V61, P95; ARTAVANISTSAKON.C, 1974, THESIS U CAMBRIDGE; BASH PA, 1991, BIOCHEMISTRY-US, V30, P5826, DOI 10.1021/bi00238a003; BLACKLOW SC, 1991, BIOCHEMISTRY-US, V30, P8470, DOI 10.1021/bi00098a026; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN FK, 1987, J MOL BIOL, V198, P533, DOI 10.1016/0022-2836(87)90298-1; BROWNE CA, 1976, J MOL BIOL, V100, P319, DOI 10.1016/S0022-2836(76)80066-6; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; CORRAN PH, 1975, BIOCHEM J, V145, P335, DOI 10.1042/bj1450335; CREIGHTON TE, 1977, J MOL BIOL, V113, P275, DOI 10.1016/0022-2836(77)90142-5; DAVENPORT RC, 1991, BIOCHEMISTRY-US, V30, P5821, DOI 10.1021/bi00238a002; DICE JF, 1973, J BIOL CHEM, V248, P4220; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; GOLDBERG AL, 1974, ANNU REV BIOCHEM, V43, P835, DOI 10.1146/annurev.bi.43.070174.004155; GRACY RW, 1990, PROG CLIN BIOL RES, V344, P787; HARTMAN FC, 1971, BIOCHEMISTRY-US, V10, P146, DOI 10.1021/bi00777a021; HARTMAN FC, 1973, BIOCHEM BIOPH RES CO, V52, P388, DOI 10.1016/0006-291X(73)90723-7; JACOBSON T M, 1990, Protein Expression and Purification, V1, P9, DOI 10.1016/1046-5928(90)90038-Z; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES RB, 1979, BIOCHEM J, V179, P623, DOI 10.1042/bj1790623; KOVIMES EA, 1991, BIOCHEMISTRY-US, V30, P3011; LEVINE RL, 1981, P NATL ACAD SCI-BIOL, V78, P2120, DOI 10.1073/pnas.78.4.2120; LINDSAY CD, 1991, BIOCHEMISTRY-US, V30, P9034, DOI 10.1021/bi00101a018; LODI PJ, 1991, BIOCHEMISTRY-US, V30, P6948, DOI 10.1021/bi00242a020; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6619, DOI 10.1021/bi00480a010; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6609, DOI 10.1021/bi00480a009; LU HS, 1984, J BIOL CHEM, V259, P1958; MAIZEL JV, 1971, METHOD VIROL, V5, P180; MCLENDON G, 1978, J BIOL CHEM, V253, P6335; RAZ A, 1990, BIOCHEM J, V269, P603, DOI 10.1042/bj2690603; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROTH M, 1971, ANAL CHEM, V43, P880, DOI 10.1021/ac60302a020; ROZACKY EE, 1971, ARCH BIOCHEM BIOPHYS, V146, P312, DOI 10.1016/S0003-9861(71)80069-3; SALO DC, 1990, J BIOL CHEM, V265, P11919; SCHNACKERZ KD, 1990, BIOCHEM BIOPH RES CO, V173, P736, DOI 10.1016/S0006-291X(05)80097-X; SCHNACKERZ KD, 1991, EUR J BIOCHEM, V199, P231, DOI 10.1111/j.1432-1033.1991.tb16114.x; SEGAL HL, 1974, J BIOL CHEM, V249, P267; SNAPKA RM, 1974, COMP BIOCHEM PHYSIOL, V49, P733, DOI 10.1016/0305-0491(74)90259-4; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; STRAUS D, 1985, P NATL ACAD SCI USA, V82, P2014, DOI 10.1073/pnas.82.7.2014; SUN AW, 1992, ARCH BIOCHEM BIOPHYS, V293, P382, DOI 10.1016/0003-9861(92)90410-X; TOLLEFSBOL TO, 1982, MECH AGEING DEV, V20, P93, DOI 10.1016/0047-6374(82)90061-6; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WEST SM, 1990, BIOCHIM BIOPHYS ACTA, V1037, P332, DOI 10.1016/0167-4838(90)90034-D; WEST SM, 1990, BIOCHEM J, V265, P45, DOI 10.1042/bj2650045; WIERENGA RK, 1991, J MOL BIOL, V220, P995, DOI 10.1016/0022-2836(91)90368-G; WIERENGA RK, 1991, PROTEINS, V10, P33, DOI 10.1002/prot.340100105; YUAN PM, 1981, MECH AGEING DEV, V17, P151, DOI 10.1016/0047-6374(81)90081-6; YUKSEL KU, 1986, ARCH BIOCHEM BIOPHYS, V248, P452, DOI 10.1016/0003-9861(86)90498-4; YUKSEL KU, 1991, STUDY ENZYMES, V2, P457	54	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20168	20174						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400336				2022-12-25	WOS:A1992JR85800068
J	THOMAS, PJ; GARBOCZI, DN; PEDERSEN, PL				THOMAS, PJ; GARBOCZI, DN; PEDERSEN, PL			MUTATIONAL ANALYSIS OF THE CONSENSUS NUCLEOTIDE BINDING SEQUENCES IN THE RAT-LIVER MITOCHONDRIAL ATP SYNTHASE BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; AMINO-ACID-SEQUENCE; ADENOSINE-TRIPHOSPHATE SYNTHASE; ION MOTIVE ATPASES; ESCHERICHIA-COLI; ADENYLATE KINASE; OXIDATIVE-PHOSPHORYLATION; ADENINE-NUCLEOTIDES; CDNA CLONING; F1 MOIETY	The coupling step in the biosynthesis of ATP in biological systems is generally believed to involve an energy-requiring release of ATP bound to the beta-subunit of the ATP synthase complex. A molecular description of the ATP binding site on the beta-subunit is, therefore, critical to understanding the mechanism of coupling in the enzyme. Previously, we reported that a purified, bacterially expressed rat liver beta-subunit binds adenine nucleotides tightly and specifically (Garboczi, D. N., Hullihen, J. H., and Pedersen, P. L. (1988) J. Biol. Chem. 263, 15694-15698). In order to assess the contribution of various regions of the isolated beta-subunit to the ATP binding site we have systematically deleted four different regions: the N-terminal region, the Walker A consensus region, the Walker B consensus region (Walker, J. E., Saraste, M., Runswick, M. J., and Gay, N. (1982) EMBO J. 1, 945-951), and a "C" region, which, like the A and B regions, bears homology to adenylate kinase. Plasmids directing the expression of double deletions of A and B regions, and B and C regions were also constructed. In addition, 2 residues outside of these regions, His-177 and Tyr-345, which have been predicted to play a central role in nucleotide binding, were mutated. Rabbit antisera to synthetic peptides of the A and C regions verified the identity of the bacterially expressed mutant proteins. Seven of the eight mutant proteins overexpressed in Escherichia coli were resistant to E. coli proteases in the preparative stages, as predicted for compact folded proteins. Furthermore, circular dichroism spectropolarimetry revealed no profound structural alterations in the purified mutant proteins. Relative to the overexpressed full-length beta-subunit, the mutant lacking the A consensus region suffered a 30-fold loss of affinity for ATP and a loss of specificity for 2'(3')-O-(2,4,6-trinitrophenyl) adenosine 5'-triphosphate (TNP-ATP) over 2'(3')-O-(2,4,6-trinitrophenyl)adenosine 5'-monophosphate. The mutant proteins lacking either the N-terminal region or the B region exhibited nucleotide binding properties similar to the full-length beta-subunit, whereas the mutant protein lacking the C region suffered an order of magnitude reduction in affinity for ATP. The affinity of the A and B region double deletion was indistinguishable from the A region deletion in regard to TNP-ATP binding, while the double deletion mutant lacking the B and C regions was not stably expressed in the E. coli SE6004. Mutant proteins bearing the single-site changes, His-177 --> Gln or Tyr-345 --> Cys, exhibited nearly identical binding properties to that of the full-length beta-subunit. This is the first study in which regions of the isolated beta-subunit of an ATP synthase complex have been systematically assessed by mutational analysis for their contribution to ATP binding. The results indicate that the A consensus sequence contributes over one-half of the total binding energy, with the C region making a significant contribution. The N-terminal region, the B region, Tyr-345, and His-177 appear to play little or no role in ATP binding.	JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, MOLEC & CELLULAR BIOENERGET LAB, BALTIMORE, MD 21205 USA	Johns Hopkins University			Thomas, Philip J/F-7115-2012		NCI NIH HHS [CA 10951] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA010951, R37CA010951] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS WW, 1984, J BIOL CHEM, V259, P4378; ARMSTRONG SK, 1990, J BIOL CHEM, V265, P14536; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; BOULAY F, 1985, BIOCHEMISTRY-US, V24, P7372, DOI 10.1021/bi00346a052; BOUTRY M, 1985, EMBO J, V4, P2159, DOI 10.1002/j.1460-2075.1985.tb03910.x; BOYER PD, 1973, P NATL ACAD SCI USA, V70, P2837, DOI 10.1073/pnas.70.10.2837; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BULLOUGH DA, 1986, J BIOL CHEM, V261, P14171; CATTERALL WA, 1971, J BIOL CHEM, V246, P4987; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DARNELL JE, 1986, P NATL ACAD SCI USA, V83, P1271, DOI 10.1073/pnas.83.5.1271; DUBOSE RF, 1989, P NATL ACAD SCI USA, V86, P9966, DOI 10.1073/pnas.86.24.9966; ENGER U, 1987, J MOL BIOL, V195, P649; FRASCH WD, 1989, J BIOL CHEM, V264, P5064; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GARBOCZI DN, 1990, J BIOL CHEM, V265, P14632; GARBOCZI DN, 1988, BIOCHEMISTRY-US, V27, P553, DOI 10.1021/bi00402a008; GARBOCZI DN, 1988, J BIOL CHEM, V263, P15694; GARIN J, 1986, BIOCHEMISTRY-US, V25, P4431, DOI 10.1021/bi00363a039; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GILBERT W, 1985, SCIENCE, V228, P823, DOI 10.1126/science.4001923; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; Harlow E., 1988, ANTIBODIES LABORATOR, P633; HARRIS DA, 1985, BIOCHEMISTRY-US, V24, P3876, DOI 10.1021/bi00336a010; HARRIS DA, 1978, BIOCHIM BIOPHYS ACTA, V463, P245, DOI 10.1016/0304-4173(78)90002-2; HIRATSUKA T, 1982, BIOCHIM BIOPHYS ACTA, V719, P509, DOI 10.1016/0304-4165(82)90240-9; HOLLEMANS M, 1983, J BIOL CHEM, V258, P9307; IWAMOTO A, 1991, J BIOL CHEM, V266, P16350; Jencks W P, 1980, Adv Enzymol Relat Areas Mol Biol, V51, P75; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KAGAWA Y, 1989, FEBS LETT, V249, P67, DOI 10.1016/0014-5793(89)80017-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JH, 1990, J BIOL CHEM, V265, P4664; LEWIS MJ, 1992, J BIOL CHEM, V267, P3482; LUNARDI J, 1987, J BIOL CHEM, V262, P15172; MILLS DA, 1991, J BIOL CHEM, V266, P7440; MITCHELL P, 1987, INTEGRATION CONTROL, P231; MUELLER DM, 1989, BIOCHEM BIOPH RES CO, V164, P381, DOI 10.1016/0006-291X(89)91730-0; OHTA S, 1988, J BIOL CHEM, V263, P11257; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; PARSONAGE D, 1987, J BIOL CHEM, V262, P8022; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PEDERSEN PL, 1987, BIOCHEMISTRY-US, V26, P8631, DOI 10.1021/bi00400a021; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; RAO R, 1988, J BIOL CHEM, V263, P5569; REIF AE, 1969, IMMUNOCHEMISTRY, V6, P723, DOI 10.1016/0019-2791(67)90136-X; ROSE T, 1991, J BIOL CHEM, V266, P10781; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; VOGEL PD, 1991, J BIOL CHEM, V266, P6101; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WEBER J, 1992, J BIOL CHEM, V267, P1712; WILLIAMS N, 1987, BIOCHEMISTRY-US, V26, P162, DOI 10.1021/bi00375a023; WILLIAMS N, 1982, J BIOL CHEM, V257, P2834; WISE JG, 1990, J BIOL CHEM, V265, P10403; WYNN RM, 1992, J BIOL CHEM, V267, P1881; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5; [No title captured]	67	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20331	20338						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400352				2022-12-25	WOS:A1992JR85800092
J	WANG, RW; NEWTON, DJ; HUSKEY, SEW; MCKEEVER, BM; PICKETT, CB; LU, AYH				WANG, RW; NEWTON, DJ; HUSKEY, SEW; MCKEEVER, BM; PICKETT, CB; LU, AYH			SITE-DIRECTED MUTAGENESIS OF GLUTATHIONE-S-TRANSFERASE YAYA - IMPORTANT ROLES OF TYROSINE-9 AND ASPARTIC ACID-101 IN CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; CLASS-PI; ESCHERICHIA-COLI; LIVER; RAT; PROTEINS; TETRACHLORO-1,4-BENZOQUINONE; INHIBITION; EXPRESSION; MECHANISM	The roles of tyrosine 9 and aspartic acid 101 in the catalytic mechanism of rat glutathione S-transferase YaYa were studied by site-directed mutagenesis. Replacement of tyrosine 9 with phenylalanine (Y9F), threonine (Y9T), histidine (Y9H), or valine (Y9V) resulted in mutant enzymes with less than 5% catalytic activity of the wild type enzymes. Kinetic studies with purified Y9F and Y9T mutants demonstrated poor catalytic efficiencies which were largely due to a drastic decrease in k(cat). The estimated pK(a) values of the sulfhydryl group of glutathione bound to Y9F and Y9T mutant enzymes were 8.5 to 8.7, similar to the chemical reaction, in contrast to the estimated pK(a) value of 6.7 to 6.8 for the glutathione enzyme complex of wild type glutathione S-transferase. These results indicate that tyrosine 9 is directly responsible for the lowering of the pK(a) of the sulfhydryl group of glutathione, presumably due to the stabilization of the thiolate anion through hydrogen bonding with the hydroxyl group of tyrosine. To examine the role of aspartic acid in the binding of glutathione to YaYa, 4 conserved aspartic acid residues at positions 61, 93, 101, and 157 were changed to glutamic acid and asparagine. All mutant enzymes retained either full or partial activity except D157N, which was virtually inactive. Kinetic studies with four mutant enzymes (D93E, D93N, D101E, and D101N) indicate that only D101N exhibited a 5-fold increase in K(m) toward glutathione. Also, the binding of this mutant to the affinity column was greatly reduced. These results demonstrate that aspartic acid 101 plays an important role in glutathione interaction to YaYa. The role of aspartic acid 157 in catalysis remains to be determined.	MERCK FROSST CTR THERAPEUT RES,POINTE CLAIRE H9R 4P8,QUEBEC,CANADA; MERCK SHARP & DOHME LTD,DEPT BIOPHYS CHEM,RAHWAY,NJ 07065	Merck & Company; Merck & Company	WANG, RW (corresponding author), MERCK SHARP & DOHME LTD,DEPT ANIM & EXPLORATORY DRUG METAB,RY80A12,POB 2000,RAHWAY,NJ 07065, USA.							ADANG AEP, 1991, BIOCHEM J, V278, P63, DOI 10.1042/bj2780063; ADANG AEP, 1988, BIOCHEM J, V255, P721; ADANG AEP, 1989, BIOCHEM J, V264, P759, DOI 10.1042/bj2640759; ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; Asaoka K, 1989, J Enzyme Inhib, V3, P77, DOI 10.3109/14756368909030366; AWASTHI YC, 1987, BIOCHEM BIOPH RES CO, V143, P965, DOI 10.1016/0006-291X(87)90345-7; BENSON AM, 1977, P NATL ACAD SCI USA, V74, P158, DOI 10.1073/pnas.74.1.158; BENSON AM, 1976, BIOCHEM BIOPH RES CO, V69, P1073, DOI 10.1016/0006-291X(76)90482-4; BOYER TD, 1989, HEPATOLOGY, V9, P486, DOI 10.1002/hep.1840090324; CARNE T, 1979, BIOCHEM J, V177, P433, DOI 10.1042/bj1770433; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; CHEN WJ, 1988, BIOCHEMISTRY-US, V27, P647, DOI 10.1021/bi00402a023; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; COLLIER GS, 1979, BIOCHEM J, V179, P281, DOI 10.1042/bj1790281; DELBOCCIO G, 1991, J BIOL CHEM, V266, P13777; DESIDERI A, 1991, J BIOL CHEM, V266, P2063; DIRR HW, 1991, EUR J BIOCHEM, V196, P693, DOI 10.1111/j.1432-1033.1991.tb15867.x; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P3562, DOI 10.1021/bi00434a062; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HAYES JD, 1986, BIOCHEM J, V233, P779, DOI 10.1042/bj2330779; HSIEH JC, 1991, BIOCHEM J, V278, P293, DOI 10.1042/bj2780293; HUSKEY SEW, 1991, J AM CHEM SOC, V113, P2283, DOI 10.1021/ja00006a056; JAKOBY WB, 1984, BIOCHEM PHARMACOL, V33, P2539, DOI 10.1016/0006-2952(84)90621-X; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P63; KATUSZ RM, 1991, BIOCHEMISTRY-US, V30, P11230, DOI 10.1021/bi00111a006; KONG KH, 1992, BIOCHEM BIOPH RES CO, V182, P1122, DOI 10.1016/0006-291X(92)91848-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINEMEYER DL, 1987, BIO-TECHNOL, V5, P960, DOI 10.1038/nbt0987-960; LIU SX, 1992, J BIOL CHEM, V267, P4296; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1981, Methods Enzymol, V77, P231; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; REDDY CC, 1981, BIOCHEM BIOPH RES CO, V101, P970; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; SHEN HT, 1991, BIOCHEM BIOPH RES CO, V179, P790; STENBERG G, 1991, FEBS LETT, V293, P153, DOI 10.1016/0014-5793(91)81174-7; STENBERG G, 1991, BIOCHEM J, V274, P549, DOI 10.1042/bj2740549; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAMAI K, 1990, BIOCHEM BIOPH RES CO, V167, P331, DOI 10.1016/0006-291X(90)91769-O; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANOMMEN B, 1988, J BIOL CHEM, V263, P12939; VANOMMEN B, 1989, EUR J BIOCHEM, V181, P423; VINCENT SH, 1988, ARCH BIOCHEM BIOPHYS, V265, P539, DOI 10.1016/0003-9861(88)90159-2; VINCENT SH, 1985, J BIOL CHEM, V260, P4521; WANG RW, 1992, ARCH BIOCHEM BIOPHYS, V297, P86, DOI 10.1016/0003-9861(92)90644-C; WANG RW, 1989, ARCH BIOCHEM BIOPHYS, V269, P536, DOI 10.1016/0003-9861(89)90137-9; WANG RW, 1991, ARCH BIOCHEM BIOPHYS, V286, P574, DOI 10.1016/0003-9861(91)90082-T; WIDERSTEN M, 1991, FEBS LETT, V293, P156, DOI 10.1016/0014-5793(91)81175-8; ZHANG PH, 1991, J BIOL CHEM, V266, P19475	50	71	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19866	19871						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400302				2022-12-25	WOS:A1992JR85800021
J	RIM, M; QURESHI, SA; GIUS, D; NHO, J; SUKHATME, VP; FOSTER, DA				RIM, M; QURESHI, SA; GIUS, D; NHO, J; SUKHATME, VP; FOSTER, DA			EVIDENCE THAT ACTIVATION OF THE EGR-1 PROMOTER BY V-RAF INVOLVES SERUM RESPONSE ELEMENTS	ONCOGENE			English	Note							PROTEIN-KINASE-C; SIGNAL TRANSDUCTION; GENE-EXPRESSION; GROWTH-FACTORS; FOS; BINDING; PHOSPHORYLATION; ENCODES; FAMILY; CELLS	The constitutively active serine/threonine kinase encoded by the v-raf oncogene, v-Raf, activates the Egr-1 promoter in transient expression assays. To characterize the v-Raf-responsive transcriptional control elements, deletion mutants of the Egr-1 promoter were used in transient expression assays. A v-Raf expression vector was co-transfected into NIH3T3 cells with reporter chloramphenicol acetyl transferase (CAT) expression vectors under the control of the Egr-1 promoter or the Egr-1 promoter containing various deletions. Responsiveness to v-Raf was restricted to a region that contained repeated CC(A/T)6GG sequences, known as CArG boxes. CArG boxes form the core of serum response elements (SREs). v-Raf-induced Egr-I promoter activation was lost by removal of the four tandemly repeated SREs. This region, between - 425 and - 250, which was necessary for v-Raf responsiveness, was also found to be sufficient for maximal Egr-1 induction by v-Raf when placed upstream from a minimal heterologous promoter. Three out of four SREs from this region were able to respond to v-Raf, however the activation of the individual SREs was lower than the clustered SREs. This cluster of SREs has previously been shown to be responsive to several mitogenic stimuli and the oncogene v-src. Thus, the SREs contained in this cluster may be an important target for cell division signals.	CUNY HUNTER COLL, INST BIOMOLEC STRUCT & FUNCT, 695 PK AVE, NEW YORK, NY 10021 USA; UNIV CHICAGO, DEPT MED MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA; CUNY HUNTER COLL, DEPT BIOL SCI, NEW YORK, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY); University of Chicago; Howard Hughes Medical Institute; University of Chicago; City University of New York (CUNY) System; Hunter College (CUNY)			Sukhatme, Vikas/W-2776-2019		NATIONAL CANCER INSTITUTE [R29CA046677, R01CA046677] Funding Source: NIH RePORTER; NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RRO-3037-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; Battey, 1986, BASIC METHODS MOL BI; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; QURESHI SA, 1991, ONCOGENE, V6, P995; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2	27	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1992	7	10					2065	2068						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408148				2022-12-25	WOS:A1992JP42400022
J	ROBINSON, HL; TRACY, SE; NAIR, N; TAGLIENTISIAN, C; GAMETT, DC				ROBINSON, HL; TRACY, SE; NAIR, N; TAGLIENTISIAN, C; GAMETT, DC			CHARACTERIZATION FO AN ANGIOSARCOMA-INDUCING MUTATION IN THE ERBB ONCOGENE	ONCOGENE			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; GROWTH-FACTOR RECEPTOR; TISSUE-SPECIFIC TRANSFORMATION; C-ERBB; V-ERBB; TYROSINE KINASE; EGF RECEPTOR; CELLS; GENE; DOMAIN	The erbB oncogenes of two transducing viruses that arose in chicken 5005 have been molecularly characterized. One of these viruses, AEV-5005, caused erythroblastosis. The other, AAV-5005, caused angiosarcoma. Both viruses had identical 5' junctions of viral and host sequences, indicating that both arose from the same proviral insertion. The erbB oncogenes of both viruses encoded transmembrane, kinase and C-terminal domains of the chicken epidermal growth factor receptor. The C-terminal domain of the AEV-5005 erbB was complete, whereas that of AAV-5005 contained a 59 amino acid internal deletion (amino acids 993-1051 of the chicken epidermal growth factor receptor). Oncogenicity tests using retroviral constructs containing the erbB sequences from AEV-5005 and AAV-5005 demonstrated that both erbB genes caused erythroblastosis and that the 59 amino acid deletion conferred the ability to induce angiosarcoma. The 59 amino acid deletion also caused increased levels of erbB autophosphorylation in cells grown in the presence of sodium orthovanadate.	UNIV MASSACHUSETTS,MED CTR,DEPT MOLEC GENET & MICROBIOL,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester	ROBINSON, HL (corresponding author), UNIV MASSACHUSETTS,MED CTR,DEPT PATHOL,55 LAKE AVE N,WORCESTER,MA 01655, USA.			Tracy, Sharon/0000-0002-5731-5228	NATIONAL CANCER INSTITUTE [R01CA023086] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 23772, R01 CA 23086] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEUG H, 1986, J VIROL, V57, P1127, DOI 10.1128/JVI.57.3.1127-1138.1986; BRUSKIN A, 1990, ONCOGENE, V5, P15; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHOI OR, 1986, MOL CELL BIOL, V6, P1751, DOI 10.1128/MCB.6.5.1751; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; DEBUIRE B, 1984, SCIENCE, V224, P1456, DOI 10.1126/science.6328658; Enzinger FM, 1983, SOFT TISSUE TUMORS, V1, P422; GAMETT DC, 1986, P NATL ACAD SCI USA, V83, P6053, DOI 10.1073/pnas.83.16.6053; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; HIHARA H, 1983, J NATL CANCER I, V70, P891; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JANSSON M, 1987, ONCOGENE, V1, P167; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; MAIHLE N J, 1988, Biochimica et Biophysica Acta, V948, P287; MILES BD, 1985, J VIROL, V54, P295, DOI 10.1128/JVI.54.2.295-303.1985; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NAIR N, 1992, MOL CELL BIOL, V12, P2010, DOI 10.1128/MCB.12.5.2010; NILSEN TW, 1985, CELL, V41, P719, DOI 10.1016/S0092-8674(85)80052-0; PELLEY RJ, 1989, P NATL ACAD SCI USA, V86, P7164, DOI 10.1073/pnas.86.18.7164; PELLEY RJ, 1988, J VIROL, V62, P1840, DOI 10.1128/JVI.62.5.1840-1844.1988; RAINES MA, 1985, P NATL ACAD SCI USA, V82, P2287, DOI 10.1073/pnas.82.8.2287; RAINES MA, 1988, J VIROL, V62, P2444, DOI 10.1128/JVI.62.7.2444-2452.1988; ROBINSON HL, 1985, J VIROL, V55, P617, DOI 10.1128/JVI.55.3.617-622.1985; SASAKI T, 1984, J BIOL CHEM, V259, P2489; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SHU HKG, 1991, J VIROL, V65, P6173, DOI 10.1128/JVI.65.11.6173-6180.1991; SHU HKG, 1990, P NATL ACAD SCI USA, V87, P9103, DOI 10.1073/pnas.87.23.9103; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; THEROUX SJ, 1992, J BIOL CHEM, V267, P7967; TRACY SE, 1985, J VIROL, V54, P304, DOI 10.1128/JVI.54.2.304-310.1985; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VIJAYA S, 1986, J VIROL, V60, P683, DOI 10.1128/JVI.60.2.683-692.1986; WALTON GM, 1990, J BIOL CHEM, V265, P1750; YAMAMOTO T, 1983, CELL, V34, P225, DOI 10.1016/0092-8674(83)90153-8; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; YONEMOTO W, 1987, MOL CELL BIOL, V7, P905, DOI 10.1128/MCB.7.2.905	37	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2025	2030						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408143				2022-12-25	WOS:A1992JP42400017
J	GUPTAROY, B; COHEN, CM				GUPTAROY, B; COHEN, CM			MATURATION OF MURINE ERYTHROLEUKEMIA-CELLS COMMITTED TO DIFFERENTIATION REQUIRES PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; PHORBOL ESTER; HL-60 CELLS; ERYTHROID-DIFFERENTIATION; MONOCYTIC DIFFERENTIATION; TERMINAL DIFFERENTIATION; MOLECULAR HETEROGENEITY; CELLULAR-REGULATION; ADDITIONAL MEMBERS; MEMBRANE-PROTEINS	Treatment of murine erythroleukemia cells (MELC) attached to fibronectin-coated dishes with dimethyl sulfoxide causes the cells to become committed to the erythroid differentiation pathway. These cells mature extensively and acquire the characteristics of erythroid cells. The cells lose their cell-surface fibronectin receptors and accumulate red cell-specific membrane proteins, such as band 3, in amounts comparable to those in erythrocytes. Previous studies of MELC have shown that the presence of protein kinase C (PKC) is required for commitment to differentiation, but that the level of PKC activity declines progressively during maturation. In this study, we have established a role for PKC in the maturation of MELC committed to differentiation. Our results show that down-regulation of PKC by addition of phorbol 12-myristate 13-acetate (PMA) to committed MELC blocks subsequent maturation of the cells. Treatment of MELC with the PKC inhibitors H7 and sphingosine had similar effects. Down-regulation of PKC was assayed by measuring cytosolic PKC activity as well as by Western blotting using PKC antibodies. MELC maturation was monitored by loss of the cell-surface fibronectin receptor, release of cells from fibronectin plates, and accumulation of the band 3 anion transport protein. Immunoprecipitation of surface-labeled proteins by an anti-fibronectin receptor (integrin) antibody showed that PMA-treated cultures had more fibronectin receptor protein than untreated cultures 6 days post-induction. As a result, cultures of committed MELC treated with PMA remained attached to fibronectin-coated plates, whereas non-PMA-treated cells were released into the culture medium. Furthermore, PKC-depleted cells accumulated much smaller amounts of band 3 protein and band 3 mRNA than did non-PKC-depleted controls. Our results show that although PKC activity declines progressively during post-commitment maturation of MELC, its continued presence is critical for the process of cellular maturation.	TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02111	Tufts University; Tufts University	GUPTAROY, B (corresponding author), ST ELIZABETH HOSP,DEPT BIOMED RES,BOSTON,MA 02135, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024382] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 24382] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMO S, 1989, J CELL BIOL, V108, P153, DOI 10.1083/jcb.108.1.153; BALAZOVICH KJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P247, DOI 10.1016/0167-4889(87)90141-8; BERNARDI P, 1987, J CELL BIOL, V105, P489, DOI 10.1083/jcb.105.1.489; CHEN ZX, 1982, P NATL ACAD SCI-BIOL, V79, P471, DOI 10.1073/pnas.79.2.471; COHEN CM, 1986, J BIOL CHEM, V261, P7701; DANILOV YN, 1990, J BIOL CHEM, V265, P2556; DURHAM JP, 1985, FEBS LETT, V185, P157, DOI 10.1016/0014-5793(85)80761-4; FALETTO DL, 1985, CELL, V43, P315, DOI 10.1016/0092-8674(85)90037-6; FELIPO V, 1990, J BIOL CHEM, V265, P9599; FIBACH E, 1977, CANCER RES, V37, P440; GAZITT Y, 1978, CANCER RES, V38, P3779; GAZITT Y, 1978, EXP CELL RES, V117, P413, DOI 10.1016/0014-4827(78)90154-4; GODSON C, 1990, J BIOL CHEM, V265, P8369; GUSELLA J, 1976, CELL, V9, P211; HAGIWARA M, 1990, BIOCHEM BIOPH RES CO, V168, P161, DOI 10.1016/0006-291X(90)91688-O; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HENSOLD JO, 1991, BLOOD, V77, P1362; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOMMA Y, 1988, CANCER RES, V48, P2744; HUANG FL, 1987, J BIOL CHEM, V262, P15714; HUANG FL, 1989, J BIOL CHEM, V264, P4238; HUBBARD BD, 1979, J CELL BIOL, V80, P166, DOI 10.1083/jcb.80.1.166; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V125, P258, DOI 10.1016/S0006-291X(84)80362-9; KIKKAWA U, 1988, COLD SPRING HARB SYM, V53, P97, DOI 10.1101/SQB.1988.053.01.015; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; KIRSCH IR, 1985, LEUKEMIA RECENT ADV, P91; KONNO Y, 1989, J BIOCHEM-TOKYO, V106, P673, DOI 10.1093/oxfordjournals.jbchem.a122915; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNERT ME, 1988, J CELL BIOL, V107, P413, DOI 10.1083/jcb.107.2.413; LING E, 1988, J BIOL CHEM, V263, P2209; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYMAN GH, 1976, BIOCHIM BIOPHYS ACTA, V448, P460, DOI 10.1016/0005-2736(76)90300-X; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MARKS PA, 1987, CANCER RES, V47, P659; MARKS PA, 1990, TUMOR SUPPRESSOR GEN, P201; MELLONI E, 1987, P NATL ACAD SCI USA, V84, P5282, DOI 10.1073/pnas.84.15.5282; MELLONI E, 1989, J BIOL CHEM, V264, P18414; MIGNOTTE V, 1990, J BIOL CHEM, V265, P22090; MINANA MD, 1989, FEBS LETT, V255, P184, DOI 10.1016/0014-5793(89)81087-7; MULER CP, 1980, CELL BIOPHYS, V2, P233; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1987, FEBS LETT, V226, P125, DOI 10.1016/0014-5793(87)80564-1; PALFREY HC, 1985, J BIOL CHEM, V260, P6021; PATEL VP, 1987, J CELL BIOL, V105, P3105, DOI 10.1083/jcb.105.6.3105; PATEL VP, 1986, J CELL BIOL, V102, P449, DOI 10.1083/jcb.102.2.449; PATEL VP, 1985, P NATL ACAD SCI USA, V82, P440, DOI 10.1073/pnas.82.2.440; PATEL VP, 1984, SCIENCE, V224, P996, DOI 10.1126/science.6585955; PELOSIN JM, 1990, BIOCHEM BIOPH RES CO, V169, P1040, DOI 10.1016/0006-291X(90)91999-9; PFEFFER SR, 1981, BIOCHIM BIOPHYS ACTA, V641, P254, DOI 10.1016/0005-2736(81)90589-7; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; RAVAL PJ, 1985, BIOCHEM J, V232, P43, DOI 10.1042/bj2320043; RIFKIND RA, 1987, BLOOD CELLS, V13, P277; ROGUE P, 1990, J BIOL CHEM, V265, P4161; RUBEN RC, 1976, P NATL ACAD SCI USA, V73, P862; Sambrook J, 1989, MOL CLONING LABORATO; SEFTON BM, 1973, J VIROL, V11, P730, DOI 10.1128/JVI.11.5.730-735.1973; SELDEN RF, 1990, CURRENT PROTOCOLS MO; SMAL J, 1989, P NATL ACAD SCI USA, V86, P4705, DOI 10.1073/pnas.86.12.4705; STONE RM, 1988, BLOOD, V72, P739; STONE RM, 1988, BLOOD, V72, P208; STRULOVICI B, 1989, BIOCHEMISTRY-US, V28, P3569, DOI 10.1021/bi00434a063; TODOKORO K, 1986, BIOCHEM BIOPH RES CO, V135, P1112, DOI 10.1016/0006-291X(86)91043-0; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; TSIFTSOGLOU AS, 1985, INT J CELL CLONING, V3, P349, DOI 10.1002/stem.5530030602; VOLLOCH V, 1982, J CELL BIOL, V93, P390, DOI 10.1083/jcb.93.2.390; ZYLBERKATZ E, 1985, CANCER RES, V45, P5159	70	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15326	15333						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1386358				2022-12-25	WOS:A1992JG11300014
J	HIRATSUKA, T				HIRATSUKA, T			SPATIAL PROXIMITY OF ATP-SENSITIVE TRYPTOPHANYL RESIDUE(S) AND CYS-697 IN MYOSIN ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SKELETAL-MUSCLE MYOSIN; GLYCINE-RICH LOOP; ADENOSINE-TRIPHOSPHATASE; HEAVY-CHAIN; CROSS-LINKING; SUBFRAGMENT-1; FRAGMENT; PEPTIDE; TRANSMISSION	The reactive thiol Cys-697 (SH2) in myosin ATPase was labeled with a fluorescent analog of maleimide, 2-(4'-maleimidylanilino)naphthalene-6-sulfonic acid (MIANS) (Hiratsuka, T. (1992) J. Biol. Chem. 267, 14941-14948). Although the tryptophan fluorescence of myosin subfragment-1 (S-1) was slightly affected by incorporation of the MIANS fluorophore, the tryptophan fluorescence of the resultant S-1 derivative (MIANS-S-1) was enhanced by ATP in a manner similar to that of unlabeled S-1. The quenching of tryptophan fluorescence of MIANS-S-1 was shown to result from a transfer of the excitation energy from tryptophanyl residue(s) to the MIANS fluorophore attached to SH2, which absorbed and fluoresced maximally at 325 and 418 nm, respectively. The energy transfer measurements were performed in the presence of acrylamide and compared to those performed in the absence of the quencher. The energy transfer efficiencies were found to be unaltered by acrylamide, indicating that the observed fluorescence energy transfer is originated exclusively from the tryptophanyl residue(s) that are not affected by acrylamide, i.e. the ATP-sensitive tryptophanyl residue(s) of S-1 (Torgerson, P. M. (1984) Biochemistry 23,3002-3007). The distance between the tryptophanyl residue(s) and Cys-697 was calculated to be 27 angstrom assuming a single donor-acceptor pair. Trp-510 is proposed to be one of the ATP-sensitive tryptophanyl residues.			HIRATSUKA, T (corresponding author), ASAHIKAWA MED COLL,DEPT CHEM,ASAHIKAWA,HOKKAIDO 078,JAPAN.							BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; BALINT M, 1978, ARCH BIOCHEM BIOPHYS, V190, P793, DOI 10.1016/0003-9861(78)90339-9; BOTTS J, 1989, P NATL ACAD SCI USA, V86, P2204, DOI 10.1073/pnas.86.7.2204; CHANCE B, 1957, ARCH BIOCHEM BIOPHYS, V71, P130, DOI 10.1016/0003-9861(57)90015-2; CHAUSSEPIED P, 1988, BIOCHEMISTRY-US, V27, P1778, DOI 10.1021/bi00405a059; CREMO CR, 1989, J BIOL CHEM, V264, P6608; ELZINGA M, 1977, P NATL ACAD SCI USA, V74, P4281, DOI 10.1073/pnas.74.10.4281; Fairclough R H, 1978, Methods Enzymol, V48, P347; Forster T., 1966, MODERN QUANTUM CHEM, P93; HIRATSUKA T, 1986, BIOCHEMISTRY-US, V25, P2101, DOI 10.1021/bi00356a039; HIRATSUKA T, 1987, BIOCHEMISTRY-US, V26, P3168, DOI 10.1021/bi00385a034; HIRATSUKA T, 1988, BIOCHEMISTRY-US, V27, P4110, DOI 10.1021/bi00411a030; HIRATSUKA T, 1990, J BIOL CHEM, V265, P18791; HIRATSUKA T, 1992, J BIOL CHEM, V267, P14941; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; MORITA F, 1967, J BIOL CHEM, V242, P4501; OKAMOTO Y, 1985, P NATL ACAD SCI USA, V82, P1575, DOI 10.1073/pnas.82.6.1575; PERRY SV, 1955, METHOD ENZYMOL, V2, P582, DOI 10.1016/S0076-6879(55)02258-1; REISLER E, 1982, METHOD ENZYMOL, V85, P84; SEKINE T, 1964, BIOCHIM BIOPHYS ACTA, V81, P336, DOI 10.1016/0926-6569(64)90049-5; SUTOH K, 1988, BIOCHEMISTRY-US, V27, P2964, DOI 10.1021/bi00408a045; SUZUKI R, 1987, J BIOL CHEM, V262, P11410; TANII I, 1985, J BIOCHEM, V98, P1201, DOI 10.1093/oxfordjournals.jbchem.a135386; TONG SW, 1990, J BIOL CHEM, V265, P4893; TORGERSON PM, 1984, BIOCHEMISTRY-US, V23, P3002, DOI 10.1021/bi00308a024; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; UE K, 1987, BIOCHEMISTRY-US, V26, P1889, DOI 10.1021/bi00381a016; WAGNER PD, 1977, J MOL BIOL, V109, P455, DOI 10.1016/S0022-2836(77)80023-5; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WERBER MM, 1987, BIOCHEMISTRY-US, V26, P2903, DOI 10.1021/bi00384a035; WERBER MM, 1972, BIOCHEMISTRY-US, V11, P2872, DOI 10.1021/bi00765a021; YAMAGUCHI M, 1966, J BIOCHEM, V59, P24, DOI 10.1093/oxfordjournals.jbchem.a128254; YAMASHITA T, 1974, J BIOCHEM, V75, P447, DOI 10.1093/oxfordjournals.jbchem.a130413	35	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14949	14954						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1386083				2022-12-25	WOS:A1992JF08800068
J	SCHLEMMER, SR; SIROTNAK, FM				SCHLEMMER, SR; SIROTNAK, FM			ENERGY-DEPENDENT EFFLUX OF METHOTREXATE IN L1210 LEUKEMIA-CELLS - EVIDENCE FOR THE ROLE OF AN ATPASE OBTAINED WITH INSIDE-OUT PLASMA-MEMBRANE VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLATE ANALOG TRANSPORT; TUMOR-CELLS; MULTIDRUG-RESISTANCE; GENETIC-VARIANTS; IDENTIFICATION; INHIBITION; PROTEINS; SYSTEMS; INVITRO; INFLUX	Earlier studies from our laboratory (Dembo, M., Sirotnak F. M., and Moccio, D. M. (1984) J. Membr. Biol. 78, 9-17) suggested that methotrexate (MTX) efflux from L1210 cells was mediated predominantly by an ATP-dependent, outwardly directed, mechanism. To examine this process further, we utilized predominately (74%) inside-out plasma membrane vesicle preparations derived from an L1210 cell variant (L1210/R24) with 15-fold reduced V(max) for [H-3]MTX influx. Efflux of [H-3]MTX, under nonionic buffer conditions, in these inside-out membrane vesicles was temperature and ATP dependent (apparent K(m) = 0.40 +/- 0.06 mM), osmotically sensitive, and unaffected by protonophores. The presence of K+, Na+, Cl-, and HCO3- at their physiological concentrations had no effect on [H-3] MTX efflux. Other triphosphonucleotides (GTP and CTP), but not a nonhydrolyzable analogue, adenosine-5'-O-(3-thiotriphosphate) (ATP-gamma-S), could also stimulate efflux, but to a lesser extent. Also, ATP-gamma-S and orthovanadate were potent inhibitors of ATP-dependent efflux of [H-3]MTX. Other experiments revealed a system with low saturability for [H-3]MTX during efflux (apparent K(m) = 46 +/- 7-mu-M), but extremely high capacity (106 +/- 15 pmol/min/mg protein), and a pH optimum in the range of 5.5-6. However, appreciable efflux was measured in the physiological range of pH 6.7-6.9. A number of inhibitors or copermeants for ATP-dependent [H-3]MTX efflux in intact L1210 cells were inhibitors of ATP-dependent efflux in inside-out plasma membrane vesicles, including, cholate, bromosulfophthalein, verapamil, quinidine, and reserpine. These findings and other results showing that bromosulfophthalein will completely inhibit efflux are consistent with a role for an ATPase in [H-3]MTX efflux, and suggest that the process under study is the bromosulfophthalein-sensitive, ATP-dependent route responsible for the majority of [H-3]MTX efflux in intact L1210 cells.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC PHARMACOL & THERAPEUT,MOLEC THERAPEUT LAB,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,ITHACA,NY 14853	Memorial Sloan Kettering Cancer Center; Cornell University					NATIONAL CANCER INSTITUTE [R01CA046673, P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [CA 46673, CA 08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BIEDLER JL, 1983, CANCER TREAT REP, V67, P859; BRANDENBERGER H, 1953, HELV CHIM ACTA, V36, P900, DOI 10.1002/hlca.19530360422; CHELLO PL, 1980, MOL PHARMACOL, V18, P274; DEMBO M, 1984, J MEMBRANE BIOL, V78, P9, DOI 10.1007/BF01872527; DEMBO M, 1976, BIOCHIM BIOPHYS ACTA, V448, P505, DOI 10.1016/0005-2736(76)90303-5; DEPIERRE JW, 1973, J CELL BIOL, V56, P275, DOI 10.1083/jcb.56.2.275; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GAREN A, 1960, BIOCHIM BIOPHYS ACTA, V38, P470, DOI 10.1016/0006-3002(60)91282-8; GOLDMAN ID, 1969, J BIOL CHEM, V244, P3779; GOLDMAN ID, 1971, ANN NY ACAD SCI, V186, P400; GREEN DE, 1955, J BIOL CHEM, V217, P551; HAKALA MT, 1965, BIOCHIM BIOPHYS ACTA, V102, P210, DOI 10.1016/0926-6585(65)90214-1; HENDERSON GB, 1988, CANCER RES, V48, P5995; HENDERSON GB, 1990, BIOCHIM BIOPHYS ACTA, V1051, P60, DOI 10.1016/0167-4889(90)90174-C; HENDERSON GB, 1984, J BIOL CHEM, V259, P1526; HENDERSON GB, 1987, J BIOL CHEM, V262, P571; HISSIN PJ, 1978, BIOCHIM BIOPHYS ACTA, V508, P401, DOI 10.1016/0005-2736(78)90342-5; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P693; KREBS EG, 1955, METHOD ENZYMOL, V1, P407, DOI 10.1016/0076-6879(55)01066-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARIN R, 1986, BIOCHIM BIOPHYS ACTA, V858, P195, DOI 10.1016/0005-2736(86)90306-8; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; NEWKIRK JD, 1971, BIOCHIM BIOPHYS ACTA, V225, P224, DOI 10.1016/0005-2736(71)90215-X; ROBINSON JD, 1979, BIOCHIM BIOPHYS ACTA, V549, P145, DOI 10.1016/0304-4173(79)90013-2; SAMUELS LL, 1985, CANCER RES, V45, P1488; SIMONS TJB, 1979, NATURE, V281, P337, DOI 10.1038/281337a0; SIROTNAK FM, 1985, CANCER RES, V45, P4732; SIROTNAK FM, 1981, CANCER RES, V41, P966; SIROTNAK FM, 1974, CANCER RES, V34, P371; SIROTNAK FM, 1991, CANCER RES, V51, P1412; SIROTNAK FM, 1980, PHARMACOL THERAPEUT, V8, P71, DOI 10.1016/0163-7258(80)90060-1; SIROTNAK FM, 1984, J BIOL CHEM, V259, P3139; SIROTNAK FM, 1986, J BIOL CHEM, V261, P1150; SIROTNAK FM, 1987, BIOCHEM PHARMACOL, V36, P1659, DOI 10.1016/0006-2952(87)90051-7; YANG CH, 1983, J MEMBRANE BIOL, V75, P11, DOI 10.1007/BF01870795; YANG CH, 1982, J MEMBRANE BIOL, V68, P19, DOI 10.1007/BF01872250; YANG CH, 1988, J BIOL CHEM, V263, P9703	42	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14746	14752						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1386081				2022-12-25	WOS:A1992JF08800039
J	HURST, RS; KAVANAUGH, MP; YAKEL, J; ADELMAN, JP; NORTH, RA				HURST, RS; KAVANAUGH, MP; YAKEL, J; ADELMAN, JP; NORTH, RA			COOPERATIVE INTERACTIONS AMONG SUBUNITS OF A VOLTAGE-DEPENDENT POTASSIUM CHANNEL - EVIDENCE FROM EXPRESSION OF CONCATENATED CDNAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE ION CHANNELS; AMINO-ACID-RESIDUES; SHAKER K+-CHANNELS; XENOPUS OOCYTES; MUTATIONS; S4-SEQUENCE	Four copies of the coding sequence for a voltage-dependent potassium channel (RBK1, rat Kv1.1) were ligated contiguously and transcribed in vitro. The resulting RNA encodes four covalently linked subunit domains ([4]RBK1). Injection of this RNA into Xenopus oocytes resulted in the expression of voltage-dependent potassium currents. A single amino acid substitution, Tyr --> Val, located within the outer mouth of the pore, introduced into the equivalent position of any of the four domains, reduced affinity for external tetraethylammonium by approximately the same amount. In constructs containing 0, 1, 2, 3, or 4 Tyr residues the free energy of binding tetraethylammonium was linearly related to the number of Tyr residues. A different amino acid substitution, Leu --> Ile, located in the S4 region, was made in the equivalent position of one, two, three, or four domains. The depolarization required for channel activation increased approximately linearly with the number of Ile residues, whereas models of independent gating of each domain predict marked nonlinearity. Expression of this concatenated channel provides direct evidence that voltage-dependent potassium channels have four subunits positioned symmetrically around a central permeation pathway and that these subunits interact cooperatively during channel activation.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT CELL BIOL & ANAT,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University			North, Richard/GQA-6156-2022	Yakel, Jerrel/0000-0001-5463-674X	NIDA NIH HHS [DA03160] Funding Source: Medline; NINDS NIH HHS [NS28504] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028504] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003160, R37DA003160] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; BECKH S, 1990, EMBO J, V9, P777, DOI 10.1002/j.1460-2075.1990.tb08173.x; BEZANILLA F, 1991, SCIENCE, V254, P679, DOI 10.1126/science.1948047; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHANDY KG, 1991, NATURE, V352, P26, DOI 10.1038/352026b0; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; DREWE JA, 1992, J NEUROSCI, V12, P538; DURELL SR, 1992, BIOPHYS J, V62, P243; GIUDICIORTICONI MT, 1990, EUR J BIOCHEM, V194, P483, DOI 10.1111/j.1432-1033.1990.tb15642.x; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HURST RS, 1991, MOL PHARMACOL, V40, P572; ISAACOFF EY, 1990, NATURE, V345, P530; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KAVANAUGH MP, 1991, J BIOL CHEM, V266, P7583; LOPEZ GA, 1991, NEURON, V7, P327, DOI 10.1016/0896-6273(91)90271-Z; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5	26	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23742	23745						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385425				2022-12-25	WOS:A1992JZ23900049
J	MA, WJ; HOLZ, RW; UHLER, MD				MA, WJ; HOLZ, RW; UHLER, MD			EXPRESSION OF A CDNA FOR A NEURONAL CALCIUM-CHANNEL ALPHA-1 SUBUNIT ENHANCES SECRETION FROM ADRENAL CHROMAFFIN CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; HUMAN GROWTH-HORMONE; FUNCTIONAL EXPRESSION; SKELETAL-MUSCLE; GENE-EXPRESSION; CA2+ CHANNELS; IDENTIFICATION; EXOCYTOSIS; ACTIVATION; RECEPTOR	A synthetic oligonucleotide was used to isolate mouse brain cDNA clones coding for a brain isoform of the alpha1 subunit of the voltage-sensitive Ca2+ channel. Twenty-six independent cDNA clones were isolated and sequenced. All the cDNA clones reported here showed high homology to the rat brain class C cDNA sequence (Snutch, T. P., Tomlinson, W. J., Leonard, J. P., and Gilbert, M. M. (1991) Neuron 7, 45-57). Comparison of the individual mouse brain class C (mbC) cDNA sequences indicated the presence of four regions within the alpha1 subunit coding sequence where alternative splicing can take place in mouse brain and raise the possibility that combinatorial arrangement of these splice variants could give rise to a heterogenous class of mbC transcripts. Northern blot analysis demonstrated that mbC mRNA sequences could be detected in highest abundance in mouse heart, at lower levels in mouse brain and spinal cord, and not at all in liver or skeletal muscle. An expression vector for one isoform of the mbC alpha1 subunit cDNA was constructed using the human cytomegalovirus promoter to direct expression, and this expression vector was used in a novel transfection assay of primary cultures of bovine adrenal chromaffin cells. Transfection of the mbC alpha1 subunit expression vector increased the secretion of human growth hormone derived from a cotransfected human growth hormone expression vector after stimulation with elevated K+ or the dihydropyridine agonist, Bay K8644. These experiments suggest that this isoform of the mbC alpha1 subunit is functional in the transfected chromaffin cells and that the number of Ca2+ channels is a limiting component in the secretion from chromaffin cells in culture.	UNIV MICHIGAN, MENTAL HLTH RES INST, 205 ZINA PITCHER PL, ANN ARBOR, MI 48109 USA; CHINESE ACAD SCI, SHANGHAI INST MATERIA MED, SHANGHAI, PEOPLES R CHINA; UNIV MICHIGAN, DEPT PHARMACOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Shanghai Institutes for Biological Sciences, CAS; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027959] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK27959] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atlas D, 1990, Curr Top Cell Regul, V31, P129; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; BURGOYNE RD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P174, DOI 10.1016/0304-4157(91)90024-Q; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CATTERALL WA, 1991, SCIENCE, V253, P1499, DOI 10.1126/science.1654596; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CURTIS BM, 1985, P NATL ACAD SCI USA, V82, P2528, DOI 10.1073/pnas.82.8.2528; DAY RN, 1990, MOL ENDOCRINOL, V4, P736, DOI 10.1210/mend-4-5-736; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIEBOLD RJ, 1992, P NATL ACAD SCI USA, V89, P1497, DOI 10.1073/pnas.89.4.1497; HOLZ RW, 1982, J NEUROCHEM, V39, P635, DOI 10.1111/j.1471-4159.1982.tb07940.x; HOLZ RW, 1991, ANN NY ACAD SCI, V635, P382, DOI 10.1111/j.1749-6632.1991.tb36506.x; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILLER RJ, 1990, FASEB J, V4, P3291, DOI 10.1096/fasebj.4.15.1979294; MILLER RJ, 1992, J BIOL CHEM, V267, P1403; MOORE HPH, 1985, J CELL BIOL, V101, P1773, DOI 10.1083/jcb.101.5.1773; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; OLSEN SR, 1991, J BIOL CHEM, V266, P11158; ROSS ME, 1990, J NEUROSCI, V10, P520; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEITZER ES, 1985, J CELL BIOL, V101, P667, DOI 10.1083/jcb.101.2.667; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; TERBUSH DR, 1990, J BIOL CHEM, V265, P21179; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; WAYMIRE JC, 1983, J NEUROSCI METH, V7, P329, DOI 10.1016/0165-0270(83)90026-2	32	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22728	22732						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1385406				2022-12-25	WOS:A1992JY16300008
J	FURUKAWA, S; SAKATA, N; GINSBERG, HN; DIXON, JL				FURUKAWA, S; SAKATA, N; GINSBERG, HN; DIXON, JL			STUDIES OF THE SITES OF INTRACELLULAR DEGRADATION OF APOLIPOPROTEIN-B IN HEP G2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CULTURED RAT HEPATOCYTES; BREFELDIN-A; ENDOPLASMIC-RETICULUM; COMBINED HYPERLIPIDEMIA; PROTEIN-DEGRADATION; GOLGI PROTEINS; OLEIC-ACID; APO-B; SECRETION	We previously reported that treatment of Hep G2 cells with oleate significantly increased apolipoprotein B (apoB) secretion by reducing early intracellular degradation of nascent apoB. In the current study, inhibitors of secretory protein transport (brefeldin A and monensin), cell fractionation studies, and protease protection assays were utilized to determine the location of apoB degradation and to better define the mechanism whereby oleate treatment reduces nascent apoB intracellular degradation. When cells were treated with brefeldin A, which blocks endoplasmic reticulum (ER) to Golgi protein transport, apoB degradation continued in control cells, suggesting that apoB is degraded in the ER. When oleate-treated cells were blocked with brefeldin A, oleate failed to protect apoB from intracellular degradation. The effects of brefeldin A were not due to effects on lipid synthesis as brefeldin A did not inhibit the synthesis of triglyceride, phospholipid, free cholesterol, or cholesteryl ester in control cells and did not prevent the increases in triglyceride (14-fold) and phospholipid (1.4-fold) synthesis seen in oleate-treated cells. Simultaneous treatment of cells with brefeldin A and nocodazole, which inhibits retrograde transport of proteins from Golgi to ER, added to the evidence for the ER as the site of apoB degradation. This conclusion received further support from experiments in which cells were treated with monensin, a Na+ ionophore which halts protein secretion at the level of the trans-Golgi network. Early degradation of nascent apoB (between 10 and 20 min of chase) was observed in monensin-treated cells, but then cellular apoB degradation ceased and apoB was stable during the remaining chase period. More apoB accumulated in the Golgi of cells that had been treated with oleate and monensin. These results suggest that ER degradation occurs in monensin-treated cells, but then stops as apoB is transferred to the Golgi. The results obtained in whole cells were confirmed in studies using isolated ER and Golgi, which indicated that ER contains a proteolytic activity which degrades apoB, in vitro, whereas Golgi does not. ApoB degradation in isolated ER was not reduced by pretreatment with oleate. Finally, protease protection assays carried out with isolated microsomes indicated that a majority of the apoB in both control or oleate-treated HepG2 cells was located on the cytosolic side of the membranes. Taken together, these results indicate that the rapid intracellular degradation of nascent apoB in HepG2 occurs in the ER, and suggest that the oleate treatment may prevent the interaction of an ER-associated protease with apoB during a vulnerable time period as the nascent protein associates with lipid and moves to the Golgi.			FURUKAWA, S (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032, USA.		Sakata, Nobuhiro/ACN-9770-2022		NHLBI NIH HHS [HL-36000, HL-47586, HL-21006] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL047586, P50HL021006, R01HL036000, R01HL047586] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAD Y, 1990, J LIPID RES, V31, P567; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1990, J BIOL CHEM, V265, P10556; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BRUNING A, 1992, J BIOL CHEM, V267, P5052; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CLADARAS C, 1986, EMBO J, V5, P3495, DOI 10.1002/j.1460-2075.1986.tb04675.x; DAVIS RA, 1989, J LIPID RES, V30, P1185; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; DIXON JL, 1992, J CELL BIOL, V117, P1161, DOI 10.1083/jcb.117.6.1161; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; FUJIWARA T, 1989, CELL STRUCT FUNCT, V14, P605, DOI 10.1247/csf.14.605; GIBSON JC, 1983, J LIPID RES, V24, P886; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GRINDE B, 1983, EXP CELL RES, V149, P27, DOI 10.1016/0014-4827(83)90377-4; JANUS ED, 1980, EUR J CLIN INVEST, V10, P161, DOI 10.1111/j.1365-2362.1980.tb02076.x; KISSEBAH AH, 1981, METABOLISM, V30, P856, DOI 10.1016/0026-0495(81)90064-0; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; ODA K, 1990, BIOCHEM J, V265, P161, DOI 10.1042/bj2650161; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; PULLINGER CR, 1989, J LIPID RES, V30, P1065; SATO R, 1990, J BIOL CHEM, V265, P11880; TABAS I, 1988, J BIOL CHEM, V263, P1266; TENG B, 1986, J CLIN INVEST, V77, P663, DOI 10.1172/JCI112360; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YU S, 1983, J BIOL CHEM, V258, P3407	38	130	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22630	22638						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429611				2022-12-25	WOS:A1992JW71900099
J	HILL, E; MACLOUF, J; MURPHY, RC; HENSON, PM				HILL, E; MACLOUF, J; MURPHY, RC; HENSON, PM			REVERSIBLE MEMBRANE ASSOCIATION OF NEUTROPHIL 5-LIPOXYGENASE IS ACCOMPANIED BY RETENTION OF ACTIVITY AND A CHANGE IN SUBSTRATE-SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE 5-LIPOXYGENASE; LEUKOTRIENE SYNTHESIS INHIBITORS; PROTEIN; TRANSLOCATION; BIOSYNTHESIS; CELLS	Ionophore activation of the human polymorphonuclear neutrophil results in eicosanoid synthesis and the accumulation of inactive 5-lipoxygenase in a membrane compartment. We report here that inhibition of self-inactivation of 5-lipoxygenase in ionophore-treated neutrophils with the reversible inhibitor zileuton, results in the accumulation of active 5-lipoxygenase in the membrane fraction. In zileuton plus ionophore-treated cells, 77% of the specific activity of the cytosolic enzyme from resting cells was diverted to the membrane fraction compared to 22% of the activity translocated when ionophore alone was used to activate the neutrophils. Accumulation of active membrane-associated 5-lipoxygenase was inhibited and reversed by the 5-lipoxygenase translocation inhibitor MK-886. The membrane-associated 5-lipoxygenase was two times more efficient in the production of leukotriene A4 from arachidonate-derived 5-hydroperoxyeicosatetraenoic acid than the cytosolic enzyme. Unlike the cytosolic enzyme, membrane-associated 5-lipoxygenase could metabolize 12(S)- and 15(S)-hydroxyeicosatetraenoic acid to 5(S),12(S)- and 5(S),15(S)-dihydroxyeicosatetraenoic acid, respectively. The ability to metabolize hydroxy fatty acids was dependent upon 5-lipoxygenase-activating protein association, but was lost if 5-lipoxygenase was eluted from the membrane by MK-886. These studies reveal for the first time that significant quantities of active 5-lipoxygenase can be detected in the membrane fraction of activated neutrophils and show that membrane association can alter the substrate specificity of 5-lipoxygenase which is further evidence for the role of the membrane-associated enzyme in the synthesis of 5-lipoxygenase metabolites.	NATL JEWISH CTR IMMUNOL & RESP MED, 1400 JACKSON ST, DENVER, CO 80206 USA; HOP LARIBOISIERE, INSERM, U348, F-75475 PARIS 10, FRANCE	National Jewish Health; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Murphy, Robert/AAO-5349-2020	Murphy, Robert/0000-0002-9430-6515	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL34303] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BORGEAT P, 1982, PROSTAGLANDINS, V23, P713, DOI 10.1016/S0090-6980(82)80009-9; BORGEAT P, 1982, LEUKOTRIENES OTHER L, P45; CARTER GW, 1991, J PHARMACOL EXP THER, V256, P929; COFFEY M, 1992, J BIOL CHEM, V267, P570; DENIS D, 1991, J BIOL CHEM, V266, P5072; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; EVANS JF, 1991, MOL PHARMACOL, V40, P22; FITZPATRICK F, 1984, J BIOL CHEM, V259, P1403; FORDHUTCHINSON AW, 1989, LEUKOTRIENES LIPOXYG, P405; HASLETT C, 1985, AM J PATHOL, V119, P101; KARGMAN S, 1991, J BIOL CHEM, V266, P23745; MACLOUF J, 1989, BLOOD, V74, P703; MANCINI JA, 1992, MOL PHARMACOL, V41, P267; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; REID GK, 1990, J BIOL CHEM, V265, P19818; ROUZER CA, 1987, P NATL ACAD SCI USA, V84, P7393, DOI 10.1073/pnas.84.21.7393; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; ROUZER CA, 1990, J BIOL CHEM, V265, P1436; ROUZER CA, 1988, J BIOL CHEM, V263, P10135; ROUZER CA, 1988, ANN NY ACAD SCI, V524, P1; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; UEDA N, 1986, J BIOL CHEM, V261, P7982; WONG A, 1988, BIOCHEMISTRY-US, V27, P6763, DOI 10.1021/bi00418a018	23	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22048	22053						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429555				2022-12-25	WOS:A1992JW71900013
J	DURONIO, V; CLARKLEWIS, I; FEDERSPPIEL, B; WIELER, JS; SCHRADER, JW				DURONIO, V; CLARKLEWIS, I; FEDERSPPIEL, B; WIELER, JS; SCHRADER, JW			TYROSINE PHOSPHORYLATION OF RECEPTOR BETA SUBUNITS AND COMMON SUBSTRATES IN RESPONSE TO INTERLEUKIN-3 AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GM-CSF RECEPTOR; GROWTH FACTOR-I; EXPRESSION CLONING; MOLECULAR-CLONING; INSULIN-RECEPTOR; GENE FAMILY; HEMATOPOIETIC-CELLS; SIGNAL TRANSDUCTION; ALPHA-CHAIN; PROTEIN	The receptors for interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF) consist of two polypeptides each belonging to a new class of molecules referred to as the hemopoietin receptor family. When expressed alone, receptor polypeptides of this family often bind their respective factors with lower affinity than the receptors identified in whole cells. Despite the lack of structural evidence for any enzymatic activity of the receptor polypeptides, both IL-3 and GM-CSF stimulate tyrosine phosphorylation of multiple intracellular substrates. We investigated IL-3 and GM-CSF receptor structure and signaling in a myeloid cell line, FDC-P1, which is dependent on either IL-3 or GM-CSF for growth. Antiphosphotyrosine antibodies were used to immunoprecipitate tyrosine-phosphorylated proteins from P-32-labeled cells or to probe immunoblots. Both IL-3 and GM-CSF stimulated the phosphorylation of a similar pattern of polypeptides on tyrosine. One tyrosine phosphorylated polypeptide migrated with M(r) = 135,000 and increased to 150,000 over a period of 10 min following stimulation of cells with IL-3 or GM-CSF. The M(r) = 135,000-150,000 polypeptide phosphorylated in response to IL-3 was shown to be primarily the Aic-2A polypeptide, the low affinity IL-3 receptor. Phosphatase treatment showed that the dramatic IL-3-induced shift in apparent molecular weight from M(r) = 125,000 in unstimulated cells was entirely due to phosphorylation. The closely related receptor, Aic-2B, was also tyrosine phosphorylated in response to IL-3, although to a lesser extent than Aic-2A. Treatment with GM-CSF resulted in tyrosine phosphorylation of the Aic-2B polypeptide exclusively. It was intriguing that GM-CSF treatment did affect the mobility of the Aic-2A polypeptide on polyacrylamide gels. Together, these results suggest that the Aic-2A polypeptide is part of the IL-3 receptor complex, but not the GM-CSF receptor. In contrast, the Aic-2B polypeptide is a component of the GM-CSF receptor, but it can also be utilized in an IL-3 receptor.	UNIV BRITISH COLUMBIA, DEPT MED, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT BIOCHEM, VANCOUVER V6T 1Z3, BC, CANADA	University of British Columbia; University of British Columbia	DURONIO, V (corresponding author), UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER V6T 1Z3, BC, CANADA.							BALLOTTI R, 1989, EMBO J, V8, P3303, DOI 10.1002/j.1460-2075.1989.tb08491.x; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BEGUINOT F, 1988, BIOCHEMISTRY-US, V27, P3222, DOI 10.1021/bi00409a015; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; CLARKLEWIS I, 1984, J BIOL CHEM, V259, P7488; CLARKLEWIS I, 1988, J IMMUNOL, V141, P881; CLARKLEWIS I, 1986, SCIENCE, V231, P134, DOI 10.1126/science.3079915; CLARKLEWIS I, 1990, PEPTIDES STRUCTURE B, P749; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS R, 1991, EMBO J, V10, P2133, DOI 10.1002/j.1460-2075.1991.tb07747.x; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DURONIO V, 1990, BIOCHEM J, V270, P27, DOI 10.1042/bj2700027; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; DURONIO V, 1992, EXP HEMATOL, V20, P505; DURONIO V, 1988, RECEPTOR BIOCH MET B, V12, P3; EVANS JPM, 1990, BLOOD, V75, P88; FARRAR W L, 1990, Cytokine, V2, P77, DOI 10.1016/1043-4666(90)90001-A; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KANAKURA Y, 1990, BLOOD, V76, P706; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; LOPEZ AF, 1989, P NATL ACAD SCI USA, V86, P7022, DOI 10.1073/pnas.86.18.7022; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; PARK LS, 1989, J BIOL CHEM, V264, P5420; QUELLE FW, 1991, J BIOL CHEM, V266, P609; SCHREURS J, 1991, INT IMMUNOL, V3, P1231, DOI 10.1093/intimm/3.12.1231; SORENSEN P, 1989, J BIOL CHEM, V264, P19253; SORENSEN PHB, 1989, BLOOD, V73, P406; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WELHAM MJ, 1992, IN PRESS J IMMUNOL; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YARDEN Y, 1988, BIOCHEMISTRY-US, V27, P3113, DOI 10.1021/bi00409a001; ZILTENER HJ, 1987, J IMMUNOL, V138, P1099	52	88	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21856	21863						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400495				2022-12-25	WOS:A1992JV01100092
J	KIKUCHI, K; BICHELL, DP; ROTWEIN, P				KIKUCHI, K; BICHELL, DP; ROTWEIN, P			CHROMATIN CHANGES ACCOMPANY THE DEVELOPMENTAL ACTIVATION OF INSULIN-LIKE GROWTH-FACTOR I GENE-TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACIDS; PLASMA SOMATOMEDIN-C; SERUM-ALBUMIN GENE; IGF-I; HYPOPHYSECTOMIZED RATS; DNA FRAGMENTS; TISSUE CONCENTRATIONS; HYPERSENSITIVE SITES; STIMULATES GROWTH; FACTOR (IGF)-I	Insulin-like growth factor I (IGF-I) is a potent regulator of postnatal growth in mammals, yet little is known about the developmental control of IGF-I synthesis. We have investigated the regulation of IGF-I expression in the rat in order to gain insight into the mechanisms of growth factor induction during early postnatal life. Steady-state levels of liver IGF-I mRNA increased by more than 15-fold during the period from fetal day 18 to postnatal day 7 and reached 50% of adult values by day 14. Transcription run-on experiments using isolated hepatic nuclei and direct analysis of nuclear RNA each demonstrated a comparable rise in nascent IGF-I mRNA over the same time period. Over 90% of transcripts were directed by promoter 1, the more 5' of the two IGF-I gene promoters. By contrast IGF-II gene transcription rates and mRNA levels fell during the first 3 weeks after birth, and albumin expression rose slightly. Analysis of chromatin structure around the IGF-I gene revealed 15 DNase I-hypersensitive sites in adult rat liver in the 120 kilobases (kb) comprising the 6 exon gene and its flanking regions (8 sites within 10 kb at the 5'-end including exons 1-3, 5 sites in the 50-kb third intron, and 2 sites in the 15-kb fifth intron). During development there was a progressive appearance of DNase I-hypersensitive sites that coincided with activation of IGF-I gene expression. One site that became fully hypersensitive by postnatal day 7 was mapped by in vivo DNAse I footprinting to the proximal 200 nucleotides of promoter 1. Since serum IGF-I values rose from 10 to 120 mug/liter during the initial postnatal week, these results indicate that transcriptional mechanisms are principally responsible for the stimulation of IGF-I synthesis that occurs shortly after birth. Because discrete changes in chromatin organization coincided with induction of IGF-I gene transcription, it is likely that a series of developmentally modulated transcription factors are involved the activation process.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT SURG,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	KIKUCHI, K (corresponding author), WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,ST LOUIS,MO 63110, USA.		Rotwein, Peter/R-5783-2019	Rotwein, Peter/0000-0002-9505-1817; Bichell, David/0000-0003-0227-1771	NATIONAL CANCER INSTITUTE [T32CA009621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037449, P60DK020579, P30DK020579] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09621] Funding Source: Medline; NIDDK NIH HHS [5-RO1-DK37449, DK20579] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMO M, 1989, ENDOCRINOLOGY, V124, P2737, DOI 10.1210/endo-124-6-2737; ADAMO ML, 1991, MOL ENDOCRINOL, V5, P1677, DOI 10.1210/mend-5-11-1677; ADAMO ML, 1991, BIOCHEM BIOPH RES CO, V176, P887, DOI 10.1016/S0006-291X(05)80269-4; BABISS LE, 1986, P NATL ACAD SCI USA, V83, P6504, DOI 10.1073/pnas.83.17.6504; BROWN AL, 1986, J BIOL CHEM, V261, P3144; BUCCI C, 1989, NUCLEIC ACIDS RES, V17, P3596, DOI 10.1093/nar/17.9.3596; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAUGHADAY WH, 1982, ENDOCRINOLOGY, V110, P575, DOI 10.1210/endo-110-2-575; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DERCOLE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P935, DOI 10.1073/pnas.81.3.935; DONOVAN SM, 1991, ENDOCRINOLOGY, V129, P149, DOI 10.1210/endo-129-1-149; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; EMLER CA, 1987, ENDOCRINOLOGY, V120, P832, DOI 10.1210/endo-120-2-832; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GRIFFEN SC, 1987, P NATL ACAD SCI USA, V84, P7300, DOI 10.1073/pnas.84.20.7300; GULER HP, 1988, P NATL ACAD SCI USA, V85, P4889, DOI 10.1073/pnas.85.13.4889; HALL LJ, 1992, DNA CELL BIOL, V11, P301, DOI 10.1089/dna.1992.11.301; HOYT EC, 1988, MOL ENDOCRINOL, V2, P1077, DOI 10.1210/mend-2-11-1077; HYNES MA, 1987, MOL ENDOCRINOL, V1, P233, DOI 10.1210/mend-1-3-233; ISGAARD J, 1988, ENDOCRINOLOGY, V123, P2605, DOI 10.1210/endo-123-6-2605; JAGODZINSKI LL, 1981, P NATL ACAD SCI-BIOL, V78, P3521, DOI 10.1073/pnas.78.6.3521; Jost A, 1979, Contrib Gynecol Obstet, V5, P1; LOWE WL, 1988, MOL ENDOCRINOL, V2, P528, DOI 10.1210/mend-2-6-528; LUND PK, 1989, MOL ENDOCRINOL, V3, P2054, DOI 10.1210/mend-3-12-2054; MAES M, 1983, J ENDOCRINOL, V97, P243, DOI 10.1677/joe.0.0970243; MAES M, 1984, ENDOCRINOLOGY, V115, P786, DOI 10.1210/endo-115-2-786; MARZLUFF WF, 1984, TRANSCRIPTION TRANSL, P95; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P433, DOI 10.1210/endo-123-1-433; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1279, DOI 10.1210/endo-120-4-1279; MURPHY LJ, 1987, ENDOCRINOLOGY, V121, P684, DOI 10.1210/endo-121-2-684; NORSTEDT G, 1988, CARCINOGENESIS, V9, P209, DOI 10.1093/carcin/9.2.209; REIK A, 1991, EMBO J, V10, P2569, DOI 10.1002/j.1460-2075.1991.tb07797.x; Rotwein P, 1991, Growth Factors, V5, P3, DOI 10.3109/08977199109000267; ROTWEIN P, 1988, P NATL ACAD SCI USA, V85, P265, DOI 10.1073/pnas.85.1.265; SCHEIWILLER E, 1986, NATURE, V323, P169, DOI 10.1038/323169a0; SCHOENLE E, 1982, NATURE, V296, P252, DOI 10.1038/296252a0; SHIMATSU A, 1987, NUCLEIC ACIDS RES, V15, P7196, DOI 10.1093/nar/15.17.7196; SHIMATSU A, 1987, J BIOL CHEM, V262, P7894; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRAUS DS, 1990, MOL ENDOCRINOL, V4, P91, DOI 10.1210/mend-4-1-91; STRAUS DS, 1991, ENDOCRINOLOGY, V128, P518, DOI 10.1210/endo-128-1-518; STRAUS DS, 1990, ENDOCRINOLOGY, V127, P1849, DOI 10.1210/endo-127-4-1849; Sussenbach J S, 1989, Prog Growth Factor Res, V1, P33, DOI 10.1016/0955-2235(89)90040-9; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TIONG TS, 1992, MOL CELL ENDOCRINOL, V83, P133, DOI 10.1016/0303-7207(92)90154-X; VANDEHAAR MJ, 1991, J ENDOCRINOL, V130, P305, DOI 10.1677/joe.0.1300305; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	55	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21505	21511						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400462				2022-12-25	WOS:A1992JV01100039
J	MCKENZIE, TL; JIANG, GJ; STRAUBHAAR, JR; CONRAD, DG; SHECHTER, I				MCKENZIE, TL; JIANG, GJ; STRAUBHAAR, JR; CONRAD, DG; SHECHTER, I			MOLECULAR-CLONING, EXPRESSION, AND CHARACTERIZATION OF THE CDNA FOR THE RAT HEPATIC SQUALENE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; SECONDARY-STRUCTURE; PROTEINS; SYNTHETASE; SEQUENCE; ACID; SOLUBILIZATION; PURIFICATION; PYROPHOSPHATE; PRODUCTS	Amino acid sequence information was obtained for the NH2 terminus, and for endogenous peptides generated by trypsin digestion, of a purified, truncated form of rat hepatic squalene synthase (RSS, EC 2.5.1.21) (Shechter, I., Klinger, E., Rucker, M. L., Engstrom, R. G., Spirito, J. A., Islam, M. A., Boettcher, B. R., and Weinstein, D. B. (1992) J. Biol. Chem. 267, 8628-8635). Degenerate primers, based on the amino acid sequences, were synthesized and used for the amplification and sequencing of a 1708-base pair (bp) cDNA for RSS from the rat hepatoma cell line H35. An open reading frame of 1248 bp encoding 416 amino acids (M(r) = 48,103) was detected for RSS. We have constructed a pRSS1327 expression vector by molecular cloning of a 1327-bp cDNA, which includes sequences of the entire coding region for RSS, into pBluescript. Expression in Escherichia coli of a functional, full-length RSS was confirmed by immunoblot analysis and enzymatic activity. We present and evaluate a model for the secondary structure of RSS and its possible membrane orientation. The model predicts a 315-residue domain at the center of the protein that contains the catalytic site and is released in a soluble form by partial proteolysis. The 33-residue NH2-terminal and 98-residue COOH-terminal sections are not involved in catalysis. Sequence analysis of the catalytic domain of RSS indicate three regions with high homology to sequences in a number of functionally distinct proteins that utilize polyprenyl diphosphate substrates.	ELEANOR ROOSEVELT INST,1899 GAYLOR ST,DENVER,CO 80206									AGNEW WS, 1978, J BIOL CHEM, V253, P4574; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; ARMSTRONG GA, 1990, P NATL ACAD SCI USA, V87, P975; ASHBY NM, 1992, J BIOL CHEM, V267, P4128; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAM BE, 1976, J LIPID RES, V17, P176; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; FAUST JR, 1979, P NATL ACAD SCI USA, V76, P5018, DOI 10.1073/pnas.76.10.5018; FRIEDMAN M, 1970, J BIOL CHEM, V245, P3868; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HANDLER B, 1991, ABSTR PAP AM CHEM S, V201, P1; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JANIN J, 1978, J MOL BIOL, V125, P357, DOI 10.1016/0022-2836(78)90408-4; JENNINGS SM, 1991, P NATL ACAD SCI USA, V88, P6038, DOI 10.1073/pnas.88.14.6038; KAMIYA Y, 1979, AGR BIOL CHEM TOKYO, V43, P363, DOI 10.1080/00021369.1979.10863433; KUSWIKRABIEGA G, 1987, J BIOL CHEM, V262, P1505; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LISCUM L, 1985, J BIOL CHEM, V260, P522; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MISAWA N, 1990, J BACTERIOL, V172, P6704, DOI 10.1128/jb.172.12.6704-6712.1990; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POULTER CD, 1981, BIOSYNTHESIS ISOPREN, P413; RAY J, 1987, NUCLEIC ACIDS RES, V15, P10587, DOI 10.1093/nar/15.24.10587; RILLING HC, 1969, J AM CHEM SOC, V19, P1041; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SASIAK K, 1988, ARCH BIOCHEM BIOPHYS, V260, P622, DOI 10.1016/0003-9861(88)90490-0; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SHECHTER I, 1971, J BIOL CHEM, V246, P7690; SHECHTER I, 1992, J BIOL CHEM, V267, P8628	39	76	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21368	21374						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400448				2022-12-25	WOS:A1992JV01100020
J	KOUNNAS, MZ; ARGRAVES, WS; STRICKLAND, DK				KOUNNAS, MZ; ARGRAVES, WS; STRICKLAND, DK			THE 39-KDA RECEPTOR-ASSOCIATED PROTEIN INTERACTS WITH 2 MEMBERS OF THE LOW-DENSITY-LIPOPROTEIN RECEPTOR FAMILY, ALPHA-2-MACROGLOBULIN RECEPTOR AND GLYCOPROTEIN-330	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEYMANN NEPHRITIS ANTIGEN; LDL-RECEPTOR; HIGH-AFFINITY; BRUSH-BORDER; BINDING; IDENTIFICATION; LIGAND; GP330; PURIFICATION; ANTIBODY	The 39-kDa receptor-associated protein (RAP) binds to the alpha2-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha2MR/LRP) and inhibits binding of ligands to this receptor. The in vivo function of RAP may be to regulate ligand binding and/or assist in the correct biosynthetic processing or trafficking of the alpha2MR/LRP. Here we show that RAP binds another putative receptor, the kidney glycoprotein 330 (gp330). Gp330 is a high molecular weight glycoprotein that is structurally similar to both the alpha2MR/LRP and low density lipoprotein receptor. The ability of RAP to bind to gp330 was demonstrated by ligand blotting and solid phase binding assays, which showed that RAP binds to gp330 with high affinity (K(d) = 8 nM). Exploiting the interaction of gp330 and RAP, we purified gp330 by affinity chromatography with a column of RAP coupled to Sepharose. Gp330 preparations obtained by this procedure were notably more homogeneous than those obtained by conventional methods. Immunocytochemical staining of human kidney sections localized RAP to the brush-border epithelium of proximal tubules. The fact that gp330 is also primarily expressed by proximal tubule epithelial cells strengthens the likelihood that the interaction between gp330 and RAP occurs in vivo. The functional significance of RAP binding to gp330 may be to antagonize ligand binding as has been demonstrated for the alpha2MR/LRP or to assist in the biosynthetic processing and/or trafficking of this receptor.	AMER RED CROSS,HOLLAND LAB,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855	American Red Cross					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042912, R01GM042581] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02113] Funding Source: Medline; NIGMS NIH HHS [GM42912, GM42581] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; DANIEL TO, 1983, J BIOL CHEM, V258, P4606; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GEORGE R, 1987, J BIOL CHEM, V262, P16838; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; KANALAS JJ, 1991, J BIOL CHEM, V266, P10825; KERJASCHKI D, 1983, J EXP MED, V157, P667, DOI 10.1084/jem.157.2.667; KERJASCHKI D, 1982, P NATL ACAD SCI-BIOL, V79, P5557, DOI 10.1073/pnas.79.18.5557; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALATHI P, 1979, BIOCHIM BIOPHYS ACTA, V554, P259, DOI 10.1016/0005-2736(79)90023-3; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PIETROMONACO S, 1990, P NATL ACAD SCI USA, V87, P1811, DOI 10.1073/pnas.87.5.1811; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; STIFANI S, 1991, J BIOL CHEM, V266, P19079; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; STRICKLAND DK, 1988, BIOCHEMISTRY-US, V27, P1458, DOI 10.1021/bi00405a010; Teyton L, 1992, Trends Cell Biol, V2, P52, DOI 10.1016/0962-8924(92)90163-H; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	27	192	201	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21162	21166						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400426				2022-12-25	WOS:A1992JT97800100
J	BJORKHEM, I; BUCHMANN, M; BYSTROM, S				BJORKHEM, I; BUCHMANN, M; BYSTROM, S			MECHANISM AND STEREOCHEMISTRY IN THE SEQUENTIAL ENZYMATIC SATURATION OF THE 2 DOUBLE-BONDS IN CHOLESTA-4,6-DIEN-3-ONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYCHOLIC-ACID; CHOLIC-ACID; RAT-LIVER; 7-ALPHA-DEHYDROXYLATION	The mechanism and stereochemistry in connection with enzymatic conversion of cholesta-4,6-dien-3-one into cholestanol was studied. Rat and mouse liver microsomes are able to catalyze NADPH-dependent sequential saturation of the two double bonds. Evidence was obtained that the saturation of the DELTA6-double bond includes transfer of a hydride ion from the B-side of the cofactor to the 7-position of the steroid (mainly 7beta-position), followed by addition of a proton to the 6alpha-position (mainly trans addition). The saturation of the DELTA4-double bond includes transfer of a hydride ion from the B-side of the cofactor to the 5alpha-position of the steroid followed by addition of a proton to the 4beta-position (trans addition). The reduction of the 3-oxo group was found to involve transfer of a hydride ion from the B-side of the cofactor NADPH to the 3alpha-position of the steroid. The results are in accord with the contention that the enzymatic saturation of the two double bonds involves a polarization of the 3-oxo group making C-7 electrophilic and C-6 nucleophilic in connection with the saturation of the DELTA6-double bond and C-5 electrophilic and C-4 nucleophilic in connection with the saturation of the DELTA4-double bond.	UNIV OSLO,RIKSHOSP,DEPT CLIN BIOCHEM,N-0027 OSLO,NORWAY; ROYAL INST TECHNOL,DEPT ORGAN CHEM,S-10044 STOCKHOLM 70,SWEDEN	University of Oslo; National Hospital Norway; Royal Institute of Technology	BJORKHEM, I (corresponding author), HUDDINGE HOSP,DEPT CLIN CHEM,S-14186 HUDDINGE,SWEDEN.			Bjorkhem, Ingemar/0000-0002-0575-9425; Bjorkhem, Ingemar/0000-0001-6087-9190				ARINGER L, 1971, STEROIDS, V18, P381, DOI 10.1016/0039-128X(71)90052-3; BERGSTROM S, 1958, J AM CHEM SOC, V80, P2337, DOI 10.1021/ja01542a081; BJORKHEM I, 1969, EUR J BIOCHEM, V8, P345, DOI 10.1111/j.1432-1033.1969.tb00534.x; BJORKHEM I, 1973, EUR J BIOCHEM, V33, P364, DOI 10.1111/j.1432-1033.1973.tb02691.x; BJORKHEM I, 1969, EUR J BIOCHEM, V7, P413, DOI 10.1111/j.1432-1033.1969.tb19625.x; BJORKHEM I, 1989, J LIPID RES, V30, P1033; BJORKHEM I, 1988, J LIPID RES, V29, P136; BJORKHEM I, 1970, EUR J BIOCHEM, V12, P80, DOI 10.1111/j.1432-1033.1970.tb00823.x; BJORKHEM I, 1971, EUR J BIOCHEM, V20, P340, DOI 10.1111/j.1432-1033.1971.tb01399.x; BJORKHEM I, 1971, EUR J BIOCHEM, V18, P299; BJORKHEM I, 1967, EUR J BIOCHEM, V2, P503; BJORKHEM I, 1989, METABOLIC BASIS INHE, P1283; Bothner-By A.A., 1965, ADV MAGNETIC OPTICAL, VVolume 1, P195; BUCHMANN MS, 1987, BIOCHIM BIOPHYS ACTA, V922, P111, DOI 10.1016/0005-2760(87)90144-5; DANIELSSON H, 1960, ACTA CHEM SCAND, V14, P846, DOI 10.3891/acta.chem.scand.14-0846; HYLEMON PB, 1991, J LIPID RES, V32, P89; KANDUTCH AAJ, 1963, LIPID RES, V4, P179; MAKITA M., 1963, ANALYT BIOCHEM, V5, P523, DOI 10.1016/0003-2697(63)90072-1; SAMUELSSON B, 1960, J BIOL CHEM, V235, P361; SKREDE S, 1988, J LIPID RES, V29, P157; WILTON DC, 1966, BIOCHEM J, V98, P29	21	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19872	19875						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400303				2022-12-25	WOS:A1992JR85800022
J	FENG, Y; FORGAC, M				FENG, Y; FORGAC, M			A NOVEL MECHANISM FOR REGULATION OF VACUOLAR ACIDIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; VESICLE PROTON PUMP; H+-ATPASE; SUBUNIT; SITE; PHOSPHORYLATION; NA+,K+-ATPASE; GLUTATHIONE; HOMOLOGY; KINASE	We have recently demonstrated that Cys-254 of the 73-kDa A subunit of the clathrin-coated vesicle (H+)-ATPase is responsible for sensitivity of the enzyme to sulfhydryl reagents (Feng, Y., and Forgac, M. (1992) J. Biol. Chem. 267, 5817-5822). In the present study we observe that for the purified enzyme, disulfide bond formation causes inactivation of proton transport which is reversed by dithiothreitol (DTT). DTT also restores activity of the oxidized enzyme following treatment with N-ethylmaleimide (NEM). These results indicate that disulfide bond formation between the NEM-reactive cysteine (Cys-254) and a closely proximal cysteine residue leads to inactivation of the (H+)-ATPase. To test whether sulfhydryl-disulfide bond interchange may play a role in regulating vacuolar acidification in vivo, we have determined what fraction of the (H+)-ATPase is disulfide-bonded in native clathrin-coated vesicles. Vesicles were isolated under conditions that prevent any change in the oxidation state of the sulfhydryl groups. NEM treatment of vesicles causes nearly complete loss of activity while subsequent treatment with DTT restores 50% of the activity of the fully reduced vesicles. By contrast, treatment of fully reduced vesicles with NEM leads to inactivation which is not reversed by DTT. These results indicate that a significant fraction of the clathrin-coated vesicle (H+)-ATPase exists in an inactive, disulfide-bonded state and suggest that sulfhydryl-disulfide bond interconversion may play a role in controlling vacuolar (H+)-ATPase (V-ATPase) activity in vivo.	TUFTS UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02111 USA	Tufts University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034478, R01GM034478] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK 34928] Funding Source: Medline; NIGMS NIH HHS [R01 GM034478, GM 34478] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P960; ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; BERNASCONI P, 1990, J BIOL CHEM, V265, P17428; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; CAIN CC, 1989, P NATL ACAD SCI USA, V86, P544, DOI 10.1073/pnas.86.2.544; FENG Y, 1992, J BIOL CHEM, V267, P5817; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GLUCK S, 1982, P NATL ACAD SCI-BIOL, V79, P4327, DOI 10.1073/pnas.79.14.4327; HIRATA R, 1990, J BIOL CHEM, V265, P6726; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KIM HJ, 1990, BIOCHEMISTRY-US, V29, P1107, DOI 10.1021/bi00457a002; LAW MY, 1983, BIOCHEM J, V210, P899, DOI 10.1042/bj2100899; MARQUEZSTERLING N, 1991, EUR J CELL BIOL, V56, P19; McCarty RE, 1988, LIGHT ENERGY TRANSDU, P290; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MULBERG AE, 1991, J BIOL CHEM, V266, P20590; NESS GC, 1985, J BIOL CHEM, V260, P2391; PENEFSKY HS, 1991, ADV ENZYMOL RAMB, V64, P173; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; YSERN X, 1988, J BIOENERG BIOMEMBR, V20, P423, DOI 10.1007/BF00762202; ZHANG JM, 1992, J BIOL CHEM, V267, P9773; ZHANG K, 1992, J BIOL CHEM, V267, P9701; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	33	79	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19769	19772						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400289				2022-12-25	WOS:A1992JR85800005
J	FUJIWARA, K; OKAMURAIKEDA, K; MOTOKAWA, Y				FUJIWARA, K; OKAMURAIKEDA, K; MOTOKAWA, Y			EXPRESSION OF MATURE BOVINE H-PROTEIN OF THE GLYCINE CLEAVAGE SYSTEM IN ESCHERICHIA-COLI AND INVITRO LIPOYLATION OF THE APOFORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE MULTIENZYME COMPLEXES; LIPOYLLYSINE RESIDUE; T-PROTEIN; ACID; MECHANISM; MUTAGENESIS; SEQUENCE; DOMAINS	H-protein, a component of the glycine cleavage system with lipoic acid as a prosthetic group, was expressed in Escherichia coli using a T7 RNA polymerase plasmid expression system. After induction with 25 muM isopropyl-beta-D-thiogalactopyranoside, bacteria harboring the recombinant plasmid expressed mature bovine H-protein as a soluble form at a level of about 10% of the total bacterial protein. Little of the H-protein was lipoylated in E. coli cultured without added lipoate, but when the cells were cultured in medium supplemented with 30 muM lipoate, about 10% of the recombinant protein expressed was the correctly lipoylated active form, 10% was an inactive aberrantly modified form, presumably with an octanoyl group, and the remaining 80% was the unlipoylated apoform. Each of the three forms was purified to homogeneity and shown to have the same NH2-terminal amino acid sequence as that of native bovine H-protein. The specific activity of the lipoylated form of H-protein expressed was consistent with that of H-protein purified from bovine liver. The purified recombinant apo-H-protein was lipoylated and consequently activated in vitro with lipoyl-AMP as a lipoyl donor by lipoyltransferase purified 150-fold from bovine liver mitochondria. The lipoylation was dependent on lipoyl-AMP, apo-H-protein, and lipoyltransferase. The partially purified lipoyltransferase had no lipoate-activating activity. These results provide the first evidence that in mammals two consecutive reactions are required for the attachment of lipoic acid to the acceptor protein: the activation of lipoic acid to lipoyl-AMP catalyzed by lipoate-activating enzyme and the transfer of the lipoyl group to an N(epsilon)-amino group of a lysine residue to apoprotein by lipoyl-AMP:N(epsilon)-lysine lipoyltransferase.	UNIV TOKUSHIMA,INST ENVIRONM RES,KURAMOTOCHO 3 CHOME,TOKUSHIMA 770,JAPAN	Tokushima University								ALI ST, 1990, MOL MICROBIOL, V4, P943, DOI 10.1111/j.1365-2958.1990.tb00667.x; BROOKFIELD DE, 1991, FEBS LETT, V295, P13, DOI 10.1016/0014-5793(91)81373-G; CRONAN JE, 1989, CELL, V58, P427, DOI 10.1016/0092-8674(89)90421-2; DARDEL F, 1990, FEBS LETT, V264, P206, DOI 10.1016/0014-5793(90)80249-I; FUJIWARA K, 1991, FEBS LETT, V293, P115, DOI 10.1016/0014-5793(91)81164-4; FUJIWARA K, 1983, J BIOL CHEM, V258, P8156; FUJIWARA K, 1986, J BIOL CHEM, V261, P8836; FUJIWARA K, 1990, J BIOL CHEM, V265, P17463; FUJIWARA K, 1984, J BIOL CHEM, V259, P664; GRIFFIN TA, 1990, J BIOL CHEM, V265, P12104; HIRAGA K, 1980, J BIOL CHEM, V255, P1671; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OKAMURAIKEDA K, 1987, J BIOL CHEM, V262, P6746; PACKMAN LC, 1991, BIOCHEM J, V277, P153, DOI 10.1042/bj2770153; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; REED LJ, 1990, J BIOL CHEM, V265, P8971; REED LJ, 1958, J BIOL CHEM, V232, P123; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSUNODA JN, 1967, ARCH BIOCHEM BIOPHYS, V118, P395, DOI 10.1016/0003-9861(67)90366-9; WHITE RH, 1980, BIOCHEMISTRY-US, V19, P15, DOI 10.1021/bi00542a003	22	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20011	20016						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400316				2022-12-25	WOS:A1992JR85800043
J	LESSL, M; BALZER, D; PANSEGRAU, W; LANKA, E				LESSL, M; BALZER, D; PANSEGRAU, W; LANKA, E			SEQUENCE SIMILARITIES BETWEEN THE RP4 TRA2 AND THE TI VIRB REGION STRONGLY SUPPORT THE CONJUGATION MODEL FOR T-DNA TRANSFER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; F-SEX FACTOR; AGROBACTERIUM-TUMEFACIENS; ESCHERICHIA-COLI; PLASMID RP4; HOST-RANGE; MEMBRANE LOCALIZATION; REGULATORY SEQUENCES; PROTEIN COMPLEX; NICK REGIONS	Transfer genes of the IncP plasmid RP4 are grouped in two separate regions, designated Tra1 and Tra2. Tra2 gene products are proposed to be mainly responsible for the formation of mating pairs in conjugating cells. To provide information relevant to understanding the function of Tra2 gene products, the nucleotide sequence of the entire RP4 Tra2 region is presented here. Twelve open reading frames were identified in the Tra2 core region, being essential for intraspecific Escherichia coli matings. Predicted sizes of 11 of the 12 Tra2 polypeptides could be verified by expression in E. coli. Based on hydropathy plot analysis, most of the Tra2 open reading frames encode proteins that may interact with membranes. Interestingly, six of the predicted Tra2 gene products exhibited significant sequence similarities to gene products encoded by the VirB operon of the Agrobacterium Ti plasmid. VirB proteins are thought to function in the formation of a transmembrane structure that mediates the passage of T-DNA molecules from bacteria into plant cells. Because of this analogy and the hydropathy of Tra2 gene products, we assume that the DNA transfer machineries acting in bacterial conjugation and T-DNA transfer are structurally and functionally similar. Therefore, the data presented here, support the hypothesis that Ti vir and IncP tra genes evolved from a common ancestor. This suggestion is favored by previous findings of sequence similarities between the IncP and Ti DNA transfer system.	MAX PLANCK INST MOLEC GENET,ABT SCHUSTER,IHNESTR 73,W-1000 BERLIN 33,GERMANY	Max Planck Society								ALDOORI Z, 1982, GENET RES, V39, P99, DOI 10.1017/S0016672300020772; BALZER D, 1992, NUCLEIC ACIDS RES, V20, P1851, DOI 10.1093/nar/20.8.1851; BARTH PT, 1978, J BACTERIOL, V133, P43, DOI 10.1128/JB.133.1.43-52.1978; BAUGHMAN G, 1984, P NATL ACAD SCI-BIOL, V81, P5389, DOI 10.1073/pnas.81.17.5389; BEIJERSBERGEN A, 1992, SCIENCE, V256, P1324, DOI 10.1126/science.256.5061.1324; BOLLAND S, 1990, J BACTERIOL, V172, P5795, DOI 10.1128/jb.172.10.5795-5802.1990; BRENDEL V, 1984, NUCLEIC ACIDS RES, V12, P4411, DOI 10.1093/nar/12.10.4411; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; BURKARDT HJ, 1979, J GEN MICROBIOL, V114, P341, DOI 10.1099/00221287-114-2-341; CHRISTIE PJ, 1989, P NATL ACAD SCI USA, V86, P9677, DOI 10.1073/pnas.86.24.9677; DATTA N, 1972, J GEN MICROBIOL, V70, P453, DOI 10.1099/00221287-70-3-453; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DURRENBERGER F, 1989, P NATL ACAD SCI USA, V86, P9154, DOI 10.1073/pnas.86.23.9154; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ENGSTROM P, 1987, J MOL BIOL, V197, P635, DOI 10.1016/0022-2836(87)90470-0; FONG ST, 1989, J GEN MICROBIOL, V135, P499; FRANKLIN FCH, 1989, PROMISCUOUS PLASMIDS, P247; GENNITY JM, 1991, J BIOL CHEM, V266, P16458; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; GRINTER NJ, 1981, PLASMID, V5, P267, DOI 10.1016/0147-619X(81)90004-4; GUINEY DG, 1989, PROMISCUOUS PLASMIDS, P27; HAAS D, 1989, PROMISCUOUS PLASMIDS, P185; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HEINEMANN JA, 1989, NATURE, V340, P205, DOI 10.1038/340205a0; HERRERAESTRELLA A, 1988, EMBO J, V7, P4055, DOI 10.1002/j.1460-2075.1988.tb03299.x; HOWARD EA, 1989, P NATL ACAD SCI USA, V86, P4017, DOI 10.1073/pnas.86.11.4017; JAGURABURDZY G, 1992, IN PRESS NUCLEIC ACI, V20; JALAJAKUMARI MB, 1989, GENE, V81, P195, DOI 10.1016/0378-1119(89)90179-0; JOVANOVIC OS, 1992, J BACTERIOL, V174, P4842, DOI 10.1128/JB.174.14.4842-4846.1992; KULDAU GA, 1990, MOL GEN GENET, V221, P256, DOI 10.1007/BF00261729; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKA E, 1983, PLASMID, V10, P303, DOI 10.1016/0147-619X(83)90047-1; LESSL M, 1991, MOL GEN GENET, V227, P120, DOI 10.1007/BF00260716; LESSL M, 1992, J BACTERIOL, V174, P2493, DOI 10.1128/jb.174.8.2493-2500.1992; MANNING PA, 1979, BACTERIAL OUTER MEMB, P409; Miele L, 1991, DNA Seq, V2, P145, DOI 10.3109/10425179109039685; Miller J. H., 1972, EXPT MOL GENETICS, P431; MIRANDA A, 1992, J BACTERIOL, V174, P2288, DOI 10.1128/JB.174.7.2288-2297.1992; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; MOTALLEBIVESHAREH M, 1992, MOL MICROBIOL, V6, P907, DOI 10.1111/j.1365-2958.1992.tb01541.x; OKAMOTO S, 1991, MOL GEN GENET, V228, P24, DOI 10.1007/BF00282443; OLSEN RH, 1973, J BACTERIOL, V113, P772, DOI 10.1128/JB.113.2.772-780.1973; PALOMBO EA, 1989, PLASMID, V22, P59, DOI 10.1016/0147-619X(89)90036-X; PANSEGRAU W, 1990, J BIOL CHEM, V265, P10637; PANSEGRAU W, 1991, NUCLEIC ACIDS RES, V19, P3455, DOI 10.1093/nar/19.12.3455; PERUMAL NB, 1984, J BIOL CHEM, V259, P5357; ROGOWSKY PM, 1990, PLASMID, V23, P85, DOI 10.1016/0147-619X(90)90028-B; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO T, 1990, P NATL ACAD SCI USA, V87, P142, DOI 10.1073/pnas.87.1.142; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; SHIRASU K, 1990, MOL MICROBIOL, V4, P1153, DOI 10.1111/j.1365-2958.1990.tb00690.x; SIMON R, 1989, PROMISCUOUS PLASMIDS, P207; SMITH CA, 1984, J MOL BIOL, V175, P251, DOI 10.1016/0022-2836(84)90347-4; SMITH CA, 1984, NUCLEIC ACIDS RES, V12, P3619, DOI 10.1093/nar/12.8.3619; SMITH CA, 1989, PROMISCUOUS PLASMIDS, P57; STACHEL SE, 1986, CELL, V47, P155, DOI 10.1016/0092-8674(86)90437-X; STRACK B, 1992, J BIOL CHEM, V267, P13062; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1987, J BIOL CHEM, V262, P16212; Thomas CM, 1989, PROMISCUOUS PLASMIDS, P1; THOMPSON DV, 1988, NUCLEIC ACIDS RES, V16, P4621, DOI 10.1093/nar/16.10.4621; VOGEL AM, 1992, J BACTERIOL, V174, P303, DOI 10.1128/jb.174.1.303-308.1992; VOGLER AP, 1991, J BACTERIOL, V173, P3564, DOI 10.1128/jb.173.11.3564-3572.1991; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARD ER, 1988, SCIENCE, V242, P927, DOI 10.1126/science.242.4880.927; WARD JE, 1988, J BIOL CHEM, V263, P5804; WARD JE, 1990, J BACTERIOL, V172, P5200, DOI 10.1128/jb.172.9.5200-5210.1990; WARD JE, 1990, J BIOL CHEM, V265, P4768; WATERS VL, 1991, P NATL ACAD SCI USA, V88, P1456, DOI 10.1073/pnas.88.4.1456; WATERS VL, 1992, IN PRESS J BACTERIOL, V174; WATSON J, 1980, PLASMID, V4, P175, DOI 10.1016/0147-619X(80)90007-4; WILKINS B, 1992, IN PRESS BACTERIAL C; WILLETTS N, 1984, MICROBIOL REV, V48, P224; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOUNG C, 1988, J BACTERIOL, V170, P3367, DOI 10.1128/jb.170.8.3367-3374.1988; YOUNG C, 1985, P NATL ACAD SCI USA, V82, P7374, DOI 10.1073/pnas.82.21.7374; YU F, 1986, J BIOL CHEM, V261, P2284; Ziegelin G, 1991, DNA Seq, V1, P303, DOI 10.3109/10425179109020786	83	137	143	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20471	20480						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400366				2022-12-25	WOS:A1992JR85800112
J	MARSH, ME; CHANG, DK; KING, GC				MARSH, ME; CHANG, DK; KING, GC			ISOLATION AND CHARACTERIZATION OF A NOVEL ACIDIC POLYSACCHARIDE CONTAINING TARTRATE AND GLYOXYLATE RESIDUES FROM THE MINERALIZED SCALES OF A UNICELLULAR COCCOLITHOPHORID ALGA PLEUROCHRYSIS-CARTERAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PHOSPHOPROTEIN PARTICLES; MULTIPLE QUANTUM NMR; HYMENOMONAS-CARTERAE; POLYACRYLAMIDE GELS; CALCIUM; PROTEINS; DENTIN; SPECTROSCOPY; SENSITIVITY; RECEPTOR	The characterization of mineral-associated polyanions from the unicellular alga Pleurochrysis carterae is described. This species is useful for the study of mineralization, because it produces calcified scales known as coccoliths in homogeneous cell culture. Three acidic polysaccharides (PS-1, PS-2, and PS-3) were extracted from the coccoliths with EDTA and were separated and purified by differential precipitation with magnesium ions and chromatography on DEAE-cellulose. PS-1 and PS-3 are predominantly polymers of galacturonic acid containing lesser amounts of other monosaccharides. PS-2 has an unusual structure. Chemical, enzymatic, and two-dimensional NMR analyses demonstrate that the repeating unit of PS-2 is [--> 4)D-glucuronate(beta 1 --> 2) meso-tartrate (3 --> 1) glyoxylate(1-]n. Thus PS-2 has a high density of negatively charged groups available for calcium ion binding, similar to the phosphoprotein polyanions of other species. Polysaccharides containing tartrate and/or glyoxylate have not been previously described; these residues may be introduced into PS-2 by a postpolymerization process involving oxidative cleavage of glucuronate or mannuronate residues.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,WM KECK CTR COMP BIOL,HOUSTON,TX 77251	Rice University	MARSH, ME (corresponding author), UNIV TEXAS,HLTH SCI CTR,INST DENT SCI,POB 20068,HOUSTON,TX 77225, USA.		Chang, Ding-Kwo/E-7079-2015		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036239] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-05759] Funding Source: Medline; NIAMS NIH HHS [AR-36239] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABEYGUNAWARDANA C, 1990, BIOCHEMISTRY-US, V29, P234, DOI 10.1021/bi00453a032; ABEYGUNAWARDANA C, 1991, BIOCHEMISTRY-US, V30, P6528, DOI 10.1021/bi00240a025; AONO R, 1990, BIOCHEM J, V270, P363, DOI 10.1042/bj2700363; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BARTNICKIGARCIA S, 1968, BIOCHIM BIOPHYS ACTA, V170, P54, DOI 10.1016/0304-4165(68)90160-8; BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BERGMEYER HU, 1984, METHOD ENZYMAT AN, V6, P624; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BUTLER WT, 1983, ARCH BIOCHEM BIOPHYS, V225, P178, DOI 10.1016/0003-9861(83)90021-8; BYRD RA, 1987, CARBOHYD RES, V166, P47, DOI 10.1016/0008-6215(87)80043-5; CASSELS FJ, 1990, J BIOL CHEM, V265, P14127; de Vrind-de Jong E. W., 1986, BIOMINERALIZATION LO, P205; DIMUZIO MT, 1978, CALC TISS RES, V25, P169, DOI 10.1007/BF02010765; GREEN MR, 1973, ANAL BIOCHEM, V56, P43, DOI 10.1016/0003-2697(73)90167-X; Guillard R.R., 1975, CULTURE MARINE INVER, P29, DOI 10.1007/978-1-4615-8714-9_3.; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Kunst A., 1984, METHOD ENZYMAT AN, VVI, P163; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SL, 1977, BIOCHEMISTRY-US, V16, P2971, DOI 10.1021/bi00632a026; LERNER L, 1987, CARBOHYD RES, V166, P35, DOI 10.1016/0008-6215(87)80042-3; Lyman J, 1940, J MAR RES, V3, P134; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MARSH ME, 1984, BIOCHEMISTRY-US, V23, P1448, DOI 10.1021/bi00302a017; MARSH ME, 1986, J EXP ZOOL, V239, P207, DOI 10.1002/jez.1402390208; MARSH ME, 1983, J EXP ZOOL, V226, P193, DOI 10.1002/jez.1402260204; MARSH ME, 1989, BIOCHEMISTRY-US, V28, P339, DOI 10.1021/bi00427a046; MENZIES IS, 1969, CHROMATOGR ELECTROPH, V1, P310; OUTKA DE, 1971, J PROTOZOOL, V18, P285, DOI 10.1111/j.1550-7408.1971.tb03319.x; SHAKA AJ, 1983, J MAGN RESON, V52, P335, DOI 10.1016/0022-2364(83)90207-X; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; STAFFORD HA, 1959, AM J BOT, V46, P347, DOI 10.2307/2439194; TAYLOR RL, 1972, BIOCHEMISTRY-US, V11, P1383, DOI 10.1021/bi00758a009; TSUCHIHASHI H, 1981, CARBOHYD RES, V98, P65, DOI 10.1016/S0008-6215(00)87142-6; VANDERWAL P, 1983, J ULTRA MOL STRUCT R, V85, P139, DOI 10.1016/S0022-5320(83)90103-X; VANDERWAL P, 1983, J ULTRASTRUCT RES, V35, P215; VANDERWAL P, 1983, ECOLOGICAL B, V35, P215; VAUGHN RH, 1946, J BACTERIOL, V52, P311, DOI 10.1128/JB.52.3.311-325.1946; WILLIAMS M, 1979, PHYTOCHEMISTRY, V18, P953, DOI 10.1016/S0031-9422(00)91456-0; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YASHPHE J, 1965, ANAL BIOCHEM, V13, P345, DOI 10.1016/0003-2697(65)90203-4; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1	42	75	78	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20507	20512						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400368				2022-12-25	WOS:A1992JR85800117
J	QUEHENBERGER, O; PROSSNITZ, ER; COCHRANE, CG; YE, RD				QUEHENBERGER, O; PROSSNITZ, ER; COCHRANE, CG; YE, RD			ABSENCE OF GI-PROTEINS IN THE SF9 INSECT CELL - CHARACTERIZATION OF THE UNCOUPLED RECOMBINANT N-FORMYL PEPTIDE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERTUSSIS TOXIN SUBSTRATE; BETA-ADRENERGIC-RECEPTOR; POLYMORPHONUCLEAR LEUKOCYTES; CHEMOATTRACTANT RECEPTOR; SIGNAL TRANSDUCTION; GUANINE-NUCLEOTIDES; HUMAN-GRANULOCYTES; NEUTROPHIL; MEMBRANES; LIGAND	We investigated the interaction of the N-formyl peptide receptor (NFPR) with G proteins in infected Sf9 insect cells expressing the recombinant NFPR. Recombinant receptor expression of up to 27 pmol/mg protein was achieved in these cells. The receptor was recognized by an antiserum raised against an NFPR carboxyl-terminal peptide, and displayed specific and saturable binding of the formyl peptide ligand fMet-Leu[H-3]Phe. Scatchard analysis of the binding data yielded a dissociation constant of approximately 62 nM, a binding affinity of 60- to 120-fold lower than that of the high affinity sites in neutrophils and in transfected mammalian cell lines expressing the NFPR. That this low binding affinity was due to a lack of receptor coupling to G protein was suggested by the failure of guanine nucleotides to regulate receptor affinity and by the lack of formyl peptide-stimulated GTPase activity in these cells. Furthermore, immunoblotting with an anti-G(i) antibody and ADP-ribosylation experiments indicated that the approximately 40-kDa G(ialpha) subunit, which couples to the NFPR in neutrophils, is not present in Sf9 cell membranes. Thus, the current study provides for the first time evidence that a major G protein is absent in the Sf9 insect cells. Potential applications of the Sf9 system for in vitro reconstitution of the NFPR-G protein interaction are discussed.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute			Ye, Richard/ABF-2413-2020; Prossnitz, Eric R./B-4543-2008; Ye, Richard/O-5223-2016	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620; Prossnitz, Eric/0000-0001-9190-8302	NIGMS NIH HHS [GM46572] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046572] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RA, 1986, BIOCHIM BIOPHYS ACTA, V882, P271, DOI 10.1016/0304-4165(86)90248-5; BOKOCH GM, 1988, J CELL BIOL, V106, P1927, DOI 10.1083/jcb.106.6.1927; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; Cochrane CG, 1990, CELLULAR MOL MECHANI, P83; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DOLMATCH B, 1983, J BIOL CHEM, V258, P7570; GEORGE ST, 1989, BIOCHEM BIOPH RES CO, V163, P1265, DOI 10.1016/0006-291X(89)91114-5; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; KOO C, 1982, BIOCHEM BIOPH RES CO, V106, P442, DOI 10.1016/0006-291X(82)91130-5; KOO C, 1983, J CLIN INVEST, V72, P748, DOI 10.1172/JCI111045; MALECH HL, 1985, J BIOL CHEM, V260, P2509; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OKAJIMA F, 1985, J BIOL CHEM, V260, P6761; PARKER EM, 1991, J BIOL CHEM, V266, P519; PARKER EM, 1991, J BIOL CHEM, V266, P9987; PARKOS CA, 1985, J BIOL CHEM, V260, P6541; POLAKIS PG, 1988, J BIOL CHEM, V263, P4969; PROSSNITZ ER, 1991, BIOCHEM BIOPH RES CO, V179, P471, DOI 10.1016/0006-291X(91)91394-R; SKLAR LA, 1987, J BIOL CHEM, V262, P135; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; TOLLEY JO, 1987, J LEUKOCYTE BIOL, V42, P43, DOI 10.1002/jlb.42.1.43; WILDE MW, 1989, J BIOL CHEM, V264, P190; YE RD, 1992, BIOCHEM BIOPH RES CO, V184, P582, DOI 10.1016/0006-291X(92)90629-Y	25	75	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19757	19760						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400288				2022-12-25	WOS:A1992JR85800002
J	STRITTMATTER, P; KITTLER, JM; COGHILL, JE				STRITTMATTER, P; KITTLER, JM; COGHILL, JE			CHARACTERIZATION OF THE ROLE OF LYSINE 110 OF NADH-CYTOCHROME-B5 REDUCTASE IN THE BINDING AND OXIDATION OF NADH BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; CYTOCHROME B5 REDUCTASE; GLUTATHIONE-REDUCTASE; ACTIVE-SITES; ACID; SEQUENCE; PARTICIPATION; DESATURATION; INVOLVEMENT; RESIDUES	An expression vector for bovine NADH-cytochrome b5 reductase was used for site-directed mutagenesis of lysine 110, the residue previously implicated in NADH interactions with this flavoprotein. Replacement of this basic residue with an uncharged glutamine resulted in an increase of 3 orders of magnitude in the K(m) for NADH and a decrease in k(cat) of an order of magnitude, strongly implicating lysine 110 in both binding of NADH to the reductase and the orientation of the reduced nicotinamide group for rapid hydride ion transfer to the flavin. Substitution of lysine 110 by histidine, to provide a pH-sensitive positive charge at this position in the neutral pH range, exhibited only a moderate 25-fold increase in K(m) and a normal k(cat) at pH 6.0, whereas at pH 8.5 the K(m) for NADH rose to 238 muM with a decrease of 45% over unmodified enzyme in the k(cat). A similar pH sensitivity in the inhibition constant for adenosine diphosphate ribose, lacking only the nicotinamide moiety of NADH, emphasizes the crucial role of the positive charge at this locus and is consistent with charge-pairing of lysine 110 with the pyrophosphate group of NADH or adenosine diphosphate ribose.			STRITTMATTER, P (corresponding author), UNIV CONNECTICUT, CTR HLTH, DEPT BIOCHEM, FARMINGTON, CT 06030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015924] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-15924] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CRAWFORD NM, 1988, P NATL ACAD SCI USA, V85, P5006, DOI 10.1073/pnas.85.14.5006; DAILEY HA, 1979, J BIOL CHEM, V254, P5388; HACKETT CS, 1984, J BIOL CHEM, V259, P3275; HACKETT CS, 1988, J BIOL CHEM, V263, P7539; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KEYES SR, 1979, J BIOL CHEM, V254, P7778; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOVERDE A, 1968, J BIOL CHEM, V243, P5779; MIKI K, 1987, J BIOL CHEM, V262, P11801; OKAYASU T, 1977, LIPIDS, V12, P267, DOI 10.1007/BF02533345; OSHINO N, 1971, J BIOCHEM, V69, P155, DOI 10.1093/oxfordjournals.jbchem.a129444; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; PAI EF, 1988, BIOCHEMISTRY-US, V27, P4465, DOI 10.1021/bi00412a038; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; REDDY VVR, 1977, J BIOL CHEM, V252, P2797; ROGERS MJ, 1975, J BIOL CHEM, V250, P5713; ROGERS MJ, 1973, J BIOL CHEM, V248, P800; SHIRABE K, 1991, J BIOL CHEM, V266, P7531; SPATZ L, 1971, P NATL ACAD SCI USA, V68, P1042, DOI 10.1073/pnas.68.5.1042; SPATZ L, 1973, J BIOL CHEM, V248, P793; STRITTMATTER P, 1956, J BIOL CHEM, V221, P277; STRITTMATTER P, 1958, J BIOL CHEM, V233, P748; STRITTMATTER P, 1959, J BIOL CHEM, V234, P2665; STRITTMATTER P, 1974, P NATL ACAD SCI USA, V71, P4565, DOI 10.1073/pnas.71.11.4565; STRITTMATTER P, 1992, J BIOL CHEM, V267, P2519; STRITTMATTER P, 1990, J BIOL CHEM, V265, P21709; YUBISUI T, 1991, J BIOL CHEM, V266, P66	30	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20164	20167						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400335				2022-12-25	WOS:A1992JR85800067
J	TEMPLIN, MF; EDWARDS, DH; HOLTJE, JV				TEMPLIN, MF; EDWARDS, DH; HOLTJE, JV			A MUREIN HYDROLASE IS THE SPECIFIC TARGET OF BULGECIN IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE LYTIC TRANSGLYCOSYLASE; BETA-LACTAM ANTIBIOTICS; PERFORMANCE LIQUID-CHROMATOGRAPHY; PENICILLIN-BINDING-PROTEINS; GRAM-NEGATIVE BACTERIA; SLT GENE; CLONING; OVEREXPRESSION; ELONGATION; ATTACHMENT	A deletion in the structural gene for the soluble lytic transglycosylase, the predominant murein hydrolase in the soluble fraction of Escherichia coli, has been constructed. The mutant grows normally but exhibits increased sensitivity toward mecillinam, a beta-lactam specific for penicillin-binding protein 2. In the presence of furazlocillin or other beta-lactams with a specificity for penicillin-binding protein 3 which normally cause filamentation, bulges were formed prior to rapid bacteriolysis. Similar morphological alterations are known to develop in wild type E. coli cells when furazlocillin is combined with bulgecin, an antibiotic of unusual glucosaminyl structure. It turned out that bulgecin specifically inhibits the Sl-transglycosylase in a noncompetitive manner. Since bulgecin shows some structural analogy to the murein subunits we postulate that the soluble lytic transglycosylase, in addition to its active site, has a recognition site for specific murein structures. The possibility of an allosteric modulation of the activity of the enzyme by changes in the structure of the murein sacculus is discussed.	UNIV EDINBURGH,DEPT MOLEC BIOL,EDINBURGH EH9 3JR,MIDLOTHIAN,SCOTLAND	University of Edinburgh	HOLTJE, JV (corresponding author), MAX PLANCK INST ENTWICKLUNGSBIOL,BIOCHEM ABT,SPEMANNSTR 35,W-7400 TUBINGEN,GERMANY.							BETZNER AS, 1990, FEMS MICROBIOL LETT, V67, P161, DOI 10.1016/0378-1097(90)90187-U; BETZNER AS, 1989, MOL GEN GENET, V219, P489, DOI 10.1007/BF00259625; BOTTA GA, 1981, J BACTERIOL, V145, P333, DOI 10.1128/JB.145.1.333-340.1981; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143; ENGEL H, 1991, J BACTERIOL, V173, P6773, DOI 10.1128/jb.173.21.6773-6782.1991; GIUDICELLI S, 1984, J BACTERIOL, V158, P1188, DOI 10.1128/JB.158.3.1188-1190.1984; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; GLAUNER B, 1988, J BIOL CHEM, V263, P10088; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HARZ H, 1990, ANAL BIOCHEM, V190, P120, DOI 10.1016/0003-2697(90)90144-X; HOLTJE JV, 1991, J GEN MICROBIOL, V137, P441, DOI 10.1099/00221287-137-3-441; HOLTJE JV, 1975, J BACTERIOL, V124, P1067; HOLTJE JV, 1976, J BIOL CHEM, V251, P4199; HOLTJE JV, 1985, MOL CYTOLOGY ESCHERI, P77; IMADA A, 1982, J ANTIBIOT, V35, P1400, DOI 10.7164/antibiotics.35.1400; IZAKI K, 1966, P NATL ACAD SCI USA, V55, P656, DOI 10.1073/pnas.55.3.656; KOCH AL, 1990, RES MICROBIOL, V141, P529, DOI 10.1016/0923-2508(90)90017-K; KOCH AL, 1990, FEMS MICROBIOL REV, V88, P15; LANZER M, 1988, P NATL ACAD SCI USA, V85, P8973, DOI 10.1073/pnas.85.23.8973; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; METT H, 1980, J BACTERIOL, V144, P45, DOI 10.1128/JB.144.1.45-52.1980; Miller J.H., 1972, EXPT MOL GENETICS; NAKAO M, 1986, ANTIMICROB AGENTS CH, V30, P414, DOI 10.1128/AAC.30.3.414; ROEDER W, 1979, MOL GEN GENET, V176, P361, DOI 10.1007/BF00333098; Rogers H.J., 1980, MICROBIAL CELL WALK, P190; ROGERS HJ, 1971, J BACTERIOL, V108, P1235, DOI 10.1128/JB.108.3.1235-1243.1971; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARZ U, 1969, J MOL BIOL, V41, P419, DOI 10.1016/0022-2836(69)90285-X; SHIMADA K, 1972, J MOL BIOL, V63, P483, DOI 10.1016/0022-2836(72)90443-3; SHINAGAWA S, 1985, J ANTIBIOT, V38, P17, DOI 10.7164/antibiotics.38.17; SHOCKMAN GD, 1965, BACTERIOL REV, V29, P345, DOI 10.1128/MMBR.29.3.345-358.1965; SPRATT BG, 1975, P NATL ACAD SCI USA, V72, P2999, DOI 10.1073/pnas.72.8.2999; TOMASZ A, 1979, ANNU REV MICROBIOL, V33, P113, DOI 10.1146/annurev.mi.33.100179.000553; Tomasz A., 1983, TARGET PENICILLIN, P155; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALDERICH B, 1991, J BACTERIOL, V173, P5668, DOI 10.1128/jb.173.18.5668-5676.1991; WAXMAN DJ, 1983, ANNU REV BIOCHEM, V52, P825, DOI 10.1146/annurev.bi.52.070183.004141; WEIDEL W, 1964, ADV ENZYMOL REL S BI, V26, P193; WILSON K, 1990, CURRENT PROTOCOLS MO; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	41	94	94	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20039	20043						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400320				2022-12-25	WOS:A1992JR85800048
J	EDWARDS, PAW; HIBY, SE; PAPKOFF, J; BRADBURY, JM				EDWARDS, PAW; HIBY, SE; PAPKOFF, J; BRADBURY, JM			HYPERPLASIA OF MOUSE MAMMARY EPITHELIUM INDUCED BY EXPRESSION OF THE WNT-1 (INT-1) ONCOGENE IN RECONSTITUTED MAMMARY-GLAND	ONCOGENE			English	Article							CELL-LINE; TRANSGENIC MICE; RETROVIRAL VECTORS; GENE-TRANSFER; MYC ONCOGENE; TUMOR VIRUS; HA-RAS; PROTEIN; GROWTH; DIFFERENTIATION	We have expressed the Wnt-1 (formerly int-1) oncogene in Balb/c mouse mammary epithelium in vivo, using a tissue reconstitution method in which primary cultures of mammary epithelial cells are infected with a retrovirus vector and then transplanted into mouse mammary fat pads from which the natural epithelium has been removed. Transplants carrying the Wnt-1 gene grew in a hyperplastic pattern, the duct epithelium showing abundant fine side-branches, but without development of clusters of alveoli. The hyperplasias were similar, but not identical, to transplants of normal epithelium in a mid-pregnant host. Transplants of epithelium that expressed Wnt-1 into mammary fat pads of male or ovari-ectomized females grew to form a similar three-dimensional pattern, but the extent of growth, and so presumably the rate of growth, was slower than in intact females, and there were no terminal end buds at the edges of the outgrowths. Thus, although Wnt-1 may enhance growth of epithelium in the male or ovari-ectomized-female environment, it does not restore the major mode of growth in the intact female, the extension of major ducts from terminal end buds. Normal epithelium showed no change in morphology when in close proximity to hyperplasia induced by Wnt-1, confirming the limited range of diffusion of Wnt-1 protein in vivo. Our results are consistent with the hypothesis that Wnt-1 acts principally by mimicking the signal that causes ducts to develop side-branches in pregnancy.	INST CANC & DEV BIOL,PALO ALTO,CA 94304		EDWARDS, PAW (corresponding author), UNIV CAMBRIDGE,DEPT PATHOL,DIV CELL & GENET PATHOL,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND.		Edwards, Paul A/M-8291-2014	Edwards, Paul A/0000-0002-4789-3374				ADAMS LM, 1987, CANCER RES, V47, P4425; AGUILARCORDOVA E, 1991, ONCOGENE, V6, P1601; AIDELLS BD, 1974, J NATL CANCER I, V52, P1855, DOI 10.1093/jnci/52.6.1855; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; BANERJEE M R, 1976, TCA (Tissue Culture Association) Manual, V2, P457, DOI 10.1007/BF00918341; BLASBAND A, 1992, ONCOGENE, V7, P153; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BRADBURY JM, 1988, INT J CANCER, V42, P923, DOI 10.1002/ijc.2910420623; BRADBURY JM, 1991, INT J CANCER, V48, P908, DOI 10.1002/ijc.2910480619; BRADLEY A, 1990, CELL, V62, P1073; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BUHLER TA, 1992, UNPUB DEV BIOL; Daniel C. W., 1987, The mammary gland. Development, regulation, and function., P3; DANIEL CW, 1989, DEV BIOL, V135, P20, DOI 10.1016/0012-1606(89)90154-1; DANIEL CW, 1987, CANCER RES, V47, P6052; DEOME KB, 1959, CANCER RES, V19, P515; EDWARDS PAW, 1988, ONCOGENE, V2, P407; FAULKIN LJ, 1960, J NATL CANCER I, V24, P953; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; GUNZBURG WH, 1988, CARCINOGENESIS, V9, P1849, DOI 10.1093/carcin/9.10.1849; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MEDINA D, 1988, CARCINOGENESIS, V9, P1113, DOI 10.1093/carcin/9.7.1113; MEDINA D, 1973, METHOD CANCER RES, V7, P3; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIYAMOTO S, 1990, CANCER RES, V50, P6010; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morris D. W., 1987, ADV VIRAL ONCOL, V7, P123; MORRIS DW, 1990, J VIROL, V64, P1794, DOI 10.1128/JVI.64.4.1794-1802.1990; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; RICHARDS J, 1988, ENDOCRINOLOGY, V123, P1335, DOI 10.1210/endo-123-3-1335; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; ROELINK H, 1992, P NATL ACAD SCI USA, V7, P487; SCULLY JL, 1991, INT J CANCER, V48, P128; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; STRANGE R, 1989, ONCOGENE, V4, P309; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILLIAMS JM, 1983, DEV BIOL, V97, P274, DOI 10.1016/0012-1606(83)90086-6; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7	52	61	61	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2041	2051						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408145				2022-12-25	WOS:A1992JP42400019
J	BO, XN; SIMON, J; BURNSTOCK, G; BARNARD, EA				BO, XN; SIMON, J; BURNSTOCK, G; BARNARD, EA			SOLUBILIZATION AND MOLECULAR-SIZE DETERMINATION OF THE P(2X) PURINOCEPTOR FROM RAT VAS-DEFERENS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P2Y PURINERGIC RECEPTOR; SENSORY NEURONS; URINARY-BLADDER; SMOOTH-MUSCLE; BINDING-SITES; ATP; PROTEIN; P2-PURINOCEPTORS; AFFINITY; SURAMIN	Membranes of the rat vas deferens were shown to contain a high density of binding sites for [H-3]alpha,beta-methylene ATP ([H-3]alpha,beta-MeATP), a ligand selective for the P2X purinoceptor. Analysis demonstrated two classes, of high affinity (K(d) = 1.8 nM, B(max) (maximum density) = 9.3 pmol/mg of protein) and of low affinity (K(d) = 34 nM, B(max) = 29 pmol/mg of protein). The high affinity [H-3]alpha,beta-MeATP binding sites were successfully solubilized with 2% digitonin: the K(d) was then 1.6 nM. Both the association and dissociation of the receptor-ligand complex were rapid (half-time for association = 6.5 min). The rank order of potency of purinergic ligands in displacing [H-3]alpha,beta-MeATP binding from the solubilized preparation was in accord with the pharmacological criteria for P2X purinoceptors. The receptor-detergent complex was separated by sucrose gradient ultracentrifugation from the ATPase enzymes also present in the preparation. The sedimentation coefficient of the receptor-detergent complex was 12.1 S. It was shown that [H-3]alpha,beta-MeATP can function as a photoaffinity labeling reagent upon exposure to ultraviolet light; in the rat vas deferens membranes, it thus became cross-linked in a specific manner to a polypeptide of apparent molecular mass = 62,000 daltons, proposed to be the ligand-binding subunit of the functional P2X purinoceptor.	MRC,MOLEC NEUROBIOL UNIT,CAMBRIDGE CB2 2QH,ENGLAND; UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,LONDON WC1E 6BT,ENGLAND; UNIV LONDON UNIV COLL,CTR NEUROSCI,LONDON WC1E 6BT,ENGLAND	University of London; University College London; University of London; University College London			Bo, Xuenong/E-9845-2012	Bo, Xuenong/0000-0002-9202-3562	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAHAM KI, 1984, BIOCHEMISTRY-US, V23, P1176, DOI 10.1021/bi00301a023; BAGINSKI ES, 1967, CLIN CHIM ACTA, V15, P155, DOI 10.1016/0009-8981(67)90340-3; BARNARD EA, 1992, RECEPTOR SUBUNITS CO, P163; BASU A, 1987, J BIOL CHEM, V262, P2369; Bean B P, 1990, Ion Channels, V2, P169; BEAN BP, 1990, J NEUROSCI, V10, P1; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BO X, 1990, BRIT J PHARMACOL, V101, P291, DOI 10.1111/j.1476-5381.1990.tb12703.x; BO XO, 1989, J AUTONOM NERV SYST, V28, P85, DOI 10.1016/0165-1838(89)90010-6; BOUVIER MM, 1991, EUR J NEUROSCI, V3, P285, DOI 10.1111/j.1460-9568.1991.tb00090.x; BOYER JL, 1989, J BIOL CHEM, V264, P884; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNSTOCK G, 1991, NUCLEOS NUCLEOT NUCL, V10, P917, DOI 10.1080/07328319108047230; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; BURNSTOCK G, 1972, PHARMACOL REV, V24, P509; CUSACK NJ, 1990, ANN NY ACAD SCI, V603, P172; DAVIDSON JS, 1990, ENDOCRINOLOGY, V126, P80, DOI 10.1210/endo-126-1-80; DUNN PM, 1988, BRIT J PHARMACOL, V93, P243, DOI 10.1111/j.1476-5381.1988.tb11427.x; FORTES PAG, 1973, BIOCHIM BIOPHYS ACTA, V318, P262, DOI 10.1016/0005-2736(73)90119-3; FRIEL DD, 1988, J PHYSIOL-LONDON, V401, P361, DOI 10.1113/jphysiol.1988.sp017167; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HOURANI SMO, 1989, GEN PHARMACOL, V20, P413, DOI 10.1016/0306-3623(89)90188-2; HOYLE CHV, 1990, BRIT J PHARMACOL, V99, P617, DOI 10.1111/j.1476-5381.1990.tb12979.x; HOYLE CHV, 1989, ADENOSINE NERVOUS SY, P43; JEFFS RA, 1991, MOL PHARMACOL, V40, P85; KRISHTAL OA, 1988, BRIT J PHARMACOL, V95, P1057, DOI 10.1111/j.1476-5381.1988.tb11739.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBERT F, 1991, EMBO J, V10, P1677, DOI 10.1002/j.1460-2075.1991.tb07691.x; MAENHAUT C, 1990, BIOCHEM BIOPH RES CO, V173, P1169, DOI 10.1016/S0006-291X(05)80909-X; MAMALAKI C, 1989, J NEUROCHEM, V52, P124, DOI 10.1111/j.1471-4159.1989.tb10906.x; MODAK MJ, 1982, J BIOL CHEM, V257, P5105; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKAZAWA K, 1990, NEUROSCI LETT, V119, P5, DOI 10.1016/0304-3940(90)90741-Q; OKAJIMA F, 1987, J BIOL CHEM, V262, P13483; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RALEVIC V, 1991, CIRCULATION, V84, P1, DOI 10.1161/01.CIR.84.1.1; RUGGIERI MR, 1990, J UROLOGY, V144, P176, DOI 10.1016/S0022-5347(17)39405-3; SALT TE, 1983, NEUROSCI LETT, V35, P53, DOI 10.1016/0304-3940(83)90526-8; SIMON J, 1984, J NEUROCHEM, V43, P957, DOI 10.1111/j.1471-4159.1984.tb12830.x; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WHITE TD, 1988, PHARMACOL THERAPEUT, V38, P129, DOI 10.1016/0163-7258(88)90095-2	41	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17581	17587						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1387637				2022-12-25	WOS:A1992JM22300019
J	GORMAN, DM; ITOH, N; JENKINS, NA; GILBERT, DJ; COPELAND, NG; MIYAJIMA, A				GORMAN, DM; ITOH, N; JENKINS, NA; GILBERT, DJ; COPELAND, NG; MIYAJIMA, A			CHROMOSOMAL LOCALIZATION AND ORGANIZATION OF THE MURINE GENES ENCODING THE BETA-SUBUNITS (AIC2A AND AIC2B) OF THE INTERLEUKIN-3, GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR, AND INTERLEUKIN-5 RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROPOIETIN RECEPTOR; GM-CSF RECEPTOR; BINDING PROTEIN; 2ND SUBUNIT; CELL-LINE; MACROPHAGE; CLONING; TRANSCRIPTION; RECONSTITUTION; IDENTIFICATION	Chromosomal genes for two mouse homologous beta-subunits (AIC2A and AIC2B) of the interleukin-3, granulocyte/macrophage colony-stimulating factor, and interleukin-5 receptors were characterized. Both AIC2A and AIC2B genes were present on a 250-kilobase MluI restriction fragment and were mapped on murine chromosome 15 (these loci were provisionally designated as Il3rb-1 (AIC2A) and Il3rb-2 (AIC2B)), closely linked to the c-sis locus. Both genes consist of 14 exons and span about 28 kb each. The major transcription inititation sites of both genes were mapped at 194 bp from the initiation codon. These genes are 95% identical up to 700 bp from the transcription initiation sites. Potential recognition sequences for hemopoietic transcription factors including GATA-1 and PU.1 in addition to a TATA-like sequence are present in the 5'-flanking region. A stretch of 20 bp including the initiation site is homologous to the corresponding region of the erythropoietin receptor and the interleukin-7 receptor genes and to the initiator sequence of the adeno-associated virus P5 promoter, suggesting a possible role in transcription initiation. Comparison of the exon/intron boundaries of AIC2A and AIC2B genes with those of other members of the cytokine receptor superfamily reveals a conserved evolutionary structure. Isolation of various forms of AIC2 cDNAs reveals differential splicing of the transcripts.	DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT MOLEC BIOL,901 CALIF AVE,PALO ALTO,CA 94304; NCI,FREDERICK CANC RES & DEV CTR,MAMMALIAN GENET LAB,ADV BIOSCI LAB,BASIC RES PROGRAM,FREDERICK,MD 21702	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BARLOW DP, 1987, EMBO J, V6, P617, DOI 10.1002/j.1460-2075.1987.tb04799.x; BRANNAN CI, 1992, IN PRESS GENOMICS; BUDEL LM, 1990, BLOOD, V75, P1439; CAMPBELL HD, 1992, GENOMICS, V12, P179, DOI 10.1016/0888-7543(92)90428-U; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DEVOS R, 1991, EMBO J, V10, P2133, DOI 10.1002/j.1460-2075.1991.tb07747.x; ELLIOTT MJ, 1989, BLOOD, V74, P2349; GESNER TG, 1988, J CELL PHYSIOL, V136, P493, DOI 10.1002/jcp.1041360314; GNARRA JR, 1990, P NATL ACAD SCI USA, V87, P3440, DOI 10.1073/pnas.87.9.3440; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; Green EL, 1981, GENETICS PROBABILITY, P77; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KANAKURA Y, 1990, BLOOD, V76, P706; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KITAMURA T, 1991, CELL, V66, P115; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEBEAU MM, 1989, BLOOD, V73, P647; LOPEZ AF, 1991, J BIOL CHEM, V266, P24741; MAOUCHE L, 1991, BLOOD, V78, P2557; MARIN DIK, 1990, NATURE, V344, P444; MIGLIACCIO AR, 1991, P NATL ACAD SCI USA, V88, P11086, DOI 10.1073/pnas.88.24.11086; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MURATA Y, 1990, BIOCHEM BIOPH RES CO, V173, P1102, DOI 10.1016/S0006-291X(05)80899-X; NOGUCHI CT, 1991, BLOOD, V78, P2548; OGOROCHI T, 1992, BLOOD, V79, P895; PARK LS, 1989, J BIOL CHEM, V264, P5420; PLEIMAN CM, 1991, MOL CELL BIOL, V11, P3052, DOI 10.1128/MCB.11.6.3052; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SCHREURS J, 1991, INT IMMUNOL, V3, P1231, DOI 10.1093/intimm/3.12.1231; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SETO Y, 1992, J IMMUNOL, V148, P259; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SHIBUYA H, 1990, NUCLEIC ACIDS RES, V18, P3697, DOI 10.1093/nar/18.13.3697; TAKAKI S, 1991, EMBO J, V10, P2833, DOI 10.1002/j.1460-2075.1991.tb07832.x; TAKETAZU F, 1991, J CELL PHYSIOL, V146, P251, DOI 10.1002/jcp.1041460209; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Wrighton N, 1992, GROWTH FACTORS, V6, P103, DOI 10.3109/08977199209011014; YANG YC, 1988, BLOOD, V71, P958; YOUSSOUFIAN H, 1990, MOL CELL BIOL, V10, P3675, DOI 10.1128/MCB.10.7.3675	46	66	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15842	15848						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1386365				2022-12-25	WOS:A1992JG11300089
J	DELSERT, CD; ROSENFELD, MG				DELSERT, CD; ROSENFELD, MG			A TISSUE-SPECIFIC SMALL NUCLEAR RIBONUCLEOPROTEIN AND THE REGULATED SPLICING OF THE CALCITONIN CALCITONIN GENE-RELATED PROTEIN TRANSCRIPT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; RAT PITUITARY; CGRP GENE; EXPRESSION; POLYPEPTIDE; BINDING; SITE; SEQUENCE; ELEMENTS; CELLS	Based on a correlation between expression patterns of an abundant tissue-specific small nuclear ribonucleoprotein (N protein) and the calcitonin gene-related protein (CGRP) splicing choice, a small nuclear ribonucleoprotein (the N factor) has been hypothesized to potentially function as a trans-acting factor involved in the regulation of the alternative splicing of the calcitonin/CGRP transcript. RNA analysis indicated that most rat, human, and simian cell lines and tissues making the CGRP mRNA splicing choice expressed the N factor mRNA. These data led us to address the effect of ectopic expression of the N factor in HeLa cells, which exhibit a calcitonin splicing choice when expressing the calcitonin/CGRP gene. Expression of the N factor exerts no effect on the calcitonin/CGRP splicing choice in HeLa cells. Furthermore, several cell lines such as the human 293 cell line make the CGRP mRNA splicing choice in the absence of any detectable level of the mRNA encoding the N factor. Together, these data reveal that the N protein is neither sufficient nor required for the tissue-specific CGRP splicing decision and that the N protein is not the trans-acting factor regulating the alternative splicing of the calcitonin/CGRP gene.	UNIV CALIF SAN DIEGO,SCH MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,EUKARYOT REGULATORY BIOL PROGRAM,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego	DELSERT, CD (corresponding author), UNIV CALIF SAN DIEGO,DEPT MED,HOWARD HUGHES MED INST,LA JOLLA,CA 92093, USA.							AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; Anderson C W, 1988, Virus Genes, V1, P149, DOI 10.1007/BF00555934; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BREITBART RE, 1987, CELL, V49, P793, DOI 10.1016/0092-8674(87)90617-9; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRENSHAW EB, 1987, CELL, V49, P389, DOI 10.1016/0092-8674(87)90291-1; DELSERT C, 1989, MOL CELL BIOL, V9, P4364, DOI 10.1128/MCB.9.10.4364; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HAMM J, 1987, EMBO J, V6, P3479, DOI 10.1002/j.1460-2075.1987.tb02672.x; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LEFF SE, 1987, CELL, V48, P517, DOI 10.1016/0092-8674(87)90202-9; LI S, 1989, P NATL ACAD SCI USA, V86, P9778, DOI 10.1073/pnas.86.24.9778; MCALLISTER G, 1989, EMBO J, V8, P1177, DOI 10.1002/j.1460-2075.1989.tb03489.x; MCALLISTER G, 1988, P NATL ACAD SCI USA, V85, P5296, DOI 10.1073/pnas.85.14.5296; MIRELL CJ, 1986, MOL CELL ENDOCRINOL, V47, P145, DOI 10.1016/0303-7207(86)90026-2; REYMOND MJ, 1984, ACTA ENDOCRINOL-COP, V106, P459, DOI 10.1530/acta.0.1060459; ROKEACH LA, 1989, J BIOL CHEM, V264, P5024; ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; SCHMAUSS C, 1989, NUCLEIC ACIDS RES, V17, P1733, DOI 10.1093/nar/17.4.1733; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SHARPE NG, 1990, MOL CELL BIOL, V10, P6817, DOI 10.1128/MCB.10.12.6817; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; STEITZ JA, 1987, STRUCTURE FUNCTION M, P71; STOLARSKYFREDMAN L, 1990, MOL ENDOCRINOL, V4, P497, DOI 10.1210/mend-4-3-497; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; TAN EM, 1982, ADV IMMUNOL, V33, P167, DOI 10.1016/S0065-2776(08)60836-6; VANDAM A, 1989, EMBO J, V8, P3853, DOI 10.1002/j.1460-2075.1989.tb08563.x; WOPPMANN A, 1990, NUCLEIC ACIDS RES, V18, P4427, DOI 10.1093/nar/18.15.4427	36	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14573	14579						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1386079				2022-12-25	WOS:A1992JF08800015
J	PRADINESFIGUERES, A; RAETZ, CRH				PRADINESFIGUERES, A; RAETZ, CRH			PROCESSING AND SECRETION OF TUMOR-NECROSIS-FACTOR-ALPHA IN ENDOTOXIN-TREATED MONO MAC-6 CELLS ARE DEPENDENT ON PHORBOL-MYRISTATE ACETATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; FACTOR GENE-EXPRESSION; MESSENGER-RNA; LIPID-A; MURINE MACROPHAGES; HUMAN-MONOCYTES; DOWN-REGULATION; FACTOR TNF; LIPOPOLYSACCHARIDE; CACHECTIN	Lipopolysaccharide (LPS, endotoxin) is a potent stimulator of tumor necrosis factor alpha (TNFalpha) synthesis and secretion in mouse macrophage tumor cells (Golenbock, D. T., Hampton, R. Y., Qureshi, N., Takayama, K., and Raetz, C. H. R. (1991) J. Biol. Chem. 266, 19490-19498). In contrast, addition of LPS (10 ng/ml) to human monomyelocytic (Mono Mac 6) cells induces very little production of TNFalpha, as judged by immunoassay of the growth medium. When 30 ng/ml 4-beta-phorbol-12-myristate 13-acetate (PMA) is added together with LPS, large amounts of TNFalpha are secreted. PMA alone is inactive. Maximal TNFalpha levels in the medium are achieved at 1 ng/ml of LPS. Protein kinase C inhibitors, such as H7 (1-(5-isoquinolinylsulfonyl)-2-methylpiperazine), staurosporine, and sphingosine, reduce TNFalpha secretion stimulated by PMA. The effect of PMA has been investigated at each stage of TNFalpha biogenesis. Treatment of Mono Mac 6 cells with LPS alone results in rapid, transient, and full expression of TNFalpha mRNA. Concomitant addition of PMA does not increase TNFalpha mRNA synthesis any further, but it prolongs the half-life of TNFalpha mRNA about 3-fold. However, mRNA stabilization does not account for the striking effect of PMA on TNFalpha secretion. Analysis of TNFalpha synthesis and secretion by immunoprecipitation indicates that LPS alone is fully effective in stimulating the formation of the intracellular 26-kDa TNFalpha precursor. LPS alone is not sufficient to allow processing of the precursor and secretion of mature 17-kDa TNFalpha. The rate of TNFalpha secretion observed immediately after the addition of PMA to LPS-pretreated cells is similar to the maximum rate from LPS/PMA-treated cells, but without the lag observed in cells after being exposed to LPS and PMA simultaneously. In summary, PMA is required for the completion of TNFalpha precursor processing and secretion in LPS-treated human Mono Mac 6 cells, whereas murine RAW cells are able to complete the terminal steps of TNFalpha processing in the absence of PMA.	MERCK SHARP & DOHME LTD,DEPT BIOCHEM,RAHWAY,NJ 07065	Merck & Company								ADAMS DO, 1987, IMMUNOL REV, V97, P5, DOI 10.1111/j.1600-065X.1987.tb00514.x; BEUSCHER HU, 1988, J BIOL CHEM, V263, P4023; BEUTLER B, 1985, J EXP MED, V161, P984, DOI 10.1084/jem.161.5.984; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; CHANTRY D, 1989, J IMMUNOL, V142, P4295; CHEN LL, 1987, NATURE, V328, P164, DOI 10.1038/328164a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANIELISSAKANI S, 1989, J BIOL CHEM, V264, P20240; DEGLIANTONI G, 1985, J EXP MED, V162, P1512, DOI 10.1084/jem.162.5.1512; DESCOTEAUX A, 1990, J IMMUNOL, V145, P846; ESPEVIK T, 1987, IMMUNOLOGY, V61, P443; FISHER H, 1990, J IMMUNOL, V144, P4663; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; GROVE DS, 1988, BIOCHEM BIOPH RES CO, V151, P94, DOI 10.1016/0006-291X(88)90563-3; HAAS JG, 1990, P NATL ACAD SCI USA, V87, P9563, DOI 10.1073/pnas.87.24.9563; HAMPTON RY, 1988, J BIOL CHEM, V263, P14802; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HENSEL G, 1989, LYMPHOKINE RES, V8, P347; HORIGUCHI J, 1989, MOL CELL BIOL, V9, P252, DOI 10.1128/MCB.9.1.252; INTRONA M, 1986, J IMMUNOL, V137, P2711; JUE DM, 1990, BIOCHEMISTRY-US, V29, P8371, DOI 10.1021/bi00488a025; KOVACS EJ, 1988, J IMMUNOL, V141, P3101; KOYABASHI Y, 1988, J IMMUNOL, V140, P2279; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LUETTIG B, 1989, J IMMUNOL, V143, P4034; MARTIN CA, 1990, CELL IMMUNOL, V128, P555, DOI 10.1016/0008-8749(90)90048-V; MOHRI M, 1990, J IMMUNOL, V144, P2678; MULLER R, 1986, FEBS LETT, V197, P99, DOI 10.1016/0014-5793(86)80306-4; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; ROSEN A, 1989, J BIOL CHEM, V264, P9118; SARIBAN E, 1988, J CLIN INVEST, V81, P1506, DOI 10.1172/JCI113482; SCUDERI P, 1989, J IMMUNOL, V143, P4034; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; SHERRY B, 1988, J CELL BIOL, V107, P1269, DOI 10.1083/jcb.107.4.1269; SHIRAI T, 1985, NATURE, V313, P803, DOI 10.1038/313803a0; STRULOVICI B, 1989, BIOCHEMISTRY-US, V28, P3569, DOI 10.1021/bi00434a063; SUNG SSJ, 1988, J EXP MED, V168, P1539, DOI 10.1084/jem.168.5.1539; SUNG SSJ, 1991, J IMMUNOL, V147, P2047; TAKASUKA N, 1991, J IMMUNOL, V146, P3824; TAKAYAMA K, 1984, INFECT IMMUN, V45, P350, DOI 10.1128/IAI.45.2.350-355.1984; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; TURNER M, 1987, EUR J IMMUNOL, V17, P1807, DOI 10.1002/eji.1830171220; WALTERS P, 1986, J CELL BIOL, V102, P1543; WIGHTMAN PD, 1984, J BIOL CHEM, V259, P48; WOLD F, 1986, TRENDS BIOCHEM SCI, V11, P58, DOI 10.1016/0968-0004(86)90254-9; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	52	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23261	23268						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429672				2022-12-25	WOS:A1992JY16300085
J	ROSENG, L; TOLLESHAUG, H; BERG, T				ROSENG, L; TOLLESHAUG, H; BERG, T			UPTAKE, INTRACELLULAR-TRANSPORT, AND DEGRADATION OF POLYETHYLENE GLYCOL-MODIFIED ASIALOFETUIN IN HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; RECEPTOR-MEDIATED ENDOCYTOSIS; LIVER ENDOTHELIAL-CELLS; COVALENT ATTACHMENT; BINDING ABILITY; FETUIN; INVIVO; GLYCOPROTEINS; INTERNALIZATION; DISAPPEARANCE	Polyethylene glycol (PEG) is attached to proteins in order to increase their half-life in the circulation and reduce their immunogenicity in vivo. For many applications involving "targeting" molecules, it is important to know how PEG modification of the molecule affects its interaction with a receptor and the subsequent internalization, intracellular transport, and lysosomal degradation. As a model system, we used asialofetuin, which binds to the galactose receptor of hepatocytes, because removal of sialic acid exposes galactose residues. We modified asialofetuin by attaching various amounts of PEG of molecular weight 1900 or 5000. The preparations were labeled with I-125 so that endocytosis and degradation could be followed in suspended hepatocytes. Depending on the number of PEG molecules attached, receptor-mediated uptake was affected to varying degrees. If two-thirds of the exposed amino groups of the asialofetuin molecule were modified, the rate of uptake decreased to less than one-fourth of controls; degradation of endocytosed molecules was 12% of controls. The reduction in endocytic uptake was due to a reduced rate of formation of the receptor-ligand complex. Subcellular frationation in density gradients showed that PEG-modified asialofetuin is transported intracellularly and degraded in the same manner as the native protein, but the rate of proteolysis is reduced. This observation explains the paradoxical result of experiments with injection of modified asialofetuin into rats in vivo: even though the clearance of one preparation of PEG-asialofetuin was much slower than that of the native protein, accumulation of radioactivity in the liver from the modified protein was twice as high. The hepatocytes accounted for 85% of the hepatic accumulation of either PEG-modified or native asialofetuin in vivo.	NYCOMED AS, DEPT EXPTL BIOL, N-0401 OSLO 4, NORWAY; UNIV OSLO, DEPT BIOL, CELL BIOL SECT, N-0316 OSLO, NORWAY	University of Oslo	ROSENG, L (corresponding author), NORWEGIAN RADIUM HOSP, ENVIRONM & OCCUPAT CANC LAB, N-0310 OSLO 3, NORWAY.							ABUCHOWSKI A, 1977, J BIOL CHEM, V252, P3578; ANDERSON WL, 1988, J IMMUNOL METHODS, V109, P37, DOI 10.1016/0022-1759(88)90439-5; ASHIHARA Y, 1978, BIOCHEM BIOPH RES CO, V83, P385, DOI 10.1016/0006-291X(78)91002-1; BARRETT AJ, 1972, LYSOSOMES LABORATORY, P116; BERG T, 1980, BIOCHEM PHARMACOL, V29, P917, DOI 10.1016/0006-2952(80)90222-1; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BLOMHOFF R, 1984, EXP CELL RES, V150, P194, DOI 10.1016/0014-4827(84)90714-6; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHARLWOOD PA, 1979, BIOCHIM BIOPHYS ACTA, V585, P61, DOI 10.1016/0304-4165(79)90325-8; DZIEGIELEWSKA KM, 1990, J BIOL CHEM, V265, P4354; FUJITA T, 1991, J PHARMACOBIO-DYNAM, V14, P623, DOI 10.1248/bpb1978.14.623; FURUNO K, 1983, J BIOCHEM-TOKYO, V93, P249, DOI 10.1093/oxfordjournals.jbchem.a134160; GOLDENBERG DM, 1987, J CANCER RES CLIN, V113, P203, DOI 10.1007/BF00396374; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; HUBBARD AL, 1979, J CELL BIOL, V83, P47, DOI 10.1083/jcb.83.1.47; Hurwitz E., 1980, J APPL BIOCHEM, V2, P25; HYSING J, 1986, BIOCHIM BIOPHYS ACTA, V887, P42, DOI 10.1016/0167-4889(86)90120-5; KATRE NV, 1990, J IMMUNOL, V144, P209; KINDBERG GM, 1984, ANAL BIOCHEM, V142, P455, DOI 10.1016/0003-2697(84)90489-5; KINDBERG GM, 1990, BIOCHEM J, V270, P197, DOI 10.1042/bj2700197; KNAUF MJ, 1988, J BIOL CHEM, V263, P15064; KNUTSON VP, 1987, J BIOL CHEM, V262, P2374; KOIDE A, 1982, FEBS LETT, V143, P73, DOI 10.1016/0014-5793(82)80276-7; KOLSET SO, 1979, EXP CELL RES, V122, P159, DOI 10.1016/0014-4827(79)90570-6; LIU TH, 1989, AM J PHYSIOL, V256, pH589, DOI 10.1152/ajpheart.1989.256.2.H589; MATSUSHIMA A, 1992, BIOCHEM INT, V26, P485; MEARES CF, 1988, INT J CANCER, P99; MEYERS FJ, 1991, CLIN PHARMACOL THER, V49, P307, DOI 10.1038/clpt.1991.33; MORI A, 1991, FEBS LETT, V284, P263, DOI 10.1016/0014-5793(91)80699-4; Morimoto Y, 1985, Crit Rev Ther Drug Carrier Syst, V2, P19; MOSLEY ST, 1981, P NATL ACAD SCI-BIOL, V78, P5717, DOI 10.1073/pnas.78.9.5717; NENSETER MS, 1988, BIOCHEM J, V254, P443, DOI 10.1042/bj2540443; ODA T, 1989, SCIENCE, V244, P974, DOI 10.1126/science.2543070; PITTMAN RC, 1983, BIOCHEM J, V212, P791, DOI 10.1042/bj2120791; REDSHAW MR, 1974, J ENDOCRINOL, V60, P527, DOI 10.1677/joe.0.0600527; SAVOCA KV, 1979, BIOCHIM BIOPHYS ACTA, V578, P47, DOI 10.1016/0005-2795(79)90111-9; SCHWARTZ AL, 1984, CRC CR REV BIOCH MOL, V16, P207, DOI 10.3109/10409238409108716; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SHEN WC, 1985, J BIOL CHEM, V260, P905; SMIT MJ, 1987, J BIOL CHEM, V262, P13020; SUZUKI T, 1984, BIOCHIM BIOPHYS ACTA, V788, P248, DOI 10.1016/0167-4838(84)90268-1; TAKAHASHI K, 1984, BIOCHEM BIOPH RES CO, V121, P261, DOI 10.1016/0006-291X(84)90716-2; TAKAHASHI K, 1984, BIOCHEM BIOPH RES CO, V125, P761, DOI 10.1016/0006-291X(84)90604-1; TANAKA H, 1991, CANCER RES, V51, P3710; TOLLESHAUG H, 1981, INT J BIOCHEM, V13, P45, DOI 10.1016/0020-711X(81)90135-X; TOLLESHAUG H, 1980, EUR J CELL BIOL, V23, P104; TOLLESHAUG H, 1984, BIOCHIM BIOPHYS ACTA, V803, P182, DOI 10.1016/0167-4889(84)90008-9; TOLLESHAUG H, 1981, EXP CELL RES, V134, P207, DOI 10.1016/0014-4827(81)90478-X; TOLLESHAUG H, 1981, J BIOL CHEM, V256, P6526; TOLLESHAUG H, 1977, BIOCHIM BIOPHYS ACTA, V499, P73, DOI 10.1016/0304-4165(77)90230-6; TOLLESHAUG H, 1980, BIOCHEM J, V190, P697, DOI 10.1042/bj1900697; WHITE CW, 1989, J APPL PHYSIOL, V66, P584, DOI 10.1152/jappl.1989.66.2.584	52	35	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22987	22993						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1385410				2022-12-25	WOS:A1992JY16300045
J	MELNICK, J; AVIEL, S; ARGON, Y				MELNICK, J; AVIEL, S; ARGON, Y			THE ENDOPLASMIC-RETICULUM STRESS PROTEIN-GRP94, IN ADDITION TO BIP, ASSOCIATES WITH UNASSEMBLED IMMUNOGLOBULIN-CHAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID SUBSTITUTION; LUMINAL ER PROTEINS; HEAVY-CHAIN; BINDING-PROTEIN; MONOCLONAL-ANTIBODIES; DISULFIDE-ISOMERASE; VARIABLE REGION; LIGHT-CHAINS; SECRETION; GLUCOSE	The molecular chaperone BiP/GRP78 associates with various polypeptides in the endoplasmic reticulum, including immunoglobulin chains. We now show, using chemical cross-linking, that another endoplasmic reticulum stress protein, GRP94, associates with newly synthesized immunoglobulin light and heavy chains. We demonstrate the presence of ternary complexes composed of immunoglobulin chains, BiP and GRP94. Because both BiP and GRP94 associate far less with fully assembled immunoglobulin than with unassembled subunits, our data suggest that GRP94, like BiP, functions as a molecular chaperone. The presence of both BiP and GRP94 in the same complex further suggests that the two stress proteins work in concert during the folding and assembly of immunoglobulins.	DUKE UNIV,MED CTR,DEPT IMMUNOL,POB 3010,DURHAM,NC 27710; BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND	Duke University					NCI NIH HHS [CA-09058] Funding Source: Medline; NIAID NIH HHS [AI-30178] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030178] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARGON Y, 1984, J IMMUNOL, V133, P1627; ARGON Y, 1983, EUR J IMMUNOL, V13, P301, DOI 10.1002/eji.1830130406; BERGMAN LW, 1979, J BIOL CHEM, V254, P5690; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DUL JL, 1990, P NATL ACAD SCI USA, V87, P8135, DOI 10.1073/pnas.87.20.8135; DUL JL, 1992, J IMMUNOL, V149, P1927; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; KAETZEL CS, 1987, BIOCHEM J, V241, P39, DOI 10.1042/bj2410039; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KOCH G, 1986, J CELL SCI, V86, P217; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LENNY N, 1991, J BIOL CHEM, V266, P20532; LEWIS MJ, 1985, J BIOL CHEM, V260, P3050; LIU ES, 1991, NUCLEIC ACIDS RES, V19, P5425, DOI 10.1093/nar/19.19.5425; MA J, 1990, MOL IMMUNOL, V27, P623, DOI 10.1016/0161-5890(90)90004-J; MAKI RG, 1990, P NATL ACAD SCI USA, V87, P5658, DOI 10.1073/pnas.87.15.5658; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MOSMANN TR, 1980, CELL, V20, P283, DOI 10.1016/0092-8674(80)90614-5; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAKAKI T, 1989, MOL CELL BIOL, V9, P2233, DOI 10.1128/MCB.9.5.2233; OETTGEN HC, 1986, NATURE, V320, P272, DOI 10.1038/320272a0; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RETH M, 1979, EUR J IMMUNOL, V9, P1004, DOI 10.1002/eji.1830091216; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; WIEST DL, 1989, J CELL BIOL, V110, P1501; WU GE, 1983, CELL, V33, P77, DOI 10.1016/0092-8674(83)90336-7	38	222	232	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21303	21306						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400441				2022-12-25	WOS:A1992JV01100009
J	SENIOR, AE; ALSHAWI, MK				SENIOR, AE; ALSHAWI, MK			FURTHER EXAMINATION OF 17 MUTATIONS IN ESCHERICHIA-COLI F1-ATPASE BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART MITOCHONDRIAL ATPASE; UNISITE CATALYTIC PATHWAY; SITE-DIRECTED MUTAGENESIS; ADENOSINE-TRIPHOSPHATASE; TRANSLOCATING ATPASE; ELEMENTARY STEPS; ALPHA-SUBUNITS; MUTANT STRAINS; RATE CONSTANTS; H+-ATPASE	Seventeen mutations in beta-subunit of Escherichia coli F1-ATPase which had previously been characterized in strain AN1272 (Mu-induced mutant) were expressed in strain JP17 (beta-subunit gene deletion). Six showed unchanged behavior, namely: C137Y; G142D; G146S; G207D; Y297F; and Y354F. Five failed to assemble F1F0 correctly, namely: G149I; G154I; G149I,G154I; G223D; and P403S,G415D. Six assembled F1F0 correctly, but with membrane ATPase lower than in AN1272, namely: K155Q; K155E; E181Q; E192Q; D242N; and D242V. AN1272 was shown to unexpectedly produce a small amount of wild-type beta-subunit; F1-ATPase activities reported previously in AN1272 were referable to hybrid enzymes containing both mutant and wild-type beta-subunits. Purified F1 was obtained from K155Q; K155E; E181Q; E192Q; and D242N mutants in JP17. V(max) ATPase values were lower, and unisite catalysis rate and equilibrium constants were perturbed to greater extent, than in AN1272. However, general patterns of perturbation revealed by difference energy diagrams were similar to those seen previously, and the new data correlated well in linear free energy relationships for reaction steps of unisite catalysis. Correlation between multisite and unisite ATPase activity was seen in the new enzymes. Overall, the data give strong support to previously proposed mechanisms of unisite catalysis, steady-state catalysis, and energy coupling in F1-ATPases (Al-Shawi, M. K., Parsonage, D. and Senior, A. E. (1990) J. Biol. Chem. 265, 4402-4410). The K155Q, K155E, D242N, and E181Q mutations caused 5000-fold, 4000-fold, 1800-fold, and 700-fold decrease, respectively, in V(max). ATPase, implying possibly direct roles for these residues in catalysis. Experiments with the D242N mutant suggested a role for residue betaD242 in catalytic site Mg2+ binding.			SENIOR, AE (corresponding author), UNIV ROCHESTER,MED CTR,DEPT BIOCHEM,ROCHESTER,NY 14642, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025349, R01GM025349] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P886, DOI 10.1021/bi00118a034; ALSHAWI MK, 1988, J BIOL CHEM, V263, P19640; ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P878, DOI 10.1021/bi00118a033; ALSHAWI MK, 1989, J BIOL CHEM, V264, P15376; ALSHAWI MK, 1990, J BIOL CHEM, V265, P4402; ALSHAWI MK, 1988, J BIOL CHEM, V263, P19633; ANDREWS WW, 1984, J BIOL CHEM, V259, P4378; DOWNIE JA, 1981, J BACTERIOL, V145, P200, DOI 10.1128/JB.145.1.200-210.1981; FAYLE DRH, 1978, BIOCHEM J, V172, P523, DOI 10.1042/bj1720523; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; KIRONDE FAS, 1989, BIOCHEM J, V259, P421, DOI 10.1042/bj2590421; LEE RSF, 1991, BIOCHEMISTRY-US, V30, P6842, DOI 10.1021/bi00242a006; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; NOUMI T, 1986, J BIOL CHEM, V261, P7070; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHTSUBO M, 1987, BIOCHEM BIOPH RES CO, V146, P705, DOI 10.1016/0006-291X(87)90586-9; PARSONAGE D, 1988, FEBS LETT, V232, P111, DOI 10.1016/0014-5793(88)80397-1; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; PARSONAGE D, 1988, ARCH BIOCHEM BIOPHYS, V261, P222, DOI 10.1016/0003-9861(88)90121-X; PARSONAGE D, 1987, J BIOL CHEM, V262, P8022; PENEFSKY HS, 1985, P NATL ACAD SCI USA, V82, P1589, DOI 10.1073/pnas.82.6.1589; PENEFSKY HS, 1986, METHOD ENZYMOL, V126, P608; PERLIN DS, 1985, BIOCHIM BIOPHYS ACTA, V807, P238, DOI 10.1016/0005-2728(85)90254-3; SATRE M, 1979, BIOCHEMISTRY-US, V18, P3134, DOI 10.1021/bi00581a034; SENIOR AE, 1983, BIOCHEM J, V210, P395, DOI 10.1042/bj2100395; SENIOR AE, 1979, BIOCHEM J, V180, P111, DOI 10.1042/bj1800111; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SKERRETT KJ, 1981, BIOCHIM BIOPHYS ACTA, V638, P120, DOI 10.1016/0005-2728(81)90194-8; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBER J, 1992, J BIOL CHEM, V267, P1712; WISE JG, 1983, BIOCHEM J, V215, P343, DOI 10.1042/bj2150343; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5	36	91	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21471	21478						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400460				2022-12-25	WOS:A1992JV01100034
J	SHIGEMATSU, Y; MIYATA, T; HIGASHI, S; MIKI, T; SADLER, JE; IWANAGA, S				SHIGEMATSU, Y; MIYATA, T; HIGASHI, S; MIKI, T; SADLER, JE; IWANAGA, S			EXPRESSION OF HUMAN SOLUBLE TISSUE FACTOR IN YEAST AND ENZYMATIC-PROPERTIES OF ITS COMPLEX WITH FACTOR-VIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CDNA; GENE; PROTEIN; PURIFICATION; COAGULATION; RECEPTOR; BINDING; INITIATION; SEQUENCE	The extracellular domain of human tissue factor (TF, amino acids 1-217) was expressed in Saccharomyces cerevisiae, using the inducible yeast acid phosphatase promoter and the yeast invertase signal sequence to direct its secretion into the culture broth. Two active soluble forms sTFalpha (high molecular weight form) and sTFbeta (low molecular weight form) were purified, the yield being approximately 10 and 1 mg/liter of culture supernatant, respectively. sTFalpha had an apparent molecular mass of 150 kDa on SDS-polyacrylamide gel electrophoresis and contained more than 200 residues of mannose/mol of protein. sTFbeta had an apparent molecular mass of 37 kDa and contained 22 residues of mannose/mol of protein. N-Glycosidase F treatments of both rTFs reduced the apparent molecular mass to 35 kDa. The amino-terminal sequences and amino acid compositions of sTFalpha and sTFbeta were consistent with those deduced from the cDNA sequence, thereby indicating that the difference in molecular mass is caused by heterogeneity of oligosaccharide structures. Of these recombinant TFs, sTFbeta enhanced factor VIIa-amidolytic activity 40-fold toward the chromogenic substrate and 147-fold toward the fluorogenic substrate, affecting mainly the k(cat) value. The enhancement was comparable with that of TF purified from human placenta. The TF-mediated enhancement of factor VIIa-amidolytic activity was inhibited by heparin-activated antithrombin III, forming a high molecular weight complex. As treatment of sTFbeta with denaturants such as guanidine hydrochloride or urea led to a biphasic loss of the activity, the extracellular domain of TF probably consists of two discrete domains. This expression system provides a significant amount of the extracellular domain of TF so that studies of interactions with factor VII are feasible.	KYUSHU UNIV 33,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN; KYUSHU UNIV 33,GRAD SCH MED SCI,DEPT MOLEC BIOL,FUKUOKA 812,JAPAN; KYUSHU UNIV 33,FAC PHARMACEUT SCI,FUKUOKA 812,JAPAN; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110	Kyushu University; Kyushu University; Kyushu University; Barnes-Jewish Hospital; Howard Hughes Medical Institute; Washington University (WUSTL)			Sadler, Evan/D-8556-2011	Sadler, J. Evan/0000-0001-5705-469X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147] Funding Source: NIH RePORTER; NHLBI NIH HHS [HLBI 14147] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS BS, 1991, GENE, V98, P265, DOI 10.1016/0378-1119(91)90184-D; BACH RR, 1988, CRC CR REV BIOCH MOL, V23, P339, DOI 10.3109/10409238809082548; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOSTIAN KA, 1980, P NATL ACAD SCI-BIOL, V77, P4504, DOI 10.1073/pnas.77.8.4504; BROZE GJ, 1980, J BIOL CHEM, V255, P1242; BROZE GJ, 1985, J BIOL CHEM, V260, P917; COLBURN JC, 1987, METHOD ENZYMOL, V139, P188; DMOCHOWSKA A, 1987, CELL, V50, P573, DOI 10.1016/0092-8674(87)90030-4; FISHER KL, 1987, THROMB RES, V48, P89, DOI 10.1016/0049-3848(87)90349-5; HARTZELL S, 1989, MOL CELL BIOL, V9, P2567, DOI 10.1128/MCB.9.6.2567; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; KAWABATA SI, 1988, EUR J BIOCHEM, V172, P17, DOI 10.1111/j.1432-1033.1988.tb13849.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIYANOHARA A, 1983, P NATL ACAD SCI-BIOL, V80, P1, DOI 10.1073/pnas.80.1.1; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; NEMERSON Y, 1988, BLOOD, V71, P1; PABORSKY LR, 1989, BIOCHEMISTRY-US, V28, P8072, DOI 10.1021/bi00446a016; PAWASHE A, 1991, THROMB HAEMOSTASIS, V66, P315; PENKE B, 1974, ANAL BIOCHEM, V60, P45, DOI 10.1016/0003-2697(74)90129-8; RANGANATHAN G, 1991, J BIOL CHEM, V266, P496; REHEMTULLA A, 1991, THROMB HAEMOSTASIS, V65, P521; RUF W, 1991, P NATL ACAD SCI USA, V88, P8430, DOI 10.1073/pnas.88.19.8430; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; SAKAI T, 1989, J BIOL CHEM, V264, P9980; Sambrook J, 1989, MOL CLONING LABORATO; SCARPATI EM, 1987, BIOCHEMISTRY-US, V26, P5234, DOI 10.1021/bi00391a004; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; SPICER EK, 1987, P NATL ACAD SCI USA, V84, P5148, DOI 10.1073/pnas.84.15.5148; TAKAYENOKI Y, 1991, BIOCHEM BIOPH RES CO, V181, P1145, DOI 10.1016/0006-291X(91)92058-R; TAKEMOTO H, 1985, ANAL BIOCHEM, V145, P245, DOI 10.1016/0003-2697(85)90357-4; VANDAMMIERAS MCE, 1983, HDB SYNTHETIC SUBSTR; YAMAMOTO A, 1989, J BIOCHEM-TOKYO, V106, P552, DOI 10.1093/oxfordjournals.jbchem.a122892	36	58	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21329	21337						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400445				2022-12-25	WOS:A1992JV01100014
J	WALKER, B; KRISHNASASTRY, M; ZORN, L; BAYLEY, H				WALKER, B; KRISHNASASTRY, M; ZORN, L; BAYLEY, H			ASSEMBLY OF THE OLIGOMERIC MEMBRANE PORE FORMED BY STAPHYLOCOCCAL ALPHA-HEMOLYSIN EXAMINED BY TRUNCATION MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIN; AUREUS; MECHANISM; PROTEINS; CHANNEL; BINDING; SUBUNIT; DOMAIN; DAMAGE	The alpha-hemolysin (alphaHL) from Staphylococcus aureus causes the lysis of susceptible cells such as rabbit erythrocytes (rRBCs). Lysis is associated with the formation of a hexameric pore in the plasma membrane. Here we show that truncation mutants of alphaHL missing 2 to 22 N-terminal amino acids form oligomers on the surfaces of rRBCs but fail to lyse the cells. By contrast, mutants missing 3 or 5 amino acids at the C terminus are very inefficient at oligomerization but do lyse rRBCs, albeit extremely slowly. The C-terminal truncation mutants, retarded as monomers on the cell surface, undergo a conformational change in which the protease-sensitive loop located near the midpoint of the polypeptide chain becomes occluded. Judged by this criterion, polypeptides truncated at the N terminus, frozen as nonlytic oligomers, are in a similar conformation. A second proteolytic site near the N terminus of the polypeptide becomes inaccessible in the lytic pore formed by the wild-type polypeptide, supporting the idea that a second conformational change occurs upon pore formation. These findings suggest a pathway for assembly of the lytic pore in which alphaHL first binds to target cells as a monomer, which is converted to a nonlytic oligomeric intermediate before formation of the pore. In keeping with this model, an N-terminal truncation mutant blocks the slow lysis induced by a C-terminal truncation mutant, presumably by diverting the weakly lytic subunits into inactive oligomers.	UNIV MASSACHUSETTS,MED CTR,GRAD SCH BIOMED SCI,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester	WALKER, B (corresponding author), WORCESTER FDN EXPTL BIOL INC,SHREWSBURY,MA 01545, USA.			Bayley, Hagan/0000-0003-2499-6116				ARBUTHNOTT JP, 1967, J BACTERIOL, V94, P1170, DOI 10.1128/JB.94.4.1170-1177.1967; BHAKDI S, 1983, TRENDS BIOCHEM SCI, V8, P134, DOI 10.1016/0968-0004(83)90237-2; BHAKDI S, 1991, IMMUNOL TODAY, V12, P318, DOI 10.1016/0167-5699(91)90007-G; BHAKDI S, 1981, P NATL ACAD SCI-BIOL, V78, P5475, DOI 10.1073/pnas.78.9.5475; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; BLOMQVIST L, 1988, MICROB PATHOGENESIS, V4, P223, DOI 10.1016/0882-4010(88)90072-1; CASSIDY P, 1976, BIOCHEMISTRY-US, V15, P2348, DOI 10.1021/bi00656a016; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; ESSER AF, 1991, IMMUNOL TODAY, V12, P316, DOI 10.1016/0167-5699(91)90006-F; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAY GS, 1984, INFECT IMMUN, V46, P615, DOI 10.1128/IAI.46.2.615-618.1984; HARSHMAN S, 1989, J BIOL CHEM, V264, P14978; HILDEBRAND A, 1991, J BIOL CHEM, V266, P17195; IKIGAI H, 1985, BIOCHEM BIOPH RES CO, V130, P175, DOI 10.1016/0006-291X(85)90398-5; JIANG JX, 1991, BIOCHEMISTRY-US, V30, P3857, DOI 10.1021/bi00230a008; KURET J, 1988, J BIOL CHEM, V263, P9149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCNIVEN AC, 1972, J MED MICROBIOL, V5, P113, DOI 10.1099/00222615-5-1-113; OLOFSSON A, 1990, J MOL BIOL, V214, P299, DOI 10.1016/0022-2836(90)90162-F; PEITSCH M C, 1991, Current Opinion in Cell Biology, V3, P710, DOI 10.1016/0955-0674(91)90045-Z; RENAUD KJ, 1991, J BIOL CHEM, V266, P20491; SCHIMMEL P, 1990, BIOCHEMISTRY-US, V29, P9496; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; THELESTAM M, 1988, TOXICON, V26, P51, DOI 10.1016/0041-0101(88)90137-7; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; TOBKES N, 1985, BIOCHEMISTRY-US, V24, P1915, DOI 10.1021/bi00329a017; TOBKES N, 1986, THESIS COLUMBIA U NE; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; VERALL S, 1992, CELL, V68, P23; WALKER B, 1992, J BIOL CHEM, V267, P10902	32	157	166	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21782	21786						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400487				2022-12-25	WOS:A1992JV01100081
J	GILCHRIST, JSC; WANG, KKW; KATZ, S; BELCASTRO, AN				GILCHRIST, JSC; WANG, KKW; KATZ, S; BELCASTRO, AN			CALCIUM-ACTIVATED NEUTRAL PROTEASE EFFECTS UPON SKELETAL-MUSCLE SARCOPLASMIC-RETICULUM PROTEIN-STRUCTURE AND CALCIUM RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-INDUCED CA-2+ RELEASE; RYANODINE RECEPTOR; TERMINAL CISTERNAE; INHIBITOR CALPASTATIN; ENDOGENOUS INHIBITOR; CHANNEL; MEMBRANE; VESICLES; CALPAIN; CALMODULIN	In this study, the effects of Ca2+-activated neutral protease (CANP) upon skeletal muscle heavy sarcoplasmic reticulum (HSR) structure and function were investigated. CANP was immunolocalized to the 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid detergent-insoluble fraction of purified HSR membranes. Ca2+ activation of the endogenous membrane-bound CANP produced a characteristic partial fragmentation of the HSR 565-kDa Ca2+ release channel. Similarly, the major substrate for both micromolar and millimolar Ca2+-sensitive isoforms of exogenous CANP was the Ca2+ release channel with proteolysis of a 88-kDa HSR protein also observed. Ca2+ release channel proteolysis was initiated at a single cleavage site with coincidental production of 410- and 150-kDa peptide fragments. Appearance of 160- and 137-kDa limiting peptides accompanied secondary proteolysis of the primary 410- and 150-kDa fragments, respectively. Despite extensive proteolysis of the Ca2+ release channel, CANP did not dramatically alter the Ca2+ handling and ryanodine binding properties of HSR membranes. The association of CANP with isolated HSR membranes suggests that, in vivo, this protease may modify an additional property of the Ca2+ release channel. This may be related to the CANP-susceptible structural association of the Ca2+ release channel with dihydropyridine receptors at T-tubule/sarcoplasmic reticulum junctions.	UNIV BRITISH COLUMBIA,FAC GRAD STUDIES,VANCOUVER V6T 1Z1,BC,CANADA; UNIV BRITISH COLUMBIA,FAC PHARMACEUT SCI,VANCOUVER V6T 1Z1,BC,CANADA; UNIV BRITISH COLUMBIA,FAC EDUC,DIV KINESIOL,VANCOUVER V6T 1Z1,BC,CANADA; PARKE DAVIS PHARMACEUT RES DIV,ANN ARBOR,MI 48105	University of British Columbia; University of British Columbia; University of British Columbia; Pfizer				Wang, Kevin/0000-0002-9343-6473				BELLES B, 1988, PFLUG ARCH EUR J PHY, V412, P554, DOI 10.1007/BF00582548; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BRANDT NR, 1990, J MEMBRANE BIOL, V113, P237, DOI 10.1007/BF01870075; CADWELL JJS, 1982, J CELL BIOL, V93, P543, DOI 10.1083/jcb.93.3.543; CASWELL AH, 1989, J BIOENERG BIOMEMBR, V21, P149, DOI 10.1007/BF00812067; CHU A, 1988, BIOCHEMISTRY-US, V27, P2827, DOI 10.1021/bi00408a025; CHU A, 1990, BIOCHEMISTRY-US, V29, P5899, DOI 10.1021/bi00477a003; COSTELLO B, 1986, J CELL BIOL, V103, P741, DOI 10.1083/jcb.103.3.741; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GILCHRIST JSC, 1990, BIOCHEM BIOPH RES CO, V168, P364, DOI 10.1016/0006-291X(90)91717-7; GILCHRIST JSC, 1992, J BIOL CHEM, V267, P20850; GILCHRIST JSC, 1990, P INT S CA2 PLUS BIN; GILCHRIST JSC, 1989, 1ST P EUR S CA2 PLUS; GOPALAKRISHNA R, 1986, J BIOL CHEM, V261, P13936; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P1740; KIM KC, 1990, J MEMBRANE BIOL, V113, P221, DOI 10.1007/BF01870074; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LAI FA, 1989, J BIOL CHEM, V264, P16676; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKS AR, 1990, BIOPHYS J, V57, pA176; MARTONOSI AN, 1984, PHYSIOL REV, V64, P1240, DOI 10.1152/physrev.1984.64.4.1240; MEISSNER G, 1989, J BIOL CHEM, V264, P1715; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MELLGREN RL, 1987, BIOCHEM BIOPH RES CO, V142, P1025, DOI 10.1016/0006-291X(87)91517-8; MELLGREN RL, 1987, FASEB J, V1, P110, DOI 10.1096/fasebj.1.2.2886390; MORII H, 1985, J BIOL CHEM, V260, P1536; MURACHI T, 1989, BIOCHEM INT, V18, P263; RARDON DP, 1990, CIRC RES, V67, P84, DOI 10.1161/01.RES.67.1.84; REEDY MK, 1975, J BIOL CHEM, V250, P4278; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUEST L, 1985, CAN J CHEM, V63, P2840, DOI 10.1139/v85-474; SEILER S, 1984, J BIOL CHEM, V259, P8550; SHOSHANBARMATZ V, 1988, J BIOL CHEM, V263, P16772; SHOSHANBARMATZ V, 1987, J BIOL CHEM, V262, P11559; SMITH JS, 1985, NATURE, V316, P446, DOI 10.1038/316446a0; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; SUZUKI K, 1990, CELL STRUCT FUNCT, V15, P1, DOI 10.1247/csf.15.1; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIMM JL, 1988, J BIOL CHEM, V263, P17443; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WANG KKW, 1988, ARCH BIOCHEM BIOPHYS, V260, P696, DOI 10.1016/0003-9861(88)90498-5; ZAIDI SIM, 1989, J MEMBRANE BIOL, V110, P209, DOI 10.1007/BF01869151; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	48	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20857	20865						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400400				2022-12-25	WOS:A1992JT97800056
J	BARRUECO, JR; OLEARY, DF; SIROTNAK, FM				BARRUECO, JR; OLEARY, DF; SIROTNAK, FM			FACILITATED TRANSPORT OF METHOTREXATE POLYGLUTAMATES INTO LYSOSOMES DERIVED FROM S180 CELLS - FURTHER CHARACTERIZATION AND EVIDENCE FOR A SIMPLE MOBILE CARRIER SYSTEM WITH BROAD SPECIFICITY FOR HOMOPEPTIDES OR HETEROPEPTIDES BEARING A C-TERMINAL GLUTAMYL MOIETY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST LYSOSOMES; AMINO-ACID TRANSPORT; SIALIC-ACID; RAT-LIVER; PHARMACOKINETICS; MEMBRANE	Studies are presented further characterizing a facilitative system transporting methotrexate (MTX) polyglutamates into lysosomes derived from S180 cells. Initial influx of [H-3]MTX + G1 (MTX with 1 additional glutamyl residue) exhibited a slightly alkaline pH optimum (pH 7.7) and was moderately temperature-dependent (Q10 27-37-degrees-C = 3.1 +/- 0.1). An analysis of the kinetics of intralysosomal accumulation of [H-3]MTX + G1 showed saturation kinetics for initial influx, but linear kinetics for the steady-state level of exchangeable [H-3]MTX + G1 at different external concentrations of [H-3]MTX + G1. In addition, the system exhibited substantial directional asymmetry with respect to the interaction with MTX + G1 during influx and efflux. Accelerated homo- and heteroexchange diffusion was demonstrated for influx of [H-3]MTX + G1, while decelerated homoexchange diffusion was demonstrated for efflux of [H-3]MTX + G1 following trans-positioning of MTX + G1 or glutamyl-gamma-glutamate in the opposite compartment. These observations were consistent with a single mobile carrier system mediating influx and efflux of this polyglutamate. Based upon an analysis of competitive interactions with [H-3] MTX + G1, this system displayed specificity for MTX-gamma-glutamates, folyl-gamma-polyglutamates, alpha- or gamma-glutamyl peptides and heteropeptides bearing a C-terminal gamma-glutamate but not for MTX or glutamate, themselves. Among polyglutamates, gamma-glutamyl chain length was not a significant factor for transport except in the case of MTX polyglutamates. Overall, our results appear to delineate in the lysosomal membrane a simple mobile carrier system with broad specificity for folyl- or non-folyl-bearing peptides responsible for the transport of MTX polyglutamates.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC PHARMACOL & THERAPEUT,MOLEC THERAPEUT LAB,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,ITHACA,NY 14853	Memorial Sloan Kettering Cancer Center; Cornell University					NCI NIH HHS [CA 08748, CA 22766, CA 18856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748, P01CA018856] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRUECO JR, 1992, J BIOL CHEM, V267, P15356; BARRUECO JR, 1991, J BIOL CHEM, V266, P11732; BAUGH CM, 1971, ANN NY ACAD SCI, V186, P7; BAUGH CM, 1973, BIOCHEM BIOPH RES CO, V52, P27, DOI 10.1016/0006-291X(73)90949-2; BERNAR J, 1986, J BIOL CHEM, V261, P7107; DEMBO M, 1984, FOLATE ANTAGONISTS T, V1, P173; Eilam Y., 1974, METHODS MEMBRANE BIO, V2, P283; ELSENHANS B, 1984, J BIOL CHEM, V250, P5982; FRY DW, 1982, J BIOL CHEM, V257, P1892; GAHL WA, 1982, J BIOL CHEM, V257, P9570; GALIVAN J, 1979, CANCER RES, V39, P735; GALIVAN J, 1980, MOL PHARMACOL, V17, P105; GEWIRTZ DA, 1979, CANCER RES, V39, P2914; GREENE AA, 1990, J BIOL CHEM, V265, P9888; Hall C W, 1978, Methods Enzymol, V50, P439; HARMS E, 1980, P NATL ACAD SCI-BIOL, V77, P6139, DOI 10.1073/pnas.77.10.6139; JOLIVET J, 1983, J CLIN INVEST, V72, P773, DOI 10.1172/JCI111048; JONAS AJ, 1982, J BIOL CHEM, V257, P13185; JONAS AJ, 1989, J BIOL CHEM, V264, P4953; KISLIUK RL, 1984, FOLATE ANTAGONISTS T, V1, P1; LESLIE GI, 1974, BIOCHEMISTRY-US, V13, P4957, DOI 10.1021/bi00721a013; MANCINI GMS, 1989, J BIOL CHEM, V264, P15247; MCGUIRE JJ, 1985, CANCER RES, V45, P6395; MCGUIRE JJ, 1981, MOL CELL BIOCHEM, V38, P19, DOI 10.1007/BF00235686; MCQUIRE JJ, 1984, FOLATES PTERINS, V1, P135; PISONI RL, 1989, J BIOL CHEM, V264, P4850; PISONI RL, 1987, J BIOL CHEM, V262, P15011; PISONI RL, 1987, J BIOL CHEM, V262, P6010; PISONI RL, 1985, J BIOL CHEM, V260, P4791; PLAGEMANN PGW, 1980, CURR TOP MEMBR TRANS, V14, P226; PRIEST DG, 1982, MOL CELL BIOCHEM, V43, P81, DOI 10.1007/BF00423095; SAMUELS LL, 1985, CANCER RES, V45, P1488; SCHILSKY RL, 1980, P NATL ACAD SCI-BIOL, V77, P2919, DOI 10.1073/pnas.77.5.2919; SILINK M, 1975, J BIOL CHEM, V250, P5982; SIROTNAK FM, 1980, PHARMACOL THERAPEUT, V8, P71, DOI 10.1016/0163-7258(80)90060-1; TIETZE F, 1989, J BIOL CHEM, V264, P15316; WANG TTY, 1986, J BIOL CHEM, V261, P3551; WHITEHEAD VM, 1975, CANCER RES, V35, P2985	38	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19986	19991						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1383199				2022-12-25	WOS:A1992JR85800040
J	FAUNDEZ, V; KRAUSS, R; HOLUIGUE, L; GARRIDO, J; GONZALEZ, A				FAUNDEZ, V; KRAUSS, R; HOLUIGUE, L; GARRIDO, J; GONZALEZ, A			EPIDERMAL GROWTH-FACTOR RECEPTOR IN SYNAPTIC FRACTIONS OF THE RAT CENTRAL-NERVOUS-SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TYROSINE KINASE; LONG-TERM POTENTIATION; FACTOR IMMUNOREACTIVE MATERIAL; EGF-RECEPTOR; MAMMALIAN BRAIN; MESSENGER-RNA; BINDING-SITE; FACTOR-ALPHA; CELLS; LOCALIZATION	Functional relationships between epidermal growth factor (EGF) and neural tissues have of late attracted increasing interest. However, in spite of reported EGF effects on neurons, the expression of the EGF receptor (EGF-R) has not yet been unambiguously demonstrated in these cells. This 170-kDa protein bears an intracellular tyrosine kinase domain in which activity is ligand-dependent. We give definitive evidence here for its presence in neonatal and adult rat neurons showing also, for the first time, its binding and functional tyrosine kinase activities in the synaptic region. Immunohistochemistry using a polyclonal antibody prepared against the receptor purified from rat liver showed positive staining localized exclusively to neurons without regionalization to any particular brain zone. Binding studies made in Percoll-obtained synaptosomes revealed specific high affinity I-125-EGF binding sites (K(d), 1.42 x 10(-10) +/- 0.58 M) accounting for 17% of total binding and a great majority of low affinity (K(d), 2.55 x 10(-9) +/- 0.35 M) binding sites. Higher binding capacity was found in synaptosomal fractions obtained from newborn rats. The identity of the synaptosomal EGF binding activity with the 170-kDa EGF-R protein was demonstrated by cross-linking experiments. Furthermore, EGF-Affi-Prep affinity chromatography adsorbs a 170-kDa protein with EGF-R immunoreactivity from whole homogenates of adult rat brain. Phosphorylation assays made in freeze-thawed or intact synaptosomes showed EGF-induced tyrosine phosphorylation in the range of 170-, 126-150-, 124-, 113-, 98-, and 70-kDa proteins including the EGF-R. Thus, the EGF-R/EGF regulatory system could have a role in synaptic function that remains to be explored.	CATHOLIC UNIV CHILE, FAC MED, DEPT INMUNOL CLIN & REUMATOL, CASILLA 114-D, SANTIAGO, CHILE; CATHOLIC UNIV CHILE, FAC CIENCIAS BIOL, SANTIAGO, CHILE	Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile			Faundez, Victor/H-5539-2012	Faundez, Victor/0000-0002-2114-5271				AVOLA R, 1988, J NEUROSCI RES, V19, P230, DOI 10.1002/jnr.490190208; BARABAN JM, 1989, AM J PSYCHIAT, V146, P1251; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BIRECREE E, 1991, DEV BRAIN RES, V60, P145, DOI 10.1016/0165-3806(91)90043-I; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CARPENTIER JL, 1987, J CELL BIOL, V105, P2751, DOI 10.1083/jcb.105.6.2751; CHENG N, 1990, J BIOL CHEM, V265, P2417; COHEN S, 1982, P NATL ACAD SCI-BIOL, V79, P6237, DOI 10.1073/pnas.79.20.6237; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P13642; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; DUNN WA, 1986, J CELL BIOL, V102, P24, DOI 10.1083/jcb.102.1.24; ELLIS PD, 1988, J NEUROCHEM, V51, P611, DOI 10.1111/j.1471-4159.1988.tb01082.x; FALLON JH, 1984, SCIENCE, V224, P1107, DOI 10.1126/science.6144184; GIRAULT JA, 1992, J NEUROCHEM, V58, P518, DOI 10.1111/j.1471-4159.1992.tb09751.x; GLADHAUG IP, 1988, CANCER RES, V48, P6560; GOMEZPINILLA F, 1988, BRAIN RES, V438, P385, DOI 10.1016/0006-8993(88)91369-8; GONATAS NK, 1971, J CELL BIOL, V51, P484, DOI 10.1083/jcb.51.2.484; GONZALEZ A, 1981, J CELL BIOL, V88, P108, DOI 10.1083/jcb.88.1.108; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; GREGORY H, 1975, NATURE, V257, P325, DOI 10.1038/257325a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HIRAMATSU M, 1988, EXPERIENTIA, V44, P23, DOI 10.1007/BF01960230; HIRANO AA, 1988, J NEUROCHEM, V50, P1447, DOI 10.1111/j.1471-4159.1988.tb03029.x; HIRATA Y, 1982, J CLIN ENDOCR METAB, V55, P1174, DOI 10.1210/jcem-55-6-1174; Johnson R A, 1979, Adv Cyclic Nucleotide Res, V10, P135; KENNEDY MB, 1989, CELL, V59, P777, DOI 10.1016/0092-8674(89)90601-6; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; KUDLOW JE, 1989, J BIOL CHEM, V264, P3880; LAKSHMANAN J, 1986, J NEUROCHEM, V46, P1081, DOI 10.1111/j.1471-4159.1986.tb00621.x; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LEUTZ A, 1982, NEUROSCI LETT, V30, P179, DOI 10.1016/0304-3940(82)90293-2; LINDEN DJ, 1989, BRAIN RES REV, V14, P279, DOI 10.1016/0165-0173(89)90004-0; MARCANTONIO EE, 1982, EUR J BIOCHEM, V124, P217, DOI 10.1111/j.1432-1033.1982.tb05928.x; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOODY TW, 1988, ANN NY ACAD SCI, V547, P114, DOI 10.1111/j.1749-6632.1988.tb23880.x; MORRISON RS, 1988, J NEUROSCI RES, V21, P71, DOI 10.1002/jnr.490210111; MORRISON RS, 1987, SCIENCE, V238, P72, DOI 10.1126/science.3498986; MOSS AM, 1990, P NATL ACAD SCI USA, V87, P4453, DOI 10.1073/pnas.87.12.4453; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAGY A, 1984, J NEUROCHEM, V43, P1114, DOI 10.1111/j.1471-4159.1984.tb12851.x; NEUFELD G, 1987, J CELL PHYSIOL, V131, P131, DOI 10.1002/jcp.1041310119; NISHIBE S, 1989, J BIOL CHEM, V264, P10335; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; OKADA M, 1988, J BIOCHEM-TOKYO, V104, P297, DOI 10.1093/oxfordjournals.jbchem.a122461; PANG DT, 1988, P NATL ACAD SCI USA, V85, P762, DOI 10.1073/pnas.85.3.762; PLATASALAMAN CR, 1988, NEUROSCI LETT, V94, P161, DOI 10.1016/0304-3940(88)90288-1; REES AR, 1984, EMBO J, V3, P1843, DOI 10.1002/j.1460-2075.1984.tb02057.x; ROBINSON RA, 1982, CANCER RES, V42, P2633; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; SCHAUDIES RP, 1989, J BIOL CHEM, V264, P10447; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; SPIEGELBERG T, 1988, MOL CELL BIOL, V8, P3338, DOI 10.1128/MCB.8.8.3338; STRATTON KR, 1989, P NATL ACAD SCI USA, V86, P2498, DOI 10.1073/pnas.86.7.2498; TALIAN JC, 1983, J CELL BIOL, V97, P1277, DOI 10.1083/jcb.97.4.1277; TERFAU H, 1989, BRAIN RES, V484, P352; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VIO CP, 1985, KIDNEY INT, V28, P36, DOI 10.1038/ki.1985.115; WALICKE PA, 1989, ANNU REV NEUROSCI, V12, P103, DOI 10.1146/annurev.neuro.12.1.103; WALKER F, 1991, J BIOL CHEM, V266, P2746; WANG SL, 1989, ENDOCRINOLOGY, V124, P240, DOI 10.1210/endo-124-1-240; WERNER MH, 1988, J HISTOCHEM CYTOCHEM, V36, P81, DOI 10.1177/36.1.3275713; WILCOX JN, 1988, J NEUROSCI, V8, P1901; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; [No title captured]	70	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20363	20370						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400354				2022-12-25	WOS:A1992JR85800096
J	YANNARIELLOBROWN, J; FROST, SJ; WEIGEL, PH				YANNARIELLOBROWN, J; FROST, SJ; WEIGEL, PH			IDENTIFICATION OF THE CA2+-INDEPENDENT ENDOCYTIC HYALURONAN RECEPTOR IN RAT-LIVER SINUSOIDAL ENDOTHELIAL-CELLS USING A PHOTOAFFINITY CROSS-LINKING REAGENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; ACID BINDING; HEPATOCYTES; SURFACE; DEGRADATION; PGP-1; SITE	The Ca2+-independent endocytic hyaluronan (HA) receptor in rat liver sinusoidal endothelial cells (LECs) was identified using a novel cross-linking derivative of HA. The heterobifunctional, photoactivatable, reducible reagent sulfosuccinimidyl 2-(p-azidosalicylamido)ethyl-1,3'-dithiopropionate (SASD) was coupled to the terminal amino group of uniquely modified HA-amine oligosaccharides (M(r) approximately 60,000) and subsequently iodinated. I-125-ASD-HA bound to cultured LECs with similar specificity and affinity as a previously characterized I-125-HA-amine/Bolton-Hunter adduct. Permeabilized LECs were incubated with I-125-ASD-HA with 10 mM EGTA and photolysed with UV light. Detergent extracts were reduced to release the HA oligosaccharides and radiolabeled proteins were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography. Two polypeptides were consistently and equally labeled at M(r) = 175,000 and 166,000. Photoaffinity labeling of these two proteins was virtually identical in cultured LECs or membranes and was competed >90% with a 100-fold excess of HA. As with the previously characterized bona fide LEC HA receptor, cross-linking was also competed by chondroitin sulfate and heparin, but less efficiently by chondroitin and not with galacturonan. We conclude that the Ca2+-independent LEC HA receptor is composed of at least two polypeptides of M(r) approximately 175,000 and 166,000 and may exist as a heterodimer of M(r) approximately 340,000. We also conclude that the LEC HA receptor is distinct from the CD44 family of HA-binding proteins.	UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston					NIA NIH HHS [AG05492] Funding Source: Medline; NIGMS NIH HHS [GM35978] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [F32AG005492] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALHO AM, 1989, J CELL BIOL, V108, P1557, DOI 10.1083/jcb.108.4.1557; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BOLTON AE, 1973, BIOCHEM J, V133, P5339; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CAMP RL, 1991, J CELL BIOL, V115, P1283, DOI 10.1083/jcb.115.5.1283; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; CULTY M, 1992, J CELL BIOL, V116, P1055, DOI 10.1083/jcb.116.4.1055; DONNER DB, 1983, J BIOL CHEM, V258, P2736; DSOUZA M, 1985, BIOCHEM INT, V10, P43; ERIKSSON S, 1983, EXP CELL RES, V144, P223, DOI 10.1016/0014-4827(83)90458-5; FAASSEN AE, 1992, J CELL BIOL, V116, P521, DOI 10.1083/jcb.116.2.521; FORSBERG N, 1991, BIOCHIM BIOPHYS ACTA, V1078, P12, DOI 10.1016/0167-4838(91)90085-E; FROST SJ, 1988, BIOCHIM BIOPHYS ACTA, V946, P66, DOI 10.1016/0005-2736(88)90458-0; FROST SJ, 1990, BIOCHIM BIOPHYS ACTA, V1034, P39, DOI 10.1016/0304-4165(90)90150-U; FROST SJ, 1990, BIOCHEMISTRY-US, V29, P10425, DOI 10.1021/bi00497a019; FROST SJ, 1990, CHARACTERIZATION PUR; GREEN SJ, 1988, J CELL SCI, V89, P145; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JACKSON DG, 1992, J BIOL CHEM, V267, P4732; JI TH, 1982, ANAL BIOCHEM, V121, P286, DOI 10.1016/0003-2697(82)90481-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT TC, 1986, BIOCHEM J, V234, P653, DOI 10.1042/bj2340653; LESLEY J, 1990, EXP CELL RES, V187, P224, DOI 10.1016/0014-4827(90)90085-O; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGARY CT, 1989, BIOCHEM J, V257, P875, DOI 10.1042/bj2570875; MCGARY CT, 1988, HYALURONIC ACID BIND; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; MURAKAMI S, 1990, J IMMUNOL, V145, P3618; NAGASAWA K, 1980, METHODS CARBOHYDR CH, V8, P287; OKA JA, 1987, J CELL PHYSIOL, V133, P243, DOI 10.1002/jcp.1041330207; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; RAJA RH, 1984, ANAL BIOCHEM, V139, P168, DOI 10.1016/0003-2697(84)90402-0; RAJA RH, 1988, J BIOL CHEM, V263, P16661; SCOTT J. E., 1960, METHODS BIOCHEM ANAL, V8, P145; SMEDSROD B, 1984, BIOCHEM J, V223, P617, DOI 10.1042/bj2230617; SMEDSROD B, 1990, BIOCHEM J, V266, P313, DOI 10.1042/bj2660313; UNDERHILL CB, 1980, J BIOL CHEM, V255, P4544; UNDERHILL CB, 1979, J CELL BIOL, V82, P475, DOI 10.1083/jcb.82.2.475; WEIGEL PH, 1992, GLYCOCONJUGATES COMP, P421; WOLLENWEBER HW, 1985, J BIOL CHEM, V260, P5068; Wong SS, 1991, CHEM PROTEIN CONJUGA; YANNARIELLOBROW.J, 1991, J CELL BIOL, V115, P262; YANNARIELLOBROWN J, 1992, J CELL BIOCHEM, V48, P73, DOI 10.1002/jcb.240480111; YANNARIELLOBROWN J, 1992, BIOCHEMISTRY-US, V31, P576, DOI 10.1021/bi00117a039	45	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20451	20456						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1383202				2022-12-25	WOS:A1992JR85800109
J	NAIR, APK; HIRSCH, HH; MORONI, C				NAIR, APK; HIRSCH, HH; MORONI, C			MAST-CELLS SENSITIVE TO V-H-RAS TRANSFORMATION ARE HYPERINDUCIBLE FOR INTERLEUKIN-3 EXPRESSION AND HAVE LOST TUMOR-SUPPRESSOR ACTIVITY	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; HEMATOPOIETIC GROWTH-FACTORS; ACUTE LYMPHOCYTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CSF MESSENGER-RNA; GM-CSF; AUTOCRINE GROWTH; FACTOR GENE; MALIGNANT TRANSFORMATION; SIGNAL-TRANSDUCTION	Subcloning of interleukin 3 (IL-3)-dependent PB-3c mastocyte cells revealed two populations, of which only one is sensitive to oncogenic transformation by v-H-ras. The corresponding tumors produce IL-3 and grow in vitro in the absence of exogenous IL-3 [Nair, A.P.K., Diamantis, I.D., Conscience, J.F., Kindler, V., Hofer, P. & Moroni, Ch. (1989). Mol. Cell. Biol., 9, 1183-11901. In the present investigation, IL-3 gene regulation was compared in ras transformable (rT) and ras nontransformable (rNT) lines. We report that upon expression of v-H-ras rT clones but not rNT clones express low levels of IL-3 mRNA as detected by reverse polymerase chain reaction. Treatment with ionomycin, a calcium ionophore, induced high levels of IL-3 expression only in ras-expressing rT clones. Somatic cell fusion between the rNT clone 20 and the IL-3-expressing mastocytoma line V2D1 led to down-regulation of IL-3 expression and to the requirement for exogenous IL-3 for in vitro growth and tumor suppression. In contrast, rT clone 15 lacked tumor-suppressor activity and failed to down-regulate IL-3 expression in somatic hybrids which grew in vitro without added IL-3. Our results indicate that IL-3 gene expression is a critical determinant for the generation of v-H-ras-induced mast cell tumors and show that disturbances in IL-3 gene regulation can be detected already at the premalignant level in v-H-ras transformation-sensitive cells.			NAIR, APK (corresponding author), UNIV BASEL,INST MED MICROBIOL,PETERSPL 10,CH-4003 BASEL,SWITZERLAND.			Hirsch, Hans H./0000-0003-0883-0423				ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; BALL PE, 1983, DIFFERENTIATION, V24, P74, DOI 10.1111/j.1432-0436.1983.tb01305.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BAUMBACH WR, 1987, MOL CELL BIOL, V7, P664, DOI 10.1128/MCB.7.2.664; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CHIAO PJ, 1991, ONCOGENE, V6, P713; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COX PM, 1991, BRIT J CANCER, V63, P651, DOI 10.1038/bjc.1991.151; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DIAMANTIS ID, 1989, P NATL ACAD SCI USA, V86, P9299, DOI 10.1073/pnas.86.23.9299; DUHRSEN U, 1990, EMBO J, V9, P1087, DOI 10.1002/j.1460-2075.1990.tb08214.x; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GAMBKE C, 1984, NATURE, V307, P476, DOI 10.1038/307476a0; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; GOUGH NM, 1984, NATURE, V309, P763, DOI 10.1038/309763a0; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; GRIMALDI JC, 1989, BLOOD, V73, P2081; HAHN S, 1991, ONCOGENE, V6, P2327; HAPEL AJ, 1986, LYMPHOKINE RES, V5, P249; HIRAI H, 1987, NATURE, V327, P430, DOI 10.1038/327430a0; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KOEFFLER HP, 1988, MOL CELL BIOL, V8, P3432, DOI 10.1128/MCB.8.8.3432; KOI M, 1989, P NATL ACAD SCI USA, V86, P8773, DOI 10.1073/pnas.86.22.8773; KRIZMAN DB, 1990, SOMAT CELL MOLEC GEN, V16, P15, DOI 10.1007/BF01650476; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LAKER C, 1989, MOL CELL BIOL, V9, P5746, DOI 10.1128/MCB.9.12.5746; MEEKER TC, 1990, BLOOD, V76, P285; MIYATAKE S, 1985, P NATL ACAD SCI USA, V82, P316, DOI 10.1073/pnas.82.2.316; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUSER J, 1989, ONCOGENE, V4, P1433; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; NEEDLEMAN SW, 1986, BLOOD, V67, P753; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; REIN A, 1985, MOL CELL BIOL, V5, P2257, DOI 10.1128/MCB.5.9.2257; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SENN HP, 1988, INT J CANCER, V41, P59, DOI 10.1002/ijc.2910410112; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; TOKSOZ D, 1987, ONCOGENE, V1, P409; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WISEMAN RW, 1988, J CELL BIOCHEM, V12, pD35; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	56	25	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1963	1972						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408138				2022-12-25	WOS:A1992JP42400009
J	KATSUYAMA, H; WANG, CLA; MORGAN, KG				KATSUYAMA, H; WANG, CLA; MORGAN, KG			REGULATION OF VASCULAR SMOOTH-MUSCLE TONE BY CALDESMON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LIGHT CHAIN PHOSPHORYLATION; ATPASE ACTIVITY; MYOSIN PHOSPHORYLATION; HEAVY-MEROMYOSIN; ACTIN-BINDING; CALMODULIN; DISSOCIATION; FRAGMENT; DOMAIN; CONTRACTION	Caldesmon is an actin-binding protein present in smooth muscle cells that also inhibits actin-activated myosin ATPase activity. To assess the possible role of caldesmon in the regulation of smooth contraction, we investigated the effects of synthetic peptides on force directly recorded from single hyperpermeable smooth muscle cells of ferret aorta and portal vein. GS17C, a peptide that contains the residues from Gly651 to Ser667 of the caldesmon sequence plus an added cysteine at the C terminus, binds calmodulin in a Ca2+-dependent manner and also binds to F-actin but does not inhibit actomyosin ATPase activity (Zhan, Q., Wong, S. S., and Wang, C.-L. A. (1991) J. Biol. Chem. 266, 21810-21814). In cells in which Ca2+ was clamped at pCa 7.0, GS17C induced a dose-dependent contraction (EC50 = 0.92-mu-M). in aorta cells, whereas it evoked little or no contraction in portal vein cells. The GS17C-induced contraction in aorta cells was inhibited at higher Ca2+ concentrations (above pCa 6.6) and by pretreatment with calmodulin. Another peptide, C16AA, which contains the residues from Ala594 to Ala609 and does not bind actin or calmodulin, did not induce contraction. Our results strongly suggest that GS17C induces contraction by the displacement of the inhibitory region of endogenous caldesmon and, furthermore, that caldesmon present in these smooth muscle cells regulates contraction by providing a basal resting inhibition of vascular tone.	BETH ISRAEL HOSP,PROGRAM SMOOTH MUSCLE RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,HARVARD THORNDIKE LAB,BOSTON,MA 02115; BOSTON BIOMED RES INST,DEPT MUSCLE RES,BOSTON,MA 02114	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Boston Biomedical Research Institute	KATSUYAMA, H (corresponding author), BETH ISRAEL HOSP,DIV CARDIOVASC,330 BROOKLINE AVE,BOSTON,MA 02215, USA.			Morgan, Kathleen/0000-0003-3300-3630	NHLBI NIH HHS [HL 31704, HL 41411, HL 42293] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041411, R01HL031704, R01HL042293] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAM LP, 1989, J BIOL CHEM, V264, P7698; BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BROZOVICH FV, 1990, PFLUG ARCH EUR J PHY, V416, P742, DOI 10.1007/BF00370624; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CHALOVICH JM, 1988, CELL BIOPHYS, V12, P73, DOI 10.1007/BF02918351; COLLINS EM, 1992, AM J PHYSIOL, V252, pH754; COLLINS J H, 1991, Protein Sequences and Data Analysis, V4, P29; DEFEO TT, 1985, PFLUG ARCH EUR J PHY, V404, P100, DOI 10.1007/BF00581502; DEFEO TT, 1985, J PHYSIOL-LONDON, V369, P269, DOI 10.1113/jphysiol.1985.sp015900; FUJII T, 1987, J BIOL CHEM, V262, P2757; GERTHOFFER WT, 1987, J PHARMACOL EXP THER, V240, P8; HAEBERLE JR, 1992, J MUSCLE RES CELL M, V13, P81, DOI 10.1007/BF01738431; HAYASHI K, 1991, J BIOL CHEM, V266, P355; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V161, P38, DOI 10.1016/0006-291X(89)91556-8; JIANG MJ, 1989, PFLUG ARCH EUR J PHY, V413, P637, DOI 10.1007/BF00581814; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; LASH JA, 1986, J BIOL CHEM, V261, P6155; LESZYK J, 1989, BIOCHEM BIOPH RES CO, V160, P1371, DOI 10.1016/S0006-291X(89)80155-X; MARSTON SB, 1991, BIOCHEM J, V279, P1; MARSTON SB, 1984, BIOCHEM SOC T, V12, P945, DOI 10.1042/bst0120945; MORELAND S, 1987, PFLUG ARCH EUR J PHY, V408, P139, DOI 10.1007/BF00581343; MORGAN JP, 1982, PFLUG ARCH EUR J PHY, V395, P75, DOI 10.1007/BF00584972; NGAI PK, 1984, J BIOL CHEM, V259, P3656; PRITCHARD K, 1986, CELL CALCIUM, V7, P309, DOI 10.1016/0143-4160(86)90035-7; RISEMAN VM, 1989, J BIOL CHEM, V264, P2869; SIEGMAN MJ, 1984, PFLUG ARCH EUR J PHY, V401, P385, DOI 10.1007/BF00584340; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOBUE K, 1982, BIOMED RES-TOKYO, V3, P188, DOI 10.2220/biomedres.3.188; SZPACENKO A, 1985, FEBS LETT, V192, P9, DOI 10.1016/0014-5793(85)80032-6; VELAZ L, 1990, J BIOL CHEM, V265, P2929; Walsh M P, 1987, Prog Clin Biol Res, V245, P119; WANG CLA, 1991, J BIOL CHEM, V266, P9166; WANG CLA, 1989, BIOCHEM BIOPH RES CO, V162, P746, DOI 10.1016/0006-291X(89)92373-5; WATSON MH, 1990, J BIOL CHEM, V265, P18860; ZHAN Q, 1991, J BIOL CHEM, V266, P21810	36	129	131	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14555	14558						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1386078				2022-12-25	WOS:A1992JF08800011
J	CHEN, D; MAGNUSON, V; HILL, S; ARNAUD, C; STEFFENSEN, B; KLEBE, RJ				CHEN, D; MAGNUSON, V; HILL, S; ARNAUD, C; STEFFENSEN, B; KLEBE, RJ			REGULATION OF INTEGRIN GENE-EXPRESSION BY SUBSTRATE ADHERENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEO-SARCOMA CELLS; ALKALINE-PHOSPHATASE ACTIVITY; LIVER TRANSCRIPTION FACTORS; GROWTH FACTOR-BETA; EXTRACELLULAR-MATRIX; SIGNAL TRANSDUCTION; DIFFERENTIATED PHENOTYPE; MONOCLONAL-ANTIBODIES; ADHESION RECEPTORS; RESPIRATORY BURST	Under substrate adherent conditions, integrin gene expression can be regulated by transforming growth factor-beta, interleukin-1beta, and prostaglandins. This report demonstrates a new mechanism that can differentially control the expression of several integrins. When MG-63 osteosarcoma cells are maintained in suspension, up-regulation of several integrin alpha-subunits takes place. Within as little as 4 h, the mRNA levels for both the alpha2- and alpha4-subunits are increased 4- and 6-fold, respectively. It was found that mRNA levels for the alpha2-, alpha4-, and alpha(v)-subunits were markedly increased in several differentiated cell lines under non-adherent conditions; however, cells that did not express a given integrin under substrate adherent conditions also did not express this integrin when maintained in suspension. The alpha5-subunit did not up-regulate during suspension growth. By immunocytochemistry, changes in integrin mRNA levels were confirmed at the protein level. Both cytochalasin B and a phorbol ester were found to induce the expression of the alpha2-subunit, but not the alpha4- and alpha5-subunits, in a dose-dependent fashion. Many investigators have documented changes in gene expression that result from changes in "cell shape." These phenomena may result from up-regulation of integrin gene expression induced by the lack of substrate adherence.			CHEN, D (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78284, USA.				NIDCR NIH HHS [DE08144] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008144] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; AULTHOUSE AL, 1989, IN VITRO CELL DEV B, V25, P659; BATES GP, 1987, IN VITRO CELL DEV B, V23, P374; BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7; BISSELL MJ, 1989, ENVIRON HEALTH PERSP, V80, P61, DOI 10.2307/3430732; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; BRADLEY WEC, 1982, SOMAT CELL GENET, V8, P207, DOI 10.1007/BF01538678; BRONNERFRASER M, 1986, DEV BIOL, V117, P528, DOI 10.1016/0012-1606(86)90320-9; BURRIDGE K, 1989, BIOESSAYS, V10, P104, DOI 10.1002/bies.950100403; CHEN LH, 1987, J BIOL CHEM, V262, P17247; DEDHAR S, 1989, J CELL PHYSIOL, V138, P291, DOI 10.1002/jcp.1041380210; DEDHAR S, 1989, EXP CELL RES, V183, P207, DOI 10.1016/0014-4827(89)90430-8; DEDHAR S, 1989, CONNECT TISSUE RES, V20, P49, DOI 10.3109/03008208909023874; DHAWAN J, 1990, J BIOL CHEM, V265, P9015; DIKE LE, 1988, P NATL ACAD SCI USA, V85, P6792, DOI 10.1073/pnas.85.18.6792; DIPERSIO CM, 1991, MOL CELL BIOL, V11, P4405, DOI 10.1128/MCB.11.9.4405; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUBOIS WT, 1991, J PERIODONTOL, V62, P190, DOI 10.1902/jop.1991.62.3.190; EIERMAN DF, 1989, J IMMUNOL, V142, P1970; GETZENBERG RH, 1990, ENDOCR REV, V11, P399, DOI 10.1210/edrv-11-3-399; GLOWACKI J, 1983, P SOC EXP BIOL MED, V172, P93; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HEINO J, 1989, J BIOL CHEM, V264, P21806; HEINO J, 1989, J BIOL CHEM, V264, P380; HOUSLAY MD, 1991, EUR J BIOCHEM, V195, P9, DOI 10.1111/j.1432-1033.1991.tb15671.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; LUIKART SD, 1983, P NATL ACAD SCI-BIOL, V80, P3738, DOI 10.1073/pnas.80.12.3738; McDonald JA, 1989, CURR OPIN CELL BIOL, V1, P995, DOI 10.1016/0955-0674(89)90071-9; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MILAM SB, 1991, J CELL PHYSIOL, V149, P173, DOI 10.1002/jcp.1041490202; MILAM SB, 1991, J ORAL MAXIL SURG, V49, P381, DOI 10.1016/0278-2391(91)90376-W; MILAM SB, 1991, CRIT REV ORAL BIOL M, V2, P451, DOI 10.1177/10454411910020040201; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; NATHAN CF, 1989, BLOOD, V73, P301; OPAS M, 1989, DEV BIOL, V131, P281, DOI 10.1016/S0012-1606(89)80001-6; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; Reid LM, 1990, CURR OPIN CELL BIOL, V2, P121, DOI 10.1016/S0955-0674(05)80042-0; RICHARDSON RL, 1988, CELL TISSUE RES, V251, P123, DOI 10.1007/BF00215456; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SOLURSH M, 1991, J CELL BIOCHEM, V45, P258, DOI 10.1002/jcb.240450306; STEFFENSEN B, 1992, BIOCHIM BIOPHYS ACTA, V1137, P95, DOI 10.1016/0167-4889(92)90105-K; STEFFENSEN B, 1992, J PERIODONTOL, V63, P584, DOI 10.1902/jop.1992.63.7.584; STICKEL SK, 1988, J CELL BIOL, V107, P1231, DOI 10.1083/jcb.107.3.1231; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; WELCH MP, 1990, J CELL BIOL, V110, P133, DOI 10.1083/jcb.110.1.133; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WERB Z, 1990, CELL DIFFER DEV, V32, P299, DOI 10.1016/0922-3371(90)90043-V; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YAMADA A, 1991, J IMMUNOL, V146, P53	52	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23502	23506						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429694				2022-12-25	WOS:A1992JZ23900016
J	KROLL, SD; CHEN, JH; DEVIVO, M; CARTY, DJ; BUKU, A; PREMONT, RT; IYENGAR, R				KROLL, SD; CHEN, JH; DEVIVO, M; CARTY, DJ; BUKU, A; PREMONT, RT; IYENGAR, R			THE Q205LG0-ALPHA-SUBUNIT EXPRESSED IN NIH-3T3-CELLS INDUCES TRANSFORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; PERTUSSIS TOXIN; BINDING PROTEIN; GO-PROTEIN; CELLS; IDENTIFICATION; ONCOGENE; RECEPTOR; DIFFERENTIATION; MUTATIONS	The growth functions of the heterotrimeric G protein G(o) was studied by expression in heterologous systems. The alpha-subunit of G(o) was mutated to convert Gln-205 to Leu (Q205L). Mutation of this conserved glutamine residue in G protein alpha-subunits is thought to persistently activate G proteins by inhibiting their GTPase activity. The wild type and mutant G(o)-alpha subunits were expressed in NIH-3T3 fibroblasts. These cells do not contain any measurable amounts of G(o)-alpha mRNA or protein. Transfection of wild type or Q205LG(o)-alpha subunit cDNA under the control of a dexamethasone-inducible promoter results in dexamethasone-dependent transcription of the mRNA and expression of the protein. The Q205LG(o)-alpha, but not wild type G(o)-alpha, stimulates mitogenesis in NIH-3T3 fibroblasts without significantly stimulating phospholipase C activity. Continuous expression of mutant G(o)-alpha induces focus formation, whereas transfections with vector alone or vector containing the native G(o)-alpha cDNA were without significant transforming effect in NIH-3T3 cells. Q205L G(o)-alpha did not induce focus formation in RAT-1 fibroblasts. Q205LG(o)-alpha-transformed NIH-3T3 cells are capable of anchorage-independent growth, as assessed by colony formation in soft agar. Q205LG(o)-alpha transformed cells induced tumors when injected into Nu/Nu mice. These results indicate that mutant G(o)-alpha subunits whose GTPase activity is presumably inhibited can induce the neoplastic transformation of NIH-3T3 cells in a phospholipase C-independent manner.	CUNY MT SINAI SCH MED,DEPT PHARMACOL & PHYSIOL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT BIOPHYS,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NATIONAL CANCER INSTITUTE [R01CA044998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761] Funding Source: NIH RePORTER; NCI NIH HHS [CA44998] Funding Source: Medline; NIDDK NIH HHS [DK38761] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; HOECK W, 1989, J BIOL CHEM, V264, P14396; IMAI A, 1987, METHOD ENZYMOL, V141, P100; IYENGAR R, 1987, J BIOL CHEM, V262, P9239; KROLL SD, 1991, P NATL ACAD SCI USA, V88, P5182, DOI 10.1073/pnas.88.12.5182; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; MUMBY S, 1988, J BIOL CHEM, V263, P2020; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PADRELL E, 1991, J BIOL CHEM, V266, P9771; POUYSSEGUR J, 1990, G PROTEINS, P555; PREMONT RT, 1989, J BIOL CHEM, V264, P14960; ROSS EM, 1977, J BIOL CHEM, V252, P5761; Sambrook J, 1989, MOL CLONING LABORATO; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; VANDONGEN AMJ, 1988, SCIENCE, V242, P1433, DOI 10.1126/science.3144040; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WU DQ, 1992, J BIOL CHEM, V267, P1811	29	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23183	23188						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429665				2022-12-25	WOS:A1992JY16300074
J	SHIRAISHI, F; SAVAGEAU, MA				SHIRAISHI, F; SAVAGEAU, MA			THE TRICARBOXYLIC-ACID CYCLE IN DICTYOSTELIUM-DISCOIDEUM .1. FORMULATION OF ALTERNATIVE KINETIC REPRESENTATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOCHEMICAL SYSTEMS-THEORY; DIFFERENTIAL-EQUATIONS; VARIANT THEORIES; COMPLEX-SYSTEMS; LAW; FORM	Enzyme systems within living cells have recently been shown to be highly ordered structures that violate classic assumptions of the Michaelis-Menten formalism, which originally was developed for the characterization of isolated reactions in vitro. This evidence suggests that a thorough examination of alternative kinetic formalisms for integrated biochemical systems is in order. The purpose of this series of papers is to assess the utility of an alternative power-law formalism by carrying out a detailed comparative analysis of a relatively large, representative system - the tricarboxylic acid cycle of Dictyostelium discoideum. This system was chosen because considerable experimental information already has been synthesized into a detailed kinetic model of the intact system. In this first paper, we set the stage for subsequent analysis within the framework of the power-law formalism: we review the underlying theory, emphasizing recent developments, formulate the model in terms that are convenient for the analysis to follow, and develop the system representation in both the Michaelis-Menten and power-law forms. In the second paper (Shiraishi, F., and Savageau, M. A. (1992) J. Biol. Chem. 267, 22919-22925), these alternative representations are shown to be internally consistent and locally equivalent. The third paper (Shiraishi, F., and Savageau, M. A. (1992) J. Biol. Chem. 267,22926-22933) provides a complete analysis of the steady state behavior and also treats the dynamic behavior of the model.	UNIV MICHIGAN,SCH MED,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIGMS NIH HHS [GM-30054] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030054] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENAVRAHAM D, 1990, J STAT PHYS, V60, P695, DOI 10.1007/BF01025990; Bode H. W., 1945, NETWORK ANAL FEEDBAC; Brody S, 1964, BIOENERGETICS GROWTH; CLEGG JS, 1984, AM J PHYSIOL, V246, pR133, DOI 10.1152/ajpregu.1984.246.2.R133; DUNN MF, 1990, BIOCHEMISTRY-US, V29, P8598, DOI 10.1021/bi00489a015; HYDE CC, 1988, J BIOL CHEM, V263, P17857; IRVINE DH, 1990, SIAM J NUMER ANAL, V27, P704, DOI 10.1137/0727042; KELLY PJ, 1979, BIOCHEM J, V184, P589, DOI 10.1042/bj1840589; KELLY PJ, 1979, BIOCHEM J, V184, P581, DOI 10.1042/bj1840581; KOPELMAN R, 1986, J STAT PHYS, V42, P185, DOI 10.1007/BF01010846; Loomis WF., 1975, DICTYOSTELIUM DISCOI; MILLHAUSER GL, 1988, P NATL ACAD SCI USA, V85, P1503, DOI 10.1073/pnas.85.5.1503; Needham J, 1950, BIOCH MORPHOGENESIS; NEWHOUSE JS, 1986, J CHEM PHYS, V85, P6804, DOI 10.1063/1.451413; REISS MJ, 1950, ALLOMETRY GROWTH REP; Roels J.A., 1983, ENERGETICS KINETICS; Savageau M, 1976, BIOCH SYSTEMS ANAL S; Savageau M. A., 1992, FUNDAMENTALS MED CEL, V3A, P45; SAVAGEAU MA, 1991, NEW BIOL, V3, P190; SAVAGEAU MA, 1979, P NATL ACAD SCI USA, V76, P5413, DOI 10.1073/pnas.76.11.5413; SAVAGEAU MA, 1979, P NATL ACAD SCI USA, V76, P6023, DOI 10.1073/pnas.76.12.6023; SAVAGEAU MA, 1991, J THEOR BIOL, V151, P509, DOI 10.1016/S0022-5193(05)80367-4; SAVAGEAU MA, 1987, MATH BIOSCI, V87, P83, DOI 10.1016/0025-5564(87)90035-6; SAVAGEAU MA, 1969, J THEOR BIOL, V25, P370, DOI 10.1016/S0022-5193(69)80027-5; SAVAGEAU MA, 1969, J THEOR BIOL, V25, P365, DOI 10.1016/S0022-5193(69)80026-3; SAVAGEAU MA, 1971, ARCH BIOCHEM BIOPHYS, V145, P612, DOI 10.1016/S0003-9861(71)80021-8; SEGAL HL, 1959, ENZYMES, V1, P1; Segel I.H., 1975, ENZYME KINETICS; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22926; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22919; SORRIBAS A, 1989, MATH BIOSCI, V94, P239, DOI 10.1016/0025-5564(89)90066-7; SORRIBAS A, 1989, MATH BIOSCI, V94, P161, DOI 10.1016/0025-5564(89)90064-3; SORRIBAS A, 1989, MATH BIOSCI, V94, P195, DOI 10.1016/0025-5564(89)90065-5; Srere PA, 1989, STRUCTURAL ORG ASPEC; Voit E., 1991, CANONICAL NONLINEAR; VOIT EO, 1987, BIOCHEMISTRY-US, V26, P6869, DOI 10.1021/bi00395a042; Von Bertanlanffy L, 1960, FUNDAMENTAL ASPECTS, P137; WEBB JL, 1963, ENZYMES METABOL INH, V1, P29; WHITE GJ, 1961, BIOCHIM BIOPHYS ACTA, V53, P285, DOI 10.1016/0006-3002(61)90441-3; WONG JTF, 1962, CAN J BIOCHEM PHYS, V40, P763; WRIGHT BE, 1992, J BIOL CHEM, V267, P3101; WRIGHT BE, 1964, BIOCHEMISTRY PHYSIOL, V3, P341; [No title captured]	43	84	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22912	22918						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429641				2022-12-25	WOS:A1992JY16300034
J	PUOTI, A; CONZELMANN, A				PUOTI, A; CONZELMANN, A			STRUCTURAL CHARACTERIZATION OF FREE GLYCOLIPIDS WHICH ARE POTENTIAL PRECURSORS FOR GLYCOPHOSPHATIDYLINOSITOL ANCHORS IN MOUSE THYMOMA CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEINS; PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; MUTANT LYMPHOMA-CELLS; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; DECAY-ACCELERATING FACTOR; GLYCOSYL-PHOSPHATIDYLINOSITOL; TRYPANOSOMA-BRUCEI; THY-1 GLYCOPROTEIN; PHOSPHOLIPASE-C	Biosynthesis of glycophosphatidylinositol-anchored membrane glycoproteins proceeds through the attachment of a preformed glycolipid onto a C-terminal amino acid rapidly after translation. Here we describe the structural analysis of two very polar glycolipids which can be observed after metabolic labeling of lymphoma cell lines S1A and EL-4 with either tritiated myo-inositol, mannose, or ethanolamine. These lipids are not made by mutant cells deficient in the biosynthesis of glycophosphatidylinositol anchors. The lipids were isolated, and their carbohydrate moiety was characterized using hydrofluoric acid dephosphorylation, nitrous acid deamination, acetolysis, exoglycosidase treatments, and combinations thereof to produce labeled fragments which could be analyzed by paper chromatography. Results are compatible with the structure (X-->)Manalpha1,2Manalpha1,6(Y-->)Manalpha-GlcN-acylinositol, X and Y being hydrofluoric acid-sensitive substituents (most likely phosphoethanolamine). The anchor oligosaccharide of the glycophosphatidylinositol protein anchors of S1A cells was isolated, similarly characterized, and found to contain the identical carbohydrate structure. Pulse-chase experiments indicate that the very polar glycolipids have half-lives which are much longer than the one of phosphatidylinositol. The results suggest that these very polar glycolipids represent supernumerary precursor glycolipids which did not get transferred onto proteins or represent processed forms of such precursors.	UNIV FRIBOURG,INST BIOCHIM,CH-1700 FRIBOURG,SWITZERLAND; UNIV LAUSANNE,INST BIOCHEM,CH-1000 LAUSANNE 17,SWITZERLAND	University of Fribourg; University of Lausanne			Puoti, Alessandro/E-5700-2012	Puoti, Alessandro/0000-0002-1396-7662				ALEMANY S, 1987, NATURE, V330, P77, DOI 10.1038/330077a0; BANGS JD, 1988, J BIOL CHEM, V263, P17697; BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CONZELMANN A, 1986, EMBO J, V5, P3291, DOI 10.1002/j.1460-2075.1986.tb04642.x; CONZELMANN A, 1988, MOL CELL BIOL, V8, P674, DOI 10.1128/MCB.8.2.674; CONZELMANN A, 1992, EMBO J, V11, P457, DOI 10.1002/j.1460-2075.1992.tb05075.x; CONZELMANN A, 1987, BIOCHEM J, V246, P605, DOI 10.1042/bj2460605; CONZELMANN A, 1990, EMBO J, V9, P653, DOI 10.1002/j.1460-2075.1990.tb08157.x; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; DOERING TL, 1990, J BIOL CHEM, V265, P611; FATEMI SH, 1986, CELL, V46, P653, DOI 10.1016/0092-8674(86)90340-5; FATEMI SH, 1988, J BIOL CHEM, V263, P1288; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; Ferguson MAJ, 1991, CURR OPIN STRUC BIOL, V1, P522, DOI 10.1016/S0959-440X(05)80072-7; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HOLLANDER N, 1988, J IMMUNOL, V141, P4283; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMANSKY P, 1990, J CELL BIOL, V110, P1525, DOI 10.1083/jcb.110.5.1525; LEMANSKY P, 1991, MOL CELL BIOL, V11, P3879, DOI 10.1128/MCB.11.8.3879; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; LOW MG, 1985, NATURE, V318, P62, DOI 10.1038/318062a0; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MAYOR S, 1990, Methods (Orlando), V1, P297, DOI 10.1016/S1046-2023(05)80331-7; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; MERIDA I, 1990, P NATL ACAD SCI USA, V87, P9421, DOI 10.1073/pnas.87.23.9421; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; PUOTI A, 1991, J BIOL CHEM, V266, P21051; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; ROSSE WF, 1990, ANNU REV MED, V41, P431; SALTIEL AR, 1987, J BIOL CHEM, V262, P1116; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SINGH N, 1991, MOL CELL BIOL, V11, P2362, DOI 10.1128/MCB.11.5.2362; STAFFORD HA, 1988, P NATL ACAD SCI USA, V85, P880, DOI 10.1073/pnas.85.3.880; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; SUZUKI S, 1991, J BIOL CHEM, V266, P8115; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; THOMAS LJ, 1991, J BIOL CHEM, V266, P23175; TROWBRIDGE IS, 1978, CELL, V14, P21, DOI 10.1016/0092-8674(78)90297-0; TSE AGD, 1985, SCIENCE, V230, P1003, DOI 10.1126/science.2865810; VARKI A, 1983, J BIOL CHEM, V258, P2808; YEH ETH, 1988, CELL, V52, P665, DOI 10.1016/0092-8674(88)90404-7	53	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22673	22680						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429614				2022-12-25	WOS:A1992JW71900104
J	AGGELER, R; CAPALDI, RA				AGGELER, R; CAPALDI, RA			CROSS-LINKING OF THE GAMMA-SUBUNIT OF THE ESCHERICHIA-COLI ATPASE (ECF(1)) VIA CYSTEINES INTRODUCED BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F1 ADENOSINE-TRIPHOSPHATASE; NUCLEOTIDE-BINDING-SITES; COUPLING FACTOR-I; EPSILON-SUBUNIT; CATALYTIC SITE; H+-ATPASE; SYNTHASE; F1-ATPASE; CONFORMATION; AUROVERTIN	The gamma subunit of the Escherichia coli F1 ATPase (ECF1) has been altered by site-directed mutagenesis to create five different mutants, gamma-S8C, gamma-S81C, gamma-T106C, gamma-S179C, and gamma-V286C, respectively. ECF1 isolated from four of these mutants had ATPase activities similar to that of a wild-type isogenic strain used as a control, the exception was enzyme isolated from mutant gamma-S81C, which had an ATPase activity of around 70-80% of the wild type. ECF1 isolated from each of the various mutants was reacted with N-(4-(7-(diethylamino)-4-methylcoumarin-3-yl))maleimide (CM). The fluorescent reagent was incorporated into Cys residues placed at positions 8, 106, 179, and 286, but not at 81, indicating which of these Cys residues are on the surface of the gamma subunit in the enzyme complex. Modification of the Cys at position 106 with CM activated the enzyme, and modification of the Cys at position 8 inhibited ATPase activity a small amount; however, modification of Cys at 179 or 286 had no effect on enzyme activity. The four mutants with a reactive Cys were reacted with tetrafluorophenylazide maleimides (TFPAMs), novel photoactivatable cross-linkers. In the mutant gamma-S8C, cross-links were formed between the introduced Cys on the gamma subunit and sites on the beta subunit. This cross-linking between gamma and beta depended on nucleotide conditions under which the photolysis was carried out, with differently migrating cross-linked products being obtained in ATP + EDTA compared with ATP + Mg2+ or ATP + Mg2+ + P(i). Cross-linking between beta and gamma inhibited ATPase activity in proportion to the yield of cross-linked product. In the mutant gamma-V286C, cross-links were formed between the introduced Cys on gamma and the alpha subunit which were the same in all nucleotide conditions and which led to inhibition of ATPase activity.			AGGELER, R (corresponding author), UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403, USA.				NHLBI NIH HHS [HL24536] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGELER R, 1990, BIOCHEMISTRY-US, V29, P10387, DOI 10.1021/bi00497a013; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; Battey, 1986, BASIC METHODS MOL BI; BRAGG PD, 1986, BIOCHIM BIOPHYS ACTA, V851, P385, DOI 10.1016/0005-2728(86)90075-7; CROSS RL, 1988, J BIOENERG BIOMEMBR, V20, P395, DOI 10.1007/BF00762200; DUNN SD, 1987, BIOCHEMISTRY-US, V26, P4488, DOI 10.1021/bi00388a047; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GAVILANESRUIZ M, 1988, BIOCHEMISTRY-US, V27, P603, DOI 10.1021/bi00402a016; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; IDA K, 1991, J BIOL CHEM, V266, P5424; IWAMOTO A, 1990, J BIOL CHEM, V265, P5043; KEANA JFW, 1990, J ORG CHEM, V55, P3640, DOI 10.1021/jo00298a048; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIGHTOWLERS R, 1987, THESIS AUSTR NATIONA; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; Maniatis T., 1982, MOL CLONING; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P10987, DOI 10.1021/bi00109a025; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; MORONEY JV, 1980, J BIOL CHEM, V255, P6670; MUSIER KM, 1987, BIOCHEMISTRY-US, V26, P5982, DOI 10.1021/bi00393a006; RICHTER ML, 1987, J BIOL CHEM, V262, P15037; SCHUMANN J, 1985, J BIOL CHEM, V260, P1817; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; TOZER RG, 1986, EUR J BIOCHEM, V161, P513, DOI 10.1111/j.1432-1033.1986.tb10472.x; VOGEL PD, 1991, J BIOL CHEM, V266, P6101; WISE JG, 1981, J BIOL CHEM, V256, P383	30	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21355	21359						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400447				2022-12-25	WOS:A1992JV01100018
J	COPELAND, WC; CHEN, MS; WANG, TSF				COPELAND, WC; CHEN, MS; WANG, TSF			HUMAN DNA POLYMERASE-ALPHA AND POLYMERASE-BETA ARE ABLE TO INCORPORATE ANTI-HIV DEOXYNUCLEOTIDES INTO DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS REVERSE-TRANSCRIPTASE; PLACEBO-CONTROLLED TRIAL; AIDS-RELATED COMPLEX; BONE-MARROW-CELLS; AZIDOTHYMIDINE AZT; INSERTION FIDELITY; DOUBLE-BLIND; 3'-AZIDO-3'-DEOXYTHYMIDINE; THERAPY; 5'-TRIPHOSPHATE	Deoxynucleoside analogs, AZT and/or ddN, are the therapeutic agents currently utilized to inhibit the human immunodeficiency virus (HIV) reverse transcriptase. The effects of their anabolic products, AZT-triphosphate (AZT-TP) and ddCTP on human cellular DNA metabolic processes were studied using highly purified, structurally and enzymatically defined forms of the two major human host DNA polymerases, alpha and beta, and compared to those of the reverse transcriptase purified from HIV viron. Human DNA polymerase alpha during processive DNA synthesis is able to incorporate AZT-monophosphate (AZT-MP) but not ddCMP into DNA, causing chain termination. During its initial encounter with a primer terminus, polymerase alpha is able to incorporate both AZT-MP and ddCMP into DNA chains. Polymerase beta is able to incorporate AZT-MP and ddCMP into DNA, causing chain termination in both modes of DNA synthesis. Steady state kinetic analyses demonstrate that polymerase alpha inserts one AZT-MP molecule into DNA for every 2500 dTMP molecules incorporated. Polymerase beta incorporates ddCMP with efficiency nearly equal to that of dCMP. HIV reverse transcriptase prefers to incorporate AZT-MP and ddCMP rather than dTMP and dCMP, respectively. The findings described here raise the concern that the capability of the two major host DNA polymerases to incorporate AZT-MP or ddCMP into DNA might cause adverse side effects on human DNA metabolism and mutation in the genomes of patients under long term continuous treatment with AZT and ddC.	STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305; SYNTEX INC,INST BIOCHEM & CELL BIOL,PALO ALTO,CA 94304	Stanford University; Syntex Corporation			Copeland, William/C-4242-2019	Copeland, William/0000-0002-0359-0953	NATIONAL CANCER INSTITUTE [R01CA014835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028873] Funding Source: NIH RePORTER; NCI NIH HHS [CA14835] Funding Source: Medline; NIAID NIH HHS [AI28873] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; CHEN GY, 1986, J BIOL CHEM, V262, P2187; COPELAND WC, 1991, J BIOL CHEM, V266, P22739; COREY L, 1992, NEW ENGL J MED, V326, P484, DOI 10.1056/NEJM199202133260710; CRETTON EM, 1991, MOL PHARMACOL, V39, P258; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HUANG P, 1992, J BIOL CHEM, V267, P2817; HUANG P, 1990, J BIOL CHEM, V265, P11914; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUMAR A, 1990, J BIOL CHEM, V265, P2124; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MITSUYA H, 1987, NATURE, V325, P773, DOI 10.1038/325773a0; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; NICKEL W, 1992, J BIOL CHEM, V267, P848; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; SOMMADOSSI JP, 1989, MOL PHARMACOL, V36, P9; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WANG TSF, 1984, J BIOL CHEM, V259, P1854; YARCHOAN R, 1988, LANCET, V1, P76; YARCHOAN R, 1987, NEW ENGL J MED, V316, P557, DOI 10.1056/NEJM198702263160925; ZHU Z, 1991, MOL PHARMACOL, V40, P838	27	87	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21459	21464						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400458				2022-12-25	WOS:A1992JV01100032
J	PLISHKER, GA; CHEVALIER, D; SEINSOTH, L; MOORE, RB				PLISHKER, GA; CHEVALIER, D; SEINSOTH, L; MOORE, RB			CALCIUM-ACTIVATED POTASSIUM-TRANSPORT AND HIGH-MOLECULAR-WEIGHT FORMS OF CALPROMOTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED BLOOD-CELLS; VONWILLEBRAND-FACTOR; CYTOPLASMIC PROTEIN; K+ CHANNELS; MULTIMERIZATION; GHOSTS; EFFLUX; PH	Investigations of human red blood cells show that a cytoplasmic protein called calpromotin is involved in the regulation of calcium-activated potassium transport. Calpromotin associates with the membrane in the presence of calcium and undergoes a chemical transformation. High performance gel filtration and gel electrophoresis show that the cytoplasmic and membrane-bound calpromotin can exist in both low and high molecular weight forms. The biochemical properties of the high molecular weight membrane-bound calpromotin are not the same as the high molecular weight cytoplasmic calpromotin. The high molecular weight membrane forms of calpromotin are increased by leupeptin and diminished by iodoacetic acid. Therefore, the leupeptin enhancement and iodoacetic inhibition of calcium-activated potassium transport may involve the high molecular weight forms of membrane-bound calpromotin.	BAYLOR COLL MED,DEPT NEUROL,HOUSTON,TX 77030; UNIV SO ALABAMA,COMPREHENS SICKLE CELL CTR,MOBILE,AL 36617	Baylor College of Medicine; University of South Alabama								BENJAMIN AM, 1984, J CELL PHYSIOL, V121, P508, DOI 10.1002/jcp.1041210309; BLUM RM, 1971, J MEMBRANE BIOL, V6, P315, DOI 10.1007/BF02116577; FERREIRA HG, 1976, NATURE, V263, P336; GRYGORCZYK R, 1984, BIOPHYS J, V45, P693, DOI 10.1016/S0006-3495(84)84211-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; LEW VL, 1978, CURR TOP MEMBR TRANS, V10, P217; MAYADAS TN, 1989, J BIOL CHEM, V264, P13497; MOORE RB, 1991, J BIOL CHEM, V266, P18964; PARKER JC, 1989, RED BLOOD CELL MEMBR, P507; PLISHKER GA, 1986, AM J PHYSIOL, V251, pC535, DOI 10.1152/ajpcell.1986.251.4.C535; PLISHKER GA, 1985, AM J PHYSIOL, V248, pC419, DOI 10.1152/ajpcell.1985.248.5.C419; SCHWARZ W, 1983, ANNU REV PHYSIOL, V45, P359, DOI 10.1146/annurev.ph.45.030183.002043; SIMONS TJB, 1976, J PHYSIOL-LONDON, V256, P227, DOI 10.1113/jphysiol.1976.sp011322; WAGNER DD, 1986, J CELL BIOL, V102, P1320, DOI 10.1083/jcb.102.4.1320	15	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21839	21843						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400494				2022-12-25	WOS:A1992JV01100089
J	ROBINSON, PJ				ROBINSON, PJ			DIFFERENTIAL STIMULATION OF PROTEIN-KINASE-C ACTIVITY BY PHORBOL ESTER OR CALCIUM PHOSPHATIDYLSERINE INVITRO AND IN INTACT SYNAPTOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CORTICAL SYNAPTOSOMES; SUBSTRATE-SPECIFICITY; SIGNAL TRANSDUCTION; INDUCED MATURATION; DOWN-REGULATION; LEUKEMIA-CELLS; FATTY-ACIDS; PHOSPHORYLATION; ACTIVATION; BRAIN	Activation of protein kinase C (PKC) by phorbol 12-myristate 13-acetate (PMA) was compared with calcium/phosphatidylserine (Ca/PS). The substrate specificity of PKC was more limited with PS/PMA. Substrates could be divided into three overlapping groups according to their relative level of phosphorylation: C1, relatively preferred substrates with Ca/PS, included dephosphin, histone, and peptide GS1-10. C2, relatively preferred with PS/PMA, included myelin basic protein and MARCKS. C3, substrates independent of activators. PS/PMA altered the V(max) of PKC for substrate, and decreased the K(m) for Mg2+. Differential substrate phosphorylation by PS/PMA also occurred for PKC isozymes resolved by hydroxylapatite chromatography and was most dramatic for PKC-alpha, which could no longer phosphorylate histone or GS1-12. Differential activities of PKC were also observed in synaptosol and in intact synaptosomes where PMA stimulated phosphorylation of MARCKS, but not dephosphin. It was further shown that dephosphin was indeed a substrate of PKC in the intact synaptosomes by use of a repolarization-dependent dephosphin phosphorylation assay. The differential PKC activities could also be distinguished by inhibitors. H-7 was equipotent, palmitoylcarnitine did not inhibit in vitro C2 phosphorylation, but inhibited dephosphin in intact synaptosomes, and sphingosine did not inhibit Cl substrates and was without effect on dephosphin in intact synaptosomes. Therefore PS/PMA alters or limits the substrate specificity of PKC, leading to a differential substrate phosphorylation in vitro and in intact synaptosomes and differential inhibitor sensitivity. The pattern of protein phosphorylation observed after PKC activation in intact cells will therefore be dependent upon the activator.			ROBINSON, PJ (corresponding author), JOHN HUNTER HOSP,ENDOCRINE UNIT,LOCKED BAG 1,HUNTER REG MAIL CTR,SYDNEY 2310,AUSTRALIA.		Robinson, Phillip J/G-4008-2011	Robinson, Phillip J/0000-0002-7878-0313				AKITA Y, 1990, BIOCHEM BIOPH RES CO, V172, P184, DOI 10.1016/S0006-291X(05)80191-3; ARCOLEO JP, 1985, CARCINOGENESIS, V6, P213, DOI 10.1093/carcin/6.2.213; ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; BAUDIER J, 1989, J BIOL CHEM, V264, P1824; BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P9317, DOI 10.1021/bi00450a011; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P7589, DOI 10.1021/bi00420a003; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COUTURIER A, 1984, BIOCHEM BIOPH RES CO, V121, P448, DOI 10.1016/0006-291X(84)90203-1; DOERNER D, 1990, J NEUROSCI, V10, P1699; DUNKLEY PR, 1986, J NEUROCHEM, V46, P1692; DUNKLEY PR, 1986, PROG BRAIN RES, V69, P273; EBANKS R, 1989, BIOCHEM J, V258, P689, DOI 10.1042/bj2580689; ELTOUNY S, 1990, J BIOL CHEM, V265, P16437; EVANS FJ, 1991, BIOCHEM SOC T, V19, P397, DOI 10.1042/bst0190397; GROVE DS, 1988, BIOCHEM BIOPH RES CO, V151, P94, DOI 10.1016/0006-291X(88)90563-3; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANSSON A, 1987, ACTA CHEM SCAND B, V41, P174, DOI 10.3891/acta.chem.scand.41b-0174; HANSSON A, 1986, BIOCHEM BIOPH RES CO, V134, P1215, DOI 10.1016/0006-291X(86)90380-3; HIDAKA H, 1987, TRENDS PHARMACOL SCI, V8, P162, DOI 10.1016/0165-6147(87)90155-6; HOUSE C, 1987, J BIOL CHEM, V262, P772; HOUSE C, 1989, FEBS LETT, V249, P243, DOI 10.1016/0014-5793(89)80632-5; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; ISSANDOU M, 1990, CANCER RES, V50, P5845; JEFFERSON AB, 1988, J BIOL CHEM, V263, P15241; KATOH N, 1981, P NATL ACAD SCI-BIOL, V78, P4813, DOI 10.1073/pnas.78.8.4813; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; KISS Z, 1986, FEBS LETT, V198, P203, DOI 10.1016/0014-5793(86)80405-7; KONNO Y, 1989, J BIOCHEM-TOKYO, V106, P673, DOI 10.1093/oxfordjournals.jbchem.a122915; KREUTTER D, 1985, J BIOL CHEM, V260, P5979; KUO JF, 1984, MOL CELL ENDOCRINOL, V35, P65, DOI 10.1016/0303-7207(84)90001-7; LEIBERSPERGER H, 1990, J BIOL CHEM, V265, P16108; LIU JP, 1992, IN PRESS MOL CELL EN; LOWE JHN, 1990, J BIOL CHEM, V265, P7188; MAKOWSKE M, 1989, J BIOL CHEM, V264, P16155; MORIN MJ, 1987, J BIOL CHEM, V262, P11758; MURAKAMI K, 1985, FEBS LETT, V192, P189, DOI 10.1016/0014-5793(85)80105-8; NELSESTUEN GL, 1991, J BIOENERG BIOMEMBR, V23, P43; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBRIAN CA, 1987, FEBS LETT, V214, P339, DOI 10.1016/0014-5793(87)80083-2; OBRIAN CA, 1987, BIOCHEM PHARMACOL, V36, P1231, DOI 10.1016/0006-2952(87)90075-X; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OISHI K, 1988, J BIOL CHEM, V263, P6865; OMRI B, 1987, EUR J BIOCHEM, V165, P83, DOI 10.1111/j.1432-1033.1987.tb11197.x; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1990, J BIOL CHEM, V265, P22434; RAMSDELL JS, 1986, J BIOL CHEM, V261, P7073; ROBILLARD JE, 1988, SEMIN PERINATOL, V12, P143; Robinson P J, 1987, Adv Exp Med Biol, V221, P155; ROBINSON PJ, 1990, J PHARMACOL EXP THER, V255, P1392; ROBINSON PJ, 1984, J NEUROCHEM, V43, P659, DOI 10.1111/j.1471-4159.1984.tb12785.x; ROBINSON PJ, 1986, NEUROCHEM INT, V9, P455, DOI 10.1016/0197-0186(86)90088-4; ROBINSON PJ, 1991, FEBS LETT, V282, P388, DOI 10.1016/0014-5793(91)80520-D; ROBINSON PJ, 1987, J NEUROCHEM, V48, P187, DOI 10.1111/j.1471-4159.1987.tb13146.x; ROBINSON PJ, 1983, J NEUROCHEM, V41, P909, DOI 10.1111/j.1471-4159.1983.tb09034.x; ROBINSON PJ, 1986, NEUROSCI LETT, V68, P1, DOI 10.1016/0304-3940(86)90219-3; ROBINSON PJ, 1991, NEUROSCI RES COMMUN, V9, P167; ROBINSON PJ, 1992, IN PRESS BIOCH PHARM; ROBINSONPJ, 1992, MOL NEUROBIOL, V5, P87; RODNIGHT R, 1986, J PHYSIOLOGY PARIS, V81, P340; SAHAL D, 1987, ANAL BIOCHEM, V167, P23, DOI 10.1016/0003-2697(87)90129-1; SAKAI K, 1987, BIOCHEM INT, V14, P63; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SCHACHTELE C, 1988, BIOCHEM BIOPH RES CO, V151, P542, DOI 10.1016/0006-291X(88)90628-6; SEIFERT R, 1988, BIOCHEM BIOPH RES CO, V154, P20, DOI 10.1016/0006-291X(88)90643-2; SEIFERT R, 1988, BIOCHEM BIOPH RES CO, V152, P585, DOI 10.1016/S0006-291X(88)80078-0; STRATTON KR, 1989, P NATL ACAD SCI USA, V86, P2498, DOI 10.1073/pnas.86.7.2498; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; VANDENBARK GR, 1984, J CLIN INVEST, V73, P448, DOI 10.1172/JCI111231; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; WAYS DK, 1987, CANCER RES, V47, P3344; WITTERS LA, 1987, METHOD ENZYMOL, V141, P412; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249; YAMAMOTO S, 1985, J BIOL CHEM, V260, P4230	77	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21637	21644						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400474				2022-12-25	WOS:A1992JV01100060
J	SANTOS, AD; IMPERIAL, JS; CHAUDHARY, T; BEAVIS, RC; CHAIT, BT; HUNSPERGER, JP; OLIVERA, BM; ADAMS, ME; HILLYARD, DR				SANTOS, AD; IMPERIAL, JS; CHAUDHARY, T; BEAVIS, RC; CHAIT, BT; HUNSPERGER, JP; OLIVERA, BM; ADAMS, ME; HILLYARD, DR			HETERODIMERIC STRUCTURE OF THE SPIDER TOXIN OMEGA-AGATOXIN-IA REVEALED BY PRECURSOR ANALYSIS AND MASS-SPECTROMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNNEL-WEB SPIDER; AMINO-ACID SEQUENCE; AGELENOPSIS-APERTA; HOLOLENA-CURTA; LETHAL NEUROTOXIN; VENOM; CLONING; CDNA; PURIFICATION; INHIBITION	We report the first molecular characterization of a precursor sequence for a small, Ca2+ channel blocking, peptide spider toxin, omega-agatoxin IA. By integrating information generated from a molecular genetic approach using agatoxin cDNAs with data provided from mass spectrometry of the mature toxin, we were able to deduce the likely mechanisms by which the toxin precursor peptide is processed to its mature heterodimeric form. A particularly interesting feature of the prepropeptide is the occurrence of two glutamate-rich sequences interposed between the signal sequences, the major peptide toxin, and the minor toxin peptide. Excision of the more distal glutamate-rich region appears to be signaled by flanking arginine residues but likely occurs only after a disulfide linkage has formed between the major and minor chains of the mature toxin. Our molecular genetic approach toward characterizing this toxin will allow us to quickly generate a series of spider sequences from which mature toxin structures can be deduced and eventually expressed. Additionally, this approach will provide insights into the evolutionary divergence observed among spider peptide toxins.	UNIV UTAH, DEPT BIOL, SALT LAKE CITY, UT 84112 USA; UNIV PHILIPPINES, INST CHEM, Quezon City 1101, PHILIPPINES; UNIV CALIF RIVERSIDE, DEPT NEUROSCI, RIVERSIDE, CA 92521 USA; UNIV CALIF RIVERSIDE, DEPT ENTOMOL, RIVERSIDE, CA 92521 USA; UNIV UTAH, DEPT PATHOL, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah; University of the Philippines System; University of the Philippines Diliman; University of California System; University of California Riverside; University of California System; University of California Riverside; Utah System of Higher Education; University of Utah			Adams, Michael/ABF-6728-2020	Adams, Michael/0000-0003-0519-6113	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024472] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00862] Funding Source: Medline; NIGMS NIH HHS [GM22737] Funding Source: Medline; NINDS NIH HHS [NS24472] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS ME, 1990, J BIOL CHEM, V265, P861; ADAMS ME, 1992, NEUROTOX 91 MOL BASI; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P432, DOI 10.1002/rcm.1290031207; BEAVIS RC, 1990, ANAL CHEM, V62, P1836, DOI 10.1021/ac00216a020; BEAVIS RC, 1990, P NATL ACAD SCI USA, V87, P6873, DOI 10.1073/pnas.87.17.6873; BINDOKAS VP, 1989, J NEUROBIOL, V20, P171, DOI 10.1002/neu.480200402; BINDOKAS VP, 1991, J NEUROPHYSIOL, V66, P590, DOI 10.1152/jn.1991.66.2.590; BOWERS CW, 1987, P NATL ACAD SCI USA, V84, P3506, DOI 10.1073/pnas.84.10.3506; BRANTON WD, 1987, J NEUROSCI, V7, P4195; BROWN MR, 1988, BIOCHEM J, V250, P401, DOI 10.1042/bj2500401; CHAIT BT, 1986, BIOCHEM BIOPH RES CO, V134, P420, DOI 10.1016/0006-291X(86)90580-2; CHAIT BT, 1984, J AM CHEM SOC, V106, P1931, DOI 10.1021/ja00319a005; CHAIT BT, 1981, INT J MASS SPECTROM, V39, P339, DOI 10.1016/0020-7381(81)87007-6; CHAUDHARY T, 1991, 38TH P ASMS C MASS S, P283; COLLEDGE CJ, 1992, IN PRESS TOXICON; HANAHAN D, 1980, GENE, V10, P63, DOI 10.1016/0378-1119(80)90144-4; KIYATKIN NI, 1990, FEBS LETT, V270, P127, DOI 10.1016/0014-5793(90)81250-R; LANGRIDGE J, 1980, ANAL BIOCHEM, V103, P264, DOI 10.1016/0003-2697(80)90266-3; MINTZ IM, 1991, P NATL ACAD SCI USA, V88, P6628, DOI 10.1073/pnas.88.15.6628; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; OLIVERA BM, 1991, ANN NY ACAD SCI, V635, P114, DOI 10.1111/j.1749-6632.1991.tb36486.x; QUISTAD GB, 1991, TOXICON, V29, P329, DOI 10.1016/0041-0101(91)90286-Z; RICHTER K, 1990, P NATL ACAD SCI USA, V87, P4836, DOI 10.1073/pnas.87.12.4836; SCOTT RH, 1990, MOL PHARMACOL, V38, P711; SHEUMACK DD, 1985, FEBS LETT, V181, P154, DOI 10.1016/0014-5793(85)81132-7; SKINNER WS, 1989, J BIOL CHEM, V264, P2150; STAPLETON A, 1990, J BIOL CHEM, V265, P2054; TAMIYA T, 1985, BIOCHIMIE, V67, P185, DOI 10.1016/S0300-9084(85)80046-8; VENEMA VJ, 1992, J BIOL CHEM, V267, P2610; WOODWARD SR, 1990, EMBO J, V9, P1015, DOI 10.1002/j.1460-2075.1990.tb08204.x	31	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20701	20705						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383207				2022-12-25	WOS:A1992JT97800031
J	YAMASAKI, H; PRAGER, D; GEBREMEDHIN, S; MELMED, S				YAMASAKI, H; PRAGER, D; GEBREMEDHIN, S; MELMED, S			HUMAN INSULIN-LIKE GROWTH FACTOR-I RECEPTOR 950TYROSINE IS REQUIRED FOR SOMATOTROPH GROWTH-FACTOR SIGNAL TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFECTED CELLS; TYROSINE PHOSPHORYLATION; PITUITARY-CELLS; SOMATOMEDIN-C; HORMONE GENE; RETROENDOCYTOSIS; DETERMINANTS; SPECIFICITY; ENDOCYTOSIS; EXPRESSION	Insulin-like growth factor I (IGF-I), a growth hormone (GH)-dependent growth factor exerts feedback regulation of GH by inhibiting GH gene expression. IGF-I inhibition of GH secretion is enhanced 3-5-fold in GC rat pituitary cells overexpressing the wild type 950Tyr human IGF-I receptor which autophosphorylates appropriately. To determine the critical amino acid sequence responsible for IGF-I signaling, insertion, deletion, and site-directed mutants were constructed to substitute for 950Tyr in exon 16 of the human IGF-I receptor beta-subunit transmembrane domain. All mutant transfectants bound IGF-I with a similar K(d) to untransfected cells but had markedly increased (7-34-fold) IGF-I-binding sites. GH responsiveness to IGF-I was tested in mutant transfectants. Overexpressed site-directed and insertion mutant IGF-I receptors exhibited a modest suppressive effect on GH in response to the IGF-I ligand, similar to that observed in untransfected cells. Deletion mutant (IG-FIR DELTA22) (amino acid 944-965) did not transduce the IGF-I signal to the GH gene. Site-directed and insertion mutants therefore did not enhance the IGF-I response of the endogenous rat receptor, unlike the 950Tyr wild type transfectants which enhanced the IGF-I signal. All mutant transfectants, except the deletion mutant, internalized radioactive ligand similarly to 950Tyr wild type transfectants. 950Tyr of the human IGF-I receptor is therefore required for IGF-I signal transduction in the pituitary somatotroph, but not for IGF-I-mediated internalization.	UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,DEPT MED,DIV ENDOCRINOL,B131,LOS ANGELES,CA 90048	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002023, R01DK033802] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 02023, DK 33802] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE H, 1983, ENDOCRINOLOGY, V113, P1319, DOI 10.1210/endo-113-4-1319; BERELOWITZ M, 1981, SCIENCE, V212, P1279, DOI 10.1126/science.6262917; BERHANU P, 1991, MOL ENDOCRINOL, V5, P1827, DOI 10.1210/mend-5-12-1827; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHIN JE, 1991, J BIOL CHEM, V266, P15587; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; IZUMI T, 1987, J BIOL CHEM, V262, P1282; JACOBS S, 1983, P NATL ACAD SCI-BIOL, V80, P1228, DOI 10.1073/pnas.80.5.1228; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; LEVY JR, 1986, ENDOCRINOLOGY, V119, P572, DOI 10.1210/endo-119-2-572; MARSHALL S, 1985, J BIOL CHEM, V260, P3524; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; PRAGER D, 1988, J BIOL CHEM, V263, P16580; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; SHEMER J, 1987, J BIOL CHEM, V262, P15476; SOOS MA, 1990, BIOCHEM J, V270, P383, DOI 10.1042/bj2700383; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; THIES RS, 1990, J BIOL CHEM, V265, P10132; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; YAMASAKI H, 1991, MOL ENDOCRINOL, V5, P890, DOI 10.1210/mend-5-7-890; YAMASAKI H, 1991, ENDOCRINOLOGY, V128, P857, DOI 10.1210/endo-128-2-857; YAMASHITA S, 1987, J CLIN INVEST, V79, P449, DOI 10.1172/JCI112832; YAMASHITA S, 1986, ENDOCRINOLOGY, V118, P176, DOI 10.1210/endo-118-1-176	27	45	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20953	20958						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400411				2022-12-25	WOS:A1992JT97800070
J	FRASER, PD; MISAWA, N; LINDEN, H; YAMANO, S; KOBAYASHI, K; SANDMANN, G				FRASER, PD; MISAWA, N; LINDEN, H; YAMANO, S; KOBAYASHI, K; SANDMANN, G			EXPRESSION IN ESCHERICHIA-COLI, PURIFICATION, AND REACTIVATION OF THE RECOMBINANT ERWINIA-UREDOVORA PHYTOENE DESATURASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYCOMYCES-BLAKESLEEANUS; CAROTENOID BIOSYNTHESIS; PATHWAY; BIOCHEMISTRY; CLONING	A plasmid has been constructed by cloning the complete crtI gene encoding phytoene desaturase from Erwinia uredovora behind the lac Z promoter of pUC18 resulting in a reading frame for the full polypeptide with additional 9 amino acids at the N terminus. This plasmid mediated the overexpression of phytoene desaturase in transformed Escherichia coli. The overexpressed enzyme was sequestrated into inclusion bodies requiring urea treatment for solubilization. Purification to homogeneity was subsequently performed on a DEAE-cellulose column and by SDS-polyacrylamide gel electrophoresis. The purification scheme allowed the isolation of 5.3 mg of homogeneous desaturase protein from 100 ml of E. coli cell suspension. On SDS-polyacrylamide gel electrophoresis an apparent molecular mass of 56.2 kDa was determined. An antiserum raised against phytoene desaturase cross-reacted with the expressed protein and was employed to monitor the isolation steps. Upon removal of urea, desaturase activity was restored. The isolated desaturase catalyzed the conversion of 15-cis-phytoene to trans-lycopene as well as to bisdehydrolycopene. FAD was involved in desaturation, whereas NAD and NADP were inhibitory. This is the first time that a membrane-integrated carotenogenic enzyme has been purified and finally obtained in an active state.	UNIV CONSTANCE, LEHRSTUHL PHYSIOL & BIOCHEM PFLANZEN, POB 5560, W-7750 CONSTANCE, GERMANY; KIRIN BREWERY CO LTD, KEY TECHNOL CENT LABS, TAKASAKI, GUNMA 37012, JAPAN	University of Konstanz; Kirin Brewery Company Limited				Misawa, Norihiko/0000-0003-1373-0769				BARTLEY GE, 1991, P NATL ACAD SCI USA, V88, P6532, DOI 10.1073/pnas.88.15.6532; BRAMLEY PM, 1975, PHYTOCHEMISTRY, V14, P463, DOI 10.1016/0031-9422(75)85110-7; BRAMLEY PM, 1985, ADV LIPID RES, V21, P243; CHAMOVITZ D, 1991, PLANT MOL BIOL, V16, P967, DOI 10.1007/BF00016069; ERNST S, 1988, ARCH MICROBIOL, V150, P590, DOI 10.1007/BF00408255; FRASER PD, 1992, BIOCHEM BIOPH RES CO, V185, P9, DOI 10.1016/S0006-291X(05)80947-7; GOODWIN TW, 1983, BIOCHEM SOC T, V11, P473, DOI 10.1042/bst0110473; KELLY SM, 1991, BIOCHEM J, V275, P745, DOI 10.1042/bj2750745; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGLEY KE, 1987, EUR J BIOCHEM, V163, P313, DOI 10.1111/j.1432-1033.1987.tb10802.x; LINDEN H, 1991, Z NATURFORSCH C, V46, P1045; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MARSTON FAO, 1990, METHOD ENZYMOL, V182, P264; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MISAWA N, 1990, J BACTERIOL, V172, P6704, DOI 10.1128/jb.172.12.6704-6712.1990; SANDMANN G, 1991, PHYSIOL PLANTARUM, V83, P186, DOI 10.1034/j.1399-3054.1991.830128.x; SANDMANN G, 1989, BIOCHEM BIOPH RES CO, V163, P916, DOI 10.1016/0006-291X(89)92309-7; SANDMANN G, 1985, PLANTA, V164, P259, DOI 10.1007/BF00396090; Sandmann G., 1989, Target sites of herbicide action., P25; SASIAK K, 1988, ARCH BIOCHEM BIOPHYS, V260, P622, DOI 10.1016/0003-9861(88)90490-0; SCHMIDT A, 1989, EUR J BIOCHEM, V184, P375, DOI 10.1111/j.1432-1033.1989.tb15029.x; SCHOEMAKER JM, 1985, EMBO J, V4, P775, DOI 10.1002/j.1460-2075.1985.tb03696.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	24	102	107	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19891	19895						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400305				2022-12-25	WOS:A1992JR85800025
J	LEGENDRE, L; HEINSTEIN, PF; LOW, PS				LEGENDRE, L; HEINSTEIN, PF; LOW, PS			EVIDENCE FOR PARTICIPATION OF GTP-BINDING PROTEINS IN ELICITATION OF THE RAPID OXIDATIVE BURST IN CULTURED SOYBEAN CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; REGULATORY PROTEINS; LEMNA-PAUCICOSTATA; MOLECULAR-CLONING; ADP-RIBOSYLATION; PLASMA-MEMBRANE; ALPHA-SUBUNIT; PLANT-CELLS; TOXIN; IDENTIFICATION	GTP-binding proteins have been shown to serve as second messengers in the transduction of hormone signals across animal cell plasma membranes. We present here three lines of evidence to demonstrate that GTP-binding proteins are also involved in the elicitation of the defense response of cultured soybean cells. First, the antigen-binding fragment (F(ab)) of an antibody that specifically recognizes GTP-binding proteins in plants and animals was delivered into soybean cells using a non-destructive biotin-mediated delivery technique developed previously. Internalization of this F(ab) enhanced up to 10-fold the rapid oxidative burst induced by elicitor molecules, whereas internalization of its heat-denatured counterpart or unrelated proteins had no effect. Because the antibody recognizes a protein of molecular mass approximately 45 kDa in soybean cell membranes that is protected from ADP-ribosylation by GTPgammaS (guanosine 5'-O-(thiotriphosphate), we propose the 45-kDa GTP-binding protein is responsible for these effects. Second, mastoparan, a specific activator of GTP-binding proteins, was shown to induce the defense-related oxidative burst in the absence of elicitor stimulation, thus mimicking an activated receptor as it is thought to do in mammalian systems. Finally, but admittedly less convincing, the A subunit of cholera toxin, an activator of certain stimulatory GTP-binding proteins (G(s)), was found to weakly enhance the conventional elicitor-induced oxidative burst. Taken together, these data argue for the involvement of GTP-binding proteins in elicitor signal transduction in soybean cells.	PURDUE UNIV, DEPT CHEM, W LAFAYETTE, IN 47907 USA; PURDUE UNIV, DEPT MED CHEM & PHARMACOGNOSY, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus				Low, Philip/0000-0001-9042-5528				APOSTOL I, 1989, PLANT PHYSIOL, V90, P109, DOI 10.1104/pp.90.1.109; BARONEPEL O, 1988, PLANTA, V175, P389, DOI 10.1007/BF00396345; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLUM W, 1988, BIOCHEM BIOPH RES CO, V156, P954, DOI 10.1016/S0006-291X(88)80936-7; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BOLWELL GP, 1991, PHYTOCHEMISTRY, V30, P397, DOI 10.1016/0031-9422(91)83692-E; BOSSEN ME, 1990, PHYSIOL PLANTARUM, V80, P55; BRADLEY DJ, 1992, CELL, V70, P21, DOI 10.1016/0092-8674(92)90530-P; BREDEHORST R, 1978, EUR J BIOCHEM, V92, P129, DOI 10.1111/j.1432-1033.1978.tb12730.x; DAVIS J, 1982, J BIOL CHEM, V257, P5816; DROBAK BK, 1988, BIOCHEM BIOPH RES CO, V150, P899, DOI 10.1016/0006-291X(88)90713-9; FAIRLEYGRENOT K, 1991, PLANT CELL, V3, P1037; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GODING JW, 1978, J IMMUNOL METHODS, V20, P241, DOI 10.1016/0022-1759(78)90259-4; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HASEGAWA PM, 1980, PLANT CELL PHYSIOL, V21, P1347, DOI 10.1093/pcp/21.8.1347; HASUNUMA K, 1987, PHOTOCHEM PHOTOBIOL, V46, P531, DOI 10.1111/j.1751-1097.1987.tb04807.x; HASUNUMA K, 1987, BIOCHEM BIOPH RES CO, V148, P133, DOI 10.1016/0006-291X(87)91086-2; HASUNUMA K, 1987, BIOCHEM BIOPH RES CO, V143, P908, DOI 10.1016/0006-291X(87)90335-4; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HINSCH KD, 1988, FEBS LETT, V238, P151; HORN MA, 1990, PLANT PHYSIOL, V93, P1492, DOI 10.1104/pp.93.4.1492; JACOBSON MK, 1990, J BIOL CHEM, V265, P10825; JONES DT, 1987, J BIOL CHEM, V262, P14241; KOPF GS, 1991, METHOD ENZYMOL, V195, P257; LEREA CL, 1986, SCIENCE, V234, P77, DOI 10.1126/science.3529395; LOW PS, 1986, ARCH BIOCHEM BIOPHYS, V249, P472, DOI 10.1016/0003-9861(86)90024-X; MA H, 1991, GENE, V107, P189; MA H, 1990, P NATL ACAD SCI USA, V87, P3821, DOI 10.1073/pnas.87.10.3821; MILLNER PA, 1987, FEBS LETT, V226, P155, DOI 10.1016/0014-5793(87)80570-7; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; NOTHNAGEL EA, 1983, PLANT PHYSIOL, V71, P916, DOI 10.1104/pp.71.4.916; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RIBEIRONETO FAP, 1985, METHOD ENZYMOL, V109, P566; STADDON JM, 1991, J CELL BIOL, V115, P949, DOI 10.1083/jcb.115.4.949; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; TANUMA S, 1988, J BIOL CHEM, V263, P5485; WARPEHA KMF, 1991, P NATL ACAD SCI USA, V88, P8925, DOI 10.1073/pnas.88.20.8925; WEINGARTEN R, 1990, IMMUNOL LETT, V26, P1, DOI 10.1016/0165-2478(90)90167-O; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WESTGATE PJ, 1990, BIOTECHNOL BIOENG, V35, P437, DOI 10.1002/bit.260350502	44	162	167	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20140	20147						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400332				2022-12-25	WOS:A1992JR85800063
J	PALMER, DJ; CHRISTIE, DL				PALMER, DJ; CHRISTIE, DL			IDENTIFICATION OF MOLECULAR AGGREGATES CONTAINING GLYCOPROTEINS-III, J, K (CARBOXYPEPTIDASE-H), AND H (KEX2-RELATED PROTEASES) IN THE SOLUBLE AND MEMBRANE-FRACTIONS OF ADRENAL-MEDULLARY CHROMAFFIN GRANULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; RETE TESTIS FLUID; SULFATED GLYCOPROTEIN-2; ENKEPHALIN CONVERTASE; SERUM PROTEIN-40,40; TISSUE DISTRIBUTION; STRUCTURAL-ANALYSIS; PROCESSING ENZYME; HUMAN PLASMA; COMPLEMENT	An investigation of the molecular properties of glycoprotein III has shown this to be a major component of molecular aggregates present in the membrane and soluble fractions of secretory vesicles from bovine adrenal medulla. These aggregates also contain components identified as glycoproteins H, J, and K which are molecular forms of Kex2-related proteases (glycoprotein H) and carboxypeptidase H (glycoprotein components J and K) and which have functions concerned with the processing of prohormones. A number of experiments indicated that these glycoproteins were associated. These components were coimmunoprecipitated from the soluble and membrane fractions of chromaffin granules. Purification of soluble glycoprotein III using wheat germ agglutinin-Sepharose resulted in the recovery of similar proportions of glycoproteins H, J, and K and gel filtration of the eluted material in combination with immunoprecipitation revealed the presence of heteroaggregates containing all of the glycoproteins. Similar results were obtained following octylglucoside solubilization of chromaffin granule membranes. Glycoprotein components III, H, J, and K were also found to have identical distributions following fractionation of chromaffin granule membranes with Triton X-114. It was concluded that the aggregates seen in the soluble fraction reflect an association of these components in the chromaffin granule membrane. This raises the possibility that these interactions are important for the targetting of these glycoproteins to secretory granules.	UNIV AUCKLAND,DEPT BIOCHEM,PRIVATE BAG 92019,AUCKLAND,NEW ZEALAND	University of Auckland			Christie, David L/C-8065-2009					BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHENG CY, 1988, BIOCHEMISTRY-US, V27, P4079, DOI 10.1021/bi00411a026; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; CHRISTIE DL, 1990, BIOCHEM J, V270, P57, DOI 10.1042/bj2700057; COLLARD MW, 1987, BIOCHEMISTRY-US, V26, P3297, DOI 10.1021/bi00386a008; DESILVA HV, 1990, J BIOL CHEM, V265, P13240; DESILVA HV, 1990, BIOCHEMISTRY-US, V29, P5380, DOI 10.1021/bi00474a025; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FRICKER LD, 1983, J BIOL CHEM, V258, P950; FRITZ IB, 1983, BIOL REPROD, V28, P1173, DOI 10.1095/biolreprod28.5.1173; GAVINE FS, 1984, J NEUROCHEM, V43, P1243, DOI 10.1111/j.1471-4159.1984.tb05379.x; HAWKES DJ, 1991, ENDOCRINOLOGY, V129, P3053; HOOK VYH, 1985, J NEUROCHEM, V45, P987, DOI 10.1111/j.1471-4159.1985.tb04094.x; HOOK VYH, 1985, P NATL ACAD SCI USA, V82, P4745, DOI 10.1073/pnas.82.14.4745; JENNE DE, 1991, J BIOL CHEM, V266, P11030; JENNE DE, 1989, P NATL ACAD SCI USA, V86, P7123, DOI 10.1073/pnas.86.18.7123; KIRSZBAUM L, 1989, EMBO J, V8, P711, DOI 10.1002/j.1460-2075.1989.tb03430.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASLOP A, 1986, NEUROSCI LETT, V72, P300, DOI 10.1016/0304-3940(86)90530-6; MAY PC, 1990, NEURON, V5, P831, DOI 10.1016/0896-6273(90)90342-D; MURPHY BF, 1988, J CLIN INVEST, V81, P1858, DOI 10.1172/JCI113531; PALMER DJ, 1990, J BIOL CHEM, V265, P6617; PARKINSON D, 1990, J BIOL CHEM, V265, P17101; PRYDE JG, 1986, BIOCHEM J, V233, P525, DOI 10.1042/bj2330525; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; STEINER D F, 1991, Current Biology, V1, P375, DOI 10.1016/0960-9822(91)90198-6; SUPATTAPONE S, 1984, J NEUROCHEM, V42, P1017, DOI 10.1111/j.1471-4159.1984.tb12705.x; TSURUTA JK, 1990, BIOCHEM J, V268, P571, DOI 10.1042/bj2680571; WINKLER H, 1990, NEUROCHEM INT, V17, P245, DOI 10.1016/0197-0186(90)90147-L; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5	33	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19806	19812						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400294				2022-12-25	WOS:A1992JR85800011
J	TAKATA, H; KURIKI, T; OKADA, S; TAKESADA, Y; IIZUKA, M; MINAMIURA, N; IMANAKA, T				TAKATA, H; KURIKI, T; OKADA, S; TAKESADA, Y; IIZUKA, M; MINAMIURA, N; IMANAKA, T			ACTION OF NEOPULLULANASE - NEOPULLULANASE CATALYZES BOTH HYDROLYSIS AND TRANSGLYCOSYLATION AT ALPHA-(1-]4)-GLUCOSIDIC AND ALPHA-(1-]6)-GLUCOSIDIC LINKAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-STEAROTHERMOPHILUS NEOPULLULANASE; GLYCOGEN-BRANCHING ENZYME; NUCLEOTIDE-SEQUENCE; ALPHA-AMYLASE; THERMOSTABLE PULLULANASE; MOLECULAR-CLONING; ESCHERICHIA-COLI; TAKA-AMYLASE; GENE; PURIFICATION	The transglycosylation reaction catalyzed by neopullulanase was analyzed. Radioactive oligosaccharides were produced when the enzyme acted on maltotriose in the presence of [U-C-14]glucose. Some of the radioactive oligosaccharides had only alpha-(1-->4)-glucosidic linkages, but others were suggested to have alpha-(1-->6)-glucosidic linkages. The existence of alpha-(1-->6)-glucosidic linkages in the products from maltotriose with neopullulanase was proven by proton NMR spectroscopy and methylation analysis. We previously reported that the one active center of neopullulanase catalyzes the hydrolysis of alpha-(l-->4)- and alpha-(l-->6)-glucosidic linkages (Kuriki, T., Takata, H., Okada, S., and Imanaka, T. (1991) J. Bacteriol. 173,6147-6152). These facts proved that neopullulanase catalyzed all four types of reactions: hydrolysis of alpha-(1-->4)-glucosidic linkage, hydrolysis of alpha-(1-->6)-glucosidic linkage, transglycosylation to form alpha-(1-->4)-glucosidic linkage, and transglycosylation to form alpha-(1-->6)-glucosidic linkage. The four reactions are typically catalyzed by alpha-amylase, pullulanase, cyclomaltodextrin glucanotransferase, and 1,4-alpha-D-glucan branching enzyme, respectively. These four enzymes have some structural similarities to one other, but reactions catalyzed by the enzymes are considered to be distinctive: the four reactions are individually catalyzed by each of the enzymes. The experimental results obtained from the analysis of the reaction of the neopullulanase exhibited that the four reactions can be catalyzed in the same mechanism.	NAGASE BIOCHEM CO LTD, FUKUCHIYAMA, KYOTO 620, JAPAN; OSAKA CITY UNIV, FAC SCI, DEPT BIOL, SUMIYOSHI KU, OSAKA 558, JAPAN; OSAKA UNIV, FAC ENGN, DEPT BIOTECHNOL, SUITA, OSAKA 565, JAPAN	Osaka Metropolitan University; Osaka University	TAKATA, H (corresponding author), EZAKI GLICO CO LTD, BIOCHEM RES LABS, 4-6-5 UTAJIMA, NISHIYODOGAWA KU, OSAKA 555, JAPAN.							BABA T, 1991, BIOCHEM BIOPH RES CO, V181, P87, DOI 10.1016/S0006-291X(05)81385-3; BOROVSKY D, 1975, EUR J BIOCHEM, V59, P615, DOI 10.1111/j.1432-1033.1975.tb02490.x; COLEMAN RD, 1987, J BACTERIOL, V169, P4302, DOI 10.1128/jb.169.9.4302-4307.1987; FERRETTI JJ, 1987, J BACTERIOL, V169, P4271, DOI 10.1128/jb.169.9.4271-4278.1987; GREENWOOD CT, 1968, ARCH BIOCHEM BIOPHYS, V126, P244, DOI 10.1016/0003-9861(68)90580-8; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HEHRE EJ, 1971, ARCH BIOCHEM BIOPHYS, V142, P382, DOI 10.1016/0003-9861(71)90297-9; IIZUKA M, 1990, J FERMENT BIOENG, V70, P277, DOI 10.1016/0922-338X(90)90064-4; IMANAKA T, 1989, J BACTERIOL, V171, P369, DOI 10.1128/jb.171.1.369-374.1989; JESPERSEN HM, 1991, BIOCHEM J, V280, P51, DOI 10.1042/bj2800051; KIEL JAKW, 1991, MOL GEN GENET, V230, P136, DOI 10.1007/BF00290661; KITAHATA S, 1983, AGR BIOL CHEM TOKYO, V47, P1441, DOI 10.1080/00021369.1983.10865801; Kitahata S., 1982, J JPN SOC STARCH SCI, V29, P13; KLEIN C, 1991, J MOL BIOL, V217, P737, DOI 10.1016/0022-2836(91)90530-J; KOSSMANN J, 1991, MOL GEN GENET, V230, P39, DOI 10.1007/BF00290648; KUBOTA M, 1991, J JPN SOC STARCH SCI, V38, P141, DOI DOI 10.5458/JAG1972.38.141; KURIKI T, 1990, J FERMENT BIOENG, V69, P204, DOI 10.1016/0922-338X(90)90213-G; KURIKI T, 1991, J BACTERIOL, V173, P6147, DOI 10.1128/jb.173.19.6147-6152.1991; KURIKI T, 1989, J GEN MICROBIOL, V135, P1521; KURIKI T, 1988, J BACTERIOL, V170, P1554, DOI 10.1128/jb.170.4.1554-1559.1988; MACGREGOR EA, 1989, BIOCHEM J, V259, P145, DOI 10.1042/bj2590145; MATSUI I, 1991, BIOCHIM BIOPHYS ACTA, V1077, P416, DOI 10.1016/0167-4838(91)90560-M; MATSUURA Y, 1984, J BIOCHEM-TOKYO, V95, P697, DOI 10.1093/oxfordjournals.jbchem.a134659; MATSUURA Y, 1991, J JPN SOC STARCH SCI, V38, P137; MELASNIEMI H, 1990, J GEN MICROBIOL, V136, P447, DOI 10.1099/00221287-136-3-447; NAKAJIMA R, 1985, J BACTERIOL, V163, P401, DOI 10.1128/JB.163.1.401-406.1985; PAZUR JH, 1960, J BIOL CHEM, V235, P297; PAZUR JH, 1966, J BIOL CHEM, V241, P4146; PLANT AR, 1987, BIOCHEM J, V246, P537, DOI 10.1042/bj2460537; RUMBAK E, 1991, J BACTERIOL, V173, P6732, DOI 10.1128/jb.173.21.6732-6741.1991; SAKANO Y, 1971, AGR BIOL CHEM TOKYO, V35, P971, DOI 10.1080/00021369.1971.10860023; SAKANO Y, 1978, CARBOHYD RES, V61, P175, DOI 10.1016/S0008-6215(00)84478-X; SAKANO Y, 1982, AGR BIOL CHEM TOKYO, V46, P1121, DOI 10.1080/00021369.1982.10865223; SPREINAT A, 1990, APPL MICROBIOL BIOT, V33, P511; SUGANUMA T, 1978, J BIOCHEM-TOKYO, V84, P293, DOI 10.1093/oxfordjournals.jbchem.a132130; SVENSSON B, 1988, FEBS LETT, V230, P72, DOI 10.1016/0014-5793(88)80644-6; SVENSSON B, 1991, J JPN SOC STARCH SCI, V38, P125; USUI T, 1974, CARBOHYD RES, V33, P105, DOI 10.1016/S0008-6215(00)82944-4; WATANABE K, 1990, EUR J BIOCHEM, V192, P609, DOI 10.1111/j.1432-1033.1990.tb19267.x	39	156	165	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18447	18452						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1388153				2022-12-25	WOS:A1992JN50200035
J	LUNN, CA; DAVIES, L; DALGARNO, D; NARULA, SK; ZAVODNY, PJ; LUNDELL, D				LUNN, CA; DAVIES, L; DALGARNO, D; NARULA, SK; ZAVODNY, PJ; LUNDELL, D			AN ACTIVE COVALENTLY LINKED DIMER OF HUMAN INTERFERON-GAMMA - SUBUNIT ORIENTATION IN THE NATIVE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNE INTERFERON; ESCHERICHIA-COLI; BIOLOGICAL-ACTIVITY; EXPRESSION; CELLS; CDNA; SEQUENCE; TERMINUS; CLONING	We have constructed and expressed a covalently linked head to tail dimer of human interferon-gamma (IFN-gamma) in which two monomers are joined head to tail via a rigid peptide hinge using genetic engineering techniques. The hinge was derived from the human immunoglobin IgA1 sequence (Hallewell, R. A., Laria, I., Tabrizi, A., Carlin, G., Getzoff, E. D., Tainer, J. A., Cousens, L. S., and Mullenbach, G. T. (1989) J. Biol. Chem. 264, 5260-5268). Analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis shows that the polypeptide produced by this construction migrates as a 30,000 polypeptide species. The protein elutes as a single species by molecular sieve chromatography under native conditions. The covalently linked dimer exhibits one-half the antiviral activity of native dimeric IFN-gamma; receptor binding assays show the covalently linked dimer binds to the IFN-gamma receptor with one-half the avidity of native IFN-gamma. This difference is not due to conformational differences between the two molecules, as the aromatic region of the NMR spectrum of the purified covalently linked dimer is identical with that of the wild type protein. From these data, we suggest that human IFN-gamma associates in a head to tail dimer in its active configuration. Regions of IFN-gamma are contiguous with the amino and carboxyl termini and are obscured by the hinge peptide in the covalently linked dimer. Our studies demonstrate that these regions may be important for receptor-ligand interaction.	SCHERING PLOUGH RES INST,DEPT PHYS ANALYT CHEM RES & DEV,BLOOMFIELD,NJ 07003	Merck & Company; Schering-Plough Research Institute	LUNN, CA (corresponding author), SCHERING PLOUGH RES INST,DEPT BIOTECHNOL MOLEC BIOL,BLOOMFIELD,NJ 07003, USA.							ARAKAWA T, 1986, J BIOL CHEM, V261, P8534; DEVOS R, 1982, NUCLEIC ACIDS RES, V10, P2487, DOI 10.1093/nar/10.8.2487; DOBELI H, 1988, J BIOTECHNOL, V7, P199, DOI 10.1016/0168-1656(88)90052-1; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; ELISH ME, 1988, J GEN MICROBIOL, V134, P1355; FOUNTOULAKIS M, 1990, J BIOL CHEM, V265, P19758; GRAY PW, 1982, NATURE, V295, P503, DOI 10.1038/295503a0; GRAY PW, 1983, P NATL ACAD SCI-BIOL, V80, P5842, DOI 10.1073/pnas.80.19.5842; HALLEWELL RA, 1989, J BIOL CHEM, V264, P5260; LUNDELL D, 1991, PROTEIN ENG, V4, P335, DOI 10.1093/protein/4.3.335; PAN YCE, 1987, EUR J BIOCHEM, V166, P145, DOI 10.1111/j.1432-1033.1987.tb13494.x; RASHIDBAIGI A, 1985, J BIOL CHEM, V260, P8514; RINDERKNECHT E, 1984, J BIOL CHEM, V259, P6790; RUBINSTEIN S, 1981, J VIROL, V37, P755, DOI 10.1128/JVI.37.2.755-758.1981; SUGIMURA K, 1988, J BACTERIOL, V170, P3650, DOI 10.1128/jb.170.8.3650-3654.1988; TANAKA S, 1983, NUCLEIC ACIDS RES, V11, P1707, DOI 10.1093/nar/11.6.1707; YPHANTIS DA, 1987, BIOCHEMISTRY-US, V26, P5422, DOI 10.1021/bi00391a031; ZAVODNY PJ, 1988, J INTERFERON RES, V8, P483, DOI 10.1089/jir.1988.8.483	18	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17920	17924						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1387644				2022-12-25	WOS:A1992JM22300067
J	MURPHY, AJ; COLL, RJ				MURPHY, AJ; COLL, RJ			FLUORIDE BINDING TO THE CALCIUM ATPASE OF SARCOPLASMIC-RETICULUM CONVERTS ITS TRANSPORT SITES TO A LOW AFFINITY, LUMEN-FACING FORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; FLUORESCEIN ISOTHIOCYANATE; VANADATE INHIBITION; CA-ATPASE; CA-2+-ATPASE; IONS; NUCLEOTIDES; PUMP; PHOSPHORYLATION; TRANSLOCATION	The sarcoplasmic reticulum CaATPase forms an inactive complex with fluoride (CaATPase-F), which in the absence of calcium reactivates very slowly (t1/2 approximately 40 h at 25-degrees-C). Reactivation is greatly accelerated (>10(3)) by calcium in the millimolar range provided it has access to luminal sites of the enzyme. Measurement of the calcium concentration dependence of the reactivation rate constant revealed a saturable effect with a midpoint of about 12 mM calcium. These results show that an effect other than phosphorylation can produce a >10(3)-fold affinity decrease and reorientation of the calcium transport sites. At a fixed calcium concentration, reactivation became faster with increasing pH (pK(a) > 8), suggesting competition between Ca2+ and H+ for transport sites. CaATPase-F lacked the ability to bind calcium with high affinity or to form phosphorylated enzyme intermediate from P(i); it bound adenyl-5'-yl methylenediphosphonate more than 10-fold less strongly than control CaATPase, had numerous sulfhydryl groups with significantly different reactivity, and was notably less susceptible (more than 10-fold) to thermal inactivation compared with control CaATPase. These results suggest that formation of CaATPase-F involves significant structural changes.			MURPHY, AJ (corresponding author), UNIV PACIFIC,SCH DENT,DEPT BIOCHEM,SAN FRANCISCO,CA 94115, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031083] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31083] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN JP, 1985, BIOCHIM BIOPHYS ACTA, V815, P9, DOI 10.1016/0005-2736(85)90467-5; ANDERSON KW, 1983, J BIOL CHEM, V258, P4276; Bevington P. R., 1969, DATA REDUCTION ERROR; CHIESI M, 1980, BIOCHEMISTRY-US, V19, P2912, DOI 10.1021/bi00554a015; COLL RJ, 1986, BIOCHEM BIOPH RES CO, V138, P652, DOI 10.1016/S0006-291X(86)80546-0; DUPONT Y, 1982, FEBS LETT, V139, P237, DOI 10.1016/0014-5793(82)80860-0; DUPONT Y, 1982, BIOCHIM BIOPHYS ACTA, V688, P75, DOI 10.1016/0005-2736(82)90580-6; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; HIGHSMITH S, 1985, BIOCHIM BIOPHYS ACTA, V817, P123, DOI 10.1016/0005-2736(85)90074-4; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1984, J BIOL CHEM, V259, P996; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1980, J BIOL CHEM, V255, P3025; JAENICKE R, 1991, CIBA F SYMP, V161, P206; Jencks W P, 1980, Adv Enzymol Relat Areas Mol Biol, V51, P75; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; LEVY D, 1990, J BIOL CHEM, V265, P19524; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARKUS S, 1986, BIOCHIM BIOPHYS ACTA, V874, P128, DOI 10.1016/0167-4838(86)90109-3; MARKUS S, 1989, BIOCHEMISTRY-US, V28, P793, DOI 10.1021/bi00428a057; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MEDDA P, 1983, EUR J BIOCHEM, V137, P7, DOI 10.1111/j.1432-1033.1983.tb07788.x; MESZAROS LG, 1992, BIOCHEMISTRY-US, V31, P1195, DOI 10.1021/bi00119a032; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MURPHY AJ, 1990, FEBS LETT, V263, P175, DOI 10.1016/0014-5793(90)80733-Y; MURPHY AJ, 1988, BIOCHIM BIOPHYS ACTA, V946, P57, DOI 10.1016/0005-2736(88)90457-9; MURPHY AJ, 1990, BIOCHEMISTRY-US, V29, P11236, DOI 10.1021/bi00503a012; MURPHY AJ, 1978, J BIOL CHEM, V253, P385; MURPHY AJ, 1992, J BIOL CHEM, V267, P5229; MURPHY AJ, 1991, J BIOL CHEM, V267, P16995; NAKAMOTO RK, 1984, J BIOL CHEM, V259, P2961; ONEAL SG, 1979, BIOCHEM BIOPH RES CO, V89, P845, DOI 10.1016/0006-291X(79)91855-2; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; ORTIZ A, 1984, BIOCHEM J, V221, P213, DOI 10.1042/bj2210213; PACE CN, 1990, TRENDS BIOCHEM SCI, V15, P14, DOI 10.1016/0968-0004(90)90124-T; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PICK U, 1982, J BIOL CHEM, V257, P6111; PICK U, 1982, J BIOL CHEM, V257, P6120; PICKART CM, 1984, J BIOL CHEM, V259, P1629; STURMER W, 1989, J MEMBRANE BIOL, V110, P67, DOI 10.1007/BF01870994; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x	44	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16990	16994						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1387398				2022-12-25	WOS:A1992JL05300042
J	MAGNIER, C; PAPP, B; CORVAZIER, E; BREDOUX, R; WUYTACK, F; EGGERMONT, J; MACLOUF, J; ENOUF, J				MAGNIER, C; PAPP, B; CORVAZIER, E; BREDOUX, R; WUYTACK, F; EGGERMONT, J; MACLOUF, J; ENOUF, J			REGULATION OF SARCO-ENDOPLASMIC RETICULUM CA2+-ATPASES DURING PLATELET-DERIVED GROWTH FACTOR-INDUCED SMOOTH-MUSCLE CELL-PROLIFERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR FREE CALCIUM; MESSENGER-RNA EXPRESSION; CYTOSOLIC FREE CALCIUM; PROTEIN KINASE-C; PROTOONCOGENE EXPRESSION; CA-2+-TRANSPORT ATPASE; SARCOPLASMIC-RETICULUM; CA-2+-ATPASE GENE; PROSTAGLANDIN; ISOFORM	The role of the sarco-endoplasmic reticulum Ca2+-ATPases (SERCA) in the regulation of cell proliferation by Ca2+ was investigated by testing the effect of platelet-derived growth factor (PDGF) on cultured pig aorta smooth muscle cells. For this purpose, the PDGF-mediated rise in the Ca2+ concentration was first examined for its ability to induce the formation of prostaglandins from the specific membrane enzyme, cyclooxygenase. In parallel experiments, similar conditions (10 ng/ml PDGF for 24 h) were used to investigate the smooth muscle cell membrane SERCA2 isoforms. Total SERCA2 activity rose by 472% as reflected by their specific formation of phosphorylated intermediate (E-P). This rise correlated with an increase in the amount of SERCA2 proteins (100 kDa) as shown by Western blotting. With isoform-specific anti-SERCA2-a and anti-SERCA2-b antibodies, we demonstrated that the increase in total SERCA2 proteins concerned the minor isoform SERCA2-a, which rose 10-fold, whereas SERCA2-b proteins were not affected. Lastly, Northern blotting using riboprobes showed that PDGF treatment increased the SERCA2-a mRNA species by 82%, and concomitantly decreased the SERCA2-b mRNA by 28%, as a result of isoform switching. We conclude that up-regulation of the SERCA2-type Ca2+-ATPases occurs in PDGF-treated smooth muscle cells, which suggests that this enzymatic system plays an essential part in cell proliferation.	CATHOLIC UNIV LEUVEN, FYSIOL LAB, B-3000 LOUVAIN, BELGIUM; NATL INST HAEMATOL & BLOOD TRANSFUS, H-1113 BUDAPEST, HUNGARY	KU Leuven	MAGNIER, C (corresponding author), HOP LARIBOISIERE, INSERM, U348, 8 RUE GUY PATIN, F-75475 PARIS 10, FRANCE.			Papp, Bela/0000-0002-5025-3087; Eggermont, Jan/0000-0002-8497-1159				BIAN JH, 1991, J BIOL CHEM, V266, P8801; BLAY J, 1989, J CELL PHYSIOL, V139, P524, DOI 10.1002/jcp.1041390311; CHAN YL, 1984, J BIOL CHEM, V259, P224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELABASTIE D, 1988, FEBS LETT, V229, P45, DOI 10.1016/0014-5793(88)80794-4; DESMEDT H, 1991, J BIOL CHEM, V266, P7092; DILIBERTO PA, 1991, J BIOL CHEM, V266, P12612; EGGERMONT JA, 1990, BIOCHEM J, V271, P649, DOI 10.1042/bj2710649; EGGERMONT JA, 1990, BIOCHEM J, V266, P901; ENOUF J, 1988, J BIOL CHEM, V263, P13922; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; HABENICHT AJR, 1985, J CLIN INVEST, V75, P1381, DOI 10.1172/JCI111839; HUANG CL, 1991, J BIOL CHEM, V266, P4045; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JONES SD, 1988, COLD SPRING HARB SYM, V53, P531, DOI 10.1101/SQB.1988.053.01.061; KACZMAREK L, 1986, LAB INVEST, V54, P365; KAEVER V, 1990, BIOCHEM PHARMACOL, V39, P1313, DOI 10.1016/0006-2952(90)90007-8; KOCHER O, 1987, DIFFERENTIATION, V34, P201, DOI 10.1111/j.1432-0436.1987.tb00067.x; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LIN AH, 1989, J BIOL CHEM, V264, P17379; MARUYAMA K, 1989, CELL MOTIL CYTOSKEL, V14, P26, DOI 10.1002/cm.970140107; MERCADIER JJ, 1990, J CLIN INVEST, V85, P305, DOI 10.1172/JCI114429; MISSIAEN L, 1991, BIOCHEM BIOPH RES CO, V174, P1183, DOI 10.1016/0006-291X(91)91546-O; NAGAI R, 1989, P NATL ACAD SCI USA, V86, P2966, DOI 10.1073/pnas.86.8.2966; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PAPP B, 1991, J BIOL CHEM, V266, P14593; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; RAEYMAEKERS L, 1985, BIOCHIM BIOPHYS ACTA, V815, P441, DOI 10.1016/0005-2736(85)90372-4; RAZ A, 1988, J BIOL CHEM, V263, P3022; ROE MW, 1989, J CELL PHYSIOL, V139, P100, DOI 10.1002/jcp.1041390115; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; SACHINIDIS A, 1990, J BIOL CHEM, V265, P10238; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; TAUBMAN MB, 1989, J CELL BIOL, V108, P1799, DOI 10.1083/jcb.108.5.1799; TUCKER RW, 1990, EUR J CELL BIOL, V51, P120; WUYTACK F, 1989, BIOCHEM J, V264, P765, DOI 10.1042/bj2640765; WUYTACK F, 1984, BIOCHEM J, V224, P445, DOI 10.1042/bj2240445; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZAGARI M, 1989, J CELL PHYSIOL, V139, P167, DOI 10.1002/jcp.1041390123; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670	41	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15808	15815						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1386363				2022-12-25	WOS:A1992JG11300084
J	GREEN, JDF; PERHAM, RN; ULLRICH, SJ; APPELLA, E				GREEN, JDF; PERHAM, RN; ULLRICH, SJ; APPELLA, E			CONFORMATIONAL STUDIES OF THE INTERDOMAIN LINKER PEPTIDES IN THE DIHYDROLIPOYL ACETYLTRANSFERASE COMPONENT OF THE PYRUVATE-DEHYDROGENASE MULTIENZYME COMPLEX OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE-CHAIN; PROTEIN; PROLINE; DOMAINS; SEGMENT; MOBILITY; RESIDUES; H-1-NMR; DESIGN; BONDS	Two peptides (PEP1, 26 residues, and PEP2, 22 residues) were synthesized with amino acid sequences identical to two of the long segments of polypeptide chain rich in alanine, proline, and charged amino acids that link the lipoyl domains together in the dihydrolipoyl acetyltransferase component of the pyruvate dehydrogenase multienzyme complex of Escherichia coli. The circular dichroism and 400-MHz H-1 NMR spectra of the peptides indicated that they lacked regular secondary structure. Even in the presence of 45% (v/v) hexafluoroisopropanol, they appeared to acquire a helical content of only 23-25%. However, C-13 NMR spectroscopy revealed that the Ala-Pro peptide bonds were all (>95%) in the trans configuration, compared with a value of 87% for the Ala-Pro bond in the model peptide AAPA, which is a recurrent sequence motif in PEP1 and PEP2. Likewise in peptides representing the N- and C-terminal halves of peptide PEP2, the Ala-Pro bonds were again all (>95%)-trans, suggesting that peptide length is the essential determinant of the cis:trans ratio. Antisera were raised against peptides PEP2 and PEP3, the latter representing a third interdomain segment of polypeptide chain (Radford, S. E., Laue, E. D., Perham, R. N., Martin, S. R., and Appella, E. (1989a) J. Biol. Chem. 264, 767-775). Despite extensive sequence similarity among peptides PEP1, PEP2, and PEP3, only limited immunological cross-reactivity was observed, which suggests that the antigenic epitope(s) in the peptides are different and distinct. It is likely that these peptides are representative of a class of inter-domain linkers or spacers found in a wide variety of proteins and endowed with varying degrees of flexibility and stiffness to match their particular biological purpose.	NCI, CELL BIOL LAB, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA; UNIV CAMBRIDGE, CAMBRIDGE CTR MOLEC RECOGNIT, DEPT BIOCHEM, CAMBRIDGE CB2 1EW, ENGLAND	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Cambridge								BHANDARI DG, 1986, EUR J BIOCHEM, V160, P349, DOI 10.1111/j.1432-1033.1986.tb09978.x; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; CANTOR CR, 1989, BIOPHYSICAL CHEM T 2, P409; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; DEBER CM, 1970, J AM CHEM SOC, V92, P6191, DOI 10.1021/ja00724a016; DESLAURIERS R, 1980, BIOL MAGN RESON, V2, P243; GRAHAM LD, 1989, BIOCHEMISTRY-US, V28, P1574, DOI 10.1021/bi00430a023; GRATHWOHL C, 1976, BIOPOLYMERS, V15, P2025, DOI 10.1002/bip.1976.360151012; GRONENBORN AM, 1981, FEBS LETT, V215, P89; Jardetzky O., 1981, NMR MOL BIOL; JUY M, 1983, INT J PEPT PROT RES, V22, P437; MAIGRET B, 1970, J THEOR BIOL, V29, P275, DOI 10.1016/0022-5193(70)90022-6; MAYER R, 1983, FEBS LETT, V153, P339, DOI 10.1016/0014-5793(83)80638-3; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PERHAM RN, 1989, ANN NY ACAD SCI, V573, P1, DOI 10.1111/j.1749-6632.1989.tb14983.x; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; PERHAM RN, 1981, NATURE, V292, P474, DOI 10.1038/292474a0; RADFORD SE, 1989, J BIOL CHEM, V264, P767; RADFORD SE, 1989, FEBS LETT, V250, P336, DOI 10.1016/0014-5793(89)80750-1; RAMACHANDRAN GN, 1976, J MOL BIOL, V107, P85, DOI 10.1016/S0022-2836(76)80019-8; REED LJ, 1990, J BIOL CHEM, V265, P8971; STEWART DE, 1990, J MOL BIOL, V214, P253, DOI 10.1016/0022-2836(90)90159-J; TEXTER FL, 1988, BIOCHEMISTRY-US, V27, P289, DOI 10.1021/bi00401a044; ULLRICH SJ, 1986, MOL IMMUNOL, V23, P545, DOI 10.1016/0161-5890(86)90118-5; WAGENKNECHT T, 1990, J BIOL CHEM, V265, P22402	26	41	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23484	23488						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429691				2022-12-25	WOS:A1992JZ23900013
J	HANDY, DE; GAVRAS, H				HANDY, DE; GAVRAS, H			PROMOTER REGION OF THE HUMAN (ALPHA-2)A ADRENERGIC-RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-2-ADRENERGIC RECEPTOR; PRE-MESSENGER RNA; ALPHA-2B-ADRENERGIC RECEPTOR; ADENYLATE-CYCLASE; ALPHA2-ADRENERGIC RECEPTORS; 5'-FLANKING REGION; MAMMALIAN-CELLS; RAT-BRAIN; EXPRESSION; CLONING	In order to locate the promoter region of the human alpha2A adrenergic receptor gene we used RNase protection analysis and antisense RNA probes to map the cap site of the alpha2 transcripts. Prior sequence analysis has shown two potential TATA box motifs in the human alpha2A adrenergic receptor gene, TATATAT and TATAAAA, located 427 and 1037 base pairs (bp), respectively, upstream of the protein coding region. RNase protection experiments and primer extension show that transcription starts downstream of the distal TATAAAA, indicating that the 5'-untranslated region is approximately 1 kilobase in length. We have used the chloramphenicol acetyltransferase reporter gene and transient transfection into HT29, a human adenocarcinoma cell line that expresses the alpha2A receptor, to show that as little as 150 bp upstream of the cap site can direct transcription. Sequence analysis shows that although this region contains the TATA box motif it lacks a CCAAT box motif. DNase I footprint analysis of a fragment from -17 to -193 (where +1 is the transcription initiation site), using nuclear extracts from HT29, showed hypersensitive sites (-68/-69) and two protected regions: -70 to -87, which includes a 10-bp palindrome, and -92 to -105, which includes a GC box, a common motif for Spl nuclear factor binding. Gel mobility shift assays indicate that Sp1 or a related factor may bind to this GC box. Deletion of the GC box and the palindrome from chloramphenicol acetyltransferase constructs abolishes transcription. We propose that these cis sequences may function in lieu of a CCAAT box to regulate transcription of the human alpha2A adrenergic receptor gene.			HANDY, DE (corresponding author), BOSTON UNIV,SCH MED,DEPT MED,80 E CONCORD ST,R206,BOSTON,MA 02118, USA.			Handy, Diane/0000-0002-4310-8527				BOYER TG, 1990, J BIOL CHEM, V265, P20524; BYLUND DB, 1985, PHARMACOL BIOCHEM BE, V22, P835, DOI 10.1016/0091-3057(85)90536-2; CHALBERG SC, 1990, MOL CELL BIOCHEM, V97, P161; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DONOFRIO C, 1985, EMBO J, V4, P1981, DOI 10.1002/j.1460-2075.1985.tb03881.x; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; FAIN JN, 1980, LIFE SCI, V26, P1183, DOI 10.1016/0024-3205(80)90062-4; FLORDELLIS CS, 1990, HYPERTENSION, V15, P881, DOI 10.1161/01.HYP.15.6.881; FLORDELLIS CS, 1991, P NATL ACAD SCI USA, V88, P1019, DOI 10.1073/pnas.88.3.1019; FRASER CM, 1989, J BIOL CHEM, V264, P11754; GOLDBERG MR, 1984, HYPERTENSION, V6, P551, DOI 10.1161/01.HYP.6.4.551; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HANDY DE, 1989, J IMMUNOL, V142, P1015; HANDY DE, 1988, IMMUNOGENETICS, V28, P81, DOI 10.1007/BF00346155; HERBOMEL P, 1984, CELL, V39, P553; HERSHEY AD, 1991, J BIOL CHEM, V266, P4366; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; LANIER SM, 1991, J BIOL CHEM, V266, P10470; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; LUFT FC, 1986, HDB HYPERTENSION, V8, P27; MCKERNAN RM, 1987, MOL PHARMACOL, V32, P258; MICHEL MC, 1989, FASEB J, V3, P139, DOI 10.1096/fasebj.3.2.2536629; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; TURNER JT, 1985, MOL PHARMACOL, V28, P422; WEINSHANK RL, 1990, MOL PHARMACOL, V38, P681; ZENG DW, 1990, P NATL ACAD SCI USA, V87, P3102, DOI 10.1073/pnas.87.8.3102	33	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24017	24022						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385431				2022-12-25	WOS:A1992JZ23900087
J	WASHKO, P; LEVINE, M				WASHKO, P; LEVINE, M			INHIBITION OF ASCORBIC-ACID TRANSPORT IN HUMAN NEUTROPHILS BY GLUCOSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; FLUORIDE-MEDIATED ACTIVATION; DEHYDROASCORBATE TRANSPORT; ACCUMULATION; PLASMA	Because of the structural similarity between glucose and ascorbic acid, we investigated the effect of glucose on uptake and accumulation of ascorbic acid in isolated normal human neutrophils. Ascorbic acid accumulation was determined using high-performance liquid chromatography with coulometric electrochemical detection, in conjunction with liquid scintillation spectrometry. Ascorbic acid accumulation in neutrophils is mediated by a high and a low affinity transport activity. In neutrophils from different volunteers, glucose inhibited uptake and accumulation of ascorbic acid by both transport activities 3-9-fold. The mechanism of inhibition was different for each transport activity: inhibition of the high affinity transport activity was noncompetitive, while inhibition of the low affinity activity was competitive. Glucose-induced inhibition of both ascorbic acid transport activities occurred in neutrophils of all donors tested and was fully reversible. Although the mechanism of ascorbic acid accumulation appeared to be different than that for glucose transport, other monosaccharides and glucose transport inhibitors also inhibited ascorbic acid accumulation. These are the first data to suggest that ascorbic acid accumulation in neutrophils can be regulated by compounds of similar structure.	NIDDKD, CELL BIOL & GENET LAB, BLDG 8, RM 415, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ANDERSON R, 1987, AM REV RESPIR DIS, V135, P1027; BASS DA, 1980, P NATL ACAD SCI-BIOL, V77, P5125, DOI 10.1073/pnas.77.9.5125; BATTAGLIA FC, 1960, BIOCHEM J, V75, P408, DOI 10.1042/bj0750408; BIGLEY R, 1983, DIABETES, V32, P545, DOI 10.2337/diabetes.32.6.545; Cooke JR, 1981, VITAMIN C, P167; Crandon JH, 1940, NEW ENGL J MED, V223, P353, DOI 10.1056/NEJM194009052231001; DECHATEL.LR, 1972, ANTIMICROB AGENTS CH, V1, P12, DOI 10.1128/AAC.1.1.12; DRATH DB, 1974, INFECT IMMUN, V10, P1077, DOI 10.1128/IAI.10.5.1077-1083.1974; EVANS RM, 1982, BRIT J NUTR, V47, P473, DOI 10.1079/BJN19820059; HARTFIELD PJ, 1990, BIOCHIM BIOPHYS ACTA, V1054, P176, DOI 10.1016/0167-4889(90)90239-A; JACOB RA, 1987, AM J CLIN NUTR, V46, P818, DOI 10.1093/ajcn/46.5.818; JACOB RA, 1992, J NUTR, V122, P1111, DOI 10.1093/jn/122.5.1111; KLEBANOFF SJ, 1978, NEUTROPHIL FUNCTION, P438; KONO T, 1988, VITAM HORM, V44, P103; KUMAR M, 1969, J NUTR, V98, P41, DOI 10.1093/jn/98.1.41; LEFEVRE PG, 1951, J GEN PHYSIOL, V34, P515, DOI 10.1085/jgp.34.5.515; LITCHFIELD WJ, 1977, INFECT IMMUN, V16, P189, DOI 10.1128/IAI.16.1.189-197.1977; MANN GV, 1974, PERSPECT BIOL MED, V17, P210; MANN GV, 1975, ANN NY ACAD SCI, V258, P243, DOI 10.1111/j.1749-6632.1975.tb29285.x; MARQUEZ LA, 1990, J BIOL CHEM, V265, P5666; MILLER TE, 1969, J BACTERIOL, V98, P949, DOI 10.1128/JB.98.3.949-955.1969; OKAMURA M, 1980, CLIN CHIM ACTA, V103, P259; OKUNO Y, 1986, FEBS LETT, V195, P303, DOI 10.1016/0014-5793(86)80182-X; RAMPAL AL, 1980, BIOCHEMISTRY-US, V19, P679, DOI 10.1021/bi00545a011; ROSS EM, 1990, PHARMACOL BASIS THER, P43; SATO P, 1978, VITAM HORM, V36, P33; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STANKOVA L, 1975, INFECT IMMUN, V12, P252, DOI 10.1128/IAI.12.2.252-256.1975; STANKOVA L, 1984, METABOLISM, V33, P347, DOI 10.1016/0026-0495(84)90197-5; TOPER R, 1987, BIOCHIM BIOPHYS ACTA, V931, P262, DOI 10.1016/0167-4889(87)90215-1; UNGER R H, 1985, P1018; WASHKO P, 1990, FEBS LETT, V260, P101, DOI 10.1016/0014-5793(90)80077-V; WASHKO P, 1989, J BIOL CHEM, V264, P18996; WASHKO PW, 1989, ANAL BIOCHEM, V181, P276, DOI 10.1016/0003-2697(89)90243-1	34	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23568	23574						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429700				2022-12-25	WOS:A1992JZ23900025
J	SEGAL, M; MARBACH, I; ENGELBERG, D; SIMCHEN, G; LEVITZKI, A				SEGAL, M; MARBACH, I; ENGELBERG, D; SIMCHEN, G; LEVITZKI, A			INTERACTION BETWEEN THE SACCHAROMYCES-CEREVISIAE CDC25 GENE-PRODUCT AND MAMMALIAN RAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE ADENYLATE-CYCLASE; GTPASE-ACTIVATING PROTEIN; TERMINAL DOMAIN; YEAST; CONSTRUCTION; DISRUPTION; EXCHANGE; MUTATION; IRA1; GAP	In order to characterize the interaction between the Saccharomyces cerevisiae Cdc25 protein and Harvey-ras (p21H-ras), we have constructed a yeast strain disrupted at the RAS1 and RAS2 loci, expressing both p21H-ras and the catalytic domain of the bovine GTPase activating protein (GAP) and containing the cdc25-2 mutation. Such a strain exhibits a temperature-sensitive phenotype. The shift to the nonpermissive temperature is accompanied by the loss of guanyl nucleotide-dependent activity of adenylylcyclase in vitro. The temperature-sensitive phenotype can be rescued by CDC25 itself, as well as by a plasmid containing a truncated SDC25 gene. In addition, wild type CDC25 significantly improves the guanyl nucleotide response observed in the background of the cdc25ts allele at the permissive temperature in a dosage-dependent manner and restores the guanyl nucleotide response at the restrictive temperature. Both CDC25 and a truncated SDC25 also restored p21H-ras-dependent guanyl nucleotide response in a strain isogenic to the one described above but containing a disrupted CDC25 locus instead of the temperature-sensitive allele. These results suggest that the S. cerevisiae Cdc25 protein interacts with p21H-ras expressed in yeast by promoting GDP-GTP exchange. It follows that the yeast system can be used for characterizing the interaction between guanyl nucleotide exchangers of Ras proteins and mammalian p21H-ras.	HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,DEPT GENET,IL-91904 JERUSALEM,ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem				Segal, Marisa/0000-0003-1848-9388				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOYMARCOTTE E, 1989, GENE, V77, P21, DOI 10.1016/0378-1119(89)90355-7; CASPERSON GF, 1983, J BIOL CHEM, V258, P7911; CLARK SG, 1985, MOL CELL BIOL, V5, P2746, DOI 10.1128/MCB.5.10.2746; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DAMAK F, 1991, MOL CELL BIOL, V11, P202, DOI 10.1128/MCB.11.1.202; DANIEL J, 1986, CURR GENET, V10, P643, DOI 10.1007/BF00410911; DEFEOJONES D, 1985, SCIENCE, V228, P179, DOI 10.1126/science.3883495; ENGELBERG D, 1990, EMBO J, V9, P641, DOI 10.1002/j.1460-2075.1990.tb08156.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; MARSHALL MS, 1987, MOL CELL BIOL, V7, P2309, DOI 10.1128/MCB.7.7.2309; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; Matsumoto K, 1985, Yeast, V1, P15, DOI 10.1002/yea.320010103; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Sambrook J, 1989, MOL CLONING LABORATO; SHERMAN F, 1986, LABORATORY COURSE MA; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TATCHELL K, 1984, NATURE, V309, P523, DOI 10.1038/309523a0; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8	30	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22747	22751						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429624				2022-12-25	WOS:A1992JY16300011
J	KATAGIRI, H; ASANO, T; ISHIHARA, H; TSUKUDA, K; LIN, JL; INUKAI, K; KIKUCHI, M; YAZAKI, Y; OKA, Y				KATAGIRI, H; ASANO, T; ISHIHARA, H; TSUKUDA, K; LIN, JL; INUKAI, K; KIKUCHI, M; YAZAKI, Y; OKA, Y			REPLACEMENT OF INTRACELLULAR C-TERMINAL DOMAIN OF GLUT1 GLUCOSE TRANSPORTER WITH THAT OF GLUT2 INCREASES V(MAX) AND K(M) OF TRANSPORT ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RESPONSIVE TISSUES; MESSENGER-RNA; HUMAN-ERYTHROCYTE; CONFORMATIONAL CHANGE; GENE LOCALIZATION; 3T3-L1 ADIPOCYTES; SKELETAL-MUSCLE; SUGAR-TRANSPORT; CYTOCHALASIN-B; RAT-BRAIN	The intracellular C-terminal domain is diverse in size and amino acid sequence among facilitative glucose transporter isoforms. The characteristics of glucose transport are also divergent, and GLUT2 has far higher K(m) and V(max) values compared with GLUT1. To investigate the role of the intracellular C-terminal domain in glucose transport, we expressed in Chinese hamster ovary cells the mutated GLUT1 protein whose intracellular C-terminal domain was replaced with that of GLUT2 by means of engineering the chimeric cDNA. Cytochalasin B, for which GLUT2 protein has much lower affinity, bound to this chimeric protein in a fashion similar to GLUT1. In contrast, greater transport activity was observed in this chimeric glucose transporter compared with the wild-type GLUT1 at 10 mM 2-deoxy-D-glucose concentration. The kinetic studies on 2-deoxy-D-glucose uptake revealed a 3.8-fold increase in K(m) and a 4.3-fold increase in V(max) in this chimeric glucose transporter compared with the wild-type GLUT1. Thus, replacement of the intracellular C-terminal domain confers the GLUT2-like property on the glucose transporter. These results strongly suggest that the diversity of intracellular C-terminal domain contributes to the diversity of glucose transport characteristics among isoforms.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN; ASAHI LIFE FDN,INST ADULT DIS,SHINJUKU KU,TOKYO 160,JAPAN	University of Tokyo; Asahi Life Foundation								ASANO T, 1991, J BIOL CHEM, V266, P24632; ASANO T, 1989, J BIOL CHEM, V264, P3416; ASANO T, 1988, BIOCHEM BIOPH RES CO, V154, P1204, DOI 10.1016/0006-291X(88)90268-9; AXELROD JD, 1983, BIOCHEMISTRY-US, V22, P222; BALDWIN JM, 1980, BIOCHIM BIOPHYS ACTA, V599, P699, DOI 10.1016/0005-2736(80)90211-4; BARNETT JEG, 1975, BIOCHEM J, V145, P417, DOI 10.1042/bj1450417a; BASKETTER DA, 1978, J PHYSIOL-LONDON, V278, P389, DOI 10.1113/jphysiol.1978.sp012311; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; CALDERHEAD DM, 1988, J BIOL CHEM, V263, P12171; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CRAIK JD, 1979, BIOCHEM J, V182, P503, DOI 10.1042/bj1820503; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434, DOI 10.1073/pnas.85.15.5434; GORGA FR, 1981, BIOCHEMISTRY-US, V20, P5108, DOI 10.1021/bi00521a003; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOLMAN GD, 1987, BIOCHIM BIOPHYS ACTA, V897, P395, DOI 10.1016/0005-2736(87)90437-8; ISHIHARA H, 1991, BIOCHEM BIOPH RES CO, V176, P922, DOI 10.1016/S0006-291X(05)80274-8; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JOHNSON JH, 1990, J BIOL CHEM, V265, P6548; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KATAGIRI H, 1991, J BIOL CHEM, V266, P7769; KAYANO T, 1988, J BIOL CHEM, V263, P15245; KAYANO T, 1990, J BIOL CHEM, V265, P13276; KRUPKA RM, 1971, BIOCHEMISTRY-US, V10, P1143, DOI 10.1021/bi00783a007; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; OKA Y, 1990, DIABETES, V39, P441, DOI 10.2337/diabetes.39.4.441; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; OKA Y, 1988, J BIOL CHEM, V263, P13432; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHIBASAKI Y, 1992, BIOCHEM J, V281, P829, DOI 10.1042/bj2810829; SILVERMAN M, 1991, ANNU REV BIOCHEM, V60, P757, DOI 10.1146/annurev.bi.60.070191.003545; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7	36	58	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22550	22555						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429604				2022-12-25	WOS:A1992JW71900087
J	MAMER, OA; REIMER, MLJ				MAMER, OA; REIMER, MLJ			ON THE MECHANISMS OF THE FORMATION OF L-ALLOISOLEUCINE AND THE 2-HYDROXY-3-METHYLVALERIC ACID STEREOISOMERS FROM L-ISOLEUCINE IN MAPLE SYRUP URINE DISEASE PATIENTS AND IN NORMAL HUMANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								2-Keto-3-methylvaleric acid (KMVA) has been found not to undergo spontaneous keto-enol tautomerization in neutral aqueous solution, alone or in the presence of large concentrations of pyridoxamine or pyridoxamine-5-phosphate. This finding denies the commonly held suppositions that 3R-KMVA is derived spontaneously from 3S-KMVA in vivo, and that L-alloisoleucine is the product of the reamination of this 3R-KMVA. Evidence presented here suggests that racemization of the 3-carbon of L-isoleucine occurs during transamination, that L-alloisoleucine is an inherently unavoidable by-product of L-isoleucine transamination (and vice versa), and that a KMVA enol is not obligate in this racemization. The four stereoisomers of 2-hydroxy-3-methylvaleric acid have been synthesized and the mass spectra of their trimethylsilyl derivatives recorded. An achiral methylsilicone column was used to separate the diastereomeric pairs and to determine their relative ratios in plasma and urine from normal controls and two maple syrup urine disease (MSUD) patients. The urinary ratio of the two diastereomers is different from that for plasma, both in normals and in MSUD patients. The plasma ratios may provide a rapid and simple measure of residual branched chain 2-keto acid dehydrogenase activity in MSUD patients.			MAMER, OA (corresponding author), MCGILL UNIV, MRC CANADA, BIOMED MASS SPECTROMETRY UNIT, MONTREAL H3A 1A3, QUEBEC, CANADA.							BABU UM, 1974, BIOCHEM BIOPH RES CO, V58, P460, DOI 10.1016/0006-291X(74)90387-8; COOPER AJL, 1976, J BIOL CHEM, V251, P1088; Danner DJ, 1989, METABOLIC BASIS INHE, P671; FUNK MA, 1987, J NUTR, V117, P1550, DOI 10.1093/jn/117.9.1550; HALPERN B, 1970, BIOCHEM MED METAB B, V4, P352, DOI 10.1016/0006-2944(70)90062-1; HOOD DW, 1950, J BIOL CHEM, V186, P195; JAKOBS C, 1977, J CHROMATOGR, V143, P31, DOI 10.1016/S0378-4347(00)81324-9; MAMER OA, 1986, BIOMED ENVIRON MASS, V13, P553, DOI 10.1002/bms.1200131007; MAMER OA, 1976, BIOCHEM J, V160, P417, DOI 10.1042/bj1600417a; MAMER OA, 1980, J CHROMATOGR, V182, P221, DOI 10.1016/S0378-4347(00)81626-6; MAMER OA, 1974, CLIN CHIM ACTA, V55, P199, DOI 10.1016/0009-8981(74)90295-2; MATTHEWS DE, 1980, PEDIATR RES, V14, P854, DOI 10.1203/00006450-198014070-00002; MEISTER A, 1955, ADV ENZYMOL REL S BI, V16, P185; MEISTER A, 1951, J BIOL CHEM, V190, P269; MEISTER A, 1951, J BIOL CHEM, V191, P211; REIMER MLJ, 1991, 39TH P ASMS C MASS S, P1027; SCHADEWALDT P, 1991, PEDIATR RES, V30, P430, DOI 10.1203/00006450-199111000-00007; SCHADEWALDT P, 1990, J INHERIT METAB DIS, V13, P137, DOI 10.1007/BF01799676; SNELL E E, 1962, Brookhaven Symp Biol, V15, P32; SNELL EE, 1959, J CELL COMPAR PHYSL, V54, P161, DOI 10.1002/jcp.1030540413; SNYDERMAN SE, 1964, PEDIATRICS, V34, P454; WEINBERG RB, 1977, BIOCHEM MED METAB B, V17, P164, DOI 10.1016/0006-2944(77)90020-5	22	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22141	22147						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429566				2022-12-25	WOS:A1992JW71900026
J	MANENTI, S; SOROKINE, O; VANDORSSELAER, A; TANIGUCHI, H				MANENTI, S; SOROKINE, O; VANDORSSELAER, A; TANIGUCHI, H			AFFINITY PURIFICATION AND CHARACTERIZATION OF MYRISTOYLATED ALANINE-RICH PROTEIN-KINASE-C SUBSTRATE (MARCKS) FROM BOVINE BRAIN - COMPARISON OF THE CYTOPLASMIC AND THE MEMBRANE-BOUND FORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMINENT CELLULAR SUBSTRATE; CALMODULIN-BINDING-PROTEIN; MAJOR SPECIFIC SUBSTRATE; MOLECULAR-CLONING; BACTERIAL LIPOPOLYSACCHARIDE; 87-KDA PROTEIN; RAT-BRAIN; PHOSPHORYLATION; 80-KDA; EXPRESSION	A major in vivo substrate of Ca2+-phospholipid-dependent protein kinase (myristoylated alanine-rich C-kinase substrate (MARCKS)) has been-purified to apparent homogeneity from the particulate as well as from the cytoplasmic fractions of calf brain using a calmodulin affinity column. The two preparations were characterized and compared with various biochemical and biophysical techniques. Although they behave similarly in various chromatographic procedures during purification, their elution positions from the gel filtration column are markedly different. Stokes radii of 85 and 45 angstrom were measured for the cytoplasmic and membrane MARCKS, respectively. Once purified, however, they show a similar small Stokes radius (45 angstrom), suggesting the dissociation of a component or a drastic conformational change in the cytoplasmic preparation during purification. The electrospray mass spectroscopic analysis of the two preparations revealed the existence of at least three major subpopulations with molecular mass differences of 80 daltons, which suggests the presence of protein phosphorylated in different degrees. The cytoplasmic preparation contains more phosphorylated species compared with the membrane preparation, whereas the calculated molecular weight of each peak was indistinguishable between the two preparations. Correspondingly, when the two preparations were phosphorylated by purified protein kinase C in vitro, more phosphate groups were transferred to the membrane preparation (4 mol/mol) than to the cytoplasmic preparation (2.9 mol/mol). A significant difference was also observed in the inhibition of calmodulin of the phosphorylation reaction. On the other hand, the circular dichroism of the two preparations showed similar spectra rich in random coil with little contribution of alpha-helix (approximately 10%), suggesting that there is not a significant difference in the overall conformation. These results clearly established that the two preparations are the same protein coded by a single gene but they differ in their degree of phosphorylation, and that the difference observed in their Stokes radius is due to the presence of an unidentified factor that is removed from the cytoplasmic MARCKS during purification.	CNRS,URA 31,CHIM ORGAN SUBSTANCES NAT LAB,F-67084 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	MANENTI, S (corresponding author), UNIV BASEL,BIOCTR,DEPT BIOPHYS CHEM,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.		manenti, stephane/P-1518-2014	manenti, stephane/0000-0002-4793-3196				ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; ALBERT KA, 1984, P NATL ACAD SCI-BIOL, V81, P3622, DOI 10.1073/pnas.81.12.3622; AMESS B, 1992, FEBS LETT, V297, P285; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; JAMES G, 1989, J BIOL CHEM, V264, P20928; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MIZUTANI A, 1992, BIOCHEM BIOPH RES CO, V182, P1395, DOI 10.1016/0006-291X(92)91888-W; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PATEL J, 1987, J BIOL CHEM, V262, P16686; ROSEN A, 1989, J BIOL CHEM, V264, P9118; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOKUMITSU H, 1989, BIOCHEM BIOPH RES CO, V163, P581, DOI 10.1016/0006-291X(89)92177-3; TOKUMITSU H, 1991, ARCH BIOCHEM BIOPHYS, V286, P94, DOI 10.1016/0003-9861(91)90012-8; UCHIDA T, 1984, J BIOL CHEM, V259, P2311; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; ZHAO D, 1991, BIOCHEM J, V277, P445, DOI 10.1042/bj2770445	31	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22310	22315						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429582				2022-12-25	WOS:A1992JW71900051
J	STANTON, LW; WHITE, RT; BRYANT, CM; PROTTER, AA; ENDEMANN, G				STANTON, LW; WHITE, RT; BRYANT, CM; PROTTER, AA; ENDEMANN, G			A MACROPHAGE FC RECEPTOR FOR IGG IS ALSO A RECEPTOR FOR OXIDIZED LOW-DENSITY-LIPOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; SCAVENGER RECEPTOR; ENDOTHELIAL-CELLS; HUMAN FIBROBLASTS; APOLIPOPROTEIN-B; DEGRADATION; RECOGNITION; OXIDATION; BINDING; DERIVATIZATION	The internalization of oxidized low density lipoprotein (OxLDL) by macrophages is hypothesized to contribute to foam cell formation and eventually to atherosclerotic lesion formation. OxLDL is a ligand for the acetylated low density lipoprotein (AcLDL) receptor, however, our data show that this receptor accounts for less than half of OxLDL uptake by mouse macrophages, suggesting additional receptors for OxLDL. We have developed a novel expression cloning strategy in order to isolate clones encoding OxLDL receptors. In addition to the AcLDL receptor, we isolated a molecular clone for a structurally unrelated receptor capable of mediating the high affinity uptake of OxLDL following transfection into cells. This receptor has been identified as the mouse FcgammaRII-B2, a member of a family of receptors known to mediate immune complex uptake through recognition of the Fc region of IgG. The uptake of OxLDL by cells transfected with the FcgammaRII-B2 clone is not blocked by AcLDL but is blocked by the anti-FcgammaRII monoclonal antibody, 2.4G2.	SCIOS INC,MT VIEW,CA 94043	Scios					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R43HL047220] Funding Source: NIH RePORTER; NHLBI NIH HHS [1 R43 HL47220-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI H, 1989, BIOCHEM BIOPH RES CO, V159, P1375, DOI 10.1016/0006-291X(89)92262-6; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BROWN MS, 1975, CELL, V6, P307, DOI 10.1016/0092-8674(75)90182-8; CONTRERAS MA, 1983, METHOD ENZYMOL, V92, P277; ENDEMANN GC, 1991, BIOCHEM J, V273, P63, DOI 10.1042/bj2730063; FONG LG, 1987, J LIPID RES, V28, P1466; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HENRIKSEN T, 1983, ARTERIOSCLEROSIS, V3, P149, DOI 10.1161/01.ATV.3.2.149; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOFF HF, 1992, J BIOL CHEM, V267, P602; JESSUP W, 1990, BIOCHEM J, V265, P399, DOI 10.1042/bj2650399; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; MELLMAN I, 1984, J CELL BIOL, V98, P1170, DOI 10.1083/jcb.98.4.1170; MELLMAN I, 1988, CURR OPIN IMMUNOL, V1, P16, DOI 10.1016/0952-7915(88)90046-5; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PARTHASARATHY S, 1986, ARTERIOSCLEROSIS, V6, P505, DOI 10.1161/01.ATV.6.5.505; POGLITSCH CL, 1991, BIOCHEMISTRY-US, V30, P6662, DOI 10.1021/bi00241a005; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; STEINBRECHER UP, 1989, J BIOL CHEM, V264, P15216; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	34	187	192	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22446	22451						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429595				2022-12-25	WOS:A1992JW71900072
J	WANG, ZY; MADDEN, SL; DEUEL, TF; RAUSCHER, FJ				WANG, ZY; MADDEN, SL; DEUEL, TF; RAUSCHER, FJ			THE WILMS-TUMOR GENE-PRODUCT, WT1, REPRESSES TRANSCRIPTION OF THE PLATELET-DERIVED GROWTH-FACTOR A-CHAIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL-GROWTH; EXPRESSION; DELETION	The Wilms' tumor locus on chromosome 11p13 contains a tumor suppressor gene, wt1, which encodes a DNA binding protein (WT1) with four zinc fingers and a glutamine-proline-rich N terminus and which functions as a repressor of transcription. The platelet-derived growth factor (PDGF) A-chain gene encodes a potent growth factor, which is expressed in high levels in a number of tumor cell lines. We initiated a search for WT1 target genes and now report that WT1 strikingly represses transcription of the PDGF A-chain gene in transient transfection assays and that the WT1 protein interacts directly with a highly G+C-rich region of the PDGF A-chain promoter in gel mobility shift assays. The results suggest that WT1 may function to repress expression of the PDGF A-chain gene and that loss of this or related repressor activities may contribute to the abnormal growth of Wilms' tumors.	WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	The Wistar Institute; Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)					NATIONAL CANCER INSTITUTE [P01CA052009, P01CA047983] Funding Source: NIH RePORTER; NCI NIH HHS [CA 10817, CA 47983, CA 52009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEJCEK BE, 1992, J BIOL CHEM, V267, P3289; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUNAGA E, 1981, HUM GENET, V57, P231; MILLER RW, 1964, NEW ENGL J MED, V270, P922, DOI 10.1056/NEJM196404302701802; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; RAUSCHER FJ, 1990, SCIENCE, V250, P1257; RICCARDI VM, 1978, PEDIATRICS, V61, P604; SPAETE RR, 1985, J VIROL, V56, P136; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; WANG ZY, 1992, J BIOL CHEM, V267, P17022; YEH HJ, 1991, CELL, V64, P209, DOI 10.1016/0092-8674(91)90222-K	20	222	231	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					21999	22002						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429549				2022-12-25	WOS:A1992JW71900004
J	ALAM, J; DEN, ZN				ALAM, J; DEN, ZN			DISTAL AP-1 BINDING-SITES MEDIATE BASAL LEVEL ENHANCEMENT AND TPA INDUCTION OF THE MOUSE HEME OXYGENASE-1 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHENOL-CHLOROFORM EXTRACTION; EMBRYONAL CARCINOMA-CELLS; SINGLE-STEP METHOD; MR 32,000 PROTEIN; BALB/C 3T3 CELLS; CHLORAMPHENICOL ACETYLTRANSFERASE; TRANSCRIPTIONAL ACTIVATION; ACCURATE TRANSCRIPTION; MAMMALIAN-CELLS	Basal expression of a chimeric gene (pMHO4CAT) consisting of approximately 7 kilobase pairs (kbp) of the 5'- flanking region of the mouse heme oxygenase-1 (HO-1) gene fused to the bacterial chloramphenicol acetyltransferase gene is 2- to 10-fold greater than that of an analogous construct containing only 1287 bp of the 5'-flanking region (pMHO1CAT) in transiently transfected cultured cells. The enhancer activity has been localized to a 268-base pair (bp) fragment positioned approximately 4 kilobase pairs upstream of the transcription initiation site. This fragment contains two high affinity protein binding sites, regions A and B, as determined by DNase I protection assays using nuclear protein extracts from rat C6 glioma cells. Both sites include core sequence elements, TGAGTCA (region A) and TGTGTCA (region B), that resemble the consensus binding site, TGA(G/C)TCA, of the Jun/Fos (AP-1) family of transcription factors. Purified, bacterially expressed AP-1 (c-Jun homodimer) specifically binds to both elements, exhibiting greater affinity for the region A motif. The expression of pMHO4CAT, but not of pMHO1CAT, is stimulated by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), and the 268-bp enhancer fragment confers TPA inducibility and c-Jun/c-Fos transactivation to the heterologous SV40 promoter. These functions are mediated by the AP-1 binding sites as multiple copies of the region A motif also confer TPA induction and c-Jun/c-Fos transactivation upon a heterologous promoter.			ALAM, J (corresponding author), ALTON OCHSNER MED FDN & OCHSNER CLIN,DEPT MOLEC GENET,NEW ORLEANS,LA 70121, USA.		Alam, Jawed/F-2596-2010	Alam, Jawed/0000-0001-6520-482X	NIDDK NIH HHS [DK-43135] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043135] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; ALAM J, 1989, J BIOL CHEM, V264, P6371; ALAM J, 1991, BIOTECHNIQUES, V10, P423; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; APPLEGATE LA, 1991, CANCER RES, V51, P974; BAKKEN AF, 1972, J CLIN INVEST, V51, P530, DOI 10.1172/JCI106841; BISSELL DM, 1976, ARCH BIOCHEM BIOPHYS, V176, P91, DOI 10.1016/0003-9861(76)90144-2; BITAR M, 1984, DIABETES, V33, P37, DOI 10.2337/diabetes.33.1.37; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CANTONI L, 1991, BIOCHEM J, V279, P891, DOI 10.1042/bj2790891; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAGARASAN MO, 1990, P NATL ACAD SCI USA, V87, P7871, DOI 10.1073/pnas.87.20.7871; GEMSA D, 1974, J CLIN INVEST, V53, P647, DOI 10.1172/JCI107599; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P45; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIWASA T, 1983, CANCER RES, V43, P5951; HIWASA T, 1982, P NATL ACAD SCI-BIOL, V79, P1800, DOI 10.1073/pnas.79.6.1800; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; KAGEYAMA H, 1988, CANCER RES, V48, P4795; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Maxam A M, 1980, Methods Enzymol, V65, P499; MESSINA JL, 1990, J BIOL CHEM, V265, P11700; MITANI K, 1992, BLOOD, V79, P255; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; MULLER RM, 1987, J BIOL CHEM, V262, P6795; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARDANA MK, 1980, J BIOL CHEM, V255, P1320; SARDANA MK, 1985, BIOCHEM PHARMACOL, V34, P2937, DOI 10.1016/0006-2952(85)90019-X; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SHIBAHARA S, 1989, EUR J BIOCHEM, V179, P557, DOI 10.1111/j.1432-1033.1989.tb14583.x; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169	58	167	169	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21894	21900						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400499				2022-12-25	WOS:A1992JV01100097
J	CONNER, GE				CONNER, GE			THE ROLE OF THE CATHEPSIN-D PROPEPTIDE IN SORTING TO THE LYSOSOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; PROCATHEPSIN-D; CARBOXYPEPTIDASE-Y; HEPG2 CELLS; ENZYME; EXPRESSION; YEAST; PROTEIN; BIOSYNTHESIS; SEQUENCES	The propeptides of lysosomal enzymes have been implicated in membrane association and mannose 6-phosphate-independent sorting to the lysosome (Rijnboutt, S., Aerts, H., Geuze, H. J., Tager, J. M., and Strous, G. J. (1991) J. Biol. Chem. 266, 4862-4868; McIntyre, G. F., and Erickson, A. H. (1991) J. Biol. Chem. 266, 15438-15445). In this report, the function of the propeptide of procathepsin D in sorting to the lysosome was directly assessed using a cathepsin D deletion mutant lacking the propeptide, and using a chimeric cDNA encoding the cathepsin D propeptide fused to the secretory protein alpha-lactalbumin. Proteins encoded by these cDNAs were expressed in mouse Ltk- cells and in human hepatoma Hep G2 cells, and then immunoprecipitated and analyzed by SDS-polyacrylamide gel electrophoresis. The deletion mutant was glycosylated but was rapidly degraded in a chloroquine-independent fashion and did not assume an active conformation. Thus the propeptide appeared to be necessary for correct folding. The chimeric protein was glycosylated and secreted. The coincidence of complex oligosaccharide modification and secretion of the chimeric protein suggested that it was slowly released from the endoplasmic reticulum and rapidly passed through the cell to the extracellular compartment. This was confirmed by immunofluorescent localization of the proteins. The data indicated that the propeptide appeared to be necessary for folding of cathepsin D but, unlike the yeast vacuolar propeptides, was not sufficient to direct a secretory protein to the lysosome in fibroblasts or in epithelial cells.			CONNER, GE (corresponding author), UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,MIAMI,FL 33101, USA.		Conner, Gregory/AAI-1285-2021	Conner, Gregory/0000-0003-2217-2252	NIGMS NIH HHS [GM35812] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035812] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CONNER GE, 1990, DNA CELL BIOL, V9, P1, DOI 10.1089/dna.1990.9.1; CONNER GE, 1989, BIOCHEMISTRY-US, V28, P3530, DOI 10.1021/bi00434a057; CONNER GE, 1989, BIOCHEM J, V263, P601, DOI 10.1042/bj2630601; DIMENT S, 1988, J BIOL CHEM, V263, P6901; ERICKSON AH, 1981, J BIOL CHEM, V256, P1224; FAUST PL, 1989, J BIOL CHEM, V264, P479; FISHER PA, 1982, J CELL BIOL, V92, P674, DOI 10.1083/jcb.92.3.674; GORMAN CM, 1983, NUCLEIC ACIDS RES, V11, P7631, DOI 10.1093/nar/11.21.7631; HARRISON TM, 1989, PROTEINS, V5, P259, DOI 10.1002/prot.340050402; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HASILIK A, 1978, EUR J BIOCHEM, V91, P567, DOI 10.1111/j.1432-1033.1978.tb12710.x; HUANG JS, 1979, J BIOL CHEM, V254, P1405; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KNIGHT CG, 1976, BIOCHEM J, V155, P117, DOI 10.1042/bj1550117; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LANG L, 1984, J BIOL CHEM, V259, P4663; LIN XL, 1989, J BIOL CHEM, V264, P4482; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; OWADA M, 1982, BIOCHEM BIOPH RES CO, V105, P814, DOI 10.1016/0006-291X(82)91042-7; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P4862; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P23586; ROACH A, 1984, GENE, V32, P389, DOI 10.1016/0378-1119(84)90014-3; ROTHMAN JH, 1989, J CELL BIOL, V109, P93, DOI 10.1083/jcb.109.1.93; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; WAHEED A, 1982, BIOCHEM BIOPH RES CO, V105, P1052, DOI 10.1016/0006-291X(82)91076-2; WANG M, 1989, J BIOL CHEM, V264, P21116; WATERS M G, 1991, Current Opinion in Cell Biology, V3, P615, DOI 10.1016/0955-0674(91)90031-S; YONEZAWA S, 1988, J BIOL CHEM, V263, P16504	37	36	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21738	21745						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400484				2022-12-25	WOS:A1992JV01100075
J	DICKINSON, CJ; DAUGHERTY, D; GUO, YJ; HUGHES, P; YAMADA, T				DICKINSON, CJ; DAUGHERTY, D; GUO, YJ; HUGHES, P; YAMADA, T			MOLECULAR ANALYSIS OF DIBASIC ENDOPROTEOLYTIC CLEAVAGE SIGNALS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CELL-LINES; EXPRESSION; CARBOXYPEPTIDASE; IDENTIFICATION; PROINSULIN; GASTRIN; DNA; PREPROGASTRIN; PURIFICATION	Biologically active peptide hormones are synthesized from larger precursor proteins by a variety of post-translational processing reactions. To characterize these processing reactions further we have expressed preprogastrin in two endocrine cell lines and examined the molecular determinants involved in endoproteolysis at dibasic cleavage sites. The Gly93-Arg94-Arg95 carboxyl-terminal processing site of progastrin must be processed sequentially by an endoprotease, a carboxypeptidase, and an amidating enzyme to produce bioactive gastrin. For these studies the dibasic Arg94-Arg95 residues that serve as signals for the initiation of this processing cascade were mutated to Lys94-Arg95, Arg94-Lys95, and Lys94-Lys95. In the GH3 cells the Lys94-Arg95 mutation slightly diminished synthesis of carboxyl-terminally amidated gastrin, whereas in the MTC 6-23 cells this mutation had no effect on amidated gastrin synthesis. In contrast, both Arg94-Lys95 and Lys94-Lys95 mutations resulted in significantly diminished production of amidated gastrin in both cell lines. A specific hierarchy of preferred cleavage signals at this progastrin processing site was demonstrated in both cell lines, indicating that cellular dibasic endoproteases have stringent substrate specificities. Progastrins with the Lys94-Arg95 mutation in GH3 cells also demonstrated diminished processing at the Lys74-Lys75 dibasic site, thus single amino acid changes at one processing site may alter cleavage at distant sites. These studies provide insight into the post-translational processing and biological activation of not only gastrin but other peptide hormones as well.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	DICKINSON, CJ (corresponding author), UNIV MICHIGAN,MED CTR,DEPT PEDIAT,PEDIAT GASTROENTEROL,C6105 MID,ANN ARBOR,MI 48109, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK001903, P30DK034933, R01DK034306] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK-34306, K08-DK-01903, P30-DK-34933] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CALAM J, 1980, EUR J CLIN INVEST, V10, P241, DOI 10.1111/j.1365-2362.1980.tb00027.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DAUGHERTY DF, 1991, AM J PHYSIOL, V260, pG783, DOI 10.1152/ajpgi.1991.260.5.G783; DAVIDSON HW, 1987, BIOCHEM J, V245, P575, DOI 10.1042/bj2450575; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DICKERSON IM, 1987, J BIOL CHEM, V262, P13646; DICKERSON IM, 1990, ENDOCRINOLOGY, V127, P133, DOI 10.1210/endo-127-1-133; DICKINSON CJ, 1989, NEUROENDOCRINOLOGY G, P63; DOCHERTY K, 1989, J BIOL CHEM, V264, P18335; DOCKRAY GJ, 1975, GASTROENTEROLOGY, V68, P222; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRICKER LD, 1983, J BIOL CHEM, V258, P950; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HILSTED L, 1986, ANAL BIOCHEM, V152, P119, DOI 10.1016/0003-2697(86)90129-6; INNIS MA, 1990, PCR PROTOCOLS; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARINO LR, 1991, J BIOL CHEM, V266, P6133; REHFELD JF, 1986, J BIOL CHEM, V261, P5841; REHFELD JF, 1981, REGUL PEPTIDES, V2, P333, DOI 10.1016/0167-0115(81)90037-9; ROSENQUIST GL, 1980, GASTROINTESTINAL HOR, P769; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; Steiner D. F., 1991, PEPTIDE BIOSYNTHESIS, P1; STOLLER TJ, 1989, J BIOL CHEM, V264, P6922; SUGANO K, 1985, J BIOL CHEM, V260, P1724; TAKEUCHI T, 1991, J BIOL CHEM, V266, P17409; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; ZEYTINOGLU FN, 1980, ENDOCRINOLOGY, V107, P509, DOI 10.1210/endo-107-2-509	32	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21795	21801						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400488				2022-12-25	WOS:A1992JV01100083
J	LATHROP, BK; BILTONEN, RL				LATHROP, BK; BILTONEN, RL			CALCIUM AND MAGNESIUM DEPENDENCE OF PHOSPHOLIPASE-A2-CATALYZED HYDROLYSIS OF PHOSPHATIDYLCHOLINE SMALL UNILAMELLAR VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE PANCREATIC PHOSPHOLIPASE-A2; AGKISTRODON-PISCIVORUS-PISCIVORUS; COBRA-VENOM PHOSPHOLIPASE-A2; TRANSITION-STATE ANALOG; CROTALUS-ADAMANTEUS; DIPALMITOYLPHOSPHATIDYLCHOLINE VESICLES; INTERFACIAL CATALYSIS; SUBSTRATE BINDING; CRYSTAL-STRUCTURE; ACTIVATION	The Ca2+ requirement for lipid hydrolysis catalyzed by phospholipase A2 from Agkistrodon piscivorus piscivorus (App-D49) and porcine pancreas has been examined using small, unilamellar vesicles of dipalmitoylphosphatidylcholine (DPPC SUV). Hydrolysis was affected by product inhibition even at early times, and the extent of this inhibition depended on the concentration of divalent cations. The Ca2+ requirement for half-maximal rates of hydrolysis reflected, in part, this non-catalytic role of divalent cations. The presence of 10 mM Mg2+, a cation which does not support catalysis, reduced the Ca2+ required for half-maximal rates of hydrolysis from millimolar concentrations to 40 muM for App-D49. Since the dissociation constant of the enzyme for Ca2+ in solution is 2 mM, these results indicate a change in the interaction of the enzyme with Ca2+ under catalytic conditions. The kinetic dissociation constant of Ca2+ for the pancreatic enzyme was 20 muM which is substantially lower than the dissociation constant in solution, 0.35 mM. The similarity of apparent kinetic dissociation constants for these enzymes suggests that structurally similar features determine the affinity for Ca2+ under catalytic conditions. Evidence is presented that the affinity of phospholipase A2 for Ca2+ changes subsequent to the initial interaction of the enzyme with the substrate interface. However, the apparent Michaelis constant, K(Mapp), for App-D49, 0.03-0.06 mM, is independent of [Ca2+] and is about the same as the equilibrium dissociation constant for DPPC SUV, 0.14 mM. We thus suggest that K(Mapp) is a steady-state constant.	UNIV VIRGINIA, HLTH SCI CTR, DEPT BIOCHEM, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037658] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 37658] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BELL JD, 1992, J BIOL CHEM, V267, P11046; BELL JD, 1989, J BIOL CHEM, V264, P225; BELL JD, 1989, J BIOL CHEM, V264, P12194; BHAMIDIPATI SP, 1989, BIOCHEMISTRY-US, V28, P6667, DOI 10.1021/bi00442a020; DEHAAS GH, 1971, BIOCHIM BIOPHYS ACTA, V239, P252, DOI 10.1016/0005-2760(71)90171-8; DIJKSTRA BW, 1981, J MOL BIOL, V147, P97, DOI 10.1016/0022-2836(81)90081-4; DIJKSTRA BW, 1983, J MOL BIOL, V168, P163, DOI 10.1016/S0022-2836(83)80328-3; DRAKENBERG T, 1984, BIOCHEMISTRY-US, V23, P2387, DOI 10.1021/bi00306a011; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEDWIG GR, 1984, BIOPHYS CHEM, V19, P1, DOI 10.1016/0301-4622(84)85001-2; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; HUANG CH, 1969, BIOCHEMISTRY-US, V8, P344, DOI 10.1021/bi00829a048; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V1002, P127, DOI 10.1016/0005-2760(89)90281-6; KRAUSE H, 1991, BIOCHEM BIOPH RES CO, V175, P532, DOI 10.1016/0006-291X(91)91597-6; KUPFERBERG JP, 1981, J BIOL CHEM, V256, P6274; MARAGANORE JM, 1984, J BIOL CHEM, V259, P3839; PIETERSON WA, 1974, BIOCHEMISTRY-US, V13, P1439, DOI 10.1021/bi00704a019; RENETSEDER R, 1985, J BIOL CHEM, V260, P1627; ROBERTS MF, 1977, J BIOL CHEM, V252, P6011; ROBERTS MF, 1977, P NATL ACAD SCI USA, V74, P1950, DOI 10.1073/pnas.74.5.1950; ROMERO G, 1987, J BIOL CHEM, V262, P13476; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; SHEN BW, 1975, J AM CHEM SOC, V97, P1205, DOI 10.1021/ja00838a040; SLOTBOOM AJ, 1978, BIOCHEMISTRY-US, V17, P4593, DOI 10.1021/bi00615a003; SUURKUUSK J, 1976, BIOCHEMISTRY-US, V15, P1393, DOI 10.1021/bi00652a007; TESHIMA K, 1989, J BIOCHEM, V106, P518, DOI 10.1093/oxfordjournals.jbchem.a122885; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; VANDAMMIERAS MCE, 1975, BIOCHEMISTRY-US, V14, P5387, DOI 10.1021/bi00696a001; VANDENBERGH CJ, 1989, EUR J BIOCHEM, V182, P307; VERGER R, 1973, J BIOL CHEM, V248, P4023; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; WELLS MA, 1972, BIOCHEMISTRY-US, V11, P1030, DOI 10.1021/bi00756a013; WHITE SP, 1990, SCIENCE, V250, P1560, DOI 10.1126/science.2274787; WONG M, 1982, BIOCHEMISTRY-US, V21, P4126, DOI 10.1021/bi00260a032	36	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21425	21431						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400456				2022-12-25	WOS:A1992JV01100028
J	MATSUURA, K; ISHIDA, T; SETOGUCHI, M; HIGUCHI, Y; AKIZUKI, S; YAMAMOTO, S				MATSUURA, K; ISHIDA, T; SETOGUCHI, M; HIGUCHI, Y; AKIZUKI, S; YAMAMOTO, S			IDENTIFICATION OF A TISSUE-SPECIFIC REGULATORY ELEMENT WITHIN THE MURINE CD14 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOMA CELL-LINE; BINDING-PROTEINS; MONOCLONAL-ANTIBODIES; RESPONSIVE ELEMENT; EXPRESSION; DNA; SEQUENCES; ANTIGENS; HYBRIDS; MOUSE	We previously isolated and sequenced the 5'-flanking region of the mouse CD14 (mCD14) gene (Matsuura, K., Setoguchi, M., Nasu, N., Higuchi, Y., Yoshida, S., Akizuki, S., and Yamamoto, S. (1989) Nucleic Acids Res. 17, 2132). To define the regulatory elements that control expression of the mCD14 gene, we analyzed the structure of the 5' end of the gene, including a region further upstream of that determined previously. Sequentially 5'-deleted, chimeric, and point mutated clones were tested for the ability to stimulate chloramphenicol acetyltransferase. An 8-base pair sequence, TGATTCAC, at position -255, which resembled the consensus sequence of the 12-O-tetradecanoylphorbol-13-acetate-responsive element (TRE), enhanced the expression of the chloramphenicol acetyltransferase gene in macrophage (aHINS-B3) and non-macrophage (glioblastoma G203 and myeloma NS1) cells. The enhancing ability of the TRE-like sequence (TLS), however, was markedly reduced in G203 cells but not in aHINS-B3 cells when the TLS was followed by the sequence immediately downstream. The TLS and sequence immediately downstream were capable of binding nuclear proteins which were unique to aHINS-B3 cells and macrophages, suggesting that these unique protein regulate the specific expression of the mCD14 gene. Binding of AP-1 to the TLS was also found in aHINS-B3 and G203 cells. Although it is uncertain whether AP-1 is involved in expression of the mCD14 gene, the effect of AP-1 in non-macrophage cells was inhibited by a nuclear protein which binds to the sequence immediately downstream of the TLS.			MATSUURA, K (corresponding author), OITA MED UNIV,DEPT PATHOL,HASAMA,OITA 87955,JAPAN.							ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BALL ED, 1982, P NATL ACAD SCI-BIOL, V79, P5374, DOI 10.1073/pnas.79.17.5374; BAZIL V, 1986, EUR J IMMUNOL, V16, P1583, DOI 10.1002/eji.1830161218; BERG AJ, 1978, P NATL ACAD SCI USA, V75, P1274; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; FUJITA T, 1985, CELL, V41, P489, DOI 10.1016/S0092-8674(85)80022-2; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOYERT SM, 1986, J IMMUNOL, V137, P3909; GRIFFIN JD, 1981, J CLIN INVEST, V68, P932, DOI 10.1172/JCI110348; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HIGUCHI Y, 1988, ONCOGENE, V2, P515; JELINEK WR, 1982, ANNU REV BIOCHEM, V51, P813, DOI 10.1146/annurev.bi.51.070182.004121; KORBER B, 1988, SCIENCE, V239, P1302, DOI 10.1126/science.3125612; MALISZEWSKI CR, 1985, J IMMUNOL, V135, P1929; MATSUURA K, 1989, NUCLEIC ACIDS RES, V17, P2132, DOI 10.1093/nar/17.5.2132; Matsuura K, 1990, J Immunol, V145, P3150; MIYAZAKI Y, 1990, J BIOL CHEM, V265, P14432; MOSHIER JA, 1987, GENE, V58, P19, DOI 10.1016/0378-1119(87)90025-4; NASU N, 1991, INT IMMUNOL, V3, P205, DOI 10.1093/intimm/3.2.205; OKUDA A, 1989, J BIOL CHEM, V264, P16919; OZONO K, 1990, J BIOL CHEM, V265, P21881; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SETOGUCHI M, 1989, MOL CELL BIOL, V9, P4515, DOI 10.1128/MCB.9.10.4515; SETOGUCHI M, 1988, SOMAT CELL MOLEC GEN, V14, P427, DOI 10.1007/BF01534710; SETOGUCHI M, 1989, BIOCHIM BIOPHYS ACTA, V1008, P213, DOI 10.1016/0167-4781(80)90012-3; TODD RF, 1981, J IMMUNOL, V126, P1435; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; YAMAMOTO S, 1984, IMMUNOGENETICS, V19, P519, DOI 10.1007/BF00403443	36	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21787	21794						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1383228				2022-12-25	WOS:A1992JV01100082
J	RICHARDSON, DR; BAKER, E				RICHARDSON, DR; BAKER, E			INTERMEDIATE STEPS IN CELLULAR IRON UPTAKE FROM TRANSFERRIN - DETECTION OF A CYTOPLASMIC POOL OF IRON, FREE OF TRANSFERRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; RAT-LIVER; PLASMA-MEMBRANE; BOUND IRON; DIFERRIC TRANSFERRIN; ENDOTHELIAL-CELLS; ERYTHROID-CELLS; MELANOMA CELL; RELEASE; TRANSPORT	The uptake of transferrin-bound iron by receptor-mediated endocytosis has been the subject of extensive experimental investigation. However, the path followed by iron (Fe) after release from transferrin (Tf) remains obscure. Once Fe is released from Tf within the endosome, it must be transported across the endosomal membrane into the cell. The present investigation describes the presence of a cytoplasmic Tf-free Fe pool which is detectable only when cells are detached from their culture dishes at low temperature, after initial incorporation of diferric transferrin at 37-degrees-C. This cellular iron pool was greatly reduced if incubation temperatures were maintained at 37-degrees-C or if cells were treated with pronase. Human melanoma cells (SK-MEL-28) in culture were prelabeled by incubation with human I-125-Fe-59-transferrin for 2 h, washed, and reincubated at 4-degrees-C or 37-degrees-C in balanced salt solution in the presence or absence of pronase. The cells were then mechanically detached from the plates and separated into "internalized" and supernatant fractions by centrifugation. Approximately 90% of cellular Fe-59 and 20% of I-125-Tf remained internalized when this reincubation procedure was carried out in balanced salt solution at 37-degrees-C. However, at 4-degrees-C, cellular internalized iron was reduced to approximately 50% of the initial value. The release of this component of cellular Fe-59 (approximately 40% of total cell Fe-59) at 4-degrees-C was completely inhibited in the presence of pronase and other general proteinases at 4-degrees-C and at 37-degrees-C, without affecting internalized transferrin levels. Similar results were obtained in fibroblasts and hepatoma cells, indicating that this phenomenon is not unique to melanoma cells. The characterization of this Tf-free cellular Fe pool which is detectable at low temperature may yield valuable insights into the metabolic fate of iron following its transport across the membrane of the endocytotic vesicle.			RICHARDSON, DR (corresponding author), UNIV WESTERN AUSTRALIA, DEPT PHYSIOL, NEDLANDS, WA 6009, AUSTRALIA.			Richardson, Des/0000-0002-5506-3274; Richardson, Des/0000-0003-0960-6415				AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; BAKER E, 1980, BRIT J HAEMATOL, V45, P607, DOI 10.1111/j.1365-2141.1980.tb07184.x; Baker E, 1988, Birth Defects Orig Artic Ser, V23, P89; BALI PK, 1991, BIOCHEMISTRY-US, V30, P324, DOI 10.1021/bi00216a003; BROWN JP, 1982, NATURE, V296, P171, DOI 10.1038/296171a0; CHAKRABORTY AK, 1992, FEBS LETT, V302, P126, DOI 10.1016/0014-5793(92)80421-C; CRANE FL, 1985, BIOCHIM BIOPHYS ACTA, V811, P233, DOI 10.1016/0304-4173(85)90013-8; CRICHTON RR, 1987, EUR J BIOCHEM, V164, P485, DOI 10.1111/j.1432-1033.1987.tb11155.x; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; EGYED A, 1988, BRIT J HAEMATOL, V68, P483, DOI 10.1111/j.1365-2141.1988.tb04241.x; FUCHS O, 1988, BIOCHIM BIOPHYS ACTA, V969, P158, DOI 10.1016/0167-4889(88)90071-7; HANKS JH, 1949, P SOC EXP BIOL MED, V71, P196; HEMMAPLARDH D, 1976, INT J APPL RADIAT IS, V27, P89, DOI 10.1016/0020-708X(76)90182-4; HOBBS AS, 1980, ANNU REV BIOPHYS BIO, V9, P259, DOI 10.1146/annurev.bb.09.060180.001355; HOLMES JM, 1989, AM J PHYSIOL, V256, pG1022, DOI 10.1152/ajpgi.1989.256.6.G1022; IACOPETTA BJ, 1983, J BIOL CHEM, V258, P9108; JACOBS A, 1977, BLOOD, V50, P433; KARIN M, 1981, J BIOL CHEM, V256, P3245; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; Kuhn L., 1990, IRON TRANSPORT STORA, P149; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MCKINLEY DN, 1988, J CELL PHYSIOL, V136, P389, DOI 10.1002/jcp.1041360302; MCNEIL PL, 1989, J CELL BIOL, V109, P811, DOI 10.1083/jcb.109.2.811; MORGAN EH, 1988, ANN NY ACAD SCI, V526, P65, DOI 10.1111/j.1749-6632.1988.tb55493.x; MORGAN EH, 1988, BIOCHIM BIOPHYS ACTA, V943, P428, DOI 10.1016/0005-2736(88)90374-4; MORGAN EH, 1981, MOL ASPECTS MED, V4, P1, DOI 10.1016/0098-2997(81)90003-0; MORRIS CE, 1990, J MEMBRANE BIOL, V113, P93, DOI 10.1007/BF01872883; MUSGROVE E, 1984, J CELL PHYSIOL, V118, P6, DOI 10.1002/jcp.1041180103; MUTHUKRISHNAN L, 1991, J CELL PHYSIOL, V148, P1, DOI 10.1002/jcp.1041480102; PAGE M, 1986, AM J PHYSIOL, V246, pG26; PIPPARD MJ, 1982, BRIT J HAEMATOL, V52, P211, DOI 10.1111/j.1365-2141.1982.tb03883.x; RICHARDSON D, 1991, BIOCHIM BIOPHYS ACTA, V1093, P20, DOI 10.1016/0167-4889(91)90133-I; RICHARDSON D, 1992, J BIOL CHEM, V267, P13972; RICHARDSON DR, 1992, BIOCHIM BIOPHYS ACTA, V1103, P275, DOI 10.1016/0005-2736(92)90097-6; RICHARDSON DR, 1990, BIOCHIM BIOPHYS ACTA, V1053, P1, DOI 10.1016/0167-4889(90)90018-9; RICHARDSON DR, 1991, BIOCHIM BIOPHYS ACTA, V1091, P294, DOI 10.1016/0167-4889(91)90192-Z; RICHARDSON DR, 1990, THESIS U W AUSTR PER; ROSE TM, 1986, P NATL ACAD SCI USA, V83, P1261, DOI 10.1073/pnas.83.5.1261; SELIGMAN PA, 1986, AM J HUM GENET, V38, P540; SIPE DM, 1991, J BIOL CHEM, V266, P8002; STPIERRE TG, 1992, BIOCHIM BIOPHYS ACTA, V1135, P154; Stryer L, 1981, BIOCHEMISTRY; SUN IL, 1987, J BIOL CHEM, V262, P15915; THORSTENSEN K, 1990, BIOCHEM J, V271, P1; THORSTENSEN K, 1988, J BIOL CHEM, V263, P8844; THORSTENSEN K, 1990, BIOCHIM BIOPHYS ACTA, V1052, P29, DOI 10.1016/0167-4889(90)90053-G; THORSTENSEN K, 1988, J BIOL CHEM, V263, P16837; TRINDER D, 1986, HEPATOLOGY, V6, P852, DOI 10.1002/hep.1840060508; WEINBERG ED, 1984, PHYSIOL REV, V64, P65, DOI 10.1152/physrev.1984.64.1.65; WRIGHT TL, 1986, J BIOL CHEM, V261, P909; WRIGHT TL, 1988, J BIOL CHEM, V263, P1842; YOSHIDA M, 1977, P NATL ACAD SCI USA, V74, P936, DOI 10.1073/pnas.74.3.936; YOUNG SP, 1981, HEPATOLOGY, V1, P114, DOI 10.1002/hep.1840010205	53	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21384	21389						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400450				2022-12-25	WOS:A1992JV01100022
J	RUFF, VA; YEM, AW; MUNNS, PL; ADAMS, LD; REARDON, IM; DEIBEL, MR; LEACH, KL				RUFF, VA; YEM, AW; MUNNS, PL; ADAMS, LD; REARDON, IM; DEIBEL, MR; LEACH, KL			TISSUE DISTRIBUTION AND CELLULAR-LOCALIZATION OF HSP56, AN FK506-BINDING PROTEIN - CHARACTERIZATION USING A HIGHLY SPECIFIC POLYCLONAL ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HEAT-SHOCK PROTEINS; STEROID-RECEPTOR COMPLEXES; MONOCLONAL-ANTIBODIES; CYCLOSPORINE-A; CELLS; CYCLOPHILIN; DISTINCT; BINDING; CYTOSOL; TARGET	Heat shock protein 56 (hsp56) has been shown to be involved in two cellular pathways, as an immunophilin for FK506 and as a component of steroid receptor complexes. To help define its role in these cellular pathways, we have developed UPJ56, a polyclonal antibody raised against hsp56 purified from Jurkat cells. In Western blot experiments, hsp56 was highly expressed in rat thymus, liver, and spleen, with low levels in lung and muscle. In immunofluorescence experiments using untreated LLC-PK1 cells, fibrillar staining was seen in the cytoplasm, suggesting a cytoskeletal localization of hsp56. The nuclei were brightly stained, except for the nucleoli. Confocal microscopy demonstrated that the staining was present in all planes of the nucleus. These results suggest that hsp56 is expressed in tissues enriched in steroid receptors and is highly expressed in tissues involved in T cell function. Furthermore, the localization of hsp56 with the cytoskeleton and throughout the nucleus is consistent with its association with steroid receptor complexes.	UPJOHN CO,DEPT CELL BIOL,301 HENRIETTA ST,KALAMAZOO,MI 49001; UPJOHN CO,DEPT BIOCHEM,KALAMAZOO,MI 49001	Pfizer; Pfizer								ADAMS LD, 1991, CURRENT PROTOCOLS MO, V88, P7111; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLLIER NC, 1986, J CELL BIOL, V103, P1495, DOI 10.1083/jcb.103.4.1495; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GALAT A, 1992, BIOCHEMISTRY-US, V31, P2427, DOI 10.1021/bi00123a031; GASC JM, 1990, EXP CELL RES, V186, P362, DOI 10.1016/0014-4827(90)90317-4; JIU YJ, 1991, P NATL ACAD SCI USA, V88, P6677; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; LEACH KL, 1988, J BIOL CHEM, V263, P13223; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MARTINS VR, 1991, MOL ENDOCRINOL, V5, P217, DOI 10.1210/mend-5-2-217; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; PERROTAPPLANAT M, 1985, ENDOCRINOLOGY, V116, P1473, DOI 10.1210/endo-116-4-1473; REDMOND T, 1989, EUR J CELL BIOL, V50, P66; SAMMONS DW, 1981, ELECTROPHORESIS, V2, P135, DOI 10.1002/elps.1150020303; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1988, MOL ENDOCRINOL, V2, P756, DOI 10.1210/mend-2-8-756; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SANCHEZ ER, 1987, J BIOL CHEM, V262, P6986; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; YEM AW, 1992, J BIOL CHEM, V267, P2868	27	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21285	21288						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1383222				2022-12-25	WOS:A1992JV01100004
J	CHEUNG, WF; HAMAGUCHI, N; SMITH, KJ; STAFFORD, DW				CHEUNG, WF; HAMAGUCHI, N; SMITH, KJ; STAFFORD, DW			THE BINDING OF HUMAN FACTOR-IX TO ENDOTHELIAL-CELLS IS MEDIATED BY RESIDUES 3-11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GAMMA-CARBOXYGLUTAMIC ACID; ATOM FORCE-FIELD; NUCLEIC-ACIDS; BOVINE PROTHROMBIN; FACTOR-X; PROTEINS; SIMULATIONS; ACTIVATION; INHIBITORS; SURFACE	We have used chimeras and point mutations of recombinant coagulation factor IX to examine factor IX's specific interaction with bovine endothelial cells. Previously (Toomey, J. R., Smith, K. J., Roberts, H. R., and Stafford, D. W. (1992) Biochemistry 31, 1806-1808), we restricted the region of factor IX responsible for binding to endothelial cells to its Gla domain. Molecular modeling of the Gla domain of factor IX using the coordinates of the Gla domain of bovine prothrombin-(1-145) (Soriano-Garcia, M., Padmanabhan, K., deVos, A. M., and Tulinsky, A. (1992) Biochemistry 31, 2554-2566) reveals two major surface determinants whose sequences differ among factors IX, X, and VII. A chimeric protein comprised of the Gla domain of factor VII with the remainder of the molecule of factor IX did not bind to the endothelial cell binding site. We changed residues 33, 34, 35, 39, and 40 to those of factor IX without restoring endothelial cell binding. Replacement of amino acid residues 3-10 with those of factor IX restored normal binding. With the knowledge that specific binding was localized to the first 11 amino acids, point mutations were made at residues predicted to be on the surface in this region of the factor IX molecule. Changing lysine 5 to alanine (K5A) or valine 10 to lysine (V10K) resulted in loss of binding with total retention of in vitro clotting activity. The lysine 5 to arginine (K5R) mutation also was fully active in vitro but displayed 3-fold tighter binding. In addition to defining the sequence of factor IX necessary for binding to endothelial cells, these results suggest that the binding site is not phospholipid but instead is specific, and in all likelihood, protein.	UNIV N CAROLINA,DEPT BIOL,442 WILSON HALL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,CHAPEL HILL,NC 27599; UNIV NEW MEXICO,SCH MED,DEPT MED,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,SCH MED,DEPT PATHOL,ALBUQUERQUE,NM 87131; UNITED BLOOD SERV,ALBUQUERQUE,NM 87131	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of New Mexico; University of New Mexico					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038973] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL38973-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRAUNSTEIN KM, 1981, J CLIN INVEST, V68, P1420, DOI 10.1172/JCI110393; CHARIFSON PS, 1991, P NATL ACAD SCI USA, V88, P424, DOI 10.1073/pnas.88.2.424; CHEUNG WF, 1991, J BIOL CHEM, V266, P8797; DERIAN CK, 1989, J BIOL CHEM, V264, P6615; FELDMAN HA, 1972, ANAL BIOCHEM, V48, P317, DOI 10.1016/0003-2697(72)90084-X; HEIMARK RL, 1983, BIOCHEM BIOPH RES CO, V111, P723, DOI 10.1016/0006-291X(83)90365-0; JANIN J, 1990, J BIOL CHEM, V265, P16027; MAYNARD AT, 1988, INT J PEPT PROT RES, V31, P137; PRZYSIECKI CT, 1987, P NATL ACAD SCI USA, V84, P7856, DOI 10.1073/pnas.84.22.7856; RIMON S, 1987, J BIOL CHEM, V262, P6023; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH KJ, 1984, THROMB RES, V33, P211, DOI 10.1016/0049-3848(84)90182-8; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; STERN DM, 1983, P NATL ACAD SCI-BIOL, V80, P4119, DOI 10.1073/pnas.80.13.4119; STERN DM, 1984, P NATL ACAD SCI-BIOL, V81, P913, DOI 10.1073/pnas.81.3.913; STERN DM, 1985, J BIOL CHEM, V260, P6717; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; TOOMEY JR, 1992, BIOCHEMISTRY-US, V31, P1806, DOI 10.1021/bi00121a031; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051	20	71	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20529	20531						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400370				2022-12-25	WOS:A1992JT97800002
J	JOSHIBARVE, S; DEBENEDETTI, A; RHOADS, RE				JOSHIBARVE, S; DEBENEDETTI, A; RHOADS, RE			PREFERENTIAL TRANSLATION OF HEAT-SHOCK MESSENGER-RNAS IN HELA-CELLS DEFICIENT IN PROTEIN-SYNTHESIS INITIATION-FACTORS EIF-4E AND EIF-4-GAMMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL INITIATION; FACTOR-III; BINDING; CAP; COMPLEX; INHIBITION; SEQUENCE; LEADER; VIRUS; INACTIVATION	Expression of antisense RNA against eukaryotic translation initiation factor 4E (eIF-4E) in HeLa cells causes a reduction in the levels of both eIF-4E and eIF-4gamma (p220) and a concomitant decrease in the rates of both cell growth and protein synthesis (De Benedetti, A., Joshi-Barve, S., Rinker-Schaffer, C., and Rhoads, R. E. (1991) Mol. Cell Biol. 11, 5435-5445). The synthesis of most proteins in the antisense RNA-expressing cells (AS cells) is decreased, but certain proteins continue to be synthesized. In the present study, we identified many of these as stress-inducible or heat shock proteins (HSPs). By mobilities on sodium dodecyl sulfate-polyacrylamide gel electrophoresis and by reactivity with monoclonal antibodies generated against human HSPs, four of these were shown to be HSP 90, HSP 70, HSP 65, and HSP 27. The steady-state levels of HSP 90, 70, and 27 were elevated in relation to total protein in AS cells. Pulse labeling and immunoprecipitation indicated that HSP 90 and HSP 70 were synthesized more rapidly in AS cells than in control cells. The accelerated synthesis of HSPs in the AS cells was not due, however, to increased mRNA levels; the levels of HSP 90 and 70 mRNAs either remained the same or decreased after induction of antisense RNA expression. Actin mRNA, a typical cellular mRNA, was found on high polysomes in control cells but shifted to smaller polysomes in AS cells, as expected from the general decrease in translational initiation caused by eIF-4E and eIF-4gamma depletion. HSP 90 and 70 mRNAs showed the opposite behavior; they were associated with small polysomes in control cells but shifted to higher polysomes in AS cells. These results demonstrate that HSP mRNAs have little or no requirement in vivo for the cap-recognition machinery and suggest that these mRNAs may utilize an alternative, cap-independent mechanism of translational initiation.	UNIV KENTUCKY, DEPT BIOCHEM, LEXINGTON, KY 40536 USA	University of Kentucky				de benedetti, arrigo/0000-0002-4198-8647	NIGMS NIH HHS [GM20818] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN M, 1989, MOL CELL BIOL, V9, P4467, DOI 10.1128/MCB.9.10.4467; ANTHONY DD, 1991, J BIOL CHEM, V266, P10218; BIENZ M, 1984, P NATL ACAD SCI-BIOL, V81, P3138, DOI 10.1073/pnas.81.10.3138; DEBENEDETTI A, 1986, J BIOL CHEM, V261, P5800; DEBENEDETTI A, 1986, J BIOL CHEM, V261, P338; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; DUNCAN R, 1987, J BIOL CHEM, V262, P380; ETCHISON D, 1984, J VIROL, V51, P832, DOI 10.1128/JVI.51.3.832-837.1984; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; HICKEY ED, 1982, BIOCHEMISTRY-US, V21, P1513, DOI 10.1021/bi00536a008; HULTMARK D, 1991, NATURE, V353, P14; KLEMENZ R, 1985, EMBO J, V4, P2053, DOI 10.1002/j.1460-2075.1985.tb03891.x; KOCH F, 1985, MOL BIOL POLIOVIRUSE, P209; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KURTZ S, 1986, SCIENCE, V231, P1154, DOI 10.1126/science.3511530; LAMPHEAR BJ, 1991, J BIOL CHEM, V266, P2789; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LINDQUIST S, 1987, TRANSLATIONAL REGULA, P187; LODISH HF, 1974, NATURE, V251, P385, DOI 10.1038/251385a0; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MAROTO FG, 1988, J BIOL CHEM, V263, P15720; MCGARRY TJ, 1985, CELL, V42, P903, DOI 10.1016/0092-8674(85)90286-7; MORLEY SJ, 1990, BIOCHIMIE, V72, P259, DOI 10.1016/0300-9084(90)90081-Q; MUNOZ A, 1984, VIROLOGY, V137, P150, DOI 10.1016/0042-6822(84)90018-7; PILIPENKO EV, 1992, CELL, V68, P119, DOI 10.1016/0092-8674(92)90211-T; Rhoads RE, 1991, CURR OPIN CELL BIOL, V3, P1019, DOI 10.1016/0955-0674(91)90123-G; Sambrook J, 1989, MOL CLONING LABORATO; SARNOW P, 1989, P NATL ACAD SCI USA, V86, P5795, DOI 10.1073/pnas.86.15.5795; Schlesinger M. J., 1982, HEAT SHOCK BACTERIA; THOMAS AAM, 1991, J VIROL, V65, P2953, DOI 10.1128/JVI.65.6.2953-2959.1991; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; ZAPATA JM, 1991, J BIOL CHEM, V266, P16007	36	65	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21038	21043						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400417				2022-12-25	WOS:A1992JT97800083
J	YALOVSKY, S; NEEMAN, E; SCHUSTER, G; PAULSEN, H; HAREL, E; NECHUSHTAI, R				YALOVSKY, S; NEEMAN, E; SCHUSTER, G; PAULSEN, H; HAREL, E; NECHUSHTAI, R			ACCUMULATION OF A LIGHT-HARVESTING CHLOROPHYLL-A/B PROTEIN IN THE CHLOROPLAST GRANA-LAMELLAE - THE LATERAL MIGRATION OF THE MEMBRANE-PROTEIN PRECURSOR IS INDEPENDENT OF ITS PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-B-PROTEIN; BINDING-PROTEIN; TRANSIT PEPTIDE; BARLEY ETIOCHLOROPLASTS; THYLAKOID MEMBRANES; ESCHERICHIA-COLI; PHOTOSYSTEM-II; COMPLEX; IMPORT; INSERTION	The events that follow the import of pLHCPIIb, the apoprotein precursor of the major light-harvesting complex of photosystem II, were studied in intact pea chloroplasts. The distribution of the events of insertion into the membrane, and processing, to yield the mature form (LHCP) between stromal and granal lamellae regions of the thylakoids were followed. pLHCP was preferentially inserted into stromal lamellae (SL) from which it migrated to granal lamellae (GL). Migration occurred before or after processing, suggesting that migration and processing are independent of each other. When migration was slowed down, LHCP accumulated in SL. Prolonged inhibition of migration induced degradation of LHCP that had accumulated in SL, whereas inhibition of processing did not affect the migration of pLHCP into GL. A small difference in electrophoretic mobility was noted between LHCP in SL and in GL. The predominant mature form in SL migrated more slowly than LHCP from GL. When thylakoids were subjected to trypsin, all of the LHCP embedded in SL underwent cleavage, whereas up to 60% of the radioactive LHCP in GL was resistant to the enzyme. The possible implications of the differences in size and in the sensitivity to trypsin of LHCP are discussed.	HEBREW UNIV JERUSALEM,DEPT BOT,IL-91904 JERUSALEM,ISRAEL; TECHNION ISRAEL INST TECHNOL,FAC BIOL,IL-32000 HAIFA,ISRAEL; UNIV MUNICH,INST BOT,W-8000 MUNICH 2,GERMANY	Hebrew University of Jerusalem; Technion Israel Institute of Technology; University of Munich			Paulsen, Harald/D-3742-2011					ABAD MS, 1991, PLANT PHYSIOL, V96, P1220, DOI 10.1104/pp.96.4.1220; Andersson B, 1985, MOD METHOD PLANT, V1, P231; ARCHER EK, 1990, J BIOENERG BIOMEMBR, V22, P789; BENNETT J, 1983, BIOCHEM J, V212, P1; CHITNIS PR, 1988, PLANT MOL BIOL, V11, P95, DOI 10.1007/BF00015663; CHITNIS PR, 1987, PLANT MOL BIOL, V10, P3, DOI 10.1007/BF00014181; CHITNIS PR, 1986, J CELL BIOL, V102, P982, DOI 10.1083/jcb.102.3.982; CHITNIS PR, 1988, PHOTOSYNTH RES, V16, P41, DOI 10.1007/BF00039485; CLARK SE, 1989, J BIOL CHEM, V264, P17544; CLARK SE, 1990, PLANT CELL, V2, P173, DOI 10.1105/tpc.2.2.173; CLINE K, 1988, PLANT PHYSIOL, V86, P1120, DOI 10.1104/pp.86.4.1120; CLINE K, 1986, J BIOL CHEM, V261, P4804; FULSOM DR, 1988, PLANT PHYSIOL, V86, P1120; HAND JM, 1989, EMBO J, V8, P3195, DOI 10.1002/j.1460-2075.1989.tb08478.x; KOHORN BD, 1990, J BIOL CHEM, V265, P2118; KOHORN BD, 1986, J CELL BIOL, V102, P972, DOI 10.1083/jcb.102.3.972; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; LETO KJ, 1985, EMBO J, V4, P1645, DOI 10.1002/j.1460-2075.1985.tb03832.x; MACHOLD O, 1979, BIOCHIM BIOPHYS ACTA, V546, P472, DOI 10.1016/0005-2728(79)90082-3; MATOO AK, 1987, P NATL ACAD SCI USA, V84, P1497; MULLET JE, 1980, BIOCHIM BIOPHYS ACTA, V589, P100, DOI 10.1016/0005-2728(80)90135-8; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; REED JE, 1990, EUR J BIOCHEM, V194, P33, DOI 10.1111/j.1432-1033.1990.tb19423.x; RYRIE IJ, 1980, EUR J BIOCHEM, V107, P345; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT GW, 1981, J CELL BIOL, V91, P468, DOI 10.1083/jcb.91.2.468; SOMMER A, 1992, REGULATION CHLOROPLA, P143; STEINBACK KE, 1979, ARCH BIOCHEM BIOPHYS, V195, P546, DOI 10.1016/0003-9861(79)90381-3; THORNBER JP, 1986, ENCY PLANT PHYSL, V19, P98; VAINSTEIN A, 1989, PLANT PHYSIOL, V89, P602, DOI 10.1104/pp.89.2.602; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; YALOVSKY S, 1990, PLANT MOL BIOL, V14, P753, DOI 10.1007/BF00016508	32	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20689	20693						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400385				2022-12-25	WOS:A1992JT97800029
J	LEU, WM; CHEN, LY; LIAW, LL; LEE, YHW				LEU, WM; CHEN, LY; LIAW, LL; LEE, YHW			SECRETION OF THE STREPTOMYCES TYROSINASE IS MEDIATED THROUGH ITS TRANSACTIVATOR PROTEIN, MELC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; ESCHERICHIA-COLI; SIGNAL PEPTIDE; HYDROPHOBIC REGION; SEQUENCE; GENE; GLAUCESCENS; ANTIBIOTICUS; EXPRESSION; EXPORT	The tyrosinase of Streptomyces antibioticus is encoded by the second open reading frame, melC2 of the melanin operon (melC). The upstream open reading frame melC1 specifies a 146-amino acid protein with a typical NH2-terminal signal-peptide characteristic of a secretory protein. The MelC1 protein is involved in the transfer of copper ion to apotyrosinase MelC2 via binary complex formation (Lee, Y.-H. W., Chen, B.-F., Wu, S.-Y., Leu, W.-M., Lin, J.-J., Chen, C. W., and Lo, S. J. (1988) Gene (Amst.) 65, 71-8 1; Chen, L.-Y., Leu, W.-M., Wang, K.-T., and Lee, Y.-H. W. (1992) J. Biol. Chem. 267, 20100-20107). To investigate whether the export of tyrosinase is also dependent on MelC1, a mutational study of its signal-peptide sequence was performed. Four different mutants were obtained. Mutation at the positively charged region (mutant M-6LE, Arg6-Arg7 --> Leu6-Glu7) or the hydrophobic region (mutant M-16D, Val16 --> Asp16) led to Mel- phenotypes. These lesions caused a severe 7-10-fold reduction of the export of both the MelC1 and MelC2 proteins and a concomitant accumulation of the two proteins in the cytosolic fraction. The cell-associated tyrosinase activity in M-6LE but not in the M-16D mutant was dramatically reduced to 4% of the activity found in the wild type strain, suggesting that the basic NH2 terminus of MelC1 is also important for the trans-activation function of this protein. Nevertheless, the defects on the trans-activation and/or secretory functions of MelC1 in mutants M-6LE and M-16D are not due to the impairment of the formation of the MelC1.MelC2 complex. The translation of melanin operon genes in these two mutants also decreased. In contrast, the tyrosinase activity and the secretion of MelC2 were not affected if the mutations occurred at the putative cleavage site of the signal peptidase (e.g. mutant M-29SM, Arg29-Ala30 --> Ser29-Met30 or mutant 29-SMG, Arg29-Ala30-Asp31 --> Ser29-Met30-Gly31). Additionally, tyrosinase activity and its export were abolished in a MelC1-negative mutant, M-950. Taken together, these results demonstrate that a functional MelC1 is essential for tyrosinase secretion and activity. Furthermore, the results suggest that like other secretory proteins, basic and hydrophobic residues in the MelC1 signal sequence are an important feature of the signal-peptide and play a pivotal role in the secretion of both the MelC1 and MelC2 proteins. These results also establish a novel role for MelC1 on tyrosinase transport in addition to a role in copper transfer to tyrosinase.	NATL YANG MING MED COLL,INST BIOCHEM,TAIPEI 112,TAIWAN	National Yang Ming Chiao Tung University				Lee Wu, Yan-Hwa/0000-0001-7299-7354				Baumann R., 1976, ACTINOMYCETALES BOUN, P55; BAUMANN R, 1976, 2ND INT S GEN IND MI, P535; BENSON SA, 1985, ANNU REV BIOCHEM, V54, P101; BERNAN V, 1985, GENE, V37, P101, DOI 10.1016/0378-1119(85)90262-8; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chater K. F., 1982, CURR TOP MICROBIOL I, V96, P69; CHEN LY, 1992, J BIOL CHEM, V267, P20100; CRAMERI R, 1982, J GEN MICROBIOL, V128, P371; FIKES JD, 1987, J BACTERIOL, V169, P2352, DOI 10.1128/jb.169.6.2352-2359.1987; FREUDL R, 1988, J BIOL CHEM, V263, P344; GENNITY J, 1990, J BIOENERG BIOMEMBR, V22, P233, DOI 10.1007/BF00763167; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GOLDSTEIN J, 1991, J BIOL CHEM, V266, P14413; GREGORY KF, 1961, NATURE, V191, P465, DOI 10.1038/191465a0; GREGORY KF, 1964, J BACTERIOL, V87, P1281, DOI 10.1128/JB.87.6.1281-1286.1964; HELD T, 1990, J GEN MICROBIOL, V136, P2413, DOI 10.1099/00221287-136-12-2413; HINTERMANN G, 1985, MOL GEN GENET, V200, P422, DOI 10.1007/BF00425726; HOPWOOD DA, 1983, J GEN MICROBIOL, V129, P2257; HUBER M, 1987, NUCLEIC ACIDS RES, V15, P8106, DOI 10.1093/nar/15.19.8106; KATZ E, 1983, J GEN MICROBIOL, V129, P2703; KIESER T, 1981, GENETICS ACTINOMYCET, P59; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kuster E., 1976, ACTINOMYCETES BOUNDA, P43; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YHW, 1988, GENE, V65, P71, DOI 10.1016/0378-1119(88)90418-0; LEHNHARDT S, 1987, J BIOL CHEM, V262, P1716; LERCH K, 1972, EUR J BIOCHEM, V31, P427, DOI 10.1111/j.1432-1033.1972.tb02549.x; LERCH K, 1981, MET IONS BIOL SYST, V13, P143; LEU WM, 1989, GENE, V84, P267; Maniatis T, 1980, Methods Enzymol, V65, P299; OLIVER D, 1985, ANNU REV MICROBIOL, V39, P615; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; POLLITT S, 1985, J BIOL CHEM, V260, P7965; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; PUGSLEY AP, 1990, ANNU REV GENET, V24, P67; PUZISS JW, 1989, J BACTERIOL, V171, P2303, DOI 10.1128/jb.171.5.2303-2311.1989; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WANDERSMAN C, 1989, MOL MICROBIOL, V3, P1825, DOI 10.1111/j.1365-2958.1989.tb00169.x	42	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20108	20113						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400329				2022-12-25	WOS:A1992JR85800058
J	MISAWA, H; ISHII, K; DEGUCHI, T				MISAWA, H; ISHII, K; DEGUCHI, T			GENE-EXPRESSION OF MOUSE CHOLINE-ACETYLTRANSFERASE - ALTERNATIVE SPLICING AND IDENTIFICATION OF A HIGHLY-ACTIVE PROMOTER REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE SEQUENCE; MAMMALIAN-CELLS; SPINAL-CORD; RAT; CULTURES; ELEMENTS; PROTEIN; RNA	Seven types of mRNA for choline acetyltransferase that differ in the 5'-noncoding region were identified in the mouse spinal cord by cDNA cloning and polymerase chain reaction. Among these transcripts, the M-type mRNA corresponding to the previously cloned mouse cDNA was most abundant in the spinal cord of mouse. A mouse genomic DNA clone containing the 5'-region of choline acetyltransferase mRNA was isolated and sequenced. Comparison of the sequences between the cDNAs and the genomic DNA revealed that the different mRNA species were transcribed from different promoter regions and produced by differential splicing. Two murine cholinergic cell lines, NS20Y and NG108-15, were shown to express the M-type mRNA almost exclusively, and were therefore used to study transcription of M-type mRNA. Fragments of the 5'-region of choline acetyltransferase gene were ligated with chloramphenicol acetyltransferase reporter gene and introduced into cultured cells. The fragment from -2752 to +46, which contained the M-type exon, a TATA-box like element upstream of the M-type exon, and the downstream intron, induced a significant expression of CAT activity in neuronal but not in non-neuronal cell lines. This result indicates that this region of choline acetyltransferase gene contains elements that regulate neuron-specific expression of choline acetyltransferase activity. However, there was no parallel correlation between reporter gene expression in the transfected cells and intrinsic choline acetyltransferase activity in these neuronal cell lines. Possible mechanisms that would explain this observation are discussed.			MISAWA, H (corresponding author), TOKYO METROPOLITAN INST NEUROSCI, DEPT MOLEC NEUROBIOL, 2-6 MUSASHIDAI, FUCHU, TOKYO 183, JAPAN.							ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARAKI E, 1988, NUCLEIC ACIDS RES, V16, P1627, DOI 10.1093/nar/16.4.1627; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BERRARD S, 1987, P NATL ACAD SCI USA, V84, P9280, DOI 10.1073/pnas.84.24.9280; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRICE A, 1989, J NEUROSCI RES, V23, P266, DOI 10.1002/jnr.490230304; FONNUM F, 1975, J NEUROCHEM, V24, P407, DOI 10.1111/j.1471-4159.1975.tb11895.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GILLER EL, 1973, SCIENCE, V182, P588, DOI 10.1126/science.182.4112.588; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; INAGAKI N, 1992, P NATL ACAD SCI USA, V89, P1045, DOI 10.1073/pnas.89.3.1045; ISHIDA I, 1983, DEV BRAIN RES, V7, P13, DOI 10.1016/0165-3806(83)90077-9; ISHII K, 1990, MOL BRAIN RES, V7, P151, DOI 10.1016/0169-328X(90)90092-R; KORNER M, 1989, NEURON, V3, P563, DOI 10.1016/0896-6273(89)90266-3; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Nachmansohn D, 1943, J NEUROPHYSIOL, V6, P397, DOI 10.1152/jn.1943.6.5.397; PATTERSON PH, 1978, ANNU REV NEUROSCI, V1, P1, DOI 10.1146/annurev.ne.01.030178.000245; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SALVATERRA PM, 1989, INT REV NEUROBIOL, V31, P81; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X	23	117	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20392	20399						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400357				2022-12-25	WOS:A1992JR85800100
J	RUSSO, GL; VANDENBERG, MT; YU, IJ; BAE, YS; FRANZA, BR; MARSHAK, DR				RUSSO, GL; VANDENBERG, MT; YU, IJ; BAE, YS; FRANZA, BR; MARSHAK, DR			CASEIN KINASE-II PHOSPHORYLATES P34(CDC2) KINASE IN G1 PHASE OF THE HELA-CELL DIVISION CYCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P34CDC2 PROTEIN-KINASE; MITOSIS-SPECIFIC PHOSPHORYLATION; RAT-LIVER CYTOSOL; SV40 T-ANTIGEN; FISSION YEAST; PROMOTING FACTOR; SCHIZOSACCHAROMYCES-POMBE; TYROSINE PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; RETINOBLASTOMA PROTEIN	The activity of p34cdc2 kinase is regulated in the phases of vertebrate cell cycle by mechanisms of phosphorylation and dephosphorylation. In this paper, we demonstrate that casein kinase II (CKII) phosphorylates p34cdc2 in vivo and in vitro at Ser 39 during the G1 phase of HeLa cell division cycle. Human p34cdc2 shows a typical phosphorylation sequence motif site for CKII at Ser39 (ES39EEE). In our experiments, either p34cdc2 expressed and purified from bacteria or p34cdc2 immunoprecipitated from HeLa cells enriched in G1 by elutriation were substrates for in vitro phosphorylation by CKII. Phosphoamino acid analysis, N-chlorosuccinimide mapping, and two-dimensional tryptic mapping of p34cdc2 phosphorylated in vitro were performed to determine the phosphorylation site. A synthetic peptide spanning residues 33-50 of human p34cdc2, including the CKII site, was used to map the site. In addition, phosphorylation at Ser39 also occurs in vivo, since p34cdc2 is phosphorylated during G1 on serine, and its two-dimensional tryptic map shows two phosphopeptides that comigrate exactly with the synthetic peptides used as standard.	ARNOLD & MABEL BECKMAN NEUROSCI CTR, WM KECK STRUCT BIOL LAB, COLD SPRING HARBOR, NY 11724 USA; COLD SPRING HARBOR LAB, FREEMAN LAB CANC CELL BIOL, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory; Cold Spring Harbor Laboratory			RUSSO, GIAN LUIGI/GQB-0962-2022	RUSSO, GIAN LUIGI/0000-0001-9321-1613; Bae, Young-Seuk/0000-0002-5520-4444	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA 13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, ONCOGENE, V6, P2179; ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; Ashihara T, 1979, Methods Enzymol, V58, P248; Barany G, 1979, PEPTIDES           A, V2, P1; BELENGUER P, 1990, MOL CELL BIOL, V10, P3607, DOI 10.1128/MCB.10.7.3607; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CLARKE PR, 1991, J CELL SCI, V100, P409; DEBENEDETTE M, 1991, J IMMUNOL, V147, P2839; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUCOMMUN B, 1991, MOL CELL BIOL, V11, P6177, DOI 10.1128/MCB.11.12.6177; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ENOCH T, 1991, J CELL BIOL, V112, P797, DOI 10.1083/jcb.112.5.797; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1988, ANTIBODIES LABORATOR; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGAN TA, 1989, PROTEIN PHOSPHORYLAT, P70; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LISCHWE MA, 1977, J BIOL CHEM, V252, P4976; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LOHKA MJ, 1989, J CELL SCI, V92, P131; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MARSHAK DR, 1991, METHOD ENZYMOL, V200, P134; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1982, FEBS LETT, V141, P257, DOI 10.1016/0014-5793(82)80061-6; MEGGIO F, 1984, EUR J BIOCHEM, V145, P593, DOI 10.1111/j.1432-1033.1984.tb08598.x; MEGGIO F, 1984, J BIOL CHEM, V259, P4576; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MULNERLORILLON O, 1990, EUR J BIOCHEM, V193, P529, DOI 10.1111/j.1432-1033.1990.tb19368.x; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NORBURY C, 1990, CIBA F SYMP, V150, P168; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PICARD A, 1989, J CELL BIOL, V109, P3347, DOI 10.1083/jcb.109.6.3347; PINES J, 1990, New Biologist, V2, P389; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; SCHNEIDER HR, 1988, BIOCHEM BIOPH RES CO, V156, P1390, DOI 10.1016/S0006-291X(88)80786-1; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; STETLER DA, 1982, BIOCHEMISTRY-US, V21, P3721, DOI 10.1021/bi00258a030; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	93	105	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20317	20325						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400350				2022-12-25	WOS:A1992JR85800090
J	ECCLES, DM; RUSSELL, SEH; HAITES, NE; ATKINSON, R; BELL, DW; GRUBER, L; HICKEY, I; KELLY, K; KITCHENER, H; LEONARD, R; LESSELLS, A; LOWRY, S; MILLER, I; MILNER, B; STEEL, M				ECCLES, DM; RUSSELL, SEH; HAITES, NE; ATKINSON, R; BELL, DW; GRUBER, L; HICKEY, I; KELLY, K; KITCHENER, H; LEONARD, R; LESSELLS, A; LOWRY, S; MILLER, I; MILNER, B; STEEL, M			EARLY LOSS OF HETEROZYGOSITY ON 17Q IN OVARIAN-CANCER	ONCOGENE			English	Note							P53 GENE; BREAST-CANCER; ALLELE LOSS; CHROMOSOME-17; TRANSMISSION; MUTATIONS; CARCINOMA; TUMORS; FAMILY	We have studied 146 ovarian tumours (94 carcinomas, 22 tumours of low malignant potential and 30 benign tumours) for evidence of allele loss on chromosome 17p and 17q sufficient to imply the proximity of a tumour-suppressor gene. We have examined two polymorphic loci (YNZ22.2 and BHP53) on 17p13 and one on chromosome 17q (17q23-qter). Loss of heterozygosity (LOH) was detected in 34/63 (54%) informative malignant tumours at YNZ22.2 and 22/47 (47%) at BHP53; on 17q, 45/64 (70%) had LOH. Allele loss was detected in a small number of benign and borderline tumours. There was a statistically significant difference between the patterns of allele loss in serous and endometrioid groups of tumours, and allele loss occurred with significantly greater frequency on 17q than on 17p. Comparison of all malignant tumours presenting with either localized (FIGO stage I/II) or widespread (FIGO stage III/IV) disease showed that, particularly on 17q, allele loss increases in the more advanced stages. The p53 tumour-suppressor gene is implicated in ovarian carcinogenesis, and our findings suggest that an important tumour-suppressor gene may be located in the region 17q23-qter. Loss of function in this gene may be responsible for the frequently observed rapid progression of serous-type adenocarcinomas to an advanced stage.	QUEENS UNIV BELFAST,DEPT ONCOL,97 LISBURN RD,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND; UNIV ABERDEEN,SCH MED,DEPT MED GENET,ABERDEEN AB9 22D,SCOTLAND; QUEENS UNIV BELFAST,DIV GENET ENGN,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND; WESTERN GEN HOSP,ICRF MED ONCOL UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	Queens University Belfast; University of Aberdeen; Queens University Belfast; University of Edinburgh; University of Edinburgh			Eccles, Diana/K-6327-2019	Eccles, Diana/0000-0002-9935-3169				Anderson MC, 1990, OVARIAN CANCER BIOL, P187; BAAK JPA, 1986, J CLIN PATHOL, V39, P1340, DOI 10.1136/jcp.39.12.1340; BAKER SJ, 1990, CANCER RES, V50, P7717; CAMPBELL S, 1989, BMJ-BRIT MED J, V299, P1363, DOI 10.1136/bmj.299.6712.1363; DELACALLEMARTIN O, 1990, NUCLEIC ACIDS RES, V18, P4963, DOI 10.1093/nar/18.16.4963; ECCLES DM, 1990, ONCOGENE, V5, P1599; FOULKES W, 1991, LANCET, V338, P444, DOI 10.1016/0140-6736(91)91065-3; FOX H, 1990, OVARIAN CANC BIOL TH, P185; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HARLOW BL, 1989, AM J EPIDEMIOL, V130, P1071, DOI 10.1093/oxfordjournals.aje.a115414; JACOBS I, 1988, LANCET, V1, P268; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOCH M, 1989, INT J EPIDEMIOL, V18, P782, DOI 10.1093/ije/18.4.782; LEE JH, 1990, CANCER RES, V50, P2724; LYNCH HT, 1991, CANCER, V67, P1460, DOI 10.1002/1097-0142(19910301)67:5<1460::AID-CNCR2820670534>3.0.CO;2-S; LYNCH HT, 1986, AM J MED, V81, P1073, DOI 10.1016/0002-9343(86)90411-0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; NAROD SA, 1991, LANCET, V338, P82; PANANI A, 1985, CANCER GENET CYTOGEN, V16, P65, DOI 10.1016/0165-4608(85)90078-0; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SATO T, 1991, CANCER RES, V51, P5118; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STENBACK F, 1981, PATHOL RES PRACT, V172, P58, DOI 10.1016/S0344-0338(81)80123-9; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0	27	95	96	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2069	2072						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408149				2022-12-25	WOS:A1992JP42400023
J	MERZAK, A; DOOGHE, Y; PIRONIN, M; PERBAL, B; VIGIER, P				MERZAK, A; DOOGHE, Y; PIRONIN, M; PERBAL, B; VIGIER, P			COOPERATION BETWEEN THE H-RAS ONCOGENE AND A TRUNCATED DERIVATIVE OF THE V-MYB ONCOGENE IN TRANSFORMATION OF HAMSTER-EMBRYO FIBROBLASTS	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; C-MYB; MONOCLONAL-ANTIBODIES; FUNCTIONAL DOMAINS; COLONY FORMATION; CELLS; DNA; PRODUCT; SEQUENCES; PROTEIN	The ras oncogenes alone fully transform established (immortalized) rodent fibroblasts in a few days, but generally transform early-passage fibroblasts only partially, unless their action is complemented by that of a nuclear, immortalizing, oncogene. Here we show that transfection of second-passage Syrian hamster embryo fibroblasts (HEFs) by the EJ-H-ras oncogene coupled to the neo gene, followed by selection with G418, gives rise to apparently normal, or only slightly transformed, clonal colonies, only a few of which become established. The study of two established clonal fines showed that they acquired only after some weeks, and stepwise, the main characteristics of full neoplastic transformation, i.e. anchorage independence, reduced requirement for serum growth factors and tumorigenicity. Later both clonal lines became increasingly tumorigenic and completely independent of exogenous growth and attachment factors, without increase in the expression of the H-ras oncogene. Transfection of one of the clones, early after its isolation, with a truncated derivative of the nuclear v-myb oncogene devoid of its transcriptional negative regulatory domain and able to partially transform chicken embryo fibroblasts [(myb(KXANM)] gave rise to more transformed cells, expressing both EJ-H-ras and myb(KXANM), which became tumorigenic earlier than the controls and remained more tumorigenic later on. With more efficient transfection techniques, numerous foci of fully transformed cells were subsequently obtained, in a few days, in cultures transfected sequentially with EJ-H-ras(neo) and myb(KXANM) and in cultures co-transfected with the two oncogenes. Highly tumorigenic, serum-independent and immortalized clones expressing both oncogenes were obtained from these cultures. Hence, the truncated myb(KXANM) oncogene accelerates the stepwise transformation of unestablished HEFs by the EJ-HH-ras oncogene and, together with this oncogene, fully transforms these same cells in a single step. The two oncogenes acting in cooperation also induce cell immortalization, but myb(KXANM), by itself, is not an immortalizing oncogene. No cooperation was observed between EJ-H-ras(neo) and the unaltered v-myb oncogene.	CTR UNIV ORSAY,INST CURIE,BIOL SECT,BATIMENT 110,F-91405 ORSAY,FRANCE; UNIV PARIS 07,F-75221 PARIS 05,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite			MERZAK, Abderrahim/AAW-9746-2021	MERZAK, Abderrahim/0000-0002-7269-2224				ANTCZAK M, 1990, J VIROL, V64, P1451, DOI 10.1128/JVI.64.4.1451-1458.1990; BADING H, 1989, ONCOGENE, V4, P33; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BART LMC, 1991, CANCER RES, V51, P1177; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1985, MOL CELL BIOL, V5, P3017, DOI 10.1128/MCB.5.11.3017; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; DOOLEY S, 1989, Methods in Molecular and Cellular Biology, V1, P95; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KRYCEVEMARTINERIE C, 1987, FEBS LETT, V214, P81, DOI 10.1016/0014-5793(87)80017-0; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LIPSICK JS, 1984, CANCER CELLS, V2, P143; MARTINERIE C, 1987, NUCLEIC ACIDS RES, V15, P1329, DOI 10.1093/nar/15.3.1329; MCCLURE DB, 1983, CELL, V32, P999, DOI 10.1016/0092-8674(83)90084-3; MERZAK A, 1991, ONCOGENE, V7, P535; PERBAL B, 1986, BIOCHIMIE, V68, P969, DOI 10.1016/S0300-9084(86)80040-2; Perbal B., 1988, PRACTICAL GUIDE MOL; PIRONIN M, 1992, INT J CANCER, V52, P1; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHWARTZ SA, 1988, CANCER RES, V48, P3470; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SORET J, 1985, J VIROL, V55, P193, DOI 10.1128/JVI.55.1.193-205.1985; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WEINBERG RA, 1989, CANCER RES, V49, P3713; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	36	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2031	2039						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408144				2022-12-25	WOS:A1992JP42400018
J	TROPPMAIR, J; BRUDER, JT; APP, H; HONG, C; LIPTAK, L; SZEBERENYI, J; COOPER, GM; RAPP, UR				TROPPMAIR, J; BRUDER, JT; APP, H; HONG, C; LIPTAK, L; SZEBERENYI, J; COOPER, GM; RAPP, UR			RAS CONTROLS COUPLING OF GROWTH-FACTOR RECEPTORS AND PROTEIN-KINASE-C IN THE MEMBRANE TO RAF-1 AND B-RAF PROTEIN SERINE KINASES IN THE CYTOSOL	ONCOGENE			English	Article							STIMULATING FACTOR-I; SIGNAL TRANSDUCTION; PC12 CELLS; PHOSPHORYLATION; ONCOGENES; DIFFERENTIATION; ACTIVATION; INSULIN; TYROSINE; GENE	A dominant negative mutant of Ras, M17 Ras, was used to study the role of Ras in receptor coupling of Raf-1 and B-Raf protein serine/threonine kinases (PSKs). We found that mutant Ras blocks serum- and 12-O-tetradecanoyl phorbol 13-acetate-induced activation of Raf-1 kinase in NIH3T3 cells and Raf-1 as well as B-Raf PSK stimulation by nerve growth factor (NGF) in PC12 pheochromocytoma cells. Mitogen stimulation of Raf kinase was measured by determination of Raf hyperphosphorylation and activity towards exogenous substrates and both of these events were inhibited in cells expressing M17 Ras. In contrast, tyrosine phosphorylation of a direct substrate of activated tyrosine kinase receptors, phospholipase C-gamma-1 (PLC-gamma-1), was unaffected. These data indicate that tyrosine phosphorylation of PLC-gamma-1 is not sufficient for growth induction in NIH3T3 cells and that Ras mediates signal transfer from activated membrane receptors to Raf kinases in the cytosol. As activated Raf induced differentiation in PC12 cells expressing M17 Ras we conclude that Raf kinase activation may be sufficient to account for this aspect of NGF function.	NCI,VIRAL CARCINOGENESIS LAB,VIRAL PATHOL SECT,FREDERICK,MD 21702; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School				Troppmair, Jakob/0000-0002-0611-3837				ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BACCARINI M, 1991, EMBO J, V11, P3649; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BORTNER DM, 1991, GENE DEV, V5, P1777, DOI 10.1101/gad.5.10.1777; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LEE RM, 1991, J BIOL CHEM, V266, P10351; LEE RM, 1992, J BIOL CHEM, V267, P1088; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORRISON DK, 1989, CELL, V58, P648; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; REED JC, 1991, CELL GROWTH DIFFER, V2, P235; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SENGUPTA A, 1988, P NATL ACAD SCI USA, V85, P8062, DOI 10.1073/pnas.85.21.8062; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	45	119	119	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1867	1873						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1386920				2022-12-25	WOS:A1992JJ37600024
J	MALHERBE, A; BLOCK, MA; JOYARD, J; DOUCE, R				MALHERBE, A; BLOCK, MA; JOYARD, J; DOUCE, R			FEEDBACK INHIBITION OF PHOSPHATIDATE PHOSPHATASE FROM SPINACH CHLOROPLAST ENVELOPE MEMBRANES BY DIACYLGLYCEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GALACTOSE; SACCHAROMYCES-CEREVISIAE; INTACT CHLOROPLASTS; PLASTID ENVELOPE; SAFFLOWER SEEDS; LIPID-SYNTHESIS; OUTER-MEMBRANE; HIGHER-PLANTS; BIOSYNTHESIS; GALACTOSYLTRANSFERASE	Because the envelope phosphatidate phosphatase plays a pivotal role in chloroplast glycerolipid metabolism, we have analyzed whether diacylglycerol could be a regulatory factor of the enzyme. Using isolated envelope membranes in which the level of diacylglycerol was modified by thermolysin treatment of intact chloroplasts to destroy the galactolipid:galactolipid galactosyltransferase, we have demonstrated that phosphatidate phosphatase activity was reduced when the membrane was enriched in diacylglycerol. All 1,2-diacylglycerol molecular species assayed were demonstrated to inhibit the enzyme to about the same extent. Kinetic studies with envelope from thermolysin-treated chloroplasts were performed in the absence and presence of diacylglycerol, and diacylglycerol was shown to be a powerful competitive inhibitor of the reaction. Finally, using isolated intact spinach chloroplasts, we have demonstrated that in situ phosphatidate phosphatase activity can be modulated by the level of diacylglycerol present in the membrane. The relevance of phosphatidate phosphatase inhibition by diacylglycerol in the regulation of chloroplast glycerolipid biosynthesis is discussed.	UNIV JOSEPH FOURIER,F-38041 GRENOBLE,FRANCE	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	MALHERBE, A (corresponding author), CEN,DEPT BIOL MOLEC & STRUCT,PHYSIOL CELLULAIRE VEGETALE LAB,CNRS,F-38041 GRENOBLE,FRANCE.							ALBAN C, 1989, BIOCHEM J, V259, P775, DOI 10.1042/bj2590775; ANDREWS J, 1985, PLANT PHYSIOL, V78, P459, DOI 10.1104/pp.78.3.459; [Anonymous], METHODS CHLOROPLAST; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BARRON EJ, 1962, BIOCHIM BIOPHYS ACTA, V60, P329, DOI 10.1016/0006-3002(62)90408-0; Bell RM, 1983, ENZYMES, V16, P87; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; BLIGNY R, 1990, J BIOL CHEM, V265, P1319; BLOCK MA, 1983, J BIOL CHEM, V258, P3281; BLOCK MA, 1983, FEBS LETT, V169, P111; BROWSE J, 1986, BIOCHEM J, V235, P25, DOI 10.1042/bj2350025; CARDE JP, 1982, BIOL CELL, V44, P315; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CLINE K, 1983, PLANT PHYSIOL, V71, P366, DOI 10.1104/pp.71.2.366; COLEMAN RA, 1983, ENZYMES, V16, P605; COVES J, 1988, P NATL ACAD SCI USA, V85, P4966, DOI 10.1073/pnas.85.14.4966; DORNE AJ, 1982, FEBS LETT, V145, P30, DOI 10.1016/0014-5793(82)81200-3; Douce, 1987, BIOCH PLANTS, P215, DOI 10.1016/B978-0-12-675409-4.50015-0; DOUCE R, 1974, SCIENCE, V183, P852, DOI 10.1126/science.183.4127.852; DOUCE R, 1973, J BIOL CHEM, V248, P7215; Douce R., 1980, The biochemistry of plants. A comprehensive treatise. Volume 4. Lipids: structure and function., P321; DOUCE R, 1990, ANNU REV CELL BIOL, V6, P173, DOI 10.1146/annurev.cb.06.110190.001133; DOUCE R, 1990, METHODS PLANT BIOCH, V4, P71; ESKO JD, 1983, ENZYMES, V16, P207; FRENTZEN M, 1986, J PLANT PHYSIOL, V124, P193, DOI 10.1016/S0176-1617(86)80034-7; GARDINER SE, 1984, BIOCHEM J, V224, P637, DOI 10.1042/bj2240637; GARDINER SE, 1983, BIOCHEM J, V210, P949, DOI 10.1042/bj2100949; HAAS R, 1980, PLANTA, V148, P238, DOI 10.1007/BF00380033; HAJRA AK, 1974, LIPIDS, V9, P502, DOI 10.1007/BF02532495; Harwood J.L., 1984, LIPIDS PLANTS MICROB; HEEMSKERK JWM, 1988, PLANT PHYSIOL, V86, P971, DOI 10.1104/pp.86.3.971; Heinz E., 1977, Lipids and lipid polymers in higher plants., P102; HEINZ E, 1983, PLANT PHYSIOL, V72, P273, DOI 10.1104/pp.72.2.273; ICHIHARA K, 1984, ARCH BIOCHEM BIOPHYS, V232, P685, DOI 10.1016/0003-9861(84)90589-7; ICHIHARA K, 1991, PLANTA, V183, P353, DOI 10.1007/BF00197733; JOYARD J, 1991, EUR J BIOCHEM, V199, P489, DOI 10.1111/j.1432-1033.1991.tb16148.x; JOYARD J, 1977, BIOCHIM BIOPHYS ACTA, V486, P273, DOI 10.1016/0005-2760(77)90023-6; JOYARD J, 1986, BIOCHIM BIOPHYS ACTA, V879, P78, DOI 10.1016/0005-2760(86)90269-9; JOYARD J, 1979, FEBS LETT, V102, P147, DOI 10.1016/0014-5793(79)80947-3; JOYARD J, 1979, THESIS U GRENOBLE; KLEPPINGERSPARACE KF, 1990, SULFUR NUTRITION AND SULFUR ASSIMILATION IN HIGHER PLANTS, P77; KLEPPINGERSPARACE KF, 1985, ARCH BIOCHEM BIOPHYS, V240, P859, DOI 10.1016/0003-9861(85)90096-7; KOSMAC U, 1985, PLANT PHYSIOL, V79, P6466; LIN YP, 1989, J BIOL CHEM, V264, P8641; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARECHAL E, 1991, CR ACAD SCI III-VIE, V313, P521; MARTIN BA, 1984, LIPIDS, V19, P117, DOI 10.1007/BF02534501; MOLLER F, 1977, BIOCHIM BIOPHYS ACTA, V486, P359, DOI 10.1016/0005-2760(77)90032-7; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; MOURIOUX G, 1981, PLANT PHYSIOL, V67, P470, DOI 10.1104/pp.67.3.470; MUDD JB, 1987, METHOD ENZYMOL, V148, P338; ROUGHAN PG, 1980, BIOCHEM J, V188, P17, DOI 10.1042/bj1880017; ROUGHAN PG, 1982, ANNU REV PLANT PHYS, V33, P97, DOI 10.1146/annurev.pp.33.060182.000525; SAKAKI T, 1990, PLANT PHYSIOL, V94, P773, DOI 10.1104/pp.94.2.773; SEIFERT U, 1992, BOT ACTA, V105, P197, DOI 10.1111/j.1438-8677.1992.tb00287.x; Stymne S., 1987, Biochemistry of Plants, V9, P175; STYMNE S, 1983, BIOCHIM BIOPHYS ACTA, V752, P198, DOI 10.1016/0005-2760(83)90113-3; TEUCHER T, 1991, PLANTA, V184, P319, DOI 10.1007/BF00195332; VANBESOUW A, 1978, BIOCHIM BIOPHYS ACTA, V529, P44, DOI 10.1016/0005-2760(78)90102-9; WALSH JP, 1986, J BIOL CHEM, V261, P6239	60	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23546	23553						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429699				2022-12-25	WOS:A1992JZ23900022
J	IKEDASAITO, M; HORI, H; ANDERSSON, LA; PRINCE, RC; PICKERING, IJ; GEORGE, GN; SANDERS, CR; LUTZ, RS; MCKELVEY, EJ; MATTERA, R				IKEDASAITO, M; HORI, H; ANDERSSON, LA; PRINCE, RC; PICKERING, IJ; GEORGE, GN; SANDERS, CR; LUTZ, RS; MCKELVEY, EJ; MATTERA, R			COORDINATION STRUCTURE OF THE FERRIC HEME IRON IN ENGINEERED DISTAL HISTIDINE MYOGLOBIN MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; MAGNETIC CIRCULAR-DICHROISM; SPERM WHALE MYOGLOBIN; LIGAND-BINDING; ESCHERICHIA-COLI; HORSERADISH-PEROXIDASE; APLYSIA MYOGLOBIN; CRYSTAL-STRUCTURE; ANIONIC LIGANDS; SPIN	Recombinant human myoglobin mutants with the distal His residue (E7, His64) replaced by Leu, Val, or Gln residues were prepared by site-directed mutagenesis and expression in Escherichia coli. Electronic and coordination structures of the ferric heme iron in the recombinant myoglobin proteins were examined by optical absorption, EPR, H-1 NMR, magnetic circular dichroism, and x-ray spectroscopy. Mutations, His --> Val and His --> Leu, remove the heme-bound water molecule resulting in a five-coordinate heme iron at neutral pH, while the heme-bound water molecule appears to be retained in the engineered myoglobin with His --> Gln substitution as in the wild-type protein. The distal Val and distal Leu ferric myoglobin mutants at neutral pH exhibited EPR spectra with g(perpendicular-to) values smaller than 6, which could be interpreted as an admixture of intermediate (S = 3/2) and high (S = 5/2) spin states. At alkaline pH, the distal Gln mutant is in the same so-called "hydroxy low spin' form as the wild-type protein, while the distal Leu and distal Val mutants are in high spin states. The ligand binding properties of these recombinant myoglobin proteins were studied by measurements of azide equilibrium and cyanide binding. The distal Leu and distal Val mutants exhibited diminished azide affinity and extremely slow cyanide binding, while the distal Gln mutant showed azide affinity and cyanide association rate constants similar to those of the wild-type protein.	OSAKA UNIV, FAC ENGN SCI, DEPT BIOPHYS ENGN, TOYONAKA, OSAKA 560, JAPAN; KANSAS STATE UNIV AGR & APPL SCI, DEPT BIOCHEM, MANHATTAN, KS 66506 USA; EXXON RES & ENGN CO, ANNANDALE, NJ 08801 USA	Osaka University; Kansas State University; Exxon Mobil Corporation	IKEDASAITO, M (corresponding author), CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA.		Pickering, Ingrid J/A-4547-2013; Ikeda-Saito, Masao/A-5992-2008; George, Graham N/E-3290-2013; Ikeda-Saito, Masao/K-2703-2015	Pickering, Ingrid J/0000-0002-0936-2994; George, Graham/0000-0002-0420-7493	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039492, R01GM047485, R29GM047485, R01GM039359] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47485, GM39359, GM39492] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; ARENTS G, 1989, J MOL BIOL, V210, P149, DOI 10.1016/0022-2836(89)90297-0; BARTNICKI DE, 1983, J BIOL CHEM, V258, P1599; Blumberg WE, 1971, PROBES STRUCTURE FUN, V2, P215; BOLOGNESI M, 1989, J MOL BIOL, V205, P529, DOI 10.1016/0022-2836(89)90224-6; BOLOGNESI M, 1990, J MOL BIOL, V213, P621, DOI 10.1016/S0022-2836(05)80249-9; BRACETE AM, 1991, BIOCHIM BIOPHYS ACTA, V1080, P264, DOI 10.1016/0167-4838(91)90012-O; CARVER TE, 1990, J BIOL CHEM, V265, P20007; CRAMER SP, 1988, NUCL INSTRUM METH A, V266, P586, DOI 10.1016/0168-9002(88)90449-4; CUTRUZZOLA F, 1991, FEBS LETT, V282, P281, DOI 10.1016/0014-5793(91)80495-O; DELEON JM, 1991, PHYS REV B, V44, P4146, DOI 10.1103/PhysRevB.44.4146; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; GEORGE GN, 1989, BIOCHEMISTRY-US, V28, P5075, DOI 10.1021/bi00438a026; GIACOMETTI GM, 1975, BIOCHEMISTRY-US, V14, P1584, DOI 10.1021/bi00679a006; GIACOMETTI GM, 1981, J MOL BIOL, V146, P363, DOI 10.1016/0022-2836(81)90393-4; HORI H, 1989, J BIOL CHEM, V264, P5715; HORI H, 1990, J BIOL CHEM, V265, P15028; IKEDASAITO M, 1985, J BIOL CHEM, V260, P1688; IKEDASAITO M, 1991, J BIOL CHEM, V266, P23641; Kotani M., 1968, ADV QUANTUM CHEM, V4, P227; KRISHNAMOORTHI R, 1984, J BIOL CHEM, V259, P265; LAMAR GN, 1990, J BIOL CHEM, V265, P16173; MALTEMPO MM, 1979, BIOCHEMISTRY-US, V18, P2935, DOI 10.1021/bi00581a003; MALTEMPO MM, 1974, J CHEM PHYS, V61, P2540, DOI 10.1063/1.1682376; MALTEMPO MM, 1974, BIOCHIM BIOPHYS ACTA, V342, P290, DOI 10.1016/0005-2795(74)90084-1; MINTOROVITCH J, 1988, BIOCHEMISTRY-US, V27, P8045, DOI 10.1021/bi00421a011; MORIKIS D, 1990, J BIOL CHEM, V265, P12143; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NOZAWA T, 1976, BIOCHIM BIOPHYS ACTA, V427, P652, DOI 10.1016/0005-2795(76)90209-9; Palmer G., 1979, PORPHYRINS, P313; PEISACH J, 1971, J BIOL CHEM, V246, P3342; PEISACH J, 1984, J BIOL CHEM, V259, P2704; PHILLIPS GN, 1990, PROTEINS, V7, P358, DOI 10.1002/prot.340070407; POULOS TL, 1988, ADV INORG BIOCHEM, V7, P1; QUILLIN ML, 1992, BIOPHYS J, V61, pA446; RAJARATHNAM K, 1991, J AM CHEM SOC, V113, P7886, DOI 10.1021/ja00021a010; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; ROTILLO G, 1971, BIOCHIM BIOPHYS ACTA, V236, P234, DOI 10.1016/0005-2795(71)90170-X; Sambrook J, 1989, MOL CLONING LABORATO; SEAMONDS B, 1972, BIOCHIM BIOPHYS ACTA, V263, P507, DOI 10.1016/0005-2795(72)90032-3; SHIRO Y, 1990, J AM CHEM SOC, V112, P2921, DOI 10.1021/ja00164a012; SMULEVICH G, 1991, BIOCHEMISTRY-US, V30, P772, DOI 10.1021/bi00217a029; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; TAKANO T, 1977, J MOL BIOL, V110, P537, DOI 10.1016/S0022-2836(77)80111-3; VARADARAJAN R, 1989, BIOCHEMISTRY-US, V28, P3771, DOI 10.1021/bi00435a022; VARADARAJAN R, 1985, P NATL ACAD SCI USA, V82, P5681, DOI 10.1073/pnas.82.17.5681; VICKERY L, 1976, J AM CHEM SOC, V98, P343, DOI 10.1021/ja00418a005; VUKPAVLOVIC S, 1977, BIOCHEM BIOPH RES CO, V79, P885, DOI 10.1016/0006-291X(77)91193-7; WILLIAMSSMITH DL, 1977, BIOCHEM J, V167, P593, DOI 10.1042/bj1670593; YOSHIKAWA S, 1985, J BIOL CHEM, V260, P3518; YOSHIMURA T, 1984, ARCH BIOCHEM BIOPHYS, V230, P466, DOI 10.1016/0003-9861(84)90427-2	52	147	149	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22843	22852						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429633				2022-12-25	WOS:A1992JY16300024
J	WU, JJ; WOODS, PE; EYRE, DR				WU, JJ; WOODS, PE; EYRE, DR			IDENTIFICATION OF CROSS-LINKING SITES IN BOVINE CARTILAGE TYPE-IX COLLAGEN REVEALS AN ANTIPARALLEL TYPE-II-TYPE-IX MOLECULAR RELATIONSHIP AND TYPE-IX TO TYPE-IX BONDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE CHAIN(S); DISULFIDE-BONDED COLLAGEN; ARTICULAR-CARTILAGE; PROTEOGLYCAN; CDNA; POLYPEPTIDE; ANTIBODIES; SEQUENCE; CLEAVAGE; PROTEINS	Type IX collagen functions in covalent cross-linkage to type II collagen in cartilage (Eyre, D. R., Apone, S., Wu, J. J., Ericsson, L. H., and Walsh, K. A. (1987) FEBS Lett. 220, 337-341). To understand this molecular relationship better, an analysis of all cross-linking sites labeled by [H-3]borohydride was undertaken using the protein prepared from fetal bovine cartilage. Sequence analysis of tryptic peptides containing the H-3-labeled cross-links showed that each of the chains of type IX collagen, alpha1(IX), alpha2(IX), and alpha3(IX), contained a site of cross-linking at the amino terminus of the COL2 triple-helix to which the alpha1(II)N-telopeptide could bond. The alpha3(IX)COL2 domain alone also had an attachment site for the alpha1(II)C-telopeptide. The distance between the alpha1(II)N-telopeptide and alpha1(II)C-telopeptide interaction sites, 137 residues, is equal to the length of the hole zone (0.6D) in a type II collagen fibril. This implies an antiparallel type II to type IX cross-linking relationship. Peptide analysis also revealed an unknown amino acid sequence linked to the COL2 cross-linking domains in both the alpha1(IX) and alpha3(IX) chains. Using antibodies to this novel peptide, its origin in the collagen alpha3(IX)NC1 domain was established. In summary, the results confirm extensive covalent cross-linking between type IX and type II collagen molecules and reveal the existence of type IX-type IX bonding. These data provide a molecular basis for the proposed function of type IX collagen as a critical contributor to the mechanical stability and resistance to swelling of the collagen type II fibril frame-work of cartilage.			WU, JJ (corresponding author), UNIV WASHINGTON,DEPT ORTHOPAED,ORTHOPAED RES LABS,RK-10,SEATTLE,WA 98195, USA.				NIAMS NIH HHS [R01 AR036794, AR36794, R37 AR037318] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR036794, R37AR037318, R01AR036794] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLEN G, 1981, LABORATORY TECHNIQUE, P30; AYAD S, 1991, BIOCHEM J, V278, P441, DOI 10.1042/bj2780441; AYAD S, 1982, FEBS LETT, V139, P300, DOI 10.1016/0014-5793(82)80875-2; BRUCKNER P, 1985, P NATL ACAD SCI USA, V82, P2608, DOI 10.1073/pnas.82.9.2608; EYRE D R, 1990, P188; EYRE DR, 1991, SEMIN ARTHRITIS RHEU, V21, P2, DOI 10.1016/0049-0172(91)90035-X; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; EYRE DR, 1987, J RHEUMATOL, V14, P25; EYRE DR, 1973, BIOCHEM J, V135, P393, DOI 10.1042/bj1350393; EYRE DR, 1984, ANNU REV BIOCHEM, V53, P717, DOI 10.1146/annurev.bi.53.070184.003441; EYRE DR, 1990, METHODS CARTILAGE RE, P28; HAREL R, 1992, J BIOL CHEM, V267, P10070; Hodge A, 1963, ASPECTS PROTEIN STRU, P289; HUBER S, 1986, J BIOL CHEM, V261, P5965; HUBER S, 1988, J BIOL CHEM, V263, P752; IRWIN MH, 1986, J BIOL CHEM, V261, P6281; KIMURA T, 1989, EUR J BIOCHEM, V179, P71, DOI 10.1111/j.1432-1033.1989.tb14522.x; KONOMI H, 1986, J BIOL CHEM, V261, P6742; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCORMICK D, 1987, P NATL ACAD SCI USA, V84, P4044, DOI 10.1073/pnas.84.12.4044; MCDEVITT CA, 1976, J BONE JOINT SURG BR, V58, P94, DOI 10.1302/0301-620X.58B1.131804; MULLERGLAUSER W, 1986, J CELL BIOL, V102, P1931, DOI 10.1083/jcb.102.5.1931; NINOMIYA Y, 1985, BIOCHEMISTRY-US, V24, P4223, DOI 10.1021/bi00336a061; NINOMIYA Y, 1984, P NATL ACAD SCI-BIOL, V81, P3014, DOI 10.1073/pnas.81.10.3014; NORO A, 1983, J BIOL CHEM, V258, P9323; REESE CA, 1981, BIOCHEMISTRY-US, V20, P5443, DOI 10.1021/bi00522a014; SHIMOKOMAKI M, 1981, BIOSCIENCE REP, V1, P561, DOI 10.1007/BF01116305; SHIMOKOMAKI M, 1980, FEBS LETT, V121, P51, DOI 10.1016/0014-5793(80)81265-8; SHIMOKOMAKI M, 1990, ANN NY ACAD SCI, V580, P1, DOI 10.1111/j.1749-6632.1990.tb17912.x; STOCKWELL RA, 1983, J ANAT, V136, P425; Van der Rest M, 1987, STRUCTURE FUNCTION C, P195; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VANDERREST M, 1985, J BIOL CHEM, V260, P220; VAUGHAN L, 1985, J BIOL CHEM, V260, P4758; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; VONDERMARK K, 1982, EUR J BIOCHEM, V124, P57; WU JJ, 1989, CONNECT TISSUE RES, V20, P241, DOI 10.3109/03008208909023893; WU JJ, 1984, BIOCHEMISTRY-US, V23, P1850, DOI 10.1021/bi00303a041; WU JJ, 1991, J BIOL CHEM, V266, P5625; WU JJ, 1984, BIOCHEM BIOPH RES CO, V123, P1033, DOI 10.1016/S0006-291X(84)80237-5	41	211	216	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23007	23014						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429648				2022-12-25	WOS:A1992JY16300048
J	EICHHOLTZ, T; VOSSEBELD, P; VANOVERVELD, M; PLOEGH, H				EICHHOLTZ, T; VOSSEBELD, P; VANOVERVELD, M; PLOEGH, H			ACTIVATION OF PROTEIN-KINASE-C ACCELERATES INTERNALIZATION OF TRANSFERRIN RECEPTOR BUT NOT OF MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I, INDEPENDENT OF THEIR PHOSPHORYLATION STATUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL-MYRISTATE ACETATE; CELL-SURFACE EXPRESSION; MHC CLASS-II; CYTOPLASMIC DOMAIN; STRUCTURAL FEATURES; T-CELLS; ENDOCYTOSIS; ANTIGENS; MOLECULES; HLA	Phosphorylation of membrane glycoproteins has often been invoked as a determinant of receptor internalization and receptor trafficking in a more general sense. Here we have studied the trafficking of major histocompatibility complex (MHC) Class I molecules and transferrin receptor (Tfr) related to their phosphorylation status in the human lymphoblastoid cell line JY. High resolution isoelectric focusing (IEF) allows the visualization of phosphorylated and non-phosphorylated protein species simultaneously, using protein backbone-labeling. Analysis on IEF was combined with a neuraminidase protection assay, in which sialic acid modification of the N-linked glycans present on Tfr and Class I molecules is used as a reporter group for cell surface expression. Phosphorylation of Class I heavy chains and Tfr was induced by exposure of cells to the phorbol ester tetradecanoyl phorbol acetate. We show that 1) phosphorylation of MHC Class I molecules is restricted to the cell surface fraction, 2) phosphorylation of MHC Class I molecules by protein kinase C (PKC) is not correlated with their internalization, as no internalization of Class I molecules, phosphorylated or non-phosphorylated, could be detected, 3) the initial rate, but not the final extent of the internalization of Tfr is affected by activation of PKC, and 4) phosphorylated Tfr behaves in a manner identical to nonphosphorylated Tfr in terms of internalization. The effect of activation of PKC on internalization of Tfr therefore most likely takes place at the level of the internalization machinery. Our data concerning the internalization of MHC Class I molecules contrast with earlier studies describing constitutive internalization in the B lymphoblastoid cell line A 46 and in HPB-ALL cells.	NETHERLANDS CANC INST,DEPT CELLULAR BIOCHEM,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute								ACRES RB, 1987, J IMMUNOL, V139, P2268; BERNABEU C, 1984, NATURE, V308, P642, DOI 10.1038/308642a0; BOYER C, 1989, J IMMUNOL, V143, P1905; BRETSCHER MS, 1988, EMBO J, V7, P4087, DOI 10.1002/j.1460-2075.1988.tb03302.x; BURGERT HG, 1985, CELL, V41, P987, DOI 10.1016/S0092-8674(85)80079-9; CAPPS GG, 1989, J CELL BIOL, V108, P1317, DOI 10.1083/jcb.108.4.1317; COX JH, 1990, SCIENCE, V247, P715, DOI 10.1126/science.2137259; DASGUPTA JD, 1988, J IMMUNOL, V141, P2577; DAVIS JE, 1990, J IMMUNOL, V144, P990; DAVIS RJ, 1987, J BIOL CHEM, V262, P16041; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; FALLON RJ, 1986, J BIOL CHEM, V261, P5081; FEUERSTEIN N, 1985, BIOCHEM BIOPH RES CO, V126, P206, DOI 10.1016/0006-291X(85)90592-3; GEFFEN I, 1991, P NATL ACAD SCI USA, V88, P8425, DOI 10.1073/pnas.88.19.8425; GUILD BC, 1984, J BIOL CHEM, V259, P9235; HOXIE JA, 1986, J IMMUNOL, V137, P1194; KLAUSNER RD, 1984, P NATL ACAD SCI-BIOL, V81, P3005, DOI 10.1073/pnas.81.10.3005; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; KRANGEL MS, 1987, J EXP MED, V165, P1141, DOI 10.1084/jem.165.4.1141; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LIPPE R, 1991, J EXP MED, V174, P1159, DOI 10.1084/jem.174.5.1159; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LOUBE SR, 1983, BIOCHEM J, V210, P79, DOI 10.1042/bj2100079; MAY WS, 1984, P NATL ACAD SCI-BIOL, V81, P2016, DOI 10.1073/pnas.81.7.2016; MCGRAW TE, 1988, J CELL BIOL, V106, P1061, DOI 10.1083/jcb.106.4.1061; MOLDERS HH, 1982, HUM IMMUNOL, V6, P111; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; NEEFJES JJ, 1986, HUM IMMUNOL, V16, P169, DOI 10.1016/0198-8859(86)90046-7; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NEEFJES JJ, 1988, EUR J IMMUNOL, V18, P801, DOI 10.1002/eji.1830180522; PARHAM P, 1979, J IMMUNOL, V123, P342; PHILLIPS DR, 1970, BIOCHEM BIOPH RES CO, V40, P284, DOI 10.1016/0006-291X(70)91007-7; POBER JS, 1978, P NATL ACAD SCI USA, V75, P6002, DOI 10.1073/pnas.75.12.6002; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; ROTHENBERGER S, 1987, CELL, V49, P423, DOI 10.1016/0092-8674(87)90295-9; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TSE DB, 1984, J EXP MED, V159, P193, DOI 10.1084/jem.159.1.193; VANDERIJN M, 1983, CYTOGENET CELL GENET, V36, P525, DOI 10.1159/000131967; VEGA MA, 1989, P NATL ACAD SCI USA, V86, P2688, DOI 10.1073/pnas.86.8.2688; WATTS C, 1985, J CELL BIOL, V100, P633, DOI 10.1083/jcb.100.2.633; ZERIAL M, 1987, EMBO J, V6, P2661, DOI 10.1002/j.1460-2075.1987.tb02557.x	44	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22490	22495						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429599				2022-12-25	WOS:A1992JW71900079
J	ISHIDA, H; NOSHIRO, M; OKUDA, K; COON, MJ				ISHIDA, H; NOSHIRO, M; OKUDA, K; COON, MJ			PURIFICATION AND CHARACTERIZATION OF 7-ALPHA-HYDROXY-4-CHOLESTEN-3-ONE 12-ALPHA-HYDROXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL 7-ALPHA-HYDROXYLASE; POLYACRYLAMIDE GELS; LIVER-MICROSOMES; BILE-ACIDS; CYTOCHROME-P-450; PROTEINS; CHROMATOGRAPHY	The isoform of cytochrome P450 that catalyzes the 12alpha-hydroxylation of 7alpha-hydroxy-4-cholesten-3-one, an intermediate in the conversion of cholesterol to cholic acid, was purified to homogeneity from rabbit liver microsomes. The extent of purification in the various steps was judged by an assay involving high performance liquid chromatography. The purified enzyme showed a single band on SDS-polyacrylamide gel electrophoresis (M(r) = 50,000). The NH2-terminal amino acid sequence is as follows: Val-Leu-Trp-Gly-Leu-Leu-Gly-Ala-Leu-Leu-Met-Val-Met-Val-Gly-, which is different from that of any other P450s so far reported. The specific content of the enzyme was 13.3 nmol of cytochrome P450/mg of protein. Upon reconstitution with NADPH-cytochrome P450 reduetase and cytochrome b5, the P450 enzyme showed a high activity of 12alpha-hydroxylation with a turnover number of 36.6 min-1 at 37-degrees-C. The omission of either cytochrome P450 or NADPH-cytochrome P450 reductase resulted in complete loss of activity, and the omission of cytochrome b5 resulted in 40% loss of activity. Antibodies prepared from mouse inhibited the 12alpha-hydroxylase activity of rabbit liver microsomes about 90% and that of the rat liver microsomes 50%. The enzyme activity was not inhibited by other antibodies raised against other forms of P450 that catalyze different monooxygenation reactions toward xenobiotics or endogenous substrates. Anti-cytochrome b5 antibody inhibited the activity 40%, suggesting the functional role of this protein, and anti-reductase inhibited the activity almost completely. The microsomal enzyme activity was markedly elevated by starvation or streptozotocin administration to the animals. However, an immunoblotting experiment showed no correlation between the enzyme activity and the amount of protein, suggesting that post-translational modification may occur.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	ISHIDA, H (corresponding author), HIROSHIMA UNIV,SCH DENT,DEPT BIOCHEM,KASUMI 1-2-3,MINAMI KU,HIROSHIMA 734,JAPAN.				NIDDK NIH HHS [DK 10339] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK010339, R37DK010339] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNHARDSSON C, 1973, BIOCHEM BIOPH RES CO, V54, P1030, DOI 10.1016/0006-291X(73)90797-3; BERSEUS O, 1965, J BIOL CHEM, V240, P2396; BLACK SD, 1987, ADV ENZYMOL RAMB, V60, P35; Coon M J, 1978, Methods Enzymol, V52, P109; EINARSSO.K, 1968, EUR J BIOCHEM, V5, P101, DOI 10.1111/j.1432-1033.1968.tb00342.x; HANSSON R, 1980, J BIOL CHEM, V255, P1643; Haslewood G. A. D, 1967, BILE SALTS; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MURAKAMI K, 1982, J BIOL CHEM, V257, P8030; MURAKAMI K, 1981, BIOCHEM BIOPH RES CO, V100, P91, DOI 10.1016/S0006-291X(81)80067-8; NERVI FO, 1978, BIOCHIM BIOPHYS ACTA, V529, P212, DOI 10.1016/0005-2760(78)90064-4; NOSHIRO M, 1978, J BIOCHEM, V83, P61, DOI 10.1093/oxfordjournals.jbchem.a131913; NOSHIRO M, 1985, STEROIDS, V45, P539, DOI 10.1016/0039-128X(85)90018-2; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OGISHIMA T, 1987, J BIOL CHEM, V262, P7646; OGURA Y, 1986, BIOL CHEM H-S, V367, P1095, DOI 10.1515/bchm3.1986.367.2.1095; OKUDA K, 1980, MICROSOMES DRUG OXID, V2, P745; OKUDA K, 1982, MICROSOMES DRUG OXID, P313; OMURA T, 1964, J BIOL CHEM, V239, P2370; POMPON D, 1984, J BIOL CHEM, V259, P5377; SHAW R, 1979, J BIOL CHEM, V254, P7177; SHIMASUE A, 1974, HIROSHIMA J MED SCI, V23, P265; SPATZ L, 1971, P NATL ACAD SCI USA, V68, P1042, DOI 10.1073/pnas.68.5.1042; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337	26	28	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21319	21323						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400444				2022-12-25	WOS:A1992JV01100012
J	EIDE, D; DAVISKAPLAN, S; JORDAN, I; SIPE, D; KAPLAN, J				EIDE, D; DAVISKAPLAN, S; JORDAN, I; SIPE, D; KAPLAN, J			REGULATION OF IRON UPTAKE IN SACCHAROMYCES-CEREVISIAE - THE FERRIREDUCTASE AND FE(II) TRANSPORTER ARE REGULATED INDEPENDENTLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCTASE; LIVER	Iron is required for the growth of Saccharomyces cerevisiae. High concentrations of iron, however, are toxic, forcing this yeast to tightly regulate its concentration of intracellular free iron. We demonstrate that S. cerevisiae accumulates iron through the combined action of a plasma membrane ferrireductase and an Fe(II) transporter. This transporter is highly selective for Fe(II). Several other transition metals did not inhibit iron uptake when these metals were present at a concentration 100-fold higher than the K(m) (0.15 muM) for iron transport. Pt(II) inhibited ferrireductase activity but not the ability of cells to transport iron that was chemically reduced to Fe(II). Incubation of cells in a synthetic iron-limited media resulted in the induction of both ferrireductase and Fe(II) transporter activities. In complex media, Fe(II) transport activity was regulated in response to media iron concentration, while the activity of the ferrireductase was not. When stationary phase cells were inoculated into fresh media, ferrireductase activity increased independent of the iron content of the media; in contrast, transporter activity varied inversely with iron levels. These results demonstrate that the ferrireductase and Fe(II) transporter are separately regulated and that iron accumulation may be limited by changes in either activity.	UNIV UTAH,COLL MED,DEPT PATHOL,DIV CELL BIOL & IMMUNOL,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah					NHLBI NIH HHS [HL 0636] Funding Source: Medline; NIDDK NIH HHS [DK 30534, DK 20630] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020630, R37DK030534, R01DK030534] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIENFAIT HF, 1985, J BIOENERG BIOMEMBR, V17, P73, DOI 10.1007/BF00744199; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; ECKER DJ, 1983, J BACTERIOL, V155, P616, DOI 10.1128/JB.155.2.616-622.1983; EIDE D, 1992, J GEN MICROBIOL, V138, P347, DOI 10.1099/00221287-138-2-347; FUHRMANN GF, 1968, BIOCHIM BIOPHYS ACTA, V163, P325, DOI 10.1016/0005-2736(68)90117-X; Haber F., 1934, P R SOC LOND A, V147, P332, DOI [10.1098/rspa.1934.0221, DOI 10.1098/RSPA.1934.0221, DOI 10.1098/rspa.1934.0221]; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; KAPLAN J, 1991, J BIOL CHEM, V266, P2997; LANDERS JW, 1958, AM J CLIN PATHOL, V29, P590; LESUISSE E, 1989, J GEN MICROBIOL, V135, P257; LESUISSE E, 1987, J GEN MICROBIOL, V133, P3229; LESUISSE E, 1991, BIOCHEM J, V280, P575; LIEB WR, 1982, RED CELL MEMBRANES M, P135; LIN CM, 1990, J BIOL CHEM, V265, P9194; RAGUZZI F, 1988, FEBS LETT, V231, P253, DOI 10.1016/0014-5793(88)80742-7; SCHWYN B, 1987, ANAL BIOCHEM, V160, P47, DOI 10.1016/0003-2697(87)90612-9; Sherman F., 1986, METHODS YEAST GENETI; SUN IL, 1987, J BIOL CHEM, V262, P15915; WICKERHAM LJ, 1946, J BACTERIOL, V52, P293, DOI 10.1128/JB.52.3.293-301.1946; Wigglesworth J. M., 1980, IRON BIOCH MED, VII, P29; Winkelmann G, 1987, IRON TRANSPORT MICRO; WRIGHT TL, 1986, J BIOL CHEM, V261, P909	23	164	169	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20774	20781						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400393				2022-12-25	WOS:A1992JT97800042
J	OGASAWARA, Y; KUROKI, Y; AKINO, T				OGASAWARA, Y; KUROKI, Y; AKINO, T			PULMONARY SURFACTANT PROTEIN-D SPECIFICALLY BINDS TO PHOSPHATIDYLINOSITOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-DEPENDENT PHOSPHOLIPID-BINDING; A SP-A; II CELLS; LUNG; SECRETION; PURIFICATION; SEQUENCE; AFFINITY; LIPIDS; CP4	Alveolar type II cells produce and secrete a complex mixture of lipids and proteins called pulmonary surfactant of which phospholipids are the major components. Surfactant proteins (SP) A, B, and C interact with phospholipids and are believed to play important roles in alveolar spaces. However, whether surfactant protein D (SP-D) interacts with phospholipids is unknown. In the present study, we examined whether SP-D binds to phospholipids and investigated phospholipid specificities of SP-D binding and the structural requirements of phospholipids for that binding using I-125-SP-D as a probe. I-125-SP-D bound exclusively to phosphatidylinositol (PI) in various phospholipids or a fraction containing phospholipids extracted from surfactant, which were developed on thin layer chromatography. I-125-SP-D also bound to PI coated on microtiter wells in a manner dependent upon the SP-D concentration. Unlabeled SP-D competed well with I-125-SP-D for PI binding and the antibody against SP-D abolished I-125-SP-D binding to PI. PI liposome also attenuated I-125-SP-D binding to the solid phase PI. Ca2+ is absolutely required for the binding of SP-D to PI. SP-D failed to bind to lyso-PI, fatty acids derived from PI digested with phospholipase A2, or diacylglycerol obtained after phospholipase C treatment of PI. SP-D bound to neither phosphatidylinositol 4-monophosphate nor phosphatidylinositol 4,5-diphosphate. We conclude that SP-D specifically binds to PI. This is the first report that demonstrates that SP-D interacts with surfactant phospholipids.	SAPPORO MED COLL,DEPT BIOCHEM,SOUTH 1,WEST 17,CHUO KU,SAPPORO,HOKKAIDO 060,JAPAN	Sapporo Medical University								BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CROUCH E, 1991, AM J RESP CELL MOL, V5, P13, DOI 10.1165/ajrcmb/5.1.13; CROUCH E, 1991, AM J PHYSIOL, V260, pL247, DOI 10.1152/ajplung.1991.260.4.L247; DETHLOFF LA, 1986, BIOCHEM J, V233, P111, DOI 10.1042/bj2330111; DOBBS LG, 1987, P NATL ACAD SCI USA, V84, P1010, DOI 10.1073/pnas.84.4.1010; FAUVEL J, 1987, FEBS LETT, V221, P397, DOI 10.1016/0014-5793(87)80963-8; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; GEISOW MJ, 1986, NATURE, V320, P636, DOI 10.1038/320636a0; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; GLENNEY JR, 1985, FEBS LETT, V192, P79, DOI 10.1016/0014-5793(85)80047-8; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; KATES M, 1972, TECHNIQUES LIPIDOLOG, P249; KING RJ, 1972, AM J PHYSIOL, V223, P707, DOI 10.1152/ajplegacy.1972.223.3.707; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KUROKI Y, 1991, BIOCHIM BIOPHYS ACTA, V1086, P185, DOI 10.1016/0005-2760(91)90006-4; KUROKI Y, 1991, BIOCHEM J, V279, P115, DOI 10.1042/bj2790115; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OGASAWARA Y, 1991, BIOCHIM BIOPHYS ACTA, V1083, P252, DOI 10.1016/0005-2760(91)90079-W; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; PERSSON A, 1990, J BIOL CHEM, V265, P5755; PERSSON A, 1988, BIOCHEMISTRY-US, V27, P8576, DOI 10.1021/bi00423a011; RICE WR, 1987, J APPL PHYSIOL, V63, P692, DOI 10.1152/jappl.1987.63.2.692; RUST K, 1991, ARCH BIOCHEM BIOPHYS, V290, P116, DOI 10.1016/0003-9861(91)90597-C; SANO K, 1987, BIOCHEM BIOPH RES CO, V144, P367, DOI 10.1016/S0006-291X(87)80519-3; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853; TSAO FHC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P29, DOI 10.1016/0005-2760(90)90200-H; VANIWAARDEN F, 1990, AM J RESP CELL MOL, V2, P91, DOI 10.1165/ajrcmb/2.1.91; VANIWAARDEN JF, 1991, AM J PHYSIOL, V261, pL204, DOI 10.1152/ajplung.1991.261.2.L204; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888	36	98	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21244	21249						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400434				2022-12-25	WOS:A1992JT97800113
J	CLEMETSON, JM; BOSCHETTI, A; CLEMETSON, KJ				CLEMETSON, JM; BOSCHETTI, A; CLEMETSON, KJ			CHLOROPLAST ENVELOPE PROTEINS ARE ENCODED BY THE CHLOROPLAST GENOME OF CHLAMYDOMONAS-REINHARDTII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE POLYPEPTIDES; SPINACH-CHLOROPLASTS; IMPORT; PRECURSOR; BINDING; ELECTROPHORESIS; TRANSPORT; RECEPTOR; SEQUENCE; ANALOGS	To characterize envelope proteins encoded by th chloroplast genome, envelopes were isolated from Chlamydomonas reinhardtii cells labeled with [S-35] sulfate while blocking synthesis by cytoplasmic ribosomes. One and two-dimensional gel electrophoresis of envelopes and fluorography revealed four highly labeled proteins. Two with masses of 29 and 30 kDa and pl 5.5 were absent from the stroma and thylakoid fractions, while the others at 54 kDa, pI 5.2 and 61 kDa, pI 5.4 were detected there in smaller amounts. The 29- and 30-kDa proteins were associated with outer envelope membranes separated from inner envelope membranes after chloroplast lysis in hypertonic solution. A 32-kDa protein not labeled by [S-35]sulfate was found exclusively in the inner membrane fraction, suggesting the existence of a phosphate translocator in C. reinhardtii. To identify envelope proteins exposed on the chloroplast surface, isolated active chloroplasts were surface-labeled with I-125 and lactoperoxidase. The 54-kDa, pI 5.2 protein as well as a protein corresponding to either of the 29- or 30-kDa proteins described above were among the labeled components. These results show that envelope proteins of C. reinhardtii are encoded by the chloroplast genome and two are located on the outer envelope membranes.	UNIV BERN, INST BIOCHEM, CH-3012 BERN, SWITZERLAND	University of Bern	CLEMETSON, JM (corresponding author), THEODOR KOCHER INST, FREIESTR 1, CH-3012 BERN, SWITZERLAND.							AMES GFL, 1976, BIOCHEMISTRY-US, V15, P616, DOI 10.1021/bi00648a026; ANDERSON CW, 1983, METHOD ENZYMOL, V101, P635; BIENZ D, 1989, J BIOL CHEM, V264, P507; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUA NH, 1977, J CELL BIOL, V74, P441, DOI 10.1083/jcb.74.2.441; CLEMETSON JM, 1988, BIOCHIM BIOPHYS ACTA, V943, P371, DOI 10.1016/0005-2736(88)90570-6; CLINE K, 1981, P NATL ACAD SCI-BIOL, V78, P3595, DOI 10.1073/pnas.78.6.3595; CORNWELL KL, 1987, PLANT PHYSIOL, V85, P780, DOI 10.1104/pp.85.3.780; DOUCE R, 1990, ANNU REV CELL BIOL, V6, P173, DOI 10.1146/annurev.cb.06.110190.001133; FLUGGE UI, 1989, EMBO J, V8, P39, DOI 10.1002/j.1460-2075.1989.tb03346.x; FLUGGE UI, 1984, FEBS LETT, V168, P255, DOI 10.1016/0014-5793(84)80257-4; HELDT HW, 1986, METHOD ENZYMOL, V125, P705; IKEUCHI M, 1987, FEBS LETT, V210, P71, DOI 10.1016/0014-5793(87)81300-5; JOY KW, 1975, BIOCHIM BIOPHYS ACTA, V378, P143, DOI 10.1016/0005-2787(75)90145-8; KLEIN U, 1983, PLANT PHYSIOL, V72, P488, DOI 10.1104/pp.72.2.488; KO K, 1992, J BIOL CHEM, V267, P2986; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMIEUX B, 1985, BIOSYSTEMS, V18, P293, DOI 10.1016/0303-2647(85)90029-2; MENDIOLAMORGENTHALER L, 1985, PLANT SCI, V41, P97, DOI 10.1016/0168-9452(85)90109-8; MENDIOLAMORGENTHALER L, 1985, PLANT SCI, V38, P33, DOI 10.1016/0168-9452(85)90076-7; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PERRY SE, 1991, J BIOL CHEM, V266, P11882; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; SCHMIDT GW, 1986, ANNU REV BIOCHEM, V55, P879; SCHNELL DJ, 1990, J CELL BIOL, V111, P1825, DOI 10.1083/jcb.111.5.1825; SCHNELL DJ, 1991, J BIOL CHEM, V266, P3335; STAEHELIN LA, 1986, ENCY PLANT PHYSL, V19, P8; SUEOKA N, 1960, P NATL ACAD SCI USA, V46, P83, DOI 10.1073/pnas.46.1.83; VERNON LP, 1960, ANAL CHEM, V32, P1144, DOI 10.1021/ac60165a029	32	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19773	19779						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400290				2022-12-25	WOS:A1992JR85800006
J	ODA, A; DRUKER, BJ; SMITH, M; SALZMAN, EW				ODA, A; DRUKER, BJ; SMITH, M; SALZMAN, EW			ASSOCIATION OF PP60SRC WITH TRITON X-100-INSOLUBLE RESIDUE IN HUMAN BLOOD-PLATELETS REQUIRES PLATELET-AGGREGATION AND ACTIN POLYMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; PROTEIN-TYROSINE PHOSPHORYLATION; COLONY-STIMULATING FACTOR; ROUS-SARCOMA VIRUS; SRC GENE-PRODUCT; MONOCLONAL-ANTIBODIES; FIBRINOGEN RECEPTOR; COMMON SET; THROMBIN; CYTOSKELETON	Protein-tyrosine phosphorylation during platelet activation is inhibited under conditions that inhibit platelet binding of fibrinogen and aggregation. We suggested that pp60src, a major platelet tyrosine kinase, or its protein substrates might become associated with the cytoskeleton upon platelet stimulation, and that this might be related to aggregation. By Western blotting with an anti-Src monoclonal antibody, we found time-dependent association of pp60src with the cytoskeleton (10,000 x g Triton X-100-insoluble matrix) but not the "membrane" cytoskeleton (100,000 x g Triton X-100-insoluble matrix) in platelets activated by U46619 (PGH2 analog). Cytoskeletal association and platelet aggregation were inhibited by the peptide Arg-Gly-Asp-Ser (RGDS) (but not by Arg-Gly-Glu-Ser (RGES)), by 10E5 antibody against glycoprotein (Gp) IIb/IIIa, and by EGTA. U46619-induced association of pp60src with cytoskeleton but not secretion or aggregation was inhibited by cytochalasin D (2 muM). Both cytochalasin D and RGDS inhibited "slow" tyrosine phosphorylation of platelet proteins. Association of pp60src with cytoskeleton induced by U46619 or ADP was not blocked by aspirin. Aspirin blocked epinephrine-induced association of pp60src with the cytoskeleton during a second phase of aggregation when an initial phase had occurred without shape change or secretion. Association of GpIIb/IIIa with the cytoskeleton also accompanied platelet aggregation, shape change, and actin polymerization; this was shown with anti-GpIIb and anti-GpIIIa antibodies. Association of pp60src and GpIIb/IIIa with the cytoskeleton and slow tyrosine phosphorylation are related phenomena.	BETH ISRAEL HOSP, DEPT SURG, 330 BROOKLINE AVE, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CELLULAR MOLEC, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School				Druker, Brian/0000-0001-8331-8206	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033014] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-33014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; COHEN I, 1989, BLOOD, V73, P1880; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; ELMORE MA, 1990, FEBS LETT, V269, P283, DOI 10.1016/0014-5793(90)81177-P; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FISCHER TH, 1990, J BIOL CHEM, V265, P19405; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; FOX JEB, 1987, THROMB DIATH HAEMO, P175; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2313; HILLERY CA, 1991, J BIOL CHEM, V266, P14663; HORAK ID, 1990, ONCOGENE, V5, P597; HORVATH AR, 1991, BIOCHEM SOC T, V19, P1150, DOI 10.1042/bst0191150; INAZU T, 1990, BIOCHEM BIOPH RES CO, V170, P259, DOI 10.1016/0006-291X(90)91268-W; ISENBERG WM, 1987, J CELL BIOL, V104, P1655, DOI 10.1083/jcb.104.6.1655; JENNINGS LK, 1990, J BIOL CHEM, V265, P3815; KANAKURA Y, 1990, BLOOD, V76, P706; KANAKURA Y, 1991, J BIOL CHEM, V266, P490; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOUNS WC, 1991, J BIOL CHEM, V266, P13891; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEREA KM, 1989, BIOCHEMISTRY-US, V28, P9286, DOI 10.1021/bi00450a008; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; ODA A, 1991, AM J PHYSIOL, V260, pC242, DOI 10.1152/ajpcell.1991.260.2.C242; ODA A, 1992, BLOOD, V79, P920; ODA A, 1992, AM J PHYSIOL, V31, pC262; PAINTER RG, 1982, J CELL BIOL, V92, P565, DOI 10.1083/jcb.92.2.565; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; RITTENHOUSE SE, 1991, THROMB HAEMOSTASIS, V65, P742; ROHRSCHNEIDER LR, 1979, CELL, V16, P11, DOI 10.1016/0092-8674(79)90183-1; SCHICK PK, 1983, BLOOD, V61, P163; SHRIVER K, 1981, J CELL BIOL, V89, P525, DOI 10.1083/jcb.89.3.525; SIESS W, 1989, PHYSIOL REV, V69, P158; STEEN VM, 1987, EUR J HAEMATOL, V38, P383; TANAKA K, 1988, J CELL BIOL, V106, P1757; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZUCKER MB, 1983, BLOOD, V61, P676	44	94	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20075	20081						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400325				2022-12-25	WOS:A1992JR85800053
J	AVIVI, A; SKORECKI, K; YAYON, A; GIVOL, D				AVIVI, A; SKORECKI, K; YAYON, A; GIVOL, D			PROMOTER REGION OF THE MURINE FIBROBLAST GROWTH-FACTOR RECEPTOR-2 (BEK KGFR) GENE	ONCOGENE			English	Article							MAMMALIAN-CELLS; EXPRESSION; CLONING; FAMILY; PURIFICATION; MECHANISMS; PLASMIDS; BINDING; MEMBER; FGF	Fibroblast growth factors (FGFs) and their receptors play an important role in cell growth, angiogenesis and embryonal development. Four distinct genes encoding fibroblast growth factor receptors (FGFRs) were identified: flg, encoding FGFR1, bek encoding FGFR2, and the genes for FGFR3 and FGFR4. Both FGFR2 and keratinocyte growth factor receptor (KGFR) are encoded by the same gene, bek. To study the regulation of expression of the FGF receptors we analysed the DNA sequence flanking the 5' region of the cDNA of murine FGFR2 to seek elements that control its transcription. A 5-kbp fragment containing the 5' end of the cDNA was isolated from mouse genomic library and used to map the promoter region. We found that the sequence encoding the 5' non-translated region of the FGFR2/KGFR cDNA contains an intron located 210 bp upstream from the translation start site. Using RNAase protection and primer extension, we identified the mRNA start 37 bp upstream from the beginning of the bek cDNA. The promoter activity was found to reside in a 1.3-kbp fragment upstream from the cDNA, and deletion mapping further localized the promoter to a 0.7-kbp fragment. The sequence of this region shows high G + C content (62%), which is particularly emphasized in the 200 bp upstream from the mRNA start (80% G + C). This region contains the CCGCCC, GGGCGG AND GGAGG motifs also found in promoters of other growth factor receptors. Neither TATA nor CAAT boxes were found near the RNA start site. The characterization of this promoter will allow studies of the regulation of expression of the FGFR2 during development and in pathophysiological states. The differences between the promoter sequence of the gene for FGFR2 (bek) and FGFR1 (flg) may explain their differential expression during development.	WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AVIVI A, 1991, ONCOGENE, V6, P1089; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; Maniatis T., 1982, MOL CLONING; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PETERS KG, 1992, DEVELOPMENT, V114, P233; RAZ V, 1991, ONCOGENE, V6, P753; RUTA M, 1988, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SAITO H, 1992, BIOCHEM BIOPH RES CO, V183, P688, DOI 10.1016/0006-291X(92)90537-U; SANGER F, 1977, P NATL ACAD SCI USA, V83, P7137; SMITH JC, 1989, DEVELOPMENT, V105, P665; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	34	33	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1992	7	10					1957	1962						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408137				2022-12-25	WOS:A1992JP42400008
J	ZHU, W; KRIAJEVSKAIA, M; CHOU, WG				ZHU, W; KRIAJEVSKAIA, M; CHOU, WG			A RETROVIRAL SEQUENCE OF THE CHINESE-HAMSTER OVARY CELL-LINE	ONCOGENE			English	Note							MURINE LEUKEMIA-VIRUS; EMBRYONAL CARCINOMA-CELLS; LONG TERMINAL REPEAT; EXPRESSION; GENOMES	A partial cDNA (B52) molecule with the characteristics of retroviral sequences was isolated from the Chinese hamster ovary (CHO) K1 cell line. The B52 cDNA contains 1184 nucleotides. The first 452 nucleotides (nt) are 71% homologous to the env gene of Moloney murine leukemia virus (MMLV) and murine endogenous retroviruses. The 139 amino acids predicted from the 452 nt have 82% homology with the carboxy-terminal amino acids of the env protein of MMLV. The remaining 732 nt have several features of a typical retroviral long terminal repeat (LTR). For example, the first 14 nt are identical to the 5' inverted repeat of the retroviral LTRs. The 41-nt sequence at the 3' end is common to the R region of retroviral LTRs. The 732-nt sequence was shown to have promoter activity. The activity is approximately twofold higher than that of the Rous sarcoma virus LTR, and 1.5-fold lower than that of the early promoter of SV40 virus. Two species of mRNA of 5.2 and 2.7 kb in size were readily detected by B52 cDNA in the CHO K1 cells.	UNIV ROCHESTER,MED CTR,DEPT RADIAT ONCOL,CTR CANC,ROCHESTER,NY 14642; UNIV ROCHESTER,MED CTR,DEPT BIOCHEM,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NATIONAL CANCER INSTITUTE [R01CA051064] Funding Source: NIH RePORTER; NCI NIH HHS [CA51064] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARKLIS E, 1986, CELL, V47, P391, DOI 10.1016/0092-8674(86)90596-9; BOSZE Z, 1986, EMBO J, V5, P1615, DOI 10.1002/j.1460-2075.1986.tb04404.x; CELANDER D, 1984, NATURE, V312, P159, DOI 10.1038/312159a0; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; CULLEN BR, 1983, P NATL ACAD SCI-BIOL, V80, P2946, DOI 10.1073/pnas.80.10.2946; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; LENZ J, 1984, NATURE, V308, P467, DOI 10.1038/308467a0; LINNEY E, 1984, NATURE, V308, P470, DOI 10.1038/308470a0; LOH TP, 1990, MOL CELL BIOL, V10, P4045, DOI 10.1128/MCB.10.8.4045; LOSARDO JE, 1989, J VIROL, V63, P1087, DOI 10.1128/JVI.63.3.1087-1094.1989; NICOLAS JF, 1976, CANCER RES, V36, P4224; PRINCE VE, 1991, J VIROL, V65, P1803, DOI 10.1128/JVI.65.4.1803-1811.1991; ROBINSON HL, 1982, P NATL ACAD SCI-BIOL, V79, P1225, DOI 10.1073/pnas.79.4.1225; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SILVER JE, 1983, J EXP MED, V158, P1693, DOI 10.1084/jem.158.5.1693; WEBER F, 1985, EMBO J, V4, P946; ZHU W, 1992, IN PRESS MUTATION RE	18	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2081	2083						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408151				2022-12-25	WOS:A1992JP42400026
J	ANDREOLA, ML; NEVINSKY, GA; BARR, PJ; SARIHCOTTIN, L; BORDIER, B; FOURNIER, M; LITVAK, S; TARRAGOLITVAK, L				ANDREOLA, ML; NEVINSKY, GA; BARR, PJ; SARIHCOTTIN, L; BORDIER, B; FOURNIER, M; LITVAK, S; TARRAGOLITVAK, L			INTERACTION OF TRANSFER RNA(LYS) WITH THE P66 P66 FORM OF HIV-1 REVERSE-TRANSCRIPTASE STIMULATES DNA-POLYMERASE AND RIBONUCLEASE-H ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMER TRANSFER-RNA; LYSINE TRANSFER-RNAS; NUCLEOTIDE-SEQUENCE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; AIDS VIRUS; EXPRESSION; DOMAIN; RETROVIRUSES; INHIBITION	The precursor homodimeric p66/p66 form of human immunodeficiency virus type-1 reverse transcriptase (HIV-1 RT) possesses the DNA polymerase and RNase H activities involved in the synthesis of the double-stranded provirus DNA. Reverse transcription is initiated from tRNA(Lys) in the case of HIV-1. The present study confirmed that interactions between HIV-1 RT and tRNA(Lys) induce protein conformational changes and demonstrated that these interactions stimulate the enzymatic activities associated with the p66 subunit. Thus, the p66/p66 form of the enzyme is strongly stimulated in both DNA polymerase and RNase H activities. Preincubation of the enzyme with tRNA is an obligatory step to obtain the stimulatory effect. The affinity of template, primer, or substrate for RT p66/p66 did not change when the enzyme was preincubated with tRNA(Lys) at stimulatory concentrations; the interaction of tRNA with p66/p66 has an effect only on the maximal rate of polymerization. It is further shown that the RNase H domain of RT is much more accessible to protease attack than the DNA polymerase active site.	CNRS, INST BIOCHIM CELLULAIRE & NEUROCHIM, 1 RUE CAMILLE ST SAENS, F-33077 BORDEAUX, FRANCE; RUSSIAN ACAD SCI, NOVOSIBIRSK INST BIOORGAN CHEM, SIBERIAN BRANCH, NOVOSIBIRSK 630090, USSR; CHIRON CO, EMERYVILLE, CA 94608 USA	Centre National de la Recherche Scientifique (CNRS); Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS; Russian Academy of Sciences			Nevinsky, Georgy/E-6053-2012					BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BARR PJ, 1987, BIO-TECHNOL, V5, P486, DOI 10.1038/nbt0587-486; BATHURST IC, 1990, BIOCHEM BIOPH RES CO, V171, P589, DOI 10.1016/0006-291X(90)91187-W; BORDIER B, 1990, NUCLEIC ACIDS RES, V18, P429, DOI 10.1093/nar/18.3.429; CHENG N, 1991, BIOCHEM BIOPH RES CO, V174, P785, DOI 10.1016/0006-291X(91)91486-V; FARMERIE WG, 1987, SCIENCE, V236, P305, DOI 10.1126/science.2436298; FERSHT A, 1977, ENZYME STRUCTURE MEC, P170; FOURNIER M, 1976, BIOCHIMIE, V58, P1159, DOI 10.1016/S0300-9084(76)80114-9; FOURNIER M, 1981, THESIS U BORDEAUX 2; FURMAN PA, 1991, P NATL ACAD SCI USA, V88, P6013, DOI 10.1073/pnas.88.14.6013; GARRET M, 1984, NUCLEIC ACIDS RES, V12, P2259, DOI 10.1093/nar/12.5.2259; HANSEN J, 1988, EMBO J, V7, P239, DOI 10.1002/j.1460-2075.1988.tb02805.x; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; KEDAR PS, 1990, BIOCHEMISTRY-US, V29, P3603, DOI 10.1021/bi00467a003; KHAN AS, 1988, SCIENCE, V241, P74, DOI 10.1126/science.2455342; LITVAK S, 1982, TRENDS BIOCHEM SCI, V7, P361, DOI 10.1016/0968-0004(82)90114-1; LOWE DM, 1988, BIOCHEMISTRY-US, V27, P8884, DOI 10.1021/bi00425a002; NISHIMURA S, 1969, BIOCHEMISTRY-US, V8, P832, DOI 10.1021/bi00831a011; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; RABA M, 1979, EUR J BIOCHEM, V97, P305, DOI 10.1111/j.1432-1033.1979.tb13115.x; RESTLE T, 1990, J BIOL CHEM, V265, P8986; ROBERT D, 1990, FEBS LETT, V277, P239, DOI 10.1016/0014-5793(90)80855-D; SABIN EA, 1989, BIO-TECHNOL, V7, P705, DOI 10.1038/nbt0789-705; SALLAFRANQUEANDREOLA ML, 1989, EUR J BIOCHEM, V184, P367, DOI 10.1111/j.1432-1033.1989.tb15028.x; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SARIH L, 1988, FEBS LETT, V230, P61, DOI 10.1016/0014-5793(88)80642-2; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4	29	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19356	19362						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1382072				2022-12-25	WOS:A1992JP59300052
J	KIRK, K; ELLORY, JC; YOUNG, JD				KIRK, K; ELLORY, JC; YOUNG, JD			TRANSPORT OF ORGANIC SUBSTRATES VIA A VOLUME-ACTIVATED CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TROUT ERYTHROCYTES; TAURINE EFFLUX; CELLS; RELEASE	We have investigated the volume-activated transport of organic solutes in flounder erythrocytes. Osmotic swelling of cells suspended in a Na+-free medium led to increased membrane transport of taurine, glucose, and uridine. For each compound there was a significant lag period (1-2 min at 10-degrees-C) between cell swelling and activation of the flux. The volume-activated fluxes of each of the substrates increased in parallel with increasing cell volume, and those of taurine and uridine increased linearly with concentration (up to 19 mM). The volume-activated fluxes of each of the three compounds showed similar sensitivities to a number of anion-selective channel blockers (5-nitro-2-(3-phenylpropylamino) benzoic acid > 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid almost-equal-to MK-196 > niflumic acid > furosemide); the IC50 for the inhibition of the volume-activated fluxes by NPPB was around 12 muM. The results are consistent with the hypothesis that the volume-activated transport of organic osmolytes is via a pathway with the characteristics of a volume-activated "chloride channel." This raises the question of whether the transport of organic substrates might represent a physiological role for such channels in other cell types.	UNIV ALBERTA,DEPT PHYSIOL,EDMONTON T6G 2H7,ALBERTA,CANADA	University of Alberta	KIRK, K (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.		Kirk, Kiaran/C-8299-2009	Kirk, Kiaran/0000-0002-5613-2622	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAGNASCO SM, 1988, AM J PHYSIOL, V254, pC788, DOI 10.1152/ajpcell.1988.254.6.C788; BANDERALI U, 1992, J MEMBRANE BIOL, V126, P219; CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, pC803, DOI 10.1152/ajpcell.1992.262.4.C803; CHRISTENSEN O, 1992, J MEMBRANE BIOL, V129, P13; COSSINS AR, 1989, J EXP BIOL, V144, P463; DACIE JC, 1975, PRACTICAL HAEMATOLOG, P39; FINCHAM DA, 1987, J MEMBRANE BIOL, V96, P45, DOI 10.1007/BF01869333; FRANCIOLINI F, 1987, J GEN PHYSIOL, V90, P453, DOI 10.1085/jgp.90.4.453; GARCIA JJ, 1991, J CELL BIOCHEM, V45, P207, DOI 10.1002/jcb.240450212; GARCIAROMEU F, 1991, J PHYSIOL-LONDON, V440, P547, DOI 10.1113/jphysiol.1991.sp018724; GOLDSTEIN L, 1991, AM J PHYSIOL, V260, pR1014, DOI 10.1152/ajpregu.1991.260.5.R1014; GOLDSTEIN L, 1990, J EXP ZOOL, V254, P114, DOI 10.1002/jez.1402540116; GREGER R, 1990, METHOD ENZYMOL, V191, P793; HARBAK H, 1991, ACTA PHYSIOL SCAND, V143, pA42; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101; JARVIS SM, 1982, BIOCHEM J, V208, P83, DOI 10.1042/bj2080083; KIRK K, 1992, J PHYSIOL-LONDON, V452, pP342; OLEA RS, 1991, J MEMBRANE BIOL, V121, P1, DOI 10.1007/BF01870646; SARKADI B, 1991, BIOCHIM BIOPHYS ACTA, V1071, P407, DOI 10.1016/0304-4157(91)90005-H; SCHOUSBOE A, 1991, J NEUROSCI RES, V30, P661, DOI 10.1002/jnr.490300409; SIEBENS AW, 1989, AM J PHYSIOL, V257, pF937, DOI 10.1152/ajprenal.1989.257.6.F937; STEIN WD, 1986, TRANSPORT DIFFUSION, P113; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0	24	193	194	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23475	23478						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385424				2022-12-25	WOS:A1992JZ23900011
J	SACCHETTINI, JC; SCAPIN, G; GOPAUL, D; GORDON, JI				SACCHETTINI, JC; SCAPIN, G; GOPAUL, D; GORDON, JI			REFINEMENT OF THE STRUCTURE OF ESCHERICHIA-COLI-DERIVED RAT INTESTINAL FATTY-ACID BINDING-PROTEIN WITH BOUND OLEATE TO 1.75-ANGSTROM RESOLUTION - CORRELATION WITH THE STRUCTURES OF THE APOPROTEIN AND THE PROTEIN WITH BOUND PALMITATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; HORMONE FUSION GENES; TRANSGENIC MICE; EXPRESSION; DIFFERENTIATION; PURIFICATION; EPITHELIUM; RETINOL; MODEL	The structure of rat intestinal fatty acid binding protein (1-FABP) with bound oleate (C18:1) has been refined with x-ray diffraction data to a resolution of 1.75 angstrom. The protein contains 10 anti-parallel, beta strands composed of 99 residues and 2 short helices of 14 residues. Oleate is located in the interior of the protein in a bent conformation with C1-C12 more ordered than C13-C18. Two of the eight ordered waters in I-FABP:oleate are part of a hydrogen bond network that includes the carboxylate of oleate, the guanidinium group of Arg106, the nitrogen of the indole group of Trp82 , and the side chain of Gln115. Most of the methylenes of bound oleate reside in a crevice formed by hydrophobic and aromatic side chains. Tyr70 and Tyr117 envelop the acyl chain from C3 to C8 forming contacts with both the convex and concave faces of its van der Waals surface. The hydroxyls of each phenolic side chain hydrogen bond to ordered water molecules. Two ordered waters make van der Waals contact with the concave face of the bound fatty acid. The omega-terminal methyl of oleate is oriented so that it points toward the center of the benzene of Phe55 allowing it to form van der Waals interactions with its component methylenes. Comparison of the structure of I-FABP:oleate with a recently refined 1.19-angstrom model of apoI-FABP and an earlier 2.0-angstrom model of I-FABP:palmitate revealed a remarkable degree of similarity in the positions of their main chain and side chain atoms and in the conformations of the bound oleate and palmitate. The principal differences were confined to a few discrete regions of the protein. The helical domain, the type I turn between beta strands C and D, and the ring of Phe55 together form a solvent-accessible portal to the interior of the protein. They are repositioned in I-FABP:oleate (and I-FABP:palmitate) so that the binding cavity is even more accessible to solvent and its volume is increased. The side chain of Phe55 which shows discrete disorder in the apoprotein functions as an omega-terminal "sensing device": moving progressively outward toward the surface as the chain length of the bound fatty acid increases by 2 methylenes. Tyr70 and Tyr117 which also show discrete disorder in the apoprotein structure due to rotation around their C(alpha)-C(beta) bonds, are stabilized in a single, well ordered position in the holoproteins. ApoI-FABP contains 24 waters, eight of which occupy positions virtually identical to those occupied by the eight internal waters of I-FABP oleate. The positions occupied by five of the 16 remaining waters in apoI-FABP correspond to those occupied by several methylenes of bound oleate. Together, these observations suggest that I-FABP may function as a molecular water pump, using (i) feeble forces (van der Waals contacts and hydrogen bonds) rather than prominent conformational adjustments to bind a fatty acid through interactions with ordered solvent and (ii) movement of ordered solvent to perhaps drive the binding mechanism.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL)	SACCHETTINI, JC (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461, USA.			GOPAUL, Deshmukh/0000-0003-1631-3303	NIDDK NIH HHS [DK30292] Funding Source: Medline; NIGMS NIH HHS [GM45859] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030292, R01DK030292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045859] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, XPLOR VERSION 2 1 MA; CHENG L, 1991, J BIOL CHEM, V266, P24404; CISTOLA DP, 1989, J BIOL CHEM, V264, P2700; GREEN RP, 1992, DNA CELL BIOL, V11, P31, DOI 10.1089/dna.1992.11.31; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI E, 1991, J BIOL CHEM, V266, P3622; LI E, 1990, J BIOL CHEM, V265, P11549; LOCKE BC, 1992, IN PRESS BIOCHEMISTR; LOWE JB, 1987, J BIOL CHEM, V262, P5931; MATARESE V, 1988, J BIOL CHEM, V263, P14544; MATARESE V, 1990, PROG LIPID RES, V28, P245; MILNERWHITE EJ, 1987, BIOCHIM BIOPHYS ACTA, V911, P261, DOI 10.1016/0167-4838(87)90017-3; NEMECZ G, 1991, J BIOL CHEM, V266, P17112; NEMECZ G, 1991, ARCH BIOCHEM BIOPHYS, V286, P300, DOI 10.1016/0003-9861(91)90044-J; NEMECZ G, 1991, J BIOL CHEM, V266, P17180; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROPSON IJ, 1990, BIOCHEMISTRY-US, V29, P9591, DOI 10.1021/bi00493a013; RUBIN DC, 1989, P NATL ACAD SCI USA, V86, P1278, DOI 10.1073/pnas.86.4.1278; RUBIN DC, 1991, J CELL BIOL, V113, P1183, DOI 10.1083/jcb.113.5.1183; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1989, P NATL ACAD SCI USA, V86, P7736, DOI 10.1073/pnas.86.20.7736; SACCHETTINI JC, 1990, MOL CELL BIOCHEM, V98, P81; SACCHETTINI JC, 1990, J BIOL CHEM, V265, P19199; SALEMME FR, 1985, METHOD ENZYMOL, V114, P140; SCAPIN G, 1992, J BIOL CHEM, V267, P4253; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SMITH JL, 1988, ACTA CRYSTALLOGR A, V44, P357, DOI 10.1107/S0108767388000303; STORCH J, 1989, J BIOL CHEM, V264, P8708; SUZUKI T, 1988, J HISTOCHEM CYTOCHEM, V36, P349, DOI 10.1177/36.4.3346538; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; SWEETSER DA, 1988, P NATL ACAD SCI USA, V85, P9611, DOI 10.1073/pnas.85.24.9611; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VINCENT SH, 1985, J BIOL CHEM, V260, P4521; XU ZH, 1992, BIOCHEMISTRY-US, V31, P3484, DOI 10.1021/bi00128a024; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; ZANOTTI G, 1992, J BIOL CHEM, V267, P18541	41	99	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23534	23545						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429698				2022-12-25	WOS:A1992JZ23900021
J	TOESCU, EC; ONEILL, SC; PETERSEN, OH; EISNER, DA				TOESCU, EC; ONEILL, SC; PETERSEN, OH; EISNER, DA			CAFFEINE INHIBITS THE AGONIST-EVOKED CYTOSOLIC CA2+ SIGNAL IN MOUSE PANCREATIC ACINAR-CELLS BY BLOCKING INOSITOL TRISPHOSPHATE PRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CALCIUM-RELEASE; SARCOPLASMIC-RETICULUM; CARDIAC-CELLS; OSCILLATIONS; CHANNELS; ACTIVATION; 1,4,5-TRISPHOSPHATE; MOBILIZATION; FLUCTUATIONS; CONTRACTION	The inhibitory effects of caffeine on receptor-activated cytosolic Ca2+ signal generation in isolated mouse pancreatic acinar cells were investigated. Using the ability of caffeine to quench Indo-1 fluorescence we measured simultaneously the free intracellular Ca2+ concentration ([Ca2+]i) and the intracellular caffeine concentration ([caffeine]i). We also measured inositol 1,4,5-trisphosphate (InsP3) production with a radioreceptor assay. When caffeine was added to the extracellular solution during a sustained receptor-activated increase in [Ca2+]i, [caffeine]i rose to its steady level within a few seconds. This was accompanied by a decrease of [Ca2+]i, which started only after [caffeine]i had reached an apparent threshold concentration (about 2 mM in the case of 0.5 muM acetylcholine (ACh) stimulation). Above this [caffeine]i level there was a linear relationship between [caffeine]i and [Ca2+]i. Throughout the caffeine exposure [Ca2+]i remained at a steady low level. Following removal of caffeine from the bath, [caffeine]i decreased to zero within seconds. There was no significant increase in [Ca2+]i until [caffeine]i had been reduced to the threshold level (about 2 mM at 0.5 muM ACh). Caffeine inhibited Ca2+ signals evoked by ACh, cholecystokinin, and ATP and also inhibited signals generated in the absence of external Ca2+. Caffeine application had the same effect as removal of agonist allowing recovery from apparent desensitization. Caffeine inhibited the agonist-evoked production of InsP3 in a dose-dependent manner. Our results demonstrate the acute and reversible dose-dependent inhibition of agonist-evoked cytosolic Ca2+ signal generation due to rapid intracellular caffeine accumulation and washout. The inhibition can be explained by the reduction of agonist-evoked InsP3 production.	UNIV LIVERPOOL,PHYSIOL LAB,MRC,SECRETORY CONTROL RES GRP,POB 147,CROWN ST,LIVERPOOL L69 3BX,ENGLAND; UNIV LIVERPOOL,DEPT VET PRECLIN SCI,LIVERPOOL L69 3BX,ENGLAND	University of Liverpool; University of Liverpool			Petersen, Ole H/E-8708-2010; Eisner, David/A-6596-2008	Eisner, David/0000-0002-7002-3748; Petersen, Ole/0000-0002-6998-0380	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1991, P ROY SOC B-BIOL SCI, V244, P57, DOI 10.1098/rspb.1991.0051; BEUCKELMANN DJ, 1988, J PHYSIOL-LONDON, V405, P233, DOI 10.1113/jphysiol.1988.sp017331; DEHLINGERKREMER M, 1991, J MEMBRANE BIOL, V119, P85, DOI 10.1007/BF01868543; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FOSKETT JK, 1991, J BIOL CHEM, V266, P1435; FRIEL DD, 1992, NEURON, V8, P1109, DOI 10.1016/0896-6273(92)90132-W; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LIPSCOMBE D, 1988, NEURON, V1, P355, DOI 10.1016/0896-6273(88)90185-7; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; ONEILL SC, 1990, J PHYSIOL-LONDON, V430, P519, DOI 10.1113/jphysiol.1990.sp018305; ONEILL SC, 1990, J PHYSIOL-LONDON, V425, P55, DOI 10.1113/jphysiol.1990.sp018092; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; OTUN H, 1991, EXP PHYSIOL, V76, P811, DOI 10.1113/expphysiol.1991.sp003547; PARKER I, 1991, J PHYSIOL-LONDON, V433, P229, DOI 10.1113/jphysiol.1991.sp018423; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; ROUSSEAU E, 1989, AM J PHYSIOL, V256, pH2; ROWLEY WH, 1990, AM J PHYSIOL, V259, pG655, DOI 10.1152/ajpgi.1990.259.4.G655; SITSAPESAN R, 1990, J PHYSIOL-LONDON, V423, P425, DOI 10.1113/jphysiol.1990.sp018031; SMITH GL, 1988, J GEN PHYSIOL, V92, P351, DOI 10.1085/jgp.92.3.351; SUMIMOTO K, 1986, PFLUG ARCH EUR J PHY, V406, P173, DOI 10.1007/BF00586679; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; VALDEOLMILLOS M, 1989, PFLUG ARCH EUR J PHY, V413, P676, DOI 10.1007/BF00581820; WAKUI M, 1991, J MEMBRANE BIOL, V124, P179, DOI 10.1007/BF01870462; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; YULE DI, 1988, FEBS LETT, V239, P358, DOI 10.1016/0014-5793(88)80951-7	31	128	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23467	23470						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429689				2022-12-25	WOS:A1992JZ23900009
J	WISPE, JR; WARNER, BB; CLARK, JC; DEY, CR; NEUMAN, J; GLASSER, SW; CRAPO, JD; CHANG, LY; WHITSETT, JA				WISPE, JR; WARNER, BB; CLARK, JC; DEY, CR; NEUMAN, J; GLASSER, SW; CRAPO, JD; CHANG, LY; WHITSETT, JA			HUMAN MN-SUPEROXIDE DISMUTASE IN PULMONARY EPITHELIAL-CELLS OF TRANSGENIC MICE CONFERS PROTECTION FROM OXYGEN INJURY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; RAT LUNGS; TOXICITY; EXPRESSION; HYPEROXIA; GENE	To test directly whether mitochondrial Mn-superoxide dismutase (Mn-SOD) protects the lung epithelium from oxygen-induced injury, transgenic mice were produced in which the expression of human Mn-SOD mRNA was directed by transcriptional elements from the human pulmonary surfactant protein C gene. Human Mn-SOD mRNA was expressed in a lung-specific manner, and increased Mn-SOD protein was detected within mitochondria of alveolar Type II and nonciliated bronchiolar cells of the distal respiratory epithelium of the transgenic mice. The activity of Mn-SOD, but not catalase, CuZn-SOD, or glutathione peroxidase, was increased in lungs of transgenic mice. Transgenic mice were highly protected from lung injury during exposure to 95% oxygen, surviving significantly longer than nontransgenic littermates. Pulmonary pathology demonstrated decreased hemorrhage, hyaline membrane formation, and alveolar and interstitial edema in transgenic animals. The finding that increased Mn-SOD in distal respiratory epithelial cells confers protection from oxygen injury provides a basis for novel therapies to protect lung from injury during oxygen therapy of acute and chronic lung diseases.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	Duke University	WISPE, JR (corresponding author), CHILDRENS HOSP RES FDN,MED CTR,DIV PULM BIOL,ELLAND & BETHESDA AVE,CINCINNATI,OH 45229, USA.				NHLBI NIH HHS [HL 39605, HL 41496, HL 42609] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496, R01HL042609, R01HL039605] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; CHANG LY, 1988, J CELL BIOL, V107, P2169, DOI 10.1083/jcb.107.6.2169; Claiborne A., 1985, CRC HDB METHODS OXYG, P283; CLARK JM, 1971, PHARMACOL REV, V23, P37; CRAPO JD, 1980, AM REV RESPIR DIS, V122, P123; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; FREEMAN BA, 1981, J BIOL CHEM, V256, P986; FRIDOVICH I, 1975, ANNU REV BIOCHEM, V44, P147, DOI 10.1146/annurev.bi.44.070175.001051; GERSCHMAN R, 1954, SCIENCE, V119, P623, DOI 10.1126/science.119.3097.623; GLASSER SW, 1990, J BIOL CHEM, V265, P21986; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HARRIS JB, 1991, AM J RESP CELL MOL, V4, P115, DOI 10.1165/ajrcmb/4.2.115; HYSLOP PA, 1988, J BIOL CHEM, V263, P1665; KAUR S, 1989, DEVELOPMENT, V105, P613; KAWANAMI O, 1982, LAB INVEST, V46, P39; KORFHAGEN TR, 1990, P NATL ACAD SCI USA, V87, P6122, DOI 10.1073/pnas.87.16.6122; KRALL J, 1988, J BIOL CHEM, V263, P1910; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASON RJ, 1991, LUNG SCI F, V1, P235; MASSARO D, 1978, FED PROC, V37, P2485; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Newman GR, 1984, IMMUNOLABELLING ELEC, P53; SCHNEEBERGER E, 1991, LUNG SCI F, V1, P205; SCHOONEN WGEJ, 1990, J BIOL CHEM, V265, P11118; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; TSAN MF, 1990, J APPL PHYSIOL, V68, P1211, DOI 10.1152/jappl.1990.68.3.1211; TURRENS JF, 1986, ARCH BIOCHEM BIOPHYS, V246, P501; WARNER BB, 1991, AM J PHYSIOL, V260, pL296, DOI 10.1152/ajplung.1991.260.4.L296; WEAVER TE, 1988, GEN PHARMACOL, V19, P361, DOI 10.1016/0306-3623(88)90029-8; WHITE CW, 1987, J CLIN INVEST, V79, P1868, DOI 10.1172/JCI113029; WHITE CW, 1991, J CLIN INVEST, V87, P2162, DOI 10.1172/JCI115249; WISPE JR, 1987, CLIN PERINATOL, V14, P651, DOI 10.1016/S0095-5108(18)30755-3; WISPE JR, 1989, BIOCHIM BIOPHYS ACTA, V994, P30, DOI 10.1016/0167-4838(89)90058-7; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6	35	286	291	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23937	23941						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385428				2022-12-25	WOS:A1992JZ23900076
J	BREIMAN, A; FAWCETT, TW; GHIRARDI, ML; MATTOO, AK				BREIMAN, A; FAWCETT, TW; GHIRARDI, ML; MATTOO, AK			PLANT ORGANELLES CONTAIN DISTINCT PEPTIDYLPROLYL CIS, TRANS-ISOMERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CIS-TRANS-ISOMERASE; CYTOSOLIC BINDING-PROTEIN; ESCHERICHIA-COLI; CYCLOSPORIN-A; CYCLOPHILIN; MEMBRANE; LIGANDS; LIVER	Peptidylprolyl cis,trans-isomerase (PPIase) activity was detected in the cytosol, mitochondria, and chloroplast of pea plants. Cyclosporin A inhibited the activity largely localized to the mitochondrial matrix while rapamycin inhibited the PPIase activity associated with the mitochondrial membranes. Differential inhibition hy the two immunosuppressive drugs, the specific binding of these drugs to different mitochondrial fractions, and the immunological detection of a putative 25-kDa rapamycin-binding protein (RBP) in mitochondrial extracts attests to the presence in plant mitochondria of both cyclophilin and RBP classes of PPIases. Cyclosporin A-sensitive PPIase detected in the chloroplast was mostly localized to the thylakoids, which is suggestive of its function in the folding of membranal proteins. PPIase associated with the chloroplast stroma and the thylakoids was not inhibited by rapamycin nor was any cross-reactive RBP detected in chloroplast extracts. These results demonstrate the presence of distinct classes of PPIases in the mitochondria and the chloroplasts of plants.	USDA ARS,BELTSVILLE AGR RES CTR,PSI,PLANT MOLEC BIOL LAB,BARC W,BLDG 006,RM 118,BELTSVILLE,MD 20705	United States Department of Agriculture (USDA)			Mattoo, Autar/G-9863-2011; Mattoo, Autar/U-9751-2019	Mattoo, Autar/0000-0001-9226-7164				ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BARTLETT SG, 1982, METHODS CHLOROPLAST, P985; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREIMAN A, 1987, THEOR APPL GENET, V73, P563, DOI 10.1007/BF00289195; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CALLAHAN FE, 1989, PLANT PHYSIOL, V91, P629, DOI 10.1104/pp.91.2.629; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; ELLIS RJ, 1991, PLANT J, V1, P9, DOI 10.1111/j.1365-313X.1991.00009.x; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GALAT A, 1992, BIOCHEMISTRY-US, V31, P2427, DOI 10.1021/bi00123a031; GASSER CS, 1990, P NATL ACAD SCI USA, V87, P9519, DOI 10.1073/pnas.87.24.9519; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HACK E, 1991, PLANT PHYSIOL, V95, P561; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V342, P755; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HULTSCH T, 1991, P NATL ACAD SCI USA, V88, P6229, DOI 10.1073/pnas.88.14.6229; KOLETSKY AJ, 1986, J IMMUNOL, V137, P1054; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; MARDER JB, 1986, METHOD ENZYMOL, V118, P384; MATTOO AK, 1987, P NATL ACAD SCI USA, V84, P1497, DOI 10.1073/pnas.84.6.1497; SCHONBRUNNER ER, 1991, J BIOL CHEM, V266, P3630; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; TROPSCHUG M, 1988, J BIOL CHEM, V263, P14433; WIERDERRECT G, 1992, BIOCHEM BIOPH RES CO, V185, P298	33	87	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21293	21296						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400439				2022-12-25	WOS:A1992JV01100006
J	GUM, JR; HICKS, JW; TORIBARA, NW; ROTHE, EM; LAGACE, RE; KIM, YS				GUM, JR; HICKS, JW; TORIBARA, NW; ROTHE, EM; LAGACE, RE; KIM, YS			THE HUMAN MUC2 INTESTINAL MUCIN HAS CYSTEINE-RICH SUBDOMAINS LOCATED BOTH UPSTREAM AND DOWNSTREAM OF ITS CENTRAL REPETITIVE REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CDNA SEQUENCES; VONWILLEBRAND-FACTOR; GENE LOCUS; PROTEIN; GLYCOPROTEINS; DOMAINS; POLYMORPHISM; CONFORMATION; CONSERVATION	The human MUC2 mucin is a large secretory glycoconjugate that coats the epithelia of the intestines, airways, and other mucus membrane-containing organs. Previous work has shown that this mucin contains an extended tandem repeat-containing domain rich in Thr and Pro. In the present work we describe two additional regions of this mucin located both upstream and downstream of the tandem repeat array. The carboxyl-terminal domain contains 984 residues and can be divided into mucin-like (139 residues) and cysteine-rich (845 residues) subdomains. This latter subdomain exhibits varying degrees of sequence similarity to a wide range of mucins and mucin-like proteins including those isolated from rats, pigs, cows, and frogs. We also report here the sequence of 1270 residues lying immediately upstream of the tandem repeats. This region contains a repetitive, mucin-like subdomain and a second cysteine-rich stretch of more than 700 residues. Both cysteine-rich subdomains of this mucin have sequence similarity with von Willebrand factor, a serum protein that exists as a disulfide-linked polymer. This suggests that these cysteine-rich subdomains are important in the catenation of mucin monomers into oligomers, the structures that confer viscoelasticity upon mucus.	UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94121 USA	University of California System; University of California San Francisco	GUM, JR (corresponding author), DEPT VET AFFAIRS MED CTR, GASTROINTESTINAL RES LAB 151M2, SAN FRANCISCO, CA 94121 USA.							Allen A., 1981, PHYSL GASTROINTESTIN, P617; AUBERT JP, 1991, AM J RESP CELL MOL, V5, P178, DOI 10.1165/ajrcmb/5.2.178; BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; BYRD JC, 1988, CANCER RES, V48, P6678; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CONG NV, 1990, HUM GENET, V86, P167; DEKKER J, 1991, BIOCHEM J, V279, P251, DOI 10.1042/bj2790251; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; FORSYTHE KH, 1989, TRANSPORT Q, V43, P259; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FROHMAN MA, 1990, P NATL ACAD SCI USA, V5, P11; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GREEN F, 1987, GENE, V57, P101, DOI 10.1016/0378-1119(87)90181-8; GRIFFITHS B, 1990, ANN HUM GENET, V54, P277, DOI 10.1111/j.1469-1809.1990.tb00383.x; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1991, J BIOL CHEM, V266, P22733; HARDING SE, 1989, ADV CARBOHYD CHEM BI, V47, P345; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOYER LW, 1981, BLOOD, V58, P1; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; LAN MS, 1990, J BIOL CHEM, V265, P15294; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MANTLE M, 1981, BIOCHEM J, V195, P277, DOI 10.1042/bj1950277; Neutra M.R., 1987, PHYSL GASTROINTESTIN, V2, P975; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; PROBST JC, 1990, BIOCHEMISTRY-US, V29, P6240, DOI 10.1021/bi00478a018; ROBERTON AM, 1989, BIOCHEM J, V261, P637, DOI 10.1042/bj2610637; SADLER JE, 1985, P NATL ACAD SCI USA, V82, P6394, DOI 10.1073/pnas.82.19.6394; SHEEHAN JK, 1991, BIOCHEM J, V274, P293, DOI 10.1042/bj2740293; SHELTONINLOES BB, 1986, BIOCHEMISTRY-US, V25, P3164, DOI 10.1021/bi00359a014; SHOGREN RL, 1986, BIOPOLYMERS, V25, P1505, DOI 10.1002/bip.360250809; SIMPSON D, 1988, BIOCHEM BIOPH RES CO, V151, P487, DOI 10.1016/0006-291X(88)90619-5; SPICER AP, 1991, J BIOL CHEM, V266, P15099; SWALLOW DM, 1987, ANN HUM GENET, V51, P289, DOI 10.1111/j.1469-1809.1987.tb01063.x; THORNTON DJ, 1990, BIOCHEM J, V265, P179, DOI 10.1042/bj2650179; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; TORIBARA NW, 1991, J CLIN INVEST, V88, P1005, DOI 10.1172/JCI115360; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VOS HL, 1991, BIOCHEM BIOPH RES CO, V181, P121, DOI 10.1016/S0006-291X(05)81390-7; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; XU G, 1992, BIOCHEM BIOPH RES CO, V183, P821, DOI 10.1016/0006-291X(92)90557-2; XU GQ, 1992, J BIOL CHEM, V267, P5401	46	250	256	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21375	21383						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400449				2022-12-25	WOS:A1992JV01100021
J	WIEDERRECHT, G; HUNG, S; CHAN, HK; MARCY, A; MARTIN, M; CALAYCAY, J; BOULTON, D; SIGAL, N; KINCAID, RL; SIEKIERKA, JJ				WIEDERRECHT, G; HUNG, S; CHAN, HK; MARCY, A; MARTIN, M; CALAYCAY, J; BOULTON, D; SIGAL, N; KINCAID, RL; SIEKIERKA, JJ			CHARACTERIZATION OF HIGH-MOLECULAR-WEIGHT FK-506 BINDING ACTIVITIES REVEALS A NOVEL FK-506-BINDING PROTEIN AS WELL AS A PROTEIN COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS ISOMERASE; PEPTIDYL-PROLYL ISOMERASE; T-CELL ACTIVATION; CYCLOSPORINE-A; IMMUNOSUPPRESSANT FK506; CALMODULIN-BINDING; LIMITED PROTEOLYSIS; MACROLIDES FK-506; CYCLOPHILIN; DISTINCT	The immunoregulant FK-506 potently inhibits particular calcium-associated signal transduction events that occur early during T-lymphocyte activation and during IgE receptor-mediated exocytosis in mast cells. FK-506 binds to a growing family of receptors termed FK-506-binding proteins (FKBPs), the most abundant being a 12-kDa cytosolic receptor, FKBP12. To date, there is no formal evidence proving that FKBP12 is the sole receptor mediating the immunosuppressive effects or toxic side effects of FK-506. Using gel filtration chromatography as an assay for novel FK-506-binding proteins, we identified FK-506 binding activities in extracts prepared from calf brain and from JURKAT cells. Both of these new activities comigrated with apparent molecular masses of 1 10 kDa. However, further characterization of both binding activities revealed that the two are not identical. The 110-kDa activity observed in brain extracts appears to be the FKBP12.FK-506.calcineurin (CaN) complex previously reported (Liu, J., Farmer, J., Lane, W., Friedman, J., Weissman, I., and Schreiber, S. (1991) Cell 66, 807-815) while the 110 kDa activity observed in JURKAT cells is a novel FK-506-binding protein. Our characterization of the FKBP12.FK-506.CaN complex reveals a dependence upon calmodulin (CaM) for formation of the complex and demonstrates that the peptidyl-prolyl cis-trans isomerase (PPIase) activity of FKBP12 is not required for binding of FKBP12.FK-506 to CaN or for inhibition of CaN phosphatase activity. The novel FK-506-binding protein in JURKAT cells has been purified to homogeneity, migrates with an apparent mass of 51 kDa on denaturing gels, and has been termed FKBP51. Like FKBP12, FKBP51 has PPIase activity, but, unlike FKBP12.FK-506, FKBP51.FK-506 does not complex with or inhibit the phosphatase activity of, CaN. These results indicate that complex formation with CaN may not be a general property of the FKBPs. Peptide sequencing reveals that FKBP51 may be similar, if not identical, to hsp56, a component of non-transformed steroid receptors.	MERCK SHARP & DOHME LTD,DEPT IMMUNOL RES,POB 2000,R80W-107,RAHWAY,NJ 07065; MERCK SHARP & DOHME LTD,DEPT BIOPHYS CHEM,RAHWAY,NJ 07065; MERCK SHARP & DOHME LTD,DEPT BIOCHEM & MOLEC PATHOL,RAHWAY,NJ 07065; NIAAA,MOLEC & CELLULAR NEUROBIOL,IMMUNOL SECT,ROCKVILLE,MD 20852	Merck & Company; Merck & Company; Merck & Company; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)								ALTSCHUH D, 1992, SCIENCE, V256, P92, DOI 10.1126/science.1566062; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FORREST MJ, 1991, BIOCHEM PHARMACOL, V42, P1221, DOI 10.1016/0006-2952(91)90257-6; FRETZ H, 1991, J AM CHEM SOC, V113, P1409, DOI 10.1021/ja00004a051; GALAT A, 1992, BIOCHEMISTRY-US, V31, P2427, DOI 10.1021/bi00123a031; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUBBARD MJ, 1987, J BIOL CHEM, V262, P15062; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; HULTSCH T, 1991, P NATL ACAD SCI USA, V88, P6229, DOI 10.1073/pnas.88.14.6229; ITOH N, 1987, J BIOL CHEM, V262, P3132; JIN YJ, 1991, P NATL ACAD SCI USA, V88, P6677, DOI 10.1073/pnas.88.15.6677; JORGENSEN WL, 1991, SCIENCE, V254, P954, DOI 10.1126/science.1719636; KINCAID RL, 1987, NATURE, V330, P176, DOI 10.1038/330176a0; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; MARONE G, 1988, RES CLIN LAB, V18, P53, DOI 10.1007/BF02918819; MARTIN FH, 1985, NUCLEIC ACIDS RES, V13, P8927, DOI 10.1093/nar/13.24.8927; OHARA K, 1990, TRANSPLANT P, V22, P83; RINGE D, 1991, NATURE, V351, P185, DOI 10.1038/351185a0; ROSEN M, 1991, SCIENCE, V248, P863; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIEKIERKA JJ, 1990, J BIOL CHEM, V265, P21011; SIEKIERKA JJ, 1989, J IMMUNOL, V143, P1580; STEWART AA, 1982, FEBS LETT, V137, P80, DOI 10.1016/0014-5793(82)80319-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TOCCI MJ, 1989, J IMMUNOL, V143, P718; VANBELLE H, 1981, CELL CALCIUM, V2, P483, DOI 10.1016/0143-4160(81)90007-5; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WALLACE RW, 1980, BIOCHEMISTRY-US, V19, P1831, DOI 10.1021/bi00550a016; WUTHRICH K, 1991, SCIENCE, V254, P953, DOI 10.1126/science.1948082; YEM AW, 1992, J BIOL CHEM, V267, P2868	44	107	111	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21753	21760						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1383226				2022-12-25	WOS:A1992JV01100077
J	YE, SQ; OLSON, LM; REARDON, CA; GETZ, GS				YE, SQ; OLSON, LM; REARDON, CA; GETZ, GS			HUMAN PLASMA-LIPOPROTEINS REGULATE APOLIPOPROTEIN-E SECRETION FROM A POST-GOLGI COMPARTMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; LOW-DENSITY LIPOPROTEINS; OVARIAN GRANULOSA-CELLS; BONE-MARROW; APO-E; BINDING; RAT; CHOLESTEROL; LIVER; METABOLISM	The molecular regulation of apolipoprotein E (apoE) synthesis and secretion is incompletely understood. In this study, we have examined the effect of human low density lipoprotein (LDL) on apoE mRNA and protein levels in HepG2 and other eukaryotic cells. Exposing HepG2 cells to LDL for times up to 4 h resulted in an increase in S-35-labeled apoE accumulation in the medium by 2.2-fold, relative to serum free controls (n = 10, p < 0.001), with no changes in apoE mRNA levels. Similar observations have been made in JeG-3 cells and Chinese hamster ovary cells stably transfected with human apoE cDNA constructs. These results indicate that the LDL effect operates at a post-transcriptional level. In pulse-chase experiments, the LDL effect on apoE accumulation in the media was observed when it was added only during the chase even in the presence of cycloheximide, indicating that LDL is functioning at a post-translational level. The use of brefeldin A (BFA), an agent that impedes protein transport from the endoplasmic reticulum to the Golgi apparatus, suggests that the LDL effect occurs in a post-Golgi compartment. The addition of protease inhibitors could not duplicate the effects of LDL on the apoE accumulation in the medium. ApoA-I accumulation in the medium of HepG2 cells, but not albumin, was also significantly increased by 1.9-fold (n = 5, p < 0.001).	UNIV CHICAGO,DEPT PATHOL,MC 3083,5841 S MARYLAND AVE,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Chicago; University of Chicago; University of Chicago					NHLBI NIH HHS [HL 15062] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL015062] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BLUE ML, 1983, P NATL ACAD SCI-BIOL, V80, P283, DOI 10.1073/pnas.80.1.283; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; DASHTI N, 1987, J LIPID RES, V28, P423; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DORY L, 1991, J LIPID RES, V32, P783; DRISCOLL DM, 1984, J LIPID RES, V25, P1368; DRISCOLL DM, 1985, J BIOL CHEM, V260, P9031; ERIKSON SK, 1986, J LIPID RES, V27, P875; GETZ GS, 1988, ARCH PATHOL LAB MED, V112, P1048; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRAIG WY, 1988, J BIOL CHEM, V263, P13880; HAY R, 1979, J LIPID RES, V20, P34; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HIWASA T, 1990, CARCINOGENESIS, V11, P75, DOI 10.1093/carcin/11.1.75; HUI DY, 1981, J BIOL CHEM, V256, P5646; HUSSAIN MM, 1989, J BIOL CHEM, V264, P9571; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; HUSSAIN MM, 1989, J BIOL CHEM, V264, P17931; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; INOUE S, 1991, J BIOL CHEM, V266, P13311; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KUSHWAHA RS, 1991, J LIPID RES, V32, P1929; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN CT, 1986, J CLIN INVEST, V78, P947, DOI 10.1172/JCI112685; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAZZONE T, 1987, J BIOL CHEM, V262, P11657; MAZZONE T, 1992, J BIOL CHEM, V267, P1081; MOKUNO H, 1990, GERONTOLOGY, V36, P42; NESS GC, 1991, J BIOL CHEM, V266, P14854; ORAM JF, 1980, J BIOL CHEM, V255, P475; ORCI L, 1991, CELL, V64, P1183; Sambrook J, 1989, MOL CLONING LABORATO; SEHAYEK E, 1991, J BIOL CHEM, V266, P18259; SHARKEY MF, 1990, J LIPID RES, V31, P2167; SHORE VG, 1973, BIOCHEMISTRY-US, V12, P502, DOI 10.1021/bi00727a022; TAM SP, 1986, SCIENCE, V234, P1234, DOI 10.1126/science.3022381; THUREN T, 1991, J BIOL CHEM, V266, P4853; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; WU AL, 1979, J BIOL CHEM, V254, P7316; WYNE KL, 1989, J BIOL CHEM, V264, P16530; WYNE KL, 1989, J BIOL CHEM, V264, P981; YAMADA N, 1986, P NATL ACAD SCI USA, V83, P3479, DOI 10.1073/pnas.83.10.3479	46	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21961	21966						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400506				2022-12-25	WOS:A1992JV01100107
J	SARASWAT, LD; PASTRALANDIS, SC; LOWEY, S				SARASWAT, LD; PASTRALANDIS, SC; LOWEY, S			MAPPING SINGLE CYSTEINE MUTANTS OF LIGHT CHAIN-2 IN CHICKEN SKELETAL MYOSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPY; MONOCLONAL-ANTIBODIES; MUSCLE-FIBERS; BINDING-SITES; SUBFRAGMENT-1; HEAD; ACANTHAMOEBA; ORIENTATION; CALMODULIN; POSITION	The NH2- and COOH-terminal regions of the regulatory light chain (LC2) have been mapped to the head/rod junction by immunoelectron microscopy, using monoclonal and anti-fluorescyl antibodies as probes. In order to map the entire length of the light chain, we have engineered and purified mutants that contain a single cysteine residue at positions 2, 73, 94, 126, or 155. The single cysteine residues were labeled with either 5-iodoacetamido fluorescein or N-ethylmaleimide-biotin. We observed that the reactivity of Cys126 is far greater than that of Cys155, confirming that cysteine 126 is the fast-reacting thiol in wild-type light chain. The labeled light chains were exchanged into myosin stripped of its native LC2 by immunoaffinity chromatography, and the reconstituted myosin was reacted with anti-fluorescein antibody or avidin prior to rotary shadowing for electron microscopy. The position of the antibody or avidin was found to be near the head/rod junction for all mutants. These mapping studies, together with our finding that cysteines widely separated in the primary sequence can form multiple disulfide bonds (Saraswat, L. D., and Lowey, S. (1991) J. Biol. Chem. 226, 19777-19785), support a model for LC2 as a flexible, globular molecule localized mainly in the vicinity of the head/rod junction of myosin.	WHEATON COLL,DEPT CHEM,NORTON,MA 02766		SARASWAT, LD (corresponding author), BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254, USA.				NIAMS NIH HHS [R37AR17350] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR017350] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALEXIS MN, 1978, BIOCHEMISTRY-US, V17, P2319, DOI 10.1021/bi00605a010; ARATA T, 1990, J MOL BIOL, V214, P471, DOI 10.1016/0022-2836(90)90194-Q; ATKINSON MAL, 1986, J BIOL CHEM, V261, P3382; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANTLER PD, 1989, J MOL BIOL, V207, P631, DOI 10.1016/0022-2836(89)90472-5; HAMBLY B, 1991, BIOPHYS J, V59, P127, DOI 10.1016/S0006-3495(91)82205-6; HAMMER JA, 1987, J CELL BIOL, V105, P913, DOI 10.1083/jcb.105.2.913; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; KATOH T, 1989, J CELL BIOL, V109, P1549, DOI 10.1083/jcb.109.4.1549; MCNALLY EM, 1991, J CELL BIOL, V113, P585, DOI 10.1083/jcb.113.3.585; MITCHELL EJ, 1989, J MOL BIOL, V208, P199, DOI 10.1016/0022-2836(89)90096-X; MITCHELL EJ, 1986, EUR J BIOCHEM, V161, P25, DOI 10.1111/j.1432-1033.1986.tb10120.x; ONISHI H, 1992, BIOCHEMISTRY-US, V31, P1201, DOI 10.1021/bi00119a033; PASTRALANDIS SC, 1986, J BIOL CHEM, V261, P4811; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; RAYMENT I, 1984, P NATL ACAD SCI-BIOL, V81, P4378; RIMM DL, 1989, J CELL BIOL, V108, P1783, DOI 10.1083/jcb.108.5.1783; Sambrook J, 1989, MOL CLONING LABORATO; SARASWAT LD, 1991, J BIOL CHEM, V266, P19777; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOKUNAGA M, 1987, J MOL BIOL, V194, P245, DOI 10.1016/0022-2836(87)90372-X; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WINKELMANN DA, 1983, CELL, V34, P295, DOI 10.1016/0092-8674(83)90160-5; WINKELMANN DA, 1986, J MOL BIOL, V188, P595, DOI 10.1016/S0022-2836(86)80009-2; YAMAMOTO K, 1980, J BIOCHEM, V87, P213, DOI 10.1093/oxfordjournals.jbchem.a132727; YAMAMOTO K, 1985, J MOL BIOL, V183, P287, DOI 10.1016/0022-2836(85)90222-0	26	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21112	21118						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400421				2022-12-25	WOS:A1992JT97800093
J	OREILLY, MA; GEISER, AG; KIM, SJ; BRUGGEMAN, LA; LUU, AX; ROBERTS, AB; SPORN, MB				OREILLY, MA; GEISER, AG; KIM, SJ; BRUGGEMAN, LA; LUU, AX; ROBERTS, AB; SPORN, MB			IDENTIFICATION OF AN ACTIVATING TRANSCRIPTION FACTOR (ATF) BINDING-SITE IN THE HUMAN TRANSFORMING GROWTH-FACTOR-BETA-2 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL SUPPRESSOR FACTOR; FACTOR-BETA; SEQUENCE-ANALYSIS; GENE-EXPRESSION; FUNCTIONAL-CHARACTERIZATION; AP-1 COMPLEX; CDNA CLONES; TGF BETA-1; PROTEIN; EMBRYOGENESIS	Transforming growth factor TGF-beta2 is encoded by multiple mRNA transcripts of 5.8, 5.1, 4.0, 3.8, and 2.8 kilobase pairs (kb) that are expressed in various human and monkey cells. Northern blot analysis using genomic fragments of DNA was used to demonstrate that some of this size heterogeneity is due to differences in the length of the 5'-untranslated region. Probes that were colinear with the first 600 nucleotides of the 5'-untranslated region detected only the 5.8-, 4.0-, and 3.8-kb transcripts. In order to identify DNA elements that regulate the transcription of these mRNA transcripts, deletion constructs of 5'-flanking DNA were ligated to the coding region for chloramphenicol acetyltransferase (CAT) and analyzed for promoter activity in several cell lines. Sequences responsible for putative enhancer and silencer regions were identified between -778 and -40 relative to the transcription initiation site. Addition of a cyclic AMP-responsive element/activating transcription factor-like element at -74 resulted in a 5-10-fold increase in CAT activity over that expressed with a construct that contained only the TATA box. This increase in CAT activity was suppressed by the addition of DNA sequences between -257 and -187, whereas sequences between -778 and -257 stimulated CAT activity. Point mutations within the ATF binding site at -74 resulted in a marked decrease in CAT expression. Cotransfection with ATF-1 or ATF-2 expression plasmids resulted in both dose-dependent stimulatory and inhibitory activities that were cell type-dependent. These studies identify multiple transcription initiation sites for TGF-beta2 and demonstrate that transcription from one of these promoters is dependent upon an ATF binding site located 5' of the TATA box.	NIDR,DEV BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	OREILLY, MA (corresponding author), NCI,CHEMOPREVENT LAB,BLDG 41,RM C629,BETHESDA,MD 20892, USA.							BENBROOK DM, 1990, ONCOGENE, V5, P295; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; BLANAR MA, 1992, SCIENCE, V256, P1013; BODMER S, 1989, J IMMUNOL, V143, P3222; BURT DW, 1991, J MOL ENDOCRINOL, V7, P175, DOI 10.1677/jme.0.0070175; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FLANDERS KC, 1991, DEVELOPMENT, V113, P183; FLINT KJ, 1991, ONCOGENE, V6, P2019; GATHERER D, 1990, DEVELOPMENT, V110, P445; GEISER AG, 1991, MOL CELL BIOL, V11, P84, DOI 10.1128/MCB.11.1.84; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HANKS SK, 1988, P NATL ACAD SCI USA, V85, P79, DOI 10.1073/pnas.85.1.79; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KIM SJ, 1989, J BIOL CHEM, V264, P402; LAFYATIS R, 1990, J BIOL CHEM, V265, P19128; MADISEN L, 1988, DNA-J MOLEC CELL BIO, V7, P1, DOI 10.1089/dna.1988.7.1; Madisen L, 1991, GROWTH FACTORS, V5, DOI 10.3109/08977199109000295; MALIPIERO U, 1990, BIOCHEM BIOPH RES CO, V171, P1145, DOI 10.1016/0006-291X(90)90804-V; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MILLAN FA, 1991, DEVELOPMENT, V111, P131; MILLER DA, 1989, MOL ENDOCRINOL, V3, P1108, DOI 10.1210/mend-3-7-1108; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Noma T, 1991, GROWTH FACTORS, V4, P247, DOI 10.3109/08977199109043910; PELTON RW, 1989, DEVELOPMENT, V106, P759; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SCHMID P, 1991, DEVELOPMENT, V111, P117; SEYEDIN SM, 1987, J BIOL CHEM, V262, P1946; TENDIJKE P, 1988, P NATL ACAD SCI USA, V85, P4715; WEBB NR, 1988, DNA-J MOLEC CELL BIO, V7, P493, DOI 10.1089/dna.1.1988.7.493; WRANN M, 1987, EMBO J, V6, P1633, DOI 10.1002/j.1460-2075.1987.tb02411.x	40	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19938	19943						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400310				2022-12-25	WOS:A1992JR85800033
J	POLLARD, TD; GOLDBERG, I; SCHWARZ, WH				POLLARD, TD; GOLDBERG, I; SCHWARZ, WH			NUCLEOTIDE EXCHANGE, STRUCTURE, AND MECHANICAL-PROPERTIES OF FILAMENTS ASSEMBLED FROM ATP-ACTIN AND ADP-ACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; MUSCLE ACTIN; POLYMERIZATION; HYDROLYSIS; PHOSPHATE; BINDING; DYNAMICS; GELSOLIN; KINETICS; IONS	Actin monomers with bound ATP, ADP, or fluorescent analogues of these nucleotides exchange the nucleotide on a second time scale, whereas filaments assembled from each of these species exchange their nucleotide with the solution at least 1,000 times slower than monomers. Filaments assembled from either ATP-actin or ADP-actin are indistinguishable by electron microscopy after negative staining. The dynamic elasticity and viscosity of filaments assembled from ATP-actin or ADP-actin or mixtures of these two species are the same over a wide range of frequencies. These observations do not support a recent suggestion (Janmey, P. A., Hvidt, S., Oster, G. F., Lamb, J., Stossel, T. P., and Hartwig, J. H. (1990) Nature 347, 95-99) that ATP hydrolysis within actin filaments stiffens the polymer and alters both their structure and affinity for nucleotides. The difference in observations between these two studies may be related to time-dependent changes in ADP-actin prepared in slightly different ways.	JOHNS HOPKINS UNIV,DEPT CHEM ENGN,BALTIMORE,MD 21218	Johns Hopkins University	POLLARD, TD (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,725 N WOLFE ST,BALTIMORE,MD 21205, USA.		Goldberg, Ilya/H-5307-2011	Goldberg, Ilya/0000-0001-8514-6110	NIGMS NIH HHS [GM-26338] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026338] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATO PA, 1986, J CELL BIOL, V102, P1074, DOI 10.1083/jcb.102.3.1074; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; CARLIER MF, 1987, J BIOL CHEM, V262, P3052; CARLIER MF, 1988, J BIOL CHEM, V263, P817; CARLIER MF, 1988, FEBS LETT, V235, P211, DOI 10.1016/0014-5793(88)81264-X; CARLIER MF, 1991, J BIOL CHEM, V266, P1; CARLIER MF, 1986, BIOCHEMISTRY-US, V25, P7789, DOI 10.1021/bi00372a001; COOPER JA, 1991, ANNU REV PHYSIOL, V53, P585, DOI 10.1146/annurev.ph.53.030191.003101; COOPER JA, 1982, METHOD ENZYMOL, V85, P182; COUE M, 1985, J BIOL CHEM, V260, P5033; DRENCKHAHN D, 1986, J BIOL CHEM, V261, P2754; DREWES G, 1991, J BIOL CHEM, V266, P5508; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; FRIEDEN C, 1988, BIOCHEMISTRY-US, V27, P3812, DOI 10.1021/bi00410a044; GERSHMAN LC, 1989, BIOCHIM BIOPHYS ACTA, V995, P109, DOI 10.1016/0167-4838(89)90068-X; GERSHMAN LC, 1986, BIOCHEM BIOPH RES CO, V135, P607, DOI 10.1016/0006-291X(86)90036-7; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; JANMEY PA, 1990, NATURE, V347, P95, DOI 10.1038/347095a0; JANMEY PA, 1988, BIOCHEMISTRY-US, V27, P8218, DOI 10.1021/bi00421a035; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KORN ED, 1987, SCIENCE, V238, P638, DOI 10.1126/science.3672117; KUEHL WM, 1969, J BIOL CHEM, V244, P4720; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MARTONOSI A, 1960, J BIOL CHEM, V235, P1700; NOWAK E, 1988, BIOCHEMISTRY-US, V27, P1785, DOI 10.1021/bi00405a060; ODONOGHUE SI, 1992, ARCH BIOCHEM BIOPHYS, V293, P110, DOI 10.1016/0003-9861(92)90372-4; OHM T, 1991, BIOCHEMISTRY-US, V30, P11193, DOI 10.1021/bi00111a001; Pollard TD, 1990, CURR OPIN CELL BIOL, V2, P33, DOI 10.1016/S0955-0674(05)80028-6; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; POLLARD TD, 1984, FEBS LETT, V170, P94, DOI 10.1016/0014-5793(84)81376-9; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; RICKARD JE, 1988, J MOL BIOL, V201, P675, DOI 10.1016/0022-2836(88)90466-4; SATO M, 1985, J BIOL CHEM, V260, P8585; STRAUB FB, 1950, BIOCHIM BIOPHYS ACTA, V4, P455, DOI 10.1016/0006-3002(50)90052-7; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; WAECHTER F, 1975, EUR J BIOCHEM, V57, P453, DOI 10.1111/j.1432-1033.1975.tb02320.x; WANG YL, 1981, P NATL ACAD SCI-BIOL, V78, P5503, DOI 10.1073/pnas.78.9.5503; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597; WANGER M, 1987, BIOCHIM BIOPHYS ACTA, V914, P105, DOI 10.1016/0167-4838(87)90052-5	39	83	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20339	20345						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400353				2022-12-25	WOS:A1992JR85800093
J	YEUNG, YG; BERG, KL; PIXLEY, FJ; ANGELETTI, RH; STANLEY, ER				YEUNG, YG; BERG, KL; PIXLEY, FJ; ANGELETTI, RH; STANLEY, ER			PROTEIN TYROSINE PHOSPHATASE-1C IS RAPIDLY PHOSPHORYLATED IN TYROSINE IN MACROPHAGES IN RESPONSE TO COLONY STIMULATING FACTOR-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GROWTH-FACTOR; FACTOR-I; POLYACRYLAMIDE GELS; KINASE-ACTIVITY; RECEPTOR; PRODUCT; CSF-1; INTERNALIZATION; IDENTIFICATION; ACTIVATION	An approximately 64-kDa cytoplasmic protein is rapidly phosphorylated in tyrosine in the response of macrophages to colony stimulating factor-1. To identify this protein, BAC1.2F5 macrophages were incubated with or without colony stimulating factor-1, the phosphotyrosine-containing portion of their cytosolic fractions subjected to size exclusion chromatography, and the 45-70-kDa fraction further fractionated by reverse phase high pressure liquid chromatography (RP-HPLC). Tryptic peptides of pooled RP-HPLC fractions from stimulated cells (containing the approximately 64-kDa protein and an approximately 54-kDa protein) and from unstimulated cells (containing the approximately 54-kDa protein alone), were sequenced directly. All seven readable sequences of 8 sequenceable peptides present uniquely in the stimulated fraction were present in the sequence of the src homology 2 domain-containing protein tyrosine phosphatase-1C (PTP-1C). The identity of the approximately 64-kDa protein was confirmed by Western blotting with an antibody raised to a PTP-1C peptide. The rapid, growth factor-induced tyrosine phosphorylation of PTP-1C suggests that it may be involved in very early events in growth factor signal transduction.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV BIOL & CANC,1300 MORRIS PK AVE,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine			Pixley, Fiona/ABD-5567-2020	Pixley, Fiona/0000-0002-1571-2532	NCI NIH HHS [P30-CA 1330, 2 T32 CA09173, CA 26504] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K04CA001330, R01CA026504, T32CA009173, R37CA026504] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baccarini M, 1991, Receptor, V1, P243; BACCARINI M, 1991, J BIOL CHEM, V266, P10941; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOWNING JR, 1988, MOL CELL BIOL, V8, P1795, DOI 10.1128/MCB.8.4.1795; GUILBERT LJ, 1980, J CELL BIOL, V85, P153, DOI 10.1083/jcb.85.1.153; HUHN RD, 1987, P NATL ACAD SCI USA, V84, P4408, DOI 10.1073/pnas.84.13.4408; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; LI W, 1991, J BIOL CHEM, V266, P6808; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PERRIMON N, 1985, GENETICS, V111, P23; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; RENLUND S, 1990, J CHROMATOGR, V512, P325, DOI 10.1016/S0021-9673(01)89499-1; RETTENMIER CW, 1985, SCIENCE, V228, P320, DOI 10.1126/science.2580348; SENGUPTA A, 1988, P NATL ACAD SCI USA, V85, P8062, DOI 10.1073/pnas.85.21.8062; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; STJOHNSTON D, 1992, CELL, V68, P201; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YEUNG YG, 1990, RECEPTOR PURIFICATIO, P315; YI T, 1992, BLOOD, V78, P2222; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836	26	123	125	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23447	23450						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385421				2022-12-25	WOS:A1992JZ23900004
J	BOGDAN, C; PAIK, J; VODOVOTZ, Y; NATHAN, C				BOGDAN, C; PAIK, J; VODOVOTZ, Y; NATHAN, C			CONTRASTING MECHANISMS FOR SUPPRESSION OF MACROPHAGE CYTOKINE RELEASE BY TRANSFORMING GROWTH-FACTOR-BETA AND INTERLEUKIN-10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MURINE PERITONEAL-MACROPHAGES; EXPERIMENTAL CUTANEOUS LEISHMANIASIS; PHENOL CHLOROFORM EXTRACTION; TOXIC TRANSMEMBRANE PROTEIN; WEHI-164 SUBCLONE-13 ASSAY; FACTOR-ALPHA PRODUCTION; SENSITIVE CELL-LINE; SINGLE-STEP METHOD; HUMAN-MONOCYTES	Transforming growth factor (TGF)-beta and interleukin (IL)-10 inhibited lipopolysaccharide (LPS)-induced macrophage production of the inflammatory cytokines tumor necrosis factor-alpha (TNF), IL-1alpha, and IL-1beta by contrasting post-transcriptional mechanisms. TGF-beta acted slowly and late, as it required 12-16 h to exert a suppressive effect, and inhibited TNF production even when added 6 h after LPS. TGF-beta affected neither the level of TNF mRNA, the release of preformed TNF nor the degradation of TNF. Thus, TGF-beta appeared to inhibit translation of TNF mRNA. IL-10 not only suppressed TNF release to a 25-fold greater extent than TGF-beta, but also inhibited release of IL-1. In contrast to TGF-beta, IL-10 acted on an early step in cytokine production, its effect being maximal 3 h after addition of LPS. Unlike TGF-beta, IL-10 markedly suppressed TNF, IL-1alpha, and IL-1beta mRNA levels. However, this was accomplished without suppressing transcription of the corresponding genes. Moreover, cycloheximide antagonized the IL-10-dependent reduction in cytokine mRNA levels. Thus, IL-10 may induce a ribonuclease active on cytokine transcripts or may induce a protein that enhances the susceptibility of TNF, IL-1alpha, and IL-1beta mRNAs to ribonucleolytic action. We conclude that IL-10 and TGF-beta induce different phenotypes of macrophage deactivation, and deactivate macrophages by different mechanisms: IL-10 promotes degradation of cytokine mRNA, while TGF-beta primarily suppresses translation.			BOGDAN, C (corresponding author), CORNELL UNIV, MED CTR,COLL MED,DEPT MED,DIV HEMATOL ONCOL, BEATRICE & SAMUEL A SEAVER LAB, BOX 57, NEW YORK, NY 10021 USA.			Bogdan, Christian/0000-0002-2300-0631	NATIONAL CANCER INSTITUTE [R01CA043610] Funding Source: NIH RePORTER; NCI NIH HHS [CA 43610] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACHWICH PR, 1986, BIOCHEM BIOPH RES CO, V136, P94, DOI 10.1016/0006-291X(86)90881-8; BEUTLER B, 1988, BIOCHEM BIOPH RES CO, V152, P973, DOI 10.1016/S0006-291X(88)80379-6; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; BOGDAN C, 1991, MONONUCLEAR PHAGOCYT; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHANTRY D, 1989, J IMMUNOL, V142, P4295; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLART MA, 1986, J EXP MED, V164, P2113, DOI 10.1084/jem.164.6.2113; DING A, 1990, J IMMUNOL, V145, P940; ESKANDARI MK, 1990, IMMUNOL INVEST, V19, P69, DOI 10.3109/08820139009042026; ESPEVIK T, 1987, J EXP MED, V166, P571, DOI 10.1084/jem.166.2.571; ESPEVIK T, 1986, J IMMUNOL METHODS, V95, P99, DOI 10.1016/0022-1759(86)90322-4; FAST DJ, 1989, INFECT IMMUN, V57, P291, DOI 10.1128/IAI.57.1.291-294.1989; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; GAZZINELLI RT, 1992, J IMMUNOL, V148, P1792; GILLIS S, 1978, J IMMUNOL, V120, P2027; GRAY PW, 1986, J IMMUNOL, V137, P3644; GREENBERG ME, 1991, CURRENT PROTOCOLS IM, V1; HALL BF, 1991, IMMUNOPARASITOL TOD, pA22; HOFFMAN MK, 1986, LYMPHOKINE RES, V5, P255; HOPKINS SJ, 1989, J IMMUNOL METHODS, V120, P271, DOI 10.1016/0022-1759(89)90252-4; KILLION JJ, 1990, CURR OPIN IMMUNOL, V2, P693, DOI 10.1016/0952-7915(90)90032-C; KOERNER TJ, 1987, CELL IMMUNOL, V109, P437, DOI 10.1016/0008-8749(87)90326-1; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; MALEFYT RD, 1991, J EXP MED, V174, P1209; MALEFYT RD, 1991, J EXP MED, V174, P915; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; McCartney-Francis N, 1990, GROWTH FACTORS, V4, DOI 10.3109/08977199009011007; MOSMANN TR, 1991, IMMUNOPARASITOL TOD, pA49; NATHAN CF, 1990, HDB EXPT PHARM, V95, P428; NELSON BJ, 1991, J IMMUNOL, V146, P1849; NELSON DS, 1981, AUST J EXP BIOL MED, V59, P229, DOI 10.1038/icb.1981.18; OGARRA A, 1990, INT IMMUNOL, V2, P821, DOI 10.1093/intimm/2.9.821; OHMORI Y, 1990, J IMMUNOL, V145, P3333; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SOMERS SD, 1986, J IMMUNOL, V136, P4199; SPRINGER T, 1991, CURRENT PROTOCOLS IM, V1; SRIMAL S, 1990, J EXP MED, V171, P1347, DOI 10.1084/jem.171.4.1347; STENGER S, 1991, EUR J IMMUNOL, V21, P1669, DOI 10.1002/eji.1830210713; THOMPSONSNIPES LA, 1991, J EXP MED, V173, P507, DOI 10.1084/jem.173.2.507; TREDE NS, 1991, J IMMUNOL, V146, P2310; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; WISEMAN DM, 1988, BIOCHEM BIOPH RES CO, V157, P793, DOI 10.1016/S0006-291X(88)80319-X	47	503	526	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23301	23308						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429677				2022-12-25	WOS:A1992JY16300091
J	DESAI, NN; ZHANG, H; OLIVERA, A; MATTIE, ME; SPIEGEL, S				DESAI, NN; ZHANG, H; OLIVERA, A; MATTIE, ME; SPIEGEL, S			SPHINGOSINE-1-PHOSPHATE, A METABOLITE OF SPHINGOSINE, INCREASES PHOSPHATIDIC-ACID LEVELS BY PHOSPHOLIPASE-D ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GROWTH-FACTOR RECEPTOR; LONG-CHAIN BASES; DIACYLGLYCEROL KINASE; SIGNAL TRANSDUCTION; CELLULAR PROLIFERATION; HUMAN-NEUTROPHILS; HUMAN-PLATELETS; HL-60 CELLS; 3T3 CELLS	Sphingosine and sphingosine-1-phosphate, metabolites of membrane sphingolipids, have recently been shown to stimulate release of calcium from internal sources and to increase proliferation of quiescent Swiss 3T3 fibroblasts (Zhang, H., Desai, N. N., Olivera, A., Seki, T., Brooker, G., and Spiegel, S. (1991) J. Cell Biol. 114, 155-167). The present study demonstrates that mitogenic concentrations of sphingosine induce early increases in sphingosine-1-phosphate levels which precede the increase in the potent mitogen, phosphatidic acid. Sphingosine-1-phosphate itself induces a more rapid increase in phosphatidic acid, thus suggesting that it may mediate the effects of sphingosine on phosphatidic acid accumulation. The concentration dependence for the formation of phosphatidic acid induced by sphingosine-1-phosphate correlates with its effect on DNA synthesis. Similar to sphingosine, sphingosine-1-phosphate also stimulates the activity of phospholipase D, although a significant effect is observed at a much lower concentration. However, in contrast to previous reports with sphingosine, sphingosine-1-phosphate does not inhibit the phosphatidic acid phosphohydrolase activity in cell homogenates. Thus, in addition to its effect on mobilization of calcium, sphingosine-1-phosphate can increase the level of phosphatidic acid, most likely via activation of phospholipase D. We suggest that sphingosine-1-phosphate mediates the effect of sphingosine on phosphatidic acid accumulation in Swiss 3T3 fibroblasts and may regulate cellular proliferation by affecting multiple transmembrane signaling pathways.	GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,357 BASIC SCI BLDG,3900 RESERVOIR RD NW,WASHINGTON,DC 20007	Georgetown University					NIGMS NIH HHS [1RO1 GM43880] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043880] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD RS, 1991, BIOCHEMISTRY-US, V30, P777; BAJJALIEH SM, 1989, J BIOL CHEM, V264, P14354; BENAV P, 1989, FEBS LETT, V259, P64, DOI 10.1016/0014-5793(89)81495-4; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; DAVIS RJ, 1988, J BIOL CHEM, V263, P5373; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; EXTON JH, 1990, J BIOL CHEM, V265, P1; FAUCHER M, 1988, J BIOL CHEM, V263, P5319; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P3138; JEFFERSON AB, 1988, J BIOL CHEM, V263, P15241; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; KISS Z, 1990, J BIOL CHEM, V265, P7345; KRISHNAMURTHI S, 1989, BIOCHIM BIOPHYS ACTA, V1010, P258, DOI 10.1016/0167-4889(89)90170-5; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; LAVIE Y, 1990, FEBS LETT, V277, P7, DOI 10.1016/0014-5793(90)80796-L; MACDONALD ML, 1988, J BIOL CHEM, V263, P1584; MAHADEVAPPA VG, 1988, BIOCHEM BIOPH RES CO, V153, P1097, DOI 10.1016/S0006-291X(88)81341-X; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; MOHR FC, 1990, AM J PHYSIOL, V258, pC217, DOI 10.1152/ajpcell.1990.258.2.C217; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MORRIS C, 1988, BIOCHEM BIOPH RES CO, V155, P561, DOI 10.1016/S0006-291X(88)80531-X; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; NUNN DL, 1987, BIOCHEM J, V243, P809, DOI 10.1042/bj2430809; PAI JK, 1988, J BIOL CHEM, V263, P12472; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SHUKLA SD, 1991, LIFE SCI, V48, P851, DOI 10.1016/0024-3205(91)90031-6; SPIEGEL S, 1989, J BIOL CHEM, V264, P16512; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P562, DOI 10.1515/bchm2.1973.354.1.562; STOFFEL W, 1970, H-S Z PHYSIOL CHEM, V351, P635, DOI 10.1515/bchm2.1970.351.1.635; Sweely CC, 1985, BIOCH LIPIDS MEMBRAN, P361; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P12502; VANVELDHOVEN PP, 1989, J LIPID RES, V30, P611; WILSON E, 1988, J BIOL CHEM, V263, P9304; WILSON E, 1986, J BIOL CHEM, V261, P2616; WINICOV I, 1988, J BIOL CHEM, V263, P12179; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; ZHANG H, 1990, J BIOL CHEM, V265, P21309	50	162	165	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23122	23128						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429659				2022-12-25	WOS:A1992JY16300065
J	HWANG, DS; KORNBERG, A				HWANG, DS; KORNBERG, A			OPENING OF THE REPLICATION ORIGIN OF ESCHERICHIA-COLI BY DNAA PROTEIN WITH PROTEIN HU OR IHF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; HISTONE-LIKE PROTEINS; CHROMOSOMAL ORIGIN; ENZYMATIC REPLICATION; INITIATION PROTEIN; AUTO-REGULATION; BINDING; INVITRO; GENE; SITES	Opening of the three tandem repeats of a 13-mer in the replication origin (oriC) of Escherichia coli is a prime event in the replication in vitro of minichromosomes (Bramhill, D., and Kornberg, A. (1988) Cell 54, 915-918). DnaA, the initiator protein, requires protein HU or IHF, along with a millimolar level of ATP and negative superhelical density in the plasmid to open this region. The extent of opening, as judged by cleavage by a single-strand-specific endonuclease (i.e. Pl nuclease), correlated closely with replication of the oriC plasmid. In an initial complex, preceding opening of the 13-mers, the footprint of DnaA protein bound by ATP covered its four 9-mer recognition sequences. The footprint of the nucleotide-free form of the protein, by contrast, was more extensive and thus, less specific.	STANFORD UNIV,MED CTR,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University								ATLUNG T, 1985, MOL GEN GENET, V200, P442, DOI 10.1007/BF00425729; BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; BONNEFOY E, 1991, EMBO J, V10, P687, DOI 10.1002/j.1460-2075.1991.tb07998.x; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BRAUN RE, 1985, CELL, V40, P159, DOI 10.1016/0092-8674(85)90319-8; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; DIXON NE, 1984, P NATL ACAD SCI-BIOL, V81, P424, DOI 10.1073/pnas.81.2.424; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FLASHNER Y, 1988, CELL, V54, P713, DOI 10.1016/S0092-8674(88)80016-3; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; GAMAS P, 1986, MOL GEN GENET, V204, P85, DOI 10.1007/BF00330192; GILLE H, 1991, EMBO J, V10, P1579, DOI 10.1002/j.1460-2075.1991.tb07678.x; HANSEN FG, 1991, J BACTERIOL, V173, P5194, DOI 10.1128/jb.173.16.5194-5199.1991; HANSEN FG, 1977, MOL GEN GENET, V155, P219, DOI 10.1007/BF00393163; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; HUISMAN O, 1989, J BACTERIOL, V171, P3704, DOI 10.1128/jb.171.7.3704-3712.1989; HWANG DS, 1992, J BIOL CHEM, V267, P23087; HWANG DS, 1990, CELL, V63, P325, DOI 10.1016/0092-8674(90)90165-B; HWANG DS, 1992, J BIOL CHEM, V267, P2209; HWANG DS, 1991, J BIOL CHEM, V266, P7537; HWNAG DS, 1990, J BIOL CHEM, V265, P19244; JOHNSON RC, 1986, CELL, V46, P531, DOI 10.1016/0092-8674(86)90878-0; KELLEY WL, 1991, J BIOL CHEM, V266, P15924; Kornberg A., 1992, DNA REPLICATION; LOBNEROLESEN A, 1989, CELL, V57, P881, DOI 10.1016/0092-8674(89)90802-7; MATSUI M, 1985, J MOL BIOL, V184, P529, DOI 10.1016/0022-2836(85)90299-2; MORISATO D, 1987, CELL, V51, P101, DOI 10.1016/0092-8674(87)90014-6; OGAWA T, 1985, P NATL ACAD SCI USA, V82, P3562, DOI 10.1073/pnas.82.11.3562; POLACZEK P, 1990, New Biologist, V2, P265; SAKAKIBARA Y, 1982, MOL GEN GENET, V186, P87, DOI 10.1007/BF00422917; SAMITT CE, 1989, EMBO J, V8, P989, DOI 10.1002/j.1460-2075.1989.tb03462.x; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SHAMBROOK J, 1989, MOL CLONING LABORATO; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; STENZEL TT, 1987, CELL, V49, P709, DOI 10.1016/0092-8674(87)90547-2; THONY B, 1991, P NATL ACAD SCI USA, V88, P4066, DOI 10.1073/pnas.88.10.4066; VONMEYENBURG K, 1987, CELLULAR MOL BIOL, V2, P1555; WADA M, 1988, J MOL BIOL, V204, P581, DOI 10.1016/0022-2836(88)90357-9; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202; YUNG BYM, 1989, J BIOL CHEM, V264, P6146; ZYSKIND JW, 1983, P NATL ACAD SCI-BIOL, V80, P1164, DOI 10.1073/pnas.80.5.1164	46	220	221	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23083	23086						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429655				2022-12-25	WOS:A1992JY16300059
J	YAN, RQ; RYCHLIK, W; ETCHISON, D; RHOADS, RE				YAN, RQ; RYCHLIK, W; ETCHISON, D; RHOADS, RE			AMINO-ACID-SEQUENCE OF THE HUMAN PROTEIN-SYNTHESIS INITIATION FACTOR-EIF-4-GAMMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING-PROTEIN; MESSENGER-RNA TRANSLATION; INFECTED HELA-CELLS; POLIOVIRUS RNA; FACTOR-III; SUBSTRATE-SPECIFICITY; 2A PROTEINASE; KINASE-C; COMPLEX; PHOSPHORYLATION	Eukaryotic protein synthesis initiation factor (eIF) 4gamma, also known as p220, is a component of the protein complex eIF-4, which is involved in the recognition of the mRNA cap, ATP-dependent unwinding of 5'-terminal secondary structure and recruitment of mRNA to the ribosome. Peptide sequence data from rabbit reticulocyte eIF-4gamma was used to synthesize oligonucleotide probes and polymerase chain reaction primers. These were used to screen lambda-cDNA libraries from rabbit and human brain, yielding a partial rabbit and a complete human cDNA sequence of 5.1 kilobases. Northern blot and primer extension analysis indicated that the cDNA sequence was complete. To confirm that the cDNA represented that of eIF-4gamma, three peptides were synthesized based on cDNA sequences and used to produce anti-peptide antibodies. The antibodies specifically recognized intact eIF-4gamma and its cleavage products following poliovirus infection. The eIF-4gamma mRNA contains AUG codons at nucleotides 6, 67, 90, 165, and 369, but only the last is followed by a long open reading frame. The eIF-4gamma polypeptide is 154 kDa (1396 amino acid residues) and contains sequence motifs of potential interest: a sequence (AGLGPR) that is similar to the substrate recognition sequence of protease 2A from rhinovirus serotype 14, five PEST regions with scores greater than 10, which are characteristic of rapidly degraded proteins, stretches of polyglutamic acid, and numerous potential phosphorylation sites.	UNIV KENTUCKY, DEPT BIOCHEM, LEXINGTON, KY 40536 USA; UNIV KANSAS, MED CTR, DEPT MICROBIOL MOLEC GENET & IMMUNOL, KANSAS CITY, KS 66160 USA	University of Kentucky; University of Kansas; University of Kansas Medical Center				Yan, Riqiang/0000-0001-7195-7617	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024356] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24356] Funding Source: Medline; NIGMS NIH HHS [GM20818] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN ML, 1992, J BIOL CHEM, V267, P23232; ALTMANN M, 1987, MOL CELL BIOL, V7, P998, DOI 10.1128/MCB.7.3.998; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BERNSTEIN HD, 1985, MOL CELL BIOL, V5, P2913, DOI 10.1128/MCB.5.11.2913; BIENKOWSKASZEWCZYK K, 1988, J VIROL, V62, P3068, DOI 10.1128/JVI.62.8.3068-3072.1988; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER JA, 1984, J BIOL CHEM, V259, P7835; CRAIGEN WJ, 1985, P NATL ACAD SCI USA, V82, P3616, DOI 10.1073/pnas.82.11.3616; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; EDERY I, 1983, J BIOL CHEM, V258, P1398; ETCHISON D, 1985, J VIROL, V54, P634, DOI 10.1128/JVI.54.2.634-638.1985; ETCHISON D, 1984, J VIROL, V51, P832, DOI 10.1128/JVI.51.3.832-837.1984; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; ETCHISON D, 1987, J VIROL, V61, P2702, DOI 10.1128/JVI.61.9.2702-2710.1987; ETCHISON D, 1980, J VIROL, V107, P135; FERAMISCO JR, 1980, J BIOL CHEM, V255, P4240; GLASS DB, 1986, J BIOL CHEM, V261, P2987; GLASS DB, 1983, J BIOL CHEM, V258, P4797; GOLD L, 1984, P NATL ACAD SCI-BIOL, V81, P7061, DOI 10.1073/pnas.81.22.7061; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; JACKSON RJ, 1991, NATURE, V353, P14, DOI 10.1038/353014a0; JOSHIBARVE S, 1992, IN PRESS J BIOL CHEM, V267; KAWASAKI E, 1990, PRC PROTOCOLS GUIDE, P119; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAUSSLICH HG, 1987, J VIROL, V61, P2711; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LINDER P, 1989, P NATL ACAD SCI USA, V86, P2286, DOI 10.1073/pnas.86.7.2286; LLOYD RE, 1988, J VIROL, V62, P4216, DOI 10.1128/JVI.62.11.4216-4223.1988; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; MILBURN SC, 1990, EMBO J, V9, P2783, DOI 10.1002/j.1460-2075.1990.tb07466.x; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; NIELSEN PJ, 1985, NUCLEIC ACIDS RES, V13, P6867, DOI 10.1093/nar/13.19.6867; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PLESS DD, 1977, P NATL ACAD SCI USA, V74, P134, DOI 10.1073/pnas.74.1.134; RHOADS RE, 1991, TRANSLATION EUKARYOT, P109; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RYCHLIK W, 1987, P NATL ACAD SCI USA, V84, P945, DOI 10.1073/pnas.84.4.945; RYCHLIK W, 1986, J BIOL CHEM, V261, P71; SAFER B, 1989, EUR J BIOCHEM, V186, P1, DOI 10.1111/j.1432-1033.1989.tb15169.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SKERN T, 1991, VIROLOGY, V181, P46, DOI 10.1016/0042-6822(91)90468-Q; SONENBERG N, 1990, New Biologist, V2, P402; STANWAY G, 1984, NUCLEIC ACIDS RES, V12, P7859, DOI 10.1093/nar/12.20.7859; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TRONO D, 1988, J VIROL, V62, P2291, DOI 10.1128/JVI.62.7.2291-2299.1988; WEST RR, 1991, J BIOL CHEM, V266, P21886; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; WYCKOFF EE, 1992, J VIROL, V66, P2943, DOI 10.1128/JVI.66.5.2943-2951.1992; ZAPATA JM, 1991, J BIOL CHEM, V266, P16007	58	131	139	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23226	23231						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429670				2022-12-25	WOS:A1992JY16300080
J	ARGETSINGER, LS; SHAFER, JA				ARGETSINGER, LS; SHAFER, JA			THE REVERSIBLE AND IRREVERSIBLE AUTOPHOSPHORYLATIONS OF INSULIN-RECEPTOR KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PROTEIN-KINASE; BETA-SUBUNIT; CYTOPLASMIC DOMAIN; DOWN-REGULATION; HUMAN-PLACENTA; PHOSPHORYLATION; ACTIVATION; BINDING; PURIFICATION; REPLACEMENT	When the catalytically active, tyrosyl-phosphorylated form of insulin receptor was isolated from human placenta and treated with ADP, only partial dephosphorylation was observed. This observation suggests the existence of two distinct classes of phosphotyrosyl residues of the phosphorylated insulin receptor: one in which the phosphoryl groups undergo reversible transfer to ADP and one in which they do not. There were 8.8 +/- 2.2 phosphorylation sites per tetrameric insulin receptor, of which 2.4 +/- 0.5 were irreversible (mean +/- S.D., n = 6). The reversible sites were determined to be equivalent and noninteracting and to have an equilibrium constant for the transfer of a phosphoryl group from ATP to a site of reversible phosphorylation of 8.7. Surprisingly, both phosphorylation and dephosphorylation at the reversible sites were relatively insensitive to the presence of insulin. Since only minimal autophosphorylation of insulin receptor was detected in the absence of insulin, the results suggest that the incorporation of phosphate into the two to three irreversible phosphorylation sites is insulin dependent. Phosphorylation of the irreversible phosphorylation sites then renders the insulin receptor relatively insensitive to the continued presence of insulin and facilitates rapid reversible phosphorylation of a second group of tyrosyl residues. The dependence of the degree of phosphorylation of insulin receptor on the ATP:ADP ratio may provide a mechanism for modulating the cellular response to insulin.	MERCK SHARP & DOHME LTD,WP 16-101,SUMNEYTOWN PIKE,W POINT,PA 19486; UNIV MICHIGAN,ANN ARBOR,MI 48109	Merck & Company; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-20572] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARON V, 1990, BIOCHEMISTRY-US, V29, P4634, DOI 10.1021/bi00471a019; BOLLAG GE, 1986, P NATL ACAD SCI USA, V83, P5822, DOI 10.1073/pnas.83.16.5822; BUTLER TM, 1980, HDB PHYSL 2, V2, P237; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; CHERQUI G, 1990, J BIOL CHEM, V265, P21254; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COBB MH, 1989, J BIOL CHEM, V264, P18701; CUATRECASAS P, 1972, P NATL ACAD SCI USA, V69, P318, DOI 10.1073/pnas.69.2.318; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; FUKAMI Y, 1983, P NATL ACAD SCI-BIOL, V80, P1872, DOI 10.1073/pnas.80.7.1872; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARRISON LC, 1980, J BIOL CHEM, V255, P2066; HERRERA R, 1986, J BIOL CHEM, V261, P1980; HUBLER L, 1989, J BIOL CHEM, V264, P1558; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KASUGA M, 1982, J BIOL CHEM, V257, P9891; KASUGA M, 1983, P NATL ACAD SCI-BIOL, V80, P2137, DOI 10.1073/pnas.80.8.2137; KASUGA M, 1982, NATURE, V298, P667, DOI 10.1038/298667a0; KEITT AS, 1966, AM J MED, V41, P762, DOI 10.1016/0002-9343(66)90036-2; KRISANDA JM, 1983, AM J PHYSIOL, V244, pC385, DOI 10.1152/ajpcell.1983.244.5.C385; KWOK YC, 1986, ARCH BIOCHEM BIOPHYS, V244, P102, DOI 10.1016/0003-9861(86)90098-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPAGE GA, 1968, MERCK INDEX, P20; MASSAGUE J, 1982, J BIOL CHEM, V257, P6729; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MORGAN DO, 1987, BIOCHEMISTRY-US, V26, P2959, DOI 10.1021/bi00385a001; PANG DT, 1985, J BIOL CHEM, V260, P7131; PANG DT, 1984, J BIOL CHEM, V259, P8589; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; Penefsky H S, 1979, Methods Enzymol, V56, P527; PIKE LJ, 1986, J BIOL CHEM, V261, P3782; RAPUANO M, 1991, J BIOL CHEM, V266, P12902; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SHIZUTA Y, 1975, J BIOL CHEM, V250, P6891; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P4593; TUAZON PT, 1985, J CELL BIOCHEM, V28, P159, DOI 10.1002/jcb.240280208; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; Williamson J.R., 1969, METHOD ENZYMOL, V13, P434, DOI 10.1016/0076-687913072-4	47	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22095	22101						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1385393				2022-12-25	WOS:A1992JW71900020
J	BIRDSALL, DL; MCPHERSON, A				BIRDSALL, DL; MCPHERSON, A			CRYSTAL-STRUCTURE DISPOSITION OF THYMIDYLIC ACID TETRAMER IN COMPLEX WITH RIBONUCLEASE-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFRACTION DATA; ACTIVE-SITE; X-RAY; PANCREATIC RIBONUCLEASE; NEUTRON-DIFFRACTION; 2.8-A RESOLUTION; REFINEMENT; BINDING; MECHANISM; D(PA)4	The crystal structure of ribonuclease A with bound thymidylic acid tetramer is reported at 2.5-angstrom resolution. The diffusion of the tetramer into native orthorhombic crystals of the ribonuclease allows for the formation of a structurally stable complex where the single-stranded nucleic acid enters and leaves the enzyme's catalytic region in a persistent 5'-3' direction. The binding of the tetramer to the enzyme's surface is facilitated and mediated by electrostatic interactions between basic protein residues and nucleotide phosphates. Two pyrimidine nucleotides are bound to the enzyme's active site in a manner similar to that observed for other complexes between ribonuclease A and nucleic acid oligomers.	UNIV CALIF RIVERSIDE, DEPT BIOCHEM, RIVERSIDE, CA 92521 USA	University of California System; University of California Riverside	BIRDSALL, DL (corresponding author), LAWRENCE LIVERMORE NATL LAB, DIV BIOMED SCI, LIVERMORE, CA 94550 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM011235] Funding Source: NIH RePORTER; NIGMS NIH HHS [5 F32 GM11235] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTONA C, 1972, J AM CHEM SOC, V94, P8205, DOI 10.1021/ja00778a043; ANFINSEN CB, 1961, ENZYMES, V5; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BLACKBURN P, 1982, ENZYMES, V15; BORKAKOTI N, 1983, EUR J BIOCHEM, V132, P89, DOI 10.1111/j.1432-1033.1983.tb07329.x; BRAYER GD, 1982, J BIOL CHEM, V257, P3359; BROWN DM, 1955, NUCLEIC ACIDS, V1, P409; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CAMPBELL RL, 1987, BIOCHEMISTRY-US, V26, P8579, DOI 10.1021/bi00400a013; IWAHASHI K, 1981, J BIOCHEM-TOKYO, V90, P1685, DOI 10.1093/oxfordjournals.jbchem.a133644; JONES TA, 1982, COMPUTATIONAL CRYSTA, P307; KARPEL RL, 1981, BIOCHEM BIOPH RES CO, V100, P760, DOI 10.1016/S0006-291X(81)80240-9; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCPHERSON A, 1986, SCIENCE, V232, P765, DOI 10.1126/science.3961503; MCPHERSON A, 1986, BIOPHYS J, V49, P209, DOI 10.1016/S0006-3495(86)83635-9; MCPHERSON A, 1986, J MOL BIOL, V189, P305, DOI 10.1016/0022-2836(86)90512-7; MCPHERSON A, 1982, PREPARATION ANAL PRO, P94; MITSUI Y, 1978, BIOCHIM BIOPHYS ACTA, V535, P299, DOI 10.1016/0005-2795(78)90096-X; MOEWS PC, 1976, J AM CHEM SOC, V98, P6628, DOI 10.1021/ja00437a035; NACHMAN J, 1990, BIOCHEMISTRY-US, V29, P928, DOI 10.1021/bi00456a012; PAVLOVSKY AG, 1978, FEBS LETT, V92, P258, DOI 10.1016/0014-5793(78)80766-2; PEARLMAN DA, 1990, J MOL BIOL, V211, P171, DOI 10.1016/0022-2836(90)90019-I; RICHARDS FM, 1973, ATLAS MOL STRUCTURES, V1; RICHARDS FM, 1971, ENZYMES, V4; SAENGER W, 1970, J MOL BIOL, V50, P153, DOI 10.1016/0022-2836(70)90112-9; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P69; SAWADA F, 1969, J BIOCHEM-TOKYO, V66, P415, DOI 10.1093/oxfordjournals.jbchem.a129162; SEKINE H, 1969, BIOCHIM BIOPHYS ACTA, V174, P202, DOI 10.1016/0005-2787(69)90243-3; SMYTH DG, 1963, J BIOL CHEM, V238, P227; SUSSMAN JL, 1985, METHOD ENZYMOL, V115, P271; TENEYCK LF, 1976, ACTA CRYSTALLOGR A, V32, P349; USHER DA, 1972, P NATL ACAD SCI USA, V69, P115, DOI 10.1073/pnas.69.1.115; USHER DA, 1970, NATURE, V228, P663, DOI 10.1038/228663a0; WALZ FG, 1971, BIOCHEMISTRY-US, V10, P2156, DOI 10.1021/bi00787a031; WEBB LE, 1973, BIOCHEMISTRY-US, V12, P5101, DOI 10.1021/bi00749a013; WLODAWER A, 1983, BIOCHEMISTRY-US, V22, P2720, DOI 10.1021/bi00280a021; WLODAWER A, 1982, ACTA CRYSTALLOGR A, V38, P239, DOI 10.1107/S0567739482000527; WLODAWER A, 1983, P NATL ACAD SCI-BIOL, V80, P3628, DOI 10.1073/pnas.80.12.3628; WLODAWER A, 1988, BIOCHEMISTRY-US, V27, P2705, DOI 10.1021/bi00408a010; WLODAWER A, 1984, BIOL MACROMOL, P393; WLODAWER A, 1985, BIOL MACROMOL, V2, P395; WODAK SY, 1977, J MOL BIOL, V116, P855, DOI 10.1016/0022-2836(77)90275-3; WYCKOFF HW, 1970, J BIOL CHEM, V245, P305	45	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22230	22236						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429575				2022-12-25	WOS:A1992JW71900039
J	FIEDOR, L; ROSENBACHBELKIN, V; SCHERZ, A				FIEDOR, L; ROSENBACHBELKIN, V; SCHERZ, A			THE STEREOSPECIFIC INTERACTION BETWEEN CHLOROPHYLLS AND CHLOROPHYLLASE - POSSIBLE IMPLICATION FOR CHLOROPHYLL BIOSYNTHESIS AND DEGRADATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOCHLOROPHYLL-A BIOSYNTHESIS; COLUMN CHROMATOGRAPHY; ORGANIC MEDIA; C-13 NMR; PHEOPHYTINS; EPIMER; LEAVES; INVIVO	Chlorophyllase-catalyzed hydrolysis and esterification of chlorophylls, bacteriochlorophylls, and their free acids, respectively, depend on the configuration around the C-13(2) atom of the corresponding substrate. The data suggest that the enzyme interacts preferentially with compounds having the isocyclic carbomethoxy and the C-17 propionic residues facing opposite sides of the porphyrin macrocycle. The relevance of this observation to chlorophyll biosynthesis and degradation in vivo is briefly discussed.	WEIZMANN INST SCI,DEPT BIOCHEM,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								Abraham R. J., 1991, CHLOROPHYLLS, P797; AKHTAR M, 1984, BIOCHEM J, V224, P187, DOI 10.1042/bj2240187; AMIRSHAPIRA D, 1987, P NATL ACAD SCI USA, V84, P1901, DOI 10.1073/pnas.84.7.1901; BENZ J, 1981, Z NATURFORSCH C, V36, P51; Brown SB., 1991, CHLOROPHYLLS, P465; CAMBOU B, 1984, J AM CHEM SOC, V106, P2687, DOI 10.1021/ja00321a033; EMERY VC, 1987, BIOCHEMISTRY-US, V26, P1200, DOI 10.1021/bi00378a031; HENDRY GAF, 1987, NEW PHYTOL, V107, P255, DOI 10.1111/j.1469-8137.1987.tb00181.x; HIYAMA T, 1987, FEBS LETT, V214, P97, DOI 10.1016/0014-5793(87)80020-0; Holden M, 1976, CHEM BIOCH PLANT PIG, P1; Hynninen P. H., 1991, CHEM CHLOROPHYLLS MO, P145; KOBAYASHI M, 1991, FEBS LETT, V284, P129, DOI 10.1016/0014-5793(91)80778-2; KOBAYASHI M, 1991, BIOCHIM BIOPHYS ACTA, V1057, P89, DOI 10.1016/S0005-2728(05)80087-8; Liljenberg C., 1977, Lipids and lipid polymers in higher plants., P259; LOTJONEN S, 1983, ORG MAGN RESONANCE, V21, P757, DOI 10.1002/omr.1270211208; MCFEETERS RF, 1975, PLANT PHYSIOL, V55, P377, DOI 10.1104/pp.55.2.377; MCFEETERS RF, 1971, PLANT PHYSIOL, V47, P609, DOI 10.1104/pp.47.5.609; MICHALSKI TJ, 1988, J AM CHEM SOC, V110, P5888, DOI 10.1021/ja00225a047; OMATA T, 1983, PLANT CELL PHYSIOL, V24, P1093; PARIDA S, 1991, J AM CHEM SOC, V113, P2253, DOI 10.1021/ja00006a051; ROSENBACHBELKIN V, 1988, THESIS WEIZMANN I RE; RUDIGER W, 1989, NATURWISSENSCHAFTEN, V76, P453, DOI 10.1007/BF00366221; RUDIGER W, 1991, CHLOROPHYLLS, P451; RUDOI A B, 1982, Biokhimiya, V47, P733; SATO N, 1978, BIOCHIM BIOPHYS ACTA, V501, P103, DOI 10.1016/0005-2728(78)90099-3; SCHERZ A, 1984, BIOCHIM BIOPHYS ACTA, V766, P653, DOI 10.1016/0005-2728(84)90127-0; SCHOCH S, 1987, J PLANT PHYSL, V126, P283; Strain HH, 1942, J BIOL CHEM, V146, P275; THORNBER JP, 1987, PHYSIOL PLANTARUM, V71, P236, DOI 10.1111/j.1399-3054.1987.tb02874.x; WATANABE T, 1985, FEBS LETT, V191, P252, DOI 10.1016/0014-5793(85)80019-3; WATANABE T, 1985, BIOCHIM BIOPHYS ACTA, V807, P110, DOI 10.1016/0005-2728(85)90113-6; WATANABE T, 1984, ANAL CHEM, V56, P251, DOI 10.1021/ac00266a030; Willstatter R, 1911, LIEBIGS ANN CHEM, V380, P148	33	52	58	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22043	22047						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429554				2022-12-25	WOS:A1992JW71900012
J	FRUH, K; YANG, Y; ARNOLD, D; CHAMBERS, J; WU, L; WATERS, JB; SPIES, T; PETERSON, PA				FRUH, K; YANG, Y; ARNOLD, D; CHAMBERS, J; WU, L; WATERS, JB; SPIES, T; PETERSON, PA			ALTERNATIVE EXON USAGE AND PROCESSING OF THE MAJOR HISTOCOMPATIBILITY COMPLEX-ENCODED PROTEASOME SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II REGION; MULTICATALYTIC PROTEINASE COMPLEXES; RAT HEPATOMA-CELLS; HUMAN MHC; MOLECULAR-CLONING; ESCHERICHIA-COLI; CDNA CLONING; TRANSMEMBRANE PROTEINS; ENDOPLASMIC-RETICULUM; TRANSCRIPTION FACTOR	The finding that two subunits of the proteasome, LMP2 and LMP7, are encoded in the major histocompatibility complex (MHC) has linked the proteasome which represents a major extralysosomal proteolytic system to the processing of intracellular antigens. Here we describe a second form of the human LMP7 cDNA, LMP7-E2, which has been identified during the characterization of novel genes in the MHC. The analysis of the genome organization of LMP7 revealed that LMP7-E1 and LMP7-E2 arise by alternative exon usage. Using specific antibodies against LMP2 and LMP7, we show that they are co-expressed with class I MHC molecules as well as a putative peptide transporter. The polypeptides encoded by LMP7 and LMP2 undergo proteolytic processing when incorporated into proteasomes, and the LMP7 precursor is derived mainly from LMP7-E2. Furthermore, our data suggest that LMP7 and LMP2 are mutually dependent for their incorporation into the proteasomal complex.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR VIROL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	FRUH, K (corresponding author), SCRIPPS RES INST, LA JOLLA, CA 92037 USA.			Frueh, Klaus/0000-0001-8014-3877				ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BLANCK G, 1988, J IMMUNOL, V141, P1734; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; DAVID-WATINE B, 1990, IMMUNOL TODAY, V11, P286, DOI 10.1016/0167-5699(90)90114-O; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FRENTZEL S, 1992, FEBS LETT, V302, P121, DOI 10.1016/0014-5793(92)80420-L; FUJIWARA T, 1990, J BIOL CHEM, V265, P16604; FUJIWARA T, 1989, BIOCHEMISTRY-US, V28, P7332, DOI 10.1021/bi00444a028; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KAPPES D, 1988, ANNU REV BIOCHEM, V57, P991, DOI 10.1146/annurev.bi.57.070188.005015; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; KUMATORI A, 1990, FEBS LETT, V264, P279, DOI 10.1016/0014-5793(90)80267-M; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LILLEY KS, 1990, FEBS LETT, V262, P327, DOI 10.1016/0014-5793(90)80220-D; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MONACO JJ, 1984, NATURE, V309, P797, DOI 10.1038/309797a0; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; PARHAM P, 1992, NATURE, V357, P193, DOI 10.1038/357193a0; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; Sambrook J, 1989, MOL CLONING LABORATO; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SPIES T, 1989, P NATL ACAD SCI USA, V86, P8955, DOI 10.1073/pnas.86.22.8955; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWEENEY ST, 1989, BIOCHEM SOC T, V17, P1126, DOI 10.1042/bst0171126; TAMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1089, P95, DOI 10.1016/0167-4781(91)90090-9; TAMURA T, 1990, FEBS LETT, V264, P91, DOI 10.1016/0014-5793(90)80773-C; TANAKA K, 1990, BIOCHEMISTRY-US, V29, P3777, DOI 10.1021/bi00467a026; TOKUNAGA F, 1990, FEBS LETT, V263, P373, DOI 10.1016/0014-5793(90)81417-M; TOWSEND A, 1989, ANNU REV IMMUNOL, V7, P601; TROWSDALE J, 1991, IMMUNOL TODAY, V12, P443, DOI 10.1016/0167-5699(91)90017-N; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928; YANG Y, 1992, J BIOL CHEM, V267, P11669; YANG Z, 1990, P NATL ACAD SCI USA, V87, P9226, DOI 10.1073/pnas.87.23.9226; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	55	118	121	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22131	22140						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429565				2022-12-25	WOS:A1992JW71900025
J	GIBSON, QH; REGAN, R; ELBER, R; OLSON, JS; CARVER, TE				GIBSON, QH; REGAN, R; ELBER, R; OLSON, JS; CARVER, TE			DISTAL POCKET RESIDUES AFFECT PICOSECOND LIGAND RECOMBINATION IN MYOGLOBIN - AN EXPERIMENTAL AND MOLECULAR-DYNAMICS STUDY OF POSITION 29 MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; SITE-DIRECTED MUTAGENESIS; HEME-PROTEINS; GEMINATE RECOMBINATION; CARBON-MONOXIDE; HUMAN-HEMOGLOBIN; BINDING; SIMULATION; KINETICS; DISSOCIATION	Time courses for intramolecular NO and O2 recombination to native and three position 29 mutants of sperm whale myoglobins were measured after laser photolysis on picosecond and nanosecond time scales. The rates for the first phase of NO recombination were 1.8, 2.5, 29, and greater-than-or-equal-to 100 ns-1 for Ala29, Val29, Leu29(native), and Phe29 myoglobin, respectively, at room temperature. This order is not correlated with the overall association rate constants for NO binding which were all in the range 20-50 x 10(6) M-1 s-1 and is the opposite of that observed for the rate constants for the overall thermal dissociation of NO which were 5.0, 2.8, 0.98, and 0.21 x 10(-4) s-1 for Ala29, Val29, Leu29(native), and Phe29 myoglobin, respectively, at 20-degrees-C. This inverse correlation suggests that photo- and thermally dissociated ligand molecules experience similar kinetic and equilibrium barriers to rebinding. The larger side chains of Leu29 and Phe29 inhibit rapid movement of the ligand away from the iron atom facilitating geminate recombination. The smaller side chains of Val29 and Ala29 increase the space available to the ligand, decreasing the rate of geminate recombination and enhancing complete dissociation. Diffusion of NO in the distal pocket of myoglobin was simulated using a variant of the molecular dynamics program CHARMM that includes the locally enhanced sampling protocol (Elber, R., and Karplus, M. (1991) J. Am. Chem. Soc. 112, 9161-9175; Roitberg, A., and Elber, R. (1991) J. Chem. Phys. 95, 9277-9287) and the x-ray structures of Carver et al. (Carver, T. E., Brantley, R. E., Jr., Singleton, E. W., Arduini, R. M., Quillin, M. L., Phillips, G. N., Jr., and Olson, J. S. (1992) J. Biol. Chem. 267, 14443-14450). Both accelerated (5,000 K) and room temperature ligands were used, and comparisons were made between simulations with a complete hydration shell surrounding the protein and those with only eight water molecules near the distal histidine. Photodissociated ligands initially move away from the heme plane, past Leu29, and toward Leu32, Phe33, Ile107, and Ile111. These theoretical results confirm that a complete description of picosecond ligand recombination must include the dynamics of ligand movement in the distal portion of the heme pocket.	UNIV ILLINOIS, DEPT CHEM, CHICAGO, IL 60680 USA; RICE UNIV, DEPT BIOCHEM & CELL BIOL, HOUSTON, TX 77251 USA; RICE UNIV, WM KECK CTR COMPUTAT BIOL, HOUSTON, TX 77251 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rice University; Rice University	GIBSON, QH (corresponding author), CORNELL UNIV, DEPT BIOCHEM MOLEC & CELL BIOL, ITHACA, NY 14853 USA.			Olson, John/0000-0002-0760-5403	NIGMS NIH HHS [GM-41905, GM-35649, GM-14276] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM014276, R01GM035649, R01GM041905] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI S, 1992, J BIOL CHEM, V267, P12614; AGMON N, 1983, J CHEM PHYS, V79, P2042, DOI 10.1063/1.445988; ANSARI A, 1986, BIOCHEMISTRY-US, V25, P3139, DOI 10.1021/bi00359a011; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BRAUNSTEIN D, 1988, P NATL ACAD SCI USA, V85, P8497, DOI 10.1073/pnas.85.22.8497; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1988, PROTEINS, V4, P148, DOI 10.1002/prot.340040208; CARVER TE, 1992, J BIOL CHEM, V267, P14443; CARVER TE, 1991, BIOCHEMISTRY-US, V30, P4697, DOI 10.1021/bi00233a009; CARVER TE, 1990, J BIOL CHEM, V265, P20007; CORNELIUS PA, 1981, P NATL ACAD SCI-BIOL, V78, P7526, DOI 10.1073/pnas.78.12.7526; CZERMINSKI R, 1991, PROTEINS, V10, P70, DOI 10.1002/prot.340100107; DUDDELL DA, 1980, PHOTOCHEM PHOTOBIOL, V31, P479, DOI 10.1111/j.1751-1097.1980.tb03732.x; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; FRAUENFELDER H, 1985, SCIENCE, V229, P337, DOI 10.1126/science.4012322; FRIEDMAN JM, 1985, SCIENCE, V229, P187, DOI 10.1126/science.4012316; GIBSON QH, 1986, J BIOL CHEM, V261, P228; GREENE BI, 1978, P NATL ACAD SCI USA, V75, P5255, DOI 10.1073/pnas.75.11.5255; HENRY ER, 1983, J MOL BIOL, V166, P443, DOI 10.1016/S0022-2836(83)80094-1; HENRY ER, 1985, P NATL ACAD SCI USA, V82, P2034, DOI 10.1073/pnas.82.7.2034; IKEDASAITO M, 1991, J BIOL CHEM, V266, P23641; JONGEWARD KA, 1988, J AM CHEM SOC, V110, P380, DOI 10.1021/ja00210a011; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KOTTALAM J, 1988, J AM CHEM SOC, V110, P7690, DOI 10.1021/ja00231a018; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LAMBRIGHT DG, 1989, J MOL BIOL, V207, P289, DOI 10.1016/0022-2836(89)90456-7; MARDEN MC, 1986, BIOCHEMISTRY-US, V25, P2786, DOI 10.1021/bi00358a008; MATHEWS AJ, 1991, J BIOL CHEM, V266, P21631; MATHEWS AJ, 1989, J BIOL CHEM, V264, P16573; MOORE EG, 1976, J BIOL CHEM, V251, P2788; NAGAI K, 1987, NATURE, V329, P858, DOI 10.1038/329858a0; NOWAK W, 1991, J AM CHEM SOC, V113, P5627, DOI 10.1021/ja00015a016; OLSON JS, 1988, NATURE, V336, P265, DOI 10.1038/336265a0; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; PETRICH JW, 1991, BIOCHEMISTRY-US, V30, P3975, DOI 10.1021/bi00230a025; PHILLIPS GN, 1990, PROTEINS, V7, P358, DOI 10.1002/prot.340070407; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; ROITBERG A, 1991, J CHEM PHYS, V95, P9277, DOI 10.1063/1.461157; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SASSAROLI M, 1986, J BIOL CHEM, V261, P6292; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; STEINBACH PJ, 1991, BIOCHEMISTRY-US, V30, P3988, DOI 10.1021/bi00230a026; STRAJER V, 1991, BIOCHEMISTRY-US, V30, P4886; TAME J, 1991, J MOL BIOL, V218, P761, DOI 10.1016/0022-2836(91)90264-7; TILTON RF, 1986, J MOL BIOL, V192, P443, DOI 10.1016/0022-2836(86)90374-8; TILTON RF, 1988, J MOL BIOL, V199, P195, DOI 10.1016/0022-2836(88)90389-0	48	150	151	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22022	22034						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429552				2022-12-25	WOS:A1992JW71900010
J	MAENZ, DD; PATIENCE, JF				MAENZ, DD; PATIENCE, JF			L-THREONINE TRANSPORT IN PIG JEJUNAL BRUSH-BORDER MEMBRANE-VESICLES - FUNCTIONAL-CHARACTERIZATION OF THE UNIQUE SYSTEM-B IN THE INTESTINAL EPITHELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-TRANSPORT; RAPID FILTRATION APPARATUS; CELL LINE; GLUCOSE COTRANSPORT; MOUSE BLASTOCYSTS; NA+; RABBIT; ASC; HEPATOCYTES	Uptake and inhibitory kinetics of [H-3]L-threonine were evaluated in preparations of pig jejunal brush border membrane vesicles. Uptake of [H-3]L-threonine under 0-trans, Na+ gradient, and 0-trans, Na+-free conditions was best described by high affinity transport (K(m) < 0.1 mM) plus a nonsaturable component. The maximal velocity of transport was 3-fold greater under Na+ gradient conditions. 100 mM concentrations of all of the dipolar amino acids and 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid caused complete inhibition of [H-3]L-threonine transport under Na+ gradient and Na+-free conditions. Imino acids, anionic amino acids, cationic amino acids, and methylamino-isobutyric acid caused significant partial inhibition of L-threonine uptake. Inhibitor concentration profiles for proline and lysine were consistent with low affinity competitive inhibition. The K(i) values of alanine and phenylalanine approximated 0.2 and 0.5 mM, respectively, under both Na+ gradient and Na+-free conditions. These data indicate that the transport system available for L-threonine in the intestinal brush border membrane (system B) is functionally distinct from other amino acid transport systems. Comparison of kinetics parameters in the presence and absence of a Na+ gradient suggests that both partially and fully loaded forms of the carrier can function to translocate substrate and that Na+ serves to accelerate L-threonine transport by a mechanism that does not involve enhanced substrate binding.			MAENZ, DD (corresponding author), UNIV SASKATCHEWAN,DEPT ANIM & POULTRY SCI,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA.		Patience, john F./A-2935-2009					BARS R, 1981, J BIOL CHEM, V256, P10259; BERTELOOT A, 1990, METHOD ENZYMOL, V192, P409; BERTELOOT A, 1991, J MEMBRANE BIOL, V122, P111, DOI 10.1007/BF01872635; BOERNER P, 1986, J BIOL CHEM, V261, P13957; CENTELLES JJ, 1991, BIOCHIM BIOPHYS ACTA, V1065, P239, DOI 10.1016/0005-2736(91)90236-2; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CHRISTENSEN HN, 1969, J BIOL CHEM, V244, P1510; CHRISTENSEN HN, 1965, J BIOL CHEM, V240, P3609; HAUSER H, 1980, BIOCHIM BIOPHYS ACTA, V602, P567, DOI 10.1016/0005-2736(80)90335-1; KUHLMANN MK, 1991, J BIOL CHEM, V266, P15042; MAENZ DD, 1992, J BIOL CHEM, V267, P1510; MAENZ DD, 1982, J MEMBRANE BIOL, V70, P125, DOI 10.1007/BF01870222; MAENZ DD, 1991, BIOCHIM BIOPHYS ACTA, V1069, P250, DOI 10.1016/0005-2736(91)90132-R; MAKOWSKE M, 1982, J BIOL CHEM, V257, P5663; MALO C, 1991, J MEMBRANE BIOL, V122, P127, DOI 10.1007/BF01872636; PARKINSO.DK, 1972, J CLIN INVEST, V51, P2292, DOI 10.1172/JCI107039; SAIER MH, 1988, J MEMBRANE BIOL, V104, P1, DOI 10.1007/BF01871898; SEMENZA G, 1984, BIOCHIM BIOPHYS ACTA, V779, P343, DOI 10.1016/0304-4157(84)90016-9; SHOTWELL MA, 1981, J BIOL CHEM, V256, P5422; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; STEVENS BR, 1982, J MEMBRANE BIOL, V66, P213, DOI 10.1007/BF01868496; STEVENS BR, 1992, IN PRESS AM J PHYSL; STEVENS BR, IN PRESS MAMMALIAN A; VADGAMA JV, 1991, AM J PHYSIOL, V260, pC392, DOI 10.1152/ajpcell.1991.260.3.C392; VADGAMA JV, 1983, J BIOL CHEM, V258, P6422; VADGAMA JV, 1984, J BIOL CHEM, V259, P3648; VANWINKLE LJ, 1988, BIOCHIM BIOPHYS ACTA, V947, P173, DOI 10.1016/0304-4157(88)90024-X; VANWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; VANWINKLE LJ, 1985, J BIOL CHEM, V260, P2118	29	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22079	22086						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429560				2022-12-25	WOS:A1992JW71900018
J	KAMATA, H; AKIYAMA, S; MOROSAWA, H; OHTA, T; HAMAMOTO, T; KAMBE, T; KAGAWA, Y; HIRATA, H				KAMATA, H; AKIYAMA, S; MOROSAWA, H; OHTA, T; HAMAMOTO, T; KAMBE, T; KAGAWA, Y; HIRATA, H			PRIMARY STRUCTURE OF THE ALANINE CARRIER PROTEIN OF THERMOPHILIC BACTERIUM-PS3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; THERMUS-THERMOPHILUS; PROLINE CARRIER; SODIUM-ION; GENE; TRANSPORT; SUBUNIT; CHAIN; POLYPEPTIDE	Purified alanine carrier proteins were cleaved into peptides either chemically after solubilization in 1,1,1,3,3,3-hexafluoro-2-propanol or proteolytically with lysylendopeptidase. From the amino acid sequence analyses of these peptides, we synthesized a DNA probe and utilized it for successful cloning of a gene encoding the alanine carrier protein (acp gene). The 5'-flanking region was determined by an inverse polymerase chain reaction, and an open reading frame consisting of 1,335 nucleotides was found. The amino acid sequence deduced from the open reading frame consists of 445 amino acids, and all the partial amino acid sequences determined are included in the sequence. Although the calculated M(r) of 47,803 is significantly larger than the apparent M(r) of 42,500 as reported previously (Hirata, H., Kambe, T., and Kagawa, Y. (1984) J. Biol. Chem. 259, 10653-10656), an in vitro translation experiment revealed that the product of the acp gene migrates at a position coinciding with that of the purified alanine carrier. Hydropathy analysis suggests that the protein contains at least 8 hydrophobic segments presumably spanning membrane. A homology search on a database reveals relatively high scores of homology with either the Escherichia coli melibiose carrier or the human Na+/glucose symporter, particularly in the region from Leu246 to Glu286. Furthermore, the region also reveals low but significant similarities to other Na+-coupled symporters.	HIMEJI INST TECHNOL,FAC SCI,DEPT LIFE SCI,HIMEJI,HYOGO 67812,JAPAN; JICHI MED SCH,DEPT BIOCHEM,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; UNIV CHIBA,FAC HORT,DEPT AGR CHEM,CHIBA 271,JAPAN; UNIV TSUKUBA,SCH MED,DEPT MICROBIOL,TSUKUBA,IBARAKI 305,JAPAN; INST PHYS & CHEM RES,GLYCO MOLEC BIOL LAB,SAITAMA 35101,JAPAN	University of Hyogo; Jichi Medical University; Chiba University; University of Tsukuba; RIKEN			Kamata, Hideaki/N-3907-2017					DEGUCHI Y, 1990, J BIOL CHEM, V265, P21704; FOSTER DL, 1983, J BIOL CHEM, V258, P31; HASAN SM, 1977, BIOCHEM BIOPH RES CO, V78, P122, DOI 10.1016/0006-291X(77)91229-3; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HIRATA H, 1976, BIOCHEM BIOPH RES CO, V69, P665, DOI 10.1016/0006-291X(76)90927-X; HIRATA H, 1984, J BIOL CHEM, V259, P653; HIRATA H, 1986, METHOD ENZYMOL, V125, P485; HIRATA H, 1979, FUNCTION MOL ASPECTS, P505; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; KABACK HR, 1986, ANNU REV BIOPHYS BIO, V15, P279; KAGAWA Y, 1986, J BIOCHEM-TOKYO, V100, P923, DOI 10.1093/oxfordjournals.jbchem.a121805; KAGAWA Y, 1984, J BIOL CHEM, V259, P2956; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MENICK DR, 1985, BIOCHEM BIOPH RES CO, V132, P860; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; NAGAHARI K, 1980, GENE, V10, P137; NAKAO T, 1987, MOL GEN GENET, V208, P70, DOI 10.1007/BF00330424; RIZZOLO LJ, 1976, BIOCHEMISTRY-US, V15, P3433, DOI 10.1021/bi00661a006; SAISHU T, 1986, BIOCHIM BIOPHYS ACTA, V867, P97, DOI 10.1016/0167-4781(86)90069-2; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SONE N, 1988, J BIOCHEM-TOKYO, V103, P606, DOI 10.1093/oxfordjournals.jbchem.a122314; TSUCHIYA T, 1978, J MEMBRANE BIOL, V42, P45, DOI 10.1007/BF01870393; TSUCHIYA T, 1985, FEBS LETT, V168, P327; URATANI Y, 1989, J MEMBRANE BIOL, V107, P57, DOI 10.1007/BF01871083; YAMATO I, 1988, J BIOL CHEM, V263, P16055; YAZYU H, 1984, J BIOL CHEM, V259, P4320	27	16	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21650	21655						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400476				2022-12-25	WOS:A1992JV01100062
J	LI, XJ; FORTE, M; NORTH, RA; ROSS, CA; SNYDER, SH				LI, XJ; FORTE, M; NORTH, RA; ROSS, CA; SNYDER, SH			CLONING AND EXPRESSION OF A RAT SOMATOSTATIN RECEPTOR ENRICHED IN BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL NERVOUS-SYSTEM; CEREBRAL-CORTEX; SENILE DEMENTIA; BINDING-SITES; DISEASE; PEPTIDES; ANALOGS; NEURONS	The tetradecapeptide somatostatin (SRIF) is a hormone release-inhibiting substance that mediates diverse effects in brain and peripheral organs via specific receptors. A cDNA encoding a rat SRIF receptor was identified by use of degenerate oligonucleotide primers and polymerase chain reaction amplification of cDNA prepared from transcripts expressed in rat brain. The complete cDNA encodes a protein of 391 amino acids with seven potential transmembrane domains. Expression of the cDNA product in transfected COS-7 cell lines provides the same high affinity of binding to [I-125-Tyr11]SRIF-14 as that of rat cerebral cortex tissues. However, the binding of [I-125-Tyr11]SRIF-14 to cloned rat SRIF receptor is not displaced by MK678, a SRIF analog that partially displaces [I-125-Tyr11]SRIF-14 binding sites in membranes of rat cerebral cortex. Northern analysis and in situ hybridization indicate that mRNA (4.0 kilobases) for cloned rat SRIF receptor is preferentially expressed in rat brain regions such as cerebral cortex and hippocampus with no detectable expression in most peripheral organs. This pattern contrasts with the exclusive peripheral expression of a recently cloned human SRIF receptor. The cDNA probe of rat receptor detects mRNA from mouse brain but not from human cerebral cortex and cerebellum.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT,BALTIMORE,MD 21205; OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PHARMACOL & MOLEC SCI,PORTLAND,OR 97201	Johns Hopkins University; Johns Hopkins University; Oregon Health & Science University; Oregon Health & Science University			North, Richard/GQA-6156-2022		NIDA NIH HHS [DA 00074, DA-00266] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH018501, R01MH018501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AGUILERA G, 1981, NATURE, V292, P262, DOI 10.1038/292262a0; BEAL MF, 1985, SCIENCE, V229, P289, DOI 10.1126/science.2861661; BRAZEAU P, 1973, SCIENCE, V179, P77, DOI 10.1126/science.179.4068.77; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER PE, 1981, NEUROLOGY, V31, P64; DAVIES P, 1980, NATURE, V288, P279, DOI 10.1038/288279a0; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EPELBAUM J, 1982, J NEUROCHEM, V38, P1515, DOI 10.1111/j.1471-4159.1982.tb06627.x; EPELBAUM J, 1986, PROG NEUROBIOL, V27, P63, DOI 10.1016/0301-0082(86)90012-2; GANZI, 1991, P NATL ACAD SCI USA, V88, P429; KEMP BE, 1990, TRENDS PHARMACOL SCI, V11, P492; LAMBERTS SWJ, 1990, NEW ENGL J MED, V323, P1246, DOI 10.1056/NEJM199011013231805; LI XJ, 1992, J BIOL CHEM, V267, P9; LI XJ, 1991, EMBO J, V10, P3221, DOI 10.1002/j.1460-2075.1991.tb04885.x; MIHARA S, 1987, J PHYSIOL-LONDON, V390, P335, DOI 10.1113/jphysiol.1987.sp016704; NEMEROFF C, 1984, SCIENCE, V221, P972; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; Pelletier G, 1986, Methods Enzymol, V124, P607; RAYNOR K, 1989, J PHARMACOL EXP THER, V251, P510; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; REISINE T, 1991, METHODS NEUROSCI, V5, P215; REUBI JC, 1981, LIFE SCI, V28, P2191, DOI 10.1016/0024-3205(81)90628-7; REUBI JC, 1985, NEUROSCIENCE, V15, P1183, DOI 10.1016/0306-4522(85)90261-1; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; ROSSOR MN, 1980, NEUROSCI LETT, V20, P373, DOI 10.1016/0304-3940(80)90177-9; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRIKANT CB, 1981, P NATL ACAD SCI USA, V78, P3930; STRIKANT CB, 1981, NATURE, V294, P259; SURPRENANT A, 1990, J PHYSIOL-LONDON, V431, P585, DOI 10.1113/jphysiol.1990.sp018349; TANAKA K, 1990, NEURON, V4, P847, DOI 10.1016/0896-6273(90)90137-5; TRAN VT, 1985, SCIENCE, V228, P492, DOI 10.1126/science.2858917; UHL GR, 1985, J COMP NEUROL, V240, P288, DOI 10.1002/cne.902400306; VALE W, 1977, ANNU REV PHYSIOL, V39, P473, DOI 10.1146/annurev.ph.39.030177.002353; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251	35	107	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21307	21312						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400442				2022-12-25	WOS:A1992JV01100010
J	LOCKER, JK; ROSE, JK; HORZINEK, MC; ROTTIER, PJM				LOCKER, JK; ROSE, JK; HORZINEK, MC; ROTTIER, PJM			MEMBRANE ASSEMBLY OF THE TRIPLE-SPANNING CORONAVIRUS M-PROTEIN - INDIVIDUAL TRANSMEMBRANE DOMAINS SHOW PREFERRED ORIENTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; OLIGONUCLEOTIDE-DIRECTED MUTAGENESIS; TRANS-GOLGI NETWORK; ONE SIGNAL SEQUENCE; SEMI-INTACT CELLS; E1 GLYCOPROTEIN; INTRACELLULAR-TRANSPORT; BREFELDIN-A; CHARGED RESIDUES; VACCINIA VIRUS	The M protein of mouse hepatitis virus strain A59 is a triple-spanning membrane protein which assembles with an uncleaved internal signal sequence, adopting an N(exo)C(cyt) orientation. To study the insertion mechanism of this protein, domains potentially involved in topogenesis were deleted and the effects analyzed in several ways. Mutant proteins were synthesized in a cell-free translation system in the presence of microsomal membranes, and their integration and topology were determined by alkaline extraction and by protease-protection experiments. By expression in COS-1 and Madin-Darby canine kidney-II cells, the topology of the mutant proteins was also analyzed in vivo. Glycosylation was used as a biochemical marker to assess the disposition of the NH2 terminus. An indirect immunofluorescence assay on semi-intact Madin-Darby canine kidney-II cells using domain-specific antibodies served to identify the cytoplasmically exposed domains. The results show that each membrane-spanning domain acts independently as an insertion and anchor signal and adopts an intrinsic preferred orientation in the lipid bilayer which corresponds to the disposition of the transmembrane domain in the wild-type assembled protein. These observations provide further insight into the mechanism of membrane integration of multispanning proteins. A model for the insertion of the coronavirus M protein is proposed.	UNIV UTRECHT,FAC VET,INST VIROL,DEPT INFECT DIS & IMMUNOL,YALELAAN 1,3584 CL UTRECHT,NETHERLANDS; YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510	Utrecht University; Yale University; Yale University			Locker, Jacomine Krijnse/E-1009-2016; Locker, Jacomine Krijnse/AAX-1185-2020		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024345, R01AI024345] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24345] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMSTRONG J, 1984, NATURE, V308, P751, DOI 10.1038/308751a0; ARMSTRONG J, 1990, J CELL SCI, V95, P191; AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BELTZER JP, 1991, J BIOL CHEM, V266, P973; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; FLEMING JO, 1989, VIROLOGY, V168, P162, DOI 10.1016/0042-6822(89)90415-7; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GARCIA PD, 1988, J CELL BIOL, V106, P1093, DOI 10.1083/jcb.106.4.1093; GRAVOTTA D, 1990, J CELL BIOL, V111, P2893, DOI 10.1083/jcb.111.6.2893; HAEUPTLE MT, 1989, J CELL BIOL, V108, P1227, DOI 10.1083/jcb.108.4.1227; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; KAPKE PA, 1988, VIROLOGY, V165, P367, DOI 10.1016/0042-6822(88)90581-8; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; LAUDE H, 1987, J GEN VIROL, V68, P1687, DOI 10.1099/0022-1317-68-6-1687; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOCKER JK, 1992, J BIOL CHEM, V267, P14094; MACHAMER CE, 1987, J CELL BIOL, V105, P1205, DOI 10.1083/jcb.105.3.1205; MAYER T, 1988, J BIOL CHEM, V263, P14956; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; RAPOPORT TA, 1986, CRC CR REV BIOCH MOL, V20, P73, DOI 10.3109/10409238609115901; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; ROTTIER P, 1985, J BIOL CHEM, V260, P4648; ROTTIER P, 1984, P NATL ACAD SCI-BIOL, V81, P1421, DOI 10.1073/pnas.81.5.1421; ROTTIER PJM, 1987, J VIROL, V61, P2042, DOI 10.1128/JVI.61.6.2042-2045.1987; ROTTIER PJM, 1981, J VIROL, V38, P20, DOI 10.1128/JVI.38.1.20-26.1981; ROTTIER PJM, 1986, BIOCHEMISTRY-US, V25, P1335, DOI 10.1021/bi00354a022; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SIMONS K, 1987, EMBO J, V6, P2241, DOI 10.1002/j.1460-2075.1987.tb02496.x; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SZCZESNASKORUPA E, 1988, P NATL ACAD SCI USA, V85, P738, DOI 10.1073/pnas.85.3.738; SZCZESNASKORUPA E, 1989, J CELL BIOL, V108, P1237, DOI 10.1083/jcb.108.4.1237; VENNEMA H, 1990, J VIROL, V64, P339, DOI 10.1128/JVI.64.1.339-346.1990; VENNEMA H, 1991, VIROLOGY, V181, P327, DOI 10.1016/0042-6822(91)90499-2; VENNEMA H, 1992, J VIROL, V66, P4951, DOI 10.1128/JVI.66.8.4951-4956.1992; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WILLIAMS MA, 1986, MOL CELL BIOL, V6, P4317, DOI 10.1128/MCB.6.12.4317; WILSON C, 1990, MOL CELL BIOL, V10, P449, DOI 10.1128/MCB.10.2.449; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	53	64	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21911	21918						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400501				2022-12-25	WOS:A1992JV01100100
J	MESHULAM, T; HERSCOVITZ, H; CASAVANT, D; BERNARDO, J; ROMAN, R; HAUGLAND, RP; STROHMEIER, GS; DIAMOND, RD; SIMONS, ER				MESHULAM, T; HERSCOVITZ, H; CASAVANT, D; BERNARDO, J; ROMAN, R; HAUGLAND, RP; STROHMEIER, GS; DIAMOND, RD; SIMONS, ER			FLOW CYTOMETRIC KINETIC MEASUREMENTS OF NEUTROPHIL PHOSPHOLIPASE-A ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; METHIONYL-LEUCYL-PHENYLALANINE; STIMULATED HUMAN-NEUTROPHILS; ARACHIDONIC-ACID METABOLISM; PLASMA-MEMBRANE VESICLES; SIGNAL TRANSDUCTION; CHEMOTACTIC PEPTIDE; DE-GRANULATION; RELEASE; PHE	The interrelationships between activation of phospholipases and neutrophil stimulus-induced Ca2+ responses remain unclear. We report here that immune complexes activate a phosphatidylcholine-specific phospholipase A in a neutrophil only after the cytoplasmic Ca2+ transient has been initiated in the same cell, while chemotactic peptide activation does not proceed via such a phospholipase A-mediated mechanism. Measurements of [Ca2+] changes and of phosphatidylcholine-specific phospholipase A activity were made by flow cytometry, using Indo-1 for Ca2+ indication, and a new fluorescent probe, bis-BODIPY(TM)-phosphatidylcholine, localized in the inner leaflet of the plasma membrane, to measure phospholipase A activation. Both 100 nM formyl-methionyl-leucyl-phenylalanine (with or without cytochalasin B) and 60 mug/ml insoluble immune complexes elicited cytoplasmic Ca2+ transients, but only insoluble immune complexes stimulated phospholipase A activation in a subpopulation of cells exhibiting an elevation of [Ca2+]in. Phospholipase A activation followed the Ca2+ transient, starting, in each cell, after [Ca2+]in had begun to decrease as Ca2+ redistributed in the activated cell. The products of this phospholipase activation were confirmed by thin layer chromatography. We conclude that neutrophils respond to immune complexes with an elevated cytoplasmic Ca2+-requiring phosphatidylcholine-specific phospholipase A activation and to chemotactic peptides by a different mechanism.	BOSTON UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02118 USA; MOLEC PROBES INC, EUGENE, OR 97402 USA	Boston University				Herscovitz, Haya/0000-0001-8067-6091; Meshulam, Tova/0000-0002-7635-0328; Bernardo, John/0000-0002-3922-0559	NHLBI NIH HHS [HL07501, HL19177] Funding Source: Medline; NIADDK NIH HHS [AM31056] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM031056] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BABIOR BM, 1987, TRENDS BIOCHEM SCI, V12, P241, DOI 10.1016/0968-0004(87)90118-6; BAULDRY SA, 1988, J BIOL CHEM, V263, P16787; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BRUNKHORST BA, 1991, J BIOL CHEM, V266, P13035; CHANG J, 1987, BIOCHEM PHARMACOL, V36, P2429, DOI 10.1016/0006-2952(87)90512-0; CHILTON FH, 1986, J BIOL CHEM, V261, P7771; CLANCY RM, 1983, P NATL ACAD SCI-BIOL, V80, P7200, DOI 10.1073/pnas.80.23.7200; DAVID EA, 1991, J CLIN INVEST, V88, P531; DELBUONO BJ, 1989, J CELL PHYSIOL, V141, P636, DOI 10.1002/jcp.1041410323; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DENNIS EA, 1987, DRUG DEVELOP RES, V10, P205, DOI 10.1002/ddr.430100404; FIORE S, 1990, J EXP MED, V172, P1451, DOI 10.1084/jem.172.5.1451; GODFREY RW, 1987, J CELL BIOL, V104, P925, DOI 10.1083/jcb.104.4.925; HAINES KA, 1987, BIOCHEM J, V241, P55, DOI 10.1042/bj2410055; HOLTZMAN MJ, 1991, AM REV RESPIR DIS, V143, P188, DOI 10.1164/ajrccm/143.1.188; KAISER E, 1990, CLIN BIOCHEM, V23, P349, DOI 10.1016/0009-9120(90)90051-U; LAZZARI KG, 1990, J BIOL CHEM, V265, P10959; LAZZARI KG, 1986, J BIOL CHEM, V261, P9710; LOFFELHOLZ K, 1989, BIOCHEM PHARMACOL, V38, P1543, DOI 10.1016/0006-2952(89)90299-2; MATSUMOTO T, 1988, BIOCHEM J, V250, P343, DOI 10.1042/bj2500343; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OCHS DL, 1983, J BIOL CHEM, V258, P116; OMANN GM, 1987, PHYSIOL REV, V67, P285, DOI 10.1152/physrev.1987.67.1.285; PAGANO RE, 1981, J CELL BIOL, V91, P872, DOI 10.1083/jcb.91.3.872; PALMER RMJ, 1983, IMMUNOLOGY, V50, P65; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; REYNOLDS LJ, 1991, METHOD ENZYMOL, V197, P3; SCHONHORN J E, 1989, Journal of Cell Biology, V109, p211A; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; SLEIGHT RG, 1984, J CELL BIOL, V99, P742, DOI 10.1083/jcb.99.2.742; VANDENBOSCH H, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; WALKER BAM, 1991, J IMMUNOL, V146, P735; WYNKOOP EM, 1986, BIOCHEM J, V236, P829, DOI 10.1042/bj2360829	37	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21465	21470						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400459				2022-12-25	WOS:A1992JV01100033
J	SAXENA, SK; RYBAK, SM; DAVEY, RT; YOULE, RJ; ACKERMAN, EJ				SAXENA, SK; RYBAK, SM; DAVEY, RT; YOULE, RJ; ACKERMAN, EJ			ANGIOGENIN IS A CYTOTOXIC, TRANSFER RNA-SPECIFIC RIBONUCLEASE IN THE RNASE-A SUPERFAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHIL-DERIVED NEUROTOXIN; AMINO-ACID SEQUENCE; FREE PROTEIN-SYNTHESIS; MAJOR BASIC-PROTEIN; XENOPUS OOCYTES; CATIONIC PROTEIN; RIBOSOMAL-RNA; ALPHA-SARCIN; TOXIN; INACTIVATION	Angiogenin is a 14.4-kDa human plasma protein with 65% homology to RNase A that retains the key active site residues and three of the four RNase A disulfide bonds. We demonstrate that recombinant angiogenin functions as a cytotoxic tRNA-specific RNase in cell-free lysates and when injected into Xenopus oocytes. Inhibition of protein synthesis by angiogenin correlates with degradation of endogenous oocyte tRNA. Exogenous, radiolabeled tRNA is also hydrolyzed by angiogenin, whereas oocyte rRNA and mRNA are not detectably degraded by angiogenin. Protein synthesis was restored to angiogenin-injected oocytes by injecting the RNase inhibitor RNasin(TM) plus total Xenopus or calf liver tRNAs, thereby demonstrating that the tRNA degradation induced by angiogenin was the sole cause of cytotoxicity. A similar tRNA-reversible inhibition of protein synthesis was seen in rabbit reticulocyte lysates. Angiogenin therefore appears to be a specific cellular tRNase, whereas five homologues in the RNase A superfamily lack angiogenin's specificity for tRNA. One of these homologues purified from human eosinophils, eosinophil-derived neurotoxin, nonspecifically degrades oocyte RNA similar to RNase A and is also cytotoxic at very low concentrations.	NIDDKD,GENET & BIOCHEM BRANCH,BLDG 10,RM 9D15,BETHESDA,MD 20892; NINDB,SURG NEUROL BRANCH,BIOCHEM SECT,BETHESDA,MD 20892; NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Saxena, Shailendra K/ABK-6489-2022	Saxena, Shailendra K/0000-0003-2856-4185	PHS HHS [1-8325256] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ACKERMAN EJ, 1988, J BIOL CHEM, V263, P17076; ACKERMAN SJ, 1983, J IMMUNOL, V131, P2977; BEINTEMA JJ, 1988, PROG BIOPHYS MOL BIO, V51, P165, DOI 10.1016/0079-6107(88)90001-6; BOND MD, 1989, BIOCHEMISTRY-US, V28, P6110, DOI 10.1021/bi00440a057; BOND MD, 1989, BIOCHEMISTRY-US, V28, P8262, DOI 10.1021/bi00446a044; DEUTSCHER MP, 1988, TRENDS BIOCHEM SCI, V13, P136, DOI 10.1016/0968-0004(88)90070-9; DURACK DT, 1981, P NATL ACAD SCI-BIOL, V78, P5165, DOI 10.1073/pnas.78.8.5165; ENDO Y, 1983, J BIOL CHEM, V258, P2662; ENDO Y, 1987, J BIOL CHEM, V262, P5908; FERNANDEZPUENTES C, 1980, CELL, V20, P769, DOI 10.1016/0092-8674(80)90323-2; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; Frankel A. E., 1988, IMMUNOTOXINS; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177, DOI DOI 10.1016/S0065-2776(08)60351-X; HAMANN KJ, 1989, GENE, V83, P161, DOI 10.1016/0378-1119(89)90414-9; HARPER JW, 1989, BIOCHEMISTRY-US, V28, P1875, DOI 10.1021/bi00430a067; HONJO T, 1968, J BIOL CHEM, V243, P3553; KURACHI K, 1985, BIOCHEMISTRY-US, V24, P5494, DOI 10.1021/bi00341a032; LEE FS, 1989, BIOCHEM BIOPH RES CO, V161, P121, DOI 10.1016/0006-291X(89)91569-6; LUNDGREN JD, 1991, J ALLERGY CLIN IMMUN, V87, P689, DOI 10.1016/0091-6749(91)90390-A; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; PRIOR TI, 1991, CELL, V64, P1017, DOI 10.1016/0092-8674(91)90325-S; RICHARDS FM, 1971, ENZYMES, V4, P647; ROSENBERG HF, 1989, P NATL ACAD SCI USA, V86, P4460, DOI 10.1073/pnas.86.12.4460; RYBAK SM, 1991, J BIOL CHEM, V266, P21202; SAXENA JK, 1990, NUCLEIC ACIDS RES, V18, P7425, DOI 10.1093/nar/18.24.7425; SAXENA SK, 1991, J BIOL CHEM, V266, P21208; SAXENA SK, 1989, J BIOL CHEM, V264, P596; Schwarz R, 1979, ATLAS PROTEIN SEQUEN, P353, DOI DOI 10.2307/2408678; SHAPIRO R, 1986, BIOCHEMISTRY-US, V25, P3527, DOI 10.1021/bi00360a008; SHAPIRO R, 1987, BIOCHEMISTRY-US, V26, P5141, DOI 10.1021/bi00390a037; SHAPIRO R, 1987, P NATL ACAD SCI USA, V84, P8783, DOI 10.1073/pnas.84.24.8783; SLIFMAN NR, 1986, J IMMUNOL, V137, P2913; SMYTH DG, 1963, J BIOL CHEM, V238, P227; STCLAIR DK, 1987, P NATL ACAD SCI USA, V84, P8330; STCLAIR DK, 1988, BIOCHEMISTRY-US, V27, P7263, DOI 10.1021/bi00419a013; STRYDOM DJ, 1985, BIOCHEMISTRY-US, V24, P5486, DOI 10.1021/bi00341a031; VITETTA ES, 1990, J CLIN IMMUNOL, V10, pS15, DOI 10.1007/BF00918687; WEINER HL, 1987, SCIENCE, V237, P280, DOI 10.1126/science.2440105	38	135	144	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21982	21986						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400510				2022-12-25	WOS:A1992JV01100111
J	XU, T; MURPHY, JR				XU, T; MURPHY, JR			BINDING OF THE METALLOREGULATORY PROTEIN DTXR TO THE DIPHTHERIA TOX OPERATOR REQUIRES A DIVALENT HEAVY-METAL ION AND PROTECTS THE PALINDROMIC SEQUENCE FROM DNASE-I DIGESTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORYNEBACTERIUM-DIPHTHERIAE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; IRON; GENE; REPRESSOR; BETA; EXPRESSION; STRAINS	Transcription of the corynebacteriophage diphtheria tox operon has been shown to be regulated through a corynebacterial determined factor DtxR. The dtxR gene has been recently cloned and expressed in Escherichia coli, and shown to regulate the expression of beta-galactosidase expression from a diphtheria tox promoter/operator-lacZ transcriptional fusion. Tao et al. (Tao, X., Boyd, J., and Murphy, J. R. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5897-5901) have recently shown by gel mobility shift assay that the binding of DtxR to the tox operator requires a divalent heavy metal ion, as well as the 27-base pair interrupted palindromic sequence. We now show the activation of DtxR in the presence of Co2+, Fe2+, or Mn2+ results in the protection of a 33- and 27-nucleotide region on the coding and non-coding strand from DNase I digestion, respectively. DtxR is also activated in the presence of Ni2+; however, this metalloregulatory factor is only weakly activated by Zn2+. The diphtheria tox regulatory region protected from DNase I digestion in the presence of activated DtxR encompasses the 27-base pair interrupted palindromic sequence.	UNIV HOSP BOSTON,DEPT MED,88 E NEWTON ST,BOSTON,MA 02118; UNIV HOSP BOSTON,EVANS DEPT CLIN RES,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021628] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-21628] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel FM., 1988, CURRENT PROTOCOLS MO; BOYD J, 1990, P NATL ACAD SCI USA, V87, P5968, DOI 10.1073/pnas.87.15.5968; BOYD J, 1988, J BACTERIOL, V170, P5949, DOI 10.1128/jb.170.12.5949-5952.1988; BOYD JM, 1992, J BACTERIOL, V174, P1268, DOI 10.1128/jb.174.4.1268-1272.1992; BUCK GA, 1985, INFECT IMMUN, V49, P679, DOI 10.1128/IAI.49.3.679-684.1985; DELORENZO V, 1987, J BACTERIOL, V169, P2624, DOI 10.1128/jb.169.6.2624-2630.1987; FOUREL G, 1989, INFECT IMMUN, V57, P3221, DOI 10.1128/IAI.57.10.3221-3225.1989; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; GROMAN N, 1979, J BACTERIOL, V135, P511; KACZOREK M, 1983, SCIENCE, V221, P855, DOI 10.1126/science.6348945; KANEI C, 1977, INFECT IMMUN, V18, P203, DOI 10.1128/IAI.18.1.203-209.1977; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maxam A M, 1980, Methods Enzymol, V65, P499; Miller J.H., 1972, EXPT MOL GENETICS; Mueller JH, 1941, J IMMUNOL, V40, P21; MURPHY JR, 1974, P NATL ACAD SCI USA, V71, P11, DOI 10.1073/pnas.71.1.11; MURPHY JR, 1976, J VIROL, V18, P235, DOI 10.1128/JVI.18.1.235-244.1976; MURPHY JR, 1979, MICROBIOLOGY 1979, P181; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; SCHMITT MP, 1991, INFECT IMMUN, V59, P1899, DOI 10.1128/IAI.59.6.1899-1904.1991; SCHMITT MP, 1991, INFECT IMMUN, V59, P3903, DOI 10.1128/IAI.59.11.3903-3908.1991; TAO X, 1992, P NATL ACAD SCI USA, V89, P5897, DOI 10.1073/pnas.89.13.5897; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WELKOS SL, 1981, J VIROL, V37, P936, DOI 10.1128/JVI.37.3.936-945.1981	24	76	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21761	21764						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400485				2022-12-25	WOS:A1992JV01100078
J	AMITAY, R; SHACHAR, I; RABINOVICH, E; HAIMOVICH, J; BARNUN, S				AMITAY, R; SHACHAR, I; RABINOVICH, E; HAIMOVICH, J; BARNUN, S			DEGRADATION OF SECRETORY IMMUNOGLOBULIN-M IN LYMPHOCYTES-B OCCURS IN A POSTENDOPLASMIC RETICULUM COMPARTMENT AND IS MEDIATED BY A CYSTEINE PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASIALOGLYCOPROTEIN RECEPTOR SUBUNITS; PERIPHERAL MEMBRANE-PROTEIN; CULTURED RAT HEPATOCYTES; CLATHRIN-COATED VESICLES; PRE-GOLGI DEGRADATION; BREFELDIN-A ARRESTS; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; RECYCLING PATHWAY	In 38C B lymphocytes, membrane IgM is expressed on the surface, whereas secretory IgM (sIgM) is rapidly degraded. Here, we localize this degradation and characterize the proteases involved in this process. Upon treatment with brefeldin A, degradation of sIgM in 38C cells was strongly inhibited, as was secretion from the sIgM-secreting D2 hybridoma. Moreover, the brefeldin A-induced Golgi resorption resulted in galactosylation of sIgM and partial resistance to endoglycosidase H. However, sIgM avoided degradation neither due to modified terminal glycosylation nor as a consequence of the brefeldin A-induced altered milieu of the endoplasmic reticulum. When these modifications were prevented by inhibiting retrograde transport with nocodazole or by abrogating terminal glycosylation with swainsonine, sIgM was still rescued from degradation. The unaffected breakdown in the presence of nocodazole also argued against recycling of sIgM to be degraded in the endoplasmic reticulum. Furthermore, upon removal of brefeldin A, degradation of galactosylated sIgM resumed in 38C cells, as did secretion from D2 cells. These results indicate that functional export of proteins from the endoplasmic reticulum is a prerequisite for sIgM degradation. Biochemical characterization of this novel postendoplasmic reticulum/pre-trans-Golgi proteolytic pathway included application of inhibitors to a broad spectrum of proteases. Among the compounds tested, only calpain inhibitor I exerted strong inhibition. The involvement of cysteine protease(s) in the degradation of sIgM was corroborated by the inhibitory effect of diamide. We conclude that B lymphocytes avoid secretion by active and selective targeting of sIgM to a developmentally regulated postendoplasmic reticulum degradation pathway in which degradation is mediated by a cysteine protease.	TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, SACKLER SCH MED, DEPT BIOCHEM, IL-69978 TEL AVIV, ISRAEL; TEL AVIV UNIV, SACKLER SCH MED, DEPT HUMAN MICROBIOL, TEL AVIV, ISRAEL	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine								ADORINI L, 1990, NATURE, V346, P63, DOI 10.1038/346063a0; ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; AMITAY R, 1991, J BIOL CHEM, V266, P12568; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; BRANDLI AW, 1991, BIOCHEM J, V276, P1; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CIECHANOVER A, 1989, TRENDS BIOCHEM SCI, V14, P483, DOI 10.1016/0968-0004(89)90180-1; CURIEL DT, 1990, MOL CELL BIOL, V10, P47, DOI 10.1128/MCB.10.1.47; DAVIS AC, 1988, EUR J IMMUNOL, V18, P1001, DOI 10.1002/eji.1830180705; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DOYLE C, 1986, J CELL BIOL, V103, P1193, DOI 10.1083/jcb.103.4.1193; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DULIS BH, 1982, J BIOL CHEM, V257, P4369; ESSER V, 1988, J BIOL CHEM, V263, P13276; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; HARRI E, 1963, HELV CHIM ACTA, V46, P1235, DOI 10.1002/hlca.19630460419; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; INOUE S, 1991, J BIOL CHEM, V266, P13311; KLAUSNER RD, 1989, CELL, V57, P703, DOI 10.1016/0092-8674(89)90783-6; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; LAU MMH, 1989, J BIOL CHEM, V264, P21376; LE A, 1990, J BIOL CHEM, V265, P14001; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; ODA K, 1990, BIOCHEM J, V265, P161, DOI 10.1042/bj2650161; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1991, CELL, V64, P1183; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; ROITELMAN J, 1991, J BIOL CHEM, V266, P16085; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTUNDO RL, 1989, J BIOL CHEM, V264, P3146; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SATO R, 1990, J BIOL CHEM, V265, P11880; SCHIMKE RT, 1973, ADV ENZYMOL RAMB, V37, P135; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SHACHAR I, 1992, IN PRESS J BIOL CHEM; SIDMAN C, 1981, CELL, V23, P379, DOI 10.1016/0092-8674(81)90133-1; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; STROUS GJ, 1991, BIOL CELL, V71, P25, DOI 10.1016/0248-4900(91)90048-R; TAKATSUKI A, 1985, AGR BIOL CHEM TOKYO, V49, P899, DOI 10.1080/00021369.1985.10866826; TAMAI M, 1986, J PHARMACOBIO-DYNAM, V9, P672, DOI 10.1248/bpb1978.9.672; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAO YS, 1992, J CELL BIOL, V116, P57, DOI 10.1083/jcb.116.1.57; ULMER JB, 1991, J BIOL CHEM, V266, P9173; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WIKSTROM L, 1992, J BIOL CHEM, V267, P5; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973; WILEMAN T, 1991, CELL REGUL, V2, P753, DOI 10.1091/mbc.2.9.753; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J	71	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20694	20700						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400386				2022-12-25	WOS:A1992JT97800030
J	PALFI, Z; BINDEREIF, A				PALFI, Z; BINDEREIF, A			IMMUNOLOGICAL CHARACTERIZATION AND INTRACELLULAR-LOCALIZATION OF TRANSSPLICEOSOMAL SMALL NUCLEAR RIBONUCLEOPROTEINS IN TRYPANOSOMA-BRUCEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-SM AUTOANTIBODIES; SPLICED LEADER; PROTEIN-COMPONENTS; RNA GENES; U2; PURIFICATION; PARTICLES; SNRNPS; IDENTIFICATION; CONSTITUENTS	Polyclonal antibodies were raised against purified protein components of the U2 small nuclear ribonucleoprotein (snRNP) from Trypanosoma brucei. Through immunoblot and immunoprecipitation analyses three antisera were characterized that reacted specifically with U2 snRNP proteins of molecular weights 40,000 (anti-40K) and 16,500 (anti-16.5K), and with each of four proteins of molecular weights 14,000, 12,500, 10,000, and 8,500 (anti-CP). Anti-40K antibodies specifically immunoprecipitated the U2 snRNP from trypanosomal extracts, whereas anti-CP antibodies recognized several snRNPs, including the SL RNP and the U2 and U4/U6 snRNPs; in addition, minor RNAs were detected, suggesting that a family of snRNPs with common or related protein components exists in trypanosomes. None of these antibodies cross-reacted significantly with total mammalian snRNP proteins, indicating that the trypanosomal snRNP proteins are immunologically distinct from their mammalian counterparts. Using immunofluorescence microscopy, the snRNP proteins exhibited a differential cellular distribution. Whereas the 40-kDa protein is localized exclusively in the nucleus, with the nucleolus being excluded, a fraction of the common proteins also resides in the cytoplasm.	MAX PLANCK INST MOLEC GENET, OTTO WARBURG LAB, IHNESTR 73, W-1000 BERLIN 33, GERMANY	Max Planck Society								AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; BRUN R, 1979, ACTA TROP, V36, P289; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CROSS M, 1991, MOL CELL BIOL, V11, P5516, DOI 10.1128/MCB.11.11.5516; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUNZL A, 1992, MOL CELL BIOL, V12, P468; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HANNON GJ, 1991, J BIOL CHEM, V266, P22792; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRD PW, 1989, TRENDS GENET, V5, P204, DOI 10.1016/0168-9525(89)90082-6; LEHMEIER T, 1990, NUCLEIC ACIDS RES, V18, P6475, DOI 10.1093/nar/18.22.6475; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MICHAELI S, 1990, J BIOL CHEM, V265, P10582; MOTTRAM J, 1989, MOL CELL BIOL, V9, P1212, DOI 10.1128/MCB.9.3.1212; PALFI Z, 1991, P NATL ACAD SCI USA, V88, P9097, DOI 10.1073/pnas.88.20.9097; PALFI Z, 1989, NUCLEIC ACIDS RES, V17, P1445, DOI 10.1093/nar/17.4.1445; REUTER R, 1984, EXP CELL RES, V154, P548, DOI 10.1016/0014-4827(84)90179-4; RUDENKO G, 1991, EMBO J, V10, P3387, DOI 10.1002/j.1460-2075.1991.tb04903.x; SILICIANO PG, 1987, SCIENCE, V237, P1484, DOI 10.1126/science.3306922; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; TOLLERVEY D, 1987, EMBO J, V6, P469, DOI 10.1002/j.1460-2075.1987.tb04777.x; TSCHUDI C, 1986, NUCLEIC ACIDS RES, V14, P8893, DOI 10.1093/nar/14.22.8893; TSCHUDI C, 1990, CELL, V61, P459, DOI 10.1016/0092-8674(90)90527-L; TSCHUDI C, 1988, NUCLEIC ACIDS RES, V16, P11375, DOI 10.1093/nar/16.23.11375; VANDOREN K, 1988, NATURE, V335, P556; ZIEVE GW, 1990, CRIT REV BIOCHEM MOL, V25, P1, DOI 10.3109/10409239009090604; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P5153, DOI 10.1093/nar/19.19.5153	31	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20159	20163						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400334				2022-12-25	WOS:A1992JR85800066
J	STEINBERG, TH; BURGESS, RR				STEINBERG, TH; BURGESS, RR			TAGETITOXIN INHIBITION OF RNA POLYMERASE-III TRANSCRIPTION RESULTS FROM ENHANCED PAUSING AT DISCRETE SITES AND IS TEMPLATE-DEPENDENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENES; U6; INVITRO; COMPLEXES; ELEMENTS	In yeast nuclear extracts, tagetitoxin inhibition of RNA Polymerase III promoter-directed single- and multiple-round transcription is characterized by pausing or stalling of the elongation complex at several discrete points on the template. Paused ternary complexes isolated from tagetitoxin-inhibited reactions can be elongated to produce full-length RNA. The distribution of "tagetitoxin-enhanced" pause sites is distinct for each of the class III genes we have examined. These tagetitoxin-enhanced pause sites may also be intrinsic pause sites for the elongation complex. Tagetitoxin inhibition of in vitro transcription of the yeast SUP4 and SUP6 tRNA(Tyr) genes demonstrates template dependence and indicates that inhibition may occur after UMP incorporation. Factor-independent transcription by purified yeast RNA polymerase III can also be inhibited by tagetitoxin, and the degree of inhibition is template-dependent. Tagetitoxin may be most effective as an inhibitor under conditions where polymerase III tends to pause on the template. We propose that differences in tagetitoxin inhibition among class III genes may reflect differences in the number and stability of these pause sites.	UNIV WISCONSIN,MCARDLE LAB CANC RES,DEPT ONCOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Burgess, Richard/0000-0001-9545-3165	NATIONAL CANCER INSTITUTE [P01CA023076, P30CA007175, T32CA009135] Funding Source: NIH RePORTER; NCI NIH HHS [CA-23076, CA-07175, CA-09135] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARRAND JR, 1982, J VIROL, V41, P376, DOI 10.1128/JVI.41.2.376-389.1982; BOGENHAGEN DF, 1982, CELL, V28, P413, DOI 10.1016/0092-8674(82)90359-2; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; BROW DA, 1987, J BIOL CHEM, V262, P13959; DAHLBERG JE, 1991, SCIENCE, V254, P1462, DOI 10.1126/science.1962205; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; EVANS CF, 1990, METHOD ENZYMOL, V181, P439; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GRONDAL EJM, 1989, EMBO J, V8, P3383, DOI 10.1002/j.1460-2075.1989.tb08502.x; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; JAT P, 1982, NUCLEIC ACIDS RES, V10, P3407, DOI 10.1093/nar/10.11.3407; JIN DJ, 1991, J BIOL CHEM, V266, P14478; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KOCK J, 1991, MOL MICROBIOL, V5, P835, DOI 10.1111/j.1365-2958.1991.tb00756.x; KROL A, 1987, NUCLEIC ACIDS RES, V15, P2463, DOI 10.1093/nar/15.6.2463; KUNKEL GR, 1991, BIOCHIM BIOPHYS ACTA, V1088, P1, DOI 10.1016/0167-4781(91)90146-D; KUNKEL GR, 1988, GENE DEV, V2, P196, DOI 10.1101/gad.2.2.196; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LUKENS JH, 1985, PLANTA, V165, P311, DOI 10.1007/BF00392227; MATHEWS DE, 1990, J BIOL CHEM, V265, P493; MATHEWS DE, 1988, THESIS U WISCONSINMA; MITCHELL RE, 1989, TETRAHEDRON LETT, V30, P501, DOI 10.1016/S0040-4039(00)95239-0; MURPHY S, 1989, TRENDS GENET, V5, P122, DOI 10.1016/0168-9525(89)90043-7; PALMER JM, 1990, TRENDS BIOCHEM SCI, V15, P300, DOI 10.1016/0968-0004(90)90018-7; REDDY R, 1988, J BIOL CHEM, V263, P15980; SCHULTZ LD, 1976, P NATL ACAD SCI USA, V73, P1029, DOI 10.1073/pnas.73.4.1029; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; STEINBERG TH, 1990, J BIOL CHEM, V265, P499; VALENZUELA P, 1976, P NATL ACAD SCI USA, V73, P1024, DOI 10.1073/pnas.73.4.1024; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x	33	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20204	20211						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400338				2022-12-25	WOS:A1992JR85800073
J	TSURUDOME, M; GLUCK, R; GRAF, R; FALCHETTO, R; SCHALLER, U; BRUNNER, J				TSURUDOME, M; GLUCK, R; GRAF, R; FALCHETTO, R; SCHALLER, U; BRUNNER, J			LIPID INTERACTIONS OF THE HEMAGGLUTININ HA2 NH2-TERMINAL SEGMENT DURING INFLUENZA VIRUS-INDUCED MEMBRANE-FUSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL-ELECTROPHORESIS; INDUCED CONFORMATIONAL CHANGE; RAPID EXTRUSION PROCEDURE; LOW-PH; PROTEIN; ECTODOMAIN; VESICLES; SUBUNIT; PEPTIDE; SITE	Fusion of influenza viruses with target membranes is induced by acid and involves complex changes in the viral fusion protein hemagglutinin (HA) and in the contact sites between viruses and target membranes (Stegmann, T., White, J. M., and Helenius, A. (1990) EMBO J. 9,4231-4241). At 0-degrees-C, in a first, kinetically distinct step, target membranes irreversibly adhere to the viruses. Fusion itself starts only after a lag-phase of several minutes (X-31 strain viruses) or after raising the temperature (PR8/34 strain viruses). We now provide evidence that the initial conformational change resulting in virus-target membrane adhesion is restricted to a (minor) subpopulation of the HA molecules. These molecules become susceptible to bromelain digestion, and they could be labeled with the photoactivatable reagent [H-3]PTPC/11, a nonexchangeable lipid present in the target lipid bilayer (Harter, C., Bachi, T., Semenza, G., and Brunner, J. (1988) Biochemistry 27, 1856-1864). Only the HA2 subunit was labeled, and analyses of 2-nitro-5-thio-cyanobenzoic acid fragments derived thereof indicate that the HA2 NH2-terminal segment (fusion peptide) inserted into the target membrane bilayer. When the temperature was raised to trigger fusion of PR8/34 viruses, labeling of HA2 increased by a factor of 130. Most (74%) of that label was incorporated into the COOH-terminal membrane anchor region, but there was also a strong increase (about 30-fold) of NH2-terminal fusion peptide labeling. This suggests that fusion is preceded., or accompanied, by further changes in HA which lead to additional extensive lipid insertions of HA2 fusion peptides.	SWISS FED INST TECHNOL, DEPT BIOCHEM, UNIV STR 16, CH-8092 ZURICH, SWITZERLAND; SWISS SERUM & VACCINE INST, CH-3021 BERN, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich								BALL EH, 1986, ANAL BIOCHEM, V155, P23, DOI 10.1016/0003-2697(86)90218-6; BENTZ J, 1990, FEBS LETT, V276, P1, DOI 10.1016/0014-5793(90)80492-2; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BRAND CM, 1972, NATURE-NEW BIOL, V238, P145, DOI 10.1038/newbio238145a0; BRUNNER J, 1989, METHOD ENZYMOL, V172, P628; BRUNNER J, 1991, BIOCHEMISTRY-US, V30, P2432, DOI 10.1021/bi00223a019; BRUNNER J, 1979, J BIOL CHEM, V254, P1821; DOMS RW, 1985, J BIOL CHEM, V260, P2973; GERHARD W, 1976, J EXP MED, V144, P985, DOI 10.1084/jem.144.4.985; GETHING MJ, 1986, J CELL BIOL, V102, P11, DOI 10.1083/jcb.102.1.11; HARTER C, 1989, J BIOL CHEM, V264, P6459; HARTER C, 1988, BIOCHEMISTRY-US, V27, P1856, DOI 10.1021/bi00406a010; HELM CA, 1989, SCIENCE, V246, P919, DOI 10.1126/science.2814514; HIRANO H, 1990, ELECTROPHORESIS, V11, P573, DOI 10.1002/elps.1150110708; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PURI A, 1990, J VIROL, V64, P3824, DOI 10.1128/JVI.64.8.3824-3832.1990; RUIGROK RWH, 1986, EMBO J, V5, P41, DOI 10.1002/j.1460-2075.1986.tb04175.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHAW JM, 1979, BIOCHEMISTRY-US, V18, P538, DOI 10.1021/bi00570a024; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; STEGMANN T, 1987, J BIOL CHEM, V262, P17744; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; Wilschut J., 1990, MEMBRANE FUSION; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WINTER G, 1981, NATURE, V292, P72, DOI 10.1038/292072a0	33	137	138	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20225	20232						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400340				2022-12-25	WOS:A1992JR85800076
J	SMITH, PL; SKELTON, TP; FIETE, D; DHARMESH, SM; BERANEK, MC; MACPHAIL, L; BROZE, GJ; BAENZIGER, JU				SMITH, PL; SKELTON, TP; FIETE, D; DHARMESH, SM; BERANEK, MC; MACPHAIL, L; BROZE, GJ; BAENZIGER, JU			THE ASPARAGINE-LINKED OLIGOSACCHARIDES ON TISSUE FACTOR PATHWAY INHIBITOR TERMINATE WITH SO4-4GALNAC-BETA-1,4GLCNAC-BETA-1,2MAN-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; PITUITARY GLYCOPROTEIN HORMONES; COAGULATION INHIBITOR; SIALYLATED OLIGOSACCHARIDES; ANIONIC OLIGOSACCHARIDES; STRUCTURAL ELUCIDATION; BOVINE LUTROPIN; LIPOPROTEIN; FOLLITROPIN; THYROTROPIN	Tissue factor pathway inhibitor (TFPI) produced by endothelial cells contains sulfated Asn-linked oligosaccharides. We have determined that >70% of the oligosaccharides on recombinant TFPI expressed in 293 cells terminate with the sequence SO4-4GalNAcbeta1, 4GlcNAcbeta1,2Manalpha. Oligosaccharides terminating with this sequence have previously been described on lutropin, thyrotropin, and pro-opiomelanocortin. glycoproteins synthesized in the anterior pituitary. A GalNAc-transferase that recognizes the tripeptide motif Pro-Xaa-Arg/Lys 6-9 residues N-terminal to Asn glycosylation sites accounts for the specific addition of GalNAc to the oligosaccharide acceptor on these glycoproteins, whereas a GalNAcbeta1,4GlcNAcbeta1,2Manalpha-4-sulfotransferase accounts for the addition of sulfate. The sulfated oligosaccharides present on these hormones are responsible for their rapid clearance from plasma by a receptor in hepatic reticuloendothelial cells. GalNAc- and sulfotransferase activities with the same properties as those expressed in the pituitary are detected at high levels in 293 cells and at lower levels in endothelial cells. Chinese hamster ovary (CHO) cells do not contain detectable levels of either transferase and rTFPI expressed in CHO cells does not contain sulfated Asn-linked oligosaccharides. TFPI contains the sequence Pro-Phe-Lys, 9 residues N-terminal to the glycosylation site at position 228; this tripeptide may act as the recognition sequence for the GalNAc-transferase. rTFPI produced by 293 cells, but not that produced by CHO cells, is bound by the receptor on hepatic reticuloendothelial cells suggesting the sulfated structures play a role in the biologic behavior of TFPI.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; JEWISH HOSP ST LOUIS,DEPT HEMATOL ONCOL,ST LOUIS,MO 63110	Washington University (WUSTL); Barnes-Jewish Hospital			Baenziger, Jacques U/E-9430-2012		NATIONAL CANCER INSTITUTE [R37CA021923] Funding Source: NIH RePORTER; NCI NIH HHS [R37-CA21923] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BAENZIGER JU, 1988, BIOCHIM BIOPHYS ACTA, V947, P287, DOI 10.1016/0304-4157(88)90012-3; BAENZIGER JU, 1991, BIOL CARBOHYDRATES, V3, P1; BAJAJ MS, 1990, P NATL ACAD SCI USA, V87, P8869, DOI 10.1073/pnas.87.22.8869; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; BROZE GJ, 1987, BLOOD, V69, P150; COLBURN P, 1988, IN VITRO CELL DEV B, V24, P1133; DAY KC, 1990, BLOOD, V76, P1538; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; GREEN ED, 1985, J BIOL CHEM, V260, P5623; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; GREEN ED, 1985, P NATL ACAD SCI USA, V82, P7850, DOI 10.1073/pnas.82.23.7850; GREEN ED, 1984, P NATL ACAD SCI-BIOL, V81, P5320, DOI 10.1073/pnas.81.17.5320; GREEN ED, 1986, ANAL BIOCHEM, V158, P42, DOI 10.1016/0003-2697(86)90585-3; MELLIS SJ, 1983, ANAL BIOCHEM, V134, P442, DOI 10.1016/0003-2697(83)90320-2; NOVOTNY WF, 1988, BLOOD, V72, P2020; NOVOTNY WF, 1991, BLOOD, V78, P387; NOVOTNY WF, 1989, J BIOL CHEM, V264, P18832; PALCIC M M, 1991, Glycobiology, V1, P205, DOI 10.1093/glycob/1.2.205; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; SANDERS NL, 1985, BLOOD, V66, P204; SANDSET PM, 1988, THROMB RES, V50, P803, DOI 10.1016/0049-3848(88)90340-4; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SKELTON TP, 1991, J BIOL CHEM, V266, P17142; SKELTON TP, 1992, J BIOL CHEM, V267, P12998; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; SMITH PL, 1990, J BIOL CHEM, V265, P874; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SMITH PL, 1990, P NATL ACAD SCI USA, V87, P7275, DOI 10.1073/pnas.87.18.7275; WARNCRAMER BJ, 1991, THROMB RES, V61, P515, DOI 10.1016/0049-3848(91)90159-T; WESSELSCHMIDT R, 1992, IN PRESS BLOOD; WUN TC, 1988, J BIOL CHEM, V263, P6001	35	73	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19140	19146						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1388166				2022-12-25	WOS:A1992JP59300023
J	RICHIERI, GV; OGATA, RT; KLEINFELD, AM				RICHIERI, GV; OGATA, RT; KLEINFELD, AM			A FLUORESCENTLY LABELED INTESTINAL FATTY-ACID BINDING-PROTEIN - INTERACTIONS WITH FATTY-ACIDS AND ITS USE IN MONITORING FREE FATTY-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ARACHIDONIC-ACID; RAT; METABOLISM; RECEPTOR; CELLS; PURIFICATION; EXPRESSION; VESICLES	The fatty acid-binding protein from rat intestine (I-FABP) has been covalently modified with the fluorescent compound Acrylodan. Acrylodan was found to label Lys27, one of the few amino acid residues found by x-ray diffraction studies to change orientation upon fatty acid (FA) binding to I-FABP. Binding of FA to this Acrylodan-modified I-FABP (ADIFAB) induces a large shift in fluorescence emission wavelength from 432 to 505 nm. As a consequence, the ratio of emission intensities provides a direct measure of the concentration of FA bound to the protein. Binding of FA is well described by single site equilibrium for FA concentration below the critical micelle concentration. ADIFAB dissociation constants (K(d)) determined at 37-degrees-C and at concentrations below the critical micelle concentration for oleate, palmitate, linoleate, arachidonate, and linolenate were, respectively, 0.28, 0.33, 0.97, 1.6, and 2.5 muM. The variation of these K(d) values with FA molecular species is highly correlated with the solubility of the FA in water, suggesting that all these FA bind with a similar conformation in the I-FABP binding site. The ADIFAB response together with the measured equilibrium constants allows a direct determination of the concentration of long chain free fatty acid (FFA) in the concentration range, depending upon the FA molecular species, between 1 nM and >20 muM. As an example of its use as a probe to measure FFA levels, ADIFAB is used here to monitor the time course for FFA release from IgE receptor- and ionomycin-activated rat basophilic leukemia (RBL) cells.	MED BIOL INST,DIV MEMBRANE BIOL,11077 N TORREY PINES RD,LA JOLLA,CA 92037						NIGMS NIH HHS [GM29831, GM44171] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029831, R01GM044171] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANEL A, 1990, BIOCHIM BIOPHYS ACTA, V1044, P323, DOI 10.1016/0005-2760(90)90076-A; APGAR JR, 1990, J IMMUNOL, V145, P3814; BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; CHINANDER LL, 1989, J BIOL CHEM, V264, P19564; CREWS FT, 1981, ARCH BIOCHEM BIOPHYS, V212, P561, DOI 10.1016/0003-9861(81)90399-4; GLATZ JFC, 1983, ANAL BIOCHEM, V132, P89, DOI 10.1016/0003-2697(83)90429-3; GOODMAN DS, 1958, J AM CHEM SOC, V80, P3887, DOI 10.1021/ja01548a023; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANNIGAN GE, 1991, SCIENCE, V251, P204, DOI 10.1126/science.1898993; HAUNERLAND N, 1984, H-S Z PHYSIOL CHEM, V365, P365, DOI 10.1515/bchm2.1984.365.1.365; HOCHACHKA PW, 1986, SCIENCE, V231, P234, DOI 10.1126/science.2417316; HWANG TC, 1990, P NATL ACAD SCI USA, V87, P5706, DOI 10.1073/pnas.87.15.5706; INOUYE S, 1987, SYNTHESIS APPLICATIO, P181; KLEINFELD AM, 1991, BIOPHYS J, V59, P637; LEWIS RA, 1981, NATURE, V293, P103, DOI 10.1038/293103a0; LIN PY, 1991, J IMMUNOL, V146, P1609; LOWE JB, 1987, J BIOL CHEM, V262, P5931; NEMECZ G, 1991, ARCH BIOCHEM BIOPHYS, V286, P300, DOI 10.1016/0003-9861(91)90044-J; POTTER BJ, 1989, ANNU REV NUTR, V9, P253, DOI 10.1146/annurev.nu.09.070189.001345; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; RICHIERI GV, 1990, J IMMUNOL, V145, P1074; SACCHETTINI JC, 1988, J BIOL CHEM, V263, P5815; SACCHETTINI JC, 1989, P NATL ACAD SCI USA, V86, P7736, DOI 10.1073/pnas.86.20.7736; SACCHETTINI JC, 1990, MOL CELL BIOCHEM, V98, P81; SCAPIN G, 1992, J BIOL CHEM, V267, P4253; SEELIG J, 1971, EUR J BIOCHEM, V21, P17, DOI 10.1111/j.1432-1033.1971.tb01434.x; SIMPSON RB, 1974, J LIPID RES, V13, P415; SMALL DM, 1986, PHYSICAL CHEM LIPIDS; SPECTOR A A, 1978, P229; STORCH J, 1986, BIOCHEMISTRY-US, V25, P1717, DOI 10.1021/bi00355a041; STORCH J, 1989, J BIOL CHEM, V264, P8708; TSIEN RY, 1986, TRENDS BIOCHEM SCI, V11, P450, DOI 10.1016/0968-0004(86)90245-8; VINCENT SH, 1985, J BIOL CHEM, V260, P4521; YAMAGUCHI T, 1986, BIOCHIM BIOPHYS ACTA, V861, P440, DOI 10.1016/0005-2736(86)90452-9	34	193	201	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23495	23501						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429693				2022-12-25	WOS:A1992JZ23900015
J	LEPOIVRE, M; FLAMAN, JM; HENRY, Y				LEPOIVRE, M; FLAMAN, JM; HENRY, Y			EARLY LOSS OF THE TYROSYL RADICAL IN RIBONUCLEOTIDE REDUCTASE OF ADENOCARCINOMA CELLS PRODUCING NITRIC-OXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC RESONANCE; TUMOR TARGET-CELLS; L-ARGININE; ACTIVATED MACROPHAGES; ENDOTHELIAL-CELLS; SENSITIVE METHOD; DNA-SYNTHESIS; CALF THYMUS; IFN-GAMMA; IRON	Nitric oxide (NO) has been previously shown to inhibit crude preparations of ribonucleotide reductase, a key enzyme in DNA synthesis, and to destroy the essential tyrosyl free radical in pure recombinant R2 subunit of the enzyme. In R2-overexpressing TA3 cells, a decrease in the tyrosyl radical was observed by whole-cell EPR spectroscopy, as soon as 4 h after NO synthase induction by immunological stimuli. Complete loss of the tyrosyl EPR signal occurred after 7 h in cells cultured at a high density. Disappearance of the tyrosyl radical was prevented by Nomega-nitro-L-arginine, a specific inhibitor of NO synthesis, and by oxyhemoglobin, which reacts rapidly with NO. It was reproduced by S-nitrosoglutathione, a NO-releasing molecule. Stable end products of NO synthase metabolism did not affect the radical. Immunoblot analysis of the R2 subunit indicated that expression of the protein was not influenced by NO synthase activity. These results establish that NO, or a labile product of NO synthase, induces the disappearance of the R2-centered tyrosyl radical. Since the radical is necessary for ribonucleotide reductase activity, its destruction by NO would contribute markedly to the antiproliferative action exerted by macrophage-type NO synthase.	INST CURIE, INSERM, U350, F-91405 ORSAY, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	LEPOIVRE, M (corresponding author), UNIV PARIS 11, INST BIOCHIM, CNRS, U 116, F-91405 ORSAY, FRANCE.		Flaman, Jean-Michel/K-8415-2018; Lepoivre, Michel/J-8578-2013	Flaman, Jean-Michel/0000-0003-3544-0199; 				AKERBLOM L, 1981, P NATL ACAD SCI-BIOL, V78, P2159, DOI 10.1073/pnas.78.4.2159; ALBINA JE, 1991, J IMMUNOL, V147, P144; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bjerrum OJ, 1986, **NON-TRADITIONAL**, V86th, P315; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHENAIS B, 1991, J CHROMATOGR, V539, P433, DOI 10.1016/S0021-9673(01)83952-2; DRAPIER JC, 1991, J BIOL CHEM, V266, P10162; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; ELIASSON R, 1990, P NATL ACAD SCI USA, V87, P3314, DOI 10.1073/pnas.87.9.3314; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; ENGSTROM Y, 1988, EMBO J, V7, P1615, DOI 10.1002/j.1460-2075.1988.tb02987.x; ENGSTROM Y, 1979, BIOCHEMISTRY-US, V18, P2941, DOI 10.1021/bi00581a004; ERIKSSON S, 1979, BIOCHEMISTRY-US, V18, P2948, DOI 10.1021/bi00581a005; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; FONTECAVE M, 1990, J BIOL CHEM, V265, P10919; GRASLUND A, 1982, J BIOL CHEM, V257, P5711; GUTHOHRL.G, 1968, ANAL BIOCHEM, V26, P188, DOI 10.1016/0003-2697(68)90045-6; HENRY Y, 1991, EUR BIOPHYS J, V20, P1; HIBBS JB, 1987, J IMMUNOL, V138, P550; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; KELM M, 1988, BIOCHEM BIOPH RES CO, V154, P236, DOI 10.1016/0006-291X(88)90675-4; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS M, 1983, STRUCT BOND, V54, P27; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LEPOIVRE M, 1990, INT CONGR SER, V897, P415; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; LEPOIVRE M, 1991, BIOCHEM BIOPH RES CO, V179, P442, DOI 10.1016/0006-291X(91)91390-X; LEPOIVRE M, 1989, CANCER RES, V49, P1970; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MCCLARTY GA, 1987, BIOCHEMISTRY-US, V26, P8004, DOI 10.1021/bi00398a068; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; NOCEK JM, 1988, BIOCHEMISTRY-US, V27, P1014, DOI 10.1021/bi00403a026; OHSHIMA H, 1990, FOOD CHEM TOXICOL, V28, P647, DOI 10.1016/0278-6915(90)90173-K; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PELLAT C, 1990, BIOCHEM BIOPH RES CO, V166, P119, DOI 10.1016/0006-291X(90)91919-J; QUE L, 1991, SCIENCE, V253, P273, DOI 10.1126/science.1857963; RADI R, 1991, J BIOL CHEM, V266, P4244; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; STUEHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; THELANDER L, 1986, MOL CELL BIOL, V6, P3433, DOI 10.1128/MCB.6.10.3433; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; THELANDER M, 1985, J BIOL CHEM, V260, P2737; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; WRIGHT JA, 1990, BIOCHEM CELL BIOL, V68, P1364, DOI 10.1139/o90-199; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	58	121	125	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22994	23000						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1385411				2022-12-25	WOS:A1992JY16300046
J	DALLAIRE, L; BELIVEAU, R				DALLAIRE, L; BELIVEAU, R			PHOSPHATE-TRANSPORT BY CAPILLARIES OF THE BLOOD-BRAIN-BARRIER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; RAT-BRAIN; VESICLES; SODIUM; CELLS; MICROVESSELS; ACIDS	Capillaries were isolated from bovine brain cortex and used for phosphate transport studies. The influx of phosphate through capillary membranes was studied by incubation with [P-32i]phosphate followed by a rapid filtration technique. Phosphate uptake by brain capillaries was mediated by a saturable high-affinity system which is independent of the sodium concentration in the incubation medium. The apparent half-saturation constant (K(m)) and maximal influx (V(max)) were estimated to 160 muM and 0.37 nmol/mg protein/30 s. Transport was inhibited by the phosphate analogues arsenate and phosphonoformic acid with apparent inhibition constants of 5 and 11 mM, respectively. The metabolic inhibitors cyanide and ouabain had no effect on the transport activity. Competition experiments showed that phosphate uptake was inhibited up to 41% by various anions (pyruvate, acetate, citrate, glutamate, and sulfate). In addition, phosphate uptake was significantly decreased by two selective inhibitors of anionic exchangers, 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid and 4-acetamido-4'-isothiocyanostilbene-2,2'-disulfonic acid. Chloride was not a substrate of the phosphate carrier as the replacement of external chloride, by nitrate, thiocyanate, or gluconate, did not increase phosphate transport. Aminohippuric acid and N'-methylnicotinamide, two specific substrates of anionic and cationic drug exchangers, did not compete with the phosphate carrier of cerebral capillaries. However, trans-stimulation with bicarbonate increased phosphate transport by 28%, and this stimulation was inhibited by 1 mM 4,4'-diisothiocyanostilbene-2, 2'-disulfonic acid, suggesting that the carrier of the cerebral capillaries could exchange phosphate with bicarbonate.	UNIV QUEBEC,MEMBRANOL GRP RECH & BIOTHERAPEUT MOLEC LAB,CP 8888,SUCC A,MONTREAL H3C 3P8,QUEBEC,CANADA	University of Quebec; University of Quebec Montreal								BELIVEAU R, 1990, BIOCHIM BIOPHYS ACTA, V1028, P110, DOI 10.1016/0005-2736(90)90146-F; BELIVEAU R, 1988, BIOCHEM J, V252, P801, DOI 10.1042/bj2520801; BELIVEAU R, 1987, M S-MED SCI, V3, P589, DOI 10.4267/10608/3611; BERNER W, 1976, BIOCHEM J, V160, P467, DOI 10.1042/bj1600467; BESSEGHIR K, 1987, RENAL PHYSIOL BIOCH, V10, P221; BETZ AL, 1983, J NEUROCHEM, V41, P1150, DOI 10.1111/j.1471-4159.1983.tb09065.x; BRADBURY MWB, 1984, FED PROC, V43, P186; BRIGHTMAN MW, 1977, EXP EYE RES, V25, P1, DOI 10.1016/S0014-4835(77)80008-0; BURCKHARDT G, 1989, KIDNEY INT, V36, P370, DOI 10.1038/ki.1989.205; CHEN ML, 1990, J CELL PHYSIOL, V143, P488, DOI 10.1002/jcp.1041430313; DALLAIRE L, 1991, BIOCHEM J, V276, P745, DOI 10.1042/bj2760745; Djuricic B M, 1978, Adv Neurol, V20, P197; DOUSA TP, 1982, MINER ELECTROL METAB, V7, P113; GANONG WF, 1989, REV MED PHYSL, P514; GOLDSTEIN GW, 1979, J PHYSIOL-LONDON, V286, P185, DOI 10.1113/jphysiol.1979.sp012613; HOFFMANN N, 1976, PFLUG ARCH EUR J PHY, V362, P147, DOI 10.1007/BF00583641; HUTCHISON HT, 1985, EXP NEUROL, V87, P260, DOI 10.1016/0014-4886(85)90216-X; KATZMAN R, 1981, BASIC NEUROCHEMISTRY, P497; MIYAMOTO Y, 1989, AM J PHYSIOL, V256, pF540, DOI 10.1152/ajprenal.1989.256.4.F540; OLDENDORF WH, 1977, ANN NEUROL, V1, P409, DOI 10.1002/ana.410010502; OLDENDORF WH, 1973, AM J PHYSIOL, V224, P1450, DOI 10.1152/ajplegacy.1973.224.6.1450; OTT RJ, 1990, BIOCHEM PHARMACOL, V40, P659, DOI 10.1016/0006-2952(90)90572-3; PARDRIDGE WM, 1988, ANNU REV PHARMACOL, V28, P25; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; SMITH QR, 1984, J NEUROCHEM, V42, P754, DOI 10.1111/j.1471-4159.1984.tb02747.x; STEFFENS TG, 1989, AM J PHYSIOL, V256, pF596, DOI 10.1152/ajprenal.1989.256.4.F596; SZCZEPANSKAKONKEL M, 1986, J BIOL CHEM, V261, P6375; TAKUWA Y, 1985, BIOCHEM J, V230, P715, DOI 10.1042/bj2300715; WIETH JO, 1985, KIDNEY PHYSL PATHOPH, P49	29	13	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22323	22327						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429584				2022-12-25	WOS:A1992JW71900053
J	BRANDL, CJ; MARTENS, JA; LIAW, PCY; FURLANETTO, AM; WOBBE, CR				BRANDL, CJ; MARTENS, JA; LIAW, PCY; FURLANETTO, AM; WOBBE, CR			TATA-BINDING PROTEIN ACTIVATES TRANSCRIPTION WHEN UPSTREAM OF A GCN4-BINDING SITE IN A NOVEL YEAST PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; MAJOR LATE PROMOTER; SACCHAROMYCES-CEREVISIAE; DNA-BINDING; SATURATION MUTAGENESIS; MOLECULAR MECHANISMS; INITIATION SITE; TFIID COMPLEX; GENE PROMOTER; BOX FACTOR	In the gal-his3 hybrid promoter, his3-GG1, GCN4 stimulates transcription at the position normally occupied by a TATA element. This expression requires two elements within gal1-10 sequences, a REB1-binding site and a second element, Z, which resides 20 base pairs upstream of the GCN4-binding site. No obvious TATA element is present in this promoter. To characterize the function of Z, we replaced it with short random oligonucleotides and selected for expression in vivo. Fourteen elements were identified and classified into groups based upon sequence and phenotypic similarities. Group 1 elements contained functional TATA sequences that were essential for activity. TATA elements can thus function when positioned upstream of a GCN4-binding site. The Group 2 elements activated transcription poorly when used as conventional TATA elements; however, mutational analyses demonstrated that their activity required TATA-like sequences. These TATA-like sequences bound the yeast TATA-binding protein (TBP) poorly in vitro but function in vivo as TBP interaction sites based upon two criteria. First mutations that improved their TATA character correspondingly improved function and second their activity could be enhanced in the presence of an altered binding specificity mutant of TBP. Furthermore, the Group 2 elements enabled the identification of mutations outside of the TATA-like core that contribute to transcriptional activation without adversely affecting TBP binding. The finding that low affinity TBP-binding sites can be used at unconventional positions suggests that many "TATA-less' promoters contain a cryptic interaction site for TBP.	MERCK SHARP & DOHME LTD,RAHWAY,NJ 07065	Merck & Company	BRANDL, CJ (corresponding author), UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON N6A 5C1,ONTARIO,CANADA.							AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BRAM RJ, 1986, EMBO J, V5, P603, DOI 10.1002/j.1460-2075.1986.tb04253.x; BRANDL CJ, 1990, MOL CELL BIOL, V10, P4256, DOI 10.1128/MCB.10.8.4256; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARCAMO J, 1989, J BIOL CHEM, V264, P7704; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; CHEN W, 1989, EMBO J, V8, P261, DOI 10.1002/j.1460-2075.1989.tb03372.x; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; FINLEY RL, 1989, MOL CELL BIOL, V9, P4282, DOI 10.1128/MCB.9.10.4282; FINLEY RL, 1990, MOL CELL BIOL, V10, P5663, DOI 10.1128/MCB.10.11.5663; FIRE A, 1984, J BIOL CHEM, V259, P2509; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GUARENTE L, 1988, CELL, V52, P303, DOI 10.1016/S0092-8674(88)80020-5; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HOMA FL, 1988, GENE DEV, V2, P40, DOI 10.1101/gad.2.1.40; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JU QD, 1990, MOL CELL BIOL, V10, P5226, DOI 10.1128/MCB.10.10.5226; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MCCORMICK A, 1991, GENE DEV, V5, P1490, DOI 10.1101/gad.5.8.1490; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MORROW BE, 1989, J BIOL CHEM, V264, P9061; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; OLIPHANT AR, 1986, GENE, V44, P177, DOI 10.1016/0378-1119(86)90180-0; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REACH M, 1991, EMBO J, V10, P3439, DOI 10.1002/j.1460-2075.1991.tb04908.x; REINBERG D, 1987, J BIOL CHEM, V262, P3322; ROSENBERG AH, 1987, GENE AMST, V56, P126; SAFER B, 1991, J BIOL CHEM, V266, P10989; Sambrook J, 1989, MOL CLONING LABORATO; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; STONE N, 1991, PHARM TECHNOL, V15, P36; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; STRUHL K, 1982, NATURE, V300, P284, DOI 10.1038/300284a0; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; TABOR S, 1990, CURRENT PROTOCOLS MO; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TAYLOR ICA, 1990, MOL CELL BIOL, V10, P165, DOI 10.1128/MCB.10.1.165; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WANG HM, 1990, MOL CELL BIOL, V10, P1743, DOI 10.1128/MCB.10.4.1743; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S	81	11	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20943	20952						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400410				2022-12-25	WOS:A1992JT97800069
J	OBEID, LM; BLOBE, GC; KAROLAK, LA; HANNUN, YA				OBEID, LM; BLOBE, GC; KAROLAK, LA; HANNUN, YA			CLONING AND CHARACTERIZATION OF THE MAJOR PROMOTER OF THE HUMAN PROTEIN-KINASE-C BETA-GENE - REGULATION BY PHORBOL ESTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATION; HL-60 DIFFERENTIATION; CELLULAR-REGULATION; 5'-FLANKING REGION; MAMMALIAN-CELLS; EXPRESSION; FAMILY; BINDING; ISOZYMES; SEQUENCE	The expression of the beta isoenzyme for protein kinase C is regulated developmentally and in response to inducers of cell differentiation (such as phorbol esters and 1alpha,25-dihydroxyvitamin D3). The 5' segment of the gene for protein kinase C beta was cloned from a human leukocyte genomic library in EMBL3 bacteriophage. This segment of the gene (greater than 54 kilobases in length) encompassed the coding sequence for the amino-terminal regulatory domain of the enzyme, the 5'-untranslated region, and the 5'-flanking region. Initiation of transcription was identified by S1 nuclease analysis and confirmed by RNase protection analysis at 197 base pairs 5' of the initiator ATG. Sequence analysis of the 5'-flanking region revealed it to be extremely G+C-rich (>80%) with many features of a CpG island. Comparison of sequence with known cis-regulatory motifs disclosed a number of potential regulatory elements including an octamer binding motif at -76, Sp1-binding sites at -94 and -63, E boxes at -110, -26, and +18, an AP-1 site at -442, and an AP-2 site at -330. To demonstrate promoter activity, a 630-base pair fragment extending from -587 to +43 was subcloned in front of a promoterless luciferase gene. This fragment was able to drive the expression of luciferase in transient transfections of human hematopoietic cells. Deletion analysis demonstrated that a fragment -111 to +43 was necessary and sufficient for promoter activity; this fragment did not contain TATA or CAAT motifs. The promoter was stimulated 8-20-fold by phorbol esters accounting for the previously observed transcriptional activation of protein kinase C beta. This phorbol ester responsiveness was conferred by the basal promoter (-111 to +43) and was independent of the AP-1 site. These results define a novel mechanism of protein kinase C autoregulation at a transcriptional level.	DUKE UNIV,MED CTR,DEPT MED,DIV GERIATR,BOX 3355,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DIV HEMATOL ONCOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University; Duke University			Blobe, Gerard/AAJ-5945-2020	Blobe, Gerard/0000-0002-4274-8901; obeid, lina/0000-0002-0734-0847	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43707] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; CHEN KH, 1990, J BIOL CHEM, V265, P19961; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; COUSSENS L, 1987, DNA-J MOLEC CELL BIO, V6, P389, DOI 10.1089/dna.1987.6.389; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KUBO K, 1987, FEBS LETT, V223, P138, DOI 10.1016/0014-5793(87)80524-0; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LEWIN B, 1990, GENES, V4; LUMELSKY NL, 1991, MOL CELL BIOL, V11, P3528, DOI 10.1128/MCB.11.7.3528; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MANIATIS T, 1982, MOL CLONING LABORATO, P320; MARTELL RE, 1987, J BIOL CHEM, V262, P5570; MCCACHREN SS, 1988, BIOCHEM BIOPH RES CO, V151, P574, DOI 10.1016/0006-291X(88)90633-X; MCSWINEKENNICK RL, 1991, J BIOL CHEM, V266, P15135; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NIINO YS, 1992, J BIOL CHEM, V267, P6158; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBEID LM, 1990, J BIOL CHEM, V265, P2370; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1990, J BIOL CHEM, V265, P22434; OTTE AP, 1992, CELL, V68, P1021, DOI 10.1016/0092-8674(92)90074-M; Sambrook J, 1989, MOL CLONING LABORATO; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SIMPSON RU, 1989, J BIOL CHEM, V264, P19710; WETSEL WC, 1992, J CELL BIOL, V117, P11; YOSHIDA Y, 1988, J BIOL CHEM, V263, P9868	39	59	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20804	20810						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400396				2022-12-25	WOS:A1992JT97800047
J	SHIN, WS; SASAKI, T; KATO, M; HARA, K; SEKO, A; YANG, WD; SHIMAMOTO, N; SUGIMOTO, T; TOYOOKA, T				SHIN, WS; SASAKI, T; KATO, M; HARA, K; SEKO, A; YANG, WD; SHIMAMOTO, N; SUGIMOTO, T; TOYOOKA, T			AUTOCRINE AND PARACRINE EFFECTS OF ENDOTHELIUM-DERIVED RELAXING FACTOR ON INTRACELLULAR CA2+ OF ENDOTHELIAL-CELLS AND VASCULAR SMOOTH-MUSCLE CELLS - IDENTIFICATION BY 2-DIMENSIONAL IMAGE-ANALYSIS IN COCULTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTERIAL GUANYLATE-CYCLASE; NITRIC-OXIDE; CORONARY VASOSPASM; SODIUM-NITRITE; CALCIUM; RELAXATION; RELEASE; ACETYLCHOLINE; MECHANISMS; RESPONSES	To elucidate the effects of endothelium-derived relaxing factor (EDRF) released from vascular endothelial cells (ECs) on handling of intracellular calcium ion (Ca2+i) in ECs themselves and vascular smooth muscle cells (VSMCs), we measured the Ca2+i by two-dimensional digital image analysis of fura-2-loaded ECs and VSMCs in tissue culture. In isoculture of one cell type, adenosine triphosphate (ATP, 1 muM) transiently increased the Ca2+i of both ECs and VSMCs. High-K+ depolarization or angiotensin II also elevated the Ca2+i of VSMCs, whereas neither stimulants changed the Ca2+i of ECs. In coculture of ECs with VSMCs, the same dose of ATP rapidly increased the Ca2+i of ECs and then transiently decreased the Ca2+i of VSMCs to below the resting level. The maximal Ca2+i-modulating effects of ATP on both cell types were reproducible after the second application of ATP. Three kinds of EDRF blockers (L-N(G)-monomethylarginine, methemoglobin, or methylene blue) potentiated the ATP-induced Ca2+i rise in ECs and attenuated the Ca"i reduction in VSMCs, suggesting the autocrine and paracrine effects of EDRF on ECs and VSMCs, respectively. However, neither indomethacin, superoxide dismutase, nor neutralizing monoclonal antibody to endothelin-1 altered the second responses. Thus, two-dimensional Ca2+i image analysis of ECs and VSMCs in coculture enabled direct visualization of the EDRF actions in ECs and VSMCs and their modifications.	UNIV TOKYO,FAC MED,CTR HLTH SERV,DEPT INTERNAL MED 2,TOKYO 113,JAPAN	University of Tokyo								ARROYO CM, 1990, BIOCHEM BIOPH RES CO, V170, P1177, DOI 10.1016/0006-291X(90)90517-Q; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CHERRY PD, 1982, P NATL ACAD SCI USA, V79, P216; CHESTER AH, 1990, INT J CARDIOL, V29, P305, DOI 10.1016/0167-5273(90)90118-O; COCKS TM, 1990, N-S ARCH PHARMACOL, V341, P364; DEMEY JG, 1981, J PHYSIOL-LONDON, V316, P347, DOI 10.1113/jphysiol.1981.sp013792; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P2334; DOMINICZAK AF, 1991, AM J PHYSIOL, V261, pH243, DOI 10.1152/ajpheart.1991.261.1.H243; EBASHI S, 1976, S SOC EXP BIOL, V30, P349; EDWARDS JC, 1984, J PHARMACOL EXP THER, V228, P33; FURCHGOTT RF, 1984, ANNU REV PHARMACOL, V24, P175, DOI 10.1146/annurev.pa.24.040184.001135; FURCHGOTT RF, 1983, CIRC RES, V53, P557, DOI 10.1161/01.RES.53.5.557; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GRUETTER DY, 1980, BIOCHEM PHARMACOL, V29, P2943, DOI 10.1016/0006-2952(80)90042-8; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALLAM TJ, 1986, FEBS LETT, V207, P95, DOI 10.1016/0014-5793(86)80019-9; IGNARRO LJ, 1980, BIOCHIM BIOPHYS ACTA, V631, P221, DOI 10.1016/0304-4165(80)90297-4; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KONISHI M, 1988, BIOPHYS J, V54, P1089, DOI 10.1016/S0006-3495(88)83045-5; LUECKHOFF A, 1992, NATURE, V355, P356; MASUO M, 1991, CIRC RES, V69, P1327, DOI 10.1161/01.RES.69.5.1327; MONCADA S, 1988, HYPERTENSION, V12, P365, DOI 10.1161/01.HYP.12.4.365; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; ORLIDGE A, 1987, J CELL BIOL, V105, P1455, DOI 10.1083/jcb.105.3.1455; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; REES DD, 1989, BRIT J PHARMACOL, V96, P418, DOI 10.1111/j.1476-5381.1989.tb11833.x; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1145, DOI 10.1152/ajpheart.1986.250.6.H1145; SHIN WS, 1991, CIRC RES, V69, P551, DOI 10.1161/01.RES.69.2.551; SHIN WS, 1989, JPN HEART J, V30, P77; SUZUKI T, 1991, J CARDIOVASC PHARM, V17, pS187, DOI 10.1097/00005344-199100177-00053; TODA N, 1990, LIFE SCI, V47, P345, DOI 10.1016/0024-3205(90)90593-G; TOKUNAGA O, 1989, AM J PATHOL, V135, P967; TOYOOKA T, 1989, CIRC RES, V64, P407, DOI 10.1161/01.RES.64.2.407; TOYOOKA T, 1981, CIRC RES, V49, P1350, DOI 10.1161/01.RES.49.6.1350; TOYOOKA T, 1991, CIRCULATION, V83, P476, DOI 10.1161/01.CIR.83.2.476; TOYOOKA T, 1991, CIRCULATION, V84, P1451, DOI 10.1161/circ.84.3.1884470; TOYOOKA T, 1991, CORONARY ARTERY DIS, V2, P314, DOI 10.1097/00019501-199105000-00005; VANE JR, 1990, NEW ENGL J MED, V323, P27; VANHOUTTE PM, 1989, CIRCULATION, V80, P1, DOI 10.1161/01.CIR.80.1.1; WARNER TD, 1989, J CARDIOVASC PHARM, V13, pS85, DOI 10.1097/00005344-198900135-00021; WATANABE T, 1990, NATURE, V344, P144; WEI EP, 1990, HYPERTENSION, V16, P162, DOI 10.1161/01.HYP.16.2.162; WHITE DG, 1989, BRIT J PHARMACOL, V97, P683, DOI 10.1111/j.1476-5381.1989.tb12004.x; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0; YANAGISAWA M, 1989, TRENDS PHARMACOL SCI, V10, P374	45	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20377	20382						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400356				2022-12-25	WOS:A1992JR85800098
J	WOO, KM; KIM, KI; GOLDBERG, AL; HA, DB; CHUNG, CH				WOO, KM; KIM, KI; GOLDBERG, AL; HA, DB; CHUNG, CH			THE HEAT-SHOCK PROTEIN CLPB IN ESCHERICHIA-COLI IS A PROTEIN-ACTIVATED ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEASE; ION GENE; REGULATORY SUBUNIT; LA; COMPONENT; SEQUENCE; BINDING; TI; HYDROLYSIS; EXPRESSION	The clpB gene in Escherichia coli encodes a heat-shock protein that is a close homolog of the clpA gene product. The latter is the ATPase subunit of the multimeric ATP-dependent protease Ti (Clp) in E. coli, which also contains the 21-kDa proteolytic subunit (ClpP). The clpB gene product has been purified to near homogeneity by DEAE-Sepharose and heparin-agarose column chromatographies. The purified ClpB consists of a major 93-kDa protein and a minor 79-kDa polypeptide as analyzed by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate. Upon gel filtration on a Superose-6 column, it behaves as a 350-kDa protein. Thus, ClpB appears to be a tetrameric complex of the 93-kDa subunit. The purified ClpB has ATPase activity which is stimulated 5-10-fold by casein. It is also activated by insulin, but not by other proteins, including globin and denatured bovine serum albumin. ClpB cleaves adenosine 5'-(alpha,beta-methylene)-triphosphate as rapidly as ATP, but not adenosine 5'-(beta,gamma-methylene)-triphosphate. GTP, CTP, and UTP are hydrolyzed 15-25% as well as ATP. ADP strongly inhibits ATP hydrolysis with a K(i) of 34 muM. ClpB has a K(m) for ATP of 1.1 mM, and casein increases its V(max) for ATP without affecting its K(m). A Mg2+ concentration of 3 mM is necessary for half-maximal ATP hydrolysis. Mn2+ supports ATPase activity as well as Mg2+, and Ca2+ has about 20% their activity. Anti-ClpB antiserum does not cross-react with ClpA nor does anti-ClpA antiserum react with ClpB. In addition, ClpB cannot replace ClpA in supporting the casein-degrading activity of ClpP. Thus, ClpB is distinct from ClpA in its structural and biochemical properties despite the similarities in their sequences.	SEOUL NATL UNIV,COLL NAT SCI,DEPT MOLEC BIOL,SEOUL 151742,SOUTH KOREA; HARVARD UNIV,SCH MED,DEPT MOLEC & CELLULAR PHYSIOL,BOSTON,MA 02115	Seoul National University (SNU); Harvard University; Harvard Medical School			KIM, KEUN IL/D-2959-2011					Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAKE MS, 1984, ANAL BIOCHEM, V136, P175; CHARETTE MF, 1981, P NATL ACAD SCI-BIOL, V78, P4728, DOI 10.1073/pnas.78.8.4728; CHIN DT, 1988, J BIOL CHEM, V263, P11718; CHUNG CH, 1981, P NATL ACAD SCI-BIOL, V78, P4931, DOI 10.1073/pnas.78.8.4931; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; FLYNN GC, 1989, SCIENCE, V248, P850; GOFF SA, 1984, P NATL ACAD SCI-BIOL, V81, P6647, DOI 10.1073/pnas.81.21.6647; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOTTESMAN S, 1989, ANNU REV GENET, V23, P163, DOI 10.1146/annurev.ge.23.120189.001115; GOTTESMAN S, 1990, J BIOL CHEM, V265, P7886; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; HWANG BJ, 1987, P NATL ACAD SCI USA, V84, P5550, DOI 10.1073/pnas.84.16.5550; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; KITAGAWA M, 1991, J BACTERIOL, V173, P4247, DOI 10.1128/JB.173.14.4247-4253.1991; KROH HE, 1990, J BACTERIOL, V172, P6026, DOI 10.1128/jb.172.10.6026-6034.1990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENON AS, 1987, J BIOL CHEM, V262, P14921; PHILLIPS TA, 1984, J BACTERIOL, V159, P283, DOI 10.1128/JB.159.1.283-287.1984; PONTIS E, 1991, BIOCHEM BIOPH RES CO, V180, P1222, DOI 10.1016/S0006-291X(05)81326-9; SHEN WF, 1982, NUCLEIC ACIDS RES, V10, P3303, DOI 10.1093/nar/10.10.3303; SQUIRES CL, 1991, J BACTERIOL, V173, P4257; SWAMY KHS, 1983, ARCH BIOCHEM BIOPHYS, V224, P543, DOI 10.1016/0003-9861(83)90242-4; WAXMAN L, 1982, P NATL ACAD SCI-BIOL, V79, P4883, DOI 10.1073/pnas.79.16.4883; WOO KM, 1989, J BIOL CHEM, V264, P2088	31	157	158	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20429	20434						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400361				2022-12-25	WOS:A1992JR85800106
J	BJORK, I; NORDLING, K; LARSSON, I; OLSON, ST				BJORK, I; NORDLING, K; LARSSON, I; OLSON, ST			KINETIC CHARACTERIZATION OF THE SUBSTRATE REACTION BETWEEN A COMPLEX OF ANTITHROMBIN WITH A SYNTHETIC REACTIVE-BOND LOOP TETRADECAPEPTIDE AND 4 TARGET PROTEINASES OF THE INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ANTI-THROMBIN; FACTOR-XA; ALPHA-1-PROTEINASE INHIBITOR; CRYSTAL-STRUCTURE; ACTIVE-SITE; SERPINS; FORM; TRYPSIN; HEPARIN; ALPHA-1-ANTITRYPSIN	A tetradecapeptide corresponding to the P1 to P14 region of the reactive-bond loop of antithrombin (AT) binds to the inhibitor, presumably as a middle strand of the A beta-sheet, thereby converting AT from an inhibitor to a substrate of thrombin (Bjork, I., Ylinenjarvi, K., Olson, S. T., and Bock, P. E. (1992) J. Biol. Chem. 267, 1976-1982). The kinetics of cleavage of the AT reactive bond in the AT-peptide complex by four target proteinases were quantified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and densitometry. The k(cat)/K(m) values for thrombin and factor IXa were indistinguishable from the second-order rate constants for AT inhibition of these enzymes, whereas the values for factor Xa and plasmin were 10-17-fold higher than the inhibition rate constants. Heparin with high affinity for AT accelerated the substrate reaction with thrombin to an extent consistent with the reduced heparin affinity of the AT-peptide complex. These data show that blocking by the peptide of the putative intramolecular association of the P1 to P14 region of the AT reactive-bond loop with the A beta-sheet leads to AT functioning as a substrate of its target enzymes with an efficiency that equals or exceeds the action of uncomplexed AT as an inhibitor and with the expected heparin activation. The results thus suggest that a substrate-like attack of the proteinase on the inhibitor reactive bond in an exposed loop initiates the inhibition reaction. This attack presumably induces the subsequent trapping of the enzyme by the insertion of the reactive-bond loop into the A beta-sheet.	HENRY FORD HOSP,DIV BIOCHEM RES,DETROIT,MI 48202	Henry Ford Health System; Henry Ford Hospital	BJORK, I (corresponding author), SWEDISH UNIV AGR SCI,CTR BIOMED,DEPT VET MED CHEM,BOX 575,S-75123 UPPSALA,SWEDEN.				NHLBI NIH HHS [HL-39888] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039888, R29HL039888] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BJORK I, 1992, J BIOL CHEM, V267, P1976; BJORK I, 1982, J BIOL CHEM, V257, P2406; BJORK I, 1989, HEPARIN CHEM BIOL PR, P229; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; DANIELSSON A, 1980, FEBS LETT, V119, P241, DOI 10.1016/0014-5793(80)80262-6; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; ENGH RA, 1990, PROTEIN ENG, V3, P469, DOI 10.1093/protein/3.6.469; FISH WW, 1979, FEBS LETT, V98, P103, DOI 10.1016/0014-5793(79)80162-3; GREEN GDJ, 1979, ANAL BIOCHEM, V93, P223, DOI 10.1016/S0003-2697(79)80070-6; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MOUREY L, 1990, BIOCHIMIE, V72, P599, DOI 10.1016/0300-9084(90)90123-X; NORDENMAN B, 1978, BIOCHEMISTRY-US, V17, P3339, DOI 10.1021/bi00609a026; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1985, J BIOL CHEM, V260, P153; OLSON ST, 1992, IN PRESS SEMIN THROM; OLSON ST, 1992, IN PRESS THROMBIN ST; PERRY DJ, 1991, FEBS LETT, V285, P248, DOI 10.1016/0014-5793(91)80809-H; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; VILLANUEVA G, 1979, BIOCHEMISTRY-US, V18, P810, DOI 10.1021/bi00572a011; WALLGREN P, 1981, EUR J BIOCHEM, V116, P493, DOI 10.1111/j.1432-1033.1981.tb05363.x; WONG RF, 1983, BIOCHEMISTRY-US, V22, P3994, DOI 10.1021/bi00286a001	32	52	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19047	19050						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1388162				2022-12-25	WOS:A1992JP59300007
J	MAYTIN, EV				MAYTIN, EV			DIFFERENTIAL-EFFECTS OF HEAT-SHOCK AND UVB LIGHT UPON STRESS PROTEIN EXPRESSION IN EPIDERMAL-KERATINOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; DNA DAMAGE; ULTRAVIOLET-RADIATION; HUMAN-FIBROBLASTS; MESSENGER-RNA; RODENT CELLS; IRRADIATION; THERMOTOLERANCE; PURIFICATION; INDUCTION	Heat stress and ultraviolet light in the UVB range ("sunburn spectrum," 290-320 nm) were found to alter the synthesis of specific proteins in cultured keratinocytes derived from mouse skin. Using giant two-dimensional gels, approximately 2,000 cellular polypeptides labeled with [S-35]methionine at 4-5 h after exposure to heat or to UVB were analyzed. Cells conditioned at sublethal temperatures (42-degrees-C for 1 h, or 47-degrees-C for 15 min) developed thermotolerance, while cells conditioned with UVB did not develop thermotolerance. Under these heat or UVB conditions, 19 stress proteins were observed. Proteins fell into three classes based upon their inducibility by heat or UVB, dose-response, and induction mechanism (transcriptional versus post-transcriptional) as defined by metabolic blockade with cordycepin (3'-deoxyadenosine). Class 1 proteins were inducible only by heat shock. They included three major heat-shock proteins (hsp 72, hsp 78, hsp 90) and a 42.5-kDa, pI 5.43 protein, and all were induced at the transcriptional level. Class 2 proteins were inducible by heat and by UVB. These included hsp 110 and eight additional polypeptides. All but one were affected by heat at the post-transcriptional level and were induced by UVB at both low (20 mJ/cm2) and high (80 mJ/cm2) doses. Class 3 proteins were inducible only at high UVB doses (survival < 10%). Class 1 and Class 2 proteins could be functionally involved in thermotolerance, while Class 3 proteins are more likely related to damage or cell death.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	MAYTIN, EV (corresponding author), MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,DEPT DERMATOL,MGH E,BLDG 149,13TH ST,BOSTON,MA 02129, USA.				NIAMS NIH HHS [5T32AR07098-15] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007098] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON RL, 1988, INT J RADIAT BIOL, V54, P285, DOI 10.1080/09553008814551711; ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; BEACH LR, 1978, J BIOL CHEM, V253, P2628; BREITKREUTZ D, 1984, DIFFERENTIATION, V26, P154, DOI 10.1111/j.1432-0436.1984.tb01389.x; BRUNET S, 1989, MUTAT RES, V219, P217, DOI 10.1016/0921-8734(89)90003-9; CARLSSON L, 1983, P NATL ACAD SCI-BIOL, V80, P4664, DOI 10.1073/pnas.80.15.4664; DIDOMENICO BJ, 1982, P NATL ACAD SCI-BIOL, V79, P6181, DOI 10.1073/pnas.79.20.6181; EPSTEIN JH, 1970, PHOTOCHEM PHOTOBIOL, V12, P57, DOI 10.1111/j.1751-1097.1970.tb06038.x; EPSTEIN JH, 1989, AGING SKIN, P307; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1988, MOL CELL BIOL, V8, P4716, DOI 10.1128/MCB.8.11.4716; GARMYN M, 1991, LAB INVEST, V65, P471; HAZUDA D, 1989, J BIOL CHEM, V264, P1689; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HERRLICH P, 1986, ADV ENZYME REGUL, V25, P485, DOI 10.1016/0065-2571(86)90030-0; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; KARTASOVA T, 1988, EXP CELL RES, V174, P421, DOI 10.1016/0014-4827(88)90312-6; KEYSE SM, 1987, J BIOL CHEM, V262, P14821; KLIGMAN LH, 1982, ARCH DERMATOL RES, V272, P229, DOI 10.1007/BF00509050; KOLLER LR, 1965, ULTRAVIOLET RAD, P105; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; KUPPER TS, 1987, J CLIN INVEST, V80, P430, DOI 10.1172/JCI113090; LAMBERT ME, 1989, MOL CELL BIOL, V9, P847, DOI 10.1128/MCB.9.2.847; LANDRY J, 1982, CANCER RES, V42, P2457; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LEENDERS HJ, 1974, EXP CELL RES, V86, P25, DOI 10.1016/0014-4827(74)90642-9; LEVENSON RM, 1986, ANAL BIOCHEM, V158, P294, DOI 10.1016/0003-2697(86)90553-1; LI GC, 1982, P NATL ACAD SCI-BIOL, V79, P3218, DOI 10.1073/pnas.79.10.3218; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; MARCELO CL, 1978, J CELL BIOL, V79, P356, DOI 10.1083/jcb.79.2.356; MAYTIN EV, 1984, J BIOL CHEM, V259, P2135; MAYTIN EV, 1991, ANAL BIOCHEM, V194, P284, DOI 10.1016/0003-2697(91)90231-H; MAYTIN EV, 1990, J INVEST DERMATOL, V95, P635, DOI 10.1111/1523-1747.ep12514303; MAYTIN EV, 1985, J BIOL CHEM, V260, P2384; MCCORMICK W, 1969, J MOL BIOL, V39, P315, DOI 10.1016/0022-2836(69)90320-9; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MORGAN RW, 1986, P NATL ACAD SCI USA, V83, P8059, DOI 10.1073/pnas.83.21.8059; PANNIERS R, 1984, EUR J BIOCHEM, V140, P209, DOI 10.1111/j.1432-1033.1984.tb08088.x; RIABOWOL KT, 1988, SCIENCE, V242, P433, DOI 10.1126/science.3175665; RONAI ZA, 1988, ONCOGENE, V2, P201; SCHORPP M, 1984, CELL, V37, P861, DOI 10.1016/0092-8674(84)90421-5; SCOTT MP, 1981, P NATL ACAD SCI-BIOL, V78, P3353, DOI 10.1073/pnas.78.6.3353; SEKIGUCHI R, 1988, INT J RADIAT ONCOL, V14, P983, DOI 10.1016/0360-3016(88)90022-3; SHEA CR, 1991, PHYSL BIOCH MOL BIOL, P910; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STORTI RV, 1980, CELL, V22, P825, DOI 10.1016/0092-8674(80)90559-0; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TAKASUGI M, 1971, TRANSPLANTATION, V12, P148, DOI 10.1097/00007890-197108000-00010; TANKE HJ, 1982, J IMMUNOL METHODS, V52, P91, DOI 10.1016/0022-1759(82)90353-2; VORIS BP, 1981, J BIOL CHEM, V256, P1319; WANG C, 1981, P NATL ACAD SCI-BIOL, V78, P3531, DOI 10.1073/pnas.78.6.3531; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; WELCH WJ, 1989, STRESS INDUCED PROTE, P187; WILLE JJ, 1984, J CELL PHYSIOL, V121, P31, DOI 10.1002/jcp.1041210106; WILLIAMS KJ, 1989, CANCER RES, V49, P2735; WU YJ, 1981, CELL, V25, P627, DOI 10.1016/0092-8674(81)90170-7; YOST HJ, 1986, CELL, V45, P185, DOI 10.1016/0092-8674(86)90382-X; YOUNG DA, 1983, METHOD ENZYMOL, V91, P190; [No title captured]	62	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23189	23196						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429666				2022-12-25	WOS:A1992JY16300075
J	NATHANSON, MH; MOYER, MS; BURGSTAHLER, AD; OCARROLL, AM; BROWNSTEIN, MJ; LOLAIT, SJ				NATHANSON, MH; MOYER, MS; BURGSTAHLER, AD; OCARROLL, AM; BROWNSTEIN, MJ; LOLAIT, SJ			MECHANISMS OF SUBCELLULAR CYTOSOLIC CA2+ SIGNALING EVOKED BY STIMULATION OF THE VASOPRESSIN V(1A) RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; INDUCED CALCIUM RELEASE; INOSITOL 1,4,5-TRISPHOSPHATE; INTRACELLULAR CALCIUM; ACINAR-CELLS; OSCILLATIONS; CA-2+; HEPATOCYTES; TRISPHOSPHATE; CHANNELS	Receptor activation may result in distinct subcellular patterns of Ca2+ release. To define the subcellular distribution of Ca2+i signals induced by stimulation of the vasopressin V1a receptor, we expressed the cloned receptor in Xenopus oocytes. Oocytes were then loaded with fluo-3 and observed using confocal microscopy. Vasopressin induced a single concentric wave of increased Ca2+ that radiated inward from the plasma membrane. With submaximal stimulation, however, regions of the Ca2+ wave spontaneously reorganized into repetitive (oscillatory) waves. Focal stimulation of a small part of the plasma membrane resulted in a Ca2+ wave which began at the point of stimulation, radiated toward the center of the cell, then reorganized into multiple foci of repetitive, colliding waves and spirals of increased Ca2+i. The pattern of Ca2+ signaling induced by foeal or global stimulation was not altered in Ca2+-free medium, although signals did not propagate as fast. Finally, subcellular Ca2+ signaling patterns induced by vasopressin were inhibited by caffeine, while neither vasopressin nor microinjection of inositol trisphosphate blocked caffeine-induced increases in cytosolic Ca2+. Thus, stimulation of the V1a receptor in this cell system induces a complex pattern of Ca2+ signaling which is influenced by (1) the magnitude of the stimulus, (2) the distribution of the surface receptors that are stimulated, and (3) mobilization of Ca2+ from the extracellular space as well as from two distinct endogenous Ca2+ pools. The manner in which a single type of receptor is activated may represent an important potential mechanism for subcellular Ca2+i signaling.	NIMH,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	NATHANSON, MH (corresponding author), YALE UNIV,SCH MED,CTR LIVER,LIVER STUDY UNIT,1080 LMP,NEW HAVEN,CT 06510, USA.		Lolait, Stephen/AAG-4483-2020; Brownstein, Michael/B-8609-2009		NIDDK NIH HHS [P30 DK34989] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034989] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKX PH, 1989, J GEN PHYSIOL, V93, P963, DOI 10.1085/jgp.93.5.963; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BURGOYNE RD, 1989, NATURE, V342, P72, DOI 10.1038/342072a0; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DELISLE S, 1990, J BIOL CHEM, V265, P11726; EXTON JH, 1988, HEPATOLOGY, V8, P152, DOI 10.1002/hep.1840080129; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FOSKETT JK, 1991, J BIOL CHEM, V266, P14535; GILKEY JC, 1978, J CELL BIOL, V76, P448, DOI 10.1083/jcb.76.2.448; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; HABARA Y, 1991, CELL CALCIUM, V12, P533, DOI 10.1016/0143-4160(91)90073-N; HUGHES BP, 1986, BIOCHEM PHARMACOL, V35, P3045, DOI 10.1016/0006-2952(86)90384-9; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LEONG DA, 1991, J BIOL CHEM, V266, P9016; MANNING M, 1989, J LAB CLIN MED, V114, P617; MAUGER JP, 1988, J HEPATOL, V7, P278, DOI 10.1016/S0168-8278(88)80492-6; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; NATHANSON MH, 1992, AM J PHYSIOL, V262, pG1079, DOI 10.1152/ajpgi.1992.262.6.G1079; NATHANSON MH, 1992, MOL BIOL CELL, V3, P113, DOI 10.1091/mbc.3.1.113; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; NATHANSON MH, 1992, CELL CALCIUM, V13, P89, DOI 10.1016/0143-4160(92)90002-A; NATHANSON MH, 1992, HEPATOLOGY, V15, P107, DOI 10.1002/hep.1840150119; PARKER I, 1991, J PHYSIOL-LONDON, V433, P229, DOI 10.1113/jphysiol.1991.sp018423; ROBINSON IM, 1991, J NEUROCHEM, V56, P1587, DOI 10.1111/j.1471-4159.1991.tb02055.x; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROUSSEAU E, 1988, ARCH BIOCHEM BIOPHYS, V267, P75, DOI 10.1016/0003-9861(88)90010-0; SAEZ JC, 1989, P NATL ACAD SCI USA, V86, P2708, DOI 10.1073/pnas.86.8.2708; SANDERSON MJ, 1990, CELL REGUL, V1, P585, DOI 10.1091/mbc.1.8.585; SCHMID A, 1990, NATURE, V346, P374, DOI 10.1038/346374a0; SHOSHANBARMATZ V, 1990, BIOCHEM J, V268, P699, DOI 10.1042/bj2680699; SPEKSNIJDER JE, 1990, DEV BIOL, V142, P246, DOI 10.1016/0012-1606(90)90168-I; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WATANABE S, 1985, LAB INVEST, V53, P275; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	42	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23282	23289						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429675				2022-12-25	WOS:A1992JY16300088
J	RHODES, CJ; LINCOLN, B; SHOELSON, SE				RHODES, CJ; LINCOLN, B; SHOELSON, SE			PREFERENTIAL CLEAVAGE OF DES-31,32-PROINSULIN OVER INTACT PROINSULIN BY THE INSULIN SECRETORY GRANULE TYPE-II ENDOPEPTIDASE - IMPLICATIONS OF A FAVORED ROUTE FOR PROHORMONE PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATT20 CELLS; BETA-CELL; CONVERSION; SITE; KEX2; CDNA; RAT; PC2; IDENTIFICATION; SEQUENCE	Two Ca2+-dependent endopeptidase activities are involved in proinsulin to insulin conversion: type I cleaves COOH-terminal to proinsulin Arg31-Arg32 (B-chain/C-peptide junction); and type II preferentially cleaves at the Lys64-Arg65 site (C-peptide/A-chain junction). To further understand the mechanism of proinsulin processing, we have investigated types I and II endopeptidase processing of intact proinsulin in parallel to that of the conversion intermediates, des31,32-proinsulin and des-64,65-proinsulin. The type I processed des-64,65-proinsulin and proinsulin at the same rate. In contrast, the type II endopeptidase processed des-31,32-proinsulin at a much faster rate (> 19-fold; p < 0.001) than it did intact proinsulin. Furthermore, unlabeled proinsulin concentrations required for competitive inhibition of I-125-labeled des-64,65-proinsulin and I-125-proinsulin processing by a purified insulin secretory granule lysate were similar (ID50 = 14-16 muM), whereas inhibition of I-125-labeled des-31,32-proinsulin processing required a higher nonradiolabeled proinsulin concentration (ID50 = 197 muM). Synthetic peptides corresponding to the sequences surrounding Lys64-Arg65 (AC-peptide/substrate) and Arg31-Arg32 (BC-peptide/substrate) of human proinsulin were synthesized for use as specific substrates or competitive inhibitors. Cleavage of the BC-substrate by type I and AC-substrate by type II was COOH-terminal of the dibasic sequence, with similar Ca2+- and pH requirements previously observed for proinsulin cleavage. Apparent K(m) and V(max) for type I processing of the BC-substrate was K(m) = 20 muM; V(max) = 22.8 pmol/min, and for type II processing of the AC-substrate was K(m) = 68 muM; V(max) = 97 pmol/min. In competitive inhibition assays, the BC-peptide similarly blocked insulin secretory granule lysate processing of des-64,65-proinsulin and proinsulin (ID50 = 45-55 muM), but did not inhibit des-31,32-proinsulin processing. However, the AC-peptide preferentially inhibited insulin secretory granule lysate processing of des-31,32-proinsulin (ID50 = 83 muM) compared to proinsulin (ID50 = 330 muM), and not des-64,65-proinsulin. We conclude that the type I endopeptidase recognized des-64,65-proinsulin and proinsulin as similar substrates, whereas the type II endopeptidase has a stronger preference for des-31,32-proinsulin compared to intact proinsulin. Furthermore, we suggest that in intact proinsulin there exists a constraint to efficient processing that is relieved following type I processing. Structural flexibility, in addition to the presence of Lys64 -Arg65, therefore appears to be important for type II endopeptidase specificity and may provide a molecular basis for a preferential route of proinsulin conversion via des-31,32-proinsulin.			RHODES, CJ (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,JOSLIN DIABET CTR,EP JOSLIN RES LAB,1 JOSLIN PL,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836] Funding Source: NIH RePORTER; NCRR NIH HHS [BRGS07RR05673] Funding Source: Medline; NIDDK NIH HHS [DK36836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEK E, 1990, BIOCHEMISTRY-US, V29, P178, DOI 10.1021/bi00453a024; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAKCH N, 1989, J BIOL CHEM, V264, P15912; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; DAVIDSON HW, 1987, BIOCHEM J, V246, P279, DOI 10.1042/bj2460279; DAVIDSON HW, 1987, BIOCHEM J, V245, P575, DOI 10.1042/bj2450575; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; DOCHERTY K, 1989, J BIOL CHEM, V264, P18335; DOCHERTY K, 1983, FEBS LETT, V162, P137, DOI 10.1016/0014-5793(83)81065-5; DOUGLASS J, 1984, ANNU REV BIOCHEM, V53, P665; EDWARDS K, 1976, BIOCHEM BIOPH RES CO, V72, P310, DOI 10.1016/0006-291X(76)90995-5; GIVEN BD, 1985, J CLIN INVEST, V76, P1398, DOI 10.1172/JCI112116; GROSS DJ, 1989, J BIOL CHEM, V264, P21486; HUTTON JC, 1989, DIABETOLOGIA, V32, P271, DOI 10.1007/BF00265542; HUTTON JC, 1982, DIABETOLOGIA, V23, P365; IKEHARA Y, 1976, BIOCHEM BIOPH RES CO, V72, P319, DOI 10.1016/0006-291X(76)90996-7; LINDBERG I, 1992, BIOCHEM BIOPH RES CO, V183, P1, DOI 10.1016/0006-291X(92)91599-L; LIOUBIN MN, 1984, PREP BIOCHEM, V14, P303, DOI 10.1080/10826068408070637; LOH YP, 1984, ANNU REV NEUROSCI, V7, P189, DOI 10.1146/annurev.ne.07.030184.001201; OLSON TS, 1988, J BIOL CHEM, V263, P7342; ORCI L, 1985, DIABETOLOGIA, V28, P528, DOI 10.1007/BF00281987; PORTE D, 1989, DIABETES, V38, P1333, DOI 10.2337/diabetes.38.11.1333; RHODES CJ, 1989, BIOCHEM J, V258, P305, DOI 10.1042/bj2580305; RHODES CJ, 1987, J BIOL CHEM, V262, P10712; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; RHODES CJ, 1989, J BIOL CHEM, V264, P14240; Segel I.H., 1975, ENZYME KINETICS; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SOBEY WJ, 1989, BIOCHEM J, V260, P535, DOI 10.1042/bj2600535; STEINER DF, 1987, P NATL ACAD SCI USA, V84, P6184, DOI 10.1073/pnas.84.17.6184; STEINER DF, 1972, HDB PHYSL 7, P175; STORER AC, 1976, BIOCHEM J, V159, P1; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8389, DOI 10.1021/bi00488a028	42	88	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22719	22727						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429623				2022-12-25	WOS:A1992JY16300007
J	ROGHANI, M; MOSCATELLI, D				ROGHANI, M; MOSCATELLI, D			BASIC FIBROBLAST GROWTH-FACTOR IS INTERNALIZED THROUGH BOTH RECEPTOR-MEDIATED AND HEPARAN SULFATE-MEDIATED MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR PRODUCTION; CAPILLARY ENDOTHELIAL-CELLS; EXTRACELLULAR-MATRIX; PROTEOLYTIC DEGRADATION; LIPOPROTEIN-LIPASE; PROTEOGLYCANS; METABOLISM; BINDING; FGF; GLYCOSAMINOGLYCAN	Basic fibroblast growth factor (bFGF) was internalized at a rapid rate by Chinese hamster ovary (CHO) cells that do not express significant numbers of high affinity receptors for bFGF as well as CHO cells that have been transfected with cDNA encoding FGF receptor-1 or FGF receptor-2. Internalization of bFGF was completely blocked by the addition of 10 mug/ml heparin in the parental CHO cells but only partially inhibited in cells expressing transfected FGF receptors. Bovine aortic endothelial cells also exhibit heparin-sensitive and heparin-resistant internalization of bFGF. The internalization of bFGF through the heparin-resistant pathway in CHO cells was efficiently competed by addition of unlabeled bFGF, was proportional to the number of receptors expressed, and approached saturation, suggesting that the heparin-resistant internalization was due to high affinity receptors. Internalization of bFGF through the heparin-sensitive pathway was not efficiently competed by unlabeled bFGF and did not approach saturation at concentrations of bFGF up to 50 ng/ml, properties similar to the interaction of bFGF with low affinity heparan sulfate binding sites on the cell surface. Internalization of bFGF in CHO cells not expressing FGF receptors was inhibited by heparin, heparan sulfate, and dermatan sulfate, the same glycosaminoglycans that block binding to cell-surface heparan sulfates. Internalization of bFGF in the parental CHO cells was inhibited at the same concentrations of heparin that block binding to cell-surface heparan sulfates. Finally, inhibition of the sulfation of CHO cell heparan sulfates by the addition of chlorate or digestion of CHO cell heparan sulfates with heparinase inhibited bFGF internalization in the parental CHO cells. These results demonstrate that bFGF can be internalized through a direct interaction with cell-surface heparan sulfates. Thus, there are two pathways for internalization of bFGF: high affinity receptor-mediated and heparan sulfate-mediated.	NYU MED CTR,DEPT CELL BIOL,550 1ST AVE,NEW YORK,NY 10016; NYU MED CTR,KAPLAN COMPREHENS CANC CTR,NEW YORK,NY 10016	New York University; New York University				Moscatelli, David/0000-0002-4627-4213	NATIONAL CANCER INSTITUTE [R01CA042229] Funding Source: NIH RePORTER; NCI NIH HHS [CA34289, CA42229] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BIENKOWSKI MJ, 1984, J BIOL CHEM, V259, P2989; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; CISAR LA, 1989, J BIOL CHEM, V264, P1767; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; GANNOUNZAKI L, 1991, EXP CELL RES, V197, P272, DOI 10.1016/0014-4827(91)90433-U; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; GROSS JL, 1982, J CELL BIOL, V95, P947; HOOGEWERF AJ, 1991, J BIOL CHEM, V266, P16564; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; IOZZO RV, 1987, J BIOL CHEM, V262, P1888; ISHIHARA M, 1986, J BIOL CHEM, V261, P3575; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; Moenner M, 1989, GROWTH FACTORS, V1, P115, DOI 10.3109/08977198909029121; MOSCATELLI D, 1989, J CELL BIOL, V109, P2519, DOI 10.1083/jcb.109.5.2519; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; Moscatelli D, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037499; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; NEUFELD G, 1985, J BIOL CHEM, V260, P3860; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PRESTA M, 1989, J CELL PHYSIOL, V140, P68, DOI 10.1002/jcp.1041400109; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; SQUIRES CH, 1988, J BIOL CHEM, V263, P16297; YANAGISHITA M, 1984, J BIOL CHEM, V259, P270; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	39	193	199	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22156	22162						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429568				2022-12-25	WOS:A1992JW71900028
J	SOMLYO, AV; HORIUTI, K; TRENTHAM, DR; KITAZAWA, T; SOMLYO, AP				SOMLYO, AV; HORIUTI, K; TRENTHAM, DR; KITAZAWA, T; SOMLYO, AP			KINETICS OF CA2+ RELEASE AND CONTRACTION INDUCED BY PHOTOLYSIS OF CAGED D-MYO-INOSITOL 1,4,5-TRISPHOSPHATE IN SMOOTH-MUSCLE - THE EFFECTS OF HEPARIN, PROCAINE, AND ADENINE-NUCLEOTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CALCIUM RELEASE; CA-2+ RELEASE; SARCOPLASMIC-RETICULUM; TRISPHOSPHATE RECEPTOR; FLASH-PHOTOLYSIS; SINGLE CELLS; PORTAL-VEIN; CHANNEL; ACTIVATION; DEPENDENCE	The kinetics of Ca2+ release and contraction induced by photolytic release of inositol 1,4,5-trisphosphate (InSP3) were determined in permeabilized smooth muscle. The rate of Ca2+ release was half-maximal at 1 muM InSP3. The concentration-dependent delay of Ca2+ release at saturating InsP3 concentration was approximately 10 ms and within the uncertainty of the measurements. The relationship between the delay and InSP3 concentration showed no evidence of a high level (n = 4 or higher) of cooperativity but could not distinguish between no cooperativity (n = 1) or a low level (n = 2) of cooperativity. Submaximal [InSP3] caused only partial Ca2+ release from the InSP3-sensitive stores. InsP3-induced Ca2+ release was markedly potentiated by ATP or by adenosine 5'-(beta,gamma-methylenetriphosphate), but neither the rate nor the amplitude of release was significantly affected by procaine (2-5 mM). Heparin increased the delay between photolysis and Ca2+ release, indicating that the off rate of inert ligand(s) bound to InsP3 receptors may contribute to the physiological delay in Ca2+ release. There was a much longer (370 ms +/- 45 S.E.) delay between the rise of Ca2+ and force development, presumably reflecting events preceding and associated with myosin light chain phosphorylation.	UNIV VIRGINIA, SCH MED, DEPT PATHOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, SCH MED, DEPT MED, CHARLOTTESVILLE, VA 22908 USA; NATL INST MED RES, LONDON NW7 1AA, ENGLAND	University of Virginia; University of Virginia; MRC National Institute for Medical Research	SOMLYO, AV (corresponding author), UNIV VIRGINIA, SCH MED,DEPT PHYSIOL,BOX 449,JORDAN HALL, 1300 JEFFERSON PK AVE, CHARLOTTESVILLE, VA 22908 USA.				NHLBI NIH HHS [5P01HL19242-16] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOND M, 1984, J PHYSIOL-LONDON, V357, P185, DOI 10.1113/jphysiol.1984.sp015496; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; CHILVERS ER, 1990, BRIT J PHARMACOL, V99, P297, DOI 10.1111/j.1476-5381.1990.tb14698.x; CHILVERS ER, 1989, EUR J PHARMACOL, V164, P587, DOI 10.1016/0014-2999(89)90269-0; DUNCAN RA, 1987, BIOCHEM PHARMACOL, V36, P307, DOI 10.1016/0006-2952(87)90286-3; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GONG MC, 1992, J BIOL CHEM, V267, P14662; GUILLEMETTE G, 1987, J BIOL CHEM, V262, P1010; HENNE V, 1988, EUR J BIOCHEM, V174, P95, DOI 10.1111/j.1432-1033.1988.tb14067.x; HIMPENS B, 1988, J PHYSIOL-LONDON, V395, P507, DOI 10.1113/jphysiol.1988.sp016932; HORIUTI K, 1989, J GEN PHYSIOL, V94, P769, DOI 10.1085/jgp.94.4.769; IINO M, 1991, J GEN PHYSIOL, V98, P681, DOI 10.1085/jgp.98.4.681; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KAMM KE, 1986, SCIENCE, V232, P80, DOI 10.1126/science.3754063; KOBAYASHI S, 1991, AM J PHYSIOL, V260, pC364, DOI 10.1152/ajpcell.1991.260.2.C364; KOBAYASHI S, 1988, BIOCHEM BIOPH RES CO, V153, P625, DOI 10.1016/S0006-291X(88)81141-0; KOBAYASHI S, 1989, J BIOL CHEM, V264, P17997; KOMORI S, 1991, J PHYSIOL-LONDON, V433, P495, DOI 10.1113/jphysiol.1991.sp018440; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MARKS AR, 1990, J BIOL CHEM, V265, P20719; MAUGER JP, 1989, J BIOL CHEM, V264, P8821; MAYRLEITNER M, 1991, CELL CALCIUM, V12, P505, DOI 10.1016/0143-4160(91)90032-A; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MILLERHANCE WC, 1988, J BIOL CHEM, V263, P13979; MINTA A, 1989, J BIOL CHEM, V264, P8171; MUALLEM S, 1989, J BIOL CHEM, V264, P205; PIETRI F, 1990, J BIOL CHEM, V265, P17478; SMITH JB, 1985, J BIOL CHEM, V260, P4413; SOMLYO AP, 1989, FASEB J, V3, P2266, DOI 10.1096/fasebj.3.11.2506092; SOMLYO AP, 1984, NATURE, V309, P516, DOI 10.1038/309516b0; SOMLYO AP, 1990, ANNU REV PHYSIOL, V52, P857; SOMLYO AP, 1988, PHILOS T ROY SOC B, V320, P399, DOI 10.1098/rstb.1988.0084; SOMLYO AP, 1991, HEART CAREDIOVASCULA; SOMLYO AV, 1990, BIOPHYS J, V57, pA293; SOMLYO AV, 1990, J PHYSIOL-LONDON, V429, pP14; SOMLYO AV, 1985, P NATL ACAD SCI USA, V82, P5231, DOI 10.1073/pnas.82.15.5231; SOMLYO AV, 1988, J GEN PHYSIOL, V91, P165, DOI 10.1085/jgp.91.2.165; SUEMATSU E, 1984, BIOCHEM BIOPH RES CO, V120, P481, DOI 10.1016/0006-291X(84)91279-8; WALKER JW, 1987, NATURE, V327, P249, DOI 10.1038/327249a0; WILLCOCKS AL, 1988, BIOCHEM J, V255, P1061, DOI 10.1042/bj2551061; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; YAGI S, 1988, P NATL ACAD SCI USA, V85, P4109, DOI 10.1073/pnas.85.11.4109; ZHAO H, 1990, J BIOL CHEM, V265, P14822	51	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22316	22322						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429583				2022-12-25	WOS:A1992JW71900052
J	WIELAND, T; RONZANI, M; JAKOBS, KH				WIELAND, T; RONZANI, M; JAKOBS, KH			STIMULATION AND INHIBITION OF HUMAN PLATELET ADENYLYLCYCLASE BY THIOPHOSPHORYLATED TRANSDUCIN BETA-GAMMA-SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY COMPONENT; ROD OUTER SEGMENTS; ADENYLATE-CYCLASE; G-PROTEINS; MEMBRANES; EPINEPHRINE; BOVINE; RECONSTITUTION; DISSOCIATION; NUCLEOTIDES	The effect of betagamma-dimers isolated from the retinal guanine nucleotide-binding protein (G protein) transducin eluted from illuminated bovine rod outer segment membranes with GTP, guanosine 5'-O-(beta,gamma-imino)triphosphate (Gpp(NH)p), or guanosine 5'-O-(gamma-thio)triphosphate (GTPgammaS) on basal and forskolin-stimulated adenylylcyclase activities in membranes of human platelets was studied. Betagamma-subunits isolated from transducin eluted with GTPgammaS (TDbetagamma(GTPgammaS)) had a concentration-dependent stimulatory effect on basal adenylylcyclase activity. The stimulatory agonist prostaglandin E1 increased the potency and the maximum extent of stimulation due to TDbetagamma(GTPgammaS). With a similar concentration dependence, TDbetagamma(GTPgammaS) exerted an inhibitory influence on forskolin-stimulated adenylylcyclase activity. At the same concentrations, betagamma-dimers isolated with either GTP or Gpp(NH)p did not alter enzyme activities. The observed effects of TDbetagamma(GTPgammaS) were similar to those of directly added GTPgammaS with regard to maximum levels, time dependence, and persistence; however, TDbetagamma(GTPgammaS) was approximately 10-fold more potent than GTPgammaS. Treatment of TDbetagamma(GTPgammaS), but not of free GTPgammaS, with hydroxylamine caused a loss of adenylylcyclase regulation by TDbetagamma(GTPgammaS). The data presented indicated that TDbetagamma(GTPgammaS) potently and efficiently activates the stimulatory and inhibitory G proteins of adenylylcyclase in human platelet membranes. Furthermore, evidence is provided suggesting that the observed effects of TDbetagamma(GTPgammaS) which can be thiophosphorylated by GTPgammaS at the beta-subunit (Wieland, T., Ulibarri, I., Gierschik, P., and Jakobs, K. H. (1991) Eur. J. Biochem. 196, 707-716), are due to formation of GTPgammaS at the G proteins.	UNIV HEIDELBERG,INST PHARMAKOL,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg	WIELAND, T (corresponding author), UNIV ESSEN GESAMTHSCH KLINIKUM,INST PHARMAKOL,HUFELANDSTR 44,W-4300 ESSEN 1,GERMANY.		Wieland, Thomas/Q-1506-2019; Wieland, Thomas/G-1772-2012	Wieland, Thomas/0000-0001-8262-8261; Wieland, Thomas/0000-0001-8262-8261				AMIRZALTSMAN Y, 1989, MOL CELL ENDOCRINOL, V63, P175, DOI 10.1016/0303-7207(89)90094-4; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; Bitte L, 1974, Methods Enzymol, V30, P563; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; ECKSTEIN F, 1979, J BIOL CHEM, V254, P9829; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FLORIO VA, 1985, J BIOL CHEM, V260, P3477; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOODY RS, 1972, BIOCHIM BIOPHYS ACTA, V276, P155, DOI 10.1016/0005-2744(72)90016-2; HOKIN LS, 1965, P NATL ACAD SCI USA, V54, P7177; JAKOBS KH, 1983, EUR J BIOCHEM, V132, P125, DOI 10.1111/j.1432-1033.1983.tb07336.x; JAKOBS KH, 1983, BIOCHIM BIOPHYS ACTA, V732, P352, DOI 10.1016/0005-2736(83)90051-2; JAKOBS KH, 1989, EUR J BIOCHEM, V183, P115, DOI 10.1111/j.1432-1033.1989.tb14903.x; JAKOBS KH, 1982, J BIOL CHEM, V257, P2829; JAKOBS KH, 1983, P NATL ACAD SCI-BIOL, V80, P3899, DOI 10.1073/pnas.80.13.3899; JAKOBS KH, 1976, J CYCLIC NUCL PROT, V2, P381; KATADA T, 1984, J BIOL CHEM, V259, P3586; KATADA T, 1984, J BIOL CHEM, V259, P3568; KATADA T, 1984, J BIOL CHEM, V259, P3578; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; WALSETH TF, 1979, BIOCHIM BIOPHYS ACTA, V562, P11, DOI 10.1016/0005-2787(79)90122-9; WIELAND T, 1990, FEBS LETT, V274, P111, DOI 10.1016/0014-5793(90)81342-L; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316	31	41	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20791	20797						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400395				2022-12-25	WOS:A1992JT97800045
J	WOLDA, SL; MOON, RT				WOLDA, SL; MOON, RT			CLONING AND DEVELOPMENTAL EXPRESSION IN XENOPUS-LAEVIS OF 7 ADDITIONAL MEMBERS OF THE WNT FAMILY	ONCOGENE			English	Article							PROTO-ONCOGENE INT-1; MOUSE DEVELOPMENT; NEURAL-TUBE; EMBRYOS; GENE; PROTOONCOGENE; INSERTION; PRODUCTS; PROTEINS; SEQUENCE	Degenerate oligonucleotide primers encoding highly conserved regions of Wnt-related proteins were used with the polymerase chain reaction (PCR) to amplify cDNA derived from Xenopus laevis embryos. cDNA sequences partially encoding seven additional members of the Xwnt gene family were isolated using this strategy. These cDNAs have been given the designation Xwnt-2, Xwnt-6, Xwnt-7A, Xwnt-7B, Xwnt-7C, Xwnt-8B and Xwnt-10 based on their amino acid identity with previously described Wnts. With regard to the timing of expression of these Xwnts during embryonic development, Xwnt-2, the least abundant transcript, was first detected during the neurula stage, while Xwnt-8B transcripts were first detected at the gastrula stage, and decreased by the tailbud stage. Multiple transcripts of Xwnt-6 were detected at varied times during development beginning at the gastrula stage. In contrast, Xwnt-7A, -7B and -10 transcripts were not detected until the tailbud stage. With regard to expression in adult tissues, Xwnt-6, -7A, -7B, -8B and -10 were all expressed abundantly in the brain, and to a lesser extent in a variety of other tissues. Whole-mount in situ hybridization was then employed to monitor the spatial expression of selected Xwnts. Xwnt-7A and -10 transcripts were detected in distinct areas of the developing brain of tailbud-stage embryos. The temporal and spatial differences in expression suggest different roles for these new Xwnt family members in Xenopus development.	UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Moon, Randall T/B-1743-2014	Moon, Randall T/0000-0002-9352-1408	NHLBI NIH HHS [T32HL07312] Funding Source: Medline; NIAMS NIH HHS [K04AR1837] Funding Source: Medline; NICHD NIH HHS [R01HD27525] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027525] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K04AR001837] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KELLY GM, 1991, METHOD CELL BIOL, V36, P389; Maniatis T., 1982, MOL CLONING; MCGREW LL, 1992, IN PRESS DEVELOPMENT; MCMAHON AP, 1989, DEVELOPMENT, V107, P161; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MCMAHON AP, 1992, ADV DEV BIOL, V1, P31; MCMAHON JA, 1989, DEVELOPMENT, V107, P643; Moon R. T., 1989, TECHNIQUE, V1, P76; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NOORDERMEER J, 1989, NUCLEIC ACIDS RES, V17, P11, DOI 10.1093/nar/17.1.11; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; NUSSE R, 1990, MOL CELL BIOL, V10, P4170, DOI 10.1128/MCB.10.8.4170; OLSON DJ, 1991, SCIENCE, V252, P1173, DOI 10.1126/science.252.5009.1173; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7	35	54	62	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1941	1947						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408135				2022-12-25	WOS:A1992JP42400006
J	OKA, S; TERAYAMA, K; KAWASHIMA, C; KAWASAKI, T				OKA, S; TERAYAMA, K; KAWASHIMA, C; KAWASAKI, T			A NOVEL GLUCURONOSYLTRANSFERASE IN NERVOUS-SYSTEM PRESUMABLY ASSOCIATED WITH THE BIOSYNTHESIS OF HNK-1 CARBOHYDRATE EPITOPE ON GLYCOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL-ADHESION MOLECULES; MYELIN-ASSOCIATED GLYCOPROTEIN; MONOCLONAL-ANTIBODY HNK-1; BINDING-PROTEINS; EXPRESSION; RAT; RECOGNITION; GLYCOLIPIDS; NEUROPATHY; BRAIN	Recently, embryonic chicken brain extract was shown to contain a glucuronyltransferase, which transfers glucuronic acid from UDP-glucuronic acid to glycolipid acceptors (neolactotetraosyl ceramide). The enzyme was also suggested to transfer glucuronic acid to glycoprotein acceptors (asialoorosomucoid) (Das, K. K., Basu, M., Basu, S., Chou, D. K. H., and Jungalwala, F. B. (1991) J. Biol. Chem. 266, 5238-5243). In this study, the glucuronyltransferase activity in rat brain extract was separated into two groups by UDP-glucuronic acid-Sepharose CL-6B column chromatography. The enzyme recovered predominantly in the effluent fraction (GlcAT-L) catalyzed the transfer of glucuronic acid to glycolipid acceptors but not to glycoprotein acceptors, whereas the enzyme recovered in the eluate fraction (GlcAT-P) transferred glucuronic acid most predominantly to glycoprotein acceptors and very little to glycolipid acceptors. GlcAT-P was able to transfer glucuronic acid to oligosaccharide chains on asialoorosomucoid. The enzyme recognized a terminal lactosamine structure, Galbeta1-4GlcNAc, on glycoproteins. It was localized in the nervous system and was hardly detectable in other tissues, including the thymus, spleen, lung, kidney, and liver. Although GlcAT-L and GlcAT-P shared some properties in common such as tissue distributions and developmental changes, they exhibited marked differences in their phospholipid dependence and in their pH profiles, apart from their respective acceptor preference to glycolipids and glycoproteins. The acceptor specificity and tissue distribution suggest that a novel glucuronyltransferase, GlcAT-P, is involved in the biosynthesis of the sulfo-glucuronylgalactose structure in the HNK-1 carbohydrate epitope that is expressed on glycoproteins.	KYOTO UNIV,FAC PHARMACEUT SCI,DEPT BIOL CHEM,KYOTO 60601,JAPAN	Kyoto University				Terayama, Koji/0000-0002-0740-9074				ARIGA T, 1987, J BIOL CHEM, V262, P848; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BURCHELL B, 1989, PHARMACOL THERAPEUT, V43, P261, DOI 10.1016/0163-7258(89)90122-8; BURGER D, 1992, J NEUROCHEM, V58, P845, DOI 10.1111/j.1471-4159.1992.tb09334.x; CHOU DKH, 1991, J BIOL CHEM, V266, P17941; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; DAS KK, 1991, J BIOL CHEM, V266, P5238; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; EDELMAN GM, 1984, ANNU REV NEUROSCI, V7, P339; FISHMAN PH, 1976, ARCH BIOCHEM BIOPHYS, V172, P618, DOI 10.1016/0003-9861(76)90116-8; ILYAS AA, 1984, BIOCHEM BIOPH RES CO, V122, P1206, DOI 10.1016/0006-291X(84)91220-8; JESSELL TM, 1990, ANNU REV NEUROSCI, V13, P227, DOI 10.1146/annurev.ne.13.030190.001303; KAWASAKI T, 1977, J BIOL CHEM, V252, P6536; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; MCGARRY RC, 1983, NATURE, V306, P376, DOI 10.1038/306376a0; MOHAN PS, 1992, BIOCHEM BIOPH RES CO, V182, P689, DOI 10.1016/0006-291X(92)91787-Q; OKA S, 1988, ARCH BIOCHEM BIOPHYS, V260, P257, DOI 10.1016/0003-9861(88)90448-1; ROTH S, 1971, J CELL BIOL, V51, P536, DOI 10.1083/jcb.51.2.536; YOSHIHARA Y, 1991, J CELL BIOL, V115, P731, DOI 10.1083/jcb.115.3.731; YOSHIHARA Y, 1991, NEUROSCI RES, V10, P83, DOI 10.1016/0168-0102(91)90033-U; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476	22	65	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22711	22714						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1385405				2022-12-25	WOS:A1992JY16300005
J	PERRINO, FW; MEKOSH, HL				PERRINO, FW; MEKOSH, HL			INCORPORATION OF CYTOSINE-ARABINOSIDE MONOPHOSPHATE INTO DNA AT INTERNUCLEOTIDE LINKAGES BY HUMAN DNA-POLYMERASE ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALF THYMUS; ENZYMOLOGICAL CHARACTERIZATION; KINETIC MECHANISM; HIGH FIDELITY; I KLENOW; REVERSE-TRANSCRIPTASE; 3'->5' EXONUCLEASE; ARA-C; PRIMASE; REPLICATION	The incorporation of cytosine arabinoside monophosphate (araCMP) into DNA at internucleotide linkages by DNA polymerase alpha (DNA pol alpha) has been investigated by using oligonucleotide primed DNA templates. The products of reactions catalyzed by DNA pol alpha in vitro were analyzed on polyacrylamide gels to measure insertion of araCMP, extension from an araCMP 3' terminus, and binding of the enzyme to an araCMP 3' terminus. The results show that insertion of araCMP opposite dGMP in the DNA template is about 3-fold less efficient than insertion of dCMP. Extension from an araCMP 3' terminus by addition of the next complementary nucleotide is approximately 2000-fold less efficient than extension from a correctly base-paired 3' terminus. In the absence of the second substrate, dNTP, DNA pol alpha binds with approximately equal affinities to DNA templates that contain oligonucleotide primers with araCMP or dCMP positioned at the 3' terminus. In the presence of dNTP, the enzyme extends the araCMP 3' terminus or dissociates, but it is not trapped at the araCMP 3' terminus in a nonproductive ternary complex as is observed at the ddCMP 3' terminus. To determine if slow phosphodiester bond formation contributes to the observed extension rate from the araCMP 3' terminus by DNA pol alpha, oligonucleotide primers with araCMP positioned at the 3' terminus were elongated by addition of the alpha-phosphorothioate analogue of the next complementary nucleotide. The rate of extension from araCMP by addition of 2'-deoxyadenosine 5'-O-phosphorothioate (dAMPalphaS) was 6-fold slower than by addition of dAMP, indicating that bond formation is partially rate limiting in the extension reaction. Thus, inefficient extension from the araCMP 3' terminus is the major determinant contributing to the low incorporation frequency of araCMP into DNA by DNA pol alpha, and this inefficiency can be attributed, in part, to slower phosphodiester bond formation at the araCMP 3' terminus.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,CTR COMPREHENS CANC,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center	PERRINO, FW (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,WINSTON SALEM,NC 27157, USA.							BEARDSLEY GP, 1988, NUCLEIC ACIDS RES, V16, P9165, DOI 10.1093/nar/16.19.9165; Benkovic S. J, 1973, ENZYMES, P201; BIALEK G, 1989, EMBO J, V8, P1833, DOI 10.1002/j.1460-2075.1989.tb03578.x; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; CATAPANO CV, 1991, CANCER RES, V51, P1829; CHANG LMS, 1984, J BIOL CHEM, V259, P4679; CHEN YC, 1979, J BIOL CHEM, V254, P1678; COPELAND WC, 1991, J BIOL CHEM, V266, P22739; COTTERILL SM, 1987, P NATL ACAD SCI USA, V84, P5635, DOI 10.1073/pnas.84.16.5635; COZZARELLI NR, 1977, ANNU REV BIOCHEM, V46, P641, DOI 10.1146/annurev.bi.46.070177.003233; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; FISHER PA, 1981, BIOCHEMISTRY-US, V20, P4570, DOI 10.1021/bi00519a009; FISHER PA, 1981, BIOCHEMISTRY-US, V20, P4560, DOI 10.1021/bi00519a008; GAO YG, 1991, BIOCHEMISTRY-US, V30, P9222; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; Kornberg A., 1992, DNA REPLICATION; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; KUFE DW, 1984, MOL PHARMACOL, V26, P128; KUFE DW, 1980, J BIOL CHEM, V255, P8997; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE MYWT, 1980, BIOCHEMISTRY-US, V19, P215, DOI 10.1021/bi00542a032; LOEB LA, 1969, J BIOL CHEM, V244, P1672; MAJOR PP, 1981, P NATL ACAD SCI-BIOL, V78, P3235, DOI 10.1073/pnas.78.5.3235; MAJOR PP, 1982, BIOCHEM PHARMACOL, V31, P2937, DOI 10.1016/0006-2952(82)90266-0; Maniatis T., 1982, MOL CLONING; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MIKITA T, 1988, BIOCHEMISTRY-US, V27, P4698, DOI 10.1021/bi00413a018; MIZRAHI V, 1985, BIOCHEMISTRY-US, V24, P4010, DOI 10.1021/bi00336a031; NASHEUER HP, 1987, BIOCHEMISTRY-US, V26, P8458, DOI 10.1021/bi00399a064; NG L, 1989, J BIOL CHEM, V264, P13018; OTTIGER H, 1987, NUCLEIC ACIDS RES, V15, P4789, DOI 10.1093/nar/15.12.4789; PARKER WB, 1987, MOL PHARMACOL, V31, P146; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; PERRINO FW, 1990, BIOCHEMISTRY-US, V29, P5226, DOI 10.1021/bi00474a002; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; REYLAND ME, 1987, J BIOL CHEM, V262, P10824; ROSS DD, 1990, CANCER RES, V50, P2658; SKARNES W, 1986, J BIOL CHEM, V261, P6629; TOWNSEND AJ, 1987, MOL PHARMACOL, V32, P330; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WAHL AF, 1984, BIOCHEMISTRY-US, V23, P1895, DOI 10.1021/bi00304a001; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WANG TSF, 1984, J BIOL CHEM, V259, P1854; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; YOSHIDA S, 1985, J BIOCHEM-TOKYO, V98, P427, DOI 10.1093/oxfordjournals.jbchem.a135297	51	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23043	23051						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429652				2022-12-25	WOS:A1992JY16300053
J	SUN, XJ; MIRALPEIX, M; MYERS, MG; GLASHEEN, EM; BACKER, JM; KAHN, CR; WHITE, MF				SUN, XJ; MIRALPEIX, M; MYERS, MG; GLASHEEN, EM; BACKER, JM; KAHN, CR; WHITE, MF			EXPRESSION AND FUNCTION OF IRS-1 IN INSULIN SIGNAL TRANSMISSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; GROWTH FACTOR-I; 3T3-L1 ADIPOCYTES; RECEPTOR; PHOSPHORYLATION; CELLS; SUBSTRATE; PROTEIN; TRANSDUCTION; SEQUENCE	IRS-1 is a major insulin receptor substrate which may play an important role in insulin signal transmission. The mRNA for IRS-1 in rat cells and tissues is about 9.5 kilobases (kb). Rat liver IRS-1 was stably expressed in Chinese hamster ovary (CHO) cells (CHO/IRS-1). Although its calculated molecular mass is 131 kDa, IRS-1 from quiescent cells migrated between 165 and 170 kDa during sodium dodecyl sulfate-polyacrylamide gel electrophoresis. IRS-1 was phosphorylated strongly on serine residues and weakly on threonine residues before insulin stimulation. Insulin immediately stimulated tyrosine phosphorylation of IRS-1, and after 10-30 min with insulin its apparent molecular mass increased to 175-180 kDa. Expression of the human insulin receptor and rat IRS-1 together in CHO/IR/IRS-1 cells increased the basal serine phosphorylation of IRS-1 and strongly increased tyrosine phosphorylation during insulin stimulation. Purified insulin receptors directly phosphorylated baculovirus-produced IRS-1 exclusively on tyrosine residues. By immunofluorescence, IRS-1 was absent from the nucleus, but otherwise distributed uniformly before and after insulin stimulation. Some IRS-1 associated with the insulin receptor during insulin stimulation. In addition, a phosphatidylinositol 3'-kinase associated with IRS-1 during insulin stimulation, and this association was more sensitive to insulin in CHO cells overexpressing the insulin receptor (CHO/IR cells), more responsive to insulin in CHO/IRS-1 cells, and both sensitive and responsive in CHO/IR/IRS-1 cells. Similarly, insulin-stimulated DNA synthesis was more sensitive to insulin in CHO/IR cells, and more responsive in CHO/IRS-1 cells; however, insulin-stimulated DNA synthesis was sensitive but poorly responsive to insulin in CHO/IR/IRS-1 cells. Together, these results suggest that IRS-1 is a direct physiologic substrate of the insulin receptor and may play an important role in insulin signal transmission.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM CELLULAR & DEV BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	SUN, XJ (corresponding author), HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02115, USA.		Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NIDDK NIH HHS [DK33201, DK 36836, DK43808] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R01DK033201, R01DK043808] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGER KR, 1992, J BIOL CHEM, V267, P5408; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1991, BIOCHEMISTRY-US, V300, P6366; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHOU CK, 1987, J BIOL CHEM, V262, P1842; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; GIBBS EM, 1986, J BIOL CHEM, V261, P6597; HARING HU, 1984, BIOCHEMISTRY-US, V23, P3298, DOI 10.1021/bi00309a028; HARING HU, 1987, P NATL ACAD SCI USA, V84, P113, DOI 10.1073/pnas.84.1.113; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; HOFMANN C, 1989, ENDOCRINOLOGY, V124, P257, DOI 10.1210/endo-124-1-257; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769; KAZLAUSKAS A, 1987, J CELL PHYSIOL, V130, P228, DOI 10.1002/jcp.1041300209; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MARGOLIS RN, 1990, BIOCHEM BIOPH RES CO, V166, P562, DOI 10.1016/0006-291X(90)90845-E; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; MYERS MG, 1991, J BIOL CHEM, V266, P10616; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; Sambrook J, 1989, MOL CLONING LABORATO; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEMER J, 1987, J BIOL CHEM, V262, P15476; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SUMMERS MD, 1988, TEX AGR EXP STN B, V1555, P1; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAYLOR SI, 1990, DIABETES CARE, V13, P257, DOI 10.2337/diacare.13.3.257; TOBE K, 1990, DIABETES, V39, P528, DOI 10.2337/diabetes.39.5.528; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358	41	293	301	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22662	22672						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1385403				2022-12-25	WOS:A1992JW71900103
J	FENG, ZH; ANGELETTI, RH; LEVIN, BE; SABBAN, EL				FENG, ZH; ANGELETTI, RH; LEVIN, BE; SABBAN, EL			GLYCOSYLATION AND MEMBRANE INSERTION OF NEWLY SYNTHESIZED RAT DOPAMINE BETA-HYDROXYLASE IN A CELL-FREE SYSTEM WITHOUT SIGNAL CLEAVAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 PHEOCHROMOCYTOMA CELLS; ADRENAL CHROMAFFIN GRANULES; NERVE GROWTH-FACTOR; MESSENGER-RNA; ENDOPLASMIC-RETICULUM; MOLECULAR-CLONING; BOUND FORMS; BOVINE; SEQUENCE; PROTEIN	Dopamine beta-hydroxylase (DBH, EC 1.14.17.1) is present in both membrane-bound and soluble forms in neurosecretory vesicles. This study was designed to investigate the differences between membrane-bound and soluble DBH and how they may arise from translation of a single mRNA. Antisera to a peptide corresponding to the carboxyl terminus of rat DBH was found to specifically immunoprecipitate the 77- and 73-kDa subunits of newly synthesized DBH in rat brain. Thus, both soluble and membrane-bound forms contain the same carboxyl terminus. To investigate differences at the amino terminus, full-length rat DBH mRNA, translated in a cell-free system, produced a 66-kDa peptide. An additional higher molecular mass product was synthesized upon co-translational addition of microsomal membranes. This product was glycosylated since it bound to concanavalin A-Sepharose and reverted to the 66-kDa polypeptide after treatment with endoglycosidase H. This glycosylated product was resistant to protease digestion and fractionated with microsomal membranes on sucrose gradients, indicating that it is incorporated into the microsomal membranes. Amino-terminal sequencing of the glycosylated translation product indicated that the amino-terminal "signal" sequence was not cleaved. The results indicate that in the cell-free system newly synthesized DBH undergoes glycosylation and incorporation into microsomal membranes without cleavage of the NH2-terminal signal sequence.	NEW YORK MED COLL,DEPT BIOCHEM & MOLEC BIOL,VALHALLA,NY 10595; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV BIOL & CANC,BRONX,NY 10461; VET ADM,NEUROL SERV,E ORANGE,NJ 07019; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT NEUROSCI,NEWARK,NJ 07103	New York Medical College; Yeshiva University; Albert Einstein College of Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028869, K04NS001121] Funding Source: NIH RePORTER; NINDS NIH HHS [NS01121, NS 28869] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALETTA JM, 1988, J NEUROCHEM, V51, P1317, DOI 10.1111/j.1471-4159.1988.tb03104.x; BJERRUM OJ, 1979, BIOCHEM J, V181, P231, DOI 10.1042/bj1810231; BON S, 1991, J NEUROCHEM, V57, P1100, DOI 10.1111/j.1471-4159.1991.tb08267.x; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CIOFFI JA, 1989, J BIOL CHEM, V264, P15052; EIPPER BA, 1992, J BIOL CHEM, V267, P4008; Erickson B. W., 1976, PROTEINS, VII, P255; FOUCHIER F, 1988, BIOCHEM J, V256, P103, DOI 10.1042/bj2560103; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GAVINE FS, 1984, J NEUROCHEM, V43, P1243, DOI 10.1111/j.1471-4159.1984.tb05379.x; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; KAUFMAN S, 1965, PHARMACOL REV, V17, P71; KENDALL DA, 1986, NATURE, V321, P706, DOI 10.1038/321706a0; KIRCHMAIR R, 1992, FEBS LETT, V297, P302, DOI 10.1016/0014-5793(92)80560-4; KOBAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P1089, DOI 10.1093/nar/17.3.1089; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUHN LJ, 1986, J BIOL CHEM, V261, P3816; LAMOUROUX A, 1987, EMBO J, V6, P3931, DOI 10.1002/j.1460-2075.1987.tb02734.x; LEWIS EJ, 1990, J BIOL CHEM, V265, P1021; LEWIS EJ, 1992, J BIOL CHEM, V267, P494; MANS RJ, 1961, ARCH BIOCHEM BIOPHYS, V94, P48, DOI 10.1016/0003-9861(61)90009-1; MCHUGH EM, 1985, J BIOL CHEM, V260, P4409; MCMAHON A, 1990, J NEUROSCI RES, V25, P395, DOI 10.1002/jnr.490250317; MCMAHON A, 1992, IN PRESS J NEUROCHEM; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; NOTHWEHR SF, 1990, J BIOL CHEM, V265, P17202; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; PIMPLIKAR SW, 1992, J BIOL CHEM, V267, P4110; RINDLER MJ, 1990, EUR J CELL BIOL, V53, P154; ROBERTSON JG, 1990, J BIOL CHEM, V265, P1029; SABBAN E, 1981, J CELL BIOL, V91, P637, DOI 10.1083/jcb.91.3.637; SABBAN EL, 1987, J NEUROSCI, V7, P192; SABBAN EL, 1983, J BIOL CHEM, V258, P7819; SABBAN EL, 1983, J BIOL CHEM, V258, P7812; SABBAN EL, 1989, BIOCHEM INT, V19, P769; SABBAN EL, 1987, ANN NY ACAD SCI, V493, P339; Sambrook J, 1989, MOL CLONING LABORATO; SAXENA A, 1983, J BIOL CHEM, V258, P4147; SETTLEMAN J, 1985, J BIOL CHEM, V260, P1641; SKOTLAND T, 1977, BIOCHEM BIOPH RES CO, V74, P1483, DOI 10.1016/0006-291X(77)90609-X; SLATER EP, 1981, ARCH BIOCHEM BIOPHYS, V211, P288, DOI 10.1016/0003-9861(81)90456-2; SOKOLOFF RL, 1985, J NEUROCHEM, V44, P411, DOI 10.1111/j.1471-4159.1985.tb05431.x; STEWART LC, 1988, J BIOL CHEM, V263, P12183; STEWART LC, 1988, ANNU REV BIOCHEM, V57, P551; TALJANIDISZ J, 1989, BIOCHEMISTRY-US, V28, P10054, DOI 10.1021/bi00452a026; TAYLOR CS, 1989, J BIOL CHEM, V264, P14; TAYLOR CS, 1989, J BIOL CHEM, V264, P15242; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P304; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WANG NY, 1990, BIOCHEMISTRY-US, V29, P6466, DOI 10.1021/bi00479a019; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5; WU HJ, 1990, J NEUROCHEM, V55, P97, DOI 10.1111/j.1471-4159.1990.tb08826.x; ZAREMBA S, 1981, J BIOL CHEM, V256, P2310	56	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21808	21815						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400490				2022-12-25	WOS:A1992JV01100085
J	HOLTZMAN, MJ; TURK, J; SHORNICK, LP				HOLTZMAN, MJ; TURK, J; SHORNICK, LP			IDENTIFICATION OF A PHARMACOLOGICALLY DISTINCT PROSTAGLANDIN-H SYNTHASE IN CULTURED EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID CYCLOOXYGENASE; SHEEP VESICULAR GLAND; ARACHIDONIC-ACID; MESSENGER-RNA; ENDOPEROXIDE SYNTHASE; PORCINE LEUKOCYTES; COMPLEMENTARY-DNA; BIOSYNTHESIS; 12-LIPOXYGENASE; OXYGENATION	Nonsteroidal anti-inflammatory drugs inhibit the action of prostaglandin H synthase (PGH synthase), and this effect may constitute the basis for therapeutic and idiosyncratic responses to these agents. We found that aspirin treatment of cultured ovine tracheal epithelial cells blocked PGH synthase-catalyzed formation of PG as expected but also caused a dose-dependent increase in 15-hydroxyeicosatetraenoic acid (15-HETE) production from arachidonic acid. In contrast, aspirin caused only inhibition of PG production without enhancing 15-HETE formation in ovine seminal vesicle and other tissues. The 15-HETE formed by aspirin-treated ovine tracheal epithelial cells was generated by a PGH synthase-dependent mechanism because: (i) the 15-HETE forming activity was just as sensitive as PG forming activity to selective inhibition by indomethacin; (ii) both 15-HETE and PG forming activities were quantitatively immunoprecipitated (depleted from supernatants and recovered in immune complex pellets) by a specific anti-PGH synthase antiserum. Additional immunoprecipitation experiments indicated that anti-PGH synthase monoclonal antibodies (cyo-1 and cyo-5) raised against the aspirin-inhibited form of the enzyme (contained in seminal vesicle) did not recognize the aspirin-stimulated 15-HETE-forming PGH synthase (contained in cultured epithelial cells). Thus, sequential immunoprecipitation of cultured epithelial cell material first with excess cyo-1 followed by anti-PGH synthase antiserum indicated that two isoforms of PGH synthase were expressed in these cells. SDS-polyacrylamide gel electrophoresis of immunoprecipitated PGH synthase from cultured epithelial cells revealed distinct protein bands for each form of the enzyme (M(r) = 70,000 and 72,000). The identification of a distinct PGH synthase which may be modified by aspirin so that selective oxygenation of fatty acid substrate is enhanced (while PG formation is inhibited) indicates that isozymes of PGH synthase exist which are pharmacologically distinct.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL)	HOLTZMAN, MJ (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,660 S EUCLID AVE,BOX 8052,ST LOUIS,MO 63110, USA.			Shornick, Laurie/0000-0001-6652-1878	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040078] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K04DK001553, P01DK038111] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-40078] Funding Source: Medline; NIDDK NIH HHS [DK-38111, DK-01553] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY JM, 1983, J LIPID RES, V24, P1419; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; DEWITT DL, 1982, METHOD ENZYMOL, V86, P229; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FLOWER R, 1973, NATURE, V240, P410; FLOWER RJ, 1974, PHARMACOL RES COMMUN, V26, P33; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HAMBERG M, 1967, J BIOL CHEM, V242, P5344; HANSBROUGH JR, 1990, J BIOL CHEM, V265, P1771; HEMLER ME, 1978, BIOCHEMISTRY-US, V17, P1772, DOI 10.1021/bi00602a031; HOLTZMAN MJ, 1992, ANNU REV PHYSIOL, V54, P303; HOLTZMAN MJ, 1988, BIOCHIM BIOPHYS ACTA, V963, P401, DOI 10.1016/0005-2760(88)90308-6; HOLTZMAN MJ, 1989, J CLIN INVEST, V84, P1446, DOI 10.1172/JCI114319; HUNTER JA, 1985, P NATL ACAD SCI USA, V82, P4633, DOI 10.1073/pnas.82.14.4633; KADUCE TL, 1989, J BIOL CHEM, V264, P6823; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1989, J BIOL CHEM, V264, P14136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAETHEM RM, 1992, J BIOL CHEM, V267, P552; LANIADOSCHWARTZMAN M, 1988, J BIOL CHEM, V263, P2536; Lechner J F, 1985, J TISSUE CULT METHOD, V9, P43; LIN AH, 1989, J BIOL CHEM, V264, P17379; LYSZ TW, 1988, BIOCHEM PHARMACOL, V37, P921, DOI 10.1016/0006-2952(88)90182-7; LYSZ TW, 1982, J NEUROCHEM, V38, P1111, DOI 10.1111/j.1471-4159.1982.tb05355.x; MAAS RL, 1983, P NATL ACAD SCI-BIOL, V80, P2884, DOI 10.1073/pnas.80.10.2884; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MIZUNO K, 1982, PROSTAGLANDINS, V23, P743; OBANION MK, 1991, J BIOL CHEM, V266, P23261; PAGELS WR, 1983, J BIOL CHEM, V258, P6517; PENTLAND AP, 1990, J CLIN INVEST; ROME LH, 1976, PROSTAGLANDINS, V11, P23, DOI 10.1016/0090-6980(76)90169-6; ROSEN GD, 1989, BIOCHEM BIOPH RES CO, V164, P1358, DOI 10.1016/0006-291X(89)91819-6; ROTH GJ, 1978, J BIOL CHEM, V253, P3782; SETTY BNY, 1985, BIOCHIM BIOPHYS ACTA, V833, P484, DOI 10.1016/0005-2760(85)90106-7; SHANNON VR, 1991, AM J PHYSIOL, V261, pL399, DOI 10.1152/ajplung.1991.261.6.L399; SHANNON VR, 1992, IN PRESS AM REV RESP, V145; SHANNON VR, 1992, IN PRESS AM J PHYSL, V263; SHANNON VR, 1993, IN PRESS AM J PHYSL, V264; SIEGEL MI, 1980, BIOCHEM BIOPH RES CO, V92, P688, DOI 10.1016/0006-291X(80)90388-5; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; TURK J, 1989, BIOCHIM BIOPHYS ACTA, V1001, P16, DOI 10.1016/0005-2760(89)90301-9; VANDEROUDERAA FJ, 1980, EUR J BIOCHEM, V524, P240; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; YOSHIMOTO T, 1990, P NATL ACAD SCI USA, V87, P2142, DOI 10.1073/pnas.87.6.2142	49	194	195	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21438	21445						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400457				2022-12-25	WOS:A1992JV01100030
J	KWONG, FYP; FINCHAM, HE; DAVIES, A; BEAUMONT, N; HENDERSON, PJF; YOUNG, JD; BALDWIN, SA				KWONG, FYP; FINCHAM, HE; DAVIES, A; BEAUMONT, N; HENDERSON, PJF; YOUNG, JD; BALDWIN, SA			MAMMALIAN NITROBENZYLTHIOINOSINE-SENSITIVE NUCLEOSIDE TRANSPORT PROTEINS - IMMUNOLOGICAL EVIDENCE THAT TRANSPORTERS DIFFERING IN SIZE AND INHIBITOR SPECIFICITY SHARE SEQUENCE HOMOLOGY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE GLUCOSE TRANSPORTER; GUINEA-PIG; ENERGY-METABOLISM; ANIMAL-CELLS; RAT LUNG; BINDING; PURIFICATION; MEMBRANE; PEPTIDE; SYSTEM	Polyclonal antibodies were raised against the nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter of human erythrocyte membranes. On Western blots of these membranes they labeled the broad "band 4.5" region (average apparent M(r) 55,000), which contains both the nucleoside and glucose transport proteins. However, they did not recognize the glucose transporter when this was prepared free of nucleoside transporter by expression from a cDNA clone. Their specificity for the nucleoside transporter was confirmed by the ability to immunoadsorb NBMPR- but not cytochalasin B-binding sites from a detergent-solubilized mixture of band 4.5 proteins. Although a large proportion of the antibodies recognized extracellular epitopes, these appeared to be located primarily on the polypeptide moiety of the glycoprotein, as demonstrated by the ability of the antibodies strongly to label the deglycosylated transporter (apparent M(r) 45,000) on Western blots. The antibodies were species-cross-reactive, recognizing nucleoside transporters from pig and rabbit erythrocytes and from rat liver. The pig protein is similar to the human transporter in its inhibitor sensitivity but is considerably larger (apparent M(r) 57,000 after deglycosylation). In contrast, the rat protein is similar in size to the human transporter (apparent M(r) 45,000 after deglycosylation) but much less sensitive to the inhibitors dilazep and dipyridamole. These findings indicate that despite their differences in size and inhibitor specificity, the NBMPR-sensitive nucleoside transporters of these mammalian species are related in amino acid sequence.	UNIV LONDON,ROYAL FREE HOSP,SCH MED,DEPT BIOCHEM & CHEM,LONDON NW3 2PF,ENGLAND; UNIV LONDON,ROYAL FREE HOSP,SCH MED,DEPT PROT & MOLEC BIOL,LONDON NW3 2PF,ENGLAND; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND; UNIV ALBERTA,DEPT PHYSIOL,EDMONTON T6G 2H7,ALBERTA,CANADA	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Cambridge; University of Alberta			Henderson, Peter JF/Q-1907-2018	Henderson, Peter/0000-0002-9187-0938				BARROS L F, 1992, Biochemical Society Transactions, V20, p244S; CAIRNS MT, 1984, BIOCHEM J, V221, P179, DOI 10.1042/bj2210179; DAVIES A, 1987, J BIOL CHEM, V262, P9347; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GORGA FR, 1981, BIOCHEMISTRY-US, V20, P5108, DOI 10.1021/bi00521a003; HASPEL HC, 1988, J BIOL CHEM, V263, P398; JARVIS SM, 1986, J MEMBRANE BIOL, V93, P1, DOI 10.1007/BF01871013; JARVIS SM, 1987, PHARMACOL THERAPEUT, V32, P339, DOI 10.1016/0163-7258(87)90080-5; JARVIS SM, 1986, J BIOL CHEM, V261, P1077; JARVIS SM, 1981, BIOCHEM J, V194, P331, DOI 10.1042/bj1940331; KIM HD, 1971, BIOCHIM BIOPHYS ACTA, V230, P1; KWONG FYP, 1988, BIOCHEM J, V255, P243; KWONG FYP, 1987, BIOCHIM BIOPHYS ACTA, V904, P105, DOI 10.1016/0005-2736(87)90091-5; KWONG FYP, 1986, BIOCHEM J, V240, P349, DOI 10.1042/bj2400349; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; SHI MM, 1986, BIOCHEM SOC T, V14, P647, DOI 10.1042/bst0140647; SHI MM, 1984, BIOCHEM BIOPH RES CO, V118, P594, DOI 10.1016/0006-291X(84)91344-5; SHI MM, 1986, BIOCHEM J, V240, P879, DOI 10.1042/bj2400879; WU JSR, 1983, J BIOL CHEM, V258, P3745; WU JSR, 1984, BIOCHEM J, V220, P499, DOI 10.1042/bj2200499; YI CK, 1992, BIOCHEM J, V283, P643, DOI 10.1042/bj2830643; YOUNG JD, 1986, AM J PHYSIOL, V251, pC90, DOI 10.1152/ajpcell.1986.251.1.C90; YOUNG JD, 1985, BIOCHIM BIOPHYS ACTA, V842, P214, DOI 10.1016/0304-4165(85)90205-3; YOUNG JD, 1983, BIOSCIENCE REP, V3, P309, DOI 10.1007/BF01122895; ZOCCOLI MA, 1978, J BIOL CHEM, V253, P6923	29	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21954	21960						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400505				2022-12-25	WOS:A1992JV01100106
J	MITTLER, R; ZILINSKAS, BA				MITTLER, R; ZILINSKAS, BA			MOLECULAR-CLONING AND CHARACTERIZATION OF A GENE ENCODING PEA CYTOSOLIC ASCORBATE PEROXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE; RESPONSIVE ELEMENT; STRESS; EXPRESSION; LEAVES; INTRON; MAIZE; BINDING	A gene encoding cytosolic ascorbate peroxidase (ApxI) from pea (Pisum sativum L.) was isolated and its nucleotide sequence determined. By homologous alignment between the ApxI cDNA (Mittler, R., and Zilinskas, B. (1991) FEBS Lett. 289, 257-259) and the genomic clone, positions of introns and exons were determined. The isolated ApxI gene was found to contain 9 introns, the first of which was located within the 5'-untranslated region of the mRNA. Southern blot analysis of pea genomic DNA suggests that in pea cytosolic ascorbate peroxidase is encoded by a single copy gene. Steady state ApxI transcript levels were found to increase in response to several stresses imposed by drought, heat, and application of ethephon, abscisic acid, and the superoxide-generating agent paraquat. Increases in ascorbate peroxidase activity in response to stresses were less marked than changes observed in transcript levels; cytosolic ascorbate peroxidase protein levels measured by immunoblot analysis remained unchanged.	RUTGERS STATE UNIV,COOK COLL,DEPT BIOCHEM & MOLEC BIOL,LIPMAN HALL,NEW BRUNSWICK,NJ 08903	Rutgers State University New Brunswick			Mittler, Ron/ABE-6496-2020					ASADA K, 1992, PHYSIOL PLANTARUM, V85, P235, DOI 10.1111/j.1399-3054.1992.tb04728.x; Asada K., 1987, PHOTOINHIBITION, P227; BECKER J, 1990, EUR J BIOCHEM, V189, P553, DOI 10.1111/j.1432-1033.1990.tb15522.x; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BOWLER C, 1989, EMBO J, V8, P31, DOI 10.1002/j.1460-2075.1989.tb03345.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAKMAK I, 1992, PLANT PHYSIOL, V98, P1222, DOI 10.1104/pp.98.4.1222; CHEN GX, 1989, PLANT CELL PHYSIOL, V30, P987; CHEN GX, 1992, PLANT CELL PHYSIOL, V33, P109; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTENSEN AH, 1989, GENE, V85, P381, DOI 10.1016/0378-1119(89)90431-9; CHRISTENSEN AH, 1992, PLANT MOL BIOL, V18, P675, DOI 10.1007/BF00020010; DAVIS LG, 1986, BASIC METHODS MOL BI, P158; DEAN C, 1987, NUCLEIC ACIDS RES, V14, P9549; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; GILLHAM DJ, 1987, PLANT SCI, V50, P105, DOI 10.1016/0168-9452(87)90145-2; GURLEY WB, 1991, BIOCHEMISTRY-US, V30, P1, DOI 10.1021/bi00215a001; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; KATAGIRI F, 1992, TRENDS GENET, V8, P22, DOI 10.1016/0168-9525(92)90020-5; KUBO A, 1992, PLANT MOL BIOL, V18, P691, DOI 10.1007/BF00020011; MASCARENHAS D, 1990, PLANT MOL BIOL, V15, P913, DOI 10.1007/BF00039430; MELHORN H, 1990, PLANT CELL ENVIRON, V13, P971; MITTLER R, 1991, PLANT PHYSIOL, V97, P962, DOI 10.1104/pp.97.3.962; MITTLER R, 1991, FEBS LETT, V289, P257, DOI 10.1016/0014-5793(91)81083-K; OKUDA A, 1989, J BIOL CHEM, V264, P16919; PEARSON L, 1990, PLANT MOL BIOL, V14, P513, DOI 10.1007/BF00027497; PERLTREVES R, 1991, PLANT MOL BIOL, V17, P745, DOI 10.1007/BF00037058; ROGERS SO, 1988, PLANT MOL BIOL MANUA, P1; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TANAKA K, 1985, PLANT CELL PHYSIOL, V26, P1425; TANAKA K, 1990, AGR BIOL CHEM TOKYO, V54, P2629, DOI 10.1080/00021369.1990.10870355; THOMSEN B, 1992, PLANTA, V186, P600, DOI 10.1007/BF00198042; TSANG EWT, 1991, PLANT CELL, V3, P783, DOI 10.1105/tpc.3.8.783; VASIL V, 1989, PLANT PHYSIOL, V91, P1575, DOI 10.1104/pp.91.4.1575; WERR W, 1985, EMBO J, V4, P1373, DOI 10.1002/j.1460-2075.1985.tb03789.x	36	188	198	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21802	21807						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400489				2022-12-25	WOS:A1992JV01100084
J	NETTO, LES; RAMAKRISHNA, NVS; KOLAR, C; CAVALIERI, EL; ROGAN, EG; LAWSON, TA; AUGUSTO, O				NETTO, LES; RAMAKRISHNA, NVS; KOLAR, C; CAVALIERI, EL; ROGAN, EG; LAWSON, TA; AUGUSTO, O			IDENTIFICATION OF C(8)-METHYLGUANINE IN THE HYDROLYSATES OF DNA FROM RATS ADMINISTERED 1,2-DIMETHYLHYDRAZINE - EVIDENCE FOR INVIVO DNA ALKYLATION BY METHYL RADICALS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDRAZINE DERIVATIVES; PURINE-BASES; CARCINOGEN 1,2-DIMETHYLHYDRAZINE; NUCLEIC-ACIDS; ASCORBIC-ACID; COLON CANCER; OXIDATION; DIMETHYLHYDRAZINE; NUCLEOSIDES; MECHANISM	C-8-Methylguanine was identified in the neutral hydrolysates of DNA isolated from the liver or colon tissue of rats administered 1,2-dimethylhydrazine. In all the samples examined, the biologically isolated adducts were characterized by co-elution with synthetic C-8-methylguanine under different high pressure liquid chromatography conditions. The sample isolated from liver DNA was also identified by UV spectroscopy at different pH values and by mass spectrometry. The estimated yields of C-8-methylguanine obtained in hydrolysates of DNA from the liver or colon tissue were comparable to those of O6-methylguanine. C-8-Methylguanine was not detected when the spin trap alpha-(4-pyridyl-1-oxide)-N-tert-butylnitrone was administered together with 1,2-dimethylhydrazine. The spin trap also inhibited N7-methylguanine and O6-methylguanine yields, although to a lesser extent. These results constitute the first evidence that DNA alkylation by carbon-centered radicals can occur in vivo.	UNIV SAO PAULO,INST QUIM,DEPT BIOCHEM,CXP 20780,BR-01498 SAO PAULO,BRAZIL; UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,OMAHA,NE 68198	Universidade de Sao Paulo; University of Nebraska System; University of Nebraska Medical Center			Netto, Luis/A-3783-2008; Augusto, Ohara/D-3839-2012	Netto, Luis/0000-0002-4250-9177; Augusto, Ohara/0000-0002-7220-4286	NCI NIH HHS [P30-CA36727] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANO E, 1989, FREE RADICAL BIO MED, V6, P3, DOI 10.1016/0891-5849(89)90152-4; ARUOMA OI, 1989, J BIOL CHEM, V264, P20509; AUGUSTO O, 1982, J BIOL CHEM, V257, P1288; AUGUSTO O, 1990, J BIOL CHEM, V265, P22093; AUGUSTO O, 1985, BIOCHEM BIOPH RES CO, V126, P853, DOI 10.1016/0006-291X(85)90263-3; AUGUSTO O, 1989, HDB BIOMEDICINE FREE, V3, P193; BALSIGER RW, 1960, J ORG CHEM, V25, P1573, DOI 10.1021/jo01079a026; CHEESEMAN KH, 1985, LIFE CHEM REPORTS, V3, P259; COOK MG, 1980, CANCER RES, V40, P1329; DEVANESAN P, 1991, P AM ASSOC CANC RES, V31, P95; Druckrey H., 1970, CARCINOMA COLON ANTE, P267; FLOYD RA, 1990, CARCINOGENESIS, V11, P1447, DOI 10.1093/carcin/11.9.1447; FONG LYY, 1990, CARCINOGENESIS, V11, P411, DOI 10.1093/carcin/11.3.411; GANNETT PM, 1991, CHEM-BIOL INTERACT, V80, P57, DOI 10.1016/0009-2797(91)90031-2; GROSS ML, 1982, INT J MASS SPECTROM, V42, P243, DOI 10.1016/0020-7381(82)80069-7; HATT HH, 1943, ORG SYNTH, V2, P208; HAWKS A, 1974, BRIT J CANCER, V30, P440, DOI 10.1038/bjc.1974.218; HERRON DC, 1981, CANCER RES, V41, P3967; HERRON DC, 1979, ANAL BIOCHEM, V100, P58, DOI 10.1016/0003-2697(79)90109-X; JACOBS MM, 1981, CANCER RES, V41, P4458; KALYANARAMAN B, 1985, ENVIRON HEALTH PERSP, V64, P179, DOI 10.2307/3430008; KANG JO, 1988, BIOCHEM PHARMACOL, V37, P2967, DOI 10.1016/0006-2952(88)90283-3; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; KAWANISHI S, 1991, BIOCHEMISTRY-US, V30, P3069, DOI 10.1021/bi00226a013; KIMBALL RF, 1977, MUTAT RES, V39, P111, DOI 10.1016/0165-1110(77)90018-5; KIRBY KS, 1967, BIOCHEM J, V104, P254, DOI 10.1042/bj1040254; KRIEK E, 1974, BIOCHIM BIOPHYS ACTA, V355, P177, DOI 10.1016/0304-419X(74)90003-1; LEITE LCC, 1989, ARCH BIOCHEM BIOPHYS, V270, P560, DOI 10.1016/0003-9861(89)90538-9; MAEDA M, 1974, TETRAHEDRON, V30, P2677, DOI 10.1016/S0040-4020(01)97428-9; NETTO LES, 1988, ARCH BIOCHEM BIOPHYS, V266, P562, DOI 10.1016/0003-9861(88)90289-5; NETTO LES, 1991, CHEM-BIOL INTERACT, V79, P1, DOI 10.1016/0009-2797(91)90048-C; OBRIEN PJ, 1985, ENVIRON HEALTH PERSP, V64, P219, DOI 10.2307/3430012; PARK JW, 1988, P NATL ACAD SCI USA, V85, P7467, DOI 10.1073/pnas.85.20.7467; PARODI S, 1981, CANCER RES, V41, P1469; PRYOR WA, 1988, FREE RADICAL BIO MED, V4, P219, DOI 10.1016/0891-5849(88)90043-3; RAMAKRISHNA NVS, 1992, J AM CHEM SOC, V114, P1863, DOI 10.1021/ja00031a047; REDDY BS, 1979, FED PROC, V38, P714; RICE JM, 1967, J AM CHEM SOC, V89, P2719, DOI 10.1021/ja00987a039; ROGAN EG, 1988, J AM CHEM SOC, V110, P4023, DOI 10.1021/ja00220a049; ROGERS KJ, 1977, CANCER RES, V37, P4082; SAFFHILL R, 1985, BIOCHIM BIOPHYS ACTA, V823, P111, DOI 10.1016/0304-419X(85)90009-5; SHIGENAGA MK, 1991, FREE RADICAL BIO MED, V10, P211, DOI 10.1016/0891-5849(91)90078-H; SNYDER CA, 1986, CANCER LETT, V33, P175, DOI 10.1016/0304-3835(86)90022-4; STEENKEN S, 1989, CHEM REV, V89, P503, DOI 10.1021/cr00093a003; STEINMAUS H, 1971, J ORG CHEM, V36, P3594; TACHIBEDFORD AM, 1988, TOXICOLOGY, V50, P181; TOTH B, 1980, J CANCER RES CLIN, V97, P97, DOI 10.1007/BF00409895; TSO POP, 1977, FREE RADICALS BIOL, V3, P251; WIESTLER OD, 1984, J CANCER RES CLIN, V108, P56, DOI 10.1007/BF00390973; ZADY MF, 1977, J AM CHEM SOC, V99, P5096, DOI 10.1021/ja00457a033	50	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21524	21527						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400464				2022-12-25	WOS:A1992JV01100042
J	RAPP, JC; BAUMGARTNER, BJ; MULLET, J				RAPP, JC; BAUMGARTNER, BJ; MULLET, J			QUANTITATIVE-ANALYSIS OF TRANSCRIPTION AND RNA LEVELS OF 15 BARLEY CHLOROPLAST GENES - TRANSCRIPTION RATES AND MESSENGER-RNA LEVELS VARY OVER 300-FOLD - PREDICTED MESSENGER-RNA STABILITIES VARY 30-FOLD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; PSBD-PSBC; ILLUMINATED BARLEY; LEAF DEVELOPMENT; PHOTOSYSTEM-II; ALPHA-SUBUNIT; RIBOSOMAL-RNA; PSAA-PSAB; RBCL GENE; ZEA-MAYS	Higher plant plastid genomes encode rRNAs, tRNAs, and protein subunits of the RNA polymerase, ribosomes, and the photosynthetic apparatus which vary over 1000-fold in abundance. Quantitative analysis of transcription and RNA levels was carried out on 15 plastid genes which are located in 14 different transcription units covering 50% of the barley plastid genome. Transcription of 16S rRNA, trnfM-trnG, and trnK was high relative to most other plastid genes. Transcription of trnfM-trnG was 5 times greater than trnK indicating that differences in tRNA levels in plastids could be due, in part, to differences in transcription. Among the protein coding genes, mRNA levels varied over 900-fold and transcription over 300-fold. The gene showing the lowest transcription rate and mRNA level, rpoB, is located in a gene cluster which encodes subunits of the plastid RNA polymerase (rpoB-rpoC1-rpoC2). RpoA, which encodes the alpha subunit of the RNA polymerase, was located in a gene cluster encoding ribosomal proteins (rpl23, rps19, rpl16) and infA. RNA from this gene cluster is 30-fold more abundant than rpoB mRNA, suggesting that expression of rpoA is regulated at the level of translation or protein stability. Polycistronic operons encoding subunits of the photosynthetic apparatus (psbB-psbH-petB-petD; psbK-psbI-psbD-psbC; atpB-atpE; psaA-psaB) had higher transcription rates and correspondingly higher mRNA levels than genes which encode ribosomal proteins or RNA polymerase subunits. RbcL and psbA, which are located in separate transcription units, exhibited the highest transcription rates and mRNA levels. Correspondence between transcription rate, mRNA level, and protein abundance indicates that transcription is a primary determinant of barley plastid gene expression. In addition, a 30-fold variation in predicted mRNA stability was observed which further increases the dynamic range of plastid mRNA abundance.	TEXAS A&M UNIV SYST,DEPT BIOCHEM & BIOPHYS,COLL STN,TX 77843	Texas A&M University System; Texas A&M University College Station								BALDAUF SL, 1990, NATURE, V344, P262, DOI 10.1038/344262a0; BAUMGARTNER BJ, 1989, PLANT PHYSIOL, V89, P1011, DOI 10.1104/pp.89.3.1011; BENDICH AJ, 1987, BIOESSAYS, V6, P279, DOI 10.1002/bies.950060608; BENNETT DC, 1990, PLANT MOL BIOL, V15, P111, DOI 10.1007/BF00017728; BERENDS T, 1987, NUCLEIC ACIDS RES, V15, P5217, DOI 10.1093/nar/15.13.5217; BOYER SK, 1988, NUCLEIC ACIDS RES, V16, P8184, DOI 10.1093/nar/16.16.8184; BURGESS RR, 1969, J BIOL CHEM, V244, P6168; CHAKHMAKHCHEVA OG, 1989, NUCLEIC ACIDS RES, V17, P2858, DOI 10.1093/nar/17.7.2858; CHOW WS, 1990, AUST J PLANT PHYSIOL, V17, P665; DEAN C, 1982, PLANT PHYSIOL, V70, P1605, DOI 10.1104/pp.70.6.1605; DENG XW, 1987, CELL, V49, P379, DOI 10.1016/0092-8674(87)90290-X; GANTT JS, 1991, EMBO J, V10, P3073, DOI 10.1002/j.1460-2075.1991.tb07859.x; GREENBERG BM, 1984, J BIOL CHEM, V259, P4880; GRUISSEM W, 1985, EMBO J, V4, P3375, DOI 10.1002/j.1460-2075.1985.tb04093.x; GRUISSEM W, 1985, MOL FORM FUNCTION PL, V83, P199; HANLEYBOWDOIN L, 1987, TRENDS BIOCHEM SCI, V12, P67, DOI 10.1016/0968-0004(87)90033-8; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; HUDSON GS, 1988, J MOL BIOL, V200, P639, DOI 10.1016/0022-2836(88)90477-9; KEUS RJA, 1984, CURR GENET, V9, P91, DOI 10.1007/BF00396209; KLAFF P, 1991, PLANT CELL, V3, P517, DOI 10.1105/tpc.3.5.517; KLEIN RR, 1987, J BIOL CHEM, V262, P4341; KLEIN RR, 1990, J BIOL CHEM, V265, P1895; KRUPINSKA K, 1989, MOL GEN GENET, V219, P467, DOI 10.1007/BF00259621; LINDAHL L, 1982, ADV GENET, V21, P53, DOI 10.1016/S0065-2660(08)60297-7; MATSUBAYASHI T, 1987, MOL GEN GENET, V210, P385, DOI 10.1007/BF00327187; MATTOO AK, 1989, CELL, V56, P241, DOI 10.1016/0092-8674(89)90897-0; MULLET JE, 1987, EMBO J, V6, P1571, DOI 10.1002/j.1460-2075.1987.tb02402.x; MULLET JE, 1985, PLANT MOL BIOL, V4, P39, DOI 10.1007/BF02498714; MULLET JE, 1990, P NATL ACAD SCI USA, V87, P4038, DOI 10.1073/pnas.87.11.4038; NEUMANN EM, 1988, CARLSBERG RES COMMUN, V53, P259, DOI 10.1007/BF02907182; NGERNPRASIRTSIRI J, 1990, CELL STRUCT FUNCT, V15, P273, DOI 10.1247/csf.15.273; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; OHYAMA K, 1988, TRENDS BIOCHEM SCI, V13, P19, DOI 10.1016/0968-0004(88)90013-8; OLIVER RP, 1984, CARLSBERG RES COMMUN, V49, P647, DOI 10.1007/BF02907497; OLIVER RP, 1984, CARLSBERG RES COMMUN, V49, P555, DOI 10.1007/BF02908683; OROZCO EM, 1985, NUCLEIC ACIDS RES, V13, P1283, DOI 10.1093/nar/13.4.1283; PALMER JD, 1990, TRENDS GENET, V6, P115, DOI 10.1016/0168-9525(90)90125-P; PALMER JD, 1985, ANNU REV GENET, V19, P325, DOI 10.1146/annurev.ge.19.120185.001545; PFITZINGER H, 1987, NUCLEIC ACIDS RES, V15, P1377, DOI 10.1093/nar/15.4.1377; POULSEN C, 1983, CARLSBERG RES COMMUN, V48, P57, DOI 10.1007/BF02906170; POULSEN C, 1984, CARLSBERG RES COMMUN, V49, P89, DOI 10.1007/BF02913968; RAJASEKHAR VK, 1991, EUR J BIOCHEM, V195, P215, DOI 10.1111/j.1432-1033.1991.tb15697.x; REVERDATTO SV, 1989, NUCLEIC ACIDS RES, V17, P2859, DOI 10.1093/nar/17.7.2859; RUF M, 1988, NUCLEIC ACIDS RES, V16, P5741, DOI 10.1093/nar/16.13.5741; Sambrook J, 1989, MOL CLONING LABORATO; SEXTON TB, 1990, EMBO J, V9, P4485, DOI 10.1002/j.1460-2075.1990.tb07899.x; SEXTON TB, 1990, CURR GENET, V17, P445, DOI 10.1007/BF00334526; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; SOGAARD B, 1987, CARLSBERG RES COMMUN, V52, P123, DOI 10.1007/BF02907531; STERN DB, 1991, PLANT CELL, V3, P285; STRITTMATTER G, 1984, NUCLEIC ACIDS RES, V12, P7633, DOI 10.1093/nar/12.20.7633; TANAKA M, 1987, MOL GEN GENET, V209, P427, DOI 10.1007/BF00331145; THOMAS F, 1988, PLANT MOL BIOL, V10, P447, DOI 10.1007/BF00014950; TILLER K, 1991, EUR J BIOCHEM, V198, P93, DOI 10.1111/j.1432-1033.1991.tb15990.x; UMESONO K, 1987, TRENDS GENET, V3, P281, DOI 10.1016/0168-9525(87)90269-1; WESTHOFF P, 1988, EUR J BIOCHEM, V171, P551, DOI 10.1111/j.1432-1033.1988.tb13824.x; WOLFE KH, 1989, P NATL ACAD SCI USA, V86, P6201, DOI 10.1073/pnas.86.16.6201; ZHOU DX, 1989, MOL GEN GENET, V101, P439; ZURAWSKI G, 1984, GENETICS, V106, P735; ZURAWSKI G, 1984, NUCLEIC ACIDS RES, V12, P2549, DOI 10.1093/nar/12.5.2549	60	91	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21404	21411						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400453				2022-12-25	WOS:A1992JV01100025
J	TIGYI, G; MILEDI, R				TIGYI, G; MILEDI, R			LYSOPHOSPHATIDATES BOUND TO SERUM-ALBUMIN ACTIVATE MEMBRANE CURRENTS IN XENOPUS OOCYTES AND NEURITE RETRACTION IN PC12 PHEOCHROMOCYTOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID COMPOSITION; PHOSPHATIDIC-ACID; HUMAN-PLATELETS; ARACHIDONATE RELEASE; IDENTIFICATION; THROMBIN; AGGREGATION; STIMULUS; TURNOVER; PROTEINS	Serum contains a factor that co-purifies with albumin and causes neurite retraction in PC12 cells, inhibits the proliferation of tumor cells in vitro, and activates the phosphatidylinositol/Ca2+ second messenger system in Xenopus oocytes and other cells. The activity of serum albumin depends on several lysophospholipids bound to albumin. Thin layer chromatographic analysis of the lipids extracted by methanol from serum albumin revealed over a dozen components, several of which evoked oscillatory currents in oocytes. In contrast to serum albumin, most of these lipids were absent in plasma, which lacks the biological activity. The most abundant naturally occurring active component was identified as stearoyl-lysophosphatidic acid. Synthetically prepared lysophosphatidates reproduced the biological activities of the natural serum factor. Adding synthetic lysophosphatidates to inactive fatty acid-free albumin restored activity to the albumin, making the active factor nondialyzable against aqueous solvents and protecting against digestion by various lipases. Since the biologically active lysophosphatidates were produced during blood clotting, in the presence of platelets, and lysophosphatidates have been shown previously to activate platelets, we propose that lysophosphatidates may play an important role in linking platelet activation to receptor-mediated tissue regeneration.	UNIV CALIF IRVINE, DEPT PSYCHOBIOL, CELLULAR & MOLEC NEUROBIOL LAB, IRVINE, CA 92717 USA	University of California System; University of California Irvine					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023284] Funding Source: NIH RePORTER; NINDS NIH HHS [NS23284] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BELL RL, 1979, P NATL ACAD SCI USA, V76, P3238, DOI 10.1073/pnas.76.7.3238; BENTON AM, 1982, BLOOD, V60, P642; BILLAH MM, 1980, J BIOL CHEM, V255, P227; BROEKMAN MJ, 1981, J BIOL CHEM, V256, P8271; BROWN JR, 1982, LIPID PROTEIN INTERA, V1, P26; CALVO M, 1988, BIOCHIM BIOPHYS ACTA, V959, P238, DOI 10.1016/0005-2760(88)90196-8; COHN EJ, 1946, J AM CHEM SOC, V68, P459, DOI 10.1021/ja01207a034; CORR PB, 1979, CIRC RES, V44, P822, DOI 10.1161/01.RES.44.6.822; DAS AK, 1984, BIOCHIM BIOPHYS ACTA, V796, P178, DOI 10.1016/0005-2760(84)90346-1; DAS AK, 1989, LIPIDS, V24, P329, DOI 10.1007/BF02535172; DYER D, 1992, MOL BRAIN RES, V14, P293, DOI 10.1016/0169-328X(92)90096-T; DYER D, 1992, MOL BRAIN RES, V14, P302, DOI 10.1016/0169-328X(92)90097-U; DYER D, 1989, 3RD INT REG S, P28; DYER D, 1992, THESIS U CALIFORNIA; ESUMI H, 1979, BIOCHEM BIOPH RES CO, V87, P1191, DOI 10.1016/S0006-291X(79)80033-9; GERRARD JM, 1979, AM J PATHOL, V96, P423; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; GERRARD JM, 1979, AM J PATHOL, V97, P531; HAMILTON JA, 1991, P NATL ACAD SCI USA, V88, P2051, DOI 10.1073/pnas.88.6.2051; HANAHAN DJ, 1980, J BIOL CHEM, V255, P5514; INOUE M, 1984, J BIOL CHEM, V259, P5083; JALINK K, 1990, J BIOL CHEM, V265, P12232; KALUZNY MA, 1985, J LIPID RES, V26, P135; KATES M, 1986, LABORATORY TECHNIQUE, V3; KRAGHHANSEN U, 1990, DAN MED BULL, V37, P57; LAPETINA EG, 1981, J BIOL CHEM, V256, P1984; LAURSEN I, 1990, ANTICANCER RES, V10, P343; MCCREA JM, 1985, BIOCHIM BIOPHYS ACTA, V842, P189, DOI 10.1016/0304-4165(85)90202-8; MILEDI R, 1982, PROC R SOC SER B-BIO, V215, P491, DOI 10.1098/rspb.1982.0056; MOOLENAAR WH, 1991, ADV CANCER RES, V57, P87; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; NAGASE S, 1979, SCIENCE, V205, P590, DOI 10.1126/science.451621; NAKAGAWA M, 1973, J BIOCHEM-TOKYO, V74, P1263, DOI 10.1093/oxfordjournals.jbchem.a130354; NEUFELD EJ, 1983, J BIOL CHEM, V258, P2461; NISHIKAWA T, 1988, JPN J PHARMACOL, V47, P143, DOI 10.1254/jjp.47.143; REED RG, 1986, J BIOL CHEM, V261, P5619; ROSSENEUMOTREFF M, 1970, J BIOCHEM, V68, P369, DOI 10.1093/oxfordjournals.jbchem.a129367; SAIFER A, 1961, J LIPID RES, V2, P268; SCHUMACHER KA, 1979, THROMB HAEMOSTASIS, V42, P631; TIGYI G, 1990, P NATL ACAD SCI USA, V87, P1521, DOI 10.1073/pnas.87.4.1521; TIGYI G, 1991, J BIOL CHEM, V266, P20602; TIGYI G, 1989, 3RD INT REG S, P28; TIGYI G, 1991, FAL BOOK ASBMB S LI, P24; TOKUMURA A, 1986, BIOCHIM BIOPHYS ACTA, V875, P31; TOKUMURA A, 1978, LIPIDS, V13, P572, DOI 10.1007/BF02533598; TOKUMURA A, 1980, ARCH INT PHARMACOD T, V245, P74; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; WRIGHT RS, 1971, J CHROMATOGR, V59, P220, DOI 10.1016/S0021-9673(01)80033-9	49	335	351	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21360	21367						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1383223				2022-12-25	WOS:A1992JV01100019
J	VALENTINRANC, C; CARLIER, MF				VALENTINRANC, C; CARLIER, MF			CHARACTERIZATION OF OLIGOMERS AS KINETIC INTERMEDIATES IN MYOSIN SUBFRAGMENT 1-INDUCED POLYMERIZATION OF G-ACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; F-ACTIN; BINDING-SITES; COMPLEX; GELSOLIN; MECHANISMS; FILAMENTS; PROTEINS; PROBE; CELLS	The nature of the kinetic intermediates involved in S1-induced polymerization of G-actin into F-acto-S1-decorated filaments has been investigated using as probes light scattering, the fluorescence of pyrenyl- or NBD-labeled actin, and the anisotropy of fluorescence of N-iodoacetyl-N'-(5-sulfo-1-napthyl)ethylene diamine (AEDANS)-labeled actin. With AEDANS-G-actin, the initial formation of a ternary G2S complex between two G-actin and one S1 molecules (Valentin-Ranc, C., Combeau, C., Carlier, M. F., and Pantaloni, D. (199 1) J. Biol. Chem. 266, 17871-17879) has been confirmed. Data obtained with all probes are consistent with the subsequent rapid formation of G-actin-S1 oligomers in which the actin/S1 molar ratio is 2:1. Oligomers form above 0.6 mum G-actin with S1(A1) and above 3.5 muM G-actin with S1(A2), at 20-degrees-C. Oligomerization is endothermic with a DELTAH of 14 kcal/mol. A tentative model is proposed to comprehensively account for the data and the structural features of the F-actin-S1 filament. Within this model, longitudinal actin-actin interactions take place in G2S, and lateral, hydrophobic actin-actin interactions appear upon formation of (G2S)n oligomers.			VALENTINRANC, C (corresponding author), CNRS,ENZYMOL LAB,F-91198 GIF SUR YVETTE,FRANCE.							BRYAN J, 1984, J BIOL CHEM, V259, P7480; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P463; CARLIER MF, 1987, J BIOL CHEM, V262, P3052; CARLIER MF, 1984, J BIOL CHEM, V259, P9983; CHAUSSEPIED P, 1989, J BIOL CHEM, V264, P20752; CHAUSSEPIED P, 1989, NATURE, V342, P950, DOI 10.1038/342950a0; CHEN T, 1991, BIOCHEMISTRY-US, V30, P4546, DOI 10.1021/bi00232a026; COMBEAU C, 1992, J BIOL CHEM, V267, P14038; COMBEAU C, 1992, BIOCHEMISTRY-US, V31, P300, DOI 10.1021/bi00116a041; COMBEAU C, 1992, BIOPHYS J, V61; COOKE R, 1971, J MOL BIOL, V60, P249, DOI 10.1016/0022-2836(71)90291-9; COOPER JA, 1991, ANNU REV PHYSIOL, V53, P585, DOI 10.1146/annurev.ph.53.030191.003101; COUE M, 1985, J BIOL CHEM, V260, P16033; DASGUPTA G, 1990, BIOCHEMISTRY-US, V29, P8503, DOI 10.1021/bi00488a043; DETMERS P, 1981, J BIOL CHEM, V256, P99; DOI YK, 1991, BIOCHEMISTRY-US, V30, P5769, DOI 10.1021/bi00237a020; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; FRIEDEN C, 1980, J BIOL CHEM, V255, P8991; GORDON DJ, 1976, J BIOL CHEM, V251, P7474; GRAZI E, 1980, FEBS LETT, V112, P67, DOI 10.1016/0014-5793(80)80129-3; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Holmes KC, 1991, CURR OPIN STRUC BIOL, V1, P270, DOI 10.1016/0959-440X(91)90073-3; KEANE AM, 1990, NATURE, V344, P265, DOI 10.1038/344265a0; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MILLER L, 1988, J BIOL CHEM, V263, P1996; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MOCKRIN S, 1980, BIOCHEMISTRY-US, V19, P5358; OFFER G, 1973, J MOL BIOL, V74, P653, DOI 10.1016/0022-2836(73)90055-7; OOSAWA F, 1975, THERMODYNAMICS POLYM, P28; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; VALENTINRANC C, 1991, J BIOL CHEM, V266, P17871; Vandekerckhove J, 1990, CURR OPIN CELL BIOL, V2, P41, DOI 10.1016/S0955-0674(05)80029-8; WEEDS AG, 1986, EUR J BIOCHEM, V161, P77, DOI 10.1111/j.1432-1033.1986.tb10126.x; WEEDS AG, 1977, J MOL BIOL, V111, P129, DOI 10.1016/S0022-2836(77)80119-8; YAGI K, 1965, J BIOL CHEM, V240, P2448; YAZAWA Y, 1973, J BIOCHEM-TOKYO, V73, P567, DOI 10.1093/oxfordjournals.jbchem.a130115	43	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21543	21550						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400465				2022-12-25	WOS:A1992JV01100045
J	LANKER, S; MULLER, PP; ALTMANN, M; GOYER, C; SONENBERG, N; TRACHSEL, H				LANKER, S; MULLER, PP; ALTMANN, M; GOYER, C; SONENBERG, N; TRACHSEL, H			INTERACTIONS OF THE EIF-4F SUBUNITS IN THE YEAST SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING-PROTEIN; EUKARYOTIC TRANSLATION INITIATION; MESSENGER-RNA; INHIBITION; POLIOVIRUS; GENES	Recognition of the cap structure at the 5' end of mRNA is one of the first events in initiation of eukaryotic translation. This step is mediated by the translation initiation factor 4F (eIF-4F). In mammalian cells this factor is composed of the cap-binding protein eIF-4E, eIF-4A, and a 220-kDa polypeptide. In yeast Saccharomyces cerevisiae, eIF-4E is found associated with a 150-kDa protein (p150) and a 20-kDa protein (p20). The resulting protein complex is proposed to represent yeast eIF-4F. To study the functions of p150 and p20 and their interaction with eIF-4E, we disrupted the genes encoding p150 and p20 and analyzed the effects on protein complex formation and cell viability. Yeast cells with single and double disruptions of the genes encoding p 150 and p20 are viable, but p150 single and p150/p20 double disruptions show a slow growth phenotype. Gel chromatography and immunoadsorption experiments with a monoclonal anti-eIF-4E antibody coupled to protein G-Sepharose show that both p150 and p20 bind independently of each other to eIF-4E.	MCGILL UNIV, DEPT BIOCHEM, MONTREAL H3G 1Y6, QUEBEC, CANADA	McGill University	LANKER, S (corresponding author), UNIV BERN, INST BIOCHEM & MOLEK BIOL, BUHLSTR 28, CH-3012 BERN, SWITZERLAND.			Mueller, Peter/0000-0002-1209-7546				ALTMANN M, 1989, NUCLEIC ACIDS RES, V17, P7520, DOI 10.1093/nar/17.18.7520; ALTMANN M, 1985, BIOCHEMISTRY-US, V24, P6085, DOI 10.1021/bi00343a009; ALTMANN M, 1989, NUCLEIC ACIDS RES, V17, P5923, DOI 10.1093/nar/17.15.5923; ALTMANN M, 1989, J BIOL CHEM, V264, P12145; ALTMANN M, 1987, MOL CELL BIOL, V7, P998, DOI 10.1128/MCB.7.3.998; ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Davis R W, 1980, Methods Enzymol, V65, P404; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DUNCAN R, 1987, J BIOL CHEM, V262, P380; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; FURUICHI Y, 1977, NATURE, V266, P235, DOI 10.1038/266235a0; GOYER C, 1989, J BIOL CHEM, V264, P7603; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; HUEMBELIN M, 1991, TRANSLATION EUKARYOT, P231; Jagus R, 1981, Prog Nucleic Acid Res Mol Biol, V25, P127, DOI 10.1016/S0079-6603(08)60484-5; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LINDER P, 1989, P NATL ACAD SCI USA, V86, P2286, DOI 10.1073/pnas.86.7.2286; LINDER P, 1990, BIOESSAYS, V12, P519, DOI 10.1002/bies.950121103; MULLER PP, 1990, EUR J BIOCHEM, V191, P257, DOI 10.1111/j.1432-1033.1990.tb19118.x; RAY BK, 1983, P NATL ACAD SCI-BIOL, V80, P663, DOI 10.1073/pnas.80.3.663; RAY BK, 1985, J BIOL CHEM, V260, P7651; RHOADS RE, 1991, TRANSLATION EUKARYOT, P109; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Sambrook J, 1989, MOL CLONING LABORATO; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; Sherman F., 1986, METHODS YEAST GENETI; SLATER MR, 1989, NUCLEIC ACIDS RES, V17, P805, DOI 10.1093/nar/17.2.805; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; SONENBERG N, 1987, ADV VIRUS RES, V33, P175, DOI 10.1016/S0065-3527(08)60318-8; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	35	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21167	21171						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400427				2022-12-25	WOS:A1992JT97800101
J	WILCOX, BD; RYDELEKFITZGERALD, L; JEFFREY, JJ				WILCOX, BD; RYDELEKFITZGERALD, L; JEFFREY, JJ			REGULATION OF COLLAGENASE GENE-EXPRESSION BY SEROTONIN AND PROGESTERONE IN RAT UTERINE SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5-HT2 BINDING CHARACTERISTICS; ENZYME PRODUCTION; TISSUE CULTURE; PURIFICATION; METABOLISM; RECEPTOR; ANALOGS	The regulation of collagenase gene expression by serotonin and progesterone was investigated in primary cultures of rat uterine smooth muscle cells. Northern blot analysis demonstrates that serotonin (5-hydroxytryptamine (5-HT)), when administered to cells in serotonin-depleted medium, causes 6-8-fold increases in levels of collagenase mRNA. Selective serotonin 5-HT2 receptor agonists were able to mimic the effect of the natural hormone, while the induction by serotonin could be blocked by 5-HT2 receptor antagonists. Addition of phorbol ester (PMA) to 5-HT-depleted cultures fully mimicked the effect of 5-HT on collagenase mRNA induction. Treatment with progesterone analogs caused a decrease in collagenase mRNA, even in the presence of saturating levels of serotonin or PMA. In all experiments, levels of secreted collagenase were observed to correspond to levels of collagenase mRNA. Experiments with cycloheximide demonstrate that serotonin- and PMA-induced increases in collagenase mRNA are dependent on protein synthesis. Furthermore, nuclear run-on analysis shows that mRNA increases are accompanied by increases in initiation of transcripts. These data indicate that transcription of collagenase mRNA in myometrial smooth muscle cells is stimulated by serotonin, possibly via activation of protein kinase C, but is in some way prevented by the negative influence of progesterone.	UNION UNIV, DEPT MED, ALBANY, NY 12208 USA; UNION UNIV, DEPT PHARMACOL & TOXICOL, ALBANY, NY 12208 USA; UNION UNIV, DEPT BIOCHEM & MOLEC BIOL, ALBANY, NY 12208 USA	Union College; Union College; Union College					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005291, R37HD005291] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 05291] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACHARYA S B, 1989, Indian Journal of Experimental Biology, V27, P505; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BLAIR HC, 1986, J CELL PHYSIOL, V129, P111, DOI 10.1002/jcp.1041290116; BRINCKERHOFF CE, 1990, ANN NY ACAD SCI, V580, P355, DOI 10.1111/j.1749-6632.1990.tb17944.x; CHALLIS JRG, 1986, OXFORD REV REPROD B, V8, P61; CONN PJ, 1984, NEUROPHARMACOLOGY, V23, P993, DOI 10.1016/0028-3908(84)90017-0; DAVIS LG, 1986, BASIC METHODS MOL BI, P143; DOYLE VM, 1986, N-S ARCH PHARMACOL, V333, P98, DOI 10.1007/BF00506510; FAHIM I, 1966, BRIT J PHARM CHEMOTH, V26, P237, DOI 10.1111/j.1476-5381.1966.tb01826.x; GLENNON RA, 1986, J MED CHEM, V29, P2375, DOI 10.1021/jm00161a038; GLENNON RA, 1986, J MED CHEM, V29, P194, DOI 10.1021/jm00152a005; HALME J, 1980, ARCH BIOCHEM BIOPHYS, V199, P51, DOI 10.1016/0003-9861(80)90255-6; HARKNESS MLR, 1956, J PHYSIOL-LONDON, V132, P492, DOI 10.1113/jphysiol.1956.sp005542; HARKNESS RD, 1964, INT REV CONNECT TISS, V2, P155; HARKNESS RD, 1956, J PHYSIOL-LONDON, V132, P502, DOI 10.1113/jphysiol.1956.sp005543; JEFFREY JJ, 1971, BIOCHIM BIOPHYS ACTA, V252, P136, DOI 10.1016/0304-4165(71)90101-2; JEFFREY JJ, 1990, J CELL PHYSIOL, V143, P396, DOI 10.1002/jcp.1041430226; JEFFREY JJ, 1991, J CELL PHYSIOL, V146, P399, DOI 10.1002/jcp.1041460310; JEFFREY JJ, 1970, BIOCHEMISTRY-US, V9, P268, DOI 10.1021/bi00804a012; JEFFREY JJ, 1971, BIOCHIM BIOPHYS ACTA, V252, P143, DOI 10.1016/0304-4165(71)90102-4; JULIUS D, 1991, ANNU REV NEUROSCI, V14, P335, DOI 10.1146/annurev.neuro.14.1.335; LEYSEN JE, 1982, MOL PHARMACOL, V21, P301; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MORRIONE TG, 1962, J EXP MED, V115, P357, DOI 10.1084/jem.115.2.357; NAGAI Y, 1966, BIOCHEMISTRY-US, V5, P3123, DOI 10.1021/bi00874a007; PEPE GJ, 1974, ENDOCRINOLOGY, V95, P275, DOI 10.1210/endo-95-1-275; PEROUTKA SJ, 1979, MOL PHARMACOL, V16, P687; QUINN CO, 1990, J BIOL CHEM, V265, P22342; ROSWIT WT, 1988, ARCH BIOCHEM BIOPHYS, V262, P67, DOI 10.1016/0003-9861(88)90169-5; RYAN JN, 1971, BIOCHEM BIOPH RES CO, V44, P144, DOI 10.1016/S0006-291X(71)80170-5; SCHATZ F, 1983, ENDOCRINOLOGY, V113, P1274, DOI 10.1210/endo-113-4-1274; SHERWOOD OD, 1983, ENDOCRINOLOGY, V113, P997, DOI 10.1210/endo-113-3-997; STRICKLIN GP, 1977, BIOCHEMISTRY-US, V16, P1607, DOI 10.1021/bi00627a013; WOESSNER JF, 1963, BIOCHEM J, V89, P75, DOI 10.1042/bj0890075	34	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20752	20757						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400391				2022-12-25	WOS:A1992JT97800039
J	NOGUCHI, J; YANAGISAWA, M; IMAMURA, M; KASUYA, Y; SAKURAI, T; TANAKA, T; MASAKI, T				NOGUCHI, J; YANAGISAWA, M; IMAMURA, M; KASUYA, Y; SAKURAI, T; TANAKA, T; MASAKI, T			COMPLETE PRIMARY STRUCTURE AND TISSUE EXPRESSION OF CHICKEN PECTORALIS M-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M-BAND PROTEINS; MUSCLE M-PROTEIN; SKELETAL-MUSCLE; IMMUNOGLOBULIN SUPERFAMILY; CREATINE-KINASE; LIMITED PROTEOLYSIS; ADHESION MOLECULE; ALPHA-ACTININS; SEQUENCE; DOMAINS	M-Protein (165 kDa) is a structural constituent of myofibrillar M-band in striated muscle. We generated a monoclonal antibody which recognized a 165-kDa protein from chicken pectoralis muscle in immunoblot analysis and stained the M-band under immunofluorescence microscopy. By screening a lambdagt11 cDNA library from chicken embryonic pectoralis muscle with this antibody, we isolated a cDNA clone encoding the M-protein. Northern blot analysis showed that M-protein mRNA is expressed in pectoralis and cardiac muscle but not in gizzard smooth muscle or non-muscle tissues. Moreover, the anterior latissimus dorsi muscle, which consists almost exclusively of slow fiber types, contains no detectable levels of the mRNA. The full-length cDNA sequence predicted a 1,450-amino acid polypeptide with a calculated molecular weight of 163 X 10(3). The encoded protein contains several copies of two different repetitive motifs: five copies of fibronectin type III repeats are in the middle part of the predicted molecule, and two and four copies of the immunoglobulin C2-type repeats are located toward the NH2-terminal and COOH-terminal regions, respectively. This indicates that M-protein, along with other thick filament-associated proteins such as C-protein, twichin, and titin, belongs to the superfamily of cytoskeletal proteins with immunoglobulin/fibronectin repeats.	UNIV TSUKUBA, INST BASIC MED SCI, TSUKUBA, IBARAKI 305, JAPAN; JAPAN RED CROSS, SAITAMA BRANCH, YONO, SAITAMA 338, JAPAN	University of Tsukuba				Kasuya, Yoshitoshi/0000-0003-0614-5836				BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; CARLSSON E, 1990, HISTOCHEMISTRY, V95, P27, DOI 10.1007/BF00737225; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; EINHEBER S, 1990, P NATL ACAD SCI USA, V87, P2157, DOI 10.1073/pnas.87.6.2157; ENDO T, 1984, J CELL BIOL, V99, P2322, DOI 10.1083/jcb.99.6.2322; ENDO T, 1982, J BIOCHEM, V92, P1457, DOI 10.1093/oxfordjournals.jbchem.a134070; EPPENBERGER HM, 1981, J CELL BIOL, V89, P185, DOI 10.1083/jcb.89.2.185; EPPENBERGER HM, 1982, METHOD ENZYMOL, V85, P139; EPSTEIN HF, 1991, SCIENCE, V251, P1039, DOI 10.1126/science.1998120; EREL Z, 1972, BIOCHEM BIOPH RES CO, V49, P383, DOI 10.1016/0006-291X(72)90422-6; FISCHMAN DA, 1991, INT CONGR SER, P211; GROVE BK, 1985, J CELL BIOL, V101, P1413, DOI 10.1083/jcb.101.4.1413; GROVE BK, 1984, J CELL BIOL, V98, P518, DOI 10.1083/jcb.98.2.518; GROVE BK, 1989, J HISTOCHEM CYTOCHEM, V37, P447, DOI 10.1177/37.4.2926123; HIKIDA RS, 1981, AM J ANAT, V160, P395, DOI 10.1002/aja.1001600404; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; IMAMURA M, 1990, MORPHOGENESIS FUNCTI, P53; INOUE A, 1989, J BIOL CHEM, V264, P14954; KOIDE T, 1973, EUR J BIOCHEM, V32, P401, DOI 10.1111/j.1432-1033.1973.tb02622.x; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LABEIT S, 1990, NATURE, V345, P273, DOI 10.1038/345273a0; LANDON MF, 1975, BIOCHEM BIOPH RES CO, V62, P241, DOI 10.1016/S0006-291X(75)80129-X; LUTHER P, 1978, J MOL BIOL, V125, P313, DOI 10.1016/0022-2836(78)90405-9; MASAKI T, 1972, J BIOCHEM, V71, P355, DOI 10.1093/oxfordjournals.jbchem.a129774; MASAKI T, 1974, J BIOCHEM, V75, P367, DOI 10.1093/oxfordjournals.jbchem.a130403; MASAKI T, 1968, J BIOCHEM-TOKYO, V64, P909, DOI 10.1093/oxfordjournals.jbchem.a128975; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; REINACH FC, 1982, J CELL BIOL, V95, P78, DOI 10.1083/jcb.95.1.78; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STREHLER EE, 1983, J MOL BIOL, V166, P141, DOI 10.1016/S0022-2836(83)80003-5; STREHLER EE, 1979, EXP CELL RES, V124, P39, DOI 10.1016/0014-4827(79)90255-6; TRINICK J, 1977, J MOL BIOL, V113, P343, DOI 10.1016/0022-2836(77)90146-2; TURNER DC, 1973, P NATL ACAD SCI USA, V70, P702, DOI 10.1073/pnas.70.3.702; WALLIMANN T, 1977, J CELL BIOL, V75, P297, DOI 10.1083/jcb.75.2.297; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WOODHEAD JL, 1983, J MOL BIOL, V168, P831, DOI 10.1016/S0022-2836(83)80077-1; WOODHEAD JL, 1982, J MOL BIOL, V157, P149, DOI 10.1016/0022-2836(82)90517-4	42	48	51	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20302	20310						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400348				2022-12-25	WOS:A1992JR85800088
J	SUWABE, A; MASON, RJ; SMITH, D; FIRESTONE, JA; BROWNING, MD; VOELKER, DR				SUWABE, A; MASON, RJ; SMITH, D; FIRESTONE, JA; BROWNING, MD; VOELKER, DR			PULMONARY SURFACTANT SECRETION IS REGULATED BY THE PHYSICAL STATE OF EXTRACELLULAR PHOSPHATIDYLCHOLINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; AMINO-ACID SEQUENCES; PROTEIN KINASE-C; II CELLS; PHOSPHOLIPID SECRETION; RAT; CDNA; CALCIUM; LUNG; PURIFICATION	Pulmonary alveolar type II cells synthesize, secrete, and recycle the components of pulmonary surfactant. In this report we present evidence that dipalmitoylphosphatidylcholine is a potent inhibitor of surfactant lipid secretion by type II cells. Monoenoic and dienoic phosphatidylcholines with fatty acids of 16 or 18 carbons are ineffective as inhibitors of surfactant lipid secretion. In contrast, disaturated phosphatidylcholines, with either symmetric or asymmetric pairs of fatty acids of 14, 16, or 18 carbons, exhibit inhibition of surfactant secretion that correlates extremely well with the phase transition temperature (Tc) of the phospholipid. The inhibitory activity of dipalmitoylphosphatidylcholine is not dependent upon lipid stereochemistry. N-Methylated derivatives of dipalmitoylphosphatidylethanolamine are significantly less effective than phosphatidylcholine as inhibitors. Phosphatidylcholines below their phase transition temperature are inhibitors of surfactant secretion, whereas those above their phase transition temperature are either ineffective or weakly inhibitory. The phase transition dependence of inhibition is observed when type II cells are incubated at 37-degrees-C with different species of phosphatidylcholine. In addition, if type II cells are stimulated to secrete at different temperatures the efficacy of a given phospholipid as an inhibitor is dependent on its relationship to Tc (i.e. dipalmitoylphosphatidylcholine with a Tc of 41-degrees-C significantly inhibits secretion at 37-degrees-C but not at 42-degrees-C). Inhibition of surfactant secretion by dipalmitoylphosphatidylcholine is abrogated when it is incorporated into the same liposome with dioleoylphosphatidylcholine as a 50:50 mixture. In contrast, the simultaneous addition of two separate populations of liposomes, one composed of dipalmitoylphosphatidylcholine and the other composed of dioleoylphosphatidylcholine, does not significantly alter the inhibitory activity found with dipalmitoylphosphatidylcholine alone. These data provide compelling evidence that the physical state of phosphatidylcholine can regulate surfactant secretion from alveolar type II cells and suggest a unique mechanism for regulating exocytosis in the alveolus of the lung.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,LORD & TAYLOR LAB LUNG BIOCHEM,1400 JACKSON ST,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029891, R37HL029891] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004418] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA003527] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 29891] Funding Source: Medline; NIAAA NIH HHS [AA03527] Funding Source: Medline; NIA NIH HHS [AG04418] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; DOBBS LG, 1986, BIOCHIM BIOPHYS ACTA, V877, P305, DOI 10.1016/0005-2760(86)90308-5; DOBBS LG, 1979, J CLIN INVEST, V63, P378, DOI 10.1172/JCI109313; DOBBS LG, 1987, P NATL ACAD SCI USA, V84, P1010, DOI 10.1073/pnas.84.4.1010; FIRESTONE JA, J NEUROCHEM, V58, P441; GLASSER SW, 1987, P NATL ACAD SCI USA, V84, P4007, DOI 10.1073/pnas.84.12.4007; GLASSER SW, 1988, J BIOL CHEM, V263, P9; GOERKE J, 1974, BIOCHIM BIOPHYS ACTA, V344, P241, DOI 10.1016/0304-4157(74)90009-4; Goerke J., 1986, HDB PHYSL RESP SYSTE, P247; HAWGOOD S, 1987, P NATL ACAD SCI USA, V84, P66, DOI 10.1073/pnas.84.1.66; HAYCOCK JW, 1988, J NEUROSCI, V8, P3233; HILDEBRAN JN, 1979, J APPL PHYSIOL, V47, P604, DOI 10.1152/jappl.1979.47.3.604; JACOBS KA, 1987, J BIOL CHEM, V262, P9808; KING RJ, 1974, FED PROC, V33, P2238; KING RJ, 1973, AM J PHYSIOL, V224, P778; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1988, J BIOL CHEM, V263, P17596; MARSH D, 1977, BIOCHIM BIOPHYS ACTA, V465, P500, DOI 10.1016/0005-2736(77)90268-1; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; PERSSON A, 1988, BIOCHEMISTRY-US, V27, P8576, DOI 10.1021/bi00423a011; PHILLIPS MC, 1970, BIOCHIM BIOPHYS ACTA, V196, P35, DOI 10.1016/0005-2736(70)90163-X; POST M, 1988, BIOCHIM BIOPHYS ACTA, V947, P249, DOI 10.1016/0304-4157(88)90011-1; RICE WR, 1990, BIOCHEM J, V266, P407, DOI 10.1042/bj2660407; RICE WR, 1987, J APPL PHYSIOL, V63, P692, DOI 10.1152/jappl.1987.63.2.692; RICE WR, 1985, EXP LUNG RES, V9, P135, DOI 10.3109/01902148509061533; SANO K, 1987, AM J PHYSIOL, V253, pC679, DOI 10.1152/ajpcell.1987.253.5.C679; SANO K, 1985, J BIOL CHEM, V260, P2725; Silvius J. R., 1982, LIPID PROTEIN INTERA; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; WARR RG, 1987, P NATL ACAD SCI USA, V84, P7915, DOI 10.1073/pnas.84.22.7915; WAYMIRE JC, 1983, J NEUROSCI METH, V7, P329, DOI 10.1016/0165-0270(83)90026-2; WEAVER TE, 1985, BIOCHIM BIOPHYS ACTA, V827, P260, DOI 10.1016/0167-4838(85)90210-9; WHITSETT JA, 1987, J BIOL CHEM, V262, P15618; WRIGHT JR, 1987, AM REV RESPIR DIS, V135, P426	34	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19884	19890						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400304				2022-12-25	WOS:A1992JR85800024
J	TWAMLEY, GM; KYPTA, RM; HALL, B; COURTNEIDGE, SA				TWAMLEY, GM; KYPTA, RM; HALL, B; COURTNEIDGE, SA			ASSOCIATION OF FYN WITH THE ACTIVATED PLATELET-DERIVED GROWTH-FACTOR RECEPTOR - REQUIREMENTS FOR BINDING AND PHOSPHORYLATION	ONCOGENE			English	Article							MIDDLE T-ANTIGEN; PROTEIN-TYROSINE KINASE; PHOSPHATIDYLINOSITOL-3 KINASE; SIGNAL TRANSDUCTION; PDGF RECEPTOR; PHOSPHOLIPASE-C; SRC FAMILY; DOMAINS; PRODUCT; IDENTIFICATION	Three members of the Src family of tyrosine kinases [pp60c-src (Src), p59fyn (Fyn) and pp62c-yes (Yes)] are ubiquitously expressed, and are thus likely to have general roles in growth control. We have previously shown that, after addition of platelet-derived growth factor (PDGF) to quiescent cells, all three kinases become activated and associated with the PDGF receptor. We have now addressed the requirements for this association. First, we have used a baculovirus expression system to show that Fyn associates with the activated PDGF receptor in vitro in the absence of other proteins, demonstrating that the association between the two molecules is direct. Second, by generating cell lines expressing chimeric molecules consisting of Fyn sequences fused to a portion of beta-galactosidase, we found that the SH2 domain of Fyn is necessary for ligand-stimulated association with the PDGF receptor in vivo. Third, those fusion proteins that associated with the PDGF receptor also became phosphorylated in vivo following PDGF treatment, and in in vitro kinase assays, suggesting that the amino-terminal half of Fyn contains the sites of PDGF-stimulated phosphorylation. Partially purified, kinase-negative Fyn also became phosphorylated in the activated PDGF receptor complex in vitro, demonstrating that the PDGF receptor phosphorylates Fyn, rather than the novel phosphorylations occurring by autophosphorylation.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Hall, Belinda/AGU-6214-2022; Kypta, Robert/F-7699-2011	Kypta, Robert/0000-0002-2389-310X; Hall, Belinda/0000-0002-3753-1978				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1991, CELL GROWTH DIFFER, V2, P483; COURTNEIDGE SA, 1991, J VIROL, V65, P3301, DOI 10.1128/JVI.65.6.3301-3308.1991; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FUKUI Y, 1991, ONCOGENE, V6, P407; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORNBLUTH S, 1990, J VIROL, V64, P1584, DOI 10.1128/JVI.64.4.1584-1589.1990; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LUO K, 1990, ONCOGENE, V5, P921; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; Summers MD, 1987, TEXAS AGR EXP STATIO, V1555; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	34	90	90	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1893	1901						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408131				2022-12-25	WOS:A1992JP42400001
J	DISCIPIO, RG				DISCIPIO, RG			FORMATION AND STRUCTURE OF THE C5B-7 COMPLEX OF THE LYTIC PATHWAY OF COMPLEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ATTACK COMPLEX; AMINO-ACID-SEQUENCE; 3RD COMPONENT; FACTOR-I; C9 POLYMERIZATION; CELL-MEMBRANES; ALPHA-SUBUNIT; PROTEIN C8; BINDING; CDNA	The formation and structure of the complement cytolytic intermediary complex, C5b-7, were studied with the aim of determining the interactive regions of C5, C6, and C7. The structure of human complement component C5 was elucidated by the application of limited proteolysis which generated well characterized major polypeptide fragments of this molecule. Plasmin, thrombin, and kallikrein cleave C5b with greater facility than C5. The most useful cleavage of C5b was effected by plasmin because the fragmentation pattern was similar to the processing of C3b by factors H, I, and kallikrein. Plasmin hydrolyzes peptide bonds within the alpha'-chain of C5b, resulting in a four-chain fragment, C5c (M(r) = 142,000), and a single chain fragment, C5d (M(r) = 43,000). Circular dichroism spectroscopic analyses indicated that C5d is substantially richer in alpha-helical content than is C5c (27 versus 9%). Polyclonal antibodies directed against C5c blocked the interaction of C5b-6 with C7, whereas antibodies directed against C5d inhibited the binding of C5 with C3b. Chemical cross-linking using a cleavable radioiodinated photoreactive reagent revealed that both C6 and C7 associate preferentially with the alpha'-chain of C5b. The reversible interactions of C5 with C6, C7, and major polypeptide fragments derived from these were investigated with solid phase binding assays. The results indicate that the carboxyl-terminal domains of C6 and C7, which have cysteine-rich modules homologous to those found in factors H and I, have the capacity to link specifically with C5.			DISCIPIO, RG (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, IMM18, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NIAID NIH HHS [AI/HL 22415] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022415] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAHR B, 1965, QUANTITATIVE ELECTRO, P880; BHAKDI S, 1980, J IMMUNOL, V124, P2451; BIESECKER G, 1980, J IMMUNOL, V124, P1291; CATTERALL CF, 1987, BIOCHEM J, V242, P849, DOI 10.1042/bj2420849; Chibber B A, 1974, Methods Enzymol, V34, P424; CLAMP JR, 1975, PLASMA PROTEINS, V2, P163; CLEGG JCS, 1982, ANAL BIOCHEM, V127, P389, DOI 10.1016/0003-2697(82)90192-0; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; COOPER NR, 1970, J EXP MED, V132, P775, DOI 10.1084/jem.132.4.775; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DAVID GS, 1972, BIOCHEM BIOPH RES CO, V48, P464, DOI 10.1016/S0006-291X(72)80074-3; DISCIPIO RG, 1987, PATHOL IMMUNOPATH R, V6, P343, DOI 10.1159/000157063; DISCIPIO RG, 1981, BIOCHEM J, V199, P485, DOI 10.1042/bj1990485; DISCIPIO RG, 1982, MOL IMMUNOL, V19, P1425, DOI 10.1016/0161-5890(82)90189-4; DISCIPIO RG, 1988, J BIOL CHEM, V263, P549; DISCIPIO RG, 1983, J BIOL CHEM, V258, P629; DISCIPIO RG, 1984, P NATL ACAD SCI-BIOL, V81, P7298, DOI 10.1073/pnas.81.23.7298; DISCIPIO RG, 1981, BIOCHEM J, V199, P497, DOI 10.1042/bj1990497; DISCIPIO RG, 1989, J BIOL CHEM, V264, P16197; DOURMASHKIN RR, 1978, IMMUNOLOGY, V35, P205; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; Engvall E, 1980, Methods Enzymol, V70, P419; FERNANDEZ HN, 1978, J BIOL CHEM, V253, P6955; GOLDBERGER G, 1987, J BIOL CHEM, V262, P10065; HAEFLIGER JA, 1989, J BIOL CHEM, V264, P18041; HAEFLIGER JA, 1987, BIOCHEMISTRY-US, V26, P3551, DOI 10.1021/bi00386a045; HAMMER CH, 1981, J BIOL CHEM, V256, P3995; HAVILAND DL, 1991, J IMMUNOL, V146, P362; HOWARD OMZ, 1987, BIOCHEMISTRY-US, V26, P3565, DOI 10.1021/bi00386a047; KAZATCHKINE MD, 1979, J IMMUNOL, V122, P75; KOLB WP, 1973, J EXP MED, V138, P428, DOI 10.1084/jem.138.2.428; LAMBRIS JD, 1988, IMMUNOL TODAY, V9, P387, DOI 10.1016/0167-5699(88)91240-6; LAW SK, 1977, P NATL ACAD SCI USA, V74, P2701, DOI 10.1073/pnas.74.7.2701; LAW SK, 1980, J IMMUNOL, V125, P634; MEUTH JL, 1983, J IMMUNOL, V130, P2605; MULLEREBERHARD HJ, 1986, ANNU REV IMMUNOL, V4, P503, DOI 10.1146/annurev.iy.04.040186.002443; NAGASE H, 1981, BIOCHEM J, V193, P187, DOI 10.1042/bj1930187; NILSSON K, 1984, METHOD ENZYMOL, V104, P56; OSHANNESSY DJ, 1990, ANAL BIOCHEM, V191, P1, DOI 10.1016/0003-2697(90)90377-L; PANGBURN MK, 1983, BIOCHEMISTRY-US, V22, P178, DOI 10.1021/bi00270a026; PODACK ER, 1980, J EXP MED, V151, P301, DOI 10.1084/jem.151.2.301; PODACK ER, 1984, J BIOL CHEM, V259, P8641; PODACK ER, 1982, J EXP MED, V156, P268, DOI 10.1084/jem.156.1.268; PODACK ER, 1984, MOL IMMUNOL, V21, P589, DOI 10.1016/0161-5890(84)90044-0; Porath J, 1976, Methods Enzymol, V44, P19; RAO AG, 1987, BIOCHEMISTRY-US, V26, P3556, DOI 10.1021/bi00386a046; Robbins K. C., 1970, METHOD ENZYMOL, V19, P184; SHEPHARD EG, 1988, ANAL BIOCHEM, V168, P306, DOI 10.1016/0003-2697(88)90323-5; SIM RB, 1981, BIOCHEM J, V193, P115, DOI 10.1042/bj1930115; SMITH CA, 1984, J ULTRA MOL STRUCT R, V89, P111, DOI 10.1016/S0022-5320(84)80008-8; STANLEY KK, 1985, EMBO J, V4, P375, DOI 10.1002/j.1460-2075.1985.tb03639.x; STEWART JL, 1987, J IMMUNOL, V139, P1960; TACK BF, 1980, P NATL ACAD SCI-BIOL, V77, P5764, DOI 10.1073/pnas.77.10.5764; TSCHOPP J, 1982, P NATL ACAD SCI-BIOL, V79, P7474, DOI 10.1073/pnas.79.23.7474; TSCHOPP J, 1984, J BIOL CHEM, V259, P7857; VOGT W, 1978, IMMUNOLOGY, V34, P29; WRIGLEY NG, 1968, J ULTRA MOL STRUCT R, V24, P454, DOI 10.1016/S0022-5320(68)80048-6	57	47	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17087	17094						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1387399				2022-12-25	WOS:A1992JL05300057
J	DIZHOOR, AM; ERICSSON, LH; JOHNSON, RS; KUMAR, S; OLSHEVSKAYA, E; ZOZULYA, S; NEUBERT, TA; STRYER, L; HURLEY, JB; WALSH, KA				DIZHOOR, AM; ERICSSON, LH; JOHNSON, RS; KUMAR, S; OLSHEVSKAYA, E; ZOZULYA, S; NEUBERT, TA; STRYER, L; HURLEY, JB; WALSH, KA			THE NH2 TERMINUS OF RETINAL RECOVERIN IS ACYLATED BY A SMALL FAMILY OF FATTY-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CALCIUM-BINDING PROTEIN; ROD GUANYLATE-CYCLASE; N-MYRISTOYLATION	Recoverin is a recently identified Ca2+-binding protein that imparts Ca2+ sensitivity to vertebrate photoreceptor guanylate cyclase. In response to photo-induced depletion of intracellular cGMP and Ca2+, recoverin stimulates resynthesis of cGMP. Bovine retinal recoverin has now been analyzed by electrospray mass spectrometry (ESI-MS) for post-translational modifications that might influence its activity. Heterogeneous acylation was detected at the NH2 terminus of bovine retinal recoverin. The NH2-terminal glycine of each retinal recoverin molecule is linked to one of four different types of acyl groups. The most abundant is myristoleate (14:1), but 14:0, 14:2, and 12:0 acyl residues are also present.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; MV LOMONOSOV STATE UNIV, AN BELOZERSKY INST PHYSICOCHEM BIOL, MOSCOW 119899, USSR; STANFORD UNIV, SCH MED, DEPT CELL BIOL, STANFORD, CA 94305 USA; UNIV WASHINGTON, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA; MM SHEMYAKIN BIOORGAN CHEM INST, PUSHCHINO 142292, USSR	University of Washington; University of Washington Seattle; Lomonosov Moscow State University; Stanford University; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences			; Zozulya, Sergey/F-2986-2015	Dizhoor, Alexander/0000-0001-6770-9186; Zozulya, Sergey/0000-0002-1179-2993	NEI NIH HHS [EYO 6641, R01 EY006641, EYO 2005] Funding Source: Medline; NIGMS NIH HHS [GM 15731] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006641, R01EY002005, R37EY002005] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BIEMANN K, 1990, METHOD ENZYMOL, V193, P455, DOI 10.1016/0076-6879(90)93433-L; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; GORDON JI, 1991, J BIOL CHEM, V266, P8647; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KUTUZOV MA, 1991, FEBS LETT, V293, P21, DOI 10.1016/0014-5793(91)81143-V; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; LAMBRECHT HG, 1991, FEBS LETT, V294, P207, DOI 10.1016/0014-5793(91)80670-X; NEUMEISTER J, 1978, ANGEW CHEM INT EDIT, V17, P939, DOI 10.1002/anie.197809392; POLANS AS, 1991, J CELL BIOL, V112, P981, DOI 10.1083/jcb.112.5.981; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; STRYER L, 1991, J BIOL CHEM, V266, P10711; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441	16	172	176	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16033	16036						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1386601				2022-12-25	WOS:A1992JJ45800008
J	SABBADINI, RA; BETTO, R; TERESI, A; FACHECHICASSANO, G; SALVIATI, G				SABBADINI, RA; BETTO, R; TERESI, A; FACHECHICASSANO, G; SALVIATI, G			THE EFFECTS OF SPHINGOSINE ON SARCOPLASMIC-RETICULUM MEMBRANE CALCIUM RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RABBIT SKELETAL-MUSCLE; TRANSVERSE TUBULAR MEMBRANES; CA-2+-INDUCED CA-2+ RELEASE; CARDIAC RYANODINE RECEPTOR; GROWTH-FACTOR RECEPTOR; TERMINAL CISTERNAE; LIPID-COMPOSITION; FAST-TWITCH; CHANNEL	In this study, we report that sphingosine is a potent inhibitor of sarcoplasmic reticulum (SR) calcium release. Evidence is presented demonstrating a direct effect of sphingosine on the SR ryanodine receptor. Calcium release from "skinned" rabbit skeletal muscle fibers and isolated junctional SR derived from the terminal cisternae (TC) was measured in response to caffeine, doxorubicin, 5'-adenylyl-beta,gamma-imidodiphosphate or calcium. Sphingosine inhibited caffeine-induced release in a dose-dependent manner with an IC50 of 0.1-mu-M for the single muscle fibers and 0.5-mu-M for the isolated TC vesicles. Near complete blockage of TC calcium release rate was observed with 3-mu-M sphingosine. Neither sphingomyelin nor sphingosylphosphorylcholine had any effect at the 3-mu-M level, suggesting that the sphingosine effect was specific. Doxorubicin-induced calcium release and spontaneous calcium release were also blocked by sphingosine. Sphingosine was also capable of stimulating calcium transport in the isolated TC vesicles without an effect on Ca-ATPase activity. Ruthenium red was not capable of substantial additional stimulation of calcium transport nor inhibition of calcium release beyond the action of sphingosine. Sphingosine's blockage of calcium release was not reversed by the protein kinase inhibitor, 1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride, suggesting that the action of sphingosine on calcium release was not dependent on ryanodine receptor phosphorylation. Sphingosine significantly increased (8-fold) the K(d) for specific [H-3]ryanodine binding to TC membranes and decreased the B(max) with a dose dependence similar to the inhibition of calcium release, but sphingosine did not affect the pCa tension relationship of skinned skeletal muscle fibers. These data are consistent with a direct effect of submicromolar sphingosine on the ryanodine receptor. Substantially higher concentrations of sphingosine (30-50-mu-M) or sphingosylphosphorylcholine (10-20-mu-M) were capable of inducing calcium release by themselves. Preliminary data indicate that the transverse tubule and not the SR contain substantial sphingomyelinase activity consistent with a transverse tubule source of sphingosine production. Considering that sphingosine is found in micromolar concentrations in some cells, our data indicate that sphingosine generated by the transverse tubule membranes may be a physiologically relevant mechanism for modulating SR calcium release.	UNIV PADUA,INST GEN PATHOL,CNR,MUSCLE BIOL & PHYSIOPATHOL UNIT,I-35121 PADUA,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Padua	SABBADINI, RA (corresponding author), SAN DIEGO STATE UNIV,INST BIOL,DEPT BIOL & MOLEC BIOL,5300 CAMPANILE DR,SAN DIEGO,CA 92182, USA.							BETTO R, 1992, EXCITATION CONTRACTI; CASWELL AH, 1989, TRENDS BIOCHEM SCI, V14, P161, DOI 10.1016/0968-0004(89)90265-X; CHU A, 1990, BIOCHEMISTRY-US, V29, P5899, DOI 10.1021/bi00477a003; CHU A, 1991, J BIOL CHEM, V266, P7699; DAMIANI E, 1991, BIOCHEM BIOPH RES CO, V175, P858, DOI 10.1016/0006-291X(91)91644-R; DAVIS RJ, 1988, J BIOL CHEM, V263, P5373; EBASHI S, 1991, ANNU REV PHYSIOL, V53, P1, DOI 10.1146/annurev.ph.53.030191.000245; FAUCHER M, 1988, J BIOL CHEM, V263, P5319; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; HAMPTON RY, 1989, SCIENCE, V246, P1050, DOI 10.1126/science.2555921; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HIDALGO C, 1986, BIOCHIM BIOPHYS ACTA, V855, P79, DOI 10.1016/0005-2736(86)90191-4; HOPE MJ, 1987, J BIOL CHEM, V262, P4360; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; JEFFERSON AB, 1988, J BIOL CHEM, V263, P15241; KOBAYASHI T, 1988, EUR J BIOCHEM, V172, P747, DOI 10.1111/j.1432-1033.1988.tb13952.x; LAI FA, 1989, J BIOENERG BIOMEMBR, V21, P227, DOI 10.1007/BF00812070; LAI FA, 1989, J BIOL CHEM, V264, P16776; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LATTANZIO FA, 1987, J BIOL CHEM, V262, P2711; LAU YH, 1979, J BIOL CHEM, V254, P540; LEVADE T, 1984, BIOCHIM BIOPHYS ACTA, V793, P321, DOI 10.1016/0005-2760(84)90337-0; LEVADE T, 1983, ANAL BIOCHEM, V130, P521, DOI 10.1016/0003-2697(83)90627-9; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MARTONOSI AN, 1984, PHYSIOL REV, V64, P1240, DOI 10.1152/physrev.1984.64.4.1240; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P244, DOI 10.1021/bi00349a034; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; PALADE P, 1987, J BIOL CHEM, V262, P6142; PALADE P, 1989, J BIOENERG BIOMEMBR, V21, P295, DOI 10.1007/BF00812074; PALADE P, 1987, J BIOL CHEM, V262, P6135; PALADE P, 1983, J BIOL CHEM, V258, P8098; PEDICONI MF, 1987, BIOCHIM BIOPHYS ACTA, V921, P398, DOI 10.1016/0005-2760(87)90042-7; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; PESSAH IN, 1990, MOL PHARMACOL, V37, P503; PESSAH IN, 1991, MOL PHARMACOL, V39, P679; ROUSSEAU E, 1988, ARCH BIOCHEM BIOPHYS, V267, P75, DOI 10.1016/0003-9861(88)90010-0; SABBADINI R A, 1992, Biophysical Journal, V61, pA24; SABBADINI R A, 1991, Biophysical Journal, V59, p105A; SABBADINI RA, 1983, ARCH BIOCHEM BIOPHYS, V223, P107, DOI 10.1016/0003-9861(83)90576-3; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SALVIATI G, 1982, BIOCHEM J, V202, P289, DOI 10.1042/bj2020289; SALVIATI G, 1990, BIOPHYS J, V57, pA346; SALVIATI G, 1982, J GEN PHYSIOL, V79, P603, DOI 10.1085/jgp.79.4.603; SALVIATI G, 1988, AM J PHYSIOL, V254, pC459, DOI 10.1152/ajpcell.1988.254.3.C459; SEILER S, 1984, J BIOL CHEM, V259, P8550; SLIFE CW, 1989, J BIOL CHEM, V264, P10371; SMITH JS, 1989, CIRC RES, V64, P352, DOI 10.1161/01.RES.64.2.352; SORRENSON MM, 1980, J MEMBRANE BIOL, V53, P1; STEPHENSON EW, 1987, J GEN PHYSIOL, V90, pA39; SUMNICHT GE, 1982, ARCH BIOCHEM BIOPHYS, V215, P628, DOI 10.1016/0003-9861(82)90124-2; TAKASAGO T, 1991, J BIOCHEM-TOKYO, V109, P163, DOI 10.1093/oxfordjournals.jbchem.a123339; TAKASAGO T, 1989, J BIOCHEM-TOKYO, V106, P872, DOI 10.1093/oxfordjournals.jbchem.a122945; TUANA BS, 1988, FEBS LETT, V235, P219, DOI 10.1016/0014-5793(88)81266-3; VARSANYI M, 1989, EUR J BIOCHEM, V179, P473, DOI 10.1111/j.1432-1033.1989.tb14577.x; VARSANYI M, 1986, BIOCHEM BIOPH RES CO, V138, P1395, DOI 10.1016/S0006-291X(86)80438-7; VOLPE P, 1986, J GEN PHYSIOL, V87, P289, DOI 10.1085/jgp.87.2.289; VOLPE P, 1985, NATURE, V316, P347, DOI 10.1038/316347a0; WILSON E, 1988, J BIOL CHEM, V263, P9304; WILSON E, 1986, J BIOL CHEM, V261, P2616; WINICOV I, 1988, J BIOL CHEM, V263, P12179; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZORZATO F, 1985, J BIOL CHEM, V260, P7349; ZORZATO F, 1989, BIOCHEM J, V261, P863, DOI 10.1042/bj2610863	74	109	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15475	15484						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1386359				2022-12-25	WOS:A1992JG11300036
J	LOLLAR, P; PARKER, ET; FAY, PJ				LOLLAR, P; PARKER, ET; FAY, PJ			COAGULANT PROPERTIES OF HYBRID HUMAN PORCINE FACTOR-VIII MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; HUMAN FACTOR-V; SUBUNIT STRUCTURE; MONOCLONAL-ANTIBODIES; PROCOAGULANT ACTIVITY; FACTOR XA; THROMBIN; INACTIVATION; CONCENTRATE; RECONSTITUTION	Human and porcine factor VIII (fVIII) are activated by thrombin to form a heterotrimer composed of subunits designated A1 and A2 derived from the fVIII heavy chain (HC) and a subunit designated A3-C1-C2 derived from the fVIII light chain (LC). Human and porcine fVIII were activated at the same rate to the same peak levels but dissociation of the A2 subunit and concomitant loss of fVIIIa activity at pH 7.4 and 22-degrees-C was 3-fold faster with human fVIIIa compared to porcine fVIIIa (0.35 min-1 versus 0.12 min-1, respectively). To determine structural requirements for the increased activity of porcine FVIII, plasma-derived hybrid human/porcine fVIII molecules were isolated. Porcine HC/human LC (pHC/hLC) fVIII had 44-fold higher coagulant activity than reconstituted human fVIII (hHC/hLC), 40-fold higher activity than hHC/pLC, and slightly (1.4-fold) higher activity than reconstituted porcine fVIII (pHC/pLC). Additionally, human and porcine A2 subunits and inactive A1/A3-C1-C2 human and porcine dimers were isolated and reconstitution experiments were done. Addition of the porcine A2 subunit to the human A1/A3-C1-C2 dimer produced coagulant activity similar to that found with porcine fVIIIa and superior to human fVIIIa. These results suggest that human fVIII has weaker coagulant activity than porcine fVIII due to faster dissociation of the A2 subunit and that the A2 subunit itself is responsible for the difference.	UNIV ROCHESTER, MED CTR, HEMATOL UNIT, ROCHESTER, NY 14642 USA	University of Rochester	LOLLAR, P (corresponding author), EMORY UNIV, DEPT MED, DIV HEMATOL ONCOL, ATLANTA, GA 30322 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046215, R01HL038199, R01HL040921] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46215, HL-40921, HL-38199] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Bevington PR, 1969, DATA REDUCTION ERROR; COOPER HA, 1975, J CLIN INVEST, V56, P751, DOI 10.1172/JCI108146; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; ESMON CT, 1979, J BIOL CHEM, V254, P964; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1989, J BIOL CHEM, V264, P14005; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1988, BIOCHIM BIOPHYS ACTA, V952, P181, DOI 10.1016/0167-4838(88)90114-8; FULCHER CA, 1985, P NATL ACAD SCI USA, V82, P7728, DOI 10.1073/pnas.82.22.7728; FULCHER CA, 1983, BLOOD, V61, P807; GATTI L, 1984, THROMB HAEMOSTASIS, V51, P379; HEMKER HC, 1967, NATURE, V215, P1201, DOI 10.1038/2151201a0; HULTIN MB, 1981, BLOOD, V57, P476; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KERNOFF PBA, 1984, BLOOD, V63, P31; KRISHNASWAMY S, 1989, J BIOL CHEM, V264, P3160; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, J BIOL CHEM, V267, P3725; LAMPHEAR BJ, 1992, IN PRESS BLOOD; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOLLAR P, 1984, ARCH BIOCHEM BIOPHYS, V233, P438, DOI 10.1016/0003-9861(84)90465-X; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1988, BLOOD, V71, P137; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; Moore J.W., 1981, KINETICS MECH, V3rd, P284; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; PIETERS J, 1989, BLOOD, V74, P1021; ROTBLAT F, 1985, BIOCHEMISTRY-US, V24, P4294, DOI 10.1021/bi00337a007; SCANDELLA D, 1989, BLOOD, V74, P1618; TOOLE JJ, 1986, P NATL ACAD SCI USA, V83, P5939, DOI 10.1073/pnas.83.16.5939; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001	45	110	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23652	23657						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429706				2022-12-25	WOS:A1992JZ23900037
J	HAEBERLE, JR; TRYBUS, KM; HEMRIC, ME; WARSHAW, DM				HAEBERLE, JR; TRYBUS, KM; HEMRIC, ME; WARSHAW, DM			THE EFFECTS OF SMOOTH-MUSCLE CALDESMON ON ACTIN FILAMENT MOTILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN GIZZARD CALDESMON; ATPASE ACTIVITY; HEAVY-MEROMYOSIN; F-ACTIN; CROSS-LINKING; MYOSIN SUBFRAGMENTS; LIGHT CHAIN; BINDING; TROPOMYOSIN; PHOSPHORYLATION	The movement of reconstituted thin filaments over an immobilized surface of thiophosphorylated smooth muscle myosin was examined using an in vitro motility assay. Reconstituted thin filaments contained actin, tropomyosin, and either purified chicken gizzard caldesmon or the purified COOH-terminal actin-binding fragment of caldesmon. Control actin-tropomyosin filaments moved at a velocity of 2.3 +/- 0.5 mum/s. Neither intact caldesmon nor the COOH-terminal fragment, when maintained in the monomeric form by treatment with 10 mM dithiothreitol, had any effect on filament velocity; and yet both were potent inhibitors of actin-activated myosin ATPase activity, indicating that caldesmon primarily inhibits myosin binding as reported by Chalovich et al. (Chalovich, J. M., Hemric, M. E., and Velaz, L. (1990) Ann. N. Y. Acad. Sci. 599, 85-99). Inhibition of filament motion was, however, observed under conditions where cross-linking of caldesmon via disulfide bridges was present. To determine if monomeric caldesmon could "tether" actin filaments to the myosin surface by forming an actin-caldesmon-myosin complex as suggested by Chalovich et al., we looked for caldesmon-dependent filament binding and motility under conditions (80 mM KCl) where filament binding to myosin is weak and motility is not normally seen. At caldesmon concentrations greater-than-or-equal-to 0.26 muM, actin filament binding was increased and filament motion (2.6 +/- 0.6 mum/s) was observed. The enhanced motility seen with intact caldesmon was not observed with the addition of up to 26 muM COOH-terminal fragment. Moreover, a molar excess of the COOH-terminal fragment competitively reversed the enhanced binding seen with intact caldesmon. These results show that tethering of actin filaments to myosin by the formation of an actin-caldesmon-myosin complex enhanced productive actomyosin interaction without placing a significant mechanical load on the moving filaments.	BRANDEIS UNIV, ROSENSTIEL BASIC MED SCI RES CTR, WALTHAM, MA 02254 USA	Brandeis University	HAEBERLE, JR (corresponding author), UNIV VERMONT, DEPT PHYSIOL & BIOPHYS, GIVEN BLDG, BURLINGTON, VT 05405 USA.				NHLBI NIH HHS [HL45161, HL28001] Funding Source: Medline; NIAMS NIH HHS [AR40259] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028001, R01HL045161] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040259] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS S, 1990, J BIOL CHEM, V265, P19652; BARTEGI A, 1990, J BIOL CHEM, V265, P2231; BRENNER B, 1990, BIOPHYS J, V57, pA397; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CHALOVICH JM, 1990, ANN NY ACAD SCI, V599, P85, DOI 10.1111/j.1749-6632.1990.tb42367.x; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; FREEDMAN M, 1992, Biophysical Journal, V61, pA154; FUJII T, 1987, J BIOL CHEM, V262, P2757; HAEBERLE JR, 1992, J MUSCLE RES CELL M, V13, P81, DOI 10.1007/BF01738431; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V164, P503, DOI 10.1016/0006-291X(89)91748-8; HAYASHI K, 1991, J BIOL CHEM, V266, P355; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V161, P38, DOI 10.1016/0006-291X(89)91556-8; HEMRIC M E, 1992, Biophysical Journal, V61, pA6; HEMRIC M E, 1991, Biophysical Journal, V59, p237A; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HEMRIC ME, 1990, J BIOL CHEM, V265, P19672; HORIUCHI KY, 1989, BIOCHEMISTRY-US, V28, P9111, DOI 10.1021/bi00449a023; IKEBE M, 1988, J BIOL CHEM, V263, P3055; KATAYAMA E, 1989, BIOCHEM BIOPH RES CO, V160, P1316, DOI 10.1016/S0006-291X(89)80147-0; LASH JA, 1986, J BIOL CHEM, V261, P6155; LEVINE BA, 1990, EUR J BIOCHEM, V193, P687, DOI 10.1111/j.1432-1033.1990.tb19388.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNCH W, 1986, METHOD ENZYMOL, V134, P37; LYNCH WP, 1987, J BIOL CHEM, V262, P7429; MABUCHI K, 1991, J MUSCLE RES CELL M, V12, P145, DOI 10.1007/BF01774033; MARSTON S, 1988, FEBS LETT, V238, P147, DOI 10.1016/0014-5793(88)80245-X; MARSTON SB, 1989, J MUSCLE RES CELL M, V10, P97, DOI 10.1007/BF01739965; OKAGAKI T, 1991, J BIOCHEM, V109, P858, DOI 10.1093/oxfordjournals.jbchem.a123471; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SUTHERLAND C, 1989, J BIOL CHEM, V264, P578; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; SZPACENKO A, 1985, FEBS LETT, V192, P9, DOI 10.1016/0014-5793(85)80032-6; TAGGART MJ, 1988, FEBS LETT, V242, P171, DOI 10.1016/0014-5793(88)81009-3; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; VELAZ L, 1990, J BIOL CHEM, V265, P2929; VELAZ L, 1989, J BIOL CHEM, V264, P9602; Walsh M P, 1989, Adv Exp Med Biol, V255, P337; WANG CLA, 1989, BIOCHEM BIOPH RES CO, V162, P746, DOI 10.1016/0006-291X(89)92373-5; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WORK SS, 1992, ANAL BIOCHEM, V202, P275, DOI 10.1016/0003-2697(92)90106-H	47	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23001	23006						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429647				2022-12-25	WOS:A1992JY16300047
J	LEADON, SA; LAWRENCE, DA				LEADON, SA; LAWRENCE, DA			STRAND-SELECTIVE REPAIR OF DNA DAMAGE IN THE YEAST GAL7-GENE REQUIRES RNA POLYMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE GENE; HAMSTER OVARY CELLS; DIFFERENTIAL REPAIR; NUCLEOTIDE-SEQUENCES; PARTIAL-PURIFICATION; TRANSCRIBED STRAND; THYMINE GLYCOLS; ACTIVE GENE; DHFR GENE; EFFICIENT	We examined the role of transcription in directing repair of DNA damage in active genes by comparing the repair of thymine glycols produced by H2O2 and of UV-induced pyrimidine dimers on each strand of the GAL7 gene of Saccharomyces cerevisiae. Repair of both thymine glycols and pyrimidine dimers on the transcribed strand of the gene occurs two to three times faster than on its nontranscribed strand or in the genome overall. When the gene is inactive, no preferential or strand-selective repair is observed. Using a yeast strain containing a temperature-sensitive mutation in one of the subunits of RNA polymerase II, we find that inactivating RNA polymerase II by shifting the cells to the nonpermissive temperature during repair eliminates the strand selectivity of repair under conditions where repair on the nontranscribed strand of the gene and in the genome overall are only slightly affected. Our observation of strand-selective repair of thymine glycols in the GAL7 gene is the first evidence that this repair process occurs for a nonbulky lesion. In addition, we demonstrate that the transcriptional complex plays a critical role in directing repair to the transcribed strand of active genes.	UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	LEADON, SA (corresponding author), UNIV N CAROLINA,DEPT RADIAT ONCOL,CB 7512,CHAPEL HILL,NC 27599, USA.				NCI NIH HHS [CA40453] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1985, DNA REPAIR; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOHR VA, 1986, J BIOL CHEM, V261, P6666; BRENT TP, 1979, BIOCHEMISTRY-US, V18, P911, DOI 10.1021/bi00572a028; CATHCART R, 1981, BIOCHEMISTRY-US, V20, P273, DOI 10.1021/bi00505a007; GOSSETT J, 1988, BIOCHEMISTRY-US, V27, P2629, DOI 10.1021/bi00407a054; Haber F., 1934, P R SOC LOND A, V147, P332, DOI [10.1098/rspa.1934.0221, DOI 10.1098/RSPA.1934.0221, DOI 10.1098/rspa.1934.0221]; HANAWALT PC, 1979, ANNU REV BIOCHEM, V48, P783, DOI 10.1146/annurev.bi.48.070179.004031; KANEKO M, 1988, MUTAT RES, V207, P17, DOI 10.1016/0165-7992(88)90005-X; LEADON SA, 1983, MUTAT RES, V112, P191, DOI 10.1016/0167-8817(83)90006-8; LEADON SA, 1986, NUCLEIC ACIDS RES, V14, P8979, DOI 10.1093/nar/14.22.8979; LEADON SA, 1988, MOL CELL BIOL, V8, P5331, DOI 10.1128/MCB.8.12.5331; LEADON SA, 1991, MUTAT RES, V255, P67, DOI 10.1016/0921-8777(91)90019-L; LEADON SA, 1988, DNA REPAIR LABORATOR, V3, P311; LIN JJ, 1989, BIOCHEMISTRY-US, V28, P7979, DOI 10.1021/bi00446a002; MADHANI HD, 1986, CELL, V45, P417, DOI 10.1016/0092-8674(86)90327-2; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SCHOLES G, 1960, J MOL BIOL, V2, P379, DOI 10.1016/S0022-2836(60)80049-6; SCICCHITANO DA, 1989, P NATL ACAD SCI USA, V86, P3050, DOI 10.1073/pnas.86.9.3050; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P8232, DOI 10.1073/pnas.88.18.8232; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STJOHN TP, 1981, J MOL BIOL, V152, P317, DOI 10.1016/0022-2836(81)90245-X; TERLETH C, 1989, NUCLEIC ACIDS RES, V17, P4433, DOI 10.1093/nar/17.12.4433; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	31	128	128	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23175	23182						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429664				2022-12-25	WOS:A1992JY16300073
J	RECNY, MA; LUTHER, MA; KNOPPERS, MH; NEIDHARDT, EA; KHANDEKAR, SS; CONCINO, MF; SCHIMKE, PA; FRANCIS, MA; MOEBIUS, U; REINHOLD, BB; REINHOLD, VN; REINHERZ, EL				RECNY, MA; LUTHER, MA; KNOPPERS, MH; NEIDHARDT, EA; KHANDEKAR, SS; CONCINO, MF; SCHIMKE, PA; FRANCIS, MA; MOEBIUS, U; REINHOLD, BB; REINHOLD, VN; REINHERZ, EL			N-GLYCOSYLATION IS REQUIRED FOR HUMAN CD2 IMMUNOADHESION FUNCTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; VESICULAR STOMATITIS-VIRUS; FUNCTION-ASSOCIATED ANTIGEN-3; SHEEP ERYTHROCYTE RECEPTOR; SURFACE-MOLECULE CD2; HUMAN LYMPHOCYTES-T; ALTERNATIVE PATHWAY; SIALYL-LEX; G-PROTEIN; 3 LFA-3	The T-lymphocyte glycoprotein receptor, CD2, mediates cell-cell adhesion by binding to the surface molecule CD58 (LFA-3) on many cell types including antigen presenting cells. Two domains comprise the CD2 extracellular segment, with all adhesion functions localized to the amino-terminal domain that contains a single N-glycosylation site at Asn65. We have defined an important role for the N-linked glycans attached to Asn65 of this domain in mediating CD2-CD58 interactions and also characterize its N-glycotype structure. Analysis of deglycosylated soluble recombinant CD2 as well as a mutant transmembrane CD2 molecule containing a single Asn65-Gln65 substitution demonstrates that neither deglycosylated CD2 nor the mutant CD2 transmembrane receptor binds CD58 or monoclonal antibodies directed at native CD2 adhesion domain epitopes. Electrospray ionization-mass spectrometry demonstrates that high mannose oligosaccharides ((Man)nGlcNAC2, n = 5-9) are the only N-glycotypes occupying Asn65 when soluble CD2 is expressed in Chinese hamster ovary cells. Based on a model of human CD2 secondary structure, we propose that N-glycosylation is required for stabilizing domain 1 in the human receptor. Thus, N-glycosylation is essential for human CD2 adhesion functions.	HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, IMMUNOBIOL LAB, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	RECNY, MA (corresponding author), PROCEPT INC, CAMBRIDGE, MA 02139 USA.				NIAID NIH HHS [AI21226] Funding Source: Medline; NIGMS NIH HHS [R01GM45781] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045781] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACH JF, 1973, TRANSPLANT REV, V16, P196; BAXLEY G, 1973, CLIN EXP IMMUNOL, V15, P385; BEBENEK K, 1989, NUCLEIC ACIDS RES, V17, P5408, DOI 10.1093/nar/17.13.5408; BIERER BE, 1988, P NATL ACAD SCI USA, V85, P1194, DOI 10.1073/pnas.85.4.1194; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BOLHUIS RLH, 1986, J IMMUNOL, V136, P3939; BRAIN P, 1970, CLIN EXP IMMUNOL, V6, P681; BROTTIER P, 1985, J IMMUNOL, V135, P1624; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; CLAYTON LK, 1987, EUR J IMMUNOL, V17, P1367, DOI 10.1002/eji.1830170922; CUMMING D A, 1991, Glycobiology, V1, P115, DOI 10.1093/glycob/1.2.115; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; DUSTIN ML, 1987, J EXP MED, V165, P677, DOI 10.1084/jem.165.3.677; DUSTIN ML, 1989, J EXP MED, V169, P503, DOI 10.1084/jem.169.2.503; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; GIBSON R, 1978, CELL, V13, P671, DOI 10.1016/0092-8674(78)90217-9; HUNIG T, 1986, EUR J IMMUNOL, V16, P1615, DOI 10.1002/eji.1830161223; HUNIG T, 1987, NATURE, V326, P298, DOI 10.1038/326298a0; JONDAL M, 1972, J EXP MED, V136, P207, DOI 10.1084/jem.136.2.207; KONIG R, 1988, J BIOL CHEM, V263, P9502; KOYASU S, 1990, P NATL ACAD SCI USA, V87, P2603, DOI 10.1073/pnas.87.7.2603; KRENSKY AM, 1984, J IMMUNOL, V132, P2180; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVITT R, 1977, J BIOL CHEM, V252, P9018; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MACHAMER CE, 1988, J BIOL CHEM, V263, P5948; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MOINGEON P, 1989, NATURE, V339, P312, DOI 10.1038/339312a0; MOINGEON P, 1989, IMMUNOL REV, V111, P111, DOI 10.1111/j.1600-065X.1989.tb00544.x; MOINGEON PE, 1991, EUR J IMMUNOL, V21, P605, DOI 10.1002/eji.1830210311; PETERSON A, 1987, NATURE, V329, P842, DOI 10.1038/329842a0; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; RECNY MA, 1990, J BIOL CHEM, V265, P8542; REINHOLD BB, 1992, J AM SOC MASS SPECTR, V3, P207, DOI 10.1016/1044-0305(92)87004-I; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAYRE PH, 1987, P NATL ACAD SCI USA, V84, P2941, DOI 10.1073/pnas.84.9.2941; SAYRE PH, 1989, J EXP MED, V169, P995, DOI 10.1084/jem.169.3.995; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; SEWELL WA, 1986, P NATL ACAD SCI USA, V83, P8718, DOI 10.1073/pnas.83.22.8718; SEWELL WA, 1987, EUR J IMMUNOL, V17, P1015, DOI 10.1002/eji.1830170718; SILICIANO RF, 1985, NATURE, V317, P428, DOI 10.1038/317428a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TADMORI W, 1985, J IMMUNOL, V134, P1709; TIFFT CJ, 1992, J BIOL CHEM, V267, P3268; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WACHOLTZ MC, 1989, J EXP MED, V170, P431, DOI 10.1084/jem.170.2.431; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILLIAMS AF, 1987, J EXP MED, V165, P368, DOI 10.1084/jem.165.2.368; WOLFF HL, 1990, J IMMUNOL, V144, P1215; YANG SY, 1986, J IMMUNOL, V137, P1097	56	62	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22428	22434						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1385399				2022-12-25	WOS:A1992JW71900069
J	RHOADES, KL; GOLUB, SH; ECONOMOU, JS				RHOADES, KL; GOLUB, SH; ECONOMOU, JS			THE REGULATION OF THE HUMAN TUMOR-NECROSIS-FACTOR-ALPHA PROMOTER REGION IN MACROPHAGE, T-CELL, AND B-CELL LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR CACHECTIN; C-FOS; GENE-EXPRESSION; PROTO-ONCOGENE; LYMPHOCYTES-T; PHORBOL ESTER; KAPPA-B; TRANSCRIPTION; AP-1; ACTIVATION	The 1311-base pair human tumor necrosis factor (TNF) alpha promoter region was fused to the luciferase (Luc) reporter gene and studied in a transient transfection system in three TNF producing cell lines, the U937 macrophage cell line, the MLA 144 T cell line, and the 729-6 B cell line. This full length promoter construct can be induced by phorbol 13-myristate acetate (PMA) in each of these cell types. Analysis of a series of 5'-truncations showed several peaks of basal and PMA induced activity suggesting the presence of several positive and negative regulatory elements. A PMA responsive element was localized to a region between -95 and -36 bp relative to the transcription start site. Within this region, single AP-2- and AP-1-like consensus sequences were noted. These AP-2 and AP-1 sites were each modified with a double point mutation. A modest (20-50%) reduction in TNF promoter activity was observed with the AP-2 site mutation. However, mutation of the AP-1 site markedly diminished both the basal and PMA-activated promoter activity. Also co-transfections of the wild-type promoter construct with an AP-1/c-jun expression vector resulted in augmented basal and PMA-induced promoter activity.	UNIV CALIF LOS ANGELES,SCH MED,DEPT SURG,DIV SURG ONCOL,54-140 CHS,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NCI NIH HHS [CA-09120, R29 CA 50780] Funding Source: Medline; PHS HHS [K08 01360] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA050780] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARZILAY J, 1987, LEUKEMIA, V1, P198; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CANN AJ, 1988, ONCOGENE, V3, P123; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; COLLART MA, 1986, J EXP MED, V164, P2113, DOI 10.1084/jem.164.6.2113; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DREXLER HG, 1989, BLOOD, V73, P1656; ECONOMOU JS, 1989, J EXP MED, V170, P321, DOI 10.1084/jem.170.1.321; ECONOMOU JS, 1989, IMMUNOLOGY, V67, P514; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; GRINSTEIN S, 1988, J BIOL CHEM, V263, P8658; HAN J, 1991, J IMMUNOL, V146, P1843; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HEINKOFF S, 1984, GENE, V28, P351; HENSEL G, 1989, LYMPHOKINE RES, V8, P347; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; NEDWIN GE, 1985, J IMMUNOL, V135, P2492; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SHOEMAKER SG, 1990, P NATL ACAD SCI USA, V87, P9650, DOI 10.1073/pnas.87.24.9650; STEFFEN M, 1988, J IMMUNOL, V140, P2621; SUNG SSJ, 1988, J EXP MED, V168, P1539, DOI 10.1084/jem.168.5.1539; SUNG SSJ, 1988, J EXP MED, V167, P937, DOI 10.1084/jem.167.3.937	33	205	209	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22102	22107						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429562				2022-12-25	WOS:A1992JW71900021
J	GILCHRIST, JSC; BELCASTRO, AN; KATZ, S				GILCHRIST, JSC; BELCASTRO, AN; KATZ, S			INTRALUMINAL CA2+ DEPENDENCE OF CA2+ AND RYANODINE-MEDIATED REGULATION OF SKELETAL-MUSCLE SARCOPLASMIC-RETICULUM CA2+ RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-INDUCED CA-2+ RELEASE; JUNCTIONAL TERMINAL CISTERNAE; CALCIUM RELEASE; CARDIAC-MUSCLE; SMOOTH-MUSCLE; GUINEA-PIG; CONTRACTION; CHANNEL; MEMBRANE; IDENTIFICATION	The action of ryanodine upon sarcoplasmic reticulum (SR) Ca2+ handling is controversial with evidence for both activation and inhibition of SR Ca2+ release. In this study, the role of the intraluminal SR Ca2+ load was probed as a potential regulator of ryanodine-mediated effects upon SR Ca2+ release. Through dual-wavelength spectroscopy of Ca2+:antipyrylazo III difference absorbance, the intraluminal Ca2+ dependence of ryanodine and Ca2+-induced Ca2+ release (CICR) from skeletal SR vesicles was examined. Ryanodine addition after initiation of Ca2+ uptake (a) increased the intraluminal Ca2+ sensitivity of CICR and (b) stimulated spontaneous Ca2+ release with a delayed onset. These ryanodine effects were inversely proportional to the intraluminal Ca2+ load. Ryanodine also inhibited subsequent CICR after reaccumulation of Ca2+ released from the initial CICR. These results provide evidence that ryanodine inhibits transitions between low and high affinity Ca2+ binding states of an intraluminal Ca2+ compartment, possibly calsequestrin. Conformational transitions of calsequestrin may be reciprocally coupled to transitions between open and closed states of the Ca2+ release channel.	UNIV BRITISH COLUMBIA,FAC GRAD STUDIES,VANCOUVER V6T 1Z1,BC,CANADA; UNIV BRITISH COLUMBIA,FAC EDUC,DIV KINESIOL,VANCOUVER V6T 1Z1,BC,CANADA; UNIV BRITISH COLUMBIA,FAC PHARMACEUT SCI,VANCOUVER V6T 1Z1,BC,CANADA	University of British Columbia; University of British Columbia; University of British Columbia								ASHIDA T, 1988, CIRC RES, V62, P854, DOI 10.1161/01.RES.62.4.854; CAMPBELL KP, 1980, BIOCHIM BIOPHYS ACTA, V602, P97, DOI 10.1016/0005-2736(80)90293-X; CANNELL MB, 1985, FED PROC, V44, P2964; CHU A, 1986, BIOCHEMISTRY-US, V25, P8315, DOI 10.1021/bi00373a028; COLLINS JH, 1990, BIOCHEM BIOPH RES CO, V167, P189, DOI 10.1016/0006-291X(90)91749-I; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FABIATO A, 1989, MOL CELL BIOCHEM, V89, P135; FABIATO A, 1985, RFED P, V41, P2238; FAIRHURST AS, 1970, EUR J BIOCHEM, V13, P504, DOI 10.1111/j.1432-1033.1970.tb00953.x; FEHER JJ, 1988, ARCH BIOCHEM BIOPHYS, V265, P171, DOI 10.1016/0003-9861(88)90382-7; FLEISCHER S, 1985, P NATL ACAD SCI USA, V82, P7256, DOI 10.1073/pnas.82.21.7256; FORD LE, 1970, SCIENCE, V167, P58, DOI 10.1126/science.167.3914.58; GILCHRIST JSC, 1990, BIOCHEM BIOPH RES CO, V168, P364, DOI 10.1016/0006-291X(90)91717-7; HANSFORD RG, 1987, J PHYSIOL-LONDON, V390, P453, DOI 10.1113/jphysiol.1987.sp016711; HUNTER DR, 1983, CIRC RES, V53, P703, DOI 10.1161/01.RES.53.5.703; IINO M, 1988, BIOCHEM BIOPH RES CO, V152, P417, DOI 10.1016/S0006-291X(88)80730-7; IKEMOTO N, 1989, J BIOENERG BIOMEMBR, V21, P247, DOI 10.1007/BF00812071; IKEMOTO N, 1984, J BIOL CHEM, V259, P3151; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IKEMOTO N, 1991, BIOCHEMISTRY-US, V30, P5230, DOI 10.1021/bi00235a017; ITO K, 1986, CIRC RES, V58, P730, DOI 10.1161/01.RES.58.5.730; KIM DH, 1983, J BIOL CHEM, V258, P9662; LAI FA, 1989, J BIOENERG BIOMEMBR, V21, P227, DOI 10.1007/BF00812070; LAI FA, 1989, J BIOL CHEM, V264, P16676; LAKATTA EG, 1985, FED PROC, V44, P2977; LIU QY, 1989, BIOPHYS J, V55, P415, DOI 10.1016/S0006-3495(89)82835-8; MARBAN E, 1985, CIRC RES, V56, P133, DOI 10.1161/01.RES.56.1.133; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MORII H, 1985, J BIOL CHEM, V260, P1536; NELSON TE, 1990, FEBS LETT, V263, P292, DOI 10.1016/0014-5793(90)81396-6; NESTEROV VP, 1988, FIZIOL ZH SSSR, V34, P60; OHNISHI ST, 1979, J BIOCHEM, V86, P1147, DOI 10.1093/oxfordjournals.jbchem.a132609; PALADE P, 1987, J BIOL CHEM, V262, P6149; PESSAH IN, 1985, BIOCHEM BIOPH RES CO, V128, P449, DOI 10.1016/0006-291X(85)91699-7; RAESS BU, 1980, J PHARMACOL METHOD, V4, P273, DOI 10.1016/0160-5402(80)90019-4; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; RUEST L, 1985, CAN J CHEM, V63, P2840, DOI 10.1139/v85-474; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SUTKO JL, 1983, J GEN PHYSIOL, V82, P385, DOI 10.1085/jgp.82.3.385	40	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20850	20856						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400399				2022-12-25	WOS:A1992JT97800055
J	LAVERY, PE; KOWALCZYKOWSKI, SC				LAVERY, PE; KOWALCZYKOWSKI, SC			BIOCHEMICAL BASIS OF THE CONSTITUTIVE REPRESSOR CLEAVAGE ACTIVITY OF RECA730 PROTEIN - A COMPARISON TO RECA441 AND RECA803 PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; LARGE-SCALE PURIFICATION; PHAGE LAMBDA-REPRESSOR; ESCHERICHIA-COLI K-12; GENETIC-RECOMBINATION; PROTEOLYTIC ACTIVITY; LEXA REPRESSOR; SOS FUNCTIONS; SSB PROTEIN; BINDING	The recA730 mutation results in constitutive SOS and prophage induction. We examined biochemical properties of recA730 protein in an effort to explain the constitutive activity observed in recA730 strains. We find that recA730 protein is more proficient than the wild-type recA protein in the competition with single-stranded DNA binding protein (SSB protein) for single-stranded DNA (ssDNA) binding sites. Because an increased aptitude in the competition with SSB protein has been previously reported for recA441 protein and recA803 protein, we directly compared their in vitro activities with those of recA730 protein. At low magnesium ion concentration, both ATP hydrolysis and lexA protein cleavage experiments demonstrate that these recA proteins displace SSB protein from ssDNA in a manner consistent with their in vivo repressor cleavage activity, i.e. recA730 protein > recA441 protein > recA803 protein > recAwt protein. Additionally, a correlation exists between the proficiency of the recA proteins in SSB protein displacement and their rate of association with ssDNA. We propose that an increased rate of association with ssDNA allows recA730 protein to displace SSB protein from the ssDNA that occurs naturally in Escherichia coli and thereby to become activated for the repressor cleavage that leads to SOS induction. RecA441 protein is similarly activated for repressor cleavage; however, in this case, significant SSB protein displacement occurs only at elevated temperature. At physiological magnesium ion concentration, we argue that recA803 protein and wild-type recA protein do not displace sufficient SSB protein from ssDNA to constitutively induce the SOS response.	UNIV CALIF DAVIS,DIV BIOL SCI,RADIOL SECT,HUTCHISON HALL 258,DAVIS,CA 95616; UNIV CALIF DAVIS,DIV BIOL SCI,MOLEC BIOL SECT,DAVIS,CA 95616; UNIV CALIF DAVIS,DIV BIOL SCI,CELL BIOL SECT,DAVIS,CA 95616; UNIV CALIF DAVIS,DIV BIOL SCI,BIOCHEM SECT,DAVIS,CA 95616; NORTHWESTERN UNIV,SCH MED,DEPT CELL MOLEC & STRUCT BIOL,CHICAGO,IL 60611	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; Northwestern University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018987] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-18987] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHABBERT M, 1987, BIOCHEMISTRY-US, V26, P2218, DOI 10.1021/bi00382a022; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; CRAIG NL, 1980, NATURE, V283, P26, DOI 10.1038/283026a0; GARVEY N, 1985, J BACTERIOL, V163, P870, DOI 10.1128/JB.163.3.870-876.1985; GOLDTHWAIT DA, 1964, CR HEBD ACAD SCI, V258, P661; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; KIRBY EP, 1967, P NATL ACAD SCI USA, V58, P1903, DOI 10.1073/pnas.58.5.1903; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1991, BIOCHIMIE, V73, P289, DOI 10.1016/0300-9084(91)90216-N; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P5872, DOI 10.1021/bi00368a006; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; LAVERY PE, 1988, J MOL BIOL, V203, P861, DOI 10.1016/0022-2836(88)90112-X; LEBOWITZ J, 1985, THESIS J HOPKINS U B; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LITTLE JW, 1980, P NATL ACAD SCI-BIOL, V77, P3225, DOI 10.1073/pnas.77.6.3225; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; LU C, 1987, J MOL BIOL, V196, P497, DOI 10.1016/0022-2836(87)90027-1; MADIRAJU MVVS, 1988, P NATL ACAD SCI USA, V85, P6592, DOI 10.1073/pnas.85.18.6592; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MENETSKI JP, 1990, J MOL BIOL, V211, P845, DOI 10.1016/0022-2836(90)90078-Z; MENETSKI JP, 1988, BIOCHEMISTRY-US, V27, P1205, DOI 10.1021/bi00404a021; MESSING J, 1983, METHOD ENZYMOL, V101, P20; PHIZICKY EM, 1981, CELL, V25, P259, DOI 10.1016/0092-8674(81)90251-8; Radding C.M., 1988, GENETIC RECOMBINATIO, P193; ROBERTS JW, 1978, P NATL ACAD SCI USA, V75, P4714, DOI 10.1073/pnas.75.10.4714; RUYECHAN WT, 1976, BIOCHEMISTRY-US, V15, P5057, DOI 10.1021/bi00668a017; SASSANFAR M, 1990, J MOL BIOL, V212, P79, DOI 10.1016/0022-2836(90)90306-7; SCHNARR M, 1985, BIOCHEMISTRY-US, V24, P2812, DOI 10.1021/bi00332a032; TAKAHASHI M, 1989, EUR J BIOCHEM, V183, P617, DOI 10.1111/j.1432-1033.1989.tb21091.x; TESSMAN ES, 1985, J BACTERIOL, V163, P677, DOI 10.1128/JB.163.2.677-687.1985; THOMAS A, 1983, J GEN MICROBIOL, V129, P681; UHLIN BE, 1981, J BACTERIOL, V148, P386, DOI 10.1128/JB.148.1.386-390.1981; VOLKERT MR, 1984, J BACTERIOL, V160, P702, DOI 10.1128/JB.160.2.702-705.1984; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WITKIN EM, 1982, MOL GEN GENET, V185, P43, DOI 10.1007/BF00333788; WITKIN EM, 1976, BACTERIOL REV, V40, P869, DOI 10.1128/MMBR.40.4.869-907.1976	40	80	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20648	20658						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400384				2022-12-25	WOS:A1992JT97800024
J	STURROCK, AB; FRANKLIN, KF; RAO, G; MARSHALL, BC; REBENTISCH, MB; LEMONS, RS; HOIDAL, JR				STURROCK, AB; FRANKLIN, KF; RAO, G; MARSHALL, BC; REBENTISCH, MB; LEMONS, RS; HOIDAL, JR			STRUCTURE, CHROMOSOMAL ASSIGNMENT, AND EXPRESSION OF THE GENE FOR PROTEINASE-3 - THE WEGENERS GRANULOMATOSIS AUTOANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL ELASTASE GENE; CATHEPSIN-G GENE; SERINE PROTEASE; GENOMIC ORGANIZATION; NUCLEOTIDE-SEQUENCE; POLYMORPHONUCLEAR LEUKOCYTE; TRANSCRIPTION FACTOR; TISSUE-INJURY; DNA-SEQUENCES; MESSENGER-RNA	Proteinase-3 (PR-3) is a neutral serine proteinase present in the azurophil granules of human polymorphonuclear leukocytes. It degrades a variety of extracellular matrix proteins including elastin in vitro and causes emphysema when administered by tracheal insufflation to hamsters. It is identical to the target autoantigen (c-ANCA) associated with Wegener's granulomatosis and to myeloblastin, a serine proteinase first identified in HL-60 leukemia cells. In this study, the gene encoding PR-3 was cloned and sequenced. The gene spans approximately 6.5 kilobase pairs and consists of five exons and four introns. The genomic organization of PR-3 is similar to that of the other serine proteinases expressed in hemopoietic cells. Each residue of the catalytic triad of PR-3 is located on a separate exon, and the positions of the residues within the exons are similar to those in human leukocyte elastase and cathepsin G. The phase and placement of the introns in the PR-3 gene are also similar to those in human leukocyte elastase and cathepsin G. The 400-base pair (bp) 5'-flanking sequence of the PR-3 gene contains a TATA box at position 379. There is no CAAT box promoter element. The 3'-untranslated region is 200 bp, extending from a TGA stop codon to the site of polyadenylation 10 bp after the canonical AATAAA signal. Amplification of PR-3 from a human/hamster hybrid cell line localizes the gene to human chromosome 19. Evidence from Northern analysis suggests that PR-3 expression is primarily confined to the promyelocytic/myelocytic stage of bone marrow development.	UNIV UTAH, DEPT MED,DIV PULM CRIT CARE & OCCUPAT PULM MED, 50 N MED DR,RM 4R240, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, DEPT PEDIAT, SALT LAKE CITY, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NHLBI NIH HHS [1K08 HL-02370, HL-37615] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002370, R01HL037615] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGGIOLINI M, 1978, AGENTS ACTIONS, V8, P3, DOI 10.1007/BF01972395; BENFEY PN, 1987, J BIOL CHEM, V262, P5377; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CAMPANELLI D, 1990, J EXP MED, V172, P1709, DOI 10.1084/jem.172.6.1709; CAMPANELLI D, 1990, J CLIN INVEST, V85, P904, DOI 10.1172/JCI114518; CAPUTO A, 1990, J IMMUNOL, V145, P737; CAUGHEY GH, 1991, J BIOL CHEM, V266, P12956; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DEININGER PL, 1986, TRENDS GENET, V2, P76, DOI 10.1016/0168-9525(86)90183-6; EWERT BH, 1991, AM J KIDNEY DIS, V18, P188, DOI 10.1016/S0272-6386(12)80879-1; FARLEY D, 1989, BIOL CHEM H-S, V370, P737, DOI 10.1515/bchm3.1989.370.2.737; FITZGERALD M, 1981, CELL, V24, P251, DOI 10.1016/0092-8674(81)90521-3; FOURET P, 1989, J EXP MED, V169, P833, DOI 10.1084/jem.169.3.833; GABAY JE, 1989, P NATL ACAD SCI USA, V86, P5610, DOI 10.1073/pnas.86.14.5610; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HADDAD P, 1990, GENE, V87, P265, DOI 10.1016/0378-1119(90)90311-E; HADDAD P, 1991, INT IMMUNOL, V3, P57, DOI 10.1093/intimm/3.1.57; HANSON RD, 1990, J BIOL CHEM, V265, P1524; HANSON RD, 1990, P NATL ACAD SCI USA, V87, P960, DOI 10.1073/pnas.87.3.960; HENSON PM, 1987, J CLIN INVEST, V79, P669, DOI 10.1172/JCI112869; HOHN PA, 1989, J BIOL CHEM, V264, P13412; IRWIN DM, 1988, J MOL BIOL, V200, P31, DOI 10.1016/0022-2836(88)90331-2; JANOFF A, 1985, ANNU REV MED, V36, P207; JENNE DE, 1991, J IMMUNOL, V147, P1045; JENNETTE JC, 1990, BLOOD, V75, P2263; JOHNSON K, 1989, NUCLEIC ACIDS RES, V17, P7985, DOI 10.1093/nar/17.19.7985; KAO RC, 1988, J CLIN INVEST, V82, P1963, DOI 10.1172/JCI113816; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; LABBAYE C, 1991, P NATL ACAD SCI USA, V88, P9253, DOI 10.1073/pnas.88.20.9253; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOBE CG, 1988, BIOCHEMISTRY-US, V27, P6941, DOI 10.1021/bi00418a040; MIN HY, 1986, NUCLEIC ACIDS RES, V14, P8879; MITANI K, 1989, AM J HEMATOL, V31, P253, DOI 10.1002/ajh.2830310407; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; NILES JL, 1989, BLOOD, V74, P1888; OHLSSON K, 1990, BIOL CHEM H-S, V371, P549, DOI 10.1515/bchm3.1990.371.2.549; OHYASHIKI K, 1990, CANCER, V65, P940, DOI 10.1002/1097-0142(19900215)65:4<940::AID-CNCR2820650420>3.0.CO;2-W; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; RAO NV, 1991, J BIOL CHEM, V266, P9540; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; SEED B, 1982, GENE, V19, P201, DOI 10.1016/0378-1119(82)90007-5; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; SUN L, 1984, NUCLEIC ACIDS RES, V12, P2669, DOI 10.1093/nar/12.6.2669; TAKAHASHI H, 1988, J BIOL CHEM, V263, P2543; TAKAHASHI H, 1988, J BIOL CHEM, V263, P14739; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TUCKER KA, 1987, BLOOD, V70, P372; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X	56	74	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21193	21199						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400430				2022-12-25	WOS:A1992JT97800105
J	ARAKI, T; FUNATSU, J; KURAMOTO, M; KONNO, H; TORIKATA, T				ARAKI, T; FUNATSU, J; KURAMOTO, M; KONNO, H; TORIKATA, T			THE COMPLETE AMINO-ACID-SEQUENCE OF YAM (DIOSCOREA-JAPONICA) CHITINASE - A NEWLY IDENTIFIED ACIDIC CLASS-I CHITINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHEAT-GERM-AGGLUTININ; ETHYLENE-INDUCED CHITINASE; BEAN-LEAVES; MESSENGER-RNA; PURIFICATION; TOBACCO; LOCALIZATION; ENDOCHITINASE; GENE; BETA-1,3-GLUCANASE	The complete amino acid sequence of acidic chitinase from yam (Dioscorea japonica) aerial tubers was determined. The protein is composed of a single polypeptide chain of 250 amino acid residues and has a calculated molecular mass of 27,890 Da. There is an NH2-terminal domain, a hinge region, and a main structure, typical for class I chitinases (Shinshi, H., Neuhaus, J.M., Ryals, J., and Meins, F., Jr. (1990) Plant Mol. Biol. 14, 357-368). We have obtained the first evidence for an acidic class I chitinase. Comparison with sequences of other class I chitinases revealed approximately 40% sequence similarity, a value lower than that for other class I chitinases (70-80%). We assume that there is a local conformational change in the molecule; cysteine residues that probably form disulfide bonds are completely conserved, with the exception of Cys-178. The difference in structure between this chitinase and other basic class I chitinases suggests that acidic and basic isoforms should be grouped into subclasses; this protein is an ethylene- or a pathogen-independent chitinase produced by a gene that is inherent in the tuber.			ARAKI, T (corresponding author), KYUSHU TOKAI UNIV,SCH AGR,DEPT BIOCHEM,ASO,KUMAMOTO 86914,JAPAN.							ARAKI T, 1988, P NATL ACAD SCI USA, V85, P679, DOI 10.1073/pnas.85.3.679; ARAKI T, 1989, BIOCHIM BIOPHYS ACTA, V994, P195, DOI 10.1016/0167-4838(89)90293-8; ARAKI T, 1987, BIOCHIM BIOPHYS ACTA, V911, P191, DOI 10.1016/0167-4838(87)90008-2; ARAKI T, 1991, J CHROMATOGR, V545, P183, DOI 10.1016/S0021-9673(01)88706-9; BERNASCONI P, 1987, BIOCHIM BIOPHYS ACTA, V915, P254, DOI 10.1016/0167-4838(87)90307-4; BLOCH R, 1974, BIOCHEM BIOPH RES CO, V58, P13, DOI 10.1016/0006-291X(74)90884-5; BOLLER T, 1984, PLANT PHYSIOL, V74, P442, DOI 10.1104/pp.74.2.442; BOLLER T, 1983, PLANTA, V157, P22, DOI 10.1007/BF00394536; BOLLER T, 1988, PHYSIOL MOL PLANT P, V33, P11, DOI 10.1016/0885-5765(88)90039-2; BROGLIE KE, 1986, P NATL ACAD SCI USA, V83, P6820, DOI 10.1073/pnas.83.18.6820; BURGER MM, 1967, P NATL ACAD SCI USA, V57, P359, DOI 10.1073/pnas.57.2.359; CHANG JY, 1978, FEBS LETT, V93, P205, DOI 10.1016/0014-5793(78)81105-3; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; GAYNOR JJ, 1988, NUCLEIC ACIDS RES, V16, P5210, DOI 10.1093/nar/16.11.5210; JEKEL PA, 1991, EUR J BIOCHEM, V200, P123, DOI 10.1111/j.1432-1033.1991.tb21057.x; KEEFE D, 1990, PLANTA, V182, P43, DOI 10.1007/BF00239982; KUROSAKI F, 1988, PLANT CELL PHYSIOL, V29, P527; KUROSAKI F, 1987, PHYSIOL MOL PLANT P, V31, P201, DOI 10.1016/0885-5765(87)90064-6; LEGRAND M, 1987, P NATL ACAD SCI USA, V84, P6750, DOI 10.1073/pnas.84.19.6750; LUCAS J, 1985, FEBS LETT, V193, P208, DOI 10.1016/0014-5793(85)80152-6; MAUCH F, 1988, PLANT PHYSIOL, V87, P325, DOI 10.1104/pp.87.2.325; MAUCH F, 1989, PLANT CELL, V1, P447, DOI 10.2307/3869105; MAUCH F, 1984, PLANT PHYSL BETHESDA, V76, P307; METRAUX JP, 1989, P NATL ACAD SCI USA, V86, P869; PAYNE G, 1990, P NATL ACAD SCI USA, V87, P98, DOI 10.1073/pnas.87.1.98; SHINSHI H, 1987, P NATL ACAD SCI USA, V84, P89, DOI 10.1073/pnas.84.1.89; SHINSHI H, 1990, PLANT MOL BIOL, V14, P357, DOI 10.1007/BF00028772; TSUKAMOTO T, 1984, AGR BIOL CHEM TOKYO, V48, P931, DOI 10.1080/00021369.1984.10866241; WRIGHT CS, 1984, BIOCHEMISTRY-US, V23, P280, DOI 10.1021/bi00297a017; YANG YC, 1979, HOPPESEYLERS Z PHYSL, V360, P1673	30	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19944	19947						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400311				2022-12-25	WOS:A1992JR85800034
J	ITO, S; HASHIMOTO, H; NEGISHI, M; SUZUKI, M; KOYANO, H; NOYORI, R; ICHIKAWA, A				ITO, S; HASHIMOTO, H; NEGISHI, M; SUZUKI, M; KOYANO, H; NOYORI, R; ICHIKAWA, A			IDENTIFICATION OF THE PROSTACYCLIN RECEPTOR BY USE OF [15-3H1]19-(3-AZIDOPHENYL)-20-NORISOCARBACYCLIN, AN IRREVERSIBLE SPECIFIC PHOTOAFFINITY PROBE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASTOCYTOMA P-815 CELLS; BINDING; PLATELETS; ANALOG; MEMBRANE; LIGAND; H-3	The prostaglandin I (PGI2) receptor of mouse mastocytoma P-815 cells was characterized by photoaffinity labeling with the stable PGI2 analogue [15-H-3(1)]-19-(3-azidophenyl)-20-norisocarbacyclin ([H-3] APNIC) used as a potential photoaffinity probe for the receptor. [H-3]APNIC bound to the mastocytoma membrane with high affinity and in a saturable manner. Scatchard plot analysis indicated a single binding site with a K(d) of 4.7 nM and a B(max) of 0.58 pmol/mg protein. The binding of [H-3]APNIC was dose dependently inhibited by APNIC and iloprost, another stable PGI2 agonist, and to a much lesser extent by PGE2. The binding of the radioligand showed sensitivity (to the guanine nucleotide guanosine 5'-O-(3-thiotriphosphate) (GTPgammaS). Photolysis of [H-3]APNIC-prelabeled membranes resulted in incorporation of radiolabel into a protein of approximately 43 kDa. Photolabeling was inhibited by PGI2 agonists and other prostaglandins with specificity for the PGI2 receptor and was modulated by GTPgammaS. A protein of approximately 45 kDa was also labeled by [H-3]APNIC in the membrane of porcine platelets, membranes that are known to be abundant in PGI2 receptors. These results demonstrate that [H-3]APNIC specifically labels a protein that may represent the PGI2 receptor and that this radioprobe will be a useful reagent for further characterization and purification of the PGI2 receptor.	KYOTO UNIV, FAC PHARMACEUT SCI, DEPT PHYSIOL CHEM, KYOTO 606, JAPAN; NAGOYA UNIV, CTR CHEM INSTRUMENT, NAGOYA, AICHI 464, JAPAN; NAGOYA UNIV, FAC SCI, DEPT CHEM, NAGOYA 46401, JAPAN	Kyoto University; Nagoya University; Nagoya University	ITO, S (corresponding author), OSAKA BIOSCI INST, DEPT CELL BIOL, 6-2-4 FURUEDAI, SUITA 565, JAPAN.		Hashimoto, Hitoshi/D-1209-2010	Hashimoto, Hitoshi/0000-0001-6548-4016				ARISTOFF PA, 1985, ADV PROSTAG THROMB L, V14, P309; ARMSTRONG RA, 1989, BRIT J PHARMACOL, V97, P657, DOI 10.1111/j.1476-5381.1989.tb12001.x; BLAIR IA, 1981, BRIT J PHARMACOL, V72, P435, DOI 10.1111/j.1476-5381.1981.tb10994.x; FEDAN JS, 1984, BIOCHEM PHARMACOL, V33, P1167, DOI 10.1016/0006-2952(84)90167-9; HALUSHKA PV, 1989, ANNU REV PHARMACOL, V29, P213; HASHIMOTO H, 1990, PROSTAGLANDINS, V40, P491, DOI 10.1016/0090-6980(90)90111-8; KEEN M, 1991, EUR J PHARM-MOLEC PH, V207, P111, DOI 10.1016/0922-4106(91)90085-V; KUNO T, 1985, BIOCHEM BIOPH RES CO, V129, P639, DOI 10.1016/0006-291X(85)91939-4; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LEIGH PJ, 1984, J BIOL CHEM, V259, P2431; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MICHALAK M, 1990, FEBS LETT, V265, P117, DOI 10.1016/0014-5793(90)80898-S; RAO CV, 1988, INT CONGR SER, V798, P171; RUAT M, 1988, P NATL ACAD SCI USA, V85, P2743, DOI 10.1073/pnas.85.8.2743; RUCKER W, 1983, BIOCHEM PHARMACOL, V32, P2405, DOI 10.1016/0006-2952(83)90683-4; SHIBASAKI M, 1983, TETRAHEDRON LETT, V24, P3493, DOI 10.1016/S0040-4039(00)86021-9; SIEGL AM, 1979, J CLIN INVEST, V63, P215, DOI 10.1172/JCI109292; SUZUKI M, 1987, J ORG CHEM, V52, P5583, DOI 10.1021/jo00234a014; SUZUKI M, 1992, TETRAHEDRON, V48, P2635, DOI 10.1016/S0040-4020(01)88526-4; TAKAHASHI S, 1991, J BIOL CHEM, V266, P5367; TOWN MH, 1982, PROSTAG OTH LIPID M, V24, P61, DOI 10.1016/0090-6980(82)90177-0; TSAI AL, 1989, J BIOL CHEM, V264, P61; USHIKUBI F, 1989, J BIOL CHEM, V264, P16496; YAMASHITA M, 1991, P NATL ACAD SCI USA, V88, P11515, DOI 10.1073/pnas.88.24.11515; YAMASHITA M, 1991, BIOCHEM BIOPH RES CO, V177, P1233, DOI 10.1016/0006-291X(91)90673-U	25	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20326	20330						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400351				2022-12-25	WOS:A1992JR85800091
J	FUJIMORI, T; JENCKS, WP				FUJIMORI, T; JENCKS, WP			BINDING OF 2 SR2+ IONS CHANGES THE CHEMICAL SPECIFICITIES FOR PHOSPHORYLATION OF THE SARCOPLASMIC-RETICULUM CALCIUM ATPASE THROUGH A STEPWISE MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIMITING CONFORMATIONAL CHANGE; (CA-2+ + MG-2+)-ATPASE; ADENOSINE-TRIPHOSPHATASE; TRANSIENT KINETICS; LANTHANIDE BINDING; MULTIPLE METALS; STOPPED FLOW; TRANSPORT; CA-2+; SITES	The sequential binding of Sr2+ and Ca2+ to the cytoplasmic transport sites of the sarcoplasmic reticulum calcium ATPase allows the formation of two different mixed complexes: (c)E.Sr.Ca, with Sr2+ bound to the "inner" site and Ca2+ bound to the "outer" site, and (c)E.Ca.Sr, with Ca2+ bound to the inner site and Sr2+ bound to the outer site (pH 7.0, 25-degrees-C, 10 mM MgCl2, 100 mM KCl). Both (c)E.Sr.Ca-45 and (c)E.Ca-45.Sr react with ATP to internalize one Ca-45/phosphoenzyme. The value of K0.5 = 83-mu-M Sr2+ for activation of the enzyme for phosphorylation by ATP is much larger than K0.5 = 28-mu-M Sr2+ for inhibition of phosphoenzyme formation from inorganic phosphate (n(H) = 1.0-1.3). These results are consistent with the sequential binding of two strontium ions with negative cooperativity and dissociation constants of K(Sr1) = 35-mu-M and K(Sr2) = 55-mu-M. The species (c)E.Sr2 and (c)E.Ca2 react rapidly with ATP but not inorganic phosphate. However, enzyme with one strontium bound, (c)E.Sr, does not react with either inorganic phosphate or ATP. Therefore, the conformational changes in the enzyme that alter the chemical specificity for phosphorylation by ATP and by inorganic phosphate are different. This requires the existence of at least three forms of the unphosphorylated enzyme with three different chemical specificities for catalysis.	BRANDEIS UNIV, DEPT BIOCHEM, WALTHAM, MA 02254 USA	Brandeis University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020888, R37GM020888] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20888] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN DG, 1977, SCIENCE, V195, P996, DOI 10.1126/science.841325; ARAV R, 1983, J BIOL CHEM, V258, P433; BERMAN MC, 1990, BIOCHIM BIOPHYS ACTA, V1029, P235, DOI 10.1016/0005-2736(90)90159-L; CHAMPEIL P, 1983, J BIOL CHEM, V258, P4453; de Meis L, 1974, Biochemistry, V13, P5032, DOI 10.1021/bi00721a026; DEMEIS L, 1981, SARCOPLASMIC RETICUL; DUPONT Y, 1982, BIOCHIM BIOPHYS ACTA, V688, P75, DOI 10.1016/0005-2736(82)90580-6; DUPONT Y, 1978, NATURE, V273, P396, DOI 10.1038/273396a0; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FABIATO A, 1981, J GEN PHYSIOL, V78, P457, DOI 10.1085/jgp.78.5.457; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FERNANDEZBELDA F, 1984, J BIOL CHEM, V259, P9687; FUJIMORI T, 1990, J BIOL CHEM, V265, P16262; FUJIMORI T, 1992, J BIOL CHEM, V267, P18466; GODT RE, 1974, J GEN PHYSIOL, V63, P722, DOI 10.1085/jgp.63.6.722; GUILLAIN F, 1980, J BIOL CHEM, V255, P2072; GUILLAIN F, 1981, J BIOL CHEM, V256, P6140; GUIMARAESMOTTA H, 1984, J BIOL CHEM, V259, P8699; HANEL AM, 1990, BIOCHEMISTRY-US, V29, P5210, DOI 10.1021/bi00473a030; HASSELBACH W, 1963, BIOCHEM Z, V339, P94; HASSELBACH W, 1974, ENZYMES, V10, P431; HERRMANN TR, 1986, EUR J BIOCHEM, V158, P555, DOI 10.1111/j.1432-1033.1986.tb09790.x; HOLGUIN JA, 1986, ARCH BIOCHEM BIOPHYS, V251, P9, DOI 10.1016/0003-9861(86)90045-7; IKEMOTO N, 1978, J BIOL CHEM, V253, P8027; IKEMOTO N, 1981, J BIOL CHEM, V256, P8593; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; INESI G, 1980, J BIOL CHEM, V255, P3025; ITOH N, 1984, J BIOCHEM-TOKYO, V95, P661, DOI 10.1093/oxfordjournals.jbchem.a134655; JENCKS WP, 1983, CURR TOP MEMBR TRANS, V19, P1; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MAKINOSE M, 1973, FEBS LETT, V37, P140, DOI 10.1016/0014-5793(73)80443-0; MARTONOSI A, 1964, J BIOL CHEM, V239, P648; MARTONOSI AN, 1983, HDB PHYSL 10, V10, P417; MERMIER P, 1976, EUR J BIOCHEM, V69, P79, DOI 10.1111/j.1432-1033.1976.tb10860.x; MYUNG J, 1991, FEBS LETT, V278, P35, DOI 10.1016/0014-5793(91)80077-G; NAKAMURA J, 1986, BIOCHIM BIOPHYS ACTA, V870, P495, DOI 10.1016/0167-4838(86)90258-X; NAKAMURA J, 1989, J BIOL CHEM, V264, P17029; OGURUSU T, 1991, BIOCHEMISTRY-US, V30, P9966, DOI 10.1021/bi00105a022; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P8626, DOI 10.1021/bi00423a018; PETITHORY JR, 1986, BIOCHEMISTRY-US, V25, P4493, DOI 10.1021/bi00364a006; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; PICKART CM, 1984, J BIOL CHEM, V259, P1629; PICKART CM, 1982, J BIOL CHEM, V257, P5319; SCOTT TL, 1984, J BIOL CHEM, V259, P4035; SCOTT TL, 1985, J BIOL CHEM, V260, P4421; SQUIER TC, 1990, J BIOL CHEM, V265, P13713; STAHL N, 1984, BIOCHEMISTRY-US, V23, P5389, DOI 10.1021/bi00318a002; STAHL N, 1987, BIOCHEMISTRY-US, V26, P7654, DOI 10.1021/bi00398a019; STEPHENS EM, 1979, BIOCHEMISTRY-US, V18, P4876, DOI 10.1021/bi00589a016; STEPHENS EM, 1978, FED PROC, V37, P1483; TADA M, 1978, PHYSIOL REV, V58, P1; TANFORD C, 1987, P NATL ACAD SCI USA, V84, P7094, DOI 10.1073/pnas.84.20.7094; VERJOVSKIALMEIDA S, 1978, BIOCHEMISTRY-US, V17, P5006, DOI 10.1021/bi00616a023; WEBER A, 1966, BIOCHEM Z, V345, P329	58	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18475	18487						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1388155				2022-12-25	WOS:A1992JN50200039
J	CENCIARELLI, C; HOHMAN, RJ; ATKINSON, TP; GUSOVSKY, F; WEISSMAN, AM				CENCIARELLI, C; HOHMAN, RJ; ATKINSON, TP; GUSOVSKY, F; WEISSMAN, AM			EVIDENCE FOR GTP-BINDING PROTEIN INVOLVEMENT IN THE TYROSINE PHOSPHORYLATION OF THE T-CELL RECEPTOR ZETA-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYTOPLASMIC FREE CALCIUM; ANTIGEN RECEPTOR; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODIES; PHOSPHOLIPASE-C; ACTIVATION; COMPLEX; POLYPEPTIDE; KINASE	The zeta-subunit of the T cell receptor (TCR) is a prominent substrate for a TCR-activated tyrosine kinase. Tyrosine phosphorylation of the zeta-subunit in response to antibody-mediated receptor cross-linking was synergized in permeabilized T cells by either of two nonhydrolyzable GTP analogues, guanosine 5'-[gamma-thio]triphosphate (GTP-gamma-S) or guanosine 5'-[beta, gamma-imido]triphosphate Gpp(NH)p. ATP analogues did not significantly affect antibody-induced tyrosine phosphorylation. Unlike the GTP analogues, the GDP analogue guanosine 5'-[beta-thio]diphosphate (GDP-beta-S) did not enhance phosphorylation of zeta. The effect induced by the GTP analogues required TCR occupancy and was independent of protein kinase C. Taken together these observations implicate a GTP-binding protein in the modulation of TCR-induced tyrosine phosphorylation.	NCI,EXPTL IMMUNOL BRANCH,BLDG 10,RM 4B17,BETHESDA,MD 20892; NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BETHESDA,MD 20892; NIDDKD,BIOORGAN CHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BONVINI E, 1991, BIOCHEM J, V275, P689, DOI 10.1042/bj2750689; BURDETT E, 1990, AM J PHYSIOL, V258, pC99, DOI 10.1152/ajpcell.1990.258.1.C99; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAVES JD, 1991, J IMMUNOL, V146, P2102; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; HOHMAN RJ, 1988, P NATL ACAD SCI USA, V85, P1624, DOI 10.1073/pnas.85.5.1624; HOWELL TW, 1987, BIOCHIM BIOPHYS ACTA, V927, P177, DOI 10.1016/0167-4889(87)90132-7; IMBODEN JB, 1985, J IMMUNOL, V134, P663; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; KING SM, 1985, P NATL ACAD SCI USA, V82, P4717, DOI 10.1073/pnas.82.14.4717; KUNG PC, 1979, SCIENCE, V206, P347, DOI 10.1126/science.314668; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; MAO SY, 1992, P NATL ACAD SCI USA, V89, P222, DOI 10.1073/pnas.89.1.222; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NASMITH PE, 1989, BIOCHEM J, V257, P893, DOI 10.1042/bj2570893; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; OSHEA JJ, 1987, J IMMUNOL, V139, P3463; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PATEL MD, 1987, J BIOL CHEM, V262, P5831; PETER ME, 1992, EMBO J, V11, P933, DOI 10.1002/j.1460-2075.1992.tb05132.x; PHILLIPS RJ, 1991, INT IMMUNOL, V3, P617, DOI 10.1093/intimm/3.7.617; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SCHREZENMEIER H, 1988, J IMMUNOL, V141, P3785; SCHREZENMEIER H, 1988, J EXP MED, V168, P817, DOI 10.1084/jem.168.2.817; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; TELFER JC, 1991, SCIENCE, V254, P439, DOI 10.1126/science.1925604; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; Weissman A M, 1989, Year Immunol, V4, P74; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x	41	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14527	14530						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1386076				2022-12-25	WOS:A1992JF08800004
J	HIRATSUKA, T				HIRATSUKA, T			MOVEMENT OF CYS-697 IN MYOSIN ATPASE ASSOCIATED WITH ATP HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SKELETAL-MUSCLE MYOSIN; GLYCINE-RICH LOOP; HEAVY-CHAIN; CROSS-LINKING; ADENOSINE-TRIPHOSPHATASE; CONFORMATIONAL-CHANGES; NUCLEOTIDE BINDING; SUBFRAGMENT-1; ACTIN	To detect movement of Cys-697 (SH2) in myosin subfragment-1 (S-1) associated with ATP hydrolysis, SH2 was labeled with the environmentally sensitive fluorescent analog of maleimide, 2-(4'-maleimidylanilino) naphthalene-6-sulfonic acid (MIANS). Complex formation of S-1 labeled at Cys-697 with MIANS (MIANS-S-1) with adenyl-5'-yl imidodiphosphate and ADP resulted in a significant decrease in the fluorescence intensity of approximately 40 and 30%, respectively. When ATP was added to MIANS-S-1, the fluorescence intensity decreased rapidly by approximately 40%, and this fluorescence level was maintained during the steady state of ATP hydrolysis. As the substrate was used up, the fluorescence intensity increased to approximately 70% of the original value. These results together with model experiments with MIANS-N-acetylcysteine indicate that in the presence of ATP, the MIANS fluorophore attached to SH2 is located in a less hydrophobic environment than is the fluorophore in the absence of ligand and that the hydrolysis of ATP enhances hydrophobicity around the fluorophore. Acrylamide fluorescence quenching studies of MIANS-S-1 confirmed these results, indicating that addition of ATP and ADP to MIANS-S-1 results in an increase in the Stern-Volmer quenching constant of the fluorophore by factors of approximately 3 and 2.5, respectively. The present observations suggest that binding of ATP causes a movement of SH2 toward the protein surface, whereas it goes back into the protein interior after ATP hydrolysis. The results also confirmed previous observations by a chemical cross-linking approach (Hiratsuka, T. (1987) Biochemistry 26, 3168-3173).			HIRATSUKA, T (corresponding author), ASAHIKAWA MED COLL, DEPT CHEM, ASAHIKAWA, HOKKAIDO 078, JAPAN.							BALINT M, 1978, ARCH BIOCHEM BIOPHYS, V190, P793, DOI 10.1016/0003-9861(78)90339-9; BOTTS J, 1984, P NATL ACAD SCI-BIOL, V81, P2060, DOI 10.1073/pnas.81.7.2060; BOTTS J, 1989, P NATL ACAD SCI USA, V86, P2204, DOI 10.1073/pnas.86.7.2204; BURKE M, 1977, BIOCHEMISTRY-US, V16, P5559, DOI 10.1021/bi00644a026; CHANCE B, 1957, ARCH BIOCHEM BIOPHYS, V71, P130, DOI 10.1016/0003-9861(57)90015-2; CHAUSSEPIED P, 1986, P NATL ACAD SCI USA, V83, P2037, DOI 10.1073/pnas.83.7.2037; CHEUNG HC, 1985, BIOCHIM BIOPHYS ACTA, V832, P52, DOI 10.1016/0167-4838(85)90173-6; CHEUNG HC, 1991, BIOPHYS CHEM, V40, P1, DOI 10.1016/0301-4622(91)85025-L; CREMO CR, 1989, J BIOL CHEM, V264, P6608; CREMO CR, 1990, BIOCHEMISTRY-US, V29, P3309, DOI 10.1021/bi00465a023; DALBEY RE, 1983, BIOCHEMISTRY-US, V22, P4696, DOI 10.1021/bi00289a014; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; ELZINGA M, 1977, P NATL ACAD SCI USA, V74, P4281, DOI 10.1073/pnas.74.10.4281; Fiske CH, 1925, J BIOL CHEM, V66, P375; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HAUGLAND RP, 1975, J SUPRAMOL STR CELL, V3, P338, DOI 10.1002/jss.400030405; HAUGLAND RP, 1989, HDB FLUORESCENT PROB, P25; HIRATSUKA T, 1986, BIOCHEMISTRY-US, V25, P2101, DOI 10.1021/bi00356a039; HIRATSUKA T, 1987, BIOCHEMISTRY-US, V26, P3168, DOI 10.1021/bi00385a034; HIRATSUKA T, 1976, BIOCHIM BIOPHYS ACTA, V453, P293, DOI 10.1016/0005-2795(76)90277-4; HIRATSUKA T, 1984, J BIOCHEM-TOKYO, V96, P155, DOI 10.1093/oxfordjournals.jbchem.a134807; HIRATSUKA T, 1988, BIOCHEMISTRY-US, V27, P4110, DOI 10.1021/bi00411a030; HIRATSUKA T, 1990, J BIOL CHEM, V265, P18786; HIRATSUKA T, 1990, J BIOL CHEM, V265, P18791; KASPRZAK AA, 1989, BIOCHEMISTRY-US, V28, P9230, DOI 10.1021/bi00449a040; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; LU RC, 1986, P NATL ACAD SCI USA, V83, P6392, DOI 10.1073/pnas.83.17.6392; MAHOWALD TA, 1965, BIOCHEMISTRY-US, V4, P732, DOI 10.1021/bi00880a019; MIYANISHI T, 1989, BIOCHEMISTRY-US, V28, P1287, DOI 10.1021/bi00429a051; PERKINS WJ, 1984, J BIOL CHEM, V259, P8786; PERRY SV, 1955, METHOD ENZYMOL, V2, P582, DOI 10.1016/S0076-6879(55)02258-1; RAJASEKHARAN KN, 1989, J BIOL CHEM, V264, P10810; REISLER E, 1982, METHOD ENZYMOL, V85, P84; REISLER E, 1974, BIOCHEMISTRY-US, V13, P3837, DOI 10.1021/bi00716a001; SEIDEL JC, 1972, ARCH BIOCHEM BIOPHYS, V152, P839, DOI 10.1016/0003-9861(72)90280-9; SEKINE T, 1964, BIOCHIM BIOPHYS ACTA, V81, P336, DOI 10.1016/0926-6569(64)90049-5; Stern O, 1919, PHYS Z, V20, P183; SUTOH K, 1981, BIOCHEMISTRY-US, V20, P3281, DOI 10.1021/bi00514a046; SUTOH K, 1988, BIOCHEMISTRY-US, V27, P2964, DOI 10.1021/bi00408a045; SUZUKI R, 1987, J BIOL CHEM, V262, P11410; TAO T, 1983, BIOCHEMISTRY-US, V20, P5051; TONG SW, 1990, J BIOL CHEM, V265, P4893; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; TRYBUS KM, 1982, BIOCHEMISTRY-US, V21, P1284, DOI 10.1021/bi00535a028; WAGNER PD, 1977, J MOL BIOL, V109, P455, DOI 10.1016/S0022-2836(77)80023-5; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBER K, 1969, J BIOL CHEM, V244, P4406; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WELLS JA, 1982, METHOD ENZYMOL, V85, P93; WIEDNER H, 1978, J BIOL CHEM, V253, P2763; YAMAGUCHI M, 1966, J BIOCHEM, V59, P24, DOI 10.1093/oxfordjournals.jbchem.a128254	51	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14941	14948						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1386082				2022-12-25	WOS:A1992JF08800067
J	KUBE, E; BECKER, T; WEBER, K; GERKE, V				KUBE, E; BECKER, T; WEBER, K; GERKE, V			PROTEIN-PROTEIN INTERACTION STUDIED BY SITE-DIRECTED MUTAGENESIS - CHARACTERIZATION OF THE ANNEXIN-II-BINDING SITE ON P11, A MEMBER OF THE S100 PROTEIN FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROPHORETIC TRANSFER; PHOSPHOLIPID-BINDING; POLYACRYLAMIDE GELS; ESCHERICHIA-COLI; TYROSINE KINASE; CLONED GENES; LIGHT-CHAIN; SUBSTRATE; CALCIUM; P36	p11, a member of the S100 protein family, forms a stable heterotetrameric complex with annexin II. The p11-binding site of annexin II resides in the N-terminal 14 residues, which form an amphiphatic alpha-helix with the hydrophobic face representing the contact site for p11 (Johnsson, N., Marriott, G., and Weber, K. (1988) EMBO J. 7, 2435-2442). We show that a corresponding peptide can be used to purify recombinant p11 by affinity chromatography. To map the annexin II-binding site on p11, we have produced progressively truncated p11 derivatives by site-directed mutagenesis. Our analysis reveals that a highly hydrophobic region between residues 85 and 91 is indispensable for annexin II-binding. It is located in the C-terminal extension, following the second distorted EF-hand. Using a series of single amino acid replacements, we have identified individual hydrophobic residues, which seem to represent contact points for annexin II. Most notably, substitution of tyrosine 85 or phenylalanine 86 by alanine drastically reduces the affinity of p11 for annexin II, whereas replacement of these residues by tryptophan has no or only a marginal effect. Thus, hydrophobic side chains on both annexin II and p11 are involved in complex formation.	MAX PLANCK INST BIOPHYS CHEM,DEPT BIOCHEM,POB 2841,W-3400 GOTTINGEN,GERMANY	Max Planck Society								AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; BAUDIER J, 1989, J BIOL CHEM, V264, P1824; BECKER T, 1990, EMBO J, V9, P4207, DOI 10.1002/j.1460-2075.1990.tb07868.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; FILIPEK A, 1991, EUR J BIOCHEM, V195, P795, DOI 10.1111/j.1432-1033.1991.tb15768.x; FUJI T, 1990, J BIOCHEM-TOKYO, V107, P133, DOI 10.1093/oxfordjournals.jbchem.a122996; GERKE V, 1985, EMBO J, V4, P2917, DOI 10.1002/j.1460-2075.1985.tb04023.x; GERKE V, 1991, GENE, V104, P259, DOI 10.1016/0378-1119(91)90259-E; GERKE V, 1985, J BIOL CHEM, V260, P1688; GERKE V, 1989, CELL MOTIL CYTOSKEL, V14, P449, DOI 10.1002/cm.970140402; GERKE V, 1991, NOVEL CALCIUM BINDIN, P139; GERKE V, 1990, STIMULUS RESPONSE CO, P311; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; GLENNEY JR, 1986, J BIOL CHEM, V261, P485; HILT DC, 1991, NOVEL CALCIUM BINDIN, P65; JOHNSSON N, 1990, J BIOL CHEM, V265, P14464; JOHNSSON N, 1990, EUR J BIOCHEM, V188, P1, DOI 10.1111/j.1432-1033.1990.tb15363.x; JOHNSSON N, 1988, EMBO J, V7, P2435, DOI 10.1002/j.1460-2075.1988.tb03089.x; JOHNSSON N, 1986, FEBS LETT, V198, P361, DOI 10.1016/0014-5793(86)80437-9; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KUBE E, 1991, GENE, V102, P255, DOI 10.1016/0378-1119(91)90086-Q; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOSS SE, 1991, NOVEL CALCIUM BINDIN, P535; OSBORN M, 1988, EXP CELL RES, V175, P81, DOI 10.1016/0014-4827(88)90257-1; PERSECHINI A, 1989, TRENDS NEUROSCI, V12, P462, DOI 10.1016/0166-2236(89)90097-0; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STRYNADKA NCJ, 1990, PROTEINS, V7, P234, DOI 10.1002/prot.340070305; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZIMMER DB, 1986, J BIOL CHEM, V261, P1424	36	102	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14175	14182						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1385811				2022-12-25	WOS:A1992JD32500061
J	MEROPOL, NJ; ALTMANN, SW; SHANAFELT, AB; KASTELEIN, RA; JOHNSON, GD; PRYSTOWSKY, MB				MEROPOL, NJ; ALTMANN, SW; SHANAFELT, AB; KASTELEIN, RA; JOHNSON, GD; PRYSTOWSKY, MB			REQUIREMENT OF HYDROPHILIC AMINO-TERMINAL RESIDUES FOR GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR BIOACTIVITY AND RECEPTOR-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; IDENTIFICATION; DELETION	Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein required for the proliferation and differentiation of granulocyte and macrophage precursors. Previous investigations have identified regions in human and murine GM-CSF that are required for bioactivity. In the present study, alanine substitution mutagenesis was undertaken to define more precisely specific amino-terminal residues in murine GM-CSF that are involved in bioactivity and receptor binding. Five double alanine mutants were identified that showed at least 10-fold reductions in bioactivity (K14AK20A, K14AE21A, H15AK20A, H15AE21A,K20AE21A). Each of these mutants maintained a normal N-linked glycosylation pattern when expressed in COS-1 cells, suggesting that native polypeptide backbone conformation was preserved. The purified prokaryotic expression products of two mutants (K14AE21A and H15AE21A) had a 100-fold decrease in bioactivity and a decrease in receptor binding, indicating that the side chains of K14, H15, and E21 are required for optimal receptor binding and maximal bioactivity.	UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT MOLEC BIOL,PALO ALTO,CA 94304; UNIV PENN,HEMATOL ONCOL SECT,PHILADELPHIA,PA 19104	University of Pennsylvania; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; University of Pennsylvania					NCI NIH HHS [CA 48648] Funding Source: Medline; NHLBI NIH HHS [HL 08268] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048648] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008268] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTMANN SW, 1991, J BIOL CHEM, V266, P5333; BROWN CB, 1990, J IMMUNOL, V144, P2184; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CLARKLEWIS I, 1988, J IMMUNOL, V141, P881; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; GOUGH NM, 1985, EMBO J, V4, P645, DOI 10.1002/j.1460-2075.1985.tb03678.x; GOUGH NM, 1987, EUR J BIOCHEM, V169, P353, DOI 10.1111/j.1432-1033.1987.tb13619.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; IHLE JN, 1990, PROG CLIN BIOL RES, V184, P85; KANAKURA Y, 1991, BLOOD, V77, P1033; KAUSHANSKY K, 1989, P NATL ACAD SCI USA, V86, P1213, DOI 10.1073/pnas.86.4.1213; LABRANCHE CC, 1990, ARCH BIOCHEM BIOPHYS, V276, P153, DOI 10.1016/0003-9861(90)90022-Q; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEROPOL NJ, 1991, HYBRIDOMA, V10, P433, DOI 10.1089/hyb.1991.10.433; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; OKAMOTO M, 1991, ARCH BIOCHEM BIOPHYS, V286, P562, DOI 10.1016/0003-9861(91)90080-3; Parry D A, 1988, J Mol Recognit, V1, P107, DOI 10.1002/jmr.300010302; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; SCHRIMSHER JL, 1987, BIOCHEM J, V247, P195, DOI 10.1042/bj2470195; SHANAFELT AB, 1991, J BIOL CHEM, V266, P13804; SHANAFELT AB, 1989, P NATL ACAD SCI USA, V86, P4872, DOI 10.1073/pnas.86.13.4872; SHENAFELT AB, 1991, EMBO J, V10, P4105; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VONKIMMENADE A, 1988, EUR J BIOCHEM, V173, P109	26	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14266	14269						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1385812				2022-12-25	WOS:A1992JD32500074
J	HEES, B; DANBOLT, NC; KANNER, BI; HAASE, W; HEITMANN, K; KOEPSELL, H				HEES, B; DANBOLT, NC; KANNER, BI; HAASE, W; HEITMANN, K; KOEPSELL, H			A MONOCLONAL-ANTIBODY AGAINST A NA+-L-GLUTAMATE COTRANSPORTER FROM RAT-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSMITTERS; D-GLUCOSE COTRANSPORTER; CENTRAL NERVOUS-SYSTEM; GRANULE CELL LOLL; TRANSPORT GLYCOPROTEIN; FUNCTIONAL EXPRESSION; PARTIAL-PURIFICATION; SELECTIVE DEPLETION; HAMSTER CEREBELLUM; CLONING	A monoclonal mouse IgM antibody (Z8E9) was raised against the Na+-L-glutamate cotransporter from rat brain. In a preparation of brain plasma membrane vesicles, Z8E9 binds specifically to a polypeptide with an apparent molecular weight of 70,000 and inhibits Na+ gradient-dependent L-glutamate cotransport (up to 50%) in brain membrane vesicles. In the membrane vesicles, the antibody does not alter the membrane permeability for Na+ and K+ nor the Na+ gradient-dependent uptake of gamma-aminobutyric acid. Kinetic experiments showed that Z8E9 does not alter the K0.5 values for L-glutamate and Na+ activation of L-glutamate transport. However, an apparent cooperativity observed for L-glutamate activation was increased, and the V(max) of L-glutamate transport was decreased. Immunostaining of rat cerebellum identified antigenic sites of Z8E9 in Golgi epithelial cells and astrocytes (by light and electron microscopy), whereas no labeling at nerve terminals was detected. The data suggest that a component of a Na+-L-glutamate cotransporter subtype has been identified that is specific for glia cells in brain.	MAX PLANCK INST BIOPHYS,KENNEDYALLEE 70,W-6000 FRANKFURT 70,GERMANY	Max Planck Society			Danbolt, Niels Christian/A-1907-2014	Danbolt, Niels Christian/0000-0003-4227-4520				BIRK HW, 1987, ANAL BIOCHEM, V164, P12, DOI 10.1016/0003-2697(87)90360-5; BOOTH RFG, 1978, BIOCHEM J, V176, P365, DOI 10.1042/bj1760365; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; DREJER J, 1982, EXP BRAIN RES, V47, P259; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; ERECINSKA M, 1983, J BIOL CHEM, V258, P9069; FERKANY J, 1986, J NEUROSCI RES, V16, P491, DOI 10.1002/jnr.490160305; FLETCHER EJ, 1991, J NEUROCHEM, V57, P911, DOI 10.1111/j.1471-4159.1991.tb08237.x; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; FONNUM F, 1981, NEUROSCIENCE, V6, P863, DOI 10.1016/0306-4522(81)90168-8; GARTHWAITE G, 1985, BRAIN RES, V343, P129, DOI 10.1016/0006-8993(85)91166-7; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HAASE W, 1989, EUR J CELL BIOL, V48, P360; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HENN FA, 1976, BRAIN RES, V101, P341, DOI 10.1016/0006-8993(76)90274-2; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KENNEDY MB, 1989, CELL, V59, P777, DOI 10.1016/0092-8674(89)90601-6; KOEPSELL H, 1988, J BIOL CHEM, V263, P18419; KOEPSELL H, 1990, J MEMBRANE BIOL, V114, P113, DOI 10.1007/BF01869093; KOEPSELL H, 1983, J BIOL CHEM, V258, P1888; KOEPSELL H, 1984, J BIOL CHEM, V259, P6548; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LEVI G, 1982, BRAIN RES, V239, P425, DOI 10.1016/0006-8993(82)90520-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; NEEB M, 1987, J BIOL CHEM, V262, P10718; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; OLNEY JW, 1989, BIOL PSYCHIAT, V26, P505, DOI 10.1016/0006-3223(89)90072-3; OTTERSEN OP, 1989, ANAT EMBRYOL, V180, P1, DOI 10.1007/BF00321895; RADIAN R, 1986, J BIOL CHEM, V261, P5437; RAUEN T, 1992, NEUROCHEM INT, V21, pB26; ROBINSON MB, 1991, BRAIN RES, V544, P196, DOI 10.1016/0006-8993(91)90054-Y; SCHOUSBOE A, 1977, J NEUROCHEM, V29, P999, DOI 10.1111/j.1471-4159.1977.tb06503.x; Schousboe A, 1981, Adv Biochem Psychopharmacol, V27, P103; SOMOGYI P, 1986, NEUROSCIENCE, V19, P1045, DOI 10.1016/0306-4522(86)90121-1; SPURR AR, 1969, J ULTRA MOL STRUCT R, V26, P31, DOI 10.1016/S0022-5320(69)90033-1; STALLCUP WB, 1979, J NEUROCHEM, V32, P57, DOI 10.1111/j.1471-4159.1979.tb04509.x; STEFFGEN J, 1991, BIOCHIM BIOPHYS ACTA, V1066, P14, DOI 10.1016/0005-2736(91)90244-3; STORMMATHISEN J, 1979, NEUROSCIENCE, V4, P1237, DOI 10.1016/0306-4522(79)90154-4; TAXT T, 1984, NEUROSCIENCE, V11, P79, DOI 10.1016/0306-4522(84)90215-X; VEYHL M, 1992, FASEB J, V6, pA1459; WANIEWSKI RA, 1984, J NEUROSCI, V4, P2237; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; WILKIN GP, 1982, BRAIN RES, V244, P69, DOI 10.1016/0006-8993(82)90905-2; YOUNG AB, 1974, BRAIN RES, V73, P1, DOI 10.1016/0006-8993(74)91002-6; ZACZEK R, 1987, J NEUROSCI RES, V18, P425, DOI 10.1002/jnr.490180307	56	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23275	23281						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429674				2022-12-25	WOS:A1992JY16300087
J	SAYRE, MH; TSCHOCHNER, H; KORNBERG, RD				SAYRE, MH; TSCHOCHNER, H; KORNBERG, RD			PURIFICATION AND PROPERTIES OF SACCHAROMYCES-CEREVISIAE RNA POLYMERASE-II GENERAL INITIATION FACTOR-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR TFIIE; PROMOTER INVITRO; PROTEINS; CLONING; SUBUNIT; MOTIFS; DNA	RNA polymerase II initiation factor a was purified to apparent homogeneity from yeast whole cell extract and consisted of two highly charged polypeptides with apparent masses of 66 and 43 kDa. Separation and renaturation of the subunits showed that both were required for transcription activity. The native mass of factor a was estimated to be 240-260 kDa by gel filtration, but its sedimentation rate in a glycerol gradient was similar to that of a much smaller globular protein, suggesting an extended conformation. Factor a was required for utilization of six different eukaryotic promoters in vitro, indicating a general role in promoter-directed transcription by yeast RNA polymerase II.			SAYRE, MH (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,STANFORD,CA 94305, USA.				NIGMS NIH HHS [GM-36659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036659, R37GM036659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1991, J BIOL CHEM, V266, P17721; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; FLORES O, 1989, J BIOL CHEM, V264, P8913; GERARD M, 1991, J BIOL CHEM, V266, P20940; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HENRY NL, 1992, J BIOL CHEM, V267, P23388; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PETERSON MG, 1991, NATURE, V354, P369; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0	27	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23383	23387						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429681				2022-12-25	WOS:A1992JY16300102
J	RICHARDSON, RM; HOSEY, MM				RICHARDSON, RM; HOSEY, MM			AGONIST-INDUCED PHOSPHORYLATION AND DESENSITIZATION OF HUMAN M2 MUSCARINIC CHOLINERGIC RECEPTORS IN SF9 INSECT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; ACETYLCHOLINE-RECEPTOR; CHICK HEART; REGULATORY PROTEINS; GUANINE-NUCLEOTIDES; ADENYLYL CYCLASE; HIGH-AFFINITY; KINASE-C; EXPRESSION; RECONSTITUTION	The human m1 (hm1) and m2 (hm2) muscarinic cholinergic receptors (mAChR) expressed in Sf9 insect cells using recombinant baculovirus were tested for their ability to undergo agonist-dependent phosphorylation and desensitization. The muscarinic agonist carbachol induced phosphorylation of the hm2 mAChR in the Sf9 cells incubated with P-32i, to an extent of 4-5 mol of phosphate/mol of receptor. In contrast, no phosphorylation of the hm1 mAChR was observed. The hm2 mAChR stimulated [S-35]GTPgammaS binding to, and GTPase activity of, the insect cell G-proteins. These receptor-mediated activities were reduced by 50% in membranes prepared from agonist-treated cells compared to control, suggesting that the agonist-induced phosphorylation of the hm2 mAChR resulted in desensitization of the receptors. No role for protein kinase C or cyclic nucleotide-dependent kinases in receptor phosphorylation and desensitization was suggested from studies using agents known to modulate the activity of these enzymes. However, pertussis toxin was found to completely eliminate the interaction of the hm2 receptors with the insect cell G-proteins, but did not perturb the ability of carbachol to induce agonist-dependent phosphorylation of the receptors. These results suggested that G-proteins and/or G-protein-activated signalling were not necessary for the agonist-induced phosphorylation of the receptors. Overall, the data indicated that the human m2 (but not the human m1) mAChR expressed in Sf9 insect cells undergo phosphorylation and desensitization in an agonist-dependent, G-protein-independent fashion by an endogenous insect cell kinase. The results demonstrated that a human G-protein-linked receptor is regulated in insect cells in a manner that is similar to that involving members of the G-protein receptor-kinase family.	NORTHWESTERN UNIV,SCH MED,DEPT PHARMACOL,CHICAGO,IL 60611	Northwestern University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031601] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007140] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 31601] Funding Source: Medline; NINDS NIH HHS [5T32-NS07140-80] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1989, TRENDS NEUROSCI, V12, P148, DOI 10.1016/0166-2236(89)90054-4; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1990, J NEUROCHEM, V54, P1639, DOI 10.1111/j.1471-4159.1990.tb01216.x; HAGA K, 1989, MOL PHARMACOL, V35, P286; HAGA K, 1989, BIOMED RES-TOKYO, V10, P293, DOI 10.2220/biomedres.10.293; HAGA K, 1986, J BIOL CHEM, V261, P133; HAGA K, 1983, J BIOL CHEM, V258, P3575; HAGA K, 1991, FEBS LETT, V268, P443; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HOSEY MM, 1992, FASEB J, V6, P845, DOI 10.1096/fasebj.6.3.1740234; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KUBO T, 1986, FEBS LETT, V209, P367, DOI 10.1016/0014-5793(86)81144-9; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; KWATRA MM, 1986, J BIOL CHEM, V261, P2429; KWATRA MM, 1987, J BIOL CHEM, V262, P16314; KWATRA MM, 1989, MOL PHARMACOL, V35, P553; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LIAO CF, 1989, J BIOL CHEM, V264, P7328; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PARKER EM, 1991, J BIOL CHEM, V266, P519; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; RICHARDSON MR, 1991, MOL PHARMACOL, V40, P908; RICHARDSON RM, 1992, J BIOL CHEM, V267, P10127; RICHARDSON RM, 1990, BIOCHEMISTRY-US, V29, P8555, DOI 10.1021/bi00489a008; SHAPIRO RA, 1989, BIOCHEMISTRY-US, V28, P8946, DOI 10.1021/bi00448a039; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; WONG SKF, 1990, J BIOL CHEM, V265, P6219	37	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22249	22255						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429577				2022-12-25	WOS:A1992JW71900042
J	GUREVICH, VV; BENOVIC, JL				GUREVICH, VV; BENOVIC, JL			CELL-FREE EXPRESSION OF VISUAL ARRESTIN - TRUNCATION MUTAGENESIS IDENTIFIES MULTIPLE DOMAINS INVOLVED IN RHODOPSIN INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DEPENDENT PHOSPHORYLATION; BETA-ADRENERGIC-RECEPTOR; 48-KDA PROTEIN; BOVINE RETINA; ALPHA-SUBUNIT; MESSENGER-RNA; BINDING; INVITRO; KINASE; ACTIVATION	Visual arrestin plays an important role in regulating light responsiveness via its ability to specifically bind to the phosphorylated and light-activated form of rhodopsin. To further characterize rhodopsin/arrestin interactions we have utilized a rabbit reticulocyte lysate translation system to synthesize bovine visual arrestin. The translated arrestin (404 amino acids) was demonstrated to be fully functional in terms of its ability to specifically recognize and bind to phosphorylated light-activated rhodopsin (P-Rh*). Competitive binding studies revealed that the in vitro synthesized arrestin and purified bovine visual arrestin had comparable affinities for P-Rh*. In an effort to assess the functional role of different regions of the arrestin molecule, two truncated arrestin mutants were produced by cutting within the open reading frame of the bovine arrestin cDNA with selective restriction enzymes. In vitro translation of the transcribed truncated mRNAs resulted in the production of arrestins truncated from the carboxyl terminus. The ability of each of the mutant arrestins to bind to dark (Rh), light-activated (Rh*), dark phosphorylated (P-Rh), and light-activated phosphorylated rhodopsin were then compared. Arrestin lacking 39 carboxyl-terminal residues binds specifically not only to P-Rh* but also to Rh* and P-Rh. This suggests that the carboxyl-terminal domain of arrestin plays an important regulatory role in ensuring strict arrestin binding selectivity to P-Rh*. Arrestin that has only the first 191 amino-terminal residues predominately discriminates the phosphorylation state of the rhodopsin; however, it also retains some binding specificity for the activation state. These results suggest that the amino-terminal half of arrestin contains key rhodopsin recognition sites responsible for interaction with both the phosphorylated and light-activated forms of rhodopsin.	THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA	Jefferson University			Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44944] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENOVIC JL, 1986, NATURE, V321, P869, DOI 10.1038/321869a0; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; GUREVICH VV, 1989, BIOL MEMBRANY, V6, P647; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HUPPERTZ B, 1990, J BIOL CHEM, V265, P9470; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; KOBILKA BK, 1990, J BIOL CHEM, V265, P7610; KOZAK M, 1983, MICROBIOL REV, V47, P1; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; OLATE J, 1988, J BIOL CHEM, V263, P10394; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P15334; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P1003, DOI 10.1073/pnas.87.3.1003; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; WACKER WB, 1977, J IMMUNOL, V119, P1949; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1986, FEBS LETT, V207, P292, DOI 10.1016/0014-5793(86)81507-1; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; YAMADA T, 1990, SCIENCE, V248, P483, DOI 10.1126/science.2158671; YAMAKI K, 1987, BIOCHEM BIOPH RES CO, V142, P904, DOI 10.1016/0006-291X(87)91499-9; ZOZULYA SA, 1990, PROTEIN ENG, V3, P453, DOI 10.1093/protein/3.5.453; ZOZULYA SA, 1988, Patent No. 1547313	32	107	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21919	21923						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400502				2022-12-25	WOS:A1992JV01100101
J	BROSCH, G; GEORGIEVA, EI; LOPEZRODAS, G; LINDNER, H; LOIDL, P				BROSCH, G; GEORGIEVA, EI; LOPEZRODAS, G; LINDNER, H; LOIDL, P			SPECIFICITY OF ZEA-MAYS HISTONE DEACETYLASE IS REGULATED BY PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NUCLEAR MATRIX; CELL-CYCLE; PHYSARUM-POLYCEPHALUM; RNA-POLYMERASE; ACETYLATION; CHROMATIN; ASSOCIATION; CHICKEN; CORES	Mono Q ion exchange high performance liquid chromatography (HPLC) reveals that the main histone deacetylase activity (HD1) of germinating Zea mays embryos consists of multiple enzyme forms. Chromatography of HD1 after treatment with alkaline phosphatase yields two distinct histone deacetylase forms (HD1-A, HD1-B). The same is true for chromatography after phosphatase treatment of a total cell extract. One of these enzyme forms (HD1-A) is subject to phosphorylation, which causes a change in the substrate specificity of the enzyme, as shown with HPLC-purified individual core histone species; the substrate specificity for H2A increases more than 2-fold after phosphorylation, whereas the specificity for H3 decreases to about 60%. The total histone deacetylase activity is quantitatively released from isolated nuclei after extraction with moderate ionic strength buffers; no significant residual enzyme activity could be detected in the nuclear matrix.	UNIV INNSBRUCK,SCH MED,DEPT MICROBIOL,A-6020 INNSBRUCK,AUSTRIA; UNIV INNSBRUCK,SCH MED,DEPT MED CHEM & BIOCHEM,A-6020 INNSBRUCK,AUSTRIA; BULGARIAN ACAD SCI,INST GENET,DEPT MOLEC GENET,BU-1113 SOFIA,BULGARIA; UNIV VALENCIA,FAC SCI,DEPT BIOCHEM & MOLEC BIOL,VALENCIA,SPAIN	University of Innsbruck; University of Innsbruck; Bulgarian Academy of Sciences; University of Valencia			Georgieva, Elena/O-1674-2019; LOPEZ-RODAS, GERARDO/I-1349-2015	LOPEZ-RODAS, GERARDO/0000-0001-8367-653X				ALONSO WR, 1986, BIOCHIM BIOPHYS ACTA, V866, P161, DOI 10.1016/0167-4781(86)90113-2; BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; DOENECKE D, 1982, MOL CELL BIOCHEM, V44, P113; FERENZ CR, 1985, NUCLEIC ACIDS RES, V13, P1977, DOI 10.1093/nar/13.6.1977; GEORGIEVA EI, 1991, J BIOL CHEM, V266, P18751; GONZALEZ PJ, 1987, J BIOL CHEM, V262, P11280; HAY CW, 1983, J BIOL CHEM, V258, P3726; HAYES JJ, 1992, P NATL ACAD SCI USA, V89, P1229, DOI 10.1073/pnas.89.4.1229; HELLIGER W, 1988, BIOCHEM J, V255, P23, DOI 10.1042/bj2550023; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; HENDZEL MJ, 1992, BIOCHIM BIOPHYS ACTA, V1130, P307, DOI 10.1016/0167-4781(92)90443-4; LOIDL P, 1987, J BIOL CHEM, V262, P10195; LOIDL P, 1987, NUCLEIC ACIDS RES, V15, P8351, DOI 10.1093/nar/15.20.8351; LOIDL P, 1988, FEBS LETT, V227, P91, DOI 10.1016/0014-5793(88)80874-3; LOPEZRODAS G, 1992, FEBS LETT, V296, P82, DOI 10.1016/0014-5793(92)80408-9; LOPEZRODAS G, 1991, J BIOL CHEM, V266, P18745; MOLD DE, 1987, BIOCHEMISTRY-US, V26, P8257, DOI 10.1021/bi00399a036; SENDRA R, 1988, PLANT MOL BIOL, V11, P857, DOI 10.1007/BF00019525; SENDRA R, 1991, PLANT SCI, V78, P43, DOI 10.1016/0168-9452(91)90160-A; TURNER BM, 1991, J CELL SCI, V99, P13; WAITZ W, 1991, ONCOGENE, V6, P29; WAITZ W, 1988, J CELL SCI, V90, P621	22	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20561	20564						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400375				2022-12-25	WOS:A1992JT97800011
J	DIGATE, RJ; MARIANS, KJ				DIGATE, RJ; MARIANS, KJ			ESCHERICHIA-COLI TOPOISOMERASE-III-CATALYZED CLEAVAGE OF RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DNA TOPOISOMERASES; RAT-LIVER; ENZYME; IDENTIFICATION; RECOMBINATION; BREAKAGE	Relaxation of superhelical DNA by Escherichia coli topoisomerase III (Topo III) was inhibited by the inclusion of tRNA in the reaction mixture. Investigation of the basis of this inhibition revealed that Topo III could bind RNA and establish a cleavage-religation equilibrium. The addition of SDS to these reaction mixtures induced cleavage of the RNA by Topo III. The nucleotide sequences of RNA and DNA cleavage sites were identical, although cleavage site preference differed. Thus, the possibility that Topo III can pass strands of RNA as well as strands of DNA must be considered in accounting for the role of this enzyme in nucleic acid metabolism.	MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34558] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEEN MD, 1981, P NATL ACAD SCI-BIOL, V78, P2883, DOI 10.1073/pnas.78.5.2883; BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; DEAN F, 1982, COLD SPRING HARB SYM, V47, P769; DEAN F, 1984, THESIS U CHICAGO; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; England T E, 1980, Methods Enzymol, V65, P65; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU LF, 1979, J BIOL CHEM, V254, P1082; Maxam A M, 1980, Methods Enzymol, V65, P499; PASTORCIC M, 1982, THESIS U CHICAGO; SCHOFIELD MA, 1992, IN PRESS J BACTERIOL; SRIVENUGOPAL KS, 1984, BIOCHEMISTRY-US, V23, P1899, DOI 10.1021/bi00304a002; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; TAPPER DP, 1981, NUCLEIC ACIDS RES, V9, P6787, DOI 10.1093/nar/9.24.6787; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665	17	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20532	20535						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383203				2022-12-25	WOS:A1992JT97800003
J	PAN, YT; KAMITANI, T; BHUVANESWARAN, C; HALLAQ, Y; WARREN, CD; YEH, ETH; ELBEIN, AD				PAN, YT; KAMITANI, T; BHUVANESWARAN, C; HALLAQ, Y; WARREN, CD; YEH, ETH; ELBEIN, AD			INHIBITION OF GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR FORMATION BY MANNOSAMINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; VARIANT SURFACE GLYCOPROTEIN; T-CELL RECEPTOR; GLYCOSYL-PHOSPHATIDYLINOSITOL; TRYPANOSOMA-BRUCEI; TAP TRANSCRIPTION; LINKAGE MUTANTS; BIOSYNTHESIS; THY-1; ACTIVATION	Many eucaryotic cell surface proteins are anchored to the plasma membrane via a glycosylphosphatidylinositol (GPI), of which the core region is highly conserved from protozoa to mammalian cells. Previous studies (Lisanti, M. P., Field, M. C., Caras, I. W., Menon, A. K., and Rodiguez-Boulan, E. (1991) EMBO J. 10, 1969-1977) showed that mannosamine blocked the expression of a recombinant GPI-anchored protein in Madin-Darby canine kidney cells and converted this protein to an unpolarized secretory product. In the present study, we examined the effect of mannosamine on the formation of the glycan portion of the GPI anchor precursors. This amino sugar inhibited the incorporation of mannose into the glycan portion, and the inhibition was dose-dependent. Mannosamine was shown to be incorporated into the glycan as mannosamine, probably mostly in the second mannose position and thereby to block the further addition of mannose and other anchor components. The products formed in the presence of this drug were characterized by gel filtration and high resolution TLC both before and after deamination with nitrous acid and dephosphorylation by HF. Galactosamine and trehalosamine were inactive in this system, whereas glucosamine also inhibited mannose incorporation into GPI intermediates.	UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT MED,BOSTON,MA 02114	University of Arkansas System; University of Arkansas Medical Sciences; Harvard University; Harvard Medical School; Massachusetts General Hospital				Kamitani, Tetsu/0000-0002-3257-9630	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021800, R01DK040930] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45851] Funding Source: Medline; NIDDK NIH HHS [DK-40930, DK-21800] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Defaye J., 1970, ADV CARBOHYD CHEM BI, V25, P181; DEGESPARI R, 1990, SCIENCE, V250, P988; DOERING TL, 1989, J BIOL CHEM, V264, P11168; DOERING TL, 1990, J BIOL CHEM, V265, P611; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; HOLDER AA, 1981, MOL BIOCHEM PARASIT, V2, P135, DOI 10.1016/0166-6851(81)90095-5; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; KANG MS, 1978, J BIOL CHEM, V253, P8860; LISANTI MP, 1991, EMBO J, V10, P1969, DOI 10.1002/j.1460-2075.1991.tb07726.x; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; PAN YT, 1992, J BIOL CHEM, V267, P8991; PAN YT, 1985, ARCH BIOCHEM BIOPHYS, V242, P447, DOI 10.1016/0003-9861(85)90229-2; PAN YT, 1979, J BACTERIOL, V139, P507, DOI 10.1128/JB.139.2.507-514.1979; PUOTI A, 1991, J BIOL CHEM, V266, P21051; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SCHWARZ RT, 1988, BIOCH SOC T LOND, V17, P746; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; TAKAMI N, 1992, J BIOL CHEM, V267, P1042; URAKAZE M, 1992, J BIOL CHEM, V267, P6459; WILLIAMS AF, 1988, IMMUNOGENETICS, V27, P265, DOI 10.1007/BF00376121; YEH ETH, 1988, CELL, V52, P665, DOI 10.1016/0092-8674(88)90404-7	25	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21250	21255						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400435				2022-12-25	WOS:A1992JT97800114
J	SHIN, K; NAKAMOTO, RK; MAEDA, M; FUTAI, M				SHIN, K; NAKAMOTO, RK; MAEDA, M; FUTAI, M			F0F1-ATPASE GAMMA-SUBUNIT MUTATIONS PERTURB THE COUPLING BETWEEN CATALYSIS AND TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; COLI H+-ATPASE; CARBOXYL-TERMINAL REGION; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; ADENOSINE-TRIPHOSPHATASE; CROSS-LINKING; ALPHA-SUBUNITS; CDNA SEQUENCE; SYNTHASE	We introduced mutations to test the function of the conserved amino-terminal region of the gamma subunit from the Escherichia coli ATP synthase (F0F1-ATPase). Plasmid-borne mutant genes were expressed in an uncG strain which is deficient for the gamma subunit (gammaGln-14 --> end). Most of the changes, which were between gammaIle-19 and gammaLys-33, gammaAsp-83 and gammaCys-87, or at gammaAsp-165, had little effect on growth by oxidative phosphorylation, membrane ATPase activity, or H+ pumping. Notable exceptions were gammaMet-23 --> Arg or Lys mutations. Strains carrying these mutations grew only very slowly by oxidative phosphorylation. Membranes prepared from the strains had substantial levels of ATPase activity, 100% compared with wild type for gammaArg-23 and 65% for gammaLys-23, but formed only 32 and 17%, respectively, of the electrochemical gradient of protons. In contrast, other mutant enzymes with similar ATPase activities (including gammaMet-23 --> Asp or Glu) formed H+ gradients like the wild type. Membranes from the gammaArg-23 and gammaLys-23 mutants were not passively leaky to protons and had functional F0 sectors. These results suggested that substitution by positively charged side chains at position 23 perturbed the energy coupling. The catalytic sites of the mutant enzymes were still regulated by the electrochemical H+ gradient but were inefficiently coupled to H+ translocation in both ATP-dependent H+ pumping and DELTAmu(H+) driven ATP synthesis.	OSAKA UNIV, INST SCI & IND RES, DEPT ORGAN CHEM & BIOCHEM, IBARAKI, OSAKA 567, JAPAN	Osaka University								ARIS JP, 1983, J BIOL CHEM, V258, P4599; BOEKEMA EJ, 1990, BIOCHIM BIOPHYS ACTA, V1020, P49, DOI 10.1016/0005-2728(90)90092-I; BRAGG PD, 1980, EUR J BIOCHEM, V106, P495, DOI 10.1111/j.1432-1033.1980.tb04596.x; BRUSILOW WSA, 1989, J BIOL CHEM, V264, P1528; COZENS AL, 1987, J MOL BIOL, V194, P359, DOI 10.1016/0022-2836(87)90667-X; DUNN SD, 1980, J BIOL CHEM, V255, P113; FALK G, 1985, BIOCHEM J, V228, P391, DOI 10.1042/bj2280391; FILLINGAME RH, 1984, J BACTERIOL, V158, P1078, DOI 10.1128/JB.158.3.1078-1083.1984; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FUTAI M, 1983, MICROBIOL REV, V47, P285, DOI 10.1128/MMBR.47.3.285-312.1983; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; FUTAI M, 1977, BIOCHEM BIOPH RES CO, V103, P604; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; INOHARA N, 1991, J BIOL CHEM, V266, P7333; IWAMOTO A, 1990, J BIOL CHEM, V265, P5043; KANAZAWA H, 1985, ARCH BIOCHEM BIOPHYS, V241, P364, DOI 10.1016/0003-9861(85)90558-2; KANAZAWA H, 1981, BIOCHEM BIOPH RES CO, V103, P604, DOI 10.1016/0006-291X(81)90494-0; KANAZAWA H, 1979, P NATL ACAD SCI USA, V76, P1126, DOI 10.1073/pnas.76.3.1126; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCARN DF, 1988, J BACTERIOL, V170, P3448, DOI 10.1128/jb.170.8.3448-3458.1988; MIKI J, 1986, ARCH BIOCHEM BIOPHYS, V251, P458, DOI 10.1016/0003-9861(86)90352-8; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; MORONEY JV, 1980, J BIOL CHEM, V255, P6670; MORONEY JV, 1979, J BIOL CHEM, V254, P8951; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SLAYMAN CL, 1989, ANN NY ACAD SCI, V574, P233; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4250; TYBULEWICZ VLJ, 1984, J MOL BIOL, V179, P185, DOI 10.1016/0022-2836(84)90465-0; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WEISS MA, 1977, J BIOL CHEM, V252, P8007; YU LM, 1988, J BIOL CHEM, V263, P19342	36	70	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20835	20839						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400398				2022-12-25	WOS:A1992JT97800052
J	CHEN, LY; LEU, WM; WANG, KT; LEE, YHW				CHEN, LY; LEU, WM; WANG, KT; LEE, YHW			COPPER TRANSFER AND ACTIVATION OF THE STREPTOMYCES APOTYROSINASE ARE MEDIATED THROUGH A COMPLEX-FORMATION BETWEEN APOTYROSINASE AND ITS TRANSACTIVATOR MELC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; TYROSINASE GENE; NEUROSPORA-CRASSA; MOLECULAR CHAPERONES; RNA-POLYMERASE; FUNCTIONAL-ANALYSIS; MOUSE TYROSINASE; EXPRESSION; GLAUCESCENS; PROTEINS	The melanin operon (melC) of Streptomyces antibioticus is composed of two genes that encode MelC1 and MelC2 proteins. MelC1 has been suggested as a trans-activator which can facilitate the incorporation of copper into the apotyrosinase (MelC2) (Lee, Y.-H. W., Chen, B.-F., Wu, S.-Y., Leu, W.-M., Lin, J.-J., Chen, C. W., and Lo, S. J. (1988) Gene (Amst.) 65, 71-81). However, the molecular mechanism of the trans-activation or copper-transfer process mediated through MelC1 to MelC2 is not clear yet. In this study, we found apotyrosinase in both the extracellular fraction and cell extract from cells grown in copper-deficient medium. Using gel-filtration and immunoaffinity chromatographies, we demonstrated that apotyrosinase (MelC2) formed a stable complex with MelC1 in the intra- and extracellular fractions. Furthermore, addition of copper ion to the complex generated tyrosinase activity. The MelC1-MelC2 complex was purified to near homogeneity by DE52 and phenyl-agarose chromatographies. In conjunction with fast protein liquid gel filtration chromatography and NH2-terminal sequencing analysis, the results indicated that the stoichiometric ratio of MelC1 and MelC2 in the purified complex was 1:1. Essentially no copper was found in the complex. Addition of copper ion to the purified complex resulted in incorporation of approximately 2 molecules of copper ion and the mature active tyrosinase was gradually released from the complex. Taken together, these results demonstrate that the molecular mechanism of activation of Streptomyces apotyrosinase by its trans-activator MelC1 is initially mediated via a binary complex formation between these two proteins, followed by incorporation of copper ion. This activation mechanism accounts for the essential role of MelC1 in the expression of melanin operon.	NATL YANG MING MED COLL,INST BIOCHEM,TAIPEI 112,TAIWAN; ACAD SINICA,INST BIOCHEM,TAIPEI 115,TAIWAN	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan				Lee Wu, Yan-Hwa/0000-0001-7299-7354				BAUMANN R, 1976, 2ND INT S GEN IND MI, P535; BELTRAMINI M, 1982, FEBS LETT, V142, P219, DOI 10.1016/0014-5793(82)80138-5; BERNAN V, 1985, GENE, V37, P101, DOI 10.1016/0378-1119(85)90262-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chater K. F., 1982, CURR TOP MICROBIOL I, V96, P69; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CRAMERI R, 1982, J GEN MICROBIOL, V128, P371; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FALCHUK KH, 1988, METHOD ENZYMOL, V158, P422, DOI 10.1016/0076-6879(88)58073-4; FUJITA N, 1987, MOL GEN GENET, V210, P5, DOI 10.1007/BF00337751; GATENBY AA, 1990, ANNU REV CELL BIOL, V6, P125; GEISTLICH M, 1989, MOL MICROBIOL, V3, P1061, DOI 10.1111/j.1365-2958.1989.tb00256.x; GREGORY KF, 1961, NATURE, V191, P465, DOI 10.1038/191465a0; GREGORY KF, 1964, J BACTERIOL, V87, P1281, DOI 10.1128/JB.87.6.1281-1286.1964; HELD T, 1990, J GEN MICROBIOL, V136, P2413, DOI 10.1099/00221287-136-12-2413; HINTERMANN G, 1985, MOL GEN GENET, V200, P422, DOI 10.1007/BF00425726; HOPWOOD DA, 1983, J GEN MICROBIOL, V129, P2257; HUBER M, 1988, BIOCHEMISTRY-US, V27, P5610, DOI 10.1021/bi00415a032; HUBER M, 1985, BIOCHEMISTRY-US, V24, P6038, DOI 10.1021/bi00343a003; HUBER M, 1987, NUCLEIC ACIDS RES, V15, P8106, DOI 10.1093/nar/15.19.8106; KATZ E, 1983, J GEN MICROBIOL, V129, P2703; KERTESZ D, 1972, BIOCHEM BIOPH RES CO, V49, P1208, DOI 10.1016/0006-291X(72)90597-9; KIESER T, 1981, GENETICS ACTINOMYCET, P59; KUPPER U, 1989, J BIOL CHEM, V264, P17250; Kuster E., 1976, ACTINOMYCETES BOUNDA, P43; KWON BS, 1988, BIOCHEM BIOPH RES CO, V153, P1301, DOI 10.1016/S0006-291X(88)81370-6; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YHW, 1988, GENE, V65, P71, DOI 10.1016/0378-1119(88)90418-0; LERCH K, 1982, J BIOL CHEM, V257, P6414; LERCH K, 1978, P NATL ACAD SCI USA, V75, P3635, DOI 10.1073/pnas.75.8.3635; LERCH K, 1972, EUR J BIOCHEM, V31, P427, DOI 10.1111/j.1432-1033.1972.tb02549.x; LERCH K, 1981, MET IONS BIOL SYST, V13, P143; LERCH K, 1980, NATURE, V284, P368, DOI 10.1038/284368a0; LEU WM, 1989, GENE, V84, P267; LEU WM, 1992, J BIOL CHEM, V267, P20108; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; PFIFFNER E, 1981, BIOCHEMISTRY-US, V20, P6029, DOI 10.1021/bi00524a017; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SHIBAHARA S, 1986, NUCLEIC ACIDS RES, V14, P2413, DOI 10.1093/nar/14.6.2413; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSENG HC, 1990, GENE, V86, P123, DOI 10.1016/0378-1119(90)90124-A; WANG SS, 1987, INT J PEPT PROT RES, V30, P662; YOSHIMOTO T, 1985, J BIOCHEM, V97, P1747, DOI 10.1093/oxfordjournals.jbchem.a135233	49	70	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20100	20107						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400328				2022-12-25	WOS:A1992JR85800057
J	MARTIN, PR; HAUSINGER, RP				MARTIN, PR; HAUSINGER, RP			SITE-DIRECTED MUTAGENESIS OF THE ACTIVE-SITE CYSTEINE IN KLEBSIELLA-AEROGENES UREASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JACK BEAN UREASE; PURIFICATION; REACTIVITY; PROTEINS; SEQUENCE; THIOL	Cysteine 319 in the large subunit of Klebsiella aerogenes urease was identified as an essential catalytic residue based on chemical modification studies (Todd, M. J., and Hausinger, R. P. (1991) J. Biol. Chem. 266, 24327-24331). Through site-directed mutagenesis, this cysteine has been changed independently to alanine, serine, aspartate, and tyrosine. None of these mutations (C319A, C319S, C319D, and C319Y, respectively) affected the size or level of synthesis of the urease subunits as monitored by polyacrylamide gel electrophoresis. The wild type enzyme and each of the mutant proteins was purified and their properties were compared. The C319Y protein possessed no detectable activity, while activity was reduced in C319A, C319S, and C319D to 48, 4.5, and 0.03% of wild type levels under normal assay conditions. All of the active mutants had a small increase in K(m) when compared to the wild type value. The active mutants displayed a greatly reduced sensitivity to inactivation by iodoacetamide in comparison to the wild type enzyme, confirming our previous assignment of the essential cysteine to this residue based on active site peptide mapping. In contrast to the wild type enzyme, inactivation of the mutant proteins was not affected by the presence of the competitive inhibitor phosphate, suggesting that the remaining slow rate of iodoacetamide inactivation is due to modification away from the active site. The pH dependence of urease activity was substantially altered in the active mutants with C319S and C319D showing a pH optimum near 5.2, and C319A near 6.7, compared to the pH 7.75 optimum of wild type urease. These data are consistent with Cys-319 facilitating catalysis at neutral and basic pH values by participating as a general acid.	MICHIGAN STATE UNIV,DEPT MICROBIOL,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University; Michigan State University				Hausinger, Robert/0000-0002-3643-2054				ANDREWS A T D B, 1970, Archives of Biochemistry and Biophysics, V141, P538, DOI 10.1016/0003-9861(70)90172-4; DIXON NE, 1975, J AM CHEM SOC, V97, P4131, DOI 10.1021/ja00847a045; DIXON NE, 1980, CAN J BIOCHEM CELL B, V58, P1335, DOI 10.1139/o80-181; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MH, 1992, J BACTERIOL, V174, P4324, DOI 10.1128/JB.174.13.4324-4330.1992; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOBLEY HLT, 1989, MICROBIOL REV, V53, P85, DOI 10.1128/MMBR.53.1.85-108.1989; MULROONEY SB, 1989, J GEN MICROBIOL, V135, P1769; MULROONEY SB, 1990, J BACTERIOL, V172, P5837, DOI 10.1128/jb.172.10.5837-5843.1990; NAKANO H, 1984, AGR BIOL CHEM TOKYO, V48, P1495, DOI 10.1080/00021369.1984.10866339; NORRIS R, 1976, BIOCHEM J, V159, P245, DOI 10.1042/bj1590245; SAADA AB, 1988, ZBL BAKT-INT J MED M, V269, P160; SANGER F, 1977, P NATL ACAD SCI USA, V80, P3963; TAKISHIMA K, 1988, EUR J BIOCHEM, V175, P151, DOI 10.1111/j.1432-1033.1988.tb14177.x; TODD MJ, 1989, J BIOL CHEM, V264, P15835; TODD MJ, 1987, J BIOL CHEM, V262, P5963; TODD MJ, 1991, J BIOL CHEM, V266, P10260; TODD MJ, 1991, J BIOL CHEM, V266, P24327; WEATHERBURN MW, 1967, ANAL CHEM, V39, P871; WINKLER RG, 1988, TRENDS BIOCHEM SCI, V13, P97, DOI 10.1016/0968-0004(88)90049-7; ZERNER B, 1991, BIOORG CHEM, V19, P116, DOI 10.1016/0045-2068(91)90048-T	22	50	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20024	20027						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400317				2022-12-25	WOS:A1992JR85800045
J	SCHMALZING, G; KRONER, S; SCHACHNER, M; GLOOR, S				SCHMALZING, G; KRONER, S; SCHACHNER, M; GLOOR, S			THE ADHESION MOLECULE ON GLIA (AMOG/BETA-2) AND ALPHA-1 SUBUNITS ASSEMBLE TO FUNCTIONAL SODIUM PUMPS IN XENOPUS-OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; NA,K-ATPASE BETA-SUBUNIT; CENTRAL-NERVOUS-SYSTEM; INTRACELLULAR-TRANSPORT; MESSENGER-RNAS; LAEVIS OOCYTES; EXPRESSION; CELLS; ISOFORMS; NEURONS	The adhesion molecule on glia, AMOG, an integral cell surface glycoprotein highly expressed by cerebellar astrocytes and involved in neuron to astrocyte adhesion and granule neuron migration (Antonicek, H., Persohn, E., and Schachner, M. (1987) J. Cell Biol. 104, 1587-1595) has been identified as a beta2 subunit isoform of the mouse sodium pump (Gloor, S., Antonicek, H., Sweadner, K. J., Pagliusi, S., Frank, R., Moos, M., and Schachner, M. (1990) J. Cell Biol. 110, 165-174). Here we demonstrate that AMOG/beta2 expressed by cRNA injection in Xenopus oocytes is capable of combining with endogenous Xenopus alpha1 subunits or coexpressed Torpedo alpha1 subunits to yield a functional alpha1/AMOG sodium pump isozyme. Determinations of the number of ouabain binding sites and ouabain-sensitive Rb-86+ uptake suggest that the alpha1/AMOG isozyme has slightly lower maximum transport rate and apparent affinity for external K+ than the alpha1/beta1 isozyme. Immunoprecipitation of alpha1/AMOG complexes from digitonin extracts of [S-35]methionine-labeled oocytes with a monoclonal anti-AMOG antibody provides direct evidence for a stable association between AMOG and the alpha1 subunits of Xenopus and Torpedo.	SWISS FED INST TECHNOL, DEPT NEUROBIOL, CH-8093 ZURICH, SWITZERLAND	ETH Zurich	SCHMALZING, G (corresponding author), MAX PLANCK INST BIOPHYS, HEINRICH HOFFMANN STR 7, W-6000 FRANKFURT 71, GERMANY.							ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; ANTONICEK H, 1987, J CELL BIOL, V104, P1587, DOI 10.1083/jcb.104.6.1587; ANTONICEK H, 1988, J NEUROSCI, V8, P2961; BROTHERUS JR, 1983, BIOCHIM BIOPHYS ACTA, V731, P290, DOI 10.1016/0005-2736(83)90021-4; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DRUMMOND DR, 1985, NUCLEIC ACIDS RES, V13, P7375, DOI 10.1093/nar/13.20.7375; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; GLOOR S, 1989, NUCLEIC ACIDS RES, V17, P10117; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; GOOD PJ, 1990, P NATL ACAD SCI USA, V87, P9088, DOI 10.1073/pnas.87.23.9088; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; HORISBERGER JD, 1991, P NATL ACAD SCI USA, V88, P8397, DOI 10.1073/pnas.88.19.8397; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOVITZ RM, 1989, EMBO J, V8, P193, DOI 10.1002/j.1460-2075.1989.tb03364.x; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MCGRAIL KM, 1991, J NEUROSCI, V11, P381, DOI 10.1523/jneurosci.11-02-00381.1991; NOGUCHI S, 1990, J BIOL CHEM, V265, P15991; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; OETTGEN HC, 1986, NATURE, V320, P272, DOI 10.1038/320272a0; RAKOWSKI RF, 1991, J MEMBRANE BIOL, V121, P177, DOI 10.1007/BF01870531; SCHMALZING G, 1991, BIOCHEM J, V279, P329, DOI 10.1042/bj2790329; SCHMALZING G, 1989, BIOCHEM J, V260, P395, DOI 10.1042/bj2600395; SHYJAN AW, 1990, J BIOL CHEM, V265, P5166; SWEADNER KJ, 1990, BIOCHIM BIOPHYS ACTA, V1029, P13, DOI 10.1016/0005-2736(90)90431-M; TAKEYASU K, 1989, CURR TOP MEMBR TRANS, V34, P143; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; TAKEYASU K, 1987, J BIOL CHEM, V262, P10733; TAMKUN MM, 1986, J BIOL CHEM, V261, P1009; VASILETS LA, 1992, J MEMBRANE BIOL, V125, P119; WATTS AG, 1991, P NATL ACAD SCI USA, V88, P7425, DOI 10.1073/pnas.88.16.7425; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42	35	85	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20212	20216						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1383200				2022-12-25	WOS:A1992JR85800074
J	ANDERSEN, JP; VILSEN, B				ANDERSEN, JP; VILSEN, B			FUNCTIONAL CONSEQUENCES OF ALTERATIONS TO GLU(309), GLU(771), AND ASP(800) IN THE CA2+-ATPASE OF SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; CALCIUM-BINDING; TRANSMEMBRANE DOMAIN; ATPASE; CA-2+-ATPASE; CA-2+; PHOSPHORYLATION; MECHANISM; TRANSPORT; SITES	Site-specific mutagenesis was used to replace Glu309, Glu771, and Asp800 in the Ca2+-ATPase of rabbit fast twitch muscle sarcoplasmic reticulum with their corresponding amides. These residues are predicted to lie in the transmembrane domain and have been suggested as oxygen ligands for Ca2+ binding at high affinity sites (Clarke, D. M., Loo, T. W., Inesi, G., and MacLennan, D. H. (1989) Nature 339, 476-478). The Glu309 --> Gln and Asp800 --> Asn mutants were unable to form a phosphoenzyme from ATP at the Ca2+ concentrations examined (up to 12.5 mM), whereas the Glu771 --> Gln mutant phosphorylated from ATP at 2.5 mM Ca2+. In all three mutants, Ca2+ at concentrations well below 12.5 mM prevented or inhibited phosphorylation with P(i), suggesting that at least one calcium-binding site was functioning in each mutant. In the mutants Glu309 --> Gln and Glu771 --> Gln, the ADP-insensitive phosphoenzyme intermediate was unusually stable, as indicated by a very low rate of dephosphorylation observed in kinetic experiments and by an increased apparent affinity for P(i) determined in equilibrium phosphorylation experiments. These data indicate a central role of Glu309 and Glu771 in the energy-transducing conformational changes and/or in the activation of phosphoenzyme hydrolysis.			ANDERSEN, JP (corresponding author), AARHUS UNIV,DANISH BIOMEMBRANE RES CTR,INST PHYSIOL,DK-8000 AARHUS,DENMARK.			Andersen, Jens Peter/0000-0003-0654-4300; Vilsen, Bente/0000-0002-4727-9382				Andersen JP, 1990, CURR OPIN CELL BIOL, V2, P722, DOI 10.1016/0955-0674(90)90116-V; ANDERSEN JP, 1989, BIOCHIM BIOPHYS ACTA, V988, P47, DOI 10.1016/0304-4157(89)90003-8; ANDERSEN JP, 1992, J BIOL CHEM, V267, P2767; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHIESI M, 1980, BIOCHEMISTRY-US, V19, P2912, DOI 10.1021/bi00554a015; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1991, J BIOL CHEM, V266, P5736; DEMEIS L, 1981, SARCOPLASMIC RETICUL, V2; FUJIMORI T, 1992, Biophysical Journal, V61, pA134; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GREEN NM, 1989, BIOCHEM SOC T, V17, P972, DOI 10.1042/bst0170972; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1983, BIOPHYS J, V44, P271, DOI 10.1016/S0006-3495(83)84299-4; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; INESI G, 1980, J BIOL CHEM, V255, P3025; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEVY D, 1990, J BIOL CHEM, V265, P19524; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MADEIRA VMC, 1978, ARCH BIOCHEM BIOPHYS, V185, P316, DOI 10.1016/0003-9861(78)90173-X; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1451; TANFORD C, 1987, P NATL ACAD SCI USA, V84, P7094, DOI 10.1073/pnas.84.20.7094; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WATANABE T, 1981, BIOCHEMISTRY-US, V20, P6617, DOI 10.1021/bi00526a015	40	77	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19383	19387						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1388169				2022-12-25	WOS:A1992JP59300057
J	CHALOVICH, JM; BRYAN, J; BENSON, CE; VELAZ, L				CHALOVICH, JM; BRYAN, J; BENSON, CE; VELAZ, L			LOCALIZATION AND CHARACTERIZATION OF A 7.3-KDA REGION OF CALDESMON WHICH REVERSIBLY INHIBITS ACTOMYOSIN ATPASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALDESMON; CHICKEN GIZZARD CALDESMON; CALMODULIN-BINDING PROTEIN; RABBIT SKELETAL-MUSCLE; F-ACTIN; CROSS-LINKING; MYOSIN SUBFRAGMENT-1; HEAVY-MEROMYOSIN; NH2-TERMINAL SEGMENT; THIN-FILAMENTS	Cleavage of caldesmon with chymotrypsin yields a series of fragments which bind both calmodulin and actin and inhibit the binding of myosin subfragments to actin and the subsequent stimulation of ATPase activity. Several of these fragments have been purified by cation exchange chromatography and their amino-terminal sequences determined. The smallest fragment has a molecular mass of about 7.3 kDa and extends from Leu597 to Phe665. This polypeptide inhibits the actin-activated ATPase of myosin S-1; this inhibition is augmented by smooth muscle tropomyosin and relieved by Ca2+-calmodulin. The binding of the 7.3-kDa fragment to actin is competitive with the binding of S-1 to actin. Thus, this polypeptide has several of the important features characteristic of intact caldesmon. However, although an intact caldesmon molecule covers between six and nine actin monomers, the 7.3-kDa fragment binds to actin in a 1:1 complex. Comparison of this fragment with others suggests that a small region of caldesmon is responsible for at least part of the interaction with both calmodulin and actin.	BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Baylor College of Medicine	CHALOVICH, JM (corresponding author), E CAROLINA UNIV, SCH MED, DEPT BIOCHEM, GREENVILLE, NC 27858 USA.			Chalovich, Joseph/0000-0002-1243-4055	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035216] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40540-01A1, AR35216, R01 AR035216] Funding Source: Medline; NIGMS NIH HHS [GM26091] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS S, 1990, J BIOL CHEM, V265, P19652; BALL EH, 1988, BIOCHEMISTRY-US, V27, P6093, DOI 10.1021/bi00416a039; BARTEGI A, 1990, J BIOL CHEM, V265, P2231; BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BERTRAND R, 1989, EUR J BIOCHEM, V181, P747, DOI 10.1111/j.1432-1033.1989.tb14787.x; BRENNER B, 1991, P NATL ACAD SCI USA, V88, P5739, DOI 10.1073/pnas.88.13.5739; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; BRYAN J, 1989, J BIOL CHEM, V264, P13873; BRYAN J, 1989, J MUSCLE RES CELL M, V10, P95, DOI 10.1007/BF01739964; BRYAN J, 1991, J MUSCLE RES CELL M, V12, P372, DOI 10.1007/BF01738592; CHALOVICH JM, 1987, J BIOL CHEM, V262, P5711; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; CLARK T, 1986, J BIOL CHEM, V261, P8028; CROSBIE R, 1991, J BIOL CHEM, V266, P20001; DABROWSKA R, 1985, BIOCHIM BIOPHYS ACTA, V842, P70, DOI 10.1016/0304-4165(85)90295-8; DASGUPTA G, 1989, J MOL BIOL, V207, P833, DOI 10.1016/0022-2836(89)90249-0; EISENBERG E, 1972, COLD SPRING HARB SYM, V37, P145; FUJII T, 1987, J BIOL CHEM, V262, P2757; GRACEFFA P, 1991, J BIOL CHEM, V266, P20305; GRACEFFA P, 1987, FEBS LETT, V218, P139, DOI 10.1016/0014-5793(87)81034-7; HAYASHI K, 1991, J BIOL CHEM, V266, P355; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HEMRIC ME, 1990, J BIOL CHEM, V265, P19672; HEMRIC ME, 1991, BIOPHYS J, V59, P57; HORIUCHI KY, 1989, BIOCHEMISTRY-US, V28, P9111, DOI 10.1021/bi00449a023; HORIUCHI KY, 1986, BIOCHEM BIOPH RES CO, V136, P962, DOI 10.1016/0006-291X(86)90426-2; IKEBE M, 1988, J BIOL CHEM, V263, P3055; KIELLEY WW, 1960, BIOCHIM BIOPHYS ACTA, V41, P401; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASH JA, 1986, J BIOL CHEM, V261, P6155; LESZYK J, 1989, BIOCHEM BIOPH RES CO, V160, P564; LEVINE BA, 1990, EUR J BIOCHEM, V193, P687, DOI 10.1111/j.1432-1033.1990.tb19388.x; MABUCHI K, 1991, J MUSCLE RES CELL M, V12, P145, DOI 10.1007/BF01774033; MAKUCH R, 1992, FEBS LETT, V297, P237, DOI 10.1016/0014-5793(92)80546-S; MEJEAN C, 1986, BIOSCIENCE REP, V6, P493, DOI 10.1007/BF01116141; MORNET D, 1988, BIOCHEM BIOPH RES CO, V155, P808, DOI 10.1016/S0006-291X(88)80567-9; MORNET D, 1988, BIOCHEM BIOPH RES CO, V154, P564, DOI 10.1016/0006-291X(88)90177-5; NGAI PK, 1987, BIOCHEM J, V244, P417, DOI 10.1042/bj2440417; NGAI PK, 1985, BIOCHEM J, V230, P695, DOI 10.1042/bj2300695; OWADA MK, 1984, P NATL ACAD SCI-BIOL, V81, P3133, DOI 10.1073/pnas.81.10.3133; RISEMAN VM, 1989, J BIOL CHEM, V264, P2869; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SMITH CWJ, 1985, FEBS LETT, V184, P115, DOI 10.1016/0014-5793(85)80665-7; SOBUE K, 1985, P NATL ACAD SCI USA, V82, P5025, DOI 10.1073/pnas.82.15.5025; SOBUE K, 1982, BIOMED RES-TOKYO, V3, P188, DOI 10.2220/biomedres.3.188; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SOBUE K, 1985, BIOCHEM BIOPH RES CO, V132, P645, DOI 10.1016/0006-291X(85)91181-7; SOBUE K, 1990, ADV EXP MED BIOL, V255, P325; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUTHERLAND C, 1989, J BIOL CHEM, V264, P578; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; TAKAGI T, 1989, J BIOCHEM-TOKYO, V106, P778, DOI 10.1093/oxfordjournals.jbchem.a122930; VELAZ L, 1990, J BIOL CHEM, V265, P2929; VELAZ L, 1989, J BIOL CHEM, V264, P9602; WANG CLA, 1991, J BIOL CHEM, V266, P9166; WANG CLA, 1991, J BIOL CHEM, V266, P13958; WANG CLA, 1989, BIOCHEM BIOPH RES CO, V162, P746, DOI 10.1016/0006-291X(89)92373-5; WANG CLA, 1988, BIOCHEM BIOPH RES CO, V156, P1033, DOI 10.1016/S0006-291X(88)80948-3; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; YAMAZAKI K, 1987, J BIOCHEM-TOKYO, V101, P1; YAZAWA M, 1987, J BIOCHEM-TOKYO, V102, P1065, DOI 10.1093/oxfordjournals.jbchem.a122144; YAZAWA M, 1980, J BIOCHEM, V87, P1313, DOI 10.1093/oxfordjournals.jbchem.a132869; ZHAN Q, 1991, J BIOL CHEM, V266, P21810	63	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16644	16650						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1386604				2022-12-25	WOS:A1992JJ45800100
J	JONES, PG; MOORE, GJ; WAISMAN, DM				JONES, PG; MOORE, GJ; WAISMAN, DM			A NONAPEPTIDE TO THE PUTATIVE F-ACTIN BINDING-SITE OF ANNEXIN-II TETRAMER INHIBITS ITS CALCIUM-DEPENDENT ACTIVATION OF ACTIN FILAMENT BUNDLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-DEPENDENT PHOSPHOLIPID-BINDING; HEAVY-CHAIN; CYTOSKELETAL PROTEIN; BRUSH-BORDER; SYNAPSIN-I; PHOSPHORYLATION; LIPOCORTIN; MYOSIN; CALPACTIN; PURIFICATION	A synthetic nonapeptide, Val-Leu-Ile-Arg-Ile-Met-Val-Ser-Arg, corresponding to residues 286-294 of annexin-II tetramer (A-IIt), was shown to completely inhibit the Ca2+-dependent bundling of F-actin by this protein. The inhibitory effect of the nonapeptide required preincubation with F-actin and was reversed by the addition of excess A-IIt. Kinetic analysis suggested that the nonapeptide reduced the K(0.5) but not the V(max) of F-actin bundling. In contrast, addition of excess nonapeptide to A-IIt-bundled F-actin did not reverse F-actin bundle formation. Although the nonapeptide produced a dose-dependent inhibition of A-IIt-dependent F-actin bundling, the binding of A-IIt to F-actin was not affected. These results identify a domain of A-IIt that is involved in the bundling activity of the protein and suggest that this domain binds transiently with F-actin, resulting in activation of the bundling activity of A-IIt.	UNIV CALGARY,DEPT MED BIOCHEM,CALGARY T2N 4N1,ALBERTA,CANADA	University of Calgary				Waisman, David/0000-0002-5097-9662				BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BENNETT JP, 1984, BIOCHEMISTRY-US, V23, P5081, DOI 10.1021/bi00316a039; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETSCHER A, 1981, P NATL ACAD SCI-BIOL, V78, P6849, DOI 10.1073/pnas.78.11.6849; BRETSCHER A, 1980, CELL, V20, P839, DOI 10.1016/0092-8674(80)90330-X; BROTSCHI EA, 1978, J BIOL CHEM, V253, P8988; BRYAN J, 1978, J MOL BIOL, V125, P207, DOI 10.1016/0022-2836(78)90345-5; BURGESS DR, 1987, J CELL BIOL, V104, P29, DOI 10.1083/jcb.104.1.29; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; ETO M, 1990, J BIOCHEM-TOKYO, V108, P499, DOI 10.1093/oxfordjournals.jbchem.a123228; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FECHHEIMER M, 1987, J CELL BIOL, V104, P1539, DOI 10.1083/jcb.104.6.1539; FENNER C, 1975, ANAL BIOCHEM, V63, P595, DOI 10.1016/0003-2697(75)90386-3; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GERKE V, 1985, J BIOL CHEM, V260, P1688; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; GLENNEY JR, 1981, J BIOL CHEM, V256, P9283; GLENNEY JR, 1985, J CELL BIOL, V100, P754, DOI 10.1083/jcb.100.3.754; HARTWIG JH, 1981, J MOL BIOL, V145, P563, DOI 10.1016/0022-2836(81)90545-3; HUSAINCHISHTI A, 1988, NATURE, V334, P718, DOI 10.1038/334718a0; IKEBUCHI NW, 1990, J BIOL CHEM, V265, P3392; KHANNA NC, 1987, CELL CALCIUM, V8, P217, DOI 10.1016/0143-4160(87)90020-0; KHANNA NC, 1988, NEW COMPREHENSIVE BI, P63; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KRISTENSEN T, 1986, BIOCHEMISTRY-US, V25, P4497, DOI 10.1021/bi00364a007; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MISCHE SM, 1987, J CELL BIOL, V105, P2837, DOI 10.1083/jcb.105.6.2837; MORNET D, 1979, BIOCHEM BIOPH RES CO, V89, P925, DOI 10.1016/0006-291X(79)91867-9; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PETRUCCI TC, 1987, J CELL BIOL, V105, P1355, DOI 10.1083/jcb.105.3.1355; POLLARD TD, 1982, METHOD ENZYMOL, V85, P211; SCHLAEPFER DD, 1987, J BIOL CHEM, V262, P6931; SMITH VL, 1990, STIMULUS RESPONSE, P8; SUTOH K, 1983, BIOCHEMISTRY-US, V22, P1579, DOI 10.1021/bi00276a009; SUZUKI R, 1987, J BIOL CHEM, V262, P11410; TELLAM R, 1982, BIOCHEMISTRY-US, V21, P3207, DOI 10.1021/bi00256a027; VIANNA AL, 1975, BIOCHIM BIOPHYS ACTA, V410, P389, DOI 10.1016/0005-2744(75)90241-7; WEGNER A, 1976, J MOL BIOL, V108, P139, DOI 10.1016/S0022-2836(76)80100-3; WILKINS JA, 1986, J CELL BIOL, V102, P1085, DOI 10.1083/jcb.102.3.1085; YAMAMOTO K, 1979, J BIOCHEM-TOKYO, V86, P1863, DOI 10.1093/oxfordjournals.jbchem.a132709	41	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13993	13997						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1385810				2022-12-25	WOS:A1992JD32500035
J	KORNBERG, L; EARP, HS; PARSONS, JT; SCHALLER, M; JULIANO, RL				KORNBERG, L; EARP, HS; PARSONS, JT; SCHALLER, M; JULIANO, RL			CELL-ADHESION OR INTEGRIN CLUSTERING INCREASES PHOSPHORYLATION OF A FOCAL ADHESION-ASSOCIATED TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EXTRACELLULAR-MATRIX COMPONENTS; GLYCOPROTEIN-IIB-IIIA; SIGNAL TRANSDUCTION; GENE-EXPRESSION; FIBRONECTIN; PROTEINS; VLA-5	We have recently shown that changes in tyrosine phosphorylation of a 130-kDa protein(s) (pp130) may be involved in integrin signaling (Kornberg, L., Earp, H. S., Turner, C., Prokop, and Juliano, R. L. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 8392-8396). One component of the pp130 protein complex reacts with an antibody generated against p125fak, which is a focal contact-associated tyrosine kinase (Schaller, M.D., Borgman, C. A., Cobb, B. S., Vines, R. R., Reynolds, A. B., and Parsons, J. T. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5192-5196). Both antibody-mediated integrin clustering and adhesion of KB cells to fibronectin leads to increased tyrosine phosphorylation of p125fak. The phosphorylation of p125fak is coincident with adhesion of cells to fibronectin and is maximal prior to cell spreading. Tyrosine phosphorylation of p125fak is induced when KB cells are allowed to adhere to fibronectin, collagen type IV, or laminin, but is not induced on polylysine. When KB cells are subjected to indirect immunofluorescence microscopy, p125fak co-localizes with talin in focal contacts. These data provide additional evidence that tyrosine kinases are involved in integrin signaling.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV VIRGINIA,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908	University of North Carolina; University of North Carolina Chapel Hill; University of Virginia	KORNBERG, L (corresponding author), UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026165] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26165] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; BENZEEV A, 1988, P NATL ACAD SCI USA, V85, P2161, DOI 10.1073/pnas.85.7.2161; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; EIERMAN DF, 1989, J IMMUNOL, V142, P1970; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HASKILL S, 1988, J IMMUNOL, V140, P1690; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INGBER DE, 1990, J CELL BIOL, V110, P1803, DOI 10.1083/jcb.110.5.1803; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; MATSUYAMA T, 1989, J EXP MED, V170, P1133, DOI 10.1084/jem.170.4.1133; MCCLAY DR, 1987, ANNU REV CELL BIOL, V3, P319, DOI 10.1146/annurev.cellbio.3.1.319; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHREINER C, 1991, CANCER RES, V51, P1738; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SCHWARZ MA, 1984, EXP CELL RES, V152, P302, DOI 10.1016/0014-4827(84)90632-3; SHIMIZU Y, 1990, J IMMUNOL, V145, P59; STREULI CH, 1990, J CELL BIOL, V110, P1405; TURNER CE, 1989, J BIOL CHEM, V264, P11938; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877	31	707	715	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23439	23442						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429685				2022-12-25	WOS:A1992JZ23900002
J	ROY, S; YU, S; BANERJEE, D; OVERTON, O; MUKHOPADHYAY, G; ODDOUX, C; GRIENINGER, G; REDMAN, C				ROY, S; YU, S; BANERJEE, D; OVERTON, O; MUKHOPADHYAY, G; ODDOUX, C; GRIENINGER, G; REDMAN, C			ASSEMBLY AND SECRETION OF FIBRINOGEN - DEGRADATION OF INDIVIDUAL CHAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTARY DEOXYRIBONUCLEIC-ACID; ASIALOGLYCOPROTEIN RECEPTOR SUBUNITS; NEWLY SYNTHESIZED PROTEINS; CELL ANTIGEN RECEPTOR; PRE-GOLGI DEGRADATION; CULTURED LIVER-CELLS; HEP G2 CELLS; BINDING-PROTEIN; ENDOPLASMIC-RETICULUM; B-BETA	Hep G2 cells produce surplus Aalpha and gamma fibrinogen chains. These excess chains, which are not secreted, exist primarily as free gamma chains and as an Aalpha-gamma complex. We have determined the intracellular location and the degradative fate of these polypeptides by treatment with endoglycosidase-H and by inhibiting lysosomal enzyme activity, using NH4Cl, chloroquine, and leupeptin. Free gamma chain and the gamma component of Aalpha-gamma are both cleaved by endoglycosidase-H, indicating that the gamma chains accumulate in a pre-Golgi compartment. Lysosomal enzyme inhibitors did not affect the disappearance of free gamma chains but inhibited Aalpha-gamma by 50%, suggesting that Aalpha-gamma is degraded in lysosomes. The degradative fate of individual chains was determined in transfected COS cells which express but do not secrete single chains. Leupeptin did not affect Bbeta chain degradation, had very little affect on gamma chain, but markedly inhibited Aalpha chain degradation. Antibody to immunoglobulin heavy chain-binding protein (GRP 78) co-immunoprecipitated Bbeta but not Aalpha or gamma chains. Preferential binding of heavy chain-binding protein to Bbeta was also noted in Hep G2 cells and in chicken hepatocytes. Taken together these studies indicate that Bbeta and gamma chains are degraded in the endoplasmic reticulum, but only Bbeta is bound to BiP. By contrast Aalpha chains and the Aalpha-gamma complex undergo lysosomal degradation.	NEW YORK BLOOD CTR,LINDSLEY F KIMBALL RES INST,NEW YORK,NY 10021	New York Blood Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037457] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37457] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALVING BM, 1982, ARCH BIOCHEM BIOPHYS, V217, P1, DOI 10.1016/0003-9861(82)90472-6; AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; AMRANI DL, 1983, BIOCHIM BIOPHYS ACTA, V743, P394, DOI 10.1016/0167-4838(83)90398-9; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLIKSTAD I, 1983, CELL, V32, P1081, DOI 10.1016/0092-8674(83)90292-1; BLOMBACK B, 1979, FIBRINOGEN FIBRIN FO, P223; BLUNT P, 1991, J CELL BIOL, V113, P1125; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; Chung D W, 1980, Ann N Y Acad Sci, V343, P210, DOI 10.1111/j.1749-6632.1980.tb47253.x; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3244, DOI 10.1021/bi00282a032; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3250, DOI 10.1021/bi00282a033; DANISHEFSKY K, 1990, BIOCHIM BIOPHYS ACTA, V1048, P202, DOI 10.1016/0167-4781(90)90057-9; DESHAIES RJ, 1988, TRENDS BIOCHEM SCI, V13, P384, DOI 10.1016/0968-0004(88)90180-6; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GRIENINGER G, 1984, J BIOL CHEM, V259, P4973; GRIENINGER G, 1984, BIOCHEMISTRY-US, V23, P5888, DOI 10.1021/bi00319a031; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HARTWIG R, 1991, J BIOL CHEM, V266, P6578; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HIROSE S, 1988, BIOCHEM J, V251, P373, DOI 10.1042/bj2510373; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KANT JA, 1983, P NATL ACAD SCI-BIOL, V80, P3953, DOI 10.1073/pnas.80.13.3953; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KUDRYK B, 1982, EUR J BIOCHEM, V125, P673, DOI 10.1111/j.1432-1033.1982.tb06735.x; KUDRYK B, 1982, BIOCHIM BIOPHYS ACTA, V703, P77, DOI 10.1016/0167-4838(82)90013-9; LEHNERT ME, 1988, J CELL BIOL, V107, P413, DOI 10.1083/jcb.107.2.413; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NICKERSON JM, 1981, BIOCHEMISTRY-US, V20, P2818, DOI 10.1021/bi00513a017; PARKES JL, 1985, J BIOL CHEM, V260, P8090; PELHAM H, 1988, NATURE, V332, P776, DOI 10.1038/332776a0; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PFEFFER SR, 1986, J CELL BIOL, V103, P103, DOI 10.1083/jcb.103.1.103; PLANT PW, 1986, J BIOL CHEM, V261, P2331; RIXON MW, 1983, BIOCHEMISTRY-US, V22, P3237, DOI 10.1021/bi00282a031; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROY SN, 1991, J BIOL CHEM, V266, P4758; ROY SN, 1990, J BIOL CHEM, V265, P6389; SASSA S, 1977, J BIOL CHEM, V252, P2428; STROUS GJ, 1985, J CELL BIOL, V101, P531, DOI 10.1083/jcb.101.2.531; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; YU S, 1980, BIOCHEM BIOPH RES CO, V96, P1032, DOI 10.1016/0006-291X(80)90056-X; YU S, 1984, J BIOL CHEM, V259, P574; YU S, 1987, THROMB RES, V46, P281, DOI 10.1016/0049-3848(87)90290-8; YU S, 1983, J BIOL CHEM, V258, P3407; YU S, 1986, SCHEME INTRACELLULAR, P665	55	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23151	23158						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1429662				2022-12-25	WOS:A1992JY16300069
J	GARCIARUIZ, C; FERNANDEZCHECA, JC; KAPLOWITZ, N				GARCIARUIZ, C; FERNANDEZCHECA, JC; KAPLOWITZ, N			BIDIRECTIONAL MECHANISM OF PLASMA-MEMBRANE TRANSPORT OF REDUCED GLUTATHIONE IN INTACT RAT HEPATOCYTES AND MEMBRANE-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXOGENOUS GLUTATHIONE; OXIDATIVE INJURY; EFFLUX; LIVER; INHIBITION; METHIONINE; ETHANOL; CELLS; PROTECTION; KINETICS	We determined the trans effects of extracellular reduced glutathione (GSH) on the rate of efflux of endogenous labeled GSH from freshly isolated rat hepatocytes. The presence of GSH (10 mM) in the medium significantly stimulated the fractional rate of efflux of [S-35]GSH from 5.2 to 12.6%/15 min (p < 0.01). This effect was concentration-dependent, had sigmoid type of kinetics (D50 of 0.32 mM), and was reversible upon removal of external GSH. trans-Stimulation (counter-transport) was also observed with 5 mM oxidized glutathione (GSSG) and ophthalmic acid (fractional [S-35]GSH efflux: 13.4% +/- 4.1 and 8.8% +/- 2.3 in 15 min, respectively, compared with control: 4.7 +/- 2.5/15 min). Bromosulphthalein-glutathione (BSP-GSH, 5 mm) in Krebs buffer inhibited the fractional [S-35]GSH efflux (1.1%/15 min), whereas in Cl--free buffer, GSH efflux was stimulated (14.2%/15 min) compared with control. trans-Stimulation was independent of chloride. BSP-GSH cis-inhibited and trans-stimulated the initial rate of GSH transport in basolateral-enriched membrane vesicles (bLPM) but not in canalicular-enriched membrane vesicles (cLPM). Gamma-glutamyl compounds also cis-inhibited and trans-stimulated GSH transport in bLPM vesicles. GSH-depleted hepatocytes incubated with 10 mM [S-35]GSH accumulated more GSH than repleted cells, but the initial rate of uptake of radioactivity was faster in repleted cells. In contrast, repleted hepatocytes incubated with tracer or 50 muM [S-35]GSH did not take up GSH. Thus, the sinusoidal membrane GSH transporter exhibits low affinity kinetics with sigmoid features for both GSH uptake and trans-stimulation of efflux, explaining the lack of uptake of GSH at low physiologic extracellular concentrations. Therefore, our findings support and explain the widely held view that GSH transport is unidirectional under physiologic conditions. However, the efflux of GSH may also occur in exchange for the uptake of organic anions and gamma-glutamyl compounds.	UNIV SO CALIF,SCH MED,DEPT MED,DIV GASTROINTESTINAL & LIVER DIS,LOS ANGELES,CA 90033	University of Southern California			Fernández-Checa, José Carlos/L-8342-2014	Fernández-Checa, José Carlos/0000-0003-3422-2990	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030312, R01DK030312] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30312] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AW TY, 1986, AM J PHYSIOL, V250, pG236, DOI 10.1152/ajpgi.1986.250.2.G236; AW TY, 1987, BIOCHEM BIOPH RES CO, V143, P377, DOI 10.1016/0006-291X(87)90676-0; AW TY, 1986, AM J PHYSIOL, V251, pG354, DOI 10.1152/ajpgi.1986.251.3.G354; AW TY, 1984, J BIOL CHEM, V259, P9355; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; FERNANDEZCHECA JC, 1991, J CLIN INVEST, V87, P397, DOI 10.1172/JCI115010; FERNANDEZCHECA JC, 1992, J BIOL CHEM, V267, P1667; FERNANDEZCHECA JC, 1987, J CLIN INVEST, V80, P57, DOI 10.1172/JCI113063; FERNANDEZCHECA JC, 1990, AM J PHYSIOL, V258, pG967, DOI 10.1152/ajpgi.1990.258.6.G967; FERNANDEZCHECA JC, 1989, J CLIN INVEST, V83, P1247, DOI 10.1172/JCI114008; FERNANDEZCHECA JC, 1988, AM J PHYSIOL, V255, pG403, DOI 10.1152/ajpgi.1988.255.4.G403; Fiske CH, 1925, J BIOL CHEM, V66, P375; HAGEN TM, 1988, KIDNEY INT, V34, P74, DOI 10.1038/ki.1988.147; HAHN R, 1978, BIOCHIM BIOPHYS ACTA, V539, P324, DOI 10.1016/0304-4165(78)90037-5; Hatefi Y, 1978, Methods Enzymol, V53, P21; HAUSSINGER D, 1990, EUR J BIOCHEM, V193, P891, DOI 10.1111/j.1432-1033.1990.tb19414.x; KAPLOWITZ N, 1985, ANNU REV PHARMACOL, V25, P715, DOI 10.1146/annurev.pa.25.040185.003435; KELTZIEN RF, 1975, ANAL BIOCHEM, V68, P537; LASH LH, 1986, P NATL ACAD SCI USA, V83, P4641, DOI 10.1073/pnas.83.13.4641; LU SC, 1990, J BIOL CHEM, V265, P16088; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Moldeus P, 1978, Methods Enzymol, V52, P60; OOKHTENS M, 1988, J CLIN INVEST, V82, P608, DOI 10.1172/JCI113639; OOKHTENS M, 1985, J CLIN INVEST, V75, P258, DOI 10.1172/JCI111682; OOKHTENS M, 1991, AM J PHYSIOL, V261, pG458; WHELAN G, 1970, J LAB CLIN MED, V75, P542; WOLKOFF AW, 1987, J CLIN INVEST, V79, P1259, DOI 10.1172/JCI112946; YOUNES M, 1990, TOXICOL LETT, V50, P229, DOI 10.1016/0378-4274(90)90015-E	29	100	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22256	22264						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429578				2022-12-25	WOS:A1992JW71900043
J	HARRIS, HW; HOSSELET, C; GUAYWOODFORD, L; ZEIDEL, ML				HARRIS, HW; HOSSELET, C; GUAYWOODFORD, L; ZEIDEL, ML			PURIFICATION AND PARTIAL CHARACTERIZATION OF CANDIDATE ANTIDIURETIC-HORMONE WATER CHANNEL PROTEINS OF M(R) 55,000 AND 53,000 FROM TOAD URINARY-BLADDER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; PERMEABILITY RESPONSE; TRANSPORT; IDENTIFICATION; QUANTITATION; VESICLES; SPECTRIN; COMPLEX; CELLS; SKIN	Antidiuretic hormone (ADH) increases toad bladder granular cell apical membrane osmotic water permeability (P(f)) by insertion of cytoplasmic vesicles containing water channels into the apical membrane. Termination of ADH stimulation results in endocytosis of water channel-containing membrane. In previous work, we have purified water channel-containing vesicles and demonstrated that they contain 12 major protein bands when analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). On the basis of vectorial labeling studies of granular cells and purified vesicles, we have proposed previously that vesicle proteins of 55, 53, and 17 kDa are ADH water channel components. In this report, we have purified and analyzed these three proteins using a combination of SDS-PAGE, peptide mapping, amino acid composition, and amino-terminal analyses. The 55- and 53-kDa proteins are distinct protein species possessing a high degree of structural similarity. Both possess a large content of cysteine. The 17-kDa protein appears to be a proteolytic fragment of the 53-kDa protein. None of these three proteins is phosphorylated or contains large amounts of covalently linked carbohydrate. ADH-elicited P(f) is inhibited by the organic mercurial reagent fluorescein mercuric acetate (FMA). Exposure of water channel-containing vesicles to FMA labels selectively four vesicle proteins of 92, 55, 53, and 29 kDa while reducing vesicle P(f) by 82%. The combination of FMA and 2-mercaptoethanol or exposure to another mercurial reagent, n-ethylmaleimide, does not inhibit vesicle P(f). Together, these data provide additional evidence for the role of the 55- and 53-kDa proteins as components of the ADH water channel. These candidate ADH water channel proteins are distinct from a 28-kDa candidate water channel protein (CHIP 28) isolated recently from human erythrocyte membranes and kidney proximal tubule by Agre and co-workers (Preston, G. M., Carroll, T. P., Guggino, W. B., and Agre, P. (1992) Science 256, 385-387).	BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; W ROXBURY VET ADM MED CTR,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital	HARRIS, HW (corresponding author), CHILDRENS HOSP,DIV NEPHROL,BOSTON,MA 02030, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038874, R01DK038690] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38874, DK 38690] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADRAGNA N, 1987, MEMBRANE BIOCHEM, V7, P23, DOI 10.3109/09687688709029427; ASTER JC, 1986, J CELL BIOL, V103, P115, DOI 10.1083/jcb.103.1.115; CALAMITA G, 1992, AM J PHYSIOL, V262, pF267, DOI 10.1152/ajprenal.1992.262.2.F267; CHEVALIER J, 1981, CELL TISSUE RES, V218, P595; COLEMAN RA, 1987, J HISTOCHEM CYTOCHEM, V35, P1405, DOI 10.1177/35.12.3119700; DAVIES PL, 1990, FASEB J, V4, P2460, DOI 10.1096/fasebj.4.8.2185972; DAVIS J, 1982, J BIOL CHEM, V257, P5816; DENKER BM, 1988, J BIOL CHEM, V263, P15634; ELDER JH, 1977, J BIOL CHEM, V252, P6510; FINKELSTEIN A, 1986, WATER MOVEMENT LIPID; GLANTZ SA, 1988, PRIMER BIOSTATISTICS; GLUCK S, 1980, NATURE, V284, P631, DOI 10.1038/284631a0; GROSSMAN E, 1990, J AM SOC NEPHROL, V1, pA674; HARRIS HW, 1990, AM J PHYSIOL, V259, pF366, DOI 10.1152/ajprenal.1990.259.2.F366; HARRIS HW, 1991, J CLIN INVEST, V88, P1, DOI 10.1172/JCI115263; HARRIS HW, 1986, J CLIN INVEST, V78, P703, DOI 10.1172/JCI112630; HARRIS HW, 1990, AM J PHYSIOL, V258, pF237, DOI 10.1152/ajprenal.1990.258.2.F237; HARRIS HW, 1987, J MEMBRANE BIOL, V96, P175, DOI 10.1007/BF01869243; HARRIS HW, 1988, P NATL ACAD SCI USA, V85, P1942, DOI 10.1073/pnas.85.6.1942; HARRIS HW, 1988, J MEMBRANE BIOL, V103, P207, DOI 10.1007/BF01993980; HARRIS HW, 1991, AM J PHYSIOL, V261, pC143, DOI 10.1152/ajpcell.1991.261.1.C143; HARRIS HW, 1990, J AM SOC NEPHROL, V1, P1114; HARVEY B, 1991, J GEN PHYSIOL, V97, P749, DOI 10.1085/jgp.97.4.749; HOCH BS, 1989, AM J PHYSIOL, V256, pF948, DOI 10.1152/ajprenal.1989.256.5.F948; IBARRA C, 1989, J MEMBRANE BIOL, V110, P115, DOI 10.1007/BF01869467; KACHADORIAN WA, 1985, AM J PHYSIOL, V248, pF260, DOI 10.1152/ajprenal.1985.248.2.F260; KONIECZKOWSKI M, 1985, J PHARMACOL EXP THER, V234, P515; LEGENDRE N, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P49; MULLER J, 1980, J CELL BIOL, V85, P83, DOI 10.1083/jcb.85.1.83; MULLER J, 1984, AM J PHYSIOL, V247, pC90, DOI 10.1152/ajpcell.1984.247.1.C90; OJCIUS DM, 1988, BIOCHIM BIOPHYS ACTA, V942, P73, DOI 10.1016/0005-2736(88)90276-3; OSHANNESSY DJ, 1987, ANAL BIOCHEM, V163, P204, DOI 10.1016/0003-2697(87)90114-X; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; SMITH BL, 1991, J BIOL CHEM, V266, P6407; STRANGE K, 1987, J MEMBRANE BIOL, V96, P27, DOI 10.1007/BF01869332; TARR GE, 1991, TECHNIQUES PROTEIN C, V2, pCH13; UNKELESS JC, 1977, J EXP MED, V145, P931, DOI 10.1084/jem.145.4.931; VALENTI G, 1991, AM J PHYSIOL, V261, pF437, DOI 10.1152/ajprenal.1991.261.3.F437; VALENTI G, 1990, BIOL CELL, V67, P115; VERBAVATZ JM, 1991, VASOPRESSIN, P105; VERKMAN AS, 1988, NATURE, V333, P268, DOI 10.1038/333268a0; Wade J B, 1981, Ann N Y Acad Sci, V372, P106, DOI 10.1111/j.1749-6632.1981.tb15464.x; WHITFIELD CF, 1985, AM J PHYSIOL, V248, pC70, DOI 10.1152/ajpcell.1985.248.1.C70; ZEIDEL M, 1992, IN PRESS AM J PHYSL	45	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22115	22121						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1429563				2022-12-25	WOS:A1992JW71900023
J	OZAKI, M; FUJINAMI, K; TANAKA, K; AMEMIYA, Y; SATO, T; OGURA, N; NAKAGAWA, H				OZAKI, M; FUJINAMI, K; TANAKA, K; AMEMIYA, Y; SATO, T; OGURA, N; NAKAGAWA, H			PURIFICATION AND INITIAL CHARACTERIZATION OF THE PROTEASOME FROM THE HIGHER-PLANT SPINACIA-OLERACEA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; MOLECULAR-WEIGHT PROTEASES; SODIUM DODECYL-SULFATE; MAMMALIAN-CELLS; RAT-LIVER; EUKARYOTIC CELLS; UBIQUITIN; SUBUNITS; DEGRADATION; INVOLVEMENT	The proteasome (multicatalytic protease complex), a high molecular weight protein complex, has been purified from spinach leaves by successive chromatography on DEAE-cellulose, Bio-Gel A-1.5m, DEAE-TOYOPEARL 650C, and DEAE-5PW. The molecular mass was estimated to be 850 kDa by gel filtration. Polyacrylamide gel electrophoresis of the proteasome gave a single protein band under nondenaturing conditions and at least 10 bands in the range of 21-32 kDa in the presence of sodium dodecyl sulfate. By electron microscopy after negative staining with uranyl acetate, the proteasome from spinach appeared as symmetrical ring-shaped particles. The substrate specificity of proteasomes indicates that they contain at least three types of activity, namely, chymotrypsin-like, Staphylococcus aureus V8 protease-like, and trypsin-like activities. The former two activities were enhanced by poly-L-lysine or sodium dodecyl sulfate. Moreover, we examined the immunological reactivities of proteasomes from various eukaryotes. As a result, cross-immunoreactivities of some subunits were observed. These properties of the proteasome are similar to those of proteasomes isolated from various other eukaryotic sources.	CHIBA UNIV, FAC HORT, PLANT PATHOL LAB, MATSUDO, CHIBA 271, JAPAN; UNIV TOKUSHIMA, INST ENZYME RES, TOKUSHIMA 770, JAPAN	Chiba University; Tokushima University	OZAKI, M (corresponding author), CHIBA UNIV, DEPT AGR CHEM, MATSUDO, CHIBA 271, JAPAN.							ARRIBAS J, 1990, J BIOL CHEM, V265, P13969; ARRIGO AP, 1988, NATURE, V331, P192, DOI 10.1038/331192a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLA DD, 1991, FEBS LETT, V280, P137; DAHLMANN B, 1985, BIOCHEM J, V228, P171, DOI 10.1042/bj2280171; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; DRISCOLL J, 1989, P NATL ACAD SCI USA, V86, P787, DOI 10.1073/pnas.86.3.787; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FALKENBURG PE, 1988, NATURE, V331, P190, DOI 10.1038/331190a0; GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531; GOLDSTEIN G, 1975, P NATL ACAD SCI USA, V72, P11, DOI 10.1073/pnas.72.1.11; HAASS C, 1989, EXP CELL RES, V180, P243, DOI 10.1016/0014-4827(89)90228-0; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; HERSHKO A, 1982, ANNU REV BIOCHEM, V51, P335, DOI 10.1146/annurev.bi.51.070182.002003; HOUGH R, 1987, J BIOL CHEM, V262, P8303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE LW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P178, DOI 10.1016/0167-4838(90)90165-C; MATSUMURA K, 1991, MOL REPROD DEV, V29, P189, DOI 10.1002/mrd.1080290215; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; NISHIMURA M, 1978, PLANT PHYSIOL, V62, P44, DOI 10.1104/pp.62.1.44; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ORINO E, 1991, FEBS LETT, V284, P206, DOI 10.1016/0014-5793(91)80686-W; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; RIVETT AJ, 1991, BIOCHEM J, V278, P171, DOI 10.1042/bj2780171; SAITOH Y, 1989, J BIOCHEM-TOKYO, V105, P254, DOI 10.1093/oxfordjournals.jbchem.a122649; SAITOH Y, 1991, COMP BIOCHEM PHYS B, V99, P71, DOI 10.1016/0305-0491(91)90009-3; SCHLIEPHACKE M, 1991, EUR J CELL BIOL, V55, P114; TANAKA K, 1989, BIOCHEM BIOPH RES CO, V164, P1253, DOI 10.1016/0006-291X(89)91804-4; TANAKA K, 1988, FEBS LETT, V236, P159, DOI 10.1016/0014-5793(88)80306-5; TANAKA K, 1990, CELL STRUCT FUNCT, V15, P127, DOI 10.1247/csf.15.127; TANAKA K, 1992, NEW BIOL, V4, P173; TANAKA K, 1988, J MOL BIOL, V203, P985, DOI 10.1016/0022-2836(88)90123-4; TANAKA K, 1988, J BIOL CHEM, V263, P16209; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TANAKA K, 1989, J BIOCHEM-TOKYO, V106, P495, DOI 10.1093/oxfordjournals.jbchem.a122880; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIERSTRA RD, 1987, PHYSIOL PLANTARUM, V70, P103, DOI 10.1111/j.1399-3054.1987.tb08704.x; WAXMAN L, 1987, J BIOL CHEM, V262, P2451	41	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21678	21684						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400479				2022-12-25	WOS:A1992JV01100066
J	SUKUMAR, M; HIGASHIJIMA, T				SUKUMAR, M; HIGASHIJIMA, T			G-PROTEIN-BOUND CONFORMATION OF MASTOPARAN-X, A RECEPTOR-MIMETIC PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; WASP VENOM; MOLECULAR-DYNAMICS; BINDING; MEMBRANE; CELLS; ALPHA	Mastoparans are a family of 14-residue peptide toxins from wasp venom which have been proposed to stimulate secretion from a variety of cells, by directly activating GTP-binding regulatory proteins (G proteins). In vitro studies have shown that mastoparans activate G proteins by a mechanism remarkably similar to that used by agonist-bound receptors (Higashijima, T., Uzu, S., Nakajima, T., and Ross, E. M. (1988) J. Biol. Chem. 263, 6491-6494). Here, we report the conformation of mastoparan-X (INWKGIAAMAKKLL-NH2) when it is bound to the alpha subunits of recombinant G(i) and G(o), derived from an analysis of transferred nuclear Overhauser effects in a two-dimensional H-1 NMR spectrum of mastoparan-X obtained in the presence of these G proteins. Restrained molecular dynamic simulations with NMR-derived distance constraints were used to determine conformations consistent with NMR data. The G(i)- and G(o)-bound conformations of mastoparan-X are very similar, and in both cases, a major part of the molecule adopts an amphiphilic alpha-helical conformation. The lysine residues are known to be crucial for activity, and it is thus likely that at least the polar face of the amphiphilic helix is in contact with the G proteins. These conclusions should be useful in the design of potent and selective analogs of mastoparan and in the development of models for receptor-G protein interaction.			SUKUMAR, M (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA.				NIGMS NIH HHS [GM40676] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040676] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUNGER AT, 1991, ACCOUNTS CHEM RES, V24, P54; CAMPBELL AP, 1991, J MAGN RESON, V93, P77, DOI 10.1016/0022-2364(91)90033-P; CLORE GM, 1986, EMBO J, V5, P2729, DOI 10.1002/j.1460-2075.1986.tb04557.x; CLORE GM, 1983, J MAGN RESON, V53, P423, DOI 10.1016/0022-2364(83)90215-9; CLORE GM, 1982, J MAGN RESON, V48, P402, DOI 10.1016/0022-2364(82)90073-7; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1984, BIOCHIM BIOPHYS ACTA, V802, P157, DOI 10.1016/0304-4165(84)90156-9; HIGASHIJIMA T, 1983, FEBS LETT, V152, P227, DOI 10.1016/0014-5793(83)80385-8; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HIGASHIJIMA T, 1987, PEPTIDE CHEM 1986, P75; HIRAI Y, 1979, CHEM PHARM BULL, V27, P1942; ITOH H, 1991, J BIOL CHEM, V266, P16226; KOIDE S, 1989, J BIOL CHEM, V264, P8676; KURIHARA H, 1986, CELL TISSUE RES, V243, P311; KURODA Y, 1980, P JPN ACAD B-PHYS, V56, P660, DOI 10.2183/pjab.56.660; LINDER ME, 1991, METHOD ENZYMOL, V195, P202; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; OIDA T, 1986, J BIOCHEM-TOKYO, V100, P99, DOI 10.1093/oxfordjournals.jbchem.a121710; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; WAKAMATSU K, 1992, BIOCHEMISTRY-US, V31, P5654, DOI 10.1021/bi00139a032; WAKAMATSU K, 1983, FEBS LETT, V162, P123, DOI 10.1016/0014-5793(83)81062-X; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC	29	85	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21421	21424						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1400455				2022-12-25	WOS:A1992JV01100027
J	KUSUBATA, M; TOKUI, T; MATSUOKA, Y; OKUMURA, E; TACHIBANA, K; HISANAGA, S; KISHIMOTO, T; YASUDA, H; KAMIJO, M; OHBA, Y; TSUJIMURA, K; YATANI, R; INAGAKI, M				KUSUBATA, M; TOKUI, T; MATSUOKA, Y; OKUMURA, E; TACHIBANA, K; HISANAGA, S; KISHIMOTO, T; YASUDA, H; KAMIJO, M; OHBA, Y; TSUJIMURA, K; YATANI, R; INAGAKI, M			P13SUC1 SUPPRESSES THE CATALYTIC FUNCTION OF P34CDC2 KINASE FOR INTERMEDIATE FILAMENT PROTEINS, INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; MATURATION-PROMOTING FACTOR; GERMINAL VESICLE BREAKDOWN; XENOPUS CDC2 PROTEIN; H-1 HISTONE KINASE; CONTROL GENE CDC2+; FISSION YEAST; M-PHASE; DIVISION CYCLE; TYROSINE DEPHOSPHORYLATION	The regulation of p34cdc2 kinase activity controls the entry into and exit from mitosis. Although genetic and biochemical evidence suggested close interactions between cyclins, p13suc1 and p34cdc2 kinase, the roles of p13suc1 on p34cdc2 kinase functions remain unclear. To examine the effects of p13suc1 on p34cdc2 kinase function we developed a simple purification procedure for p34cdc2 kinase, unassociated with p13suc1. The key to the purification procedures we used was buffer containing 0.5 m NaCl and 50% ethylene glycol, as a specific elutant of p34cdc2 kinase from p13suc1-Sepharose. This purified p34cdc2 kinase stoichiometrically phosphorylated vimentin and desmin. Exogenous p13suc1 suppressed the phosphorylation of these filament proteins by the kinase and prevented disassembly, although histone H1 phosphorylation was not affected. Peptide mapping analysis showed a similar extent of inhibition by p13suc1 for all five phosphorylation sites by p34cdc2 kinase of vimentin and desmin, hence these p13suc1-induced inhibitions are probably not site-specific. It thus appears that p13suc1 has a selective effect on the catalytic activity of p34cdc2 kinase for these filament proteins.	TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT NEUROPHYSIOL,ITABASHI KU,TOKYO 173,JAPAN; MIE UNIV,SCH MED,DEPT PATHOL,TSU,MIE 514,JAPAN; AICHI CANC CTR,RES INST,EXPTL RADIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,CELL & DEV BIOL LAB,YOKOHAMA,KANAGAWA 227,JAPAN; KANAZAWA UNIV,FAC PHARMACEUT SCI,DIV BIOL,KANAZAWA,ISHIKAWA 920,JAPAN	Mie University; Aichi Cancer Center; Tokyo Institute of Technology; Kanazawa University			Inagaki, Masaki/B-9920-2016					BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BELLE R, 1989, FEBS LETT, V255, P101, DOI 10.1016/0014-5793(89)81069-5; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRADBURY EM, 1974, NATURE, V249, P553, DOI 10.1038/249553a0; BRADBURY EM, 1974, NATURE, V247, P257, DOI 10.1038/247257a0; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CELIS JE, 1983, J CELL BIOL, V97, P1429, DOI 10.1083/jcb.97.5.1429; CHOU YH, 1991, J BIOL CHEM, V266, P7325; CHOU YH, 1989, P NATL ACAD SCI USA, V86, P1885, DOI 10.1073/pnas.86.6.1885; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EVANS RM, 1988, EUR J CELL BIOL, V46, P152; EVANS RM, 1984, J BIOL CHEM, V259, P5372; EVANS RM, 1989, J CELL BIOL, V108, P67, DOI 10.1083/jcb.108.1.67; EVANS RM, 1982, CELL, V29, P43, DOI 10.1016/0092-8674(82)90088-5; FEY SJ, 1983, FEBS LETT, V157, P251; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GEISLER N, 1982, EMBO J, V1, P1649, DOI 10.1002/j.1460-2075.1982.tb01368.x; GEISLER N, 1988, EMBO J, V7, P15, DOI 10.1002/j.1460-2075.1988.tb02778.x; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; HOFSTEE BHJ, 1973, BIOCHEM BIOPH RES CO, V50, P751, DOI 10.1016/0006-291X(73)91308-9; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; INAGAKI M, 1988, J BIOL CHEM, V263, P5970; KISHIMOTO T, 1982, EXP CELL RES, V137, P121, DOI 10.1016/0014-4827(82)90014-3; KISHIMOTO T, 1976, NATURE, V260, P321, DOI 10.1038/260321a0; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LAZARUS LH, 1976, ANAL BIOCHEM, V174, P138; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MAK AS, 1991, J BIOL CHEM, V266, P6678; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SMITH LD, 1971, DEV BIOL, V25, P232, DOI 10.1016/0012-1606(71)90029-7; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; SUNKARA PS, 1979, P NATL ACAD SCI USA, V76, P2799, DOI 10.1073/pnas.76.6.2799; TACHIBANA K, 1987, J CELL SCI, V88, P273; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WESTWOOD JT, 1985, J BIOL CHEM, V260, P308; YASUDA H, 1990, BIOCHEM BIOPH RES CO, V172, P371, DOI 10.1016/0006-291X(90)90682-D	68	75	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20937	20942						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1400409				2022-12-25	WOS:A1992JT97800068
J	GENG, JG; HEAVNER, GA; MCEVER, RP				GENG, JG; HEAVNER, GA; MCEVER, RP			LECTIN DOMAIN PEPTIDES FROM SELECTINS INTERACT WITH BOTH CELL-SURFACE LIGANDS AND CA2+ IONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION MOLECULE-1; LYMPHOCYTE HOMING RECEPTOR; MANNOSE-BINDING PROTEIN; CARBOHYDRATE LIGAND; GMP-140 BINDS; SIALYL-LEX; T-CELLS; CALCIUM; ELAM-1; RECOGNITION	Selectins are receptors that mediate leukocyte adhesion to platelets or endothelial cells through Ca2+-dependent interactions with cell surface oligosaccharides. We found that peptides corresponding to residues 23-30, 54-63, and 70-79 of the N-terminal lectin domain of P-selectin inhibited leukocyte adhesion to P-selectin. Peptides corresponding to the homologous 23-30 and 54-63 regions of E-selectin and L-selectin also prevented cell binding to P-selectin. Immobilized albumin conjugates of the three P-selectin peptides supported adhesion of myeloid cells and certain other cells expressing fucosylated oligosaccharides. Ca2+ was required for optimal cell adhesion to the conjugates containing the 23-30 and 54-63 sequences. Furthermore, Ca2+ interacted with the 23-30 and 54-63 peptides of all three selectins, as detected by changes in intrinsic fluorescence emission intensity. These data suggest that residues contained within the 23-30 and 54-63 regions of the selectins represent contact sites for carbohydrate structures on target cells. Furthermore, binding of Ca2+ to these sequences may directly enhance their ability to interact with cell surface ligands.	UNIV OKLAHOMA, HLTH SCI CTR, DEPT MED, 825 NE 13TH ST, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, WK WARREN MED RES INST, DEPT BIOCHEM, OKLAHOMA CITY, OK 73104 USA; OKLAHOMA MED RES FDN, CARDIOVASC BIOL RES PROGRAM, OKLAHOMA CITY, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation					NHLBI NIH HHS [HL 45510, HL 34363] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034363, R01HL045510, R37HL034363] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSEN TT, 1982, J BIOL CHEM, V257, P8036; BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BERG EL, 1991, J BIOL CHEM, V266, P14869; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BRASS LF, 1989, METHOD ENZYMOL, V169, P355; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GENG JG, 1991, J BIOL CHEM, V266, P22313; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; HANDA K, 1991, BIOCHEM BIOPH RES CO, V181, P1223, DOI 10.1016/0006-291X(91)92069-V; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HESSION C, 1990, P NATL ACAD SCI USA, V87, P1673, DOI 10.1073/pnas.87.5.1673; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LEE RT, 1991, J BIOL CHEM, V266, P4810; LOEB JA, 1988, J BIOL CHEM, V263, P9752; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MCEVER RP, 1991, THROMB HAEMOSTASIS, V66, P80; MCEVER RP, 1991, J CELL BIOCHEM, V45, P156, DOI 10.1002/jcb.240450206; MOORE KL, 1992, BIOCHEM BIOPH RES CO, V186, P173, DOI 10.1016/S0006-291X(05)80790-9; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PIGOTT R, 1991, J IMMUNOL, V147, P130; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; QUESENBERRY M S, 1991, Glycobiology, V1, P615, DOI 10.1093/glycob/1.6.615; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; SHARON N, 1990, FASEB J, V4, P3198, DOI 10.1096/fasebj.4.14.2227211; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; WATSON SR, 1991, J CELL BIOL, V115, P235, DOI 10.1083/jcb.115.1.235; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; YAMAMOTO K, 1991, FEBS LETT, V281, P258, DOI 10.1016/0014-5793(91)80406-S; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	50	68	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19846	19853						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1383198				2022-12-25	WOS:A1992JR85800018
J	JORDAN, SP; ZUGAY, J; DARKE, PL; KUO, LC				JORDAN, SP; ZUGAY, J; DARKE, PL; KUO, LC			ACTIVITY AND DIMERIZATION OF HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE AS A FUNCTION OF SOLVENT COMPOSITION AND ENZYME CONCENTRATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETIC HIV-1 PROTEASE; RETROVIRAL PROTEASES; TYPE-1 PROTEASE; INHIBITION; EXPRESSION; DIMER; GAG	The activity of human immunodeficiency virus 1 (HIV-1) protease has been examined as a function of solvent composition, incubation time, and enzyme concentration at 37-degrees-C in the pH 4.5-5.5 range. Glycerol and dimethyl sulfoxide inhibit the enzyme, while polyethylene glycol and bovine serum albumin activate the enzyme. When incubated at a concentration of 50-200 nM, the activity of the protease decreases irreversibly with an apparent first-order rate constant of 4-9 x 10(-3) min-1. The presence of 0.1% (w/v) polyethylene glycol or bovine serum albumin in the reaction buffer dramatically stabilizes enzyme activity. In the absence of prolonged incubation of the enzyme at submicromolar concentration, the specific activity of HIV-1 protease in buffers of either high or low ionic strength is constant over the enzyme concentration range of 0.25-5 nM, indicating that dissociation of the dimeric protease, if occurring, can only be governed by a picomolar dissociation constant. Similarly, the variation of the specific activity of HIV-2 protease over the enzyme concentration of 4-85 nM is consistent only with a dimer dissociation constant of less than 10 nM. We conclude that: 1) the assumption of a nondissociating HIV-1 protease is a valid one for kinetic studies of tight-binding inhibitors where nanomolar concentrations of the enzymes are employed; 2) stock protease solutions of submicromolar concentration in the absence of activity-stabilizing compounds may lead to erroneous kinetic data and complicate mechanistic interpretations.	MERCK SHARP & DOHME LTD,DEPT BIOL CHEM,WP26-431,W POINT,PA 19486	Merck & Company								BOURINBAIAR AS, 1991, NATURE, V349, P111, DOI 10.1038/349111b0; CHENG YSE, 1990, P NATL ACAD SCI USA, V87, P9660, DOI 10.1073/pnas.87.24.9660; DARKE PL, 1989, J BIOL CHEM, V264, P2307; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DIIANNI CL, 1990, J BIOL CHEM, V265, P17348; FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209; HEIMBACH JC, 1989, BIOCHEM BIOPH RES CO, V164, P955, DOI 10.1016/0006-291X(89)91762-2; HOLZMAN TF, 1991, J BIOL CHEM, V266, P19217; HYLAND LJ, 1991, BIOCHEMISTRY-US, V30, P8454, DOI 10.1021/bi00098a024; JACKS T, 1988, NATURE, V331, P280, DOI 10.1038/331280a0; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161; MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486; MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0; MOORE ML, 1989, BIOCHEM BIOPH RES CO, V159, P420, DOI 10.1016/0006-291X(89)90008-9; MYERS G, 1991, HUMAN RETROVIRUSES A; TOMASSELLI AG, 1990, BIOCHEMISTRY-US, V29, P264, DOI 10.1021/bi00453a036; VACCA JP, 1991, J MED CHEM, V34, P1225, DOI 10.1021/jm00107a050; WASIEWSKI W, 1976, THROMB RES, V8, P881, DOI 10.1016/0049-3848(76)90017-7; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; ZHANG ZY, 1991, J BIOL CHEM, V266, P15591	21	51	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20028	20032						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400318				2022-12-25	WOS:A1992JR85800046
J	MARTIN, E; SAGITOV, V; BUROVA, E; NIKIFOROV, V; GOLDFARB, A				MARTIN, E; SAGITOV, V; BUROVA, E; NIKIFOROV, V; GOLDFARB, A			GENETIC DISSECTION OF THE TRANSCRIPTION CYCLE - A MUTANT RNA-POLYMERASE THAT CANNOT HOLD ONTO A PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDO-TEMPLATED TRANSCRIPTION; RIBONUCLEIC-ACID POLYMERASE; LAC UV5 PROMOTER; ESCHERICHIA-COLI; TERNARY COMPLEXES; BETA-SUBUNIT; NUCLEOTIDE-SEQUENCE; SIGMA-70 SUBUNIT; CORE SUBUNITS; INITIATION	Deletion of 10 amino acids from a conserved motif in the beta subunit of Escherichia coli RNA polymerase (RNAP) leads to an interrupted transcription cycle and lethal phenotype. RNAP carrying the mutant subunit retains catalytic function and specificity of promoter recognition but is unable to efficiently hold onto DNA in the binary complex, resulting in a diminished initiation frequency. However, inefficient initiation by the mutant enzyme leads to processive and stable ternary elongating complex. Thus, the mutation dissects the traits of promoter selectivity, binary complex stability, and ternary complex processivity reflecting compartmentalization of function within the RNAP molecule.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032; RUSSIAN ACAD SCI,INST MOLEC GENET,MOSCOW 123182,USSR	Columbia University; Russian Academy of Sciences					NIGMS NIH HHS [GM30717] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030717] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGHOFER B, 1988, NUCLEIC ACIDS RES, V16, P8113, DOI 10.1093/nar/16.16.8113; BORODIN AM, 1988, DOKL AKAD NAUK SSSR+, V302, P1261; BORUKHOV S, 1991, J BIOL CHEM, V266, P23921; BRUNNER M, 1987, EMBO J, V6, P3139, DOI 10.1002/j.1460-2075.1987.tb02624.x; Burgess R.R., 1987, RNA POLYM REGULATION, P3; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHAMBERLIN M, 1964, J MOL BIOL, V8, P708, DOI 10.1016/S0022-2836(64)80120-0; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; FALKENBURG D, 1987, J MOL BIOL, V195, P929, DOI 10.1016/0022-2836(87)90496-7; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; GRAGEROV AI, 1980, MOL GEN GENET, V180, P399, DOI 10.1007/BF00425854; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HEUMANN H, 1988, J MOL BIOL, V201, P115, DOI 10.1016/0022-2836(88)90443-3; HUDSON GS, 1988, J MOL BIOL, V200, P639, DOI 10.1016/0022-2836(88)90477-9; JACQUES JP, 1991, GENE DEV, V5, P707, DOI 10.1101/gad.5.5.707; JACQUES JP, 1990, GENE DEV, V4, P1801, DOI 10.1101/gad.4.10.1801; JIN DJ, 1991, J BIOL CHEM, V266, P14478; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; JOHNSTON DE, 1976, RNA POLYM, P101; KAMAR G, 1984, NUCLEIC ACIDS RES, V12, P7269; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LANDICK R, 1990, J BACTERIOL, V172, P2844, DOI 10.1128/jb.172.6.2844-2854.1990; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LARIONOV OA, 1979, MOL GEN GENET, V176, P105, DOI 10.1007/BF00334301; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6018, DOI 10.1073/pnas.88.14.6018; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; MUSTAEV A, 1991, J BIOL CHEM, V266, P23927; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; OVCHINNIKOV YA, 1981, EUR J BIOCHEM, V116, P621, DOI 10.1111/j.1432-1033.1981.tb05381.x; RHODES G, 1974, J BIOL CHEM, V249, P6675; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; SIMPSON RB, 1979, CELL, V18, P277, DOI 10.1016/0092-8674(79)90047-3; STRANEY SB, 1987, BIOCHEMISTRY-US, V26, P5063, DOI 10.1021/bi00390a027; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2; ZUBER P, 1989, J MOL BIOL, V206, P605, DOI 10.1016/0022-2836(89)90569-X	45	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20175	20180						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400337				2022-12-25	WOS:A1992JR85800069
J	TERCERO, JC; WICKNER, RB				TERCERO, JC; WICKNER, RB			MAK3 ENCODES AN N-ACETYLTRANSFERASE WHOSE MODIFICATION OF THE L-A GAG NH2 TERMINUS IS NECESSARY FOR VIRUS PARTICLE ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; CAPSID PROTEIN VP4; SACCHAROMYCES-CEREVISIAE; COAT PROTEIN; YEAST; GENES; MYRISTYLATION; INVIVO; IDENTIFICATION; REPLICATION	The MAK3 gene is necessary for propagation of the L-A double-stranded RNA virus of Saccharomyces cerevisiae. MAK3 encodes a protein with substantial homology to the Escherichia coli rimI N-acetyltransferase that acetylates the NH, terminus of ribosomal protein S18, and shares consensus sequences with a group of N-acetyltransferases. The NH2 terminus of the viral major coat protein encoded by L-A is normally blocked, but we find that it is unblocked in a mak3-1 mutant. L-A virus-encoded proteins produced from a cDNA clone of L-A can encapsidate the L-A (+)-strands in a wild-type host, but not in a mak3-1 mutant strain. The amount of major coat protein found in the particle fraction is reduced >100-fold, and the amount in the total cell extract is reduced 5-10-fold. A modified beta-galactosidase, having as its NH2-terminal the NH2-terminal 13 residues of the L-A-encoded major coat protein, is blocked in a wild-type host, but not in a mak3-1 host. We propose that MAK3 encodes an N-acetyltransferase whose modification of the L-A major coat protein NH2 terminus is essential for viral assembly, and that unassembled coat protein is unstable.			TERCERO, JC (corresponding author), NIDDKD,GENET SIMPLE EUKARYOTES SECT,BIOCHEM PHARMACOL LAB,BETHESDA,MD 20892, USA.		Bueren, Juan/L-6112-2014	Bueren, Juan/0000-0002-3228-7013				BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; DIHANICH M, 1989, MOL CELL BIOL, V9, P1100, DOI 10.1128/MCB.9.3.1100; DINMAN JD, 1991, P NATL ACAD SCI USA, V88, P174, DOI 10.1073/pnas.88.1.174; ESTEBAN R, 1986, MOL CELL BIOL, V6, P1552, DOI 10.1128/MCB.6.5.1552; ESTEBAN R, 1988, J VIROL, V62, P1278, DOI 10.1128/JVI.62.4.1278-1285.1988; FUJIMURA T, 1988, CELL, V55, P663, DOI 10.1016/0092-8674(88)90225-5; FUJIMURA T, 1990, CELL, V62, P819, DOI 10.1016/0092-8674(90)90125-X; GOWDA SD, 1989, J BIOL CHEM, V264, P8459; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GUARENTE L, 1983, METHOD ENZYMOL, V3, P117; HARRIS JI, 1961, J MOL BIOL, V3, P117; HENDERSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P339, DOI 10.1073/pnas.80.2.339; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; ICHO T, 1989, J BIOL CHEM, V264, P6716; KENDALL RL, 1990, METHOD ENZYMOL, V185, P398; KRAAL B, 1972, EUR J BIOCHEM, V28, P20, DOI 10.1111/j.1432-1033.1972.tb01879.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Maniatis T., 1982, MOL CLONING; MIKI T, 1968, VIROLOGY, V36, P168, DOI 10.1016/0042-6822(68)90132-3; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; NARITA K, 1958, BIOCHIM BIOPHYS ACTA, V28, P184, DOI 10.1016/0006-3002(58)90445-1; PALMITER RD, 1978, VIROLOGY, V91, P423, DOI 10.1016/0042-6822(78)90388-4; PAUL AV, 1987, P NATL ACAD SCI USA, V84, P7827, DOI 10.1073/pnas.84.22.7827; REILLY D, 1983, THESIS STATE U NEW Y; REIN A, 1986, P NATL ACAD SCI USA, V83, P7246, DOI 10.1073/pnas.83.19.7246; RHEE SS, 1987, J VIROL, V61, P1045, DOI 10.1128/JVI.61.4.1045-1053.1987; SCHULTZ AM, 1983, J VIROL, V46, P355, DOI 10.1128/JVI.46.2.355-361.1983; SHERMAN F, 1985, BIOESSAYS, V3, P27, DOI 10.1002/bies.950030108; SHIRE SJ, 1990, BIOCHEMISTRY-US, V29, P5119, DOI 10.1021/bi00473a017; SOMMER SS, 1982, CELL, V31, P429, DOI 10.1016/0092-8674(82)90136-2; SUNG P, 1991, EMBO J, V10, P2187, DOI 10.1002/j.1460-2075.1991.tb07754.x; TERCERO JC, 1992, J BIOL CHEM, V267, P20270; TERCERO JC, 1988, ANAL BIOCHEM, V174, P128, DOI 10.1016/0003-2697(88)90526-X; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WELSH JD, 1980, NUCLEIC ACIDS RES, V8, P2349, DOI 10.1093/nar/8.11.2349; WICKNER RB, 1991, J VIROL, V65, P155, DOI 10.1128/JVI.65.1.155-161.1991; WICKNER RB, 1976, J MOL BIOL, V105, P427, DOI 10.1016/0022-2836(76)90102-9; Wickner RB, 1991, MOL CELLULAR BIOL YE, P263; YOSHIKAWA A, 1987, MOL GEN GENET, V209, P481, DOI 10.1007/BF00331153	41	89	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20277	20281						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400344				2022-12-25	WOS:A1992JR85800083
J	ROSE, K; SIMONA, MG; SAVOY, LA; REGAMEY, PO; GREEN, BN; CLORE, GM; GRONENBORN, AM; WINGFIELD, PT				ROSE, K; SIMONA, MG; SAVOY, LA; REGAMEY, PO; GREEN, BN; CLORE, GM; GRONENBORN, AM; WINGFIELD, PT			PYRUVIC-ACID IS ATTACHED THROUGH ITS CENTRAL CARBON-ATOM TO THE AMINO TERMINUS OF THE RECOMBINANT DNA-DERIVED DNA-BINDING PROTEIN NER OF BACTERIOPHAGE-MU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROSPRAY	Ner protein of bacteriophage Mu, produced by recombinant DNA techniques in Escherichia coli, has been found to possess a molecule of pyruvic acid attached covalently through carbon-2 to the amino-terminal cysteine residue. The intact protein and the amino-terminal chymotryptic peptide were found by mass spectrometry to be 70 mass units heavier than expected. The modified peptide was unstable under mildly acid or mildly basic conditions. Two-dimensional nuclear magnetic resonance spectroscopy of the modified and unmodified forms of the amino-terminal chymotryptic peptide was consistent with the presence of pyruvate linked through carbon-2 to the amino-terminal Cys residue. Treatment of the modified form with 2,4-dinitrophenylhydrazine in acid medium led to the expected hydrazone of pyruvic acid, which was identified by high pressure liquid chromatography. Of the two proteins known to be modified by pyruvate through its central carbon (the other being human adult hemoglobin, in which the modified form represents only a very minor fraction), Ner is the first protein found to be modified quantitatively. Given the instability of the modification, it may be more prevalent than recognized hitherto. Incubation with 2,4-dinitrophenylhydrazine may offer a useful means of detecting the presence of pyruvate linked to proteins in this way.	VG BIOTECH, ALTRINCHAM WA14 5RZ, CHESHIRE, ENGLAND; NIDDKD, CHEM PHYS LAB, BETHESDA, MD 20892 USA; PFIZER INC, CENT RES, GROTON, CT 06340 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Pfizer	ROSE, K (corresponding author), CTR MED UNIV GENEVA, DEPT BIOCHIM MED, 1 RUE MICHEL SERVET, CH-1211 GENEVA 4, SWITZERLAND.		Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018	Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027; Gronenborn, Angela M/0000-0001-9072-3525; Wingfield, Paul/0000-0002-9515-4752				ALLET B, 1988, GENE, V65, P259, DOI 10.1016/0378-1119(88)90462-3; BAX A, 1989, METHOD ENZYMOL, V176, P151; CHOWDHURY SK, 1990, J AM SOC MASS SPECTR, V1, P382, DOI 10.1016/1044-0305(90)85018-H; PROME D, 1991, J BIOL CHEM, V266, P13050; ROSE K, 1989, ADV MASS SPECTROM A, V11, P484; VANLEERDAM E, 1982, VIROLOGY, V123, P19; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333	7	5	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19101	19106						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1388164				2022-12-25	WOS:A1992JP59300017
